nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at
NCT04506268,NA,8/7/2020,NA,NA,3/10/2021,8/7/2020,8/10/2020,Actual,NA,NA,NA,NA,NA,NA,3/10/2021,3/11/2021,Actual,9-Sep-20,Actual,9/9/2020,Mar-21,3/31/2021,30-Oct-20,Actual,10/30/2020,30-Oct-20,Actual,10/30/2020,NA,Interventional,COVID SAFE,NA,COVID-19 SAFE Enrollment,Opt-In Versus Opt-Out for COVID Screening Assessment for Exposure,Completed,NA,Not Applicable,412,Actual,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:55Z,2021-10-12T06:58:55Z
NCT04505592,NA,8/6/2020,NA,NA,9/20/2021,8/6/2020,8/10/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/21/2021,Actual,25-Sep-20,Actual,9/25/2020,Sep-21,9/30/2021,Oct-21,Anticipated,10/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Tenecteplase in Patients With COVID-19,Tenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19,Enrolling by invitation,NA,Phase 2,60,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:00Z,2021-10-12T06:59:00Z
NCT04502667,NA,8/4/2020,NA,NA,8/4/2020,8/4/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2020,8/6/2020,Actual,15-Jul-20,Actual,7/15/2020,Aug-20,8/31/2020,Apr-21,Anticipated,4/30/2021,Feb-21,Anticipated,2/28/2021,NA,Interventional,COVID-19,NA,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19: Open Controlled Clinical Trial,Recruiting,NA,Phase 3,40,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:23Z,2021-10-12T06:59:23Z
NCT04508075,NA,8/7/2020,NA,NA,9/6/2021,8/8/2020,8/11/2020,Actual,NA,NA,NA,NA,NA,NA,9/6/2021,9/8/2021,Actual,10-Aug-20,Actual,8/10/2020,Sep-21,9/30/2021,31-Aug-21,Actual,8/31/2021,9-Jan-21,Actual,1/9/2021,NA,Interventional,COVID-19,NA,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia",Completed,NA,Phase 3,1620,Actual,PT Bio Farma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:42Z,2021-10-12T06:58:42Z
NCT04504877,NA,8/4/2020,NA,NA,9/27/2021,8/6/2020,8/7/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/28/2021,Actual,16-Jun-20,Actual,6/16/2020,Sep-21,9/30/2021,16-Dec-20,Actual,12/16/2020,16-Nov-20,Actual,11/16/2020,NA,Interventional,BONSAI,NA,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19: a Randomised Controlled Trial,Completed,NA,Phase 2/Phase 3,120,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately the following publication. No end date,"Researchers who provide a methodologically sound proposal. Depending on the level of the proposed use of data, approval by an independent review committee will be required for the identified purpose.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification",2021-10-12T06:59:05Z,2021-10-12T06:59:05Z
NCT04502342,NA,8/4/2020,NA,NA,8/5/2020,8/4/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2020,8/7/2020,Actual,1-Jun-20,Actual,6/1/2020,Aug-20,8/31/2020,30-Sep-20,Anticipated,9/30/2020,30-Aug-20,Anticipated,8/30/2020,NA,Interventional,CANCOVID-19,NA,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Ã‰valuationefficacitÃ© et tolÃ©rance d'Une mÃ©dication Ã  Base de CosphÃ©runate et d'un phytomÃ©dicament Antiviral Par Voie Orale en Comparaison Avec un Traitement Ã  Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications,Enrolling by invitation,NA,Phase 2,30,Actual,Institute for Research and Development of Medicinal and Food Plants of Guinea,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The data could be available from september 30th to december 30th,partnership framework established,NA,Yes,"The samples stored in the biobank could be shared with other researchers with a view to in-depth analyzes in order to dig for example a posteriori on the hypotheses relating to the blood levels of the phytomedicine, hydroxychloroquine, etc., cardio-metabolic biological markers infarction, insulin sensitivity, thrombosis, specific antibodies, genetic markers, viral markers ...",2021-10-12T06:59:26Z,2021-10-12T06:59:26Z
NCT04505761,NA,7/3/2020,NA,NA,4/5/2021,8/7/2020,8/10/2020,Actual,NA,NA,NA,NA,NA,NA,4/5/2021,4/6/2021,Actual,1-Aug-20,Actual,8/1/2020,Jun-20,6/30/2020,31-Mar-21,Actual,3/31/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,COVRehab,NA,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19","The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19: An Explorative Study",Completed,NA,Not Applicable,48,Actual,Radboud University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Only upon asking.,2021-10-12T06:59:00Z,2021-10-12T06:59:00Z
NCT04558125,NA,9/19/2020,9/21/2021,NA,10/20/2021,9/21/2020,9/22/2020,Actual,10/20/2021,10/26/2021,Actual,NA,NA,NA,10/20/2021,10/26/2021,Actual,8-Sep-20,Actual,9/8/2020,Oct-21,10/31/2021,8-Aug-21,Actual,8/8/2021,10-Jul-21,Actual,7/10/2021,NA,Interventional,NA,"The study was terminated early and never unblinded. With only 2 subjects, statistical significance could never be demonstrated. Therefore, Arm/Group randomization information is not available.",Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,"Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial",Terminated,NA,Phase 4,2,Actual,Cedars-Sinai Medical Center,,2,NA,Identification of eligible patients was slower than anticipated.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:58:14Z,2021-12-04T22:58:14Z
NCT04500366,NA,7/31/2020,NA,NA,8/31/2021,8/4/2020,8/5/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/1/2021,Actual,26-Aug-20,Actual,8/26/2020,Aug-21,8/31/2021,30-Nov-21,Anticipated,11/30/2021,31-Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,GERAS Frailty Rehabilitation at Home During COVID-19,GERAS Frailty Rehabilitation at Home: Virtual Bundled Care for Seniors Who Are Frail to Build Strength and Resilience During COVID-19,"Active, not recruiting",NA,Not Applicable,70,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:59:42Z,2021-10-12T06:59:42Z
NCT04501783,NA,8/5/2020,NA,NA,8/5/2020,8/5/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2020,8/6/2020,Actual,20-May-20,Actual,5/20/2020,Aug-20,8/31/2020,Aug-20,Anticipated,8/31/2020,29-Jul-20,Actual,7/29/2020,NA,Interventional,NA,NA,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2/COVID-19),"Active, not recruiting",NA,Phase 3,168,Anticipated,R-Pharm,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:32Z,2021-10-12T06:59:32Z
NCT04502472,NA,8/4/2020,NA,NA,8/4/2020,8/4/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2020,8/6/2020,Actual,6-Jun-20,Actual,6/6/2020,Jul-20,7/31/2020,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,Inova-CCP,NA,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2),Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Inova Health Care Services,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:28Z,2021-10-12T06:59:28Z
NCT04502433,NA,8/3/2020,NA,NA,8/3/2021,8/5/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/6/2021,Actual,6-Jan-21,Actual,1/6/2021,Aug-21,8/31/2021,31-Jan-22,Anticipated,1/31/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19),"Multicenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, CurosurfÂ®) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS)",Recruiting,NA,Phase 2,70,Anticipated,Chiesi Farmaceutici S.p.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:26Z,2021-10-12T06:59:26Z
NCT04501965,NA,8/3/2020,NA,NA,8/5/2020,8/4/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2020,8/7/2020,Actual,1-Jun-20,Actual,6/1/2020,Jul-20,7/31/2020,30-Sep-20,Anticipated,9/30/2020,30-Aug-20,Anticipated,8/30/2020,NA,Interventional,PHYTCOVID-19,NA,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,"Evaluation de l'efficacitÃ© et de la tolÃ©rance de Quinquina et d'un phytomÃ©dicament "" ACAR "" en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptÃ´mes",Enrolling by invitation,NA,Phase 2,231,Actual,Institute for Research and Development of Medicinal and Food Plants of Guinea,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The data could be available from september 30th to december 30th,partnership framework established,NA,Yes,"The samples stored in the biobank could be shared with other researchers with a view to in-depth analyzes in order to dig for example a posteriori on the hypotheses relating to the blood levels of the phytomedicine, hydroxychloroquine, etc., cardio-metabolic biological markers infarction, insulin sensitivity, thrombosis, specific antibodies, genetic markers, viral markers ...",2021-10-12T06:59:30Z,2021-10-12T06:59:30Z
NCT04500067,NA,7/15/2020,NA,NA,10/12/2020,8/4/2020,8/5/2020,Actual,NA,NA,NA,NA,NA,NA,10/12/2020,10/14/2020,Actual,7-May-20,Actual,5/7/2020,Oct-20,10/31/2020,15-Sep-20,Actual,9/15/2020,15-Sep-20,Actual,9/15/2020,NA,Interventional,NA,NA,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment","An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2",Completed,NA,Phase 3,76,Actual,Biopharma Plasma LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After trial result publication 3 months later,"For specialists in medicine, pharmacy, scientists",NA,Yes,"After completion of the trial, results will be published. Access to parts CSR planned after the release of scientific publications",2021-10-12T06:59:45Z,2021-10-12T06:59:45Z
NCT04499391,NA,7/31/2020,NA,NA,8/10/2021,8/3/2020,8/5/2020,Actual,NA,NA,NA,NA,NA,NA,8/10/2021,8/11/2021,Actual,4-Dec-20,Actual,12/4/2020,Aug-21,8/31/2021,Jul-22,Anticipated,7/31/2022,Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,COVID-19 Project ECHO in Nursing Homes,"COVID-19 Project ECHO for Nursing Homes: A Patient-centered, Randomized-controlled Trial to Implement Infection Control and Quality of Life Best Practice",Recruiting,NA,Not Applicable,136,Anticipated,Milton S. Hershey Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:51Z,2021-10-12T06:59:51Z
NCT04501445,NA,8/4/2020,NA,NA,9/15/2021,8/5/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,9/15/2021,9/16/2021,Actual,14-Sep-20,Actual,9/14/2020,Sep-21,9/30/2021,31-Jul-21,Actual,7/31/2021,8-Apr-21,Actual,4/8/2021,NA,Interventional,NA,NA,Psychological Symptoms and Families of COVID-19 Patients,Relieving the Burden of Psychological Symptoms Among Families of Critically Ill Patients With COVID-19,Completed,NA,Not Applicable,90,Actual,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:59:34Z,2021-10-12T06:59:34Z
NCT04500418,NA,8/4/2020,NA,NA,8/25/2020,8/4/2020,8/5/2020,Actual,NA,NA,NA,NA,NA,NA,8/25/2020,8/26/2020,Actual,25-Aug-20,Actual,8/25/2020,Aug-20,8/31/2020,30-Sep-21,Anticipated,9/30/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Recruiting,NA,Phase 2,183,Anticipated,"Charite University, Berlin, Germany",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Undecided at this moment. (08/2020),2021-10-12T06:59:46Z,2021-10-12T06:59:46Z
NCT04497623,NA,7/27/2020,NA,NA,9/22/2020,8/1/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,9/22/2020,9/24/2020,Actual,28-Jul-20,Actual,7/28/2020,Sep-20,9/30/2020,20-Sep-20,Actual,9/20/2020,13-Aug-20,Actual,8/13/2020,NA,Interventional,SabanaHerons,NA,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.","Clinical Evaluation of Ventilator Innovation Product in Colombia in the SARS Pandemic Covid 19, Unisabana Herons - A Cohort Study - Phase 1",Completed,NA,Not Applicable,5,Actual,FundaciÃ³n Neumologica Colombiana,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The clinical and ventilatory data of the patients will be entered into an anonymized database hosted on the RedCap platform with which the University of La Sabana has an agreement.,2021-10-12T07:00:05Z,2021-10-12T07:00:05Z
NCT04499313,NA,7/27/2020,NA,NA,8/17/2020,8/4/2020,8/5/2020,Actual,NA,NA,NA,NA,NA,NA,8/17/2020,8/18/2020,Actual,2-Aug-20,Actual,8/2/2020,Aug-20,8/31/2020,30-Nov-20,Anticipated,11/30/2020,15-Nov-20,Anticipated,11/15/2020,NA,Interventional,NA,NA,Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19,Recruiting,NA,Phase 3,60,Anticipated,Chattogram General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:53Z,2021-10-12T06:59:53Z
NCT04501458,NA,8/5/2020,NA,NA,9/21/2021,8/5/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/22/2021,Actual,10-Aug-20,Actual,8/10/2020,Sep-21,9/30/2021,10-Jun-22,Anticipated,6/10/2022,10-Jun-22,Anticipated,6/10/2022,NA,Interventional,NA,NA,Western Kenya Integrated COVID-19 Response,"Western Kenya Integrated COVID-19 Response Leveraging the Community Health Strategy, Youth, and Technology to Flatten the COVID-19 Curve and Improve COVID-19 Case Detection, Isolation and Management in Western Kenya","Active, not recruiting",NA,Not Applicable,200000,Anticipated,Surgical Systems Research Group,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately following publication; indefinitely.,Anyone with an approved proposal who wishes to access the data.,NA,Yes,De-identified participant data will be available when results are reported.,2021-10-12T06:59:34Z,2021-10-12T06:59:34Z
NCT04500132,NA,8/4/2020,NA,NA,8/5/2020,8/4/2020,8/5/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2020,8/6/2020,Actual,28-May-20,Actual,5/28/2020,Aug-20,8/31/2020,May-22,Anticipated,5/31/2022,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,"Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia",Recruiting,NA,Phase 2,60,Anticipated,Enzychem Lifesciences Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:46Z,2021-10-12T06:59:46Z
NCT04497298,NA,7/31/2020,NA,NA,7/6/2021,8/3/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,7/6/2021,7/9/2021,Actual,10-Aug-20,Actual,8/10/2020,Jul-21,7/31/2021,12-May-21,Actual,5/12/2021,12-May-21,Actual,5/12/2021,NA,Interventional,COVID-19-101,NA,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase",Completed,NA,Phase 1,90,Actual,Institut Pasteur,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:09Z,2021-10-12T07:00:09Z
NCT04381988,NA,5/8/2020,10/25/2021,NA,10/25/2021,5/8/2020,5/11/2020,Actual,10/25/2021,10/27/2021,Actual,NA,NA,NA,10/25/2021,10/27/2021,Actual,7-May-20,Actual,5/7/2020,Apr-21,4/30/2021,21-Apr-21,Actual,4/21/2021,21-Apr-21,Actual,4/21/2021,NA,Interventional,NA,The study was terminated before more participants were accrued.,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID),Terminated,NA,Phase 2,4,Actual,Memorial Sloan Kettering Cancer Center,,2,NA,The study was terminated based results of other studies and use of the new vaccine.,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-12-04T22:58:18Z,2021-12-04T22:58:18Z
NCT04498442,NA,8/3/2020,NA,NA,9/23/2021,8/3/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/24/2021,Actual,22-May-20,Actual,5/22/2020,Sep-21,9/30/2021,22-Oct-20,Actual,10/22/2020,22-Oct-20,Actual,10/22/2020,NA,Interventional,NA,NA,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls","A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Completed,NA,Not Applicable,8519,Actual,Beth Israel Deaconess Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:57Z,2021-10-12T06:59:57Z
NCT04497389,NA,6/9/2020,NA,NA,11/4/2020,8/3/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,11/4/2020,11/6/2020,Actual,28-Oct-20,Actual,10/28/2020,Nov-20,11/30/2020,15-Sep-21,Anticipated,9/15/2021,15-Sep-21,Anticipated,9/15/2021,NA,Interventional,NA,NA,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,A Phase I/II Randomized Double-blinded Placebo-controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:09Z,2021-10-12T07:00:09Z
NCT04497987,NA,7/31/2020,NA,NA,7/2/2021,7/31/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,7/2/2021,7/6/2021,Actual,2-Aug-20,Actual,8/2/2020,Jul-21,7/31/2021,20-May-21,Actual,5/20/2021,16-Jan-21,Actual,1/16/2021,NA,Interventional,BLAZE-2,NA,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination With LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study",Completed,NA,Phase 3,1374,Actual,Eli Lilly and Company,,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2021-10-12T07:00:03Z,2021-10-12T07:00:03Z
NCT04496245,NA,7/26/2020,NA,NA,9/8/2021,7/31/2020,8/3/2020,Actual,NA,NA,NA,NA,NA,NA,9/8/2021,9/9/2021,Actual,24-Aug-20,Actual,8/24/2020,Sep-21,9/30/2021,30-Sep-21,Anticipated,9/30/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,COVIDRASP,NA,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,"Active, not recruiting",NA,Phase 3,59,Actual,The University of Queensland,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:17Z,2021-10-12T07:00:17Z
NCT04498936,NA,4/14/2020,NA,NA,11/10/2020,8/3/2020,8/5/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2020,11/12/2020,Actual,15-Jul-20,Actual,7/15/2020,Nov-20,11/30/2020,30-Oct-20,Actual,10/30/2020,30-Oct-20,Actual,10/30/2020,NA,Interventional,NA,NA,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial",Completed,NA,Phase 4,240,Actual,Assiut University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:54Z,2021-10-12T06:59:54Z
NCT04497649,NA,8/1/2020,NA,NA,12/2/2020,8/1/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2020,12/3/2020,Actual,1-Jul-20,Actual,7/1/2020,Dec-20,12/31/2020,10-Apr-21,Anticipated,4/10/2021,1-Apr-21,Anticipated,4/1/2021,NA,Interventional,NA,NA,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients: A Randomized Controlled Trial.,Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:08Z,2021-10-12T07:00:08Z
NCT04495543,NA,7/23/2020,NA,NA,12/22/2020,7/28/2020,8/3/2020,Actual,NA,NA,NA,NA,NA,NA,12/22/2020,12/24/2020,Actual,1-Dec-20,Actual,12/1/2020,Dec-20,12/31/2020,Aug-21,Anticipated,8/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living',"Mitigating Suicide Risk During the COVID-19 Pandemic Via Telehealth Using an Intensive Single Session of ""Brief Skills for Safer Living""",Recruiting,NA,Not Applicable,75,Anticipated,Unity Health Toronto,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:25Z,2021-10-12T07:00:25Z
NCT04497454,NA,7/31/2020,NA,NA,7/31/2020,7/31/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,7/31/2020,8/4/2020,Actual,8-May-20,Actual,5/8/2020,Jul-20,7/31/2020,1-Dec-21,Anticipated,12/1/2021,1-Jul-21,Anticipated,7/1/2021,NA,Interventional,COVEN,NA,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19) - COVEN Study,Recruiting,NA,Not Applicable,128,Anticipated,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:07Z,2021-10-12T07:00:07Z
NCT04495933,NA,7/13/2020,NA,NA,8/23/2021,7/31/2020,8/3/2020,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/27/2021,Actual,13-Jul-20,Actual,7/13/2020,Aug-21,8/31/2021,2-Feb-22,Anticipated,2/2/2022,6-Nov-21,Anticipated,11/6/2021,NA,Interventional,NA,NA,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults","A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over","Active, not recruiting",NA,Phase 1,216,Actual,The University of Queensland,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,"Immediately following publication, no end date",Available only to achieve the aims in the approved proposal,NA,Yes,individual participant data underlying published results only on a case-by-case basis at the discretion of Primary Sponsor,2021-10-12T07:00:22Z,2021-10-12T07:00:22Z
NCT04497272,NA,8/3/2020,NA,NA,9/13/2021,8/3/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,9/13/2021,9/14/2021,Actual,7-Aug-20,Actual,8/7/2020,Nov-20,11/30/2020,7-Oct-21,Anticipated,10/7/2021,7-Aug-21,Actual,8/7/2021,NA,Interventional,SignCov,NA,Assesment of the Metabolomic Signature in COVID-19 Patients,Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study),"Active, not recruiting",NA,Not Applicable,150,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:10Z,2021-10-12T07:00:10Z
NCT04494867,NA,7/29/2020,NA,NA,9/23/2020,7/29/2020,7/31/2020,Actual,NA,NA,NA,NA,NA,NA,9/23/2020,9/25/2020,Actual,19-Aug-20,Actual,8/19/2020,Sep-20,9/30/2020,Dec-20,Anticipated,12/31/2020,Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,"Core Warming of COVID-19 Patients Undergoing Mechanical Ventilation: a Randomized, Single Center Pilot Study",Recruiting,NA,Not Applicable,20,Anticipated,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:34Z,2021-10-12T07:00:34Z
NCT04495803,NA,7/30/2020,NA,NA,3/15/2021,7/30/2020,8/3/2020,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,1-Sep-20,Actual,9/1/2020,Mar-21,3/31/2021,1-Aug-22,Anticipated,8/1/2022,1-Aug-22,Anticipated,8/1/2022,NA,Interventional,NA,NA,Augmented CBGT for Perinatal Anxiety During a Global Pandemic (COVID-19),Augmented Cognitive Behavioural Group Therapy for Perinatal Anxiety During a Global Pandemic (COVID-19),Recruiting,NA,Not Applicable,120,Anticipated,St. Joseph's Healthcare Hamilton,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:23Z,2021-10-12T07:00:23Z
NCT04495101,NA,7/28/2020,NA,NA,7/7/2021,7/30/2020,7/31/2020,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/8/2021,Actual,29-Jul-20,Actual,7/29/2020,Jul-21,7/31/2021,10-Jun-21,Actual,6/10/2021,26-Apr-21,Actual,4/26/2021,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:27Z,2021-10-12T07:00:27Z
NCT04494984,NA,7/29/2020,NA,NA,2/9/2021,7/30/2020,7/31/2020,Actual,NA,NA,NA,NA,NA,NA,2/9/2021,2/11/2021,Actual,27-Jul-20,Actual,7/27/2020,Feb-21,2/28/2021,30-Dec-20,Actual,12/30/2020,23-Nov-20,Actual,11/23/2020,NA,Interventional,NA,NA,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","A Stage 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV2 Disease.",Completed,NA,Phase 2/Phase 3,242,Actual,Inmunova S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:29Z,2021-10-12T07:00:29Z
NCT04495842,NA,7/30/2020,NA,NA,7/27/2021,7/31/2020,8/3/2020,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,8/2/2021,Actual,1-Oct-20,Actual,10/1/2020,Jul-21,7/31/2021,31-Mar-22,Anticipated,3/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,The Effect of Aromatherapy on COVID-19-induced Anxiety,The Effect of Aromatherapy on COVID-19-induced Anxiety,Recruiting,NA,Not Applicable,100,Anticipated,Franklin School of Integrative Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:22Z,2021-10-12T07:00:22Z
NCT04494646,NA,7/29/2020,NA,NA,5/11/2021,7/29/2020,7/31/2020,Actual,NA,NA,NA,NA,NA,NA,5/11/2021,5/12/2021,Actual,8-Sep-20,Actual,9/8/2020,May-21,5/31/2021,8-Jan-21,Actual,1/8/2021,8-Jan-21,Actual,1/8/2021,NA,Interventional,NA,NA,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),"BARCONA: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)",Completed,NA,Phase 2,40,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Sripal.Bangalore@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices) will be shared upon reasonable request.",2021-10-12T07:00:34Z,2021-10-12T07:00:34Z
NCT04494724,NA,7/21/2020,NA,NA,7/30/2020,7/30/2020,7/31/2020,Actual,NA,NA,NA,NA,NA,NA,7/30/2020,7/31/2020,Actual,13-Jul-20,Actual,7/13/2020,Jul-20,7/31/2020,31-Jul-21,Anticipated,7/31/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Clazakizumab vs. Placebo - COVID-19 Infection,A Phase 2 Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection,Recruiting,NA,Phase 2,60,Anticipated,The Methodist Hospital Research Institute,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:34Z,2021-10-12T07:00:34Z
NCT04489446,NA,7/25/2020,NA,NA,9/27/2021,7/25/2020,7/28/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/29/2021,Actual,19-Aug-20,Actual,8/19/2020,Sep-21,9/30/2021,30-Jun-21,Actual,6/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,NA,NA,Sildenafil in COVID-19,Sildenafil for Treating Patients With COVID-19 and Perfusion Mismatch: A Pilot Randomised Trial,Completed,NA,Phase 1/Phase 2,40,Actual,Universidad Nacional Andres Bello,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:15Z,2021-10-12T07:01:15Z
NCT04494204,NA,7/28/2020,NA,NA,12/19/2020,7/30/2020,7/31/2020,Actual,NA,NA,NA,NA,NA,NA,12/19/2020,12/22/2020,Actual,7-Aug-20,Actual,8/7/2020,Dec-20,12/31/2020,20-Dec-20,Actual,12/20/2020,1-Dec-20,Actual,12/1/2020,NA,Interventional,NA,NA,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,"An Open Label, Multicenter, Randomized, Controlled, Clinical Study to Evaluate the Efficacy and Safety of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets Compared With Standard Treatment Protocol in the Treatment of Mild to Moderate COVID-19 Patients.",Completed,NA,Phase 2/Phase 3,100,Actual,Nutrin GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"The trial is meant for pandemic, and any data is fruitful to the society will be shared with researchers only, without compromising personal data of the participant.",2021-10-12T07:00:39Z,2021-10-12T07:00:39Z
NCT04494399,NA,7/28/2020,NA,NA,7/29/2020,7/29/2020,7/31/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2020,7/31/2020,Actual,29-Jul-20,Actual,7/29/2020,Jul-20,7/31/2020,1-Aug-22,Anticipated,8/1/2022,1-Jul-22,Anticipated,7/1/2022,NA,Interventional,NA,NA,IFN Beta-1b and Ribavirin for Covid-19,"An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection",Recruiting,NA,Phase 2,96,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:39Z,2021-10-12T07:00:39Z
NCT04494386,NA,7/24/2020,NA,NA,3/8/2021,7/29/2020,7/31/2020,Actual,NA,NA,NA,NA,NA,NA,3/8/2021,3/9/2021,Actual,23-Jul-20,Actual,7/23/2020,Mar-21,3/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,ULSC,NA,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,"Restem, LLC.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:39Z,2021-10-12T07:00:39Z
NCT04492514,NA,7/28/2020,NA,NA,7/28/2020,7/28/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,7/28/2020,7/30/2020,Actual,20-May-20,Actual,5/20/2020,Jul-20,7/31/2020,31-May-21,Anticipated,5/31/2021,31-May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Recruiting,NA,Phase 2,60,Anticipated,University of Cincinnati,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:52Z,2021-10-12T07:00:52Z
NCT04492358,NA,7/28/2020,NA,NA,11/5/2020,7/29/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,11/5/2020,11/9/2020,Actual,22-Oct-20,Actual,10/22/2020,Jul-20,7/31/2020,Oct-21,Anticipated,10/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center","Phase 2/3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",Recruiting,NA,Phase 2/Phase 3,144,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:55Z,2021-10-12T07:00:55Z
NCT04493359,NA,7/29/2020,NA,NA,9/28/2021,7/29/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,10/6/2021,Actual,25-Jul-20,Actual,7/25/2020,Sep-21,9/30/2021,28-Sep-21,Actual,9/28/2021,28-Sep-21,Actual,9/28/2021,NA,Interventional,SWITCH-COVID,NA,Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19,Switch or Maintenance of Renin-Angiotensin System Inhibitors in Patients With Covid-19: A Randomized Proof of Concept Trial,Terminated,NA,Phase 2/Phase 3,18,Actual,University of Sao Paulo,,2,NA,Dificulteis in enrolling patients,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,Data may be requested for collaboration projects,2021-10-12T07:00:47Z,2021-10-12T07:00:47Z
NCT04489628,NA,7/24/2020,NA,NA,9/28/2021,7/24/2020,7/28/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,10/6/2021,Actual,1-Aug-20,Actual,8/1/2020,Sep-21,9/30/2021,1-Jun-21,Actual,6/1/2021,1-Jun-21,Actual,6/1/2021,NA,Interventional,NA,NA,Tele-health Enabled Clinical Trial for COVID-19,Tele-health Enabled Clinical Trial for COVID-19: Vitamin D as an Immunomodulator to Prevent Complications and Reduce Resource Utilization in Outpatients,Terminated,NA,Phase 1/Phase 2,110,Actual,University Hospitals Cleveland Medical Center,,2,NA,Unable to overcome hurdles to study recruitment,FALSE,NA,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:15Z,2021-10-12T07:01:15Z
NCT04490200,NA,7/19/2020,NA,NA,3/1/2021,7/23/2020,7/29/2020,Actual,NA,NA,NA,NA,NA,NA,3/1/2021,3/3/2021,Actual,1-Mar-21,Actual,3/1/2021,Mar-21,3/31/2021,15-Feb-22,Anticipated,2/15/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,Effectiveness of a Novel Respirator With Chitosan Nanoparticles,Effectiveness of a Novel Respirator With Chitosan Nanoparticles to Reduce the Incidence of SARS-CoV-2 Infection in Healthcare Professionals: Randomized Controlled Trial (VESTA Trial),Recruiting,NA,Not Applicable,1000,Anticipated,University of Brasilia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:11Z,2021-10-12T07:01:11Z
NCT04490473,NA,7/25/2020,NA,NA,12/22/2020,7/28/2020,7/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/22/2020,12/23/2020,Actual,24-Jul-20,Actual,7/24/2020,Dec-20,12/31/2020,24-Apr-21,Anticipated,4/24/2021,24-Mar-21,Anticipated,3/24/2021,NA,Interventional,NA,NA,Turkish of the SARS-CoV-2 Anxiety Scale,Turkish Validity And Reliability of the SARS-CoV-2 Anxiety Scale,Recruiting,NA,Not Applicable,300,Anticipated,Eskisehir Osmangazi University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,will be shared after the work is finished.,It will be shared with researchers who want to use the anxiety scale.,NA,Yes,It is planned to be published in the journal after the study is completed. The study will be shared with other researchers after it is published in the journal.,2021-10-12T07:01:08Z,2021-10-12T07:01:08Z
NCT04492410,NA,7/28/2020,NA,NA,6/9/2021,7/29/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/10/2021,Actual,21-Jul-20,Actual,7/21/2020,Jun-21,6/30/2021,Nov-21,Anticipated,11/30/2021,12-May-21,Actual,5/12/2021,NA,Interventional,NEOSCREENCOVID,NA,COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),"Active, not recruiting",NA,Not Applicable,500,Anticipated,Centre Antoine Lacassagne,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:54Z,2021-10-12T07:00:54Z
NCT04492228,NA,7/25/2020,NA,NA,9/28/2020,7/29/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2020,9/30/2020,Actual,1-Sep-20,Actual,9/1/2020,Sep-20,9/30/2020,30-May-21,Anticipated,5/30/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,ketocovidiet,NA,Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,Randomized Open Controlled Clinical Trial to Evaluate the Effectiveness of a Eucaloric Ketogenic Nutrition in Comparison With a Standard Nutrition in Covid-19 Disease in Reducing Cytokine Storm Syndrome and ARDS,Recruiting,NA,Not Applicable,100,Anticipated,Ospedale Policlinico San Martino,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:55Z,2021-10-12T07:00:55Z
NCT04492254,NA,7/22/2020,NA,NA,4/13/2021,7/29/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/13/2021,4/19/2021,Actual,15-Sep-20,Actual,9/15/2020,Apr-21,4/30/2021,Sep-21,Anticipated,9/30/2021,Jul-21,Anticipated,7/31/2021,NA,Interventional,ETHIC,NA,Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients,"Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients",Recruiting,NA,Phase 3,1370,Anticipated,Thrombosis Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:54Z,2021-10-12T07:00:54Z
NCT04490278,NA,7/23/2020,NA,NA,10/4/2021,7/23/2020,7/29/2020,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/6/2021,Actual,29-Sep-20,Actual,9/29/2020,Oct-21,10/31/2021,30-Jun-21,Actual,6/30/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,NA,NA,CoV-PICS: A Virtual Post-ICU Clinic,"COVID-19 Virtual Post Intensive Care Syndrome (CoV-PICS) Clinic: Modern, Convenient and Practical Recovery Care",Completed,NA,Not Applicable,23,Actual,Washington University School of Medicine,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:11Z,2021-10-12T07:01:11Z
NCT04487691,NA,7/23/2020,NA,NA,3/15/2021,7/24/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,8-Dec-20,Actual,12/8/2020,Mar-21,3/31/2021,30-Dec-21,Anticipated,12/30/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,Nebulized PL for Post-COVID-19 Syndrome,Autologous Nebulized Platelet Lysate for Post COVID-19 Syndrome,"Active, not recruiting",NA,Not Applicable,1,Actual,"Regenexx, LLC",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:27Z,2021-10-12T07:01:27Z
NCT04492501,NA,7/28/2020,NA,NA,7/28/2020,7/28/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,7/28/2020,7/30/2020,Actual,1-Apr-20,Actual,4/1/2020,Jul-20,7/31/2020,20-Jul-20,Actual,7/20/2020,20-Jul-20,Actual,7/20/2020,NA,Interventional,NA,NA,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,"Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19",Completed,NA,Not Applicable,600,Actual,UNICEF,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months from completion of study,email,NA,Yes,data can be shared on demand in SPSS sheet,2021-10-12T07:00:55Z,2021-10-12T07:00:55Z
NCT04490824,NA,7/27/2020,NA,NA,2/9/2021,7/27/2020,7/29/2020,Actual,NA,NA,NA,NA,NA,NA,2/9/2021,2/12/2021,Actual,1-Oct-20,Actual,10/1/2020,Sep-20,9/30/2020,30-Apr-21,Anticipated,4/30/2021,30-Mar-21,Anticipated,3/30/2021,NA,Interventional,NA,NA,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Can Inhalation of KELEA Excellerated Water Reduce the Time Required for Covid-19 Infected Individuals to Become Symptom-Free and to Test Negative Using Either the PCR or Antigen Assay,Recruiting,NA,Not Applicable,100,Anticipated,Institute of Progressive Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:06Z,2021-10-12T07:01:06Z
NCT04492527,NA,7/28/2020,NA,NA,8/26/2021,7/28/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/30/2021,Actual,28-Jul-20,Actual,7/28/2020,Aug-21,8/31/2021,30-Jun-21,Actual,6/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,NA,NA,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,A Student-delivered Community Outreach teleheAlth Program for Covid Education and Health Promotion (COACH),Completed,NA,Not Applicable,75,Actual,University of British Columbia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:55Z,2021-10-12T07:00:55Z
NCT04490850,NA,7/28/2020,NA,NA,8/24/2021,7/28/2020,7/29/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/25/2021,Actual,15-Jul-20,Actual,7/15/2020,Aug-21,8/31/2021,15-Dec-21,Anticipated,12/15/2021,15-Dec-21,Anticipated,12/15/2021,NA,Interventional,EPI-COVID-POP,NA,COVID-19 Seroprevalence Study in French Guiana,COVID-19 Seroprevalence Study in French Guiana,Recruiting,NA,Not Applicable,1500,Anticipated,Institut Pasteur,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:06Z,2021-10-12T07:01:06Z
NCT04488796,NA,7/22/2020,NA,NA,4/6/2021,7/26/2020,7/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/6/2021,4/8/2021,Actual,7-Sep-20,Actual,9/7/2020,Apr-21,4/30/2021,16-Dec-20,Actual,12/16/2020,16-Dec-20,Actual,12/16/2020,NA,Interventional,NA,NA,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,"STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers, a Pilot Randomized Controlled Trial",Completed,NA,Not Applicable,148,Actual,"Western University, Canada",,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:19Z,2021-10-12T07:01:19Z
NCT04488081,NA,7/14/2020,NA,NA,7/19/2021,7/24/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/21/2021,Actual,31-Jul-20,Actual,7/31/2020,Jul-21,7/31/2021,1-Nov-22,Anticipated,11/1/2022,24-Jul-22,Anticipated,7/24/2022,NA,Interventional,I-SPY_COVID,NA,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients,Recruiting,NA,Phase 2,1500,Anticipated,QuantumLeap Healthcare Collaborative,,7,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Post publication or earlier if warranted.,Sharing criteria are based on the circumstances of the request and whether the data have been published.,NA,Yes,We will share data on a case by case basis with appropriate IRB review and review by our Data Safety Monitoring Comittee.,2021-10-12T07:01:24Z,2021-10-12T07:01:24Z
NCT04483960,NA,7/22/2020,NA,NA,8/20/2021,7/22/2020,7/23/2020,Actual,NA,NA,NA,NA,NA,NA,8/20/2021,8/25/2021,Actual,28-Jul-20,Actual,7/28/2020,Aug-21,8/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,ASCOT ADAPT,NA,Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial,"A Multi-centre Randomised Adaptive Platform Clinical Trial to Assess Clinical, Virological and Immunological Outcomes in Patients With SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 3,2400,Anticipated,University of Melbourne,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:56Z,2021-10-12T07:01:56Z
NCT04487210,NA,7/22/2020,NA,NA,8/2/2021,7/22/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/4/2021,Actual,7-Oct-20,Actual,10/7/2020,Aug-21,8/31/2021,30-Dec-21,Anticipated,12/30/2021,1-Jun-21,Actual,6/1/2021,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,"A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901","Active, not recruiting",NA,Phase 1,45,Actual,Medigen Vaccine Biologics Corp.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:30Z,2021-10-12T07:01:30Z
NCT04485169,NA,7/21/2020,NA,NA,9/24/2020,7/22/2020,7/24/2020,Actual,NA,NA,NA,NA,NA,NA,9/24/2020,9/28/2020,Actual,1-Apr-20,Actual,4/1/2020,Sep-20,9/30/2020,31-Jul-20,Actual,7/31/2020,31-Jul-20,Actual,7/31/2020,NA,Interventional,Plex,NA,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; a Retrospective Propensity Matched Control Study,Completed,NA,Not Applicable,280,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data is available right now and will remain available (6 months),By email,NA,Yes,data can be shared on demand in SPSS sheet,2021-10-12T07:01:45Z,2021-10-12T07:01:45Z
NCT04486508,NA,7/22/2020,NA,NA,8/14/2021,7/22/2020,7/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/14/2021,8/17/2021,Actual,30-Jul-20,Actual,7/30/2020,Aug-21,8/31/2021,5-Jul-21,Actual,7/5/2021,4-Apr-21,Actual,4/4/2021,NA,Interventional,INSPIRATION,NA,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19,Completed,NA,Phase 3,600,Actual,Rajaie Cardiovascular Medical and Research Center,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:35Z,2021-10-12T07:01:35Z
NCT04487964,NA,7/24/2020,NA,NA,7/25/2020,7/24/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,7/25/2020,7/28/2020,Actual,1-Jan-20,Actual,1/1/2020,Jul-20,7/31/2020,Jan-21,Anticipated,1/31/2021,1-Dec-20,Anticipated,12/1/2020,NA,Interventional,NA,NA,Complementary Intervention for COVID-19,Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine,Recruiting,NA,Not Applicable,70,Anticipated,Egyptian Biomedical Research Network,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"A pilot study for evaluation of the potential therapeutic effect of food supplement, licorice extract, and Boswellia Serrata gum",2021-10-12T07:01:27Z,2021-10-12T07:01:27Z
NCT04486313,NA,7/23/2020,NA,NA,3/31/2021,7/23/2020,7/24/2020,Actual,NA,NA,NA,NA,NA,NA,3/31/2021,4/1/2021,Actual,13-Aug-20,Actual,8/13/2020,Mar-21,3/31/2021,8-Feb-21,Actual,2/8/2021,8-Feb-21,Actual,2/8/2021,NA,Interventional,NA,NA,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19",Completed,NA,Phase 3,1092,Actual,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:37Z,2021-10-12T07:01:37Z
NCT04487574,NA,7/22/2020,NA,NA,11/11/2020,7/24/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2020,11/13/2020,Actual,25-Jul-20,Actual,7/25/2020,Nov-20,11/30/2020,29-Oct-20,Actual,10/29/2020,29-Oct-20,Actual,10/29/2020,NA,Interventional,NA,NA,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,"A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19",Completed,NA,Phase 3,118,Actual,RSV Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:31Z,2021-10-12T07:01:31Z
NCT04487990,NA,7/23/2020,NA,NA,5/14/2021,7/24/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2021,5/17/2021,Actual,29-Jun-20,Actual,6/29/2020,Apr-21,4/30/2021,Aug-21,Anticipated,8/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,NA,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,CoV-Hep Study: Randomized and Paired Clinical Trial Comparing Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,"Active, not recruiting",NA,Not Applicable,118,Actual,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:25Z,2021-10-12T07:01:25Z
NCT04486001,NA,7/22/2020,NA,NA,1/29/2021,7/23/2020,7/24/2020,Actual,NA,NA,NA,NA,NA,NA,1/29/2021,2/2/2021,Actual,15-Dec-20,Actual,12/15/2020,Jan-21,1/31/2021,15-Jan-22,Anticipated,1/15/2022,15-Jan-22,Anticipated,1/15/2022,NA,Interventional,CoronaStem1,NA,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,COVID-19 Stem Cell Therapy: A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem Cells,Recruiting,NA,Phase 1,20,Anticipated,"Sorrento Therapeutics, Inc.",,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:38Z,2021-10-12T07:01:38Z
NCT04487639,NA,7/21/2020,NA,NA,7/23/2020,7/23/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,7/23/2020,7/27/2020,Actual,10-Jul-20,Actual,7/10/2020,Jul-20,7/31/2020,Jul-21,Anticipated,7/31/2021,Jul-21,Anticipated,7/31/2021,NA,Interventional,FERTICOVID,NA,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients During the COVID-19 Pandemic ?,Recruiting,NA,Not Applicable,250,Anticipated,"University Hospital, Clermont-Ferrand",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:28Z,2021-10-12T07:01:28Z
NCT04484493,NA,7/22/2020,NA,NA,11/11/2020,7/22/2020,7/23/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2020,11/13/2020,Actual,8-Aug-20,Actual,8/8/2020,Nov-20,11/30/2020,3-Nov-20,Actual,11/3/2020,25-Oct-20,Actual,10/25/2020,NA,Interventional,NA,NA,Corticosteroid Nasal Spray in COVID-19 Anosmia,Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients,Completed,NA,Phase 3,100,Actual,Benha University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:50Z,2021-10-12T07:01:50Z
NCT04488484,NA,7/20/2020,NA,NA,8/19/2021,7/27/2020,7/28/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/20/2021,Actual,1-Jul-20,Actual,7/1/2020,Aug-21,8/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,PERSO-COVID,NA,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group,"Active, not recruiting",NA,Not Applicable,450,Anticipated,Groupe Hospitalier Paris Saint Joseph,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:24Z,2021-10-12T07:01:24Z
NCT04485130,NA,7/22/2020,NA,NA,5/5/2021,7/22/2020,7/24/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/10/2021,Actual,1-May-21,Actual,5/1/2021,May-21,5/31/2021,30-Apr-22,Anticipated,4/30/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,DISCO,NA,DISulfiram for COvid-19 (DISCO) Trial,"DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19",Recruiting,NA,Phase 2,60,Anticipated,"University of California, San Francisco",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,After publication of study results,De-identified data,NA,Yes,Planned sharing of de-identified individual participant data for the purposes of collaboration and meta-analyses.,2021-10-12T07:01:45Z,2021-10-12T07:01:45Z
NCT04487886,NA,7/23/2020,NA,NA,12/11/2020,7/23/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,12/11/2020,12/16/2020,Actual,18-Nov-20,Actual,11/18/2020,Dec-20,12/31/2020,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,DAMPEN-CI,NA,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection,Recruiting,NA,Phase 2,80,Anticipated,Emory University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will be made available for sharing at the conclusion of the study and will be available for one year.,Data will be available for sharing with academic or pharmaceutical investigators for analyses including comparison of DAMPEN-CI results with those from other drug trials in similar patient cohorts. Researchers wishing to use data should email the investigators of DAMPEN-Cl. A summary of the research plan will be required prior to release of the DAMPEN-CI data.,NA,Yes,"The researchers plan to share individual participant data including participant status ordinal score at baseline and end of treatment, study drug allocation, duration of treatment, and survival status at Day 60.",2021-10-12T07:01:27Z,2021-10-12T07:01:27Z
NCT04483752,NA,7/21/2020,NA,NA,8/6/2021,7/22/2020,7/23/2020,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/9/2021,Actual,8-Jun-20,Actual,6/8/2020,Aug-21,8/31/2021,24-Dec-22,Anticipated,12/24/2022,24-Dec-21,Anticipated,12/24/2021,NA,Interventional,PREDISCAN,NA,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Recruiting,NA,Not Applicable,100,Anticipated,Centre Chirurgical Marie Lannelongue,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:58Z,2021-10-12T07:01:58Z
NCT04487444,NA,7/22/2020,NA,NA,9/14/2021,7/24/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/16/2021,Actual,10-Sep-20,Actual,9/10/2020,Sep-21,9/30/2021,Jun-22,Anticipated,6/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,Ta1,NA,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,A Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With Lymphocytopenia,Recruiting,NA,Phase 2,80,Anticipated,Rhode Island Hospital,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:30Z,2021-10-12T07:01:30Z
NCT04487171,NA,7/24/2020,NA,NA,7/24/2020,7/24/2020,7/27/2020,Actual,NA,NA,NA,NA,NA,NA,7/24/2020,7/27/2020,Actual,21-Jul-20,Actual,7/21/2020,Jul-20,7/31/2020,Aug-21,Anticipated,8/31/2021,Jul-21,Anticipated,7/31/2021,NA,Interventional,COVIE-19/20,NA,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Recruiting,NA,Not Applicable,248,Anticipated,"Centre Hospitalier Universitaire, Amiens",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:30Z,2021-10-12T07:01:30Z
NCT04483830,NA,7/22/2020,NA,NA,9/7/2020,7/22/2020,7/23/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2020,9/9/2020,Actual,5-Jun-20,Actual,6/5/2020,Sep-20,9/30/2020,7-Sep-20,Actual,9/7/2020,6-Aug-20,Actual,8/6/2020,NA,Interventional,SulES-COVID,NA,Suloexide in the Treatment of Early Stages of COVID-19,Sulodexide in the Treatment of Early Stages of COVID-19,Completed,NA,Phase 2/Phase 3,243,Actual,Clinedem,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,individual participant data will be confidential,2021-10-12T07:01:55Z,2021-10-12T07:01:55Z
NCT04486482,NA,7/23/2020,NA,NA,8/12/2021,7/23/2020,7/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/13/2021,Actual,12-Jan-21,Actual,1/12/2021,Aug-21,8/31/2021,30-Mar-21,Actual,3/30/2021,30-Mar-21,Actual,3/30/2021,NA,Interventional,NA,NA,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,"An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting",Completed,NA,Not Applicable,49,Actual,Kaleido Biosciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:37Z,2021-10-12T07:01:37Z
NCT04481685,NA,7/15/2020,NA,NA,6/22/2021,7/20/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,6/22/2021,6/23/2021,Actual,20-Jul-20,Actual,7/20/2020,May-20,5/31/2020,1-Jun-21,Actual,6/1/2021,25-Feb-21,Actual,2/25/2021,NA,Interventional,NA,NA,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)","A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19",Completed,NA,Phase 2,20,Actual,University of Kansas Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:11Z,2021-10-12T07:02:11Z
NCT04482387,NA,7/17/2020,NA,NA,1/12/2021,7/21/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,1/12/2021,1/14/2021,Actual,24-Jul-20,Actual,7/24/2020,Jan-21,1/31/2021,1-Jul-21,Anticipated,7/1/2021,1-Jul-21,Anticipated,7/1/2021,NA,Interventional,NA,NA,DigiVis: Self-testing Vision App for Telephone Consultations,DigiVis: Validation of Self-testing Visual Acuity Web-based App to Aid Ophthalmic Telephone Consultations During Covid19 Lockdown and Subsequent Social Distancing Crisis,Recruiting,NA,Not Applicable,250,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:08Z,2021-10-12T07:02:08Z
NCT04480593,NA,7/12/2020,NA,NA,9/28/2020,7/20/2020,7/21/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2020,9/30/2020,Actual,2-Jun-20,Actual,6/2/2020,Sep-20,9/30/2020,30-Aug-20,Actual,8/30/2020,30-Aug-20,Actual,8/30/2020,NA,Interventional,Bee-Covid,NA,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,"The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.",Completed,NA,Phase 2/Phase 3,120,Actual,D'Or Institute for Research and Education,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:19Z,2021-10-12T07:02:19Z
NCT04483271,NA,7/18/2020,NA,NA,12/5/2020,7/22/2020,7/23/2020,Actual,NA,NA,NA,NA,NA,NA,12/5/2020,12/8/2020,Actual,2-Oct-20,Actual,10/2/2020,Jul-20,7/31/2020,10-Feb-21,Anticipated,2/10/2021,15-Dec-20,Anticipated,12/15/2020,NA,Interventional,NA,NA,The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm,The Effect of Omega-3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People,Enrolling by invitation,NA,Not Applicable,100,Anticipated,Applied Science Private University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:03Z,2021-10-12T07:02:03Z
NCT04482634,NA,7/21/2020,NA,NA,11/4/2020,7/21/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,11/4/2020,11/5/2020,Actual,1-Sep-20,Actual,9/1/2020,Jul-20,7/31/2020,Aug-22,Anticipated,8/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Is Tele-rehabilitation Superior to Home Exercise Program in the Pulmonary Rehabilitation of the Patients With COVID-19 With Post-intensive Care Syndrome? A Randomized Controlled Trial,Recruiting,NA,Not Applicable,122,Anticipated,KoÃ§ University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:06Z,2021-10-12T07:02:06Z
NCT04483635,NA,6/29/2020,NA,NA,5/26/2021,7/21/2020,7/23/2020,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/28/2021,Actual,8-Feb-21,Actual,2/8/2021,May-21,5/31/2021,25-May-21,Actual,5/25/2021,4-May-21,Actual,5/4/2021,NA,Interventional,PROTECT,NA,PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams,PROTECT RCT (PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams,Terminated,NA,Phase 3,34,Actual,St. Justine's Hospital,,2,NA,"A premature discontinuation was recommended by the Data Safety Monitoring Board and agreed upon by the principal investigator, because the significantly lower recruitment than planned, in the context of mass vaccination of the target population.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:59Z,2021-10-12T07:01:59Z
NCT04480957,NA,7/17/2020,NA,NA,8/12/2021,7/17/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/18/2021,Actual,4-Aug-20,Actual,8/4/2020,Aug-21,8/31/2021,29-Jan-21,Actual,1/29/2021,29-Jan-21,Actual,1/29/2021,NA,Interventional,NA,NA,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,"A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects",Completed,NA,Phase 1/Phase 2,106,Actual,"Arcturus Therapeutics, Inc.",,8,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:16Z,2021-10-12T07:02:16Z
NCT04483375,NA,7/17/2020,NA,NA,3/21/2021,7/22/2020,7/23/2020,Actual,NA,NA,NA,NA,NA,NA,3/21/2021,3/23/2021,Actual,24-Jul-20,Actual,7/24/2020,Jul-20,7/31/2020,17-Nov-20,Actual,11/17/2020,17-Nov-20,Actual,11/17/2020,NA,Interventional,NA,NA,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects","A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of SCTA01 in Healthy Subjects",Completed,NA,Phase 1,33,Actual,Sinocelltech Ltd.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:01:58Z,2021-10-12T07:01:58Z
NCT04482621,NA,7/21/2020,NA,NA,9/27/2021,7/21/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/28/2021,Actual,14-Sep-20,Actual,9/14/2020,May-21,5/31/2021,Mar-22,Anticipated,3/31/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,DART,NA,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial,Recruiting,NA,Phase 2,40,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:05Z,2021-10-12T07:02:05Z
NCT04477993,NA,7/13/2020,NA,NA,4/5/2021,7/17/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,4/5/2021,4/8/2021,Actual,14-Aug-20,Actual,8/14/2020,Apr-21,4/30/2021,29-Mar-21,Actual,3/29/2021,29-Mar-21,Actual,3/29/2021,NA,Interventional,RUXO-COVID,NA,Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19,"Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection",Terminated,NA,Phase 2/Phase 3,5,Actual,University of Sao Paulo General Hospital,,2,NA,Low accrual,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:37Z,2021-10-12T07:02:37Z
NCT04480112,NA,7/19/2020,NA,NA,8/27/2021,7/19/2020,7/21/2020,Actual,NA,NA,NA,NA,NA,NA,8/27/2021,8/30/2021,Actual,2-Jun-20,Actual,6/2/2020,Aug-21,8/31/2021,11-Jun-21,Actual,6/11/2021,11-Jun-21,Actual,6/11/2021,NA,Interventional,NA,NA,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Impact of Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults With and Without Cognitive Impairment,Completed,NA,Not Applicable,196,Actual,Boston University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:22Z,2021-10-12T07:02:22Z
NCT04479540,NA,7/6/2020,NA,NA,8/26/2021,7/20/2020,7/21/2020,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/27/2021,Actual,26-May-20,Actual,5/26/2020,Aug-21,8/31/2021,5-Mar-22,Anticipated,3/5/2022,26-Feb-22,Anticipated,2/26/2022,NA,Interventional,COVIDEP,NA,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With SARS Coronavirus (COV-2) Lung Disease,Recruiting,NA,Not Applicable,220,Anticipated,Hopital Foch,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:27Z,2021-10-12T07:02:27Z
NCT04482673,NA,7/1/2020,NA,NA,7/31/2020,7/21/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,7/31/2020,8/4/2020,Actual,31-Jul-20,Actual,7/31/2020,Jul-20,7/31/2020,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,VitD-COVID19,NA,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,The Role of Vitamin D in Mitigating COVID-19 Infection Severity: Focusing on Reducing Health Disparities in South Carolina,Recruiting,NA,Phase 4,140,Anticipated,Medical University of South Carolina,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:05Z,2021-10-12T07:02:05Z
NCT04482647,NA,7/21/2020,NA,NA,3/26/2021,7/21/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,3/26/2021,3/29/2021,Actual,17-Jun-20,Actual,6/17/2020,Mar-21,3/31/2021,1-Jul-21,Anticipated,7/1/2021,1-Jul-21,Anticipated,7/1/2021,NA,Interventional,NA,NA,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,Breathing Techniques and Meditation for Health Care Workers During COVID-19,Recruiting,NA,Phase 1,50,Anticipated,M.D. Anderson Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:05Z,2021-10-12T07:02:05Z
NCT04476992,NA,7/16/2020,NA,NA,4/1/2021,7/16/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,4/1/2021,4/6/2021,Actual,24-Jul-20,Actual,7/24/2020,Apr-21,4/30/2021,17-Sep-21,Anticipated,9/17/2021,17-Jul-21,Anticipated,7/17/2021,NA,Interventional,NICOR,NA,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,A Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 Patients,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Tomsk National Research Medical Center of the Russian Academy of Sciences,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:46Z,2021-10-12T07:02:46Z
NCT04477954,NA,7/16/2020,NA,NA,1/13/2021,7/17/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,1/13/2021,1/15/2021,Actual,6-Jul-20,Actual,7/6/2020,Jan-21,1/31/2021,30-Dec-20,Actual,12/30/2020,6-Nov-20,Actual,11/6/2020,NA,Interventional,NA,NA,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Terminated,NA,Phase 2,40,Actual,AsociaciÃ³n Argentina de Medicina HiperbÃ¡rica e InvestigaciÃ³n,,2,NA,"Investigators and Ethic Committee endorsed early suspension of the protocol because of superiority and safety. For the interim analysys, the statistical methodology presented by Pocock was followed.",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:38Z,2021-10-12T07:02:38Z
NCT04478019,NA,7/15/2020,NA,NA,9/1/2021,7/15/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,9/1/2021,9/2/2021,Actual,7-Jul-20,Actual,7/7/2020,Apr-21,4/30/2021,30-Apr-22,Anticipated,4/30/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,SHIELD,NA,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,Role of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission: SHIELD Study,Recruiting,NA,Early Phase 1,250,Anticipated,"University of Wisconsin, Madison",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Data will be shared after enrollment goals are reached for this study. Data will be shared via this website and publication in peer-reviewed journals.,NA,NA,Yes,De-identified study results will be shared with other researchers.,2021-10-12T07:02:38Z,2021-10-12T07:02:38Z
NCT04477668,NA,7/9/2020,NA,NA,9/5/2021,7/16/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,9/5/2021,9/13/2021,Actual,8-Feb-21,Actual,2/8/2021,Sep-21,9/30/2021,Feb-22,Anticipated,2/28/2022,Sep-21,Anticipated,9/30/2021,NA,Interventional,Helmet-COVID,NA,Helmet Non-Invasive Ventilation for COVID-19 Patients,Helmet Non-Invasive Ventilation for COVID-19 Patients,Recruiting,NA,Not Applicable,320,Anticipated,King Abdullah International Medical Research Center,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:41Z,2021-10-12T07:02:41Z
NCT04477655,NA,7/15/2020,NA,NA,4/12/2021,7/16/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,4/12/2021,4/13/2021,Actual,3-May-20,Actual,5/3/2020,Apr-21,4/30/2021,26-Jan-21,Actual,1/26/2021,26-Jan-21,Actual,1/26/2021,NA,Interventional,PRO-CARF,NA,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Prone Positioning in Non-intubated Patients With Severe COVID-19: a Randomized Controlled Trial,Completed,NA,Not Applicable,430,Actual,Hospital Civil de Guadalajara,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:41Z,2021-10-12T07:02:41Z
NCT04477083,NA,7/14/2020,NA,NA,7/17/2020,7/17/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,7/17/2020,7/20/2020,Actual,15-Jul-20,Actual,7/15/2020,Jul-20,7/31/2020,15-Aug-20,Anticipated,8/15/2020,15-Aug-20,Anticipated,8/15/2020,NA,Interventional,NA,NA,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Active, not recruiting",NA,Not Applicable,40,Anticipated,Mansoura University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:45Z,2021-10-12T07:02:45Z
NCT04473170,NA,7/14/2020,NA,NA,7/15/2020,7/15/2020,7/16/2020,Actual,NA,NA,NA,NA,NA,NA,7/15/2020,7/16/2020,Actual,4-Apr-20,Actual,4/4/2020,Jul-20,7/31/2020,14-Jul-20,Actual,7/14/2020,20-May-20,Actual,5/20/2020,NA,Interventional,SENTAD-COVID,NA,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,"Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)",Completed,NA,Phase 1/Phase 2,146,Actual,Abu Dhabi Stem Cells Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:15Z,2021-10-12T07:03:15Z
NCT04472559,NA,7/13/2020,NA,NA,6/16/2021,7/13/2020,7/15/2020,Actual,NA,NA,NA,NA,NA,NA,6/16/2021,6/18/2021,Actual,16-Jun-21,Actual,6/16/2021,Jun-21,6/30/2021,25-Dec-21,Anticipated,12/25/2021,1-Oct-21,Anticipated,10/1/2021,NA,Interventional,NA,NA,Acupressure for COVID-19 Related Quality of Life and Stress,Randomized Controlled Trial of Acupressure for Health-Related Quality of Life and Perception of Stress Among Health Care Providers During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,200,Anticipated,"University of California, Los Angeles",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:17Z,2021-10-12T07:03:17Z
NCT04476979,NA,7/16/2020,NA,NA,4/16/2021,7/16/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,4/16/2021,4/19/2021,Actual,16-Jul-20,Actual,7/16/2020,Jul-20,7/31/2020,31-Dec-21,Anticipated,12/31/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,TOCIDEX,NA,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,NA,Phase 2,660,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:44Z,2021-10-12T07:02:44Z
NCT04475913,NA,7/14/2020,NA,NA,2/24/2021,7/14/2020,7/17/2020,Actual,NA,NA,NA,NA,NA,NA,2/24/2021,3/1/2021,Actual,11-Jul-18,Actual,7/11/2018,Jul-20,7/31/2020,20-Aug-20,Actual,8/20/2020,11-Jul-20,Actual,7/11/2020,NA,Interventional,NA,NA,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,"In a Post -Covid-19 World, What is the Clinical Influence of Digital vs Analog Impression in Cases of All-on-4 - Prosthesis ?",Completed,NA,Not Applicable,56,Actual,October University for Modern Sciences and Arts,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:53Z,2021-10-12T07:02:53Z
NCT04471519,NA,7/11/2020,NA,NA,5/18/2021,7/14/2020,7/15/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/20/2021,Actual,15-Jul-20,Actual,7/15/2020,May-21,5/31/2021,30-Jun-21,Anticipated,6/30/2021,31-Jul-20,Actual,7/31/2020,NA,Interventional,BBV152,NA,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,755,Actual,Bharat Biotech International Limited,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:25Z,2021-10-12T07:03:25Z
NCT04470544,NA,7/9/2020,NA,NA,1/7/2021,7/13/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,1/7/2021,1/11/2021,Actual,28-Jul-20,Actual,7/28/2020,Jan-21,1/31/2021,15-Sep-22,Anticipated,9/15/2022,15-Sep-22,Anticipated,9/15/2022,NA,Interventional,RECOVER,NA,Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,"RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor",Recruiting,NA,Phase 2,264,Anticipated,Academic and Community Cancer Research United,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:32Z,2021-10-12T07:03:32Z
NCT04475120,NA,7/16/2020,NA,NA,5/12/2021,7/16/2020,7/17/2020,Actual,NA,NA,NA,NA,NA,NA,5/12/2021,5/14/2021,Actual,15-Apr-20,Actual,4/15/2020,May-21,5/31/2021,2-Jul-20,Actual,7/2/2020,2-Jul-20,Actual,7/2/2020,NA,Interventional,NA,NA,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Interventional Pilot Study to Assess the Use of Oral and Intra-nasal Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,NA,Phase 2/Phase 3,92,Actual,University of Rome Tor Vergata,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:02:59Z,2021-10-12T07:02:59Z
NCT04473274,NA,6/22/2020,NA,NA,12/2/2020,7/14/2020,7/16/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2020,12/4/2020,Actual,21-May-20,Actual,5/21/2020,Dec-20,12/31/2020,1-Dec-20,Actual,12/1/2020,1-Nov-20,Actual,11/1/2020,NA,Interventional,GOTCHA,NA,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study","GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,NA,Phase 4,10,Actual,Samaritan Health Services,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:12Z,2021-10-12T07:03:12Z
NCT04470869,NA,7/3/2020,NA,NA,5/28/2021,7/9/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,5/28/2021,6/1/2021,Actual,12-Jun-20,Actual,6/12/2020,May-21,5/31/2021,12-Oct-21,Anticipated,10/12/2021,12-Oct-21,Anticipated,10/12/2021,NA,Interventional,OLAF,NA,Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.,Impact of the Psychiatric Intervention OLAF on the Post Traumatic Disorder in the Relatives of Patients Hospitalized in Intensive Care Unit During the SARS-Cov-2 Pandemic Confinement in France.,"Active, not recruiting",NA,Not Applicable,129,Actual,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:30Z,2021-10-12T07:03:30Z
NCT04473248,NA,7/14/2020,NA,NA,11/11/2020,7/14/2020,7/16/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2020,11/13/2020,Actual,28-Jun-20,Actual,6/28/2020,Jul-20,7/31/2020,30-Aug-20,Actual,8/30/2020,30-Aug-20,Actual,8/30/2020,NA,Interventional,NA,NA,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Evaluation of Clinical Sample Collection Project: Spartan COVID-19,Completed,NA,Not Applicable,27,Actual,Spartan Bioscience Inc.,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:14Z,2021-10-12T07:03:14Z
NCT04473053,NA,7/9/2020,NA,NA,9/8/2021,7/15/2020,7/16/2020,Actual,NA,NA,NA,NA,NA,NA,9/8/2021,9/16/2021,Actual,3-Jul-20,Actual,7/3/2020,Sep-21,9/30/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,DEFINE,NA,DEFINE - Evaluating Therapies for COVID-19,DEFINE - Evaluating Therapies for COVID-19,"Active, not recruiting",NA,Phase 1/Phase 2,200,Anticipated,University of Edinburgh,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,90 days after data analysis has been completed for each arm. This data will be available on request and a time frame can be discussed further when required.,NA,NA,Yes,The research team actively encourage data sharing to expedite the development of COVID-19 treatments. The study team will provide data to other researchers on request and following the agreement of a data sharing plan. No confidential information regarding participants will be shared.,2021-10-12T07:03:15Z,2021-10-12T07:03:15Z
NCT04470258,NA,6/10/2020,NA,NA,4/18/2021,7/11/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,4/18/2021,4/20/2021,Actual,25-Jun-20,Actual,6/25/2020,Apr-21,4/30/2021,30-Nov-20,Actual,11/30/2020,30-Aug-20,Actual,8/30/2020,NA,Interventional,NA,NA,Elmo Respiratory Support Project - COVID-19,Elmo Respiratory Support Project for Patients With Hypoxemic Respiratory Insufficiency in Covid-19: Proof Of Concept and Usability,Completed,NA,Not Applicable,10,Actual,Escola de SaÃºde PÃºblica do CearÃ¡,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:34Z,2021-10-12T07:03:34Z
NCT04468646,NA,7/7/2020,NA,NA,7/10/2020,7/10/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,7/10/2020,7/13/2020,Actual,15-Jun-20,Actual,6/15/2020,Jul-20,7/31/2020,30-Aug-20,Anticipated,8/30/2020,15-Jul-20,Anticipated,7/15/2020,NA,Interventional,NA,NA,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,NA,Phase 3,100,Anticipated,University of Health Sciences Lahore,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:47Z,2021-10-12T07:03:47Z
NCT04468139,NA,7/5/2020,NA,NA,7/9/2020,7/9/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,7/9/2020,7/13/2020,Actual,20-Jun-20,Actual,6/20/2020,Jul-20,7/31/2020,30-Jul-20,Anticipated,7/30/2020,20-Jul-20,Anticipated,7/20/2020,NA,Interventional,NA,NA,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19","The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",Recruiting,NA,Phase 4,60,Anticipated,"Ministry of Health, Saudi Arabia",,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:49Z,2021-10-12T07:03:49Z
NCT04466540,NA,7/3/2020,NA,NA,8/24/2021,7/9/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/25/2021,Actual,12-May-20,Actual,5/12/2020,Aug-21,8/31/2021,28-Aug-21,Anticipated,8/28/2021,28-Jul-21,Actual,7/28/2021,NA,Interventional,COALITION-V,NA,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),"Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19","Active, not recruiting",NA,Phase 4,1372,Anticipated,Hospital AlemÃ£o Oswaldo Cruz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:03Z,2021-10-12T07:04:03Z
NCT04466098,NA,7/8/2020,NA,NA,3/22/2021,7/8/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,3/22/2021,3/23/2021,Actual,30-Jul-20,Actual,7/30/2020,Mar-21,3/31/2021,1-Dec-21,Anticipated,12/1/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),"Multi-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)","Active, not recruiting",NA,Phase 2,9,Actual,"Masonic Cancer Center, University of Minnesota",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:09Z,2021-10-12T07:04:09Z
NCT04464395,NA,7/7/2020,NA,NA,7/20/2021,7/8/2020,7/9/2020,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,1-Jul-20,Actual,7/1/2020,Jul-21,7/31/2021,9-Jul-21,Actual,7/9/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,NA,NA,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody,Completed,NA,Phase 1,30,Actual,"Corvus Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:21Z,2021-10-12T07:04:21Z
NCT04466683,NA,6/20/2020,NA,NA,3/11/2021,7/9/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,3/11/2021,3/15/2021,Actual,28-Aug-20,Actual,8/28/2020,Mar-21,3/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,PREVENT,NA,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,Phase II Protocol of Low-Dose Whole Thorax Megavoltage Radiotherapy for Patients With SARS-COV-2 Pneumonia,Recruiting,NA,Phase 2,100,Anticipated,Ohio State University Comprehensive Cancer Center,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:01Z,2021-10-12T07:04:01Z
NCT04467840,NA,7/9/2020,NA,NA,7/19/2021,7/9/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/20/2021,Actual,21-Aug-20,Actual,8/21/2020,Jul-21,7/31/2021,18-Jul-21,Actual,7/18/2021,18-Jul-21,Actual,7/18/2021,NA,Interventional,NA,NA,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia",Completed,NA,Phase 2/Phase 3,475,Actual,RedHill Biopharma Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:54Z,2021-10-12T07:03:54Z
NCT04463602,NA,7/7/2020,NA,NA,4/22/2021,7/8/2020,7/9/2020,Actual,NA,NA,NA,NA,NA,NA,4/22/2021,4/23/2021,Actual,25-Jul-20,Actual,7/25/2020,Apr-21,4/30/2021,31-Mar-21,Actual,3/31/2021,25-Jan-21,Actual,1/25/2021,NA,Interventional,NA,NA,Desidustat in the Management of COVID-19 Patients,"A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients",Completed,NA,Phase 2,24,Actual,Cadila Healthcare Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:29Z,2021-10-12T07:04:29Z
NCT04463472,NA,7/8/2020,NA,NA,8/17/2021,7/8/2020,7/9/2020,Actual,NA,NA,NA,NA,NA,NA,8/17/2021,8/18/2021,Actual,29-Jun-20,Actual,6/29/2020,Aug-21,8/31/2021,12-Aug-21,Actual,8/12/2021,28-Sep-20,Actual,9/28/2020,NA,Interventional,NA,NA,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"A Non-randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg/2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:28Z,2021-10-12T07:04:28Z
NCT04468009,NA,7/9/2020,NA,NA,8/23/2021,7/9/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/25/2021,Actual,25-Jun-20,Actual,6/25/2020,Aug-21,8/31/2021,19-Jun-21,Actual,6/19/2021,19-Jan-21,Actual,1/19/2021,NA,Interventional,NA,NA,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Completed,NA,Phase 2,134,Actual,Hospital de Infecciosas Francisco Javier Muniz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:54Z,2021-10-12T07:03:54Z
NCT04461925,NA,7/1/2020,NA,NA,7/7/2020,7/7/2020,7/8/2020,Actual,NA,NA,NA,NA,NA,NA,7/7/2020,7/8/2020,Actual,2-May-20,Actual,5/2/2020,Jun-20,6/30/2020,Dec-21,Anticipated,12/31/2021,2-May-21,Anticipated,5/2/2021,NA,Interventional,NA,NA,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Institute of Cell Therapy,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:41Z,2021-10-12T07:04:41Z
NCT04465604,NA,7/2/2020,NA,NA,3/4/2021,7/9/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,3/4/2021,3/5/2021,Actual,1-Feb-21,Actual,2/1/2021,Mar-21,3/31/2021,May-22,Anticipated,5/31/2022,1-Nov-21,Anticipated,11/1/2021,NA,Interventional,NA,NA,Hypertonic Saline for COVID-19 Symptoms,HYPERTONIC SALINE COATED FACE MASK FOR REDUCING RESPIRATORY SYMPTOM SEVERITY IN PATIENTS WITH COVID-19,Recruiting,NA,Not Applicable,50,Anticipated,King Faisal Specialist Hospital & Research Center,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:10Z,2021-10-12T07:04:10Z
NCT04460443,NA,7/4/2020,NA,NA,12/3/2020,7/4/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,12/3/2020,12/8/2020,Actual,1-Aug-20,Actual,8/1/2020,Dec-20,12/31/2020,31-Aug-21,Anticipated,8/31/2021,1-Aug-21,Anticipated,8/1/2021,NA,Interventional,NA,NA,Sofosbuvir in Treatment of COVID 19,Sofosbuvir Based Regimens in Treatment of COVID 19 Patients,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Tanta University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:52Z,2021-10-12T07:04:52Z
NCT04460690,NA,7/6/2020,NA,NA,8/31/2021,7/6/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/8/2021,Actual,13-Jul-20,Actual,7/13/2020,Jul-21,7/31/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,NA,"Rapid, Onsite COVID-19 Detection","Rapid, Onsite COVID-19 Detection",Completed,NA,Not Applicable,93,Actual,"University of Wisconsin, Madison",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,NA,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin - Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2021-10-12T07:04:49Z,2021-10-12T07:04:49Z
NCT04459455,NA,6/29/2020,NA,NA,10/19/2020,7/5/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,10/19/2020,10/20/2020,Actual,19-Aug-20,Actual,8/19/2020,Oct-20,10/31/2020,15-Oct-20,Actual,10/15/2020,15-Oct-20,Actual,10/15/2020,NA,Interventional,NA,NA,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic","Project HF-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,NA,Not Applicable,500,Actual,Stony Brook University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:59Z,2021-10-12T07:04:59Z
NCT04462757,NA,6/12/2020,NA,NA,4/27/2021,7/7/2020,7/8/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/30/2021,Actual,28-May-20,Actual,5/28/2020,Apr-21,4/30/2021,23-Dec-20,Actual,12/23/2020,31-Aug-20,Actual,8/31/2020,NA,Interventional,SCIL_COV19,NA,SCIL-1Ra in COVID-19 Feasibility & PK/PD,Subcutaneous and Intravenous IL-1Ra (Anakinra) in COVID-19 Infection - Feasibility & Pharmacokinetics/Pharmacodynamics Study,Terminated,NA,Phase 2,5,Actual,University of Manchester,,2,NA,Lack of patients in the trial population from which to recruit and lack of funding,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:33Z,2021-10-12T07:04:33Z
NCT04459962,NA,7/3/2020,NA,NA,1/28/2021,7/3/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,1/28/2021,1/29/2021,Actual,29-Jun-20,Actual,6/29/2020,Jul-20,7/31/2020,7-Jan-21,Actual,1/7/2021,7-Jan-21,Actual,1/7/2021,NA,Interventional,NA,NA,Covid-19 Breath Test,Breath Test Feasibility Trial for Covid-19 Infection Diagnosis,Completed,NA,Not Applicable,330,Actual,Ancon Technologies Ltd,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:56Z,2021-10-12T07:04:56Z
NCT04457609,NA,5/27/2020,NA,NA,7/2/2020,7/2/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,7/2/2020,7/7/2020,Actual,Jul-20,Anticipated,7/31/2020,Jul-20,7/31/2020,Sep-20,Anticipated,9/30/2020,Aug-20,Anticipated,8/31/2020,NA,Interventional,NA,NA,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Recruiting,NA,Phase 1,40,Anticipated,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:12Z,2021-10-12T07:05:12Z
NCT04459325,NA,7/3/2020,NA,NA,10/13/2020,7/3/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,10/13/2020,10/14/2020,Actual,1-Jun-20,Actual,6/1/2020,Jul-20,7/31/2020,20-Jul-20,Actual,7/20/2020,20-Jul-20,Actual,7/20/2020,NA,Interventional,NA,NA,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,A Prospective Open-label Study of the TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,NA,Phase 3,100,Actual,AO GENERIUM,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:58Z,2021-10-12T07:04:58Z
NCT04457726,NA,7/2/2020,NA,NA,7/2/2020,7/2/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,7/2/2020,7/7/2020,Actual,1-Jul-20,Anticipated,7/1/2020,Jun-20,6/30/2020,Dec-22,Anticipated,12/31/2022,Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,NA,Phase 1/Phase 2,18,Anticipated,KK Women's and Children's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:11Z,2021-10-12T07:05:11Z
NCT04458519,NA,7/1/2020,NA,NA,5/27/2021,7/2/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,5/27/2021,6/1/2021,Actual,16-Jul-20,Actual,7/16/2020,Jul-20,7/31/2020,27-May-21,Actual,5/27/2021,27-May-21,Actual,5/27/2021,NA,Interventional,NA,NA,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Randomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Completed,NA,Not Applicable,23,Actual,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:05Z,2021-10-12T07:05:05Z
NCT04458298,NA,6/29/2020,NA,NA,7/22/2021,7/2/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/29/2021,Actual,11-Aug-20,Actual,8/11/2020,Jul-21,7/31/2021,2-Jun-22,Anticipated,6/2/2022,2-Jun-22,Anticipated,6/2/2022,NA,Interventional,PRANA,NA,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,"A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19","Active, not recruiting",NA,Phase 2,24,Actual,"Orpheris, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:10Z,2021-10-12T07:05:10Z
NCT04456452,NA,6/30/2020,NA,NA,1/12/2021,6/30/2020,7/2/2020,Actual,NA,NA,NA,NA,NA,NA,1/12/2021,1/13/2021,Actual,27-Jul-20,Actual,7/27/2020,Jan-21,1/31/2021,30-Nov-20,Actual,11/30/2020,8-Sep-20,Actual,9/8/2020,NA,Interventional,NA,NA,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampionâ„¢ in Adult COVID-19 Patients Requiring Oxygen Supplementation,Completed,NA,Phase 1,10,Actual,Ampio Pharmaceuticals. Inc.,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:22Z,2021-10-12T07:05:22Z
NCT04456413,NA,6/30/2020,NA,NA,2/24/2021,6/30/2020,7/2/2020,Actual,NA,NA,NA,NA,NA,NA,2/24/2021,3/1/2021,Actual,6-Nov-20,Actual,11/6/2020,Feb-21,2/28/2021,Nov-21,Anticipated,11/30/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,Phase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 Infection,Recruiting,NA,Phase 2,306,Anticipated,Hackensack Meridian Health,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:23Z,2021-10-12T07:05:23Z
NCT04454606,NA,6/26/2020,NA,NA,6/30/2020,6/30/2020,7/1/2020,Actual,NA,NA,NA,NA,NA,NA,6/30/2020,7/1/2020,Actual,1-May-20,Actual,5/1/2020,Jun-20,6/30/2020,31-May-20,Actual,5/31/2020,15-May-20,Actual,5/15/2020,NA,Interventional,NA,NA,The New Silicone N99 Half-Piece Respirator,The New Silicone N99 Half-Piece Respirator:VJR-NMU N99:New and Effective Tool to Prevent COVID-19,Completed,NA,Not Applicable,43,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:39Z,2021-10-12T07:05:39Z
NCT04455360,NA,6/26/2020,NA,NA,9/28/2021,7/1/2020,7/2/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/29/2021,Actual,1-Oct-20,Actual,10/1/2020,Sep-21,9/30/2021,20-Sep-21,Actual,9/20/2021,20-Sep-21,Actual,9/20/2021,NA,Interventional,Cov-EMERALD,NA,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,EMERALD: Can a Virtual Eye Movement Desensitisation and Reprocessing Intervention Improve Psychological Outcome Following Covid-19 Related Critical Illness: A Feasibility Trial,Completed,NA,Not Applicable,26,Actual,University Hospital Southampton NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:31Z,2021-10-12T07:05:31Z
NCT04453774,NA,5/6/2020,NA,NA,5/19/2021,6/29/2020,7/1/2020,Actual,NA,NA,NA,NA,NA,NA,5/19/2021,5/24/2021,Actual,1-Nov-20,Actual,11/1/2020,May-21,5/31/2021,Apr-23,Anticipated,4/30/2023,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,At Home Monitoring for Patients With Covid19,Covidfree@Home: At Home Monitoring Using Mobile Devices for Patients With Covid19,Recruiting,NA,Not Applicable,1000,Anticipated,"University Health Network, Toronto",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:45Z,2021-10-12T07:05:45Z
NCT04456361,NA,6/23/2020,NA,NA,8/3/2020,6/30/2020,7/2/2020,Actual,NA,NA,NA,NA,NA,NA,8/3/2020,8/4/2020,Actual,16-Apr-20,Actual,4/16/2020,Jun-20,6/30/2020,15-Dec-20,Anticipated,12/15/2020,15-Oct-20,Anticipated,10/15/2020,NA,Interventional,NA,NA,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,A Study of Mesenchymal Stem Cells as a Treatment in Patients With Acute Respiratory Distress Syndrome Caused by COVID-19,"Active, not recruiting",NA,Early Phase 1,9,Anticipated,Instituto de Medicina Regenerativa,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:23Z,2021-10-12T07:05:23Z
NCT04456062,NA,6/30/2020,NA,NA,5/20/2021,6/30/2020,7/2/2020,Actual,NA,NA,NA,NA,NA,NA,5/20/2021,5/21/2021,Actual,4-Aug-20,Actual,8/4/2020,May-21,5/31/2021,31-Jul-21,Anticipated,7/31/2021,20-Jul-21,Anticipated,7/20/2021,NA,Interventional,NA,NA,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,"Active, not recruiting",NA,Not Applicable,102,Actual,Sunnybrook Health Sciences Centre,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:25Z,2021-10-12T07:05:25Z
NCT04455308,NA,6/30/2020,NA,NA,11/3/2020,7/1/2020,7/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2020,11/4/2020,Actual,21-Jul-20,Actual,7/21/2020,Nov-20,11/30/2020,19-Oct-20,Actual,10/19/2020,19-Oct-20,Actual,10/19/2020,NA,Interventional,ECCES,NA,COVID-19 and Chilblains,"Chilblains, COVID-19 and Lockdown: Epidemiologic Study",Completed,NA,Not Applicable,269,Actual,Rennes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:33Z,2021-10-12T07:05:33Z
NCT04480138,NA,7/20/2020,NA,NA,6/28/2021,7/20/2020,7/21/2020,Actual,NA,NA,NA,NA,NA,NA,6/28/2021,6/29/2021,Actual,11-Aug-20,Actual,8/11/2020,Jun-21,6/30/2021,31-Aug-21,Anticipated,8/31/2021,31-Jul-21,Anticipated,7/31/2021,NA,Interventional,NA,NA,Pegylated Interferon - Î±2b With SARSCoV- 2 (COVID-19),"A Phase II, Multicenter, Open-label, Randomized, Comparator Controlled Study to Evaluate the Efficacy and Safety of Pegylated Interferon - Î±2b in the Treatment of Adult Patients Diagnosed With SARS-CoV2 (COVID-19)","Active, not recruiting",NA,Phase 2,40,Anticipated,Cadila Healthcare Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:23Z,2021-10-12T07:02:23Z
NCT04481633,NA,7/21/2020,NA,NA,8/31/2021,7/21/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/8/2021,Actual,9-Sep-20,Actual,9/9/2020,Aug-21,8/31/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,PREPCOV,NA,Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,Real-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and/or Gougerot's Disease,Recruiting,NA,Not Applicable,800,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:12Z,2021-10-12T07:02:12Z
NCT04479202,NA,5/13/2020,NA,NA,7/19/2020,7/19/2020,7/21/2020,Actual,NA,NA,NA,NA,NA,NA,7/19/2020,7/21/2020,Actual,8-Feb-20,Actual,2/8/2020,May-20,5/31/2020,23-Apr-20,Actual,4/23/2020,18-Apr-20,Actual,4/18/2020,NA,Interventional,BOIFIM,NA,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,NA,Phase 4,76,Actual,Chinese Medical Association,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,We have other articles about covid-19 yet to be published,2021-10-12T07:02:28Z,2021-10-12T07:02:28Z
NCT04479163,NA,6/29/2020,NA,NA,12/19/2020,7/19/2020,7/21/2020,Actual,NA,NA,NA,NA,NA,NA,12/19/2020,12/22/2020,Actual,4-Jun-20,Actual,6/4/2020,Dec-20,12/31/2020,25-Oct-20,Actual,10/25/2020,25-Oct-20,Actual,10/25/2020,NA,Interventional,NA,NA,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.,Completed,NA,Not Applicable,165,Actual,Fundacion Infant,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:28Z,2021-10-12T07:02:28Z
NCT04476680,NA,7/16/2020,NA,NA,3/19/2021,7/16/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,3/19/2021,3/23/2021,Actual,1-Sep-20,Actual,9/1/2020,Mar-21,3/31/2021,28-Apr-21,Anticipated,4/28/2021,28-Apr-21,Anticipated,4/28/2021,NA,Interventional,IMPACTCOVID,NA,Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion,Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion,Recruiting,NA,Not Applicable,900,Anticipated,Royal Centre for Defence Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Anonymised IPD may be available upon request,2021-10-12T07:02:48Z,2021-10-12T07:02:48Z
NCT04475601,NA,6/8/2020,NA,NA,8/22/2021,7/16/2020,7/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/22/2021,8/26/2021,Actual,15-Jul-20,Actual,7/15/2020,Aug-21,8/31/2021,29-May-21,Actual,5/29/2021,24-Mar-21,Actual,3/24/2021,NA,Interventional,COVIDENZA,NA,Enzalutamide Treatment in COVID-19,"A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)",Terminated,NA,Phase 2,42,Actual,VÃ¤sterbotten County Council,,2,NA,"By sponsor, based on DSMB recommendations",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,The extent of sharing will be regulated during the trial to consider the integrity of the data according GDPR and national laws,2021-10-12T07:02:57Z,2021-10-12T07:02:57Z
NCT04478539,NA,7/14/2020,NA,NA,7/17/2020,7/17/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,7/17/2020,7/20/2020,Actual,1-Jun-20,Actual,6/1/2020,Jul-20,7/31/2020,1-Jul-21,Anticipated,7/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,Extracorporeal Blood Purification as a Treatment Modality for COVID-19,Clinical Efficacy and Safety of Extracorporeal Blood Purification to Control Hyperinflammation and Hypercoagulability in COVID-19 Patients,Recruiting,NA,Not Applicable,35,Anticipated,Zan Mitrev Clinic,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:35Z,2021-10-12T07:02:35Z
NCT04474340,NA,7/15/2020,NA,NA,7/17/2020,7/15/2020,7/16/2020,Actual,NA,NA,NA,NA,NA,NA,7/17/2020,7/21/2020,Actual,21-May-20,Actual,5/21/2020,Jul-20,7/31/2020,30-Dec-20,Anticipated,12/30/2020,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients: Multicenter Interventional Study,Recruiting,NA,Phase 1,300,Anticipated,"Ministry of Health, Kuwait",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:03:04Z,2021-10-12T07:03:04Z
NCT04476888,NA,7/16/2020,NA,NA,1/18/2021,7/17/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,1/18/2021,1/20/2021,Actual,26-Apr-20,Actual,4/26/2020,Jan-21,1/31/2021,10-Oct-20,Actual,10/10/2020,15-Sep-20,Actual,9/15/2020,NA,Interventional,COLLATE,NA,Convalescent Plasma Treatment in COVID-19,Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan,Completed,NA,Not Applicable,110,Actual,Aga Khan University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:45Z,2021-10-12T07:02:45Z
NCT04475991,NA,7/15/2020,NA,NA,8/23/2021,7/15/2020,7/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/24/2021,Actual,13-Jul-21,Actual,7/13/2021,Aug-21,8/31/2021,Feb-22,Anticipated,2/28/2022,Oct-21,Anticipated,10/31/2021,NA,Interventional,COMVIVIR,NA,Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults,"Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19""",Recruiting,NA,Phase 2,100,Anticipated,Hospital General de MÃ©xico Dr. Eduardo Liceaga,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Information will be shared upon completion of the study for collaborative purposes,Upon request,NA,Yes,Inter-institutional exchange of data,2021-10-12T07:02:54Z,2021-10-12T07:02:54Z
NCT04475107,NA,7/14/2020,NA,NA,5/27/2021,7/15/2020,7/17/2020,Actual,NA,NA,NA,NA,NA,NA,5/27/2021,6/1/2021,Actual,9-Jul-20,Actual,7/9/2020,Apr-21,4/30/2021,15-Apr-21,Actual,4/15/2021,25-Mar-21,Actual,3/25/2021,NA,Interventional,NA,NA,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,"A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase â…¡ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients",Completed,NA,Phase 2,113,Actual,Shin Poong Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:59Z,2021-10-12T07:02:59Z
NCT04473898,NA,7/14/2020,NA,NA,2/17/2021,7/14/2020,7/16/2020,Actual,NA,NA,NA,NA,NA,NA,2/17/2021,2/18/2021,Actual,19-Jun-20,Actual,6/19/2020,Jul-20,7/31/2020,17-Feb-21,Actual,2/17/2021,19-Oct-20,Actual,10/19/2020,NA,Interventional,NA,NA,Telerehabilitation After Coronavirus,Telerehabilitation After Covid-19: Effectiveness of Respiratory and Aerobic Training,Completed,NA,Not Applicable,35,Actual,KTO Karatay University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:09Z,2021-10-12T07:03:09Z
NCT04475562,NA,7/15/2020,NA,NA,7/16/2020,7/16/2020,7/17/2020,Actual,NA,NA,NA,NA,NA,NA,7/16/2020,7/17/2020,Actual,6-Apr-20,Actual,4/6/2020,Jul-20,7/31/2020,1-Jul-20,Actual,7/1/2020,6-May-20,Actual,5/6/2020,NA,Interventional,NA,NA,Can the Electronic Nose Smell COVID-19?,Can the Electronic Nose Smell COVID-19? A Proof-of-principle Study,Completed,NA,Not Applicable,219,Actual,Maastricht University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:02:56Z,2021-10-12T07:02:56Z
NCT04476953,NA,7/15/2020,NA,NA,8/10/2021,7/16/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,8/10/2021,8/12/2021,Actual,3-Aug-20,Actual,8/3/2020,Aug-21,8/31/2021,Jul-22,Anticipated,7/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation,COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults,Enrolling by invitation,NA,Phase 2,70,Anticipated,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:45Z,2021-10-12T07:02:45Z
NCT04476745,NA,7/16/2020,NA,NA,12/5/2020,7/16/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,12/5/2020,12/8/2020,Actual,5-Oct-20,Actual,10/5/2020,Dec-20,12/31/2020,20-Feb-21,Anticipated,2/20/2021,15-Dec-20,Anticipated,12/15/2020,NA,Interventional,NA,NA,The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People,"The Effect of Weekly 50,000 IU Vitamin D3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People With Vitamin D Deficiency",Enrolling by invitation,NA,Not Applicable,100,Anticipated,Applied Science Private University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:48Z,2021-10-12T07:02:48Z
NCT04475575,NA,7/15/2020,NA,NA,7/16/2020,7/16/2020,7/17/2020,Actual,NA,NA,NA,NA,NA,NA,7/16/2020,7/17/2020,Actual,6-Apr-20,Actual,4/6/2020,Jul-20,7/31/2020,1-Jul-20,Actual,7/1/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,NA,NA,Can the Electronic Nose Smell COVID-19 Antibodies?,Can the Electronic Nose Smell COVID-19 Antibodies? A Proof-of-principle Study,Completed,NA,Not Applicable,222,Actual,Maastricht University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:02:56Z,2021-10-12T07:02:56Z
NCT04476667,NA,7/13/2020,NA,NA,9/7/2021,7/16/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/9/2021,Actual,15-Jun-20,Actual,6/15/2020,Sep-21,9/30/2021,1-May-21,Actual,5/1/2021,1-May-21,Actual,5/1/2021,NA,Interventional,NA,NA,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19","Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Completed,NA,Not Applicable,80,Actual,Queen's University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Ethics and Data Privacy: Only care providers involved in care of participant will have access to charts. Patients will only be identifiable by ID number on OPTT platform and real identity and consent forms will be stored locally in locked file cabinet and destroyed 5 years after study completion date. Only anonymized data will be provided to analysis team members.

OPTT is HIPAA, PIPEDA and SOC-2 compliant and all servers and databases are hosted in AWS Canada cloud infrastructure which is managed by Medstack to assure all provincial and federal privacy and security regulations are met. OPTT will not collect any identifiable personal information or IP addresses for privacy purposes. OPTT will only collect anonymized metadata to improve its service quality and provide advanced analytics to the clinician team. All data is encrypted by OPTT and no employee has direct access to patient data. All encrypted backups are kept in the S3 storage that is dedicated to Queen's University.",2021-10-12T07:02:48Z,2021-10-12T07:02:48Z
NCT04475302,NA,7/16/2020,NA,NA,9/17/2021,7/16/2020,7/17/2020,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/20/2021,Actual,1-Jul-20,Actual,7/1/2020,Sep-21,9/30/2021,30-Dec-21,Anticipated,12/30/2021,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India,"Active, not recruiting",NA,Phase 3,2175,Actual,"Tuberculosis Research Centre, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:57Z,2021-10-12T07:02:57Z
NCT04474483,NA,5/15/2020,NA,NA,6/9/2021,7/15/2020,7/16/2020,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/11/2021,Actual,6-Nov-20,Actual,11/6/2020,Jun-21,6/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,COVID-19,NA,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection,Recruiting,NA,Phase 2,30,Anticipated,State University of New York at Buffalo,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:03Z,2021-10-12T07:03:03Z
NCT04473261,NA,7/14/2020,NA,NA,7/4/2021,7/14/2020,7/16/2020,Actual,NA,NA,NA,NA,NA,NA,7/4/2021,7/7/2021,Actual,14-Jul-20,Actual,7/14/2020,Jul-21,7/31/2021,15-Oct-21,Anticipated,10/15/2021,15-Aug-21,Anticipated,8/15/2021,NA,Interventional,I-COVID-PK,NA,Efficacy of Iodine Complex Against COVID-19 Patients,Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,200,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:14Z,2021-10-12T07:03:14Z
NCT04472585,NA,7/14/2020,NA,NA,2/13/2021,7/14/2020,7/15/2020,Actual,NA,NA,NA,NA,NA,NA,2/13/2021,2/17/2021,Actual,14-Nov-20,Actual,11/14/2020,Feb-21,2/28/2021,30-Oct-21,Anticipated,10/30/2021,15-Aug-21,Anticipated,8/15/2021,NA,Interventional,SIZI-COVID-PK,NA,Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients,Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,180,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:17Z,2021-10-12T07:03:17Z
NCT04470531,NA,7/11/2020,NA,NA,7/15/2020,7/13/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/15/2020,7/16/2020,Actual,12-Jul-20,Actual,7/12/2020,Jul-20,7/31/2020,30-Jan-21,Anticipated,1/30/2021,12-Oct-20,Anticipated,10/12/2020,NA,Interventional,NA,NA,Role of Co-trimoxazole in Severe COVID-19 Patients,Role of Co-trimoxazole in Severe COVID-19 Patients,Recruiting,NA,Phase 2,94,Anticipated,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,six months,"Available on public domain like figshare, researchgate and others",NA,Yes,Data will be shared with the journal authority and make public as part of the publication,2021-10-12T07:03:32Z,2021-10-12T07:03:32Z
NCT04469621,NA,6/28/2020,NA,NA,11/10/2020,7/12/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2020,11/13/2020,Actual,17-Jul-20,Actual,7/17/2020,Nov-20,11/30/2020,23-Oct-20,Actual,10/23/2020,23-Oct-20,Actual,10/23/2020,NA,Interventional,NA,NA,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19",Completed,NA,Phase 1,68,Actual,Sanofi,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-12T07:03:41Z,2021-10-12T07:03:41Z
NCT04473690,NA,7/14/2020,NA,NA,10/5/2021,7/15/2020,7/16/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/6/2021,Actual,30-Dec-20,Actual,12/30/2020,Oct-21,10/31/2021,31-Dec-22,Anticipated,12/31/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,"A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85","Active, not recruiting",NA,Phase 1/Phase 2,101,Actual,"Kentucky BioProcessing, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Plan is to share study data by dosing group in publications,2021-10-12T07:03:09Z,2021-10-12T07:03:09Z
NCT04472611,NA,7/14/2020,NA,NA,2/25/2021,7/14/2020,7/15/2020,Actual,NA,NA,NA,NA,NA,NA,2/25/2021,3/2/2021,Actual,30-Oct-20,Actual,10/30/2020,Feb-21,2/28/2021,1-Aug-22,Anticipated,8/1/2022,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,COLSTAT,NA,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,Recruiting,NA,Phase 3,466,Anticipated,Yale University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:18Z,2021-10-12T07:03:18Z
NCT04471636,NA,7/9/2020,NA,NA,4/11/2021,7/13/2020,7/15/2020,Actual,NA,NA,NA,NA,NA,NA,4/11/2021,4/14/2021,Actual,18-Sep-20,Actual,9/18/2020,Apr-21,4/30/2021,Dec-21,Anticipated,12/31/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,COVID-SMART,NA,Telemedicine in Outpatient Covid-19 Patients,Munich Remote SpO2 and Electrocardiogram Assessment in Covid-19 Patients,Recruiting,NA,Not Applicable,600,Anticipated,Ludwig-Maximilians - University of Munich,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:26Z,2021-10-12T07:03:26Z
NCT04470999,NA,7/9/2020,NA,NA,3/16/2021,7/13/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,3/16/2021,3/17/2021,Actual,15-Apr-20,Actual,4/15/2020,Mar-21,3/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,Changes in Cellular Immune Profile During COVID-19 Infection,Cellular Immune Profile Changes in Individuals With Active or Past COVID-19 Infection,Recruiting,NA,Not Applicable,25,Anticipated,Seraph Research Institute,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:28Z,2021-10-12T07:03:28Z
NCT04470739,NA,7/12/2020,NA,NA,7/13/2020,7/13/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/13/2020,7/14/2020,Actual,30-May-20,Actual,5/30/2020,Jul-20,7/31/2020,30-Oct-20,Anticipated,10/30/2020,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Recruiting,NA,Not Applicable,20,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:32Z,2021-10-12T07:03:32Z
NCT04466241,NA,7/6/2020,NA,NA,2/3/2021,7/9/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,2/3/2021,2/4/2021,Actual,27-Nov-20,Actual,11/27/2020,Feb-21,2/28/2021,26-Mar-21,Anticipated,3/26/2021,26-Mar-21,Anticipated,3/26/2021,NA,Interventional,INTENSE-COV,NA,Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV): a Phase IIb Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,294,Anticipated,"ANRS, Emerging Infectious Diseases",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:07Z,2021-10-12T07:04:07Z
NCT04470609,NA,7/13/2020,NA,NA,7/13/2020,7/13/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/13/2020,7/14/2020,Actual,10-Jul-20,Actual,7/10/2020,Jul-20,7/31/2020,Nov-21,Anticipated,11/30/2021,Nov-20,Anticipated,11/30/2020,NA,Interventional,NA,NA,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged â©¾60 Years",Enrolling by invitation,NA,Phase 1/Phase 2,471,Anticipated,Chinese Academy of Medical Sciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:33Z,2021-10-12T07:03:33Z
NCT04466085,NA,7/8/2020,NA,NA,12/1/2020,7/8/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2020,12/3/2020,Actual,12-Jul-20,Actual,7/12/2020,Dec-20,12/31/2020,15-Dec-21,Anticipated,12/15/2021,22-Oct-20,Actual,10/22/2020,NA,Interventional,NA,NA,Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years","Active, not recruiting",NA,Phase 2,900,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:07Z,2021-10-12T07:04:07Z
NCT04469491,NA,7/13/2020,NA,NA,3/3/2021,7/13/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,3/3/2021,3/4/2021,Actual,20-Sep-20,Actual,9/20/2020,Mar-21,3/31/2021,Sep-21,Anticipated,9/30/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,COV-NI,NA,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,Recruiting,NA,Phase 2,146,Anticipated,"Centre Hospitalier Universitaire, Amiens",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:39Z,2021-10-12T07:03:39Z
NCT04465513,NA,7/8/2020,NA,NA,10/4/2021,7/9/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/5/2021,Actual,31-Aug-20,Actual,8/31/2020,Jun-21,6/30/2021,4-Oct-21,Actual,10/4/2021,4-Oct-21,Actual,10/4/2021,NA,Interventional,NA,NA,Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19,"A Randomized, Open-label, Parallel Study to Investigate the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19 Who Are Hospitalized as Well as Patients Following the Guidance From Public Health",Completed,NA,Not Applicable,14,Actual,Hofseth Biocare ASA,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:12Z,2021-10-12T07:04:12Z
NCT04466280,NA,7/9/2020,NA,NA,7/9/2020,7/9/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,7/9/2020,7/10/2020,Actual,15-Jul-20,Anticipated,7/15/2020,Jul-20,7/31/2020,15-Dec-20,Anticipated,12/15/2020,15-Nov-20,Anticipated,11/15/2020,NA,Interventional,NA,NA,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19","Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Disease in Healthcare Providers at Baqiyatallah Hospital in Tehran",Recruiting,NA,Not Applicable,180,Anticipated,Baqiyatallah Medical Sciences University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:07Z,2021-10-12T07:04:07Z
NCT04467918,NA,7/3/2020,NA,NA,9/27/2021,7/9/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/28/2021,Actual,6-Jul-20,Actual,7/6/2020,Sep-21,9/30/2021,16-Nov-21,Anticipated,11/16/2021,16-Nov-21,Anticipated,11/16/2021,NA,Interventional,CANDIDATE,NA,CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,"Cannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019: A Randomized, Double-blind, Placebo-controlled Clinical Trial","Active, not recruiting",NA,Phase 2/Phase 3,100,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately the following publication. No end date.,"Researchers who provide a methodologically sound proposal. Depending on the level of the proposed use of data, approval by an independent review committee will be required for the identified purpose.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-10-12T07:03:53Z,2021-10-12T07:03:53Z
NCT04469114,NA,7/10/2020,NA,NA,8/2/2021,7/10/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/9/2021,Actual,16-Sep-20,Actual,9/16/2020,Jul-20,7/31/2020,9-Jan-21,Actual,1/9/2021,9-Jan-21,Actual,1/9/2021,NA,Interventional,NA,NA,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia",Completed,NA,Phase 3,289,Actual,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:45Z,2021-10-12T07:03:45Z
NCT04468971,NA,7/10/2020,NA,NA,6/21/2021,7/10/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/22/2021,Actual,29-Sep-20,Actual,9/29/2020,Sep-20,9/30/2020,30-Sep-21,Anticipated,9/30/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,RESOLVE,NA,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,"Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)","Active, not recruiting",NA,Phase 1,45,Anticipated,"Cellenkos, Inc.",,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:43Z,2021-10-12T07:03:43Z
NCT04466670,NA,7/8/2020,NA,NA,6/4/2021,7/8/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,6/4/2021,6/9/2021,Actual,11-Jul-20,Actual,7/11/2020,Jun-21,6/30/2021,30-May-22,Anticipated,5/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,Hemostasis in COVID-19: an Adaptive Clinical Trial,Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial,Recruiting,NA,Phase 2,379,Anticipated,University of Sao Paulo General Hospital,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:01Z,2021-10-12T07:04:01Z
NCT04465695,NA,7/9/2020,NA,NA,7/13/2020,7/9/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,7/13/2020,7/15/2020,Actual,14-Jul-20,Actual,7/14/2020,Jul-20,7/31/2020,30-Sep-21,Anticipated,9/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,"An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection",Recruiting,NA,Phase 2,81,Anticipated,The University of Hong Kong,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 12 months of study published,To be approved by the HKU/ IRB clinical trial study panel of valid research purpose,NA,Yes,To share anonymised participant data,2021-10-12T07:04:11Z,2021-10-12T07:04:11Z
NCT04466605,NA,7/9/2020,NA,NA,7/9/2020,7/9/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,7/9/2020,7/10/2020,Actual,30-Mar-20,Actual,3/30/2020,Jul-20,7/31/2020,6-Jul-20,Actual,7/6/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,NA,NA,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown: Randomized Clinical Trial,Completed,NA,Not Applicable,64,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:04:03Z,2021-10-12T07:04:03Z
NCT04464486,NA,6/26/2020,NA,NA,6/29/2021,7/8/2020,7/9/2020,Actual,NA,NA,NA,NA,NA,NA,6/29/2021,6/30/2021,Actual,21-Apr-20,Actual,4/21/2020,Jun-21,6/30/2021,31-Mar-22,Anticipated,3/31/2022,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,NA,NA,Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic,Remote COVID-19 Symptom Tracking and Improved Cancer Symptom Control for Cancer Patients at Home During the Pandemic,Enrolling by invitation,NA,Not Applicable,300,Anticipated,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After acceptance of the main findings publications in peer reviewed scientific journals.,"Data will be available to address research questions/hypothesis of the request. Once the Principal Investigator reviews the research question proposed, the data elements that can address the question will be shared.",NA,Yes,Secondary data analysis and use by other investigators is welcomed once the proposed aims have been analyzed and published. PI Mooney will share de-identified data with other investigators for study by proposing aims/hypotheses and identifying the data elements required and receiving agreement from the research team. Data will be shared with investigators working under an institution with a Federal Wide Assurance (FWA). The research team agrees to share data in a manner that is fully consistent with the data sharing policies of NIH and the University of Utah as well as applicable laws and regulations.,2021-10-12T07:04:21Z,2021-10-12T07:04:21Z
NCT04463264,NA,6/26/2020,NA,NA,10/7/2020,7/7/2020,7/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/7/2020,10/8/2020,Actual,26-Jun-20,Actual,6/26/2020,Jun-20,6/30/2020,26-Dec-20,Anticipated,12/26/2020,15-Nov-20,Anticipated,11/15/2020,NA,Interventional,NA,NA,Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),"Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study",Recruiting,NA,Phase 2/Phase 3,135,Anticipated,Laboratorios Roemmers S.A.I.C.F.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:31Z,2021-10-12T07:04:31Z
NCT04463849,NA,7/2/2020,NA,NA,9/27/2021,7/8/2020,7/9/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/28/2021,Actual,30-Jun-20,Actual,6/30/2020,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Oct-21,Anticipated,10/31/2021,NA,Interventional,COBETOX,NA,Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,Effects of SARS-CoV-2 Infection on Beta-cell Function in Euglycemic Patients,Recruiting,NA,Not Applicable,90,Anticipated,University of Milan,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:25Z,2021-10-12T07:04:25Z
NCT04461379,NA,7/2/2020,NA,NA,11/12/2020,7/7/2020,7/8/2020,Actual,NA,NA,NA,NA,NA,NA,11/12/2020,11/13/2020,Actual,21-Jul-20,Actual,7/21/2020,Nov-20,11/30/2020,1-Jan-21,Anticipated,1/1/2021,1-Jan-21,Anticipated,1/1/2021,NA,Interventional,NA,NA,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial","Active, not recruiting",NA,Phase 3,908,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:44Z,2021-10-12T07:04:44Z
NCT04463433,NA,4/12/2020,NA,NA,7/8/2020,7/8/2020,7/9/2020,Actual,NA,NA,NA,NA,NA,NA,7/8/2020,7/9/2020,Actual,1-Feb-20,Actual,2/1/2020,Jul-20,7/31/2020,31-Jan-22,Anticipated,1/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Recruiting,NA,Not Applicable,300,Anticipated,Beijing Normal University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:28Z,2021-10-12T07:04:28Z
NCT04462627,NA,7/7/2020,NA,NA,1/27/2021,7/7/2020,7/8/2020,Actual,NA,NA,NA,NA,NA,NA,1/27/2021,1/28/2021,Actual,14-Apr-20,Actual,4/14/2020,Jan-21,1/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Reduction of COVID 19 Transmission to Health Care Professionals,Reduction of COVID 19 Transmission to Health Care Professionals,Recruiting,NA,Not Applicable,500,Anticipated,Brugmann University Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:35Z,2021-10-12T07:04:35Z
NCT04463420,NA,7/4/2020,NA,NA,11/3/2020,7/8/2020,7/9/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2020,11/4/2020,Actual,15-Aug-20,Actual,8/15/2020,Nov-20,11/30/2020,15-Dec-20,Anticipated,12/15/2020,15-Nov-20,Anticipated,11/15/2020,NA,Interventional,NA,NA,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 a Multi-center Randomized Blinding Clinical Trial Study,Recruiting,NA,Not Applicable,224,Anticipated,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:28Z,2021-10-12T07:04:28Z
NCT04458246,NA,7/1/2020,NA,NA,7/2/2020,7/2/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,7/2/2020,7/7/2020,Actual,Jul-20,Anticipated,7/31/2020,Jul-20,7/31/2020,Jun-21,Anticipated,6/30/2021,Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic,"Online, Home-based, Aerobic Training Program Among Adolescents With Chronic Diseases During COVID-19 Pandemic: A Randomized Controlled Trial",Recruiting,NA,Not Applicable,140,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:08Z,2021-10-12T07:05:08Z
NCT04460651,NA,7/2/2020,NA,NA,9/10/2021,7/6/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,9/10/2021,9/17/2021,Actual,14-Aug-20,Actual,8/14/2020,Aug-21,8/31/2021,30-Aug-21,Actual,8/30/2021,30-Aug-21,Actual,8/30/2021,NA,Interventional,PREPARE-IT,NA,PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial,PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial,Completed,NA,Phase 3,4093,Actual,Estudios ClÃ­nicos Latino AmÃ©rica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:48Z,2021-10-12T07:04:48Z
NCT04458948,NA,6/9/2020,NA,NA,6/30/2020,6/30/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,6/30/2020,7/7/2020,Actual,24-Mar-20,Actual,3/24/2020,Apr-20,4/30/2020,24-Mar-25,Anticipated,3/24/2025,24-Mar-21,Anticipated,3/24/2021,NA,Interventional,NA,NA,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 Infection,"Active, not recruiting",NA,Phase 2,10000,Anticipated,University of New Mexico,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:02Z,2021-10-12T07:05:02Z
NCT04459676,NA,7/3/2020,NA,NA,4/12/2021,7/3/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,4/12/2021,4/15/2021,Actual,31-Jul-20,Actual,7/31/2020,Apr-21,4/30/2021,30-Apr-21,Anticipated,4/30/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,"A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of ANG- 3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia","Active, not recruiting",NA,Phase 2,100,Anticipated,Angion Biomedica Corp,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:57Z,2021-10-12T07:04:57Z
NCT04461340,NA,7/4/2020,NA,NA,9/6/2020,7/7/2020,7/8/2020,Actual,NA,NA,NA,NA,NA,NA,9/6/2020,9/9/2020,Actual,15-Aug-20,Actual,8/15/2020,Sep-20,9/30/2020,30-Nov-20,Anticipated,11/30/2020,30-Oct-20,Anticipated,10/30/2020,NA,Interventional,NA,NA,Efficacy and Safety of Sirolimus in COVID-19 Infection,Efficacy and Safety of Sirolimus for Treating COVID-19 Infection,Recruiting,NA,Phase 2,40,Anticipated,Alexandria University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:04:44Z,2021-10-12T07:04:44Z
NCT04460183,NA,7/3/2020,NA,NA,1/11/2021,7/3/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,1/11/2021,1/12/2021,Actual,29-Jul-20,Actual,7/29/2020,Nov-20,11/30/2020,23-Apr-21,Anticipated,4/23/2021,27-Jan-21,Anticipated,1/27/2021,NA,Interventional,NA,NA,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,"An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 WHO Grade 3&4 (NOCoV2)",Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Thirty Respiratory Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:52Z,2021-10-12T07:04:52Z
NCT04460534,NA,7/2/2020,NA,NA,8/16/2021,7/2/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/17/2021,Actual,7-May-20,Actual,5/7/2020,Aug-21,8/31/2021,12-May-21,Actual,5/12/2021,12-May-21,Actual,5/12/2021,NA,Interventional,COVISPERM,NA,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Detection of SARS-CoV-2 in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Completed,NA,Not Applicable,52,Actual,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:51Z,2021-10-12T07:04:51Z
NCT04460027,NA,7/1/2020,NA,NA,4/26/2021,7/2/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,4/26/2021,4/28/2021,Actual,22-Jun-20,Actual,6/22/2020,Apr-21,4/30/2021,30-Nov-20,Actual,11/30/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,NA,NA,W-SUDs for COVID-19,Woebot for Substance Use Disorders During COVID-19,Completed,NA,Phase 1,180,Actual,"Woebot Labs, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:55Z,2021-10-12T07:04:55Z
NCT04459520,NA,7/5/2020,NA,NA,8/19/2020,7/5/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2020,8/20/2020,Actual,23-Jul-20,Actual,7/23/2020,Aug-20,8/31/2020,29-Jul-20,Actual,7/29/2020,28-Jul-20,Actual,7/28/2020,NA,Interventional,NA,NA,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,NA,Not Applicable,1400,Actual,"University of California, Los Angeles",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:56Z,2021-10-12T07:04:56Z
NCT04457388,NA,6/30/2020,NA,NA,7/7/2020,6/30/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,7/7/2020,7/8/2020,Actual,25-Mar-20,Actual,3/25/2020,Jul-20,7/31/2020,15-Jun-20,Actual,6/15/2020,15-Jun-20,Actual,6/15/2020,NA,Interventional,NA,NA,Tele-Yoga Therapy for Chronic Pain,Tele- Yoga Therapy for Patients With Chronic Pain During Covid-19 Lockdown: A Prospective Non-randomized Single Arm Clinical Trial,Completed,NA,Not Applicable,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:13Z,2021-10-12T07:05:13Z
NCT04453384,NA,6/22/2020,NA,NA,7/15/2021,6/30/2020,7/1/2020,Actual,NA,NA,NA,NA,NA,NA,7/15/2021,7/21/2021,Actual,1-Sep-20,Actual,9/1/2020,Jul-21,7/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,POLYCOR,NA,Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,"A Randomized, Double-blind, Placebo-controlled Phase 2 (2a and 2b) Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia","Active, not recruiting",NA,Phase 2,416,Actual,Nantes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:48Z,2021-10-12T07:05:48Z
NCT04457349,NA,6/30/2020,NA,NA,1/1/2021,7/2/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,1/1/2021,1/5/2021,Actual,25-Jul-20,Actual,7/25/2020,Jan-21,1/31/2021,20-Jan-21,Anticipated,1/20/2021,29-Dec-20,Actual,12/29/2020,NA,Interventional,NA,NA,Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,Does Therapeutic Plasma Exchange Have A Role in Resistant Cytokine Storm State Of COVID-19 Infection?,Recruiting,NA,Not Applicable,10,Anticipated,Alexandria University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:16Z,2021-10-12T07:05:16Z
NCT04456595,NA,6/30/2020,NA,NA,2/10/2021,6/30/2020,7/2/2020,Actual,NA,NA,NA,NA,NA,NA,2/10/2021,2/11/2021,Actual,21-Jul-20,Actual,7/21/2020,Feb-21,2/28/2021,Feb-22,Anticipated,2/28/2022,17-Dec-20,Actual,12/17/2020,NA,Interventional,PROFISCOV,NA,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac","Active, not recruiting",NA,Phase 3,12688,Actual,Butantan Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:22Z,2021-10-12T07:05:22Z
NCT04453514,NA,6/30/2020,NA,NA,7/20/2021,6/30/2020,7/1/2020,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,21-Jul-20,Actual,7/21/2020,Jul-21,7/31/2021,19-Jun-21,Actual,6/19/2021,19-Jun-21,Actual,6/19/2021,NA,Interventional,NA,NA,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Cultivating Calm During COVID-19: A Feasibility Study of Video-based Trauma-informed Yoga,Completed,NA,Not Applicable,212,Actual,National University of Natural Medicine,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:49Z,2021-10-12T07:05:49Z
NCT04452669,NA,6/29/2020,NA,NA,8/4/2021,6/29/2020,6/30/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/5/2021,Actual,15-Sep-20,Actual,9/15/2020,Aug-21,8/31/2021,29-Jun-21,Actual,6/29/2021,29-Jun-21,Actual,6/29/2021,NA,Interventional,VPCOVID,NA,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,"Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation",Completed,NA,Phase 2,11,Actual,Aerogen Pharma Limited,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:54Z,2021-10-12T07:05:54Z
NCT04453657,NA,6/26/2020,NA,NA,9/2/2021,6/30/2020,7/1/2020,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/5/2021,Actual,4-Feb-21,Actual,2/4/2021,Sep-21,9/30/2021,Sep-22,Anticipated,9/30/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,"Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19","Adapting and Delivering a Tele-Wellness Supported Digital Toolkit to Baltimore City's Approved Family Child Care Home Providers Caring for Children of Essential Workers: Promoting Health, Early Literacy, and Quality Parent Engagement Amid COVID-19: A Pilot Study",Enrolling by invitation,NA,Not Applicable,270,Anticipated,Johns Hopkins University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:46Z,2021-10-12T07:05:46Z
NCT04451291,NA,6/26/2020,NA,NA,8/10/2021,6/26/2020,6/30/2020,Actual,NA,NA,NA,NA,NA,NA,8/10/2021,8/11/2021,Actual,25-Sep-20,Actual,9/25/2020,Aug-21,8/31/2021,25-Mar-22,Anticipated,3/25/2022,25-Sep-21,Anticipated,9/25/2021,NA,Interventional,NA,NA,Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure,DSC-COVID-19: An Open-label Study on the Safety and Efficacy of Decidual Stromal Cells in Respiratory Failure Induced by COVID-19,"Active, not recruiting",NA,Not Applicable,19,Actual,"University Health Network, Toronto",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:06Z,2021-10-12T07:06:06Z
NCT04453852,NA,6/3/2020,NA,NA,5/5/2021,6/30/2020,7/1/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/6/2021,Actual,30-Jun-20,Actual,6/30/2020,May-21,5/31/2021,14-Apr-21,Actual,4/14/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,COVAX19,NA,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Completed,NA,Phase 1,40,Actual,Vaxine Pty Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:43Z,2021-10-12T07:05:43Z
NCT04445246,NA,6/9/2020,NA,NA,6/23/2020,6/23/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,6/23/2020,6/24/2020,Actual,23-May-20,Actual,5/23/2020,May-20,5/31/2020,31-May-21,Anticipated,5/31/2021,31-May-21,Anticipated,5/31/2021,NA,Interventional,ILOCOVID,NA,Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,Inhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory Failure,Recruiting,NA,Phase 2,40,Anticipated,Hamad Medical Corporation,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:55Z,2021-10-12T07:06:55Z
NCT04452565,NA,6/26/2020,NA,NA,9/4/2020,6/26/2020,6/30/2020,Actual,NA,NA,NA,NA,NA,NA,9/4/2020,9/7/2020,Actual,15-Oct-20,Anticipated,10/15/2020,Jul-20,7/31/2020,15-Feb-21,Anticipated,2/15/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NATADEX,NA,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection","Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection",Recruiting,NA,Phase 2/Phase 3,525,Anticipated,"NeuroActiva, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:56Z,2021-10-12T07:05:56Z
NCT04452773,NA,6/25/2020,NA,NA,7/14/2020,6/29/2020,6/30/2020,Actual,NA,NA,NA,NA,NA,NA,7/14/2020,7/15/2020,Actual,14-Jul-20,Actual,7/14/2020,Jul-20,7/31/2020,Dec-21,Anticipated,12/31/2021,Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Efficacy of Food Supplement ManremycÂ® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,"Double-blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of the ManremycÂ® Food Supplement to Prevent SARS-CoV-2 Infection",Recruiting,NA,Not Applicable,315,Anticipated,Reig Jofre Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:52Z,2021-10-12T07:05:52Z
NCT04451889,NA,6/29/2020,NA,NA,7/22/2020,6/29/2020,6/30/2020,Actual,NA,NA,NA,NA,NA,NA,7/22/2020,7/24/2020,Actual,1-Aug-20,Anticipated,8/1/2020,Jun-20,6/30/2020,1-Sep-21,Anticipated,9/1/2021,1-Jul-21,Anticipated,7/1/2021,NA,Interventional,NA,NA,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Recruiting,NA,Not Applicable,15,Anticipated,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2021-10-12T07:06:01Z,2021-10-12T07:06:01Z
NCT04449380,NA,6/23/2020,NA,NA,4/28/2021,6/25/2020,6/26/2020,Actual,NA,NA,NA,NA,NA,NA,4/28/2021,5/3/2021,Actual,2-Nov-20,Actual,11/2/2020,Apr-21,4/30/2021,30-Mar-21,Actual,3/30/2021,30-Mar-21,Actual,3/30/2021,NA,Interventional,INTERCOP,NA,Clinical Study for the Treatment With Interferon-ÃŸ-1a (IFNÃŸ-1a) of COVID-19 Patients,"Randomized, Controlled, Open Label, Phase 2 Clinical Trial of Interferon-Î²-1a (IFNÎ²-1a) in COVID-19 Patients",Terminated,NA,Phase 2,56,Actual,IRCCS San Raffaele,,2,NA,Futility,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:22Z,2021-10-12T07:06:22Z
NCT04453475,NA,6/29/2020,NA,NA,9/29/2021,6/30/2020,7/1/2020,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,10/7/2021,Actual,1-Jul-20,Actual,7/1/2020,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,AnhandCOV19,NA,Feasibility and Benefits of Digital Services During the COVID19 Pandemic,Therapies to Achieve Treatment Goals While Being Exposed to Hygiene and Distance Rules: Feasibility and Benefits of Digital Services During the COVID19 Pandemic (Anhand-COVID19),Recruiting,NA,Not Applicable,2000,Anticipated,Jacobs University Bremen gGmbH,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data (IPD) will not be published. Other researchers are welcome to get in contact with the PI to get access to anonymous data.,2021-10-12T07:05:49Z,2021-10-12T07:05:49Z
NCT04447781,NA,6/16/2020,NA,NA,8/18/2020,6/24/2020,6/25/2020,Actual,NA,NA,NA,NA,NA,NA,8/18/2020,8/19/2020,Actual,15-Jul-20,Actual,7/15/2020,Aug-20,8/31/2020,22-Feb-22,Anticipated,2/22/2022,22-Feb-22,Anticipated,2/22/2022,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19","A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,International Vaccine Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,TRUE,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 3 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be anonymized and may be made available upon reasonable request.,2021-10-12T07:06:32Z,2021-10-12T07:06:32Z
NCT04452318,NA,6/26/2020,NA,NA,10/6/2021,6/26/2020,6/30/2020,Actual,NA,NA,NA,NA,NA,NA,10/6/2021,10/7/2021,Actual,13-Jul-20,Actual,7/13/2020,Oct-21,10/31/2021,4-Oct-21,Actual,10/4/2021,4-Oct-21,Actual,10/4/2021,NA,Interventional,NA,NA,COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2",Completed,NA,Phase 3,3303,Actual,Regeneron Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-12T07:05:58Z,2021-10-12T07:05:58Z
NCT04447404,NA,6/23/2020,NA,NA,3/18/2021,6/23/2020,6/25/2020,Actual,NA,NA,NA,NA,NA,NA,3/18/2021,3/22/2021,Actual,21-Sep-20,Actual,9/21/2020,Mar-21,3/31/2021,4-Mar-21,Actual,3/4/2021,4-Mar-21,Actual,3/4/2021,NA,Interventional,NA,NA,"DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury","A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Safety and Efficacy of DUR-928 in Subjects Infected With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury",Terminated,NA,Phase 2,2,Actual,Durect,,2,NA,low enrollment,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:38Z,2021-10-12T07:06:38Z
NCT04450004,NA,6/18/2020,NA,NA,10/21/2020,6/25/2020,6/29/2020,Actual,NA,NA,NA,NA,NA,NA,10/21/2020,10/23/2020,Actual,10-Jul-20,Actual,7/10/2020,Oct-20,10/31/2020,31-Dec-21,Anticipated,12/31/2021,20-Sep-21,Anticipated,9/20/2021,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age","Active, not recruiting",NA,Phase 1,180,Anticipated,Medicago,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:16Z,2021-10-12T07:06:16Z
NCT04447235,NA,6/22/2020,NA,NA,7/28/2020,6/23/2020,6/25/2020,Actual,NA,NA,NA,NA,NA,NA,7/28/2020,7/29/2020,Actual,23-Jul-20,Actual,7/23/2020,Jun-20,6/30/2020,Feb-21,Anticipated,2/28/2021,Dec-20,Anticipated,12/31/2020,NA,Interventional,TITAN,NA,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,"Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19",Recruiting,NA,Phase 2,176,Anticipated,Instituto do Cancer do Estado de SÃ£o Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,no plan to share individual participant data,2021-10-12T07:06:37Z,2021-10-12T07:06:37Z
NCT04451174,NA,6/26/2020,NA,NA,5/30/2021,6/26/2020,6/30/2020,Actual,NA,NA,NA,NA,NA,NA,5/30/2021,6/3/2021,Actual,23-Jun-20,Actual,6/23/2020,May-21,5/31/2021,30-Jan-21,Actual,1/30/2021,30-Jan-21,Actual,1/30/2021,NA,Interventional,PREDCOVID,NA,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia (PREDCOVID),Terminated,NA,Phase 3,60,Actual,University of Chile,,2,NA,Corticosteroid use approval,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,starting 6 months after publication,NA,NA,Yes,NA,2021-10-12T07:06:06Z,2021-10-12T07:06:06Z
NCT04447534,NA,6/23/2020,NA,NA,12/2/2020,6/23/2020,6/25/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2020,12/3/2020,Actual,23-Jun-20,Actual,6/23/2020,Dec-20,12/31/2020,1-Oct-30,Anticipated,10/1/2030,1-Oct-30,Anticipated,10/1/2030,NA,Interventional,NA,NA,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19?,Recruiting,NA,Phase 3,200,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:36Z,2021-10-12T07:06:36Z
NCT04449718,NA,6/16/2020,NA,NA,11/16/2020,6/25/2020,6/29/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2020,11/17/2020,Actual,1-Jun-20,Actual,6/1/2020,Jun-20,6/30/2020,7-Oct-20,Actual,10/7/2020,7-Oct-20,Actual,10/7/2020,NA,Interventional,NA,NA,Vitamin D Supplementation in Patients With COVID-19,"Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial",Completed,NA,Not Applicable,240,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:18Z,2021-10-12T07:06:18Z
NCT04448769,NA,6/23/2020,NA,NA,8/18/2020,6/25/2020,6/26/2020,Actual,NA,NA,NA,NA,NA,NA,8/18/2020,8/19/2020,Actual,26-Jun-20,Actual,6/26/2020,Aug-20,8/31/2020,24-Jul-20,Actual,7/24/2020,24-Jul-20,Actual,7/24/2020,NA,Interventional,COVAL-NANCY,NA,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) in the Population of the Grand Nancy Metropolitan Area,Completed,NA,Not Applicable,2006,Actual,"Central Hospital, Nancy, France",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:06:26Z,2021-10-12T07:06:26Z
NCT04447469,NA,6/23/2020,NA,NA,3/5/2021,6/24/2020,6/25/2020,Actual,NA,NA,NA,NA,NA,NA,3/5/2021,3/9/2021,Actual,27-Jul-20,Actual,7/27/2020,Mar-21,3/31/2021,Feb-22,Anticipated,2/28/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,"A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation",Recruiting,NA,Phase 2/Phase 3,588,Anticipated,"Kiniksa Pharmaceuticals, Ltd.",,6,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,IPD requests will be accepted after publication of the primary data manuscript,"IPD access will be provided to qualified academic researchers pending the Sponsor's review of the proposed research, including scientific novelty, review of the analytical and publication plans, funding source of the proposed research, any potential conflicts of interest, and institutional capabilities to perform the planned research.",NA,Yes,The Sponsor will review IPD requests proposals from qualified researchers,2021-10-12T07:06:34Z,2021-10-12T07:06:34Z
NCT04448756,NA,6/25/2020,NA,NA,9/5/2021,6/25/2020,6/26/2020,Actual,NA,NA,NA,NA,NA,NA,9/5/2021,9/8/2021,Actual,29-Jul-20,Actual,7/29/2020,Sep-21,9/30/2021,16-Aug-21,Actual,8/16/2021,16-Aug-21,Actual,8/16/2021,NA,Interventional,NA,NA,Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE),"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)",Completed,NA,Phase 2,151,Actual,EMD Serono,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html",2021-10-12T07:06:24Z,2021-10-12T07:06:24Z
NCT04446377,NA,6/23/2020,NA,NA,11/3/2020,6/23/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2020,11/4/2020,Actual,15-Jul-20,Actual,7/15/2020,Jun-20,6/30/2020,30-Apr-21,Anticipated,4/30/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,A Study of LAM-002A for the Prevention of Progression of COVID-19,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19",Recruiting,NA,Phase 2,142,Anticipated,"AI Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:46Z,2021-10-12T07:06:46Z
NCT04445935,NA,6/23/2020,NA,NA,6/23/2020,6/23/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,6/23/2020,6/24/2020,Actual,28-Jun-20,Anticipated,6/28/2020,Jun-20,6/30/2020,28-Mar-21,Anticipated,3/28/2021,28-Sep-20,Anticipated,9/28/2020,NA,Interventional,NA,NA,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial,Recruiting,NA,Phase 4,100,Anticipated,Hamad Medical Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,this will depend on IRB advice,2021-10-12T07:06:47Z,2021-10-12T07:06:47Z
NCT04446104,NA,5/11/2020,NA,NA,10/13/2020,6/23/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,10/13/2020,10/19/2020,Actual,13-May-20,Actual,5/13/2020,May-20,5/31/2020,31-Aug-20,Actual,8/31/2020,31-Aug-20,Actual,8/31/2020,NA,Interventional,NA,NA,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial),Completed,NA,Phase 3,4257,Actual,"National University Hospital, Singapore",,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:47Z,2021-10-12T07:06:47Z
NCT04445311,NA,6/19/2020,NA,NA,6/19/2020,6/19/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,6/19/2020,6/24/2020,Actual,31-May-20,Actual,5/31/2020,Jun-20,6/30/2020,15-Aug-20,Anticipated,8/15/2020,30-Jul-20,Anticipated,7/30/2020,NA,Interventional,NA,NA,Ivermectin in Treatment of COVID-19,Use of Ivermectin as a Therapeutic Option for Patients With COVID-19,Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:52Z,2021-10-12T07:06:52Z
NCT04445454,NA,6/19/2020,NA,NA,8/31/2021,6/22/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/1/2021,Actual,12-Jun-20,Actual,6/12/2020,Aug-21,8/31/2021,30-Sep-22,Anticipated,9/30/2022,30-Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,NA,Phase 1/Phase 2,20,Anticipated,University of Liege,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:51Z,2021-10-12T07:06:51Z
NCT04445376,NA,6/22/2020,NA,NA,10/6/2020,6/22/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,10/6/2020,10/8/2020,Actual,3-Jul-20,Actual,7/3/2020,Oct-20,10/31/2020,3-Oct-20,Actual,10/3/2020,10-Sep-20,Actual,9/10/2020,NA,Interventional,NA,NA,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Effect of Aerobic Exercises on Cardio-respiratory Fitness and Quality of Life in Recovered COVID 19 Recovered Patients.,Completed,NA,Not Applicable,20,Actual,Government College University Faisalabad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:51Z,2021-10-12T07:06:51Z
NCT04445285,NA,6/22/2020,NA,NA,5/26/2021,6/22/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/28/2021,Actual,28-Apr-20,Actual,4/28/2020,May-21,5/31/2021,28-Feb-22,Anticipated,2/28/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,DAMPENCOVID,NA,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,NA,Phase 2,44,Anticipated,University of South Alabama,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:06:53Z,2021-10-12T07:06:53Z
NCT04445597,NA,6/22/2020,NA,NA,11/27/2020,6/22/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/27/2020,12/1/2020,Actual,7-May-20,Actual,5/7/2020,Nov-20,11/30/2020,31-Dec-22,Anticipated,12/31/2022,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,ANOSMIC-19,NA,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,Recruiting,NA,Not Applicable,90,Anticipated,Universitaire Ziekenhuizen Leuven,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:50Z,2021-10-12T07:06:50Z
NCT04442048,NA,6/19/2020,NA,NA,5/17/2021,6/19/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,5/17/2021,5/18/2021,Actual,25-Jun-20,Actual,6/25/2020,May-21,5/31/2021,31-Mar-22,Anticipated,3/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,COV-IMMUNO,NA,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,"COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure","Active, not recruiting",NA,Phase 3,195,Actual,Canadian Cancer Trials Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:17Z,2021-10-12T07:07:17Z
NCT04445272,NA,6/13/2020,NA,NA,5/31/2021,6/23/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,5/31/2021,6/2/2021,Actual,22-May-20,Actual,5/22/2020,Jun-20,6/30/2020,23-Dec-20,Actual,12/23/2020,23-Dec-20,Actual,12/23/2020,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,"A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia: the BREATH-19 Study",Completed,NA,Phase 2,495,Actual,Fundacion SEIMC-GESIDA,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:52Z,2021-10-12T07:06:52Z
NCT04445220,NA,6/22/2020,NA,NA,8/31/2021,6/22/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/8/2021,Actual,19-Nov-20,Actual,11/19/2020,Aug-21,8/31/2021,Sep-22,Anticipated,9/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,"A Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement Therapy",Recruiting,NA,Phase 1/Phase 2,22,Anticipated,"Sentien Biotechnologies, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:52Z,2021-10-12T07:06:52Z
NCT04448119,NA,6/24/2020,NA,NA,8/11/2021,6/24/2020,6/25/2020,Actual,NA,NA,NA,NA,NA,NA,8/11/2021,8/13/2021,Actual,16-Oct-20,Actual,10/16/2020,Aug-21,8/31/2021,Nov-21,Anticipated,11/30/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Control of COVID-19 Outbreaks in Long Term Care,Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID),"Active, not recruiting",NA,Phase 2,760,Anticipated,Appili Therapeutics Inc.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:31Z,2021-10-12T07:06:31Z
NCT04442958,NA,6/17/2020,NA,NA,6/30/2020,6/19/2020,6/23/2020,Actual,NA,NA,NA,NA,NA,NA,6/30/2020,7/1/2020,Actual,15-May-20,Actual,5/15/2020,Jun-20,6/30/2020,17-Jun-20,Actual,6/17/2020,15-Jun-20,Actual,6/15/2020,NA,Interventional,NA,NA,Effectiveness of Convalescent Immune Plasma Therapy,Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome,Completed,NA,Not Applicable,60,Actual,Bagcilar Training and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:10Z,2021-10-12T07:07:10Z
NCT04445467,NA,6/22/2020,NA,NA,10/6/2021,6/22/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,10/6/2021,10/7/2021,Actual,30-Jul-20,Actual,7/30/2020,Oct-21,10/31/2021,Dec-21,Anticipated,12/31/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,VIRCO,NA,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection,"Active, not recruiting",NA,Phase 2,190,Actual,Bayside Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:06:50Z,2021-10-12T07:06:50Z
NCT04439825,NA,6/18/2020,NA,NA,3/11/2021,6/18/2020,6/19/2020,Actual,NA,NA,NA,NA,NA,NA,3/11/2021,3/15/2021,Actual,20-Jul-20,Actual,7/20/2020,Mar-21,3/31/2021,1-Dec-20,Actual,12/1/2020,3-Sep-20,Actual,9/3/2020,NA,Interventional,NA,NA,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Randomized Controlled Single Blind Cross Over Trial Evaluating the Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction in a Post Covid Period.,Completed,NA,Phase 1,45,Actual,DeNova Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:36Z,2021-10-12T07:07:36Z
NCT04443881,NA,6/18/2020,NA,NA,5/27/2021,6/20/2020,6/23/2020,Actual,NA,NA,NA,NA,NA,NA,5/27/2021,6/1/2021,Actual,8-May-20,Actual,5/8/2020,May-21,5/31/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,ANA-COVID-GEAS,NA,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),"Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection",Completed,NA,Phase 2/Phase 3,179,Actual,Fundacion Miguel Servet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2021-10-12T07:07:07Z,2021-10-12T07:07:07Z
NCT04442191,NA,5/11/2020,NA,NA,6/19/2020,6/19/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,6/19/2020,6/22/2020,Actual,5-May-20,Actual,5/5/2020,Jun-20,6/30/2020,5-May-21,Anticipated,5/5/2021,5-May-21,Anticipated,5/5/2021,NA,Interventional,NA,NA,Convalescent Plasma as a Possible Treatment for COVID-19,"Infusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19): A Double-blinded, Placebo-controlled, Proof-of-concept Study",Recruiting,NA,Phase 2,50,Anticipated,University of Illinois at Chicago,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:16Z,2021-10-12T07:07:16Z
NCT04441684,NA,5/20/2020,NA,NA,7/26/2021,6/19/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/27/2021,Actual,17-Apr-20,Actual,4/17/2020,Jul-21,7/31/2021,16-Jul-21,Actual,7/16/2021,7-May-20,Actual,5/7/2020,NA,Interventional,SeroCoV-HUS,NA,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)","Study of the Seroprevalence of SARS-CoV-2 in Hospital Staff in Strasbourg University Hospital, Strasbourg, France",Completed,NA,Not Applicable,1466,Actual,"University Hospital, Strasbourg, France",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:19Z,2021-10-12T07:07:19Z
NCT04445324,NA,6/22/2020,NA,NA,11/19/2020,6/22/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/19/2020,11/23/2020,Actual,25-Aug-20,Actual,8/25/2020,Oct-20,10/31/2020,Dec-20,Anticipated,12/31/2020,25-Aug-20,Actual,8/25/2020,NA,Interventional,NA,NA,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19 : A Feasibility Study of a Trial,"Active, not recruiting",NA,Not Applicable,30,Actual,Centre de Recherche de l'Institut Universitaire en santÃ© Mentale de MontrÃ©al,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:56Z,2021-10-12T07:06:56Z
NCT04445194,NA,6/16/2020,NA,NA,12/1/2020,6/21/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2020,12/3/2020,Actual,22-Jun-20,Actual,6/22/2020,Dec-20,12/31/2020,20-Sep-21,Anticipated,9/20/2021,22-Oct-20,Actual,10/22/2020,NA,Interventional,NA,NA,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:55Z,2021-10-12T07:06:55Z
NCT04444596,NA,6/18/2020,NA,NA,6/22/2020,6/22/2020,6/23/2020,Actual,NA,NA,NA,NA,NA,NA,6/22/2020,6/23/2020,Actual,17-Jun-20,Actual,6/17/2020,Apr-20,4/30/2020,31-Mar-21,Anticipated,3/31/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,Medical University Innsbruck,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:57Z,2021-10-12T07:06:57Z
NCT04441385,NA,6/18/2020,NA,NA,7/7/2020,6/18/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,7/7/2020,7/9/2020,Actual,26-Jun-20,Actual,6/26/2020,Jul-20,7/31/2020,20-Dec-20,Anticipated,12/20/2020,30-Nov-20,Anticipated,11/30/2020,NA,Interventional,MARACOVID,NA,Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,"Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).",Recruiting,NA,Phase 2,200,Anticipated,Hospital Universitario Infanta Leonor,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:23Z,2021-10-12T07:07:23Z
NCT04444271,NA,5/27/2020,NA,NA,6/27/2020,6/21/2020,6/23/2020,Actual,NA,NA,NA,NA,NA,NA,6/27/2020,6/30/2020,Actual,1-May-20,Actual,5/1/2020,Jun-20,6/30/2020,30-Sep-20,Anticipated,9/30/2020,30-Aug-20,Anticipated,8/30/2020,NA,Interventional,NA,NA,Mesenchymal Stem Cell Infusion for COVID-19 Infection,"Prospective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19)",Recruiting,NA,Phase 2,20,Anticipated,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:00Z,2021-10-12T07:07:00Z
NCT04439006,NA,6/17/2020,NA,NA,9/7/2021,6/18/2020,6/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/10/2021,Actual,23-Oct-20,Actual,10/23/2020,Sep-21,9/30/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In,Recruiting,NA,Phase 2,78,Anticipated,Ohio State University Comprehensive Cancer Center,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:43Z,2021-10-12T07:07:43Z
NCT04442178,NA,6/19/2020,NA,NA,2/15/2021,6/19/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,2/15/2021,2/16/2021,Actual,15-Sep-20,Actual,9/15/2020,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,ILIAD-7-US-I,NA,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious Cohort",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Publication,2021-10-12T07:07:16Z,2021-10-12T07:07:16Z
NCT04441424,NA,6/12/2020,NA,NA,6/20/2020,6/19/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,6/20/2020,6/23/2020,Actual,3-Apr-20,Actual,4/3/2020,Jun-20,6/30/2020,1-Jun-20,Actual,6/1/2020,1-Jun-20,Actual,6/1/2020,NA,Interventional,NA,NA,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,"The Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, Iraq",Completed,NA,Not Applicable,49,Actual,Alkarkh Health Directorate-Baghdad,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:23Z,2021-10-12T07:07:23Z
NCT04441632,NA,6/18/2020,NA,NA,8/11/2020,6/18/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,8/11/2020,8/12/2020,Actual,15-Jun-20,Actual,6/15/2020,Aug-20,8/31/2020,30-Jul-20,Actual,7/30/2020,26-Jul-20,Actual,7/26/2020,NA,Interventional,TEAM-ICU,NA,Effect of Positive Attitudes on Behavior and Wellness,"The Impact of Positive Reinforcement on Teamwork Climate, Resiliency, and Burnout During the COVID-19 Pandemic: the TEAM-ICU Study (Transforming Employee Attitudes Via Messaging Strengthens Interconnection, Communication, and Unity)",Completed,NA,Not Applicable,24,Actual,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:21Z,2021-10-12T07:07:21Z
NCT04442152,NA,6/19/2020,NA,NA,6/19/2020,6/19/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,6/19/2020,6/22/2020,Actual,Jun-20,Anticipated,6/30/2020,Jun-20,6/30/2020,Aug-20,Anticipated,8/31/2020,Aug-20,Anticipated,8/31/2020,NA,Interventional,NA,NA,Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants,Phone Survey for Understanding the Impact of COVID-19 on Caregiving and Family Dynamics on Bandebereho Study Participants,Enrolling by invitation,NA,Not Applicable,1000,Anticipated,"Promundo, United States",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:14Z,2021-10-12T07:07:14Z
NCT04438057,NA,6/17/2020,NA,NA,8/19/2020,6/17/2020,6/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2020,8/21/2020,Actual,12-Aug-20,Actual,8/12/2020,Aug-20,8/31/2020,12-Aug-21,Anticipated,8/12/2021,12-Aug-20,Actual,8/12/2020,NA,Interventional,NA,NA,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Recruiting,NA,Phase 2,150,Anticipated,Metro Infectious Disease Consultants,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:49Z,2021-10-12T07:07:49Z
NCT04435717,NA,6/11/2020,NA,NA,8/24/2021,6/16/2020,6/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/30/2021,Actual,4-May-20,Actual,5/4/2020,Aug-21,8/31/2021,10-Feb-21,Actual,2/10/2021,4-Nov-20,Actual,11/4/2020,NA,Interventional,COVITOZ-01,NA,Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01),"Unicenter, Randomized, Open-label Clinical Trial on the Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19",Terminated,NA,Phase 2,26,Actual,Hospital Universitario Ramon y Cajal,,3,NA,Futility,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:07Z,2021-10-12T07:08:07Z
NCT04436471,NA,6/16/2020,NA,NA,8/11/2020,6/17/2020,6/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/11/2020,8/12/2020,Actual,17-Jun-20,Actual,6/17/2020,Jun-20,6/30/2020,10-Aug-20,Actual,8/10/2020,3-Aug-20,Actual,8/3/2020,NA,Interventional,NA,NA,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:59Z,2021-10-12T07:07:59Z
NCT04431180,NA,6/12/2020,NA,NA,6/12/2020,6/12/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,6/12/2020,6/16/2020,Actual,13-Jun-20,Anticipated,6/13/2020,Jun-20,6/30/2020,30-Jun-20,Anticipated,6/30/2020,13-Jun-20,Anticipated,6/13/2020,NA,Interventional,NA,NA,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19#Second Repeat Trial#,Enrolling by invitation,NA,Not Applicable,403535,Anticipated,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:08:45Z,2021-10-12T07:08:45Z
NCT04435353,NA,6/14/2020,NA,NA,6/16/2020,6/16/2020,6/17/2020,Actual,NA,NA,NA,NA,NA,NA,6/16/2020,6/17/2020,Actual,22-Mar-20,Actual,3/22/2020,Jun-20,6/30/2020,1-Feb-21,Anticipated,2/1/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Recruiting,NA,Not Applicable,200,Anticipated,Astana Medical University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:11Z,2021-10-12T07:08:11Z
NCT04434131,NA,6/9/2020,NA,NA,6/14/2020,6/14/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,6/14/2020,6/16/2020,Actual,28-Apr-20,Actual,4/28/2020,Jun-20,6/30/2020,28-Apr-25,Anticipated,4/28/2025,28-Apr-21,Anticipated,4/28/2021,NA,Interventional,NA,NA,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,"Open, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19",Recruiting,NA,Phase 2,30,Anticipated,University of New Mexico,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:21Z,2021-10-12T07:08:21Z
NCT04435522,NA,6/15/2020,NA,NA,2/2/2021,6/15/2020,6/17/2020,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/4/2021,Actual,1-Oct-20,Actual,10/1/2020,Jun-20,6/30/2020,31-Dec-20,Actual,12/31/2020,31-Dec-20,Actual,12/31/2020,NA,Interventional,NA,NA,Maraviroc in Patients With Moderate and Severe COVID-19,Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2,Completed,NA,Phase 1,9,Actual,Rhode Island Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:09Z,2021-10-12T07:08:09Z
NCT04432298,NA,6/12/2020,NA,NA,3/31/2021,6/12/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,3/31/2021,4/2/2021,Actual,20-Jun-20,Actual,6/20/2020,Mar-21,3/31/2021,22-Mar-21,Actual,3/22/2021,22-Mar-21,Actual,3/22/2021,NA,Interventional,NA,NA,"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease","Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF), in Hospitalized Patients With Acute COVID-19 Disease",Terminated,NA,Phase 2,22,Actual,FibroGen,,2,NA,The study was terminated by Sponsor due to low enrollment.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:08:38Z,2021-10-12T07:08:38Z
NCT04432103,NA,6/12/2020,NA,NA,7/30/2021,6/12/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,7/30/2021,8/2/2021,Actual,8-Aug-20,Actual,8/8/2020,Jul-21,7/31/2021,29-Jan-21,Actual,1/29/2021,29-Jan-21,Actual,1/29/2021,NA,Interventional,NA,NA,Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma,Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma,Terminated,NA,Phase 3,6,Actual,Centro Medico ABC,,2,NA,There is new evidence that the Convalescent plasma is not useful for severe and critical COVID-19 Pneumonia,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:37Z,2021-10-12T07:08:37Z
NCT04429594,NA,6/10/2020,NA,NA,10/15/2020,6/11/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,10/15/2020,10/19/2020,Actual,28-Jul-20,Actual,7/28/2020,Jun-20,6/30/2020,31-Dec-25,Anticipated,12/31/2025,15-Jul-25,Anticipated,7/15/2025,NA,Interventional,CovImmune 2,NA,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement,Recruiting,NA,Not Applicable,1000,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:00Z,2021-10-12T07:09:00Z
NCT04432987,NA,6/15/2020,NA,NA,6/15/2020,6/15/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2020,6/16/2020,Actual,25-May-20,Actual,5/25/2020,May-20,5/31/2020,25-Sep-20,Anticipated,9/25/2020,25-Aug-20,Anticipated,8/25/2020,NA,Interventional,NA,NA,Dornase Alpha for the Treatment of COVID-19,Determination of Dornase Alpha Effectiveness in COVID-19 Treatment,Recruiting,NA,Phase 2,60,Anticipated,Acibadem University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:32Z,2021-10-12T07:08:32Z
NCT04432805,NA,6/15/2020,NA,NA,6/15/2020,6/15/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2020,6/16/2020,Actual,15-Jun-20,Actual,6/15/2020,Jun-20,6/30/2020,15-Jun-21,Anticipated,6/15/2021,15-Jun-21,Anticipated,6/15/2021,NA,Interventional,LUSCOVIDPREG,NA,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Recruiting,NA,Not Applicable,160,Anticipated,Assistance Publique Hopitaux De Marseille,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:31Z,2021-10-12T07:08:31Z
NCT04431856,NA,6/12/2020,NA,NA,11/30/2020,6/12/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,11/30/2020,12/1/2020,Actual,15-May-20,Actual,5/15/2020,Nov-20,11/30/2020,17-Nov-20,Actual,11/17/2020,17-Nov-20,Actual,11/17/2020,NA,Interventional,Co-PARENT,NA,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,NA,Not Applicable,80,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:40Z,2021-10-12T07:08:40Z
NCT04431297,NA,6/12/2020,NA,NA,8/19/2021,6/12/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/20/2021,Actual,22-Mar-21,Actual,3/22/2021,Aug-21,8/31/2021,14-May-21,Actual,5/14/2021,14-May-21,Actual,5/14/2021,NA,Interventional,NA,NA,Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic,The Impact of Virtual Mindfulness Education Sessions on Staff Perceived Stress During COVID-19,Completed,NA,Not Applicable,15,Actual,Icahn School of Medicine at Mount Sinai,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:45Z,2021-10-12T07:08:45Z
NCT04428021,NA,6/7/2020,NA,NA,4/5/2021,6/10/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,4/5/2021,4/6/2021,Actual,15-Jun-20,Actual,6/15/2020,Apr-21,4/30/2021,31-Oct-21,Anticipated,10/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,PLACO-COVID,NA,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,"Effectiveness of Adding Standard Plasma or COVID-19 Convalescent Plasma to Standard Treatment, Versus Standard Treatment Alone, in Patients With Recent Onset of COVID-19 Respiratory Failure. A Randomized, Three-arms, Phase 2 Trial","Active, not recruiting",NA,Phase 2,180,Actual,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available after 12 months from study ending and for the following 5 years,Data requests should be submitted to the corresponding author for consideration.,NA,Yes,"All Individual Participant Data requests should be submitted to the corresponding author for consideration. Access to deidentified participant data may be granted following review, after the publication of major results",2021-10-12T07:09:11Z,2021-10-12T07:09:11Z
NCT04429724,NA,6/10/2020,NA,NA,5/21/2021,6/11/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/24/2021,Actual,6-Jul-20,Actual,7/6/2020,Jan-21,1/31/2021,Dec-21,Anticipated,12/31/2021,16-Mar-21,Actual,3/16/2021,NA,Interventional,SERODRON,NA,Health Professional Exposure Assessment to Covid-19,Health Professional Exposure Assessment to Covid-19,"Active, not recruiting",NA,Not Applicable,2129,Actual,Tourcoing Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:56Z,2021-10-12T07:08:56Z
NCT04443673,NA,6/18/2020,NA,NA,8/20/2020,6/19/2020,6/23/2020,Actual,NA,NA,NA,NA,NA,NA,8/20/2020,8/24/2020,Actual,20-Aug-20,Actual,8/20/2020,Aug-20,8/31/2020,30-Jun-21,Anticipated,6/30/2021,28-Feb-21,Anticipated,2/28/2021,NA,Interventional,NA,NA,Glycine Supplement for Severe COVID-19,Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation,Recruiting,NA,Not Applicable,82,Anticipated,Instituto Nacional de Enfermedades Respiratorias,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,From publication of results in a scientific journal onward.,Reasonable request by E-mail (mhvargasb@yahoo.com.mx),NA,Yes,IPD can be shared on a reasonable basis and after authorization from the Instituto Nacional de Enfermedades Respiratorias' IRB.,2021-10-12T07:07:05Z,2021-10-12T07:07:05Z
NCT04442230,NA,6/17/2020,NA,NA,7/13/2021,6/19/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,7/13/2021,7/19/2021,Actual,10-Oct-20,Actual,10/10/2020,Jul-21,7/31/2021,15-Feb-21,Actual,2/15/2021,15-Feb-21,Actual,2/15/2021,NA,Interventional,NA,NA,NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),"Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)",Terminated,NA,Phase 2,48,Actual,"Altimmune, Inc.",,2,NA,Enrollment,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:15Z,2021-10-12T07:07:15Z
NCT04441918,NA,6/6/2020,NA,NA,6/18/2020,6/18/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,6/18/2020,6/22/2020,Actual,5-Jun-20,Actual,6/5/2020,Jun-20,6/30/2020,11-Dec-20,Anticipated,12/11/2020,11-Dec-20,Anticipated,12/11/2020,NA,Interventional,NA,NA,"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects","A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile and Immunogenicity of JS016 (Anti-SARS-CoV-2 Monoclonal Antibody) Injection in Chinese Healthy Subjects After Intravenous Infusion of Single Dose",Recruiting,NA,Phase 1,40,Anticipated,"Shanghai Junshi Bioscience Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:19Z,2021-10-12T07:07:19Z
NCT04439045,NA,6/3/2020,NA,NA,3/18/2021,6/18/2020,6/19/2020,Actual,NA,NA,NA,NA,NA,NA,3/18/2021,3/22/2021,Actual,24-Jun-20,Actual,6/24/2020,Aug-20,8/31/2020,1-Dec-21,Anticipated,12/1/2021,2-Sep-21,Anticipated,9/2/2021,NA,Interventional,COBRA,NA,Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study: Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity","Active, not recruiting",NA,Phase 3,122,Actual,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:43Z,2021-10-12T07:07:43Z
NCT04444674,NA,6/15/2020,NA,NA,11/23/2020,6/22/2020,6/23/2020,Actual,NA,NA,NA,NA,NA,NA,11/23/2020,11/27/2020,Actual,24-Jun-20,Actual,6/24/2020,Nov-20,11/30/2020,Dec-21,Anticipated,12/31/2021,Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV","Active, not recruiting",NA,Phase 1/Phase 2,2130,Actual,University of Oxford,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,within 1 year of trial completion,Any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.,NA,Yes,"The data accumulated from this study will be stored at RMPRU/ Wits. In collaboration with UK collaborators, we aim to make the data available, within one year of completion of the study to any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.

De-identified data will be shared. Related trial documents will be available (protocol, ICFs, statistical analysis plan)",2021-10-12T07:06:57Z,2021-10-12T07:06:57Z
NCT04438980,NA,6/18/2020,NA,NA,5/14/2021,6/18/2020,6/19/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2021,5/17/2021,Actual,15-May-20,Actual,5/15/2020,May-21,5/31/2021,9-Apr-21,Actual,4/9/2021,12-Mar-21,Actual,3/12/2021,NA,Interventional,CORTIVID,NA,Glucocorticoids in COVID-19 (CORTIVID),Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial,Completed,NA,Phase 3,72,Actual,Fundacion Miguel Servet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2021-10-12T07:07:42Z,2021-10-12T07:07:42Z
NCT04438070,NA,6/17/2020,NA,NA,6/17/2020,6/17/2020,6/18/2020,Actual,NA,NA,NA,NA,NA,NA,6/17/2020,6/18/2020,Actual,10-Apr-20,Actual,4/10/2020,Jun-20,6/30/2020,Jun-20,Anticipated,6/30/2020,Jun-20,Anticipated,6/30/2020,NA,Interventional,NA,NA,COVID Screening Strategies in Homeless Shelters,COVID Screening Strategies in Homeless Shelters,Recruiting,NA,Not Applicable,400,Anticipated,St. Joseph's Healthcare Hamilton,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:07:49Z,2021-10-12T07:07:49Z
NCT04438694,NA,6/16/2020,NA,NA,9/25/2020,6/17/2020,6/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/25/2020,9/29/2020,Actual,1-Jun-20,Actual,6/1/2020,Sep-20,9/30/2020,31-Dec-21,Anticipated,12/31/2021,31-May-21,Anticipated,5/31/2021,NA,Interventional,CP IN COVID19,NA,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Recruiting,NA,Phase 1/Phase 2,67,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:44Z,2021-10-12T07:07:44Z
NCT04438850,NA,4/10/2020,NA,NA,6/17/2021,6/18/2020,6/19/2020,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/23/2021,Actual,31-Jul-20,Actual,7/31/2020,Jun-21,6/30/2021,8-Jun-21,Actual,6/8/2021,8-Jun-21,Actual,6/8/2021,NA,Interventional,COVER,NA,COVidIVERmectin: Ivermectin for Treatment of Covid-19,"Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19",Terminated,NA,Phase 2,93,Actual,IRCCS Sacro Cuore Don Calabria di Negrar,,3,NA,Incidence has dramatically dropped and there is lack of eligible patients,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,The database will be available upon publication of the results,The data will be available in a public repository,NA,Yes,The anonymized database will be uploaded into a public repository,2021-10-12T07:07:43Z,2021-10-12T07:07:43Z
NCT04435587,NA,6/15/2020,NA,NA,1/7/2021,6/15/2020,6/17/2020,Actual,NA,NA,NA,NA,NA,NA,1/7/2021,1/11/2021,Actual,13-Jul-20,Actual,7/13/2020,Jan-21,1/31/2021,Nov-21,Anticipated,11/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,IDRA-COVID19,NA,Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection,Comparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir/ Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 Infection,Recruiting,NA,Phase 4,80,Anticipated,Mahidol University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:07Z,2021-10-12T07:08:07Z
NCT04435275,NA,6/9/2020,NA,NA,1/7/2021,6/15/2020,6/17/2020,Actual,NA,NA,NA,NA,NA,NA,1/7/2021,1/8/2021,Actual,2-Jan-21,Actual,1/2/2021,May-20,5/31/2020,1-May-21,Anticipated,5/1/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,Virtual Assistant for COVID-19 PPE,Development of an Automated and Scalable Virtual Assistant to Aid in PPE Adherence and Clinical Protocols for Healthcare Worker Safety,Recruiting,NA,Not Applicable,50,Anticipated,"University Health Network, Toronto",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:10Z,2021-10-12T07:08:10Z
NCT04435795,NA,6/16/2020,NA,NA,7/25/2021,6/16/2020,6/17/2020,Actual,NA,NA,NA,NA,NA,NA,7/25/2021,7/30/2021,Actual,14-Sep-20,Actual,9/14/2020,Jul-21,7/31/2021,8-Jul-21,Actual,7/8/2021,8-Jun-21,Actual,6/8/2021,NA,Interventional,CONTAIN,NA,Inhaled Ciclesonide for Outpatients With COVID19,Ciclesonide Clinical Trial for COVID-19 Treatment,Terminated,NA,Phase 2/Phase 3,215,Actual,McGill University Health Centre/Research Institute of the McGill University Health Centre,,2,NA,could not meet target enrolment,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:06Z,2021-10-12T07:08:06Z
NCT04437719,NA,6/17/2020,NA,NA,8/19/2021,6/17/2020,6/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/20/2021,Actual,29-Jun-20,Actual,6/29/2020,Aug-21,8/31/2021,31-Dec-21,Anticipated,12/31/2021,28-Jun-21,Actual,6/28/2021,NA,Interventional,OBVIONCO,NA,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic","Longitudinal Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group, Paris, France for a Period of 6 Months During the COVID-19 Pandemic in 2020","Active, not recruiting",NA,Not Applicable,34,Actual,Groupe Hospitalier Paris Saint Joseph,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:51Z,2021-10-12T07:07:51Z
NCT04437875,NA,6/16/2020,NA,NA,8/11/2020,6/17/2020,6/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/11/2020,8/12/2020,Actual,17-Jun-20,Actual,6/17/2020,Jun-20,6/30/2020,10-Aug-20,Actual,8/10/2020,3-Aug-20,Actual,8/3/2020,NA,Interventional,NA,NA,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:49Z,2021-10-12T07:07:49Z
NCT04433910,NA,5/6/2020,NA,NA,3/16/2021,6/15/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,3/16/2021,3/17/2021,Actual,30-Aug-20,Actual,8/30/2020,Mar-21,3/31/2021,22-Feb-21,Actual,2/22/2021,21-Jan-21,Actual,1/21/2021,NA,Interventional,CAPSID,NA,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,"A Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19",Completed,NA,Phase 2,106,Actual,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:21Z,2021-10-12T07:08:21Z
NCT04433546,NA,5/28/2020,NA,NA,12/9/2020,6/13/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,12/9/2020,12/11/2020,Actual,15-Jul-20,Actual,7/15/2020,Dec-20,12/31/2020,2-Dec-20,Actual,12/2/2020,2-Dec-20,Actual,12/2/2020,NA,Interventional,VANGARD,NA,"Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).","A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)",Terminated,NA,Phase 2,54,Actual,PhaseBio Pharmaceuticals Inc.,,3,NA,Company no longer pursing indication,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:26Z,2021-10-12T07:08:26Z
NCT04437823,NA,6/17/2020,NA,NA,6/17/2020,6/17/2020,6/18/2020,Actual,NA,NA,NA,NA,NA,NA,6/17/2020,6/18/2020,Actual,1-Jun-20,Actual,6/1/2020,Jun-20,6/30/2020,30-Jun-21,Anticipated,6/30/2021,31-May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,NA,Phase 2,20,Anticipated,Jinnah Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,At the end of completion of the study,Available online,NA,Yes,The report will be published and available online.,2021-10-12T07:07:48Z,2021-10-12T07:07:48Z
NCT04434248,NA,6/13/2020,NA,NA,6/15/2020,6/15/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2020,6/16/2020,Actual,23-Apr-20,Actual,4/23/2020,Jun-20,6/30/2020,Jul-20,Anticipated,7/31/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19","Active, not recruiting",NA,Phase 2/Phase 3,330,Actual,Chromis LLC,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:20Z,2021-10-12T07:08:20Z
NCT04430608,NA,5/26/2020,NA,NA,6/11/2020,6/11/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,6/11/2020,6/12/2020,Actual,25-May-20,Actual,5/25/2020,May-20,5/31/2020,25-May-21,Anticipated,5/25/2021,25-Apr-21,Anticipated,4/25/2021,NA,Interventional,CGM-ISO,NA,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Remote Glucose Monitoring of Patients With Diabetes Quarantined During the COVID-19 Pandemic - a Hospital-Based Randomized Controlled Trial of the Effect of Remote Continuous Glucose Monitoring Compared to Usual Glucose Monitoring,Recruiting,NA,Not Applicable,72,Anticipated,Nordsjaellands Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"Undecided, will be updated",2021-10-12T07:08:50Z,2021-10-12T07:08:50Z
NCT04429555,NA,6/9/2020,NA,NA,7/29/2021,6/11/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/2/2021,Actual,11-Jan-21,Actual,1/11/2021,Jul-21,7/31/2021,1-Dec-22,Anticipated,12/1/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,"Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome",Recruiting,NA,Phase 2,40,Anticipated,MediciNova,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:00Z,2021-10-12T07:09:00Z
NCT04432324,NA,6/12/2020,NA,NA,3/9/2021,6/12/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,3/9/2021,3/10/2021,Actual,2-Jun-20,Actual,6/2/2020,Mar-21,3/31/2021,3-Mar-21,Actual,3/3/2021,3-Mar-21,Actual,3/3/2021,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:36Z,2021-10-12T07:08:36Z
NCT04432051,NA,6/11/2020,NA,NA,8/6/2020,6/12/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,8/6/2020,8/7/2020,Actual,26-May-20,Actual,5/26/2020,Aug-20,8/31/2020,10-Aug-20,Anticipated,8/10/2020,8-Aug-20,Anticipated,8/8/2020,NA,Interventional,NA,NA,The Use of Lung Ultrasonography in COVID-19 Patients,The Significance of Lung Ultrasonography in the Follow-up and Treatment of COVID-19 Patients With Respiratory Failure,Recruiting,NA,Not Applicable,100,Anticipated,Gaziosmanpasa Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:39Z,2021-10-12T07:08:39Z
NCT04433949,NA,6/12/2020,NA,NA,6/17/2021,6/15/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/22/2021,Actual,12-Jun-20,Actual,6/12/2020,Jun-21,6/30/2021,30-May-22,Anticipated,5/30/2022,30-May-22,Anticipated,5/30/2022,NA,Interventional,RESCUE1-19,NA,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 (RESCUE 1-19): A Randomized Phase III Trial of Best Supportive Care Plus Provider's Choice of Pharmaceutical Treatment With or Without Whole Lung Low-Dose Radiation Therapy (LD-RT) in Hospitalized Patients With COVID-19,Recruiting,NA,Phase 3,52,Anticipated,Emory University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.",2021-10-12T07:08:23Z,2021-10-12T07:08:23Z
NCT04428008,NA,6/7/2020,NA,NA,4/22/2021,6/10/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,4/22/2021,4/23/2021,Actual,12-Jan-21,Actual,1/12/2021,Apr-21,4/30/2021,May-22,Anticipated,5/31/2022,Aug-21,Anticipated,8/31/2021,NA,Interventional,Ta1,NA,Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients,A Pilot Trial of Thymalfasin (Ta1) to Prevent COVID-19 Infection in Renal Dialysis Patients,Recruiting,NA,Phase 2,240,Anticipated,Inova Health System,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:12Z,2021-10-12T07:09:12Z
NCT04429529,NA,6/9/2020,NA,NA,4/6/2021,6/10/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,4/6/2021,4/8/2021,Actual,9-Jun-20,Actual,6/9/2020,Sep-20,9/30/2020,20-Jan-21,Actual,1/20/2021,19-Nov-20,Actual,11/19/2020,NA,Interventional,NA,NA,"Safety of TY027, a Treatment for COVID-19, in Humans","Phase 1 First-in-Human, Time Lagged, Randomised, Placebo Controlled, Double Blind, Single Ascending Dose Study of TY027 in Healthy Adult Volunteers",Completed,NA,Phase 1,32,Actual,Tychan Pte Ltd.,,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:58Z,2021-10-12T07:08:58Z
NCT04429867,NA,6/10/2020,NA,NA,6/11/2020,6/11/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,6/11/2020,6/16/2020,Actual,7-May-20,Actual,5/7/2020,Jun-20,6/30/2020,7-Dec-20,Anticipated,12/7/2020,7-Dec-20,Anticipated,12/7/2020,NA,Interventional,NA,NA,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,"Active, not recruiting",NA,Phase 4,700,Anticipated,WellStar Health System,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:55Z,2021-10-12T07:08:55Z
NCT04424797,NA,6/5/2020,NA,NA,6/15/2021,6/8/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2021,6/18/2021,Actual,13-Jul-20,Actual,7/13/2020,Jun-21,6/30/2021,31-Jul-22,Anticipated,7/31/2022,31-Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Recruiting,NA,Not Applicable,100,Anticipated,Poudre Valley Health System,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:36Z,2021-10-12T07:09:36Z
NCT04429711,NA,5/24/2020,NA,NA,6/14/2020,6/11/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,6/14/2020,6/16/2020,Actual,12-May-20,Actual,5/12/2020,Jun-20,6/30/2020,31-Oct-20,Anticipated,10/31/2020,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,"Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled Trial",Recruiting,NA,Not Applicable,100,Anticipated,Sheba Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:57Z,2021-10-12T07:08:57Z
NCT04429334,NA,5/29/2020,NA,NA,7/5/2021,6/11/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,7/5/2021,7/9/2021,Actual,23-Sep-20,Actual,9/23/2020,Jul-21,7/31/2021,Jun-23,Anticipated,6/30/2023,Jun-23,Anticipated,6/30/2023,NA,Interventional,ESSENTIAL,NA,Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support and Features of Systemic Inflammation.,"Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features",Recruiting,NA,Phase 2/Phase 3,730,Anticipated,Inotrem,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:01Z,2021-10-12T07:09:01Z
NCT04429828,NA,6/11/2020,NA,NA,8/26/2021,6/11/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/27/2021,Actual,13-Jun-20,Actual,6/13/2020,Aug-21,8/31/2021,30-Dec-20,Actual,12/30/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,PoWerS,NA,COVID-19 Psychological Wellbeing for Healthcare Students,PoWerS Study: Psychological Wellbeing for Healthcare Students: Evaluation of a COVID-19 Digital Learning Package,Completed,NA,Not Applicable,42,Actual,University of Nottingham,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Interview data will be available on request at study end (after publication of findings).,On request.,NA,Yes,Interview data will be made available on request (after study end).,2021-10-12T07:08:55Z,2021-10-12T07:08:55Z
NCT04428099,NA,6/9/2020,NA,NA,6/10/2020,6/10/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/10/2020,6/11/2020,Actual,13-Jan-20,Actual,1/13/2020,Jun-20,6/30/2020,12-Jul-22,Anticipated,7/12/2022,12-Jan-22,Anticipated,1/12/2022,NA,Interventional,NA,NA,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Effectiveness of a Healthy Lifestyle Promotion Program as Adjunctive Teletherapy for Treatment-resistant Major Depression During Covid 19 Pandemic: A Randomized Clinical Trial Protocol,Recruiting,NA,Not Applicable,186,Anticipated,University of the Balearic Islands,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:08Z,2021-10-12T07:09:08Z
NCT04427137,NA,6/10/2020,NA,NA,8/5/2021,6/10/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2021,8/6/2021,Actual,9-Jun-20,Actual,6/9/2020,Aug-21,8/31/2021,9-Nov-21,Anticipated,11/9/2021,9-Nov-21,Anticipated,11/9/2021,NA,Interventional,NA,NA,Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic,A Novel and Practical Accelerated Low-frequency Right-sided Stimulation Protocol as a Substitute for Patients With Bipolar Depression Needing Electroconvulsive Therapy During the COVID-19 Pandemic,"Active, not recruiting",NA,Not Applicable,29,Actual,Centre for Addiction and Mental Health,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:18Z,2021-10-12T07:09:18Z
NCT04427566,NA,6/5/2020,NA,NA,3/11/2021,6/9/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,3/11/2021,3/15/2021,Actual,23-Jul-20,Actual,7/23/2020,Mar-21,3/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,VENTED,NA,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,Vented COVID: A Phase II Study Of The Use Of Ultra Low-Dose Bilateral Whole Lung Radiation Therapy in the Treatment Of Critically Ill Patients With COVID-19 Respiratory Compromise,Recruiting,NA,Phase 2,24,Anticipated,Ohio State University Comprehensive Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:13Z,2021-10-12T07:09:13Z
NCT04427098,NA,5/29/2020,NA,NA,6/15/2020,6/10/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2020,6/17/2020,Actual,22-May-20,Actual,5/22/2020,Jun-20,6/30/2020,30-Oct-20,Anticipated,10/30/2020,30-Oct-20,Anticipated,10/30/2020,NA,Interventional,INHIXACOV19,NA,Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,"Intermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19: A Pilot Phase II Single-arm Study, INHIXACOVID19",Recruiting,NA,Phase 2,300,Anticipated,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:19Z,2021-10-12T07:09:19Z
NCT04425707,NA,6/8/2020,NA,NA,6/8/2020,6/8/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/8/2020,6/11/2020,Actual,9-Jun-20,Actual,6/9/2020,Jun-20,6/30/2020,1-Sep-20,Anticipated,9/1/2020,1-Jul-20,Anticipated,7/1/2020,NA,Interventional,NA,NA,Ivermectin In Treatment of COVID 19 Patients,The Use of Ivermectin In the Treatment of COVID 19 Patients,Recruiting,NA,Not Applicable,100,Anticipated,"Ministry of Health and Population, Egypt",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:30Z,2021-10-12T07:09:30Z
NCT04426305,NA,6/3/2020,NA,NA,6/7/2021,6/9/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/7/2021,6/8/2021,Actual,21-May-20,Actual,5/21/2020,May-20,5/31/2020,30-Oct-20,Actual,10/30/2020,20-Jun-20,Actual,6/20/2020,NA,Interventional,NA,NA,Community Health Workers Against COVID19,Community Health Workers Against COVID19 Tackling Psychosocial Suffering Due to Physical Distancing,Completed,NA,Not Applicable,140,Actual,University Ghent,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:09:23Z,2021-10-12T07:09:23Z
NCT04425616,NA,6/3/2020,NA,NA,1/22/2021,6/5/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,1/22/2021,1/25/2021,Actual,4-Jun-20,Actual,6/4/2020,Jan-21,1/31/2021,30-Nov-22,Anticipated,11/30/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions to Maintain and Improve Mental and Physical Health in People With Cancer Who Are Following Social Distancing Guidance: A COVID-19 Targeted Trial,Recruiting,NA,Not Applicable,1100,Anticipated,University Hospital Southampton NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:30Z,2021-10-12T07:09:30Z
NCT04425629,NA,6/8/2020,NA,NA,10/1/2021,6/8/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,10/1/2021,10/8/2021,Actual,16-Jun-20,Actual,6/16/2020,Oct-21,10/31/2021,18-May-22,Anticipated,5/18/2022,29-Dec-21,Anticipated,12/29/2021,NA,Interventional,NA,NA,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19","A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19",Recruiting,NA,Phase 3,10500,Anticipated,Regeneron Pharmaceuticals,,1,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-12T07:09:31Z,2021-10-12T07:09:31Z
NCT04423289,NA,6/6/2020,NA,NA,6/8/2020,6/8/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,6/8/2020,6/9/2020,Actual,31-Mar-20,Actual,3/31/2020,Jun-20,6/30/2020,18-May-20,Actual,5/18/2020,4-May-20,Actual,5/4/2020,NA,Interventional,NA,NA,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,COVID Follow-App: Telematic Monitoring Through a Mobile Application of Patients With COVID-19: A Randomized Clinical Trial,Completed,NA,Not Applicable,150,Actual,Hospital Universitari Vall d'Hebron Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:49Z,2021-10-12T07:09:49Z
NCT04426318,NA,6/9/2020,NA,NA,1/22/2021,6/9/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,1/22/2021,1/26/2021,Actual,14-Jun-20,Actual,6/14/2020,Nov-20,11/30/2020,12-Jan-21,Actual,1/12/2021,12-Jan-21,Actual,1/12/2021,NA,Interventional,CAHMP-ED,NA,COVID-19 and the Healthy Minds Program for Educators,COVID-19 and the Healthy Minds Program for Educators,Completed,NA,Not Applicable,733,Actual,"University of Wisconsin, Madison",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be de-identified and made publicly available based on the publication of preregistered study hypotheses following peer review.,Researcher consent. Any reasonable request will be granted.,NA,Yes,"Data will be de-identified and listed in public data registries (i.e., osf) based on the publication of preregistered study hypotheses on a manuscript by manuscript basis.",2021-10-12T07:09:23Z,2021-10-12T07:09:23Z
NCT04426006,NA,6/9/2020,NA,NA,7/5/2021,6/9/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,7/5/2021,7/9/2021,Actual,1-Jun-20,Actual,6/1/2020,Jul-21,7/31/2021,1-Jan-23,Anticipated,1/1/2023,1-Jan-22,Anticipated,1/1/2022,NA,Interventional,PRO-SERO-COV,NA,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut BergoniÃ© in the Context of the COVID-19 Pandemic,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut BergoniÃ© in the Context of the COVID-19 Pandemic - PRO-SERO-COV,"Active, not recruiting",NA,Not Applicable,550,Actual,Institut BergoniÃ©,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:26Z,2021-10-12T07:09:26Z
NCT04425317,NA,5/27/2020,NA,NA,7/6/2021,6/9/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,7/6/2021,7/7/2021,Actual,10-Sep-20,Actual,9/10/2020,Jul-21,7/31/2021,15-Jul-22,Anticipated,7/15/2022,6-Jul-21,Actual,7/6/2021,NA,Interventional,COVID_OFF,NA,Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,Detection of SARS-CoV-2 in Follicular Fluid and Cumu-lus-oocyte-complexes From COVID-19 Patients During Controlled Ovarian Stimulation for ICSI Treatment,Recruiting,NA,Not Applicable,20,Anticipated,CRG UZ Brussel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:33Z,2021-10-12T07:09:33Z
NCT04425252,NA,6/9/2020,NA,NA,1/15/2021,6/9/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,1/15/2021,1/19/2021,Actual,1-Aug-20,Actual,8/1/2020,Jan-21,1/31/2021,29-Dec-20,Actual,12/29/2020,29-Dec-20,Actual,12/29/2020,NA,Interventional,CRISIS,NA,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19),Completed,NA,Phase 1/Phase 2,23,Actual,"Clear Creek Bio, Inc.",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:34Z,2021-10-12T07:09:34Z
NCT04426201,NA,6/9/2020,NA,NA,6/2/2021,6/9/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/2/2021,6/3/2021,Actual,20-Dec-20,Actual,12/20/2020,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,ILIAD-7-US-O,NA,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ),"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Publication,2021-10-12T07:09:25Z,2021-10-12T07:09:25Z
NCT04425005,NA,6/8/2020,NA,NA,1/18/2021,6/9/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,1/18/2021,1/22/2021,Actual,10-May-20,Actual,5/10/2020,Jan-21,1/31/2021,7-Dec-20,Actual,12/7/2020,7-Dec-20,Actual,12/7/2020,NA,Interventional,NA,NA,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Effect of Home-based Exercise Training Program During the Covid-19 Pandemic in Post-bariatric Patients: A Randomized Controlled Trial,Completed,NA,Not Applicable,55,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:34Z,2021-10-12T07:09:34Z
NCT04424212,NA,6/4/2020,NA,NA,2/18/2021,6/8/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,2/18/2021,2/21/2021,Actual,10-Jun-20,Actual,6/10/2020,Feb-21,2/28/2021,Aug-21,Anticipated,8/31/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,CoronaCope - Internet-based Cognitive Behavioural Therapy for Adults Suffering From Mental Health Problems Related to the Coronavirus Pandemic,"Active, not recruiting",NA,Not Applicable,120,Anticipated,Linkoeping University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:42Z,2021-10-12T07:09:42Z
NCT04424953,NA,6/1/2020,NA,NA,3/16/2021,6/5/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,3/16/2021,3/17/2021,Actual,1-Jun-20,Actual,6/1/2020,Mar-21,3/31/2021,25-Sep-20,Actual,9/25/2020,25-Sep-20,Actual,9/25/2020,NA,Interventional,NA,NA,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,A Randomised Controlled Trial to Compare McGrath Videolaryngoscope Against Direct Laryngoscope for Endotracheal Intubation When Powered Air Purifying Respirator is Worn During the Current Coronavirus Disease 2019 Pandemic,Completed,NA,Not Applicable,28,Actual,Singapore General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:34Z,2021-10-12T07:09:34Z
NCT04424082,NA,6/7/2020,NA,NA,5/27/2021,6/8/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,5/27/2021,5/28/2021,Actual,9-Jun-20,Actual,6/9/2020,May-21,5/31/2021,27-May-21,Actual,5/27/2021,25-Jun-20,Actual,6/25/2020,NA,Interventional,NA,NA,External Dead Space in Ventilated COVID-19 Patients,Influence of External Dead Space on Volumetric Capnography Derived Parameters in Mechanically Ventilated COVID-19 Patients,Completed,NA,Not Applicable,10,Actual,Karolinska Institutet,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:42Z,2021-10-12T07:09:42Z
NCT04427254,NA,5/26/2020,NA,NA,3/1/2021,6/10/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,3/1/2021,3/2/2021,Actual,26-Jun-20,Actual,6/26/2020,Mar-21,3/31/2021,Jan-23,Anticipated,1/31/2023,Jan-23,Anticipated,1/31/2023,NA,Interventional,CORONEVRAXE,NA,Study of the Sars-Cov2 Neuroinvasiveness - COVID19,Study of the Sars-Cov2 Neuroinvasiveness - COVID19,Recruiting,NA,Not Applicable,500,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:16Z,2021-10-12T07:09:16Z
NCT04423991,NA,6/8/2020,NA,NA,6/8/2020,6/8/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,6/8/2020,6/9/2020,Actual,10-Mar-20,Actual,3/10/2020,Jun-20,6/30/2020,4-Jun-20,Actual,6/4/2020,4-Jun-20,Actual,6/4/2020,NA,Interventional,IDENTIFY,NA,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning: the IDENTIFY Trial,Completed,NA,Not Applicable,290,Actual,Dascena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:41Z,2021-10-12T07:09:41Z
NCT04424901,NA,5/29/2020,NA,NA,9/28/2021,6/8/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/29/2021,Actual,3-May-20,Actual,5/3/2020,Sep-21,9/30/2021,30-May-22,Anticipated,5/30/2022,1-May-22,Anticipated,5/1/2022,NA,Interventional,TOLD,NA,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,"A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients",Recruiting,NA,Phase 2,100,Anticipated,UConn Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:35Z,2021-10-12T07:09:35Z
NCT04417257,NA,5/28/2020,NA,NA,10/3/2021,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/3/2021,10/5/2021,Actual,29-Jun-20,Actual,6/29/2020,Oct-21,10/31/2021,15-Jul-21,Actual,7/15/2021,15-Jul-21,Actual,7/15/2021,NA,Interventional,RESOLUTION,NA,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,"RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease",Completed,NA,Phase 2,240,Actual,Laurent Pharmaceuticals Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:34Z,2021-10-12T07:10:34Z
NCT04420806,NA,6/5/2020,NA,NA,11/12/2020,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,11/12/2020,11/13/2020,Actual,14-Mar-20,Actual,3/14/2020,Nov-20,11/30/2020,30-Oct-20,Actual,10/30/2020,30-Jul-20,Actual,7/30/2020,NA,Interventional,NA,NA,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Effects of Three Months of COVID-19 Lockdown Induced Deconditioning After 13 Months of High Intensity Exercise Training in Early Postmenopausal Women,Completed,NA,Not Applicable,21,Actual,University of Erlangen-NÃ¼rnberg Medical School,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:08Z,2021-10-12T07:10:08Z
NCT04419025,NA,6/3/2020,NA,NA,5/26/2021,6/3/2020,6/5/2020,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/28/2021,Actual,23-Sep-20,Actual,9/23/2020,May-21,5/31/2021,14-May-21,Actual,5/14/2021,14-May-21,Actual,5/14/2021,NA,Interventional,NA,NA,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease,Completed,NA,Phase 2,165,Actual,Cambridge Health Alliance,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Six months after publication available for a year,Written request; to be reviewed by the PI,http://www.NACinCOVID.info,Yes,Information that underlies results in published data,2021-10-12T07:10:20Z,2021-10-12T07:10:20Z
NCT04422509,NA,6/3/2020,NA,NA,7/11/2021,6/8/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,7/11/2021,7/13/2021,Actual,30-Oct-20,Actual,10/30/2020,Jul-21,7/31/2021,30-Apr-21,Actual,4/30/2021,25-Feb-21,Actual,2/25/2021,NA,Interventional,COVID_LAN,NA,Lanadelumab for Treatment of COVID-19 Disease,Lanadelumab for Treatment of COVID-19 Disease,Completed,NA,Phase 1/Phase 2,43,Actual,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,this has not yet been decided,2021-10-12T07:09:54Z,2021-10-12T07:09:54Z
NCT04420260,NA,5/25/2020,NA,NA,7/8/2021,6/4/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,7/8/2021,7/15/2021,Actual,18-Mar-21,Actual,3/18/2021,Jul-21,7/31/2021,5-Jul-21,Actual,7/5/2021,23-Jun-21,Actual,6/23/2021,NA,Interventional,PI-Covid-19,NA,Primary Prevention of Infection by COVID-19 in Workers,"Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in MedellÃ­n-Antioquia",Completed,NA,Not Applicable,152,Actual,Unidad de InvestigaciÃ³n GenÃ©tica Molecular,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:10Z,2021-10-12T07:10:10Z
NCT04421508,NA,6/5/2020,NA,NA,4/26/2021,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,4/26/2021,4/28/2021,Actual,12-Jul-20,Actual,7/12/2020,Apr-21,4/30/2021,22-Jan-21,Actual,1/22/2021,28-Dec-20,Actual,12/28/2020,NA,Interventional,COViNOX,NA,A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)",Terminated,NA,Phase 3,191,Actual,Bellerophon,,2,NA,Futility,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:03Z,2021-10-12T07:10:03Z
NCT04420676,NA,6/4/2020,NA,NA,1/14/2021,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,1/14/2021,1/20/2021,Actual,24-Sep-20,Actual,9/24/2020,Jan-21,1/31/2021,Dec-22,Anticipated,12/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,SynCov,NA,Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,"Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection: A Randomized, Double-blind, Placebo Controlled, Telemedicine Study (SynCov Study)",Recruiting,NA,Not Applicable,120,Anticipated,Medical University of Graz,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,1 year after completion,free,NA,Yes,Upload of microbiome sequences and metadata to a repository,2021-10-12T07:10:07Z,2021-10-12T07:10:07Z
NCT04419623,NA,6/3/2020,NA,NA,5/10/2021,6/4/2020,6/5/2020,Actual,NA,NA,NA,NA,NA,NA,5/10/2021,5/12/2021,Actual,9-Jul-20,Actual,7/9/2020,May-21,5/31/2021,15-Dec-20,Actual,12/15/2020,22-Sep-20,Actual,9/22/2020,NA,Interventional,NA,NA,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,"A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer",Completed,NA,Phase 1,7,Actual,"Telios Pharma, Inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:15Z,2021-10-12T07:10:15Z
NCT04420299,NA,6/5/2020,NA,NA,6/8/2020,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,6/8/2020,6/11/2020,Actual,4-Jun-20,Actual,6/4/2020,Jun-20,6/30/2020,31-Mar-21,Anticipated,3/31/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,"A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19",Recruiting,NA,Phase 2,120,Anticipated,FundaciÃ³n de investigaciÃ³n HM,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:12Z,2021-10-12T07:10:12Z
NCT04418505,NA,6/3/2020,NA,NA,6/10/2021,6/3/2020,6/5/2020,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/14/2021,Actual,2-Sep-20,Actual,9/2/2020,Jun-21,6/30/2021,30-Sep-21,Anticipated,9/30/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,COVIDLight,NA,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,A Randomized Study Evaluating the Efficacy of the Vielight RX Plus in the Treatment of COVID-19 Respiratory Symptoms,"Active, not recruiting",NA,Not Applicable,295,Actual,Vielight Inc.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:23Z,2021-10-12T07:10:23Z
NCT04420338,NA,6/5/2020,NA,NA,6/15/2020,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2020,6/17/2020,Actual,5-Jun-20,Actual,6/5/2020,Jun-20,6/30/2020,15-Dec-20,Anticipated,12/15/2020,15-Dec-20,Anticipated,12/15/2020,NA,Interventional,SeroCOVIDial,NA,"SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study","SeroCOVIDial Study: Assessment of SARS-COV2 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study",Recruiting,NA,Not Applicable,800,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:12Z,2021-10-12T07:10:12Z
NCT04418206,NA,5/18/2020,NA,NA,11/6/2020,6/4/2020,6/5/2020,Actual,NA,NA,NA,NA,NA,NA,11/6/2020,11/9/2020,Actual,1-Jun-20,Actual,6/1/2020,May-20,5/31/2020,1-Jun-21,Anticipated,6/1/2021,1-Dec-20,Anticipated,12/1/2020,NA,Interventional,EliSpot,NA,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Recruiting,NA,Not Applicable,300,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:25Z,2021-10-12T07:10:25Z
NCT04421391,NA,6/4/2020,NA,NA,6/5/2020,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,6/5/2020,6/9/2020,Actual,8-Jun-20,Anticipated,6/8/2020,Jun-20,6/30/2020,8-Nov-20,Anticipated,11/8/2020,1-Nov-20,Anticipated,11/1/2020,NA,Interventional,NA,NA,QuadraMune(TM) for Prevention of COVID-19,Phase II Study of QuadraMune(TM) for Prevention of COVID-19 in High Risk Populations,Recruiting,NA,Not Applicable,500,Anticipated,Therapeutic Solutions International,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:05Z,2021-10-12T07:10:05Z
NCT04419610,NA,4/16/2020,NA,NA,5/25/2021,6/4/2020,6/5/2020,Actual,NA,NA,NA,NA,NA,NA,5/25/2021,5/27/2021,Actual,9-Oct-20,Actual,10/9/2020,May-21,5/31/2021,12-May-21,Actual,5/12/2021,12-May-21,Actual,5/12/2021,NA,Interventional,NA,NA,RAS and Coagulopathy in COVID19,Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19,Completed,NA,Early Phase 1,30,Actual,Imperial College London,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:15Z,2021-10-12T07:10:15Z
NCT04422353,NA,6/7/2020,NA,NA,5/11/2021,6/7/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,5/11/2021,5/14/2021,Actual,1-May-20,Actual,5/1/2020,May-21,5/31/2021,30-Dec-24,Anticipated,12/30/2024,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,PTT-Online,NA,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,The Impact of Video Dance Class and Unsupervised Physical Activity on Parkinson's People During the Covid-19 Pandemic: Interventional,Recruiting,NA,Not Applicable,60,Anticipated,Federal University of Rio Grande do Sul,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:56Z,2021-10-12T07:09:56Z
NCT04416360,NA,5/19/2020,NA,NA,6/3/2020,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,6/3/2020,6/4/2020,Actual,5-May-20,Actual,5/5/2020,Jun-20,6/30/2020,Jan-21,Anticipated,1/31/2021,Jul-20,Anticipated,7/31/2020,NA,Interventional,CLIECO,NA,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak,Recruiting,NA,Not Applicable,40,Anticipated,"University Hospital, Toulouse",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:42Z,2021-10-12T07:10:42Z
NCT04421612,NA,6/4/2020,NA,NA,5/5/2021,6/4/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/6/2021,Actual,2-Apr-20,Actual,4/2/2020,Aug-20,8/31/2020,1-Jan-21,Actual,1/1/2021,1-Jan-21,Actual,1/1/2021,NA,Interventional,Co-COVID-19,NA,COVID-19 - No Health Without Mental Health,COVID-19 - No Health Without Mental Health,Completed,NA,Not Applicable,91,Actual,Haukeland University Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,There is a plan to share anonymous interaction-data. Health data are undecided,2021-10-12T07:09:59Z,2021-10-12T07:09:59Z
NCT04421027,NA,6/5/2020,NA,NA,7/15/2021,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,7/15/2021,7/19/2021,Actual,12-Jun-20,Actual,6/12/2020,Jul-21,7/31/2021,10-Jun-21,Actual,6/10/2021,12-Feb-21,Actual,2/12/2021,NA,Interventional,COV-BARRIER,NA,A Study of Baricitinib (LY3009104) in Participants With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection",Completed,NA,Phase 3,1585,Actual,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2021-10-12T07:10:08Z,2021-10-12T07:10:08Z
NCT04420390,NA,5/14/2020,NA,NA,6/4/2020,6/4/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,6/4/2020,6/9/2020,Actual,1-May-20,Actual,5/1/2020,Jun-20,6/30/2020,8-Sep-20,Anticipated,9/8/2020,31-Jul-20,Anticipated,7/31/2020,NA,Interventional,LOWRAD-Cov19,NA,Low Dose Radiotherapy for COVID-19 Pneumonitis,Low Dose Radiotherapy as Antinflammatory Treatment for COVID-19 Pneumonitis,Recruiting,NA,Not Applicable,41,Anticipated,"Hospital San Carlos, Madrid",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:10Z,2021-10-12T07:10:10Z
NCT04420247,NA,6/2/2020,NA,NA,5/10/2021,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,5/10/2021,5/12/2021,Actual,16-Apr-20,Actual,4/16/2020,May-21,5/31/2021,3-Sep-20,Actual,9/3/2020,20-Aug-20,Actual,8/20/2020,NA,Interventional,NA,NA,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,NA,Phase 3,142,Actual,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:13Z,2021-10-12T07:10:13Z
NCT04420182,NA,5/29/2020,NA,NA,5/20/2021,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,5/20/2021,5/21/2021,Actual,17-Aug-20,Actual,8/17/2020,May-21,5/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,COVID-19 Virtual Care at Home,COVID-19 Virtual Care at Home,Recruiting,NA,Not Applicable,2000,Anticipated,Lawson Health Research Institute,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:11Z,2021-10-12T07:10:11Z
NCT04421625,NA,5/18/2020,NA,NA,5/4/2021,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,5/4/2021,5/5/2021,Actual,15-Jun-20,Actual,6/15/2020,May-21,5/31/2021,15-Jun-22,Anticipated,6/15/2022,15-Jun-22,Anticipated,6/15/2022,NA,Interventional,PAPESCO-19,NA,Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,"Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic: Constitution of a Biological Collection Linked to a Prospective, Multicenter Cohort Study",Recruiting,NA,Not Applicable,2300,Anticipated,Institut Cancerologie de l'Ouest,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:03Z,2021-10-12T07:10:03Z
NCT04417335,NA,5/25/2020,NA,NA,6/3/2020,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,6/3/2020,6/4/2020,Actual,16-Apr-20,Actual,4/16/2020,May-20,5/31/2020,May-21,Anticipated,5/31/2021,May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 4,2014,Actual,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:31Z,2021-10-12T07:10:31Z
NCT04421664,NA,6/5/2020,NA,NA,9/18/2020,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,9/18/2020,9/22/2020,Actual,25-Mar-20,Actual,3/25/2020,Sep-20,9/30/2020,17-Aug-20,Actual,8/17/2020,17-Aug-20,Actual,8/17/2020,NA,Interventional,NA,NA,Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Terminated,NA,Phase 3,70,Actual,McGill University Health Centre/Research Institute of the McGill University Health Centre,,2,NA,Request of Health Canada after publication of https://doi.org/10.7326/M20-4207,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,At time of publication,To be publicly provided,http://www.covid-19research.ca,Yes,De-identified dataset will be included with publication.,2021-10-12T07:09:59Z,2021-10-12T07:09:59Z
NCT04416308,NA,5/27/2020,NA,NA,4/13/2021,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,4/13/2021,4/14/2021,Actual,29-May-20,Actual,5/29/2020,Apr-21,4/30/2021,12-Oct-20,Actual,10/12/2020,10-Jul-20,Actual,7/10/2020,NA,Interventional,AntiCoV-HB,NA,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne,Completed,NA,Not Applicable,9453,Actual,Rennes University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:38Z,2021-10-12T07:10:38Z
NCT04412668,NA,6/1/2020,NA,NA,1/28/2021,6/1/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,1/28/2021,1/29/2021,Actual,12-Jun-20,Actual,6/12/2020,Jan-21,1/31/2021,21-Dec-20,Actual,12/21/2020,21-Dec-20,Actual,12/21/2020,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19),Completed,NA,Phase 2,32,Actual,"aTyr Pharma, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:05Z,2021-10-12T07:11:05Z
NCT04414618,NA,5/26/2020,NA,NA,3/8/2021,5/29/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,3/8/2021,3/10/2021,Actual,2-Jul-20,Actual,7/2/2020,Mar-21,3/31/2021,23-Dec-20,Actual,12/23/2020,26-Nov-20,Actual,11/26/2020,NA,Interventional,COVID-19,NA,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia",Completed,NA,Phase 2,42,Actual,RedHill Biopharma Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:52Z,2021-10-12T07:10:52Z
NCT04413006,NA,5/21/2020,NA,NA,6/1/2020,6/1/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,6/1/2020,6/2/2020,Actual,25-May-20,Anticipated,5/25/2020,May-20,5/31/2020,31-Mar-21,Anticipated,3/31/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Self-compassion for Chronic Pain Virtual Group Treatment Program,A Self-compassion Group-based Treatment for Chronic Pain Via Video Conferencing During the COVID-19 Pandemic: Feasibility Study for a Potential New Mode of Treatment Delivery,Recruiting,NA,Not Applicable,28,Anticipated,University of Manitoba,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:04Z,2021-10-12T07:11:04Z
NCT04416919,NA,5/13/2020,NA,NA,3/4/2021,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,3/4/2021,3/5/2021,Actual,20-May-20,Actual,5/20/2020,Mar-21,3/31/2021,1-Jul-21,Anticipated,7/1/2021,1-Jun-20,Actual,6/1/2020,NA,Interventional,NA,NA,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,A Proposed Alternative to the N-95 Mask Shortage in the COVID-19 Pandemic. A Feasibility Study,"Active, not recruiting",NA,Not Applicable,20,Actual,University of Oklahoma,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:36Z,2021-10-12T07:10:36Z
NCT04417270,NA,6/1/2020,NA,NA,3/1/2021,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,3/1/2021,3/2/2021,Actual,12-Jun-20,Actual,6/12/2020,Mar-21,3/31/2021,30-Nov-20,Actual,11/30/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,NA,NA,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Completed,NA,Not Applicable,52,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,The team has not decided whether to share the results with other researchers. The team will consider publishing results after study completion,2021-10-12T07:10:32Z,2021-10-12T07:10:32Z
NCT04413864,NA,4/21/2020,NA,NA,6/18/2021,6/2/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,6/18/2021,6/21/2021,Actual,24-Apr-20,Actual,4/24/2020,May-21,5/31/2021,24-Oct-22,Anticipated,10/24/2022,24-Oct-22,Anticipated,10/24/2022,NA,Interventional,DEXDO-COVID,NA,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,NA,Not Applicable,50,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:56Z,2021-10-12T07:10:56Z
NCT04416139,NA,5/30/2020,NA,NA,6/3/2020,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,6/3/2020,6/4/2020,Actual,1-May-20,Actual,5/1/2020,Jun-20,6/30/2020,1-May-21,Anticipated,5/1/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,COVID-19,NA,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study,Recruiting,NA,Phase 2,10,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:39Z,2021-10-12T07:10:39Z
NCT04416334,NA,6/3/2020,NA,NA,9/8/2021,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,9/8/2021,9/9/2021,Actual,19-Aug-20,Actual,8/19/2020,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,25-Dec-21,Anticipated,12/25/2021,NA,Interventional,COLCHI-COVID,NA,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19),Recruiting,NA,Phase 3,954,Anticipated,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:37Z,2021-10-12T07:10:37Z
NCT04416113,NA,5/24/2020,NA,NA,8/5/2021,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2021,8/6/2021,Actual,5-Aug-21,Actual,8/5/2021,Aug-21,8/31/2021,Feb-22,Anticipated,2/28/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Photodynamic Therapy for the Treatment of COVID-19,Photobiomodulation and Photodynamic Therapy for the Treatment of COVID-19 A Randomized Controlled Clinical Trials,"Active, not recruiting",NA,Not Applicable,60,Anticipated,Cairo University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,if the results are positive we will invite other researchers to share,2021-10-12T07:10:43Z,2021-10-12T07:10:43Z
NCT04412239,NA,5/30/2020,NA,NA,11/16/2020,5/30/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2020,11/18/2020,Actual,20-Apr-20,Actual,4/20/2020,Nov-20,11/30/2020,20-Dec-20,Anticipated,12/20/2020,20-Dec-20,Anticipated,12/20/2020,NA,Interventional,Coronavirus19,NA,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,Recruiting,NA,Not Applicable,200,Anticipated,Health Science Center of Xi'an Jiaotong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:10Z,2021-10-12T07:11:10Z
NCT04320953,NA,3/21/2020,NA,NA,4/15/2020,3/23/2020,3/25/2020,Actual,NA,NA,NA,NA,NA,NA,4/15/2020,4/17/2020,Actual,16-Mar-20,Actual,3/16/2020,Apr-20,4/30/2020,9-Apr-20,Actual,4/9/2020,26-Mar-20,Actual,3/26/2020,NA,Interventional,NA,NA,Non-contact Endoscopy at Covid-19 Outbreak,Non-contact Endoscopy at Covid-19 Outbreak,Completed,NA,Not Applicable,5,Actual,Changhai Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:35Z,2021-10-12T07:22:35Z
NCT04412330,NA,5/12/2020,NA,NA,6/8/2021,6/1/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,6/8/2021,6/11/2021,Actual,1-May-20,Actual,5/1/2020,Jun-21,6/30/2021,5-May-21,Actual,5/5/2021,5-May-21,Actual,5/5/2021,NA,Interventional,OPTIMAL,NA,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19 (OPTImAL) - a Single Center Prospective Study,Completed,NA,Not Applicable,32,Actual,University of Kentucky,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:09Z,2021-10-12T07:11:09Z
NCT04414293,NA,6/1/2020,NA,NA,2/12/2021,6/2/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/15/2021,Actual,1-Oct-20,Actual,10/1/2020,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,31-Jul-21,Anticipated,7/31/2021,NA,Interventional,COVRTE-19,NA,Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,Phase II Study of Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,Recruiting,NA,Not Applicable,41,Anticipated,Hospital Provincial de Castellon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:52Z,2021-10-12T07:10:52Z
NCT04414124,NA,6/1/2020,NA,NA,8/12/2021,6/1/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/13/2021,Actual,2-Aug-20,Actual,8/2/2020,Aug-21,8/31/2021,2-Feb-21,Actual,2/2/2021,2-Feb-21,Actual,2/2/2021,NA,Interventional,NA,NA,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,"A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19",Completed,NA,Not Applicable,350,Actual,Kaleido Biosciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:54Z,2021-10-12T07:10:54Z
NCT04413968,NA,6/2/2020,NA,NA,10/23/2020,6/2/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/23/2020,10/26/2020,Actual,2-Jun-20,Actual,6/2/2020,May-20,5/31/2020,2-Oct-20,Actual,10/2/2020,2-Jul-20,Actual,7/2/2020,NA,Interventional,COVIDOCRECHE,NA,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants","Contamination and Transmission of the SARS-CoV-2 Virus in Exposed, Confined and Community-based Infants: A Cross-sectional, Multicentre, Interventional Seroprevalence Study",Completed,NA,Not Applicable,600,Actual,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:56Z,2021-10-12T07:10:56Z
NCT04414371,NA,5/31/2020,NA,NA,6/2/2020,6/2/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,6/2/2020,6/4/2020,Actual,20-May-20,Actual,5/20/2020,Jun-20,6/30/2020,31-Dec-20,Anticipated,12/31/2020,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Recruiting,NA,Not Applicable,200,Anticipated,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:53Z,2021-10-12T07:10:53Z
NCT04410692,NA,5/27/2020,NA,NA,5/30/2020,5/29/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,5/30/2020,6/2/2020,Actual,15-May-20,Actual,5/15/2020,May-20,5/31/2020,17-May-20,Actual,5/17/2020,16-May-20,Actual,5/16/2020,NA,Interventional,NA,NA,Can the Prediction Market Improve Predictions of COVID-19?,Can the Prediction Market Improve Predictions of COVID-19?,Completed,NA,Not Applicable,560,Actual,"National University, Singapore",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,After completion of all analysis. It will be made available in the supporting documentation.,It will be made available in the supporting documentation.,NA,Yes,"Investigators will not be storing or sharing any personal identifiers. All individual level data will be anonymized, and only anonymized data will be shared with other researchers, upon request.",2021-10-12T07:11:17Z,2021-10-12T07:11:17Z
NCT04412785,NA,6/1/2020,NA,NA,5/4/2021,6/1/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,5/4/2021,5/6/2021,Actual,30-Jun-20,Actual,6/30/2020,May-21,5/31/2021,Dec-21,Anticipated,12/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Cyclosporine in Patients With Moderate COVID-19,Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19,"Active, not recruiting",NA,Phase 1,20,Anticipated,University of Pennsylvania,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:03Z,2021-10-12T07:11:03Z
NCT04414267,NA,6/1/2020,NA,NA,5/9/2021,6/1/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,5/9/2021,5/11/2021,Actual,26-May-20,Actual,5/26/2020,May-21,5/31/2021,7-May-21,Actual,5/7/2021,28-Apr-21,Actual,4/28/2021,NA,Interventional,ACTIVATEII,NA,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial,Completed,NA,Phase 4,301,Actual,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:53Z,2021-10-12T07:10:53Z
NCT04412538,NA,5/21/2020,NA,NA,6/2/2020,6/1/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,6/2/2020,6/4/2020,Actual,15-May-20,Actual,5/15/2020,Jun-20,6/30/2020,Sep-21,Anticipated,9/30/2021,Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 1/Phase 2,942,Anticipated,Chinese Academy of Medical Sciences,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:05Z,2021-10-12T07:11:05Z
NCT04416048,NA,6/2/2020,NA,NA,6/7/2021,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,6/7/2021,6/9/2021,Actual,30-Nov-20,Actual,11/30/2020,Jun-21,6/30/2021,31-Jan-22,Anticipated,1/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,COVID-PREVENT,NA,Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19,Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Phase 2,400,Anticipated,"Charite University, Berlin, Germany",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,after protection period,2021-10-12T07:10:39Z,2021-10-12T07:10:39Z
NCT04415060,NA,6/2/2020,NA,NA,4/9/2021,6/2/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2021,4/14/2021,Actual,15-Jun-20,Actual,6/15/2020,Apr-21,4/30/2021,15-Jun-23,Anticipated,6/15/2023,15-Jun-23,Anticipated,6/15/2023,NA,Interventional,SAVE-ICU,NA,SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,"SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study",Recruiting,NA,Phase 3,752,Anticipated,Sunnybrook Health Sciences Centre,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:48Z,2021-10-12T07:10:48Z
NCT04416399,NA,6/3/2020,NA,NA,2/3/2021,6/3/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,2/3/2021,2/8/2021,Actual,16-Jul-20,Actual,7/16/2020,Jul-20,7/31/2020,12-Jan-21,Actual,1/12/2021,12-Jan-21,Actual,1/12/2021,NA,Interventional,STOIC,NA,STerOids in COVID-19 Study,Use of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and Hospitalisation,Terminated,NA,Phase 2,146,Actual,University of Oxford,,2,NA,Independent statistical review advice,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:38Z,2021-10-12T07:10:38Z
NCT04412772,NA,6/1/2020,NA,NA,11/13/2020,6/1/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/13/2020,11/17/2020,Actual,12-Jun-20,Actual,6/12/2020,Nov-20,11/30/2020,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,ARCHITECTS,NA,Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19",Recruiting,NA,Phase 3,300,Anticipated,Queen's Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:03Z,2021-10-12T07:11:03Z
NCT04410328,NA,5/28/2020,NA,NA,10/21/2020,5/29/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,10/21/2020,10/23/2020,Actual,21-Oct-20,Actual,10/21/2020,Oct-20,10/31/2020,15-Dec-21,Anticipated,12/15/2021,15-Mar-21,Anticipated,3/15/2021,NA,Interventional,ATTAC-19,NA,Aggrenox To Treat Acute Covid-19,A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection,Recruiting,NA,Phase 3,132,Anticipated,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:20Z,2021-10-12T07:11:20Z
NCT04412356,NA,5/24/2020,NA,NA,9/20/2021,5/31/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/22/2021,Actual,6-Jun-20,Actual,6/6/2020,Sep-21,9/30/2021,20-Sep-21,Actual,9/20/2021,1-Jun-21,Actual,6/1/2021,NA,Interventional,TTCOV19,NA,Timing of Tracheotomy in Covid-19 Patients,"Timing of Tracheotomy in Covid-19 Positive Patients: a Randomized, Controlled Trial",Completed,NA,Not Applicable,150,Actual,"Sahlgrenska University Hospital, Sweden",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:08Z,2021-10-12T07:11:08Z
NCT04412291,NA,6/1/2020,NA,NA,2/17/2021,6/1/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,2/17/2021,2/18/2021,Actual,11-Jun-20,Actual,6/11/2020,Feb-21,2/28/2021,Jun-21,Anticipated,6/30/2021,Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","A Multi-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Recruiting,NA,Phase 2,120,Anticipated,Karolinska University Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:11:07Z,2021-10-12T07:11:07Z
NCT04412057,NA,5/29/2020,NA,NA,3/1/2021,5/29/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,3/1/2021,3/2/2021,Actual,9-Jun-20,Actual,6/9/2020,Sep-20,9/30/2020,19-Jan-21,Actual,1/19/2021,2-Dec-20,Actual,12/2/2020,NA,Interventional,NA,NA,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID 19 Pneumonia and Acute Lung Injury",Completed,NA,Phase 2,83,Actual,Cerecor Inc,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:10Z,2021-10-12T07:11:10Z
NCT04412343,NA,5/29/2020,NA,NA,11/2/2020,5/29/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/2/2020,11/3/2020,Actual,23-May-20,Actual,5/23/2020,Nov-20,11/30/2020,5-Oct-20,Actual,10/5/2020,5-Oct-20,Actual,10/5/2020,NA,Interventional,SCOPE,NA,The Seniors COvid-19 Pandemic and Exercise Study,The Seniors COvid-19 Pandemic and Exercise Study: A Randomized Controlled Trial,Completed,NA,Not Applicable,241,Actual,University of British Columbia,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available from this trial 1 year after completion of the study. The data will remain available indefinitely.,"The nature of the request for sharing access will be reviewed by the PI (Beauchamp, M) and the data management team. Data will be shared via secure platforms (Redcap). Contact for data access can be done through personal communications (e.g., email) with PI Beauchamp.",https://osf.io/xw9gm,Yes,"The protocol for this study will be available on Open Science Framework (after 4 months to allow for study completion). The Statistical Analysis Plan will also be available on Open Science Framework. The Consent form is freely available if requested from the Primary Investigator (PI: Beauchamp, M.).",2021-10-12T07:11:07Z,2021-10-12T07:11:07Z
NCT04411680,NA,5/29/2020,NA,NA,6/17/2021,5/29/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/21/2021,Actual,18-Aug-20,Actual,8/18/2020,Jun-21,6/30/2021,19-May-21,Actual,5/19/2021,2-Mar-21,Actual,3/2/2021,NA,Interventional,iLeukPulm,NA,Study of Sargramostim in Patients With COVID-19,A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia,Completed,NA,Phase 2,122,Actual,"Partner Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:10Z,2021-10-12T07:11:10Z
NCT04411446,NA,5/26/2020,NA,NA,7/28/2021,5/31/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,7/28/2021,7/30/2021,Actual,11-Aug-20,Actual,8/11/2020,Mar-21,3/31/2021,28-Jul-21,Actual,7/28/2021,28-Jul-21,Actual,7/28/2021,NA,Interventional,CARED,NA,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients,Completed,NA,Phase 4,218,Actual,Vitamin D Study Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:14Z,2021-10-12T07:11:14Z
NCT04410536,NA,5/25/2020,NA,NA,10/8/2020,5/29/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,10/8/2020,10/9/2020,Actual,15-Jun-20,Actual,6/15/2020,Oct-20,10/31/2020,Jul-22,Anticipated,7/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,MOHC,NA,Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency,Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency: Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up,Recruiting,NA,Not Applicable,25,Anticipated,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:21Z,2021-10-12T07:11:21Z
NCT04409496,NA,5/26/2020,NA,NA,3/2/2021,5/26/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,3/2/2021,3/4/2021,Actual,2-Jun-20,Actual,6/2/2020,Mar-21,3/31/2021,22-Jan-21,Actual,1/22/2021,22-Jan-21,Actual,1/22/2021,NA,Interventional,NA,NA,Chat-based Support for Preventing Smoking Relapse,Chat-based Instant Messaging Support for Preventing Smoking Relapse in the Context of COVID-19 Outbreak: a Pilot Randomised Clinical Trial,Completed,NA,Not Applicable,108,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:29Z,2021-10-12T07:11:29Z
NCT04409509,NA,5/28/2020,NA,NA,1/21/2021,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,1/21/2021,1/22/2021,Actual,1-Jul-20,Actual,7/1/2020,Jan-21,1/31/2021,12-Jan-21,Actual,1/12/2021,12-Jan-21,Actual,1/12/2021,NA,Interventional,NA,NA,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),"A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)",Completed,NA,Phase 2,124,Actual,CSL Behring,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.,"Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.

An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.

The requesting party must execute an appropriate data sharing agreement before IPD will be made available.",NA,Yes,"CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.",2021-10-12T07:11:27Z,2021-10-12T07:11:27Z
NCT04410016,NA,5/22/2020,NA,NA,8/26/2021,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/30/2021,Actual,25-May-20,Actual,5/25/2020,Aug-21,8/31/2021,30-Oct-20,Actual,10/30/2020,31-Jul-20,Actual,7/31/2020,NA,Interventional,COVID-WELL,NA,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Evaluation of a Workplace Intervention to Implement Supported COVID-19 Wellbeing Centres in a Healthcare Workplace During and After the Coronavirus Pandemic: The COVID-WELL Study,Completed,NA,Not Applicable,819,Actual,University of Nottingham,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Interview data will be available on request at study end (after publication of findings).,On request.,NA,Yes,Interview data will be made available on request (after study end).,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z
NCT04408066,NA,4/30/2020,NA,NA,7/22/2021,5/27/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/23/2021,Actual,30-Apr-20,Actual,4/30/2020,Jul-21,7/31/2021,30-Apr-22,Anticipated,4/30/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,CAPTURE,NA,COVID-19: A POC Test Under Research & Evaluation,Specimen Collection for Development and Performance Evaluation of the LumiraDx Platform Point of Care Tests for Sars-Cov-2 IgG/IgM & Antigen to be Used as an Aid in Diagnosis of COVID-19,Recruiting,NA,Not Applicable,2000,Anticipated,LumiraDx UK Limited,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:38Z,2021-10-12T07:11:38Z
NCT04409925,NA,5/13/2020,NA,NA,1/20/2021,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,1/20/2021,1/22/2021,Actual,25-Dec-20,Actual,12/25/2020,Jan-21,1/31/2021,Aug-21,Anticipated,8/31/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,DISCONNECT-1,NA,DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1),Phase I Pilot Study Investigating the Safety and Feasibility of Inhaled rhDNase1 and Its Impact on Neutrophil Extracellular Traps (NETs) in Non-Ventilated COVID-19 Infected Patients,Recruiting,NA,Phase 1,25,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z
NCT04408157,NA,5/26/2020,NA,NA,9/2/2021,5/28/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/5/2021,Actual,20-May-20,Actual,5/20/2020,Sep-21,9/30/2021,22-Dec-21,Anticipated,12/22/2021,1-Oct-21,Anticipated,10/1/2021,NA,Interventional,SWitCh,NA,A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,A Research Study to Evaluate the Efficacy of a Self-management Booklet (Stay Well During COVID-19; SWitCh) to Promote Wellbeing During the COVID-19 Pandemic,"Active, not recruiting",NA,Not Applicable,185,Actual,King's College London,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will be confidentially and securely stored for 7 years as per University policy. Anonymised aggregated data will be made available upon request to the corresponding author.,2021-10-12T07:11:37Z,2021-10-12T07:11:37Z
NCT04408287,NA,5/20/2020,NA,NA,8/31/2021,5/28/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/2/2021,Actual,15-Sep-20,Actual,9/15/2020,Sep-20,9/30/2020,31-Dec-21,Anticipated,12/31/2021,28-Dec-21,Anticipated,12/28/2021,NA,Interventional,NA,NA,Improving Activity Engagement Among Persons With SCI During COVID-19,Improving Activity Engagement Among Persons With SCI During COVID-19,Recruiting,NA,Not Applicable,50,Anticipated,Lawson Health Research Institute,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:36Z,2021-10-12T07:11:36Z
NCT04409821,NA,5/22/2020,NA,NA,2/2/2021,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/3/2021,Actual,29-May-20,Actual,5/29/2020,Feb-21,2/28/2021,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,CO-CarES,NA,Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care,COVID-19 Caregiver Emotional Support,Recruiting,NA,Not Applicable,50,Anticipated,"Rigshospitalet, Denmark",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z
NCT04406389,NA,5/26/2020,NA,NA,7/29/2021,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/2/2021,Actual,13-Oct-20,Actual,10/13/2020,Jul-21,7/31/2021,Dec-22,Anticipated,12/31/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,IMPACT,NA,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial),Recruiting,NA,Phase 4,186,Anticipated,Weill Medical College of Cornell University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:50Z,2021-10-12T07:11:50Z
NCT04411433,NA,5/23/2020,NA,NA,1/29/2021,5/29/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,1/29/2021,2/1/2021,Actual,8-May-20,Actual,5/8/2020,Jan-21,1/31/2021,1-Jun-21,Anticipated,6/1/2021,31-Dec-20,Actual,12/31/2020,NA,Interventional,NA,NA,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,"An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19","Active, not recruiting",NA,Phase 3,1008,Actual,"Ministry of Health, Turkey",,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:14Z,2021-10-12T07:11:14Z
NCT04410458,NA,5/29/2020,NA,NA,5/29/2020,5/29/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,5/29/2020,6/1/2020,Actual,31-May-20,Anticipated,5/31/2020,May-20,5/31/2020,12-Jun-20,Anticipated,6/12/2020,31-May-20,Anticipated,5/31/2020,NA,Interventional,NA,NA,Recruit Blood Donors Via SMS During Epidemic of COVID-19 ï¼ˆRepeat Trialï¼‰,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19ï¼ˆRepeat Trialï¼‰,Enrolling by invitation,NA,Not Applicable,506517,Anticipated,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:21Z,2021-10-12T07:11:21Z
NCT04408027,NA,5/26/2020,NA,NA,8/17/2021,5/27/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,8/17/2021,8/19/2021,Actual,1-Jun-20,Actual,6/1/2020,Aug-21,8/31/2021,1-Jun-22,Anticipated,6/1/2022,1-Jun-22,Anticipated,6/1/2022,NA,Interventional,NA,NA,Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions,Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions,Recruiting,NA,Not Applicable,20,Anticipated,The Hospital for Sick Children,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:37Z,2021-10-12T07:11:37Z
NCT04410562,NA,5/26/2020,NA,NA,9/8/2021,5/29/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,9/8/2021,9/9/2021,Actual,13-May-20,Actual,5/13/2020,Apr-21,4/30/2021,1-Oct-21,Anticipated,10/1/2021,13-May-21,Actual,5/13/2021,NA,Interventional,COVID-Preg,NA,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Recruiting,NA,Phase 3,714,Anticipated,Barcelona Institute for Global Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,By the end of study,NA,NA,Yes,It would be shared at time of publication.,2021-10-12T07:11:21Z,2021-10-12T07:11:21Z
NCT04409873,NA,5/28/2020,NA,NA,9/27/2021,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,10/4/2021,Actual,31-Mar-21,Actual,3/31/2021,Sep-21,9/30/2021,28-Feb-22,Anticipated,2/28/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,AMPoL,NA,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19),Recruiting,NA,Phase 2,150,Anticipated,"University of California, San Francisco",,5,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z
NCT04409262,NA,5/28/2020,NA,NA,3/9/2021,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,3/9/2021,3/11/2021,Actual,16-Jun-20,Actual,6/16/2020,Mar-21,3/31/2021,8-Mar-21,Actual,3/8/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,REMDACTA,NA,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,"A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,649,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-12T07:11:29Z,2021-10-12T07:11:29Z
NCT04405908,NA,5/25/2020,NA,NA,1/11/2021,5/25/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,1/11/2021,1/12/2021,Actual,19-Jun-20,Actual,6/19/2020,Jan-21,1/31/2021,25-May-21,Anticipated,5/25/2021,16-Oct-20,Actual,10/16/2020,NA,Interventional,NA,NA,SCB-2019 as COVID-19 Vaccine,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.","Active, not recruiting",NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,,15,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:54Z,2021-10-12T07:11:54Z
NCT04407390,NA,5/22/2020,NA,NA,5/29/2020,5/27/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,5/29/2020,6/2/2020,Actual,1-Jun-20,Anticipated,6/1/2020,May-20,5/31/2020,1-May-22,Anticipated,5/1/2022,1-May-21,Anticipated,5/1/2021,NA,Interventional,NR-COVID19,NA,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,"Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19",Recruiting,NA,Phase 2,100,Anticipated,University of Copenhagen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z
NCT04409327,NA,5/28/2020,NA,NA,2/5/2021,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,2/5/2021,2/10/2021,Actual,11-Jul-20,Actual,7/11/2020,Feb-21,2/28/2021,24-Jan-21,Actual,1/24/2021,27-Dec-20,Actual,12/27/2020,NA,Interventional,NA,NA,Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,Randomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults â‰¥65 Years in a Nursing Home in Which â‰¥1 Person(s) Have Lab Confirmed COVID19,Terminated,NA,Phase 2,36,Actual,Restorbio Inc.,,2,NA,Insufficient accrual rate,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:29Z,2021-10-12T07:11:29Z
NCT04410510,NA,5/27/2020,NA,NA,8/6/2021,5/29/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/10/2021,Actual,30-Sep-20,Actual,9/30/2020,Aug-21,8/31/2021,30-Nov-21,Anticipated,11/30/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,NA,NA,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,"Study of the P2Et Extract Obtained From Caesalpinia Spinosa in the Symptomatic Treatment of Subjects With COVID-19 at the Hospital Universitario San Ignacio, Colombia.",Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Hospital Universitario San Ignacio,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:20Z,2021-10-12T07:11:20Z
NCT04407208,NA,5/16/2020,NA,NA,6/27/2020,5/28/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,6/27/2020,6/30/2020,Actual,1-May-20,Actual,5/1/2020,Jun-20,6/30/2020,22-Jun-20,Actual,6/22/2020,22-Jun-20,Actual,6/22/2020,NA,Interventional,NA,NA,Convalescent Plasma Therapy in Patients With COVID-19,Convalescent Plasma Therapy in Patients With COVID-19,Completed,NA,Phase 1,10,Actual,Biofarma,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z
NCT04407689,NA,5/27/2020,NA,NA,1/13/2021,5/28/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,1/13/2021,1/15/2021,Actual,8-Jun-20,Actual,6/8/2020,Jan-21,1/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,ILIAD-7-FR,NA,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,publication,2021-10-12T07:11:41Z,2021-10-12T07:11:41Z
NCT04408209,NA,5/25/2020,NA,NA,11/3/2020,5/28/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2020,11/4/2020,Actual,23-Apr-20,Actual,4/23/2020,Nov-20,11/30/2020,15-Sep-21,Anticipated,9/15/2021,30-Aug-21,Anticipated,8/30/2021,NA,Interventional,NA,NA,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection - A Multicenter Phase II Trial,Recruiting,NA,Not Applicable,60,Anticipated,National and Kapodistrian University of Athens,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:36Z,2021-10-12T07:11:36Z
NCT04410354,NA,4/28/2020,NA,NA,12/4/2020,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,12/4/2020,12/8/2020,Actual,16-Jun-20,Actual,6/16/2020,Dec-20,12/31/2020,1-Dec-20,Actual,12/1/2020,1-Dec-20,Actual,12/1/2020,NA,Interventional,NA,NA,Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)",Terminated,NA,Phase 2,44,Actual,"ViralClear Pharmaceuticals, Inc.",,2,NA,Failure to meet primary endpoint,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:20Z,2021-10-12T07:11:20Z
NCT04408131,NA,5/28/2020,NA,NA,5/28/2020,5/28/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,5/28/2020,5/29/2020,Actual,28-May-20,Actual,5/28/2020,May-20,5/31/2020,27-Jan-21,Anticipated,1/27/2021,27-Jan-21,Anticipated,1/27/2021,NA,Interventional,COVIDHomeless,NA,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Recruiting,NA,Not Applicable,2000,Anticipated,Assistance Publique Hopitaux De Marseille,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:39Z,2021-10-12T07:11:39Z
NCT04409522,NA,5/28/2020,NA,NA,5/28/2020,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,5/28/2020,6/1/2020,Actual,12-May-20,Actual,5/12/2020,May-20,5/31/2020,25-Sep-20,Anticipated,9/25/2020,5-Jun-20,Anticipated,6/5/2020,NA,Interventional,NA,NA,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,NA,Not Applicable,55,Anticipated,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:26Z,2021-10-12T07:11:26Z
NCT04408456,NA,5/24/2020,NA,NA,8/1/2020,5/28/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,8/1/2020,8/4/2020,Actual,1-Mar-20,Actual,3/1/2020,Aug-20,8/31/2020,31-Jul-20,Actual,7/31/2020,31-Jul-20,Actual,7/31/2020,NA,Interventional,PEP-CQ,NA,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial,Completed,NA,Phase 3,325,Actual,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will be shared with the concerned authority and Institutional Ethics committee as and when required.,2021-10-12T07:11:36Z,2021-10-12T07:11:36Z
NCT04408040,NA,5/15/2020,NA,NA,9/14/2021,5/27/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/20/2021,Actual,14-Jul-20,Actual,7/14/2020,Sep-21,9/30/2021,14-Sep-21,Actual,9/14/2021,14-Sep-21,Actual,9/14/2021,NA,Interventional,NA,NA,Use of Convalescent Plasma for COVID-19,"Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak",Terminated,NA,Phase 2,7,Actual,"Northside Hospital, Inc.",,4,NA,New information regarding use of plasma in covid + patients,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:40Z,2021-10-12T07:11:40Z
NCT04405999,NA,5/18/2020,NA,NA,9/2/2020,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,9/2/2020,9/3/2020,Actual,14-May-20,Actual,5/14/2020,Sep-20,9/30/2020,31-Aug-20,Actual,8/31/2020,9-Aug-20,Actual,8/9/2020,NA,Interventional,NA,NA,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial,Completed,NA,Phase 4,50,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:52Z,2021-10-12T07:11:52Z
NCT04405570,NA,5/26/2020,NA,NA,2/22/2021,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/23/2021,Actual,16-Jun-20,Actual,6/16/2020,Feb-21,2/28/2021,21-Feb-21,Actual,2/21/2021,21-Feb-21,Actual,2/21/2021,NA,Interventional,NA,NA,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19",Completed,NA,Phase 2,204,Actual,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:54Z,2021-10-12T07:11:54Z
NCT04404361,NA,5/22/2020,NA,NA,9/23/2021,5/22/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/28/2021,Actual,22-May-20,Actual,5/22/2020,Sep-21,9/30/2021,21-Sep-21,Actual,9/21/2021,21-Sep-21,Actual,9/21/2021,NA,Interventional,NA,NA,PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer",Terminated,NA,Phase 3,200,Actual,CTI BioPharma,,2,NA,decision to close enrollment early,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:04Z,2021-10-12T07:12:04Z
NCT04406246,NA,5/24/2020,NA,NA,3/29/2021,5/27/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,3/29/2021,3/30/2021,Actual,21-May-20,Actual,5/21/2020,Mar-21,3/31/2021,31-Dec-20,Actual,12/31/2020,31-Dec-20,Actual,12/31/2020,NA,Interventional,NA,NA,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide,Completed,NA,Phase 4,150,Actual,Materno-Perinatal Hospital of the State of Mexico,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The Data will be available upon request after a publication is reached.,2021-10-12T07:11:50Z,2021-10-12T07:11:50Z
NCT04405986,NA,5/8/2020,NA,NA,4/7/2021,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/7/2021,4/8/2021,Actual,19-May-20,Actual,5/19/2020,Apr-21,4/30/2021,10-Mar-21,Actual,3/10/2021,10-Mar-21,Actual,3/10/2021,NA,Interventional,BRAINCOV,NA,Exploring Brain Damages After COVID-19 Infection,Exploring Brain Damages After COVID-19 Infection,Completed,NA,Not Applicable,38,Actual,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:53Z,2021-10-12T07:11:53Z
NCT04406181,NA,4/28/2020,NA,NA,5/28/2020,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,5/28/2020,6/1/2020,Actual,18-May-20,Actual,5/18/2020,May-20,5/31/2020,1-Jan-21,Anticipated,1/1/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,Effect on the COVID-19 Pandemic-induced Reduction in Elective Surgery on Medical Events and Psychological Well-being of Patients Waiting for Cardiac Surgery,Recruiting,NA,Not Applicable,200,Anticipated,Universitair Ziekenhuis Brussel,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:51Z,2021-10-12T07:11:51Z
NCT04405310,NA,5/26/2020,NA,NA,12/16/2020,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,12/16/2020,12/21/2020,Actual,20-May-20,Actual,5/20/2020,Dec-20,12/31/2020,10-Dec-20,Actual,12/10/2020,20-Nov-20,Actual,11/20/2020,NA,Interventional,CPC-SARS,NA,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,"Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial",Completed,NA,Phase 2,42,Actual,Grupo Mexicano para el Estudio de la Medicina Intensiva,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,3 months after completion up to five years,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2021-10-12T07:12:00Z,2021-10-12T07:12:00Z
NCT04407182,NA,5/25/2020,NA,NA,1/7/2021,5/28/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,1/7/2021,1/8/2021,Actual,4-May-20,Actual,5/4/2020,May-20,5/31/2020,1-Oct-20,Actual,10/1/2020,1-Aug-20,Actual,8/1/2020,NA,Interventional,NA,NA,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19,Completed,NA,Phase 2,60,Actual,Catalysis SL,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:11:43Z,2021-10-12T07:11:43Z
NCT04406493,NA,5/23/2020,NA,NA,5/27/2020,5/27/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,5/27/2020,5/28/2020,Actual,28-Apr-20,Actual,4/28/2020,May-20,5/31/2020,28-Apr-21,Anticipated,4/28/2021,28-Apr-21,Anticipated,4/28/2021,NA,Interventional,NA,NA,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Monitoring of Lung Fluid Status of Hospitalized COVID-19 Patients by Lung Impedance Technique,Recruiting,NA,Not Applicable,50,Anticipated,Hillel Yaffe Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:50Z,2021-10-12T07:11:50Z
NCT04407130,NA,5/17/2020,NA,NA,2/1/2021,5/28/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,2/1/2021,2/4/2021,Actual,16-Jun-20,Actual,6/16/2020,Jun-20,6/30/2020,20-Nov-20,Actual,11/20/2020,30-Oct-20,Actual,10/30/2020,NA,Interventional,NA,NA,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,"Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19: a Randomised, Double-blind, Placebo-controlled Trial.",Completed,NA,Phase 2,72,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z
NCT04405102,NA,5/26/2020,NA,NA,5/27/2021,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,5/27/2021,6/1/2021,Actual,16-Sep-20,Actual,9/16/2020,May-21,5/31/2021,1-Jan-24,Anticipated,1/1/2024,1-Jan-23,Anticipated,1/1/2023,NA,Interventional,COZI,NA,COVID-19 Ozanimod Intervention Study,A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial,Recruiting,NA,Phase 2,48,Anticipated,"Institut universitaire de cardiologie et de pneumologie de QuÃ©bec, University Laval",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:00Z,2021-10-12T07:12:00Z
NCT04403685,NA,5/24/2020,NA,NA,8/22/2020,5/24/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,8/22/2020,8/26/2020,Actual,8-May-20,Actual,5/8/2020,Aug-20,8/31/2020,21-Jul-20,Actual,7/21/2020,8-Jul-20,Actual,7/8/2020,NA,Interventional,TOCIBRAS,NA,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers: a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS),Terminated,NA,Phase 3,129,Actual,BeneficÃªncia Portuguesa de SÃ£o Paulo,,2,NA,Safety,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:10Z,2021-10-12T07:12:10Z
NCT04402957,NA,5/12/2020,NA,NA,5/5/2021,5/25/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/6/2021,Actual,14-Oct-20,Actual,10/14/2020,May-21,5/31/2021,30-Jun-21,Anticipated,6/30/2021,31-May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)","Active, not recruiting",NA,Phase 2,60,Anticipated,Arch Biopartners Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:14Z,2021-10-12T07:12:14Z
NCT04404218,NA,5/24/2020,NA,NA,6/21/2021,5/24/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/23/2021,Actual,4-Aug-20,Actual,8/4/2020,Jun-21,6/30/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,ACAI,NA,The AÃ§aÃ­ Berry COVID-19 Anti-Inflammation Trial,Randomized Clinical Trial of AÃ§aÃ­ Palm Berry Extract as an Intervention in Patients Diagnosed With COVID-19,Recruiting,NA,Phase 2,480,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:06Z,2021-10-12T07:12:06Z
NCT04405739,NA,5/26/2020,NA,NA,9/20/2021,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/22/2021,Actual,16-Jun-20,Actual,6/16/2020,Feb-21,2/28/2021,8-Jan-22,Anticipated,1/8/2022,16-Dec-21,Anticipated,12/16/2021,NA,Interventional,NA,NA,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2,Recruiting,NA,Phase 2,96,Anticipated,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:56Z,2021-10-12T07:11:56Z
NCT04403555,NA,5/23/2020,NA,NA,7/29/2021,5/23/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/2/2021,Actual,1-Jun-20,Actual,6/1/2020,Jul-21,7/31/2021,1-Dec-20,Actual,12/1/2020,31-Oct-20,Actual,10/31/2020,NA,Interventional,NA,NA,Ivermectin as a Novel Therapy in COVID-19 Treatment,The Efficacy of Ivermectin in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,164,Actual,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:11Z,2021-10-12T07:12:11Z
NCT04402879,NA,5/22/2020,NA,NA,12/14/2020,5/22/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,12/14/2020,12/17/2020,Actual,10-Nov-20,Actual,11/10/2020,May-20,5/31/2020,1-Jun-22,Anticipated,6/1/2022,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,CORONA,NA,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,A Prospective Randomized Trial of Prone Positioning Versus Usual Care for Patients With Do-not-intubate Goals of Care and Hypoxemic Respiratory Failure During the Coronavirus SARS-CoV-2 (COVID-19) Pandemic,Recruiting,NA,Not Applicable,596,Anticipated,University of Calgary,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:15Z,2021-10-12T07:12:15Z
NCT04401423,NA,5/21/2020,NA,NA,7/27/2021,5/21/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,7/29/2021,Actual,10-Feb-21,Actual,2/10/2021,Jul-21,7/31/2021,10-Jun-21,Actual,6/10/2021,10-Jun-21,Actual,6/10/2021,NA,Interventional,NA,NA,TXA127 for the Treatment of Severe COVID-19,Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19,Completed,NA,Phase 2,22,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z
NCT04402918,NA,5/18/2020,NA,NA,8/2/2021,5/25/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,17-May-20,Actual,5/17/2020,Jul-21,7/31/2021,2-Aug-21,Actual,8/2/2021,19-May-20,Actual,5/19/2020,NA,Interventional,TRANSCOVID,NA,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 During Pregnancy,Completed,NA,Not Applicable,160,Actual,Centre Hospitalier Universitaire de Besancon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:16Z,2021-10-12T07:12:16Z
NCT04400929,NA,5/8/2020,NA,NA,7/2/2020,5/21/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,7/2/2020,7/7/2020,Actual,2-Jun-20,Actual,6/2/2020,Jul-20,7/31/2020,Jun-22,Anticipated,6/30/2022,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial,Recruiting,NA,Phase 2,30,Anticipated,Singapore General Hospital,,5,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:31Z,2021-10-12T07:12:31Z
NCT04405843,NA,5/23/2020,NA,NA,12/24/2020,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,12/24/2020,12/28/2020,Actual,14-Jul-20,Actual,7/14/2020,Dec-20,12/31/2020,21-Dec-20,Actual,12/21/2020,21-Dec-20,Actual,12/21/2020,NA,Interventional,EPIC,NA,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),"Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19",Completed,NA,Phase 2/Phase 3,476,Actual,Centro de Estudios en InfectogÃ­a Pediatrica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:11:53Z,2021-10-12T07:11:53Z
NCT04405544,NA,5/26/2020,NA,NA,10/29/2020,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2020,10/30/2020,Actual,22-May-20,Actual,5/22/2020,Oct-20,10/31/2020,29-Oct-20,Actual,10/29/2020,22-Jul-20,Actual,7/22/2020,NA,Interventional,NA,NA,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,NA,Not Applicable,51,Actual,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:56Z,2021-10-12T07:11:56Z
NCT04403269,NA,5/18/2020,NA,NA,5/22/2020,5/22/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/22/2020,5/27/2020,Actual,5-May-20,Actual,5/5/2020,May-20,5/31/2020,5-May-21,Anticipated,5/5/2021,5-May-21,Anticipated,5/5/2021,NA,Interventional,GERONIMO 19,NA,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE","""STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE"" GERONIMO 19",Recruiting,NA,Phase 2,35,Anticipated,Versailles Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:14Z,2021-10-12T07:12:14Z
NCT04402060,NA,5/22/2020,NA,NA,8/30/2021,5/22/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/1/2021,Actual,28-May-20,Actual,5/28/2020,Aug-21,8/31/2021,19-Feb-21,Actual,2/19/2021,19-Feb-21,Actual,2/19/2021,NA,Interventional,NA,NA,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,"A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19",Completed,NA,Phase 1/Phase 2,65,Actual,"Apellis Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:21Z,2021-10-12T07:12:21Z
NCT04404426,NA,5/22/2020,NA,NA,5/28/2021,5/25/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/28/2021,6/2/2021,Actual,4-Nov-20,Actual,11/4/2020,May-21,5/31/2021,28-May-21,Actual,5/28/2021,25-Mar-21,Actual,3/25/2021,NA,Interventional,CACOLAC,NA,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,Not Applicable,33,Actual,Rennes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:04Z,2021-10-12T07:12:04Z
NCT04400890,NA,5/22/2020,NA,NA,8/24/2021,5/22/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/26/2021,Actual,12-Sep-20,Actual,9/12/2020,Aug-21,8/31/2021,1-Mar-21,Actual,3/1/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,NA,NA,"Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19","Randomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of Resveratrol, a Plant Polyphenol, for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19)",Terminated,NA,Phase 2,100,Actual,Mount Carmel Health System,,2,NA,Feasibility,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:12:32Z,2021-10-12T07:12:32Z
NCT04403646,NA,5/22/2020,NA,NA,12/19/2020,5/26/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,12/19/2020,12/22/2020,Actual,12-Jun-20,Actual,6/12/2020,Dec-20,12/31/2020,1-Nov-20,Actual,11/1/2020,20-Oct-20,Actual,10/20/2020,NA,Interventional,TanCOVID,NA,Tannin Specific Natural Extract for COVID-19 Infection,Efficacy of Tannin Specific Natural Extract for Coronavirus Disease (COVID-19): Randomized Controlled Trial,Terminated,NA,Not Applicable,124,Actual,Hospital de Clinicas JosÃ© de San MartÃ­n,,2,NA,low rate of covid patients,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:11Z,2021-10-12T07:12:11Z
NCT04403100,NA,5/23/2020,NA,NA,1/25/2021,5/23/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/26/2021,Actual,3-Jun-20,Actual,6/3/2020,Jan-21,1/31/2021,1-Feb-21,Anticipated,2/1/2021,1-Feb-21,Anticipated,2/1/2021,NA,Interventional,NA,NA,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""","Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: ""The Hope Coalition""",Recruiting,NA,Phase 3,1968,Anticipated,Cardresearch,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:13Z,2021-10-12T07:12:13Z
NCT04401150,NA,5/21/2020,NA,NA,3/23/2021,5/21/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,3/23/2021,3/24/2021,Actual,14-Aug-20,Actual,8/14/2020,Mar-21,3/31/2021,Jan-22,Anticipated,1/31/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,LOVIT-COVID,NA,Lessening Organ Dysfunction With VITamin C - COVID-19,Lessening Organ Dysfunction With VITamin C - COVID,Recruiting,NA,Phase 3,800,Anticipated,UniversitÃ© de Sherbrooke,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z
NCT04401475,NA,5/21/2020,NA,NA,4/29/2021,5/21/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2021,5/3/2021,Actual,25-Nov-20,Actual,11/25/2020,Apr-21,4/30/2021,Apr-21,Anticipated,4/30/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,396,Anticipated,Edesa Biotech Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:24Z,2021-10-12T07:12:24Z
NCT04402866,NA,5/22/2020,NA,NA,5/17/2021,5/22/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/17/2021,5/19/2021,Actual,24-Jun-20,Actual,6/24/2020,May-21,5/31/2021,21-Apr-21,Actual,4/21/2021,21-Apr-21,Actual,4/21/2021,NA,Interventional,NA,NA,TD-0903 for ALI Associated With COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19",Completed,NA,Phase 2,235,Actual,Theravance Biopharma,,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2021-10-12T07:12:15Z,2021-10-12T07:12:15Z
NCT04402203,NA,5/19/2020,NA,NA,5/22/2020,5/22/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,5/22/2020,5/26/2020,Actual,May-20,Anticipated,5/31/2020,May-20,5/31/2020,Jul-20,Anticipated,7/31/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,NA,Phase 2/Phase 3,50,Anticipated,Bangladesh Medical Research Council (BMRC),,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:20Z,2021-10-12T07:12:20Z
NCT04402840,NA,5/22/2020,NA,NA,10/29/2020,5/22/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2020,11/3/2020,Actual,24-Apr-20,Actual,4/24/2020,Jul-20,7/31/2020,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Not Applicable,5,Anticipated,West Virginia University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:15Z,2021-10-12T07:12:15Z
NCT04402983,NA,5/22/2020,NA,NA,12/11/2020,5/22/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,12/11/2020,12/14/2020,Actual,27-May-20,Actual,5/27/2020,May-20,5/31/2020,1-Dec-20,Actual,12/1/2020,1-Dec-20,Actual,12/1/2020,NA,Interventional,NA,NA,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Completed,NA,Not Applicable,34,Actual,Istanbul Medipol University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:15Z,2021-10-12T07:12:15Z
NCT04400032,NA,4/27/2020,NA,NA,4/23/2021,5/20/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,4/23/2021,4/26/2021,Actual,15-May-20,Actual,5/15/2020,Apr-21,4/30/2021,22-Apr-21,Actual,4/22/2021,22-Apr-21,Actual,4/22/2021,NA,Interventional,CIRCA-19,NA,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19),Completed,NA,Phase 1/Phase 2,15,Actual,Ottawa Hospital Research Institute,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:38Z,2021-10-12T07:12:38Z
NCT04403477,NA,5/20/2020,NA,NA,5/24/2020,5/24/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/24/2020,5/27/2020,Actual,20-May-20,Actual,5/20/2020,May-20,5/31/2020,30-Oct-20,Anticipated,10/30/2020,20-Jul-20,Anticipated,7/20/2020,NA,Interventional,NA,NA,Convalescent Plasma Therapy in Severe COVID-19 Infection,"Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT",Recruiting,NA,Phase 2,20,Anticipated,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,six months,"Available on public domain like figshare, researchgate and others",NA,Yes,Data will be shared with the journal authority and make public as part of the publication,2021-10-12T07:12:10Z,2021-10-12T07:12:10Z
NCT04399317,NA,5/18/2020,NA,NA,6/23/2020,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,6/23/2020,6/25/2020,Actual,28-May-20,Actual,5/28/2020,May-20,5/31/2020,Aug-20,Anticipated,8/31/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,Flow Controlled Ventilation in ARDS Associated With COVID-19,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,NA,Not Applicable,20,Anticipated,Hamad Medical Corporation,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,A decision regarding sharing information will be taken at later stage.,2021-10-12T07:12:42Z,2021-10-12T07:12:42Z
NCT04399109,NA,5/21/2020,NA,NA,5/21/2020,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,5/21/2020,5/22/2020,Actual,20-May-20,Actual,5/20/2020,May-20,5/31/2020,19-May-21,Anticipated,5/19/2021,19-May-21,Anticipated,5/19/2021,NA,Interventional,ReCOVER,NA,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),ReCOVER (Remote COVID-19 Evaluation and Response): a Prospective Non-randomised Controlled Trial to Evaluate the Effect of a Novel Smartphone Application-centric Model of Care for the Remote Monitoring of COVID-19 Patients in the Community.,Recruiting,NA,Not Applicable,2000,Anticipated,"Prince of Wales Hospital, Sydney",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:46Z,2021-10-12T07:12:46Z
NCT04399005,NA,5/19/2020,NA,NA,6/23/2020,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,6/23/2020,6/25/2020,Actual,25-May-20,Actual,5/25/2020,May-20,5/31/2020,10-Jun-20,Actual,6/10/2020,5-Jun-20,Actual,6/5/2020,NA,Interventional,NA,NA,The Efficacy Comparing Daily and After-each-case Room Disinfection.,The Efficacy Comparing Daily and After-each-case Room Disinfection in the Endoscopy Unit During the COVID-19 Pandemic.,Completed,NA,Not Applicable,240,Actual,The First Affiliated Hospital of Zhejiang Chinese Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,individual participant data sharing will be consider after study,2021-10-12T07:12:45Z,2021-10-12T07:12:45Z
NCT04401046,NA,5/22/2020,NA,NA,7/21/2021,5/22/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/22/2021,Actual,20-May-20,Actual,5/20/2020,Jul-21,7/31/2021,2-Feb-21,Actual,2/2/2021,26-Nov-20,Actual,11/26/2020,NA,Interventional,COVID-TRAUMA,NA,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,COVID-19 EPIDEMIC Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Completed,NA,Not Applicable,1096,Actual,Institut Paoli-Calmettes,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z
NCT04399681,NA,5/21/2020,NA,NA,5/21/2020,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,5/21/2020,5/22/2020,Actual,10-May-20,Actual,5/10/2020,May-20,5/31/2020,10-Sep-20,Anticipated,9/10/2020,10-Aug-20,Anticipated,8/10/2020,NA,Interventional,NA,NA,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19 at Emergency Department,Recruiting,NA,Not Applicable,100,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:41Z,2021-10-12T07:12:41Z
NCT04399252,NA,5/19/2020,NA,NA,7/12/2021,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/14/2021,Actual,24-Jun-20,Actual,6/24/2020,Jul-21,7/31/2021,8-Jul-21,Actual,7/8/2021,8-Jul-21,Actual,7/8/2021,NA,Interventional,NA,NA,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,A Randomized Trial of the Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Completed,NA,Not Applicable,182,Actual,Duke University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:43Z,2021-10-12T07:12:43Z
NCT04398277,NA,5/20/2020,NA,NA,5/20/2020,5/20/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,5/20/2020,5/21/2020,Actual,1-May-20,Actual,5/1/2020,May-20,5/31/2020,Apr-21,Anticipated,4/30/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,A Daily Coping Toolkit for Medical Personnel and First-Responders During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,1000,Anticipated,Kent State University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,12 months after data collection is complete,Contact the PI,NA,Yes,All data and materials will be made available.,2021-10-12T07:12:52Z,2021-10-12T07:12:52Z
NCT04400279,NA,5/21/2020,NA,NA,1/8/2021,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,1/8/2021,1/11/2021,Actual,1-Jun-20,Actual,6/1/2020,Jan-21,1/31/2021,28-Nov-20,Actual,11/28/2020,28-Nov-20,Actual,11/28/2020,NA,Interventional,COPE,NA,The COVID-19 Pandemic and Exercise Study,COvid-19 Pandemic and Exercise (COPE) Trial: A Randomized Study Examining Physical Activities and Wellbeing in Individuals Mandated to Stay at Home,Completed,NA,Not Applicable,334,Actual,University of British Columbia,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"4 months following trial's end, materials will be made available. following publication, all data will be made available.",Investigators whose proposed use of the data has been approved by an independent review committee identified for the purpose for the purpose of meta-analyses and to achieve aims in the approved proposal. Investigators of the study need to approve the proposals. Proposals should be directed to eli.puterman@Ubc.ca,https://osf.io/g9xqp,Yes,"All of the individual participant data collected during the trial, after de-identification upon request and cleared for approval by principal investigator.

All of the protocols, statistical analysis plan, informed consent form, analytic code.",2021-10-12T07:12:36Z,2021-10-12T07:12:36Z
NCT04399746,NA,5/19/2020,NA,NA,5/20/2020,5/20/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,5/20/2020,5/22/2020,Actual,15-Mar-20,Actual,3/15/2020,May-20,5/31/2020,10-Jun-20,Anticipated,6/10/2020,20-May-20,Actual,5/20/2020,NA,Interventional,IvAzCol,NA,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol,Recruiting,NA,Not Applicable,30,Anticipated,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:38Z,2021-10-12T07:12:38Z
NCT04397692,NA,5/19/2020,NA,NA,7/6/2020,5/20/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,7/6/2020,7/8/2020,Actual,13-Jun-20,Actual,6/13/2020,Jul-20,7/31/2020,30-Sep-20,Anticipated,9/30/2020,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,NA,Not Applicable,20,Anticipated,Beyond Air Inc.,,2,NA,NA,NA,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:55Z,2021-10-12T07:12:55Z
NCT04397666,NA,5/20/2020,NA,NA,8/6/2021,5/20/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/9/2021,Actual,15-May-20,Actual,5/15/2020,Aug-21,8/31/2021,15-Dec-21,Anticipated,12/15/2021,15-Dec-20,Actual,12/15/2020,NA,Interventional,P20/09,NA,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,RT-PCR on Conjunctival Sample for the Detection of SARS-Cov-2 in Patients With Covid-19,"Active, not recruiting",NA,Not Applicable,68,Actual,Versailles Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:54Z,2021-10-12T07:12:54Z
NCT04397757,NA,5/19/2020,NA,NA,6/9/2021,5/19/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/10/2021,Actual,13-May-20,Actual,5/13/2020,Jun-21,6/30/2021,8-Mar-21,Actual,3/8/2021,6-Feb-21,Actual,2/6/2021,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,"An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.",Completed,NA,Phase 1,80,Actual,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:54Z,2021-10-12T07:12:54Z
NCT04393818,NA,5/18/2020,NA,NA,9/9/2020,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/9/2020,9/10/2020,Actual,5-May-20,Actual,5/5/2020,Aug-20,8/31/2020,24-Aug-20,Actual,8/24/2020,24-Aug-20,Actual,8/24/2020,NA,Interventional,PsyCovid_App,NA,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,A Double-blinded Randomized Controlled Trial to Examine the Effectiveness of a Mobile-based Intervention to Reduce Mental Health Problems in Healthcare Workers at the Frontline Against COVID-19 in Spain: the PsyCovidApp Trial,Completed,NA,Phase 3,560,Actual,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:24Z,2021-10-12T07:13:24Z
NCT04345419,NA,4/11/2020,NA,NA,7/29/2021,4/13/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/2/2021,Actual,16-Jun-20,Actual,6/16/2020,Jul-21,7/31/2021,1-Dec-20,Actual,12/1/2020,1-Dec-20,Actual,12/1/2020,NA,Interventional,NA,NA,Remdesivir Efficacy in Coronavirus Disease,Remdesivir in COVID-19 Treatment: A Randomised Trial,Completed,NA,Phase 2/Phase 3,200,Actual,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:30Z,2021-10-12T07:19:30Z
NCT04398004,NA,5/17/2020,NA,NA,1/8/2021,5/20/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,1/8/2021,1/11/2021,Actual,6-May-20,Actual,5/6/2020,Jan-21,1/31/2021,30-Nov-20,Actual,11/30/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,ACHIEVE,NA,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial,Completed,NA,Phase 2,90,Actual,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:53Z,2021-10-12T07:12:53Z
NCT04394455,NA,5/3/2020,NA,NA,6/30/2020,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,6/30/2020,7/2/2020,Actual,30-Jun-20,Anticipated,6/30/2020,Jun-20,6/30/2020,30-Dec-20,Anticipated,12/30/2020,30-Nov-20,Anticipated,11/30/2020,NA,Interventional,NA,NA,Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms,Effect of Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry in Medical Staff During the COVID-19 Pandemic: A Multicentric Randomized Controlled Trial,Enrolling by invitation,NA,Not Applicable,236,Anticipated,Universidad Nacional Autonoma de Honduras,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:21Z,2021-10-12T07:13:21Z
NCT04394013,NA,5/18/2020,NA,NA,2/22/2021,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/24/2021,Actual,26-Aug-20,Actual,8/26/2020,Feb-21,2/28/2021,31-Dec-20,Actual,12/31/2020,31-Dec-20,Actual,12/31/2020,NA,Interventional,NA,NA,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Completed,NA,Not Applicable,70,Actual,Monash University Malaysia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Upon request via direct contact to researcher,2021-10-12T07:13:25Z,2021-10-12T07:13:25Z
NCT04393415,NA,5/15/2020,NA,NA,7/24/2020,5/15/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,7/24/2020,7/27/2020,Actual,25-May-20,Actual,5/25/2020,Jul-20,7/31/2020,1-Sep-20,Anticipated,9/1/2020,25-Aug-20,Anticipated,8/25/2020,NA,Interventional,NA,NA,Using PRP and Cord Blood in Treatment of Covid -19,the Effect of PRP and Cord Blood in Improving the Symptoms of Covid-19,Recruiting,NA,Not Applicable,100,Anticipated,Aljazeera Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:27Z,2021-10-12T07:13:27Z
NCT04397705,NA,5/20/2020,NA,NA,2/9/2021,5/20/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,2/9/2021,2/11/2021,Actual,12-Oct-20,Actual,10/12/2020,Feb-21,2/28/2021,Apr-21,Anticipated,4/30/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,RECAP,NA,Remote Monitoring of Cancer Patients With Suspected Covid-19,Remote Monitoring of Cancer Patients Presenting With Symptoms Suggestive of Covid-19 - Pilot Phase.,Recruiting,NA,Phase 1,30,Anticipated,The Christie NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"The physiological data represents a rich clinical data resource which has the potential to be valuable in other contexts to answer future unanticipated questions. We therefore propose storing this pseudoanonymised data in a Data Bank with a lifespan initially of five years with potential for extension if appropriate ethical approval is gained. This Data Bank could then be used, under ethical approval for other research in order to maximise the potential utility of the data.",2021-10-12T07:12:55Z,2021-10-12T07:12:55Z
NCT04395807,NA,5/18/2020,NA,NA,4/12/2021,5/19/2020,5/20/2020,Actual,NA,NA,NA,NA,NA,NA,4/12/2021,4/15/2021,Actual,3-Jun-20,Actual,6/3/2020,Apr-21,4/30/2021,12-Apr-21,Actual,4/12/2021,12-Apr-21,Actual,4/12/2021,NA,Interventional,COVID HELMET,NA,Helmet CPAP Versus HFNC in COVID-19,Helmet Continuous Positive Airway Pressure Versus High-Flow Nasal Cannula in COVID-19: A Pragmatic Randomised Clinical Trial,Terminated,NA,Not Applicable,2,Actual,Lund University,,2,NA,"Few eligible patients at study start
Patients received HFNC prior to intermediate care ward admission
NIV was locally considered a step-up therapy to HFNC
Full-face masks replaced the Helmet interface as local NIV standard",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:08Z,2021-10-12T07:13:08Z
NCT04397614,NA,5/20/2020,NA,NA,8/27/2021,5/20/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,8/27/2021,9/2/2021,Actual,22-Jul-20,Actual,7/22/2020,Aug-21,8/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,Mobile Health Study and Enhanced Symptom Monitoring to Prevent Severe Illness From COVID-19 in Cancer Patients,Recruiting,NA,Not Applicable,500,Anticipated,University of Oklahoma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:55Z,2021-10-12T07:12:55Z
NCT04394403,NA,5/13/2020,NA,NA,2/8/2021,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/9/2021,Actual,14-May-20,Actual,5/14/2020,Feb-21,2/28/2021,30-Jun-22,Anticipated,6/30/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,CoronaStress,NA,Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress,Pilot Internet-based Self-Help Program for Managing Corona Stress vs. Waitlist Control,Recruiting,NA,Not Applicable,120,Anticipated,Hebrew University of Jerusalem,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z
NCT04390594,NA,5/14/2020,NA,NA,9/3/2020,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,9/3/2020,9/7/2020,Actual,13-Aug-20,Actual,8/13/2020,Sep-20,9/30/2020,12-Aug-21,Anticipated,8/12/2021,12-Feb-21,Anticipated,2/12/2021,NA,Interventional,SEN-CoV-Fadj,NA,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,"Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal",Recruiting,NA,Phase 3,186,Anticipated,Institut Pasteur de Dakar,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:50Z,2021-10-12T07:13:50Z
NCT04397510,NA,5/19/2020,NA,NA,2/22/2021,5/20/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/23/2021,Actual,1-Jun-20,Actual,6/1/2020,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,NA,Phase 4,50,Anticipated,Frederick Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:57Z,2021-10-12T07:12:57Z
NCT04393246,NA,5/16/2020,NA,NA,6/9/2021,5/16/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/10/2021,Actual,3-Jul-20,Actual,7/3/2020,Jun-21,6/30/2021,15-Jun-22,Anticipated,6/15/2022,15-Feb-22,Anticipated,2/15/2022,NA,Interventional,NA,NA,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E),Recruiting,NA,Phase 2/Phase 3,1407,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:29Z,2021-10-12T07:13:29Z
NCT04394442,NA,5/17/2020,NA,NA,5/18/2020,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2020,5/19/2020,Actual,21-Mar-20,Actual,3/21/2020,May-20,5/31/2020,Aug-20,Anticipated,8/31/2020,Aug-20,Anticipated,8/31/2020,NA,Interventional,NA,NA,Hydroxychloroquine in COVID-19 Patients,Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial,Recruiting,NA,Phase 2,200,Anticipated,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z
NCT04393636,NA,5/11/2020,NA,NA,6/5/2020,5/14/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,6/5/2020,6/9/2020,Actual,5-Jun-20,Actual,6/5/2020,Jun-20,6/30/2020,31-Dec-22,Anticipated,12/31/2022,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,DCC,NA,Digital Cardiac Counseling Trial: DCC Trial,Randomized Controlled Trial of Digital Cardiac Counseling in Patients With Delayed Cardiac Surgical Treatment Due to Covid-19 Pandemic (DCC Trial),Recruiting,NA,Not Applicable,394,Anticipated,Academisch Ziekenhuis Maastricht,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:26Z,2021-10-12T07:13:26Z
NCT04393961,NA,4/24/2020,NA,NA,5/16/2020,5/16/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,5/16/2020,5/19/2020,Actual,5-Apr-20,Actual,4/5/2020,Apr-20,4/30/2020,29-Aug-20,Anticipated,8/29/2020,29-Jul-20,Anticipated,7/29/2020,NA,Interventional,NA,NA,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,NA,Not Applicable,600,Anticipated,ProofPilot,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,As soon reasonably sized data sets are available.,No personally identifiable information will be provided. Those who wish to access must have a ProofPilot account. All access must be approved by study investigators.,http://go.proofpilot.com,Yes,"Given the enormous policy and health implications, we will be making results available as soon as there are sufficient data sets to analyze. We will also provide our study design for replication in other environments and via other tests.",2021-10-12T07:13:24Z,2021-10-12T07:13:24Z
NCT04392414,NA,5/13/2020,NA,NA,9/23/2020,5/15/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,9/23/2020,9/25/2020,Actual,1-May-20,Actual,5/1/2020,Jun-20,6/30/2020,23-Sep-20,Actual,9/23/2020,10-Jul-20,Actual,7/10/2020,NA,Interventional,NA,NA,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,"Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",Completed,NA,Phase 2,60,Actual,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2021-10-12T07:13:34Z,2021-10-12T07:13:34Z
NCT04397796,NA,5/18/2020,NA,NA,5/26/2021,5/19/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/27/2021,Actual,3-Aug-20,Actual,8/3/2020,May-20,5/31/2020,Jun-21,Anticipated,6/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,"Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical Ventilation","Active, not recruiting",NA,Phase 1,45,Anticipated,"ImmunityBio, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:56Z,2021-10-12T07:12:56Z
NCT04394377,NA,5/8/2020,NA,NA,6/8/2021,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,6/8/2021,6/10/2021,Actual,21-Jun-20,Actual,6/21/2020,May-20,5/31/2020,30-May-21,Actual,5/30/2021,26-Mar-21,Actual,3/26/2021,NA,Interventional,ACTION,NA,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial,Completed,NA,Phase 4,615,Actual,Brazilian Clinical Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z
NCT04395911,NA,5/17/2020,NA,NA,8/4/2021,5/18/2020,5/20/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/5/2021,Actual,10-Sep-20,Actual,9/10/2020,Aug-21,8/31/2021,21-Jul-21,Actual,7/21/2021,5-Jul-21,Actual,7/5/2021,NA,Interventional,NA,NA,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,A Multi-Center Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients Developing Acute Kidney Injury (AKI) or Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 Infection,Completed,NA,Not Applicable,22,Actual,SeaStar Medical,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,Data will be collected throughout the study conduct.,Participant data will be accessible to the Investigational Site and CRO through a secured electronic data capture system. CRO personnel will be responsible for data verification. De-identified Participant information will be accessible to the CRO and the Sponsor.,NA,Yes,Unidentified participant data collected for this study will be submitted to a CRO for data analysis. All data will be submitted to the Sponsor.,2021-10-12T07:13:08Z,2021-10-12T07:13:08Z
NCT04394416,NA,5/8/2020,NA,NA,8/11/2021,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/11/2021,8/12/2021,Actual,2-Jun-20,Actual,6/2/2020,Aug-21,8/31/2021,1-Jun-23,Anticipated,6/1/2023,1-Jun-22,Anticipated,6/1/2022,NA,Interventional,NA,NA,Trial of Imatinib for Hospitalized Adults With COVID-19,Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19,Recruiting,NA,Phase 3,204,Anticipated,"University of Maryland, Baltimore",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z
NCT04392973,NA,5/10/2020,NA,NA,8/19/2021,5/13/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/20/2021,Actual,21-May-20,Actual,5/21/2020,Aug-21,8/31/2021,26-Apr-21,Actual,4/26/2021,26-Jan-21,Actual,1/26/2021,NA,Interventional,FACCT,NA,FAvipiravir and HydroxyChloroquine Combination Therapy,A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19,Completed,NA,Not Applicable,268,Actual,King Abdullah International Medical Research Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:31Z,2021-10-12T07:13:31Z
NCT04395430,NA,2/3/2020,NA,NA,8/18/2021,5/18/2020,5/20/2020,Actual,NA,NA,NA,NA,NA,NA,8/18/2021,8/19/2021,Actual,18-Sep-20,Actual,9/18/2020,Aug-21,8/31/2021,Oct-22,Anticipated,10/31/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,A Novel School-clinic-community Online Model of Child Obesity Treatment in Singapore During COVID-19,Adapting the US-based Clinic-community Model of Child Obesity Treatment Into an Online Intervention Model in Singapore During COVID-19,"Active, not recruiting",NA,Not Applicable,40,Actual,KK Women's and Children's Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:12Z,2021-10-12T07:13:12Z
NCT04391829,NA,5/13/2020,NA,NA,10/26/2020,5/15/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,10/26/2020,10/28/2020,Actual,31-Aug-20,Actual,8/31/2020,May-20,5/31/2020,31-Aug-21,Anticipated,8/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,COVIDSPERM,NA,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,NA,Not Applicable,20,Anticipated,Universitair Ziekenhuis Brussel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:41Z,2021-10-12T07:13:41Z
NCT04390516,NA,5/14/2020,NA,NA,6/10/2020,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,6/10/2020,6/12/2020,Actual,24-Mar-20,Actual,3/24/2020,Jun-20,6/30/2020,30-May-20,Actual,5/30/2020,4-May-20,Actual,5/4/2020,NA,Interventional,READY,NA,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Prediction Of Respiratory Decompensation In Covid-19 Patients Using Machine Learning: The READY Trial,Completed,NA,Not Applicable,197,Actual,Dascena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:49Z,2021-10-12T07:13:49Z
NCT04391179,NA,5/15/2020,NA,NA,3/16/2021,5/15/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,3/16/2021,3/18/2021,Actual,31-May-20,Actual,5/31/2020,Mar-21,3/31/2021,22-Feb-21,Actual,2/22/2021,22-Feb-21,Actual,2/22/2021,NA,Interventional,DICER,NA,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Completed,NA,Phase 2,100,Actual,University of Michigan,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:46Z,2021-10-12T07:13:46Z
NCT04393077,NA,5/11/2020,NA,NA,11/20/2020,5/15/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,11/20/2020,11/24/2020,Actual,10-May-20,Actual,5/10/2020,Nov-20,11/30/2020,20-May-20,Actual,5/20/2020,15-May-20,Actual,5/15/2020,NA,Interventional,NA,NA,Emotional Freedom Technique (EFT) Effect on Nurses,"Emotional Freedom Technique (EFT) Effect on Nurses' Stress, Anxiety and Burnout Levels During the COVID-19 Pandemic Process: A Randomized Controlled Study",Completed,NA,Not Applicable,80,Actual,Istanbul Saglik Bilimleri University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:30Z,2021-10-12T07:13:30Z
NCT04389840,NA,5/13/2020,NA,NA,5/24/2021,5/13/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,5/24/2021,5/26/2021,Actual,3-Jun-20,Actual,6/3/2020,May-20,5/31/2020,20-May-21,Actual,5/20/2021,20-May-21,Actual,5/20/2021,NA,Interventional,NA,NA,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Terminated,NA,Phase 2/Phase 3,3,Actual,Chimerix,,2,NA,Limited enrollment,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:54Z,2021-10-12T07:13:54Z
NCT04389450,NA,5/14/2020,NA,NA,8/8/2021,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,8/8/2021,8/10/2021,Actual,1-Oct-20,Actual,10/1/2020,Oct-20,10/31/2020,Jun-22,Anticipated,6/30/2022,17-May-21,Actual,5/17/2021,NA,Interventional,NA,NA,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19","Active, not recruiting",NA,Phase 2,66,Actual,Pluristem Ltd.,,5,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:57Z,2021-10-12T07:13:57Z
NCT04390503,NA,5/14/2020,NA,NA,7/2/2021,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,7/2/2021,7/7/2021,Actual,12-Mar-21,Actual,3/12/2021,Jul-21,7/31/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Convalescent Plasma for Early Treatment of COVID-19,"A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Plasma for Early Treatment of COVID-19",Recruiting,NA,Phase 2,150,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:49Z,2021-10-12T07:13:49Z
NCT04390152,NA,5/12/2020,NA,NA,1/13/2021,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,1/13/2021,1/15/2021,Actual,13-Jan-20,Actual,1/13/2020,Jan-21,1/31/2021,Apr-22,Anticipated,4/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,Safety and Efficacy of Intravenous Infusion of Wharton's Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19: A Randomized Controlled Trial,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,BioXcellerator,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual data won't be shared.,2021-10-12T07:13:54Z,2021-10-12T07:13:54Z
NCT04388514,NA,5/11/2020,NA,NA,5/13/2020,5/13/2020,5/14/2020,Actual,NA,NA,NA,NA,NA,NA,5/13/2020,5/14/2020,Actual,8-Apr-20,Actual,4/8/2020,May-20,5/31/2020,8-Oct-20,Anticipated,10/8/2020,8-Oct-20,Anticipated,10/8/2020,NA,Interventional,CORMOR,NA,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,NA,Not Applicable,90,Anticipated,Azienda Sanitaria-Universitaria Integrata di Udine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,starting 6 months after publication,Contacting the Principal Investigator,NA,Yes,all IPD that underlie results in a publication,2021-10-12T07:14:06Z,2021-10-12T07:14:06Z
NCT04389385,NA,5/12/2020,NA,NA,5/14/2020,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2020,5/15/2020,Actual,1-May-20,Actual,5/1/2020,May-20,5/31/2020,31-May-21,Anticipated,5/31/2021,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),Aerosol Inhalation of the Exosomes Derived From Allogenic COVID-19 T Cell in the Treatment of Early Stage Novel Coronavirus Pneumonia,"Active, not recruiting",NA,Phase 1,60,Anticipated,TC Erciyes University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:01Z,2021-10-12T07:14:01Z
NCT04390477,NA,5/7/2020,NA,NA,7/20/2021,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,4-May-20,Actual,5/4/2020,Jul-21,7/31/2021,30-Apr-21,Actual,4/30/2021,21-Mar-21,Actual,3/21/2021,NA,Interventional,NA,NA,Study to Evaluate the Effect of a Probiotic in COVID-19,The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection,Completed,NA,Not Applicable,41,Actual,Bioithas SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:49Z,2021-10-12T07:13:49Z
NCT04385849,NA,5/7/2020,NA,NA,8/23/2021,5/12/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/24/2021,Actual,22-Jul-20,Actual,7/22/2020,Aug-21,8/31/2021,11-Jul-22,Anticipated,7/11/2022,11-Jul-22,Anticipated,7/11/2022,NA,Interventional,NA,NA,Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19,"Phase 1b, Randomized, Blinded, Placebo-controlled Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent (N-803 in Adults With COVID-19","Active, not recruiting",NA,Phase 1,1,Actual,"ImmunityBio, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:25Z,2021-10-12T07:14:25Z
NCT04385199,NA,5/9/2020,NA,NA,5/26/2021,5/11/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/27/2021,Actual,4-May-20,Actual,5/4/2020,May-21,5/31/2021,1-Aug-20,Actual,8/1/2020,1-Aug-20,Actual,8/1/2020,NA,Interventional,NA,NA,Convalescent Plasma for Patients With COVID-19,The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease,Completed,NA,Phase 2,30,Actual,Henry Ford Health System,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:27Z,2021-10-12T07:14:27Z
NCT04385043,NA,5/4/2020,NA,NA,5/11/2020,5/11/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,5/11/2020,5/12/2020,Actual,1-May-20,Actual,5/1/2020,May-20,5/31/2020,15-May-21,Anticipated,5/15/2021,15-Oct-20,Anticipated,10/15/2020,NA,Interventional,COV2-CP,NA,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection,Recruiting,NA,Phase 2/Phase 3,400,Anticipated,University of Catanzaro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:32Z,2021-10-12T07:14:32Z
NCT04386616,NA,5/11/2020,NA,NA,8/16/2021,5/12/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/18/2021,Actual,2-Jun-20,Actual,6/2/2020,Aug-21,8/31/2021,12-Feb-21,Actual,2/12/2021,8-Jan-21,Actual,1/8/2021,NA,Interventional,COVASTIL,NA,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 2,410,Actual,"Genentech, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).

For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-12T07:14:21Z,2021-10-12T07:14:21Z
NCT04385108,NA,5/5/2020,NA,NA,12/23/2020,5/11/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,12/23/2020,12/28/2020,Actual,4-Mar-20,Actual,3/4/2020,Dec-20,12/31/2020,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,COVIDBioToul,NA,Predictive Immune Biomarkers for COVID-19 Pathogenesis,Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management,Recruiting,NA,Not Applicable,400,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:29Z,2021-10-12T07:14:29Z
NCT04386668,NA,5/12/2020,NA,NA,10/6/2020,5/12/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,10/6/2020,10/8/2020,Actual,26-May-20,Actual,5/26/2020,Oct-20,10/31/2020,31-Aug-20,Actual,8/31/2020,12-Jul-20,Actual,7/12/2020,NA,Interventional,LIO-C,NA,Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic,Let It Out (LIO) and COVID19: a Randomised Controlled Trial of an Online Emotional Disclosure-based Intervention for Adults During the COVID19 Pandemic,Terminated,NA,Not Applicable,80,Actual,"University College, London",,2,NA,Interim analysis indicated adaptations to intervention may be required.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,Open access,NA,Yes,Fully anonymised participant data will be made available open access via ESRC data repository ReShare,2021-10-12T07:14:18Z,2021-10-12T07:14:18Z
NCT04384458,NA,5/8/2020,NA,NA,10/5/2020,5/9/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2020,10/6/2020,Actual,20-Jul-20,Actual,7/20/2020,Oct-20,10/31/2020,Apr-21,Anticipated,4/30/2021,10-Sep-20,Actual,9/10/2020,NA,Interventional,NA,NA,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,NA,Not Applicable,400,Anticipated,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:35Z,2021-10-12T07:14:35Z
NCT04383574,NA,5/9/2020,NA,NA,8/16/2021,5/9/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/18/2021,Actual,22-May-20,Actual,5/22/2020,Jul-21,7/31/2021,30-Jul-22,Anticipated,7/30/2022,28-Dec-21,Anticipated,12/28/2021,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above","Active, not recruiting",NA,Phase 1/Phase 2,422,Anticipated,"Sinovac Biotech Co., Ltd",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:42Z,2021-10-12T07:14:42Z
NCT04386694,NA,5/8/2020,NA,NA,10/28/2020,5/11/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,10/28/2020,10/29/2020,Actual,18-May-20,Actual,5/18/2020,Oct-20,10/31/2020,17-Sep-20,Actual,9/17/2020,17-Sep-20,Actual,9/17/2020,NA,Interventional,NA,NA,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?,Completed,NA,Not Applicable,30,Actual,University of Nove de Julho,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:18Z,2021-10-12T07:14:18Z
NCT04384731,NA,5/7/2020,NA,NA,2/2/2021,5/11/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/3/2021,Actual,29-May-20,Actual,5/29/2020,Feb-21,2/28/2021,31-Jul-21,Anticipated,7/31/2021,29-May-21,Anticipated,5/29/2021,NA,Interventional,Caards-1,NA,CurosurfÂ® in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Randomized Controlled Phase II Trial of Poractant Alfa (CurosurfÂ®) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral Pneumonia,Recruiting,NA,Phase 2,20,Anticipated,Versailles Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:34Z,2021-10-12T07:14:34Z
NCT04385810,NA,4/29/2020,NA,NA,11/13/2020,5/12/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,11/13/2020,11/16/2020,Actual,27-Apr-20,Actual,4/27/2020,Nov-20,11/30/2020,29-Jul-20,Actual,7/29/2020,29-Jul-20,Actual,7/29/2020,NA,Interventional,DOCOV,NA,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,NA,Not Applicable,23,Actual,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:26Z,2021-10-12T07:14:26Z
NCT04385017,NA,5/10/2020,NA,NA,9/13/2021,5/11/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,9/13/2021,9/14/2021,Actual,11-May-20,Actual,5/11/2020,Sep-21,9/30/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,CoVInnate,NA,Role of Inflammasomes in COVID-19 Disease,Role of Inflammasomes in COVID-19 Disease,Recruiting,NA,Not Applicable,40,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:31Z,2021-10-12T07:14:31Z
NCT04386798,NA,5/6/2020,NA,NA,8/18/2021,5/8/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,8/18/2021,8/19/2021,Actual,25-Jul-20,Actual,7/25/2020,Aug-21,8/31/2021,25-Dec-21,Anticipated,12/25/2021,22-Dec-20,Actual,12/22/2020,NA,Interventional,NA,NA,Stress and Anxiety Levels of Mothers Lying in the Baby Newborn Intensive Care Unit,Determination of Stress and Anxiety Levels of Mothers Lying in the Newborn Intensive Care Unit During Coronavirus Disease Pandemic Period,Recruiting,NA,Not Applicable,60,Anticipated,Eskisehir Osmangazi University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"When the study is completed and published in the journal, it will be shared",NA,NA,Yes,"When the study is completed and published in the journal, it will be shared",2021-10-12T07:14:17Z,2021-10-12T07:14:17Z
NCT04382755,NA,5/7/2020,NA,NA,7/1/2021,5/8/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,7/1/2021,7/2/2021,Actual,22-May-20,Actual,5/22/2020,Jul-21,7/31/2021,9-Apr-21,Actual,4/9/2021,29-Dec-20,Actual,12/29/2020,NA,Interventional,ZILU-COV,NA,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With ZilucoplanÂ® in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure",Completed,NA,Phase 2,81,Actual,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:50Z,2021-10-12T07:14:50Z
NCT04382131,NA,5/8/2020,NA,NA,9/1/2020,5/8/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,9/1/2020,9/2/2020,Actual,23-Jun-20,Actual,6/23/2020,Jul-20,7/31/2020,31-Oct-20,Anticipated,10/31/2020,31-Oct-20,Anticipated,10/31/2020,NA,Interventional,NA,NA,Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),Hypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19: Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19),Recruiting,NA,Not Applicable,405,Anticipated,University of Edinburgh,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:52Z,2021-10-12T07:14:52Z
NCT04385836,NA,5/10/2020,NA,NA,5/12/2020,5/12/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,5/12/2020,5/13/2020,Actual,1-Jun-20,Anticipated,6/1/2020,May-20,5/31/2020,1-Sep-20,Anticipated,9/1/2020,1-Sep-20,Anticipated,9/1/2020,NA,Interventional,NA,NA,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,NA,Early Phase 1,150,Anticipated,"Ministry of Health, Saudi Arabia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:25Z,2021-10-12T07:14:25Z
NCT04382378,NA,5/4/2020,NA,NA,3/11/2021,5/8/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,3/11/2021,3/15/2021,Actual,1-Feb-21,Actual,2/1/2021,Mar-21,3/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,NUMBERNMES,NA,Effects of NMES in Critically Ill Patients,Effects of Different Regimen Protocols of NMES in COVID 19 Critically Ill Patients,Recruiting,NA,Not Applicable,120,Anticipated,Escola Superior de Ciencias da Saude,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:51Z,2021-10-12T07:14:51Z
NCT04381052,NA,5/6/2020,NA,NA,9/17/2021,5/7/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/23/2021,Actual,18-May-20,Actual,5/18/2020,Sep-21,9/30/2021,12-Mar-21,Actual,3/12/2021,3-Feb-21,Actual,2/3/2021,NA,Interventional,NA,NA,Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,NA,Phase 2,1,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Coded data will be shared with New York University (NYU) Langone for the purpose of statistical analysis and scientific reporting.,2021-10-12T07:15:03Z,2021-10-12T07:15:03Z
NCT04382391,NA,4/14/2020,NA,NA,8/5/2021,5/8/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2021,8/12/2021,Actual,8-May-20,Actual,5/8/2020,Aug-21,8/31/2021,1-Dec-21,Anticipated,12/1/2021,21-Jul-21,Actual,7/21/2021,NA,Interventional,SAVIORII,NA,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII)","Active, not recruiting",NA,Not Applicable,60,Anticipated,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:49Z,2021-10-12T07:14:49Z
NCT04385901,NA,5/6/2020,NA,NA,2/4/2021,5/12/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,2/4/2021,2/8/2021,Actual,19-May-20,Actual,5/19/2020,Feb-21,2/28/2021,19-Sep-20,Actual,9/19/2020,19-Sep-20,Actual,9/19/2020,NA,Interventional,NA,NA,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Completed,NA,Not Applicable,26,Actual,University of Missouri-Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:26Z,2021-10-12T07:14:26Z
NCT04381884,NA,5/5/2020,NA,NA,10/1/2020,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,10/1/2020,10/5/2020,Actual,18-May-20,Actual,5/18/2020,Oct-20,10/31/2020,29-Sep-20,Actual,9/29/2020,29-Sep-20,Actual,9/29/2020,NA,Interventional,NA,NA,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,"A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19",Completed,NA,Phase 2,45,Actual,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:54Z,2021-10-12T07:14:54Z
NCT04380532,NA,4/29/2020,NA,NA,5/22/2020,5/6/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,5/22/2020,5/27/2020,Actual,15-May-20,Actual,5/15/2020,May-20,5/31/2020,15-Jun-21,Anticipated,6/15/2021,15-May-21,Anticipated,5/15/2021,NA,Interventional,COVID-19,NA,Tableted COVID-19 Therapeutic Vaccine,Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Immunitor LLC,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,when become public,non-confidential data,http://immunitor.com,Yes,Free dissemination of published data,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z
NCT04397718,NA,5/14/2020,NA,NA,6/30/2021,5/19/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,6/30/2021,7/2/2021,Actual,6-Jul-20,Actual,7/6/2020,Jun-21,6/30/2021,8-Jun-21,Actual,6/8/2021,8-Jun-21,Actual,6/8/2021,NA,Interventional,HITCH,NA,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,"Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix",Completed,NA,Phase 2,96,Actual,VA Office of Research and Development,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:56Z,2021-10-12T07:12:56Z
NCT04395768,NA,5/18/2020,NA,NA,9/9/2020,5/19/2020,5/20/2020,Actual,NA,NA,NA,NA,NA,NA,9/9/2020,9/11/2020,Actual,9-Sep-20,Actual,9/9/2020,Sep-20,9/30/2020,31-Dec-21,Anticipated,12/31/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,"Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study",Recruiting,NA,Phase 2,200,Anticipated,"National Institute of Integrative Medicine, Australia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:09Z,2021-10-12T07:13:09Z
NCT04397523,NA,5/20/2020,NA,NA,5/10/2021,5/20/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,5/10/2021,5/11/2021,Actual,30-Apr-20,Actual,4/30/2020,Feb-21,2/28/2021,10-May-21,Actual,5/10/2021,10-May-21,Actual,5/10/2021,NA,Interventional,NA,NA,Efficacy and Safety of COVID-19 Convalescent Plasma,Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety,Completed,NA,Not Applicable,200,Actual,Institute for Transfusion Medicine of RNM,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:57Z,2021-10-12T07:12:57Z
NCT04392713,NA,5/5/2020,NA,NA,5/17/2020,5/17/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,5/17/2020,5/19/2020,Actual,15-Apr-20,Actual,4/15/2020,May-20,5/31/2020,Jul-20,Anticipated,7/31/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,Efficacy of Ivermectin in COVID-19,Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial,Recruiting,NA,Not Applicable,100,Anticipated,"Combined Military Hospital, Pakistan",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:35Z,2021-10-12T07:13:35Z
NCT04394793,NA,5/17/2020,NA,NA,8/30/2020,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2020,9/1/2020,Actual,13-Jun-20,Actual,6/13/2020,Aug-20,8/31/2020,Sep-20,Anticipated,9/30/2020,27-Aug-20,Actual,8/27/2020,NA,Interventional,NA,NA,Low Dose Radiation Therapy for Covid-19 Pneumonia,Low Dose Radiation Therapy for Covid-19 Pneumonia: A Pilot Study,"Active, not recruiting",NA,Not Applicable,10,Actual,"All India Institute of Medical Sciences, New Delhi",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:19Z,2021-10-12T07:13:19Z
NCT04395144,NA,5/15/2020,NA,NA,3/21/2021,5/18/2020,5/20/2020,Actual,NA,NA,NA,NA,NA,NA,3/21/2021,3/23/2021,Actual,15-May-20,Actual,5/15/2020,Mar-21,3/31/2021,15-Mar-21,Actual,3/15/2021,15-Mar-21,Actual,3/15/2021,NA,Interventional,COVAYDE,NA,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19,Completed,NA,Not Applicable,13,Actual,HÃ´pital de Verdun,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:14Z,2021-10-12T07:13:14Z
NCT04392778,NA,4/25/2020,NA,NA,5/22/2021,5/17/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,5/22/2021,5/25/2021,Actual,1-Apr-20,Actual,4/1/2020,May-20,5/31/2020,30-Nov-20,Actual,11/30/2020,1-Nov-20,Actual,11/1/2020,NA,Interventional,NA,NA,Clinical Use of Stem Cells for the Treatment of Covid-19,What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study),Completed,NA,Phase 1/Phase 2,30,Actual,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:33Z,2021-10-12T07:13:33Z
NCT04393948,NA,5/15/2020,NA,NA,6/23/2020,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,6/23/2020,6/25/2020,Actual,Jun-20,Anticipated,6/30/2020,Jun-20,6/30/2020,Nov-20,Anticipated,11/30/2020,Oct-20,Anticipated,10/31/2020,NA,Interventional,NA,NA,Lung Irradiation for COVID-19 Pneumonia,Pilot Study of Low-Dose Single or Bilateral Whole Lung Irradiation for SARS-CoV-2 Pneumonia,Recruiting,NA,Not Applicable,48,Anticipated,Brigham and Women's Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:24Z,2021-10-12T07:13:24Z
NCT04394039,NA,5/13/2020,NA,NA,7/9/2021,5/13/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,7/9/2021,7/15/2021,Actual,1-Jun-20,Actual,6/1/2020,Jul-21,7/31/2021,31-Dec-20,Actual,12/31/2020,1-Aug-20,Actual,8/1/2020,NA,Interventional,NA,NA,Post-Pandemic Perception of Public Space in Singapore,Effects of COVID-19-Related Self-isolation on Psychological Response to Different Outdoor Environments in Singapore - Before & After Brain and Behavior Study,Completed,NA,Not Applicable,34,Actual,"National University, Singapore",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:25Z,2021-10-12T07:13:25Z
NCT04394208,NA,5/15/2020,NA,NA,8/16/2020,5/16/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/16/2020,8/18/2020,Actual,16-Aug-20,Actual,8/16/2020,Aug-20,8/31/2020,28-Feb-21,Anticipated,2/28/2021,30-Jan-21,Anticipated,1/30/2021,NA,Interventional,SCOPE,NA,Silymarin in COVID-19 Pneumonia,Trial of Silymarin in Adults With COVID-19 Pneumonia,Recruiting,NA,Phase 3,50,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z
NCT04393792,NA,5/18/2020,NA,NA,9/16/2021,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2021,9/17/2021,Actual,5-May-20,Actual,5/5/2020,Sep-21,9/30/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?,Recruiting,NA,Phase 1,40,Anticipated,Hampshire Hospitals NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:25Z,2021-10-12T07:13:25Z
NCT04392453,NA,5/15/2020,NA,NA,2/12/2021,5/15/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/15/2021,Actual,26-Oct-20,Actual,10/26/2020,Feb-21,2/28/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Upper Limb Robotic Rehabilitation During COVID-19 Outbreak,Upper Limb Robotic Rehabilitation in Stroke Survivors Using a Portable Device During the COVID-19 Outbreak. A Feasibility Study,Recruiting,NA,Not Applicable,40,Anticipated,Fondazione Don Carlo Gnocchi Onlus,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:36Z,2021-10-12T07:13:36Z
NCT04394182,NA,5/15/2020,NA,NA,5/16/2020,5/16/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,5/16/2020,5/19/2020,Actual,21-Apr-20,Actual,4/21/2020,May-20,5/31/2020,21-Apr-21,Anticipated,4/21/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,ULTRA-COVID,NA,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers,Recruiting,NA,Not Applicable,15,Anticipated,Fundacion GenesisCare,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Medical history and biographical and clinical data of each patient will be recorded and shared.

The overall results of any research conducted will be available on study data publication.",2021-10-12T07:13:21Z,2021-10-12T07:13:21Z
NCT04395105,NA,5/16/2020,NA,NA,5/28/2021,5/18/2020,5/20/2020,Actual,NA,NA,NA,NA,NA,NA,5/28/2021,6/2/2021,Actual,21-May-20,Actual,5/21/2020,May-21,5/31/2021,21-May-21,Actual,5/21/2021,5-Apr-21,Actual,4/5/2021,NA,Interventional,NA,NA,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",High Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS: a Multicenter and Randomized Open-label Clinical Trial,Terminated,NA,Phase 3,100,Actual,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,,2,NA,Low rate of recruitment,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:14Z,2021-10-12T07:13:14Z
NCT04393038,NA,5/18/2020,NA,NA,6/28/2021,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,6/28/2021,6/30/2021,Actual,1-Jul-20,Actual,7/1/2020,Jun-21,6/30/2021,16-Apr-21,Actual,4/16/2021,5-Mar-21,Actual,3/5/2021,NA,Interventional,Mir-Age,NA,ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,"A Phase 2/3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged â‰¥ 65 and Patients Aged â‰¥18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.",Terminated,NA,Phase 2/Phase 3,509,Actual,Abivax S.A.,,2,NA,Interim analysis concludes that the study is futile,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:31Z,2021-10-12T07:13:31Z
NCT04391309,NA,5/14/2020,NA,NA,7/13/2021,5/14/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,7/13/2021,7/14/2021,Actual,12-Apr-21,Actual,4/12/2021,Jul-21,7/31/2021,Feb-22,Anticipated,2/28/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,CaTT,NA,COVID-19 and Anti-CD14 Treatment Trial,"Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,300,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:46Z,2021-10-12T07:13:46Z
NCT04389333,NA,5/9/2020,NA,NA,7/19/2020,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,7/19/2020,7/21/2020,Actual,26-Mar-20,Actual,3/26/2020,Jul-20,7/31/2020,20-May-20,Actual,5/20/2020,26-Apr-20,Actual,4/26/2020,NA,Interventional,NA,NA,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,"Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic: a Prospective, Open-label, Pilot, Randomized Trial",Completed,NA,Not Applicable,40,Actual,Changhai Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:57Z,2021-10-12T07:13:57Z
NCT04393727,NA,5/16/2020,NA,NA,11/9/2020,5/16/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2020,11/12/2020,Actual,1-May-20,Actual,5/1/2020,Nov-20,11/30/2020,30-Sep-20,Actual,9/30/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,TSUNAMI,NA,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial,Terminated,NA,Phase 2,1,Actual,"Azienda Ospedaliero, Universitaria Pisana",,2,NA,Study was stopped because the Promoter was changed and a new study on convalescent plasma promoted by AIFA was started in Italy.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:25Z,2021-10-12T07:13:25Z
NCT04392531,NA,5/3/2020,NA,NA,8/26/2021,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/27/2021,Actual,16-Apr-20,Actual,4/16/2020,Aug-21,8/31/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,NA,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,"Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection",Completed,NA,Phase 4,111,Actual,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:35Z,2021-10-12T07:13:35Z
NCT04387292,NA,5/12/2020,NA,NA,8/2/2021,5/12/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,7-Sep-20,Actual,9/7/2020,Aug-21,8/31/2021,15-May-21,Actual,5/15/2021,21-Jan-21,Actual,1/21/2021,NA,Interventional,SOCOVID,NA,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Completed,NA,Not Applicable,34,Actual,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:13Z,2021-10-12T07:14:13Z
NCT04387409,NA,5/11/2020,NA,NA,9/29/2020,5/11/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,9/29/2020,9/30/2020,Actual,25-May-20,Actual,5/25/2020,Sep-20,9/30/2020,1-May-21,Anticipated,5/1/2021,1-May-21,Anticipated,5/1/2021,NA,Interventional,NA,NA,Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic,"A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System","Active, not recruiting",NA,Phase 3,59,Actual,Vakzine Projekt Management GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is uncertainty whether the European Union General Data Protection Regulation allows dissemination of individual participant data to other researchers. Some reasons why the EU Regulation would not allow this are the lack of suitable safeguards when person data are transferred to any researcher asking for it and the impairment of the rights of the subjects for erasure of their data once they are disseminated.,2021-10-12T07:14:11Z,2021-10-12T07:14:11Z
NCT04390464,NA,5/8/2020,NA,NA,5/14/2020,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2020,5/18/2020,Actual,8-May-20,Actual,5/8/2020,May-20,5/31/2020,1-May-22,Anticipated,5/1/2022,7-May-21,Anticipated,5/7/2021,NA,Interventional,TACTIC-R,NA,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,NA,Phase 4,1167,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:48Z,2021-10-12T07:13:48Z
NCT04389944,NA,5/12/2020,NA,NA,8/3/2020,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,8/3/2020,8/4/2020,Actual,31-Mar-20,Actual,3/31/2020,Aug-20,8/31/2020,30-Jun-20,Actual,6/30/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,NA,NA,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19),Completed,NA,Not Applicable,15,Actual,"University Hospital, Basel, Switzerland",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:53Z,2021-10-12T07:13:53Z
NCT04391127,NA,5/12/2020,NA,NA,11/6/2020,5/14/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,11/6/2020,11/9/2020,Actual,4-May-20,Actual,5/4/2020,Nov-20,11/30/2020,6-Nov-20,Actual,11/6/2020,6-Nov-20,Actual,11/6/2020,NA,Interventional,NA,NA,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial,Completed,NA,Phase 3,108,Actual,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:46Z,2021-10-12T07:13:46Z
NCT04390412,NA,5/13/2020,NA,NA,11/6/2020,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,11/6/2020,11/10/2020,Actual,4-May-20,Actual,5/4/2020,Jul-20,7/31/2020,Dec-20,Anticipated,12/31/2020,30-Aug-20,Actual,8/30/2020,NA,Interventional,NA,NA,Low Dose Radiotherapy in COVID-19 Pneumonia,Assessment of Adding Low Dose Pulmonary Radiotherapy to the National Protocol of COVID-19 Management: A Pilot Trial,"Active, not recruiting",NA,Phase 1/Phase 2,5,Actual,Shahid Beheshti University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After the completion of trial for one year.,Verified researchers,NA,Yes,IPD will be shared after the completion of study to other researchers.,2021-10-12T07:13:50Z,2021-10-12T07:13:50Z
NCT04391712,NA,5/4/2020,NA,NA,8/3/2020,5/15/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/3/2020,8/5/2020,Actual,30-Apr-20,Actual,4/30/2020,Aug-20,8/31/2020,16-Jul-20,Actual,7/16/2020,15-May-20,Actual,5/15/2020,NA,Interventional,NA,NA,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,NA,Phase 2,10,Actual,Lowell General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:42Z,2021-10-12T07:13:42Z
NCT04388527,NA,5/4/2020,NA,NA,6/9/2021,5/12/2020,5/14/2020,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/10/2021,Actual,30-Apr-20,Actual,4/30/2020,Jun-21,6/30/2021,30-Jan-21,Actual,1/30/2021,25-Jan-21,Actual,1/25/2021,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,"An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2",Completed,NA,Phase 1,32,Actual,University of Pennsylvania,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:06Z,2021-10-12T07:14:06Z
NCT04391140,NA,5/10/2020,NA,NA,8/14/2020,5/14/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/14/2020,8/18/2020,Actual,13-May-20,Actual,5/13/2020,May-20,5/31/2020,Jun-21,Anticipated,6/30/2021,Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Effectiveness of Prone Positioning Combined With High-flow Nasal Cannula for Patients With COVID-19 Induced ARDS,Recruiting,NA,Not Applicable,248,Anticipated,Hospital Universitari Vall d'Hebron Research Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be shared when first 200 patients (counting the 5 studies participating in the meta-trial) will be included and at the end of inclusion,NA,NA,Yes,"Data will be shared to perform a meta-trial including other studies that assess the effectiveness of prone position in COVID-19 patients supported with nasal high flow.

No patient identifying data will be transferred to the data repository. The data set will use pseudoanonymised data. The consent process for the study will highlight that this is a meta-trial and that both aggregated and individual data without personal identifying features will be used to formulate the results from the study. Local regulation for the management of patient data needs to be adhered to as part of agreement for involvement in the study.

Data will be shared during the study at two points, Time 1 An interim analysis at 200 patients in which aggregated outcome data for the primary outcome and severe adverse effects will be analyzed

Time 2 Final analysis outlining salient clinical feature of patients for each group, outcomes",2021-10-12T07:13:44Z,2021-10-12T07:13:44Z
NCT04390191,NA,5/12/2020,NA,NA,8/12/2021,5/13/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/19/2021,Actual,7-May-20,Actual,5/7/2020,Aug-21,8/31/2021,7-Jul-21,Actual,7/7/2021,18-Feb-21,Actual,2/18/2021,NA,Interventional,PAP-COVID,NA,Early CPAP in COVID-19 Confirmed or Suspected Patients,Early Continuous Positive Airway Pressure (CPAP) in COVID-19 Confirmed or Suspected Patients,Terminated,NA,Not Applicable,4,Actual,Icahn School of Medicine at Mount Sinai,,2,NA,Declining cases of COVID in New York due to vaccinations and new treatments for outpatient management,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:54Z,2021-10-12T07:13:54Z
NCT04390139,NA,5/7/2020,NA,NA,4/7/2021,5/13/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,4/7/2021,4/8/2021,Actual,13-May-20,Actual,5/13/2020,Apr-21,4/30/2021,Dec-21,Anticipated,12/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,COVIDMES,NA,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,"A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19",Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Banc de Sang i Teixits,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:53Z,2021-10-12T07:13:53Z
NCT04389710,NA,4/27/2020,NA,NA,6/3/2021,5/14/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,6/3/2021,6/4/2021,Actual,15-Apr-20,Actual,4/15/2020,Jun-21,6/30/2021,7-Dec-20,Actual,12/7/2020,3-Nov-20,Actual,11/3/2020,NA,Interventional,NA,NA,Convalescent Plasma for the Treatment of COVID-19,Convalescent Plasma for the Treatment of Patients With COVID-19,Completed,NA,Phase 2,52,Actual,Thomas Jefferson University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:56Z,2021-10-12T07:13:56Z
NCT04388683,NA,5/13/2020,NA,NA,9/23/2021,5/13/2020,5/14/2020,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/30/2021,Actual,12-May-20,Actual,5/12/2020,Sep-21,9/30/2021,23-Nov-20,Actual,11/23/2020,23-Nov-20,Actual,11/23/2020,NA,Interventional,NO-COVID-19,NA,Inhaled Nitric Oxide for Preventing Progression in COVID-19,Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.,Terminated,NA,Phase 2,10,Actual,Tufts Medical Center,,2,NA,Bellerophon requested study to be stopped.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data from this pilot study will be used to plan future a larger randomized controlled outcome trial.,2021-10-12T07:14:03Z,2021-10-12T07:14:03Z
NCT04388410,NA,5/12/2020,NA,NA,8/24/2020,5/12/2020,5/14/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2020,8/26/2020,Actual,25-Aug-20,Actual,8/25/2020,Aug-20,8/31/2020,31-Dec-20,Anticipated,12/31/2020,30-Nov-20,Anticipated,11/30/2020,NA,Interventional,EPCOvid-1,NA,Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,Phase 2b/3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients.,Recruiting,NA,Phase 2/Phase 3,410,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Plan to make IPD still not decided and would need approval by regulatory authorities,2021-10-12T07:14:04Z,2021-10-12T07:14:04Z
NCT04386291,NA,5/11/2020,NA,NA,5/27/2021,5/11/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,5/27/2021,6/1/2021,Actual,25-May-20,Actual,5/25/2020,May-21,5/31/2021,30-Jan-22,Anticipated,1/30/2022,19-Apr-21,Actual,4/19/2021,NA,Interventional,NA,NA,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,Meditation and Yoga for Heightened Anxiety Related to COVID-19,"Active, not recruiting",NA,Not Applicable,360,Anticipated,"Research Foundation for Mental Hygiene, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:20Z,2021-10-12T07:14:20Z
NCT04389372,NA,5/5/2020,NA,NA,5/14/2020,5/11/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2020,5/18/2020,Actual,15-Mar-20,Actual,3/15/2020,May-20,5/31/2020,Dec-21,Anticipated,12/31/2021,Mar-21,Anticipated,3/31/2021,NA,Interventional,ChroMig-Smart,NA,"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",Feasibility and Effectiveness of Mindfulness Program by Smartphone for Patients With Chronic Migraine and Medication Overuse During Covid-19 Emergency,Recruiting,NA,Not Applicable,50,Anticipated,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:59Z,2021-10-12T07:13:59Z
NCT04382547,NA,5/8/2020,NA,NA,8/20/2021,5/8/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,8/20/2021,8/23/2021,Actual,11-May-20,Actual,5/11/2020,Aug-21,8/31/2021,30-Jun-21,Actual,6/30/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,NA,NA,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Completed,NA,Phase 1/Phase 2,32,Actual,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:48Z,2021-10-12T07:14:48Z
NCT04385940,NA,5/8/2020,NA,NA,5/17/2021,5/11/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,5/17/2021,5/19/2021,Actual,19-Mar-21,Actual,3/19/2021,May-21,5/31/2021,Jan-23,Anticipated,1/31/2023,Jan-23,Anticipated,1/31/2023,NA,Interventional,NA,NA,Vitamin D and COVID-19 Management,Improving Vitamin D Status in the Management of COVID-19,Recruiting,NA,Phase 3,64,Anticipated,University of Alberta,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:22Z,2021-10-12T07:14:22Z
NCT04386239,NA,5/7/2020,NA,NA,7/19/2021,5/12/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/20/2021,Actual,1-Jan-21,Actual,1/1/2021,Jan-21,1/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Study on the Use of Sarilumab in Patients With COVID-19 Infection,Pilot Study on the Use of Sarilumab in Patients With COVID-19 Infection,Recruiting,NA,Early Phase 1,40,Anticipated,ASST Fatebenefratelli Sacco,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:21Z,2021-10-12T07:14:21Z
NCT04383535,NA,5/6/2020,NA,NA,9/29/2020,5/8/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,9/29/2020,9/30/2020,Actual,15-May-20,Actual,5/15/2020,Sep-20,9/30/2020,27-Sep-20,Actual,9/27/2020,27-Sep-20,Actual,9/27/2020,NA,Interventional,PLASM-AR,NA,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,"Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria",Completed,NA,Not Applicable,333,Actual,Hospital Italiano de Buenos Aires,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:40Z,2021-10-12T07:14:40Z
NCT04382729,NA,5/8/2020,NA,NA,5/8/2020,5/8/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,5/8/2020,5/11/2020,Actual,17-Apr-20,Actual,4/17/2020,May-20,5/31/2020,Jul-20,Anticipated,7/31/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Effects of Neuromuscular Electrical Stimulation Therapy on Physical Function in Patients With COVID-19 Associated Pneumonia: Study Protocol of a Randomized Controlled Trial,Recruiting,NA,Not Applicable,80,Anticipated,"University of Turin, Italy",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:48Z,2021-10-12T07:14:48Z
NCT04385095,NA,4/24/2020,NA,NA,3/19/2021,5/11/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,3/19/2021,3/23/2021,Actual,16-Mar-20,Actual,3/16/2020,Mar-21,3/31/2021,31-May-21,Anticipated,5/31/2021,17-Feb-21,Actual,2/17/2021,NA,Interventional,NA,NA,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-Î²1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection,"Active, not recruiting",NA,Phase 2,820,Anticipated,Synairgen Research Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plan to share data,2021-10-12T07:14:29Z,2021-10-12T07:14:29Z
NCT04384549,NA,5/6/2020,NA,NA,8/17/2020,5/9/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,8/17/2020,8/18/2020,Actual,20-May-20,Actual,5/20/2020,Aug-20,8/31/2020,20-Feb-21,Anticipated,2/20/2021,20-Feb-21,Anticipated,2/20/2021,NA,Interventional,COVID-BCG,NA,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Randomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and GuÃ©rin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,NA,Phase 3,1120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:33Z,2021-10-12T07:14:33Z
NCT04382586,NA,5/7/2020,NA,NA,6/15/2021,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2021,6/16/2021,Actual,6-Jul-20,Actual,7/6/2020,Jun-21,6/30/2021,1-Feb-21,Actual,2/1/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,NA,NA,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,"A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress",Completed,NA,Phase 2,67,Actual,BeiGene,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:51Z,2021-10-12T07:14:51Z
NCT04381858,NA,5/6/2020,NA,NA,11/26/2020,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2020,11/30/2020,Actual,6-May-20,Actual,5/6/2020,May-20,5/31/2020,26-Nov-20,Actual,11/26/2020,26-Nov-20,Actual,11/26/2020,NA,Interventional,NA,NA,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial,Completed,NA,Phase 3,196,Actual,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:00Z,2021-10-12T07:15:00Z
NCT04386850,NA,5/11/2020,NA,NA,6/10/2020,5/11/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,6/10/2020,6/12/2020,Actual,14-Apr-20,Actual,4/14/2020,May-20,5/31/2020,15-Mar-21,Anticipated,3/15/2021,15-Nov-20,Anticipated,11/15/2020,NA,Interventional,NA,NA,Oral 25-hydroxyvitamin D3 and COVID-19,Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults,Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Tehran University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 month and ending 36 months following article publication.,Investigators whose proposed use of the data has been approved by the current study principal investigators.,NA,Yes,The datasets used and analyzed during the current study will be available from the Study Principal Investigators (zhilayas@gmeil.com) on reasonable request .,2021-10-12T07:14:17Z,2021-10-12T07:14:17Z
NCT04384380,NA,4/7/2020,NA,NA,7/31/2020,5/10/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,7/31/2020,8/4/2020,Actual,1-Apr-20,Actual,4/1/2020,Mar-20,3/31/2020,31-May-20,Actual,5/31/2020,31-May-20,Actual,5/31/2020,NA,Interventional,NA,NA,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,"A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",Completed,NA,Not Applicable,33,Actual,Taoyuan General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The study outcome will be shared with the experts and persons interested in this field.,2021-10-12T07:14:34Z,2021-10-12T07:14:34Z
NCT04382846,NA,5/7/2020,NA,NA,12/2/2020,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2020,12/4/2020,Actual,8-May-20,Actual,5/8/2020,Dec-20,12/31/2020,1-Dec-30,Anticipated,12/1/2030,1-Dec-30,Anticipated,12/1/2030,NA,Interventional,NA,NA,Novel Regimens in COVID-19 Treatment,Nitazoxanide in Treatment of COVID-19,Recruiting,NA,Phase 3,160,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:46Z,2021-10-12T07:14:46Z
NCT04380909,NA,5/7/2020,NA,NA,8/23/2021,5/7/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/24/2021,Actual,6-May-20,Actual,5/6/2020,Aug-21,8/31/2021,29-Jul-21,Actual,7/29/2021,29-Jul-21,Actual,7/29/2021,NA,Interventional,ROCO,NA,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19,Completed,NA,Not Applicable,107,Actual,University of Bern,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:03Z,2021-10-12T07:15:03Z
NCT04382560,NA,5/5/2020,NA,NA,3/30/2021,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,3/30/2021,4/1/2021,Actual,2-May-20,Actual,5/2/2020,Mar-21,3/31/2021,31-May-20,Actual,5/31/2020,31-May-20,Actual,5/31/2020,NA,Interventional,NA,NA,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Resting Heart Rate Variability as a Predictor of Coping Strategies and Responsiveness to a Brief Online Intervention During Forced Quarantine,Completed,NA,Not Applicable,69,Actual,University of Parma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:48Z,2021-10-12T07:14:48Z
NCT04382092,NA,5/6/2020,NA,NA,5/8/2020,5/8/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,5/8/2020,5/11/2020,Actual,23-Mar-20,Actual,3/23/2020,May-20,5/31/2020,24-Apr-20,Actual,4/24/2020,24-Apr-20,Actual,4/24/2020,NA,Interventional,NA,NA,Co-infection Management in COVID-19 Critically Ill,Co-infections in COVID-19 Critically Ill and Antibiotic Management,Completed,NA,Not Applicable,32,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:52Z,2021-10-12T07:14:52Z
NCT04384445,NA,5/9/2020,NA,NA,2/22/2021,5/9/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/23/2021,Actual,8-Sep-20,Actual,9/8/2020,Dec-20,12/31/2020,31-Jul-21,Anticipated,7/31/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Zofin (Organicell Flow) for Patients With COVID-19,"A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Moderate to SARS Related to COVID-19 Infection vs Placebo",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Organicell Regenerative Medicine,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:34Z,2021-10-12T07:14:34Z
NCT04384588,NA,4/29/2020,NA,NA,5/9/2020,5/9/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,5/9/2020,5/12/2020,Actual,7-Apr-20,Actual,4/7/2020,May-20,5/31/2020,6-Apr-21,Anticipated,4/6/2021,6-Apr-21,Anticipated,4/6/2021,NA,Interventional,FALP-COVID,NA,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria: FALP 001-2020 Trial (FALP-COVID),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Fundacion Arturo Lopez Perez,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:33Z,2021-10-12T07:14:33Z
NCT04383002,NA,5/1/2020,NA,NA,5/12/2021,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,5/12/2021,5/13/2021,Actual,2-Sep-20,Actual,9/2/2020,May-21,5/31/2021,11-Jun-21,Anticipated,6/11/2021,11-May-21,Actual,5/11/2021,NA,Interventional,NA,NA,High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19,"Active, not recruiting",NA,Phase 1,21,Actual,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:46Z,2021-10-12T07:14:46Z
NCT04382651,NA,5/8/2020,NA,,7/7/2021,5/8/2020,5/11/2020,Actual,NA,NA,NA,,,,7/7/2021,7/8/2021,Actual,11-Jun-20,Actual,6/11/2020,Jul-21,7/31/2021,21-Apr-21,Actual,4/21/2021,6-Jan-21,Actual,1/6/2021,NA,Interventional,MAS-COVID,NA,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,"A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,140,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-10-12T07:14:47Z,2021-10-12T07:14:47Z
NCT04381962,NA,5/7/2020,NA,NA,5/4/2021,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,5/4/2021,5/6/2021,Actual,3-Jun-20,Actual,6/3/2020,May-20,5/31/2020,20-Apr-21,Actual,4/20/2021,29-Jan-21,Actual,1/29/2021,NA,Interventional,ATOMIC2,NA,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2),Completed,NA,Phase 3,298,Actual,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:55Z,2021-10-12T07:14:55Z
NCT04380818,NA,5/4/2020,NA,NA,7/29/2021,5/7/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,7/30/2021,Actual,5-Jun-20,Actual,6/5/2020,Jul-21,7/31/2021,1-Nov-21,Anticipated,11/1/2021,4-Sep-21,Anticipated,9/4/2021,NA,Interventional,NA,NA,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19: Multi-central Prospective Study,Recruiting,NA,Not Applicable,106,Anticipated,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Protocol/ICF from approval Individual epidemiological and clinical data after recruitment is complete.,NA,NA,Yes,Individual epidemiological and clinical data will be shared after recruitment is complete.,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z
NCT04382040,NA,5/7/2020,NA,NA,8/25/2021,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,8/25/2021,8/31/2021,Actual,8-May-20,Actual,5/8/2020,May-20,5/31/2020,21-Dec-20,Actual,12/21/2020,5-Nov-20,Actual,11/5/2020,NA,Interventional,NA,NA,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Completed,NA,Phase 2,50,Actual,MGC Pharmaceuticals d.o.o,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:54Z,2021-10-12T07:14:54Z
NCT04381364,NA,5/7/2020,NA,NA,5/6/2021,5/7/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/10/2021,Actual,29-May-20,Actual,5/29/2020,May-21,5/31/2021,1-May-22,Anticipated,5/1/2022,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,HALT,NA,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Recruiting,NA,Phase 2,446,Anticipated,St Goran's Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:00Z,2021-10-12T07:15:00Z
NCT04383613,NA,5/5/2020,NA,NA,5/12/2021,5/8/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,5/12/2021,5/13/2021,Actual,15-May-20,Actual,5/15/2020,May-21,5/31/2021,1-Jun-21,Anticipated,6/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,COVID-PRONE,NA,Prone Positioning for Patients on General Medical Wards With COVID19,Prone Positioning for Patients on General Medical Wards With COVID19: A Multicenter Pragmatic Randomized Trial [COVID-PRONE],"Active, not recruiting",NA,Not Applicable,340,Anticipated,Unity Health Toronto,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:41Z,2021-10-12T07:14:41Z
NCT04381377,NA,5/7/2020,NA,NA,2/15/2021,5/7/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,2/15/2021,2/16/2021,Actual,29-Apr-20,Actual,4/29/2020,Feb-21,2/28/2021,Apr-21,Anticipated,4/30/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Efficacy and Safety of PolyoxidoniumÂ® in Hospitalized Patients With Coronavirus Disease COVID-19,"A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of PolyoxidoniumÂ®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).","Active, not recruiting",NA,Phase 2/Phase 3,394,Actual,NPO Petrovax,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:00Z,2021-10-12T07:15:00Z
NCT04380935,NA,5/4/2020,NA,NA,8/16/2020,5/7/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,8/16/2020,8/18/2020,Actual,18-May-20,Actual,5/18/2020,Aug-20,8/31/2020,31-Oct-20,Anticipated,10/31/2020,31-Oct-20,Anticipated,10/31/2020,NA,Interventional,NA,NA,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:03Z,2021-10-12T07:15:03Z
NCT04382768,NA,5/6/2020,NA,NA,6/10/2020,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/10/2020,6/11/2020,Actual,1-May-20,Actual,5/1/2020,Jun-20,6/30/2020,Jan-21,Anticipated,1/31/2021,Jan-21,Anticipated,1/31/2021,NA,Interventional,CÃ³rdobaTrail,NA,Inhaled Ibuprofen to Treat COVID-19,"Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.",Recruiting,NA,Not Applicable,40,Anticipated,QuÃ­mica Luar SRL,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:46Z,2021-10-12T07:14:46Z
NCT04379037,NA,5/5/2020,NA,NA,6/1/2021,5/5/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,6/1/2021,6/4/2021,Actual,27-Jun-20,Actual,6/27/2020,Jun-21,6/30/2021,1-Nov-20,Actual,11/1/2020,1-Sep-20,Actual,9/1/2020,NA,Interventional,NA,NA,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Completed,NA,Not Applicable,50,Actual,Nemechek Technologies,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:21Z,2021-10-12T07:15:21Z
NCT04380519,NA,5/6/2020,NA,NA,9/28/2020,5/6/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2020,9/29/2020,Actual,23-Apr-20,Actual,4/23/2020,Sep-20,9/30/2020,24-Jul-20,Actual,7/24/2020,10-Jul-20,Actual,7/10/2020,NA,Interventional,NA,NA,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),"An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 2/Phase 3,372,Actual,R-Pharm,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z
NCT04379661,NA,5/5/2020,NA,NA,1/7/2021,5/6/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,1/7/2021,1/8/2021,Actual,7-May-20,Actual,5/7/2020,Jan-21,1/31/2021,31-Aug-20,Actual,8/31/2020,7-Jul-20,Actual,7/7/2020,NA,Interventional,NA,NA,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19,Completed,NA,Not Applicable,32,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:16Z,2021-10-12T07:15:16Z
NCT04378738,NA,5/1/2020,NA,NA,5/6/2020,5/6/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,5/6/2020,5/7/2020,Actual,1-May-20,Actual,5/1/2020,May-20,5/31/2020,8-May-20,Anticipated,5/8/2020,7-May-20,Anticipated,5/7/2020,NA,Interventional,NA,NA,Social Media and Covid19 Pandemic,The Role of Social Media as an Information Source in Covid19 Pandemic,Enrolling by invitation,NA,Not Applicable,212,Anticipated,Acibadem University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,if requested to.,2021-10-12T07:15:23Z,2021-10-12T07:15:23Z
NCT04381000,NA,5/7/2020,NA,NA,6/30/2020,5/7/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,6/30/2020,7/1/2020,Actual,1-Apr-20,Actual,4/1/2020,Jun-20,6/30/2020,10-Jun-20,Actual,6/10/2020,29-May-20,Actual,5/29/2020,NA,Interventional,NA,NA,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.,Completed,NA,Not Applicable,170,Actual,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:02Z,2021-10-12T07:15:02Z
NCT04380402,NA,5/1/2020,NA,NA,3/17/2021,5/6/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,3/17/2021,3/19/2021,Actual,25-Jun-20,Actual,6/25/2020,Mar-21,3/31/2021,8-May-22,Anticipated,5/8/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,STATCO19,NA,Atorvastatin as Adjunctive Therapy in COVID-19,Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19,Recruiting,NA,Phase 2,300,Anticipated,Mount Auburn Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:07Z,2021-10-12T07:15:07Z
NCT04379076,NA,5/5/2020,NA,NA,6/7/2021,5/5/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,6/7/2021,6/8/2021,Actual,14-May-20,Actual,5/14/2020,Jun-21,6/30/2021,30-Dec-21,Anticipated,12/30/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,ILIAD-7-UK,NA,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,publication,2021-10-12T07:15:21Z,2021-10-12T07:15:21Z
NCT04376476,NA,4/28/2020,NA,NA,5/7/2020,5/5/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,5/7/2020,5/8/2020,Actual,5-May-20,Actual,5/5/2020,May-20,5/31/2020,5-Jun-21,Anticipated,6/5/2021,5-Jun-21,Anticipated,6/5/2021,NA,Interventional,HPI-COVID-19,NA,Host-pathogen Interactions During SARS-CoV-2 Infection,Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Not Applicable,450,Anticipated,Hospices Civils de Lyon,,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:38Z,2021-10-12T07:15:38Z
NCT04380376,NA,5/6/2020,NA,NA,5/10/2020,5/6/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,5/10/2020,5/12/2020,Actual,30-Apr-20,Actual,4/30/2020,May-20,5/31/2020,30-Oct-20,Anticipated,10/30/2020,30-Oct-20,Anticipated,10/30/2020,NA,Interventional,MICOV,NA,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,"Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19",Recruiting,NA,Phase 2,60,Anticipated,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:09Z,2021-10-12T07:15:09Z
NCT04377620,NA,5/4/2020,NA,NA,3/11/2021,5/4/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,3/11/2021,3/15/2021,Actual,24-May-20,Actual,5/24/2020,Mar-21,3/31/2021,26-Feb-21,Actual,2/26/2021,26-Feb-21,Actual,2/26/2021,NA,Interventional,NA,NA,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",Terminated,NA,Phase 3,211,Actual,Incyte Corporation,,3,NA,Study terminated by sponsor,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:31Z,2021-10-12T07:15:31Z
NCT04377308,NA,4/18/2020,NA,NA,5/4/2020,5/4/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,5/4/2020,5/6/2020,Actual,1-May-20,Actual,5/1/2020,May-20,5/31/2020,20-Oct-21,Anticipated,10/20/2021,20-Apr-21,Anticipated,4/20/2021,NA,Interventional,NA,NA,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,NA,Phase 4,2000,Anticipated,University of Toledo Health Science Campus,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:34Z,2021-10-12T07:15:34Z
NCT04380961,NA,5/7/2020,NA,NA,7/13/2021,5/7/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,7/13/2021,7/14/2021,Actual,24-Apr-20,Actual,4/24/2020,Jul-21,7/31/2021,24-Jun-21,Actual,6/24/2021,9-Apr-21,Actual,4/9/2021,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease",Completed,NA,Phase 2,212,Actual,"Janssen Pharmaceutica N.V., Belgium",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-10-12T07:15:02Z,2021-10-12T07:15:02Z
NCT04379453,NA,4/27/2020,NA,NA,5/7/2020,5/6/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,5/7/2020,5/8/2020,Actual,27-Apr-20,Anticipated,4/27/2020,Apr-20,4/30/2020,27-Apr-20,Anticipated,4/27/2020,27-Apr-20,Anticipated,4/27/2020,NA,Interventional,NA,NA,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Recruiting,NA,Not Applicable,10,Anticipated,Hospital Israelita Albert Einstein,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:16Z,2021-10-12T07:15:16Z
NCT04379531,NA,4/30/2020,NA,NA,6/10/2020,5/6/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,6/10/2020,6/12/2020,Actual,25-Apr-20,Actual,4/25/2020,May-20,5/31/2020,22-May-20,Actual,5/22/2020,22-May-20,Actual,5/22/2020,NA,Interventional,LDCTiP,NA,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,NA,Not Applicable,230,Actual,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:14Z,2021-10-12T07:15:14Z
NCT04377750,NA,4/23/2020,NA,NA,5/5/2020,5/5/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2020,5/6/2020,Actual,8-Apr-20,Actual,4/8/2020,Apr-20,4/30/2020,8-May-21,Anticipated,5/8/2021,29-Apr-20,Actual,4/29/2020,NA,Interventional,NA,NA,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,NA,Phase 4,500,Anticipated,Hadassah Medical Organization,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,No plan,2021-10-12T07:15:29Z,2021-10-12T07:15:29Z
NCT04373096,NA,4/30/2020,NA,NA,1/7/2021,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,1/7/2021,1/11/2021,Actual,7-Dec-20,Actual,12/7/2020,Apr-20,4/30/2020,31-Oct-21,Anticipated,10/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers,Development of a Novel Hood Shield to Enhance PPE Security and Minimize COVID-19 Transmission to Front-line Health Care Workers Performing High-risk Procedures,Recruiting,NA,Not Applicable,42,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:05Z,2021-10-12T07:16:05Z
NCT04379375,NA,5/4/2020,NA,NA,9/30/2020,5/4/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,9/30/2020,10/5/2020,Actual,27-Jul-20,Actual,7/27/2020,Sep-20,9/30/2020,30-Sep-20,Actual,9/30/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,NA,NA,Nudges to Improve Health Behaviors That Limit COVID-19 Spread,Using Behavioral Nudges to Improve Preventive Health Behaviors That Limit COVID-19 Spread,Terminated,NA,Not Applicable,45,Actual,Medical College of Wisconsin,,2,NA,Slow enrollment rate,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:16Z,2021-10-12T07:15:16Z
NCT04376788,NA,5/1/2020,NA,NA,7/7/2020,5/4/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,7/7/2020,7/9/2020,Actual,20-May-20,Actual,5/20/2020,Jul-20,7/31/2020,1-Sep-20,Anticipated,9/1/2020,1-Jul-20,Anticipated,7/1/2020,NA,Interventional,COVID-19,NA,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Recruiting,NA,Phase 2,15,Anticipated,Ain Shams University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:37Z,2021-10-12T07:15:37Z
NCT04380701,NA,5/6/2020,NA,NA,4/20/2021,5/7/2020,5/8/2020,Actual,NA,NA,NA,NA,NA,NA,4/20/2021,4/22/2021,Actual,23-Apr-20,Actual,4/23/2020,Apr-21,4/30/2021,Apr-23,Anticipated,4/30/2023,Apr-23,Anticipated,4/30/2023,NA,Interventional,NA,NA,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy and Immunocompromised Adults",Recruiting,NA,Phase 1/Phase 2,476,Anticipated,BioNTech SE,,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z
NCT04378803,NA,5/4/2020,NA,NA,8/14/2020,5/4/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,8/14/2020,8/17/2020,Actual,13-May-20,Actual,5/13/2020,Aug-20,8/31/2020,4-Aug-20,Actual,8/4/2020,4-Aug-20,Actual,8/4/2020,NA,Interventional,NA,NA,Mindfulness Training for Seniors,Mindfulness Training for Older Adults During the COVID-19 Pandemic,Completed,NA,Not Applicable,53,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:21Z,2021-10-12T07:15:21Z
NCT04379154,NA,4/28/2020,NA,NA,3/15/2021,5/6/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,14-Apr-20,Actual,4/14/2020,Mar-21,3/31/2021,Apr-21,Anticipated,4/30/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,VOC-COVID,NA,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by (SARS-CoV-2): Predictive Interest in Short-term Evolution,Recruiting,NA,Not Applicable,60,Anticipated,Hopital Foch,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:18Z,2021-10-12T07:15:18Z
NCT04379271,NA,5/1/2020,NA,NA,4/23/2021,5/6/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,4/23/2021,4/26/2021,Actual,11-Jun-20,Actual,6/11/2020,Apr-21,4/30/2021,23-Feb-21,Actual,2/23/2021,12-Jan-21,Actual,1/12/2021,NA,Interventional,NA,NA,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)","A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19",Completed,NA,Phase 2/Phase 3,223,Actual,Immunic AG,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:18Z,2021-10-12T07:15:18Z
NCT04377789,NA,5/1/2020,NA,NA,2/17/2021,5/5/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,2/17/2021,2/18/2021,Actual,20-Mar-20,Actual,3/20/2020,Feb-21,2/28/2021,31-Aug-20,Actual,8/31/2020,31-Jul-20,Actual,7/31/2020,NA,Interventional,NA,NA,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Completed,NA,Not Applicable,447,Actual,Kanuni Sultan Suleyman Training and Research Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:28Z,2021-10-12T07:15:28Z
NCT04373291,NA,5/1/2020,NA,NA,10/7/2021,5/1/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/7/2021,10/8/2021,Actual,18-May-20,Actual,5/18/2020,Oct-21,10/31/2021,1-Oct-21,Actual,10/1/2021,31-Jul-21,Actual,7/31/2021,NA,Interventional,NA,NA,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial,Completed,NA,Phase 3,1293,Actual,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2021-10-12T07:16:02Z,2021-10-12T07:16:02Z
NCT04376814,NA,5/3/2020,NA,NA,6/12/2020,5/4/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,6/12/2020,6/16/2020,Actual,29-Mar-20,Actual,3/29/2020,May-20,5/31/2020,25-May-20,Actual,5/25/2020,5-Apr-20,Actual,4/5/2020,NA,Interventional,NA,NA,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,"The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study",Completed,NA,Not Applicable,40,Actual,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:39Z,2021-10-12T07:15:39Z
NCT04377477,NA,5/4/2020,NA,NA,7/21/2020,5/5/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,7/21/2020,7/22/2020,Actual,10-May-20,Actual,5/10/2020,Jul-20,7/31/2020,30-Aug-22,Anticipated,8/30/2022,10-Aug-21,Anticipated,8/10/2021,NA,Interventional,COLOR-19,NA,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19),Recruiting,NA,Not Applicable,30,Anticipated,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available starting six months from the publication and for five years.,"Written request to principal investigator , indicating the details of the data requested, the reasons of the inquiry and the purpose of the data use; data will be released after Local Ethics Committee approval. Data will be released only for no-profit use, in particular for research purposes.",NA,Yes,All Individual Participant Data that underlie results in the publication,2021-10-12T07:15:35Z,2021-10-12T07:15:35Z
NCT04378712,NA,4/29/2020,NA,NA,5/13/2020,5/5/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,5/13/2020,5/15/2020,Actual,21-Jan-20,Actual,1/21/2020,May-20,5/31/2020,23-Mar-20,Actual,3/23/2020,23-Mar-20,Actual,3/23/2020,NA,Interventional,NA,NA,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),"Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial",Completed,NA,Not Applicable,90,Actual,Guangzhou Institute of Respiratory Disease,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:23Z,2021-10-12T07:15:23Z
NCT04377165,NA,5/4/2020,NA,NA,3/4/2021,5/4/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,3/4/2021,3/9/2021,Actual,6-May-20,Actual,5/6/2020,Apr-20,4/30/2020,26-Aug-20,Actual,8/26/2020,26-Aug-20,Actual,8/26/2020,NA,Interventional,NA,NA,Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities,Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care,Terminated,NA,Not Applicable,34,Actual,The University of Queensland,,2,NA,"Engagement issues, poor recruitment to study",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:35Z,2021-10-12T07:15:35Z
NCT04374942,NA,4/30/2020,NA,NA,4/27/2021,4/30/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/29/2021,Actual,30-Apr-20,Actual,4/30/2020,Apr-21,4/30/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,HEROs,NA,Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,"Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada",Terminated,NA,Phase 3,13,Actual,"University Health Network, Toronto",,2,NA,"Due to unproven issues associated with hydroxychloroquine use and safety, further complicated by media and political misinformation which in effect rendered all global studies on HCQ to stop enrolling participants.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"At the time of completion of the analysis of primary and secondary outcomes, the HEROS Steering Committee will review all applications for use of participant level data and make recommendations.",2021-10-12T07:15:52Z,2021-10-12T07:15:52Z
NCT04374591,NA,5/2/2020,NA,NA,10/2/2020,5/2/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,10/2/2020,10/6/2020,Actual,1-Aug-20,Actual,8/1/2020,Jul-20,7/31/2020,1-Nov-20,Anticipated,11/1/2020,1-Nov-20,Anticipated,11/1/2020,NA,Interventional,NA,NA,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia: A Preliminary Report of Short Term Follow up,"Active, not recruiting",NA,Not Applicable,180,Anticipated,Mansoura University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:54Z,2021-10-12T07:15:54Z
NCT04375098,NA,5/3/2020,NA,NA,9/12/2020,5/4/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,9/12/2020,9/16/2020,Actual,4-May-20,Actual,5/4/2020,Sep-20,9/30/2020,17-Aug-20,Actual,8/17/2020,17-Aug-20,Actual,8/17/2020,NA,Interventional,NA,NA,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial,Completed,NA,Phase 2,58,Actual,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:50Z,2021-10-12T07:15:50Z
NCT04374526,NA,5/2/2020,NA,NA,5/27/2021,5/2/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,5/27/2021,5/28/2021,Actual,27-May-20,Actual,5/27/2020,May-20,5/31/2020,26-May-21,Actual,5/26/2021,26-May-21,Actual,5/26/2021,NA,Interventional,LIFESAVER,NA,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.,Completed,NA,Phase 2/Phase 3,29,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:56Z,2021-10-12T07:15:56Z
NCT04375124,NA,5/1/2020,NA,NA,5/14/2020,5/1/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2020,5/15/2020,Actual,25-Apr-20,Actual,4/25/2020,May-20,5/31/2020,30-Sep-20,Anticipated,9/30/2020,31-Aug-20,Anticipated,8/31/2020,NA,Interventional,NA,NA,Treatment of Angiotensin Peptide (1-7) for COVID-19,Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19,Recruiting,NA,Not Applicable,20,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:51Z,2021-10-12T07:15:51Z
NCT04374487,NA,4/29/2020,NA,NA,7/20/2020,5/1/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,7/20/2020,7/22/2020,Actual,9-May-20,Actual,5/9/2020,Jul-20,7/31/2020,9-Aug-21,Anticipated,8/9/2021,9-Aug-21,Anticipated,8/9/2021,NA,Interventional,NA,NA,Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,"A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications","Active, not recruiting",NA,Phase 2,100,Actual,Max Healthcare Insititute Limited,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:55Z,2021-10-12T07:15:55Z
NCT04374786,NA,5/1/2020,NA,NA,6/1/2020,5/1/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,6/1/2020,6/4/2020,Actual,15-May-20,Actual,5/15/2020,Jun-20,6/30/2020,1-Oct-20,Anticipated,10/1/2020,1-Sep-20,Anticipated,9/1/2020,NA,Interventional,NA,NA,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Effects of a Mobile App on Health and Well-being During COVID-19 Pandemic in House Staff at Banner University Medical Center Phoenix,Enrolling by invitation,NA,Not Applicable,328,Anticipated,University of Arizona,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:52Z,2021-10-12T07:15:52Z
NCT04374032,NA,4/30/2020,NA,NA,12/23/2020,5/4/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,12/23/2020,12/24/2020,Actual,1-May-20,Actual,5/1/2020,Dec-20,12/31/2020,3-Nov-20,Actual,11/3/2020,7-Oct-20,Actual,10/7/2020,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,"An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTENÂ® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection",Completed,NA,Phase 2/Phase 3,120,Actual,Bosnalijek D.D,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:59Z,2021-10-12T07:15:59Z
NCT04372602,NA,4/30/2020,NA,NA,5/21/2021,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/25/2021,Actual,12-Oct-20,Actual,10/12/2020,May-21,5/31/2021,30-Apr-22,Anticipated,4/30/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Duvelisib to Combat COVID-19,A Pilot Study of Duvelisib to Combat COVID-19,Recruiting,NA,Phase 2,28,Anticipated,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:09Z,2021-10-12T07:16:09Z
NCT04377711,NA,5/5/2020,NA,NA,8/10/2021,5/5/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,8/10/2021,8/16/2021,Actual,8-Jun-20,Actual,6/8/2020,Aug-21,8/31/2021,5-Jan-21,Actual,1/5/2021,5-Jan-21,Actual,1/5/2021,NA,Interventional,NA,NA,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection",Completed,NA,Phase 3,400,Actual,Covis Pharma S.Ã .r.l.,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:29Z,2021-10-12T07:15:29Z
NCT04374539,NA,5/2/2020,NA,NA,7/1/2020,5/2/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,7/1/2020,7/7/2020,Actual,29-Apr-20,Actual,4/29/2020,May-20,5/31/2020,29-Aug-21,Anticipated,8/29/2021,5-May-21,Anticipated,5/5/2021,NA,Interventional,REP-COVID,NA,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,NA,Phase 2,116,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:55Z,2021-10-12T07:15:55Z
NCT04376840,NA,5/4/2020,NA,NA,11/26/2020,5/5/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2020,11/30/2020,Actual,28-May-20,Actual,5/28/2020,Nov-20,11/30/2020,28-Oct-22,Anticipated,10/28/2022,28-Jan-22,Anticipated,1/28/2022,NA,Interventional,NA,NA,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia,Recruiting,NA,Not Applicable,270,Anticipated,CHU de Reims,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:35Z,2021-10-12T07:15:35Z
NCT04373824,NA,4/26/2020,NA,NA,5/1/2020,5/1/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,5/1/2020,5/4/2020,Actual,25-Apr-20,Actual,4/25/2020,May-20,5/31/2020,25-Jul-20,Anticipated,7/25/2020,25-Jul-20,Anticipated,7/25/2020,NA,Interventional,NA,NA,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,NA,Not Applicable,50,Anticipated,Max Healthcare Insititute Limited,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:59Z,2021-10-12T07:15:59Z
NCT04375774,NA,4/17/2020,NA,NA,5/4/2020,5/4/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,5/4/2020,5/5/2020,Actual,May-20,Anticipated,5/31/2020,May-20,5/31/2020,May-20,Anticipated,5/31/2020,May-20,Anticipated,5/31/2020,NA,Interventional,VADER,NA,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Verification of Alternative Do-it-yourself Equipment Respirators,Recruiting,NA,Not Applicable,10,Anticipated,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All data will be presented in the future manuscript,2021-10-12T07:15:44Z,2021-10-12T07:15:44Z
NCT04375202,NA,4/29/2020,NA,NA,9/27/2021,5/3/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/28/2021,Actual,18-Apr-20,Actual,4/18/2020,Sep-21,9/30/2021,31-Oct-22,Anticipated,10/31/2022,31-Oct-22,Anticipated,10/31/2022,NA,Interventional,COLVID-19,NA,Colchicine in COVID-19: a Pilot Study,Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study,Recruiting,NA,Phase 2,308,Anticipated,University Of Perugia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:51Z,2021-10-12T07:15:51Z
NCT04374565,NA,4/27/2020,NA,NA,8/20/2020,5/1/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,8/20/2020,8/21/2020,Actual,5-May-20,Actual,5/5/2020,Aug-20,8/31/2020,5-Apr-21,Anticipated,4/5/2021,5-Apr-21,Anticipated,4/5/2021,NA,Interventional,NA,NA,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial,"Active, not recruiting",NA,Phase 2,29,Anticipated,University of Virginia,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:55Z,2021-10-12T07:15:55Z
NCT04374461,NA,5/1/2020,NA,NA,7/21/2021,5/1/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/22/2021,Actual,1-May-20,Actual,5/1/2020,Jul-21,7/31/2021,May-23,Anticipated,5/31/2023,May-23,Anticipated,5/31/2023,NA,Interventional,NA,NA,A Study of N-acetylcysteine in Patients With COVID-19 Infection,Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection,"Active, not recruiting",NA,Phase 2,48,Actual,Memorial Sloan Kettering Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-10-12T07:15:56Z,2021-10-12T07:15:56Z
NCT04375397,NA,5/4/2020,NA,NA,7/7/2021,5/4/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/8/2021,Actual,6-Jun-20,Actual,6/6/2020,Jul-21,7/31/2021,8-Jun-21,Actual,6/8/2021,10-May-21,Actual,5/10/2021,NA,Interventional,iNSPIRE,NA,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE),Completed,NA,Phase 2,46,Actual,AbbVie,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.",Requests for access to individual participant data from ibrutinib clinical studies conducted by AbbVie can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu,http://yoda.yale.edu/,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2021-10-12T07:15:46Z,2021-10-12T07:15:46Z
NCT04374019,NA,5/1/2020,NA,NA,6/29/2021,5/1/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,6/29/2021,6/30/2021,Actual,1-May-20,Actual,5/1/2020,Jun-21,6/30/2021,May-22,Anticipated,5/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,"Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients",Recruiting,NA,Phase 2,240,Anticipated,University of Kentucky,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:59Z,2021-10-12T07:15:59Z
NCT04373382,NA,4/30/2020,NA,NA,11/3/2020,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2020,11/5/2020,Actual,27-Jul-20,Actual,7/27/2020,Nov-20,11/30/2020,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,"Active, not recruiting",NA,Not Applicable,882,Actual,"Mount Sinai Hospital, Canada",,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:04Z,2021-10-12T07:16:04Z
NCT04372979,NA,4/24/2020,NA,NA,12/18/2020,4/29/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,12/18/2020,12/21/2020,Actual,14-Sep-20,Actual,9/14/2020,Dec-20,12/31/2020,Jun-21,Anticipated,6/30/2021,May-21,Anticipated,5/31/2021,NA,Interventional,PLASCOSSA,NA,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.,Recruiting,NA,Phase 3,80,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:06Z,2021-10-12T07:16:06Z
NCT04376684,NA,5/4/2020,NA,NA,9/10/2021,5/4/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,9/10/2021,9/14/2021,Actual,28-May-20,Actual,5/28/2020,Sep-21,9/30/2021,16-Aug-21,Actual,8/16/2021,15-Jul-21,Actual,7/15/2021,NA,Interventional,OSCAR,NA,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,"A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease",Completed,NA,Phase 2,1156,Actual,GlaxoSmithKline,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2021-10-12T07:15:38Z,2021-10-12T07:15:38Z
NCT04376034,NA,4/19/2020,NA,NA,5/1/2020,5/1/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,5/1/2020,5/6/2020,Actual,16-Apr-20,Actual,4/16/2020,May-20,5/31/2020,30-Mar-21,Anticipated,3/30/2021,30-Mar-21,Anticipated,3/30/2021,NA,Interventional,NA,NA,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma,Recruiting,NA,Phase 3,240,Anticipated,West Virginia University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:43Z,2021-10-12T07:15:43Z
NCT04373161,NA,4/30/2020,NA,NA,5/5/2020,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2020,5/6/2020,Actual,20-Mar-20,Actual,3/20/2020,May-20,5/31/2020,22-Apr-20,Actual,4/22/2020,22-Apr-20,Actual,4/22/2020,NA,Interventional,NA,NA,Home Pulse Oximeter Use in Patients With COVID-19,Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression,Completed,NA,Not Applicable,209,Actual,Swedish Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:05Z,2021-10-12T07:16:05Z
NCT04373135,NA,4/30/2020,NA,NA,10/11/2020,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/11/2020,10/14/2020,Actual,8-May-20,Actual,5/8/2020,Oct-20,10/31/2020,Mar-21,Anticipated,3/31/2021,Feb-21,Anticipated,2/28/2021,NA,Interventional,UC-COVID,NA,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19",A Study to Evaluate Health Behavior and Access Impacts Due to COVID-19 and for Community Engagement of Stakeholders Surrounding Scarce Resource Allocation Policy.,"Active, not recruiting",NA,Not Applicable,2500,Actual,"University of California, Los Angeles",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 4 months of study closure,Reasonable request to investigators,NA,Yes,Data requests for analysis may be approved by the investigators upon reasonable request.,2021-10-12T07:16:05Z,2021-10-12T07:16:05Z
NCT04373200,NA,4/22/2020,NA,NA,6/28/2021,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,6/28/2021,6/29/2021,Actual,25-May-20,Actual,5/25/2020,Jun-21,6/30/2021,25-Sep-22,Anticipated,9/25/2022,25-Sep-22,Anticipated,9/25/2022,NA,Interventional,HARMONICOV,NA,Human Ab Response & immunoMONItoring of COVID-19 Patients,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,NA,Not Applicable,75,Anticipated,Rennes University Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:06Z,2021-10-12T07:16:06Z
NCT04372680,NA,4/30/2020,NA,NA,3/2/2021,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,3/2/2021,3/4/2021,Actual,22-Apr-20,Actual,4/22/2020,Mar-21,3/31/2021,22-Oct-21,Anticipated,10/22/2021,22-Oct-21,Anticipated,10/22/2021,NA,Interventional,INVICTUS,NA,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,"WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound: a Prospective, Multicenter, Randomized, Open-label, Parallel-group Clinical Trial",Recruiting,NA,Not Applicable,200,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:07Z,2021-10-12T07:16:07Z
NCT04366908,NA,4/25/2020,NA,NA,8/24/2021,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/25/2021,Actual,7-May-20,Actual,5/7/2020,Aug-21,8/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,COVIDIOL,NA,Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS),Recruiting,NA,Phase 2,1008,Anticipated,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Since the end publication of the results.,Contact uicec@imibic.org,NA,Yes,All the information will be published and accessible. It will be also available on demand.,2021-10-12T07:16:54Z,2021-10-12T07:16:54Z
NCT04365439,NA,4/18/2020,NA,NA,3/24/2021,4/26/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,3/24/2021,3/29/2021,Actual,20-Jul-20,Actual,7/20/2020,Mar-21,3/31/2021,30-Jun-21,Anticipated,6/30/2021,20-Dec-20,Actual,12/20/2020,NA,Interventional,NA,NA,Convalescent Plasma for COVID-19,Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study,"Active, not recruiting",NA,Not Applicable,11,Actual,"Ente Ospedaliero Cantonale, Bellinzona",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:03Z,2021-10-12T07:17:03Z
NCT04373044,NA,4/17/2020,NA,NA,5/21/2021,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/26/2021,Actual,1-May-20,Actual,5/1/2020,May-21,5/31/2021,12-May-21,Actual,5/12/2021,12-May-21,Actual,5/12/2021,NA,Interventional,NA,NA,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19,Terminated,NA,Phase 2,6,Actual,University of Southern California,,2,NA,The study was terminated after the release of results of ACTT-2 (NCT04401579).,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:07Z,2021-10-12T07:16:07Z
NCT04368260,NA,4/24/2020,NA,NA,4/27/2020,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2020,4/29/2020,Actual,24-Apr-20,Actual,4/24/2020,Apr-20,4/30/2020,31-Jul-20,Anticipated,7/31/2020,31-Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,NA,Not Applicable,40,Anticipated,University of Virginia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,Starting 6 months after publication,Requests to made to Principal Investigator,NA,Yes,All individual participant data (IPD) that underlie results in a publication will be shared.,2021-10-12T07:16:44Z,2021-10-12T07:16:44Z
NCT04371029,NA,4/28/2020,NA,NA,6/4/2021,4/30/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,6/4/2021,6/7/2021,Actual,28-Apr-20,Actual,4/28/2020,Jun-21,6/30/2021,9-Dec-20,Actual,12/9/2020,9-Sep-20,Actual,9/9/2020,NA,Interventional,COVISLEEP,NA,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Completed,NA,Not Applicable,17,Actual,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:23Z,2021-10-12T07:16:23Z
NCT04369469,NA,4/28/2020,NA,NA,9/16/2021,4/28/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2021,9/22/2021,Actual,11-May-20,Actual,5/11/2020,Sep-21,9/30/2021,8-Apr-21,Actual,4/8/2021,8-Feb-21,Actual,2/8/2021,NA,Interventional,NA,NA,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,"A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome",Terminated,NA,Phase 3,202,Actual,Alexion Pharmaceuticals,,2,NA,Met futility bar at interim analysis.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:32Z,2021-10-12T07:16:32Z
NCT04368845,NA,4/20/2020,NA,NA,1/27/2021,4/28/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,1/27/2021,1/28/2021,Actual,11-May-20,Actual,5/11/2020,Apr-20,4/30/2020,31-Mar-21,Anticipated,3/31/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,ATHLOS,NA,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,"A Telerehabilitation Approach to Improve Long-term Physical Ability and Quality of Life in Patients With Severe Acute Respiratory Syndrome Coronavirus (SARSCoV-2, COVID-19) Immediately After Hospitalization. The ATHLOS Study",Recruiting,NA,Not Applicable,100,Anticipated,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:38Z,2021-10-12T07:16:38Z
NCT04367662,NA,4/16/2020,NA,NA,6/5/2020,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,6/5/2020,6/9/2020,Actual,9-Apr-20,Actual,4/9/2020,Jun-20,6/30/2020,14-May-20,Actual,5/14/2020,14-May-20,Actual,5/14/2020,NA,Interventional,COVID'HEMOS,NA,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,NA,Not Applicable,99,Actual,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:45Z,2021-10-12T07:16:45Z
NCT04369378,NA,4/24/2020,NA,NA,8/27/2021,4/28/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,8/27/2021,8/30/2021,Actual,19-Aug-20,Actual,8/19/2020,Aug-21,8/31/2021,26-Aug-21,Actual,8/26/2021,28-Apr-21,Actual,4/28/2021,NA,Interventional,NA,NA,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Completed,NA,Not Applicable,103,Actual,Lake Erie College of Osteopathic Medicine,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Upon publication of findings,Upon written request to corresponding author on publication,NA,Yes,"De-identified participant data will be reported as individual data points, as well as means +/- SD or medians with quartiles.",2021-10-12T07:16:33Z,2021-10-12T07:16:33Z
NCT04368377,NA,4/23/2020,NA,NA,4/28/2020,4/28/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,4/28/2020,4/29/2020,Actual,6-Apr-20,Actual,4/6/2020,Apr-20,4/30/2020,23-Apr-20,Actual,4/23/2020,23-Apr-20,Actual,4/23/2020,NA,Interventional,PIC-19,NA,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol,Completed,NA,Phase 2,5,Actual,University of Milan,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:41Z,2021-10-12T07:16:41Z
NCT04372693,NA,4/27/2020,NA,NA,7/30/2021,4/29/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,7/30/2021,8/3/2021,Actual,1-Sep-20,Actual,9/1/2020,Jul-21,7/31/2021,31-Jul-21,Anticipated,7/31/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,(COVID-19),NA,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Unplanned Shifting the Traditional Classroom-Based to Online Distance Learning as a Result of (COVID-19) Social Distancing Measures: Nursing Students' Perception and Achievement,Enrolling by invitation,NA,Not Applicable,180,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,the study will be available to interested researchers by Publication in the indexed journal at the end of the study completion,2021-10-12T07:16:09Z,2021-10-12T07:16:09Z
NCT04371367,NA,4/29/2020,NA,NA,5/26/2021,4/30/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/27/2021,Actual,27-Apr-20,Actual,4/27/2020,May-21,5/31/2021,30-Mar-21,Actual,3/30/2021,30-Mar-21,Actual,3/30/2021,NA,Interventional,FORCE,NA,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia",Completed,NA,Phase 2,208,Actual,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:19Z,2021-10-12T07:16:19Z
NCT04370236,NA,4/29/2020,NA,NA,2/3/2021,4/29/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,2/3/2021,2/5/2021,Actual,21-Oct-20,Actual,10/21/2020,Feb-21,2/28/2021,Feb-21,Anticipated,2/28/2021,Feb-21,Anticipated,2/28/2021,NA,Interventional,NA,NA,INB03 for the Treatment of Pulmonary Complications From COVID-19,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)",Recruiting,NA,Phase 2/Phase 3,366,Anticipated,"Inmune Bio, Inc.",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:25Z,2021-10-12T07:16:25Z
NCT04371393,NA,4/28/2020,NA,NA,4/1/2021,4/28/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,4/1/2021,4/5/2021,Actual,30-Apr-20,Actual,4/30/2020,Apr-21,4/30/2021,Feb-22,Anticipated,2/28/2022,14-Jan-21,Actual,1/14/2021,NA,Interventional,NA,NA,MSCs in COVID-19 ARDS,Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome,"Active, not recruiting",NA,Phase 3,223,Actual,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.",Anyone who wishes to access the data.,NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-10-12T07:16:17Z,2021-10-12T07:16:17Z
NCT04368156,NA,4/20/2020,NA,NA,2/12/2021,4/28/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/16/2021,Actual,20-Apr-20,Actual,4/20/2020,Feb-21,2/28/2021,23-Feb-21,Anticipated,2/23/2021,23-Feb-21,Anticipated,2/23/2021,NA,Interventional,SAVIOR,NA,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)","Active, not recruiting",NA,Not Applicable,110,Actual,Hospital ClÃ­nico Universitario de Valencia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:43Z,2021-10-12T07:16:43Z
NCT04371510,NA,4/28/2020,NA,NA,4/30/2020,4/30/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,4/30/2020,5/1/2020,Actual,22-Apr-20,Actual,4/22/2020,Apr-20,4/30/2020,22-Feb-21,Anticipated,2/22/2021,22-Oct-20,Anticipated,10/22/2020,NA,Interventional,PredictCovid-D,NA,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,NA,Not Applicable,115,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:17Z,2021-10-12T07:16:17Z
NCT04370782,NA,4/26/2020,NA,NA,12/8/2020,4/29/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,12/8/2020,12/9/2020,Actual,28-Apr-20,Actual,4/28/2020,Dec-20,12/31/2020,30-Sep-20,Actual,9/30/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,NA,NA,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting,Completed,NA,Phase 4,18,Actual,"St. Francis Hospital, New York",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:22Z,2021-10-12T07:16:22Z
NCT04369742,NA,4/25/2020,NA,NA,6/11/2021,4/29/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,6/11/2021,6/14/2021,Actual,15-Apr-20,Actual,4/15/2020,Jun-21,6/30/2021,1-Apr-21,Actual,4/1/2021,1-Apr-21,Actual,4/1/2021,NA,Interventional,NA,NA,Treating COVID-19 With Hydroxychloroquine (TEACH),"Treating COVID-19 With Hydroxychloroquine: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults",Terminated,NA,Phase 2,131,Actual,NYU Langone Health,,2,NA,Investigator decision,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"Requests should be directed to mark.mulligan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-10-12T07:16:30Z,2021-10-12T07:16:30Z
NCT04369456,NA,4/27/2020,NA,NA,4/30/2020,4/27/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/30/2020,5/1/2020,Actual,22-Apr-20,Actual,4/22/2020,Apr-20,4/30/2020,22-Oct-20,Anticipated,10/22/2020,22-Oct-20,Anticipated,10/22/2020,NA,Interventional,PredictCovidT,NA,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,NA,Not Applicable,115,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:32Z,2021-10-12T07:16:32Z
NCT04372589,NA,4/24/2020,NA,NA,7/26/2021,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/27/2021,Actual,20-May-20,Actual,5/20/2020,Jan-21,1/31/2021,17-May-21,Actual,5/17/2021,17-May-21,Actual,5/17/2021,NA,Interventional,ATTACC,NA,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)",Completed,NA,Phase 2/Phase 3,1200,Actual,University of Manitoba,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:10Z,2021-10-12T07:16:10Z
NCT04369365,NA,4/27/2020,NA,NA,4/29/2020,4/29/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2020,5/1/2020,Actual,27-Apr-20,Actual,4/27/2020,Apr-20,4/30/2020,27-Dec-20,Anticipated,12/27/2020,27-Aug-20,Anticipated,8/27/2020,NA,Interventional,NA,NA,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,NA,Phase 2,200,Anticipated,Medical University of Vienna,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:33Z,2021-10-12T07:16:33Z
NCT04369820,NA,4/29/2020,NA,NA,4/30/2020,4/29/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/30/2020,5/4/2020,Actual,31-Mar-20,Actual,3/31/2020,Apr-20,4/30/2020,Nov-20,Anticipated,11/30/2020,Sep-20,Anticipated,9/30/2020,NA,Interventional,C5-COV,NA,C5a Receptor Expression - COVID-19 (C5-COV),C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,Assistance Publique Hopitaux De Marseille,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:29Z,2021-10-12T07:16:29Z
NCT04371978,NA,4/30/2020,NA,NA,5/28/2021,4/30/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,5/28/2021,6/2/2021,Actual,1-Oct-20,Actual,10/1/2020,May-21,5/31/2021,4-May-21,Actual,5/4/2021,4-Apr-21,Actual,4/4/2021,NA,Interventional,NA,NA,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Terminated,NA,Phase 3,64,Actual,Rabin Medical Center,,2,NA,End of COVID-19 outbreak in Israel,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:15Z,2021-10-12T07:16:15Z
NCT04370288,NA,4/29/2020,NA,NA,4/30/2020,4/29/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/30/2020,5/4/2020,Actual,19-Apr-20,Actual,4/19/2020,Apr-20,4/30/2020,21-Sep-20,Anticipated,9/21/2020,20-Sep-20,Anticipated,9/20/2020,NA,Interventional,Covid-19,NA,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients,Recruiting,NA,Phase 1,20,Anticipated,Mashhad University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:16:29Z,2021-10-12T07:16:29Z
NCT04369066,NA,4/27/2020,NA,NA,5/18/2021,4/29/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/19/2021,Actual,28-Apr-20,Actual,4/28/2020,May-21,5/31/2021,Feb-22,Anticipated,2/28/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,Curie-O-SA,NA,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur","COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur","Active, not recruiting",NA,Not Applicable,1971,Actual,Institut Curie,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:35Z,2021-10-12T07:16:35Z
NCT04367168,NA,4/24/2020,NA,NA,5/26/2020,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,5/26/2020,5/28/2020,Actual,27-May-20,Actual,5/27/2020,Apr-20,4/30/2020,27-Apr-21,Anticipated,4/27/2021,27-Apr-21,Anticipated,4/27/2021,NA,Interventional,ColchiVID,NA,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,"Double-blind, Placebo-controlled Clinical Trial of the Use of Colchicine for the Management of Patients With Mild and Severe SARS-Cov2 Infection",Recruiting,NA,Phase 2,174,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,6 months after publication of the clinical trial,Reviewers of scientific journals and researchers who contact the principal researcher by e-mail,NA,Yes,All IPD that underlie results in a publication,2021-10-12T07:16:50Z,2021-10-12T07:16:50Z
NCT04372004,NA,4/29/2020,NA,NA,8/7/2020,4/29/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,8/7/2020,8/11/2020,Actual,8-May-20,Actual,5/8/2020,May-20,5/31/2020,Jun-21,Anticipated,6/30/2021,May-21,Anticipated,5/31/2021,NA,Interventional,CATCH COVID-19,NA,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Recruiting,NA,Phase 1,100,Anticipated,Texas Cardiac Arrhythmia Research Foundation,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:13Z,2021-10-12T07:16:13Z
NCT04367636,NA,4/20/2020,NA,NA,2/18/2021,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,2/18/2021,2/21/2021,Actual,30-Apr-20,Actual,4/30/2020,Apr-20,4/30/2020,Sep-21,Anticipated,9/30/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,OCAT,NA,The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19,The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19: Validation of a New Online Treatment,Recruiting,NA,Not Applicable,100,Anticipated,University Ghent,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:46Z,2021-10-12T07:16:46Z
NCT04366960,NA,4/24/2020,NA,NA,6/7/2021,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,6/7/2021,6/8/2021,Actual,14-May-20,Actual,5/14/2020,Jun-21,6/30/2021,25-May-21,Actual,5/25/2021,25-May-21,Actual,5/25/2021,NA,Interventional,X-Covid 19,NA,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial,Completed,NA,Phase 3,189,Actual,Niguarda Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z
NCT04367831,NA,4/27/2020,NA,NA,9/27/2021,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/29/2021,Actual,2-May-20,Actual,5/2/2020,Sep-21,9/30/2021,12-May-21,Actual,5/12/2021,12-May-21,Actual,5/12/2021,NA,Interventional,IMPROVE,NA,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID),Completed,NA,Phase 4,94,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:46Z,2021-10-12T07:16:46Z
NCT04371965,NA,4/29/2020,NA,NA,10/23/2020,4/30/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,10/23/2020,10/26/2020,Actual,1-Sep-20,Actual,9/1/2020,Jul-20,7/31/2020,23-Oct-20,Actual,10/23/2020,23-Oct-20,Actual,10/23/2020,NA,Interventional,KILLER,NA,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2",Completed,NA,Phase 2,24,Actual,Poitiers University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:14Z,2021-10-12T07:16:14Z
NCT04368299,NA,4/25/2020,NA,NA,7/26/2021,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/28/2021,Actual,1-May-20,Actual,5/1/2020,Jul-21,7/31/2021,31-Dec-21,Anticipated,12/31/2021,17-Dec-21,Anticipated,12/17/2021,NA,Interventional,NA,NA,Telemedicine for Follow-up of Systemic Lupus Erythematosus,"Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus (""TeleSLE"") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial","Active, not recruiting",NA,Not Applicable,144,Actual,Chinese University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:41Z,2021-10-12T07:16:41Z
NCT04369794,NA,4/27/2020,NA,NA,8/5/2020,4/28/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2020,8/7/2020,Actual,10-Aug-20,Anticipated,8/10/2020,Aug-20,8/31/2020,Aug-23,Anticipated,8/31/2023,Jun-21,Anticipated,6/30/2021,NA,Interventional,BATTLE,NA,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,NA,Phase 4,1000,Anticipated,"University of Campinas, Brazil",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:29Z,2021-10-12T07:16:29Z
NCT04365309,NA,4/24/2020,NA,NA,4/27/2020,4/27/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2020,4/28/2020,Actual,10-Feb-20,Actual,2/10/2020,Mar-20,3/31/2020,Jun-20,Anticipated,6/30/2020,Apr-20,Anticipated,4/30/2020,NA,Interventional,PEAC,NA,Protective Effect of Aspirin on COVID-19 Patients,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,NA,Phase 2/Phase 3,128,Anticipated,Xijing Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:04Z,2021-10-12T07:17:04Z
NCT04370886,NA,4/28/2020,NA,NA,5/28/2020,4/28/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,5/28/2020,6/1/2020,Actual,30-Apr-20,Actual,4/30/2020,Apr-20,4/30/2020,10-May-20,Actual,5/10/2020,30-Apr-20,Actual,4/30/2020,NA,Interventional,NA,NA,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19,Completed,NA,Not Applicable,456517,Actual,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:20Z,2021-10-12T07:16:20Z
NCT04371601,NA,3/25/2020,NA,NA,4/30/2020,4/30/2020,5/1/2020,Actual,NA,NA,NA,NA,NA,NA,4/30/2020,5/1/2020,Actual,1-Mar-20,Actual,3/1/2020,Mar-20,3/31/2020,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",NA,Early Phase 1,60,Actual,Fuzhou General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:16Z,2021-10-12T07:16:16Z
NCT04368000,NA,4/24/2020,NA,NA,12/1/2020,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2020,12/3/2020,Actual,29-Apr-20,Actual,4/29/2020,Dec-20,12/31/2020,6-Aug-20,Actual,8/6/2020,6-Aug-20,Actual,8/6/2020,NA,Interventional,PAPR,NA,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Terminated,NA,Not Applicable,30,Actual,University of Utah,,2,NA,Study was terminated due to lack of adherence to the protocol in the intervention arm.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:43Z,2021-10-12T07:16:43Z
NCT04366297,NA,4/23/2020,NA,NA,4/27/2020,4/27/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2020,4/28/2020,Actual,12-Jan-20,Actual,1/12/2020,Apr-20,4/30/2020,25-Feb-20,Actual,2/25/2020,25-Feb-20,Actual,2/25/2020,NA,Interventional,NA,NA,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial,Completed,NA,Not Applicable,41,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,the investigators will add data into manuscript,2021-10-12T07:16:55Z,2021-10-12T07:16:55Z
NCT04366141,NA,4/24/2020,NA,NA,2/23/2021,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,2/23/2021,2/24/2021,Actual,1-May-20,Actual,5/1/2020,Feb-21,2/28/2021,1-Feb-21,Actual,2/1/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,NA,NA,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,The Impact of a Barrier Enclosure on Endotracheal Intubation Duration and First Pass Attempt - A Randomized Controlled Trial,Completed,NA,Not Applicable,100,Actual,University of British Columbia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:56Z,2021-10-12T07:16:56Z
NCT04367545,NA,4/27/2020,NA,NA,11/4/2020,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,11/4/2020,11/5/2020,Actual,16-Apr-20,Actual,4/16/2020,Nov-20,11/30/2020,17-May-20,Actual,5/17/2020,17-May-20,Actual,5/17/2020,NA,Interventional,MolCOVID,NA,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,NA,Not Applicable,130,Actual,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:47Z,2021-10-12T07:16:47Z
NCT04367077,NA,4/27/2020,NA,NA,9/7/2021,4/27/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/9/2021,Actual,28-Apr-20,Actual,4/28/2020,Sep-21,9/30/2021,Dec-23,Anticipated,12/31/2023,Jan-23,Anticipated,1/31/2023,NA,Interventional,MACoVIA,NA,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStemÂ® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2/Phase 3,400,Anticipated,"Athersys, Inc",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:50Z,2021-10-12T07:16:50Z
NCT04366245,NA,4/22/2020,NA,NA,7/21/2021,4/27/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/22/2021,Actual,23-Apr-20,Actual,4/23/2020,Jul-21,7/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,"Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,Andalusian Network for Design and Translation of Advanced Therapies,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:56Z,2021-10-12T07:16:56Z
NCT04366063,NA,4/20/2020,NA,NA,4/29/2020,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2020,4/30/2020,Actual,5-Apr-20,Actual,4/5/2020,Apr-20,4/30/2020,10-Dec-20,Anticipated,12/10/2020,6-Jun-20,Anticipated,6/6/2020,NA,Interventional,NA,NA,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Royan Institute,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months after publication,Researchers and clinicians,NA,Yes,NA,2021-10-12T07:16:58Z,2021-10-12T07:16:58Z
NCT04366882,NA,4/22/2020,NA,NA,4/28/2020,4/28/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,4/28/2020,4/29/2020,Actual,14-Apr-20,Actual,4/14/2020,Apr-20,4/30/2020,Dec-20,Anticipated,12/31/2020,Dec-20,Anticipated,12/31/2020,NA,Interventional,MIA-COVID-19,NA,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,"Increasing Our Understanding of COVID-19: Minimal Invasive Autopsies to Investigate Clinical, Radiological, Microbiological and Histopathological Changes in Deceased COVID-19 Patients",Recruiting,NA,Not Applicable,45,Anticipated,Jessa Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z
NCT04365972,NA,4/24/2020,NA,NA,5/6/2020,4/27/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,5/6/2020,5/8/2020,Actual,23-Apr-20,Actual,4/23/2020,May-20,5/31/2020,30-Apr-20,Actual,4/30/2020,30-Apr-20,Actual,4/30/2020,NA,Interventional,NA,NA,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial,Completed,NA,Not Applicable,20,Actual,Tel Aviv University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:59Z,2021-10-12T07:16:59Z
NCT04365608,NA,4/24/2020,NA,NA,12/17/2020,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2020,12/19/2020,Actual,20-Mar-20,Actual,3/20/2020,Dec-20,12/31/2020,10-Dec-20,Actual,12/10/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,NA,NA,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope,Completed,NA,Not Applicable,90,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after manuscript publishing,NA,NA,Yes,NA,2021-10-12T07:17:02Z,2021-10-12T07:17:02Z
NCT04366947,NA,4/23/2020,NA,NA,12/17/2020,4/28/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2020,12/19/2020,Actual,14-Apr-20,Actual,4/14/2020,Dec-20,12/31/2020,30-Oct-20,Actual,10/30/2020,20-Sep-20,Actual,9/20/2020,NA,Interventional,NA,NA,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting,Completed,NA,Not Applicable,60,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,the investigators will decide after study finishing,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z
NCT04366232,NA,4/27/2020,NA,NA,12/11/2020,4/27/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,12/11/2020,12/16/2020,Actual,19-Aug-20,Actual,8/19/2020,Dec-20,12/31/2020,2-Oct-20,Actual,10/2/2020,2-Oct-20,Actual,10/2/2020,NA,Interventional,JAKINCOV,NA,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation,"Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation: Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib",Terminated,NA,Phase 2,2,Actual,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,,2,NA,investigator decision,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:56Z,2021-10-12T07:16:56Z
NCT04368676,NA,4/26/2020,NA,NA,3/29/2021,4/29/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,3/29/2021,4/1/2021,Actual,25-Jun-20,Actual,6/25/2020,Mar-21,3/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,BREATH,NA,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness During the COVID-19 Pandemic,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness (BREATH): an RCT for Frontline Hospital and Long-term Care Home Staff Managing the COVID-19 Pandemic,"Active, not recruiting",NA,Early Phase 1,60,Anticipated,Lawson Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:39Z,2021-10-12T07:16:39Z
NCT04366180,NA,4/27/2020,NA,NA,4/28/2020,4/27/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/28/2020,4/30/2020,Actual,24-Apr-20,Actual,4/24/2020,Apr-20,4/30/2020,Oct-20,Anticipated,10/31/2020,Jun-20,Anticipated,6/30/2020,NA,Interventional,NA,NA,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19,Recruiting,NA,Not Applicable,314,Anticipated,Biosearch S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:55Z,2021-10-12T07:16:55Z
NCT04365985,NA,4/26/2020,NA,NA,9/2/2021,4/26/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/10/2021,Actual,29-Apr-20,Actual,4/29/2020,Sep-21,9/30/2021,1-Apr-21,Actual,4/1/2021,1-Apr-21,Actual,4/1/2021,NA,Interventional,SINK COVID-19,NA,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Terminated,NA,Phase 2,70,Actual,William Beaumont Hospitals,,3,NA,"Because of the decrease in COVID cases, enrollment is extremely low. Given the current study design, it is not possible to gather data necessary to answer the question about whether study treatment reduces mortality",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:59Z,2021-10-12T07:16:59Z
NCT04366089,NA,4/22/2020,NA,NA,4/27/2020,4/27/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2020,4/28/2020,Actual,26-Mar-20,Actual,3/26/2020,Apr-20,4/30/2020,31-Dec-20,Anticipated,12/31/2020,30-Oct-20,Anticipated,10/30/2020,NA,Interventional,PROBIOZOVID,NA,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora,Recruiting,NA,Phase 2,152,Anticipated,Azienda Policlinico Umberto I,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:57Z,2021-10-12T07:16:57Z
NCT04366050,NA,4/24/2020,NA,NA,1/19/2021,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,1/19/2021,1/20/2021,Actual,11-May-20,Actual,5/11/2020,Jan-21,1/31/2021,May-21,Anticipated,5/31/2021,May-21,Anticipated,5/31/2021,NA,Interventional,RAMIC,NA,Ramipril for the Treatment of COVID-19,"A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19",Recruiting,NA,Phase 2,560,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:59Z,2021-10-12T07:16:59Z
NCT04366323,NA,4/22/2020,NA,NA,11/27/2020,4/27/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,11/27/2020,11/30/2020,Actual,27-Apr-20,Actual,4/27/2020,Nov-20,11/30/2020,Oct-21,Anticipated,10/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19","Active, not recruiting",NA,Phase 1/Phase 2,26,Actual,Andalusian Network for Design and Translation of Advanced Therapies,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:57Z,2021-10-12T07:16:57Z
NCT04365738,NA,4/26/2020,NA,NA,4/26/2020,4/26/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/26/2020,4/28/2020,Actual,11-Mar-20,Actual,3/11/2020,Apr-20,4/30/2020,26-Apr-20,Actual,4/26/2020,10-Apr-20,Actual,4/10/2020,NA,Interventional,NA,NA,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial,Completed,NA,Not Applicable,270,Actual,Istanbul Bilgi University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:01Z,2021-10-12T07:17:01Z
NCT04366817,NA,4/20/2020,NA,NA,7/31/2021,4/28/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,7/31/2021,8/3/2021,Actual,27-Apr-20,Actual,4/27/2020,Jul-21,7/31/2021,Aug-21,Anticipated,8/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,COVMUM,NA,Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact,Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic,"Active, not recruiting",NA,Not Applicable,287,Actual,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:52Z,2021-10-12T07:16:52Z
NCT04370262,NA,4/27/2020,NA,NA,12/10/2020,4/29/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,12/10/2020,12/11/2020,Actual,7-Apr-20,Actual,4/7/2020,Dec-20,12/31/2020,7-Sep-20,Actual,9/7/2020,7-Sep-20,Actual,9/7/2020,NA,Interventional,NA,NA,Multi-site Adaptive Trials for COVID-19,"A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,233,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:25Z,2021-10-12T07:16:25Z
NCT04368923,NA,4/24/2020,NA,NA,6/19/2020,4/28/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,6/19/2020,6/23/2020,Actual,15-Mar-20,Actual,3/15/2020,Jun-20,6/30/2020,23-Jun-20,Anticipated,6/23/2020,21-Jun-20,Anticipated,6/21/2020,NA,Interventional,NA,NA,Management of Covid-19 Patients During Home Isolation,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",NA,Not Applicable,60,Actual,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:37Z,2021-10-12T07:16:37Z
NCT04365127,NA,4/24/2020,NA,NA,1/25/2021,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/27/2021,Actual,27-Apr-20,Actual,4/27/2020,Jan-21,1/31/2021,20-Aug-20,Actual,8/20/2020,20-Aug-20,Actual,8/20/2020,NA,Interventional,NA,NA,Progesterone for the Treatment of COVID-19 in Hospitalized Men,"A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men",Completed,NA,Phase 1,40,Actual,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:04Z,2021-10-12T07:17:04Z
NCT04363606,NA,4/24/2020,NA,NA,4/19/2021,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,4/19/2021,4/20/2021,Actual,27-May-20,Actual,5/27/2020,Apr-21,4/30/2021,Dec-22,Anticipated,12/31/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,FatCovid-19,NA,Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,Chronic Fatigue Etiology and Recovery in Covid-19 Patients : the Role of Fatigability and Stay in Intensive Care,Recruiting,NA,Not Applicable,102,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:15Z,2021-10-12T07:17:15Z
NCT04363827,NA,4/24/2020,NA,NA,2/11/2021,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,2/11/2021,2/12/2021,Actual,14-May-20,Actual,5/14/2020,Feb-21,2/28/2021,Sep-21,Anticipated,9/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,PROTECT,NA,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19),"Active, not recruiting",NA,Phase 2,2300,Anticipated,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:14Z,2021-10-12T07:17:14Z
NCT04363853,NA,4/17/2020,NA,NA,11/26/2020,4/23/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2020,11/30/2020,Actual,1-Jun-20,Actual,6/1/2020,Nov-20,11/30/2020,1-Aug-21,Anticipated,8/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,Tocilizumab Treatment in Patients With COVID-19,Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab,"Active, not recruiting",NA,Phase 2,200,Anticipated,Instituto Nacional de Cancerologia de Mexico,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data wil be avaible in july 2020,NA,NA,Yes,NA,2021-10-12T07:17:16Z,2021-10-12T07:17:16Z
NCT04363593,NA,4/24/2020,NA,NA,12/9/2020,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,12/9/2020,12/10/2020,Actual,4-May-20,Actual,5/4/2020,Dec-20,12/31/2020,16-Nov-20,Actual,11/16/2020,16-Nov-20,Actual,11/16/2020,NA,Interventional,ROCOCO,NA,Serology COVID-19 From the Cornwall Hospital Union,Serology COVID-19 From the Cornwall Hospital Union,Completed,NA,Not Applicable,2587,Actual,Centre Hospitalier de Cornouaille,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:16Z,2021-10-12T07:17:16Z
NCT04363541,NA,4/23/2020,NA,NA,11/3/2020,4/23/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2020,11/5/2020,Actual,27-Aug-20,Actual,8/27/2020,Nov-20,11/30/2020,Jun-22,Anticipated,6/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,TherMoCoV,NA,Local Thermotherapy for Patients With Mild-to-moderate COVID-19,"A Multicenter, Open-label, Parallel-group, Randomized, Adaptive Trial to Evaluate Local Thermotherapy in Patients With Mild-to-moderate COVID-19, to Prevent Disease Progression",Recruiting,NA,Not Applicable,274,Anticipated,Instituto Nacional de Perinatologia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:16Z,2021-10-12T07:17:16Z
NCT04363437,NA,4/23/2020,NA,NA,5/6/2020,4/23/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/6/2020,5/8/2020,Actual,26-Apr-20,Actual,4/26/2020,May-20,5/31/2020,14-Jun-20,Anticipated,6/14/2020,31-May-20,Anticipated,5/31/2020,NA,Interventional,COMBATCOVID19,NA,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study),Recruiting,NA,Phase 2,70,Anticipated,Maimonides Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:18Z,2021-10-12T07:17:18Z
NCT04362358,NA,4/21/2020,NA,NA,9/24/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/27/2021,Actual,20-Jul-20,Actual,7/20/2020,Sep-21,9/30/2021,1-Sep-21,Actual,9/1/2021,1-Sep-21,Actual,9/1/2021,NA,Interventional,REST,NA,Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic,Efficacy of an Online Cognitive Behavioral Therapy (CBT) Programme Aiming at Reducing the Stress of Health Workers Involved in the Care of Patients During the Covid-19 Epidemic: a Randomized-controlled Trial,Completed,NA,Not Applicable,156,Actual,"University Hospital, Strasbourg, France",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:27Z,2021-10-12T07:17:27Z
NCT04360824,NA,4/13/2020,NA,NA,6/18/2020,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,6/18/2020,6/19/2020,Actual,6-May-20,Actual,5/6/2020,Jun-20,6/30/2020,16-Apr-21,Anticipated,4/16/2021,16-Apr-21,Anticipated,4/16/2021,NA,Interventional,NA,NA,Covid-19 Associated Coagulopathy,COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19,Recruiting,NA,Phase 4,170,Anticipated,University of Iowa,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,No individual participant data will be shared,2021-10-12T07:17:38Z,2021-10-12T07:17:38Z
NCT04364009,NA,4/17/2020,NA,NA,1/14/2021,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,1/14/2021,1/15/2021,Actual,27-Apr-20,Actual,4/27/2020,Apr-20,4/30/2020,3-Nov-20,Actual,11/3/2020,20-Oct-20,Actual,10/20/2020,NA,Interventional,ANACONDA,NA,Anakinra for COVID-19 Respiratory Symptoms,"Efficacy and Safety of ANAkinra During Adult "" COVID-19 "" With Aggravating Respiratory Symptoms: a Multicenter Open-label Controlled Randomized Trial",Terminated,NA,Phase 3,71,Actual,"University Hospital, Tours",,2,NA,Efficiency and safety reasons,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:13Z,2021-10-12T07:17:13Z
NCT04359875,NA,4/18/2020,NA,NA,4/7/2021,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/7/2021,4/12/2021,Actual,30-Apr-20,Actual,4/30/2020,Apr-21,4/30/2021,31-Dec-20,Actual,12/31/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,COVIQuest,NA,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial,Completed,NA,Not Applicable,22000,Actual,"University Hospital, Tours",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,1 year,email,NA,Yes,"One-month-data can be shared, whereas 6-month data are not legally sharable (electronic health records).",2021-10-12T07:17:42Z,2021-10-12T07:17:42Z
NCT04361474,NA,4/22/2020,NA,NA,8/2/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,18-May-20,Actual,5/18/2020,Aug-21,8/31/2021,25-Jun-21,Actual,6/25/2021,24-Nov-20,Actual,11/24/2020,NA,Interventional,COVIDORL,NA,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Completed,NA,Phase 3,120,Actual,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:35Z,2021-10-12T07:17:35Z
NCT04364828,NA,4/22/2020,NA,NA,2/16/2021,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,2/16/2021,2/17/2021,Actual,21-Oct-20,Actual,10/21/2020,Feb-21,2/28/2021,Aug-22,Anticipated,8/31/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,COVID-19 NGS,NA,NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression,NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression,Recruiting,NA,Not Applicable,1000,Anticipated,University Hospital Tuebingen,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available after analysis and unlimited.,Authorized users within the participating organizations.,NA,Yes,The COVID-19 NGS study will provide data in a pseudonymized manner to national and international databases set up to increase the diagnostic yield through advanced analysis tools.,2021-10-12T07:17:07Z,2021-10-12T07:17:07Z
NCT04361448,NA,4/20/2020,NA,NA,2/11/2021,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,2/11/2021,2/15/2021,Actual,20-Apr-20,Actual,4/20/2020,Feb-21,2/28/2021,30-Jun-20,Actual,6/30/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,NA,NA,Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,Comparison of the Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,Terminated,NA,Not Applicable,30,Actual,Jessa Hospital,,1,NA,Insufficient sample number,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:32Z,2021-10-12T07:17:32Z
NCT04362111,NA,4/21/2020,NA,NA,8/30/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/1/2021,Actual,29-Jul-20,Actual,7/29/2020,Aug-21,8/31/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Early Treatment of Cytokine Storm Syndrome in Covid-19,Early Treatment of Cytokine Storm Syndrome in Covid-19,"Active, not recruiting",NA,Phase 3,15,Actual,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,During study enrollment,wchatham@uabmc.edu,NA,Yes,Contact PI by e-mail for protocol specifics Submission of results for peer reviewed publication,2021-10-12T07:17:28Z,2021-10-12T07:17:28Z
NCT04364737,NA,4/22/2020,NA,NA,8/30/2021,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/1/2021,Actual,17-Apr-20,Actual,4/17/2020,Aug-21,8/31/2021,31-Dec-22,Anticipated,12/31/2022,29-Mar-21,Actual,3/29/2021,NA,Interventional,NA,NA,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients,"Active, not recruiting",NA,Phase 2,384,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Mila.Ortigoza@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"IPD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared.",2021-10-12T07:17:07Z,2021-10-12T07:17:07Z
NCT04364802,NA,4/25/2020,NA,NA,6/3/2021,4/25/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,6/3/2021,6/7/2021,Actual,29-Apr-20,Actual,4/29/2020,Jun-21,6/30/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,PIIPPI,NA,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic,Recruiting,NA,Phase 2,300,Anticipated,University of Kentucky,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:08Z,2021-10-12T07:17:08Z
NCT04361214,NA,4/22/2020,NA,NA,10/27/2020,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,10/27/2020,10/29/2020,Actual,5-May-20,Actual,5/5/2020,Oct-20,10/31/2020,Feb-21,Anticipated,2/28/2021,Feb-21,Anticipated,2/28/2021,NA,Interventional,NA,NA,Leflunomide in Mild COVID-19 Patients,Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:35Z,2021-10-12T07:17:35Z
NCT04361396,NA,4/22/2020,NA,NA,6/10/2021,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/11/2021,Actual,16-Jun-20,Actual,6/16/2020,Dec-20,12/31/2020,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,LAPTRANSCOV,NA,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients,Recruiting,NA,Not Applicable,60,Anticipated,Centre Hospitalier RenÃ© Dubos,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:35Z,2021-10-12T07:17:35Z
NCT04365101,NA,4/22/2020,NA,NA,6/17/2021,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/21/2021,Actual,13-May-20,Actual,5/13/2020,Mar-21,3/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,CYNKCOVID,NA,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19,"Active, not recruiting",NA,Phase 1/Phase 2,86,Actual,Celularity Incorporated,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:06Z,2021-10-12T07:17:06Z
NCT04364022,NA,4/23/2020,NA,NA,4/9/2021,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2021,4/12/2021,Actual,23-Apr-20,Actual,4/23/2020,Apr-21,4/30/2021,24-Mar-21,Actual,3/24/2021,24-Mar-21,Actual,3/24/2021,NA,Interventional,COPEP,NA,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial,Completed,NA,Phase 3,326,Actual,"University Hospital, Geneva",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:14Z,2021-10-12T07:17:14Z
NCT04359251,NA,4/13/2020,NA,NA,4/21/2020,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/21/2020,4/24/2020,Actual,5-Mar-20,Actual,3/5/2020,Apr-20,4/30/2020,25-Mar-20,Actual,3/25/2020,25-Mar-20,Actual,3/25/2020,NA,Interventional,NA,NA,Different PEEP Settings of COVID-19 Induced ARDS,Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study,Completed,NA,Not Applicable,20,Actual,"Southeast University, China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:49Z,2021-10-12T07:17:49Z
NCT04361916,NA,4/14/2020,NA,NA,9/10/2020,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,9/10/2020,9/14/2020,Actual,21-Apr-20,Actual,4/21/2020,Aug-20,8/31/2020,30-Jun-20,Actual,6/30/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,Mon-Covid,NA,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Terminated,NA,Not Applicable,37,Actual,Mario Negri Institute for Pharmacological Research,,1,NA,interrupted early due to the drastic reduction in the number of cases,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,data will be available from the study sponsor upon legitimate request,2021-10-12T07:17:29Z,2021-10-12T07:17:29Z
NCT04359953,NA,4/17/2020,NA,NA,8/31/2021,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/1/2021,Actual,25-Apr-20,Actual,4/25/2020,Aug-21,8/31/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,COVID-Aging,NA,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19: a Randomized, Multicenter, Adaptative Study",Recruiting,NA,Phase 3,1600,Anticipated,"University Hospital, Strasbourg, France",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:43Z,2021-10-12T07:17:43Z
NCT04364594,NA,4/22/2020,NA,NA,7/22/2020,4/25/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,7/22/2020,7/23/2020,Actual,26-Mar-20,Actual,3/26/2020,Jul-20,7/31/2020,30-May-20,Actual,5/30/2020,24-Apr-20,Actual,4/24/2020,NA,Interventional,COVID-T,NA,COVID-19 Search in Conjunctival Cells,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.,Completed,NA,Not Applicable,50,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will be available immediately after the statistical analysis of the results and will remain available for at least 1 year,On request by e-mail,NA,Yes,"Study Protocol approved by Ethical Committee, informed consent, clinical study report, will be available",2021-10-12T07:17:11Z,2021-10-12T07:17:11Z
NCT04360837,NA,4/22/2020,NA,NA,5/19/2020,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,5/19/2020,5/21/2020,Actual,6-May-20,Actual,5/6/2020,May-20,5/31/2020,1-Jun-21,Anticipated,6/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill COVID-19 Patients Under Electric Impedance Tomography (EIT),Recruiting,NA,Not Applicable,10,Anticipated,Szeged University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:37Z,2021-10-12T07:17:37Z
NCT04359537,NA,4/20/2020,NA,NA,5/16/2020,4/20/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,5/16/2020,5/19/2020,Actual,1-May-20,Actual,5/1/2020,May-20,5/31/2020,25-Sep-20,Anticipated,9/25/2020,25-Aug-20,Anticipated,8/25/2020,NA,Interventional,CHEER,NA,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel,Recruiting,NA,Phase 2,200,Anticipated,Shaheed Zulfiqar Ali Bhutto Medical University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:45Z,2021-10-12T07:17:45Z
NCT04359264,NA,4/16/2020,NA,NA,7/6/2020,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,7/6/2020,7/7/2020,Actual,20-Apr-20,Actual,4/20/2020,Jul-20,7/31/2020,30-Dec-20,Anticipated,12/30/2020,29-May-20,Actual,5/29/2020,NA,Interventional,DISTANSE COVID,NA,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial (DISTANSE COVID-19 RCT),"Active, not recruiting",NA,Not Applicable,392,Actual,Unity Health Toronto,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:47Z,2021-10-12T07:17:47Z
NCT04364893,NA,4/7/2020,NA,NA,7/1/2020,4/25/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,7/1/2020,7/2/2020,Actual,9-Apr-20,Actual,4/9/2020,Jul-20,7/31/2020,1-Dec-20,Anticipated,12/1/2020,1-Oct-20,Anticipated,10/1/2020,NA,Interventional,BRACE-CORONA,NA,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection (COVID-19). A Randomized Trial,Recruiting,NA,Not Applicable,700,Anticipated,D'Or Institute for Research and Education,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:07Z,2021-10-12T07:17:07Z
NCT04362189,NA,4/21/2020,NA,NA,7/2/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,7/2/2021,7/6/2021,Actual,30-Jun-20,Actual,6/30/2020,Oct-20,10/31/2020,31-Oct-21,Anticipated,10/31/2021,31-Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19","Active, not recruiting",NA,Phase 2,100,Anticipated,Hope Biosciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:27Z,2021-10-12T07:17:27Z
NCT04360551,NA,4/21/2020,NA,NA,7/30/2020,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,7/30/2020,8/3/2020,Actual,1-Jul-20,Actual,7/1/2020,Jul-20,7/31/2020,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,"Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients",Recruiting,NA,Phase 2,40,Anticipated,University of Hawaii,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:40Z,2021-10-12T07:17:40Z
NCT04363346,NA,4/23/2020,NA,NA,2/1/2021,4/23/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,2/1/2021,2/2/2021,Actual,14-May-20,Actual,5/14/2020,Feb-21,2/28/2021,Jan-22,Anticipated,1/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia,"Active, not recruiting",NA,Phase 1,5,Actual,"Masonic Cancer Center, University of Minnesota",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:19Z,2021-10-12T07:17:19Z
NCT04363502,NA,4/23/2020,NA,NA,6/10/2021,4/23/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/14/2021,Actual,7-May-20,Actual,5/7/2020,Jun-21,6/30/2021,May-22,Anticipated,5/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,NA,Phase 2,30,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:17Z,2021-10-12T07:17:17Z
NCT04363385,NA,4/21/2020,NA,NA,7/30/2021,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,7/30/2021,8/2/2021,Actual,31-May-20,Actual,5/31/2020,Jul-21,7/31/2021,31-May-22,Anticipated,5/31/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,Cohort of Patients With Covid19: Constitution of Blood Samples Collections With Clinical Characterization,Recruiting,NA,Not Applicable,500,Anticipated,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:21Z,2021-10-12T07:17:21Z
NCT04361253,NA,4/23/2020,NA,NA,8/9/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/9/2021,8/13/2021,Actual,30-Apr-20,Actual,4/30/2020,Aug-21,8/31/2021,30-Jun-21,Actual,6/30/2021,1-Apr-21,Actual,4/1/2021,NA,Interventional,(ESCAPE),NA,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,"A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity",Terminated,NA,Phase 3,45,Actual,Brigham and Women's Hospital,,2,NA,Futility,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,Beginning 3 months after study publication. No end date.,Proposals should be submitted to rmkaufman@bwh.harvard.edu.,NA,Yes,Deidentified data will be made available upon request to the principal investigator following the publication of the primary manuscript.,2021-10-12T07:17:35Z,2021-10-12T07:17:35Z
NCT04363749,NA,4/20/2020,NA,NA,8/27/2021,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,8/27/2021,8/30/2021,Actual,27-Apr-20,Actual,4/27/2020,Aug-21,8/31/2021,11-Jan-21,Actual,1/11/2021,11-Jan-21,Actual,1/11/2021,NA,Interventional,CRC-COVID,NA,COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities,Do Respiratory Control Center Anomalies Explain the Lack of Respiratory Sensations Perceptions Observed in Patients Affected by COVID-19 ?,Completed,NA,Not Applicable,50,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:15Z,2021-10-12T07:17:15Z
NCT04363450,NA,4/23/2020,NA,NA,8/31/2020,4/23/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2020,9/2/2020,Actual,27-Apr-20,Actual,4/27/2020,Aug-20,8/31/2020,1-Jun-21,Anticipated,6/1/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,HCQPreP,NA,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,NA,Phase 3,1700,Anticipated,Louisiana State University Health Sciences Center in New Orleans,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:18Z,2021-10-12T07:17:18Z
NCT04360811,NA,4/22/2020,NA,NA,4/22/2020,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/22/2020,4/24/2020,Actual,17-Apr-20,Actual,4/17/2020,Apr-20,4/30/2020,Apr-22,Anticipated,4/30/2022,Apr-21,Anticipated,4/30/2021,NA,Interventional,COroFet,NA,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic","Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic by Creation and Analysis of a Biological and Tissue Collection of Pregnancy Outcomes",Recruiting,NA,Not Applicable,3600,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:44Z,2021-10-12T07:17:44Z
NCT04359862,NA,4/21/2020,NA,NA,7/20/2021,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/27/2021,Actual,16-Apr-20,Actual,4/16/2020,Jul-21,7/31/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,SEVO-COVID19,NA,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Terminated,NA,Phase 4,19,Actual,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,,2,NA,Low recruitment ratio,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:43Z,2021-10-12T07:17:43Z
NCT04361526,NA,4/21/2020,NA,NA,4/23/2020,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/23/2020,4/24/2020,Actual,17-Apr-20,Actual,4/17/2020,Apr-20,4/30/2020,Jul-20,Anticipated,7/31/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,CytokCOVID19,NA,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19),Recruiting,NA,Not Applicable,40,Anticipated,Hospital Clinic of Barcelona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:31Z,2021-10-12T07:17:31Z
NCT04363528,NA,4/23/2020,NA,NA,8/4/2021,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/5/2021,Actual,24-Apr-20,Actual,4/24/2020,Aug-21,8/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Dec-20,Actual,12/30/2020,NA,Interventional,COVIDOP-DVT,NA,Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,"Active, not recruiting",NA,Not Applicable,50,Actual,Versailles Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:17Z,2021-10-12T07:17:17Z
NCT04362332,NA,4/20/2020,NA,NA,6/17/2020,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,6/17/2020,6/19/2020,Actual,14-Apr-20,Actual,4/14/2020,Jun-20,6/30/2020,8-Jun-20,Actual,6/8/2020,8-Jun-20,Actual,6/8/2020,NA,Interventional,ARCHAIC,NA,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Terminated,NA,Phase 4,25,Actual,UMC Utrecht,,3,NA,"Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be expected we need more than 1000 inclusions",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,12 months,NA,NA,Yes,NA,2021-10-12T07:17:28Z,2021-10-12T07:17:28Z
NCT04359290,NA,4/15/2020,NA,NA,8/23/2021,4/20/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/24/2021,Actual,1-Jul-20,Actual,7/1/2020,Nov-20,11/30/2020,30-Jul-21,Actual,7/30/2021,31-Dec-20,Actual,12/31/2020,NA,Interventional,RuXoCoil,NA,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study",Completed,NA,Phase 2,15,Actual,Philipps University Marburg Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,3 Months after publication,Central server,NA,Yes,Study protocol will be provided after publication,2021-10-12T07:17:48Z,2021-10-12T07:17:48Z
NCT04358926,NA,4/21/2020,NA,NA,2/1/2021,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,2/1/2021,2/3/2021,Actual,30-Apr-20,Actual,4/30/2020,Nov-20,11/30/2020,1-Nov-20,Actual,11/1/2020,15-Oct-20,Actual,10/15/2020,NA,Interventional,HBOTCOVID19,NA,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,NA,Not Applicable,30,Actual,Assaf-Harofeh Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Within 1 month of request,Specific requests,NA,Yes,Sharing upon specific requests will be considered,2021-10-12T07:17:52Z,2021-10-12T07:17:52Z
NCT04360980,NA,4/22/2020,NA,NA,12/30/2020,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,12/30/2020,12/31/2020,Actual,20-Mar-20,Actual,3/20/2020,Dec-20,12/31/2020,30-Nov-21,Anticipated,11/30/2021,1-Sep-21,Anticipated,9/1/2021,NA,Interventional,NA,NA,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial,Recruiting,NA,Phase 2,80,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:37Z,2021-10-12T07:17:37Z
NCT04361942,NA,4/17/2020,NA,NA,3/8/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,3/8/2021,3/10/2021,Actual,1-May-20,Actual,5/1/2020,Oct-20,10/31/2020,31-Dec-21,Anticipated,12/31/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,COVID_MSV,NA,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),"Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)",Recruiting,NA,Phase 2,24,Anticipated,Red de Terapia Celular,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:29Z,2021-10-12T07:17:29Z
NCT04362059,NA,4/20/2020,NA,NA,9/8/2020,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,9/8/2020,9/9/2020,Actual,18-Jun-20,Actual,6/18/2020,Sep-20,9/30/2020,16-Nov-21,Anticipated,11/16/2021,27-Jul-21,Anticipated,7/27/2021,NA,Interventional,COVSurf,NA,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,NA,Not Applicable,24,Anticipated,University Hospital Southampton NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:27Z,2021-10-12T07:17:27Z
NCT04361838,NA,4/16/2020,NA,NA,7/28/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,7/28/2021,7/30/2021,Actual,21-May-20,Actual,5/21/2020,Feb-21,2/28/2021,31-Aug-21,Anticipated,8/31/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,NA,NA,The COVID-19 ICU PRAYER Study,Impact of Multi-Denominational Prayer on Morbidity and Mortality of Patients Admitted to the Intensive Care Unite With Corona Virus Infection,Recruiting,NA,Not Applicable,1000,Anticipated,Kansas City Heart Rhythm Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:32Z,2021-10-12T07:17:32Z
NCT04355364,NA,4/15/2020,NA,NA,4/21/2021,4/17/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,4/21/2021,4/22/2021,Actual,21-Apr-20,Actual,4/21/2020,Apr-21,4/30/2021,21-Apr-22,Anticipated,4/21/2022,21-Dec-21,Anticipated,12/21/2021,NA,Interventional,COVIDORNASE,NA,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19,Recruiting,NA,Phase 3,100,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:16Z,2021-10-12T07:18:16Z
NCT04359810,NA,4/21/2020,NA,NA,5/16/2021,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,5/16/2021,5/18/2021,Actual,21-Apr-20,Actual,4/21/2020,May-21,5/31/2021,30-Dec-20,Actual,12/30/2020,30-Dec-20,Actual,12/30/2020,NA,Interventional,NA,NA,Plasma Therapy of COVID-19 in Severely Ill Patients,"A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19",Completed,NA,Phase 2,223,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,The data-sharing plans for this study will be made available at a later date.,2021-10-12T07:17:46Z,2021-10-12T07:17:46Z
NCT04357782,NA,4/17/2020,NA,NA,12/21/2020,4/20/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2020,12/23/2020,Actual,16-Apr-20,Actual,4/16/2020,Dec-20,12/31/2020,13-Oct-20,Actual,10/13/2020,13-Oct-20,Actual,10/13/2020,NA,Interventional,AVoCaDO,NA,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial",Completed,NA,Phase 1/Phase 2,20,Actual,Hunter Holmes Mcguire Veteran Affairs Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:00Z,2021-10-12T07:18:00Z
NCT04359901,NA,4/20/2020,NA,NA,3/5/2021,4/20/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,3/5/2021,3/8/2021,Actual,10-Apr-20,Actual,4/10/2020,Mar-21,3/31/2021,Apr-23,Anticipated,4/30/2023,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Sarilumab for Patients With Moderate COVID-19 Disease,Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design,"Active, not recruiting",NA,Phase 2,50,Actual,VA Boston Healthcare System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Within one year of primary publication.,"Consistent with VA Privacy, Regulatory and IT requirements and VHA Handbook 1200.12",NA,Yes,"Digital data underlying primary scientific publications will be held as part of a data sharing resource. Study data held for this purpose may include data, data content, format, and organization. The data may contain but are not limited to individually identifiable information, other PHI, and study codes. The data may be available to the public and other VA and non-VA researchers under certain conditions and consistent with the informed consent and CSP policy that prioritize protecting participants' privacy and confidentiality to the fullest extent possible. A detailed plan will be developed in accordance with current technology, infrastructure, best practices, and policies and procedures in place at the time of oversight committee reviews (e.g., Privacy Board, Information Security, and Information Technology standards). The plan will include how data will be discovered, retrieved, analyzed, and managed and will note the materials that are available in machine-readable formats.",2021-10-12T07:17:42Z,2021-10-12T07:17:42Z
NCT04358406,NA,4/16/2020,NA,NA,3/12/2021,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,3/12/2021,3/16/2021,Actual,30-Jul-20,Actual,7/30/2020,Mar-21,3/31/2021,1-Jun-21,Anticipated,6/1/2021,1-May-21,Anticipated,5/1/2021,NA,Interventional,NA,NA,Rhu-pGSN for Severe Covid-19 Pneumonia,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia","Active, not recruiting",NA,Phase 2,60,Anticipated,BioAegis Therapeutics Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:55Z,2021-10-12T07:17:55Z
NCT04357340,NA,4/13/2020,NA,NA,5/30/2020,4/18/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,5/30/2020,6/2/2020,Actual,2-Apr-20,Actual,4/2/2020,May-20,5/31/2020,30-May-20,Actual,5/30/2020,30-Apr-20,Actual,4/30/2020,NA,Interventional,NA,NA,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia,Completed,NA,Not Applicable,40,Actual,Tehran University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 12 months following article publication,Researchers who provide an approved methodologically proposal in the same purpose,NA,Yes,"Individual participant data that underline the results reported in this article, after de-identification",2021-10-12T07:18:02Z,2021-10-12T07:18:02Z
NCT04357808,NA,4/14/2020,NA,NA,2/10/2021,4/20/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,2/10/2021,2/11/2021,Actual,13-Apr-20,Actual,4/13/2020,Feb-21,2/28/2021,4-Dec-20,Actual,12/4/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,SARCOVID,NA,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection,Completed,NA,Phase 2,30,Actual,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:00Z,2021-10-12T07:18:00Z
NCT04358939,NA,4/16/2020,NA,NA,4/15/2021,4/20/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/15/2021,4/19/2021,Actual,27-Apr-20,Actual,4/27/2020,Jan-21,1/31/2021,21-Feb-21,Actual,2/21/2021,21-Feb-21,Actual,2/21/2021,NA,Interventional,NA,NA,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome,Completed,NA,Not Applicable,405,Actual,"University Hospital, Tours",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available immediately following publication and ending in 5 years.,Contact with the corresponding author.,NA,Yes,Individual participant data after de-identification can be obtained by contacting the corresponding author.,2021-10-12T07:17:50Z,2021-10-12T07:17:50Z
NCT04354428,NA,4/16/2020,NA,NA,11/9/2020,4/16/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2020,11/12/2020,Actual,16-Apr-20,Actual,4/16/2020,Nov-20,11/30/2020,Jan-21,Anticipated,1/31/2021,Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Treatment for COVID-19 in High-Risk Adult Outpatients,Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial,"Active, not recruiting",NA,Phase 2/Phase 3,300,Anticipated,University of Washington,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2021-10-12T07:18:24Z,2021-10-12T07:18:24Z
NCT04354259,NA,4/16/2020,NA,NA,9/27/2021,4/20/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/29/2021,Actual,13-May-20,Actual,5/13/2020,Jul-21,7/31/2021,15-Jan-22,Anticipated,1/15/2022,15-Dec-21,Anticipated,12/15/2021,NA,Interventional,ILIAD,NA,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,"Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19",Recruiting,NA,Phase 2,240,Anticipated,"University Health Network, Toronto",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:24Z,2021-10-12T07:18:24Z
NCT04357366,NA,4/20/2020,NA,NA,2/12/2021,4/21/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/15/2021,Actual,15-Apr-20,Actual,4/15/2020,Feb-21,2/28/2021,15-Apr-22,Anticipated,4/15/2022,15-Apr-22,Anticipated,4/15/2022,NA,Interventional,SAVE,NA,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),"suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial",Recruiting,NA,Phase 2,1000,Anticipated,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:02Z,2021-10-12T07:18:02Z
NCT04355234,NA,4/17/2020,NA,NA,4/2/2021,4/17/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,4/2/2021,4/5/2021,Actual,4-May-20,Actual,5/4/2020,Apr-20,4/30/2020,31-Aug-21,Anticipated,8/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,COVIPREG,NA,"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns","Prevalence and Impact of SARS-COV-2 Infection in Pregnant Women, Fetuses and Newborns","Active, not recruiting",NA,Not Applicable,2500,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z
NCT04359680,NA,4/20/2020,NA,NA,2/5/2021,4/20/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,2/5/2021,2/8/2021,Actual,13-May-20,Actual,5/13/2020,Feb-21,2/28/2021,29-Mar-21,Anticipated,3/29/2021,29-Mar-21,Anticipated,3/29/2021,NA,Interventional,NA,NA,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection","Active, not recruiting",NA,Phase 3,1407,Actual,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:45Z,2021-10-12T07:17:45Z
NCT04355351,NA,4/17/2020,NA,NA,7/21/2021,4/17/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/22/2021,Actual,5-May-20,Actual,5/5/2020,Jul-21,7/31/2021,22-Oct-21,Anticipated,10/22/2021,22-Oct-21,Anticipated,10/22/2021,NA,Interventional,CovImmune,NA,Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),Study of Immune Response During SARS-CoV-2 Infection,Recruiting,NA,Not Applicable,400,Anticipated,Centre Hospitalier Universitaire de Nice,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:16Z,2021-10-12T07:18:16Z
NCT04355936,NA,4/17/2020,NA,NA,12/23/2020,4/20/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,12/23/2020,12/24/2020,Actual,19-May-20,Actual,5/19/2020,Dec-20,12/31/2020,30-Nov-20,Actual,11/30/2020,2-Nov-20,Actual,11/2/2020,NA,Interventional,NA,NA,Telmisartan for Treatment of COVID-19 Patients,Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial,Completed,NA,Phase 4,400,Actual,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:13Z,2021-10-12T07:18:13Z
NCT04357860,NA,4/20/2020,NA,NA,7/6/2021,4/20/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,7/6/2021,7/7/2021,Actual,28-Apr-20,Actual,4/28/2020,Apr-20,4/30/2020,6-Apr-21,Actual,4/6/2021,9-Mar-21,Actual,3/9/2021,NA,Interventional,SARICOR,NA,Clinical Trial of Sarilumab in Adults With COVID-19,Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome,Completed,NA,Phase 2,120,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After the end of the trial.,Contact uicec@imibic.org,NA,Yes,All the information will be published and it will be available in open access.,2021-10-12T07:17:58Z,2021-10-12T07:17:58Z
NCT04353674,NA,4/7/2020,NA,NA,3/29/2021,4/16/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,3/29/2021,4/1/2021,Actual,28-Apr-20,Actual,4/28/2020,Mar-21,3/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Modulation of Hyperinflammation in COVID-19,Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients,Recruiting,NA,Not Applicable,40,Anticipated,Lawson Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:28Z,2021-10-12T07:18:28Z
NCT04358783,NA,4/21/2020,NA,NA,5/24/2021,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,5/24/2021,5/26/2021,Actual,27-Apr-20,Actual,4/27/2020,May-21,5/31/2021,1-May-21,Actual,5/1/2021,1-May-21,Actual,5/1/2021,NA,Interventional,COP-COVID-19,NA,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia",Completed,NA,Phase 2,31,Actual,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:52Z,2021-10-12T07:17:52Z
NCT04355143,NA,4/14/2020,NA,NA,6/14/2021,4/20/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,6/14/2021,6/15/2021,Actual,1-May-20,Actual,5/1/2020,Jun-21,6/30/2021,8-Sep-21,Anticipated,9/8/2021,8-Sep-21,Anticipated,9/8/2021,NA,Interventional,COLHEART-19,NA,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),"Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)","Active, not recruiting",NA,Phase 2,91,Actual,"University of California, Los Angeles",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:18Z,2021-10-12T07:18:18Z
NCT04358614,NA,4/19/2020,NA,NA,4/21/2020,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/21/2020,4/24/2020,Actual,16-Mar-20,Actual,3/16/2020,Apr-20,4/30/2020,7-Apr-20,Actual,4/7/2020,5-Apr-20,Actual,4/5/2020,NA,Interventional,NA,NA,Baricitinib Therapy in COVID-19,Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact,Completed,NA,Phase 2/Phase 3,12,Actual,Hospital of Prato,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:52Z,2021-10-12T07:17:52Z
NCT04357327,NA,4/15/2020,NA,NA,11/2/2020,4/18/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,11/2/2020,11/4/2020,Actual,16-Apr-20,Actual,4/16/2020,Nov-20,11/30/2020,31-Jul-20,Actual,7/31/2020,31-May-20,Actual,5/31/2020,NA,Interventional,NA,NA,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study,Completed,NA,Not Applicable,122,Actual,UniversitÃ  degli Studi dell'Insubria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be available at the end of the study, once statistical analyses is conducted",Contact Principal Investigator,NA,Yes,"We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.",2021-10-12T07:18:05Z,2021-10-12T07:18:05Z
NCT04359095,NA,4/15/2020,NA,NA,8/4/2021,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/12/2021,Actual,18-Aug-20,Actual,8/18/2020,Aug-21,8/31/2021,30-Jun-21,Actual,6/30/2021,20-Mar-21,Actual,3/20/2021,NA,Interventional,NA,NA,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial,Completed,NA,Phase 2/Phase 3,650,Actual,Universidad Nacional de Colombia,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,As soon we have checked the quality of data of recruited participants,Approved by the monitor committee of the study,NA,Yes,Communicating trial results and data to be able to combine data from multiple studies (live SR),2021-10-12T07:17:48Z,2021-10-12T07:17:48Z
NCT04357106,NA,4/14/2020,NA,NA,4/21/2020,4/21/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,4/21/2020,4/22/2020,Actual,13-Apr-20,Actual,4/13/2020,Apr-20,4/30/2020,Aug-20,Anticipated,8/31/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,COPLA,NA,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,NA,Phase 2,10,Anticipated,Centro de HematologÃ­a y Medicina Interna,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:04Z,2021-10-12T07:18:04Z
NCT04355533,NA,4/17/2020,NA,NA,3/23/2021,4/17/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,3/23/2021,3/26/2021,Actual,29-Jul-20,Actual,7/29/2020,Mar-21,3/31/2021,Dec-22,Anticipated,12/31/2022,Jul-22,Anticipated,7/31/2022,NA,Interventional,PED-COVID,NA,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents,Recruiting,NA,Not Applicable,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z
NCT04358549,NA,4/16/2020,NA,,9/30/2021,4/21/2020,4/24/2020,Actual,NA,NA,NA,,,,9/30/2021,10/5/2021,Actual,17-Apr-20,Actual,4/17/2020,Sep-21,9/30/2021,30-Oct-20,Actual,10/30/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,NA,NA,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,50,Actual,"Fujifilm Pharmaceuticals U.S.A., Inc.",,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:55Z,2021-10-12T07:17:55Z
NCT04354155,NA,4/13/2020,NA,NA,7/19/2021,4/16/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/20/2021,Actual,2-Jun-20,Actual,6/2/2020,Jul-21,7/31/2021,4-Jun-21,Actual,6/4/2021,4-Jun-21,Actual,6/4/2021,NA,Interventional,NA,NA,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Completed,NA,Phase 2,40,Actual,Johns Hopkins All Children's Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:26Z,2021-10-12T07:18:26Z
NCT04357990,NA,4/20/2020,NA,NA,9/15/2020,4/20/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,9/15/2020,9/17/2020,Actual,4-Sep-20,Actual,9/4/2020,Sep-20,9/30/2020,Mar-21,Anticipated,3/31/2021,Mar-21,Anticipated,3/31/2021,NA,Interventional,KONS-COVID19,NA,Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,"Use of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa",Recruiting,NA,Not Applicable,128,Anticipated,Kerecis Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:57Z,2021-10-12T07:17:57Z
NCT04356495,NA,4/11/2020,NA,NA,8/2/2021,4/19/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,29-Jul-20,Actual,7/29/2020,Aug-21,8/31/2021,28-Feb-22,Anticipated,2/28/2022,29-Jan-22,Anticipated,1/29/2022,NA,Interventional,COVERAGEFrance,NA,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France),Recruiting,NA,Phase 2/Phase 3,820,Anticipated,"University Hospital, Bordeaux",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:08Z,2021-10-12T07:18:08Z
NCT04355897,NA,4/15/2020,NA,NA,5/18/2020,4/20/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2020,5/20/2020,Actual,28-Apr-20,Actual,4/28/2020,May-20,5/31/2020,Aug-20,Anticipated,8/31/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,CoVID-19 Plasma in Treatment of COVID-19 Patients,Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease,Recruiting,NA,Early Phase 1,100,Anticipated,The Christ Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:13Z,2021-10-12T07:18:13Z
NCT04357444,NA,4/10/2020,NA,NA,10/1/2021,4/20/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/1/2021,10/4/2021,Actual,23-Oct-20,Actual,10/23/2020,Apr-21,4/30/2021,5-Apr-21,Actual,4/5/2021,2-Nov-20,Actual,11/2/2020,NA,Interventional,LILIADE-COVID,NA,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Completed,NA,Phase 2,30,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:03Z,2021-10-12T07:18:03Z
NCT04355637,NA,4/15/2020,NA,NA,9/21/2021,4/17/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/22/2021,Actual,21-Apr-20,Actual,4/21/2020,Sep-21,9/30/2021,30-Jun-21,Actual,6/30/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,NA,NA,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia,Completed,NA,Phase 4,120,Actual,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:15Z,2021-10-12T07:18:15Z
NCT04358809,NA,4/21/2020,NA,NA,12/20/2020,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,12/20/2020,12/22/2020,Actual,30-Jun-20,Actual,6/30/2020,Dec-20,12/31/2020,30-Apr-21,Anticipated,4/30/2021,28-Feb-21,Anticipated,2/28/2021,NA,Interventional,NA,NA,"Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill","A Randomized, Double-blind, Two Arm, Controlled Clinical Trial to Compare the Efficacy and Safety of Mycobacterium w (Mw) Administered Along With Standard of Care Versus Placebo Administered Along With Standard of Care, in Adult, COVID 19 Positive Patients Hospitalized But Not Critically Ill.",Recruiting,NA,Phase 3,480,Anticipated,Cadila Pharnmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:53Z,2021-10-12T07:17:53Z
NCT04356482,NA,4/17/2020,NA,NA,6/3/2020,4/17/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,6/3/2020,6/5/2020,Actual,20-May-20,Actual,5/20/2020,Jun-20,6/30/2020,Dec-20,Anticipated,12/31/2020,Nov-20,Anticipated,11/30/2020,NA,Interventional,COPLASCOV19,NA,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:09Z,2021-10-12T07:18:09Z
NCT04355026,NA,4/15/2020,NA,NA,4/18/2020,4/18/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,4/18/2020,4/21/2020,Actual,10-Apr-20,Anticipated,4/10/2020,Apr-20,4/30/2020,31-Jul-20,Anticipated,7/31/2020,30-Jun-20,Anticipated,6/30/2020,NA,Interventional,NA,NA,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,NA,Phase 4,90,Anticipated,General and Teaching Hospital Celje,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:20Z,2021-10-12T07:18:20Z
NCT04358003,NA,4/20/2020,NA,NA,8/6/2021,4/20/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/10/2021,Actual,20-May-20,Actual,5/20/2020,Aug-21,8/31/2021,1-Mar-22,Anticipated,3/1/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Plasma Adsorption in Patients With Confirmed COVID-19,Plasma Adsorption in Patients With Confirmed COVID-19 Infection,Recruiting,NA,Not Applicable,2000,Anticipated,Marker Therapeutics AG,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:57Z,2021-10-12T07:17:57Z
NCT04357730,NA,4/18/2020,NA,NA,5/6/2021,4/21/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/10/2021,Actual,14-May-20,Actual,5/14/2020,May-21,5/31/2021,Nov-21,Anticipated,11/30/2021,21-Mar-21,Actual,3/21/2021,NA,Interventional,NA,NA,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial,"Active, not recruiting",NA,Phase 2,50,Actual,Denver Health and Hospital Authority,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,A de-identified dataset will be made available to other investigators who may submit proposals to the PI for additional analyses or validation.,2021-10-12T07:17:59Z,2021-10-12T07:17:59Z
NCT04354610,NA,4/14/2020,NA,NA,9/30/2021,4/16/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,9/30/2021,10/1/2021,Actual,27-Apr-20,Actual,4/27/2020,Jan-21,1/31/2021,26-Mar-21,Actual,3/26/2021,19-Dec-20,Actual,12/19/2020,NA,Interventional,Nancy-CovH-AKI,NA,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection,Completed,NA,Not Applicable,73,Actual,"Central Hospital, Nancy, France",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:24Z,2021-10-12T07:18:24Z
NCT04356690,NA,4/17/2020,NA,NA,4/28/2021,4/20/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,4/28/2021,4/29/2021,Actual,8-May-20,Actual,5/8/2020,Apr-21,4/30/2021,Jun-22,Anticipated,6/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Etoposide in Patients With COVID-19 Infection,"A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection","Active, not recruiting",NA,Phase 2,8,Actual,Boston Medical Center,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:09Z,2021-10-12T07:18:09Z
NCT04355247,NA,4/17/2020,NA,NA,4/17/2020,4/17/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,4/17/2020,4/21/2020,Actual,14-Apr-20,Actual,4/14/2020,Apr-20,4/30/2020,30-Apr-21,Anticipated,4/30/2021,31-Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,NA,Phase 2,20,Anticipated,Auxilio Mutuo Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z
NCT04355962,NA,3/26/2020,NA,NA,7/16/2021,4/19/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,7/16/2021,7/19/2021,Actual,23-Apr-20,Actual,4/23/2020,Jul-21,7/31/2021,16-Jul-21,Actual,7/16/2021,25-Jun-21,Actual,6/25/2021,NA,Interventional,NA,NA,Sevoflurane in COVID-19 ARDS (SevCov),Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial,Completed,NA,Phase 3,68,Actual,University of Zurich,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:13Z,2021-10-12T07:18:13Z
NCT04351906,NA,4/9/2020,NA,NA,9/13/2021,4/15/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,9/13/2021,9/14/2021,Actual,3-May-20,Actual,5/3/2020,Sep-21,9/30/2021,30-Jun-22,Anticipated,6/30/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Low-flow Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform for Correction of Hypercapnia in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,NA,Not Applicable,20,Anticipated,University of Giessen,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:42Z,2021-10-12T07:18:42Z
NCT04356833,NA,4/14/2020,NA,NA,4/1/2021,4/21/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,4/1/2021,4/6/2021,Actual,22-Apr-20,Actual,4/22/2020,Apr-21,4/30/2021,30-Apr-21,Anticipated,4/30/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,PACA,NA,Nebulised Rt-PA for ARDS Due to COVID-19,"A Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA)",Recruiting,NA,Phase 2,66,Anticipated,"University College, London",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:08Z,2021-10-12T07:18:08Z
NCT04352959,NA,4/15/2020,NA,NA,2/10/2021,4/17/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,2/10/2021,2/11/2021,Actual,27-Apr-20,Actual,4/27/2020,Feb-21,2/28/2021,11-Dec-20,Actual,12/11/2020,11-Dec-20,Actual,12/11/2020,NA,Interventional,BBCovid,NA,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,"COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study",Completed,NA,Not Applicable,176,Actual,Claude Bernard University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:33Z,2021-10-12T07:18:33Z
NCT04350580,NA,4/8/2020,NA,NA,8/14/2021,4/14/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/14/2021,8/19/2021,Actual,11-Apr-20,Actual,4/11/2020,Aug-21,8/31/2021,20-Feb-21,Actual,2/20/2021,20-Nov-20,Actual,11/20/2020,NA,Interventional,ICAR,NA,Polyvalent Immunoglobulin in COVID-19 Related ARds,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Completed,NA,Phase 3,146,Actual,Centre Hospitalier St Anne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:52Z,2021-10-12T07:18:52Z
NCT04351347,NA,4/15/2020,NA,NA,3/8/2021,4/15/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,3/8/2021,3/10/2021,Actual,16-Jun-20,Actual,6/16/2020,Mar-21,3/31/2021,1-Dec-30,Anticipated,12/1/2030,1-Dec-30,Anticipated,12/1/2030,NA,Interventional,NA,NA,The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment,Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:46Z,2021-10-12T07:18:46Z
NCT04352608,NA,4/14/2020,NA,NA,7/26/2021,4/16/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/29/2021,Actual,16-Apr-20,Actual,4/16/2020,Jul-21,7/31/2021,30-Sep-21,Anticipated,9/30/2021,10-Jul-20,Actual,7/10/2020,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years","Active, not recruiting",NA,Phase 1/Phase 2,744,Anticipated,"Sinovac Biotech Co., Ltd",,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:39Z,2021-10-12T07:18:39Z
NCT04353271,NA,3/25/2020,NA,NA,8/18/2020,4/17/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,8/18/2020,8/20/2020,Actual,17-Apr-20,Actual,4/17/2020,Aug-20,8/31/2020,8-Jul-20,Actual,7/8/2020,8-Jul-20,Actual,7/8/2020,NA,Interventional,THICK,NA,Trial of Hydroxychloroquine In Covid-19 Kinetics,A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics,Terminated,NA,Phase 2/Phase 3,58,Actual,University of South Alabama,,2,NA,FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:32Z,2021-10-12T07:18:32Z
NCT04351542,NA,4/14/2020,NA,NA,4/15/2020,4/15/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,4/15/2020,4/17/2020,Actual,6-Mar-20,Actual,3/6/2020,Apr-20,4/30/2020,12-Apr-20,Actual,4/12/2020,6-Apr-20,Actual,4/6/2020,NA,Interventional,NA,NA,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial,Completed,NA,Not Applicable,32,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:45Z,2021-10-12T07:18:45Z
NCT04352348,NA,3/31/2020,NA,NA,7/5/2021,4/14/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,7/5/2021,7/8/2021,Actual,31-Mar-20,Actual,3/31/2020,Jun-21,6/30/2021,31-May-22,Anticipated,5/31/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,COVIDeF,NA,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,Cohort of Patients Infected With SARS-CoV2 or Suspected of Being (COVID-19 in Ile-de-France),"Active, not recruiting",NA,Not Applicable,2003,Actual,Assistance Publique - HÃ´pitaux de Paris,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:38Z,2021-10-12T07:18:38Z
NCT04353518,NA,4/16/2020,NA,NA,12/20/2020,4/16/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,12/20/2020,12/22/2020,Actual,30-Jun-20,Actual,6/30/2020,Apr-20,4/30/2020,30-May-21,Anticipated,5/30/2021,30-Mar-21,Anticipated,3/30/2021,NA,Interventional,NA,NA,Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19,"A Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19.",Recruiting,NA,Phase 3,4000,Anticipated,Cadila Pharnmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:31Z,2021-10-12T07:18:31Z
NCT04352933,NA,4/7/2020,NA,NA,5/11/2020,4/15/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,5/11/2020,5/13/2020,Actual,11-May-20,Actual,5/11/2020,May-20,5/31/2020,Apr-21,Anticipated,4/30/2021,31-Oct-20,Anticipated,10/31/2020,NA,Interventional,NA,NA,PROLIFIC ChemoprophylaxisTrial (COVID-19),ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial),Recruiting,NA,Phase 3,1000,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:35Z,2021-10-12T07:18:35Z
NCT04349241,NA,4/13/2020,NA,NA,6/24/2020,4/15/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,6/24/2020,6/25/2020,Actual,18-Apr-20,Actual,4/18/2020,Jun-20,6/30/2020,20-Jun-20,Actual,6/20/2020,1-Jun-20,Actual,6/1/2020,NA,Interventional,FAV-001,NA,Efficacy and Safety of Favipiravir in Management of COVID-19,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,NA,Phase 3,100,Actual,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:02Z,2021-10-12T07:19:02Z
NCT04352400,NA,4/3/2020,NA,NA,6/4/2021,4/15/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,6/4/2021,6/9/2021,Actual,4-Jun-21,Actual,6/4/2021,Jun-21,6/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,RACONA,NA,Efficacy of Nafamostat in Covid-19 Patients (RACONA Study),RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study),Recruiting,NA,Phase 2/Phase 3,256,Anticipated,University Hospital Padova,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:39Z,2021-10-12T07:18:39Z
NCT04353336,NA,4/15/2020,NA,NA,7/29/2021,4/17/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/2/2021,Actual,23-Mar-20,Actual,3/23/2020,Jul-21,7/31/2021,1-Jul-20,Actual,7/1/2020,1-Jun-20,Actual,6/1/2020,NA,Interventional,NA,NA,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,194,Actual,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:30Z,2021-10-12T07:18:30Z
NCT04351620,NA,4/14/2020,NA,NA,4/14/2020,4/14/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,4/14/2020,4/17/2020,Actual,Apr-20,Anticipated,4/30/2020,Apr-20,4/30/2020,Jun-20,Anticipated,6/30/2020,Jun-20,Anticipated,6/30/2020,NA,Interventional,NA,NA,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:44Z,2021-10-12T07:18:44Z
NCT04351763,NA,4/14/2020,NA,NA,8/30/2021,4/16/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/5/2021,Actual,20-May-20,Actual,5/20/2020,Aug-21,8/31/2021,5-Jun-21,Actual,6/5/2021,25-May-21,Actual,5/25/2021,NA,Interventional,ReCOVery-SIRIO,NA,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Completed,NA,Phase 2/Phase 3,804,Actual,Nicolaus Copernicus University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:41Z,2021-10-12T07:18:41Z
NCT04353284,NA,4/16/2020,NA,NA,10/6/2021,4/17/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,10/6/2021,10/8/2021,Actual,9-Jun-20,Actual,6/9/2020,Oct-21,10/31/2021,22-Apr-21,Actual,4/22/2021,3-Mar-21,Actual,3/3/2021,NA,Interventional,NA,NA,Camostat Mesylate in COVID-19 Outpatients,"The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial",Completed,NA,Phase 2,74,Actual,Yale University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:31Z,2021-10-12T07:18:31Z
NCT04353596,NA,4/14/2020,NA,NA,2/25/2021,4/16/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,2/25/2021,3/2/2021,Actual,20-Apr-20,Actual,4/20/2020,Feb-21,2/28/2021,24-Feb-21,Actual,2/24/2021,16-Feb-21,Actual,2/16/2021,NA,Interventional,ACEI-COVID,NA,Stopping ACE-inhibitors in COVID-19,Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial,Completed,NA,Phase 4,216,Actual,Medical University Innsbruck,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:30Z,2021-10-12T07:18:30Z
NCT04352751,NA,4/16/2020,NA,NA,9/28/2020,4/17/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2020,9/29/2020,Actual,1-May-20,Actual,5/1/2020,Apr-20,4/30/2020,Apr-21,Anticipated,4/30/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,NA,Not Applicable,2000,Anticipated,Hilton Pharma,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:34Z,2021-10-12T07:18:34Z
NCT04347980,NA,4/9/2020,NA,NA,8/6/2021,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/12/2021,Actual,17-Apr-20,Actual,4/17/2020,Aug-21,8/31/2021,7-Aug-20,Actual,8/7/2020,7-Aug-20,Actual,8/7/2020,NA,Interventional,DHYSCO,NA,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,"Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial",Terminated,NA,Phase 3,5,Actual,Centre Chirurgical Marie Lannelongue,,2,NA,ANSM RECOMMANDATION,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Beginning 3 months and ending 24 months following article publication,Researchers who provide a methodologically sound and proposal. Data are available for 24 months and request should be addressed by email,NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)",2021-10-12T07:19:12Z,2021-10-12T07:19:12Z
NCT04350593,NA,4/14/2020,NA,NA,9/13/2021,4/14/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,9/13/2021,9/14/2021,Actual,22-Apr-20,Actual,4/22/2020,Sep-21,9/30/2021,11-Jun-21,Actual,6/11/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,DARE-19,NA,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19",Completed,NA,Phase 3,1250,Actual,Saint Luke's Health System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:53Z,2021-10-12T07:18:53Z
NCT04349618,NA,4/8/2020,NA,NA,2/12/2021,4/14/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/15/2021,Actual,15-Apr-20,Actual,4/15/2020,Feb-21,2/28/2021,15-Apr-23,Anticipated,4/15/2023,15-Apr-23,Anticipated,4/15/2023,NA,Interventional,VT4COVID,NA,Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,Open Label Randomized Controlled Trial of Ultraprotective Ventilation Without Extracorporeal Circulation in Patients With COVID 19 Pneumonia and Moderate to Severe ARDS,Recruiting,NA,Not Applicable,200,Anticipated,Hospices Civils de Lyon,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:58Z,2021-10-12T07:18:58Z
NCT04348929,NA,4/10/2020,NA,NA,8/30/2021,4/15/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/5/2021,Actual,16-Apr-20,Actual,4/16/2020,Aug-21,8/31/2021,1-Oct-23,Anticipated,10/1/2023,16-Aug-23,Anticipated,8/16/2023,NA,Interventional,CONFINE,NA,Birth Experience During COVID-19 Confinement,Birth Experience During COVID-19 Confinement (Confinement and Fostering Intrapartum Care),Recruiting,NA,Not Applicable,927,Anticipated,"Central Hospital, Nancy, France",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"All data generated during this study will be made available via CIC-EC, CHRU Nancy, Nancy- FRANCE in accordance with protocol promotor. Data obtained from this study will be deposited at CIC-EC Nancy where they will be maintained for a minimum of 15 years.",2021-10-12T07:19:03Z,2021-10-12T07:19:03Z
NCT04350320,NA,4/14/2020,NA,NA,1/11/2021,4/16/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,1/11/2021,1/12/2021,Actual,30-Apr-20,Actual,4/30/2020,Jan-21,1/31/2021,30-Dec-20,Actual,12/30/2020,20-Oct-20,Actual,10/20/2020,NA,Interventional,COL-COVID,NA,Trial to Study the Benefit of Colchicine in Patients With COVID-19,"Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.",Completed,NA,Phase 3,102,Actual,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:52Z,2021-10-12T07:18:52Z
NCT04347382,NA,4/11/2020,NA,NA,11/9/2020,4/11/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2020,11/12/2020,Actual,30-Apr-20,Actual,4/30/2020,Nov-20,11/30/2020,30-Aug-20,Actual,8/30/2020,30-Aug-20,Actual,8/30/2020,NA,Interventional,HNS-COVID-PK,NA,Honey & Nigella Sativa Trial Against COVID-19,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan",Completed,NA,Phase 3,313,Actual,Sheikh Zayed Federal Postgraduate Medical Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:16Z,2021-10-12T07:19:16Z
NCT04349371,NA,4/12/2020,NA,NA,2/8/2021,4/15/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/10/2021,Actual,21-Apr-20,Actual,4/21/2020,Feb-21,2/28/2021,7-Jan-21,Actual,1/7/2021,7-Jan-21,Actual,1/7/2021,NA,Interventional,NA,NA,Saved From COVID-19,Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID,Terminated,NA,Phase 2,8,Actual,Columbia University,,2,NA,Low enrollment.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:01Z,2021-10-12T07:19:01Z
NCT04350684,NA,4/14/2020,NA,NA,4/16/2020,4/14/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,4/16/2020,4/20/2020,Actual,15-Apr-20,Anticipated,4/15/2020,Apr-20,4/30/2020,24-Apr-20,Anticipated,4/24/2020,22-Apr-20,Anticipated,4/22/2020,NA,Interventional,UAIIC,NA,Umifenovir in Hospitalized COVID-19 Patients,"Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,There is no further information.,2021-10-12T07:18:53Z,2021-10-12T07:18:53Z
NCT04349592,NA,4/12/2020,NA,NA,2/21/2021,4/14/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,2/21/2021,2/23/2021,Actual,14-Apr-20,Actual,4/14/2020,Feb-21,2/28/2021,30-Aug-20,Actual,8/30/2020,14-Aug-20,Actual,8/14/2020,NA,Interventional,NA,NA,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Completed,NA,Not Applicable,456,Actual,Hamad Medical Corporation,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:58Z,2021-10-12T07:18:58Z
NCT04351724,NA,4/10/2020,NA,NA,2/25/2021,4/16/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,2/25/2021,3/2/2021,Actual,16-Apr-20,Actual,4/16/2020,Feb-21,2/28/2021,31-Mar-22,Anticipated,3/31/2022,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,ACOVACT,NA,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),"A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)",Recruiting,NA,Phase 2/Phase 3,500,Anticipated,Medical University of Vienna,,14,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Anonymized and pseudonymized data will be published in peer reviewed journals and may be presented at congresses and conferences,2021-10-12T07:18:41Z,2021-10-12T07:18:41Z
NCT04347031,NA,4/7/2020,NA,NA,1/26/2021,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,1/26/2021,1/27/2021,Actual,8-Apr-20,Actual,4/8/2020,Jan-21,1/31/2021,20-Nov-20,Actual,11/20/2020,1-Nov-20,Actual,11/1/2020,NA,Interventional,NA,NA,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC ""Farmzashita"" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19",Completed,NA,Phase 2/Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:19Z,2021-10-12T07:19:19Z
NCT04350281,NA,4/13/2020,NA,NA,7/27/2020,4/13/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,7/27/2020,7/28/2020,Actual,9-Apr-20,Actual,4/9/2020,Jul-20,7/31/2020,7-Jul-20,Actual,7/7/2020,1-Jul-20,Actual,7/1/2020,NA,Interventional,NA,NA,Double Therapy With IFN-beta 1b and Hydroxychloroquine,"An Open-label Randomized Controlled Trial on Interferon Î²-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection",Completed,NA,Phase 2,60,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:56Z,2021-10-12T07:18:56Z
NCT04350736,NA,4/14/2020,NA,NA,6/29/2021,4/14/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,6/29/2021,7/1/2021,Actual,23-Apr-20,Actual,4/23/2020,Jun-21,6/30/2021,1-Jul-20,Actual,7/1/2020,24-Jun-20,Actual,6/24/2020,NA,Interventional,NA,NA,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,NA,Phase 1,54,Actual,Theravance Biopharma,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2021-10-12T07:18:50Z,2021-10-12T07:18:50Z
NCT04349631,NA,4/6/2020,NA,NA,7/2/2021,4/14/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,7/2/2021,7/7/2021,Actual,22-Apr-20,Actual,4/22/2020,Mar-21,3/31/2021,1-May-21,Actual,5/1/2021,24-Nov-20,Actual,11/24/2020,NA,Interventional,NA,NA,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease",Completed,NA,Phase 2,56,Actual,Hope Biosciences,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:00Z,2021-10-12T07:19:00Z
NCT04351789,NA,4/11/2020,NA,NA,8/21/2020,4/15/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/21/2020,8/24/2020,Actual,1-May-20,Actual,5/1/2020,Aug-20,8/31/2020,Apr-23,Anticipated,4/30/2023,Apr-23,Anticipated,4/30/2023,NA,Interventional,PISCA,NA,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Impact of a Minimal Psychoeducational Intervention Versus Standard of Care on Anxiety Among Hospitalized COVID-19 Patients in Denmark: a Randomized Clinical Trial,Recruiting,NA,Not Applicable,66,Anticipated,"Copenhagen University Hospital, Hvidovre",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will not be shared with other researchers due to regulatory restrictions.,2021-10-12T07:18:42Z,2021-10-12T07:18:42Z
NCT04348370,NA,3/30/2020,NA,NA,10/5/2021,4/14/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/6/2021,Actual,20-Apr-20,Actual,4/20/2020,Oct-21,10/31/2021,May-22,Anticipated,5/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,BADAS,NA,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,"Active, not recruiting",NA,Phase 4,1800,Anticipated,Texas A&M University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,There is not a plan to make IPD available.,2021-10-12T07:19:07Z,2021-10-12T07:19:07Z
NCT04351191,NA,4/14/2020,NA,NA,3/8/2021,4/15/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,3/8/2021,3/10/2021,Actual,15-Apr-20,Actual,4/15/2020,Mar-21,3/31/2021,30-Aug-20,Actual,8/30/2020,23-Aug-20,Actual,8/23/2020,NA,Interventional,PRECISE,NA,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate,Terminated,NA,Phase 4,137,Actual,"Government of Punjab, Specialized Healthcare and Medical Education Department",,4,NA,Poor accrual,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:47Z,2021-10-12T07:18:47Z
NCT04346589,NA,4/9/2020,NA,NA,6/5/2020,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,6/5/2020,6/9/2020,Actual,15-Apr-20,Actual,4/15/2020,Jun-20,6/30/2020,Aug-20,Anticipated,8/31/2020,Aug-20,Anticipated,8/31/2020,NA,Interventional,NA,NA,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Not Applicable,10,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:22Z,2021-10-12T07:19:22Z
NCT04351581,NA,4/14/2020,NA,NA,6/22/2021,4/14/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,6/22/2021,6/25/2021,Actual,18-May-20,Actual,5/18/2020,Jun-21,6/30/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,RASCOVID-19,NA,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19,Recruiting,NA,Not Applicable,255,Anticipated,"University Hospital, Gentofte, Copenhagen",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:47Z,2021-10-12T07:18:47Z
NCT04351152,NA,4/15/2020,NA,NA,3/1/2021,4/15/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,3/1/2021,3/3/2021,Actual,5-May-20,Actual,5/5/2020,Mar-21,3/31/2021,Mar-21,Anticipated,3/31/2021,Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,"A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia","Active, not recruiting",NA,Phase 3,520,Actual,"Humanigen, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:18:48Z,2021-10-12T07:18:48Z
NCT04345679,NA,4/11/2020,NA,NA,2/23/2021,4/13/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,2/23/2021,2/25/2021,Actual,14-Apr-20,Actual,4/14/2020,Feb-21,2/28/2021,1-Sep-21,Anticipated,9/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,Anti COVID-19 Convalescent Plasma Therapy,Anti COVID-19 Convalescent Plasma Therapy,Recruiting,NA,Early Phase 1,20,Anticipated,Orthosera Kft.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:30Z,2021-10-12T07:19:30Z
NCT04348409,NA,4/3/2020,NA,NA,6/8/2020,4/13/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,6/8/2020,6/9/2020,Actual,25-May-20,Actual,5/25/2020,Apr-20,4/30/2020,31-Jul-20,Anticipated,7/31/2020,31-Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,"Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.",Recruiting,NA,Not Applicable,50,Anticipated,Azidus Brasil,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2021-10-12T07:19:08Z,2021-10-12T07:19:08Z
NCT04349410,NA,4/11/2020,NA,NA,11/10/2020,4/14/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2020,11/12/2020,Actual,11-Apr-20,Actual,4/11/2020,Oct-20,10/31/2020,14-Sep-20,Actual,9/14/2020,14-Sep-20,Actual,9/14/2020,NA,Interventional,FMTVDM,NA,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,NA,Phase 2/Phase 3,1800,Actual,The Camelot Foundation,,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,This will depend upon the availability of staff given the multi-nation approach to this project.,Expressed request through email as listed.,NA,Yes,Data will be made available through electronic request from approved individuals and institutions.,2021-10-12T07:19:02Z,2021-10-12T07:19:02Z
NCT04345549,NA,4/10/2020,NA,NA,4/10/2020,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,4/10/2020,4/14/2020,Actual,26-Feb-20,Actual,2/26/2020,Apr-20,4/30/2020,30-Mar-20,Actual,3/30/2020,30-Mar-20,Actual,3/30/2020,NA,Interventional,NA,NA,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak,Completed,NA,Not Applicable,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:29Z,2021-10-12T07:19:29Z
NCT04350671,NA,4/14/2020,NA,NA,4/16/2020,4/14/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,4/16/2020,4/20/2020,Actual,15-Apr-20,Anticipated,4/15/2020,Apr-20,4/30/2020,24-Apr-20,Anticipated,4/24/2020,20-Apr-20,Anticipated,4/20/2020,NA,Interventional,IB1aIC,NA,Interferon Beta 1a in Hospitalized COVID-19 Patients,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,There is no further information.,2021-10-12T07:18:53Z,2021-10-12T07:18:53Z
NCT04347174,NA,3/31/2020,NA,NA,1/25/2021,4/11/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/27/2021,Actual,30-Apr-20,Actual,4/30/2020,Jan-21,1/31/2021,21-Aug-20,Actual,8/21/2020,10-Aug-20,Actual,8/10/2020,NA,Interventional,NA,NA,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection,Completed,NA,Not Applicable,40,Actual,Cadila Pharnmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:19Z,2021-10-12T07:19:19Z
NCT04348435,NA,4/14/2020,NA,NA,8/19/2021,4/14/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/20/2021,Actual,14-May-20,Actual,5/14/2020,Mar-21,3/31/2021,30-Jul-21,Actual,7/30/2021,9-Jul-21,Actual,7/9/2021,NA,Interventional,NA,NA,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19",Completed,NA,Phase 2,55,Actual,Hope Biosciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:07Z,2021-10-12T07:19:07Z
NCT04346667,NA,4/13/2020,NA,NA,3/8/2021,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,3/8/2021,3/10/2021,Actual,14-Apr-20,Actual,4/14/2020,Mar-21,3/31/2021,30-Aug-20,Actual,8/30/2020,23-Aug-20,Actual,8/23/2020,NA,Interventional,PEACE,NA,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate,Terminated,NA,Phase 4,125,Actual,"Government of Punjab, Specialized Healthcare and Medical Education Department",,4,NA,Poor accrual.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:22Z,2021-10-12T07:19:22Z
NCT04346017,NA,4/13/2020,NA,NA,9/28/2021,4/13/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/29/2021,Actual,20-Mar-20,Actual,3/20/2020,Sep-21,9/30/2021,23-Nov-20,Actual,11/23/2020,23-Nov-20,Actual,11/23/2020,NA,Interventional,NA,NA,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome,Completed,NA,Not Applicable,63,Actual,Brugmann University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:27Z,2021-10-12T07:19:27Z
NCT04347915,NA,4/14/2020,NA,NA,1/25/2021,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/27/2021,Actual,6-May-20,Actual,5/6/2020,Jan-21,1/31/2021,31-Mar-21,Anticipated,3/31/2021,30-Jan-21,Anticipated,1/30/2021,NA,Interventional,NA,NA,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,"A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19",Recruiting,NA,Phase 2,60,Anticipated,Bukwang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:12Z,2021-10-12T07:19:12Z
NCT04348695,NA,4/13/2020,NA,NA,4/15/2020,4/13/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,4/15/2020,4/17/2020,Actual,12-Apr-20,Actual,4/12/2020,Apr-20,4/30/2020,13-May-20,Anticipated,5/13/2020,13-May-20,Anticipated,5/13/2020,NA,Interventional,Ruxo-Sim-20,NA,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.,Recruiting,NA,Phase 2,94,Anticipated,FundaciÃ³n de investigaciÃ³n HM,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:04Z,2021-10-12T07:19:04Z
NCT04345523,NA,4/2/2020,NA,NA,5/12/2021,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,5/12/2021,5/13/2021,Actual,3-Apr-20,Actual,4/3/2020,May-21,5/31/2021,5-Apr-21,Actual,4/5/2021,5-Feb-21,Actual,2/5/2021,NA,Interventional,ConPlas-19,NA,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,"Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients",Completed,NA,Phase 2,350,Actual,Puerta de Hierro University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research,The investigator who proposed to use the data will have access to the data upon reasonable request.,NA,Yes,"PD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared. The data will be available after main report is published.",2021-10-12T07:19:29Z,2021-10-12T07:19:29Z
NCT04348305,NA,4/11/2020,NA,NA,9/20/2021,4/14/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/21/2021,Actual,17-Apr-20,Actual,4/17/2020,Sep-21,9/30/2021,8-Sep-21,Actual,9/8/2021,10-Sep-20,Actual,9/10/2020,NA,Interventional,COVID STEROID,NA,Hydrocortisone for COVID-19 and Severe Hypoxia,Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial,Completed,NA,Phase 3,30,Actual,Scandinavian Critical Care Trials Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-trial/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2021-10-12T07:19:07Z,2021-10-12T07:19:07Z
NCT04346355,NA,4/12/2020,NA,NA,6/18/2020,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,6/18/2020,6/22/2020,Actual,31-Mar-20,Actual,3/31/2020,Jun-20,6/30/2020,6-Jun-20,Actual,6/6/2020,6-Jun-20,Actual,6/6/2020,NA,Interventional,NA,NA,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia,Terminated,NA,Phase 2,126,Actual,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,,2,NA,Based on interim analysis for futility and given an enrolment rate almost nil,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:23Z,2021-10-12T07:19:23Z
NCT04348513,NA,4/9/2020,NA,NA,9/16/2021,4/14/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2021,9/23/2021,Actual,29-May-20,Actual,5/29/2020,Sep-21,9/30/2021,19-Apr-21,Actual,4/19/2021,19-Apr-21,Actual,4/19/2021,NA,Interventional,Thy-Support,NA,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support),Terminated,NA,Phase 2,5,Actual,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,,2,NA,Due to specific inclusion criteria no more subjects could be enrolled.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:08Z,2021-10-12T07:19:08Z
NCT04346797,NA,4/6/2020,NA,NA,4/23/2020,4/10/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,4/23/2020,4/27/2020,Actual,16-Apr-20,Actual,4/16/2020,Apr-20,4/30/2020,31-Dec-20,Anticipated,12/31/2020,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,CORIMUNO19-ECU,NA,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,NA,Phase 2,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:20Z,2021-10-12T07:19:20Z
NCT04346420,NA,4/8/2020,NA,NA,6/5/2020,4/13/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,6/5/2020,6/9/2020,Actual,9-Apr-20,Actual,4/9/2020,Jun-20,6/30/2020,1-May-20,Actual,5/1/2020,1-May-20,Actual,5/1/2020,NA,Interventional,NA,NA,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19,Completed,NA,Not Applicable,12,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:21Z,2021-10-12T07:19:21Z
NCT04348383,NA,4/8/2020,NA,NA,2/4/2021,4/15/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,2/4/2021,2/9/2021,Actual,8-Apr-20,Actual,4/8/2020,Aug-20,8/31/2020,15-May-21,Anticipated,5/15/2021,15-Apr-21,Anticipated,4/15/2021,NA,Interventional,DEFACOVID,NA,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,"Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome",Recruiting,NA,Phase 2,150,Anticipated,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:08Z,2021-10-12T07:19:08Z
NCT04345692,NA,4/9/2020,NA,NA,11/13/2020,4/13/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,11/13/2020,11/17/2020,Actual,26-Mar-20,Actual,3/26/2020,Nov-20,11/30/2020,31-Aug-20,Actual,8/31/2020,31-Aug-20,Actual,8/31/2020,NA,Interventional,OAHU-COVID19,NA,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients",Terminated,NA,Phase 3,17,Actual,Queen's Medical Center,,2,NA,RECOVERY Trial results - no efficacy,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:29Z,2021-10-12T07:19:29Z
NCT04345601,NA,4/10/2020,NA,NA,9/29/2021,4/13/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,10/6/2021,Actual,12-Feb-21,Actual,2/12/2021,Sep-21,9/30/2021,Oct-22,Anticipated,10/31/2022,Oct-22,Anticipated,10/31/2022,NA,Interventional,NA,NA,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),"Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID-19 Induced ARDS: A Non-Blinded Randomized, Controlled Study",Recruiting,NA,Phase 1/Phase 2,66,Anticipated,Baylor College of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:29Z,2021-10-12T07:19:29Z
NCT04347239,NA,4/13/2020,NA,NA,7/30/2021,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,7/30/2021,8/2/2021,Actual,15-Apr-20,Actual,4/15/2020,Apr-21,4/30/2021,15-Oct-21,Anticipated,10/15/2021,24-Aug-21,Anticipated,8/24/2021,NA,Interventional,NA,NA,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,394,Anticipated,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:17Z,2021-10-12T07:19:17Z
NCT04345848,NA,4/7/2020,NA,NA,9/7/2021,4/9/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/14/2021,Actual,28-Apr-20,Actual,4/28/2020,Sep-21,9/30/2021,2-Jun-21,Actual,6/2/2021,2-Jun-21,Actual,6/2/2021,NA,Interventional,COVID-HEP,NA,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,"Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Multicentric Randomized, Open-label Clinical Trial",Terminated,NA,Phase 3,160,Actual,"University Hospital, Geneva",,2,NA,Low recruitement,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:27Z,2021-10-12T07:19:27Z
NCT04346628,NA,4/10/2020,NA,NA,4/19/2021,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,4/19/2021,4/20/2021,Actual,12-Jul-20,Actual,7/12/2020,Apr-21,4/30/2021,16-Apr-21,Actual,4/16/2021,16-Apr-21,Actual,4/16/2021,NA,Interventional,NA,NA,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19",Completed,NA,Phase 2,149,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,No current plan to share individual participant data (IPD).,2021-10-12T07:19:22Z,2021-10-12T07:19:22Z
NCT04346147,NA,4/7/2020,NA,NA,8/2/2021,4/11/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,7-May-20,Actual,5/7/2020,Aug-21,8/31/2021,Sep-21,Anticipated,9/30/2021,2-Jun-21,Actual,6/2/2021,NA,Interventional,Covid19COVINIB,NA,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,"Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS Cov2 Pneumonia","Active, not recruiting",NA,Phase 2,168,Actual,Hospital Universitario de Fuenlabrada,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:27Z,2021-10-12T07:19:27Z
NCT04346927,NA,4/13/2020,NA,NA,3/24/2021,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,3/24/2021,3/26/2021,Actual,10-Aug-20,Actual,8/10/2020,Mar-21,3/31/2021,30-Nov-20,Actual,11/30/2020,10-Oct-20,Actual,10/10/2020,NA,Interventional,COVID-19,NA,Telerehabilitation for Patients Diagnosed With Coronavirus,Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home,Completed,NA,Not Applicable,30,Actual,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:18Z,2021-10-12T07:19:18Z
NCT04346446,NA,4/14/2020,NA,NA,6/11/2020,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,6/11/2020,6/12/2020,Actual,20-Apr-20,Actual,4/20/2020,Jun-20,6/30/2020,30-May-20,Actual,5/30/2020,30-May-20,Actual,5/30/2020,NA,Interventional,NA,NA,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,Completed,NA,Phase 2,29,Actual,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:21Z,2021-10-12T07:19:21Z
NCT04345614,NA,4/7/2020,NA,NA,7/30/2021,4/13/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/30/2021,8/3/2021,Actual,8-Apr-20,Actual,4/8/2020,Jul-21,7/31/2021,30-Jul-21,Actual,7/30/2021,28-Jun-21,Actual,6/28/2021,NA,Interventional,NA,NA,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,"A Randomized Double Blind, Placebo-Controlled Study of Auxora for the Treatment of Severe COVID-19 Pneumonia (CARDEA)",Completed,NA,Phase 2,284,Actual,"CalciMedica, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:30Z,2021-10-12T07:19:30Z
NCT04341389,NA,4/7/2020,NA,NA,5/14/2020,4/9/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2020,5/18/2020,Actual,12-Apr-20,Actual,4/12/2020,May-20,5/31/2020,31-Jan-21,Anticipated,1/31/2021,31-Jan-21,Anticipated,1/31/2021,NA,Interventional,CTII-nCoV,NA,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Active, not recruiting",NA,Phase 2,508,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:59Z,2021-10-12T07:19:59Z
NCT04344210,NA,4/7/2020,NA,NA,10/11/2020,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/11/2020,10/14/2020,Actual,17-Apr-20,Actual,4/17/2020,Oct-20,10/31/2020,20-Sep-20,Actual,9/20/2020,20-Sep-20,Actual,9/20/2020,NA,Interventional,NA,NA,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial,Completed,NA,Not Applicable,149,Actual,Federal University of Rio Grande do Sul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:19:39Z,2021-10-12T07:19:39Z
NCT04343794,NA,2/20/2020,NA,NA,4/13/2020,4/9/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,4/13/2020,4/15/2020,Actual,1-Apr-20,Actual,4/1/2020,Apr-20,4/30/2020,31-Jan-22,Anticipated,1/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,NA,Not Applicable,200,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:42Z,2021-10-12T07:19:42Z
NCT04341584,NA,4/7/2020,NA,NA,1/29/2021,4/7/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,1/29/2021,2/1/2021,Actual,8-Apr-20,Actual,4/8/2020,Apr-20,4/30/2020,25-Jul-20,Actual,7/25/2020,10-May-20,Actual,5/10/2020,NA,Interventional,CORIMUNO-ANA,NA,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19",Completed,NA,Phase 2,161,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z
NCT04345289,NA,4/10/2020,NA,NA,7/29/2020,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2020,7/31/2020,Actual,1-May-20,Actual,5/1/2020,Jul-20,7/31/2020,15-Jun-21,Anticipated,6/15/2021,15-Jun-21,Anticipated,6/15/2021,NA,Interventional,CCAP,NA,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,"Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial",Recruiting,NA,Phase 3,1100,Anticipated,Hvidovre University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:31Z,2021-10-12T07:19:31Z
NCT04344951,NA,4/6/2020,NA,NA,9/16/2021,4/9/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2021,9/23/2021,Actual,6-Apr-20,Actual,4/6/2020,Sep-21,9/30/2021,30-Nov-20,Actual,11/30/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,HOPE,NA,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Terminated,NA,Phase 2,29,Actual,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,,1,NA,No clinical efficacy against SARS-CoV-2 recorded,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:33Z,2021-10-12T07:19:33Z
NCT04344288,NA,4/10/2020,NA,NA,10/23/2020,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/23/2020,10/26/2020,Actual,21-Apr-20,Actual,4/21/2020,Oct-20,10/31/2020,18-Aug-20,Actual,8/18/2020,18-Aug-20,Actual,8/18/2020,NA,Interventional,CORTI-Covid,NA,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Terminated,NA,Phase 2,11,Actual,Hospices Civils de Lyon,,2,NA,Competent Authority's decision,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:38Z,2021-10-12T07:19:38Z
NCT04343976,NA,4/9/2020,NA,NA,10/4/2021,4/9/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/11/2021,Estimate,22-Jun-20,Actual,6/22/2020,Oct-21,10/31/2021,30-Jul-21,Actual,7/30/2021,30-Jul-21,Actual,7/30/2021,NA,Interventional,NA,NA,Pegylated Interferon Lambda Treatment for COVID-19,A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19,Terminated,NA,Phase 2,14,Actual,Massachusetts General Hospital,,2,NA,"Unable to meet enrollment goal, lack of funding.",FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data is anticiapted to be made available within 3 months of study completion. Safety data, specifically treatment related adverse events, will be shared in real time",researchers accessing IPD must be an approved and have a data use agreement in place with Partners Healthcare to access the data,NA,Yes,Coded data is anticipated to be shared with outside institutions. Safety data will be shared with the drug manufacturer,2021-10-12T07:19:42Z,2021-10-12T07:19:42Z
NCT04344080,NA,4/9/2020,NA,NA,6/30/2021,4/9/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,6/30/2021,7/2/2021,Actual,1-Apr-20,Actual,4/1/2020,Jun-21,6/30/2021,28-Apr-21,Actual,4/28/2021,10-Apr-21,Actual,4/10/2021,NA,Interventional,CYTOCOV-19,NA,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Completed,NA,Not Applicable,24,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:41Z,2021-10-12T07:19:41Z
NCT04343053,NA,4/3/2020,NA,NA,9/28/2021,4/8/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/29/2021,Actual,8-Apr-20,Actual,4/8/2020,Sep-21,9/30/2021,9-Jun-23,Anticipated,6/9/2023,9-Jun-20,Actual,6/9/2020,NA,Interventional,ATTAC-Co,NA,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Patterns and Changes in Platelet Reactivity, Thrombotic Status and Endothelial Function in Hospitalized Patients With SARS-Cov-2 Infection",Recruiting,NA,Not Applicable,100,Anticipated,University Hospital of Ferrara,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,After specific request to study PIs,2021-10-12T07:19:48Z,2021-10-12T07:19:48Z
NCT04341675,NA,4/5/2020,NA,NA,5/18/2020,4/8/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2020,5/20/2020,Actual,24-Apr-20,Actual,4/24/2020,May-20,5/31/2020,Sep-20,Anticipated,9/30/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,SCOPE,NA,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial),Recruiting,NA,Phase 2,30,Anticipated,University of Cincinnati,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,De-identified aggregate data will be made available to other researchers on a case-by-case basis.,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z
NCT04338958,NA,4/7/2020,NA,NA,8/12/2021,4/7/2020,4/8/2020,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/13/2021,Actual,22-Apr-20,Actual,4/22/2020,Aug-21,8/31/2021,15-Jul-21,Actual,7/15/2021,15-Jul-21,Actual,7/15/2021,NA,Interventional,RuxCoFlam,NA,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation,Completed,NA,Phase 2,193,Actual,University of Jena,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:18Z,2021-10-12T07:20:18Z
NCT04344730,NA,4/9/2020,NA,NA,2/6/2021,4/13/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,2/6/2021,2/9/2021,Actual,10-Apr-20,Actual,4/10/2020,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,COVIDICUS,NA,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS,"Active, not recruiting",NA,Not Applicable,550,Actual,Assistance Publique - HÃ´pitaux de Paris,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:36Z,2021-10-12T07:19:36Z
NCT04344184,NA,4/9/2020,NA,NA,6/1/2021,4/9/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,6/1/2021,6/3/2021,Actual,18-Dec-20,Actual,12/18/2020,Jun-21,6/30/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),Recruiting,NA,Phase 2,60,Anticipated,Virginia Commonwealth University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,There is no default plan to share individual participant data. May be considered upon reaching the VCU IRB,2021-10-12T07:19:38Z,2021-10-12T07:19:38Z
NCT04342182,NA,3/31/2020,NA,NA,11/13/2020,4/9/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,11/13/2020,11/16/2020,Actual,8-Apr-20,Actual,4/8/2020,Nov-20,11/30/2020,31-Jul-21,Anticipated,7/31/2021,1-Jul-21,Anticipated,7/1/2021,NA,Interventional,ConCoVid-19,NA,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19,"Active, not recruiting",NA,Phase 2/Phase 3,426,Anticipated,Erasmus Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:54Z,2021-10-12T07:19:54Z
NCT04341207,NA,4/8/2020,NA,NA,4/9/2020,4/9/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2020,4/10/2020,Actual,3-Apr-20,Actual,4/3/2020,Apr-20,4/30/2020,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,ONCOVID,NA,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients,Recruiting,NA,Phase 2,1000,Anticipated,"Gustave Roussy, Cancer Campus, Grand Paris",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:02Z,2021-10-12T07:20:02Z
NCT04344600,NA,4/10/2020,NA,NA,9/24/2021,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/30/2021,Actual,29-Jun-20,Actual,6/29/2020,Sep-21,9/30/2021,24-Sep-21,Actual,9/24/2021,24-Sep-21,Actual,9/24/2021,NA,Interventional,PROTECT,NA,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection,Terminated,NA,Phase 2,6,Actual,Johns Hopkins University,,2,NA,Single center study with low enrollment,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:38Z,2021-10-12T07:19:38Z
NCT04345276,NA,4/10/2020,NA,NA,6/1/2020,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,6/1/2020,6/2/2020,Actual,18-Mar-20,Actual,3/18/2020,Mar-20,3/31/2020,15-Apr-20,Actual,4/15/2020,15-Apr-20,Actual,4/15/2020,NA,Interventional,NA,NA,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,10,Actual,Huoshenshan Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:34Z,2021-10-12T07:19:34Z
NCT04342650,NA,4/4/2020,NA,NA,8/2/2021,4/8/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/9/2021,Actual,8-Apr-20,Actual,4/8/2020,Jul-20,7/31/2020,8-Jun-20,Actual,6/8/2020,14-May-20,Actual,5/14/2020,NA,Interventional,CloroCOVID19II,NA,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Completed,NA,Phase 2,152,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after study publication,Upon formal request to researchers.,NA,Yes,all patient data will be shared after study publication,2021-10-12T07:19:51Z,2021-10-12T07:19:51Z
NCT04344015,NA,4/9/2020,NA,NA,5/7/2021,4/9/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,5/7/2021,5/10/2021,Actual,13-Apr-20,Actual,4/13/2020,May-21,5/31/2021,2-Jun-20,Actual,6/2/2020,2-Jun-20,Actual,6/2/2020,NA,Interventional,NA,NA,COVID-19 Plasma Collection,Collection of COVID-19 Convalescent Plasma,Completed,NA,Not Applicable,206,Actual,Thomas Jefferson University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:42Z,2021-10-12T07:19:42Z
NCT04341493,NA,4/7/2020,NA,NA,3/29/2021,4/7/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,3/29/2021,4/1/2021,Actual,6-Apr-20,Actual,4/6/2020,Mar-21,3/31/2021,30-Dec-20,Actual,12/30/2020,30-Aug-20,Actual,8/30/2020,NA,Interventional,NA,NA,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome,Terminated,NA,Phase 4,44,Actual,Materno-Perinatal Hospital of the State of Mexico,,2,NA,Concerns about safety of Hydroxychloroquine,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After finishing the study.,Requested by the journal or after publication if any researcher in the world express interest if the information of this survey.,NA,Yes,"If the final selected medical journal to send the paper of our research request it, we will add the full database of the studied population.",2021-10-12T07:19:58Z,2021-10-12T07:19:58Z
NCT04341142,NA,4/8/2020,NA,NA,7/29/2020,4/8/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2020,7/31/2020,Actual,9-Apr-20,Actual,4/9/2020,Jul-20,7/31/2020,9-Apr-24,Anticipated,4/9/2024,9-Apr-23,Anticipated,4/9/2023,NA,Interventional,COVID-SER,NA,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,NA,Not Applicable,550,Anticipated,Hospices Civils de Lyon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:01Z,2021-10-12T07:20:01Z
NCT04343755,NA,4/8/2020,NA,NA,6/1/2021,4/9/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,6/1/2021,6/2/2021,Actual,9-Apr-20,Actual,4/9/2020,Jun-21,6/30/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection,"Active, not recruiting",NA,Phase 2,52,Actual,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:43Z,2021-10-12T07:19:43Z
NCT04342221,NA,4/8/2020,NA,NA,4/28/2021,4/9/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,4/28/2021,5/3/2021,Actual,29-Mar-20,Actual,3/29/2020,Mar-20,3/31/2020,26-Feb-21,Actual,2/26/2021,26-Feb-21,Actual,2/26/2021,NA,Interventional,COV-HCQ,NA,Hydroxychloroquine for COVID-19,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19,Terminated,NA,Phase 3,30,Actual,University Hospital Tuebingen,,2,NA,Reduced acceptance of IMP,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:54Z,2021-10-12T07:19:54Z
NCT04343729,NA,4/9/2020,NA,NA,7/21/2021,4/9/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/28/2021,Actual,18-Apr-20,Actual,4/18/2020,Jul-21,7/31/2021,20-Oct-20,Actual,10/20/2020,16-Jun-20,Actual,6/16/2020,NA,Interventional,MetCOVID,NA,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.",Completed,NA,Phase 2,416,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after study publication.,upon formal request.,NA,Yes,all patient data will be shared after study publication,2021-10-12T07:19:44Z,2021-10-12T07:19:44Z
NCT04342728,NA,4/8/2020,NA,NA,2/12/2021,4/8/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/16/2021,Actual,8-Apr-20,Actual,4/8/2020,Feb-21,2/28/2021,11-Feb-21,Actual,2/11/2021,30-Dec-20,Actual,12/30/2020,NA,Interventional,COVIDAtoZ,NA,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Completed,NA,Not Applicable,214,Actual,The Cleveland Clinic,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:50Z,2021-10-12T07:19:50Z
NCT04344444,NA,4/10/2020,NA,NA,8/21/2020,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,8/21/2020,8/24/2020,Actual,13-Apr-20,Actual,4/13/2020,Aug-20,8/31/2020,10-Dec-21,Anticipated,12/10/2021,10-Apr-21,Anticipated,4/10/2021,NA,Interventional,RCT,NA,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial,"Active, not recruiting",NA,Phase 3,600,Anticipated,LCMC Health,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:38Z,2021-10-12T07:19:38Z
NCT04342689,NA,4/8/2020,NA,NA,9/15/2021,4/8/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,9/15/2021,9/17/2021,Actual,3-Jun-20,Actual,6/3/2020,Sep-21,9/30/2021,1-Mar-22,Anticipated,3/1/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,NA,NA,The Role of Resistant Starch in COVID-19 Infection,The Role of Resistant Starch in COVID-19 Infection,Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Yale University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"After publication, indefinitely",NA,NA,Yes,Deidentified data underlying results for publication are planned to be made available after publication.,2021-10-12T07:19:50Z,2021-10-12T07:19:50Z
NCT04341922,NA,4/7/2020,NA,NA,10/15/2020,4/9/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,10/15/2020,10/19/2020,Actual,9-May-20,Actual,5/9/2020,Oct-20,10/31/2020,10-Sep-21,Anticipated,9/10/2021,20-Aug-20,Actual,8/20/2020,NA,Interventional,NA,NA,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial,"Active, not recruiting",NA,Not Applicable,670,Actual,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:56Z,2021-10-12T07:19:56Z
NCT04344379,NA,3/27/2020,NA,NA,7/31/2021,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/31/2021,8/3/2021,Actual,17-Apr-20,Actual,4/17/2020,Jul-21,7/31/2021,18-Jun-20,Actual,6/18/2020,18-Jun-20,Actual,6/18/2020,NA,Interventional,PREP-COVID,NA,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus,Completed,NA,Phase 3,122,Actual,Assistance Publique - HÃ´pitaux de Paris,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:39Z,2021-10-12T07:19:39Z
NCT04343651,NA,3/31/2020,NA,NA,9/28/2021,4/9/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/29/2021,Actual,1-Apr-20,Actual,4/1/2020,Sep-21,9/30/2021,20-Sep-21,Actual,9/20/2021,21-Jul-20,Actual,7/21/2020,NA,Interventional,NA,NA,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Completed,NA,Phase 2,86,Actual,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:45Z,2021-10-12T07:19:45Z
NCT04341441,NA,4/7/2020,NA,NA,12/17/2020,4/7/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2020,12/21/2020,Actual,7-Apr-20,Actual,4/7/2020,Dec-20,12/31/2020,15-Dec-20,Actual,12/15/2020,15-Dec-20,Actual,12/15/2020,NA,Interventional,WHIP COVID-19,NA,Will Hydroxychloroquine Impede or Prevent COVID-19,Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study,Terminated,NA,Phase 3,624,Actual,Henry Ford Health System,,4,NA,"Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:59Z,2021-10-12T07:19:59Z
NCT04344041,NA,4/9/2020,NA,NA,4/29/2021,4/9/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2021,4/30/2021,Actual,15-Apr-20,Actual,4/15/2020,Apr-21,4/30/2021,14-Jan-21,Actual,1/14/2021,14-Jan-21,Actual,1/14/2021,NA,Interventional,NA,NA,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Completed,NA,Phase 3,260,Actual,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:41Z,2021-10-12T07:19:41Z
NCT04343768,NA,4/8/2020,NA,NA,5/2/2020,4/9/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,5/2/2020,5/5/2020,Actual,9-Apr-20,Actual,4/9/2020,May-20,5/31/2020,27-Apr-20,Actual,4/27/2020,27-Apr-20,Actual,4/27/2020,NA,Interventional,COVIFERON,NA,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,NA,Phase 2,60,Actual,Shahid Beheshti University of Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,One year after the publication of the results in a journal.,"Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question.",NA,Yes,"One year after the publication of the results in a journal, Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question can have access to data and supporting information.",2021-10-12T07:19:43Z,2021-10-12T07:19:43Z
NCT04342169,NA,4/7/2020,NA,NA,9/28/2021,4/9/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/30/2021,Actual,4-Apr-20,Actual,4/4/2020,Sep-21,9/30/2021,Oct-21,Anticipated,10/31/2021,1-Jun-21,Actual,6/1/2021,NA,Interventional,NA,NA,University of Utah COVID-19 Hydrochloroquine Trial,Hydroxychloroquine for Outpatients With Confirmed COVID-19,"Active, not recruiting",NA,Phase 2,368,Actual,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:54Z,2021-10-12T07:19:54Z
NCT04343248,NA,4/8/2020,NA,NA,3/31/2021,4/8/2020,4/13/2020,Actual,NA,NA,NA,NA,NA,NA,3/31/2021,4/1/2021,Actual,12-May-20,Actual,5/12/2020,Mar-21,3/31/2021,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","Active, not recruiting",NA,Phase 3,800,Anticipated,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:47Z,2021-10-12T07:19:47Z
NCT04344457,NA,4/8/2020,NA,NA,6/29/2020,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,6/29/2020,7/1/2020,Actual,16-Apr-20,Actual,4/16/2020,Jun-20,6/30/2020,30-Sep-20,Anticipated,9/30/2020,20-Jun-20,Anticipated,6/20/2020,NA,Interventional,COVID-19,NA,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms",Recruiting,NA,Phase 1/Phase 2,80,Anticipated,"Perseverance Research Center, LLC",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:36Z,2021-10-12T07:19:36Z
NCT04344561,NA,4/10/2020,NA,NA,5/14/2021,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2021,5/17/2021,Actual,25-May-20,Actual,5/25/2020,May-21,5/31/2021,1-Jun-22,Anticipated,6/1/2022,1-May-22,Anticipated,5/1/2022,NA,Interventional,UPSAT,NA,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT),Recruiting,NA,Not Applicable,70,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Access to IPD on reasonable request,2021-10-12T07:19:37Z,2021-10-12T07:19:37Z
NCT04341038,NA,4/7/2020,NA,NA,4/8/2020,4/8/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,4/8/2020,4/10/2020,Actual,1-Apr-20,Actual,4/1/2020,Apr-20,4/30/2020,1-Jul-20,Anticipated,7/1/2020,1-Jun-20,Anticipated,6/1/2020,NA,Interventional,TACROVID,NA,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19,Recruiting,NA,Phase 3,84,Anticipated,Hospital Universitari de Bellvitge,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:02Z,2021-10-12T07:20:02Z
NCT04344431,NA,4/9/2020,NA,NA,10/24/2020,4/11/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/24/2020,10/27/2020,Actual,14-Apr-20,Actual,4/14/2020,Oct-20,10/31/2020,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,OHB10cov,NA,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:37Z,2021-10-12T07:19:37Z
NCT04343963,NA,4/9/2020,NA,NA,7/6/2020,4/9/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/6/2020,7/7/2020,Actual,4-Apr-20,Actual,4/4/2020,Apr-20,4/30/2020,30-Apr-21,Anticipated,4/30/2021,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,PISCO,NA,Pyridostigmine in Severe SARS-CoV-2 Infection,Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection,Recruiting,NA,Phase 2/Phase 3,436,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:44Z,2021-10-12T07:19:44Z
NCT04337541,NA,4/2/2020,NA,NA,7/29/2020,4/5/2020,4/7/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2020,8/3/2020,Actual,2-Apr-20,Actual,4/2/2020,Jul-20,7/31/2020,2-Jun-20,Actual,6/2/2020,2-Jun-20,Actual,6/2/2020,NA,Interventional,NA,NA,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,NA,Not Applicable,6000,Actual,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:31Z,2021-10-12T07:20:31Z
NCT04344106,NA,4/8/2020,NA,NA,4/10/2020,4/10/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,4/10/2020,4/14/2020,Actual,1-Apr-20,Actual,4/1/2020,Apr-20,4/30/2020,1-May-20,Anticipated,5/1/2020,15-Apr-20,Anticipated,4/15/2020,NA,Interventional,ProCov,NA,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov),Recruiting,NA,Not Applicable,25,Anticipated,Centre Hospitalier Intercommunal Aix-Pertuis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:41Z,2021-10-12T07:19:41Z
NCT04339660,NA,4/2/2020,NA,NA,4/5/2020,4/5/2020,4/9/2020,Actual,NA,NA,NA,NA,NA,NA,4/5/2020,4/9/2020,Actual,1-Feb-20,Actual,2/1/2020,Apr-20,4/30/2020,30-Jun-20,Anticipated,6/30/2020,30-Jun-20,Anticipated,6/30/2020,NA,Interventional,NA,NA,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Puren Hospital Affiliated to Wuhan University of Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:11Z,2021-10-12T07:20:11Z
NCT04341415,NA,4/7/2020,NA,NA,4/8/2021,4/7/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,4/8/2021,4/13/2021,Actual,9-Apr-20,Actual,4/9/2020,Apr-21,4/30/2021,15-Jan-21,Actual,1/15/2021,20-Nov-20,Actual,11/20/2020,NA,Interventional,SOS-COVID19,NA,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.,Terminated,NA,Not Applicable,31,Actual,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,Inclusion stopped at 50% after interim analysis: primary efficacy endpoint not significant,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z
NCT04340544,NA,4/3/2020,NA,NA,10/29/2020,4/8/2020,4/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2020,11/2/2020,Actual,22-Apr-20,Actual,4/22/2020,Apr-20,4/30/2020,12-Oct-20,Actual,10/12/2020,12-Oct-20,Actual,10/12/2020,NA,Interventional,COMIHY,NA,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Terminated,NA,Phase 2,17,Actual,University Hospital Tuebingen,,2,NA,"It appeared to be impossible for the study centres to recruit the targeted number of patients, due to reduced incidence and reduced acceptance to IMP",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:04Z,2021-10-12T07:20:04Z
NCT04340050,NA,4/7/2020,NA,NA,12/23/2020,4/8/2020,4/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/23/2020,12/28/2020,Actual,10-Apr-20,Actual,4/10/2020,Dec-20,12/31/2020,23-Dec-20,Actual,12/23/2020,23-Dec-20,Actual,12/23/2020,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma,Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center,Completed,NA,Early Phase 1,10,Actual,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database,NA,NA,Yes,We will share individual participant data that is de-identified available to all qualified investigators,2021-10-12T07:20:09Z,2021-10-12T07:20:09Z
NCT04339816,NA,4/6/2020,NA,NA,11/5/2020,4/6/2020,4/9/2020,Actual,NA,NA,NA,NA,NA,NA,11/5/2020,11/6/2020,Actual,13-May-20,Actual,5/13/2020,Nov-20,11/30/2020,4-Nov-20,Actual,11/4/2020,4-Nov-20,Actual,11/4/2020,NA,Interventional,AZIQUINE-ICU,NA,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial,Terminated,NA,Phase 3,3,Actual,"Charles University, Czech Republic",,3,NA,Steering Committee decision in accordance with stopping rule 1: Emergence of new data,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,within 6 months of study completion,NA,http://mendeley.com,Yes,Deidentified record-level data will be shared in a public database,2021-10-12T07:20:12Z,2021-10-12T07:20:12Z
NCT04339426,NA,4/7/2020,NA,NA,12/1/2020,4/7/2020,4/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2020,12/2/2020,Actual,20-Apr-20,Actual,4/20/2020,Dec-20,12/31/2020,Dec-21,Anticipated,12/31/2021,Jul-21,Anticipated,7/31/2021,NA,Interventional,NA,NA,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,"Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection",Recruiting,NA,Phase 2,25,Anticipated,HonorHealth Research Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:14Z,2021-10-12T07:20:14Z
NCT04338841,NA,4/5/2020,NA,NA,9/22/2020,4/7/2020,4/8/2020,Actual,NA,NA,NA,NA,NA,NA,9/22/2020,9/23/2020,Actual,9-Apr-20,Actual,4/9/2020,Apr-20,4/30/2020,17-Jun-20,Actual,6/17/2020,17-Jun-20,Actual,6/17/2020,NA,Interventional,HOME-CoV,NA,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Completed,NA,Not Applicable,3133,Actual,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:21Z,2021-10-12T07:20:21Z
NCT04337996,NA,4/1/2020,NA,NA,1/25/2021,4/3/2020,4/8/2020,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/26/2021,Actual,13-Jul-20,Actual,7/13/2020,Jan-21,1/31/2021,13-Jan-21,Actual,1/13/2021,13-Jan-21,Actual,1/13/2021,NA,Interventional,TRODVID-19,NA,Dynamic Evaluation of COVID-19 Diagnostic Tests,Dynamic Evaluation of COVID-19 Diagnostic Tests,Completed,NA,Not Applicable,8,Actual,Tourcoing Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:25Z,2021-10-12T07:20:25Z
NCT04341727,NA,4/4/2020,NA,NA,10/5/2021,4/8/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/7/2021,Actual,4-Apr-20,Actual,4/4/2020,Oct-21,10/31/2021,1-Apr-21,Actual,4/1/2021,1-Apr-21,Actual,4/1/2021,NA,Interventional,WU352,NA,"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","WU 352: Open-label, Randomized Controlled Trial of Hydroxychloroquine Alone or Hydroxychloroquine Plus Azithromycin or Chloroquine Alone or Chloroquine Plus Azithromycin in the Treatment of SARS CoV-2 Infection",Terminated,NA,Phase 3,31,Actual,Washington University School of Medicine,,4,NA,DSMB recommended study suspension slow accrual,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z
NCT04337918,NA,4/6/2020,NA,NA,2/8/2021,4/6/2020,4/8/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/10/2021,Actual,8-May-20,Actual,5/8/2020,Feb-21,2/28/2021,2-Feb-21,Actual,2/2/2021,31-Jan-21,Actual,1/31/2021,NA,Interventional,NOCOVID,NA,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Completed,NA,Phase 2,143,Actual,Sanotize Research and Development corp.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:27Z,2021-10-12T07:20:27Z
NCT04335097,NA,4/1/2020,NA,NA,5/14/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2021,5/17/2021,Actual,22-Apr-20,Actual,4/22/2020,May-21,5/31/2021,20-Dec-25,Anticipated,12/20/2025,8-Apr-22,Anticipated,4/8/2022,NA,Interventional,HSC19,NA,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,"Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study",Recruiting,NA,Not Applicable,214,Anticipated,Oslo University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:50Z,2021-10-12T07:20:50Z
NCT04336332,NA,3/31/2020,NA,NA,9/20/2021,4/2/2020,4/7/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/21/2021,Actual,1-Apr-20,Actual,4/1/2020,Sep-21,9/30/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,"Active, not recruiting",NA,Phase 2,160,Anticipated,"Rutgers, The State University of New Jersey",,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:38Z,2021-10-12T07:20:38Z
NCT04340349,NA,4/2/2020,NA,NA,6/26/2021,4/8/2020,4/9/2020,Actual,NA,NA,NA,NA,NA,NA,6/26/2021,6/29/2021,Actual,1-Feb-21,Actual,2/1/2021,Jun-21,6/30/2021,30-Jun-21,Anticipated,6/30/2021,30-May-21,Actual,5/30/2021,NA,Interventional,ELEVATE,NA,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial),Enrolling by invitation,NA,Early Phase 1,214,Anticipated,Instituto Nacional de Rehabilitacion,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"Under Mexican Law, we are not able to provide IPD",2021-10-12T07:20:08Z,2021-10-12T07:20:08Z
NCT04338698,NA,4/4/2020,NA,NA,7/12/2020,4/4/2020,4/8/2020,Actual,NA,NA,NA,NA,NA,NA,7/12/2020,7/15/2020,Actual,22-Apr-20,Actual,4/22/2020,Jul-20,7/31/2020,30-Nov-20,Anticipated,11/30/2020,1-Sep-20,Anticipated,9/1/2020,NA,Interventional,PROTECT,NA,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment,Recruiting,NA,Phase 3,500,Anticipated,University of Health Sciences Lahore,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"On completion of study, investigators are open to participation in planned IPD projects with a prospective registration, subject to appropriate approvals",2021-10-12T07:20:20Z,2021-10-12T07:20:20Z
NCT04335305,NA,3/31/2020,NA,NA,11/25/2020,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,11/25/2020,11/27/2020,Actual,9-Apr-20,Actual,4/9/2020,Oct-20,10/31/2020,30-Jun-21,Anticipated,6/30/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,COPERNICO,NA,Checkpoint Blockade in COVID-19 Pandemic,"A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia",Recruiting,NA,Phase 2,24,Anticipated,MedSIR,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:46Z,2021-10-12T07:20:46Z
NCT04338828,NA,4/5/2020,NA,NA,2/13/2021,4/5/2020,4/8/2020,Actual,NA,NA,NA,NA,NA,NA,2/13/2021,2/16/2021,Actual,18-Apr-20,Actual,4/18/2020,Feb-21,2/28/2021,Apr-22,Anticipated,4/30/2022,Apr-21,Anticipated,4/30/2021,NA,Interventional,NO COV-ED,NA,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department,"Active, not recruiting",NA,Phase 2,47,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:21Z,2021-10-12T07:20:21Z
NCT04338568,NA,4/4/2020,NA,NA,8/14/2020,4/7/2020,4/8/2020,Actual,NA,NA,NA,NA,NA,NA,8/14/2020,8/17/2020,Actual,16-Apr-20,Actual,4/16/2020,Aug-20,8/31/2020,30-Dec-20,Anticipated,12/30/2020,30-Nov-20,Anticipated,11/30/2020,NA,Interventional,SCOUT,NA,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia,Recruiting,NA,Not Applicable,50,Anticipated,Hasselt University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,no plan,2021-10-12T07:20:20Z,2021-10-12T07:20:20Z
NCT04334460,NA,4/2/2020,NA,NA,2/22/2021,4/3/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/23/2021,Actual,4-May-20,Actual,5/4/2020,Feb-21,2/28/2021,Nov-21,Anticipated,11/30/2021,11-Nov-20,Actual,11/11/2020,NA,Interventional,NA,NA,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment","Active, not recruiting",NA,Phase 2,120,Actual,Blade Therapeutics,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:56Z,2021-10-12T07:20:56Z
NCT04333654,NA,4/1/2020,NA,NA,7/10/2020,4/2/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,7/10/2020,7/14/2020,Actual,12-Apr-20,Actual,4/12/2020,Jul-20,7/31/2020,26-May-20,Actual,5/26/2020,26-May-20,Actual,5/26/2020,NA,Interventional,NA,NA,Hydroxychloroquine in Outpatient Adults With COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19",Terminated,NA,Phase 1,8,Actual,Sanofi,,2,NA,Rate of enrollment too slow to allow completion in a reasonable timeframe,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-12T07:21:00Z,2021-10-12T07:21:00Z
NCT04339712,NA,4/1/2020,NA,NA,1/8/2021,4/6/2020,4/9/2020,Actual,NA,NA,NA,NA,NA,NA,1/8/2021,1/11/2021,Actual,2-Apr-20,Actual,4/2/2020,Jan-21,1/31/2021,8-Jan-21,Actual,1/8/2021,1-Dec-20,Actual,12/1/2020,NA,Interventional,ESCAPE,NA,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Completed,NA,Phase 2,102,Actual,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:14Z,2021-10-12T07:20:14Z
NCT04333914,NA,4/1/2020,NA,NA,8/4/2021,4/2/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/5/2021,Actual,15-Apr-20,Actual,4/15/2020,Aug-21,8/31/2021,Dec-21,Anticipated,12/31/2021,6-Jul-21,Actual,7/6/2021,NA,Interventional,IMMUNONCOVID,NA,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,"A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.","Active, not recruiting",NA,Phase 2,219,Anticipated,Centre Leon Berard,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:59Z,2021-10-12T07:20:59Z
NCT04336904,NA,4/3/2020,NA,NA,4/7/2020,4/3/2020,4/7/2020,Actual,NA,NA,NA,NA,NA,NA,4/7/2020,4/8/2020,Actual,25-Mar-20,Actual,3/25/2020,Apr-20,4/30/2020,Jul-20,Anticipated,7/31/2020,Jul-20,Anticipated,7/31/2020,NA,Interventional,NA,NA,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type","Active, not recruiting",NA,Phase 3,100,Anticipated,ASST Fatebenefratelli Sacco,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:35Z,2021-10-12T07:20:35Z
NCT04334265,NA,4/1/2020,NA,NA,4/22/2020,4/3/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,4/22/2020,4/24/2020,Actual,1-Apr-20,Actual,4/1/2020,Apr-20,4/30/2020,1-Dec-20,Anticipated,12/1/2020,1-Jun-20,Anticipated,6/1/2020,NA,Interventional,NA,NA,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,"Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study",Recruiting,NA,Not Applicable,750,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:54Z,2021-10-12T07:20:54Z
NCT04336254,NA,3/28/2020,NA,NA,3/8/2021,4/3/2020,4/7/2020,Actual,NA,NA,NA,NA,NA,NA,3/8/2021,3/10/2021,Actual,6-May-20,Actual,5/6/2020,Mar-21,3/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,"Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19ï¼ša Single-center, Prospective, Randomised Clinical Trial",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Renmin Hospital of Wuhan University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:38Z,2021-10-12T07:20:38Z
NCT04335201,NA,3/31/2020,NA,NA,2/12/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/16/2021,Actual,20-May-20,Actual,5/20/2020,Feb-21,2/28/2021,31-Aug-21,Anticipated,8/31/2021,20-Jun-21,Anticipated,6/20/2021,NA,Interventional,DEFI-VID19,NA,Defibrotide in COVID-19 Pneumonia,Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 2,50,Anticipated,IRCCS San Raffaele,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:49Z,2021-10-12T07:20:49Z
NCT04334434,NA,4/2/2020,NA,NA,1/30/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,1/30/2021,2/3/2021,Actual,30-Jul-20,Actual,7/30/2020,Jan-21,1/31/2021,15-Dec-20,Actual,12/15/2020,15-Sep-20,Actual,9/15/2020,NA,Interventional,NA,NA,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic,Completed,NA,Not Applicable,30,Actual,Istanbul University-Cerrahpasa,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:55Z,2021-10-12T07:20:55Z
NCT04328285,NA,3/25/2020,NA,NA,7/16/2021,3/27/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,7/16/2021,7/22/2021,Actual,14-Apr-20,Actual,4/14/2020,Jul-21,7/31/2021,30-Mar-22,Anticipated,3/30/2022,30-Mar-22,Anticipated,3/30/2022,NA,Interventional,COVIDAXIS,NA,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial,"Active, not recruiting",NA,Phase 3,1200,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z
NCT04335123,NA,3/31/2020,NA,NA,5/6/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/10/2021,Actual,4-Apr-20,Actual,4/4/2020,May-21,5/31/2021,17-Aug-20,Actual,8/17/2020,21-Jun-20,Actual,6/21/2020,NA,Interventional,NA,NA,Study of Open Label Losartan in COVID-19,An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19,Completed,NA,Phase 1,34,Actual,University of Kansas Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Beginning 3 months and ending 5 years following article publication,"Proposals should be directed to msalathe@kumc.edu. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)",2021-10-12T07:20:47Z,2021-10-12T07:20:47Z
NCT04337008,NA,4/3/2020,NA,NA,4/21/2020,4/3/2020,4/7/2020,Actual,NA,NA,NA,NA,NA,NA,4/21/2020,4/24/2020,Actual,3-Apr-20,Actual,4/3/2020,Apr-20,4/30/2020,31-Jul-20,Anticipated,7/31/2020,3-Jun-20,Anticipated,6/3/2020,NA,Interventional,SRA-COV,NA,Renin Angiotensin System - CoronaVirus,Renin Angiotensin System - CoronaVirus,Recruiting,NA,Not Applicable,50,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:35Z,2021-10-12T07:20:35Z
NCT04336462,NA,3/25/2020,NA,NA,4/3/2020,4/3/2020,4/7/2020,Actual,NA,NA,NA,NA,NA,NA,4/3/2020,4/7/2020,Actual,15-Feb-20,Actual,2/15/2020,Apr-20,4/30/2020,1-Aug-20,Anticipated,8/1/2020,21-Feb-20,Actual,2/21/2020,NA,Interventional,COVID-19,NA,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,"A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19",Recruiting,NA,Not Applicable,100,Anticipated,Shanghai Asclepius Meditec Inc.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:38Z,2021-10-12T07:20:38Z
NCT04335851,NA,4/2/2020,NA,NA,6/4/2020,4/3/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,6/4/2020,6/9/2020,Actual,6-Apr-20,Actual,4/6/2020,Jun-20,6/30/2020,3-Jun-20,Actual,6/3/2020,15-May-20,Actual,5/15/2020,NA,Interventional,NA,NA,Video-Based Exercises and Well-Being During Social Isolation,Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation,Completed,NA,Not Applicable,68,Actual,Biruni University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:42Z,2021-10-12T07:20:42Z
NCT04335279,NA,4/1/2020,NA,NA,11/26/2020,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2020,11/30/2020,Actual,9-Apr-20,Actual,4/9/2020,Nov-20,11/30/2020,24-Jul-20,Actual,7/24/2020,3-Jun-20,Actual,6/3/2020,NA,Interventional,SPIN-CHAT,NA,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients,Completed,NA,Not Applicable,172,Actual,Lady Davis Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,12 months after the collection of the primary outcome,Approval of proposed purpose for data access,NA,Yes,Upon request,2021-10-12T07:20:45Z,2021-10-12T07:20:45Z
NCT04335786,NA,4/2/2020,NA,NA,9/19/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,9/19/2021,9/24/2021,Actual,17-Apr-20,Actual,4/17/2020,Apr-20,4/30/2020,25-May-21,Actual,5/25/2021,25-May-21,Actual,5/25/2021,NA,Interventional,NA,NA,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,"PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease",Terminated,NA,Phase 4,23,Actual,Radboud University,,2,NA,Enrollment was stopped to facilitate successful enrollment for the ACE2RAS-domain of the REMAP-CAP trial.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:43Z,2021-10-12T07:20:43Z
NCT04332380,NA,3/30/2020,NA,NA,8/12/2020,4/1/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,8/12/2020,8/17/2020,Actual,1-May-20,Actual,5/1/2020,Aug-20,8/31/2020,28-Jul-20,Actual,7/28/2020,28-Jul-20,Actual,7/28/2020,NA,Interventional,CP-COVID-19,NA,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,NA,Phase 2,10,Actual,Universidad del Rosario,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:09Z,2021-10-12T07:21:09Z
NCT04334928,NA,4/2/2020,NA,NA,9/15/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,9/15/2021,9/16/2021,Actual,15-Apr-20,Actual,4/15/2020,Sep-21,9/30/2021,11-Jul-21,Actual,7/11/2021,25-Feb-21,Actual,2/25/2021,NA,Interventional,EPICOS,NA,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,Completed,NA,Phase 3,1002,Actual,Plan Nacional sobre el Sida (PNS),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:50Z,2021-10-12T07:20:50Z
NCT04333589,NA,4/1/2020,NA,NA,4/22/2020,4/1/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,4/22/2020,4/24/2020,Actual,1-Apr-20,Actual,4/1/2020,Apr-20,4/30/2020,15-Sep-20,Anticipated,9/15/2020,1-Jun-20,Anticipated,6/1/2020,NA,Interventional,NA,NA,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,"The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",Recruiting,NA,Not Applicable,210,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:02Z,2021-10-12T07:21:02Z
NCT04334629,NA,4/2/2020,NA,NA,10/22/2020,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,10/22/2020,10/23/2020,Actual,26-May-20,Actual,5/26/2020,May-20,5/31/2020,25-Sep-21,Anticipated,9/25/2021,25-May-21,Anticipated,5/25/2021,NA,Interventional,LIBERATE,NA,LIBERATE Trial in COVID-19,"Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial",Recruiting,NA,Phase 4,230,Anticipated,King's College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:51Z,2021-10-12T07:20:51Z
NCT04335071,NA,4/2/2020,NA,NA,10/12/2020,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,10/12/2020,10/14/2020,Actual,26-Apr-20,Actual,4/26/2020,Oct-20,10/31/2020,27-Sep-20,Actual,9/27/2020,27-Sep-20,Actual,9/27/2020,NA,Interventional,CORON-ACT,NA,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),"CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)",Terminated,NA,Phase 2,5,Actual,"University Hospital Inselspital, Berne",,2,NA,"1.) Not possible to recruit the planned number of patients during the planned study period; 2.) ""Dexamethason"" was included in the standard of care for the study population during the course of the study and inclusion criteria could no longer be met.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:50Z,2021-10-12T07:20:50Z
NCT04332094,NA,3/31/2020,NA,NA,5/3/2021,4/1/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,5/3/2021,5/6/2021,Actual,2-Apr-20,Actual,4/2/2020,May-21,5/31/2021,Jul-21,Anticipated,7/31/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,TOCOVID,NA,Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19),"Pilot, Randomized, Multicenter, Open-label Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 2,276,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:12Z,2021-10-12T07:21:12Z
NCT04331613,NA,2/6/2020,NA,NA,3/31/2020,3/31/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,3/31/2020,4/2/2020,Actual,27-Jan-20,Actual,1/27/2020,Jan-20,1/31/2020,Dec-20,Anticipated,12/31/2020,Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,9,Anticipated,Chinese Academy of Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:16Z,2021-10-12T07:21:16Z
NCT04333368,NA,3/29/2020,NA,NA,9/9/2021,4/1/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,9/9/2021,9/10/2021,Actual,6-Apr-20,Actual,4/6/2020,Sep-21,9/30/2021,1-Nov-21,Anticipated,11/1/2021,2-Nov-20,Actual,11/2/2020,NA,Interventional,STROMA-CoV2,NA,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,"Active, not recruiting",NA,Phase 1/Phase 2,47,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:01Z,2021-10-12T07:21:01Z
NCT04333407,NA,4/1/2020,NA,NA,4/8/2020,4/1/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,4/8/2020,4/9/2020,Actual,3-Apr-20,Actual,4/3/2020,Apr-20,4/30/2020,30-Mar-21,Anticipated,3/30/2021,30-Mar-21,Anticipated,3/30/2021,NA,Interventional,C-19-ACS,NA,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,NA,Not Applicable,3170,Anticipated,Imperial College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No individual participant data will be shared with other researchers or organisations. Anonymised data might be shared with other research organisations,2021-10-12T07:21:02Z,2021-10-12T07:21:02Z
NCT04333420,NA,4/1/2020,NA,NA,10/1/2021,4/1/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,10/1/2021,10/4/2021,Actual,31-Mar-20,Actual,3/31/2020,Oct-21,10/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,PANAMO,NA,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 2/Phase 3,390,Anticipated,InflaRx GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:01Z,2021-10-12T07:21:01Z
NCT04331795,NA,4/1/2020,NA,NA,3/5/2021,4/1/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,3/5/2021,3/9/2021,Actual,4-Apr-20,Actual,4/4/2020,Mar-21,3/31/2021,5-Jun-20,Actual,6/5/2020,5-Jun-20,Actual,6/5/2020,NA,Interventional,COVIDOSE,NA,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis,Completed,NA,Phase 2,32,Actual,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:15Z,2021-10-12T07:21:15Z
NCT04334850,NA,4/2/2020,NA,NA,7/31/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,7/31/2021,8/3/2021,Actual,20-Apr-20,Actual,4/20/2020,Jul-21,7/31/2021,23-Jun-21,Actual,6/23/2021,20-Dec-20,Actual,12/20/2020,NA,Interventional,MultiCov,NA,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,"Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial",Completed,NA,Not Applicable,194,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:51Z,2021-10-12T07:20:51Z
NCT04334382,NA,4/2/2020,NA,NA,4/7/2020,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,4/7/2020,4/9/2020,Actual,2-Apr-20,Actual,4/2/2020,Apr-20,4/30/2020,31-Dec-21,Anticipated,12/31/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,HyAzOUT,NA,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial,Recruiting,NA,Phase 3,1550,Anticipated,"Intermountain Health Care, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2021-10-12T07:20:55Z,2021-10-12T07:20:55Z
NCT04333628,NA,4/1/2020,NA,NA,10/13/2020,4/2/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,10/13/2020,10/14/2020,Actual,1-Jun-20,Actual,6/1/2020,Oct-20,10/31/2020,1-Sep-20,Actual,9/1/2020,1-Sep-20,Actual,9/1/2020,NA,Interventional,NA,NA,Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,"Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial",Terminated,NA,Phase 2/Phase 3,5,Actual,"HaEmek Medical Center, Israel",,3,NA,Teminated due to changes in treatment guidelines .,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:00Z,2021-10-12T07:21:00Z
NCT04333355,NA,3/31/2020,NA,NA,2/8/2021,4/1/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/10/2021,Actual,8-May-20,Actual,5/8/2020,Feb-21,2/28/2021,20-Aug-20,Actual,8/20/2020,20-Aug-20,Actual,8/20/2020,NA,Interventional,NA,NA,Safety in Convalescent Plasma Transfusion to COVID-19,Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection,Terminated,NA,Phase 1,12,Actual,Hospital San Jose Tec de Monterrey,,1,NA,Other clinical trails probed that the use of convalescent plasma for patients with COVID-19 is safe .,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:02Z,2021-10-12T07:21:02Z
NCT04334044,NA,4/1/2020,NA,NA,7/5/2021,4/2/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,7/5/2021,7/7/2021,Actual,1-Sep-20,Actual,9/1/2020,Jul-21,7/31/2021,30-Apr-21,Actual,4/30/2021,12-Apr-21,Actual,4/12/2021,NA,Interventional,NA,NA,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib,Completed,NA,Phase 1/Phase 2,77,Actual,Grupo Cooperativo de HemopatÃ­as Malignas,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:58Z,2021-10-12T07:20:58Z
NCT04334512,NA,4/2/2020,NA,NA,9/2/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/5/2021,Actual,22-Jun-20,Actual,6/22/2020,Sep-21,9/30/2021,Sep-24,Anticipated,9/30/2024,Jun-23,Anticipated,6/30/2023,NA,Interventional,HAZDpaC,NA,A Study of Quintuple Therapy to Treat COVID-19 Infection,"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection",Recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:52Z,2021-10-12T07:20:52Z
NCT04333550,NA,4/1/2020,NA,NA,4/30/2020,4/1/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,4/30/2020,5/4/2020,Actual,Apr-20,Anticipated,4/30/2020,Apr-20,4/30/2020,Mar-21,Anticipated,3/31/2021,Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,Application of Desferal to Treat COVID-19,Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Kermanshah University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:01Z,2021-10-12T07:21:01Z
NCT04331470,NA,3/30/2020,NA,NA,4/9/2020,3/31/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2020,4/13/2020,Actual,4-Apr-20,Actual,4/4/2020,Apr-20,4/30/2020,20-May-20,Anticipated,5/20/2020,20-Apr-20,Anticipated,4/20/2020,NA,Interventional,NA,NA,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease,Recruiting,NA,Phase 2/Phase 3,30,Anticipated,Fasa University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,between 1 to 2 months after analyzing the raw data.,Results will be available in Journals.,http://journal.fums.ac.ir/en,Yes,All IPD that underlie results in a publication and is comply with ethics will be revealed.,2021-10-12T07:21:17Z,2021-10-12T07:21:17Z
NCT04331665,NA,4/1/2020,NA,NA,8/13/2021,4/1/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,8/13/2021,8/19/2021,Actual,21-May-20,Actual,5/21/2020,Aug-21,8/31/2021,24-Mar-21,Actual,3/24/2021,5-Jan-21,Actual,1/5/2021,NA,Interventional,NA,NA,Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia,A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia,Terminated,NA,Not Applicable,3,Actual,"University Health Network, Toronto",,1,NA,"A Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint. With this news, recruitment was stopped for this study.",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:15Z,2021-10-12T07:21:15Z
NCT04331600,NA,3/30/2020,NA,NA,2/10/2021,4/1/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,2/10/2021,2/11/2021,Actual,16-Apr-20,Actual,4/16/2020,May-20,5/31/2020,17-Dec-20,Actual,12/17/2020,17-Dec-20,Actual,12/17/2020,NA,Interventional,NA,NA,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications",Completed,NA,Phase 4,16,Actual,Wroclaw Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:16Z,2021-10-12T07:21:16Z
NCT04330586,NA,3/31/2020,NA,NA,6/19/2021,3/31/2020,4/1/2020,Actual,NA,NA,NA,NA,NA,NA,6/19/2021,6/24/2021,Actual,1-Apr-20,Actual,4/1/2020,Jun-21,6/30/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,NA,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19,Completed,NA,Phase 2,68,Actual,Korea University Guro Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:25Z,2021-10-12T07:21:25Z
NCT04332835,NA,3/31/2020,NA,NA,11/25/2020,4/1/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,11/25/2020,11/27/2020,Actual,8-Aug-20,Actual,8/8/2020,Nov-20,11/30/2020,15-Nov-20,Actual,11/15/2020,31-Oct-20,Actual,10/31/2020,NA,Interventional,CP-COVID-19,NA,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,NA,Phase 2/Phase 3,92,Actual,Universidad del Rosario,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:08Z,2021-10-12T07:21:08Z
NCT04330638,NA,3/31/2020,NA,NA,9/28/2021,3/31/2020,4/1/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/29/2021,Actual,3-Apr-20,Actual,4/3/2020,Sep-21,9/30/2021,12-Apr-21,Actual,4/12/2021,18-Dec-20,Actual,12/18/2020,NA,Interventional,COV-AID,NA,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome",Completed,NA,Phase 3,342,Actual,"University Hospital, Ghent",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:27Z,2021-10-12T07:21:27Z
NCT04329611,NA,3/29/2020,NA,NA,7/29/2020,3/31/2020,4/1/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2020,7/31/2020,Actual,13-Apr-20,Actual,4/13/2020,Jul-20,7/31/2020,20-Jul-20,Actual,7/20/2020,20-Jul-20,Actual,7/20/2020,NA,Interventional,NA,NA,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.",Terminated,NA,Phase 3,148,Actual,University of Calgary,,2,NA,"Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack of Covid19 cases.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,24 months after study close out.,pending.,NA,Yes,NA,2021-10-12T07:21:29Z,2021-10-12T07:21:29Z
NCT04331808,NA,3/31/2020,NA,NA,4/26/2020,3/31/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,4/26/2020,4/28/2020,Actual,30-Mar-20,Actual,3/30/2020,Mar-20,3/31/2020,31-Dec-21,Anticipated,12/31/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,CORIMUNO-TOC,NA,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI),"Active, not recruiting",NA,Phase 2,228,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:13Z,2021-10-12T07:21:13Z
NCT04329832,NA,3/30/2020,NA,NA,8/31/2020,3/30/2020,4/1/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2020,9/2/2020,Actual,30-Mar-20,Actual,3/30/2020,Aug-20,8/31/2020,31-Dec-21,Anticipated,12/31/2021,18-Dec-20,Anticipated,12/18/2020,NA,Interventional,HAHPS,NA,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial,"Active, not recruiting",NA,Phase 2,85,Actual,"Intermountain Health Care, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2021-10-12T07:21:30Z,2021-10-12T07:21:30Z
NCT04331834,NA,4/1/2020,NA,NA,2/15/2021,4/1/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,2/15/2021,2/16/2021,Actual,3-Apr-20,Actual,4/3/2020,Apr-20,4/30/2020,31-Dec-20,Actual,12/31/2020,25-Jun-20,Actual,6/25/2020,NA,Interventional,PrEP_COVID,NA,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial",Completed,NA,Phase 3,275,Actual,Barcelona Institute for Global Health,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:14Z,2021-10-12T07:21:14Z
NCT04328480,NA,3/30/2020,NA,NA,4/26/2021,3/30/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,4/26/2021,4/27/2021,Actual,17-Apr-20,Actual,4/17/2020,Apr-21,4/30/2021,26-Apr-21,Actual,4/26/2021,25-Apr-21,Actual,4/25/2021,NA,Interventional,COLCOVID,NA,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,The ECLA PHRI COLCOVID Trial,Completed,NA,Phase 3,1279,Actual,Estudios ClÃ­nicos Latino AmÃ©rica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z
NCT04331054,NA,3/29/2020,NA,NA,7/31/2021,4/1/2020,4/2/2020,Actual,NA,NA,NA,NA,NA,NA,7/31/2021,8/3/2021,Actual,13-Apr-20,Actual,4/13/2020,Jul-21,7/31/2021,28-May-21,Actual,5/28/2021,28-May-21,Actual,5/28/2021,NA,Interventional,INHASCO,NA,Protective Role of Inhaled Steroids for Covid-19 Infection,Protective Role of Inhaled Steroids for Covid-19 Infection,Terminated,NA,Phase 3,146,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,Insufficient recruitment,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:19Z,2021-10-12T07:21:19Z
NCT04329650,NA,3/31/2020,NA,NA,4/16/2020,3/31/2020,4/1/2020,Actual,NA,NA,NA,NA,NA,NA,4/16/2020,4/17/2020,Actual,15-Apr-20,Actual,4/15/2020,Apr-20,4/30/2020,20-May-20,Anticipated,5/20/2020,20-May-20,Anticipated,5/20/2020,NA,Interventional,NA,NA,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia",Recruiting,NA,Phase 2,200,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:29Z,2021-10-12T07:21:29Z
NCT04330690,NA,3/23/2020,NA,NA,5/20/2021,3/31/2020,4/1/2020,Actual,NA,NA,NA,NA,NA,NA,5/20/2021,5/21/2021,Actual,18-Mar-20,Actual,3/18/2020,May-21,5/31/2021,18-May-22,Anticipated,5/18/2022,18-Mar-22,Anticipated,3/18/2022,NA,Interventional,CATCO,NA,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,"A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)",Recruiting,NA,Phase 2,2900,Anticipated,Sunnybrook Health Sciences Centre,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Unknown and variable,NA,NA,Yes,"As per World Health Organization policies on data sharing in a Public Health Emergency, any clinical trial outcome data will be shared at the earliest possible opportunity. In addition, given the nature of this protocol, being performed across regions, the DSMB may access other regions trials, and possibly recommend alterations in study design based on accumulating data, through a centralized data repository being built under the auspices of the World Health Organization.

Data Sharing for Secondary Research Data from this study may be used for secondary research. All of the individual subject data collected during the trial will be made available after de-identification through expert determination. The SAP and Analytic Code will also be made available. This data will be available immediately following publication, with no end date, as part of data sharing requirements from journals and funding agencies.",2021-10-12T07:21:23Z,2021-10-12T07:21:23Z
NCT04325867,NA,3/21/2020,NA,NA,3/30/2020,3/27/2020,3/30/2020,Actual,NA,NA,NA,NA,NA,NA,3/30/2020,4/1/2020,Actual,31-Mar-20,Actual,3/31/2020,Mar-20,3/31/2020,1-Oct-20,Anticipated,10/1/2020,1-Oct-20,Anticipated,10/1/2020,NA,Interventional,eCardioCovid19,NA,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,"Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic",Recruiting,NA,Not Applicable,200,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"If this platform will be functional, we are willing to provide the system and protocols and know-how to other centers in Romania.",2021-10-12T07:21:57Z,2021-10-12T07:21:57Z
NCT04329533,NA,3/26/2020,NA,NA,11/11/2020,3/30/2020,4/1/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2020,11/13/2020,Actual,13-Apr-20,Actual,4/13/2020,Nov-20,11/30/2020,1-Nov-20,Actual,11/1/2020,1-Nov-20,Actual,11/1/2020,NA,Interventional,NA,NA,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial,Completed,NA,Not Applicable,101,Actual,University of Arizona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:33Z,2021-10-12T07:21:33Z
NCT04327349,NA,3/24/2020,NA,NA,3/30/2020,3/30/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,3/30/2020,3/31/2020,Actual,28-Mar-20,Anticipated,3/28/2020,Mar-20,3/31/2020,30-Sep-20,Anticipated,9/30/2020,20-May-20,Anticipated,5/20/2020,NA,Interventional,NA,NA,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,NA,Not Applicable,30,Anticipated,Mazandaran University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:47Z,2021-10-12T07:21:47Z
NCT04328129,NA,3/23/2020,NA,NA,9/21/2020,3/27/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,9/21/2020,9/23/2020,Actual,23-Mar-20,Actual,3/23/2020,Sep-20,9/30/2020,23-Mar-22,Anticipated,3/23/2022,23-Mar-22,Anticipated,3/23/2022,NA,Interventional,EPI-COVID-19,NA,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in Tropical Regions,Recruiting,NA,Not Applicable,1300,Anticipated,Institut Pasteur,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z
NCT04325633,NA,3/26/2020,NA,NA,2/24/2021,3/26/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,2/24/2021,2/25/2021,Actual,24-Apr-20,Actual,4/24/2020,Feb-21,2/28/2021,15-Dec-20,Actual,12/15/2020,15-Dec-20,Actual,12/15/2020,NA,Interventional,ENACOVID,NA,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Terminated,NA,Phase 3,30,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,Stop inclusions for insufficient recruitment,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:59Z,2021-10-12T07:21:59Z
NCT04326452,NA,3/25/2020,NA,NA,10/5/2020,3/27/2020,3/30/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2020,10/6/2020,Actual,27-Mar-20,Actual,3/27/2020,Mar-20,3/31/2020,27-Mar-21,Anticipated,3/27/2021,27-Mar-21,Anticipated,3/27/2021,NA,Interventional,NA,NA,Treating COVID-19 With a Bidirectional Oxygenation Valve,The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection,Recruiting,NA,Not Applicable,30,Anticipated,TMC HealthCare,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:54Z,2021-10-12T07:21:54Z
NCT04328493,NA,3/27/2020,NA,NA,5/20/2021,3/30/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,5/20/2021,5/24/2021,Actual,7-Apr-20,Actual,4/7/2020,May-21,5/31/2021,10-Sep-20,Actual,9/10/2020,10-Sep-20,Actual,9/10/2020,NA,Interventional,VICO,NA,The Vietnam Chloroquine Treatment on COVID-19,A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam,Completed,NA,Phase 2,10,Actual,"Oxford University Clinical Research Unit, Vietnam",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:39Z,2021-10-12T07:21:39Z
NCT04329195,NA,3/28/2020,NA,NA,4/8/2021,3/28/2020,4/1/2020,Actual,NA,NA,NA,NA,NA,NA,4/8/2021,4/9/2021,Actual,9-Apr-20,Actual,4/9/2020,Apr-21,4/30/2021,9-Jan-21,Actual,1/9/2021,9-Dec-20,Actual,12/9/2020,NA,Interventional,ACORES-2,NA,ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic,ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study,Terminated,NA,Phase 3,44,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,insufficient recrutment,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:34Z,2021-10-12T07:21:34Z
NCT04327401,NA,3/26/2020,NA,NA,8/5/2020,3/27/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2020,8/7/2020,Actual,13-Apr-20,Actual,4/13/2020,Aug-20,8/31/2020,22-Jul-20,Actual,7/22/2020,22-Jul-20,Actual,7/22/2020,NA,Interventional,CoDEX,NA,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,"COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)",Terminated,NA,Phase 3,299,Actual,Hospital Sirio-Libanes,,2,NA,"The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial results, which was accepted by the CoDEX Steering Committee.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:46Z,2021-10-12T07:21:46Z
NCT04326920,NA,3/24/2020,NA,NA,3/1/2021,3/27/2020,3/30/2020,Actual,NA,NA,NA,NA,NA,NA,3/1/2021,3/2/2021,Actual,24-Mar-20,Actual,3/24/2020,Mar-21,3/31/2021,26-Feb-21,Actual,2/26/2021,28-Sep-20,Actual,9/28/2020,NA,Interventional,SARPAC,NA,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (LeukineÂ®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.",Completed,NA,Phase 4,80,Actual,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:49Z,2021-10-12T07:21:49Z
NCT04326036,NA,3/26/2020,NA,NA,10/8/2020,3/26/2020,3/30/2020,Actual,NA,NA,NA,NA,NA,NA,10/8/2020,10/12/2020,Actual,25-Mar-20,Actual,3/25/2020,Oct-20,10/31/2020,31-Dec-21,Anticipated,12/31/2021,1-Nov-21,Anticipated,11/1/2021,NA,Interventional,GARM-COVID19,NA,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection,Recruiting,NA,Early Phase 1,10,Anticipated,"Black Tie Medical, Inc.",,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,In discussion phase,2021-10-12T07:21:57Z,2021-10-12T07:21:57Z
NCT04325061,NA,3/25/2020,NA,NA,2/2/2021,3/26/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/3/2021,Actual,3-Apr-20,Actual,4/3/2020,Feb-21,2/28/2021,19-Jun-20,Actual,6/19/2020,19-Jun-20,Actual,6/19/2020,NA,Interventional,DEXA-COVID19,NA,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Terminated,NA,Phase 4,19,Actual,Dr. Negrin University Hospital,,2,NA,Lack of enrollment,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:04Z,2021-10-12T07:22:04Z
NCT04324606,NA,3/20/2020,NA,NA,4/8/2021,3/26/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,4/8/2021,4/13/2021,Actual,23-Apr-20,Actual,4/23/2020,Mar-21,3/31/2021,Oct-21,Anticipated,10/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,1090,Actual,University of Oxford,,19,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:09Z,2021-10-12T07:22:09Z
NCT04328441,NA,3/27/2020,NA,NA,5/9/2021,3/27/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,5/9/2021,5/11/2021,Actual,25-Mar-20,Actual,3/25/2020,May-21,5/31/2021,30-May-21,Anticipated,5/30/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,BCG-CORONA,NA,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial.","Active, not recruiting",NA,Phase 3,1500,Anticipated,UMC Utrecht,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,"The content of the study protocol is published. The statistical analysis plan is attached. The informed consent form (in Dutch) could be obtained by sending a mail to one of the contact persons.

The clinical study report and analytic code could be obtained by sending a mail to one of the contact persons after publication of the study in a peer-reviewed journal.",NA,NA,Yes,The results of this study will be disclosed unreservedly at the end of the study.,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z
NCT04326426,NA,3/26/2020,NA,NA,4/16/2020,3/27/2020,3/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/16/2020,4/20/2020,Actual,13-Apr-20,Actual,4/13/2020,Apr-20,4/30/2020,31-Aug-20,Anticipated,8/31/2020,1-Aug-20,Anticipated,8/1/2020,NA,Interventional,NA,NA,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,"ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection",Enrolling by invitation,NA,Phase 3,300,Anticipated,Vanda Pharmaceuticals,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:54Z,2021-10-12T07:21:54Z
NCT04328012,NA,3/27/2020,NA,NA,2/12/2021,3/27/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/16/2021,Actual,6-Apr-20,Actual,4/6/2020,Feb-21,2/28/2021,1-Aug-21,Anticipated,8/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,COVIDMED,NA,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19,Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Bassett Healthcare,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:41Z,2021-10-12T07:21:41Z
NCT04325893,NA,3/25/2020,NA,NA,10/2/2020,3/27/2020,3/30/2020,Actual,NA,NA,NA,NA,NA,NA,10/2/2020,10/6/2020,Actual,1-Apr-20,Actual,4/1/2020,Apr-20,4/30/2020,18-Jun-20,Actual,6/18/2020,18-Jun-20,Actual,6/18/2020,NA,Interventional,HYCOVID,NA,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,"Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study",Terminated,NA,Phase 3,259,Actual,"University Hospital, Angers",,2,NA,decrease in number of eligible patients,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:58Z,2021-10-12T07:21:58Z
NCT04324996,NA,3/25/2020,NA,NA,11/16/2020,3/25/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2020,11/17/2020,Actual,21-Feb-20,Actual,2/21/2020,Nov-20,11/30/2020,31-Aug-22,Anticipated,8/31/2022,20-Feb-22,Anticipated,2/20/2022,NA,Interventional,NA,NA,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Chongqing Public Health Medical Center,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:05Z,2021-10-12T07:22:05Z
NCT04322344,NA,3/23/2020,NA,NA,9/11/2020,3/23/2020,3/26/2020,Actual,NA,NA,NA,NA,NA,NA,9/11/2020,9/16/2020,Actual,23-Mar-20,Actual,3/23/2020,Sep-20,9/30/2020,30-Dec-20,Anticipated,12/30/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,add-on-COV2,NA,Escin in Patients With Covid-19 Infection,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,University of Catanzaro,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:24Z,2021-10-12T07:22:24Z
NCT04324463,NA,3/25/2020,NA,NA,4/29/2021,3/25/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2021,5/4/2021,Actual,21-Apr-20,Actual,4/21/2020,Apr-21,4/30/2021,30-Apr-22,Anticipated,4/30/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,ACTCOVID19,NA,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",Recruiting,NA,Phase 3,4000,Anticipated,Population Health Research Institute,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:07Z,2021-10-12T07:22:07Z
NCT04324190,NA,3/26/2020,NA,NA,4/11/2020,3/26/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,4/11/2020,4/14/2020,Actual,8-Apr-20,Actual,4/8/2020,Apr-20,4/30/2020,Dec-21,Anticipated,12/31/2021,Jun-20,Anticipated,6/30/2020,NA,Interventional,DISPOSE,NA,DIgital Online SuPport for COVID-19 StrEss,Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic,Recruiting,NA,Not Applicable,600,Anticipated,International Psychoanalytic University Berlin,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:10Z,2021-10-12T07:22:10Z
NCT04324021,NA,3/25/2020,NA,NA,12/11/2020,3/25/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,12/11/2020,12/14/2020,Actual,2-Apr-20,Actual,4/2/2020,Dec-20,12/31/2020,13-Nov-20,Actual,11/13/2020,13-Nov-20,Actual,11/13/2020,NA,Interventional,NA,NA,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,"A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNÎ³) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.",Terminated,NA,Phase 2/Phase 3,16,Actual,Swedish Orphan Biovitrum,,3,NA,"Standard of care evolved during the timeframe of the study and had critical impact on recruitment.

Early termination is not based on safety reasons but because of recruitment issues.

Patients ongoing will be completed. Planned LPLV 25Jan2021",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:09Z,2021-10-12T07:22:09Z
NCT04322773,NA,3/24/2020,NA,NA,10/8/2020,3/24/2020,3/26/2020,Actual,NA,NA,NA,NA,NA,NA,10/8/2020,10/9/2020,Actual,5-Apr-20,Actual,4/5/2020,Oct-20,10/31/2020,8-Oct-20,Actual,10/8/2020,8-Oct-20,Actual,10/8/2020,NA,Interventional,TOCIVID,NA,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,"Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial",Terminated,NA,Phase 2,20,Actual,Frederiksberg University Hospital,,4,NA,The study has been terminated due to changed clinical conditions and too few patients available,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:22:22Z,2021-10-12T07:22:22Z
NCT04323800,NA,3/24/2020,NA,NA,4/6/2021,3/26/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,4/6/2021,4/8/2021,Actual,10-Jun-20,Actual,6/10/2020,Mar-21,3/31/2021,Jan-23,Anticipated,1/31/2023,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,CSSC-001,NA,Convalescent Plasma to Stem Coronavirus (CSSC-001),"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","Active, not recruiting",NA,Phase 2,500,Anticipated,Johns Hopkins University,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Sharing is governed by Johns Hopkins University Institutional Guidelines,2021-10-12T07:22:12Z,2021-10-12T07:22:12Z
NCT04326790,NA,3/26/2020,NA,NA,4/2/2021,3/26/2020,3/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/2/2021,4/6/2021,Actual,3-Apr-20,Actual,4/3/2020,Apr-21,4/30/2021,27-Apr-20,Actual,4/27/2020,27-Apr-20,Actual,4/27/2020,NA,Interventional,GRECCO-19,NA,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Terminated,NA,Phase 2,105,Actual,National and Kapodistrian University of Athens,,2,NA,Slow enrollment as a result of the rapid flattening of the curve of COVID-19 cases in Greece,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:52Z,2021-10-12T07:21:52Z
NCT04325906,NA,3/26/2020,NA,NA,4/21/2021,3/27/2020,3/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/21/2021,4/23/2021,Actual,2-Apr-20,Actual,4/2/2020,Apr-21,4/30/2021,21-Feb-21,Actual,2/21/2021,26-Jan-21,Actual,1/26/2021,NA,Interventional,NA,NA,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Completed,NA,Not Applicable,222,Actual,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:58Z,2021-10-12T07:21:58Z
NCT04322565,NA,3/24/2020,NA,NA,7/9/2020,3/24/2020,3/26/2020,Actual,NA,NA,NA,NA,NA,NA,7/9/2020,7/10/2020,Actual,20-Apr-20,Actual,4/20/2020,Jul-20,7/31/2020,21-Dec-20,Anticipated,12/21/2020,20-Dec-20,Anticipated,12/20/2020,NA,Interventional,ColCOVID-19,NA,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia,Recruiting,NA,Phase 2,310,Anticipated,Azienda Ospedaliero-Universitaria di Parma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data will be avaliable from July 2020 and documentation will be shared for 10 years,The sponsor recognizes the importance of communicating study data and will disclose and publish the results in a suitable form regardless of outcome. The sponsor will publish the results of this study in scientific journals,NA,Yes,NA,2021-10-12T07:22:21Z,2021-10-12T07:22:21Z
NCT04324528,NA,3/25/2020,NA,NA,3/11/2021,3/25/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,3/11/2021,3/15/2021,Actual,27-Mar-20,Actual,3/27/2020,Mar-21,3/31/2021,27-Jan-21,Actual,1/27/2021,27-Jan-21,Actual,1/27/2021,NA,Interventional,CYCOV,NA,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Completed,NA,Not Applicable,34,Actual,University Hospital Freiburg,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:08Z,2021-10-12T07:22:08Z
NCT04323527,NA,3/19/2020,NA,NA,8/2/2021,3/25/2020,3/26/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/9/2021,Actual,23-Mar-20,Actual,3/23/2020,Aug-21,8/31/2021,7-Jun-20,Actual,6/7/2020,7-May-20,Actual,5/7/2020,NA,Interventional,CloroCOVID19,NA,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Completed,NA,Phase 2,278,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2021-10-12T07:22:15Z,2021-10-12T07:22:15Z
NCT04324489,NA,3/25/2020,NA,NA,5/1/2020,3/25/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/1/2020,5/5/2020,Actual,6-Mar-20,Actual,3/6/2020,May-20,5/31/2020,30-Apr-20,Actual,4/30/2020,16-Apr-20,Actual,4/16/2020,NA,Interventional,NA,NA,DAS181 for Severe COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Completed,NA,Not Applicable,4,Actual,Renmin Hospital of Wuhan University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:06Z,2021-10-12T07:22:06Z
NCT04323228,NA,3/23/2020,NA,NA,9/18/2020,3/24/2020,3/26/2020,Actual,NA,NA,NA,NA,NA,NA,9/18/2020,9/22/2020,Actual,1-Sep-20,Actual,9/1/2020,Sep-20,9/30/2020,30-Dec-20,Anticipated,12/30/2020,1-Dec-20,Anticipated,12/1/2020,NA,Interventional,ONSCOVID19,NA,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 2/Phase 3,40,Anticipated,King Saud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,starting 6 months after publication.,Access will be available for any researcher interested in this type of research on considerable consent.,NA,Yes,all IPD that underlie results in a publication will be shared,2021-10-12T07:22:19Z,2021-10-12T07:22:19Z
NCT04318444,NA,3/20/2020,NA,NA,4/23/2020,3/20/2020,3/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/23/2020,4/27/2020,Actual,29-Mar-20,Actual,3/29/2020,Apr-20,4/30/2020,Mar-22,Anticipated,3/31/2022,Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:53Z,2021-10-12T07:22:53Z
NCT04324073,NA,3/25/2020,NA,NA,4/14/2020,3/25/2020,3/27/2020,Actual,NA,NA,NA,NA,NA,NA,4/14/2020,4/15/2020,Actual,27-Mar-20,Actual,3/27/2020,Mar-20,3/31/2020,31-Dec-21,Anticipated,12/31/2021,27-Mar-21,Anticipated,3/27/2021,NA,Interventional,CORIMUNO-SARI,NA,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",NA,Phase 2/Phase 3,239,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:22:11Z,2021-10-12T07:22:11Z
NCT04321993,NA,3/24/2020,NA,NA,7/22/2020,3/24/2020,3/26/2020,Actual,NA,NA,NA,NA,NA,NA,7/22/2020,7/24/2020,Actual,17-Apr-20,Actual,4/17/2020,Jul-20,7/31/2020,Mar-22,Anticipated,3/31/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,NA,Phase 2,800,Anticipated,Nova Scotia Health Authority,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:27Z,2021-10-12T07:22:27Z
NCT04319731,NA,3/22/2020,NA,NA,4/15/2020,3/22/2020,3/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/15/2020,4/17/2020,Actual,20-Mar-20,Actual,3/20/2020,Apr-20,4/30/2020,20-Mar-21,Anticipated,3/20/2021,20-Mar-21,Anticipated,3/20/2021,NA,Interventional,NA,NA,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,NA,Early Phase 1,10,Anticipated,University of Utah,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:47Z,2021-10-12T07:22:47Z
NCT04321421,NA,3/23/2020,NA,NA,5/27/2020,3/23/2020,3/25/2020,Actual,NA,NA,NA,NA,NA,NA,5/27/2020,5/28/2020,Actual,17-Mar-20,Actual,3/17/2020,May-20,5/31/2020,7-May-20,Actual,5/7/2020,28-Apr-20,Actual,4/28/2020,NA,Interventional,COV19-PLASMA,NA,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,Completed,NA,Not Applicable,49,Actual,Foundation IRCCS San Matteo Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,will be decided,2021-10-12T07:22:33Z,2021-10-12T07:22:33Z
NCT04321616,NA,3/23/2020,NA,NA,4/10/2020,3/24/2020,3/25/2020,Actual,NA,NA,NA,NA,NA,NA,4/10/2020,4/14/2020,Actual,28-Mar-20,Actual,3/28/2020,Apr-20,4/30/2020,Nov-20,Anticipated,11/30/2020,Aug-20,Anticipated,8/31/2020,NA,Interventional,NA,NA,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients,Recruiting,NA,Phase 2/Phase 3,700,Anticipated,Oslo University Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The study will end according the requirements to WHO,WHO COVID 19 investigators,NA,Yes,All patients included in this study will automatically be included in the WHO COVID 19 protocol,2021-10-12T07:22:30Z,2021-10-12T07:22:30Z
NCT04321096,NA,3/23/2020,NA,NA,4/27/2021,3/24/2020,3/25/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/30/2021,Actual,4-Apr-20,Actual,4/4/2020,Apr-21,4/30/2021,1-May-22,Anticipated,5/1/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,CamoCO-19,NA,The Impact of Camostat Mesilate on COVID-19 Infection,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial",Recruiting,NA,Phase 1/Phase 2,580,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposals should be addressed to olesoega@rm.dk.,NA,Yes,"Data sharing plan: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan). Data will become available following publication with no planned end date.",2021-10-12T07:22:35Z,2021-10-12T07:22:35Z
NCT04323345,NA,3/23/2020,NA,NA,4/18/2020,3/24/2020,3/26/2020,Actual,NA,NA,NA,NA,NA,NA,4/18/2020,4/21/2020,Actual,15-Apr-20,Anticipated,4/15/2020,Apr-20,4/30/2020,15-Jan-21,Anticipated,1/15/2021,15-Dec-20,Anticipated,12/15/2020,NA,Interventional,NA,NA,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial",Recruiting,NA,Phase 3,1000,Anticipated,Misr University for Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:15Z,2021-10-12T07:22:15Z
NCT04323514,NA,3/18/2020,NA,NA,3/24/2020,3/24/2020,3/26/2020,Actual,NA,NA,NA,NA,NA,NA,3/24/2020,3/26/2020,Actual,13-Mar-20,Actual,3/13/2020,Mar-20,3/31/2020,13-Mar-21,Anticipated,3/13/2021,13-Mar-21,Anticipated,3/13/2021,NA,Interventional,NA,NA,Use of Ascorbic Acid in Patients With COVID 19,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,NA,Not Applicable,500,Anticipated,University of Palermo,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:15Z,2021-10-12T07:22:15Z
NCT04319900,NA,3/20/2020,NA,NA,3/22/2020,3/22/2020,3/24/2020,Actual,NA,NA,NA,NA,NA,NA,3/22/2020,3/24/2020,Actual,5-Mar-20,Actual,3/5/2020,Mar-20,3/31/2020,25-Jun-20,Anticipated,6/25/2020,30-Apr-20,Anticipated,4/30/2020,NA,Interventional,NA,NA,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,Beijing Chao Yang Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:44Z,2021-10-12T07:22:44Z
NCT04322123,NA,3/24/2020,NA,NA,4/15/2021,3/24/2020,3/26/2020,Actual,NA,NA,NA,NA,NA,NA,4/15/2021,4/19/2021,Actual,1-Apr-20,Actual,4/1/2020,Apr-21,4/30/2021,30-Aug-21,Anticipated,8/30/2021,30-Aug-20,Actual,8/30/2020,NA,Interventional,Coalition-I,NA,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients","Active, not recruiting",NA,Phase 3,630,Anticipated,Hospital do Coracao,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:26Z,2021-10-12T07:22:26Z
NCT04318015,NA,3/19/2020,NA,NA,4/15/2020,3/19/2020,3/23/2020,Actual,NA,NA,NA,NA,NA,NA,4/15/2020,4/17/2020,Actual,14-Apr-20,Actual,4/14/2020,Apr-20,4/30/2020,31-Mar-21,Anticipated,3/31/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,PHYDRA,NA,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial),Recruiting,NA,Phase 3,400,Anticipated,"National Institute of Respiratory Diseases, Mexico",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:58Z,2021-10-12T07:22:58Z
NCT04319445,NA,3/20/2020,NA,NA,4/30/2021,3/23/2020,3/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/30/2021,5/6/2021,Actual,22-Mar-20,Actual,3/22/2020,Mar-21,3/31/2021,30-Mar-21,Actual,3/30/2021,31-Aug-20,Actual,8/31/2020,NA,Interventional,NA,NA,Mindfulness During COVID-19,Mindfulness During COVID-19 - Remote Mindfulness Sessions,Completed,NA,Not Applicable,233,Actual,Wake Forest University Health Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:49Z,2021-10-12T07:22:49Z
NCT04320238,NA,3/21/2020,NA,NA,3/30/2020,3/21/2020,3/24/2020,Actual,NA,NA,NA,NA,NA,NA,3/30/2020,3/31/2020,Actual,21-Jan-20,Actual,1/21/2020,Mar-20,3/31/2020,Jun-20,Anticipated,6/30/2020,May-20,Anticipated,5/31/2020,NA,Interventional,NA,NA,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area,Recruiting,NA,Phase 3,2944,Anticipated,Shanghai Jiao Tong University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:41Z,2021-10-12T07:22:41Z
NCT04316377,NA,3/13/2020,NA,NA,6/4/2020,3/18/2020,3/20/2020,Actual,NA,NA,NA,NA,NA,NA,6/4/2020,6/5/2020,Actual,25-Mar-20,Actual,3/25/2020,Jun-20,6/30/2020,3-Mar-25,Anticipated,3/3/2025,25-May-20,Actual,5/25/2020,NA,Interventional,NO COVID-19,NA,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,"Active, not recruiting",NA,Phase 4,53,Actual,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:23:09Z,2021-10-12T07:23:09Z
NCT04313023,NA,3/16/2020,NA,NA,9/1/2021,3/16/2020,3/18/2020,Actual,NA,NA,NA,NA,NA,NA,9/1/2021,9/2/2021,Actual,9-Jun-20,Actual,6/9/2020,Sep-21,9/30/2021,31-Jul-21,Actual,7/31/2021,31-Jul-21,Actual,7/31/2021,NA,Interventional,NA,NA,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Completed,NA,Phase 2,217,Actual,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:38Z,2021-10-12T07:23:38Z
NCT04312243,NA,3/15/2020,NA,NA,3/8/2021,3/16/2020,3/18/2020,Actual,NA,NA,NA,NA,NA,NA,3/8/2021,3/10/2021,Actual,7-Apr-20,Actual,4/7/2020,Mar-21,3/31/2021,7-Apr-22,Anticipated,4/7/2022,7-Apr-21,Anticipated,4/7/2021,NA,Interventional,NOpreventCOVID,NA,NO Prevention of COVID-19 for Healthcare Providers,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers,"Active, not recruiting",NA,Phase 2,24,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:42Z,2021-10-12T07:23:42Z
NCT04320056,NA,3/19/2020,NA,NA,4/20/2020,3/23/2020,3/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/20/2020,4/21/2020,Actual,20-Apr-20,Actual,4/20/2020,Apr-20,4/30/2020,31-Oct-21,Anticipated,10/31/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia),Recruiting,NA,Not Applicable,216,Anticipated,Laval University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No There is not plan to share individual participant data. All data if shared with be de-identified. Data will be stored on a secure server with access only by study personal.,2021-10-12T07:22:43Z,2021-10-12T07:22:43Z
NCT04321928,NA,3/20/2020,NA,NA,6/5/2020,3/23/2020,3/25/2020,Actual,NA,NA,NA,NA,NA,NA,6/5/2020,6/9/2020,Actual,1-Apr-20,Actual,4/1/2020,Jun-20,6/30/2020,21-Aug-21,Anticipated,8/21/2021,21-Apr-21,Anticipated,4/21/2021,NA,Interventional,PROACTIVE-19,NA,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19),Recruiting,NA,Not Applicable,7576,Anticipated,University of Pecs,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:28Z,2021-10-12T07:22:28Z
NCT04321278,NA,3/23/2020,NA,NA,1/15/2021,3/23/2020,3/25/2020,Actual,NA,NA,NA,NA,NA,NA,1/15/2021,1/20/2021,Actual,28-Mar-20,Actual,3/28/2020,Mar-20,3/31/2020,14-Jun-20,Actual,6/14/2020,14-Jun-20,Actual,6/14/2020,NA,Interventional,NA,NA,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients,Completed,NA,Phase 3,440,Actual,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:34Z,2021-10-12T07:22:34Z
NCT04318431,NA,3/20/2020,NA,NA,7/8/2020,3/23/2020,3/24/2020,Actual,NA,NA,NA,NA,NA,NA,7/8/2020,7/9/2020,Actual,14-Apr-20,Actual,4/14/2020,Jul-20,7/31/2020,1-Jun-20,Actual,6/1/2020,12-May-20,Actual,5/12/2020,NA,Interventional,COVILLE,NA,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.",Completed,NA,Not Applicable,605,Actual,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:54Z,2021-10-12T07:22:54Z
NCT04315896,NA,3/18/2020,NA,NA,7/24/2020,3/18/2020,3/20/2020,Actual,NA,NA,NA,NA,NA,NA,7/24/2020,7/27/2020,Actual,14-Apr-20,Actual,4/14/2020,Jul-20,7/31/2020,15-Aug-20,Anticipated,8/15/2020,1-Jul-20,Actual,7/1/2020,NA,Interventional,HYDRA,NA,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),"Active, not recruiting",NA,Phase 3,500,Anticipated,"National Institute of Respiratory Diseases, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,As requested by other investigators.,2021-10-12T07:23:16Z,2021-10-12T07:23:16Z
NCT04317092,NA,3/19/2020,NA,NA,3/2/2021,3/19/2020,3/20/2020,Actual,NA,NA,NA,NA,NA,NA,3/2/2021,3/3/2021,Actual,19-Mar-20,Actual,3/19/2020,Oct-20,10/31/2020,19-Dec-22,Anticipated,12/19/2022,19-Dec-21,Anticipated,12/19/2021,NA,Interventional,TOCIVID-19,NA,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia,"Active, not recruiting",NA,Phase 2,402,Actual,"National Cancer Institute, Naples",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"After peer-reviewed publication of the primary results, with no time limits",Motivated requests to access to IPD are to be sent by email to the Principal Investigator (f.perrone@istitutotumori.na.it),NA,Yes,"Data will be shared upon reasonable request to the Principal Investigator of the study

The following IPD will be available for sharing:

Baseline characteristics of patients
Treatment data
Safety data
Follow-up data",2021-10-12T07:23:06Z,2021-10-12T07:23:06Z
NCT04315480,NA,3/14/2020,NA,NA,4/9/2020,3/18/2020,3/19/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2020,4/13/2020,Actual,12-Mar-20,Actual,3/12/2020,Apr-20,4/30/2020,May-20,Anticipated,5/31/2020,9-Apr-20,Anticipated,4/9/2020,NA,Interventional,NA,NA,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia,"Active, not recruiting",NA,Phase 2,38,Actual,UniversitÃ  Politecnica delle Marche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:16Z,2021-10-12T07:23:16Z
NCT04312997,NA,3/16/2020,NA,NA,7/14/2021,3/16/2020,3/18/2020,Actual,NA,NA,NA,NA,NA,NA,7/14/2021,7/16/2021,Actual,16-Jun-20,Actual,6/16/2020,Jul-21,7/31/2021,2-Jul-21,Actual,7/2/2021,2-Jul-21,Actual,7/2/2021,NA,Interventional,NA,NA,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Completed,NA,Phase 2,101,Actual,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:38Z,2021-10-12T07:23:38Z
NCT04313127,NA,3/15/2020,NA,NA,8/2/2021,3/17/2020,3/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/4/2021,Actual,16-Mar-20,Actual,3/16/2020,May-20,5/31/2020,20-Feb-21,Actual,2/20/2021,20-Jan-21,Actual,1/20/2021,NA,Interventional,CTCOVID-19,NA,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",Completed,NA,Phase 1,108,Actual,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2021-10-12T07:23:36Z,2021-10-12T07:23:36Z
NCT04311177,NA,3/13/2020,NA,NA,9/17/2021,3/13/2020,3/17/2020,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/24/2021,Actual,9-Apr-20,Actual,4/9/2020,Sep-21,9/30/2021,1-Feb-21,Actual,2/1/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,NA,NA,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,NA,Phase 2,162,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:53Z,2021-10-12T07:23:53Z
NCT04310228,NA,3/9/2020,NA,NA,4/8/2020,3/14/2020,3/17/2020,Actual,NA,NA,NA,NA,NA,NA,4/8/2020,4/10/2020,Actual,8-Mar-20,Actual,3/8/2020,Apr-20,4/30/2020,May-20,Anticipated,5/31/2020,May-20,Anticipated,5/31/2020,NA,Interventional,NA,NA,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study",Recruiting,NA,Not Applicable,150,Anticipated,Peking University First Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:23:57Z,2021-10-12T07:23:57Z
NCT04312009,NA,3/13/2020,NA,NA,8/16/2021,3/13/2020,3/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/18/2021,Actual,13-Apr-20,Actual,4/13/2020,Aug-21,8/31/2021,1-Feb-21,Actual,2/1/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,NA,NA,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,NA,Phase 2,205,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:46Z,2021-10-12T07:23:46Z
NCT04311697,NA,3/14/2020,NA,NA,9/5/2021,3/14/2020,3/17/2020,Actual,NA,NA,NA,NA,NA,NA,9/5/2021,9/13/2021,Actual,15-May-20,Actual,5/15/2020,Sep-21,9/30/2021,22-Feb-21,Actual,2/22/2021,22-Feb-21,Actual,2/22/2021,NA,Interventional,COVID-AIV,NA,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure,Completed,NA,Phase 2/Phase 3,196,Actual,"NeuroRx, Inc.",,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Currently available,Public access,NA,Yes,NeuroRx will share study protocol and statistical analysis plan upon request by qualified researchers,2021-10-12T07:23:49Z,2021-10-12T07:23:49Z
NCT04313322,NA,3/15/2020,NA,NA,3/15/2020,3/15/2020,3/18/2020,Actual,NA,NA,NA,NA,NA,NA,3/15/2020,3/18/2020,Actual,16-Mar-20,Anticipated,3/16/2020,Mar-20,3/31/2020,30-Sep-20,Anticipated,9/30/2020,30-Jun-20,Anticipated,6/30/2020,NA,Interventional,NA,NA,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,NA,Phase 1,5,Anticipated,Stem Cells Arabia,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:37Z,2021-10-12T07:23:37Z
NCT04306393,NA,3/10/2020,NA,NA,5/21/2021,3/10/2020,3/12/2020,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/25/2021,Actual,21-Mar-20,Actual,3/21/2020,May-21,5/31/2021,21-Dec-22,Anticipated,12/21/2022,21-Dec-21,Anticipated,12/21/2021,NA,Interventional,NOSARSCOVID,NA,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.,"Active, not recruiting",NA,Phase 2,200,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:24:29Z,2021-10-12T07:24:29Z
NCT04304313,NA,2/14/2020,NA,NA,3/14/2020,3/10/2020,3/11/2020,Actual,NA,NA,NA,NA,NA,NA,3/14/2020,3/17/2020,Actual,9-Feb-20,Actual,2/9/2020,Mar-20,3/31/2020,9-Nov-20,Anticipated,11/9/2020,1-Mar-20,Actual,3/1/2020,NA,Interventional,NA,NA,A Pilot Study of Sildenafil in COVID-19,A Pilot Study of Sildenafi in the Treatment of COVID-19,Recruiting,NA,Phase 3,10,Anticipated,Tongji Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:24:46Z,2021-10-12T07:24:46Z
NCT04305457,NA,3/9/2020,NA,NA,12/28/2020,3/11/2020,3/12/2020,Actual,NA,NA,NA,NA,NA,NA,12/28/2020,12/29/2020,Actual,21-Mar-20,Actual,3/21/2020,Dec-20,12/31/2020,1-Apr-22,Anticipated,4/1/2022,1-Apr-21,Anticipated,4/1/2021,NA,Interventional,NoCovid,NA,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,"Active, not recruiting",NA,Phase 2,70,Anticipated,Massachusetts General Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:24:37Z,2021-10-12T07:24:37Z
NCT04307693,NA,3/10/2020,NA,NA,5/25/2020,3/12/2020,3/13/2020,Actual,NA,NA,NA,NA,NA,NA,5/25/2020,5/27/2020,Actual,11-Mar-20,Actual,3/11/2020,May-20,5/31/2020,30-Apr-20,Actual,4/30/2020,30-Apr-20,Actual,4/30/2020,NA,Interventional,NA,NA,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,NA,Phase 2,65,Actual,Asan Medical Center,,3,NA,Terminated early because no patients were further enrolled since mid-Apr 2020.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:24:19Z,2021-10-12T07:24:19Z
NCT04306055,NA,3/8/2020,NA,NA,4/9/2020,3/10/2020,3/12/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2020,4/13/2020,Actual,13-Mar-20,Actual,3/13/2020,Apr-20,4/30/2020,3-Apr-20,Actual,4/3/2020,13-Mar-20,Actual,3/13/2020,NA,Interventional,NA,NA,Blood Donor Recruitment During Epidemic of COVID-19,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China",Completed,NA,Not Applicable,19491,Actual,Guangzhou Blood Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:24:31Z,2021-10-12T07:24:31Z
NCT04303299,NA,2/24/2020,NA,NA,8/28/2021,3/8/2020,3/11/2020,Actual,NA,NA,NA,NA,NA,NA,8/28/2021,9/2/2021,Actual,19-Aug-20,Actual,8/19/2020,Aug-21,8/31/2021,28-Aug-21,Actual,8/28/2021,28-Aug-21,Actual,8/28/2021,NA,Interventional,FIGHT-COVID-19,NA,Fight COVID-19 Trial,"A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19",Completed,NA,Phase 3,320,Actual,Rajavithi Hospital,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:24:52Z,2021-10-12T07:24:52Z
NCT04304053,NA,3/5/2020,NA,NA,6/26/2020,3/7/2020,3/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/26/2020,6/30/2020,Actual,18-Mar-20,Actual,3/18/2020,Jun-20,6/30/2020,15-Jun-20,Actual,6/15/2020,15-Jun-20,Actual,6/15/2020,NA,Interventional,HCQ4COV19,NA,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Completed,NA,Phase 3,2300,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,30 days after start of treatment,Open access for everybody,http://www.estudicovid19.org,Yes,Open access,2021-10-12T07:24:47Z,2021-10-12T07:24:47Z
NCT04308317,NA,3/4/2020,NA,NA,3/13/2020,3/13/2020,3/16/2020,Actual,NA,NA,NA,NA,NA,NA,3/13/2020,3/16/2020,Actual,5-Mar-20,Anticipated,3/5/2020,Mar-20,3/31/2020,1-May-21,Anticipated,5/1/2021,1-Mar-21,Anticipated,3/1/2021,NA,Interventional,TT-NPC,NA,Tetrandrine Tablets Used in the Treatment of COVID-19,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19,Enrolling by invitation,NA,Phase 4,60,Anticipated,Henan Provincial People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:24:14Z,2021-10-12T07:24:14Z
NCT04304690,NA,3/9/2020,NA,NA,11/30/2020,3/9/2020,3/11/2020,Actual,NA,NA,NA,NA,NA,NA,11/30/2020,12/1/2020,Actual,16-Mar-20,Actual,3/16/2020,Apr-20,4/30/2020,16-Oct-21,Anticipated,10/16/2021,16-May-21,Anticipated,5/16/2021,NA,Interventional,SEROCOV,NA,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic","Active, not recruiting",NA,Not Applicable,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:24:44Z,2021-10-12T07:24:44Z
NCT04305106,NA,3/9/2020,NA,NA,3/24/2020,3/9/2020,3/12/2020,Actual,NA,NA,NA,NA,NA,NA,3/24/2020,3/26/2020,Actual,17-Mar-20,Actual,3/17/2020,Mar-20,3/31/2020,31-Jul-20,Anticipated,7/31/2020,30-Jun-20,Anticipated,6/30/2020,NA,Interventional,BEST-RCT,NA,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial,Recruiting,NA,Not Applicable,140,Anticipated,Qilu Hospital of Shandong University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:24:41Z,2021-10-12T07:24:41Z
NCT04299724,NA,3/5/2020,NA,NA,3/6/2020,3/6/2020,3/9/2020,Actual,NA,NA,NA,NA,NA,NA,3/6/2020,3/9/2020,Actual,15-Feb-20,Actual,2/15/2020,Mar-20,3/31/2020,31-Dec-24,Anticipated,12/31/2024,31-Jul-23,Anticipated,7/31/2023,NA,Interventional,NA,NA,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:25:19Z,2021-10-12T07:25:19Z
NCT04303507,NA,3/6/2020,NA,NA,5/6/2021,3/10/2020,3/11/2020,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/11/2021,Actual,29-Apr-20,Actual,4/29/2020,Apr-21,4/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,COPCOV,NA,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Recruiting,NA,Not Applicable,40000,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2021-10-12T07:24:52Z,2021-10-12T07:24:52Z
NCT04296643,NA,3/3/2020,NA,NA,2/9/2021,3/3/2020,3/5/2020,Actual,NA,NA,NA,NA,NA,NA,2/9/2021,2/12/2021,Actual,1-Apr-20,Actual,4/1/2020,Mar-20,3/31/2020,1-Apr-21,Anticipated,4/1/2021,1-Feb-21,Anticipated,2/1/2021,NA,Interventional,NA,NA,Medical Masks vs N95 Respirators for COVID-19,Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial,Recruiting,NA,Not Applicable,576,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:25:42Z,2021-10-12T07:25:42Z
NCT04291729,NA,2/27/2020,NA,NA,4/9/2020,2/28/2020,3/2/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2020,4/13/2020,Actual,17-Feb-20,Actual,2/17/2020,Mar-20,3/31/2020,19-Mar-20,Actual,3/19/2020,19-Mar-20,Actual,3/19/2020,NA,Interventional,NA,NA,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:26:19Z,2021-10-12T07:26:19Z
NCT04288102,NA,2/24/2020,NA,NA,8/18/2020,2/25/2020,2/28/2020,Actual,NA,NA,NA,NA,NA,NA,8/18/2020,8/19/2020,Actual,5-Mar-20,Actual,3/5/2020,Aug-20,8/31/2020,9-Jul-20,Actual,7/9/2020,12-May-20,Actual,5/12/2020,NA,Interventional,NA,NA,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),"A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients",Completed,NA,Phase 2,100,Actual,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"After approval from the steering committee and the Human Genetic Resources Administration of China, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed.",2021-10-12T07:26:48Z,2021-10-12T07:26:48Z
NCT04279197,NA,2/15/2020,NA,NA,9/21/2020,2/19/2020,2/21/2020,Actual,NA,NA,NA,NA,NA,NA,9/21/2020,9/23/2020,Actual,23-Apr-20,Actual,4/23/2020,Sep-20,9/30/2020,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,The Efficacy of Treating Pulmonary Fibrosis and Pulmonary Function Injury in COVID-19 With the Fuzheng Huayu Tablets: a Multicenter Randomized Controlled Trial,Recruiting,NA,Phase 2,160,Anticipated,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:27:58Z,2021-10-12T07:27:58Z
NCT04282902,NA,2/10/2020,NA,NA,2/21/2020,2/21/2020,2/25/2020,Actual,NA,NA,NA,NA,NA,NA,2/21/2020,2/25/2020,Actual,4-Feb-20,Actual,2/4/2020,Feb-20,2/29/2020,1-Jun-20,Anticipated,6/1/2020,30-Apr-20,Anticipated,4/30/2020,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:27:26Z,2021-10-12T07:27:26Z
NCT04276896,NA,2/17/2020,NA,NA,3/17/2020,2/17/2020,2/19/2020,Actual,NA,NA,NA,NA,NA,NA,3/17/2020,3/19/2020,Actual,24-Mar-20,Anticipated,3/24/2020,Mar-20,3/31/2020,31-Dec-24,Anticipated,12/31/2024,31-Jul-23,Anticipated,7/31/2023,NA,Interventional,NA,NA,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:28:15Z,2021-10-12T07:28:15Z
NCT04280224,NA,2/13/2020,NA,NA,4/5/2021,2/20/2020,2/21/2020,Actual,NA,NA,NA,NA,NA,NA,4/5/2021,4/8/2021,Actual,15-Feb-20,Actual,2/15/2020,Dec-20,12/31/2020,30-Dec-22,Anticipated,12/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,NK Cells Treatment for COVID-19,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:27:50Z,2021-10-12T07:27:50Z
NCT04276987,NA,2/16/2020,NA,NA,9/3/2020,2/18/2020,2/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/3/2020,9/7/2020,Actual,15-Feb-20,Actual,2/15/2020,Sep-20,9/30/2020,31-Jul-20,Actual,7/31/2020,31-May-20,Actual,5/31/2020,NA,Interventional,NA,NA,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Completed,NA,Phase 1,24,Actual,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2021-10-12T07:28:15Z,2021-10-12T07:28:15Z
NCT04276688,NA,2/11/2020,NA,NA,4/13/2020,2/17/2020,2/19/2020,Actual,NA,NA,NA,NA,NA,NA,4/13/2020,4/15/2020,Actual,10-Feb-20,Actual,2/10/2020,Apr-20,4/30/2020,31-Mar-20,Actual,3/31/2020,30-Mar-20,Actual,3/30/2020,NA,Interventional,NA,NA,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:28:15Z,2021-10-12T07:28:15Z
NCT04275414,NA,2/14/2020,NA,NA,9/10/2020,2/16/2020,2/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/10/2020,9/14/2020,Actual,15-Feb-20,Actual,2/15/2020,Feb-20,2/29/2020,2-May-20,Actual,5/2/2020,5-Apr-20,Actual,4/5/2020,NA,Interventional,BEST-CP,NA,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP),Completed,NA,Phase 2,27,Actual,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:28:24Z,2021-10-12T07:28:24Z
NCT04275245,NA,2/6/2020,NA,NA,4/7/2021,2/16/2020,2/19/2020,Actual,NA,NA,NA,NA,NA,NA,4/7/2021,4/9/2021,Actual,3-Feb-20,Actual,2/3/2020,Apr-21,4/30/2021,9-Mar-20,Actual,3/9/2020,9-Mar-20,Actual,3/9/2020,NA,Interventional,NA,NA,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Completed,NA,Phase 1/Phase 2,17,Actual,Tang-Du Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:28:28Z,2021-10-12T07:28:28Z
NCT04269525,NA,2/7/2020,NA,NA,6/29/2020,2/12/2020,2/13/2020,Actual,NA,NA,NA,NA,NA,NA,6/29/2020,7/1/2020,Actual,6-Feb-20,Actual,2/6/2020,Jun-20,6/30/2020,30-Dec-20,Anticipated,12/30/2020,1-Dec-20,Anticipated,12/1/2020,NA,Interventional,NA,NA,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection,Recruiting,NA,Phase 2,16,Anticipated,Zhongnan Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:29:09Z,2021-10-12T07:29:09Z
NCT04273763,NA,2/14/2020,NA,NA,4/29/2020,2/14/2020,2/18/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2020,5/1/2020,Actual,16-Feb-20,Actual,2/16/2020,Apr-20,4/30/2020,1-Jun-20,Anticipated,6/1/2020,10-May-20,Anticipated,5/10/2020,NA,Interventional,NA,NA,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",NA,Not Applicable,18,Actual,Second Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:28:38Z,2021-10-12T07:28:38Z
NCT04273321,NA,2/15/2020,NA,NA,5/8/2020,2/17/2020,2/18/2020,Actual,NA,NA,NA,NA,NA,NA,5/8/2020,5/11/2020,Actual,14-Feb-20,Actual,2/14/2020,Apr-20,4/30/2020,15-Apr-20,Actual,4/15/2020,15-Apr-20,Actual,4/15/2020,NA,Interventional,NA,NA,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Completed,NA,Not Applicable,86,Actual,Beijing Chao Yang Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:28:40Z,2021-10-12T07:28:40Z
NCT04263402,NA,2/2/2020,NA,NA,3/14/2020,2/7/2020,2/10/2020,Actual,NA,NA,NA,NA,NA,NA,3/14/2020,3/17/2020,Actual,1-Feb-20,Actual,2/1/2020,Mar-20,3/31/2020,1-Jul-20,Anticipated,7/1/2020,1-Jun-20,Anticipated,6/1/2020,NA,Interventional,NA,NA,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:30:01Z,2021-10-12T07:30:01Z
NCT04264533,NA,2/4/2020,NA,NA,10/8/2020,2/8/2020,2/11/2020,Actual,NA,NA,NA,NA,NA,NA,10/8/2020,10/12/2020,Actual,14-Feb-20,Actual,2/14/2020,Oct-20,10/31/2020,29-Mar-20,Actual,3/29/2020,2-Mar-20,Actual,3/2/2020,NA,Interventional,NA,NA,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial,Terminated,NA,Phase 2,56,Actual,Zhongnan Hospital,,2,NA,"the study was started in the second half of the outbreak, and the number of qualifying COVID-19 patients decreased with the control of the epidemic so that we had to stop our trial before reaching the predefined sample size.",FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:29:51Z,2021-10-12T07:29:51Z
NCT04261270,NA,2/4/2020,NA,NA,3/14/2020,2/6/2020,2/7/2020,Actual,NA,NA,NA,NA,NA,NA,3/14/2020,3/17/2020,Actual,1-Feb-20,Actual,2/1/2020,Mar-20,3/31/2020,1-Jul-20,Anticipated,7/1/2020,1-May-20,Anticipated,5/1/2020,NA,Interventional,NA,NA,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia",Recruiting,NA,Phase 3,60,Anticipated,Tongji Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:30:26Z,2021-10-12T07:30:26Z
NCT04261517,NA,2/6/2020,NA,NA,4/9/2020,2/6/2020,2/7/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2020,4/13/2020,Actual,6-Feb-20,Actual,2/6/2020,Apr-20,4/30/2020,25-Feb-20,Actual,2/25/2020,25-Feb-20,Actual,2/25/2020,NA,Interventional,NA,NA,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:30:25Z,2021-10-12T07:30:25Z
NCT04252118,NA,1/27/2020,NA,NA,4/13/2020,1/30/2020,2/5/2020,Actual,NA,NA,NA,NA,NA,NA,4/13/2020,4/15/2020,Actual,27-Jan-20,Actual,1/27/2020,Apr-20,4/30/2020,Dec-21,Anticipated,12/31/2021,Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19,Recruiting,NA,Phase 1,20,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:31:38Z,2021-10-12T07:31:38Z
NCT04260594,NA,2/6/2020,NA,NA,9/6/2021,2/6/2020,2/7/2020,Actual,NA,NA,NA,NA,NA,NA,9/6/2021,9/8/2021,Actual,8-Feb-20,Actual,2/8/2020,Sep-21,9/30/2021,30-Dec-20,Actual,12/30/2020,12-Mar-20,Actual,3/12/2020,NA,Interventional,NA,NA,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).",Completed,NA,Phase 4,236,Actual,Ruijin Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:30:31Z,2021-10-12T07:30:31Z
NCT04257656,NA,1/31/2020,NA,NA,4/13/2020,2/3/2020,2/6/2020,Actual,NA,NA,NA,NA,NA,NA,4/13/2020,4/15/2020,Actual,6-Feb-20,Actual,2/6/2020,Apr-20,4/30/2020,10-Apr-20,Actual,4/10/2020,30-Mar-20,Actual,3/30/2020,NA,Interventional,NA,NA,A Trial of Remdesivir in Adults With Severe COVID-19,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.",Terminated,NA,Phase 3,237,Actual,Capital Medical University,,2,NA,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be enrolled at present.",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:30:57Z,2021-10-12T07:30:57Z
NCT04252274,NA,1/29/2020,NA,NA,4/9/2020,1/31/2020,2/5/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2020,4/13/2020,Actual,30-Jan-20,Actual,1/30/2020,Apr-20,4/30/2020,31-Dec-20,Anticipated,12/31/2020,31-Aug-20,Anticipated,8/31/2020,NA,Interventional,DC-COVID-19,NA,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,NA,Phase 3,30,Anticipated,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:31:38Z,2021-10-12T07:31:38Z
NCT04252885,NA,1/30/2020,NA,NA,6/29/2020,1/31/2020,2/5/2020,Actual,NA,NA,NA,NA,NA,NA,6/29/2020,7/1/2020,Actual,28-Jan-20,Actual,1/28/2020,Jun-20,6/30/2020,31-May-20,Actual,5/31/2020,30-Apr-20,Actual,4/30/2020,NA,Interventional,ELACOI,NA,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Completed,NA,Phase 4,86,Actual,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:31:35Z,2021-10-12T07:31:35Z
NCT04255017,NA,2/2/2020,NA,NA,3/14/2020,2/2/2020,2/5/2020,Actual,NA,NA,NA,NA,NA,NA,3/14/2020,3/17/2020,Actual,1-Feb-20,Actual,2/1/2020,Mar-20,3/31/2020,1-Jul-20,Anticipated,7/1/2020,1-Jun-20,Anticipated,6/1/2020,NA,Interventional,NA,NA,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,400,Anticipated,Tongji Hospital,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:31:15Z,2021-10-12T07:31:15Z
NCT04254874,NA,2/2/2020,NA,NA,3/14/2020,2/2/2020,2/5/2020,Actual,NA,NA,NA,NA,NA,NA,3/14/2020,3/17/2020,Actual,1-Feb-20,Actual,2/1/2020,Mar-20,3/31/2020,1-Jul-20,Anticipated,7/1/2020,1-Jun-20,Anticipated,6/1/2020,NA,Interventional,NA,NA,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:31:16Z,2021-10-12T07:31:16Z
NCT05075304,NA,8/22/2021,NA,NA,10/8/2021,10/8/2021,10/12/2021,Estimate,NA,NA,NA,NA,NA,NA,10/8/2021,10/12/2021,Estimate,21-Feb-20,Actual,2/21/2020,Aug-21,8/31/2021,14-Apr-20,Actual,4/14/2020,14-Apr-20,Actual,4/14/2020,NA,Interventional,NA,NA,"A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients","A Phase Ib, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BDB-001 Injection in Patients With Novel Coronavirus (2019-nCoV) Infection",Completed,NA,Phase 1,18,Actual,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T17:59:42Z,2021-10-12T17:59:42Z
NCT04251871,NA,1/28/2020,NA,NA,5/4/2020,1/30/2020,2/5/2020,Actual,NA,NA,NA,NA,NA,NA,5/4/2020,5/5/2020,Actual,22-Jan-20,Actual,1/22/2020,May-20,5/31/2020,22-Jan-21,Anticipated,1/22/2021,22-Jan-21,Anticipated,1/22/2021,NA,Interventional,NA,NA,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,"Effects of Traditional Chinese Medicines (TCMs) on Patients With COVID-19 Infection: A Perspective, Open-labeled, Randomized, Controlled Trial",Recruiting,NA,Not Applicable,150,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:31:41Z,2021-10-12T07:31:41Z
NCT04244591,NA,1/23/2020,NA,NA,6/13/2020,1/25/2020,1/28/2020,Actual,NA,NA,NA,NA,NA,NA,6/13/2020,6/16/2020,Actual,26-Jan-20,Actual,1/26/2020,Feb-20,2/29/2020,13-Apr-20,Actual,4/13/2020,13-Apr-20,Actual,4/13/2020,NA,Interventional,NA,NA,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial",Completed,NA,Phase 2/Phase 3,80,Actual,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:32:36Z,2021-10-12T07:32:36Z
NCT05075499,NA,10/6/2021,NA,NA,10/6/2021,10/6/2021,10/12/2021,Estimate,NA,NA,NA,NA,NA,NA,10/6/2021,10/12/2021,Estimate,20-Mar-21,Actual,3/20/2021,Oct-21,10/31/2021,Sep-22,Anticipated,9/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab,LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED WITH TERIFLUNOMIDE (AUBAGIO) OR ALEMTUZUMAB (LEMTRADA),Recruiting,NA,Not Applicable,70,Anticipated,Sheba Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T17:59:42Z,2021-10-12T17:59:42Z
NCT04667247,NA,12/3/2020,NA,NA,10/11/2021,12/11/2020,12/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/11/2021,10/12/2021,Estimate,3-Dec-20,Actual,12/3/2020,Oct-21,10/31/2021,1-Dec-22,Anticipated,12/1/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,MACH19,NA,Mushroom-based Product for COVID-19,"Multicenter Double Blind, Placebo Controlled RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19",Recruiting,NA,Phase 1/Phase 2,66,Anticipated,"University of California, San Diego",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:00:42Z,2021-10-12T18:00:42Z
NCT05004805,NA,8/11/2021,NA,NA,10/11/2021,8/11/2021,8/13/2021,Actual,NA,NA,NA,NA,NA,NA,10/11/2021,10/12/2021,Estimate,6-Aug-21,Actual,8/6/2021,Oct-21,10/31/2021,8-Nov-21,Anticipated,11/8/2021,25-Oct-21,Anticipated,10/25/2021,NA,Interventional,COMBAT,NA,COVID-19 Methylene Blue Antiviral Treatment,COVID-19 Methylene Blue Antiviral Treatment,"Active, not recruiting",NA,Phase 2,24,Actual,Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T18:00:11Z,2021-10-12T18:00:11Z
NCT04962022,NA,7/10/2021,NA,NA,10/11/2021,7/10/2021,7/14/2021,Actual,NA,NA,NA,NA,NA,NA,10/11/2021,10/12/2021,Estimate,20-Jul-21,Actual,7/20/2021,Oct-21,10/31/2021,30-Sep-21,Actual,9/30/2021,30-Sep-21,Actual,9/30/2021,NA,Interventional,NA,NA,Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants,"COVID-19: A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF PF-07321332/RITONAVIR IN HEALTHY PARTICIPANTS",Completed,NA,Phase 1,12,Actual,Pfizer,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-12T18:00:17Z,2021-10-12T18:00:17Z
NCT05074368,NA,8/24/2021,NA,NA,10/5/2021,10/5/2021,10/12/2021,Estimate,NA,NA,NA,NA,NA,NA,10/5/2021,10/12/2021,Estimate,6-Jul-21,Actual,7/6/2021,Oct-21,10/31/2021,30-Jun-22,Anticipated,6/30/2022,19-Nov-21,Anticipated,11/19/2021,NA,Interventional,NA,NA,Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination,Comparative Analysis of Neutralizing Antibody Response Among Heterologous ChAdOx1-nCov-19/mRNA-1273 Vaccination and Homologous ChAdOx1-nCov-19 or Homologous mRNA-1273 Vaccination,"Active, not recruiting",NA,Not Applicable,500,Anticipated,National Taiwan University Hospital,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T17:59:53Z,2021-10-12T17:59:53Z
NCT05074979,NA,10/3/2021,NA,NA,10/8/2021,10/8/2021,10/12/2021,Estimate,NA,NA,NA,NA,NA,NA,10/8/2021,10/12/2021,Estimate,20-Oct-21,Anticipated,10/20/2021,Oct-21,10/31/2021,1-Aug-22,Anticipated,8/1/2022,1-Apr-22,Anticipated,4/1/2022,NA,Interventional,NA,NA,Telerehabilitation in COVID-19 Survivors,Determining the Effectiveness of Telerehabilitation in COVID-19 Survivors,Recruiting,NA,Not Applicable,45,Anticipated,BandÄ±rma Onyedi EylÃ¼l University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T17:59:48Z,2021-10-12T17:59:48Z
NCT04427501,NA,6/9/2020,NA,NA,10/11/2021,6/11/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,10/11/2021,10/12/2021,Estimate,17-Jun-20,Actual,6/17/2020,1-Oct-21,10/1/2021,17-Dec-21,Anticipated,12/17/2021,16-Feb-21,Actual,2/16/2021,NA,Interventional,BLAZE-1,NA,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,"A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness","Active, not recruiting",NA,Phase 2/Phase 3,3290,Anticipated,Eli Lilly and Company,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,NA,2021-10-12T18:01:06Z,2021-10-12T18:01:06Z
NCT04521296,NA,7/7/2020,NA,NA,10/5/2021,8/19/2020,8/20/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/12/2021,Estimate,11-Sep-20,Actual,9/11/2020,Oct-21,10/31/2021,Dec-22,Anticipated,12/31/2022,17-Dec-20,Actual,12/17/2020,NA,Interventional,NA,NA,Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo,"A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase II/III Study to Evaluate the Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19","Active, not recruiting",NA,Phase 2/Phase 3,428,Anticipated,Daewoong Pharmaceutical Co. LTD.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:00:57Z,2021-10-12T18:00:57Z
NCT04449588,NA,6/26/2020,NA,NA,10/11/2021,6/26/2020,6/29/2020,Actual,NA,NA,NA,NA,NA,NA,10/11/2021,10/12/2021,Estimate,23-Jul-20,Actual,7/23/2020,Feb-21,2/28/2021,7-Aug-22,Anticipated,8/7/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,"A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III",Recruiting,NA,Phase 2/Phase 3,368,Anticipated,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:01:03Z,2021-10-12T18:01:03Z
NCT04431466,NA,6/10/2020,NA,NA,10/7/2021,6/11/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,10/7/2021,10/12/2021,Estimate,1-Jul-20,Actual,7/1/2020,Oct-21,10/31/2021,1-Dec-20,Actual,12/1/2020,1-Dec-20,Actual,12/1/2020,NA,Interventional,IFORS,NA,A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2),Terminated,NA,Phase 2,32,Actual,Universidade Federal de Sao Carlos,,4,NA,"Preliminary data from a pilot study suggest that the administration of ivermectin in patients with SARS-CoV-2 is safe, reducing symptoms and viral load. The antiviral effects of ivermectin appear to depend on the dose administered.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:01:05Z,2021-10-12T18:01:05Z
NCT04542408,NA,9/6/2020,NA,NA,10/11/2021,9/6/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/11/2021,10/12/2021,Estimate,12-Nov-20,Actual,11/12/2020,Oct-21,10/31/2021,Sep-22,Anticipated,9/30/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,HERO-19,NA,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Recruiting,NA,Phase 3,172,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:00:54Z,2021-10-12T18:00:54Z
NCT04830033,NA,3/31/2021,NA,NA,11/22/2021,3/31/2021,4/2/2021,Actual,NA,NA,NA,NA,NA,NA,11/22/2021,12/3/2021,Estimate,28-Apr-21,Actual,4/28/2021,Nov-21,11/30/2021,23-Sep-21,Actual,9/23/2021,23-Sep-21,Actual,9/23/2021,NA,Interventional,SHIELD ENO,NA,ENO Breathe vs Usual Care in COVID-19 Recovery,A Randomised Controlled Trial of the English National Opera Breathe Programme Compared With Usual Care in People Recovering From COVID-19,Completed,NA,Not Applicable,153,Actual,Imperial College London,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"The data will be available from the date of publication of the main study, and will remain available for at least 2 years.",Data will be shared on reasonable request.,NA,Yes,Data will be shared on reasonable request.,2021-12-06T10:34:53Z,2021-12-06T10:34:53Z
NCT04980326,NA,7/16/2021,NA,NA,11/22/2021,7/18/2021,7/28/2021,Actual,NA,NA,NA,NA,NA,NA,11/22/2021,12/3/2021,Estimate,1-Nov-21,Actual,11/1/2021,Nov-21,11/30/2021,31-Aug-22,Anticipated,8/31/2022,31-Aug-22,Anticipated,8/31/2022,NA,Interventional,RESPOND-HCW,NA,A Scalable Psychological Intervention to Reduce Psychological Distress Among Healthcare Workers,A Scalable Low-intensity Psychological Intervention to Reduce Psychological Distress Among Healthcare Workers Involved in the First COVID-19 Outbreak in Spain: a Randomized Trial,Recruiting,NA,Not Applicable,212,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-06T10:31:37Z,2021-12-06T10:31:37Z
NCT05143372,NA,11/22/2021,NA,NA,11/22/2021,11/22/2021,12/3/2021,Estimate,NA,NA,NA,NA,NA,NA,11/22/2021,12/3/2021,Estimate,9-Nov-21,Actual,11/9/2021,Nov-21,11/30/2021,1-Jul-22,Anticipated,7/1/2022,1-Jun-22,Anticipated,6/1/2022,NA,Interventional,NA,NA,Influence of Vibroacoustic Therapy Modes on the Course of Coronavirus Infection,The Effect of Various Modes of Vibroacoustic Therapy on the Course of Coronavirus Infection Complicated by Acute Respiratory Failure.,Recruiting,NA,Not Applicable,80,Anticipated,Astana Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-06T10:26:32Z,2021-12-06T10:26:32Z
NCT05118737,NA,11/11/2021,NA,NA,11/22/2021,11/11/2021,11/12/2021,Actual,NA,NA,NA,NA,NA,NA,11/22/2021,12/3/2021,Estimate,1-Oct-21,Actual,10/1/2021,Oct-21,10/31/2021,30-Aug-22,Anticipated,8/30/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.,Adding Colchicine to Tocilizumab in Hospitalized Patients With Severe COVID-19 Pneumonia: An Open-Label Randomized Controlled Trial,Recruiting,NA,Early Phase 1,230,Anticipated,Hamad Medical Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Not allowed as per organization rules for researches with informed consents,2021-12-06T10:28:18Z,2021-12-06T10:28:18Z
NCT04776317,NA,2/25/2021,NA,NA,12/2/2021,2/25/2021,3/1/2021,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/3/2021,Estimate,25-Mar-21,Actual,3/25/2021,17-Aug-21,8/17/2021,19-Sep-22,Anticipated,9/19/2022,19-Sep-22,Anticipated,9/19/2022,NA,Interventional,NA,NA,Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults,"A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults",Recruiting,NA,Phase 1,147,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,17,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-06T10:35:55Z,2021-12-06T10:35:55Z
NCT04821674,NA,3/25/2021,NA,NA,12/2/2021,3/25/2021,3/29/2021,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/3/2021,Estimate,15-Mar-21,Actual,3/15/2021,Dec-21,12/31/2021,31-Dec-22,Anticipated,12/31/2022,13-Aug-21,Actual,8/13/2021,NA,Interventional,NA,NA,Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects,"A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects","Active, not recruiting",NA,Phase 1/Phase 2,152,Anticipated,"Daiichi Sankyo, Inc.",,10,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T10:35:01Z,2021-12-06T10:35:01Z
NCT04628039,NA,11/9/2020,NA,NA,12/2/2021,11/12/2020,11/13/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/3/2021,Estimate,28-May-21,Actual,5/28/2021,Dec-21,12/31/2021,31-Oct-24,Anticipated,10/31/2024,31-Dec-23,Anticipated,12/31/2023,NA,Interventional,LAUREL,NA,"Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs","Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs (LAUREL Study)",Recruiting,NA,Not Applicable,476,Anticipated,VA Office of Research and Development,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-06T10:39:28Z,2021-12-06T10:39:28Z
NCT04707664,NA,1/11/2021,NA,NA,12/2/2021,1/11/2021,1/13/2021,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/3/2021,Estimate,27-Apr-21,Actual,4/27/2021,Dec-21,12/31/2021,Jan-22,Anticipated,1/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,SCOPE,NA,Sargramostim Use in COVID-19 to Recover Patient Health,A Randomized Phase 2b Trial Evaluating Clinical Outcomes of Inhaled Sargramostim in High-risk Patients With Mild-moderate COVID-19,"Active, not recruiting",NA,Phase 2,500,Anticipated,"Partner Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-06T10:37:48Z,2021-12-06T10:37:48Z
NCT04649736,NA,11/30/2020,NA,NA,12/1/2021,11/30/2020,12/2/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/3/2021,Estimate,26-Oct-20,Actual,10/26/2020,May-21,5/31/2021,19-Jun-21,Actual,6/19/2021,19-Jun-21,Actual,6/19/2021,NA,Interventional,WAYRA,NA,Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients,Prevalence of Altered Pulmonary Function Post-infection by COVID-19 and Impact of Participation in a Pilot Program of Comprehensive Rehabilitation in the Short and Medium-term,Completed,NA,Not Applicable,108,Actual,Universidad Peruana Cayetano Heredia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Results will be published in an indexed peer-review journals.,2021-12-06T10:38:54Z,2021-12-06T10:38:54Z
NCT04600895,NA,9/15/2020,NA,NA,11/29/2021,10/22/2020,10/23/2020,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,12/3/2021,Estimate,30-Nov-20,Actual,11/30/2020,Nov-21,11/30/2021,20-Oct-21,Actual,10/20/2021,20-Oct-21,Actual,10/20/2021,NA,Interventional,PRESECO,NA,The Prevent Severe COVID-19 (PRESECO) Study,Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19),Completed,NA,Phase 3,1231,Actual,Appili Therapeutics Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-06T10:39:42Z,2021-12-06T10:39:42Z
NCT04551898,NA,9/10/2020,NA,NA,12/2/2021,9/15/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/3/2021,Estimate,2-Dec-20,Actual,12/2/2020,Dec-21,12/31/2021,25-May-21,Actual,5/25/2021,25-May-21,Actual,5/25/2021,NA,Interventional,NA,NA,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19",Completed,NA,Phase 2,181,Actual,BeiGene,,4,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-06T10:40:27Z,2021-12-06T10:40:27Z
NCT04524507,NA,8/21/2020,11/15/2021,NA,12/1/2021,8/21/2020,8/24/2020,Actual,11/15/2021,11/23/2021,Actual,NA,NA,NA,12/1/2021,12/3/2021,Estimate,27-Aug-20,Actual,8/27/2020,Jun-21,6/30/2021,4-Jun-21,Actual,6/4/2021,4-Jan-21,Actual,1/4/2021,NA,Interventional,UNC CCP RCT,NA,Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients,"IGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19",Completed,NA,Phase 2,56,Actual,"University of North Carolina, Chapel Hill",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,12-24 months after publication,"Investigators/researchers who propose to use study data will need to have IRB, IEC, or REB approval and an executed data use/sharing agreement with UNC.",NA,Yes,"De-identified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator/researcher who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-12-06T10:40:55Z,2021-12-06T10:40:55Z
NCT04425538,NA,6/8/2020,8/23/2021,NA,12/1/2021,6/8/2020,6/11/2020,Actual,12/1/2021,12/3/2021,Estimate,NA,NA,NA,12/1/2021,12/3/2021,Estimate,1-Jun-20,Actual,6/1/2020,Dec-21,12/31/2021,22-Jan-21,Actual,1/22/2021,22-Jan-21,Actual,1/22/2021,NA,Interventional,NA,NA,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Completed,NA,Phase 2,17,Actual,Tufts Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T10:42:16Z,2021-12-06T10:42:16Z
NCT04382924,NA,5/8/2020,11/22/2021,NA,12/1/2021,5/8/2020,5/11/2020,Actual,12/1/2021,12/3/2021,Estimate,NA,NA,NA,12/1/2021,12/3/2021,Estimate,5-Aug-20,Actual,8/5/2020,Dec-21,12/31/2021,26-Jan-21,Actual,1/26/2021,24-Dec-20,Actual,12/24/2020,NA,Interventional,NA,NA,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,Completed,NA,Phase 2/Phase 3,168,Actual,Algernon Pharmaceuticals,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-06T10:42:42Z,2021-12-06T10:42:42Z
NCT04384497,NA,5/7/2020,NA,NA,12/2/2021,5/9/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/3/2021,Estimate,7-May-20,Actual,5/7/2020,Dec-21,12/31/2021,1-Dec-20,Actual,12/1/2020,1-Jun-20,Actual,6/1/2020,NA,Interventional,NA,NA,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Completed,NA,Phase 1/Phase 2,10,Actual,Karolinska University Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"The investigators will be sharing the data, but the management plan is being designed.",2021-12-06T10:42:36Z,2021-12-06T10:42:36Z
NCT04335032,NA,4/1/2020,NA,NA,11/26/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,12/3/2021,Estimate,8-Jan-21,Actual,1/8/2021,Nov-21,11/30/2021,1-Dec-21,Anticipated,12/1/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2),"A Randomised, Double-blind, Placebo Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalised Subjects With Confirmed SARS-CoV-2",Recruiting,NA,Phase 3,284,Anticipated,S.L.A. Pharma AG,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T10:43:16Z,2021-12-06T10:43:16Z
NCT04283461,NA,2/21/2020,NA,NA,12/2/2021,2/21/2020,2/25/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/3/2021,Estimate,16-Mar-20,Actual,3/16/2020,26-Aug-21,8/26/2021,22-Nov-22,Anticipated,11/22/2022,22-Nov-22,Anticipated,11/22/2022,NA,Interventional,NA,NA,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","Active, not recruiting",NA,Phase 1,120,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,15,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-06T10:43:47Z,2021-12-06T10:43:47Z
NCT04961541,NA,7/9/2021,NA,NA,12/2/2021,7/9/2021,7/14/2021,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/6/2021,Estimate,8-Sep-21,Actual,9/8/2021,Dec-21,12/31/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine,"A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine With Matrix M1â„¢ Adjuvant in Healthy Participants â‰¥ 50 to â‰¤ 70 Years of Age","Active, not recruiting",NA,Phase 1/Phase 2,642,Actual,Novavax,,16,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-06T20:08:17Z,2021-12-06T20:08:17Z
NCT04957082,NA,7/6/2021,NA,NA,12/3/2021,7/7/2021,7/12/2021,Actual,NA,NA,NA,NA,NA,NA,12/3/2021,12/6/2021,Estimate,4-Aug-21,Actual,8/4/2021,Dec-21,12/31/2021,1-Jun-23,Anticipated,6/1/2023,1-Jun-23,Anticipated,6/1/2023,NA,Interventional,NA,NA,Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake,Culturally-targeted Communication to Promote SARS-CoV-2 Antibody Testing in Saliva: Enabling Evaluation of Inflammatory Pathways in COVID-19 Racial Disparities,Recruiting,NA,Not Applicable,500,Anticipated,Michigan State University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Upon Study Completion,NA,NA,Yes,"Data will be made available per requirements and sharing structures established by NCI ""SeroNet"" initiative.",2021-12-06T20:08:22Z,2021-12-06T20:08:22Z
NCT04615949,NA,11/2/2020,NA,NA,12/2/2021,11/3/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/6/2021,Estimate,30-Apr-21,Actual,4/30/2021,Dec-21,12/31/2021,Apr-22,Anticipated,4/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors,"Study to Evaluate the Efficacy and Safety of CardiolRxâ„¢ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial",Recruiting,NA,Phase 2/Phase 3,422,Anticipated,Cardiol Therapeutics Inc.,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will become available in Q4 2021,Access to the journal in which article has been published,NA,Yes,The data will become available once the study has been published,2021-12-06T20:11:51Z,2021-12-06T20:11:51Z
NCT04852978,NA,4/19/2021,NA,NA,12/3/2021,4/19/2021,4/21/2021,Actual,NA,NA,NA,NA,NA,NA,12/3/2021,12/6/2021,Estimate,29-Apr-21,Actual,4/29/2021,Dec-21,12/31/2021,22-Nov-22,Anticipated,11/22/2022,29-Dec-21,Anticipated,12/29/2021,NA,Interventional,NA,NA,"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","Active, not recruiting",NA,Phase 2,295,Actual,Regeneron Pharmaceuticals,,12,NA,NA,TRUE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-12-06T20:09:26Z,2021-12-06T20:09:26Z
NCT04635943,NA,11/9/2020,NA,NA,12/3/2021,11/18/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/3/2021,12/6/2021,Estimate,29-Aug-20,Actual,8/29/2020,Mar-21,3/31/2021,30-Apr-21,Actual,4/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,SAINT-PERU,NA,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Completed,NA,Phase 2,186,Actual,Universidad Peruana Cayetano Heredia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-06T20:11:40Z,2021-12-06T20:11:40Z
NCT04344535,NA,4/10/2020,9/20/2021,NA,12/2/2021,4/13/2020,4/14/2020,Actual,12/2/2021,12/6/2021,Estimate,NA,NA,NA,12/2/2021,12/6/2021,Estimate,8-Apr-20,Actual,4/8/2020,Dec-21,12/31/2021,1-Feb-21,Actual,2/1/2021,1-Jan-21,Actual,1/1/2021,NA,Interventional,NA,NA,Convalescent Plasma vs. Standard Plasma for COVID-19,Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection,Terminated,NA,Phase 1/Phase 2,82,Actual,Stony Brook University,,2,NA,Insufficient eligible and consenting patients,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:13:53Z,2021-12-06T20:13:53Z
NCT04583995,NA,10/9/2020,NA,NA,12/2/2021,10/9/2020,10/12/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/6/2021,Estimate,28-Nov-20,Actual,11/28/2020,Dec-21,12/31/2021,14-Jan-22,Anticipated,1/14/2022,14-Jan-22,Anticipated,1/14/2022,NA,Interventional,NA,NA,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom","Active, not recruiting",NA,Phase 3,15000,Anticipated,Novavax,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:12:06Z,2021-12-06T20:12:06Z
NCT04493242,NA,7/29/2020,NA,NA,11/23/2021,7/29/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,12/6/2021,Estimate,24-Sep-20,Actual,9/24/2020,Nov-21,11/30/2021,22-May-21,Actual,5/22/2021,1-May-21,Actual,5/1/2021,NA,Interventional,EXIT-COVID19,NA,Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial,Completed,NA,Phase 2,120,Actual,"Direct Biologics, LLC",,3,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:13:08Z,2021-12-06T20:13:08Z
NCT04368988,NA,4/24/2020,NA,NA,12/2/2021,4/28/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/6/2021,Estimate,25-May-20,Actual,5/25/2020,Dec-21,12/31/2021,21-May-22,Anticipated,5/21/2022,21-May-22,Anticipated,5/21/2022,NA,Interventional,NA,NA,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-Mâ„¢ Adjuvant In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,1419,Actual,Novavax,,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:13:42Z,2021-12-06T20:13:42Z
NCT04355728,NA,4/13/2020,10/15/2021,NA,12/1/2021,4/17/2020,4/21/2020,Actual,12/1/2021,12/6/2021,Estimate,NA,NA,NA,12/1/2021,12/6/2021,Estimate,25-Apr-20,Actual,4/25/2020,Dec-21,12/31/2021,31-Oct-20,Actual,10/31/2020,31-Oct-20,Actual,10/31/2020,NA,Interventional,NA,NA,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1/Phase 2,24,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-06T20:13:48Z,2021-12-06T20:13:48Z
NCT05091307,NA,10/1/2021,NA,NA,11/23/2021,10/22/2021,10/25/2021,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,12/7/2021,Estimate,2-Nov-21,Actual,11/2/2021,Nov-21,11/30/2021,12-Aug-22,Anticipated,8/12/2022,6-Jan-22,Anticipated,1/6/2022,NA,Interventional,NA,NA,A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults,"A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,1680,Anticipated,Janssen Vaccines & Prevention B.V.,,4,NA,NA,TRUE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-08T10:21:35Z,2021-12-08T10:21:35Z
NCT05114655,NA,10/29/2021,NA,NA,12/6/2021,10/29/2021,11/10/2021,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/7/2021,Estimate,11-Nov-21,Actual,11/11/2021,Dec-21,12/31/2021,31-Jan-22,Anticipated,1/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Aromatherapy for Stress and Burnout Among Healthcare Providers,"The Effects of Aromatherapy on Stress and Burnout Among Healthcare Providers During the COVID-19 Pandemic: A 3-Arm Randomized, Double Blind, Controlled Trial",Recruiting,NA,Not Applicable,125,Anticipated,Franklin School of Integrative Health Sciences,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-08T10:20:53Z,2021-12-08T10:20:53Z
NCT05077176,NA,10/13/2021,NA,NA,12/2/2021,10/13/2021,10/14/2021,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/7/2021,Estimate,8-Oct-21,Actual,10/8/2021,Nov-21,11/30/2021,1-Apr-23,Anticipated,4/1/2023,29-Sep-22,Anticipated,9/29/2022,NA,Interventional,NA,NA,Phase 3 Booster Vaccination Against COVID-19,"Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 3,7400,Anticipated,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-08T10:21:54Z,2021-12-08T10:21:54Z
NCT05033847,NA,8/30/2021,NA,NA,11/23/2021,9/1/2021,9/5/2021,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,12/7/2021,Estimate,12-Sep-21,Actual,9/12/2021,Nov-21,11/30/2021,Jan-24,Anticipated,1/31/2024,Nov-23,Anticipated,11/30/2023,NA,Interventional,NA,NA,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Recruiting,NA,Phase 2,1800,Anticipated,"National Vaccine and Serum Institute, China",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-08T10:22:46Z,2021-12-08T10:22:46Z
NCT04894721,NA,5/6/2021,NA,NA,12/1/2021,5/12/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/7/2021,Estimate,1-Jun-21,Actual,6/1/2021,Dec-21,12/31/2021,1-Oct-21,Actual,10/1/2021,30-Sep-21,Actual,9/30/2021,NA,Interventional,IVERNEX-TUC,NA,Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC),Study of Efficacy and Safety of Ivermectin for COVID-19 Prophylaxis in Post-exposure Contact or Epidemiological Link,Completed,NA,Phase 2/Phase 3,172,Actual,"Ministry of Public Health, Argentina",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-08T10:24:40Z,2021-12-08T10:24:40Z
NCT05007275,NA,8/12/2021,NA,NA,12/6/2021,8/12/2021,8/16/2021,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/7/2021,Estimate,10-Oct-21,Actual,10/10/2021,Dec-21,12/31/2021,Sep-22,Anticipated,9/30/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,COVAXAER01,NA,A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers,A Phase I Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers,Recruiting,NA,Phase 1,15,Anticipated,Imperial College London,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data will become available approximately 6 months from the last patient's last visit and remain available indefinitely.,According to study protocol.,NA,Yes,"The expectation is that after analysis the data from this study will be widely distributed in the medical and scientific community. Facilitated with presentations at local, national and international meetings, the hope is to publish widely in the medical literature. In addition, there is an excellent media department at Imperial College that will publicise research that has public interest when it is published.

The Investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study. Data from the study may also be used as part of a thesis for a PhD or MD.

All data will be anonymised and aggregated or pseudonymised; no identifying participant information will be published.",2021-12-08T10:23:13Z,2021-12-08T10:23:13Z
NCT04392232,NA,5/15/2020,NA,NA,12/3/2021,5/15/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,12/3/2021,12/7/2021,Estimate,5-May-20,Actual,5/5/2020,Dec-21,12/31/2021,21-Sep-21,Actual,9/21/2021,21-Sep-21,Actual,9/21/2021,NA,Interventional,NA,NA,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Completed,NA,Phase 2,159,Actual,TriHealth Inc.,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-08T10:29:40Z,2021-12-08T10:29:40Z
NCT04581863,NA,10/7/2020,NA,NA,12/6/2021,10/8/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/7/2021,Estimate,30-Nov-20,Actual,11/30/2020,Dec-21,12/31/2021,31-Oct-22,Anticipated,10/31/2022,5-Feb-21,Actual,2/5/2021,NA,Interventional,NA,NA,COVID-19 Watch + COVID-19 Pulse,Randomized Trial of Adding Pulse Oximetry to an Automated Text-messaging Program for Remotely Monitoring Patients at Home With COVID-19,"Active, not recruiting",NA,Not Applicable,850,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-08T10:27:58Z,2021-12-08T10:27:58Z
NCT04515147,NA,8/13/2020,NA,NA,12/6/2021,8/13/2020,8/17/2020,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/7/2021,Estimate,28-Sep-20,Actual,9/28/2020,Dec-21,12/31/2021,18-Feb-22,Anticipated,2/18/2022,18-Feb-22,Anticipated,2/18/2022,NA,Interventional,NA,NA,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age","Active, not recruiting",NA,Phase 2,674,Actual,CureVac AG,,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-08T10:28:48Z,2021-12-08T10:28:48Z
NCT04343989,NA,4/9/2020,NA,NA,12/3/2021,4/9/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,12/3/2021,12/7/2021,Estimate,31-Mar-20,Actual,3/31/2020,Dec-21,12/31/2021,12-Mar-21,Actual,3/12/2021,3-Feb-21,Actual,2/3/2021,NA,Interventional,NA,NA,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,NA,Phase 2,180,Actual,NYU Langone Health,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,Upon reasonable request by an investigator who proposes to use the data.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-12-08T10:29:54Z,2021-12-08T10:29:54Z
NCT05148845,NA,11/9/2021,NA,NA,12/4/2021,12/4/2021,12/8/2021,Estimate,NA,NA,NA,NA,NA,NA,12/4/2021,12/8/2021,Estimate,10-Nov-21,Actual,11/10/2021,Dec-21,12/31/2021,Jun-23,Anticipated,6/30/2023,17-Dec-21,Anticipated,12/17/2021,NA,Interventional,Sisonke Boost,NA,Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.,"Open-label, Single-arm Phase 3B Implementation Study to Evaluate the Effectiveness of the Homologous Boostof Ad26.COV2.S COVID-19 Vaccine Following the Prime Dose Among Sisonke Participants in South Africa(VAC31518COV30XX)",Recruiting,NA,Phase 3,500000,Anticipated,Wits Health Consortium (Pty) Ltd,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 12 months of completion of study,on request,https://www.samrc.ac.za,Yes,"All study team scientists will disseminate the trial results as broadly as possible. Data will be shared with JNJ prior to release to the public. The study data will be published consistent with normal scientific practices.

The results from this research may also be disseminated through presentations at scientific institutions/ meetings, and/or publication in scientific journals. All publications will be uploaded to a publication repository. After sharing the results with study participants, they will be presented to communities from which participants are recruited, following Good Participatory Practice guidelines. The results will also be shared with global and local policy makers. Summary results of the trial will be made publicly available through the clinical trial registry. Any datasets used for analysis in publications can be requested by investigators via an online request to the organisation. Measures will be taken to protect identifiable information in the datasets",2021-12-09T09:11:14Z,2021-12-09T09:11:14Z
NCT05148962,NA,12/3/2021,NA,NA,12/3/2021,12/3/2021,12/8/2021,Estimate,NA,NA,NA,NA,NA,NA,12/3/2021,12/8/2021,Estimate,16-Sep-21,Actual,9/16/2021,Dec-21,12/31/2021,4-Nov-22,Anticipated,11/4/2022,4-Nov-22,Anticipated,11/4/2022,NA,Interventional,NA,NA,Study of GRT-R910 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Boost Vaccine in Healthy Volunteers,"A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of a Self-Amplifying mRNA Prophylactic Vaccine Boost Against SARS-CoV-2 in Previously Vaccinated Healthy Elderly Adults",Recruiting,NA,Phase 1,120,Anticipated,"Gritstone Oncology, Inc.",,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-09T09:11:10Z,2021-12-09T09:11:10Z
NCT05148936,NA,3/31/2021,NA,NA,12/3/2021,12/3/2021,12/8/2021,Estimate,NA,NA,NA,NA,NA,NA,12/3/2021,12/8/2021,Estimate,25-Oct-20,Actual,10/25/2020,Dec-21,12/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Communities Fighting COVID-19!,Communities Fighting COVID!,Recruiting,NA,Not Applicable,42000,Anticipated,San Diego State University,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Shared on a periodic basis. RPPR shared with NIH on a 6-month basis,Anonymized data access,NA,Yes,Plan to share with Rad-X UP Coordinating Center,2021-12-09T09:11:11Z,2021-12-09T09:11:11Z
NCT05057221,NA,9/23/2021,NA,NA,12/6/2021,9/23/2021,9/27/2021,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/8/2021,Estimate,12-Nov-21,Actual,11/12/2021,Dec-21,12/31/2021,Nov-23,Anticipated,11/30/2023,Nov-23,Anticipated,11/30/2023,NA,Interventional,NA,NA,"Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia","A Pilot Study to Assess the Safety, Tolerability and Efficacy of Selectin Inhibitor Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia",Recruiting,NA,Phase 1/Phase 2,15,Anticipated,University of Michigan,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-09T09:14:18Z,2021-12-09T09:14:18Z
NCT05047640,NA,9/13/2021,NA,NA,12/7/2021,9/16/2021,9/17/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/8/2021,Estimate,14-Sep-21,Actual,9/14/2021,Dec-21,12/31/2021,30-Apr-22,Anticipated,4/30/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,COVID-19 3rd Dose Vaccine in Transplant Patients,"A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients",Recruiting,NA,Phase 3,200,Anticipated,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-09T09:14:29Z,2021-12-09T09:14:29Z
NCT04936997,NA,6/18/2021,NA,NA,12/6/2021,6/22/2021,6/23/2021,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/8/2021,Estimate,7-Jun-21,Actual,6/7/2021,Dec-21,12/31/2021,1-Feb-27,Anticipated,2/1/2027,1-Feb-22,Anticipated,2/1/2022,NA,Interventional,NA,NA,Immune Response to the COVID-19 Vaccine,Immune Response to the COVID-19 Vaccine,"Active, not recruiting",NA,Early Phase 1,1000,Anticipated,University of Arizona,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-09T09:15:41Z,2021-12-09T09:15:41Z
NCT04992260,NA,8/3/2021,NA,NA,12/7/2021,8/3/2021,8/5/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/8/2021,Estimate,10-Sep-21,Actual,9/10/2021,Jul-21,7/31/2021,1-Apr-23,Anticipated,4/1/2023,25-May-22,Anticipated,5/25/2022,NA,Interventional,NA,NA,"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase â…¢ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine(Vero Cell) ,Inactivated in Children and Adolescents Aged 6 Months to 17 Years",Recruiting,NA,Phase 3,14000,Anticipated,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-09T09:15:15Z,2021-12-09T09:15:15Z
NCT04859517,NA,4/21/2021,NA,NA,12/6/2021,4/23/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/8/2021,Estimate,23-Apr-21,Actual,4/23/2021,Dec-21,12/31/2021,Mar-23,Anticipated,3/31/2023,Jul-22,Anticipated,7/31/2022,NA,Interventional,EVADE,NA,Evaluation of ADG20 for the Prevention of COVID-19,"A Phase 2/3 Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID 19 (EVADE)",Recruiting,NA,Phase 2/Phase 3,6412,Anticipated,"Adagio Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-09T09:16:37Z,2021-12-09T09:16:37Z
NCT04920942,NA,5/31/2021,NA,NA,11/24/2021,6/8/2021,6/10/2021,Actual,NA,NA,NA,NA,NA,NA,11/24/2021,12/8/2021,Estimate,31-May-21,Actual,5/31/2021,Nov-21,11/30/2021,31-Oct-21,Actual,10/31/2021,31-Oct-21,Actual,10/31/2021,NA,Interventional,I-TECH,NA,Ivermectin Treatment Efficacy in Covid-19 High Risk Patients,Ivermectin Treatment Efficacy in Covid-19 High Risk Patients (I-TECH Study): A Multicenter Open-label Randomized Controlled Trial,Completed,NA,Phase 3,500,Actual,"Clinical Research Centre, Malaysia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-09T09:15:58Z,2021-12-09T09:15:58Z
NCT04913129,NA,5/31/2021,NA,NA,12/7/2021,5/31/2021,6/4/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/8/2021,Estimate,4-Nov-21,Actual,11/4/2021,Dec-21,12/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,The Burden of COVID-19 Survivorship,The Burden of COVID-19 Survivorship: Exercise Therapy to Combat the Sequelae of COVID-19,Recruiting,NA,Not Applicable,50,Anticipated,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-09T09:16:00Z,2021-12-09T09:16:00Z
NCT04625972,NA,11/10/2020,NA,NA,12/7/2021,11/10/2020,11/12/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/8/2021,Estimate,2-Dec-20,Actual,12/2/2020,Dec-21,12/31/2021,19-Jun-22,Anticipated,6/19/2022,7-Apr-21,Actual,4/7/2021,NA,Interventional,STORM CHASER,NA,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19","Active, not recruiting",NA,Phase 3,1121,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-09T09:18:34Z,2021-12-09T09:18:34Z
NCT04830761,NA,3/25/2021,NA,NA,11/25/2021,4/1/2021,4/5/2021,Actual,NA,NA,NA,NA,NA,NA,11/25/2021,12/8/2021,Estimate,26-Mar-21,Actual,3/26/2021,Nov-21,11/30/2021,1-Apr-22,Anticipated,4/1/2022,1-Apr-22,Anticipated,4/1/2022,NA,Interventional,NA,NA,Behavior Change in Context to Contain the Spread of COVID-19,Behaviour Change in Context to Contain the Spread of COVID-19,Recruiting,NA,Not Applicable,710,Anticipated,University of Bern,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-09T09:17:01Z,2021-12-09T09:17:01Z
NCT04818801,NA,3/19/2021,NA,NA,12/6/2021,3/23/2021,3/26/2021,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/8/2021,Estimate,18-Jun-21,Actual,6/18/2021,Dec-21,12/31/2021,Jul-22,Anticipated,7/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"Safety, Reactogenicity and Immunogenicity Study of ReCOV","A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of ReCOV, a Vaccine for COVID-19, in Healthy Adult Subjects","Active, not recruiting",NA,Early Phase 1,99,Actual,"Jiangsu Rec-Biotechnology Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-09T09:17:03Z,2021-12-09T09:17:03Z
NCT04668209,NA,12/2/2020,NA,NA,12/6/2021,12/11/2020,12/16/2020,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/8/2021,Estimate,1-Jan-21,Actual,1/1/2021,Dec-21,12/31/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,CX4945,NA,Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19),"Phase II, Randomized, Investigator Initiated Trial to Evaluate Safety and to Explore Clinical Benefit of Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,40,Anticipated,University of Arizona,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Study results will be published on clinicaltrials.gov.,2021-12-09T09:18:17Z,2021-12-09T09:18:17Z
NCT04582201,NA,10/6/2020,NA,NA,12/6/2021,10/8/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/8/2021,Estimate,21-Sep-20,Actual,9/21/2020,Dec-21,12/31/2021,31-Jan-23,Anticipated,1/31/2023,1-Oct-22,Anticipated,10/1/2022,NA,Interventional,NA,NA,An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.,A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients,Recruiting,NA,Phase 1,55,Anticipated,Agenus Inc.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-09T09:18:58Z,2021-12-09T09:18:58Z
NCT04508023,NA,8/10/2020,NA,NA,12/7/2021,8/10/2020,8/11/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/8/2021,Estimate,13-Aug-20,Actual,8/13/2020,Dec-21,12/31/2021,22-Feb-22,Anticipated,2/22/2022,22-Feb-22,Anticipated,2/22/2022,NA,Interventional,PREVENT-HD,NA,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection","A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 Infection",Recruiting,NA,Phase 3,4000,Anticipated,"Janssen Research & Development, LLC",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-09T09:19:29Z,2021-12-09T09:19:29Z
NCT04469634,NA,7/13/2020,NA,NA,12/7/2021,7/13/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/8/2021,Estimate,31-Jul-20,Actual,7/31/2020,Dec-21,12/31/2021,Dec-22,Anticipated,12/31/2022,Dec-22,Anticipated,12/31/2022,NA,Interventional,ImmCoV,NA,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,"Active, not recruiting",NA,Not Applicable,150,Actual,"Institute of Tropical Medicine, Belgium",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-09T09:19:41Z,2021-12-09T09:19:41Z
NCT05151614,NA,11/27/2021,NA,NA,11/27/2021,11/27/2021,12/9/2021,Estimate,NA,NA,NA,NA,NA,NA,11/27/2021,12/9/2021,Estimate,1-Apr-21,Actual,4/1/2021,Nov-21,11/30/2021,30-Oct-21,Actual,10/30/2021,30-Oct-21,Actual,10/30/2021,NA,Interventional,NA,NA,Adjuvant Use Of Colchicine With The Standard Therapy In Moderate And Severe Corona Virus Disease-19 Infection,Adjuvant Use Of Colchicine With The Standard Therapy In Moderate And Severe Corona Virus Disease-19 Infection: Randomized Controlled Clinical Trial,Completed,NA,Phase 1,160,Actual,University of Baghdad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:29:40Z,2021-12-10T11:29:40Z
NCT05069610,NA,10/4/2021,NA,NA,12/8/2021,10/5/2021,10/6/2021,Actual,NA,NA,NA,NA,NA,NA,12/8/2021,12/9/2021,Estimate,15-Dec-21,Anticipated,12/15/2021,Dec-21,12/31/2021,15-Apr-22,Anticipated,4/15/2022,15-Apr-22,Anticipated,4/15/2022,NA,Interventional,NA,NA,"Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild COVID-19","A Parallel Group Treatment, Phase 2a, Double-blind, Randomized, Placebo-controlled, 4-arm Study to Evaluate the Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults Participants Aged 20 to 70 Years With Mild COVID-19",Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Advagene Biopharma Co. Ltd.,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:33:08Z,2021-12-10T11:33:08Z
NCT05150860,NA,12/3/2021,NA,NA,12/7/2021,12/7/2021,12/9/2021,Estimate,NA,NA,NA,NA,NA,NA,12/7/2021,12/9/2021,Estimate,17-Oct-21,Actual,10/17/2021,Dec-21,12/31/2021,30-Jul-23,Anticipated,7/30/2023,30-Jul-23,Anticipated,7/30/2023,NA,Interventional,NA,NA,Communities Fighting COVID Return to School,Communities Fighting COVID!: Returning Our Kids Back to School Safely,Recruiting,NA,Not Applicable,3000,Anticipated,San Diego State University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Data will be shared with the NIH RADx-UP Coordination and Data Collection Center (CDCC). The CDCC is charged by the NIH with making data funded by the RADx-UP initiative available to other researchers.,2021-12-10T11:30:20Z,2021-12-10T11:30:20Z
NCT04584684,NA,10/9/2020,NA,NA,12/1/2021,10/9/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/9/2021,Estimate,18-Dec-20,Actual,12/18/2020,Dec-21,12/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,MOR,NA,Mouth Rinses for Inactivation of COVID-19,Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus,"Active, not recruiting",NA,Phase 2,129,Actual,"University of North Carolina, Chapel Hill",,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,following publication up to 1 year,"Deidentified individual data that supports the results will be shared beginning following publication up to 1 year provided the investigator who proposes to use the data has approval from an IRB, IEC, or REB as applicable, and an executed data use/sharing agreement with UNC.",NA,Yes,"Deidentified individual data that supports the results will be shared beginning following publication up to 1 year provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-12-10T11:39:57Z,2021-12-10T11:39:57Z
NCT04609423,NA,10/22/2020,NA,NA,11/26/2021,10/28/2020,10/30/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,12/9/2021,Estimate,10-Nov-20,Actual,11/10/2020,Nov-21,11/30/2021,May-23,Anticipated,5/31/2023,2-Jun-21,Actual,6/2/2021,NA,Interventional,NA,NA,Cod Liver Oil for Covid-19 Prevention Study,"A Randomized, Parallel-group Treatment, Quadruple Masked, Two-arm Study, to Assess the Effectiveness of Cod Liver Oil Compared to Placebo in the Prevention of Covid-19 and Airway Infections in Healthy Adults",Recruiting,NA,Phase 4,80000,Anticipated,Oslo University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"IPD is complicated to share under the European General Data Protection Regulative, however, it is an aim of the study to make such data available within these regulations.",2021-12-10T11:39:36Z,2021-12-10T11:39:36Z
NCT04847050,NA,4/14/2021,NA,NA,12/8/2021,4/14/2021,4/15/2021,Actual,NA,NA,NA,NA,NA,NA,12/8/2021,12/9/2021,Estimate,28-Apr-21,Actual,4/28/2021,6-Dec-21,12/6/2021,25-Feb-23,Anticipated,2/25/2023,1-Jan-22,Anticipated,1/1/2022,NA,Interventional,NA,NA,"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Boost...","A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster Doses of Vaccine",Recruiting,NA,Phase 2,220,Anticipated,National Institutes of Health Clinical Center (CC),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-10T11:36:10Z,2021-12-10T11:36:10Z
NCT04750759,NA,2/8/2021,NA,NA,11/26/2021,2/8/2021,2/11/2021,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,12/9/2021,Estimate,3-Feb-21,Actual,2/3/2021,Nov-21,11/30/2021,29-Oct-21,Actual,10/29/2021,29-Oct-21,Actual,10/29/2021,NA,Interventional,NICCAM,NA,Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat,"A Randomized, Single Blind, Placebo-controlled, Multiple Dose, Parallel-arm Study to Investigate the Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat to Treat COVID-19 (""NICCAM"")",Terminated,NA,Phase 2,4,Actual,CharitÃ© Research Organisation GmbH,,2,NA,sub-therapeutic plasma levels of active substance,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:37:26Z,2021-12-10T11:37:26Z
NCT04715997,NA,1/18/2021,NA,NA,11/25/2021,1/18/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,11/25/2021,12/9/2021,Estimate,30-Dec-20,Actual,12/30/2020,Nov-21,11/30/2021,30-Jun-22,Anticipated,6/30/2022,30-Jul-21,Actual,7/30/2021,NA,Interventional,NA,NA,"Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,170,Anticipated,"Genexine, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:37:42Z,2021-12-10T11:37:42Z
NCT04527198,NA,6/2/2020,NA,NA,11/26/2021,8/24/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,12/9/2021,Estimate,14-Sep-20,Actual,9/14/2020,Nov-21,11/30/2021,31-Dec-20,Actual,12/31/2020,31-Dec-20,Actual,12/31/2020,NA,Interventional,BRAINSTEM-COV,NA,Brainstem Dysfunction in COVID-19 Critically Ill Patients: a Prospective Observational Study,Brainstem Dysfunction in Ventilated and Deeply Sedated COVID-19 Critically Ill Patients: a Prospective Observational Study,Completed,NA,Not Applicable,52,Actual,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:40:30Z,2021-12-10T11:40:30Z
NCT04526821,NA,8/21/2020,NA,NA,12/1/2021,8/21/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/9/2021,Estimate,17-Oct-20,Actual,10/17/2020,Aug-20,8/31/2020,10-Feb-21,Actual,2/10/2021,10-Feb-21,Actual,2/10/2021,NA,Interventional,LF-COVID,NA,Lactoferrin for Prevention of COVID-19 in Health Care Workers,"Bovine Lactoferrin for the Prevention of COVID-19 Infection in Physicians and Nurses in Hospitals in Lima, Peru: a Double Blinded Randomized Clinical Trial (LF-COVID)",Terminated,NA,Phase 2,209,Actual,Universidad Peruana Cayetano Heredia,,2,NA,The study was interrupted due to the arrival and distribution of the vaccine to hospital workers in Peru,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Immediately following publication of the study,",Contact the study PI ( Theresa.ochoa@upch.pe),NA,Yes,"Individual participant data collected during the trial, after deidentification, will be shared with researchers who provide a methodological sound study protocol previously approved by an independent ethics committee.",2021-12-10T11:40:33Z,2021-12-10T11:40:33Z
NCT04516512,NA,8/17/2020,NA,NA,11/26/2021,8/17/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,12/9/2021,Estimate,14-Jan-21,Actual,1/14/2021,Nov-21,11/30/2021,8-Jul-21,Actual,7/8/2021,8-Jul-21,Actual,7/8/2021,NA,Interventional,COVIDET,NA,Assessment of SARS-CoV-2 Seroprevalence in Detention,SARS-CoV-2 Seroprevalence Among Adults People Living in Jail,Completed,NA,Not Applicable,1044,Actual,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-10T11:40:38Z,2021-12-10T11:40:38Z
NCT04445389,NA,6/19/2020,NA,NA,11/25/2021,6/22/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/25/2021,12/9/2021,Estimate,17-Jun-20,Actual,6/17/2020,Nov-21,11/30/2021,30-Mar-22,Anticipated,3/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,60,Actual,"Genexine, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:41:07Z,2021-12-10T11:41:07Z
NCT04365257,NA,4/24/2020,NA,NA,12/7/2021,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/9/2021,Estimate,13-May-20,Actual,5/13/2020,Dec-21,12/31/2021,30-Mar-22,Anticipated,3/30/2022,30-Mar-22,Anticipated,3/30/2022,NA,Interventional,PREVENT,NA,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection,Recruiting,NA,Phase 2,220,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-10T11:42:06Z,2021-12-10T11:42:06Z
NCT05152849,NA,11/29/2021,NA,NA,11/29/2021,11/29/2021,12/10/2021,Estimate,NA,NA,NA,NA,NA,NA,11/29/2021,12/10/2021,Estimate,Dec-21,Anticipated,12/31/2021,Nov-21,11/30/2021,Jun-22,Anticipated,6/30/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,"Efficacy, Safety, Tolerability of AXA1125 in Fatigue Predominant PASC","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of AXA1125 in Subjects With Fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection",Recruiting,NA,Phase 2,40,Anticipated,"Axcella Health, Inc",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-13T10:15:31Z,2021-12-13T10:15:31Z
NCT05092698,NA,10/22/2021,NA,NA,11/27/2021,10/22/2021,10/25/2021,Actual,NA,NA,NA,NA,NA,NA,11/27/2021,12/10/2021,Estimate,1-May-20,Actual,5/1/2020,Nov-21,11/30/2021,Jan-22,Anticipated,1/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,COVID-VIT,NA,The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19,The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-13T10:17:10Z,2021-12-13T10:17:10Z
NCT05124171,NA,11/8/2021,NA,NA,12/9/2021,11/16/2021,11/17/2021,Actual,NA,NA,NA,NA,NA,NA,12/9/2021,12/10/2021,Estimate,8-Dec-21,Actual,12/8/2021,Dec-21,12/31/2021,Dec-22,Anticipated,12/31/2022,Dec-22,Anticipated,12/31/2022,NA,Interventional,COVIBOOST,NA,Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination,"Immunogenicity and Reactogenicity Following a 3rd Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered as a Booster in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination: A Randomized, Single-blinded Multicenter Clinical Trial",Recruiting,NA,Phase 3,300,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-13T10:16:26Z,2021-12-13T10:16:26Z
NCT04785144,NA,3/4/2021,NA,NA,12/9/2021,3/4/2021,3/5/2021,Actual,NA,NA,NA,NA,NA,NA,12/9/2021,12/10/2021,Estimate,29-Mar-21,Actual,3/29/2021,6-Apr-21,4/6/2021,31-Aug-22,Anticipated,8/31/2022,31-Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults,"Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults","Active, not recruiting",NA,Phase 1,135,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,10,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-13T10:21:14Z,2021-12-13T10:21:14Z
NCT04803409,NA,3/16/2021,NA,NA,12/8/2021,3/16/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,12/8/2021,12/10/2021,Estimate,22-Mar-21,Actual,3/22/2021,Dec-21,12/31/2021,31-Dec-21,Anticipated,12/31/2021,15-Dec-21,Anticipated,12/15/2021,NA,Interventional,UNITE,NA,UNITE Study (UCSD-SW) for COVID-19,Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UCSD-SW) for COVID-19,"Active, not recruiting",NA,Not Applicable,40,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-13T10:21:06Z,2021-12-13T10:21:06Z
NCT04638634,NA,11/19/2020,NA,NA,12/9/2021,11/19/2020,11/20/2020,Actual,NA,NA,NA,NA,NA,NA,12/9/2021,12/10/2021,Estimate,2-Feb-21,Actual,2/2/2021,Dec-21,12/31/2021,9-Jun-21,Actual,6/9/2021,9-Jun-21,Actual,6/9/2021,NA,Interventional,NA,NA,"Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects","A Single Center, Phase 1, Single-Ascending Dose, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects",Terminated,NA,Phase 1,12,Actual,CSL Behring,,2,NA,"For business reasons, not a safety issue",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.,"Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.

An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.

The requesting party must execute an appropriate data sharing agreement before IPD will be made available.",NA,Yes,"CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.",2021-12-13T10:22:23Z,2021-12-13T10:22:23Z
NCT04616846,NA,11/2/2020,NA,NA,12/8/2021,11/4/2020,11/5/2020,Actual,NA,NA,NA,NA,NA,NA,12/8/2021,12/10/2021,Estimate,4-Aug-20,Actual,8/4/2020,Dec-21,12/31/2021,15-Feb-22,Anticipated,2/15/2022,15-Feb-22,Anticipated,2/15/2022,NA,Interventional,NEOTHROCOVID,NA,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Recruiting,NA,Not Applicable,120,Anticipated,Centre Antoine Lacassagne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-13T10:22:43Z,2021-12-13T10:22:43Z
NCT04446429,NA,6/22/2020,1/22/2021,NA,12/8/2021,6/23/2020,6/24/2020,Actual,1/29/2021,2/3/2021,Actual,NA,NA,NA,12/8/2021,12/10/2021,Estimate,21-Oct-20,Actual,10/21/2020,Dec-21,12/31/2021,21-Jan-21,Actual,1/21/2021,24-Dec-20,Actual,12/24/2020,NA,Interventional,NA,NA,Anti-Androgen Treatment for COVID-19,Anti-Androgen Treatment for COVID-19,Completed,NA,Not Applicable,268,Actual,"Applied Biology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-13T10:24:19Z,2021-12-13T10:24:19Z
NCT04331366,NA,3/31/2020,2/5/2021,NA,2/16/2021,3/31/2020,4/2/2020,Actual,2/5/2021,2/10/2021,Actual,NA,NA,NA,2/16/2021,2/18/2021,Actual,8-Apr-20,Actual,4/8/2020,Feb-21,2/28/2021,31-Aug-20,Actual,8/31/2020,31-Aug-20,Actual,8/31/2020,NA,Interventional,GO2 PEEP,NA,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,NA,Not Applicable,2,Actual,Emory University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-13T22:54:58Z,2021-12-13T22:54:58Z
NCT04372017,NA,4/25/2020,12/6/2021,NA,12/8/2021,4/30/2020,5/1/2020,Actual,12/8/2021,12/10/2021,Estimate,NA,NA,NA,12/8/2021,12/10/2021,Estimate,14-May-20,Actual,5/14/2020,Dec-21,12/31/2021,4-Jun-21,Actual,6/4/2021,4-Jun-21,Actual,6/4/2021,NA,Interventional,NA,No subjects or data analyzed. Study was closed to enrollment before analysis.,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection",Terminated,NA,Phase 3,1,Actual,Sanford Health,,4,NA,Unlikelihood of benefit based on other studies.,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-13T10:24:58Z,2021-12-13T10:24:58Z
NCT05047770,NA,9/15/2021,NA,NA,12/10/2021,9/15/2021,9/17/2021,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/13/2021,Estimate,7-Oct-21,Actual,10/7/2021,Dec-21,12/31/2021,27-Jul-22,Anticipated,7/27/2022,29-Mar-22,Anticipated,3/29/2022,NA,Interventional,NA,NA,A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine,"A Phase III, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Immune Response and Safety of Both Herpes Zoster Subunit Vaccine in Healthy Adults Aged 50 Years and Older AND the Influenza Virus Vaccine in Healthy Adults Aged 18 Years and Older When Administered Sequentially or Coadministered With mRNA-1273 Booster Vaccination","Active, not recruiting",NA,Phase 3,1546,Anticipated,GlaxoSmithKline,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",NA,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2021-12-14T09:35:20Z,2021-12-14T09:35:20Z
NCT04924660,NA,6/9/2021,NA,NA,12/9/2021,6/10/2021,6/14/2021,Actual,NA,NA,NA,NA,NA,NA,12/9/2021,12/13/2021,Estimate,15-Jul-21,Actual,7/15/2021,Dec-21,12/31/2021,30-Dec-23,Anticipated,12/30/2023,31-May-23,Anticipated,5/31/2023,NA,Interventional,NECTAR,NA,Novel Experimental COVID-19 Therapies Affecting Host Response,"CONNECTS Master Protocol for Clinical Trials Targeting Macro-, Micro-immuno-thrombosis, Vascular Hyperinflammation, and Hypercoagulability and Renin-angiotensin-aldosterone System (RAAS) in Hospitalized Patients With COVID-19 (ACTIV-4 Host Tissue)",Recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Vanderbilt University Medical Center,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:36:53Z,2021-12-14T09:36:53Z
NCT04973449,NA,7/2/2021,NA,NA,12/10/2021,7/21/2021,7/22/2021,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/13/2021,Estimate,27-Jun-21,Actual,6/27/2021,Dec-21,12/31/2021,13-Jul-22,Anticipated,7/13/2022,26-Jan-22,Anticipated,1/26/2022,NA,Interventional,AZD2816,NA,"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19","Active, not recruiting",NA,Phase 2/Phase 3,2849,Anticipated,AstraZeneca,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

URL:

https://astrazenecagroup-dt.pharmacm.com/DT/Home",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-14T09:36:18Z,2021-12-14T09:36:18Z
NCT04966013,NA,7/9/2021,NA,NA,12/10/2021,7/13/2021,7/19/2021,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/13/2021,Estimate,17-Jun-21,Actual,6/17/2021,Dec-21,12/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19,"A Phase II, Randomized, Sham Controlled Dose Finding Study of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19",Recruiting,NA,Not Applicable,210,Anticipated,KNOWBio Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:36:21Z,2021-12-14T09:36:21Z
NCT04960215,NA,6/11/2021,NA,NA,12/8/2021,7/9/2021,7/13/2021,Actual,NA,NA,NA,NA,NA,NA,12/8/2021,12/13/2021,Estimate,25-May-21,Actual,5/25/2021,Jun-21,6/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,QVID,NA,Coenzyme Q10 as Treatment for Long Term COVID-19,Coenzyme Q10 as Treatment for Long Term COVID-19,Recruiting,NA,Phase 2,120,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-14T09:36:24Z,2021-12-14T09:36:24Z
NCT04749173,NA,1/20/2021,NA,NA,11/29/2021,2/9/2021,2/11/2021,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,12/13/2021,Estimate,21-Nov-20,Actual,11/21/2020,Feb-21,2/28/2021,18-Jun-21,Actual,6/18/2021,18-Jun-21,Actual,6/18/2021,NA,Interventional,NA,NA,"To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.","A Double-blind, Randomized, Placebo-controlled, Single-ascending Dose Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Following Intramuscular Administration in Healthy Volunteers",Completed,NA,Phase 1,24,Actual,Daewoong Pharmaceutical Co. LTD.,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:38:19Z,2021-12-14T09:38:19Z
NCT04876274,NA,5/5/2021,10/5/2021,NA,11/3/2021,5/5/2021,5/6/2021,Actual,11/3/2021,12/13/2021,Estimate,NA,NA,NA,11/3/2021,12/13/2021,Estimate,14-Jul-20,Actual,7/14/2020,Nov-21,11/30/2021,29-Dec-20,Actual,12/29/2020,29-Dec-20,Actual,12/29/2020,NA,Interventional,NA,NA,Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic,Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic: a Randomized Controlled Trial in Taiwan,Completed,NA,Not Applicable,181,Actual,Taipei Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:37:25Z,2021-12-14T09:37:25Z
NCT04721457,NA,1/19/2021,NA,NA,12/10/2021,1/19/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/13/2021,Estimate,3-Jan-21,Actual,1/3/2021,Dec-21,12/31/2021,10-Dec-21,Actual,12/10/2021,28-Mar-21,Actual,3/28/2021,NA,Interventional,NA,NA,The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load,The Efficacy of Pre-procedural Mouth Rinses on SARS-CoV-2 Saliva Viral Load: A Randomized Control Clinical Trial,Completed,NA,Phase 4,120,Actual,King Abdulaziz University,,5,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:38:32Z,2021-12-14T09:38:32Z
NCT04655586,NA,12/2/2020,NA,NA,12/9/2021,12/3/2020,12/7/2020,Actual,NA,NA,NA,NA,NA,NA,12/9/2021,12/13/2021,Estimate,10-Dec-20,Actual,12/10/2020,Dec-21,12/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,ASPEN,NA,"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19","Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN-COVID-19)","Active, not recruiting",NA,Phase 2/Phase 3,160,Anticipated,"ARCA Biopharma, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:38:52Z,2021-12-14T09:38:52Z
NCT04501796,NA,7/27/2020,NA,NA,12/10/2021,8/5/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/13/2021,Estimate,27-Nov-20,Actual,11/27/2020,Dec-21,12/31/2021,Jun-22,Anticipated,6/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,A Trial of NT-I7 in COVID-19 (SPESELPIS),"A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19",Recruiting,NA,Phase 1,30,Anticipated,NeoImmuneTech,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:40:18Z,2021-12-14T09:40:18Z
NCT04524598,NA,8/20/2020,9/30/2021,NA,12/9/2021,8/20/2020,8/24/2020,Actual,12/9/2021,12/13/2021,Estimate,NA,NA,NA,12/9/2021,12/13/2021,Estimate,20-Jul-20,Actual,7/20/2020,Dec-21,12/31/2021,16-Jan-22,Anticipated,1/16/2022,3-Sep-21,Actual,9/3/2021,NA,Interventional,NA,NA,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,Limbix Spark: A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,"Active, not recruiting",NA,Not Applicable,227,Actual,"Limbix Health, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:40:04Z,2021-12-14T09:40:04Z
NCT04366856,NA,4/26/2020,NA,NA,12/10/2021,4/28/2020,4/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/13/2021,Estimate,26-Jun-20,Actual,6/26/2020,Dec-21,12/31/2021,23-Sep-21,Actual,9/23/2021,23-Sep-21,Actual,9/23/2021,NA,Interventional,PROVID,NA,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Completed,NA,Not Applicable,446,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-14T09:41:05Z,2021-12-14T09:41:05Z
NCT04441996,NA,6/19/2020,NA,,12/8/2021,6/19/2020,6/22/2020,Actual,NA,NA,NA,,,,12/8/2021,12/13/2021,Estimate,17-Jul-20,Actual,7/17/2020,Dec-21,12/31/2021,18-Mar-21,Actual,3/18/2021,18-Mar-21,Actual,3/18/2021,NA,Interventional,NA,NA,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Completed,NA,Phase 4,20,Actual,Emory University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-14T09:40:39Z,2021-12-14T09:40:39Z
NCT04326075,NA,3/26/2020,NA,NA,12/10/2021,3/27/2020,3/30/2020,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/13/2021,Estimate,1-Dec-20,Actual,12/1/2020,Dec-21,12/31/2021,31-Jan-22,Anticipated,1/31/2022,30-Jun-21,Actual,6/30/2021,NA,Interventional,EC-COVID-RCT,NA,Early CPAP in COVID-19 Patients With Respiratory Failure.,EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial,Recruiting,NA,Not Applicable,900,Anticipated,Mario Negri Institute for Pharmacological Research,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-14T09:41:19Z,2021-12-14T09:41:19Z
NCT05157178,NA,12/10/2021,NA,NA,12/10/2021,12/10/2021,12/14/2021,Estimate,NA,NA,NA,NA,NA,NA,12/10/2021,12/14/2021,Estimate,20-Jun-21,Actual,6/20/2021,Dec-21,12/31/2021,27-Jun-22,Anticipated,6/27/2022,11-Feb-22,Anticipated,2/11/2022,NA,Interventional,NA,NA,Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.,Immunogenicity Study of the Covid-19 (Recombinante) Vaccine - Fiocruz/AstraZeneca When Administered With a 4 or 8 Weeks Interval Between the First Two Doses.,"Active, not recruiting",NA,Phase 4,1264,Actual,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:08:29Z,2021-12-15T09:08:29Z
NCT05157139,NA,12/10/2021,NA,NA,12/10/2021,12/10/2021,12/14/2021,Estimate,NA,NA,NA,NA,NA,NA,12/10/2021,12/14/2021,Estimate,1-Nov-21,Actual,11/1/2021,Dec-21,12/31/2021,Apr-22,Anticipated,4/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease,Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,Alexandria University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,up to March 2022,NA,NA,Yes,The research team will share after results,2021-12-15T09:08:31Z,2021-12-15T09:08:31Z
NCT05157230,NA,12/11/2021,NA,NA,12/11/2021,12/11/2021,12/14/2021,Estimate,NA,NA,NA,NA,NA,NA,12/11/2021,12/14/2021,Estimate,1-Sep-21,Actual,9/1/2021,Dec-21,12/31/2021,25-Dec-21,Anticipated,12/25/2021,15-Dec-21,Anticipated,12/15/2021,NA,Interventional,NA,NA,Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination,Evaluation of Deltoid Muscle Exercises on Injection Site and Arm Pain After Pfizer - BioNTech (BNT162b2) COVID - 19 Vaccination,Recruiting,NA,Not Applicable,300,Anticipated,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:08:26Z,2021-12-15T09:08:26Z
NCT05112913,NA,11/8/2021,NA,NA,12/13/2021,11/8/2021,11/9/2021,Actual,NA,NA,NA,NA,NA,NA,12/13/2021,12/14/2021,Estimate,27-Jul-21,Actual,7/27/2021,Oct-21,10/31/2021,25-Jun-22,Anticipated,6/25/2022,17-Nov-21,Actual,11/17/2021,NA,Interventional,NA,NA,Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years,"A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVacï¼‰Between Different Workshops for Prevention of COVID-19 in Healthy Children Aged 3-17 Years","Active, not recruiting",NA,Phase 4,2520,Anticipated,"Sinovac Biotech Co., Ltd",,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:10:31Z,2021-12-15T09:10:31Z
NCT05156723,NA,11/26/2021,NA,NA,12/13/2021,12/13/2021,12/14/2021,Estimate,NA,NA,NA,NA,NA,NA,12/13/2021,12/14/2021,Estimate,19-Jul-21,Actual,7/19/2021,Nov-21,11/30/2021,30-May-22,Anticipated,5/30/2022,30-Aug-21,Actual,8/30/2021,NA,Interventional,NA,NA,"The Objectives of This Study Are Study the Immunogenicity, Safety and Tolerability of the Coronavirus Vaccine in Healthy Adult Volunteer Aged 18 to 60 Years.","A Double-blind, Randomized, Prospective, Placebo-controlled Trial to Assess the Immunogenicity, Safety, and Tolerability of a Coronavirus Vaccine in Healthy Volunteers Aged 18 to 60 Years","Active, not recruiting",NA,Phase 1/Phase 2,155,Anticipated,St. Petersburg Research Institute of Vaccines and Sera,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:08:56Z,2021-12-15T09:08:56Z
NCT05137418,NA,11/26/2021,NA,NA,12/13/2021,11/26/2021,11/30/2021,Actual,NA,NA,NA,NA,NA,NA,12/13/2021,12/14/2021,Estimate,27-Nov-21,Actual,11/27/2021,Nov-21,11/30/2021,27-Feb-23,Anticipated,2/27/2023,27-Feb-22,Anticipated,2/27/2022,NA,Interventional,NA,NA,"Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years","An Open-labelled, Bridging Phase â…¢ Clinical Trial to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine in Healthy Population Aged From 3 to 11 Years","Active, not recruiting",NA,Phase 3,1000,Anticipated,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:10:09Z,2021-12-15T09:10:09Z
NCT04904744,NA,5/25/2021,NA,NA,12/13/2021,5/25/2021,5/27/2021,Actual,NA,NA,NA,NA,NA,NA,12/13/2021,12/14/2021,Estimate,28-May-21,Actual,5/28/2021,Dec-21,12/31/2021,10-Dec-21,Actual,12/10/2021,31-Oct-21,Actual,10/31/2021,NA,Interventional,NA,NA,"Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination","Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination",Completed,NA,Not Applicable,1235,Actual,"Children's Hospital Medical Center, Cincinnati",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-15T09:13:24Z,2021-12-15T09:13:24Z
NCT04530539,NA,8/26/2020,NA,NA,12/13/2021,8/26/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,12/13/2021,12/14/2021,Estimate,5-Oct-20,Actual,10/5/2020,Dec-21,12/31/2021,30-Jun-22,Anticipated,6/30/2022,1-Jul-21,Actual,7/1/2021,NA,Interventional,NA,NA,The Effect of Melatonin and Vitamin C on COVID-19,The Effect of Melatonin and Vitamin C on COVID-19,"Active, not recruiting",NA,Not Applicable,122,Actual,Lancaster General Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-15T09:17:25Z,2021-12-15T09:17:25Z
NCT04456153,NA,6/30/2020,11/10/2021,NA,12/12/2021,6/30/2020,7/2/2020,Actual,12/12/2021,12/14/2021,Estimate,NA,NA,NA,12/12/2021,12/14/2021,Estimate,22-Jul-20,Actual,7/22/2020,Dec-21,12/31/2021,31-Jan-21,Actual,1/31/2021,31-Jan-21,Actual,1/31/2021,NA,Interventional,NA,NA,Atovaquone for Treatment of COVID-19,Atovaquone for Treatment of COVID-19,Completed,NA,Phase 2,60,Actual,University of Texas Southwestern Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,There is no specified plan made.,2021-12-15T09:18:20Z,2021-12-15T09:18:20Z
NCT04460014,NA,7/6/2020,NA,NA,11/30/2021,7/6/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/14/2021,Estimate,30-Sep-20,Actual,9/30/2020,Nov-21,11/30/2021,1-Dec-22,Anticipated,12/1/2022,1-Aug-22,Anticipated,8/1/2022,NA,Interventional,NA,NA,Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT,"Reducing Intrusive Memories After Trauma Via a Simple Cognitive Intervention During COVID-19 in Hospital Staff: ""EKUT-P"" (Enkel Kognitiv Uppgift Efter Trauma Under COVID-19 - sjukvÃ¥rdspersonal) - A Randomized Controlled Trial (RCT)",Recruiting,NA,Not Applicable,164,Anticipated,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:18:11Z,2021-12-15T09:18:11Z
NCT04394169,NA,5/13/2020,NA,NA,12/13/2021,5/16/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/13/2021,12/14/2021,Estimate,25-May-20,Actual,5/25/2020,Dec-21,12/31/2021,22-Oct-21,Actual,10/22/2021,15-Oct-21,Actual,10/15/2021,NA,Interventional,PAIN-COVID,NA,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,"Early Care, Therapeutic Education, and Psychological Intervention for the Management of Post-intensive Care Syndrome and Chronic Pain After Coronavirus Disease 2019 Infection. Simple-blind, Controlled, Randomized Trial.",Completed,NA,Not Applicable,102,Actual,Hospital Clinic of Barcelona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-15T09:18:51Z,2021-12-15T09:18:51Z
NCT04351243,NA,4/15/2020,11/26/2021,NA,12/10/2021,4/15/2020,4/17/2020,Actual,12/6/2021,12/10/2021,Actual,NA,NA,NA,12/10/2021,12/14/2021,Estimate,15-Apr-20,Actual,4/15/2020,Dec-21,12/31/2021,1-Apr-21,Actual,4/1/2021,1-Dec-20,Actual,12/1/2020,NA,Interventional,NA,NA,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),"A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)",Completed,NA,Phase 2,227,Actual,Kinevant Sciences GmbH,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-15T09:19:10Z,2021-12-15T09:19:10Z
NCT04379518,NA,5/6/2020,NA,NA,12/10/2021,5/6/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/14/2021,Estimate,17-Nov-20,Actual,11/17/2020,Dec-21,12/31/2021,17-Nov-23,Anticipated,11/17/2023,17-Nov-23,Anticipated,11/17/2023,NA,Interventional,NA,NA,Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients,Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19,Recruiting,NA,Phase 1/Phase 2,64,Anticipated,Roswell Park Cancer Institute,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-15T09:19:05Z,2021-12-15T09:19:05Z
NCT04321174,NA,3/18/2020,NA,NA,11/29/2021,3/23/2020,3/25/2020,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,12/14/2021,Estimate,17-Apr-20,Actual,4/17/2020,Nov-21,11/30/2021,31-Mar-22,Anticipated,3/31/2022,27-Aug-21,Actual,8/27/2021,NA,Interventional,CORIPREV-LR,NA,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,"Active, not recruiting",NA,Phase 3,123,Actual,Unity Health Toronto,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,TBA,2021-12-15T09:19:22Z,2021-12-15T09:19:22Z
NCT05158855,NA,12/14/2021,NA,NA,12/14/2021,12/14/2021,12/15/2021,Estimate,NA,NA,NA,NA,NA,NA,12/14/2021,12/15/2021,Estimate,1-Jun-21,Actual,6/1/2021,Dec-21,12/31/2021,30-Jul-22,Anticipated,7/30/2022,20-Apr-22,Anticipated,4/20/2022,NA,Interventional,NA,NA,Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine,Human Pilot Test of an Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine,Recruiting,NA,Not Applicable,30,Anticipated,DreamTec Research Limited,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-16T09:09:45Z,2021-12-16T09:09:45Z
NCT05158842,NA,3/29/2021,NA,NA,12/14/2021,12/14/2021,12/15/2021,Estimate,NA,NA,NA,NA,NA,NA,12/14/2021,12/15/2021,Estimate,8-Oct-21,Actual,10/8/2021,Dec-21,12/31/2021,31-Jan-22,Anticipated,1/31/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,Adult-bCPAP,NA,Treatment of COVID-19 Positive/Negative Bangladeshi Adults With Severe Respiratory Complaints by a Locally Made bCPAP: Feasibility Study,Optimising the Treatment of COVID-19 Positive/Negative Adults With Severe Pneumonia and/or ARDS in Bangladesh Using an Adaptive Version of Locally Made Bubble CPAP: Feasibility Study,Recruiting,NA,Not Applicable,20,Anticipated,"International Centre for Diarrhoeal Disease Research, Bangladesh",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-16T09:09:45Z,2021-12-16T09:09:45Z
NCT05115071,NA,11/6/2021,NA,NA,12/14/2021,11/9/2021,11/10/2021,Actual,NA,NA,NA,NA,NA,NA,12/14/2021,12/15/2021,Estimate,8-Nov-21,Actual,11/8/2021,Dec-21,12/31/2021,10-Dec-21,Actual,12/10/2021,25-Nov-21,Actual,11/25/2021,NA,Interventional,NA,NA,Online Childbirth Preparation Education in Covid-19 Pandemic,"The Effect of Online Childbirth Preparation Education in Pregnancy on Worries and Fear of Birth, Preparation for Birth, and Well-being of Self and Baby in the Covid 19 Pandemic",Completed,NA,Not Applicable,44,Actual,Pamukkale University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-16T09:11:58Z,2021-12-16T09:11:58Z
NCT05076253,NA,10/8/2021,NA,NA,12/14/2021,10/12/2021,10/13/2021,Actual,NA,NA,NA,NA,NA,NA,12/14/2021,12/15/2021,Estimate,1-Sep-21,Actual,9/1/2021,Dec-21,12/31/2021,1-Dec-21,Actual,12/1/2021,1-Dec-21,Actual,12/1/2021,NA,Interventional,NA,NA,Efficacy of Ivermectin in COVID-19,"Efficacy and Safety of Ivermectin in Treatment of Mild to Moderate COVID-19 Infection: a Randomized ,Double Blind,Placebo,Controlled Trial",Completed,NA,Phase 1/Phase 2,72,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication,NA,NA,Yes,Data will be made available upon request after publication,2021-12-16T09:12:36Z,2021-12-16T09:12:36Z
NCT05030974,NA,8/20/2021,NA,NA,11/30/2021,8/26/2021,9/1/2021,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/15/2021,Estimate,21-Oct-21,Actual,10/21/2021,Nov-21,11/30/2021,Jan-23,Anticipated,1/31/2023,Nov-22,Anticipated,11/30/2022,NA,Interventional,NA,NA,RECOVAC Third Vaccination Study,"Optimal Third Dose Strategy for SARS-CoV-2 Vaccination in Kidney Transplant Patients A Prospective, Randomized Multicenter Study by the REnal Patients COVID-19 VACcination (RECOVAC) Consortium",Recruiting,NA,Phase 4,460,Anticipated,University Medical Center Groningen,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The data of this study will be available from the principal investigator, upon reasonable request.",2021-12-16T09:13:25Z,2021-12-16T09:13:25Z
NCT04739020,NA,2/1/2021,NA,NA,12/14/2021,2/1/2021,2/4/2021,Actual,NA,NA,NA,NA,NA,NA,12/14/2021,12/15/2021,Estimate,18-Jan-21,Actual,1/18/2021,Dec-21,12/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,Respiratory Aerosols in Patients With COVID-19 and Healthy Controls,Measurement of Respiratory Aerosols in PCR SARS-CoV-2 Positive and Negative Children and Adults,Recruiting,NA,Not Applicable,525,Anticipated,Johann Wolfgang Goethe University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"After end of study, anticipated between June and December 2021",The data will be available after the end of study and successful publication of the results (anticipated June 2022) for 10 years,NA,Yes,Anonymized data will be provided of the investigated cohort,2021-12-16T09:16:39Z,2021-12-16T09:16:39Z
NCT04644172,NA,11/23/2020,NA,NA,11/30/2021,11/23/2020,11/25/2020,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/15/2021,Estimate,1-Nov-20,Actual,11/1/2020,Nov-21,11/30/2021,Nov-24,Anticipated,11/30/2024,Nov-23,Anticipated,11/30/2023,NA,Interventional,NA,NA,Improving Thinking in Everyday Life After Covid-19,Improving Thinking in Everyday Life: Pilot Study C,Recruiting,NA,Not Applicable,40,Anticipated,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,This is pilot study. A major purpose of this study is simply to develop the intervention. Sharing individual data is premature.,2021-12-16T09:17:16Z,2021-12-16T09:17:16Z
NCT04682197,NA,12/16/2020,NA,NA,12/14/2021,12/22/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,12/14/2021,12/15/2021,Estimate,14-Dec-21,Actual,12/14/2021,Aug-21,8/31/2021,Nov-23,Anticipated,11/30/2023,Nov-22,Anticipated,11/30/2022,NA,Interventional,NA,NA,Cereset Research In Healthcare Workers During COVID-19,Cereset Research To Reduce Stress In Healthcare Workers In The Time Of COVID-19,Recruiting,NA,Not Applicable,138,Anticipated,Wake Forest University Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-16T09:17:01Z,2021-12-16T09:17:01Z
NCT04377672,NA,5/4/2020,NA,NA,12/14/2021,5/4/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,12/14/2021,12/15/2021,Estimate,28-May-20,Actual,5/28/2020,Dec-21,12/31/2021,13-Dec-21,Actual,12/13/2021,1-Sep-21,Actual,9/1/2021,NA,Interventional,NA,NA,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2,Completed,NA,Phase 1,14,Actual,Johns Hopkins University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-16T09:19:45Z,2021-12-16T09:19:45Z
NCT04519216,NA,8/12/2020,NA,NA,12/13/2021,8/18/2020,8/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/13/2021,12/15/2021,Estimate,31-Jul-20,Actual,7/31/2020,Dec-21,12/31/2021,10-Dec-21,Actual,12/10/2021,30-Oct-21,Actual,10/30/2021,NA,Interventional,NA,NA,Breastfeeding Education in the Time of COVID-19,"Breastfeeding Education in the Time of COVID-19. Hybrid Telesimulation With Standardized Patients for Pediatric and Family Medicine Trainees, a Randomized Trial",Completed,NA,Not Applicable,46,Actual,"University of California, Davis",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-16T09:18:48Z,2021-12-16T09:18:48Z
NCT05022472,NA,8/18/2021,NA,NA,12/14/2021,8/24/2021,8/26/2021,Actual,NA,NA,NA,NA,NA,NA,12/14/2021,12/16/2021,Estimate,16-Jul-21,Actual,7/16/2021,Dec-21,12/31/2021,31-Jan-26,Anticipated,1/31/2026,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,2VIDA!,NA,Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California,Project 2VIDA! SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California,Recruiting,NA,Phase 4,1000,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:16:31Z,2021-12-17T09:16:31Z
NCT04345861,NA,4/5/2020,NA,NA,12/14/2021,4/9/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,12/14/2021,12/15/2021,Estimate,11-Apr-20,Actual,4/11/2020,Dec-21,12/31/2021,9-Apr-21,Actual,4/9/2021,9-Feb-21,Actual,2/9/2021,NA,Interventional,COVIDOC,NA,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia,Terminated,NA,Phase 2/Phase 3,7,Actual,"University Hospital, Montpellier",,2,NA,halted prematurely.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-16T09:19:58Z,2021-12-16T09:19:58Z
NCT05160766,NA,11/11/2021,NA,NA,12/14/2021,12/14/2021,12/16/2021,Estimate,NA,NA,NA,NA,NA,NA,12/14/2021,12/16/2021,Estimate,8-Nov-21,Actual,11/8/2021,Dec-21,12/31/2021,May-23,Anticipated,5/31/2023,Apr-22,Anticipated,4/30/2022,NA,Interventional,EU-COVAT-1,NA,Assessing Immune Response of Different COVID-19 Vaccines in Older Adults,"A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (â‰¥75) Already Vaccinated Against SARS-COV-2 (EU-COVAT-1_AGED)",Recruiting,NA,Phase 2,600,Anticipated,University of Cologne,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:11:27Z,2021-12-17T09:11:27Z
NCT05132855,NA,11/11/2021,NA,NA,12/6/2021,11/22/2021,11/24/2021,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/16/2021,Estimate,30-Nov-21,Actual,11/30/2021,Nov-21,11/30/2021,Apr-23,Anticipated,4/30/2023,Apr-23,Anticipated,4/30/2023,NA,Interventional,NA,NA,The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine,"Safety, Reactogenicity, and Immunogenicity of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine: a Single-blind and Randomized Study",Recruiting,NA,Phase 1/Phase 2,400,Anticipated,Chang Gung Memorial Hospital,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-17T09:14:02Z,2021-12-17T09:14:02Z
NCT05043324,NA,9/8/2021,NA,NA,12/1/2021,9/10/2021,9/14/2021,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/16/2021,Estimate,20-Feb-20,Actual,2/20/2020,Dec-21,12/31/2021,27-Feb-22,Anticipated,2/27/2022,20-Feb-22,Anticipated,2/20/2022,NA,Interventional,AntiCov-220,NA,"Prevention and Treatment of Patient Before, During, and After Covid-19 Infection","Prevention and Treatment of Patient Before, During, and After Covid-19 Infection","Active, not recruiting",NA,Phase 2,82,Anticipated,"Trieu, Nguyen Thi, M.D.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:16:01Z,2021-12-17T09:16:01Z
NCT05000216,NA,8/6/2021,NA,NA,12/15/2021,8/6/2021,8/11/2021,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/16/2021,Estimate,13-Aug-21,Actual,8/13/2021,Dec-21,12/31/2021,Dec-22,Anticipated,12/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders,Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01),Recruiting,NA,Phase 2,600,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,15,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"On average, within 24 months after database lock for the trial.",Open access.,https://www.immport.org/home,Yes,"The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.",2021-12-17T09:16:49Z,2021-12-17T09:16:49Z
NCT04967742,NA,7/12/2021,NA,NA,12/15/2021,7/15/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/16/2021,Estimate,5-Aug-21,Actual,8/5/2021,Sep-21,9/30/2021,31-Oct-21,Actual,10/31/2021,22-Aug-21,Actual,8/22/2021,NA,Interventional,NA,NA,"A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-Label Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,NA,Phase 1,50,Actual,"United Biomedical Inc., Asia",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:17:19Z,2021-12-17T09:17:19Z
NCT04880642,NA,4/28/2021,NA,NA,12/15/2021,5/10/2021,5/11/2021,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/16/2021,Estimate,16-Sep-21,Actual,9/16/2021,Dec-21,12/31/2021,Mar-22,Anticipated,3/31/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,ATTRACT-3,NA,A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as Add on to Standard of Care in Adult Subjects With COVID-19.",Recruiting,NA,Phase 3,600,Anticipated,Vicore Pharma AB,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-17T09:18:41Z,2021-12-17T09:18:41Z
NCT04805671,NA,3/17/2021,NA,NA,12/15/2021,3/17/2021,3/18/2021,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/16/2021,Estimate,26-Jul-21,Actual,7/26/2021,Dec-21,12/31/2021,Feb-23,Anticipated,2/28/2023,Jan-22,Anticipated,1/31/2022,NA,Interventional,STAMP,NA,Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19,"A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants With Mild or Moderate COVID-19 (STAMP)",Recruiting,NA,Phase 2/Phase 3,1084,Anticipated,"Adagio Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-17T09:19:47Z,2021-12-17T09:19:47Z
NCT04784559,NA,3/4/2021,NA,NA,12/15/2021,3/4/2021,3/5/2021,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/16/2021,Estimate,4-Jun-21,Actual,6/4/2021,Dec-21,12/31/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,Neptuno,NA,Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection,"A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patient Requiring Hospitalisation for Management of Moderate COVID-19 Infection",Recruiting,NA,Phase 3,609,Anticipated,PharmaMar,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:19:58Z,2021-12-17T09:19:58Z
NCT04690387,NA,12/28/2020,NA,NA,12/14/2021,12/29/2020,12/30/2020,Actual,NA,NA,NA,NA,NA,NA,12/14/2021,12/16/2021,Estimate,7-Dec-20,Actual,12/7/2020,Dec-21,12/31/2021,15-Jan-21,Actual,1/15/2021,13-Jan-21,Actual,1/13/2021,NA,Interventional,NA,NA,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Completed,NA,Phase 1,27,Actual,"Aivita Biomedical, Inc.",,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-17T09:21:07Z,2021-12-17T09:21:07Z
NCT04661813,NA,10/29/2020,NA,NA,12/1/2021,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/16/2021,Estimate,1-Mar-21,Actual,3/1/2021,Dec-21,12/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,AAIM-High,NA,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,Recruiting,NA,Not Applicable,75,Anticipated,Case Western Reserve University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication of the primary manuscript,Data will be made available upon request or on a data share site after publication of the primary manuscript.,NA,Yes,"In collaboration with the National Institutes of Health funding body, we will develop a process to facilitate providing other investigators with access to appropriately de-identified study data. We will make the following available upon request after the primary manuscript is published: de-identified data set, trial description information, data collection forms, and data structure.",2021-12-17T09:21:28Z,2021-12-17T09:21:28Z
NCT04545008,NA,9/1/2020,NA,NA,12/1/2021,9/9/2020,9/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/16/2021,Estimate,20-Oct-20,Actual,10/20/2020,Dec-21,12/31/2021,2-Jun-21,Actual,6/2/2021,2-Jun-21,Actual,6/2/2021,NA,Interventional,NA,NA,Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19,A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection,Terminated,NA,Phase 1,2,Actual,Prisma Health-Upstate,,12,NA,Study was stopped due to poor accrual.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-17T09:22:55Z,2021-12-17T09:22:55Z
NCT04439071,NA,6/17/2020,NA,NA,12/15/2021,6/17/2020,6/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/16/2021,Estimate,9-Jul-20,Actual,7/9/2020,Dec-21,12/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,FITE19,NA,A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19),Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19),Recruiting,NA,Phase 2/Phase 3,380,Anticipated,PTC Therapeutics,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-17T09:24:09Z,2021-12-17T09:24:09Z
NCT04499677,NA,6/16/2020,NA,NA,12/14/2021,8/3/2020,8/5/2020,Actual,NA,NA,NA,NA,NA,NA,12/14/2021,12/16/2021,Estimate,24-Sep-20,Actual,9/24/2020,Dec-21,12/31/2021,1-Dec-21,Actual,12/1/2021,1-Dec-21,Actual,12/1/2021,NA,Interventional,FLARE,NA,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,"Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19",Completed,NA,Phase 2,240,Actual,"University College, London",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,No plan to share IPD has been made at this time.,2021-12-17T09:23:27Z,2021-12-17T09:23:27Z
NCT04378920,NA,5/5/2020,NA,NA,12/15/2021,5/6/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/16/2021,Estimate,14-Apr-20,Actual,4/14/2020,Dec-21,12/31/2021,24-Aug-21,Actual,8/24/2021,24-Aug-21,Actual,8/24/2021,NA,Interventional,NA,NA,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes","A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Completed,NA,Phase 1/Phase 2,37,Actual,Institut de cancÃ©rologie Strasbourg Europe,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-17T09:24:54Z,2021-12-17T09:24:54Z
NCT04390178,NA,4/10/2020,NA,NA,12/1/2021,5/13/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/16/2021,Estimate,10-Apr-20,Actual,4/10/2020,Dec-21,12/31/2021,31-Dec-20,Actual,12/31/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,NA,NA,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease,Completed,NA,Phase 1/Phase 2,10,Actual,Karolinska University Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,We will be sharing data but data the management plan is being designed.,2021-12-17T09:24:35Z,2021-12-17T09:24:35Z
NCT04381936,NA,5/7/2020,NA,NA,12/15/2021,5/7/2020,5/11/2020,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/16/2021,Estimate,19-Mar-20,Actual,3/19/2020,Dec-21,12/31/2021,Nov-32,Anticipated,11/30/2032,Nov-22,Anticipated,11/30/2022,NA,Interventional,RECOVERY,NA,Randomised Evaluation of COVID-19 Therapy,Randomised Evaluation of COVID-19 Therapy,Recruiting,NA,Phase 2/Phase 3,45000,Anticipated,University of Oxford,,16,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,Proposals for substudies must be approved by the Trial Steering Committee. Procedures for accessing the data for this study are available on https://www.ndph.ox.ac.uk/data-access,https://www.ndph.ox.ac.uk/data-access,Yes,The data-sharing plans for this study have been provided in the Data Sharing Statement in RECOVERY publication: N Engl J Med. 2020 Jul 17;NEJMoa2021436. doi: 10.1056/NEJMoa2021436,2021-12-17T09:24:49Z,2021-12-17T09:24:49Z
NCT04328961,NA,3/23/2020,10/8/2021,NA,12/14/2021,3/29/2020,4/1/2020,Actual,12/14/2021,12/16/2021,Estimate,NA,NA,NA,12/14/2021,12/16/2021,Estimate,31-Mar-20,Actual,3/31/2020,Dec-21,12/31/2021,8-Oct-20,Actual,10/8/2020,24-Sep-20,Actual,9/24/2020,NA,Interventional,NA,The above participants contributed to the Modified Intention-to-Treat Cohort.,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Completed,NA,Phase 2/Phase 3,943,Actual,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2021-12-17T09:25:19Z,2021-12-17T09:25:19Z
NCT05135624,NA,11/9/2021,NA,NA,12/10/2021,11/23/2021,11/26/2021,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/17/2021,Estimate,1-Dec-21,Actual,12/1/2021,Dec-21,12/31/2021,Mar-24,Anticipated,3/31/2024,Mar-23,Anticipated,3/31/2023,NA,Interventional,NA,NA,SP16 as a Therapeutic for COVID-19 Induced ARDS,SP16 as a Therapeutic for SARS-CoV-2 Induced ARDS,Recruiting,NA,Phase 1/Phase 2,20,Anticipated,"Serpin Pharma, LLC",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-18T09:12:49Z,2021-12-18T09:12:49Z
NCT05067933,NA,9/16/2021,NA,NA,12/15/2021,10/1/2021,10/5/2021,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/17/2021,Estimate,1-Oct-21,Actual,10/1/2021,Dec-21,12/31/2021,Jun-23,Anticipated,6/30/2023,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine,"A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety, Immunogenicity and Efficacy of an Adenoviral-Vector Based Vaccine Expressing Severe Acute Respiratory Syndrome (SARS-CoV-2) and dsRNA Adjuvant Administered Orally",Recruiting,NA,Phase 2,896,Anticipated,Vaxart,,10,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-18T09:14:37Z,2021-12-18T09:14:37Z
NCT04889209,NA,5/13/2021,NA,NA,12/2/2021,5/13/2021,5/17/2021,Actual,NA,NA,NA,NA,NA,NA,12/2/2021,12/17/2021,Estimate,28-May-21,Actual,5/28/2021,23-Nov-21,11/23/2021,1-Dec-22,Anticipated,12/1/2022,1-Dec-22,Anticipated,12/1/2022,NA,Interventional,NA,NA,Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines,A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines,Recruiting,NA,Phase 1/Phase 2,950,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,15,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-18T09:17:34Z,2021-12-18T09:17:34Z
NCT04765449,NA,2/19/2021,NA,NA,12/15/2021,2/19/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/17/2021,Estimate,15-Sep-21,Actual,9/15/2021,Dec-21,12/31/2021,29-Jul-22,Anticipated,7/29/2022,29-Jul-22,Anticipated,7/29/2022,NA,Interventional,NA,NA,Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection,Third-Party COVID-19-Specific Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients With COVID-19 Infection,Recruiting,NA,Phase 1,24,Anticipated,Thomas Jefferson University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-18T09:19:15Z,2021-12-18T09:19:15Z
NCT04911777,NA,6/1/2021,NA,NA,12/16/2021,6/2/2021,6/3/2021,Actual,NA,NA,NA,NA,NA,NA,12/16/2021,12/17/2021,Estimate,24-Aug-21,Actual,8/24/2021,Dec-21,12/31/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandirâ„¢ UPPTA for Patients With Early COVID-19","A Randomized, Double-Blind, Placebo-Controlled, Proof of Principle Study of Pentarlandirâ„¢ UPPTA for the Treatment of Patients With Early COVID-19",Recruiting,NA,Phase 2,90,Anticipated,SyneuRx International (Taiwan) Corp,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-18T09:17:10Z,2021-12-18T09:17:10Z
NCT04518410,NA,8/17/2020,NA,NA,12/15/2021,8/18/2020,8/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/17/2021,Estimate,19-Aug-20,Actual,8/19/2020,Dec-21,12/31/2021,31-Dec-23,Anticipated,12/31/2023,31-Dec-23,Anticipated,12/31/2023,NA,Interventional,NA,NA,ACTIV-2: A Study for Outpatients With COVID-19,Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID),Recruiting,NA,Phase 2/Phase 3,8797,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,15,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-18T09:21:55Z,2021-12-18T09:21:55Z
NCT04526912,NA,8/21/2020,NA,NA,12/16/2021,8/21/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,12/16/2021,12/17/2021,Estimate,28-Aug-20,Actual,8/28/2020,Dec-21,12/31/2021,19-May-21,Actual,5/19/2021,8-Apr-21,Actual,4/8/2021,NA,Interventional,ALI,NA,Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,A Proof of Concept Study of the Safety and Efficacy of VIB7734 for the Treatment and Prevention of Acute Lung Injury (ALI) in Patients With SARS-CoV-2 Infection,Terminated,NA,Phase 1,10,Actual,Viela Bio,,2,NA,Study met predefined futility criteria for efficacy endpoints.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-18T09:21:48Z,2021-12-18T09:21:48Z
NCT04402944,NA,5/12/2020,NA,NA,12/7/2021,5/25/2020,5/27/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/17/2021,Estimate,5-Jul-20,Actual,7/5/2020,Dec-21,12/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Pulmozyme to Improve COVID-19 ARDS Outcomes,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,NA,Phase 2,60,Anticipated,Boston Children's Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-18T09:22:59Z,2021-12-18T09:22:59Z
NCT04376593,NA,5/3/2020,NA,NA,12/16/2021,5/4/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,12/16/2021,12/17/2021,Estimate,1-May-20,Actual,5/1/2020,Dec-21,12/31/2021,Dec-22,Anticipated,12/31/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,PET/CT Imaging in COVID-19 Patients,18F-Î±vÎ²6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection,Enrolling by invitation,NA,Early Phase 1,10,Anticipated,"University of California, Davis",,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-18T09:23:32Z,2021-12-18T09:23:32Z
NCT05163496,NA,12/6/2021,NA,NA,12/6/2021,12/6/2021,12/20/2021,Estimate,NA,NA,NA,NA,NA,NA,12/6/2021,12/20/2021,Estimate,15-Dec-21,Anticipated,12/15/2021,Dec-21,12/31/2021,Dec-23,Anticipated,12/31/2023,Jan-23,Anticipated,1/31/2023,NA,Interventional,NA,NA,Frontline Clinician Psilocybin Study,"A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout",Recruiting,NA,Phase 1/Phase 2,30,Anticipated,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,We anticipate sharing these data starting with publication of study results and for at least 3 years.,To be determined.,NA,Yes,IPD that underlie results in a publication,2021-12-21T09:12:14Z,2021-12-21T09:12:14Z
NCT05164120,NA,12/15/2021,NA,NA,12/16/2021,12/16/2021,12/20/2021,Estimate,NA,NA,NA,NA,NA,NA,12/16/2021,12/20/2021,Estimate,14-Dec-21,Actual,12/14/2021,Dec-21,12/31/2021,1-Oct-22,Anticipated,10/1/2022,1-Apr-22,Anticipated,4/1/2022,NA,Interventional,NA,NA,"Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19","A Proof of Concept, Randomized, Double-blind, Placebo-controlled Trial of Orally Administered Belnacasan Tablets for the Treatment of Mild to Moderate COVID-19",Recruiting,NA,Phase 2,40,Anticipated,Medstar Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-21T09:11:40Z,2021-12-21T09:11:40Z
NCT05163743,NA,12/16/2021,NA,NA,12/16/2021,12/16/2021,12/20/2021,Estimate,NA,NA,NA,NA,NA,NA,12/16/2021,12/20/2021,Estimate,23-May-21,Actual,5/23/2021,Dec-21,12/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Diet and COVID-19 Vaccination,COVID-19 Vaccination in Subjects With Obesity: Impact of Metabolic Health and the Role of a Ketogenic Diet,Recruiting,NA,Not Applicable,24,Anticipated,University of Roma La Sapienza,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:12:01Z,2021-12-21T09:12:01Z
NCT05163730,NA,11/6/2021,NA,NA,12/17/2021,12/17/2021,12/20/2021,Estimate,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,1-Nov-21,Actual,11/1/2021,Dec-21,12/31/2021,30-Jun-22,Anticipated,6/30/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Clinical Evaluation of the Panbioâ„¢ COVID-19/ Flu A&B Rapid Panel,Clinical Evaluation of the Panbioâ„¢ COVID-19/ Flu A&B Rapid Panel,Recruiting,NA,Not Applicable,665,Anticipated,Abbott Rapid Diagnostics Jena GmbH,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:12:02Z,2021-12-21T09:12:02Z
NCT05163613,NA,12/17/2021,NA,NA,12/17/2021,12/17/2021,12/20/2021,Estimate,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,1-Jan-21,Actual,1/1/2021,Dec-21,12/31/2021,1-Apr-22,Anticipated,4/1/2022,1-Apr-21,Actual,4/1/2021,NA,Interventional,NA,NA,Use of Low-frequency Magnetic Fields in the Hybrid Treatment of COVID-19 Patients,Use of Low-frequency Magnetic Fields in the Hybrid Treatment of COVID-19 Patients: Preliminary Reports.,"Active, not recruiting",NA,Not Applicable,120,Anticipated,Medical University of Lodz,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:12:08Z,2021-12-21T09:12:08Z
NCT04969250,NA,7/16/2021,NA,NA,12/17/2021,7/16/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,25-Aug-21,Actual,8/25/2021,Dec-21,12/31/2021,Jul-22,Anticipated,7/31/2022,Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,Vaccination for Recovered Inpatients With COVID-19 (VATICO),SARS-CoV-2 Vaccination Strategies in Previously Hospitalized and Recovered COVID-19 Patients,Recruiting,NA,Phase 4,640,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-21T09:16:28Z,2021-12-21T09:16:28Z
NCT05140005,NA,11/29/2021,NA,NA,12/17/2021,11/29/2021,12/1/2021,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,6-Dec-21,Actual,12/6/2021,Dec-21,12/31/2021,17-Dec-21,Actual,12/17/2021,14-Dec-21,Actual,12/14/2021,NA,Interventional,NA,NA,GlowTest COVID-19 Antigen Home Test Kit QRI Use Study,GlowTest COVID-19 Antigen Home Test Kit Usability Study,Completed,NA,Not Applicable,33,Actual,Arion Bio,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:13:33Z,2021-12-21T09:13:33Z
NCT05074446,NA,10/10/2021,NA,NA,12/6/2021,10/10/2021,10/12/2021,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/20/2021,Estimate,15-Nov-21,Actual,11/15/2021,Dec-21,12/31/2021,31-Jan-22,Anticipated,1/31/2022,1-Jan-22,Anticipated,1/1/2022,NA,Interventional,NA,NA,Stereotype Threat Effect On the Performance of the Non-Intensivist Physicians Assigned in Covid-19 Intensive Care Unit,Stereotype Threat Effect On the Performance of the Non-Intensivist Physicians Assigned in Covid-19 Intensive Care Unit,Recruiting,NA,Not Applicable,40,Anticipated,Hacettepe University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,at the end of the study,NA,NA,Yes,Ä°ndividual participant data (IPD) will be anonymized to available to other researchers.,2021-12-21T09:14:59Z,2021-12-21T09:14:59Z
NCT04959760,NA,7/1/2021,NA,NA,12/17/2021,7/12/2021,7/13/2021,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,3-Jun-21,Actual,6/3/2021,Dec-21,12/31/2021,30-Mar-22,Anticipated,3/30/2022,30-Mar-22,Anticipated,3/30/2022,NA,Interventional,NA,NA,BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test,Clinical Evaluation of the BinaxNOWâ„¢ COVID-19 IgG Rapid Test Device and the BinaxNOWâ„¢ COVID-19 Antibody Self Test Clinical Study Protocol,Recruiting,NA,Not Applicable,185,Anticipated,Abbott Rapid Diagnostics Jena GmbH,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:16:36Z,2021-12-21T09:16:36Z
NCT04813497,NA,3/21/2021,NA,NA,12/3/2021,3/23/2021,3/24/2021,Actual,NA,NA,NA,NA,NA,NA,12/3/2021,12/20/2021,Estimate,5-Feb-21,Actual,2/5/2021,Dec-21,12/31/2021,25-Dec-21,Anticipated,12/25/2021,25-Dec-21,Anticipated,12/25/2021,NA,Interventional,NA,NA,Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members,Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members: Protocol for an Interventional Cohort Study in 2020-2021,Enrolling by invitation,NA,Not Applicable,4000,Anticipated,Grand HÃ´pital de Charleroi,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:18:16Z,2021-12-21T09:18:16Z
NCT04501978,NA,8/3/2020,NA,NA,12/17/2021,8/5/2020,8/6/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,4-Aug-20,Actual,8/4/2020,Dec-21,12/31/2021,Jul-22,Anticipated,7/31/2022,Jul-22,Anticipated,7/31/2022,NA,Interventional,TICO,NA,ACTIV-3: Therapeutics for Inpatients With COVID-19,"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19",Recruiting,NA,Phase 3,10000,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-21T09:20:52Z,2021-12-21T09:20:52Z
NCT04858425,NA,4/21/2021,NA,NA,12/17/2021,4/21/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,30-Apr-21,Actual,4/30/2021,Nov-21,11/30/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,RESERVOIR,NA,Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection,"A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection",Recruiting,NA,Phase 2,159,Anticipated,"AzurRx BioPharma, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:17:53Z,2021-12-21T09:17:53Z
NCT04843761,NA,4/9/2021,NA,NA,12/17/2021,4/9/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,20-Apr-21,Actual,4/20/2021,Dec-21,12/31/2021,Apr-23,Anticipated,4/30/2023,Oct-22,Anticipated,10/31/2022,NA,Interventional,TESICO,NA,ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19,"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With Acute Respiratory Distress Syndrome Associated With COVID-19",Recruiting,NA,Phase 3,640,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-21T09:18:05Z,2021-12-21T09:18:05Z
NCT04816669,NA,3/24/2021,NA,NA,12/17/2021,3/24/2021,3/25/2021,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,1-Apr-21,Actual,4/1/2021,Dec-21,12/31/2021,1-Dec-21,Actual,12/1/2021,1-Dec-21,Actual,12/1/2021,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE",Completed,NA,Phase 3,629,Actual,BioNTech SE,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-21T09:18:14Z,2021-12-21T09:18:14Z
NCT04762186,NA,2/11/2021,NA,NA,12/17/2021,2/18/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,8-Dec-21,Actual,12/8/2021,Dec-21,12/31/2021,1-Feb-23,Anticipated,2/1/2023,1-Feb-23,Anticipated,2/1/2023,NA,Interventional,ACT-COVID-19,NA,Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19,A Phase I/ Randomized Phase II Trial to Analyse Safety and Efficacy of Human SARS-CoV-2-specific T Lymphocyte Transfer in Patients With COVID-19 in Need of Treatment or at Risk of Severe COVID-19,Recruiting,NA,Phase 1,12,Anticipated,UniversitÃ¤tsklinikum KÃ¶ln,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-21T09:18:41Z,2021-12-21T09:18:41Z
NCT04760730,NA,2/17/2021,NA,NA,12/9/2021,2/17/2021,2/18/2021,Actual,NA,NA,NA,NA,NA,NA,12/9/2021,12/20/2021,Estimate,13-Jul-21,Actual,7/13/2021,Dec-21,12/31/2021,30-Jun-22,Anticipated,6/30/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,NA,NA,Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19),A Phase I/II Single-Blinded Randomised Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID-19,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,R-Pharm,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-21T09:18:42Z,2021-12-21T09:18:42Z
NCT04681092,NA,12/22/2020,NA,NA,12/9/2021,12/22/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,12/9/2021,12/20/2021,Estimate,6-Apr-21,Actual,4/6/2021,Dec-21,12/31/2021,30-May-22,Anticipated,5/30/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,ACT,NA,Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study,Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study,"Active, not recruiting",NA,Phase 1/Phase 2,112,Actual,University Medical Center Groningen,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:19:22Z,2021-12-21T09:19:22Z
NCT04662086,NA,12/8/2020,NA,NA,12/17/2021,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,23-Apr-21,Actual,4/23/2021,May-21,5/31/2021,Aug-22,Anticipated,8/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19",Recruiting,NA,Phase 2,240,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:19:28Z,2021-12-21T09:19:28Z
NCT04662073,NA,12/8/2020,NA,NA,12/17/2021,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,23-Apr-21,Actual,4/23/2021,May-21,5/31/2021,Aug-22,Anticipated,8/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,COPPS,NA,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19","Active, not recruiting",NA,Phase 2,120,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:19:29Z,2021-12-21T09:19:29Z
NCT04662060,NA,12/8/2020,NA,NA,12/17/2021,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,23-Apr-21,Actual,4/23/2021,May-21,5/31/2021,Aug-22,Anticipated,8/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,COPPS,NA,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19",Recruiting,NA,Phase 2,120,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:19:30Z,2021-12-21T09:19:30Z
NCT04591015,NA,10/5/2020,NA,NA,12/16/2021,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/16/2021,12/20/2021,Estimate,1-Feb-21,Actual,2/1/2021,Dec-21,12/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19,Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19,Recruiting,NA,Phase 3,172,Anticipated,Scripps Whittier Diabetes Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:20:11Z,2021-12-21T09:20:11Z
NCT04588480,NA,10/14/2020,NA,NA,12/17/2021,10/14/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,21-Oct-20,Actual,10/21/2020,Dec-21,12/31/2021,25-Nov-21,Actual,11/25/2021,25-Nov-21,Actual,11/25/2021,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS",Completed,NA,Phase 1/Phase 2,160,Actual,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-21T09:20:13Z,2021-12-21T09:20:13Z
NCT04588428,NA,10/6/2020,NA,NA,12/17/2021,10/13/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,21-Jun-21,Actual,6/21/2021,Dec-21,12/31/2021,15-Jun-24,Anticipated,6/15/2024,15-Jun-24,Anticipated,6/15/2024,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers","Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers",Recruiting,NA,Phase 2,542,Anticipated,Inovio Pharmaceuticals,,10,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,TRUE,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-12-21T09:20:14Z,2021-12-21T09:20:14Z
NCT04568122,NA,9/25/2020,NA,NA,12/17/2021,9/26/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,20-Nov-20,Actual,11/20/2020,Apr-21,4/30/2021,Nov-22,Anticipated,11/30/2022,Nov-22,Anticipated,11/30/2022,NA,Interventional,NA,NA,"Rapid Turnaround, Home-based Saliva Testing for COVID-19","Rapid Turnaround, Home-based Saliva Testing for COVID-19",Recruiting,NA,Not Applicable,3015,Anticipated,Stanford University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:20:31Z,2021-12-21T09:20:31Z
NCT04466800,NA,7/9/2020,NA,NA,12/17/2021,7/9/2020,7/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,30-Jul-20,Actual,7/30/2020,Dec-21,12/31/2021,30-Jun-23,Anticipated,6/30/2023,31-Jul-22,Anticipated,7/31/2022,NA,Interventional,RECOVER-19,NA,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients,Recruiting,NA,Not Applicable,160,Anticipated,Rennes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:21:07Z,2021-12-21T09:21:07Z
NCT04373707,NA,5/1/2020,NA,NA,12/17/2021,5/1/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,13-May-20,Actual,5/13/2020,Dec-21,12/31/2021,14-Sep-21,Actual,9/14/2021,29-Apr-21,Actual,4/29/2021,NA,Interventional,COVI-DOSE,NA,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE,Completed,NA,Phase 4,1000,Actual,"Central Hospital, Nancy, France",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:21:42Z,2021-12-21T09:21:42Z
NCT04431453,NA,6/8/2020,NA,NA,12/17/2021,6/11/2020,6/16/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,21-Jul-20,Actual,7/21/2020,Dec-21,12/31/2021,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,CARAVAN,NA,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)","A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With COVID-19",Recruiting,NA,Phase 2/Phase 3,52,Anticipated,Gilead Sciences,,1,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:21:20Z,2021-12-21T09:21:20Z
NCT04372628,NA,4/30/2020,NA,NA,12/17/2021,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/20/2021,Estimate,1-Jun-20,Actual,6/1/2020,Dec-21,12/31/2021,1-Jun-22,Anticipated,6/1/2022,1-Apr-22,Anticipated,4/1/2022,NA,Interventional,TREATNOW,NA,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19,"Active, not recruiting",NA,Phase 2,600,Anticipated,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-21T09:21:44Z,2021-12-21T09:21:44Z
NCT05166005,NA,12/12/2021,NA,NA,12/20/2021,12/20/2021,12/21/2021,Estimate,NA,NA,NA,NA,NA,NA,12/20/2021,12/21/2021,Estimate,1-Apr-20,Actual,4/1/2020,Dec-21,12/31/2021,1-Dec-22,Anticipated,12/1/2022,23-Aug-21,Actual,8/23/2021,NA,Interventional,NA,NA,Severity of COVID-19 and Vitamin D Supplementation,The Effect of Vitamin D Supplementation in Standard Therapy on Reducing Severity of COVID-19 Among Hospitalized Patients,"Active, not recruiting",NA,Phase 4,350,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:10:32Z,2021-12-22T09:10:32Z
NCT05165966,NA,12/20/2021,NA,NA,12/20/2021,12/20/2021,12/21/2021,Estimate,NA,NA,NA,NA,NA,NA,12/20/2021,12/21/2021,Estimate,20-Oct-21,Actual,10/20/2021,Dec-21,12/31/2021,20-Jun-22,Anticipated,6/20/2022,20-Feb-22,Anticipated,2/20/2022,NA,Interventional,NA,NA,"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","A Randomized, Double-Blinded Clinical Trial to Evaluate the Immunogenicity Using Additional Dose of Medium-dosage or High-dosage COVID-19 Vaccine (Vero Cell), Inactivated in Populations Who Have Completed Primary Immunization 5-9 Months","Active, not recruiting",NA,Phase 4,340,Anticipated,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:10:34Z,2021-12-22T09:10:34Z
NCT05096832,NA,10/21/2021,NA,NA,12/19/2021,10/25/2021,10/27/2021,Actual,NA,NA,NA,NA,NA,NA,12/19/2021,12/21/2021,Estimate,3-Nov-21,Actual,11/3/2021,Dec-21,12/31/2021,14-Mar-23,Anticipated,3/14/2023,27-Jan-23,Anticipated,1/27/2023,NA,Interventional,COVID-19,NA,Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study,"A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines",Recruiting,NA,Phase 3,10722,Anticipated,Livzon Pharmaceutical Group Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:13:14Z,2021-12-22T09:13:14Z
NCT04952857,NA,6/8/2021,NA,NA,12/19/2021,7/3/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,12/19/2021,12/21/2021,Estimate,1-Aug-21,Actual,8/1/2021,Dec-21,12/31/2021,10-Dec-21,Actual,12/10/2021,30-Nov-21,Actual,11/30/2021,NA,Interventional,SHADE-S,NA,"Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease","Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease",Completed,NA,Phase 4,90,Actual,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:15:07Z,2021-12-22T09:15:07Z
NCT04904471,NA,5/26/2021,NA,NA,12/19/2021,5/26/2021,5/27/2021,Actual,NA,NA,NA,NA,NA,NA,12/19/2021,12/21/2021,Estimate,15-Jun-21,Actual,6/15/2021,May-21,5/31/2021,31-Dec-22,Anticipated,12/31/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells),"A Global Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells), for the Prevention of COVID-19 in Adults Aged 18 Years and Older",Enrolling by invitation,NA,Phase 3,40000,Anticipated,"WestVac Biopharma Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:15:47Z,2021-12-22T09:15:47Z
NCT04899232,NA,5/20/2021,NA,NA,12/3/2021,5/20/2021,5/24/2021,Actual,NA,NA,NA,NA,NA,NA,12/3/2021,12/21/2021,Estimate,6-Jul-21,Actual,7/6/2021,Dec-21,12/31/2021,21-Jul-22,Anticipated,7/21/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Antithrombin III in Infectious Disease Caused by COVID-19,Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19),Recruiting,NA,Phase 2,75,Anticipated,University of Miami,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-22T09:15:53Z,2021-12-22T09:15:53Z
NCT04821934,NA,3/26/2021,NA,NA,12/20/2021,3/29/2021,3/30/2021,Actual,NA,NA,NA,NA,NA,NA,12/20/2021,12/21/2021,Estimate,26-Mar-21,Actual,3/26/2021,Dec-21,12/31/2021,20-Dec-21,Actual,12/20/2021,20-Dec-21,Actual,12/20/2021,NA,Interventional,NA,NA,Tele-rehabilitation Program After Hospitalization for COVID-19,Efficacy of a Tele-rehabilitation Program After Hospitalization for COVID-19 Pneumonia: a Randomized Controlled Trial,Completed,NA,Not Applicable,74,Actual,Istituti Clinici Scientifici Maugeri SpA,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-22T09:16:47Z,2021-12-22T09:16:47Z
NCT04860297,NA,4/21/2021,NA,NA,12/18/2021,4/22/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,12/18/2021,12/21/2021,Estimate,16-Apr-21,Actual,4/16/2021,Dec-21,12/31/2021,31-Mar-23,Anticipated,3/31/2023,31-Mar-23,Anticipated,3/31/2023,NA,Interventional,NA,NA,A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants,"A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls",Recruiting,NA,Phase 3,240,Anticipated,"ModernaTX, Inc.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-22T09:16:25Z,2021-12-22T09:16:25Z
NCT04792567,NA,3/8/2021,NA,NA,12/20/2021,3/8/2021,3/11/2021,Actual,NA,NA,NA,NA,NA,NA,12/20/2021,12/21/2021,Estimate,19-Apr-21,Actual,4/19/2021,Dec-21,12/31/2021,2-Apr-22,Anticipated,4/2/2022,17-Jan-22,Anticipated,1/17/2022,NA,Interventional,AMA-VACC,NA,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod),"Active, not recruiting",NA,Phase 4,41,Actual,Novartis,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.",2021-12-22T09:17:07Z,2021-12-22T09:17:07Z
NCT04788459,NA,3/1/2021,NA,NA,12/20/2021,3/5/2021,3/9/2021,Actual,NA,NA,NA,NA,NA,NA,12/20/2021,12/21/2021,Estimate,25-Feb-21,Actual,2/25/2021,Dec-21,12/31/2021,Sep-22,Anticipated,9/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers","A Phase I/II Study to Assess the Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,160,Anticipated,Takis,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:17:10Z,2021-12-22T09:17:10Z
NCT04644328,NA,11/13/2020,10/26/2021,NA,12/15/2021,11/20/2020,11/25/2020,Actual,12/15/2021,12/21/2021,Estimate,NA,NA,NA,12/15/2021,12/21/2021,Estimate,12-Nov-20,Actual,11/12/2020,Dec-21,12/31/2021,11-Feb-21,Actual,2/11/2021,11-Feb-21,Actual,2/11/2021,NA,Interventional,NA,"The experiment was run during two periods: Thanksgiving (Period 1) and Christmas (Period 2). During Thanksgiving, 820 counties were analyzed (410 high-intensity, 410 low-intensity). Of these counties, 767 were analyzed during Christmas (386 high-intensity, 381 low-intensity). Fewer counties were analyzed at Christmas because we removed counties in rural, conservative areas from the study due to potential negative impacts resulting from polarization in the wake of the 2020 presidential election.",The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,Completed,NA,Not Applicable,820,Actual,"National Bureau of Economic Research, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The pre-analysis plan will be posted publicly. The ability to share IPD will be based on discussions with our partner organization.,2021-12-22T09:18:25Z,2021-12-22T09:18:25Z
NCT04796896,NA,3/11/2021,NA,NA,12/18/2021,3/11/2021,3/15/2021,Actual,NA,NA,NA,NA,NA,NA,12/18/2021,12/21/2021,Estimate,15-Mar-21,Actual,3/15/2021,Dec-21,12/31/2021,12-Jun-23,Anticipated,6/12/2023,12-Jun-23,Anticipated,6/12/2023,NA,Interventional,NA,NA,A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age,"A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age",Recruiting,NA,Phase 2/Phase 3,13275,Anticipated,"ModernaTX, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:17:06Z,2021-12-22T09:17:06Z
NCT04482595,NA,7/17/2020,NA,NA,12/20/2021,7/21/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,12/20/2021,12/21/2021,Estimate,11-Nov-20,Actual,11/11/2020,Dec-21,12/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,BIO 300 Oral Suspension in Discharged COVID-19 Patients,A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients,Recruiting,NA,Phase 2,66,Anticipated,Humanetics Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-22T09:19:49Z,2021-12-22T09:19:49Z
NCT04470427,NA,7/11/2020,NA,NA,12/18/2021,7/11/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,12/18/2021,12/21/2021,Estimate,27-Jul-20,Actual,7/27/2020,Dec-21,12/31/2021,27-Oct-22,Anticipated,10/27/2022,27-Oct-22,Anticipated,10/27/2022,NA,Interventional,NA,NA,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 3,30000,Actual,"ModernaTX, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-22T09:19:53Z,2021-12-22T09:19:53Z
NCT04401410,NA,5/21/2020,NA,NA,12/16/2021,5/21/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,12/16/2021,12/21/2021,Estimate,4-Nov-20,Actual,11/4/2020,Dec-21,12/31/2021,12-Oct-21,Actual,10/12/2021,12-Oct-21,Actual,10/12/2021,NA,Interventional,BATIT,NA,Anti-SARS Cov-2 T Cell Infusions for COVID 19,BAT IT: Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19,Terminated,NA,Phase 1,4,Actual,Baylor College of Medicine,,3,NA,"Due to trial's eligibility criteria and the low census of hospitalized COVID-19 patients meeting eligibility criteria, the Sponsor will be unable to enroll a meaningful number of patients in this single-center trial in a reasonable time frame.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-22T09:20:18Z,2021-12-22T09:20:18Z
NCT05167227,NA,12/17/2021,NA,NA,12/20/2021,12/20/2021,12/22/2021,Actual,NA,NA,NA,NA,NA,NA,12/20/2021,12/22/2021,Actual,30-Nov-21,Actual,11/30/2021,Dec-21,12/31/2021,31-Jul-24,Anticipated,7/31/2024,31-Jul-24,Anticipated,7/31/2024,NA,Interventional,LC&FIRP,NA,Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?,"The Long COVID and Fatiguing Illness Recovery Program - A Pragmatic, Quality Improvement, Professional Cluster, Randomized Controlled Trial.",Recruiting,NA,Not Applicable,20,Anticipated,Family Health Centers of San Diego,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:20:32Z,2021-12-29T08:20:32Z
NCT05167357,NA,9/5/2021,NA,NA,12/21/2021,12/21/2021,12/22/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,18-Mar-21,Actual,3/18/2021,Mar-21,3/31/2021,30-Nov-22,Anticipated,11/30/2022,30-Nov-22,Anticipated,11/30/2022,NA,Interventional,CORONALTITUDE,NA,Multicentric Evaluation of the Impact on Hypoxia Sensitivity of Patients With COVID-19,Multicentric Evaluation of the Impact on Hypoxia Sensitivity of Patients With COVID-19,Recruiting,NA,Not Applicable,90,Anticipated,Institut de Formation et de Recherche en MÃ©decine de Montagne,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:20:26Z,2021-12-29T08:20:26Z
NCT05167279,NA,12/13/2021,NA,NA,12/21/2021,12/21/2021,12/22/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/23/2021,Actual,17-Dec-21,Actual,12/17/2021,Dec-21,12/31/2021,31-Dec-22,Anticipated,12/31/2022,30-Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19,"A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic Profiles, and Immunogenicity of JS026 and JS026 in Together With JS016 Administered Intravenously to Healthy Chinese Subjects",Recruiting,NA,Phase 1,48,Anticipated,"Shanghai Junshi Bioscience Co., Ltd.",,7,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:20:29Z,2021-12-29T08:20:29Z
NCT05166915,NA,12/20/2021,NA,NA,12/22/2021,12/20/2021,12/22/2021,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/28/2021,Estimate,Dec-21,Anticipated,12/31/2021,Dec-21,12/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,"Respiratory COVID-19: A Randomized, Sham-Controlled Study","Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Randomized, Sham-Controlled Study",Recruiting,NA,Not Applicable,40,Anticipated,"Aytu BioPharma, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:20:46Z,2021-12-29T08:20:46Z
NCT05148949,NA,12/3/2021,NA,NA,12/23/2021,12/3/2021,12/8/2021,Actual,NA,NA,NA,NA,NA,NA,12/23/2021,12/28/2021,Estimate,22-Dec-21,Actual,12/22/2021,Dec-21,12/31/2021,10-Aug-22,Anticipated,8/10/2022,10-May-22,Anticipated,5/10/2022,NA,Interventional,NA,NA,Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients,"Safety and Immunogenicity of Three Doses of an Inactivated SARS-CoV-2 Vaccine in Chinese Pulmonary Tuberculosis Patients Aged 18-75 Years: a Randomized, Double-blind, Parallel-controlled Clinical Trial",Recruiting,NA,Phase 4,240,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:21:53Z,2021-12-29T08:21:53Z
NCT05148832,NA,12/5/2021,NA,NA,12/7/2021,12/5/2021,12/8/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/22/2021,Actual,1-May-21,Actual,5/1/2021,Dec-21,12/31/2021,15-Nov-21,Actual,11/15/2021,20-Aug-21,Actual,8/20/2021,NA,Interventional,NA,NA,Administration of Systemic Corticosteroids and the Recovery of Gustatory Functions in Patients With COVID-19,Association Between Administration of Systemic Corticosteroids and the Recovery of Olfactory and/or Gustatory Functions in Patients With COVID-19: A Prospective Cohort Study,Completed,NA,Not Applicable,80,Actual,Fayoum University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:21:55Z,2021-12-29T08:21:55Z
NCT05143567,NA,11/20/2021,NA,NA,12/6/2021,11/20/2021,12/3/2021,Actual,NA,NA,NA,NA,NA,NA,12/6/2021,12/28/2021,Estimate,1-Nov-21,Actual,11/1/2021,Dec-21,12/31/2021,1-Nov-26,Anticipated,11/1/2026,1-Nov-26,Anticipated,11/1/2026,NA,Interventional,NA,NA,Hemostasis and Inflammation in COVID19 Patients With Venous and Arterial Thrombotic Complications,Comprehensive Assessment of the Hemostasis and Inflammation in Patients With Venous and Arterial Thrombotic Complications in Treatment of New Coronaviral Infection,Recruiting,NA,Not Applicable,150,Anticipated,Ryazan State Medical University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:22:19Z,2021-12-29T08:22:19Z
NCT05135585,NA,11/23/2021,NA,NA,12/23/2021,11/24/2021,11/26/2021,Actual,NA,NA,NA,NA,NA,NA,12/23/2021,12/27/2021,Actual,1-Dec-21,Actual,12/1/2021,Oct-21,10/31/2021,12-Oct-22,Anticipated,10/12/2022,12-Oct-22,Anticipated,10/12/2022,NA,Interventional,COVCAL,NA,Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population,Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population,Recruiting,NA,Not Applicable,660,Anticipated,Institut Pasteur,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:22:48Z,2021-12-29T08:22:48Z
NCT05097053,NA,10/17/2021,NA,NA,12/7/2021,10/18/2021,10/27/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/23/2021,Actual,7-Oct-21,Actual,10/7/2021,Dec-21,12/31/2021,Jul-22,Anticipated,7/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19,"A Parallel Group, Prospective, Randomized, Two-arm, Open-label Study to Evaluate the Immunogenicity, Safety, and Tolerability of Heterologous 3rd Boost of MVC-COV1901 in Adults With 2 Doses of ChAdOx1-nCov-19 in 3 Months and 6 Months",Recruiting,NA,Phase 4,200,Anticipated,Taoyuan General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:24:37Z,2021-12-29T08:24:37Z
NCT05063825,NA,9/30/2021,NA,NA,12/22/2021,9/30/2021,10/1/2021,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/23/2021,Actual,6-Oct-21,Actual,10/6/2021,Dec-21,12/31/2021,13-Dec-21,Actual,12/13/2021,13-Dec-21,Actual,12/13/2021,NA,Interventional,NA,NA,Understanding Reactions to Emotional Material in the Media During COVID-19 - Study 2,Understanding Reactions to Emotional Material in the Media During COVID-19 and the Connections to Cognitive Activities - Study 2,Completed,NA,Not Applicable,98,Actual,Uppsala University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:25:52Z,2021-12-29T08:25:52Z
NCT05087173,NA,10/20/2021,NA,NA,12/25/2021,10/20/2021,10/21/2021,Actual,NA,NA,NA,NA,NA,NA,12/25/2021,12/28/2021,Estimate,11-Oct-21,Actual,10/11/2021,Dec-21,12/31/2021,28-Feb-22,Anticipated,2/28/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination,Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination,Recruiting,NA,Not Applicable,1200,Anticipated,Sun Yat-sen University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:25:01Z,2021-12-29T08:25:01Z
NCT05067894,NA,10/1/2021,NA,NA,12/22/2021,10/1/2021,10/5/2021,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/27/2021,Actual,10-Dec-21,Actual,12/10/2021,Dec-21,12/31/2021,Apr-22,Anticipated,4/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine,"A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Populations Aged 18 Years and Above in Indonesia",Recruiting,NA,Phase 1,60,Anticipated,PT Bio Farma,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:25:42Z,2021-12-29T08:25:42Z
NCT05057923,NA,9/21/2021,12/18/2021,NA,12/22/2021,9/23/2021,9/27/2021,Actual,12/22/2021,12/23/2021,Actual,NA,NA,NA,12/22/2021,12/23/2021,Actual,10-Jul-21,Actual,7/10/2021,Dec-21,12/31/2021,1-Nov-21,Actual,11/1/2021,20-Oct-21,Actual,10/20/2021,NA,Interventional,NA,The baseline population does not differ from the participant flow.,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Expressing and Displaying the Receptor Binding Domain of Spike Protein of SARS-COV2,Completed,NA,Not Applicable,9,Actual,DreamTec Research Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:25:59Z,2021-12-29T08:25:59Z
NCT05036941,NA,8/26/2021,NA,NA,12/7/2021,9/2/2021,9/8/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/22/2021,Actual,13-Nov-21,Actual,11/13/2021,Dec-21,12/31/2021,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,A Trial of Two Mask Systems in Preventing SARS CoV-2 in Healthcare Workers (HCW),A Cluster Randomized Trial of Two Mask Systems (Acteevâ„¢ N95 + Acteevâ„¢ Fabric Masks vs. Standard N95 + Fabric Masks During Shifts & in Community) in Preventing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) in HCWs,Recruiting,NA,Not Applicable,1600,Anticipated,Ascend Performance Materials,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:26:36Z,2021-12-29T08:26:36Z
NCT05007080,NA,8/9/2021,NA,NA,12/21/2021,8/9/2021,8/16/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,27-Sep-21,Actual,9/27/2021,Dec-21,12/31/2021,31-Oct-23,Anticipated,10/31/2023,31-Aug-23,Anticipated,8/31/2023,NA,Interventional,HORIZON 2,NA,A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive,"A Randomized, Observer-blind, Phase 2/3 Adaptive Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Adolescents From 12 to 17 Years Inclusive",Recruiting,NA,Phase 2/Phase 3,3300,Anticipated,Janssen Vaccines & Prevention B.V.,,12,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-29T08:27:22Z,2021-12-29T08:27:22Z
NCT04992273,NA,8/3/2021,NA,NA,12/11/2021,8/3/2021,8/5/2021,Actual,NA,NA,NA,NA,NA,NA,12/11/2021,12/27/2021,Actual,13-Sep-21,Actual,9/13/2021,Dec-21,12/31/2021,17-Nov-22,Anticipated,11/17/2022,17-Nov-22,Anticipated,11/17/2022,NA,Interventional,NA,NA,COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age,"A Phase 2A, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti- Spike(s) SARS-COV-2 Monoclonal Antibodies (Casirivimab and Imdevimab) in High-Risk Pediatric Subjects Under 12 Years of Age",Recruiting,NA,Phase 2,28,Anticipated,Regeneron Pharmaceuticals,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-12-29T08:27:52Z,2021-12-29T08:27:52Z
NCT04956887,NA,7/7/2021,NA,NA,12/7/2021,7/7/2021,7/9/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/23/2021,Actual,3-Aug-21,Actual,8/3/2021,Dec-21,12/31/2021,31-Dec-24,Anticipated,12/31/2024,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Cognitive Training in Survivors of Covid-19: A Randomized Trial,Cognitive Training in Survivors of Covid-19: A Randomized Trial,Recruiting,NA,Not Applicable,100,Anticipated,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-29T08:28:35Z,2021-12-29T08:28:35Z
NCT04955626,NA,6/9/2021,NA,NA,12/21/2021,6/29/2021,7/9/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,1-Jul-21,Actual,7/1/2021,Dec-21,12/31/2021,20-Sep-23,Anticipated,9/20/2023,20-Sep-23,Anticipated,9/20/2023,NA,Interventional,NA,NA,"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a Booster Dose of BNT162b2 Against COVID-19 in Participants â‰¥12 Years of Age.",A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2,"Active, not recruiting",NA,Phase 3,10000,Anticipated,BioNTech SE,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-29T08:28:35Z,2021-12-29T08:28:35Z
NCT05057169,NA,9/24/2021,NA,NA,12/21/2021,9/24/2021,9/27/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,18-Nov-21,Actual,11/18/2021,Dec-21,12/31/2021,31-Mar-24,Anticipated,3/31/2024,31-Mar-23,Anticipated,3/31/2023,NA,Interventional,NA,NA,Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study),Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study),Recruiting,NA,Phase 4,400,Anticipated,The University of Hong Kong,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-29T08:26:04Z,2021-12-29T08:26:04Z
NCT04988035,NA,7/29/2021,NA,NA,12/22/2021,7/29/2021,8/3/2021,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/27/2021,Actual,21-Jul-21,Actual,7/21/2021,21-Jul-21,7/21/2021,22-Dec-22,Anticipated,12/22/2022,31-Oct-22,Anticipated,10/31/2022,NA,Interventional,NA,NA,ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults,Recruiting,NA,Phase 2,200,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:27:56Z,2021-12-29T08:27:56Z
NCT04987957,NA,7/30/2021,NA,NA,12/8/2021,7/30/2021,8/3/2021,Actual,NA,NA,NA,NA,NA,NA,12/8/2021,12/23/2021,Actual,8-Dec-21,Actual,12/8/2021,Dec-21,12/31/2021,31-Jul-22,Anticipated,7/31/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Effect Of MusÄ±c Therapy On AnxÄ±ety Levels In COVID-19 PandemÄ±c,Effect Of MusÄ±c Therapy On AnxÄ±ety Levels In PrÄ±mary Care FamÄ±ly Health Workers In COVID-19 PandemÄ±c,Recruiting,NA,Not Applicable,42,Anticipated,Abant Izzet Baysal University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:27:57Z,2021-12-29T08:27:57Z
NCT04951310,NA,6/16/2021,NA,NA,12/21/2021,7/1/2021,7/6/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,7-Jun-21,Actual,6/7/2021,Dec-21,12/31/2021,14-Aug-21,Actual,8/14/2021,14-Aug-21,Actual,8/14/2021,NA,Interventional,NA,NA,COVID-19 Vaccinations With a Sweepstakes,COVID-19 Vaccinations With a Sweepstakes,Completed,NA,Not Applicable,1241810,Actual,University of Pennsylvania,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:28:39Z,2021-12-29T08:28:39Z
NCT04939428,NA,6/24/2021,NA,NA,12/22/2021,6/24/2021,6/25/2021,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/23/2021,Actual,11-Aug-21,Actual,8/11/2021,Dec-21,12/31/2021,3-Apr-22,Anticipated,4/3/2022,3-Apr-22,Anticipated,4/3/2022,NA,Interventional,MOVe-AHEAD,NA,Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013),"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19",Recruiting,NA,Phase 3,1332,Anticipated,Merck Sharp & Dohme Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-29T08:28:53Z,2021-12-29T08:28:53Z
NCT04935476,NA,6/21/2021,NA,NA,12/22/2021,6/21/2021,6/23/2021,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/27/2021,Actual,22-Nov-21,Actual,11/22/2021,Dec-21,12/31/2021,31-Jul-22,Anticipated,7/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,DAP-CORONA,NA,Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19,"A Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dapsone for the Treatment of COVID-19 Positive Patients.",Recruiting,NA,Phase 3,3000,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:28:58Z,2021-12-29T08:28:58Z
NCT04920890,NA,5/26/2021,NA,NA,12/21/2021,6/9/2021,6/10/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/23/2021,Actual,16-May-21,Actual,5/16/2021,Dec-21,12/31/2021,29-Nov-21,Actual,11/29/2021,20-Jul-21,Actual,7/20/2021,NA,Interventional,NA,NA,Radiofrequency Intervention in Post COVID-19 Patients,"Radiofrequency Intervention in Neurological, Pneumological and Musculoskeletal Pathologies Post COVID-19",Completed,NA,Not Applicable,24,Actual,Clinica Gema Leon,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The request for the data will be studied and considered upon prior and justified request.,2021-12-29T08:29:21Z,2021-12-29T08:29:21Z
NCT04908722,NA,5/27/2021,NA,NA,12/21/2021,5/27/2021,6/1/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,18-Jun-21,Actual,6/18/2021,Dec-21,12/31/2021,31-Mar-23,Anticipated,3/31/2023,18-Apr-22,Anticipated,4/18/2022,NA,Interventional,NA,NA,A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults,"A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults",Recruiting,NA,Phase 3,1590,Anticipated,Janssen Vaccines & Prevention B.V.,,6,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-29T08:29:37Z,2021-12-29T08:29:37Z
NCT04894305,NA,5/18/2021,NA,NA,12/21/2021,5/18/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,25-May-21,Actual,5/25/2021,Dec-21,12/31/2021,8-Dec-21,Actual,12/8/2021,8-Dec-21,Actual,12/8/2021,NA,Interventional,NA,NA,A Study of Ad26.COV2.S in Healthy Adults (COVID-19),"A Phase 1, Randomized, Observer-blind Study to Compare the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S at a Single Dose of 5*10^10 vp in 2 Different Volumes in Healthy Adults",Completed,NA,Phase 1,380,Actual,Janssen Vaccines & Prevention B.V.,,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-29T08:29:56Z,2021-12-29T08:29:56Z
NCT04871854,NA,4/25/2021,NA,NA,12/7/2021,5/1/2021,5/4/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/22/2021,Actual,26-Apr-21,Actual,4/26/2021,Dec-21,12/31/2021,26-Aug-22,Anticipated,8/26/2022,26-Jul-22,Anticipated,7/26/2022,NA,Interventional,NA,NA,Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints,Comparative Study Evaluating Clinical Outcomes for Patients Treated With Tocilizumab for Sever COVID-19 Infection in Breast Cancer Patients Versus Non Cancer Patients,Recruiting,NA,Phase 2,60,Anticipated,Beni-Suef University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:30:20Z,2021-12-29T08:30:20Z
NCT04828161,NA,3/24/2021,NA,NA,12/7/2021,3/30/2021,4/1/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/23/2021,Actual,24-May-21,Actual,5/24/2021,Nov-21,11/30/2021,Jun-22,Anticipated,6/30/2022,May-22,Anticipated,5/31/2022,NA,Interventional,EMPATHY,NA,"A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19","A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 - The ""EMPATHY"" Trial",Recruiting,NA,Phase 2/Phase 3,2100,Anticipated,Molecular Partners AG,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:31:10Z,2021-12-29T08:31:10Z
NCT04826588,NA,3/31/2021,NA,NA,12/7/2021,3/31/2021,4/1/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/23/2021,Actual,23-May-21,Actual,5/23/2021,Dec-21,12/31/2021,Jul-22,Anticipated,7/31/2022,Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY),Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY),Recruiting,NA,Phase 3,75,Anticipated,University Children's Hospital Basel,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:31:12Z,2021-12-29T08:31:12Z
NCT04780321,NA,9/23/2020,NA,NA,12/27/2021,3/2/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,12/27/2021,12/28/2021,Estimate,30-Oct-20,Actual,10/30/2020,Dec-21,12/31/2021,30-Mar-22,Anticipated,3/30/2022,30-Mar-22,Anticipated,3/30/2022,NA,Interventional,NA,NA,JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy, Safety, Pharmacokinetic Profiles and Immunogenicity of JS016 in Participants With Mild and Moderate COVID-19 or of SARS-CoV-2 Asymptomatic Infection",Recruiting,NA,Phase 1/Phase 2,90,Anticipated,"Shanghai Junshi Bioscience Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:32:02Z,2021-12-29T08:32:02Z
NCT04885530,NA,4/30/2021,NA,NA,12/21/2021,5/11/2021,5/13/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/23/2021,Actual,8-Jun-21,Actual,6/8/2021,Dec-21,12/31/2021,Mar-23,Anticipated,3/31/2023,Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,ACTIV-6: COVID-19 Study of Repurposed Medications,ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications,Recruiting,NA,Phase 3,15000,Anticipated,Duke University,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Up to 36 months after publication,Interested investigators will need to seek prior IRB approval before access to any data is granted.,NA,Yes,We will share this data after it has been de-identified. We will share data beginning around 6 months after publication and for up to 36 months afterward. Access will only be shared with those who have obtained prior IRB approval to be able to access this data.,2021-12-29T08:30:11Z,2021-12-29T08:30:11Z
NCT04858451,NA,4/19/2021,NA,NA,12/17/2021,4/23/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,12/17/2021,12/27/2021,Actual,30-Apr-21,Actual,4/30/2021,Dec-21,12/31/2021,Apr-23,Anticipated,4/30/2023,Apr-23,Anticipated,4/30/2023,NA,Interventional,CORVIS,NA,COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2,"Community Participants With COPD or Bronchiectasis and at Risk of Respiratory Viral Infections Including SARS-CoV-2: An Open-label, Multicentre Feasibility Study of an Inhaled Nitric Oxide Generating Solution (RESP301)",Recruiting,NA,Phase 2,150,Anticipated,Thirty Respiratory Limited,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-29T08:30:32Z,2021-12-29T08:30:32Z
NCT04842747,NA,4/9/2021,NA,NA,12/22/2021,4/9/2021,4/13/2021,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/27/2021,Actual,18-May-21,Actual,5/18/2021,Dec-21,12/31/2021,19-Mar-22,Anticipated,3/19/2022,5-Jan-22,Anticipated,1/5/2022,NA,Interventional,VERU-111,NA,VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study,"Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).",Recruiting,NA,Phase 3,300,Anticipated,Veru Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:30:55Z,2021-12-29T08:30:55Z
NCT04841759,NA,4/7/2021,NA,NA,12/23/2021,4/9/2021,4/12/2021,Actual,NA,NA,NA,NA,NA,NA,12/23/2021,12/27/2021,Actual,1-Apr-21,Actual,4/1/2021,Dec-21,12/31/2021,22-Dec-21,Actual,12/22/2021,3-Dec-21,Actual,12/3/2021,NA,Interventional,NA,NA,The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome,The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome,Completed,NA,Not Applicable,46,Actual,Medical University of Vienna,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:30:56Z,2021-12-29T08:30:56Z
NCT04816643,NA,3/19/2021,NA,NA,12/21/2021,3/24/2021,3/25/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,24-Mar-21,Actual,3/24/2021,Dec-21,12/31/2021,5-May-26,Anticipated,5/5/2026,5-May-26,Anticipated,5/5/2026,NA,Interventional,NA,NA,"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults","PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN and Young Adults",Recruiting,NA,Phase 2/Phase 3,11422,Anticipated,BioNTech SE,,22,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-29T08:31:22Z,2021-12-29T08:31:22Z
NCT04795557,NA,3/8/2021,NA,NA,12/27/2021,3/11/2021,3/12/2021,Actual,NA,NA,NA,NA,NA,NA,12/27/2021,12/28/2021,Estimate,19-Apr-21,Actual,4/19/2021,Dec-21,12/31/2021,26-Dec-21,Actual,12/26/2021,11-Nov-21,Actual,11/11/2021,NA,Interventional,NA,NA,Efficacy of Adaptogens in Patients With Long COVID-19,"Effect of ADAPT232 Supplementation on Recovery of Patients in Rehabilitation Period in Long COVID-19: a Randomized, Double-blind, Placebo-controlled Trial",Completed,NA,Phase 2/Phase 3,100,Actual,Swedish Herbal Institute AB,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:31:44Z,2021-12-29T08:31:44Z
NCT04745351,NA,2/8/2021,NA,NA,12/21/2021,2/8/2021,2/9/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/23/2021,Actual,31-Mar-21,Actual,3/31/2021,Dec-21,12/31/2021,Sep-22,Anticipated,9/30/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,REDPINE,NA,Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19),"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for COVID-19",Recruiting,NA,Phase 3,1116,Anticipated,Gilead Sciences,,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:32:46Z,2021-12-29T08:32:46Z
NCT04758962,NA,2/8/2021,NA,NA,12/23/2021,2/16/2021,2/17/2021,Actual,NA,NA,NA,NA,NA,NA,12/23/2021,12/27/2021,Actual,15-Feb-21,Actual,2/15/2021,Dec-21,12/31/2021,2-May-22,Anticipated,5/2/2022,4-Jun-21,Actual,6/4/2021,NA,Interventional,NA,NA,A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults,"A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age","Active, not recruiting",NA,Phase 1,10,Actual,GlaxoSmithKline,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",NA,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2021-12-29T08:32:36Z,2021-12-29T08:32:36Z
NCT04762680,NA,2/18/2021,NA,NA,12/27/2021,2/18/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,12/27/2021,12/28/2021,Estimate,24-Feb-21,Actual,2/24/2021,Dec-21,12/31/2021,30-Mar-23,Anticipated,3/30/2023,30-Mar-23,Anticipated,3/30/2023,NA,Interventional,VAT00002,NA,Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent),Recruiting,NA,Phase 2/Phase 3,5414,Anticipated,Sanofi,,15,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-29T08:32:31Z,2021-12-29T08:32:31Z
NCT04659746,NA,12/7/2020,NA,NA,12/23/2021,12/7/2020,12/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/23/2021,12/28/2021,Estimate,9-Dec-20,Actual,12/9/2020,Dec-21,12/31/2021,9-Dec-21,Actual,12/9/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,MejoraCare_P,NA,MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay,mHealth Technology to Optimize Mental Health in Chronic Patients During the COVID-19 Outbreak in Paraguay,Completed,NA,Not Applicable,138,Actual,Universidad AutÃ³noma de EncarnaciÃ³n,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:34:26Z,2021-12-29T08:34:26Z
NCT04715243,NA,1/9/2021,NA,NA,12/22/2021,1/16/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/23/2021,Actual,2-Feb-21,Actual,2/2/2021,Dec-21,12/31/2021,11-Nov-21,Actual,11/11/2021,9-Aug-21,Actual,8/9/2021,NA,Interventional,NIV COVID19,NA,"Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients","Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients",Completed,NA,Not Applicable,161,Actual,Sultan Qaboos University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,after July 2021,NA,NA,Yes,Publish in a journal,2021-12-29T08:33:14Z,2021-12-29T08:33:14Z
NCT04646044,NA,11/14/2020,NA,NA,12/23/2021,11/24/2020,11/27/2020,Actual,NA,NA,NA,NA,NA,NA,12/23/2021,12/27/2021,Actual,13-Nov-20,Actual,11/13/2020,Dec-21,12/31/2021,18-May-21,Actual,5/18/2021,11-May-21,Actual,5/11/2021,NA,Interventional,NA,NA,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,"A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19",Completed,NA,Phase 1,30,Actual,Nektar Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:34:37Z,2021-12-29T08:34:37Z
NCT04708327,NA,1/12/2021,NA,NA,12/7/2021,1/12/2021,1/13/2021,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/22/2021,Actual,5-Dec-21,Actual,12/5/2021,Dec-21,12/31/2021,30-Sep-22,Anticipated,9/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Single-Blind Study of STAT-205 in Mild COVID-19,"Randomized, Single-Blind Study to Evaluate the Pharmacokinetics, Biomarkers, Safety and Tolerability of STAT-205 in Adult Patients With Mild COVID 19 Who Are at High Risk of Disease Progression",Recruiting,NA,Phase 1,24,Anticipated,"Cytocom, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:33:26Z,2021-12-29T08:33:26Z
NCT04685655,NA,12/23/2020,NA,NA,12/27/2021,12/24/2020,12/28/2020,Actual,NA,NA,NA,NA,NA,NA,12/27/2021,12/28/2021,Estimate,7-Jan-20,Actual,1/7/2020,Dec-21,12/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,RELAX,NA,RescuE pLAsma eXchange in Severe COVID-19,RescuE pLAsma eXchange in Severe COVID-19 (RELAX Severe COVID-19),Recruiting,NA,Not Applicable,228,Anticipated,Heidelberg University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,On request,2021-12-29T08:33:45Z,2021-12-29T08:33:45Z
NCT04673292,NA,12/16/2020,NA,NA,12/7/2021,12/16/2020,12/17/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/27/2021,Actual,8-Feb-21,Actual,2/8/2021,Dec-21,12/31/2021,May-24,Anticipated,5/31/2024,May-23,Anticipated,5/31/2023,NA,Interventional,NA,NA,Community Collaboration to Combat COVID-19 (C-FORWARD),Community Collaboration to Combat COVID-19,Enrolling by invitation,NA,Not Applicable,3000,Anticipated,Johns Hopkins University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:34:00Z,2021-12-29T08:34:00Z
NCT04652518,NA,12/2/2020,NA,NA,12/21/2021,12/2/2020,12/3/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,11-Dec-20,Actual,12/11/2020,Dec-21,12/31/2021,Apr-22,Anticipated,4/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,LYT-100 in Post-acute COVID-19 Respiratory Disease,"A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease",Recruiting,NA,Phase 2,168,Anticipated,PureTech,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:34:31Z,2021-12-29T08:34:31Z
NCT04640194,NA,11/20/2020,NA,NA,12/22/2021,11/20/2020,11/23/2020,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/23/2021,Actual,16-Dec-20,Actual,12/16/2020,Dec-21,12/31/2021,15-Aug-22,Anticipated,8/15/2022,12-Jun-22,Anticipated,6/12/2022,NA,Interventional,TRISTARDS,NA,A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19,"The TRISTARDS Trial - ThRombolysIS Therapy for ARDS A Phase IIb/III Operationally Seamless, Open-label, Randomised, Sequential, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Daily Intravenous Alteplase Treatment Given up to 5 Days on Top of Standard of Care (SOC) Compared With SOC Alone, in Patients With Acute Respiratory Distress Syndrome (ARDS) Triggered by COVID-19.",Recruiting,NA,Phase 2/Phase 3,320,Anticipated,Boehringer Ingelheim,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.","For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.",https://www.mystudywindow.com/msw/datasharing,Yes,"After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed ""Document Sharing Agreement"".

Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

The data shared are the raw clinical study data sets.",2021-12-29T08:34:47Z,2021-12-29T08:34:47Z
NCT04614948,NA,11/3/2020,NA,NA,12/21/2021,11/3/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,16-Nov-20,Actual,11/16/2020,Dec-21,12/31/2021,31-May-23,Anticipated,5/31/2023,10-May-22,Anticipated,5/10/2022,NA,Interventional,ENSEMBLE 2,NA,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 3,31836,Actual,Janssen Vaccines & Prevention B.V.,,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-29T08:35:27Z,2021-12-29T08:35:27Z
NCT04632706,NA,10/26/2020,12/14/2021,NA,12/22/2021,11/16/2020,11/17/2020,Actual,12/22/2021,12/27/2021,Actual,NA,NA,NA,12/22/2021,12/27/2021,Actual,22-Sep-20,Actual,9/22/2020,Dec-21,12/31/2021,9-Mar-21,Actual,3/9/2021,9-Mar-21,Actual,3/9/2021,NA,Interventional,NA,NA,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,"A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers",Completed,NA,Phase 1,24,Actual,MedinCell S.A,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:34:54Z,2021-12-29T08:34:54Z
NCT04631367,NA,11/13/2020,NA,NA,12/23/2021,11/13/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,12/23/2021,12/28/2021,Estimate,1-Feb-21,Actual,2/1/2021,Dec-21,12/31/2021,31-Oct-21,Actual,10/31/2021,20-Aug-21,Actual,8/20/2021,NA,Interventional,NA,NA,mHealth Intervention for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Uganda,"Kukaa Salama (Staying Safe): A Pre-Post Trial of a mHealth Social Group for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Kampala, Uganda",Completed,NA,Not Applicable,330,Actual,University of Toronto,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The data collected during this study will not be made publicly available due to the possibility of identifying participants using a combination of common demographic and response characteristics. The data may be made available from the corresponding author on reasonable request and upon completing suitable data sharing agreements.,2021-12-29T08:34:58Z,2021-12-29T08:34:58Z
NCT04583956,NA,10/9/2020,NA,NA,12/22/2021,10/9/2020,10/12/2020,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/27/2021,Actual,14-Oct-20,Actual,10/14/2020,21-Jul-21,7/21/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults,"Active, not recruiting",NA,Phase 2,167,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:35:56Z,2021-12-29T08:35:56Z
NCT04537208,NA,9/2/2020,NA,NA,12/23/2021,9/2/2020,9/3/2020,Actual,NA,NA,NA,NA,NA,NA,12/23/2021,12/27/2021,Actual,3-Sep-20,Actual,9/3/2020,Dec-21,12/31/2021,19-Nov-21,Actual,11/19/2021,19-Nov-21,Actual,11/19/2021,NA,Interventional,NA,NA,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older,Completed,NA,Phase 1/Phase 2,442,Actual,Sanofi,,21,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-29T08:36:50Z,2021-12-29T08:36:50Z
NCT04559035,NA,9/21/2020,NA,NA,12/15/2021,9/21/2020,9/22/2020,Actual,NA,NA,NA,NA,NA,NA,12/15/2021,12/28/2021,Estimate,24-Sep-20,Actual,9/24/2020,Dec-21,12/31/2021,4-Nov-21,Actual,11/4/2021,18-Jan-21,Actual,1/18/2021,NA,Interventional,NA,NA,Nasal Irrigation to Reduce COVID-19 Morbidity,Nasal Irrigation to Reduce COVID-19 Morbidity,Completed,NA,Not Applicable,239,Actual,Augusta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:36:28Z,2021-12-29T08:36:28Z
NCT04565665,NA,9/22/2020,NA,NA,12/21/2021,9/24/2020,9/25/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/23/2021,Actual,29-Jul-20,Actual,7/29/2020,Dec-21,12/31/2021,30-Apr-23,Anticipated,4/30/2023,30-Apr-23,Anticipated,4/30/2023,NA,Interventional,NA,NA,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 1/Phase 2,70,Anticipated,M.D. Anderson Cancer Center,,3,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:36:22Z,2021-12-29T08:36:22Z
NCT04535791,NA,7/30/2020,NA,NA,12/7/2021,8/31/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/22/2021,Actual,15-Jul-20,Actual,7/15/2020,Dec-21,12/31/2021,15-Jul-21,Actual,7/15/2021,30-Dec-20,Actual,12/30/2020,NA,Interventional,COVID-19,NA,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial,Completed,NA,Phase 3,321,Actual,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:36:51Z,2021-12-29T08:36:51Z
NCT04535453,NA,8/27/2020,NA,NA,12/21/2021,8/27/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,28-Aug-20,Actual,8/28/2020,Dec-21,12/31/2021,28-Mar-22,Anticipated,3/28/2022,28-Mar-22,Anticipated,3/28/2022,NA,Interventional,NA,NA,A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents,"A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older and to Evaluate 2 Dose Levels of Ad26.COV2.S in Healthy Adolescents Aged 12 to 17 Years Inclusive","Active, not recruiting",NA,Phase 2,635,Actual,Janssen Vaccines & Prevention B.V.,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-29T08:36:51Z,2021-12-29T08:36:51Z
NCT04523246,NA,8/20/2020,NA,NA,12/7/2021,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2021,12/23/2021,Actual,1-Sep-20,Actual,9/1/2020,Dec-21,12/31/2021,30-Sep-22,Anticipated,9/30/2022,30-Nov-21,Actual,11/30/2021,NA,Interventional,NH-Shingrix,NA,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents: A Randomized, Doubled-Blinded, Comparative Group Observational Study","Active, not recruiting",NA,Early Phase 1,217,Actual,University of Oklahoma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:37:00Z,2021-12-29T08:37:00Z
NCT04498247,NA,8/3/2020,12/20/2021,NA,12/20/2021,8/3/2020,8/4/2020,Actual,12/20/2021,12/23/2021,Actual,NA,NA,NA,12/20/2021,12/23/2021,Actual,27-Aug-20,Actual,8/27/2020,Dec-21,12/31/2021,5-Mar-21,Actual,3/5/2021,5-Mar-21,Actual,3/5/2021,NA,Interventional,NA,NA,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants",Terminated,NA,Phase 1/Phase 2,263,Actual,Merck Sharp & Dohme Corp.,,10,NA,The study was terminated based on an interim assessment of immunogenicity,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-29T08:37:21Z,2021-12-29T08:37:21Z
NCT04513990,NA,6/5/2020,NA,NA,12/21/2021,8/13/2020,8/14/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,9-Apr-20,Actual,4/9/2020,Dec-21,12/31/2021,30-Apr-23,Anticipated,4/30/2023,30-Apr-23,Anticipated,4/30/2023,NA,Interventional,END CoV-2,NA,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),Evaluation of a Novel Point-of-Care Diagnostic Test for SARS-CoV-2,"Active, not recruiting",NA,Not Applicable,257,Actual,M.D. Anderson Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-29T08:37:08Z,2021-12-29T08:37:08Z
NCT04505722,NA,7/31/2020,NA,NA,12/21/2021,8/7/2020,8/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,7-Sep-20,Actual,9/7/2020,Dec-21,12/31/2021,2-Jan-23,Anticipated,1/2/2023,22-Jan-21,Actual,1/22/2021,NA,Interventional,ENSEMBLE,NA,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 3,44325,Actual,Janssen Vaccines & Prevention B.V.,,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-29T08:37:14Z,2021-12-29T08:37:14Z
NCT04436276,NA,6/15/2020,NA,NA,12/21/2021,6/15/2020,6/18/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,15-Jul-20,Actual,7/15/2020,Dec-21,12/31/2021,1-Apr-24,Anticipated,4/1/2024,2-Feb-24,Anticipated,2/2/2024,NA,Interventional,NA,NA,A Study of Ad26.COV2.S in Adults (COVID-19),"A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older","Active, not recruiting",NA,Phase 1/Phase 2,1085,Actual,Janssen Vaccines & Prevention B.V.,,5,NA,NA,TRUE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-29T08:38:19Z,2021-12-29T08:38:19Z
NCT04412018,NA,5/29/2020,NA,NA,12/21/2021,5/29/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,4-Jun-20,Actual,6/4/2020,Dec-21,12/31/2021,12-Dec-20,Actual,12/12/2020,6-Nov-20,Actual,11/6/2020,NA,Interventional,NA,NA,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19),Completed,NA,Phase 2,100,Actual,Canadian Medical and Surgical Knowledge Translation Research Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-29T08:38:35Z,2021-12-29T08:38:35Z
NCT04368728,NA,4/27/2020,NA,NA,12/21/2021,4/29/2020,4/30/2020,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/22/2021,Actual,29-Apr-20,Actual,4/29/2020,Dec-21,12/31/2021,15-May-23,Anticipated,5/15/2023,15-May-23,Anticipated,5/15/2023,NA,Interventional,NA,NA,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS",Recruiting,NA,Phase 2/Phase 3,43998,Anticipated,BioNTech SE,,20,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-29T08:39:12Z,2021-12-29T08:39:12Z
NCT04359797,NA,4/20/2020,12/13/2021,NA,12/22/2021,4/20/2020,4/24/2020,Actual,12/22/2021,12/27/2021,Actual,NA,NA,NA,12/22/2021,12/27/2021,Actual,27-Apr-20,Actual,4/27/2020,Dec-21,12/31/2021,17-Jan-21,Actual,1/17/2021,17-Dec-20,Actual,12/17/2020,NA,Interventional,NA,NA,COVID-19 Patient Positioning Pragmatic Trial,Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone,Completed,NA,Not Applicable,501,Actual,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.,NA,Yes,Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.,2021-12-29T08:39:21Z,2021-12-29T08:39:21Z
NCT05172102,NA,12/25/2021,NA,NA,12/25/2021,12/25/2021,12/29/2021,Actual,NA,NA,NA,NA,NA,NA,12/25/2021,12/29/2021,Actual,20-Dec-21,Actual,12/20/2021,Dec-21,12/31/2021,30-Jun-22,Anticipated,6/30/2022,20-May-22,Anticipated,5/20/2022,NA,Interventional,Covid-19,NA,Quality of Life and Lung Function on Post Covid-19 Patient,"Effect of Breathing Exercise on Chest Expansion, Quality of Life and Lung Function on Post Covid-19 Patient: A Randomized Controlled Trial",Recruiting,NA,Not Applicable,40,Anticipated,Qassim University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months after publication,relevance to the topic of the study and approval of all co-authors within 1 month of receiving the request.,NA,Yes,The data sets generated during and/or analyzed during the current study is available from the corresponding author on reasonable request.,2021-12-30T20:33:59Z,2021-12-30T20:33:59Z
NCT05172050,NA,12/23/2021,NA,NA,12/23/2021,12/23/2021,12/29/2021,Actual,NA,NA,NA,NA,NA,NA,12/23/2021,12/29/2021,Actual,22-Jan-21,Actual,1/22/2021,Dec-21,12/31/2021,12-Jun-21,Actual,6/12/2021,12-Jun-21,Actual,6/12/2021,NA,Interventional,NA,NA,"Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.","Multicenter, Adaptive, Randomized, Placebo-controlled, Double Blind, Parallel-group Phase 2/3 Trial, to Study Efficacy and Safety of Two Doses of Raloxifene in Adult Paucisymptomatic COVID-19 Patients.",Completed,NA,Phase 2/Phase 3,68,Actual,DompÃ© Farmaceutici S.p.A,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-30T20:34:02Z,2021-12-30T20:34:02Z
NCT05172037,NA,12/26/2021,NA,NA,12/26/2021,12/26/2021,12/29/2021,Actual,NA,NA,NA,NA,NA,NA,12/26/2021,12/29/2021,Actual,28-Oct-21,Actual,10/28/2021,Dec-21,12/31/2021,Jun-22,Anticipated,6/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Phase III Study of Novaferon in Non-hospitalized Adult Patients With Mild COVID-19,"An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients With Mild COVID-19",Recruiting,NA,Phase 3,222,Anticipated,Genova Inc.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-30T20:34:02Z,2021-12-30T20:34:02Z
NCT05171829,NA,12/21/2021,NA,NA,12/21/2021,12/21/2021,12/29/2021,Actual,NA,NA,NA,NA,NA,NA,12/21/2021,12/29/2021,Actual,27-Dec-21,Anticipated,12/27/2021,Dec-21,12/31/2021,15-May-22,Anticipated,5/15/2022,15-May-22,Anticipated,5/15/2022,NA,Interventional,TrackU,NA,An Educational Self-tracking Tool for Identification of SARS-CoV-2 Risk Transmission,An Educational Self-tracking Tool for Identification of SARS-CoV-2 Risk Transmission: a Randomised Controlled Trial,Enrolling by invitation,NA,Not Applicable,180,Anticipated,Hospital Clinic of Barcelona,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-30T20:34:16Z,2021-12-30T20:34:16Z
NCT05168813,NA,12/21/2021,NA,NA,12/28/2021,12/21/2021,12/23/2021,Actual,NA,NA,NA,NA,NA,NA,12/28/2021,12/29/2021,Actual,1-Dec-21,Actual,12/1/2021,Dec-21,12/31/2021,1-Jun-23,Anticipated,6/1/2023,1-Jun-23,Anticipated,6/1/2023,NA,Interventional,CoVPN3008,NA,Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern,"Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern",Recruiting,NA,Phase 2/Phase 3,14000,Anticipated,COVID-19 Prevention Network,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-30T20:34:51Z,2021-12-30T20:34:51Z
NCT05077969,NA,10/7/2021,NA,NA,12/29/2021,10/12/2021,10/14/2021,Actual,NA,NA,NA,NA,NA,NA,12/29/2021,12/30/2021,Estimate,29-Dec-21,Actual,12/29/2021,Dec-21,12/31/2021,Nov-22,Anticipated,11/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2),"A Virtual Phase 2 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Post-exposure Prophylaxis (PEP) for Newly-infected COVID-19 Patients",Recruiting,NA,Phase 2,1465,Anticipated,Leidos Life Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,It is not yet known if there will be a plan to make individual participant data (IPD) available.,2021-12-30T20:37:26Z,2021-12-30T20:37:26Z
NCT05123755,NA,11/8/2021,NA,NA,12/28/2021,11/15/2021,11/17/2021,Actual,NA,NA,NA,NA,NA,NA,12/28/2021,12/29/2021,Actual,20-Dec-21,Actual,12/20/2021,Dec-21,12/31/2021,Jun-22,Anticipated,6/30/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,AV-001 for Hospitalized Patients With COVID-19 Disease,"A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 in Patients Hospitalized With Confirmed Severe COVID-19 Disease",Recruiting,NA,Phase 2,120,Anticipated,"Vasomune Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-30T20:36:23Z,2021-12-30T20:36:23Z
NCT05077332,NA,10/7/2021,NA,NA,12/29/2021,10/12/2021,10/14/2021,Actual,NA,NA,NA,NA,NA,NA,12/29/2021,12/30/2021,Estimate,29-Dec-21,Actual,12/29/2021,Dec-21,12/31/2021,Nov-22,Anticipated,11/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,LEAP-CT for Treatment of COVID-19 Patients (Master Protocol),Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients,"Active, not recruiting",NA,Phase 2,2000,Anticipated,Leidos Life Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,It is not yet known if there will be a plan to make IPD available.,2021-12-30T20:37:27Z,2021-12-30T20:37:27Z
NCT04999111,NA,8/3/2021,NA,NA,12/22/2021,8/3/2021,8/10/2021,Actual,NA,NA,NA,NA,NA,NA,12/22/2021,12/30/2021,Estimate,6-Aug-21,Actual,8/6/2021,Dec-21,12/31/2021,27-Oct-22,Anticipated,10/27/2022,27-Oct-21,Actual,10/27/2021,NA,Interventional,Amplify,NA,A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2,"A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Ad26.COV2.S Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2","Active, not recruiting",NA,Phase 2,1540,Anticipated,Janssen Vaccines & Prevention B.V.,,6,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-12-30T20:39:01Z,2021-12-30T20:39:01Z
NCT04690400,NA,12/20/2020,NA,NA,12/10/2021,12/29/2020,12/30/2020,Actual,NA,NA,NA,NA,NA,NA,12/10/2021,12/30/2021,Estimate,15-Jan-21,Actual,1/15/2021,Dec-21,12/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic,"Adaptations From a Telehealth Stretching Exercise Program on Painful Conditions, Depression, Sleep and Functionality of Women With Fibromyalgia During the Covid-19 Pandemic: a Randomized Clinical Trial","Active, not recruiting",NA,Not Applicable,28,Actual,Federal University of Pelotas,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-30T20:42:48Z,2021-12-30T20:42:48Z
NCT04941703,NA,6/24/2021,NA,NA,12/9/2021,6/24/2021,6/28/2021,Actual,NA,NA,NA,NA,NA,NA,12/9/2021,12/30/2021,Estimate,4-Nov-21,Actual,11/4/2021,Jun-21,6/30/2021,30-Jun-24,Anticipated,6/30/2024,25-Jun-23,Anticipated,6/25/2023,NA,Interventional,CHANGE,NA,"""CHANGE COVID-19 Severity""",Investigation of Choice Alteration of the Gut Metagenome on COVID-19 Severity,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-30T20:39:52Z,2021-12-30T20:39:52Z
NCT04682873,NA,12/22/2020,NA,NA,12/8/2021,12/23/2020,12/24/2020,Actual,NA,NA,NA,NA,NA,NA,12/8/2021,12/29/2021,Actual,15-May-20,Actual,5/15/2020,Nov-21,11/30/2021,26-Mar-21,Actual,3/26/2021,26-Mar-21,Actual,3/26/2021,NA,Interventional,NA,NA,"A Clinical Study to Assess the Efficacy and Safety of AmizonÂ® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus","A Multi-centre, Double-blind, Randomised, Placebo-controlled, Trial to Assess the Efficacy and Safety of AmizonÂ® Max, Manufactured by Farmak JSC, in Combination With Basic Treatment, in Subjects With Moderate Covid-19, Which is Caused by the SARS-CoV-2 Virus",Completed,NA,Phase 3,592,Actual,"Joint Stock Company ""Farmak""",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-30T20:42:53Z,2021-12-30T20:42:53Z
NCT04607928,NA,10/28/2020,NA,NA,12/29/2021,10/28/2020,10/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/29/2021,12/30/2021,Estimate,1-Aug-20,Actual,8/1/2020,Dec-21,12/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Jan-22,Anticipated,1/30/2022,NA,Interventional,FIBRO-COVID,NA,Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19,Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis,Recruiting,NA,Phase 2,148,Anticipated,Institut d'InvestigaciÃ³ BiomÃ¨dica de Bellvitge,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-30T20:43:45Z,2021-12-30T20:43:45Z
NCT04569786,NA,9/24/2020,12/22/2021,NA,12/22/2021,9/24/2020,9/30/2020,Actual,12/22/2021,12/29/2021,Actual,NA,NA,NA,12/22/2021,12/29/2021,Actual,29-Oct-20,Actual,10/29/2020,Dec-21,12/31/2021,18-Feb-21,Actual,2/18/2021,18-Feb-21,Actual,2/18/2021,NA,Interventional,NA,NA,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults",Terminated,NA,Phase 1,232,Actual,Merck Sharp & Dohme Corp.,,9,NA,The study was terminated based on an interim assessment of immunogenicity.,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-30T20:44:05Z,2021-12-30T20:44:05Z
NCT04569266,NA,9/10/2020,NA,NA,12/29/2021,9/28/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/29/2021,12/30/2021,Estimate,7-Aug-20,Actual,8/7/2020,Dec-21,12/31/2021,31-Dec-22,Anticipated,12/31/2022,6-Aug-22,Anticipated,8/6/2022,NA,Interventional,RECOVER,NA,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Recruiting,NA,Not Applicable,200,Anticipated,Groupe Hospitalier Paris Saint Joseph,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-30T20:44:12Z,2021-12-30T20:44:12Z
NCT04475185,NA,7/15/2020,NA,NA,12/8/2021,7/16/2020,7/17/2020,Actual,NA,NA,NA,NA,NA,NA,12/8/2021,12/29/2021,Actual,20-Jul-20,Actual,7/20/2020,Dec-21,12/31/2021,19-Dec-20,Actual,12/19/2020,19-Dec-20,Actual,12/19/2020,NA,Interventional,COVRESP,NA,Safety and Effectiveness Assessment of the MakAir Artificial Ventilator,"Interventional, Open, Non-comparative, Multicenter Study to Assess the Safety and Effectiveness of the Use of the MakAir Artificial Ventilator in the Expected Situation of a Shortage of Technical Devices for Invasive Mechanical Ventilation, Linked to the Coronavirus COVID-19",Terminated,NA,Not Applicable,4,Actual,Nantes University Hospital,,1,NA,Manufacturer's decision following failure of sequence 2. Protocol unadapted to the security and performance evaluation of the new MakAir device capabilities in non-invasive ventilation (NIV).,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-30T20:45:04Z,2021-12-30T20:45:04Z
NCT04420741,NA,6/4/2020,NA,NA,12/8/2021,6/5/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/8/2021,12/29/2021,Actual,15-Jun-20,Actual,6/15/2020,Dec-21,12/31/2021,23-Apr-21,Actual,4/23/2021,23-Feb-21,Actual,2/23/2021,NA,Interventional,COMBAT-COVID,NA,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/ Kilo(kg)/Minute(Min)) in Patients With COVID-19 Induced Pulmonary Endotheliopathy,Completed,NA,Phase 2,80,Actual,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-30T20:45:23Z,2021-12-30T20:45:23Z
NCT04407286,NA,5/19/2020,NA,NA,12/29/2021,5/27/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/29/2021,12/30/2021,Estimate,19-May-20,Actual,5/19/2020,Dec-21,12/31/2021,30-Nov-20,Actual,11/30/2020,30-Aug-20,Actual,8/30/2020,NA,Interventional,NA,NA,Vitamin D Testing and Treatment for COVID 19,Vitamin D Testing and Treatment for Adults With COVID 19,Completed,NA,Phase 1,41,Actual,Arizona State University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Contact us if you wish to discuss sharing of de-identified data,2021-12-30T20:45:30Z,2021-12-30T20:45:30Z
NCT04333472,NA,4/1/2020,NA,NA,12/29/2021,4/2/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,12/29/2021,12/30/2021,Estimate,6-Jan-21,Actual,1/6/2021,Nov-21,11/30/2021,6-Jul-22,Anticipated,7/6/2022,6-Mar-22,Anticipated,3/6/2022,NA,Interventional,NA,NA,Piclidenoson for Treatment of COVID-19,"Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial","Active, not recruiting",NA,Phase 2,6,Actual,Can-Fite BioPharma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"January 2021, indefinitely",To be determined,NA,Yes,To be determined,2021-12-30T20:46:19Z,2021-12-30T20:46:19Z
NCT04978259,NA,7/20/2021,NA,NA,10/12/2021,7/22/2021,7/27/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/13/2021,Estimate,24-Jul-21,Actual,7/24/2021,Oct-21,10/31/2021,31-Dec-23,Anticipated,12/31/2023,28-Feb-23,Anticipated,2/28/2023,NA,Interventional,NA,NA,SOLIDARITY Finland Long COVID-19,Long-term Follow-up of a Randomized Multicenter Trial on Impact of Long-COVID in Hospitalized COVID-19 Patients,Recruiting,NA,Phase 4,202,Anticipated,Clinical Urology and Epidemiology Working Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-13T20:01:47Z,2021-10-13T20:01:47Z
NCT04964570,NA,7/13/2021,NA,NA,10/5/2021,7/14/2021,7/16/2021,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/13/2021,Estimate,4-Aug-21,Actual,8/4/2021,Oct-21,10/31/2021,25-Dec-21,Anticipated,12/25/2021,25-Dec-21,Anticipated,12/25/2021,NA,Interventional,NA,NA,Digital Mental Health Care for COVID-19 High-Risk Populations,Digital Mental Health Care for COVID-19 High-Risk Populations,"Active, not recruiting",NA,Not Applicable,4200,Anticipated,"Research Foundation for Mental Hygiene, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No identifying data of participants will be shared,2021-10-13T20:01:54Z,2021-10-13T20:01:54Z
NCT04931888,NA,6/11/2021,NA,NA,10/7/2021,6/11/2021,6/18/2021,Actual,NA,NA,NA,NA,NA,NA,10/7/2021,10/13/2021,Estimate,23-Jun-21,Actual,6/23/2021,Oct-21,10/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Aug-21,Actual,8/31/2021,NA,Interventional,NA,NA,Implementing and Evaluating a Social-Emotional Learning Program for Refugee Children During the COVID-19 Pandemic,Implementing and Evaluating a Wellness and Social-Emotional Learning Program for Refugee Children During the COVID-19 Pandemic: EMPOWER (Emotions Program Outside the Clinic and Wellness Education for Refugees),Enrolling by invitation,NA,Not Applicable,70,Anticipated,Yale University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-13T20:02:18Z,2021-10-13T20:02:18Z
NCT04951323,NA,6/2/2021,NA,NA,10/12/2021,7/1/2021,7/6/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/13/2021,Estimate,22-Mar-21,Actual,3/22/2021,Oct-21,10/31/2021,1-Jan-23,Anticipated,1/1/2023,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Impact of the Immune System on Response to COVID-19 Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Recruiting,NA,Phase 3,50,Anticipated,University of Liege,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-13T20:02:06Z,2021-10-13T20:02:06Z
NCT04497415,NA,8/2/2020,NA,NA,10/5/2021,8/2/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/13/2021,Estimate,21-Oct-20,Actual,10/21/2020,Oct-21,10/31/2021,30-Jan-21,Actual,1/30/2021,30-Nov-20,Actual,11/30/2020,NA,Interventional,NA,NA,The COVID-19 and Healthcare Workers: An Active Intervention,The COVID-19 and Healthcare Workers: An Active Intervention,Completed,NA,Not Applicable,350,Actual,"Research Foundation for Mental Hygiene, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-13T20:05:16Z,2021-10-13T20:05:16Z
NCT04638842,NA,11/19/2020,NA,NA,10/12/2021,11/19/2020,11/20/2020,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/13/2021,Estimate,24-Dec-20,Actual,12/24/2020,Oct-21,10/31/2021,1-Jun-21,Actual,6/1/2021,1-Jun-21,Actual,6/1/2021,NA,Interventional,NA,NA,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,"Effectiveness of a Self-applied Multi-component Psychological Online Intervention Based on UX, for the Prevention of Complicated Grief Disorder in the Mexican Population During the COVID-19 Outbreak: A Randomized Clinical Trial",Completed,NA,Not Applicable,43,Actual,Universidad Internacional de Valencia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,This data will be available approximately in April 2021 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published.,Through the servers of the journal(s) where we will publish the articles.,NA,Yes,"The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.",2021-10-13T20:04:31Z,2021-10-13T20:04:31Z
NCT04471766,NA,7/14/2020,NA,NA,10/5/2021,7/14/2020,7/15/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/13/2021,Estimate,20-Jul-20,Actual,7/20/2020,Mar-21,3/31/2021,Oct-21,Anticipated,10/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,Evaluation of Locally Produced Cloth Face Mask on COVID-19 and Respiratory Illnesses Prevention at the Community Level - a Cluster-randomized Trial,"Active, not recruiting",NA,Not Applicable,40000,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-13T20:05:23Z,2021-10-13T20:05:23Z
NCT04468893,NA,7/10/2020,NA,NA,10/12/2021,7/10/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/13/2021,Estimate,20-May-20,Actual,5/20/2020,Oct-21,10/31/2021,31-Jul-21,Actual,7/31/2021,31-Jul-21,Actual,7/31/2021,NA,Interventional,NA,NA,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,"Effectiveness of a Self-applied Positive Psychology Online Intervention Program ""Mental Health COVID-19"" in Mexican Population: A Randomized Controlled Trial.",Completed,NA,Not Applicable,35,Actual,Universidad Internacional de Valencia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,This data will be available approximately in december 2020 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published,Through the servers of the journal(s) where we will publish the articles.,NA,Yes,"The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.",2021-10-13T20:05:25Z,2021-10-13T20:05:25Z
NCT04346693,NA,4/8/2020,NA,NA,10/5/2021,4/10/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/13/2021,Estimate,8-Apr-20,Actual,4/8/2020,Oct-21,10/31/2021,20-Nov-20,Actual,11/20/2020,1-Nov-20,Actual,11/1/2020,NA,Interventional,NA,NA,An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19,An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19),Completed,NA,Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-13T20:06:08Z,2021-10-13T20:06:08Z
NCT04455815,NA,6/25/2020,NA,NA,10/12/2021,7/1/2020,7/2/2020,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/13/2021,Estimate,25-Sep-20,Actual,9/25/2020,Oct-21,10/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,SPIKE-1,NA,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive.,"A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.","Active, not recruiting",NA,Phase 2,100,Anticipated,Cancer Research UK,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-13T20:05:33Z,2021-10-13T20:05:33Z
NCT04379336,NA,5/4/2020,NA,NA,10/12/2021,5/6/2020,5/7/2020,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/13/2021,Estimate,4-May-20,Actual,5/4/2020,Oct-21,10/31/2021,31-May-22,Anticipated,5/31/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,"Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 3,1000,Actual,TASK Applied Science,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will only be shared among researchers included in the protocol team at this stage.,2021-10-13T20:06:03Z,2021-10-13T20:06:03Z
NCT05079152,NA,10/5/2021,NA,NA,10/5/2021,10/5/2021,10/15/2021,Estimate,NA,NA,NA,NA,NA,NA,10/5/2021,10/15/2021,Estimate,6-May-21,Actual,5/6/2021,Oct-21,10/31/2021,Dec-21,Anticipated,12/31/2021,29-May-21,Actual,5/29/2021,NA,Interventional,NA,NA,Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Wuhan) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)","Active, not recruiting",NA,Phase 4,1404,Actual,China National Biotec Group Company Limited,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T21:58:54Z,2021-10-15T21:58:54Z
NCT05077943,NA,9/29/2021,NA,NA,10/12/2021,10/12/2021,10/14/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/14/2021,Actual,1-Sep-21,Actual,9/1/2021,Oct-21,10/31/2021,31-May-22,Anticipated,5/31/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,The Effect of Home-based Exercise on Functional Capacity of Covid-19 Survivor With Cardiovascular Comorbidity,The Effect of Home-based Breathing and Chest Mobilisation Exercise on Cardiorespiratory Functional Capacity of Covid-19 Survivor With Cardiovascular Comorbidity,Recruiting,NA,Not Applicable,66,Anticipated,National Cardiovascular Center Harapan Kita Hospital Indonesia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T21:59:51Z,2021-10-15T21:59:51Z
NCT05077930,NA,10/8/2021,NA,NA,10/12/2021,10/12/2021,10/14/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/14/2021,Actual,Oct-21,Anticipated,10/31/2021,Oct-21,10/31/2021,Jan-22,Anticipated,1/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Convalescent Plasma Therapy for Hospitalized Patients With COVID-19,Validation Protocol for The Clinical Use of Convalescent Plasma for Hospitalized Patients With COVID-19. A Prospective Study at a Hospital in Southern Brazil.,Recruiting,NA,Phase 2,200,Anticipated,Science Valley Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-15T21:59:52Z,2021-10-15T21:59:52Z
NCT05077306,NA,10/8/2021,NA,NA,10/12/2021,10/12/2021,10/14/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/14/2021,Actual,15-Apr-21,Actual,4/15/2021,Oct-21,10/31/2021,30-Jun-21,Actual,6/30/2021,15-May-21,Actual,5/15/2021,NA,Interventional,MADC-19,NA,Receptive Music Therapy on Anxiety and Vital Parameters in Hospitalized Covid-19 Patients.,Effect of Musical Listening on Anxiety and Depression in Patients Hospitalized for Covid-19: a Randomized Controlled Trial,Completed,NA,Not Applicable,40,Actual,Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:00:25Z,2021-10-15T22:00:25Z
NCT05077241,NA,6/30/2021,NA,NA,10/12/2021,10/12/2021,10/14/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/14/2021,Actual,11-Aug-21,Actual,8/11/2021,Oct-21,10/31/2021,31-Jul-23,Anticipated,7/31/2023,31-May-23,Anticipated,5/31/2023,NA,Interventional,NA,NA,Efficacy of Home Inspiratory Muscle Training in Post-covid-19 Patients: a Randomized Clinical Trial,Efficacy of Home Inspiratory Muscle Training in Post-covid-19 Patients: a Randomized Clinical Trial,Recruiting,NA,Not Applicable,10,Anticipated,Universidade Federal do Rio Grande do Norte,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:00:28Z,2021-10-15T22:00:28Z
NCT04930965,NA,6/16/2021,NA,NA,10/12/2021,6/16/2021,6/18/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/14/2021,Actual,5-Oct-21,Actual,10/5/2021,Oct-21,10/31/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate,Louisiana Community-Engagement Alliance Against COVID-19 Disparities (LA-CEAL): Impact of HALT COVID Ambassador Program on Likelihood to Vaccinate,Recruiting,NA,Not Applicable,100,Anticipated,Tulane University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:04:25Z,2021-10-15T22:04:25Z
NCT05047445,NA,8/27/2021,NA,NA,10/6/2021,9/16/2021,9/17/2021,Actual,NA,NA,NA,NA,NA,NA,10/6/2021,10/14/2021,Actual,30-Sep-21,Actual,9/30/2021,Oct-21,10/31/2021,Jun-22,Anticipated,6/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection,"A First Time in Human Phase 1 Open-Label Study of the Safety, Tolerability, and Immunogenicity of COVIDITY Vaccine Administered by Needle-free Intradermal Injection or Needle-free Intramuscular Injection in Healthy Adults (COVIDITY-001)",Recruiting,NA,Phase 1,40,Anticipated,Scancell Ltd,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is not a plan to make individual patient data available.,2021-10-15T22:01:48Z,2021-10-15T22:01:48Z
NCT04890509,NA,5/17/2021,NA,NA,10/13/2021,5/17/2021,5/18/2021,Actual,NA,NA,NA,NA,NA,NA,10/13/2021,10/14/2021,Actual,20-Oct-20,Actual,10/20/2020,Oct-21,10/31/2021,25-May-21,Actual,5/25/2021,25-May-21,Actual,5/25/2021,NA,Interventional,NA,NA,A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients,"A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients",Completed,NA,Phase 2,115,Actual,BerGenBio ASA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 5 years following article publication,"Proposal should be directed to HYPERLINK ""mailto:clinical@bergenbio.com"" clinical@bergenbio.com. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in the article, after deidentification [text, tables, figures and appendices].",2021-10-15T22:05:02Z,2021-10-15T22:05:02Z
NCT04754698,NA,2/8/2021,NA,NA,10/5/2021,2/12/2021,2/15/2021,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/14/2021,Actual,9-Feb-21,Actual,2/9/2021,Feb-21,2/28/2021,31-May-22,Anticipated,5/31/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,CoronavRheum,NA,COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS,Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS,"Active, not recruiting",NA,Phase 4,2067,Anticipated,University of Sao Paulo General Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:07:11Z,2021-10-15T22:07:11Z
NCT04750343,NA,2/10/2021,NA,NA,10/14/2021,2/10/2021,2/11/2021,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/15/2021,Estimate,3-Feb-21,Actual,2/3/2021,Feb-21,2/28/2021,Jun-22,Anticipated,6/30/2022,28-Jul-21,Actual,7/28/2021,NA,Interventional,NA,NA,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19),"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults","Active, not recruiting",NA,Phase 1/Phase 2,328,Actual,"SK Bioscience Co., Ltd.",,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:07:15Z,2021-10-15T22:07:15Z
NCT04808284,NA,3/16/2021,NA,NA,10/13/2021,3/18/2021,3/22/2021,Actual,NA,NA,NA,NA,NA,NA,10/13/2021,10/14/2021,Actual,10-Aug-21,Actual,8/10/2021,Oct-21,10/31/2021,11-Oct-21,Actual,10/11/2021,11-Oct-21,Actual,10/11/2021,NA,Interventional,NA,NA,Neuromodulation in COVID-19 Patients,Neuromodulation in COVID-19 Patients,Completed,NA,Phase 1/Phase 2,60,Actual,D'Or Institute for Research and Education,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:06:14Z,2021-10-15T22:06:14Z
NCT04425915,NA,6/7/2020,NA,NA,10/6/2021,6/10/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,10/6/2021,10/14/2021,Actual,14-Jun-20,Actual,6/14/2020,Jun-21,6/30/2021,15-Dec-20,Actual,12/15/2020,15-Dec-20,Actual,12/15/2020,NA,Interventional,NA,NA,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19: A Randomized Control Trial,Completed,NA,Phase 3,400,Actual,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication till 5 years,It will be available for researcher scientist & government agencies.,NA,Yes,NA,2021-10-15T22:11:36Z,2021-10-15T22:11:36Z
NCT04734886,NA,12/10/2020,NA,NA,10/14/2021,1/30/2021,2/2/2021,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/15/2021,Estimate,27-Nov-20,Actual,11/27/2020,Sep-21,9/30/2021,13-Sep-21,Actual,9/13/2021,13-Sep-21,Actual,9/13/2021,NA,Interventional,NA,NA,The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19,Exploratory Study on the Effects of Probiotic Supplementation on SARS-CoV-2 Antibody Response in Healthy Adults,Completed,NA,Not Applicable,161,Actual,"Ã–rebro University, Sweden",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"IPD will not be shared, results will shared only on group-level",2021-10-15T22:07:30Z,2021-10-15T22:07:30Z
NCT04641858,NA,11/22/2020,NA,NA,10/14/2021,11/22/2020,11/24/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/15/2021,Estimate,3-Dec-20,Actual,12/3/2020,Oct-21,10/31/2021,Aug-22,Anticipated,8/31/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,EDCTP,NA,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,BCG Vaccine to Reduce Unplanned Absenteeism Due to Illness of Health Care Workers During the COVID-19 Pandemic. A Multi-center Randomised Controlled Trial (BCG-COVID-RCT),Recruiting,NA,Phase 4,1050,Anticipated,University of Southern Denmark,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed.,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to ifronteira@ihmt.unl.pt,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to professor InÃªs Fronteira ifronteira@ihmt.unl.pt,2021-10-15T22:08:50Z,2021-10-15T22:08:50Z
NCT04551911,NA,9/15/2020,NA,NA,10/14/2021,9/15/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/15/2021,Estimate,26-Oct-20,Actual,10/26/2020,Oct-21,10/31/2021,8-Oct-21,Actual,10/8/2021,8-Oct-21,Actual,10/8/2021,NA,Interventional,NA,NA,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,"A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)",Completed,NA,Phase 2,171,Actual,"OPKO Health, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:10:03Z,2021-10-15T22:10:03Z
NCT04510454,NA,8/11/2020,NA,NA,10/14/2021,8/11/2020,8/12/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/15/2021,Estimate,2-Nov-20,Actual,11/2/2020,Oct-21,10/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,ONCOVID-21,NA,Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19,Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19,"Active, not recruiting",NA,Not Applicable,100,Actual,Centre Leon Berard,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:10:43Z,2021-10-15T22:10:43Z
NCT04408183,NA,5/22/2020,NA,NA,10/13/2021,5/27/2020,5/29/2020,Actual,NA,NA,NA,NA,NA,NA,10/13/2021,10/14/2021,Actual,10-Jun-20,Actual,6/10/2020,Aug-21,8/31/2021,Dec-22,Anticipated,12/31/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19),"Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection",Recruiting,NA,Phase 2,225,Anticipated,"GeneOne Life Science, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:11:50Z,2021-10-15T22:11:50Z
NCT04742738,NA,2/4/2021,NA,NA,10/14/2021,2/5/2021,2/8/2021,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/15/2021,Estimate,20-Jan-21,Actual,1/20/2021,Jan-21,1/31/2021,Apr-22,Anticipated,4/30/2022,30-Jul-21,Actual,7/30/2021,NA,Interventional,NA,NA,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19),"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide in Healthy Younger and Older Adults","Active, not recruiting",NA,Phase 1/Phase 2,260,Actual,"SK Bioscience Co., Ltd.",,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:07:19Z,2021-10-15T22:07:19Z
NCT04715438,NA,1/11/2021,NA,NA,10/5/2021,1/15/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/14/2021,Actual,8-Jan-21,Actual,1/8/2021,Oct-21,10/31/2021,Apr-23,Anticipated,4/30/2023,4-Jun-21,Actual,6/4/2021,NA,Interventional,VOICE,NA,Vaccination Against COVID-19 in Cancer,Vaccination Against cOvid In CancEr,"Active, not recruiting",NA,Not Applicable,791,Actual,University Medical Center Groningen,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,we start the make interim results available second half of 2021,"we aim to share as much as possible also through own website, and COVID-19 platforms that are considered for this kind of research",NA,Yes,"Alignment and reuse Our options for reusing data, biological materials, and/or other resources (from research or practice) in your project.

Data: Clinicopathological parameters as described in the protocol
Biological materials: Blood
Research software: R statistical package, Castor, MOLGENIS
Other resources, i.e.,Nederlandse Kankerregistratie (NKR), the Dutch Cancer Registry, electronic patient dossiers (EPDs)

FAIR data within the COVID-19 research community

A COVID-19 related or other Findability, Accessibility, Interoperability, and Reuse (FAIR) data points
COVID-19 research platform for data sharing

we will make protocol etc. available on the website soon voicetrial.nl",2021-10-15T22:07:44Z,2021-10-15T22:07:44Z
NCT04539275,NA,8/27/2020,NA,NA,10/5/2021,9/3/2020,9/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/14/2021,Actual,16-Nov-20,Actual,11/16/2020,Oct-21,10/31/2021,30-Sep-21,Actual,9/30/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,VA CURES-1,NA,COVID-19 (VA CURES-1),VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1),Completed,NA,Phase 3,75,Actual,VA Office of Research and Development,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:10:17Z,2021-10-15T22:10:17Z
NCT04350723,NA,4/14/2020,NA,NA,10/14/2021,4/14/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/15/2021,Estimate,10-Jun-20,Actual,6/10/2020,Oct-21,10/31/2021,17-Jul-21,Actual,7/17/2021,17-Jul-21,Actual,7/17/2021,NA,Interventional,COVI-PRONE,NA,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE),Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Completed,NA,Not Applicable,400,Actual,St. Joseph's Healthcare Hamilton,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:12:35Z,2021-10-15T22:12:35Z
NCT05080920,NA,10/16/2020,NA,NA,10/5/2021,10/5/2021,10/18/2021,Estimate,NA,NA,NA,NA,NA,NA,10/5/2021,10/18/2021,Estimate,28-Oct-20,Actual,10/28/2020,Oct-21,10/31/2021,31-Dec-22,Anticipated,12/31/2022,30-Sep-22,Anticipated,9/30/2022,NA,Interventional,OnCOVInf,NA,RosmalipÂ® for Cancer Infections Prevention,"A Pilot, Randomized, Double Blind, Placebo Controlled Study to Evaluate an Immune System Modulator Nutritional Supplement for the Prevention of Infections in Cancer Patients Receiving Oncologic Treatment During the COVID-19 Pandemia.",Enrolling by invitation,NA,Not Applicable,200,Anticipated,FundaciÃ³n InvestigaciÃ³n E InnovaciÃ³n BiomÃ©dica Hospital Universitario Infanta Sofia-Henares,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-19T10:05:33Z,2021-10-19T10:05:33Z
NCT05012943,NA,8/13/2021,NA,NA,10/15/2021,8/13/2021,8/19/2021,Actual,NA,NA,NA,NA,NA,NA,10/15/2021,10/18/2021,Estimate,15-Aug-21,Actual,8/15/2021,Oct-21,10/31/2021,31-Aug-23,Anticipated,8/31/2023,28-Feb-23,Anticipated,2/28/2023,NA,Interventional,ARCT-154-01,NA,The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01),"A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the SARS-CoV-2 Self- Amplifying RNA Vaccine ARCT-154 in Adults",Recruiting,NA,Phase 2/Phase 3,21000,Anticipated,Vinbiocare Biotechnology Joint Stock Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD is the sole property of VinBioCare. VinBioCare may share a copy of the study IPD with their collaborative partners if requested.,2021-10-19T10:07:13Z,2021-10-19T10:07:13Z
NCT04838795,NA,2/17/2021,NA,NA,10/13/2021,4/6/2021,4/9/2021,Actual,NA,NA,NA,NA,NA,NA,10/13/2021,10/18/2021,Estimate,18-Feb-21,Actual,2/18/2021,Oct-21,10/31/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,Sisonke,NA,Sisonke (Together): OPEN LABEL TRIAL COVID-19,"Open-label, Single-arm Phase 3B Implementation Study to Monitor the Effectiveness of the Single-dose Ad26.COV2.S COVID-19 Vaccine Among Health Care Workers in South Africa (VAC31518COV3012)",Recruiting,NA,Phase 3,500000,Anticipated,Wits Health Consortium (Pty) Ltd,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-19T10:09:20Z,2021-10-19T10:09:20Z
NCT04522089,NA,8/12/2020,NA,NA,10/14/2021,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/18/2021,Estimate,24-Aug-20,Actual,8/24/2020,Aug-21,8/31/2021,31-Oct-21,Anticipated,10/31/2021,20-Nov-20,Actual,11/20/2020,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,"A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers","Active, not recruiting",NA,Phase 1,70,Anticipated,Adimmune Corporation,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-19T10:12:06Z,2021-10-19T10:12:06Z
NCT04516564,NA,8/13/2020,NA,NA,10/15/2021,8/16/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,10/15/2021,10/18/2021,Estimate,29-Sep-20,Actual,9/29/2020,Oct-21,10/31/2021,18-Jun-21,Actual,6/18/2021,4-Mar-21,Actual,3/4/2021,NA,Interventional,NA,NA,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects",Completed,NA,Phase 1,29,Actual,Akeso,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-19T10:12:07Z,2021-10-19T10:12:07Z
NCT04357457,NA,4/20/2020,NA,NA,10/15/2021,4/20/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/15/2021,10/18/2021,Estimate,3-Sep-20,Actual,9/3/2020,Oct-21,10/31/2021,Oct-21,Anticipated,10/31/2021,1-Oct-21,Actual,10/1/2021,NA,Interventional,AIRVM-COVID,NA,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium,"Active, not recruiting",NA,Phase 3,181,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Yes, upon request, after approval by the primary investigator and clinical research platform of East Paris. For the purpose of IPD meta-analysis, or secondary analysis. Unidentifying data will be shared.",2021-10-19T10:13:07Z,2021-10-19T10:13:07Z
NCT04345991,NA,4/10/2020,NA,NA,10/15/2021,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,10/15/2021,10/18/2021,Estimate,15-Apr-20,Actual,4/15/2020,Oct-21,10/31/2021,28-May-21,Actual,5/28/2021,28-May-21,Actual,5/28/2021,NA,Interventional,CORIPLASM,NA,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS,Completed,NA,Phase 2,120,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-19T10:13:11Z,2021-10-19T10:13:11Z
NCT05081362,NA,10/7/2021,NA,NA,10/18/2021,10/15/2021,10/18/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/19/2021,Estimate,18-Oct-21,Actual,10/18/2021,Oct-21,10/31/2021,6-Oct-22,Anticipated,10/6/2022,6-Oct-22,Anticipated,10/6/2022,NA,Interventional,COVIDans,NA,Cardiovascular Assessment in Patient Recovered From COVID-19 and Recovery of Autonomic Nervous System in Association With the Severity of the Disease,Cardiovascular Assessment in Patient Recovered From COVID-19 and Recovery of Autonomic Nervous System in Association With the Severity of the Disease,Recruiting,NA,Not Applicable,90,Anticipated,IRCCS Policlinico S. Donato,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:06:27Z,2021-10-20T11:06:27Z
NCT04565249,NA,9/15/2020,NA,NA,10/8/2021,9/24/2020,9/25/2020,Actual,NA,NA,NA,NA,NA,NA,10/8/2021,10/18/2021,Estimate,22-Oct-20,Actual,10/22/2020,Sep-20,9/30/2020,2-Aug-21,Actual,8/2/2021,1-Jun-21,Actual,6/1/2021,NA,Interventional,NA,NA,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19","A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)",Terminated,NA,Phase 2,6,Actual,"Pliant Therapeutics, Inc.",,3,NA,Study halted and will not resume; participants are no longer being examined or receiving intervention,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-19T10:11:46Z,2021-10-19T10:11:46Z
NCT05082727,NA,10/15/2021,NA,NA,10/15/2021,10/15/2021,10/19/2021,Estimate,NA,NA,NA,NA,NA,NA,10/15/2021,10/19/2021,Estimate,1-Jul-21,Actual,7/1/2021,Oct-21,10/31/2021,15-Nov-22,Anticipated,11/15/2022,15-Sep-22,Anticipated,9/15/2022,NA,Interventional,NA,NA,Safety and Efficacy of KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR),"Randomized, Double-blind, Placebo-controlled, Phase IIb Study, Safety Evaluation and Exploration of the Effect on Virologic Dynamics of KOVIR (TD.0068) in Combination With Background Therapy in Patients With Patients With COVID-19 Have Not Shown Signs of Acute Respiratory Failure.",Recruiting,NA,Phase 2,60,Anticipated,Sunstar Joint Stock Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:05:58Z,2021-10-20T11:05:58Z
NCT05027815,NA,8/26/2021,NA,NA,10/15/2021,8/26/2021,8/30/2021,Actual,NA,NA,NA,NA,NA,NA,10/15/2021,10/19/2021,Estimate,11-Oct-21,Actual,10/11/2021,Oct-21,10/31/2021,Nov-22,Anticipated,11/30/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,regARDS,NA,Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS),A Phase 1/2a Study of Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells (cePolyTregs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With SARS-CoV-2 Infection (regARDS),Recruiting,NA,Phase 1,18,Anticipated,"University of California, San Francisco",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:07:51Z,2021-10-20T11:07:51Z
NCT04918927,NA,6/4/2021,NA,NA,10/18/2021,6/7/2021,6/9/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/19/2021,Estimate,12-Oct-21,Actual,10/12/2021,Oct-21,10/31/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,FANTAZE,NA,Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19,"Favipiravir and/or Nitazoxanide: a Randomized, Double-blind, Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 (FANTAZE)",Recruiting,NA,Phase 2,120,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,No plan to share IPD has been made at this time,2021-10-20T11:09:18Z,2021-10-20T11:09:18Z
NCT05042141,NA,9/8/2021,NA,NA,10/16/2021,9/9/2021,9/13/2021,Actual,NA,NA,NA,NA,NA,NA,10/16/2021,10/19/2021,Estimate,28-Jul-21,Actual,7/28/2021,Sep-21,9/30/2021,12-Sep-21,Actual,9/12/2021,11-Aug-21,Actual,8/11/2021,NA,Interventional,KOVIR,NA,Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR),A Study to Evaluate the Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients Without Symptoms of Acute Respiratory Distress,Completed,NA,Not Applicable,66,Actual,Sunstar Joint Stock Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:07:31Z,2021-10-20T11:07:31Z
NCT05032950,NA,8/27/2021,NA,NA,10/18/2021,8/27/2021,9/2/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/19/2021,Estimate,17-Sep-21,Actual,9/17/2021,Oct-21,10/31/2021,3-Dec-21,Anticipated,12/3/2021,3-Dec-21,Anticipated,12/3/2021,NA,Interventional,NA,NA,Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants,"COVID-19: A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY PARTICIPANTS.",Recruiting,NA,Phase 1,12,Anticipated,Pfizer,,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-20T11:07:43Z,2021-10-20T11:07:43Z
NCT04951336,NA,6/30/2021,NA,NA,10/11/2021,7/1/2021,7/6/2021,Actual,NA,NA,NA,NA,NA,NA,10/11/2021,10/19/2021,Estimate,10-Jun-21,Actual,6/10/2021,Oct-21,10/31/2021,1-Jun-22,Anticipated,6/1/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,MACH19,NA,RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination,"Multicenter Double-Blind, Placebo-Controlled RCT of Fomitopsis Officinalis/Trametes Versicolor for COVID-19",Recruiting,NA,Not Applicable,66,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:08:51Z,2021-10-20T11:08:51Z
NCT04942405,NA,6/24/2021,NA,NA,10/18/2021,6/24/2021,6/28/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/19/2021,Estimate,21-Jun-21,Actual,6/21/2021,Jun-21,6/30/2021,31-Mar-23,Anticipated,3/31/2023,21-Jan-22,Anticipated,1/21/2022,NA,Interventional,NA,NA,"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine","Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial",Recruiting,NA,Phase 3,40800,Anticipated,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-20T11:09:02Z,2021-10-20T11:09:02Z
NCT04806074,NA,3/17/2021,NA,NA,10/14/2021,3/17/2021,3/19/2021,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/19/2021,Estimate,14-Aug-20,Actual,8/14/2020,Oct-21,10/31/2021,6-Sep-21,Actual,9/6/2021,6-Dec-20,Actual,12/6/2020,NA,Interventional,NA,NA,FOODLIT-Trial: Digital Behaviour Change Intervention to Improve Food Literacy Amidst the COVID-19 Pandemic,FOODLIT-Trial: Protocol of a Randomised Controlled Digital Intervention to Promote Food Literacy and Food Sustainability Behaviours in Adults Using the Health Action Process Approach (HAPA) and the Behaviour Change Techniques Taxonomy (BCTT) During the COVID-19 Pandemic,Completed,NA,Not Applicable,215,Actual,"ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:10:40Z,2021-10-20T11:10:40Z
NCT04869228,NA,4/29/2021,NA,NA,10/18/2021,4/29/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/19/2021,Estimate,4-Aug-21,Actual,8/4/2021,Jul-21,7/31/2021,30-May-22,Anticipated,5/30/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,"A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients","A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients",Recruiting,NA,Phase 3,724,Anticipated,"Suzhou Kintor Pharmaceutical Inc,",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-20T11:09:54Z,2021-10-20T11:09:54Z
NCT04852861,NA,4/14/2021,NA,NA,10/18/2021,4/19/2021,4/21/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/19/2021,Estimate,10-May-21,Actual,5/10/2021,Oct-21,10/31/2021,30-Sep-22,Anticipated,9/30/2022,30-Jul-21,Actual,7/30/2021,NA,Interventional,REDU-VAC,NA,COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine,COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population,Enrolling by invitation,NA,Phase 4,150,Anticipated,Sciensano,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-20T11:10:05Z,2021-10-20T11:10:05Z
NCT04527614,NA,8/18/2020,NA,NA,10/18/2021,8/25/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/19/2021,Estimate,24-Sep-20,Actual,9/24/2020,Oct-21,10/31/2021,30-May-22,Anticipated,5/30/2022,30-May-22,Anticipated,5/30/2022,NA,Interventional,PICOV,NA,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection (PICOV) A Multicentre Academic Prospective Cohort Study in Nursing Home During the Winter Season 2020-2021,Enrolling by invitation,NA,Not Applicable,2000,Anticipated,Sciensano,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-20T11:12:55Z,2021-10-20T11:12:55Z
NCT05084898,NA,1/26/2021,NA,NA,10/6/2021,10/6/2021,10/20/2021,Actual,NA,NA,NA,NA,NA,NA,10/6/2021,10/20/2021,Actual,1-Oct-21,Actual,10/1/2021,Oct-21,10/31/2021,30-Apr-23,Anticipated,4/30/2023,28-Feb-23,Anticipated,2/28/2023,NA,Interventional,UVCinLTCs,NA,Far-UVC Light Devices in Long-term Care Facilities to Reduce Infections,"Do Far-UVC Light Devices Reduce the Incidence of Influenza-Like Illnesses, Respiratory Illnesses, and COVID-19 Infections in Long-term Care Facilities?",Enrolling by invitation,NA,Not Applicable,200,Anticipated,Nova Scotia Health Authority,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:02:37Z,2021-10-22T11:02:37Z
NCT05085145,NA,8/20/2021,NA,NA,10/18/2021,10/18/2021,10/20/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/20/2021,Actual,1-Sep-21,Actual,9/1/2021,Aug-21,8/31/2021,1-Sep-22,Anticipated,9/1/2022,1-Sep-22,Anticipated,9/1/2022,NA,Interventional,NA,NA,Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV,The Efficacy of COVID-19 Vaccine in Patients With HIV Infectionï¼Œa Prospective and Multicenter Clinical Trial,Recruiting,NA,Phase 4,200,Anticipated,Beijing 302 Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:02:26Z,2021-10-22T11:02:26Z
NCT05074771,NA,10/8/2021,NA,NA,10/12/2021,10/11/2021,10/12/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/20/2021,Actual,26-Mar-21,Actual,3/26/2021,Oct-21,10/31/2021,Nov-21,Anticipated,11/30/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,RICOMINCIARE,NA,At Home REhabilitation and Monitoring of People in poST-covid Condition Through ARc-inTellicare Platform (RESTART/RICOMINCIARE),RIabilitazione di Pazienti COvid e Loro Monitoraggio IN Casa Con la pIattaforma ARc-IntEllicare - (RICOMINCIARE),Enrolling by invitation,NA,Not Applicable,20,Anticipated,Camlin Ltd,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:03:38Z,2021-10-22T11:03:38Z
NCT05028257,NA,7/31/2021,NA,NA,10/15/2021,8/30/2021,8/31/2021,Actual,NA,NA,NA,NA,NA,NA,10/15/2021,10/20/2021,Actual,15-Sep-21,Actual,9/15/2021,Oct-21,10/31/2021,May-22,Anticipated,5/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,COVALL,NA,Allergy and COVID-19 Vaccines,Pursuit of Vaccination in Anaphylactic Reaction to COVID19 Vaccines,Recruiting,NA,Phase 3,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:05:07Z,2021-10-22T11:05:07Z
NCT04962204,NA,7/5/2021,NA,NA,10/12/2021,7/5/2021,7/14/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/20/2021,Actual,6-Jul-21,Actual,7/6/2021,Oct-21,10/31/2021,30-Jun-22,Anticipated,6/30/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,ISEEU,NA,Virtual Visitation in Intensive Care Unit Study,Efficacy of Virtual Visitation in Intensive Care Unit During COVID-19 Pandemic: Randomized Controlled Trial,Recruiting,NA,Not Applicable,100,Anticipated,Seoul National University Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-22T11:06:31Z,2021-10-22T11:06:31Z
NCT04980534,NA,7/26/2021,NA,NA,10/20/2021,7/26/2021,7/28/2021,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/21/2021,Estimate,8-Jan-21,Actual,1/8/2021,Jul-21,7/31/2021,15-Sep-21,Actual,9/15/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,NA,NA,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Completed,NA,Not Applicable,80,Actual,Catalysis SL,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-22T11:06:05Z,2021-10-22T11:06:05Z
NCT04952376,NA,6/7/2021,NA,NA,10/19/2021,7/2/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/21/2021,Estimate,Jan-22,Anticipated,1/31/2022,Oct-21,10/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Equitable Access to COVID-19 Vaccines,Enabling Equitable Access to COVID-19 Vaccine in Under-Resourced Communities,Recruiting,NA,Not Applicable,1500,Anticipated,Mayo Clinic,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:06:39Z,2021-10-22T11:06:39Z
NCT04927182,NA,6/14/2021,NA,NA,10/19/2021,6/14/2021,6/15/2021,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/20/2021,Actual,15-Oct-20,Actual,10/15/2020,Oct-21,10/31/2021,30-Sep-21,Actual,9/30/2021,30-Sep-21,Actual,9/30/2021,NA,Interventional,NA,NA,Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.,Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.,Completed,NA,Not Applicable,102,Actual,Riphah International University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:07:20Z,2021-10-22T11:07:20Z
NCT04790851,NA,3/8/2021,NA,NA,10/12/2021,3/8/2021,3/10/2021,Actual,NA,NA,NA,NA,NA,NA,10/12/2021,10/20/2021,Actual,10-Mar-21,Actual,3/10/2021,Oct-21,10/31/2021,5-Sep-21,Actual,9/5/2021,5-Sep-21,Actual,9/5/2021,NA,Interventional,NA,NA,Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Beijing) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)",Completed,NA,Phase 4,1133,Actual,China National Biotec Group Company Limited,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:09:15Z,2021-10-22T11:09:15Z
NCT04896866,NA,5/17/2021,NA,NA,10/13/2021,5/19/2021,5/21/2021,Actual,NA,NA,NA,NA,NA,NA,10/13/2021,10/21/2021,Estimate,1-Mar-21,Actual,3/1/2021,Oct-21,10/31/2021,Jan-22,Anticipated,1/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,COVASP,NA,Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP),Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients: A Pragmatic Clinical Trial,Recruiting,NA,Not Applicable,530,Anticipated,University of Alberta,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,The study protocol will be published in an open journal.,2021-10-22T11:07:54Z,2021-10-22T11:07:54Z
NCT04931238,NA,6/13/2021,NA,NA,10/13/2021,6/16/2021,6/18/2021,Actual,NA,NA,NA,NA,NA,NA,10/13/2021,10/21/2021,Estimate,20-Jan-21,Actual,1/20/2021,Oct-21,10/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19),"Efficacy and Safety of a Recombinant Neutralizing Human Anti-SARS-CoV-2 Monoclonal Antibody JS016 in Chinese Hospitalized Patients With SARS-CoV-2 Infection (COVID-19): a Multicenter, Randomized, Open-label, Controlled Trial",Recruiting,NA,Phase 2,200,Anticipated,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:07:09Z,2021-10-22T11:07:09Z
NCT04726098,NA,1/23/2021,NA,NA,10/19/2021,1/26/2021,1/27/2021,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/20/2021,Actual,15-Jan-21,Actual,1/15/2021,Oct-21,10/31/2021,31-Aug-21,Actual,8/31/2021,31-Aug-21,Actual,8/31/2021,NA,Interventional,HIGHLOWDEXA,NA,Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Completed,NA,Phase 4,198,Actual,Hospital Clinico Universitario de Santiago,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:10:19Z,2021-10-22T11:10:19Z
NCT04528771,NA,8/25/2020,NA,NA,10/13/2021,8/25/2020,8/27/2020,Actual,NA,NA,NA,NA,NA,NA,10/13/2021,10/21/2021,Estimate,5-Aug-21,Actual,8/5/2021,Oct-21,10/31/2021,30-Apr-22,Anticipated,4/30/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,S-Nitrosylation Therapy of COVID-19,Proof of Concept Safety Trial for S-Nitrosylation Therapy to Improve Oxygenation Status in Severe Covid-19 Patients Receiving Supplemental Oxygen Support,"Active, not recruiting",NA,Early Phase 1,24,Anticipated,University Hospitals Cleveland Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:12:55Z,2021-10-22T11:12:55Z
NCT04701502,NA,1/4/2021,NA,NA,10/20/2021,1/7/2021,1/8/2021,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/21/2021,Estimate,9-Nov-20,Actual,11/9/2020,Nov-20,11/30/2020,15-Feb-21,Actual,2/15/2021,15-Feb-21,Actual,2/15/2021,NA,Interventional,NA,NA,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Completed,NA,Phase 2,60,Actual,Catalysis SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-22T11:10:43Z,2021-10-22T11:10:43Z
NCT04595773,NA,10/20/2020,NA,NA,10/19/2021,10/20/2020,10/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/20/2021,Actual,22-Jan-21,Actual,1/22/2021,14-Oct-21,10/14/2021,31-Dec-23,Anticipated,12/31/2023,31-Dec-23,Anticipated,12/31/2023,NA,Interventional,NA,NA,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)","COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE): A Randomized Controlled Trial",Recruiting,NA,Phase 1/Phase 2,90,Anticipated,National Institutes of Health Clinical Center (CC),,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:12:07Z,2021-10-22T11:12:07Z
NCT04581200,NA,10/4/2020,NA,NA,10/19/2021,10/6/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/21/2021,Estimate,25-Jan-21,Actual,1/25/2021,Oct-21,10/31/2021,30-Jan-22,Anticipated,1/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,LIFTCOVID,NA,Lift Mobile Mindfulness for COVID-19 Distress Symptoms,"Addressing Psychological Distress Symptoms Among Serious Illness Survivors of a Viral Pandemic With a Completely Self-directed, Symptom-responsive Mobile Mindfulness Intervention: a Randomized Controlled Trial",Recruiting,NA,Not Applicable,300,Anticipated,Duke University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,We will follow NIH guidelines.,We will follow NIH and institutional guidelines.,NA,Yes,We will follow NIH/NCCIH guidelines for data access.,2021-10-22T11:12:24Z,2021-10-22T11:12:24Z
NCT04470622,NA,7/13/2020,NA,NA,10/13/2021,7/13/2020,7/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/13/2021,10/20/2021,Actual,20-Jul-20,Actual,7/20/2020,Oct-21,10/31/2021,3-Jun-21,Actual,6/3/2021,9-Apr-21,Actual,4/9/2021,NA,Interventional,NA,NA,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19",Terminated,NA,Phase 2,27,Actual,Heron Therapeutics,,2,NA,"Study was terminated early by Heron, and was not terminated for safety reasons.",FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:13:28Z,2021-10-22T11:13:28Z
NCT04348864,NA,4/13/2020,NA,NA,10/13/2021,4/13/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,10/13/2021,10/21/2021,Estimate,16-Apr-20,Actual,4/16/2020,Oct-21,10/31/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Assessment of COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Recruiting,NA,Not Applicable,200,Anticipated,Neuroganics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:14:46Z,2021-10-22T11:14:46Z
NCT04335084,NA,4/2/2020,NA,NA,10/19/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/21/2021,Estimate,22-Jun-20,Actual,6/22/2020,Oct-21,10/31/2021,Jul-25,Anticipated,7/31/2025,Dec-24,Anticipated,12/31/2024,NA,Interventional,HELPCOVID-19,NA,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:14:54Z,2021-10-22T11:14:54Z
NCT04400838,NA,5/12/2020,NA,NA,10/14/2021,5/22/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/20/2021,Actual,28-May-20,Actual,5/28/2020,Jun-21,6/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Investigating a Vaccine Against COVID-19,"A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19","Active, not recruiting",NA,Phase 2/Phase 3,12390,Anticipated,University of Oxford,,29,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:14:03Z,2021-10-22T11:14:03Z
NCT04400305,NA,5/21/2020,NA,NA,10/19/2021,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/21/2021,Estimate,20-May-20,Actual,5/20/2020,Oct-21,10/31/2021,30-Aug-21,Actual,8/30/2021,30-Aug-21,Actual,8/30/2021,NA,Interventional,COVID-19,NA,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""","""Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Completed,NA,Not Applicable,37,Actual,University of Victoria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:14:05Z,2021-10-22T11:14:05Z
NCT04394117,NA,5/18/2020,NA,NA,10/19/2021,5/18/2020,5/19/2020,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/21/2021,Estimate,19-Jun-20,Actual,6/19/2020,Oct-21,10/31/2021,18-Jan-22,Anticipated,1/18/2022,2-Nov-21,Anticipated,11/2/2021,NA,Interventional,CLARITY,NA,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,"Active, not recruiting",NA,Phase 4,1500,Anticipated,The George Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,To be confirmed,To be determined,NA,Yes,"Trial data will be disseminated in the form of a publication to a relevant clinical journal and presentation at appropriate scientific conferences.

Individual participant data that underlie the results reported, after de-identification (text, tables, figures, and appendices), may be shared with Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose.",2021-10-22T11:14:14Z,2021-10-22T11:14:14Z
NCT05089045,NA,10/11/2021,NA,NA,10/21/2021,10/21/2021,10/22/2021,Estimate,NA,NA,NA,NA,NA,NA,10/21/2021,10/22/2021,Estimate,31-Aug-21,Actual,8/31/2021,Oct-21,10/31/2021,30-Sep-21,Actual,9/30/2021,16-Sep-21,Actual,9/16/2021,NA,Interventional,NA,NA,Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity,A Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant New Coronavirus Vaccine (CHO Cells) After Vaccination With Two Inactivated Vaccine in Healthy People Aged 18 and Above,Completed,NA,Not Applicable,360,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:35:52Z,2021-10-25T10:35:52Z
NCT05084911,NA,10/19/2021,NA,NA,10/20/2021,10/19/2021,10/20/2021,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/22/2021,Estimate,18-Oct-21,Actual,10/18/2021,Oct-21,10/31/2021,30-Sep-22,Anticipated,9/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3),"A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase III Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients",Recruiting,NA,Phase 3,1420,Anticipated,Shin Poong Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:36:25Z,2021-10-25T10:36:25Z
NCT04932915,NA,6/18/2021,NA,NA,10/21/2021,6/18/2021,6/21/2021,Actual,NA,NA,NA,NA,NA,NA,10/21/2021,10/22/2021,Estimate,3-Sep-21,Actual,9/3/2021,Oct-21,10/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,PREVENT,NA,Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19,A Randomized Placebo-controlled Phase 2 Study to Assess the Safety and Efficacy of UNI91103 Intranasal Administration in Adults With Asymptomatic or Mildly Symptomatic COVID-19,Recruiting,NA,Phase 2,330,Anticipated,UNION therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:38:44Z,2021-10-25T10:38:44Z
NCT05007951,NA,8/9/2021,NA,NA,10/14/2021,8/9/2021,8/17/2021,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/22/2021,Estimate,30-Aug-21,Actual,8/30/2021,Sep-21,9/30/2021,Sep-22,Anticipated,9/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19),"A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,3990,Anticipated,"SK Bioscience Co., Ltd.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:37:47Z,2021-10-25T10:37:47Z
NCT05077267,NA,10/11/2021,NA,NA,10/14/2021,10/11/2021,10/14/2021,Actual,NA,NA,NA,NA,NA,NA,10/14/2021,10/22/2021,Estimate,19-Aug-21,Actual,8/19/2021,Oct-21,10/31/2021,1-Feb-24,Anticipated,2/1/2024,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects,"An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects",Recruiting,NA,Phase 2,210,Anticipated,Bavarian Nordic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-25T10:36:43Z,2021-10-25T10:36:43Z
NCT05075083,NA,10/4/2021,NA,NA,10/20/2021,10/6/2021,10/12/2021,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/22/2021,Estimate,8-Oct-21,Actual,10/8/2021,Oct-21,10/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:46Z,2021-10-25T10:36:46Z
NCT05075070,NA,10/5/2021,NA,NA,10/21/2021,10/6/2021,10/12/2021,Actual,NA,NA,NA,NA,NA,NA,10/21/2021,10/22/2021,Estimate,8-Oct-21,Actual,10/8/2021,Oct-21,10/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With Human Immunodeficiency Virus Infected,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:46Z,2021-10-25T10:36:46Z
NCT05075057,NA,10/5/2021,NA,NA,10/20/2021,10/6/2021,10/12/2021,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/22/2021,Estimate,8-Oct-21,Actual,10/8/2021,Oct-21,10/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥60 Years With Chronic Bronchitis and COPD,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥60 Years With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:47Z,2021-10-25T10:36:47Z
NCT05075044,NA,10/5/2021,NA,NA,10/20/2021,10/6/2021,10/12/2021,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/22/2021,Estimate,8-Oct-21,Actual,10/8/2021,Oct-21,10/31/2021,30-Dec-22,Anticipated,12/30/2022,30-Dec-22,Anticipated,12/30/2022,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged â‰¥18 Years With HIV Infected,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥18 Years With Human Immunodeficiency Virus Infected,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:48Z,2021-10-25T10:36:48Z
NCT04952389,NA,7/2/2021,NA,NA,10/20/2021,7/2/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/22/2021,Estimate,Dec-21,Anticipated,12/31/2021,Oct-21,10/31/2021,Aug-23,Anticipated,8/31/2023,Jul-23,Anticipated,7/31/2023,NA,Interventional,NA,NA,Acupuncture Therapy for COVID-Related Olfactory Loss,Acupuncture Therapy for COVID-Related Olfactory Loss,Recruiting,NA,Not Applicable,100,Anticipated,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:38:27Z,2021-10-25T10:38:27Z
NCT04484025,NA,7/13/2020,NA,NA,10/20/2021,7/21/2020,7/23/2020,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/22/2021,Estimate,12-Oct-21,Actual,10/12/2021,Oct-21,10/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,SPI-1005 Treatment in Moderate COVID-19 Patients,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients",Enrolling by invitation,NA,Phase 2,60,Anticipated,"Sound Pharmaceuticals, Incorporated",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:42:23Z,2021-10-25T10:42:23Z
NCT04483973,NA,7/13/2020,NA,NA,10/20/2021,7/21/2020,7/23/2020,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/22/2021,Estimate,27-Aug-21,Actual,8/27/2021,Oct-21,10/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,SPI-1005 Treatment in Severe COVID-19 Patients,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients",Enrolling by invitation,NA,Phase 2,60,Anticipated,"Sound Pharmaceuticals, Incorporated",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:42:24Z,2021-10-25T10:42:24Z
NCT05091411,NA,10/12/2021,NA,NA,10/12/2021,10/12/2021,10/25/2021,Estimate,NA,NA,NA,NA,NA,NA,10/12/2021,10/25/2021,Estimate,9-Sep-21,Actual,9/9/2021,Oct-21,10/31/2021,Dec-22,Anticipated,12/31/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells),"Randomized, Double-blind, Parallel-controlled Evaluation of the Immunogenicity Consistency and Safety of the Three Batches of Recombinant Novel Coronavirus Vaccine (CHO Cells) After Process Verification in the 18-59-year-old Population, and the Comparison With the Pilot-scale Batch Immunogenicity Non-inferiority Bridging and Safety Clinical Trials",Recruiting,NA,Phase 3,1680,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:28:44Z,2021-10-26T10:28:44Z
NCT05092607,NA,10/1/2021,NA,NA,10/22/2021,10/22/2021,10/25/2021,Estimate,NA,NA,NA,NA,NA,NA,10/22/2021,10/25/2021,Estimate,15-Jul-21,Actual,7/15/2021,Sep-21,9/30/2021,30-Jun-22,Anticipated,6/30/2022,15-Jan-22,Anticipated,1/15/2022,NA,Interventional,CoviBlood,NA,Evaluation of the Detection Performance of the N Antigenemia of SARS-CoV-2 in the General Population for the Diagnosis and Screening of COVID-19,Evaluation of the Detection Performance of the N Antigenemia of SARS-CoV-2 in the General Population for the Diagnosis and Screening of COVID-19,Recruiting,NA,Not Applicable,1467,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-26T10:27:45Z,2021-10-26T10:27:45Z
NCT05092542,NA,10/22/2021,NA,NA,10/22/2021,10/22/2021,10/25/2021,Estimate,NA,NA,NA,NA,NA,NA,10/22/2021,10/25/2021,Estimate,18-Oct-21,Actual,10/18/2021,Oct-21,10/31/2021,31-Jul-26,Anticipated,7/31/2026,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,RIWP+,NA,Multilevel Community-Based Mental Health Intervention to Address Structural Inequities and Adverse Disparate Consequences of COVID-19 Pandemic on Latinx Immigrant and African Refugees,Multilevel Community-Based Mental Health Intervention to Address Structural Inequities and Adverse Disparate Consequences of COVID-19 Pandemic on Latinx Immigrant and African Refugees,Recruiting,NA,Phase 3,1300,Anticipated,University of New Mexico,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 6 months of the end of data collection in Year 4,"The NDA provides basic descriptive and aggregate summary information for general public use. Such summary information may include summary counts and general statistics on completed assessment instruments. Access to subject level datasets submitted and stored in the NDA will only be provided for research purposes through the completion of the NDA Data Use Certification: OMB Control Number: 0925-0667. For the majority of the data available in the NDA, Data Use Certifications will only be accepted from researchers who are sponsored by an institution registered in the NIH's eRA Commons with an active Federal-wide Assurance issued through the Office for Human Research Protections (OHRP). Additionally, the application must include a reason for access related to scientific investigation, scholarship or teaching, or other form of research.",https://s3.amazonaws.com/nda.nih.gov/Documents/NIMH+Data+Archive+Policy.pdf,Yes,"After all analyses are completed and presentations/publications are finalized, a de-identified dataset will be available to other researchers, communities, or providers, upon request. All requests would have to be approved by the Community Advisory Council and would have to demonstrate that the proposed use of the data would contribute to the reduction of mental health disparities (e.g., through improved detection, diagnosis, treatment or prevention of mental illness or through contributing to knowledge of these issues) and would not harm any individuals or communities (e.g., through naÃ¯ve use of the data that might result in misrepresentation of the experiences of Latinx immigrants or African refugee individuals, families, or communities).

Also, the data will be entered and available through the NIMH Data Archive.",2021-10-26T10:27:48Z,2021-10-26T10:27:48Z
NCT04874766,NA,4/23/2021,NA,NA,10/19/2021,5/2/2021,5/6/2021,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/25/2021,Estimate,28-May-21,Actual,5/28/2021,Oct-21,10/31/2021,31-Aug-21,Actual,8/31/2021,15-Jul-21,Actual,7/15/2021,NA,Interventional,NA,NA,The Effects of Wearing a Face Mask During Exercise in Youth Hockey Players During COVID-19,The Effects of Wearing a Face Mask on Exercise Tolerance in Children's Hockey During the COVID-19 Pandemic,Completed,NA,Not Applicable,26,Actual,University of Saskatchewan,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:32:43Z,2021-10-26T10:32:43Z
NCT05072210,NA,8/24/2021,NA,NA,10/15/2021,10/5/2021,10/8/2021,Actual,NA,NA,NA,NA,NA,NA,10/15/2021,10/25/2021,Estimate,1-May-21,Actual,5/1/2021,Oct-21,10/31/2021,1-Jul-22,Anticipated,7/1/2022,1-Jul-22,Anticipated,7/1/2022,NA,Interventional,NA,NA,Mobile Interventions for the Prevention and Detection of Distress,"Could Mobile-based Interventions Aid To ""Understand and Flatten the Curve"" of Stress, Anxiety, Distress and Depression Among Healthcare Providers at Unity Health Toronto During and After the COVID-19 Pandemic?",Recruiting,NA,Not Applicable,50,Anticipated,Unity Health Toronto,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:30:14Z,2021-10-26T10:30:14Z
NCT05069129,NA,10/3/2021,NA,NA,10/17/2021,10/5/2021,10/6/2021,Actual,NA,NA,NA,NA,NA,NA,10/17/2021,10/25/2021,Estimate,14-Oct-21,Actual,10/14/2021,Oct-21,10/31/2021,Feb-24,Anticipated,2/29/2024,Dec-23,Anticipated,12/31/2023,NA,Interventional,NA,NA,"Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above","A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above",Recruiting,NA,Phase 1/Phase 2,1848,Anticipated,"National Vaccine and Serum Institute, China",,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-26T10:30:22Z,2021-10-26T10:30:22Z
NCT04952350,NA,7/1/2021,NA,NA,10/22/2021,7/2/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,10/22/2021,10/25/2021,Estimate,14-Aug-21,Actual,8/14/2021,Oct-21,10/31/2021,Apr-22,Anticipated,4/30/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,COVID-STAT,NA,Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT,"Atorvastatin in Hospitalized COVID-19 Patients: A Randomized, Double-blinded, Placebo-Controlled, Clinical Trial","Active, not recruiting",NA,Phase 3,220,Actual,Mansoura University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,will be updtaed shortly,will be updated shortly,NA,Yes,We will make the anonymous individual data available at reasonable request after publication. Patient confidentiality will be kept safe.,2021-10-26T10:31:51Z,2021-10-26T10:31:51Z
NCT04415151,NA,6/2/2020,NA,NA,10/18/2021,6/2/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/25/2021,Estimate,14-Oct-20,Actual,10/14/2020,Oct-21,10/31/2021,28-Feb-21,Actual,2/28/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,I-TOMIC,NA,Tofacitinib for Treatment of Moderate COVID-19,Investigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC),Terminated,NA,Phase 2,24,Actual,Yale University,,2,NA,Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:35:55Z,2021-10-26T10:35:55Z
NCT04716985,NA,1/13/2021,NA,NA,10/18/2021,1/19/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/25/2021,Estimate,22-Jan-21,Actual,1/22/2021,Jan-21,1/31/2021,22-May-23,Anticipated,5/22/2023,22-May-22,Anticipated,5/22/2022,NA,Interventional,HYDRO COVID,NA,Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care,"Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care. Double-blind, Randomized, Comparative Study",Recruiting,NA,Not Applicable,580,Anticipated,AGIR Ã  Dom,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:34:00Z,2021-10-26T10:34:00Z
NCT04710199,NA,1/5/2021,NA,NA,10/15/2021,1/13/2021,1/14/2021,Actual,NA,NA,NA,NA,NA,NA,10/15/2021,10/25/2021,Estimate,23-Feb-21,Actual,2/23/2021,Apr-21,4/30/2021,8-Jul-21,Actual,7/8/2021,8-Jul-21,Actual,7/8/2021,NA,Interventional,COVIMAR,NA,Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19),Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19,Completed,NA,Phase 2,44,Actual,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-26T10:34:04Z,2021-10-26T10:34:04Z
NCT04399889,NA,5/21/2020,NA,NA,10/22/2021,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/22/2021,10/25/2021,Estimate,18-Jun-20,Actual,6/18/2020,Oct-21,10/31/2021,31-Jul-22,Anticipated,7/31/2022,1-Apr-22,Anticipated,4/1/2022,NA,Interventional,NA,NA,hCT-MSCs for COVID19 ARDS,Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Duke University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:36:00Z,2021-10-26T10:36:00Z
NCT05093530,NA,9/29/2021,NA,NA,10/13/2021,10/13/2021,10/26/2021,Estimate,NA,NA,NA,NA,NA,NA,10/13/2021,10/26/2021,Estimate,13-Oct-21,Actual,10/13/2021,Oct-21,10/31/2021,15-Apr-22,Anticipated,4/15/2022,15-Apr-22,Anticipated,4/15/2022,NA,Interventional,NA,NA,Safety and Tolerability of Single and Multiple Doses of Neumifil,"A Two-part, Randomized, Double-blind, Placebo Controlled, Ascending Dose Study to Assess the Safety and Tolerability of Single and Multiple Doses of Neumifil (a Novel Drug Candidate With Potential for Treatment of COVID-19)",Recruiting,NA,Phase 1,60,Anticipated,Pneumagen Ltd.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T12:57:51Z,2021-10-27T12:57:51Z
NCT05094726,NA,10/23/2021,NA,NA,10/23/2021,10/23/2021,10/26/2021,Estimate,NA,NA,NA,NA,NA,NA,10/23/2021,10/26/2021,Estimate,8-Sep-21,Actual,9/8/2021,Oct-21,10/31/2021,15-Nov-21,Anticipated,11/15/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,NA,NA,Effect of PBM on Functional Capacity and Fatigability in Post Covid-19 Elderly,A Comparative Study Between Photobiomodulation and Placebo on Functional Capacity and Fatigability in Post Covid-19 Elderly,Recruiting,NA,Not Applicable,100,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T12:56:48Z,2021-10-27T12:56:48Z
NCT05094674,NA,10/22/2021,NA,NA,10/24/2021,10/24/2021,10/26/2021,Estimate,NA,NA,NA,NA,NA,NA,10/24/2021,10/26/2021,Estimate,22-Oct-21,Actual,10/22/2021,Oct-21,10/31/2021,30-Jul-22,Anticipated,7/30/2022,22-Jun-22,Anticipated,6/22/2022,NA,Interventional,NA,NA,Clinical Validation of Breath Analyser Tests for Diagnosis of COVID-19.,Clinical Validation of Biosafety Technologies Breath Analyser Tests for the Diagnosis of COVID-19; the Project Aims to Validate the Diagnostic Device and to Assess the Comparative Performance With RT-PCR Currently Being Deployed in the NHS.,Recruiting,NA,Not Applicable,500,Anticipated,Tera Group,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T12:56:50Z,2021-10-27T12:56:50Z
NCT05094661,NA,4/22/2021,NA,NA,10/22/2021,10/22/2021,10/26/2021,Estimate,NA,NA,NA,NA,NA,NA,10/22/2021,10/26/2021,Estimate,18-Feb-21,Actual,2/18/2021,Oct-21,10/31/2021,31-Oct-22,Anticipated,10/31/2022,31-Oct-22,Anticipated,10/31/2022,NA,Interventional,RUTIROX,NA,Predictors of Non-invasive Respiratory Support Failure in COVID-19 Pneumonia,Predictors of Non-invasive Respiratory Support Failure in COVID-19 Pneumonia,Recruiting,NA,Not Applicable,130,Anticipated,Germans Trias i Pujol Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T12:56:51Z,2021-10-27T12:56:51Z
NCT05082935,NA,10/15/2021,NA,NA,10/18/2021,10/15/2021,10/19/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/26/2021,Estimate,15-Sep-21,Actual,9/15/2021,Oct-21,10/31/2021,31-Aug-23,Anticipated,8/31/2023,31-Aug-22,Anticipated,8/31/2022,NA,Interventional,OSJP,NA,COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos) Phase II,Optimizing SARS-CoV-2 Testing and Promotores Interventions to Serve Latinx Communities,Recruiting,NA,Not Applicable,1100,Anticipated,University of Oregon,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,IPD will be shared in accordance with timeframes set by the RADX-UP CDCC,The RADX-UP CDCC will make these determinations,http://radx-up.org/about/,Yes,"The investigators will share IPD with the RADx-Up CDCC. All Tier 1 data elements required by the CDCC will be shared, unless we receive an official exception for some items from the CDCC and NIH.",2021-10-27T12:58:46Z,2021-10-27T12:58:46Z
NCT05079308,NA,9/8/2021,NA,NA,10/18/2021,10/14/2021,10/15/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/26/2021,Estimate,1-Mar-21,Actual,3/1/2021,Oct-21,10/31/2021,31-Aug-21,Actual,8/31/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,NA,NA,"Clinical Trial on the Efficacy of Different Masks With and Without a Peripheral Sealing Device, Against Covid-19","Clinical Trial on the Level of Respiratory Protection of Surgical Face Masks and Filtering Face Pieces (FFP2), With and Without a Peripheral Sealing Device, Against Covid-19",Completed,NA,Not Applicable,210,Actual,University of the Balearic Islands,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T12:58:54Z,2021-10-27T12:58:54Z
NCT05037201,NA,9/7/2021,NA,NA,10/21/2021,9/7/2021,9/8/2021,Actual,NA,NA,NA,NA,NA,NA,10/21/2021,10/26/2021,Estimate,11-Oct-21,Actual,10/11/2021,Oct-21,10/31/2021,8-Nov-21,Anticipated,11/8/2021,25-Oct-21,Anticipated,10/25/2021,NA,Interventional,NA,NA,Text Message Nudges for COVID-19 Vaccination,A Randomized Trial of Text Message-Based Nudges to Increase COVID-19 Vaccination,"Active, not recruiting",NA,Not Applicable,2000,Actual,Ascension South East Michigan,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual patient data will not be shared,2021-10-27T12:59:40Z,2021-10-27T12:59:40Z
NCT05054621,NA,9/13/2021,NA,NA,10/19/2021,9/22/2021,9/23/2021,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/26/2021,Estimate,15-Sep-21,Actual,9/15/2021,Aug-21,8/31/2021,31-Aug-22,Anticipated,8/31/2022,31-Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,Immunogenicity of COVID-19 Vaccine on Heterologous Schedule,"A Single-blind, Randomized Study to Evaluate the Immunogenicity of Heterologous Prime-boost COVID-19 Vaccine Schedule",Recruiting,NA,Phase 2,110,Anticipated,Chang Gung Memorial Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T12:59:21Z,2021-10-27T12:59:21Z
NCT04657809,NA,12/2/2020,NA,NA,10/25/2021,12/2/2020,12/8/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/26/2021,Estimate,1-Oct-20,Actual,10/1/2020,Oct-21,10/31/2021,20-Mar-21,Actual,3/20/2021,18-Feb-21,Actual,2/18/2021,NA,Interventional,NA,NA,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,"""Insulin Fast Dissolving Film for Intranasal Delivery Via Olfactory Region, a Promising Approach for the Treatment of Anosmia in COVID 19 Patients: Design, In-vitro Characterization and Clinical Evaluation.""",Completed,NA,Phase 2,40,Actual,Deraya University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:03:37Z,2021-10-27T13:03:37Z
NCT04655638,NA,12/3/2020,NA,NA,10/25/2021,12/4/2020,12/7/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/26/2021,Estimate,10-Feb-21,Actual,2/10/2021,Oct-21,10/31/2021,25-Oct-21,Actual,10/25/2021,22-Sep-21,Actual,9/22/2021,NA,Interventional,COVID-HIGH,NA,HFNT vs. COT in COVID-19,High-Flow Nasal Therapy Versus Conventional Oxygen Therapy in Patients With COVID-19: A Randomized Controlled Trial (The COVID-HIGH Trial),Completed,NA,Not Applicable,364,Actual,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:03:38Z,2021-10-27T13:03:38Z
NCT04880109,NA,4/29/2021,NA,NA,10/24/2021,5/7/2021,5/10/2021,Actual,NA,NA,NA,NA,NA,NA,10/24/2021,10/26/2021,Estimate,20-Oct-21,Actual,10/20/2021,Oct-21,10/31/2021,Mar-23,Anticipated,3/31/2023,Feb-23,Anticipated,2/28/2023,NA,Interventional,NA,NA,A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.,"A Phase 2, Double-blind, Placebo-controlled, Efficacy, and Safety Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.",Recruiting,NA,Phase 2,80,Anticipated,"Aptabio Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-27T13:01:42Z,2021-10-27T13:01:42Z
NCT04859699,NA,4/16/2021,NA,NA,10/18/2021,4/21/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/26/2021,Estimate,5-Apr-21,Actual,4/5/2021,Oct-21,10/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,ROSSEY,NA,Reopening Schools Safely and Educating Youth (ROSSEY) COVID-19 Health Disparities Research Study,Reopening Schools Safely and Educating Youth (ROSSEY) Research Study,"Active, not recruiting",NA,Not Applicable,1500,Anticipated,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:01:56Z,2021-10-27T13:01:56Z
NCT04853836,NA,4/16/2021,NA,NA,10/24/2021,4/20/2021,4/21/2021,Actual,NA,NA,NA,NA,NA,NA,10/24/2021,10/26/2021,Estimate,15-Nov-20,Actual,11/15/2020,Oct-21,10/31/2021,1-Oct-21,Actual,10/1/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,NA,NA,Olfactory Disfunction and Co-ultraPEALut,Olfactory Disfunction After COVID-19: Conventional Therapy Versus Intervention Treatment With Co-ultraPEALut,Completed,NA,Phase 4,200,Actual,University Of Perugia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,request to PI,NA,Yes,"Shared, only anonymized data directly requested to PI",2021-10-27T13:02:02Z,2021-10-27T13:02:02Z
NCT04704544,NA,1/6/2021,NA,NA,10/25/2021,1/8/2021,1/11/2021,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/26/2021,Estimate,15-Sep-21,Actual,9/15/2021,Oct-21,10/31/2021,30-Nov-22,Anticipated,11/30/2022,30-Nov-22,Anticipated,11/30/2022,NA,Interventional,NA,NA,Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE),Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis,Recruiting,NA,Not Applicable,320,Anticipated,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:03:15Z,2021-10-27T13:03:15Z
NCT04703205,NA,12/1/2020,NA,NA,10/24/2021,1/8/2021,1/11/2021,Actual,NA,NA,NA,NA,NA,NA,10/24/2021,10/26/2021,Estimate,16-Sep-20,Actual,9/16/2020,Oct-21,10/31/2021,31-May-22,Anticipated,5/31/2022,22-Oct-21,Actual,10/22/2021,NA,Interventional,NA,NA,Study in COvid-19 Patients With iveRmectin (CORVETTE-01),"A Placebo-controlled, Randomized, Double-blind Study in COvid-19 Patients With iveRmectin; An inVEstigator iniTiaTEd Trial",Recruiting,NA,Phase 2,240,Anticipated,Kitasato University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:03:16Z,2021-10-27T13:03:16Z
NCT04631705,NA,11/10/2020,NA,NA,10/23/2021,11/14/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,10/23/2021,10/26/2021,Estimate,14-Dec-20,Actual,12/14/2020,Oct-21,10/31/2021,23-Sep-21,Actual,9/23/2021,23-Sep-21,Actual,9/23/2021,NA,Interventional,NA,NA,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation,A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,Completed,NA,Phase 1/Phase 2,45,Actual,University of Cologne,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:03:50Z,2021-10-27T13:03:50Z
NCT04575610,NA,8/5/2020,NA,NA,10/18/2021,10/2/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/26/2021,Estimate,27-Nov-20,Actual,11/27/2020,Oct-21,10/31/2021,6-Oct-21,Actual,10/6/2021,6-Oct-21,Actual,10/6/2021,NA,Interventional,NA,NA,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC),Terminated,NA,Phase 2,7,Actual,Yale University,,2,NA,Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:04:19Z,2021-10-27T13:04:19Z
NCT04619680,NA,11/5/2020,NA,NA,10/23/2021,11/5/2020,11/6/2020,Actual,NA,NA,NA,NA,NA,NA,10/23/2021,10/26/2021,Estimate,18-Nov-20,Actual,11/18/2020,Oct-21,10/31/2021,Apr-24,Anticipated,4/30/2024,Apr-24,Anticipated,4/30/2024,NA,Interventional,ENDCOV-I,NA,The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19,Early Nintedanib Deployment in COVID-19 Interstitial Lung Disease,Recruiting,NA,Phase 4,170,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 5 years following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose. Proposals should be directed to Maria.Padilla@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-10-27T13:03:55Z,2021-10-27T13:03:55Z
NCT04542850,NA,8/16/2020,NA,NA,10/25/2021,9/6/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/26/2021,Estimate,15-Nov-20,Actual,11/15/2020,Aug-21,8/31/2021,31-Oct-21,Anticipated,10/31/2021,31-Aug-21,Actual,8/31/2021,NA,Interventional,NA,NA,"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19","An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Not Applicable,40,Anticipated,Royal College of Surgeons in Ireland - Medical University of Bahrain,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be collected in the case report form to allow for cross referencing to check validity.

Study documents (paper) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point).",Study documents (paper) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T13:04:39Z,2021-10-27T13:04:39Z
NCT04504240,NA,8/6/2020,NA,NA,10/23/2021,8/6/2020,8/7/2020,Actual,NA,NA,NA,NA,NA,NA,10/23/2021,10/26/2021,Estimate,1-Aug-20,Actual,8/1/2020,Oct-21,10/31/2021,15-Apr-21,Actual,4/15/2021,15-Apr-21,Actual,4/15/2021,NA,Interventional,NA,NA,Role of Famotidine in the Clinical Improvement of COVID-19 Patients.,Role of Famotidine in the Clinical Recovery and Symptomatic Improvement of COVID-19 Patients.,Completed,NA,Phase 3,208,Actual,Chattogram General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:04:54Z,2021-10-27T13:04:54Z
NCT04444700,NA,6/22/2020,NA,NA,10/25/2021,6/22/2020,6/23/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/26/2021,Estimate,4-Jul-20,Actual,7/4/2020,Oct-21,10/31/2021,14-Oct-21,Actual,10/14/2021,10-May-21,Actual,5/10/2021,NA,Interventional,RAPID-BRAZIL,NA,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,UtilizaÃ§Ã£o da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com sÃ­ndrome respiratÃ³ria Aguda Grave Por COVID-19,Completed,NA,Phase 3,465,Actual,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:05:18Z,2021-10-27T13:05:18Z
NCT04435379,NA,6/16/2020,NA,NA,10/25/2021,6/16/2020,6/17/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/26/2021,Estimate,18-Jun-20,Actual,6/18/2020,Oct-21,10/31/2021,12-Oct-21,Actual,10/12/2021,12-Oct-21,Actual,10/12/2021,NA,Interventional,NA,NA,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System",Completed,NA,Phase 3,2038,Actual,Vakzine Projekt Management GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is uncertainty whether the European Union General Data Protection Regulation allows dissemination of individual participant data to other researchers. Some reasons why the EU Regulation would not allow this are the lack of suitable safeguards when personal data are transferred to any researcher asking for it and the impairment of the rights of the subjects for erasure of their data once they are disseminated.,2021-10-27T13:05:20Z,2021-10-27T13:05:20Z
NCT04429854,NA,6/9/2020,NA,NA,10/18/2021,6/9/2020,6/12/2020,Actual,NA,NA,NA,NA,NA,NA,10/18/2021,10/26/2021,Estimate,2-May-20,Actual,5/2/2020,Oct-21,10/31/2021,30-Apr-21,Actual,4/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,DAWN-Plasma,NA,Donated Antibodies Working Against nCoV,"A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19: DAWN-PLASMA",Completed,NA,Phase 2,483,Actual,Universitaire Ziekenhuizen Leuven,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:05:23Z,2021-10-27T13:05:23Z
NCT04469179,NA,7/8/2020,NA,NA,10/25/2021,7/10/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/26/2021,Estimate,20-Aug-20,Actual,8/20/2020,Oct-21,10/31/2021,Nov-21,Anticipated,11/30/2021,25-Feb-21,Actual,2/25/2021,NA,Interventional,NA,NA,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19","A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of SAB-185 in Ambulatory Subjects With COVID-19","Active, not recruiting",NA,Phase 1,21,Actual,"SAb Biotherapeutics, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Starting 6 months after publication and ending 36 months following article publication,Anyone who wishes to access the data.,NA,Yes,"Individual participant data that underlie the results reported in the published article, after deidentification (test, tables, figures, and appendices)",2021-10-27T13:05:08Z,2021-10-27T13:05:08Z
NCT04387760,NA,5/9/2020,NA,NA,10/25/2021,5/13/2020,5/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/26/2021,Estimate,11-Aug-20,Actual,8/11/2020,Aug-21,8/31/2021,7-Apr-21,Actual,4/7/2021,6-Mar-21,Actual,3/6/2021,NA,Interventional,NA,NA,Favipiravir vs Hydroxychloroquine vs Control in COVID -19,Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial,Completed,NA,Phase 2,150,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.

Data will be collected in the case report form to allow for cross referencing to check validity.

Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T13:05:42Z,2021-10-27T13:05:42Z
NCT04362085,NA,4/20/2020,NA,NA,10/22/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,10/22/2021,10/26/2021,Estimate,11-May-20,Actual,5/11/2020,Oct-21,10/31/2021,14-Oct-21,Actual,10/14/2021,10-May-21,Actual,5/10/2021,NA,Interventional,NA,NA,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG),Completed,NA,Phase 3,465,Actual,Unity Health Toronto,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:05:56Z,2021-10-27T13:05:56Z
NCT04356534,NA,4/15/2020,NA,NA,10/25/2021,4/17/2020,4/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/26/2021,Estimate,19-Apr-20,Actual,4/19/2020,Jul-20,7/31/2020,9-Jul-20,Actual,7/9/2020,15-Jun-20,Actual,6/15/2020,NA,Interventional,NA,NA,Convalescent Plasma Trial in COVID -19 Patients,Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial,Completed,NA,Not Applicable,40,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.

Data will be collected in the case report form to allow for cross referencing to check validity.

Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T13:05:57Z,2021-10-27T13:05:57Z
NCT04839042,NA,4/7/2021,NA,NA,10/19/2021,4/7/2021,4/9/2021,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/27/2021,Estimate,28-Jun-21,Actual,6/28/2021,Oct-21,10/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers","A Phase 1, First-In-Human, Open-label, Single Ascending Dose and Multidose Study to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 Given Via Intramuscular or Intranasal Administration in Healthy Volunteers",Recruiting,NA,Phase 1,100,Anticipated,Tetherex Pharmaceuticals Corporation,,10,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:08:24Z,2021-10-28T11:08:24Z
NCT05074745,NA,10/7/2021,NA,NA,10/19/2021,10/7/2021,10/12/2021,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/27/2021,Estimate,18-Feb-21,Actual,2/18/2021,Oct-21,10/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,CORDAGES,NA,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Buccal Screening Evaluation Using an RT-PCR Assay and a Rapid ELISA Test Among Symptomatic and Asymptomatic Patients,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Buccal Screening Evaluation Using an RT-PCR Assay and a Rapid ELISA Test Among Symptomatic and Asymptomatic Patients: the CORDAGES Study,Recruiting,NA,Not Applicable,1500,Anticipated,Centre Scientifique de Monaco,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:05:05Z,2021-10-28T11:05:05Z
NCT04960228,NA,6/30/2021,NA,NA,10/26/2021,7/9/2021,7/13/2021,Actual,NA,NA,NA,NA,NA,NA,10/26/2021,10/27/2021,Estimate,30-Jul-21,Actual,7/30/2021,Oct-21,10/31/2021,13-Sep-21,Actual,9/13/2021,13-Sep-21,Actual,9/13/2021,NA,Interventional,NA,NA,Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention,Enhancing COVID-19 Vaccination Intentions by Eliciting Prosocial Altruistic Motives: Evaluating the Efficacy of a Brief Video-Based Intervention,Completed,NA,Not Applicable,1623,Actual,Sir Mortimer B. Davis - Jewish General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Consent form, data collection method, and organizational policy means only aggregated data will be shared with other researchers.",2021-10-28T11:07:01Z,2021-10-28T11:07:01Z
NCT04952402,NA,6/28/2021,NA,NA,10/26/2021,7/2/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,10/26/2021,10/27/2021,Estimate,16-Jul-21,Actual,7/16/2021,Oct-21,10/31/2021,Jun-23,Anticipated,6/30/2023,Jun-23,Anticipated,6/30/2023,NA,Interventional,NA,NA,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,Recruiting,NA,Phase 4,700,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2021-10-28T11:07:03Z,2021-10-28T11:07:03Z
NCT05096845,NA,10/21/2021,NA,NA,10/25/2021,10/25/2021,10/27/2021,Estimate,NA,NA,NA,NA,NA,NA,10/25/2021,10/27/2021,Estimate,25-Aug-21,Actual,8/25/2021,Oct-21,10/31/2021,22-Apr-23,Anticipated,4/22/2023,2-Mar-23,Anticipated,3/2/2023,NA,Interventional,COVID-19,NA,Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III,"A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,22500,Anticipated,Livzon Pharmaceutical Group Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-28T11:02:20Z,2021-10-28T11:02:20Z
NCT05096026,NA,10/25/2021,NA,NA,10/26/2021,10/26/2021,10/27/2021,Estimate,NA,NA,NA,NA,NA,NA,10/26/2021,10/27/2021,Estimate,29-Mar-21,Actual,3/29/2021,Oct-21,10/31/2021,31-Aug-21,Actual,8/31/2021,20-May-21,Actual,5/20/2021,NA,Interventional,NA,NA,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Completed,NA,Not Applicable,8287,Actual,Kaiser Permanente,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"December 1, 2022 through December 1, 2024","Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",NA,Yes,"Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",2021-10-28T11:03:10Z,2021-10-28T11:03:10Z
NCT04478071,NA,7/15/2020,NA,NA,10/21/2021,7/15/2020,7/20/2020,Actual,NA,NA,NA,NA,NA,NA,10/21/2021,10/27/2021,Estimate,22-Aug-20,Actual,8/22/2020,Oct-21,10/31/2021,31-Dec-23,Anticipated,12/31/2023,31-Dec-23,Anticipated,12/31/2023,NA,Interventional,NA,NA,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Phase 2,650,Anticipated,"The University of Texas Health Science Center, Houston",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:11:50Z,2021-10-28T11:11:50Z
NCT04632381,NA,11/12/2020,NA,NA,10/19/2021,11/16/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,10/19/2021,10/27/2021,Estimate,1-Jul-21,Actual,7/1/2021,Aug-21,8/31/2021,31-Mar-22,Anticipated,3/31/2022,29-Dec-21,Anticipated,12/29/2021,NA,Interventional,PROPEL,NA,Intravenous Zotatifin in Adults With Mild or Moderate COVID-19,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial of Intravenous Zotatifin in Adults With Mild or Moderate Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 1,36,Anticipated,Effector Therapeutics,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Following completion of the study, the data may be considered for publication.",2021-10-28T11:10:21Z,2021-10-28T11:10:21Z
NCT04514302,NA,8/12/2020,NA,NA,10/20/2021,8/13/2020,8/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/27/2021,Estimate,27-Oct-21,Anticipated,10/27/2021,Oct-21,10/31/2021,20-Feb-22,Anticipated,2/20/2022,20-Feb-22,Anticipated,2/20/2022,NA,Interventional,NA,NA,Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19,"Phase I, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Antiviral Efficacy of Three Different Single Doses of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) in Adult Patients With Mild COVID-19",Recruiting,NA,Phase 1,30,Anticipated,Hospital San Jose Tec de Monterrey,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:11:29Z,2021-10-28T11:11:29Z
NCT04507256,NA,8/7/2020,NA,NA,10/26/2021,8/7/2020,8/11/2020,Actual,NA,NA,NA,NA,NA,NA,10/26/2021,10/27/2021,Estimate,18-Aug-20,Actual,8/18/2020,Oct-21,10/31/2021,19-Oct-21,Actual,10/19/2021,19-Oct-21,Actual,10/19/2021,NA,Interventional,NA,NA,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults",Completed,NA,Phase 1,60,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-10-28T11:11:34Z,2021-10-28T11:11:34Z
NCT04492891,NA,7/20/2020,NA,NA,10/26/2021,7/28/2020,7/30/2020,Actual,NA,NA,NA,NA,NA,NA,10/26/2021,10/27/2021,Estimate,23-Nov-20,Actual,11/23/2020,Oct-21,10/31/2021,23-Nov-25,Anticipated,11/23/2025,23-Nov-25,Anticipated,11/23/2025,NA,Interventional,NA,NA,Cyclosporine For The Treatment Of COVID-19(+),Randomized Phase IIa Clinical Trial Of Cyclosporine For The Treatment Of COVID-19(+) Non-ICU Hospital Inpatients,Recruiting,NA,Phase 2,75,Anticipated,Baylor College of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:11:42Z,2021-10-28T11:11:42Z
NCT04449276,NA,6/18/2020,NA,NA,10/26/2021,6/23/2020,6/26/2020,Actual,NA,NA,NA,NA,NA,NA,10/26/2021,10/27/2021,Estimate,18-Jun-20,Actual,6/18/2020,Jul-21,7/31/2021,Jan-22,Anticipated,1/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults","Active, not recruiting",NA,Phase 1,280,Actual,CureVac AG,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:12:04Z,2021-10-28T11:12:04Z
NCT04415086,NA,6/1/2020,NA,NA,10/22/2021,6/2/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/22/2021,10/27/2021,Estimate,1-Jun-20,Actual,6/1/2020,Oct-21,10/31/2021,22-May-22,Anticipated,5/22/2022,20-Apr-22,Anticipated,4/20/2022,NA,Interventional,COOPCOVID-19,NA,Treatment of Patients With COVID-19 With Convalescent Plasma,"Treatment of Patients With COVID-19 With Convalescent Plasma Transfusion: a Multicenter, Open-labeled, Randomized and Controlled Study","Active, not recruiting",NA,Phase 2,129,Actual,University of Sao Paulo General Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:12:35Z,2021-10-28T11:12:35Z
NCT04410549,NA,5/21/2020,NA,NA,10/26/2021,5/29/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,10/26/2021,10/27/2021,Estimate,1-Jun-20,Actual,6/1/2020,Oct-21,10/31/2021,30-Sep-21,Actual,9/30/2021,30-Sep-21,Actual,9/30/2021,NA,Interventional,NA,NA,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Optical Coherence Tomography for Microvascular Lung Vessels Obstructive Thromboinflammatory Syndrome Assessment in Patients With COVID-19: an Exploratory Study,Completed,NA,Not Applicable,13,Actual,IRCCS San Raffaele,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:12:40Z,2021-10-28T11:12:40Z
NCT04400058,NA,5/21/2020,NA,NA,10/25/2021,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/27/2021,Estimate,1-Jun-20,Actual,6/1/2020,Mar-21,3/31/2021,28-Feb-22,Anticipated,2/28/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,"Active, not recruiting",NA,Phase 3,208,Actual,Octapharma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:12:46Z,2021-10-28T11:12:46Z
NCT05087524,NA,10/18/2021,NA,NA,10/21/2021,10/18/2021,10/21/2021,Actual,NA,NA,NA,NA,NA,NA,10/21/2021,10/28/2021,Estimate,9-Jan-21,Actual,1/9/2021,Oct-21,10/31/2021,8-Apr-21,Actual,4/8/2021,8-Apr-21,Actual,4/8/2021,NA,Interventional,NA,NA,BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19),Feasibility and Specificity of BinaxNOW for Diagnosis and Surveillance of Infection With SARS-CoV-2 in Schoolchildren,Terminated,NA,Not Applicable,65,Actual,"University of Wisconsin, Madison",,1,NA,changes in in-person schooling per COVID-19 pandemic,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:06:37Z,2021-10-29T11:06:37Z
NCT05069623,NA,10/4/2021,NA,NA,10/27/2021,10/4/2021,10/6/2021,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,10/28/2021,Estimate,27-Oct-21,Anticipated,10/27/2021,Oct-21,10/31/2021,Oct-23,Anticipated,10/31/2023,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers,"A Phase 1/2, Open Label, Dose Escalation Study to Determine Safety and Immunogenicity of Two (Prophylactic) COVID 19 DNA Vaccine Candidates (VB10.2129 [C1], a RBD Candidate and VB10.2210 [C2], a T Cell Candidate), in Healthy Adult Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Vaccibody AS,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 25 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-10-29T11:07:24Z,2021-10-29T11:07:24Z
NCT05062473,NA,9/2/2021,NA,NA,10/27/2021,9/20/2021,9/30/2021,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,10/28/2021,Estimate,4-Oct-21,Actual,10/4/2021,Oct-21,10/31/2021,Jan-22,Anticipated,1/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Utilizing Telemedicine for Hypertension Treatment Lifestyle Modification in Central Harlem,Hypertension Control in the Age of COVID-19: Utilizing Telemedicine for Hypertension Treatment Lifestyle Modification in Central Harlem,Recruiting,NA,Not Applicable,40,Anticipated,Weill Medical College of Cornell University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:07:28Z,2021-10-29T11:07:28Z
NCT05012267,NA,8/11/2021,NA,NA,10/27/2021,8/17/2021,8/19/2021,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,10/28/2021,Estimate,25-Mar-21,Actual,3/25/2021,Oct-21,10/31/2021,27-Oct-21,Actual,10/27/2021,27-Oct-21,Actual,10/27/2021,NA,Interventional,OmeLEtte,NA,Duration of Prone Position in the Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).,OptiMal pronE Position LEnghT in Patients With acuTE Respiratory Distress Syndrome Due to COVID-19.,Completed,NA,Not Applicable,61,Actual,Hospital Universitario 12 de Octubre,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:08:18Z,2021-10-29T11:08:18Z
NCT04901689,NA,5/24/2021,NA,NA,10/26/2021,5/24/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,10/26/2021,10/28/2021,Estimate,23-Oct-21,Actual,10/23/2021,May-21,5/31/2021,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation,"A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation",Recruiting,NA,Phase 3,316,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:09:54Z,2021-10-29T11:09:54Z
NCT04956224,NA,6/21/2021,NA,NA,10/20/2021,6/29/2021,7/9/2021,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/28/2021,Estimate,9-Aug-21,Actual,8/9/2021,Oct-21,10/31/2021,Mar-23,Anticipated,3/31/2023,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Immunogenicity of VLA2101 Compared to VLA2001.,"A Randomized, Observer-Blind, Controlled, Non-Inferiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2101 Vaccine To VLA2001 Vaccine, In Volunteers Aged â‰¥12 Years.","Active, not recruiting",NA,Phase 3,900,Anticipated,Valneva Austria GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:09:07Z,2021-10-29T11:09:07Z
NCT04919031,NA,6/7/2021,NA,NA,10/22/2021,6/7/2021,6/9/2021,Actual,NA,NA,NA,NA,NA,NA,10/22/2021,10/28/2021,Estimate,1-Aug-21,Actual,8/1/2021,Oct-21,10/31/2021,1-Feb-22,Anticipated,2/1/2022,23-Jan-22,Anticipated,1/23/2022,NA,Interventional,NA,NA,Inspiratory Muscle Trainer and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID-19 Persistent Symptoms,Inspiratory Muscle Trainer Impact on Post Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID-19 Hypertensive Patients With Long Term Persistent Symptoms,Recruiting,NA,Not Applicable,60,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,one year after study actual completion date,NA,NA,Yes,NA,2021-10-29T11:09:44Z,2021-10-29T11:09:44Z
NCT04497324,NA,7/31/2020,NA,NA,10/20/2021,7/31/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/28/2021,Estimate,21-Sep-20,Actual,9/21/2020,Mar-21,3/31/2021,17-Apr-21,Actual,4/17/2021,17-Apr-21,Actual,4/17/2021,NA,Interventional,NA,NA,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,PERUCONPLASMA: Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19,Completed,NA,Phase 2,100,Actual,Universidad Peruana Cayetano Heredia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:13:47Z,2021-10-29T11:13:47Z
NCT04773067,NA,2/23/2021,NA,NA,10/20/2021,2/24/2021,2/26/2021,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/28/2021,Estimate,30-Jan-21,Actual,1/30/2021,Sep-21,9/30/2021,30-Jun-22,Anticipated,6/30/2022,27-Jun-21,Actual,6/27/2021,NA,Interventional,NA,NA,"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers","A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers",Recruiting,NA,Phase 2,3850,Anticipated,"United Biomedical Inc., Asia",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-29T11:11:04Z,2021-10-29T11:11:04Z
NCT04756271,NA,2/13/2021,NA,NA,10/21/2021,2/15/2021,2/16/2021,Actual,NA,NA,NA,NA,NA,NA,10/21/2021,10/28/2021,Estimate,11-Feb-21,Actual,2/11/2021,Oct-21,10/31/2021,Nov-21,Anticipated,11/30/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection,Safety and Immunogenicity of Oxford AstraZeneca Vaccine in Zagazig University Hospital Health-care Workers,Recruiting,NA,Phase 3,140,Anticipated,Zagazig University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:11:10Z,2021-10-29T11:11:10Z
NCT04593940,NA,9/23/2020,NA,NA,10/27/2021,10/19/2020,10/20/2020,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,10/28/2021,Estimate,15-Oct-20,Actual,10/15/2020,Oct-21,10/31/2021,Sep-22,Anticipated,9/30/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,ACTIV-1 IM,NA,Immune Modulators for Treating COVID-19,Randomized Master Protocol for Immune Modulators for Treating COVID-19,Recruiting,NA,Phase 3,1990,Anticipated,Duke University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:12:54Z,2021-10-29T11:12:54Z
NCT04414241,NA,6/1/2020,NA,NA,10/20/2021,6/1/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/20/2021,10/28/2021,Estimate,25-Jun-20,Actual,6/25/2020,Jun-20,6/30/2020,23-Nov-20,Actual,11/23/2020,23-Nov-20,Actual,11/23/2020,NA,Interventional,NA,NA,Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19,"Hydroxychloroquine to Prevent SARS-CoV-2 Infection Among Healthcare Workers: Randomized Controlled, Open-label, Phase 3 Clinical Trial",Completed,NA,Phase 3,68,Actual,Universidad Peruana Cayetano Heredia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:14:06Z,2021-10-29T11:14:06Z
NCT04399356,NA,5/19/2020,NA,NA,10/27/2021,5/21/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,10/28/2021,Estimate,1-Oct-20,Actual,10/1/2020,Oct-21,10/31/2021,19-Aug-21,Actual,8/19/2021,20-Apr-21,Actual,4/20/2021,NA,Interventional,NA,NA,Niclosamide for Mild to Moderate COVID-19,Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19),Completed,NA,Phase 2,73,Actual,Tufts Medical Center,,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-29T11:14:13Z,2021-10-29T11:14:13Z
NCT04573322,NA,9/29/2020,NA,NA,10/27/2021,9/30/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,10/29/2021,Estimate,10-Sep-20,Actual,9/10/2020,Oct-21,10/31/2021,29-Apr-21,Actual,4/29/2021,17-Mar-21,Actual,3/17/2021,NA,Interventional,NA,NA,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,"Open-label, Pharmacokinetic, Pharmacodynamic, Ascending Dose Safety lead-in Followed by a Single-center, Placebo-controlled, Double-blind, Adaptive, Safety and Efficacy, Pilot Study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 Infected Subjects",Completed,NA,Phase 1/Phase 2,25,Actual,Diffusion Pharmaceuticals Inc,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:46:04Z,2021-11-01T10:46:04Z
NCT04992208,NA,8/2/2021,NA,NA,10/28/2021,8/4/2021,8/5/2021,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,10/29/2021,Estimate,24-Jul-21,Actual,7/24/2021,Aug-21,8/31/2021,25-Dec-22,Anticipated,12/25/2022,25-Feb-22,Anticipated,2/25/2022,NA,Interventional,NA,NA,Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents,"Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 3~17 Years : A Multicenter,Open-label Study",Recruiting,NA,Phase 4,33000,Anticipated,"Sinovac Biotech Co., Ltd",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:43:00Z,2021-11-01T10:43:00Z
NCT04864561,NA,4/23/2021,NA,NA,10/25/2021,4/24/2021,4/29/2021,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,10/29/2021,Estimate,26-Apr-21,Actual,4/26/2021,Oct-21,10/31/2021,16-Mar-23,Anticipated,3/16/2023,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,COV-COMPARE,NA,"Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine","A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults Including a Randomized, Observer-blind, Placebo Controlled Part in Adolescents (â‰¥12 to <18 Years)",Recruiting,NA,Phase 3,4679,Anticipated,Valneva Austria GmbH,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-01T10:44:08Z,2021-11-01T10:44:08Z
NCT04671017,NA,12/15/2020,NA,NA,10/21/2021,12/15/2020,12/17/2020,Actual,NA,NA,NA,NA,NA,NA,10/21/2021,10/29/2021,Estimate,16-Dec-20,Actual,12/16/2020,Oct-21,10/31/2021,31-Mar-22,Anticipated,3/31/2022,26-Feb-21,Actual,2/26/2021,NA,Interventional,NA,NA,"Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects","A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,153,Actual,Valneva Austria GmbH,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-01T10:45:15Z,2021-11-01T10:45:15Z
NCT04347538,NA,4/11/2020,NA,NA,10/27/2021,4/11/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,10/28/2021,Estimate,1-May-20,Actual,5/1/2020,Oct-21,10/31/2021,Jun-22,Anticipated,6/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,"Active, not recruiting",NA,Not Applicable,90,Anticipated,Vanderbilt University Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:14:40Z,2021-10-29T11:14:40Z
NCT05099497,NA,10/5/2021,NA,NA,10/18/2021,10/18/2021,10/29/2021,Estimate,NA,NA,NA,NA,NA,NA,10/18/2021,10/29/2021,Estimate,21-Sep-21,Actual,9/21/2021,Oct-21,10/31/2021,1-Sep-22,Anticipated,9/1/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Supporting Audit and Feedback to Encourage Vaccine Uptake,Big Data and Little Behaviours: Feedback and Quality Improvement Supports to Primary Care to Facilitate COVID Vaccine Uptake,"Active, not recruiting",NA,Not Applicable,600,Actual,Women's College Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data analysis will take place at the Institute for Clinical Evaluative Sciences (ICES). Ontario Health will provide ICES with a list of physicians that were in either the control or intervention group. This list will be transferred to ICES using a secure portal process (axway). Data will be captured from administrative databases (including COVaxON registry data) held at ICES. Data will be linked at the physician level using their encrypted CPSO (College of Physicians and Surgeons of Ontario) number.,2021-11-01T10:40:51Z,2021-11-01T10:40:51Z
NCT05080244,NA,9/28/2021,NA,NA,10/28/2021,10/13/2021,10/15/2021,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,10/29/2021,Estimate,28-Oct-21,Actual,10/28/2021,Oct-21,10/31/2021,Aug-22,Anticipated,8/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,PROVID-LD,NA,WHO COVID-19 - Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID,Evaluation of the Efficacy of Probiotics Taken During the Acute Phase of COVID-19 to Reduce the Occurrence of Long COVID,Recruiting,NA,Not Applicable,618,Anticipated,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-01T10:41:58Z,2021-11-01T10:41:58Z
NCT04911790,NA,6/2/2021,NA,NA,10/28/2021,6/2/2021,6/3/2021,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,10/29/2021,Estimate,5-Jun-21,Actual,6/5/2021,May-21,5/31/2021,31-Dec-22,Anticipated,12/31/2022,5-Oct-21,Actual,10/5/2021,NA,Interventional,NA,NA,Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults,"Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 18 Years and Older: A Multicenter,Open-label Study",Recruiting,NA,Phase 4,121000,Anticipated,"Sinovac Biotech Co., Ltd",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-01T10:43:45Z,2021-11-01T10:43:45Z
NCT04621071,NA,11/5/2020,NA,NA,10/28/2021,11/6/2020,11/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,10/29/2021,Estimate,12-Jan-21,Actual,1/12/2021,Oct-21,10/31/2021,12-Oct-21,Actual,10/12/2021,19-Aug-21,Actual,8/19/2021,NA,Interventional,PROVID-19,NA,Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19,"Evaluation of the Efficacy of Probiotics to Reduce the Duration and Symptoms of COVID-19 (PROVID-19 Study): a Randomized, Double-blind, Controlled Trial",Completed,NA,Not Applicable,17,Actual,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:45:40Z,2021-11-01T10:45:40Z
NCT04505774,NA,8/6/2020,NA,NA,10/27/2021,8/7/2020,8/10/2020,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,10/29/2021,Estimate,4-Sep-20,Actual,9/4/2020,Oct-21,10/31/2021,Dec-22,Anticipated,12/31/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,ACTIV-4A,NA,Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE,"A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19",Recruiting,NA,Phase 4,3000,Anticipated,University of Pittsburgh,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Data will be shared as per NIH guidelines.,2021-11-01T10:46:34Z,2021-11-01T10:46:34Z
NCT05102565,NA,10/9/2021,NA,NA,10/20/2021,10/20/2021,11/1/2021,Estimate,NA,NA,NA,NA,NA,NA,10/20/2021,11/1/2021,Estimate,20-Aug-21,Actual,8/20/2021,Oct-21,10/31/2021,31-Dec-22,Anticipated,12/31/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers,A Dyadic Telehealth Program to Support Alzheimer's Disease Patients and Their Caregivers During COVID-19,Recruiting,NA,Not Applicable,15,Anticipated,"University of California, Los Angeles",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-02T11:26:09Z,2021-11-02T11:26:09Z
NCT04937556,NA,6/14/2021,NA,NA,10/25/2021,6/23/2021,6/24/2021,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,11/1/2021,Estimate,25-Oct-21,Actual,10/25/2021,Oct-21,10/31/2021,30-Apr-22,Anticipated,4/30/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,PROVID,NA,Evaluation of a Probiotic Supplementation in the Immune Response of Participants With COVID-19 (Coronavirus Disease).,"Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of the Lactobacillus Probiotic Strain in the Immune Response in Participants Positive for SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2) Infection.",Recruiting,NA,Not Applicable,60,Anticipated,ProbiSearch SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:30:39Z,2021-11-02T11:30:39Z
NCT04927065,NA,6/14/2021,NA,NA,10/25/2021,6/14/2021,6/15/2021,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,11/1/2021,Estimate,28-May-21,Actual,5/28/2021,Oct-21,10/31/2021,30-Nov-22,Anticipated,11/30/2022,16-Jun-22,Anticipated,6/16/2022,NA,Interventional,NA,NA,A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants,A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants,Recruiting,NA,Phase 2/Phase 3,3620,Anticipated,"ModernaTX, Inc.",,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-02T11:30:48Z,2021-11-02T11:30:48Z
NCT04894266,NA,5/5/2021,NA,NA,10/28/2021,5/18/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,11/1/2021,Estimate,1-Nov-21,Anticipated,11/1/2021,May-21,5/31/2021,22-Sep-22,Anticipated,9/22/2022,22-Mar-22,Anticipated,3/22/2022,NA,Interventional,NA,NA,An Open-Label Study of Apabetalone in Covid Infection,An Open-Label Study to Assess the Safety and Effect on Clinical Course and Key Biomarkers of Oral Apabetalone in Hospitalized Subjects With Covid-19 Infection in Addition to Standard of Care (SOC),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Resverlogix Corp,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:31:16Z,2021-11-02T11:31:16Z
NCT04870606,NA,4/27/2021,NA,NA,10/28/2021,4/29/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,11/1/2021,Estimate,5-Mar-21,Actual,3/5/2021,May-21,5/31/2021,24-May-22,Anticipated,5/24/2022,24-Jan-22,Anticipated,1/24/2022,NA,Interventional,NA,NA,Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness,"A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness",Recruiting,NA,Phase 3,668,Anticipated,"Suzhou Kintor Pharmaceutical Inc,",,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-02T11:31:28Z,2021-11-02T11:31:28Z
NCT04685681,NA,12/7/2020,NA,NA,10/25/2021,12/22/2020,12/28/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,11/1/2021,Estimate,7-Jan-21,Actual,1/7/2021,Oct-21,10/31/2021,6-Apr-22,Anticipated,4/6/2022,6-Apr-22,Anticipated,4/6/2022,NA,Interventional,GO,NA,The Get Outside Study,Examining Adults' Activity Choices During COVID-19: The UB GO Study,"Active, not recruiting",NA,Not Applicable,53,Actual,State University of New York at Buffalo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:33:02Z,2021-11-02T11:33:02Z
NCT04896840,NA,5/14/2021,NA,NA,10/29/2021,5/19/2021,5/21/2021,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/1/2021,Estimate,27-Aug-21,Actual,8/27/2021,Oct-21,10/31/2021,27-Oct-21,Anticipated,10/27/2021,27-Oct-21,Actual,10/27/2021,NA,Interventional,NA,NA,Tele-rehabilitation in Children With Cerebral Palsy in the Covid-19 Pandemic,The Effect of Motor Learning Based Tele-rehabilitation on Quality of Life in Children With Cerebral Palsy During the Covid-19 Epidemic Process,Recruiting,NA,Not Applicable,30,Anticipated,Inonu University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The information of the patients participating in the study will be kept confidential.,2021-11-02T11:31:09Z,2021-11-02T11:31:09Z
NCT04500626,NA,7/31/2020,NA,NA,10/29/2021,8/4/2020,8/5/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/1/2021,Estimate,15-Apr-21,Actual,4/15/2021,Oct-21,10/31/2021,Aug-22,Anticipated,8/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Multicentre Randomized Controlled Trial of Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Recruiting,NA,Phase 2/Phase 3,234,Anticipated,Ottawa Hospital Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:34:38Z,2021-11-02T11:34:38Z
NCT04422613,NA,6/5/2020,NA,NA,10/29/2021,6/8/2020,6/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/1/2021,Estimate,28-May-20,Actual,5/28/2020,Oct-21,10/31/2021,29-Oct-21,Actual,10/29/2021,1-Jul-21,Actual,7/1/2021,NA,Interventional,PULCO-19,NA,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,Completed,NA,Not Applicable,73,Actual,"University Hospital, Toulouse",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:35:09Z,2021-11-02T11:35:09Z
NCT04495816,NA,7/30/2020,NA,NA,10/28/2021,7/30/2020,8/3/2020,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,11/1/2021,Estimate,15-Jul-20,Actual,7/15/2020,Oct-21,10/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,COVID-19 Anosmia Study,COVID-19 Anosmia Study,"Active, not recruiting",NA,Phase 2,126,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:34:39Z,2021-11-02T11:34:39Z
NCT04351295,NA,4/15/2020,NA,NA,10/29/2021,4/15/2020,4/17/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/1/2021,Estimate,20-Apr-20,Actual,4/20/2020,Oct-21,10/31/2021,28-Sep-20,Actual,9/28/2020,28-Sep-20,Actual,9/28/2020,NA,Interventional,NA,NA,Efficacy of Faviprevir in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,92,Actual,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:35:45Z,2021-11-02T11:35:45Z
NCT04425031,NA,6/5/2020,NA,NA,10/24/2021,6/10/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,10/24/2021,11/1/2021,Estimate,25-Aug-20,Actual,8/25/2020,Oct-21,10/31/2021,1-Mar-24,Anticipated,3/1/2024,1-Dec-22,Anticipated,12/1/2022,NA,Interventional,HOT-COVID,NA,Handling Oxygenation Targets in COVID-19,Handling Oxygenation Targets in COVID-19 Patients With Acute Hypoxaemic Respiratory Failure in the Intensive Care Unit: A Randomised Clinical Trial of a Lower Versus a Higher Oxygenation Target,Recruiting,NA,Phase 4,780,Anticipated,Aalborg University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,"Access Criteria:

Managed by the Steering Committee of the HOT-COVID trial.",http://cric.nu/hot-covid,Yes,"All original records (incl. consent forms, electronic clinical report forms (eCRFs), and relevant correspondences) will be archived at trial sites for 15 years. The clean electronic trial database file will be delivered to the EudraCT Database and Zenodo data repository (https://zenodo.org/) and maintained for 15 years and anonymised if requested by the authorities.",2021-11-02T11:35:08Z,2021-11-02T11:35:08Z
NCT04396106,NA,5/16/2020,NA,NA,10/25/2021,5/19/2020,5/20/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,11/1/2021,Estimate,26-May-20,Actual,5/26/2020,Oct-21,10/31/2021,Aug-22,Anticipated,8/31/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19",Recruiting,NA,Phase 2,190,Anticipated,"Atea Pharmaceuticals, Inc.",,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-02T11:35:24Z,2021-11-02T11:35:24Z
NCT04344587,NA,4/8/2020,NA,NA,10/25/2021,4/9/2020,4/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,11/1/2021,Estimate,23-Apr-20,Actual,4/23/2020,Oct-21,10/31/2021,7-May-21,Actual,5/7/2021,7-May-21,Actual,5/7/2021,NA,Interventional,APPEX-19,NA,Awake Prone Position for Early Hypoxemia in COVID-19,Awake Prone Position for Early Hypoxemia in COVID-19,Completed,NA,Not Applicable,305,Actual,Boston University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:35:50Z,2021-11-02T11:35:50Z
NCT04333732,NA,3/31/2020,NA,NA,10/25/2021,4/2/2020,4/3/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2021,11/1/2021,Estimate,4-Sep-20,Actual,9/4/2020,Oct-21,10/31/2021,31-Dec-21,Anticipated,12/31/2021,10-Aug-21,Actual,8/10/2021,NA,Interventional,CROWN CORONA,NA,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,"An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Adults","Active, not recruiting",NA,Phase 3,3545,Actual,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,From 3 months after the last patient last visit onward.,Investigators whose proposed use of the data has been approved by a review committee identified for this purpose.,NA,Yes,"Individual participant data that underlie the results reported in the main publication may be shared, after de-identification.",2021-11-02T11:36:01Z,2021-11-02T11:36:01Z
NCT05052580,NA,9/20/2021,NA,NA,10/27/2021,9/21/2021,9/22/2021,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,11/2/2021,Estimate,1-Oct-21,Actual,10/1/2021,Oct-21,10/31/2021,26-Sep-23,Anticipated,9/26/2023,26-Sep-23,Anticipated,9/26/2023,NA,Interventional,NA,NA,Test to Stay in School: COVID-19 Testing Following Exposure in School Communities,Test to Stay in School: COVID-19 Testing Following Exposure in School Communities,Enrolling by invitation,NA,Not Applicable,1000000,Anticipated,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:03:43Z,2021-11-03T11:03:43Z
NCT04930861,NA,6/16/2021,NA,NA,11/1/2021,6/17/2021,6/18/2021,Actual,NA,NA,NA,NA,NA,NA,11/1/2021,11/2/2021,Estimate,29-Mar-21,Actual,3/29/2021,Nov-21,11/30/2021,9-Aug-21,Actual,8/9/2021,27-May-21,Actual,5/27/2021,NA,Interventional,Codivir,NA,Study of Codivir in Patients With COVID-19,Phase 1 Clinical Study of Codivir in Outpatients With COVID-19,Completed,NA,Phase 1,12,Actual,Code Pharma,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:05:28Z,2021-11-03T11:05:28Z
NCT04504734,NA,8/4/2020,NA,NA,10/29/2021,8/6/2020,8/7/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/2/2021,Estimate,27-Nov-20,Actual,11/27/2020,Oct-21,10/31/2021,30-Nov-21,Anticipated,11/30/2021,31-Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Bucillamine in Treatment of Patients With COVID-19,"Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19",Enrolling by invitation,NA,Phase 3,1000,Anticipated,"Revive Therapeutics, Ltd.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-03T11:08:50Z,2021-11-03T11:08:50Z
NCT04642638,NA,11/23/2020,NA,NA,10/29/2021,11/23/2020,11/24/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/2/2021,Estimate,30-Nov-20,Actual,11/30/2020,Oct-21,10/31/2021,Jan-23,Anticipated,1/31/2023,Jan-23,Anticipated,1/31/2023,NA,Interventional,NA,NA,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure","Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure",Recruiting,NA,Phase 2/Phase 3,7517,Anticipated,Inovio Pharmaceuticals,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-11-03T11:07:47Z,2021-11-03T11:07:47Z
NCT04482686,NA,7/21/2020,NA,NA,10/26/2021,7/21/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/26/2021,11/2/2021,Estimate,9-Dec-20,Actual,12/9/2020,Oct-21,10/31/2021,Jul-22,Anticipated,7/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Trial of Combination Therapy to Treat COVID-19 Infection,A Phase I Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection,"Active, not recruiting",NA,Phase 1,31,Actual,ProgenaBiome,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:08:55Z,2021-11-03T11:08:55Z
NCT04459286,NA,7/3/2020,NA,NA,10/29/2021,7/3/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/2/2021,Estimate,9-Oct-20,Actual,10/9/2020,Oct-21,10/31/2021,2-May-21,Actual,5/2/2021,2-May-21,Actual,5/2/2021,NA,Interventional,NACOVID,NA,The Nitazoxanide Plus Atazanavir for COVID-19 Study,"A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study",Completed,NA,Phase 2,57,Actual,Obafemi Awolowo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:09:07Z,2021-11-03T11:09:07Z
NCT04459247,NA,7/3/2020,NA,NA,10/30/2021,7/3/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,10/30/2021,11/2/2021,Estimate,15-Jun-20,Actual,6/15/2020,Oct-21,10/31/2021,10-Apr-21,Actual,4/10/2021,30-Mar-21,Actual,3/30/2021,NA,Interventional,SHADE,NA,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Short Term, High Dose Vitamin D Supplementation for COVID-19 Disease: Double Blind, Controlled, Study",Completed,NA,Not Applicable,40,Actual,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:09:07Z,2021-11-03T11:09:07Z
NCT04667780,NA,12/11/2020,NA,NA,10/30/2021,12/12/2020,12/16/2020,Actual,NA,NA,NA,NA,NA,NA,10/30/2021,11/2/2021,Estimate,1-Dec-20,Actual,12/1/2020,Oct-21,10/31/2021,9-Jul-21,Actual,7/9/2021,9-Jul-21,Actual,7/9/2021,NA,Interventional,NA,NA,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Completed,NA,Phase 3,102,Actual,Ayub Teaching Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:07:39Z,2021-11-03T11:07:39Z
NCT04341116,NA,4/4/2020,NA,NA,10/29/2021,4/9/2020,4/10/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/2/2021,Estimate,11-Apr-20,Actual,4/11/2020,Oct-21,10/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),"A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2/Phase 3,384,Anticipated,I-Mab Biopharma Co. Ltd.,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:09:52Z,2021-11-03T11:09:52Z
NCT05104827,NA,11/1/2021,NA,NA,11/2/2021,11/2/2021,11/3/2021,Estimate,NA,NA,NA,NA,NA,NA,11/2/2021,11/3/2021,Estimate,31-Dec-20,Actual,12/31/2020,Nov-21,11/30/2021,1-Jun-23,Anticipated,6/1/2023,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Integrative Medicine Impact on Frontline COVID-19 Personnel Wellbeing,Eran Ben-Arye is the Study Primary Investigator,Recruiting,NA,Not Applicable,300,Anticipated,Carmel Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:45:58Z,2021-11-04T08:45:58Z
NCT05104749,NA,10/28/2021,NA,NA,11/1/2021,11/1/2021,11/3/2021,Estimate,NA,NA,NA,NA,NA,NA,11/1/2021,11/3/2021,Estimate,15-Sep-21,Actual,9/15/2021,Nov-21,11/30/2021,28-Feb-22,Anticipated,2/28/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Homeopathic Treatment of Post-acute COVID-19 Syndrome,Homeopathic Treatment of Post-acute COVID-19 Syndrome- A Pilot Randomized Controlled Trial,Recruiting,NA,Phase 3,62,Anticipated,Southwest College of Naturopathic Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:46:01Z,2021-11-04T08:46:01Z
NCT05104372,NA,10/25/2021,NA,NA,11/1/2021,11/1/2021,11/3/2021,Estimate,NA,NA,NA,NA,NA,NA,11/1/2021,11/3/2021,Estimate,1-May-21,Actual,5/1/2021,Nov-21,11/30/2021,30-Nov-21,Anticipated,11/30/2021,15-Nov-21,Anticipated,11/15/2021,NA,Interventional,HSNIG,NA,Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19 in Pakistan,"Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19: Pragmatic, Web-based Bayesian Adaptive Randomised Controlled Trial in Pakistan",Recruiting,NA,Not Applicable,405,Anticipated,"The Allergy and Asthma Institute, Pakistan",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The study is anonymized, and individual participant data (IPD) will not be available to other researchers.",2021-11-04T08:46:18Z,2021-11-04T08:46:18Z
NCT04700462,NA,1/6/2021,NA,NA,11/2/2021,1/6/2021,1/7/2021,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/3/2021,Estimate,5-Feb-21,Actual,2/5/2021,Jan-21,1/31/2021,30-Oct-21,Actual,10/30/2021,30-Oct-21,Actual,10/30/2021,NA,Interventional,NA,NA,COVID-19 Preventive Behavior in African Americans,Optimizing Tailored-feedback Message to Promote Adherence Behavior to Prevent COVID-19 in African Americans,Completed,NA,Not Applicable,250,Actual,Johns Hopkins University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:51:52Z,2021-11-04T08:51:52Z
NCT04847141,NA,4/14/2021,NA,NA,11/2/2021,4/14/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/3/2021,Estimate,28-Apr-21,Actual,4/28/2021,Nov-21,11/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,COVID-19,NA,A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients,"A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) Versus Placebo in Asymptomatic Ambulatory Outpatients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection",Recruiting,NA,Phase 3,801,Anticipated,Grifols Therapeutics LLC,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:50:25Z,2021-11-04T08:50:25Z
NCT04546737,NA,9/10/2020,NA,NA,11/2/2021,9/10/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/3/2021,Estimate,8-Sep-20,Actual,9/8/2020,Nov-21,11/30/2021,May-22,Anticipated,5/31/2022,1-Jul-21,Actual,7/1/2021,NA,Interventional,NSpectroCovid,NA,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients","Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients","Active, not recruiting",NA,Not Applicable,20,Actual,"Centre Hospitalier Universitaire, Amiens",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:53:09Z,2021-11-04T08:53:09Z
NCT04642950,NA,11/19/2020,NA,NA,11/1/2021,11/19/2020,11/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/1/2021,11/3/2021,Estimate,17-Dec-20,Actual,12/17/2020,Nov-21,11/30/2021,25-Oct-21,Actual,10/25/2021,25-Oct-21,Actual,10/25/2021,NA,Interventional,NA,NA,A Phase II/III Study of Sargramostim,A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19),Completed,NA,Phase 2/Phase 3,70,Actual,Nobelpharma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:52:18Z,2021-11-04T08:52:18Z
NCT04528667,NA,8/20/2020,NA,NA,11/1/2021,8/25/2020,8/27/2020,Actual,NA,NA,NA,NA,NA,NA,11/1/2021,11/3/2021,Estimate,6-Jan-21,Actual,1/6/2021,Nov-21,11/30/2021,7-Oct-21,Actual,10/7/2021,23-Aug-21,Actual,8/23/2021,NA,Interventional,NA,NA,Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19",Completed,NA,Phase 2,396,Actual,"Sorrento Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:53:26Z,2021-11-04T08:53:26Z
NCT05107375,NA,11/1/2021,NA,NA,11/3/2021,11/3/2021,11/4/2021,Estimate,NA,NA,NA,NA,NA,NA,11/3/2021,11/4/2021,Estimate,3-Sep-21,Actual,9/3/2021,Nov-21,11/30/2021,4-Mar-22,Anticipated,3/4/2022,19-Nov-21,Anticipated,11/19/2021,NA,Interventional,NA,NA,Clinical Study of Recombinant Novel Coronavirusï¼ˆCOVID-19ï¼‰ Vaccine (CHO Cell) Combined With Influenza Vaccine,Clinical Study on Immunogenicity and Safety of Recombinant Novel Coronavirusï¼ˆCOVID-19ï¼‰Vaccine (CHO Cell) Combined With Tetravalent Influenza Virus Lysis Vaccine in People Aged 18 Years and Over,Recruiting,NA,Phase 3,300,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:03:28Z,2021-11-05T12:03:28Z
NCT04440007,NA,6/17/2020,NA,NA,11/1/2021,6/18/2020,6/19/2020,Actual,NA,NA,NA,NA,NA,NA,11/1/2021,11/3/2021,Estimate,9-Oct-20,Actual,10/9/2020,Nov-21,11/30/2021,23-Aug-21,Actual,8/23/2021,1-Jul-21,Actual,7/1/2021,NA,Interventional,SOC,NA,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,92,Actual,"Sorrento Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:54:07Z,2021-11-04T08:54:07Z
NCT04951388,NA,6/30/2021,NA,NA,11/2/2021,7/1/2021,7/6/2021,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/4/2021,Estimate,22-Jul-21,Actual,7/22/2021,Aug-21,8/31/2021,May-22,Anticipated,5/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents,"A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents","Active, not recruiting",NA,Phase 2,399,Actual,Medigen Vaccine Biologics Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:06:57Z,2021-11-05T12:06:57Z
NCT05048849,NA,9/3/2021,NA,NA,11/2/2021,9/15/2021,9/17/2021,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/4/2021,Estimate,19-Jul-21,Actual,7/19/2021,Sep-21,9/30/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study","A Phase II, Prospective, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Extension Study","Active, not recruiting",NA,Phase 2,274,Actual,Medigen Vaccine Biologics Corp.,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:05:36Z,2021-11-05T12:05:36Z
NCT05038618,NA,8/25/2021,NA,NA,11/2/2021,8/31/2021,9/9/2021,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/4/2021,Estimate,2-Aug-21,Actual,8/2/2021,Oct-21,10/31/2021,Feb-22,Anticipated,2/28/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,"A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study","A Phase II, Prospective, Open-Label, Single-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Sub-study","Active, not recruiting",NA,Phase 2,399,Actual,Medigen Vaccine Biologics Corp.,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:05:47Z,2021-11-05T12:05:47Z
NCT05083000,NA,10/11/2021,NA,NA,10/27/2021,10/18/2021,10/19/2021,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,11/4/2021,Estimate,16-Aug-21,Actual,8/16/2021,Sep-21,9/30/2021,31-Mar-22,Anticipated,3/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care,Phase I Dose-escalation Study of Topotecan in Moderate-severe COVID-19 Patients,Recruiting,NA,Phase 1,24,Anticipated,"National University Hospital, Singapore",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:04:56Z,2021-11-05T12:04:56Z
NCT04977024,NA,6/11/2021,NA,NA,11/2/2021,7/22/2021,7/26/2021,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/4/2021,Estimate,27-Sep-21,Actual,9/27/2021,Nov-21,11/30/2021,1-Jun-23,Anticipated,6/1/2023,1-Jun-23,Anticipated,6/1/2023,NA,Interventional,NA,NA,SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer,"A Multi-Center, Observer-Blinded, EUA Vaccine-Controlled, Randomized Phase II Study to Evaluate the Biological Activity of COH04S1 (SARS-CoV-2 Vaccine) Compared to EUA SARS-CoV-2 Vaccines in Hematology Patients Who Have Received Cellular Therapy (HCT or CAR-T)",Recruiting,NA,Phase 2,240,Anticipated,City of Hope Medical Center,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:06:38Z,2021-11-05T12:06:38Z
NCT04611425,NA,10/7/2020,NA,NA,10/27/2021,10/30/2020,11/2/2020,Actual,NA,NA,NA,NA,NA,NA,10/27/2021,11/4/2021,Estimate,30-Nov-20,Actual,11/30/2020,Oct-21,10/31/2021,22-Oct-21,Actual,10/22/2021,2-Dec-20,Actual,12/2/2020,NA,Interventional,REHSCU,NA,REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study,"REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19. The Non-randomized, Non-controlled, Pilot, Open, Mono-centric REHSCU Study",Completed,NA,Phase 2,30,Actual,Nantes University Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:10:26Z,2021-11-05T12:10:26Z
NCT04822025,NA,3/25/2021,NA,NA,11/2/2021,3/28/2021,3/30/2021,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/4/2021,Estimate,20-May-21,Actual,5/20/2021,Jun-21,6/30/2021,Jan-22,Anticipated,1/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults,"A Phase II, Prospective, Randomized, Double-Blind, Dose-Comparison, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901 in Elderly Adults","Active, not recruiting",NA,Phase 2,420,Actual,Medigen Vaccine Biologics Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:08:05Z,2021-11-05T12:08:05Z
NCT04821999,NA,3/29/2021,NA,NA,11/3/2021,3/29/2021,3/30/2021,Actual,NA,NA,NA,NA,NA,NA,11/3/2021,11/4/2021,Estimate,10-Apr-21,Actual,4/10/2021,Nov-21,11/30/2021,1-Oct-21,Actual,10/1/2021,20-Sep-21,Actual,9/20/2021,NA,Interventional,NA,NA,Diode Laser 940 nm in Management of Loss of Taste Sensation,Diode Laser 940 nm in Management of Loss of Taste Sensation in Patients With Post SARS-CoV 2 Infection,Completed,NA,Not Applicable,40,Actual,Fayoum University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:08:06Z,2021-11-05T12:08:06Z
NCT04732949,NA,1/28/2021,NA,NA,11/3/2021,1/29/2021,2/1/2021,Actual,NA,NA,NA,NA,NA,NA,11/3/2021,11/4/2021,Estimate,12-Jan-21,Actual,1/12/2021,Jan-21,1/31/2021,30-Nov-21,Anticipated,11/30/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,SPRINTER,NA,Study to Assess Efficacy and Safety of Inhaled Interferon-Î² Therapy for COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19",Recruiting,NA,Phase 3,610,Anticipated,Synairgen Research Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-05T12:09:08Z,2021-11-05T12:09:08Z
NCT04695652,NA,12/31/2020,NA,NA,11/2/2021,1/4/2021,1/5/2021,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/4/2021,Estimate,30-Dec-20,Actual,12/30/2020,Dec-20,12/31/2020,Jun-22,Anticipated,6/30/2022,2-Jun-21,Actual,6/2/2021,NA,Interventional,COVID-19,NA,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,"A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901","Active, not recruiting",NA,Phase 2,3854,Actual,Medigen Vaccine Biologics Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:09:32Z,2021-11-05T12:09:32Z
NCT04426292,NA,6/8/2020,NA,NA,11/3/2021,6/9/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2021,11/4/2021,Estimate,12-May-20,Actual,5/12/2020,Jun-21,6/30/2021,25-Dec-21,Anticipated,12/25/2021,23-Dec-21,Anticipated,12/23/2021,NA,Interventional,COVEMUZ,NA,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,Recruiting,NA,Not Applicable,3500,Anticipated,Universitair Ziekenhuis Brussel,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-05T12:11:53Z,2021-11-05T12:11:53Z
NCT04498377,NA,7/31/2020,NA,NA,11/3/2021,7/31/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2021,11/4/2021,Estimate,26-Jan-21,Actual,1/26/2021,Jan-21,1/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19",Recruiting,NA,Phase 2,38,Anticipated,Generon (Shanghai) Corporation Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:11:28Z,2021-11-05T12:11:28Z
NCT04575597,NA,9/30/2020,NA,NA,11/2/2021,10/2/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/4/2021,Estimate,19-Oct-20,Actual,10/19/2020,Nov-21,11/30/2021,5-May-22,Anticipated,5/5/2022,5-May-22,Anticipated,5/5/2022,NA,Interventional,NA,NA,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.","Active, not recruiting",NA,Phase 2/Phase 3,1850,Anticipated,Merck Sharp & Dohme Corp.,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-11-05T12:10:46Z,2021-11-05T12:10:46Z
NCT04362176,NA,4/21/2020,NA,NA,11/3/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2021,11/4/2021,Estimate,24-Apr-20,Actual,4/24/2020,Nov-21,11/30/2021,6-Aug-21,Actual,8/6/2021,6-Jul-21,Actual,7/6/2021,NA,Interventional,PassItOn,NA,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Passive Immunity Trial for Our Nation (PassItOn),Completed,NA,Phase 3,974,Actual,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:12:22Z,2021-11-05T12:12:22Z
NCT05102084,NA,10/20/2021,NA,NA,10/29/2021,10/20/2021,11/1/2021,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/5/2021,Estimate,1-Jul-21,Actual,7/1/2021,Oct-21,10/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,The Effect Of Music On Compliance Of Patients Ä°n COVÄ°D-19 Intensive Care Unit With CPAP Device,The Effect Of Music On Compliance Of Patients Ä°n COVÄ°D-19 Intensive Care Unit With CPAP Device,Recruiting,NA,Not Applicable,35,Anticipated,Ataturk University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:19:55Z,2021-11-08T11:19:55Z
NCT04980573,NA,7/26/2021,NA,NA,10/29/2021,7/26/2021,7/28/2021,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/5/2021,Estimate,5-Aug-21,Actual,8/5/2021,Oct-21,10/31/2021,31-Oct-21,Anticipated,10/31/2021,30-Sep-21,Actual,9/30/2021,NA,Interventional,NA,NA,Essential Oils and Post COVID-19 Fatigue,"The Effects of Aromatherapy on Post COVID-19 Fatigue: A Randomized, Double Blind, Controlled Trial","Active, not recruiting",NA,Not Applicable,47,Actual,Franklin School of Integrative Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:22:13Z,2021-11-08T11:22:13Z
NCT05024474,NA,8/24/2021,NA,NA,10/29/2021,8/25/2021,8/27/2021,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/5/2021,Estimate,24-Aug-21,Actual,8/24/2021,Oct-21,10/31/2021,Dec-24,Anticipated,12/31/2024,Dec-22,Anticipated,12/31/2022,NA,Interventional,IMT-ReCov,NA,Effects of Inspiratory Muscle Training After Covid-19 (ReCOV),Effects of Inspiratory Muscle Training After Covid-19,Recruiting,NA,Not Applicable,90,Anticipated,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:21:40Z,2021-11-08T11:21:40Z
NCT04909905,NA,5/30/2021,NA,NA,11/4/2021,6/1/2021,6/2/2021,Actual,NA,NA,NA,NA,NA,NA,11/4/2021,11/5/2021,Estimate,30-May-21,Actual,5/30/2021,Nov-21,11/30/2021,30-Oct-21,Actual,10/30/2021,25-Oct-21,Actual,10/25/2021,NA,Interventional,NA,NA,Glutamine Supplementation and Short-term Mortality in Covid-19,The Impact of Glutamine Supplementation Upon the Short-term Mortality of COVID-19 Diseased Patients Admitted in ICU: A Double Blind Randomized Clinical Trial,Completed,NA,Phase 3,60,Actual,Assiut University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-08T11:22:55Z,2021-11-08T11:22:55Z
NCT04958902,NA,7/8/2021,NA,NA,11/4/2021,7/9/2021,7/12/2021,Actual,NA,NA,NA,NA,NA,NA,11/4/2021,11/5/2021,Estimate,22-Oct-21,Actual,10/22/2021,Nov-21,11/30/2021,1-Nov-21,Anticipated,11/1/2021,1-Nov-21,Anticipated,11/1/2021,NA,Interventional,NA,NA,RESTORE in Patients Who Had COVID-19 and Close Others,RESTORE: An Online Self-directed Mental Health Intervention for Individuals Who Had COVID-19 and Close Others,Recruiting,NA,Not Applicable,20,Anticipated,"University Health Network, Toronto",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:22:27Z,2021-11-08T11:22:27Z
NCT04953078,NA,6/14/2021,NA,NA,10/29/2021,7/6/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/5/2021,Estimate,11-Sep-21,Actual,9/11/2021,Oct-21,10/31/2021,Feb-23,Anticipated,2/28/2023,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19","A Phase 1, Randomized, Open-label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Reactogenicity of Escalating Doses of the Baiya SARS-CoV-2 Vax 1 Vaccine in Healthy Adults",Recruiting,NA,Phase 1,96,Anticipated,"Baiya Phytopharm Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:22:35Z,2021-11-08T11:22:35Z
NCT04849598,NA,4/13/2021,NA,NA,11/4/2021,4/15/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,11/4/2021,11/5/2021,Estimate,13-Apr-21,Actual,4/13/2021,Nov-21,11/30/2021,27-Aug-21,Actual,8/27/2021,27-Aug-21,Actual,8/27/2021,NA,Interventional,NA,NA,Automatic Oxygen Titration in Patients After SARS-CoV-2 Infection,Effects of an Automatic Oxygen Titration vs. Constant Oxygen Flow Rates During Daily Activities in Patients After SARS-CoV-2 Infection,Completed,NA,Not Applicable,15,Actual,SchÃ¶n Klinik Berchtesgadener Land,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:23:32Z,2021-11-08T11:23:32Z
NCT04799392,NA,3/14/2021,NA,NA,10/28/2021,3/14/2021,3/16/2021,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,11/5/2021,Estimate,1-Apr-21,Actual,4/1/2021,Oct-21,10/31/2021,28-Oct-21,Actual,10/28/2021,28-Oct-21,Actual,10/28/2021,NA,Interventional,NA,NA,NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons,NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons,Terminated,NA,Not Applicable,50,Actual,"NOWDiagnostics, Inc.",,2,NA,FDA will not authorize COVID-19 Ab tests for use over-the-counter.,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:23:52Z,2021-11-08T11:23:52Z
NCT04625738,NA,11/4/2020,NA,NA,10/28/2021,11/10/2020,11/12/2020,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,11/5/2021,Estimate,6-Nov-20,Actual,11/6/2020,Oct-21,10/31/2021,1-Sep-21,Actual,9/1/2021,14-May-21,Actual,5/14/2021,NA,Interventional,MSC-COVID19,NA,Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome,Efficacy of Infusions of Mesenchymal Stem Cells From Wharton Jelly in the Moderate to Severe SARS-Cov-2 Related Acute Respiratory Distress Syndrome (COVID-19): A Phase IIa Double-blind Randomized Controlled Trial,Completed,NA,Phase 2,30,Actual,"Central Hospital, Nancy, France",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:25:28Z,2021-11-08T11:25:28Z
NCT04488575,NA,7/23/2020,NA,NA,10/29/2021,7/25/2020,7/28/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/5/2021,Estimate,26-Aug-20,Actual,8/26/2020,Oct-21,10/31/2021,19-May-21,Actual,5/19/2021,16-May-21,Actual,5/16/2021,NA,Interventional,NA,NA,Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,A Phase 2 Double-blind Placebo-controlled Study Investigating the Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With SARS-CoV-2 Infection,Terminated,NA,Phase 2,16,Actual,"Evelo Biosciences, Inc.",,2,NA,Insufficient study defined patient population,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:26:32Z,2021-11-08T11:26:32Z
NCT04569383,NA,9/21/2020,NA,NA,11/4/2021,9/28/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,11/4/2021,11/5/2021,Estimate,5-Oct-20,Actual,10/5/2020,Nov-21,11/30/2021,24-Aug-21,Actual,8/24/2021,24-Aug-21,Actual,8/24/2021,NA,Interventional,NA,NA,Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19,"An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19",Completed,NA,Phase 1,30,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:26:01Z,2021-11-08T11:26:01Z
NCT04472494,NA,7/14/2020,NA,NA,10/28/2021,7/14/2020,7/15/2020,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,11/5/2021,Estimate,14-Oct-20,Actual,10/14/2020,Oct-21,10/31/2021,12-Sep-21,Actual,9/12/2021,12-Sep-21,Actual,9/12/2021,NA,Interventional,NA,NA,Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,"Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise",Terminated,NA,Phase 2,61,Actual,Bristol-Myers Squibb,,2,NA,Slow accrual,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:26:37Z,2021-11-08T11:26:37Z
NCT04468087,NA,7/3/2020,NA,NA,10/28/2021,7/10/2020,7/13/2020,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,11/5/2021,Estimate,15-Feb-21,Actual,2/15/2021,Oct-21,10/31/2021,28-Feb-22,Anticipated,2/28/2022,28-Nov-21,Anticipated,11/28/2021,NA,Interventional,REVOLUTIOn,NA,Antiviral Agents Against COVID-19 Infection,"Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection: a Randomized, Phase 2/3, Multicenter, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX: REVOLUTIOn",Recruiting,NA,Phase 2/Phase 3,1005,Anticipated,Hospital do Coracao,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:26:37Z,2021-11-08T11:26:37Z
NCT04464408,NA,6/28/2020,NA,NA,11/4/2021,7/8/2020,7/9/2020,Actual,NA,NA,NA,NA,NA,NA,11/4/2021,11/5/2021,Estimate,23-Jul-20,Actual,7/23/2020,Nov-21,11/30/2021,4-Aug-21,Actual,8/4/2021,4-Aug-21,Actual,8/4/2021,NA,Interventional,Avi-Mild,NA,Favipiravir Therapy in Adults With Mild COVID-19,A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19,Completed,NA,Phase 2/Phase 3,231,Actual,King Abdullah International Medical Research Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:26:39Z,2021-11-08T11:26:39Z
NCT04460703,NA,7/2/2020,NA,NA,10/28/2021,7/6/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,10/28/2021,11/5/2021,Estimate,3-Jul-20,Actual,7/3/2020,Oct-21,10/31/2021,8-Jul-20,Actual,7/8/2020,8-Jul-20,Actual,7/8/2020,NA,Interventional,NA,NA,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,Not Applicable,4000,Actual,Yale University,,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2021-11-08T11:26:40Z,2021-11-08T11:26:40Z
NCT04460677,NA,7/6/2020,NA,NA,11/3/2021,7/6/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2021,11/5/2021,Estimate,12-Aug-20,Actual,8/12/2020,Nov-21,11/30/2021,31-May-22,Anticipated,5/31/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19 (Coronavirus Disease),Enrolling by invitation,NA,Not Applicable,80,Anticipated,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:26:41Z,2021-11-08T11:26:41Z
NCT04348656,NA,4/13/2020,NA,NA,11/2/2021,4/13/2020,4/16/2020,Actual,NA,NA,NA,NA,NA,NA,11/2/2021,11/5/2021,Estimate,14-Mar-20,Actual,3/14/2020,Nov-21,11/30/2021,16-Jun-21,Actual,6/16/2021,5-Mar-21,Actual,3/5/2021,NA,Interventional,CONCOR-1,NA,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1),Terminated,NA,Phase 3,940,Actual,McMaster University,,2,NA,Study was terminated after the planned interim analysis as the pre-defined futility threshold was met,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:27:11Z,2021-11-08T11:27:11Z
NCT05110560,NA,10/6/2021,NA,NA,11/3/2021,11/3/2021,11/8/2021,Estimate,NA,NA,NA,NA,NA,NA,11/3/2021,11/8/2021,Estimate,1-Jun-21,Actual,6/1/2021,Nov-21,11/30/2021,1-Sep-21,Actual,9/1/2021,1-Aug-21,Actual,8/1/2021,NA,Interventional,NA,NA,Effects of the Programme Developed for Sedentary Elderly in the COVID-19 Pandemic: Mobile Interventional Study,"Effects of the ""Stay at Home-Take a Step"" Programme Developed for Sedentary Elderly in the COVID-19 Pandemic: Mobile Interventional Study",Completed,NA,Not Applicable,32,Actual,Namik Kemal University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-09T12:28:50Z,2021-11-09T12:28:50Z
NCT05104346,NA,10/31/2021,NA,NA,11/1/2021,11/1/2021,11/3/2021,Actual,NA,NA,NA,NA,NA,NA,11/1/2021,11/8/2021,Estimate,31-Mar-19,Actual,3/31/2019,Nov-21,11/30/2021,1-Oct-21,Actual,10/1/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,AA,NA,Presentation and Outcomes of Acute Appendicitis During COVID Pandemic,Presentation and Outcomes of Acute Appendicitis During COVID Pandemic: Lessons Learned From the Middle East (Multicenter Study),Completed,NA,Not Applicable,1945,Actual,Mansoura University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,available for any researcher at any time,elnakeebayman@yahoo.com,http://www.mans.edu.eg/,Yes,the study protocol will be available for other researcher,2021-11-09T12:29:17Z,2021-11-09T12:29:17Z
NCT04790240,NA,2/23/2021,NA,NA,10/31/2021,3/9/2021,3/10/2021,Actual,NA,NA,NA,NA,NA,NA,10/31/2021,11/8/2021,Estimate,1-Feb-21,Actual,2/1/2021,May-21,5/31/2021,Mar-23,Anticipated,3/31/2023,Dec-22,Anticipated,12/31/2022,NA,Interventional,COVID,NA,Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID),The Trial Uses Medicinal Herbs to Direct T Cells to Engulf the COVID-19 Virus and Protect the Organs Well,Recruiting,NA,Phase 1/Phase 2,120,Anticipated,"All Natural Medicine Clinic, LLC",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"The clinical study may start on February 1, 2021; the ending of the say maybe is December 31, 2022. The IPD sharing will begin after the publication in six months.","Viruses, including COVID-19, are highly likely to mutate. This capacity makes it particularly challenging to kill the virus with drugs. This clinical study designed two groups, both of they used the same drugs, but the treatment group pluses medical herbs, then both groups parallelly receive the treatment, then compare participants symptoms, blood test of immunity, the lungs imagine, and COVID-19 virus index, the difference in both group, analysis the symptoms and the mechanism.",http://www.anmedicine.com,Yes,"When we finish the project of the clinical study, we will share the individual participant's data (IPD) (but is not personal private to share) when the results in the publication",2021-11-09T12:35:01Z,2021-11-09T12:35:01Z
NCT04910230,NA,5/24/2021,NA,NA,10/29/2021,6/1/2021,6/2/2021,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/8/2021,Estimate,1-Mar-20,Actual,3/1/2020,Oct-21,10/31/2021,2-Apr-20,Actual,4/2/2020,2-Apr-20,Actual,4/2/2020,NA,Interventional,NA,NA,Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19,Efficiency and Safety of Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19: A Randomized Clinical Trial,Completed,NA,Not Applicable,24,Actual,Shenyang Northern Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:33:38Z,2021-11-09T12:33:38Z
NCT04709835,NA,1/12/2021,NA,NA,11/1/2021,1/13/2021,1/14/2021,Actual,NA,NA,NA,NA,NA,NA,11/1/2021,11/8/2021,Estimate,3-Feb-21,Actual,2/3/2021,Nov-21,11/30/2021,13-Oct-21,Actual,10/13/2021,17-Sep-21,Actual,9/17/2021,NA,Interventional,NA,NA,Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19",Completed,NA,Phase 2,104,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2021-11-09T12:36:17Z,2021-11-09T12:36:17Z
NCT04842734,NA,4/10/2021,NA,NA,10/29/2021,4/10/2021,4/13/2021,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/8/2021,Estimate,27-Mar-21,Actual,3/27/2021,Oct-21,10/31/2021,27-Feb-22,Anticipated,2/27/2022,27-Jun-21,Actual,6/27/2021,NA,Interventional,NA,NA,Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease During the Covid-19 Pandemic,Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease During the Covid-19 Pandemic,"Active, not recruiting",NA,Not Applicable,60,Actual,Yeditepe University,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-09T12:34:28Z,2021-11-09T12:34:28Z
NCT04689542,NA,12/29/2020,NA,NA,11/5/2021,12/29/2020,12/30/2020,Actual,NA,NA,NA,NA,NA,NA,11/5/2021,11/8/2021,Estimate,1-Jan-21,Actual,1/1/2021,Nov-21,11/30/2021,2-Apr-21,Actual,4/2/2021,2-Apr-21,Actual,4/2/2021,NA,Interventional,NA,NA,Surgical Face Mask Effects in Patients With COVID-19,Effects of Surgical Face Mask on Submaximal Exercise Test in Patients With COVID-19,Completed,NA,Not Applicable,28,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:36:27Z,2021-11-09T12:36:27Z
NCT04615936,NA,11/2/2020,NA,NA,10/29/2021,11/2/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2021,11/8/2021,Estimate,13-Oct-20,Actual,10/13/2020,Oct-21,10/31/2021,19-Oct-21,Actual,10/19/2021,7-Jul-21,Actual,7/7/2021,NA,Interventional,NA,NA,Nasal Photodisinfection COVID-19 Proof of Concept Study,Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract,Completed,NA,Not Applicable,45,Actual,Sunnybrook Health Sciences Centre,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:37:34Z,2021-11-09T12:37:34Z
NCT04531254,NA,8/24/2020,NA,NA,10/31/2021,8/27/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,10/31/2021,11/8/2021,Estimate,10-Aug-20,Actual,8/10/2020,Oct-21,10/31/2021,31-Aug-20,Actual,8/31/2020,31-Aug-20,Actual,8/31/2020,NA,Interventional,NA,NA,Back to School COVID-19 Simulation Study,Understanding the Impact of Public Health Measures Planned for School Reopening During COVID-19 Using Simulation Exercises,Completed,NA,Not Applicable,174,Actual,The Hospital for Sick Children,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-09T12:38:40Z,2021-11-09T12:38:40Z
NCT04327505,NA,3/25/2020,NA,NA,11/5/2021,3/27/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,11/5/2021,11/8/2021,Estimate,3-Jun-20,Actual,6/3/2020,Nov-21,11/30/2021,31-Dec-22,Anticipated,12/31/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,COVID-19-HBO,NA,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,"A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19",Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Starting after publication and for 36 months,A full description of the intended use of the data must be sent to the corresponding author for review and approval. Participant consent for data sharing is conditioned and new ethics approval may be required.,NA,Yes,"The full study protocol, statistical plan and consent form will be publicly available when results are published. Data will be available on patient level; data will be pseudonymized. The full dataset and statistical code will be available upon request.",2021-11-09T12:40:56Z,2021-11-09T12:40:56Z
NCT04392323,NA,5/15/2020,NA,NA,11/4/2021,5/15/2020,5/18/2020,Actual,NA,NA,NA,NA,NA,NA,11/4/2021,11/8/2021,Estimate,13-May-20,Actual,5/13/2020,May-20,5/31/2020,4-Oct-20,Actual,10/4/2020,1-Oct-20,Actual,10/1/2020,NA,Interventional,NA,NA,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Completed,NA,Not Applicable,111,Actual,Northwell Health,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-09T12:40:05Z,2021-11-09T12:40:05Z
NCT04409743,NA,5/28/2020,NA,NA,11/5/2021,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,11/5/2021,11/8/2021,Estimate,7-Jun-20,Actual,6/7/2020,Nov-21,11/30/2021,Apr-22,Anticipated,4/30/2022,14-Oct-21,Actual,10/14/2021,NA,Interventional,NA,NA,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,"Harnessing Telehealth to Mitigate the Impact of the COVID-19 Pandemic on Sleep, Suicidality, and Neuropsychiatric Symptoms","Active, not recruiting",NA,Not Applicable,49,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-09T12:39:45Z,2021-11-09T12:39:45Z
NCT04353206,NA,4/16/2020,NA,NA,11/1/2021,4/16/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,11/1/2021,11/8/2021,Estimate,27-Jun-20,Actual,6/27/2020,Nov-21,11/30/2021,1-Nov-20,Actual,11/1/2020,1-Nov-20,Actual,11/1/2020,NA,Interventional,NA,NA,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19,Terminated,NA,Early Phase 1,6,Actual,Cedars-Sinai Medical Center,,1,NA,The initiation of the expanded access program for convalescent plasma.,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:40:41Z,2021-11-09T12:40:41Z
NCT05115435,NA,11/8/2021,NA,NA,11/9/2021,11/9/2021,11/10/2021,Estimate,NA,NA,NA,NA,NA,NA,11/9/2021,11/10/2021,Estimate,1-Mar-21,Actual,3/1/2021,Nov-21,11/30/2021,1-Nov-21,Actual,11/1/2021,1-Aug-21,Actual,8/1/2021,NA,Interventional,NA,NA,The Effect of Neuro Linguistic Programming on COVID-19 Fear in Kidney Transplant,The Effect of Neuro Linguistic Programming on COVID-19 Fear in Kidney Transplant,Completed,NA,Not Applicable,74,Actual,Inonu University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Data can be shared with the permission of the researchers.,2021-11-10T21:57:26Z,2021-11-10T21:57:26Z
NCT05109624,NA,11/3/2021,NA,NA,11/5/2021,11/3/2021,11/5/2021,Actual,NA,NA,NA,NA,NA,NA,11/5/2021,11/10/2021,Estimate,1-Oct-21,Actual,10/1/2021,Nov-21,11/30/2021,1-Jan-22,Anticipated,1/1/2022,1-Jan-22,Anticipated,1/1/2022,NA,Interventional,NA,NA,Is Prolonged Period of Prone Position Effective and Safe in Mechanically Ventilated Patients With SARS-COV-2?,Is Prolonged Period of Prone Position Effective and Safe in Mechanically Ventilated Patients With SARS-COV-2? A Randomized Clinical Trial,Recruiting,NA,Not Applicable,52,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T22:00:16Z,2021-11-10T22:00:16Z
NCT05112887,NA,11/5/2021,NA,NA,11/5/2021,11/5/2021,11/9/2021,Actual,NA,NA,NA,NA,NA,NA,11/5/2021,11/9/2021,Actual,31-Mar-21,Actual,3/31/2021,Mar-21,3/31/2021,13-Sep-21,Actual,9/13/2021,13-Sep-21,Actual,9/13/2021,NA,Interventional,NA,NA,Osteopathic Manipulative Therapy Effects on Prolonged Post-COVID Olfactory Dysfunction,Osteopathic Manipulative Therapy Effects on Prolonged Post-COVID Olfactory Dysfunction,Completed,NA,Not Applicable,20,Actual,Ohio University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:59:45Z,2021-11-10T21:59:45Z
NCT05115162,NA,11/1/2021,NA,NA,11/1/2021,11/1/2021,11/10/2021,Estimate,NA,NA,NA,NA,NA,NA,11/1/2021,11/10/2021,Estimate,1-Dec-20,Actual,12/1/2020,Oct-21,10/31/2021,30-Apr-21,Actual,4/30/2021,17-Jan-21,Actual,1/17/2021,NA,Interventional,NA,NA,The Effects of the Hybrid Telerehabilitation Exercise in Inactive Students,The Effects of the Hybrid Telerehabilitation Exercise Program in Inactive University Students During Covid-19 Pandemic - A Randomized Controlled Study,Completed,NA,Not Applicable,63,Actual,Marmara University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T21:57:40Z,2021-11-10T21:57:40Z
NCT05113849,NA,10/29/2021,NA,NA,11/8/2021,11/8/2021,11/9/2021,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/9/2021,Actual,16-Sep-21,Actual,9/16/2021,Nov-21,11/30/2021,Feb-23,Anticipated,2/28/2023,Feb-23,Anticipated,2/28/2023,NA,Interventional,NA,NA,Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19),"A Phase 1, Open-label, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults Aged at 19 to 55 Years",Recruiting,NA,Phase 1,40,Anticipated,HK inno.N Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:58:54Z,2021-11-10T21:58:54Z
NCT05113823,NA,10/25/2021,NA,NA,11/8/2021,11/8/2021,11/9/2021,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/9/2021,Actual,16-Nov-20,Actual,11/16/2020,Nov-21,11/30/2021,15-Mar-21,Actual,3/15/2021,19-Nov-20,Actual,11/19/2020,NA,Interventional,NA,NA,In Situ Simulation Training in Transferring Critically Ill COVID-19 Patients,In Situ Simulation Training for a Better Interprofessional Team Performance in Transferring Critically Ill COVID-19 Patients: A Prospective Randomized Control Trial,Completed,NA,Not Applicable,40,Actual,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:58:55Z,2021-11-10T21:58:55Z
NCT05087381,NA,10/19/2021,NA,NA,11/8/2021,10/19/2021,10/21/2021,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/9/2021,Actual,1-Oct-21,Actual,10/1/2021,Nov-21,11/30/2021,30-Jan-22,Anticipated,1/30/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community,"Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community With Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide in Decreasing Recovery Time",Recruiting,NA,Phase 4,1800,Anticipated,Chulalongkorn University,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:01:52Z,2021-11-10T22:01:52Z
NCT05065619,NA,10/1/2021,NA,NA,11/9/2021,10/1/2021,10/4/2021,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/10/2021,Estimate,2-Oct-21,Actual,10/2/2021,Nov-21,11/30/2021,Feb-23,Anticipated,2/28/2023,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Safety Immunogenicity Study of MT-2766 in Japanese Adultsï¼ˆCOVID-19ï¼‰,"A Phase I/II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of MT-2766 in Japanese Adults (COVID-19)",Recruiting,NA,Phase 1/Phase 2,145,Anticipated,Medicago,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:02:35Z,2021-11-10T22:02:35Z
NCT04841707,NA,3/31/2021,NA,NA,11/3/2021,4/8/2021,4/12/2021,Actual,NA,NA,NA,NA,NA,NA,11/3/2021,11/10/2021,Estimate,10-May-21,Actual,5/10/2021,Nov-21,11/30/2021,22-Feb-23,Anticipated,2/22/2023,22-Feb-22,Anticipated,2/22/2022,NA,Interventional,NA,NA,Total-Body Parametric 18F-FDG PET of COVID-19,Total-Body Parametric 18F-FDG PET of COVID-19,Recruiting,NA,Not Applicable,15,Anticipated,"University of California, Davis",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:06:51Z,2021-11-10T22:06:51Z
NCT04953052,NA,6/29/2021,NA,NA,11/8/2021,7/5/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/9/2021,Actual,Nov-21,Anticipated,11/30/2021,Oct-21,10/31/2021,Apr-22,Anticipated,4/30/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,IMPRESS COVID,NA,A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.,"A Randomized, Double-blind, Multicentre 2-arm, Parallel-group, Placebo-controlled Study to Investigate the Efficacy and Safety of Intravenous Imatinib Mesylate in Reducing the Severity of Hypoxemic Respiratory Failure in Patients With Critical COVID-19 Receiving Standard of Care.",Recruiting,NA,Phase 2,84,Anticipated,Exvastat Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-10T22:04:58Z,2021-11-10T22:04:58Z
NCT04864548,NA,4/20/2021,NA,NA,11/1/2021,4/23/2021,4/29/2021,Actual,NA,NA,NA,NA,NA,NA,11/1/2021,11/9/2021,Actual,27-May-21,Actual,5/27/2021,Nov-21,11/30/2021,Nov-22,Anticipated,11/30/2022,Nov-22,Anticipated,11/30/2022,NA,Interventional,NA,NA,COV-CHIM01: SARS-CoV-2 (COVID-19) Dose Finding Infection Study,"A Dose Finding Human Experimental Infection Study With SARS-CoV-2 in Healthy Volunteers With Previous, Microbiologically Confirmed, SARS-CoV-2 Infection",Recruiting,NA,Phase 1,64,Anticipated,University of Oxford,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:06:33Z,2021-11-10T22:06:33Z
NCT04818489,NA,2/13/2021,NA,NA,11/7/2021,3/25/2021,3/26/2021,Actual,NA,NA,NA,NA,NA,NA,11/7/2021,11/9/2021,Actual,25-Mar-21,Actual,3/25/2021,Nov-21,11/30/2021,20-Oct-21,Actual,10/20/2021,25-Aug-21,Actual,8/25/2021,NA,Interventional,NA,NA,Colchicine and Post-COVID-19 Pulmonary Fibrosis,Impact of Colchicine on the Clinical Outcome of COVID-19 and the Development of Post-COVID-19 Pulmonary Fibrosis: Randomized Controlled Clinical Trial,Completed,NA,Phase 4,260,Actual,ClinAmygate,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:07:19Z,2021-11-10T22:07:19Z
NCT04802408,NA,3/10/2021,NA,NA,11/3/2021,3/16/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,11/3/2021,11/10/2021,Estimate,1-Oct-21,Actual,10/1/2021,Nov-21,11/30/2021,30-May-22,Anticipated,5/30/2022,30-May-22,Anticipated,5/30/2022,NA,Interventional,SNOW,NA,SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial,SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial,Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Milton S. Hershey Medical Center,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:07:30Z,2021-11-10T22:07:30Z
NCT04633772,NA,11/6/2020,NA,NA,11/8/2021,11/17/2020,11/18/2020,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/9/2021,Actual,5-Aug-20,Actual,8/5/2020,Nov-21,11/30/2021,1-Nov-21,Actual,11/1/2021,1-Nov-21,Actual,11/1/2021,NA,Interventional,NA,NA,Use of Angiotensin-(1-7) in COVID-19,Randomized Clinical Trial Phase I/II for the Use of Angiotensin-(1-7) in the Treatment of Severe Infection by Sars-CoV-2,Completed,NA,Phase 1/Phase 2,112,Actual,Erasme University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:09:31Z,2021-11-10T22:09:31Z
NCT04672564,NA,12/16/2020,NA,NA,11/9/2021,12/16/2020,12/17/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/10/2021,Estimate,30-Mar-21,Actual,3/30/2021,May-21,5/31/2021,28-Jul-22,Anticipated,7/28/2022,28-Jul-22,Anticipated,7/28/2022,NA,Interventional,NA,NA,Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients,"A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 3,300,Anticipated,"Shenyang Tonglian Group CO., Ltd",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T22:08:56Z,2021-11-10T22:08:56Z
NCT04615429,NA,10/25/2020,NA,NA,11/9/2021,11/2/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/10/2021,Estimate,15-Sep-20,Actual,9/15/2020,Nov-21,11/30/2021,Feb-22,Anticipated,2/28/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,"Double-blind, Randomized, Controlled, Clinical Trial to Assess the Efficacy of Allogenic Mesenchymal Stromal Cells in Patients With Acute Respiratory Distress Syndrome Due to COVID-19",Recruiting,NA,Phase 2,20,Anticipated,Puerta de Hierro University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:09:51Z,2021-11-10T22:09:51Z
NCT04389671,NA,5/13/2020,NA,NA,11/8/2021,5/13/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/9/2021,Actual,2-Nov-20,Actual,11/2/2020,Nov-21,11/30/2021,30-Jan-22,Anticipated,1/30/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19),"A Multicenter, Single-Treatment Study to Assess the Safety and Tolerability of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury",Recruiting,NA,Phase 2,20,Anticipated,Windtree Therapeutics,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The preparation and submittal for publication of a manuscript containing the study results shall be in accordance with a process determined by a mutual written agreement among Windtree and participating institutions.

The publication or presentation of any study results shall comply with all applicable privacy laws, including but not limited to HIPAA. This trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted. In addition, every attempt will be made to publish results in peer-reviewed journals.",2021-11-10T22:12:52Z,2021-11-10T22:12:52Z
NCT04547140,NA,9/10/2020,NA,NA,11/8/2021,9/10/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/9/2021,Actual,29-Jan-21,Actual,1/29/2021,Nov-21,11/30/2021,Feb-22,Anticipated,2/28/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19",Recruiting,NA,Phase 2,100,Anticipated,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:10:44Z,2021-11-10T22:10:44Z
NCT04414631,NA,5/19/2020,NA,NA,11/1/2021,6/2/2020,6/4/2020,Actual,NA,NA,NA,NA,NA,NA,11/1/2021,11/9/2021,Actual,6-Aug-20,Actual,8/6/2020,Nov-21,11/30/2021,15-Sep-21,Actual,9/15/2021,15-Sep-21,Actual,9/15/2021,NA,Interventional,NA,NA,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,"Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).",Terminated,NA,Phase 2,80,Actual,"University Hospital, Basel, Switzerland",,2,NA,Aim to enroll 120 patients deemed not sufficient to show a difference in the primary outcome measure. Standard of care treatment recently changed in Switzerland adding further heterogeneity to trial population when including future participants.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T22:12:28Z,2021-11-10T22:12:28Z
NCT04359654,NA,4/21/2020,NA,NA,11/8/2021,4/21/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/9/2021,Actual,16-Jun-20,Actual,6/16/2020,Nov-21,11/30/2021,5-Nov-21,Actual,11/5/2021,12-Aug-21,Actual,8/12/2021,NA,Interventional,COVASE,NA,Nebulised Dornase Alfa for Treatment of COVID-19,"A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19",Completed,NA,Phase 2,41,Actual,"University College, London",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Anonymised results will be published in a scientific journal (TBC) and posted on the Breathing Matters website www.breathingatters@ucl.ac.uk,2021-11-10T22:13:15Z,2021-11-10T22:13:15Z
NCT04822818,NA,3/25/2021,NA,NA,11/8/2021,3/29/2021,3/30/2021,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/11/2021,Estimate,17-Apr-21,Actual,4/17/2021,Nov-21,11/30/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,BEVA,NA,EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEVÂ®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19,"TRIAL EVALUATING EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEVÂ®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19, NESTED IN THE CORIMUNO-19 COHORT",Recruiting,NA,Phase 3,174,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-11T21:25:40Z,2021-11-11T21:25:40Z
NCT05046561,NA,9/8/2021,NA,NA,11/4/2021,9/8/2021,9/16/2021,Actual,NA,NA,NA,NA,NA,NA,11/4/2021,11/11/2021,Estimate,4-Nov-21,Actual,11/4/2021,Nov-21,11/30/2021,Aug-23,Anticipated,8/31/2023,Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial,"Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate The Safety and Efficacy of STRI Formula in Non-Hospitalized Participants With COVID-19",Recruiting,NA,Phase 2,598,Anticipated,"Eyecheck, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data from this study may be requested from other researchers 3 years after the completion of the primary endpoint by contacting the PI.,Users of the STRI Dataset will be required to agree to terms that prohibit unlawful uses and intentional violations of privacy and require attribution.,NA,Yes,"After the study is completed, the de-identified, archived data may be transmitted to and stored for use by other researchers including those outside of the study. Permission to transmit de-identified data to other researchers has been included in the informed consent.

Data from this study may be requested from other researchers 3 years after the completion of the primary endpoint by contacting the PI.",2021-11-11T21:23:00Z,2021-11-11T21:23:00Z
NCT05089305,NA,10/14/2021,NA,NA,11/9/2021,10/14/2021,10/22/2021,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/11/2021,Estimate,4-Sep-21,Actual,9/4/2021,Nov-21,11/30/2021,21-Dec-22,Anticipated,12/21/2022,25-Nov-22,Anticipated,11/25/2022,NA,Interventional,NA,NA,Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection,Effect of Inhalation Administration of Ozone Plasma on Lung Function and Inflammatory Parameters in Patients With Pulmonary Sequelae Associated With Coronavirus 19 Infection (SARS-COV-2),Enrolling by invitation,NA,Phase 2,35,Anticipated,"Centro Universitario de Ciencias de la Salud, Mexico",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:22:20Z,2021-11-11T21:22:20Z
NCT04540939,NA,9/4/2020,NA,NA,11/9/2021,9/4/2020,9/7/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/11/2021,Estimate,19-Oct-20,Actual,10/19/2020,Nov-21,11/30/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Recruiting,NA,Not Applicable,60,Anticipated,University of Michigan,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Within 36 months of completion of the project.,"Access to data generated by the project will be available for educational, research and non-profit purposes to researchers who provide a methodologically sound proposal. Data generated under this project will be administered in accordance with NIH Sharing policies, including NIH Policy on Dissemination of NIH-Funded Clinical Trial Information (8/2016), and the NIH Grants Policy Statement (Availability of Research Results) (11/2015). Depending on such NIH policies, Data generated by this project may be available for educational, research or non-commercial purposes under the terms of a data use agreement. Data will be stored in an established data repository (e.g. Inter-university Consortium for Political and Social Research (ICPSR): icpsr.umich.edu) with appropriate provisions for curation and longterm preservation.",NA,Yes,We plan to make available data from human subjects initially to collaborators for independent replication / data pooling. Completely de-identified research data (redacted according to NIH practice to prevent disclosure of personal identifiers) which documents the research findings will be made available after the main findings from the finalized research dataset have been accepted for publication.,2021-11-11T21:27:59Z,2021-11-11T21:27:59Z
NCT04625725,NA,11/10/2020,NA,NA,11/10/2021,11/10/2020,11/12/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/11/2021,Estimate,21-Nov-20,Actual,11/21/2020,Nov-21,11/30/2021,29-Jun-22,Anticipated,6/29/2022,5-May-21,Actual,5/5/2021,NA,Interventional,PROVENT,NA,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.","A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19.","Active, not recruiting",NA,Phase 3,5197,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-11-11T21:27:12Z,2021-11-11T21:27:12Z
NCT04482699,NA,7/20/2020,NA,NA,11/3/2021,7/21/2020,7/22/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2021,11/11/2021,Estimate,30-Dec-20,Actual,12/30/2020,Nov-21,11/30/2021,13-Sep-21,Actual,9/13/2021,13-Sep-21,Actual,9/13/2021,NA,Interventional,NA,NA,RAPA-501-Allo Therapy of COVID-19-ARDS,Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for COVID-19-Related ARDS,Terminated,NA,Phase 1/Phase 2,1,Actual,Rapa Therapeutics LLC,,4,NA,Change in eligible patient population,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:28Z,2021-11-11T21:28:28Z
NCT04523571,NA,8/18/2020,NA,NA,11/5/2021,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,11/5/2021,11/11/2021,Estimate,28-Jul-20,Actual,7/28/2020,Nov-21,11/30/2021,10-Aug-21,Actual,8/10/2021,30-Sep-20,Actual,9/30/2020,NA,Interventional,NA,NA,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study",Completed,NA,Phase 1,144,Actual,BioNTech SE,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:12Z,2021-11-11T21:28:12Z
NCT04375735,NA,4/22/2020,NA,NA,11/4/2021,5/4/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,11/4/2021,11/11/2021,Estimate,23-Nov-20,Actual,11/23/2020,Nov-21,11/30/2021,6-Oct-21,Actual,10/6/2021,1-Sep-21,Actual,9/1/2021,NA,Interventional,LESSCOVID,NA,London's Exogenous Surfactant Study for COVID19,Phase I/II Trial: Exogenous Surfactant Administration for Patients With COVID-19,Completed,NA,Phase 1/Phase 2,20,Actual,Lawson Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:29:06Z,2021-11-11T21:29:06Z
NCT04363814,NA,4/19/2020,NA,NA,11/10/2021,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/11/2021,Estimate,10-Jun-20,Actual,6/10/2020,Nov-21,11/30/2021,31-Jan-22,Anticipated,1/31/2022,1-Jan-22,Anticipated,1/1/2022,NA,Interventional,NA,NA,Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,"A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19","Active, not recruiting",NA,Phase 3,100,Anticipated,Inmunotek S.L.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:29:12Z,2021-11-11T21:29:12Z
NCT04480424,NA,7/20/2020,NA,NA,11/10/2021,7/20/2020,7/21/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/11/2021,Estimate,17-Sep-20,Actual,9/17/2020,Nov-21,11/30/2021,25-Oct-21,Actual,10/25/2021,19-Aug-21,Actual,8/19/2021,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:28Z,2021-11-11T21:28:28Z
NCT05118373,NA,8/18/2021,NA,NA,11/11/2021,11/11/2021,11/12/2021,Estimate,NA,NA,NA,NA,NA,NA,11/11/2021,11/12/2021,Estimate,18-Aug-21,Actual,8/18/2021,Nov-21,11/30/2021,23-Sep-21,Actual,9/23/2021,23-Sep-21,Actual,9/23/2021,NA,Interventional,NA,NA,Generic Behavioural Change Campaign for COVID-19 Prevention,Evaluation of a Generic Behavioural Change Campaign for COVID-19 Prevention in Zambia,Completed,NA,Not Applicable,2004,Actual,Centre for Infectious Disease Research in Zambia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:23:19Z,2021-11-15T12:23:19Z
NCT05046548,NA,8/26/2021,NA,NA,11/11/2021,9/13/2021,9/16/2021,Actual,NA,NA,NA,NA,NA,NA,11/11/2021,11/12/2021,Estimate,3-Oct-20,Actual,10/3/2020,Nov-21,11/30/2021,1-Oct-21,Actual,10/1/2021,15-Oct-20,Actual,10/15/2020,NA,Interventional,NA,NA,"This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19","Double-blind, Placebo-controlled, Randomized Study of Tolerability, Safety and Immunogenicity of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers at the Age of 18-60 Years",Completed,NA,Phase 1/Phase 2,400,Actual,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-15T12:24:34Z,2021-11-15T12:24:34Z
NCT05037097,NA,8/30/2021,NA,NA,11/10/2021,9/3/2021,9/8/2021,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/12/2021,Estimate,30-Aug-21,Actual,8/30/2021,Nov-21,11/30/2021,Mar-23,Anticipated,3/31/2023,Mar-23,Anticipated,3/31/2023,NA,Interventional,NA,NA,A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults,"A Phase 1/2 Randomized, Observer-Blind Study of the Safety, Reactogenicity, and Immunogenicity of 3 SARS-CoV-2 RNA Vaccine Candidates in Adults Previously Vaccinated and Not Previously Vaccinated Against SARS-CoV-2",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,"Arcturus Therapeutics, Inc.",,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-11-15T12:24:40Z,2021-11-15T12:24:40Z
NCT04860518,NA,4/22/2021,NA,NA,11/11/2021,4/22/2021,4/27/2021,Actual,NA,NA,NA,NA,NA,NA,11/11/2021,11/12/2021,Estimate,23-Aug-21,Actual,8/23/2021,Nov-21,11/30/2021,Apr-22,Anticipated,4/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,HIBISCUS,NA,Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With CoronavirUS,"A Phase II Multi-Center, Double-Blind, Randomized and Controlled Study of the Safety and Efficacy of Intravenous Recombinant Human Interferon Beta-1a in Comparison to Dexamethasone for the Treatment of Hospitalized Patients With COVID-19 Infection",Recruiting,NA,Phase 2,140,Anticipated,Faron Pharmaceuticals Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-15T12:26:13Z,2021-11-15T12:26:13Z
NCT04530604,NA,8/25/2020,NA,NA,11/10/2021,8/26/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/12/2021,Estimate,1-Oct-20,Actual,10/1/2020,Nov-21,11/30/2021,9-Apr-21,Actual,4/9/2021,26-Mar-21,Actual,3/26/2021,NA,Interventional,NA,NA,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1,12,Actual,University of Michigan,,1,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:28:27Z,2021-11-15T12:28:27Z
NCT04472728,NA,7/6/2020,NA,NA,11/10/2021,7/13/2020,7/15/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/12/2021,Estimate,16-Jun-20,Actual,6/16/2020,Feb-21,2/28/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,COVA,NA,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,"Adaptive Design Phase 2 to 3, Randomized, Double-blind, to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BIO101 in the Prevention of the Respiratory Deterioration in Hospitalized COVID-19 Patients",Recruiting,NA,Phase 2/Phase 3,310,Anticipated,Biophytis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:28:35Z,2021-11-15T12:28:35Z
NCT04400799,NA,5/15/2020,NA,NA,11/11/2021,5/22/2020,5/26/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2021,11/12/2021,Estimate,15-Jun-20,Actual,6/15/2020,Nov-21,11/30/2021,14-Apr-22,Anticipated,4/14/2022,14-Mar-22,Anticipated,3/14/2022,NA,Interventional,NA,NA,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial,Recruiting,NA,Phase 3,1000,Anticipated,University of Zurich,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:29:00Z,2021-11-15T12:29:00Z
NCT05119634,NA,7/28/2021,NA,NA,11/11/2021,11/11/2021,11/15/2021,Estimate,NA,NA,NA,NA,NA,NA,11/11/2021,11/15/2021,Estimate,18-Oct-21,Actual,10/18/2021,Nov-21,11/30/2021,20-Dec-22,Anticipated,12/20/2022,21-Aug-22,Anticipated,8/21/2022,NA,Interventional,NA,NA,The Effect of Whole Body Vibration Training in Individuals With Post COVID - 19,The Effect of Whole Body Vibration Training in Individuals With Post COVID - 19,Recruiting,NA,Not Applicable,60,Anticipated,Istanbul University-Cerrahpasa,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,the data will become available by 2022,NA,NA,Yes,outcomes and method will be share,2021-11-16T00:47:27Z,2021-11-16T00:47:27Z
NCT04650087,NA,11/30/2020,NA,NA,11/11/2021,11/30/2020,12/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2021,11/15/2021,Estimate,15-Feb-21,Actual,2/15/2021,Nov-21,11/30/2021,Aug-22,Anticipated,8/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis,"COVID-19 Post-hospital Thrombosis Prevention Trial: An Adaptive, Multicenter, Prospective, Randomized Platform Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients With COVID-19 Following Hospital Discharge",Recruiting,NA,Phase 3,5320,Anticipated,Duke University,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-16T00:53:09Z,2021-11-16T00:53:09Z
NCT05056883,NA,9/15/2021,NA,NA,11/12/2021,9/15/2021,9/27/2021,Actual,NA,NA,NA,NA,NA,NA,11/12/2021,11/15/2021,Estimate,12-Nov-21,Anticipated,11/12/2021,Nov-21,11/30/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,A Phase III Confirmatory Study of K-237,"A Phase III Confirmatory Study of K-237-A Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Mild COVID-19",Recruiting,NA,Phase 3,1000,Anticipated,"Kowa Company, Ltd.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:49:04Z,2021-11-16T00:49:04Z
NCT04969601,NA,7/19/2021,NA,NA,11/8/2021,7/19/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,11/8/2021,11/15/2021,Estimate,29-Sep-21,Actual,9/29/2021,Nov-21,11/30/2021,29-Mar-23,Anticipated,3/29/2023,29-May-22,Anticipated,5/29/2022,NA,Interventional,PACIFIC,NA,Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings,Anti-Covid-19 Vaccine Protection in Immunocompromised Children (1 to 15 Years Old) With Acute Leukemia and Their Siblings (â‰¥12 Years Old). Phase I-II Trial Evaluating Post-vaccine Safety and Humoral and Cellular Immunogenicity.,Recruiting,NA,Phase 1/Phase 2,150,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-16T00:50:19Z,2021-11-16T00:50:19Z
NCT04816019,NA,3/15/2021,NA,NA,11/12/2021,3/24/2021,3/25/2021,Actual,NA,NA,NA,NA,NA,NA,11/12/2021,11/15/2021,Estimate,1-Apr-21,Actual,4/1/2021,Nov-21,11/30/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,A Study of Intranasal ChAdOx1 nCOV-19,"A Phase I Study to Determine Safety, Tolerability and Immunogenicity of Intranasal Administration of the COVID Vaccine ChAdOx1 nCOV-19 in Healthy UK Adults",Recruiting,NA,Phase 1,54,Anticipated,University of Oxford,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:51:55Z,2021-11-16T00:51:55Z
NCT04884295,NA,5/6/2021,NA,NA,11/12/2021,5/7/2021,5/12/2021,Actual,NA,NA,NA,NA,NA,NA,11/12/2021,11/15/2021,Estimate,26-Aug-21,Actual,8/26/2021,Nov-21,11/30/2021,Jun-22,Anticipated,6/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,"Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19","A 2-part Clinical Study Including a First in Human, Open Label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double Blind, Placebo-controlled Part (Phase 2) to Evaluate the Efficacy and Safety of XVR011 in Patients Hospitalised for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 1/Phase 2,279,Anticipated,ExeVir Bio BV,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-16T00:51:16Z,2021-11-16T00:51:16Z
NCT04634409,NA,11/17/2020,NA,NA,11/12/2021,11/17/2020,11/18/2020,Actual,NA,NA,NA,NA,NA,NA,11/12/2021,11/15/2021,Estimate,29-Oct-20,Actual,10/29/2020,Nov-21,11/30/2021,20-Oct-21,Actual,10/20/2021,27-Jul-21,Actual,7/27/2021,NA,Interventional,BLAZE-4,NA,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,"A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)",Completed,NA,Phase 2,1631,Actual,Eli Lilly and Company,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",http://vivli.org/,Yes,NA,2021-11-16T00:53:26Z,2021-11-16T00:53:26Z
NCT04602507,NA,10/22/2020,NA,NA,11/11/2021,10/23/2020,10/26/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2021,11/15/2021,Estimate,10-Dec-20,Actual,12/10/2020,Nov-21,11/30/2021,9-Dec-21,Anticipated,12/9/2021,9-Dec-21,Anticipated,12/9/2021,NA,Interventional,NA,NA,Ivermectin in Adults With Severe COVID-19.,Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial,Recruiting,NA,Phase 2,100,Anticipated,CES University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,One year,Under direct request to principal investigator,NA,Yes,"For a reasonable scientific purpose, we may share individual patient data (IPD) that underlie results in a publication under direct request to the principal investigator. We reserve our right to share IPD.",2021-11-16T00:53:43Z,2021-11-16T00:53:43Z
NCT05122260,NA,11/1/2021,NA,NA,11/12/2021,11/12/2021,11/16/2021,Estimate,NA,NA,NA,NA,NA,NA,11/12/2021,11/16/2021,Estimate,11-Nov-21,Actual,11/11/2021,Nov-21,11/30/2021,Feb-22,Anticipated,2/28/2022,15-Dec-21,Anticipated,12/15/2021,NA,Interventional,NA,NA,PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray,"A Phase 1a Safety, Acceptability and Pharmacokinetics Study of Q-Griffithsin Intranasal Spray for Broad-spectrum Coronavirus Pre-exposure Prophylaxis: A Study of the PREVENT-COVID-19Program",Recruiting,NA,Phase 1,18,Anticipated,University of Louisville,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:51:25Z,2021-11-17T09:51:25Z
NCT04354831,NA,4/14/2020,NA,NA,11/11/2021,4/16/2020,4/21/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2021,11/15/2021,Estimate,11-May-20,Actual,5/11/2020,Nov-21,11/30/2021,1-May-23,Anticipated,5/1/2023,1-May-22,Anticipated,5/1/2022,NA,Interventional,NA,NA,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,"An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection","Active, not recruiting",NA,Phase 2,131,Anticipated,Medical College of Wisconsin,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:55:35Z,2021-11-16T00:55:35Z
NCT05122234,NA,11/13/2021,NA,NA,11/13/2021,11/13/2021,11/16/2021,Estimate,NA,NA,NA,NA,NA,NA,11/13/2021,11/16/2021,Estimate,10-Aug-20,Actual,8/10/2020,Nov-21,11/30/2021,14-Nov-21,Actual,11/14/2021,30-Jul-21,Actual,7/30/2021,NA,Interventional,NA,NA,Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19,Effectiveness and Safety Profile of Mesenchymal Stem Cell Secretomes as a Treatment for Severe Cases of COVID-19,Completed,NA,Phase 3,40,Actual,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-17T09:51:27Z,2021-11-17T09:51:27Z
NCT04910269,NA,6/1/2021,NA,NA,11/15/2021,6/1/2021,6/2/2021,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/16/2021,Estimate,6-Aug-21,Actual,8/6/2021,Nov-21,11/30/2021,Aug-23,Anticipated,8/31/2023,Aug-23,Anticipated,8/31/2023,NA,Interventional,OTAC,NA,Outpatient Treatment With Anti-Coronavirus Immunoglobulin,"An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19",Recruiting,NA,Phase 3,820,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,A public data set will be made available at the end of the trial.,2021-11-17T09:56:04Z,2021-11-17T09:56:04Z
NCT04905888,NA,5/25/2021,NA,NA,11/7/2021,5/26/2021,5/28/2021,Actual,NA,NA,NA,NA,NA,NA,11/7/2021,11/16/2021,Estimate,8-Nov-21,Actual,11/8/2021,Nov-21,11/30/2021,31-Dec-23,Anticipated,12/31/2023,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela,Hyperbaric Oxygen Therapy for Long COVID Patients With Pulmonary Sequela - Pilot Study,Recruiting,NA,Phase 2,24,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:56:05Z,2021-11-17T09:56:05Z
NCT04954157,NA,7/6/2021,NA,NA,11/15/2021,7/6/2021,7/8/2021,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/16/2021,Estimate,29-Jun-20,Actual,6/29/2020,Nov-21,11/30/2021,28-Feb-22,Anticipated,2/28/2022,29-Jan-22,Anticipated,1/29/2022,NA,Interventional,NA,NA,Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients,Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients,Recruiting,NA,Not Applicable,100,Anticipated,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:55:26Z,2021-11-17T09:55:26Z
NCT04723537,NA,1/18/2021,NA,NA,11/15/2021,1/21/2021,1/25/2021,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/16/2021,Estimate,16-Feb-21,Actual,2/16/2021,Nov-21,11/30/2021,Sep-22,Anticipated,9/30/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,"Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease","Phase 2/3 Study of Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease","Active, not recruiting",NA,Phase 2/Phase 3,310,Anticipated,RedHill Biopharma Limited,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:57:45Z,2021-11-17T09:57:45Z
NCT04828668,NA,3/10/2021,NA,NA,11/12/2021,4/1/2021,4/2/2021,Actual,NA,NA,NA,NA,NA,NA,11/12/2021,11/16/2021,Estimate,2-Apr-21,Actual,4/2/2021,Nov-21,11/30/2021,30-Nov-22,Anticipated,11/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,"""BAC-PAC""",NA,Study to Evaluate Benefits & Safety of Endourage Formula Câ„¢ Oral Drops in People With Post-Acute COVID-19 Syndrome.,"A Single-Blind, Randomized, Placebo Controlled, Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula Câ„¢ Sublingual Drops in People With Post -Acute COVID-19 Syndrome (PACS).","Active, not recruiting",NA,Not Applicable,60,Anticipated,"Endourage, LLC",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:56:46Z,2021-11-17T09:56:46Z
NCT04723446,NA,1/5/2021,NA,NA,11/15/2021,1/22/2021,1/25/2021,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/16/2021,Estimate,19-May-21,Actual,5/19/2021,Nov-21,11/30/2021,25-Oct-21,Actual,10/25/2021,25-Oct-21,Actual,10/25/2021,NA,Interventional,COVID-19,NA,Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva,Efficacy of Three Antimicrobial Mouthwashes in Reducing SARS-CoV-2 Viral Load in the Saliva of Patients Diagnosed With COVID-19: A Pilot Study,Completed,NA,Not Applicable,54,Actual,Queen Mary University of London,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Aggregated/collective data regarding the efficacy of the different mouthwashes will be shared with the scientific community as a de-identified/coded information,2021-11-17T09:57:46Z,2021-11-17T09:57:46Z
NCT05124132,NA,11/15/2021,NA,NA,11/15/2021,11/15/2021,11/17/2021,Estimate,NA,NA,NA,NA,NA,NA,11/15/2021,11/17/2021,Estimate,Jan-22,Anticipated,1/31/2022,Nov-21,11/30/2021,Aug-26,Anticipated,8/31/2026,Aug-26,Anticipated,8/31/2026,NA,Interventional,MEDEX-2,NA,Resilience and Brain Health of Older Adults During the COVID-19 Pandemic (MEDEX-2),Resilience and Brain Health of Older Adults During the COVID-19 Pandemic (MEDEX-2),Enrolling by invitation,NA,Not Applicable,468,Anticipated,Washington University School of Medicine,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Contact PI. Estimated date of availability December 2026.,2021-11-18T11:22:34Z,2021-11-18T11:22:34Z
NCT04652596,NA,11/30/2020,NA,NA,11/14/2021,12/2/2020,12/3/2020,Actual,NA,NA,NA,NA,NA,NA,11/14/2021,11/16/2021,Estimate,8-Feb-21,Actual,2/8/2021,Nov-21,11/30/2021,Oct-22,Anticipated,10/31/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Reducing Food Insecurity During COVID-19,Comparative Effectiveness of Two Interventions to Reduce Food Insecurity During the COVID-19 Pandemic,Enrolling by invitation,NA,Not Applicable,250,Anticipated,Boston Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:58:16Z,2021-11-17T09:58:16Z
NCT04347681,NA,4/8/2020,NA,NA,11/14/2021,4/12/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,11/14/2021,11/16/2021,Estimate,18-Apr-20,Actual,4/18/2020,Nov-21,11/30/2021,16-Nov-20,Actual,11/16/2020,1-Nov-20,Actual,11/1/2020,NA,Interventional,NA,NA,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Completed,NA,Phase 2,575,Actual,King Fahad Specialist Hospital Dammam,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T10:00:47Z,2021-11-17T10:00:47Z
NCT05087329,NA,10/19/2021,NA,NA,11/9/2021,10/19/2021,10/21/2021,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/17/2021,Estimate,5-May-21,Actual,5/5/2021,Nov-21,11/30/2021,May-22,Anticipated,5/31/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,CALMS,NA,Mindfulness Practice in Pregnancy as an Intervention to Decrease Prenatal Stress During the COVID-19 Pandemic,Mindfulness Practice in Pregnancy as an Intervention to Decrease Prenatal Stress During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,248,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-18T11:24:49Z,2021-11-18T11:24:49Z
NCT05113862,NA,11/5/2021,NA,NA,11/9/2021,11/8/2021,11/9/2021,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/17/2021,Estimate,Dec-21,Anticipated,12/31/2021,Nov-21,11/30/2021,Nov-22,Anticipated,11/30/2022,Oct-22,Anticipated,10/31/2022,NA,Interventional,naNO-COVID,NA,Evaluation of Safety and Immunogenicity of a T-Cell Priming Peptide Vaccine Against Coronavirus COVID-19,"A Phase-I, Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against Coronavirus COVID-19 in Healthy Adults in Switzerland",Recruiting,NA,Phase 1,26,Anticipated,Emergex Vaccines Holding Ltd.,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 12 months of study completion,Peer-reviewed publication,NA,Yes,"The Investigators will be involved in writing and /or reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study.

Apart from the obvious flaws to conduct of the study, which may preclude data publication, safety and efficacy data will be published under the supervision and authorisation of the PI and Sponsor.

Publication will include as much individual level data as possible to ensure reproducibility of results without compromising participant privacy.",2021-11-18T11:24:04Z,2021-11-18T11:24:04Z
NCT04921228,NA,5/20/2021,NA,NA,11/16/2021,6/9/2021,6/10/2021,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/17/2021,Estimate,8-Nov-21,Actual,11/8/2021,Nov-21,11/30/2021,1-Apr-22,Anticipated,4/1/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,NA,NA,Biofeedback for CHAMPS,Heart Rate Variability Biofeedback in Healthcare Providers During COVID-19: A Pilot Feasibility Study,Recruiting,NA,Not Applicable,28,Anticipated,Villanova University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,When available,NA,NA,Yes,Data will be shared with investigators who contact the PI after establishing terms of use and collaborative agreement,2021-11-18T11:27:24Z,2021-11-18T11:27:24Z
NCT04870593,NA,4/28/2021,NA,NA,11/16/2021,4/29/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/17/2021,Estimate,17-Apr-21,Actual,4/17/2021,Nov-21,11/30/2021,10-Jul-23,Anticipated,7/10/2023,10-Jul-23,Anticipated,7/10/2023,NA,Interventional,NA,NA,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,"Active, not recruiting",NA,Not Applicable,3006,Actual,"National Bureau of Economic Research, Inc.",,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:27:46Z,2021-11-18T11:27:46Z
NCT05037110,NA,9/2/2021,NA,NA,11/9/2021,9/3/2021,9/8/2021,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/17/2021,Estimate,25-Oct-21,Actual,10/25/2021,Nov-21,11/30/2021,Jun-23,Anticipated,6/30/2023,Jun-23,Anticipated,6/30/2023,NA,Interventional,CAPS,NA,Physical Activity and Smell Trainings to Help Individuals With Coronavirus Disease (COVID-19) Recover From Persistent Smell and Taste Impairments - A Pilot Study,Physical Activity and Sensory Trainings to Help COVID-19 Patients Recover From Persistent Smell and Taste Impairments - A Pilot Study,Recruiting,NA,Not Applicable,75,Anticipated,UniversitÃ© de MontrÃ©al,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The analyses will be centralized in Dr. Mathieu's laboratory and collaborations are welcomed.,2021-11-18T11:25:55Z,2021-11-18T11:25:55Z
NCT04979858,NA,7/22/2021,NA,NA,11/16/2021,7/22/2021,7/28/2021,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/17/2021,Estimate,6-Sep-21,Actual,9/6/2021,Nov-21,11/30/2021,1-Feb-22,Anticipated,2/1/2022,30-Oct-21,Actual,10/30/2021,NA,Interventional,NA,NA,Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask,Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask for Community Use,Recruiting,NA,Not Applicable,200,Anticipated,Georgia Institute of Technology,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-18T11:26:43Z,2021-11-18T11:26:43Z
NCT04913675,NA,5/27/2021,NA,NA,11/9/2021,6/2/2021,6/4/2021,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/17/2021,Estimate,10-Jun-21,Actual,6/10/2021,Nov-21,11/30/2021,Aug-22,Anticipated,8/31/2022,18-Sep-21,Actual,9/18/2021,NA,Interventional,NA,NA,Intramuscular VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19,"A Phase 3 Randomized, Multi-center, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Monoclonal Antibody VIR-7831 (Sotrovimab) Given Intramuscularly Versus Intravenously for the Treatment of Mild/Moderate Coronavirus Disease 2019 (COVID-19) in High-risk Non-hospitalized Patients.","Active, not recruiting",NA,Phase 3,983,Actual,"Vir Biotechnology, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:27:27Z,2021-11-18T11:27:27Z
NCT04640168,NA,11/19/2020,NA,NA,11/16/2021,11/19/2020,11/23/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/17/2021,Estimate,24-Nov-20,Actual,11/24/2020,15-Apr-21,4/15/2021,18-Jun-21,Actual,6/18/2021,18-May-21,Actual,5/18/2021,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4)",Completed,NA,Phase 3,4074,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:29:44Z,2021-11-18T11:29:44Z
NCT04793464,NA,2/25/2021,NA,NA,11/9/2021,3/10/2021,3/11/2021,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/17/2021,Estimate,4-Feb-21,Actual,2/4/2021,Nov-21,11/30/2021,31-Mar-23,Anticipated,3/31/2023,31-Aug-22,Anticipated,8/31/2022,NA,Interventional,OSJP,NA,COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos),Scaling Up SARS-CoV-2 Testing to Serve Latinx Communities,Recruiting,NA,Not Applicable,3600,Anticipated,University of Oregon,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,IPD will be shared in accordance with timeframes set by the RADX-UP CDCC,The RADX-UP CDCC will make these determinations,https://radx-up.org/about/,Yes,We will share IPD with the RADx-Up CDCC. All Tier 1 data elements required by the CDCC will be shared.,2021-11-18T11:28:30Z,2021-11-18T11:28:30Z
NCT04828538,NA,3/12/2021,NA,NA,11/9/2021,3/31/2021,4/2/2021,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/17/2021,Estimate,1-Jan-21,Actual,1/1/2021,Nov-21,11/30/2021,30-Nov-21,Anticipated,11/30/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NUTROVID,NA,"Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19","Prevent and Treat Double-Blind Factorial Randomized Trials of Daily Oral Vitamin D, Omega 3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19","Active, not recruiting",NA,Not Applicable,1800,Anticipated,Hospital de la Soledad,,8,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:28:12Z,2021-11-18T11:28:12Z
NCT04828434,NA,3/23/2021,NA,NA,11/9/2021,3/31/2021,4/2/2021,Actual,NA,NA,NA,NA,NA,NA,11/9/2021,11/17/2021,Estimate,1-Apr-21,Actual,4/1/2021,Jun-21,6/30/2021,1-Sep-25,Anticipated,9/1/2025,1-Apr-23,Anticipated,4/1/2023,NA,Interventional,V-iCST,NA,Virtual Individual Cognitive Stimulation Therapy: a Proof of Concept Study,Virtual CST - A Collaborative Proof of Concept Study With FaceCog HK in Response to the Covid-19 Pandemic,Recruiting,NA,Not Applicable,34,Anticipated,"University College, London",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Upon study completion.,Email authors.,NA,Yes,"Study results will be published in peer-reviewed journals, doctoral theses and presented at conferences, and disseminated to the public through information sheets. Participants who indicate their interest in receiving further information regarding dissemination will be sent a letter with the main findings of the study upon completion.",2021-11-18T11:28:13Z,2021-11-18T11:28:13Z
NCT04384965,NA,5/8/2020,NA,NA,11/16/2021,5/9/2020,5/12/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/17/2021,Estimate,12-May-20,Actual,5/12/2020,Nov-21,11/30/2021,1-Nov-22,Anticipated,11/1/2022,1-May-22,Anticipated,5/1/2022,NA,Interventional,NA,NA,Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,A Novel and Practical Accelerated Intermittent Theta Burst Protocol as a Substitute for Depressed Patients Needing Electroconvulsive Therapy During the COVID-19 Pandemic,"Active, not recruiting",NA,Not Applicable,176,Actual,Centre for Addiction and Mental Health,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:32:00Z,2021-11-18T11:32:00Z
NCT05126563,NA,11/12/2021,NA,NA,11/17/2021,11/17/2021,11/19/2021,Estimate,NA,NA,NA,NA,NA,NA,11/17/2021,11/19/2021,Estimate,20-Dec-21,Anticipated,12/20/2021,Nov-21,11/30/2021,20-Dec-25,Anticipated,12/20/2025,20-Dec-23,Anticipated,12/20/2023,NA,Interventional,HBPCOVID02,NA,Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome,"A Randomized, Double-blinded, Single-center, Phase 2 Efficacy, and Safety Study of Allogeneic HB-adMSCs for the Treatment of Patients With Chronic Post-COVID-19 Syndrome.",Recruiting,NA,Phase 2,80,Anticipated,Hope Biosciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:22:06Z,2021-11-19T20:22:06Z
NCT05126628,NA,11/7/2021,NA,NA,11/17/2021,11/17/2021,11/19/2021,Estimate,NA,NA,NA,NA,NA,NA,11/17/2021,11/19/2021,Estimate,6-Mar-21,Actual,3/6/2021,Nov-21,11/30/2021,15-Apr-21,Actual,4/15/2021,16-Mar-21,Actual,3/16/2021,NA,Interventional,NA,NA,The South Proxa-Rescue AndroCoV Trial Against COVID-19,Proxalutamide Treatment for Hospitalized COVID-19 Patients in Southern Brazil - The South Proxa-Rescue AndroCoV Trial,Completed,NA,Phase 3,133,Actual,Corpometria Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:22:03Z,2021-11-19T20:22:03Z
NCT05126602,NA,11/12/2021,NA,NA,11/17/2021,11/17/2021,11/19/2021,Estimate,NA,NA,NA,NA,NA,NA,11/17/2021,11/19/2021,Estimate,1-Apr-21,Actual,4/1/2021,Nov-21,11/30/2021,1-Nov-21,Actual,11/1/2021,30-Sep-21,Actual,9/30/2021,NA,Interventional,NA,NA,Vitamin D Supplementation and Clinical Improvement in COVID-19,"Vitamin D Supplementation and Changes of Hematology Parameter, Coagulation Profile, and Clinical Improvement Among COVID-19 Patients",Completed,NA,Not Applicable,60,Actual,Hasanuddin University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No data sharing will be done,2021-11-19T20:22:04Z,2021-11-19T20:22:04Z
NCT05125874,NA,11/9/2021,NA,NA,11/14/2021,11/14/2021,11/18/2021,Actual,NA,NA,NA,NA,NA,NA,11/14/2021,11/18/2021,Actual,30-Sep-21,Actual,9/30/2021,Nov-21,11/30/2021,30-Sep-23,Anticipated,9/30/2023,30-Aug-23,Anticipated,8/30/2023,NA,Interventional,COVID-19,NA,Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization,A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines,"Active, not recruiting",NA,Not Applicable,45,Actual,Livzon Pharmaceutical Group Inc.,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:22:43Z,2021-11-19T20:22:43Z
NCT05125562,NA,11/11/2021,NA,NA,11/16/2021,11/16/2021,11/18/2021,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/18/2021,Actual,7-May-21,Actual,5/7/2021,Nov-21,11/30/2021,7-Aug-22,Anticipated,8/7/2022,7-Aug-22,Anticipated,8/7/2022,NA,Interventional,NA,NA,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial,Recruiting,NA,Phase 2,30,Anticipated,"Direct Biologics, LLC",,3,NA,NA,TRUE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:22:56Z,2021-11-19T20:22:56Z
NCT04847102,NA,4/13/2021,NA,NA,11/10/2021,4/13/2021,4/15/2021,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/18/2021,Actual,22-Jul-21,Actual,7/22/2021,Nov-21,11/30/2021,30-May-23,Anticipated,5/30/2023,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above,"A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older",Recruiting,NA,Phase 3,28000,Anticipated,"Walvax Biotechnology Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:30:24Z,2021-11-19T20:30:24Z
NCT05049226,NA,9/14/2021,NA,NA,11/11/2021,9/16/2021,9/20/2021,Actual,NA,NA,NA,NA,NA,NA,11/11/2021,11/19/2021,Estimate,24-Sep-21,Actual,9/24/2021,Nov-21,11/30/2021,Sep-23,Anticipated,9/30/2023,Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine,"A Randomized, Observer-blind Trial to Assess the Immunogenicity and Safety of Third Dose Vaccination With AstraZeneca COVID-19 Vaccine or Pfizer/BioNTech COVID-19 Vaccine Among Thai Adults Receiving Two Doses of Sinovac",Enrolling by invitation,NA,Phase 2,1320,Anticipated,Mahidol University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,2 years,as document attach when completed study in NCT clinicaltrials.gov,NA,Yes,data or left over specimen will be shared for future study ONLY subject who consent allow using their data/specimens. Sharing will be done without personnel identification,2021-11-19T20:26:51Z,2021-11-19T20:26:51Z
NCT05047718,NA,9/14/2021,NA,NA,11/17/2021,9/14/2021,9/17/2021,Actual,NA,NA,NA,NA,NA,NA,11/17/2021,11/18/2021,Actual,5-Oct-21,Actual,10/5/2021,Nov-21,11/30/2021,3-Mar-23,Anticipated,3/3/2023,1-Sep-22,Anticipated,9/1/2022,NA,Interventional,COVIMMUNAGE,NA,Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19,Factors Influencing the COVID-19 Vaccine Immune Response (Reactogenicity and Immunogenicity) According to Age and Presence or Not of a Past History of COVID-19,Recruiting,NA,Phase 4,200,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:26:54Z,2021-11-19T20:26:54Z
NCT04869358,NA,4/29/2021,NA,NA,11/10/2021,4/29/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/18/2021,Actual,27-May-21,Actual,5/27/2021,Nov-21,11/30/2021,31-May-23,Anticipated,5/31/2023,31-May-22,Anticipated,5/31/2022,NA,Interventional,KYRIOS,NA,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab,Tracking the Immune Response to SARS-CoV-2 modRNA Vaccines in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS),Recruiting,NA,Phase 4,40,Anticipated,Novartis,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.",2021-11-19T20:30:04Z,2021-11-19T20:30:04Z
NCT04822701,NA,3/29/2021,NA,NA,11/18/2021,3/29/2021,3/30/2021,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,11/19/2021,Estimate,21-Apr-21,Actual,4/21/2021,Nov-21,11/30/2021,4-Oct-21,Actual,10/4/2021,2-Jul-21,Actual,7/2/2021,NA,Interventional,NA,NA,A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19,"A Phase II/III Seamless, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential Study to Evaluate Efficacy, Safety and Tolerability of BI 767551 for the Treatment of Symptomatic, Non-hospitalized Adults With Mild to Moderate COVID-19.",Terminated,NA,Phase 2/Phase 3,5,Actual,Boehringer Ingelheim,,6,NA,not due to safety reasons,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"After all regulatory activities are completed in the United States (US) and European Union (EU) for the product and indication, and after the primary manuscript has been accepted for publication.","For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.",https://www.mystudywindow.com/msw/datasharing,Yes,"After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed ""Document Sharing Agreement"". Also, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

The data shared are the raw clinical study data sets.",2021-11-19T20:30:52Z,2021-11-19T20:30:52Z
NCT04949061,NA,7/1/2021,NA,NA,11/17/2021,7/1/2021,7/2/2021,Actual,NA,NA,NA,NA,NA,NA,11/17/2021,11/18/2021,Actual,17-Nov-21,Actual,11/17/2021,Jul-21,7/31/2021,Dec-22,Anticipated,12/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,The Effectiveness of Culturally Adapted Cognitive Behavioral Intervention Among COVID-19 Survivors,Culturally Adapted Cognitive Behavioral Intervention to Reduce Psychological Distress Among COVID-19 Survivors: A Randomized Controlled Trial,Recruiting,NA,Not Applicable,86,Anticipated,KoÃ§ University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:28:29Z,2021-11-19T20:28:29Z
NCT04663945,NA,12/8/2020,NA,NA,11/16/2021,12/10/2020,12/11/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/18/2021,Actual,11-Dec-20,Actual,12/11/2020,Nov-21,11/30/2021,31-Dec-21,Anticipated,12/31/2021,12-Aug-21,Actual,8/12/2021,NA,Interventional,AFTER,NA,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID Survivors,"Active, not recruiting",NA,Not Applicable,45,Anticipated,"University of Colorado, Denver",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:33:05Z,2021-11-19T20:33:05Z
NCT04800133,NA,3/1/2021,NA,NA,11/10/2021,3/15/2021,3/16/2021,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/18/2021,Actual,8-May-21,Actual,5/8/2021,Nov-21,11/30/2021,31-Mar-25,Anticipated,3/31/2025,31-Mar-25,Anticipated,3/31/2025,NA,Interventional,COVAC,NA,Covid-19 Vaccination in Adolescents and Children,To Compare the Reactogenicity and Immunogenicity of Recommended COVID-19 Vaccines in Young Adolescents and Children in Hong Kong,Recruiting,NA,Phase 2,1000,Anticipated,The University of Hong Kong,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:31:12Z,2021-11-19T20:31:12Z
NCT04798027,NA,3/11/2021,NA,NA,11/18/2021,3/12/2021,3/15/2021,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,11/19/2021,Estimate,12-Mar-21,Actual,3/12/2021,18-Nov-21,11/18/2021,2-Nov-22,Anticipated,11/2/2022,2-Nov-22,Anticipated,11/2/2022,NA,Interventional,VAW00001,NA,Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",NA,Phase 1/Phase 2,182,Actual,Sanofi,,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-11-19T20:31:15Z,2021-11-19T20:31:15Z
NCT04729595,NA,1/25/2021,NA,NA,11/16/2021,1/26/2021,1/28/2021,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/18/2021,Actual,1-Sep-21,Actual,9/1/2021,Oct-21,10/31/2021,30-Sep-22,Anticipated,9/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.,"A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection",Recruiting,NA,Phase 2/Phase 3,248,Anticipated,Adamis Pharmaceuticals Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-19T20:32:21Z,2021-11-19T20:32:21Z
NCT04705597,NA,1/4/2021,NA,NA,11/12/2021,1/8/2021,1/12/2021,Actual,NA,NA,NA,NA,NA,NA,11/12/2021,11/19/2021,Estimate,18-Mar-21,Actual,3/18/2021,Nov-21,11/30/2021,Sep-22,Anticipated,9/30/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure","A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19",Recruiting,NA,Phase 2,312,Anticipated,"BioAge Labs, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:32:38Z,2021-11-19T20:32:38Z
NCT04510194,NA,8/7/2020,NA,NA,11/16/2021,8/10/2020,8/12/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/18/2021,Actual,1-Jan-21,Actual,1/1/2021,Nov-21,11/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19),COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Phase 3,1160,Anticipated,University of Minnesota,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-19T20:35:21Z,2021-11-19T20:35:21Z
NCT04584567,NA,10/6/2020,NA,NA,11/18/2021,10/6/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,11/19/2021,Estimate,20-Nov-20,Actual,11/20/2020,Nov-21,11/30/2021,1-Nov-21,Actual,11/1/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,NA,NA,"OD-doxy-PNV-COVID-19 Old Drug "" DOXY "" for Prevention of New Virus "" COVID-19 """,Covid-19 Infection Prophylaxis With Low Dose of Doxycycline and Zinc in Health Care Workers,Completed,NA,Phase 3,194,Actual,"General Administration of Military Health, Tunisia",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:34:16Z,2021-11-19T20:34:16Z
NCT04539795,NA,9/3/2020,NA,NA,11/16/2021,9/3/2020,9/7/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/18/2021,Actual,25-Jan-21,Actual,1/25/2021,Nov-21,11/30/2021,29-Oct-21,Actual,10/29/2021,29-Oct-21,Actual,10/29/2021,NA,Interventional,COSTA,NA,COVID-19 Study of Safety and Tolerability of Alvelestat,"A Phase Ib/II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)",Completed,NA,Phase 1/Phase 2,15,Actual,University of Alabama at Birmingham,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:35:00Z,2021-11-19T20:35:00Z
NCT04397562,NA,5/19/2020,NA,NA,11/15/2021,5/20/2020,5/21/2020,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/18/2021,Actual,29-Apr-20,Actual,4/29/2020,Nov-20,11/30/2020,3-Aug-20,Actual,8/3/2020,3-Jul-20,Actual,7/3/2020,NA,Interventional,CORONA,NA,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19",Completed,NA,Phase 3,206,Actual,Biocad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-19T20:36:38Z,2021-11-19T20:36:38Z
NCT05126511,NA,11/17/2021,NA,NA,11/19/2021,11/18/2021,11/19/2021,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,11/22/2021,Estimate,19-Nov-21,Actual,11/19/2021,Nov-21,11/30/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19,Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19 - a Randomised Controlled Pilot Study,Recruiting,NA,Not Applicable,40,Anticipated,SchÃ¶n Klinik Berchtesgadener Land,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:37:43Z,2021-11-23T11:37:43Z
NCT04373733,NA,5/1/2020,NA,NA,11/17/2021,5/1/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,11/17/2021,11/18/2021,Actual,1-May-20,Actual,5/1/2020,Nov-21,11/30/2021,25-Jun-21,Actual,6/25/2021,25-Jun-21,Actual,6/25/2021,NA,Interventional,PIONEER,NA,Early Intervention in COVID-19: Favipiravir Verses Standard Care,A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir and StaNdard Care vErsEs Standard CaRe,Completed,NA,Phase 3,502,Actual,Chelsea and Westminster NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Research team wishes to enable any meta-analyses of COVID-19 trials making appropriate requests. No plan to share IPD has been made at this time.,2021-11-19T20:36:57Z,2021-11-19T20:36:57Z
NCT04346615,NA,4/9/2020,NA,NA,11/18/2021,4/10/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,11/19/2021,Estimate,25-Apr-20,Actual,4/25/2020,Nov-21,11/30/2021,30-Apr-22,Anticipated,4/30/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,"BHV3500-203: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant* (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen",Recruiting,NA,Phase 2/Phase 3,120,Anticipated,"Biohaven Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:37:06Z,2021-11-19T20:37:06Z
NCT04336410,NA,4/3/2020,NA,NA,11/18/2021,4/3/2020,4/7/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,11/19/2021,Estimate,3-Apr-20,Actual,4/3/2020,Nov-21,11/30/2021,Jan-22,Anticipated,1/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","Active, not recruiting",NA,Phase 1,120,Actual,Inovio Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-11-19T20:37:08Z,2021-11-19T20:37:08Z
NCT04327206,NA,3/25/2020,NA,NA,11/10/2021,3/27/2020,3/31/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2021,11/18/2021,Actual,30-Mar-20,Actual,3/30/2020,Nov-21,11/30/2021,30-Mar-22,Anticipated,3/30/2022,20-Nov-21,Anticipated,11/20/2021,NA,Interventional,BRACE,NA,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers (BRACE) Trial,"Active, not recruiting",NA,Phase 3,10078,Anticipated,Murdoch Childrens Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:

Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2021-11-19T20:37:16Z,2021-11-19T20:37:16Z
NCT04405934,NA,5/7/2020,NA,NA,11/18/2021,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,11/19/2021,Estimate,15-Oct-20,Actual,10/15/2020,Nov-21,11/30/2021,8-Oct-21,Actual,10/8/2021,26-Apr-21,Actual,4/26/2021,NA,Interventional,COG-UK HOCI,NA,COG-UK Project Hospital-Onset COVID-19 Infections Study,"A Phase III Prospective, Interventional, Cohort, Superiority Study to Evaluate the Benefit of Rapid COVID-19 Genomic Sequencing (the COVID-19 GENOMICS UK Project) on Infection Control in Preventing the Spread of the Virus in United Kingdom NHS Hospitals",Completed,NA,Not Applicable,2170,Actual,"University College, London",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:36:30Z,2021-11-19T20:36:30Z
NCT04399967,NA,5/19/2020,NA,NA,11/11/2021,5/19/2020,5/22/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2021,11/19/2021,Estimate,13-Jun-20,Actual,6/13/2020,Nov-21,11/30/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-21,Actual,6/30/2021,NA,Interventional,QTW2020,NA,"COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020","Building Capacity and Promoting Smoking Cessation in the Community Via ""Quit to Win"" Contest 2020: a Single-blind Randomized Controlled Trial on COVID-19 Related Brief Advice and Personalized Chat-based Intervention for Smoking Cessation","Active, not recruiting",NA,Not Applicable,842,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:36:35Z,2021-11-19T20:36:35Z
NCT05128721,NA,11/12/2021,NA,NA,11/18/2021,11/18/2021,11/22/2021,Estimate,NA,NA,NA,NA,NA,NA,11/18/2021,11/22/2021,Estimate,14-Nov-21,Actual,11/14/2021,Nov-21,11/30/2021,23-May-23,Anticipated,5/23/2023,23-Feb-23,Anticipated,2/23/2023,NA,Interventional,NA,NA,Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19),"A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Vaccine Against COVID-19 in Healthy Adults",Recruiting,NA,Phase 1,72,Anticipated,"National Research Centre, Egypt",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,About one year after completion of the trial,Data will be shared upon individual request by contacting the sponsor of the trial.,NA,Yes,Data will be shared upon individual request.,2021-11-23T11:37:12Z,2021-11-23T11:37:12Z
NCT05128643,NA,11/18/2021,NA,NA,11/18/2021,11/18/2021,11/22/2021,Estimate,NA,NA,NA,NA,NA,NA,11/18/2021,11/22/2021,Estimate,17-Sep-21,Actual,9/17/2021,Nov-21,11/30/2021,12-Oct-22,Anticipated,10/12/2022,12-Apr-22,Anticipated,4/12/2022,NA,Interventional,NA,NA,Clinical Study on the Immune Program of Recombinant Novel Coronavirusï¼ˆCOVID-19) Vaccine (CHO Cell),"Clinical Study on the Immunogenicity and Safety of the Recombinant New Coronavirusï¼ˆCOVID-19ï¼‰Vaccine (CHO Cell) 0, 1, and 6 Months Immunization Program in People 18 Years of Age and Older",Recruiting,NA,Phase 3,300,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:37:15Z,2021-11-23T11:37:15Z
NCT04839146,NA,3/11/2021,NA,NA,11/18/2021,4/8/2021,4/9/2021,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,11/22/2021,Estimate,11-Mar-21,Actual,3/11/2021,Mar-21,3/31/2021,20-Dec-21,Anticipated,12/20/2021,20-Dec-21,Anticipated,12/20/2021,NA,Interventional,COUGH-1,NA,Safety and Tolerability of COVID-19 Vaccine (ABNCoV2),First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naÃ¯ve Adult Volunteers in Good Health,"Active, not recruiting",NA,Phase 1,45,Actual,Radboud University,,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:41:46Z,2021-11-23T11:41:46Z
NCT05109598,NA,11/4/2021,NA,NA,11/14/2021,11/4/2021,11/5/2021,Actual,NA,NA,NA,NA,NA,NA,11/14/2021,11/22/2021,Estimate,4-Nov-21,Actual,11/4/2021,Nov-21,11/30/2021,Mar-23,Anticipated,3/31/2023,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirusï¼ˆCOVID-19ï¼‰ Vaccine (CHO Cell),A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age.,Recruiting,NA,Phase 2,400,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:38:11Z,2021-11-23T11:38:11Z
NCT04442087,NA,6/8/2020,NA,NA,11/19/2021,6/19/2020,6/22/2020,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,11/22/2021,Estimate,19-Jun-20,Actual,6/19/2020,Nov-21,11/30/2021,30-Apr-21,Actual,4/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,FamilyPEDCOVID,NA,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Seroprevalence of Anti-SARS-CoV2 Among Children According to Parents' SARS-CoV2 Serological Status. Study in a Hospital Population Assistance Publique-HÃ´pitaux Paris,Completed,NA,Not Applicable,563,Actual,Assistance Publique - HÃ´pitaux de Paris,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:44:47Z,2021-11-23T11:44:47Z
NCT04742595,NA,2/3/2021,NA,NA,11/19/2021,2/5/2021,2/8/2021,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,11/22/2021,Estimate,18-Dec-20,Actual,12/18/2020,Nov-21,11/30/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Viral Specific T Cell Therapy for COVID-19 Related Pneumonia,"Administration of Expanded, Most Closely HLA Matched SARS-CoV-2-Specific T Cells for the Treatment of COVID-19 in Patients With Cancer",Recruiting,NA,Early Phase 1,16,Anticipated,M.D. Anderson Cancer Center,,1,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:42:37Z,2021-11-23T11:42:37Z
NCT04558450,NA,8/31/2020,NA,NA,11/15/2021,9/21/2020,9/22/2020,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/22/2021,Estimate,21-Sep-20,Actual,9/21/2020,Nov-21,11/30/2021,Mar-33,Anticipated,3/31/2033,Mar-23,Anticipated,3/31/2023,NA,Interventional,CARTESIAN,NA,Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN),Covid-19 Effects on ARTErial StIffness and Vascular AgiNg,Recruiting,NA,Not Applicable,360,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,One year after the last publication,"Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team. The founder could be involved in the decision.

Teams wishing obtain IPD must meet the sponsor and PI team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization.",NA,Yes,Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared,2021-11-23T11:44:11Z,2021-11-23T11:44:11Z
NCT04765371,NA,2/18/2021,NA,NA,11/19/2021,2/19/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,11/22/2021,Estimate,3-Mar-21,Actual,3/3/2021,Nov-21,11/30/2021,Oct-23,Anticipated,10/31/2023,Oct-23,Anticipated,10/31/2023,NA,Interventional,COPreDex,NA,"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19","Comparison Between Prednisolone and Dexamethasone on D28 Mortality in Patients on Oxygen Therapy, With CoViD-19: Multicenter, Randomized, Open-label Non-inferiority Study",Recruiting,NA,Phase 3,220,Anticipated,Centre Hospitalier RenÃ© Dubos,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:42:25Z,2021-11-23T11:42:25Z
NCT04458363,NA,6/25/2020,NA,NA,11/13/2021,7/2/2020,7/7/2020,Actual,NA,NA,NA,NA,NA,NA,11/13/2021,11/22/2021,Estimate,4-Jul-20,Actual,7/4/2020,Nov-21,11/30/2021,1-Sep-20,Actual,9/1/2020,1-Sep-20,Actual,9/1/2020,NA,Interventional,NA,NA,Convalescent Plasma in Pediatric COVID-19,Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients: A Feasibility Study,Completed,NA,Early Phase 1,3,Actual,Emory University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:44:40Z,2021-11-23T11:44:40Z
NCT04373460,NA,4/30/2020,NA,NA,11/15/2021,4/30/2020,5/4/2020,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/22/2021,Estimate,3-Jun-20,Actual,6/3/2020,Oct-21,10/31/2021,31-Jan-23,Anticipated,1/31/2023,21-Dec-22,Anticipated,12/21/2022,NA,Interventional,CSSC-004,NA,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19,"Active, not recruiting",NA,Phase 2,1344,Anticipated,Johns Hopkins University,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,After publication of initial study manuscript,Public,NA,Yes,"Anonymized individual participant data (IPD) collected in this study, including data dictionaries, will be made available to other researchers after the end of the study.",2021-11-23T11:45:34Z,2021-11-23T11:45:34Z
NCT05130736,NA,9/3/2021,NA,NA,11/19/2021,11/19/2021,11/23/2021,Estimate,NA,NA,NA,NA,NA,NA,11/19/2021,11/23/2021,Estimate,1-Aug-21,Actual,8/1/2021,Nov-21,11/30/2021,31-Dec-22,Anticipated,12/31/2022,31-Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,Rehabilitation Robot in Patients With Post-Coronavirus Disease (COVID-19) Fatigue Syndrome,The Use of a Rehabilitation Robot in Patients With Post-COVID-19 Fatigue Syndrome,Recruiting,NA,Not Applicable,80,Anticipated,Poznan University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:53:58Z,2021-11-24T09:53:58Z
NCT05130671,NA,11/21/2021,NA,NA,11/21/2021,11/21/2021,11/23/2021,Estimate,NA,NA,NA,NA,NA,NA,11/21/2021,11/23/2021,Estimate,25-Oct-21,Actual,10/25/2021,Nov-21,11/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"Nutritional Supplementation of Vitamin D, Quercetin and Curcumin With Standard of Care for Managing Mild Early Symptoms of COVID-19","Adjuvant Combination of Vitamin D, Quercetin and Curcumin Supplements With Standard of Care for Managing Mild Early Symptoms of COVID-19",Recruiting,NA,Not Applicable,50,Anticipated,King Edward Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T09:54:01Z,2021-11-24T09:54:01Z
NCT05130541,NA,5/4/2021,NA,NA,11/21/2021,11/21/2021,11/23/2021,Estimate,NA,NA,NA,NA,NA,NA,11/21/2021,11/23/2021,Estimate,1-Jun-20,Actual,6/1/2020,Nov-21,11/30/2021,1-May-21,Actual,5/1/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,PREACHR,NA,Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study,Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study,Completed,NA,Not Applicable,219,Actual,New York Hospital Queens,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Will consider compelling cases if appropriately deidentified and, of course, if reviewers or journal editors request",2021-11-24T09:54:06Z,2021-11-24T09:54:06Z
NCT05107557,NA,11/2/2021,NA,NA,11/22/2021,11/2/2021,11/4/2021,Actual,NA,NA,NA,NA,NA,NA,11/22/2021,11/23/2021,Estimate,5-Nov-21,Actual,11/5/2021,Nov-21,11/30/2021,5-May-22,Anticipated,5/5/2022,5-Dec-21,Anticipated,12/5/2021,NA,Interventional,NA,NA,"Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)","A Randomized and Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine (Vero Cell) in Children Aged 3-5 Years Old",Recruiting,NA,Phase 4,520,Anticipated,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T09:54:58Z,2021-11-24T09:54:58Z
NCT05043376,NA,9/11/2021,NA,NA,11/21/2021,9/11/2021,9/14/2021,Actual,NA,NA,NA,NA,NA,NA,11/21/2021,11/23/2021,Estimate,10-Sep-21,Actual,9/10/2021,Nov-21,11/30/2021,21-Nov-21,Actual,11/21/2021,21-Nov-21,Actual,11/21/2021,NA,Interventional,NA,NA,Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Mild-to-moderate COVID-19,"A Randomized, Open-label, and Controlled Clinical Trial to Study the Adjuvant Treatment Benefits of Probiotic Streptococcus Salivarius K12 to Prevent/Reduce Lung Inflammation in Mild-to-moderate Hospitalised Patients With COVID-19",Completed,NA,Not Applicable,50,Actual,King Edward Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:56:19Z,2021-11-24T09:56:19Z
NCT04954287,NA,6/30/2021,NA,NA,11/15/2021,6/30/2021,7/8/2021,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/23/2021,Estimate,6-Aug-21,Actual,8/6/2021,Nov-21,11/30/2021,Feb-23,Anticipated,2/28/2023,Mar-22,Anticipated,3/31/2022,NA,Interventional,CVXGA1-001,NA,Phase 1 Study of Intranasal PIV5-vectored COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of Intranasal Parainfluenza Virus Type 5-SARS-CoV-2 S Vaccine (CVXGA1) in Healthy Adults Aged 18 to 75 Years",Recruiting,NA,Phase 1,80,Anticipated,CyanVac LLC,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"5 years, beginning as soon as possible (but no later than 12 months) after article publication",Data will be made available to investigators and institutions upon request. Requests should be directed to the CyanVac authors of the publication(s).,NA,Yes,"De-identified IPD underlying the results reported in any published articles (text, tables, figures, appendices) will be shared.",2021-11-24T09:57:22Z,2021-11-24T09:57:22Z
NCT05028361,NA,8/30/2021,NA,NA,11/15/2021,8/30/2021,8/31/2021,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/23/2021,Estimate,4-Oct-21,Actual,10/4/2021,Nov-21,11/30/2021,14-Jul-22,Anticipated,7/14/2022,5-Apr-22,Anticipated,4/5/2022,NA,Interventional,NA,NA,Simultaneous mRNA COVID-19 and IIV4 Vaccination Study,Safety of Simultaneous Versus Sequential Administration of mRNA COVID-19 Vaccines and Quadrivalent Inactivated Influenza Vaccine (IIV4) in Adults and Adolescents: A Randomized Observer Blinded Study,Recruiting,NA,Phase 4,450,Anticipated,Duke University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:56:36Z,2021-11-24T09:56:36Z
NCT04873401,NA,3/24/2021,NA,NA,11/19/2021,5/3/2021,5/5/2021,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,11/23/2021,Estimate,10-Jun-21,Actual,6/10/2021,Nov-21,11/30/2021,31-Oct-22,Anticipated,10/31/2022,31-Oct-22,Anticipated,10/31/2022,NA,Interventional,NA,NA,Leveraging Social Networks to Increase COVID-19 Testing Uptake,Leveraging Social Networks to Increase COVID-19 Testing Uptake: A Comparison of Credible Messenger and Chain Referral Recruitment Approaches,Recruiting,NA,Not Applicable,500,Anticipated,New York State Psychiatric Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T09:58:15Z,2021-11-24T09:58:15Z
NCT05022329,NA,8/23/2021,NA,NA,11/22/2021,8/25/2021,8/26/2021,Actual,NA,NA,NA,NA,NA,NA,11/22/2021,11/23/2021,Estimate,30-Sep-21,Actual,9/30/2021,Nov-21,11/30/2021,30-Sep-23,Anticipated,9/30/2023,30-Sep-22,Anticipated,9/30/2022,NA,Interventional,BOOST KIDNEY,NA,COVID-19 Vaccine Boosters in Patients With CKD,A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 Versus mRNA( Messenger Ribonucleic Acid) -1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response Following COVID-19 ( Corona Virus Disease of 2019)Vaccination,Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Sunnybrook Health Sciences Centre,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-11-24T09:56:43Z,2021-11-24T09:56:43Z
NCT04847362,NA,4/12/2021,NA,NA,11/22/2021,4/14/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,11/22/2021,11/23/2021,Estimate,11-Apr-21,Actual,4/11/2021,Nov-21,11/30/2021,30-Jan-22,Anticipated,1/30/2022,22-Nov-21,Anticipated,11/22/2021,NA,Interventional,NA,NA,The Effect of Tele-Health Education Provided in the Postpartum Period in the Covid 19 Pandemic,"Investigation of the Effect of Tele-Health Education Provided in the Postpartum Period in the Covid 19 Pandemic on the Depression, Attachment and Anxiety Levels of Women: A Randomized Controlled Study",Recruiting,NA,Not Applicable,74,Anticipated,Saglik Bilimleri Universitesi,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-24T09:58:32Z,2021-11-24T09:58:32Z
NCT04830774,NA,4/1/2021,NA,NA,11/15/2021,4/1/2021,4/5/2021,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/23/2021,Estimate,15-Apr-21,Actual,4/15/2021,Nov-21,11/30/2021,31-Dec-23,Anticipated,12/31/2023,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,unCOVer-AF,NA,Natural History of COVID-19-Related Atrial Fibrillation,"Natural History and Recurrence Rate of Atrial Fibrillation After the First, COVID-19-Related Atrial Arrhythmic Episode: A Prospective Evaluation Using Continuous Cardiac Rhythm Monitoring",Recruiting,NA,Not Applicable,200,Anticipated,Texas Cardiac Arrhythmia Research Foundation,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:58:37Z,2021-11-24T09:58:37Z
NCT04590586,NA,10/14/2020,NA,NA,11/19/2021,10/14/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,11/23/2021,Estimate,24-Nov-20,Actual,11/24/2020,Nov-21,11/30/2021,3-Aug-21,Actual,8/3/2021,3-Aug-21,Actual,8/3/2021,NA,Interventional,NA,NA,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Completed,NA,Phase 3,516,Actual,Amgen,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.,"Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.",http://www.amgen.com/datasharing,Yes,De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.,2021-11-24T10:00:30Z,2021-11-24T10:00:30Z
NCT04590547,NA,10/13/2020,NA,NA,11/22/2021,10/13/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,11/22/2021,11/23/2021,Estimate,7-May-21,Actual,5/7/2021,Nov-21,11/30/2021,Sep-22,Anticipated,9/30/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19),"Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection",Recruiting,NA,Phase 2,132,Anticipated,"GeneOne Life Science, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-24T10:00:31Z,2021-11-24T10:00:31Z
NCT04377100,NA,5/5/2020,NA,NA,11/20/2021,5/5/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,11/20/2021,11/23/2021,Estimate,8-May-20,Actual,5/8/2020,19-Nov-21,11/19/2021,19-Nov-21,Actual,11/19/2021,9-Apr-21,Actual,4/9/2021,NA,Interventional,NA,NA,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses.,Completed,NA,Not Applicable,2962,Actual,National Institutes of Health Clinical Center (CC),,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T10:02:15Z,2021-11-24T10:02:15Z
NCT04353128,NA,4/16/2020,NA,NA,11/22/2021,4/17/2020,4/20/2020,Actual,NA,NA,NA,NA,NA,NA,11/22/2021,11/23/2021,Estimate,20-Apr-20,Actual,4/20/2020,Apr-20,4/30/2020,1-Dec-20,Actual,12/1/2020,1-Oct-20,Actual,10/1/2020,NA,Interventional,MeCOVID,NA,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.,Completed,NA,Phase 2/Phase 3,450,Actual,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T10:02:22Z,2021-11-24T10:02:22Z
NCT05019456,NA,8/18/2021,NA,NA,9/28/2021,8/18/2021,8/24/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,10/1/2021,Actual,9-Mar-21,Actual,3/9/2021,Sep-21,9/30/2021,25-Dec-22,Anticipated,12/25/2022,25-Dec-22,Anticipated,12/25/2022,NA,Interventional,VIC,NA,Exercise and COVID-19 Viral T-cell Immunity,The Effect of Acute Exercise on the Mobilization of SARS-CoV-2 Specific T-cells,Recruiting,NA,Not Applicable,30,Anticipated,University of Arizona,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:10:42Z,2021-12-02T02:10:42Z
NCT05133609,NA,11/1/2021,NA,NA,11/23/2021,11/23/2021,11/24/2021,Estimate,NA,NA,NA,NA,NA,NA,11/23/2021,11/24/2021,Estimate,15-Jan-21,Actual,1/15/2021,Nov-21,11/30/2021,30-Dec-23,Anticipated,12/30/2023,1-Aug-22,Anticipated,8/1/2022,NA,Interventional,NA,NA,COVID-19 VACCINE SAFETY AND EFFECTIVENESS,COVID-19 VACCINE SAFETY AND EFFECTIVENESS,Recruiting,NA,Phase 1/Phase 2,550,Anticipated,Federal University of Espirito Santo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-25T10:06:59Z,2021-11-25T10:06:59Z
NCT05133622,NA,11/23/2021,NA,NA,11/23/2021,11/23/2021,11/24/2021,Estimate,NA,NA,NA,NA,NA,NA,11/23/2021,11/24/2021,Estimate,1-Dec-21,Anticipated,12/1/2021,Nov-21,11/30/2021,25-Feb-22,Anticipated,2/25/2022,25-Feb-22,Anticipated,2/25/2022,NA,Interventional,NA,NA,Physical Fitness in Young Healthy Adults After COVID-19 Infection,"Muscle Strength, Muscle Endurance, Flexibility and Balance in Young Healthy Adults After COVID-19 Infection",Enrolling by invitation,NA,Not Applicable,118,Anticipated,Baskent University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:06:58Z,2021-11-25T10:06:58Z
NCT05132972,NA,11/23/2021,NA,NA,11/23/2021,11/23/2021,11/24/2021,Estimate,NA,NA,NA,NA,NA,NA,11/23/2021,11/24/2021,Estimate,17-Jan-21,Actual,1/17/2021,Nov-21,11/30/2021,Nov-21,Anticipated,11/30/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,UCMSC,NA,Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients,Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19,Recruiting,NA,Phase 2/Phase 3,42,Anticipated,"Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:07:33Z,2021-11-25T10:07:33Z
NCT05132933,NA,11/23/2021,NA,NA,11/23/2021,11/23/2021,11/24/2021,Estimate,NA,NA,NA,NA,NA,NA,11/23/2021,11/24/2021,Estimate,1-Oct-21,Actual,10/1/2021,Nov-21,11/30/2021,30-Dec-22,Anticipated,12/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Gas Exchange Derangement Physiopathology in Critically Ill Patients With COVID-19,Gas Exchange Derangement Physiopathology and Response to Different Levels of Positive End-expiratory Pressure in Critically Ill Patients With COVID-19,Recruiting,NA,Not Applicable,14,Anticipated,Policlinico Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-25T10:07:35Z,2021-11-25T10:07:35Z
NCT05119348,NA,11/12/2021,NA,NA,11/16/2021,11/12/2021,11/15/2021,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/24/2021,Estimate,14-Sep-20,Actual,9/14/2020,Nov-21,11/30/2021,15-Dec-21,Anticipated,12/15/2021,4-Aug-21,Actual,8/4/2021,NA,Interventional,TRACE,NA,Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments,Transmission of COVID19 in Crowded Environments,"Active, not recruiting",NA,Not Applicable,114,Actual,Desmond Tutu HIV Foundation,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There are no plans to share individual participant data with other researchers.,2021-11-25T10:08:51Z,2021-11-25T10:08:51Z
NCT05074433,NA,10/8/2021,NA,NA,11/22/2021,10/8/2021,10/12/2021,Actual,NA,NA,NA,NA,NA,NA,11/22/2021,11/24/2021,Estimate,25-Oct-21,Actual,10/25/2021,Nov-21,11/30/2021,26-Jun-23,Anticipated,6/26/2023,3-Apr-23,Anticipated,4/3/2023,NA,Interventional,NA,NA,A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants",Recruiting,NA,Phase 3,8752,Anticipated,Regeneron Pharmaceuticals,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-11-25T10:09:40Z,2021-11-25T10:09:40Z
NCT05037266,NA,9/6/2021,NA,NA,11/23/2021,9/6/2021,9/8/2021,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,11/24/2021,Estimate,20-Sep-21,Actual,9/20/2021,Sep-21,9/30/2021,30-Apr-24,Anticipated,4/30/2024,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,CoviCompare_J,NA,Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen,Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen,Recruiting,NA,Phase 4,120,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:10:32Z,2021-11-25T10:10:32Z
NCT04818320,NA,3/24/2021,NA,NA,11/15/2021,3/24/2021,3/26/2021,Actual,NA,NA,NA,NA,NA,NA,11/15/2021,11/24/2021,Estimate,16-Feb-21,Actual,2/16/2021,Nov-21,11/30/2021,13-Jul-21,Actual,7/13/2021,1-Jul-21,Actual,7/1/2021,NA,Interventional,NA,NA,Favipiravir in High-risk COVID-19 Patients,"Efficacy of Favipiravir in High Risk COVID-19 Patients: A Randomised, Open-label, Multicenter Clinical Trial",Completed,NA,Phase 3,500,Actual,"Penang Hospital, Malaysia",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:13:15Z,2021-11-25T10:13:15Z
NCT04765384,NA,2/19/2021,NA,NA,11/23/2021,2/19/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,11/24/2021,Estimate,27-Aug-21,Actual,8/27/2021,Nov-21,11/30/2021,18-Sep-24,Anticipated,9/18/2024,16-Jan-23,Anticipated,1/16/2023,NA,Interventional,HORIZON 1,NA,A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19),"An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants",Recruiting,NA,Phase 2,400,Anticipated,Janssen Vaccines & Prevention B.V.,,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-11-25T10:13:39Z,2021-11-25T10:13:39Z
NCT04754594,NA,2/9/2021,NA,NA,11/16/2021,2/11/2021,2/15/2021,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/24/2021,Estimate,16-Feb-21,Actual,2/16/2021,Nov-21,11/30/2021,24-Aug-22,Anticipated,8/24/2022,24-Aug-22,Anticipated,8/24/2022,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER","Active, not recruiting",NA,Phase 2/Phase 3,343,Actual,BioNTech SE,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-11-25T10:13:45Z,2021-11-25T10:13:45Z
NCT04589117,NA,10/12/2020,NA,NA,11/16/2021,10/14/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/24/2021,Estimate,27-May-20,Actual,5/27/2020,Nov-21,11/30/2021,2-Aug-20,Actual,8/2/2020,2-Aug-20,Actual,8/2/2020,NA,Interventional,NA,NA,Expressive Writing for COVID-19 Resilience for Parents,Expressive Writing for COVID-19 Resilience for Parents,Completed,NA,Not Applicable,11,Actual,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:14:51Z,2021-11-25T10:14:51Z
NCT04315948,NA,3/13/2020,NA,NA,11/16/2021,3/18/2020,3/20/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/24/2021,Estimate,22-Mar-20,Actual,3/22/2020,Nov-21,11/30/2021,Mar-23,Anticipated,3/31/2023,Mar-23,Anticipated,3/31/2023,NA,Interventional,DisCoVeRy,NA,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,2416,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Study protocol and statistical analysis plan will be available from September 2020 with no time limit.

Other data will be available upon request after first publication of the results for at least 5 years",Study protocol and statistical analysis plan will be published. All requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team that can be contacted via the principal investigator: florence.ader@chu-lyon.fr,NA,Yes,"Study protocol and statistical analysis plan will be available. Systematic individual patient data sharing is not intended, but all requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team.",2021-11-25T10:16:36Z,2021-11-25T10:16:36Z
NCT05135598,NA,9/2/2021,NA,NA,11/24/2021,11/24/2021,11/26/2021,Actual,NA,NA,NA,NA,NA,NA,11/24/2021,11/26/2021,Actual,1-Mar-20,Actual,3/1/2020,Nov-21,11/30/2021,Feb-23,Anticipated,2/28/2023,Feb-23,Anticipated,2/28/2023,NA,Interventional,NA,NA,Partners For Life: Off-line Health Promotion Program for Ultra-orthodox Jewish Women During the COVID-19 Pandemic,Partners For Life: Off-line Health Promotion Program for Ultra-orthodox Jewish Women During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,100,Anticipated,Hadassah Medical Organization,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-30T11:17:36Z,2021-11-30T11:17:36Z
NCT04509947,NA,8/11/2020,NA,NA,11/23/2021,8/11/2020,8/12/2020,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,11/24/2021,Estimate,11-Aug-20,Actual,8/11/2020,Nov-21,11/30/2021,16-Nov-21,Actual,11/16/2021,22-Feb-21,Actual,2/22/2021,NA,Interventional,NA,NA,A Study of Ad26.COV2.S in Adults (COVID-19),"A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Adults",Completed,NA,Phase 1,250,Actual,Janssen Pharmaceutical K.K.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-11-25T10:15:21Z,2021-11-25T10:15:21Z
NCT04445428,NA,6/22/2020,NA,NA,11/16/2021,6/22/2020,6/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/24/2021,Estimate,15-Jul-20,Actual,7/15/2020,Nov-21,11/30/2021,Dec-21,Anticipated,12/31/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,OPV as Potential Protection Against COVID-19,Oral Polio Vaccine as Potential Protection Against COVID-19: A Cluster-randomised Trial in Guinea-Bissau,"Active, not recruiting",NA,Phase 4,3400,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Provided request, data can be made available",2021-11-25T10:15:37Z,2021-11-25T10:15:37Z
NCT04374084,NA,4/20/2020,NA,NA,11/16/2021,5/2/2020,5/5/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/24/2021,Estimate,10-May-20,Actual,5/10/2020,Aug-21,8/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Moxibustion Plus Cupping in Convalescent Patients With COVID-19: A Randomized Clinical Trial,Recruiting,NA,Not Applicable,60,Anticipated,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,It depends.,It depends.,NA,Yes,Individual participant data are available on reasonable request. You can send e-mail to us if you have any question.,2021-11-25T10:16:12Z,2021-11-25T10:16:12Z
NCT05054075,NA,8/3/2021,NA,NA,11/16/2021,9/22/2021,9/23/2021,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/26/2021,Actual,1-Oct-21,Actual,10/1/2021,Nov-21,11/30/2021,Jul-22,Anticipated,7/31/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19,Methodological Design for Evaluating the Immune Capacity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Human Infection: Intelligent Medicine Integration.,Enrolling by invitation,NA,Phase 2,40,Anticipated,Universidade do Porto,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:20:55Z,2021-11-30T11:20:55Z
NCT05081388,NA,10/14/2021,NA,NA,11/24/2021,10/14/2021,10/18/2021,Actual,NA,NA,NA,NA,NA,NA,11/24/2021,11/26/2021,Actual,8-Nov-21,Actual,11/8/2021,Nov-21,11/30/2021,10-Nov-22,Anticipated,11/10/2022,10-Nov-22,Anticipated,11/10/2022,NA,Interventional,NA,NA,"COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease","A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease",Recruiting,NA,Phase 1/Phase 2,1359,Anticipated,Regeneron Pharmaceuticals,,5,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-11-30T11:20:13Z,2021-11-30T11:20:13Z
NCT05074888,NA,10/5/2021,NA,NA,11/25/2021,10/8/2021,10/12/2021,Actual,NA,NA,NA,NA,NA,NA,11/25/2021,11/29/2021,Estimate,15-Oct-21,Actual,10/15/2021,Nov-21,11/30/2021,31-Dec-24,Anticipated,12/31/2024,31-Dec-24,Anticipated,12/31/2024,NA,Interventional,NA,NA,Ð¡linical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.,"A Multicenter, Double-blind, Placebo-controlled, Parallel-group, Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Patients With Post-COVID-19 Asthenia.",Recruiting,NA,Phase 3,680,Anticipated,Materia Medica Holding,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:20:23Z,2021-11-30T11:20:23Z
NCT05069649,NA,10/4/2021,NA,NA,11/25/2021,10/4/2021,10/6/2021,Actual,NA,NA,NA,NA,NA,NA,11/25/2021,11/29/2021,Estimate,6-Oct-21,Actual,10/6/2021,Nov-21,11/30/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2,"Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Ergoferon as Non-specific COVID-19 Prevention During Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 3,3600,Anticipated,Materia Medica Holding,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:20:33Z,2021-11-30T11:20:33Z
NCT05009732,NA,8/16/2021,NA,NA,11/23/2021,8/16/2021,8/17/2021,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,11/26/2021,Actual,30-Sep-21,Actual,9/30/2021,Nov-21,11/30/2021,Nov-22,Anticipated,11/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects,"A Randomized, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects",Recruiting,NA,Phase 3,1030,Anticipated,"Suzhou Kintor Pharmaceutical Inc,",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-30T11:21:52Z,2021-11-30T11:21:52Z
NCT04867174,NA,4/27/2021,NA,NA,11/16/2021,4/28/2021,4/30/2021,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/26/2021,Actual,24-May-21,Actual,5/24/2021,Nov-21,11/30/2021,24-May-22,Anticipated,5/24/2022,15-Aug-21,Actual,8/15/2021,NA,Interventional,NA,NA,COVID-19 Vaccination Take-Up,COVID-19 Vaccination Take-Up in a County-Run Medicaid Managed Care Population,"Active, not recruiting",NA,Not Applicable,2825,Actual,University of Southern California,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Our partner will not allow data sharing. Code will be shared.,2021-11-30T11:24:25Z,2021-11-30T11:24:25Z
NCT04928430,NA,5/27/2021,NA,NA,11/26/2021,6/14/2021,6/16/2021,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,11/29/2021,Estimate,28-Apr-21,Actual,4/28/2021,Nov-21,11/30/2021,1-Apr-22,Anticipated,4/1/2022,1-Apr-22,Anticipated,4/1/2022,NA,Interventional,NA,NA,Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19,"An International, Placebo-controlled, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of 150 mg XAV-19 Infusion, in Patients With Moderate to Severe COVID-19: the EUROXAV Study",Recruiting,NA,Phase 2/Phase 3,722,Anticipated,Xenothera SAS,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:23:19Z,2021-11-30T11:23:19Z
NCT04904549,NA,5/26/2021,NA,NA,11/25/2021,5/26/2021,5/27/2021,Actual,NA,NA,NA,NA,NA,NA,11/25/2021,11/29/2021,Estimate,26-May-21,Actual,5/26/2021,25-Nov-21,11/25/2021,8-Mar-23,Anticipated,3/8/2023,8-Mar-23,Anticipated,3/8/2023,NA,Interventional,VAT00008,NA,Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older,"A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,21046,Anticipated,Sanofi,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-11-30T11:23:48Z,2021-11-30T11:23:48Z
NCT04903327,NA,5/21/2021,NA,NA,11/23/2021,5/21/2021,5/26/2021,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,11/26/2021,Actual,16-Nov-21,Actual,11/16/2021,Nov-21,11/30/2021,Feb-22,Anticipated,2/28/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress,Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells,Recruiting,NA,Phase 2,100,Anticipated,"Sorrento Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:23:51Z,2021-11-30T11:23:51Z
NCT04720612,NA,1/13/2021,NA,NA,11/24/2021,1/20/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,11/24/2021,11/26/2021,Actual,15-Oct-21,Actual,10/15/2021,Nov-21,11/30/2021,Jul-22,Anticipated,7/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,CIAO,NA,COVID-19 Immunologic Antiviral Therapy With Omalizumab,COVID-19 Immunologic Antiviral Therapy With Omalizumab - An Adaptive Phase II Randomized-Controlled Clinical Trial,Recruiting,NA,Phase 2,200,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-30T11:26:17Z,2021-11-30T11:26:17Z
NCT04776044,NA,2/26/2021,NA,NA,11/25/2021,2/26/2021,3/1/2021,Actual,NA,NA,NA,NA,NA,NA,11/25/2021,11/29/2021,Estimate,12-Apr-21,Actual,4/12/2021,Nov-21,11/30/2021,Jun-22,Anticipated,6/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,RESPIRE,NA,Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19,"RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,220,Anticipated,Atriva Therapeutics GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:25:25Z,2021-11-30T11:25:25Z
NCT04622332,NA,11/3/2020,NA,NA,11/23/2021,11/6/2020,11/9/2020,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,11/26/2021,Actual,18-Dec-20,Actual,12/18/2020,Nov-21,11/30/2021,15-Dec-21,Anticipated,12/15/2021,15-Dec-21,Anticipated,12/15/2021,NA,Interventional,NA,NA,A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19","Active, not recruiting",NA,Phase 1,45,Actual,"Sironax USA, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:27:32Z,2021-11-30T11:27:32Z
NCT04644705,NA,11/2/2020,NA,NA,11/26/2021,11/19/2020,11/25/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,11/29/2021,Estimate,2-Nov-20,Actual,11/2/2020,Nov-21,11/30/2021,3-May-21,Actual,5/3/2021,3-May-21,Actual,5/3/2021,NA,Interventional,NIC-002,NA,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,A 3-part Study to Investigate the Safety and Pharmacokinetics of a Novel Niclosamide Solution as a Treatment Option for COVID-19 in Combination With Camostat,Completed,NA,Phase 1,28,Actual,CharitÃ© Research Organisation GmbH,,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-30T11:27:16Z,2021-11-30T11:27:16Z
NCT04639466,NA,11/4/2020,NA,NA,11/23/2021,11/19/2020,11/20/2020,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,11/26/2021,Actual,11-Dec-20,Actual,12/11/2020,Nov-21,11/30/2021,10-Nov-22,Anticipated,11/10/2022,10-Nov-22,Anticipated,11/10/2022,NA,Interventional,NA,NA,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19","Phase 1 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-Based SARS-CoV-2 Vaccine, Administered as One or Two Injections to Healthy Adult Volunteers",Recruiting,NA,Phase 1,129,Anticipated,City of Hope Medical Center,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:27:19Z,2021-11-30T11:27:19Z
NCT04636034,NA,11/18/2020,NA,NA,11/25/2021,11/18/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,11/25/2021,11/29/2021,Estimate,12-Jan-21,Actual,1/12/2021,Nov-21,11/30/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection,"The Effect of Ganglion Sphenopalatine Block (SPG-block) Versus Placebo on Persistent Headache Following COVID-19 Infection: a Randomised, Blinded, Clinical Trial",Recruiting,NA,Phase 3,60,Anticipated,University Hospital Bispebjerg and Frederiksberg,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:27:22Z,2021-11-30T11:27:22Z
NCT04387955,NA,4/29/2020,NA,NA,11/26/2021,5/13/2020,5/14/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,11/29/2021,Estimate,30-Apr-20,Actual,4/30/2020,Nov-21,11/30/2021,30-Jul-21,Actual,7/30/2021,30-Jul-21,Actual,7/30/2021,NA,Interventional,ACROVID,NA,Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),Analysis of Chilblains Profile During COVID-19 Epidemic,Completed,NA,Not Applicable,11,Actual,Poitiers University Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:30:07Z,2021-11-30T11:30:07Z
NCT04387253,NA,5/12/2020,NA,NA,11/26/2021,5/12/2020,5/13/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,11/29/2021,Estimate,23-May-20,Actual,5/23/2020,Nov-21,11/30/2021,25-Jul-22,Anticipated,7/25/2022,25-Jul-22,Anticipated,7/25/2022,NA,Interventional,NA,NA,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Recruiting,NA,Not Applicable,80,Anticipated,Poitiers University Hospital,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:30:16Z,2021-11-30T11:30:16Z
NCT04359329,NA,4/21/2020,NA,NA,11/16/2021,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2021,11/26/2021,Actual,20-Apr-20,Actual,4/20/2020,Apr-20,4/30/2020,30-Jul-20,Actual,7/30/2020,30-Jul-20,Actual,7/30/2020,NA,Interventional,NA,NA,Estrogen Patch for COVID-19 Symptoms,Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients,Terminated,NA,Phase 2,2,Actual,Stony Brook University,,2,NA,Poor accrual,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-30T11:30:25Z,2021-11-30T11:30:25Z
NCT05082714,NA,10/18/2021,NA,NA,11/17/2021,10/18/2021,10/19/2021,Actual,NA,NA,NA,NA,NA,NA,11/17/2021,11/30/2021,Estimate,18-Oct-21,Actual,10/18/2021,Nov-21,11/30/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Tocilizumab Versus Baricitinib in Patients With Severe COVID-19,"Tocilizumab Versus Baricitinib in Hospitalized Patients With Severe COVID-19: an Open Label, Prospective Study",Recruiting,NA,Not Applicable,164,Anticipated,University Hospital of Patras,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,data will be available upon request,2021-12-01T10:25:37Z,2021-12-01T10:25:37Z
NCT05047783,NA,9/16/2021,NA,NA,11/29/2021,9/16/2021,9/17/2021,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,11/30/2021,Estimate,23-Nov-21,Actual,11/23/2021,Nov-21,11/30/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Masitinib in Patients With Symptomatic Mild to Moderate COVID-19,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Anti-viral Efficacy of Masitinib in Patients With Symptomatic Mild to Moderate COVID-19",Recruiting,NA,Phase 2,78,Anticipated,AB Science,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Masitinib is under clinical investigation and has not yet been approved in any sought-after indication by any health authority worldwide. As such, there is no plan for data-sharing at this point in time.",2021-12-01T10:26:11Z,2021-12-01T10:26:11Z
NCT04979949,NA,7/15/2021,NA,NA,11/17/2021,7/26/2021,7/28/2021,Actual,NA,NA,NA,NA,NA,NA,11/17/2021,11/30/2021,Estimate,12-Jul-21,Actual,7/12/2021,Nov-21,11/30/2021,11-Mar-22,Anticipated,3/11/2022,11-Mar-22,Anticipated,3/11/2022,NA,Interventional,NA,NA,Booster Vaccination Against COVID-19,"Double-Blind, Randomized, Controlled, Multi-Centered, Phase 2 Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2","Active, not recruiting",NA,Phase 2,222,Actual,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-01T10:27:29Z,2021-12-01T10:27:29Z
NCT04905836,NA,5/27/2021,NA,NA,11/17/2021,5/27/2021,5/28/2021,Actual,NA,NA,NA,NA,NA,NA,11/17/2021,11/30/2021,Estimate,16-Nov-21,Actual,11/16/2021,Nov-21,11/30/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress,Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells,Recruiting,NA,Phase 2,60,Anticipated,"Sorrento Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-01T10:28:40Z,2021-12-01T10:28:40Z
NCT04878211,NA,5/3/2021,NA,NA,11/28/2021,5/6/2021,5/7/2021,Actual,NA,NA,NA,NA,NA,NA,11/28/2021,11/30/2021,Estimate,10-Jun-21,Actual,6/10/2021,Nov-21,11/30/2021,18-Nov-22,Anticipated,11/18/2022,26-Nov-21,Anticipated,11/26/2021,NA,Interventional,NA,NA,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously,Recruiting,NA,Phase 4,66,Anticipated,Novartis,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.",2021-12-01T10:29:13Z,2021-12-01T10:29:13Z
NCT04895449,NA,4/24/2021,NA,NA,11/23/2021,5/15/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,11/30/2021,Estimate,16-Jul-21,Actual,7/16/2021,Nov-21,11/30/2021,1-Mar-22,Anticipated,3/1/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,MVA-SARS2-ST,NA,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19","A Multi-center Phase Ib Trial to Assess the Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST in Adults",Recruiting,NA,Phase 1,60,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-01T10:28:55Z,2021-12-01T10:28:55Z
NCT04803812,NA,2/8/2021,NA,NA,11/29/2021,3/16/2021,3/18/2021,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,11/30/2021,Estimate,26-Jan-21,Actual,1/26/2021,Nov-21,11/30/2021,2-Sep-21,Actual,9/2/2021,2-Sep-21,Actual,9/2/2021,NA,Interventional,NA,NA,Supporting the Wellness of Ontario Physicians During COVID-19,Supporting the Wellness of Ontario Physicians During COVID-19,Completed,NA,Not Applicable,19124,Actual,Ontario Medical Association,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-01T10:30:08Z,2021-12-01T10:30:08Z
NCT04844138,NA,4/5/2021,NA,NA,11/23/2021,4/8/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,11/23/2021,11/30/2021,Estimate,30-Apr-21,Actual,4/30/2021,Nov-21,11/30/2021,30-Apr-22,Anticipated,4/30/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Evaluating Overcoming Anxiety in Pregnancy and Postpartum as an Online Self-Directed Program,Evaluating a Self-Directed Cognitive Behavioural Therapy E-Health and M-Health Program for Anxiety in Pregnancy and Postpartum During COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,University of Manitoba,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-01T10:29:39Z,2021-12-01T10:29:39Z
NCT04602000,NA,10/18/2020,NA,NA,11/18/2021,10/23/2020,10/26/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,11/30/2021,Estimate,25-Sep-20,Actual,9/25/2020,Nov-21,11/30/2021,20-Oct-21,Actual,10/20/2021,21-May-21,Actual,5/21/2021,NA,Interventional,NA,NA,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,"A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection",Completed,NA,Phase 2/Phase 3,1642,Actual,Celltrion,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-01T10:32:15Z,2021-12-01T10:32:15Z
NCT04568564,NA,9/18/2020,NA,NA,11/26/2021,9/25/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,11/30/2021,Estimate,1-Oct-20,Actual,10/1/2020,Nov-21,11/30/2021,1-Dec-21,Anticipated,12/1/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,Telerehabilitation in Lung Surgery Patients,Telerehabilitation of Reduced Physiotherapy Service in SARS-CoV-2 Pandemic Process in Lung Surgery Patients,Recruiting,NA,Not Applicable,40,Anticipated,Istanbul Medipol University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-01T10:32:39Z,2021-12-01T10:32:39Z
NCT04568031,NA,8/21/2020,NA,NA,11/29/2021,9/25/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,11/30/2021,Estimate,23-Aug-20,Actual,8/23/2020,Nov-21,11/30/2021,22-Nov-21,Actual,11/22/2021,22-Nov-21,Actual,11/22/2021,NA,Interventional,NA,NA,Study of AZD1222 for the Prevention of COVID-19 in Japan,"A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19",Completed,NA,Phase 1/Phase 2,256,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-01T10:32:40Z,2021-12-01T10:32:40Z
NCT04409834,NA,5/28/2020,NA,NA,11/17/2021,5/28/2020,6/1/2020,Actual,NA,NA,NA,NA,NA,NA,11/17/2021,11/30/2021,Estimate,5-Aug-20,Actual,8/5/2020,Nov-21,11/30/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,COVID-PACT,NA,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,"A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients",Recruiting,NA,Phase 4,750,Anticipated,The TIMI Study Group,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-01T10:33:46Z,2021-12-01T10:33:46Z
NCT04405076,NA,5/13/2020,NA,NA,11/27/2021,5/26/2020,5/28/2020,Actual,NA,NA,NA,NA,NA,NA,11/27/2021,11/30/2021,Estimate,29-May-20,Actual,5/29/2020,Nov-21,11/30/2021,26-Oct-21,Actual,10/26/2021,26-Oct-21,Actual,10/26/2021,NA,Interventional,NA,NA,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older",Completed,NA,Phase 2,660,Actual,"ModernaTX, Inc.",,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-01T10:33:49Z,2021-12-01T10:33:49Z
NCT04377659,NA,5/4/2020,NA,NA,11/29/2021,5/4/2020,5/6/2020,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,11/30/2021,Estimate,1-May-20,Actual,5/1/2020,Nov-21,11/30/2021,1-May-22,Anticipated,5/1/2022,1-May-22,Anticipated,5/1/2022,NA,Interventional,NA,NA,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection,"Active, not recruiting",NA,Phase 2,9,Actual,Memorial Sloan Kettering Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-12-01T10:33:55Z,2021-12-01T10:33:55Z
NCT04347226,NA,4/2/2020,NA,NA,11/18/2021,4/14/2020,4/15/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,11/30/2021,Estimate,16-Apr-20,Actual,4/16/2020,Nov-21,11/30/2021,1-Mar-21,Actual,3/1/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,NA,NA,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19,Terminated,NA,Phase 2,43,Actual,Columbia University,,2,NA,Interim analysis indicated that futility boundary was reached.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-01T10:34:04Z,2021-12-01T10:34:04Z
NCT04334980,NA,3/31/2020,NA,NA,11/26/2021,4/2/2020,4/6/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,11/30/2021,Estimate,2-Nov-20,Actual,11/2/2020,Nov-21,11/30/2021,28-Feb-22,Anticipated,2/28/2022,8-Feb-22,Anticipated,2/8/2022,NA,Interventional,NA,NA,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults","Active, not recruiting",NA,Phase 1,24,Anticipated,Symvivo Corporation,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-01T10:34:06Z,2021-12-01T10:34:06Z
NCT04629703,NA,11/13/2020,NA,NA,11/19/2021,11/13/2020,11/16/2020,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,11/30/2021,Estimate,22-Feb-21,Actual,2/22/2021,Nov-21,11/30/2021,May-22,Anticipated,5/31/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,"Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects","Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",Recruiting,NA,Phase 3,308,Anticipated,Rigel Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-01T10:31:58Z,2021-12-01T10:31:58Z
NCT04498273,NA,8/3/2020,NA,NA,11/17/2021,8/3/2020,8/4/2020,Actual,NA,NA,NA,NA,NA,NA,11/17/2021,11/30/2021,Estimate,7-Sep-20,Actual,9/7/2020,Nov-21,11/30/2021,5-Aug-21,Actual,8/5/2021,5-Aug-21,Actual,8/5/2021,NA,Interventional,NA,NA,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,COVID-19 Outpatient Thrombosis Prevention Trial: A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of Diagnosis,Terminated,NA,Phase 3,657,Actual,University of Pittsburgh,,4,NA,an event rate lower than anticipated,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Undecided,2021-12-01T10:33:13Z,2021-12-01T10:33:13Z
NCT05069454,NA,6/10/2021,NA,NA,10/5/2021,10/5/2021,10/6/2021,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/6/2021,Actual,10-May-21,Actual,5/10/2021,Jul-21,7/31/2021,20-Jul-22,Anticipated,7/20/2022,20-May-22,Anticipated,5/20/2022,NA,Interventional,VaccEffect,NA,Study on COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan,Cohort Study to Measure COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan,Recruiting,NA,Not Applicable,1500,Anticipated,Public health and reforms Center of Ministry of Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T01:37:29Z,2021-12-02T01:37:29Z
NCT05069103,NA,10/5/2021,NA,NA,10/5/2021,10/5/2021,10/6/2021,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/6/2021,Actual,5-Jul-21,Actual,7/5/2021,Jun-21,6/30/2021,Jul-22,Anticipated,7/31/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,INROADE,NA,ImplementatioN of Remote Surgical wOund Assessment During the coviD-19 pandEmic,ImplementatioN of Remote Surgical wOund Assessment During the coviD-19 pandEmic,Recruiting,NA,Not Applicable,200,Anticipated,University of Edinburgh,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,One year following publication,Request from chief investigator (Professor Ewen Harrison),NA,Yes,Anonomysed IPD shared for research purposes,2021-12-02T01:37:47Z,2021-12-02T01:37:47Z
NCT05060939,NA,9/28/2021,NA,NA,9/28/2021,9/28/2021,9/29/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/29/2021,Actual,30-Jul-21,Actual,7/30/2021,Sep-21,9/30/2021,30-Jul-23,Anticipated,7/30/2023,30-Jul-22,Anticipated,7/30/2022,NA,Interventional,COVID-IVAC,NA,SARS-CoV-2 Infection in COVID-19 Vaccinated Patients,Characterization of the Viral Genome and Humoral Immune Response in COVID-19 Vaccinated Patients With SARS-CoV-2 Infection,Recruiting,NA,Not Applicable,5000,Anticipated,Hospices Civils de Lyon,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:42:38Z,2021-12-02T01:42:38Z
NCT05062681,NA,9/24/2021,NA,NA,9/28/2021,9/28/2021,9/30/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/30/2021,Actual,15-Sep-21,Actual,9/15/2021,Sep-21,9/30/2021,15-Mar-22,Anticipated,3/15/2022,15-Dec-21,Anticipated,12/15/2021,NA,Interventional,NA,NA,RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow,Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow,Recruiting,NA,Phase 4,60,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:41:46Z,2021-12-02T01:41:46Z
NCT05060991,NA,9/24/2021,NA,NA,9/27/2021,9/27/2021,9/29/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/29/2021,Actual,24-Sep-21,Actual,9/24/2021,Sep-21,9/30/2021,24-Sep-22,Anticipated,9/24/2022,24-Dec-21,Anticipated,12/24/2021,NA,Interventional,ADIVKT,NA,Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients,Impact of Immunosuppression Adjustment on the Immune Response to SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients (ADIVKT),Recruiting,NA,Phase 4,50,Anticipated,"University of California, Davis",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:42:39Z,2021-12-02T01:42:39Z
NCT05058742,NA,9/25/2021,NA,NA,9/30/2021,9/25/2021,9/28/2021,Actual,NA,NA,NA,NA,NA,NA,9/30/2021,10/8/2021,Actual,15-Jul-21,Actual,7/15/2021,Sep-21,9/30/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Non-invasive Nervus Vagus Stimulation in Patients With COVID-19 and ARDS,"Noninvasive Vagal Nerve Stimulation in Patients With COVID-19 and ARDS for the Reduction of Respiratory, Hemodynamic and Neuropsychiatric Complications",Recruiting,NA,Not Applicable,20,Anticipated,Vienna Hospital Association,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:43:56Z,2021-12-02T01:43:56Z
NCT05060510,NA,9/20/2021,NA,NA,9/29/2021,9/28/2021,9/29/2021,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,10/6/2021,Actual,14-Sep-21,Actual,9/14/2021,Sep-21,9/30/2021,30-Jun-22,Anticipated,6/30/2022,14-Sep-21,Actual,9/14/2021,NA,Interventional,NA,NA,The School SPIT Study - COVID-19 Testing in Secondary Schools,The School SPIT Study (Saliva to Promote Improved Testing): A Prospective Evaluation of a Home Saliva Testing Program for COVID-19 Implemented With a Stepped-wedge Cluster Randomized Design in Secondary Schools.,"Active, not recruiting",NA,Not Applicable,60,Anticipated,The Hospital for Sick Children,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T01:42:57Z,2021-12-02T01:42:57Z
NCT05059106,NA,9/24/2021,NA,NA,9/24/2021,9/24/2021,9/28/2021,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/28/2021,Actual,1-Jun-21,Actual,6/1/2021,Sep-21,9/30/2021,30-Oct-22,Anticipated,10/30/2022,1-Jun-22,Anticipated,6/1/2022,NA,Interventional,NA,NA,"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19","EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19",Recruiting,NA,Phase 2/Phase 3,29637,Anticipated,Federal University of Espirito Santo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:43:41Z,2021-12-02T01:43:41Z
NCT05057182,NA,9/24/2021,NA,NA,9/24/2021,9/24/2021,9/27/2021,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/27/2021,Actual,27-Sep-21,Anticipated,9/27/2021,Sep-21,9/30/2021,31-Dec-23,Anticipated,12/31/2023,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Third Dose of mRNA Vaccination to Boost COVID-19 Immunity,"mRNA Vaccination to Boost Antibodies Against SARS-CoV-2 in Recipients of Inactivated Vaccines (the ""mBoost"" Study)",Recruiting,NA,Phase 4,100,Anticipated,The University of Hong Kong,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T01:45:00Z,2021-12-02T01:45:00Z
NCT05055427,NA,9/21/2021,NA,NA,9/23/2021,9/23/2021,9/24/2021,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/24/2021,Actual,20-Aug-21,Actual,8/20/2021,Sep-21,9/30/2021,20-Aug-22,Anticipated,8/20/2022,20-Dec-21,Anticipated,12/20/2021,NA,Interventional,NA,NA,Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients,"Efficacy of Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang With Ginseng) on Mild and Moderate COVID-19 Patients: A Multicenter, Prospective, Randomized Controlled Trial",Recruiting,NA,Phase 2/Phase 3,300,Anticipated,University of Medicine and Pharmacy at Ho Chi Minh City,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:46:17Z,2021-12-02T01:46:17Z
NCT05054114,NA,9/21/2021,NA,NA,9/23/2021,9/21/2021,9/23/2021,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/29/2021,Actual,21-Dec-20,Actual,12/21/2020,Sep-21,9/30/2021,2-Sep-21,Actual,9/2/2021,25-May-21,Actual,5/25/2021,NA,Interventional,NA,NA,"Study of the Use of Nasal IFN-Î³ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19","Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19",Completed,NA,Not Applicable,630,Actual,SPP Pharmaclon Ltd.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:47:09Z,2021-12-02T01:47:09Z
NCT05055492,NA,9/20/2021,NA,NA,9/27/2021,9/20/2021,9/24/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,10/4/2021,Actual,14-Sep-21,Actual,9/14/2021,Sep-21,9/30/2021,30-Jun-22,Anticipated,6/30/2022,14-Sep-21,Actual,9/14/2021,NA,Interventional,NA,NA,The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions,The School SPIT Study (Saliva to Promote Improved Testing): A Prospective Evaluation of a Home Saliva Testing Program Implemented With a Stepped-wedge Cluster Randomized Design in Elementary Schools in High SARS-CoV-2 Incidence Regions,"Active, not recruiting",NA,Not Applicable,120,Anticipated,The Hospital for Sick Children,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T01:46:19Z,2021-12-02T01:46:19Z
NCT05055505,NA,9/20/2021,NA,NA,9/27/2021,9/20/2021,9/24/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,10/4/2021,Actual,14-Sep-21,Actual,9/14/2021,Sep-21,9/30/2021,30-Jun-22,Anticipated,6/30/2022,14-Sep-21,Actual,9/14/2021,NA,Interventional,NA,NA,The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions,The School SPIT Study (Saliva to Promote Improved Testing): A Prospective Evaluation of a Home Saliva Testing Program Implemented With a Stepped-wedge Cluster Randomized Design in Elementary Schools in Low SARS-CoV-2 Incidence Regions,"Active, not recruiting",NA,Not Applicable,120,Anticipated,The Hospital for Sick Children,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T01:46:21Z,2021-12-02T01:46:21Z
NCT05054322,NA,9/20/2021,NA,NA,9/21/2021,9/21/2021,9/23/2021,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/23/2021,Actual,22-Sep-21,Anticipated,9/22/2021,Sep-21,9/30/2021,30-Aug-22,Anticipated,8/30/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,FLOT,NA,FLuticasone in cOvid Treatment (FLOT),"A Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Fluticasone Propionate MDI Added to Standard Care at Early Stage of COVID-19 in Reducing the Incidence of Adverse Outcomes in Symptomatic Patients Either From 18 to 49 Year Old With Risk Factors or Older Than 50 Year Old",Recruiting,NA,Phase 2/Phase 3,500,Anticipated,University of Medicine and Pharmacy at Ho Chi Minh City,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,From Oct 2021 to September 2022.,Researchers who proposed use of data has been approved by a review committee.,NA,Yes,"Individual participant data collected during the trial, after deidentification.",2021-12-02T01:47:01Z,2021-12-02T01:47:01Z
NCT05050201,NA,8/5/2021,NA,NA,9/17/2021,9/17/2021,9/20/2021,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/20/2021,Actual,20-Apr-21,Actual,4/20/2021,Sep-21,9/30/2021,30-Sep-22,Anticipated,9/30/2022,20-Apr-22,Anticipated,4/20/2022,NA,Interventional,NA,NA,Implementation of Digital CBT for Insomnia in First Episode Psychosis,Implementation of a Digital Cognitive Behavioural Therapy Intervention for Insomnia in First Episode Psychosis in the Context of Covid19: A Mixed Methods Study,Recruiting,NA,Not Applicable,22,Anticipated,NHS Greater Glasgow and Clyde,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:49:50Z,2021-12-02T01:49:50Z
NCT05050474,NA,9/13/2021,NA,NA,9/13/2021,9/13/2021,9/20/2021,Actual,NA,NA,NA,NA,NA,NA,9/13/2021,9/20/2021,Actual,7-Aug-21,Actual,8/7/2021,Sep-21,9/30/2021,3-Feb-22,Anticipated,2/3/2022,23-Aug-21,Actual,8/23/2021,NA,Interventional,NA,NA,Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),A Clinical Study to Evaluate the Immunogenicity and Safety of the Third Dose Booster Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants,"Active, not recruiting",NA,Phase 1,43,Actual,Livzon Pharmaceutical Group Inc.,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:49:47Z,2021-12-02T01:49:47Z
NCT05049213,NA,9/16/2021,NA,NA,9/21/2021,9/16/2021,9/20/2021,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/27/2021,Actual,20-Sep-21,Anticipated,9/20/2021,Sep-21,9/30/2021,30-Sep-23,Anticipated,9/30/2023,30-Sep-23,Anticipated,9/30/2023,NA,Interventional,LT-COVID19,NA,Effect of Local Treatment(Carrageenan Nasal Spray and PVP-I Mouthwash) in Reducing Viral Load in Patients With COVID-19,Investigating the Therapeutic Role of Topical Medical Treatment in Oral and Nasal Cavities on the Patients With Positive Severe Cute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection,Recruiting,NA,Phase 4,40,Anticipated,National Taiwan University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,no plan to share individual participant data (IPD),2021-12-02T01:50:27Z,2021-12-02T01:50:27Z
NCT05047952,NA,9/12/2021,NA,NA,9/16/2021,9/16/2021,9/17/2021,Actual,NA,NA,NA,NA,NA,NA,9/16/2021,9/23/2021,Actual,16-Sep-21,Actual,9/16/2021,Sep-21,9/30/2021,Sep-22,Anticipated,9/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Vortioxetine for Post-Covid-19 Syndrome,"Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons With Post-COVID-19 Syndrome",Recruiting,NA,Phase 2,200,Anticipated,Brain and Cognition Discovery Foundation,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:51:13Z,2021-12-02T01:51:13Z
NCT05047692,NA,9/14/2021,NA,NA,9/14/2021,9/14/2021,9/17/2021,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/17/2021,Actual,9-Sep-21,Actual,9/9/2021,Sep-21,9/30/2021,Sep-22,Anticipated,9/30/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.",Recruiting,NA,Phase 1,40,Anticipated,"Cellid Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:51:25Z,2021-12-02T01:51:25Z
NCT05045989,NA,9/6/2021,NA,NA,9/15/2021,9/9/2021,9/16/2021,Actual,NA,NA,NA,NA,NA,NA,9/15/2021,9/22/2021,Actual,1-Apr-21,Actual,4/1/2021,Sep-21,9/30/2021,31-Jul-21,Actual,7/31/2021,31-Jul-21,Actual,7/31/2021,NA,Interventional,RB-TPP,NA,Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot,Mixed-methods Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot on a UK University Campus During the COVID-19 Pandemic.,Completed,NA,Not Applicable,152,Actual,University of Nottingham,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The datasets generated and/or analysed during the current study are not publicly available due to risk of identification of participants and service providers but are available from the corresponding author on reasonable request.,2021-12-02T01:52:30Z,2021-12-02T01:52:30Z
NCT05043259,NA,9/13/2021,NA,NA,9/15/2021,9/13/2021,9/14/2021,Actual,NA,NA,NA,NA,NA,NA,9/15/2021,9/16/2021,Actual,13-Sep-21,Actual,9/13/2021,Sep-21,9/30/2021,1-May-22,Anticipated,5/1/2022,13-Oct-21,Anticipated,10/13/2021,NA,Interventional,NA,NA,Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine,"Immunogenicity and Safety of the Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine in Adults at 18 Years of Age or Above: a Randomised, Open-label, Parallel-controlled Clinical Trial",Recruiting,NA,Phase 1/Phase 2,420,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:54:21Z,2021-12-02T01:54:21Z
NCT05043220,NA,9/13/2021,NA,NA,9/29/2021,9/13/2021,9/14/2021,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,10/7/2021,Actual,29-Sep-21,Actual,9/29/2021,Sep-21,9/30/2021,31-Aug-22,Anticipated,8/31/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,CO-SI-ONKO,NA,Covid-19 Predictors: Safety of Gynecological Oncology Patients Undergoing Chemotherapy,COVID-19-PrÃ¤diktoren: Klinische Studie Zur Sicherheit Von gynÃ¤kologisch Onkologischen Patientinnen Unter Chemotherapie - CO-SI-ONKO-Studie,Recruiting,NA,Not Applicable,100,Anticipated,Technische UniversitÃ¤t MÃ¼nchen,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:54:11Z,2021-12-02T01:54:11Z
NCT05041907,NA,9/7/2021,NA,NA,10/1/2021,9/10/2021,9/13/2021,Actual,NA,NA,NA,NA,NA,NA,10/1/2021,10/8/2021,Actual,30-Sep-21,Actual,9/30/2021,Sep-21,9/30/2021,Aug-23,Anticipated,8/31/2023,Aug-23,Anticipated,8/31/2023,NA,Interventional,PLATCOV,NA,Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV),Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV),Recruiting,NA,Phase 2,750,Anticipated,University of Oxford,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after the main paper has been published,"MORU Data Sharing Policy https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing.

The criteria for authorship will be consistent with the international guidelines (http://www.icmje.org/#author).",http://wellcome.ac.uk/press-release/statement-data-sharing-public-health-emergencies,Yes,"With patient's consent, clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.

Data generated from this study will adhere to the 2016 ""Statement on data sharing in public health emergencies""(https://wellcome.ac.uk/press-release/statement-data-sharing-public-health-emergencies).",2021-12-02T01:55:14Z,2021-12-02T01:55:14Z
NCT05035576,NA,8/24/2021,NA,NA,9/3/2021,9/3/2021,9/5/2021,Actual,NA,NA,NA,NA,NA,NA,9/3/2021,9/5/2021,Actual,1-Sep-21,Actual,9/1/2021,Sep-21,9/30/2021,Oct-21,Anticipated,10/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19,"A Randomized, Adaptive Design, Proof of Concept, Single Dose Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19",Recruiting,NA,Phase 1,30,Anticipated,Optinose US Inc.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:59:17Z,2021-12-02T01:59:17Z
NCT05040724,NA,9/9/2021,NA,NA,9/9/2021,9/9/2021,9/10/2021,Actual,NA,NA,NA,NA,NA,NA,9/9/2021,9/10/2021,Actual,28-May-21,Actual,5/28/2021,Jun-21,6/30/2021,Jun-22,Anticipated,6/30/2022,May-22,Anticipated,5/31/2022,NA,Interventional,IVERCoV,NA,Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19,Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19 on the Time to Negativation of the SARS-COV-2 Viral Load Determinated by RT-PCR,"Active, not recruiting",NA,Phase 3,200,Anticipated,Raincy Montfermeil Hospital Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:56:04Z,2021-12-02T01:56:04Z
NCT05038488,NA,3/18/2021,NA,NA,11/29/2021,9/7/2021,9/9/2021,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,12/1/2021,Estimate,26-Oct-21,Actual,10/26/2021,Nov-21,11/30/2021,20-Aug-22,Anticipated,8/20/2022,28-Apr-22,Anticipated,4/28/2022,NA,Interventional,NA,NA,Phase 2a MIB-626 vs. Placebo COVID-19,A Phase 2a Randomized Controlled Trial of MIB-626 (NAD-boosting Drug) vs. Placebo in Adults With COVID-19 Infection and Early Acute Kidney Injury,Recruiting,NA,Phase 2,50,Anticipated,"Metro International Biotech, LLC",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will not be shared,2021-12-02T01:57:29Z,2021-12-02T01:57:29Z
NCT05038514,NA,9/5/2021,NA,NA,9/7/2021,9/7/2021,9/9/2021,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/9/2021,Actual,1-Sep-21,Actual,9/1/2021,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,1-Sep-21,Actual,9/1/2021,NA,Interventional,NA,NA,The Effect of Music Therapy in COVID-19 Patients Given Prone Position,The Effect of Music Therapy on Adaptation and Anxiety Levels in COVID-19 Patients Given Prone Position: A Triple-blind Randomized Controlled Clinical Trial,Recruiting,NA,Not Applicable,30,Anticipated,Kutahya Health Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The decision to share the study results will be made during the study period or when it is concluded.,2021-12-02T01:57:31Z,2021-12-02T01:57:31Z
NCT05037188,NA,9/7/2021,NA,NA,9/7/2021,9/7/2021,9/8/2021,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/8/2021,Actual,10-Aug-21,Actual,8/10/2021,Sep-21,9/30/2021,Dec-22,Anticipated,12/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,COVER,NA,Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19),"A Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless Phase I / II Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5-RBD-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Biocad,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:58:27Z,2021-12-02T01:58:27Z
NCT05040737,NA,8/1/2021,NA,NA,9/9/2021,9/9/2021,9/10/2021,Actual,NA,NA,NA,NA,NA,NA,9/9/2021,9/10/2021,Actual,17-Apr-20,Actual,4/17/2020,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,8-Feb-21,Actual,2/8/2021,NA,Interventional,Dial-COVID,NA,PMMA vs Polysulfone in SARS-CoV-2 Infection Hemodialysis Patients,Comparison of Two Types of Dialyzers (PMMA vs Polysulfone) on Cytokine Extraction in Hemodialysis Patients and COVID Infection. A Multicenter Prospective Study,"Active, not recruiting",NA,Not Applicable,12,Actual,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:55:58Z,2021-12-02T01:55:58Z
NCT05037253,NA,8/25/2021,NA,NA,9/6/2021,9/6/2021,9/8/2021,Actual,NA,NA,NA,NA,NA,NA,9/6/2021,9/8/2021,Actual,30-Oct-20,Actual,10/30/2020,Aug-21,8/31/2021,30-May-21,Actual,5/30/2021,30-May-21,Actual,5/30/2021,NA,Interventional,NA,NA,COVID-19 Morbidity in Healthcare Workers and Vitamin D Supplementation,The Effect of Vitamin D Supplementation in Reducing COVID-19 Morbidity Among Healthcare Workers,Completed,NA,Phase 4,128,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:58:20Z,2021-12-02T01:58:20Z
NCT05037240,NA,9/3/2021,NA,NA,9/6/2021,9/6/2021,9/8/2021,Actual,NA,NA,NA,NA,NA,NA,9/6/2021,9/8/2021,Actual,12-Jan-21,Actual,1/12/2021,Sep-21,9/30/2021,25-May-21,Actual,5/25/2021,6-Apr-21,Actual,4/6/2021,NA,Interventional,NA,NA,Quercetin in the Prevention of Covid-19 Infection,"Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of an Oral Nutritional Supplement Based on Quercetin in the Prevention of Covid-19 Infection for a Duration of 3 Months",Completed,NA,Not Applicable,80,Actual,Azienda di Servizi alla Persona di Pavia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:58:21Z,2021-12-02T01:58:21Z
NCT05037448,NA,8/24/2021,NA,NA,8/31/2021,8/31/2021,9/8/2021,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/8/2021,Actual,17-Aug-20,Actual,8/17/2020,Mar-21,3/31/2021,28-Feb-21,Actual,2/28/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,NA,NA,Exploring Telehealth to Deliver Me & My Wishes During Coronavirus-19,Me & My Wishes: An Efficacy Trial of Long Term Care Residents With Alzheimer's Using Videos to Communicate Care Preferences With Caregivers,Completed,NA,Not Applicable,17,Actual,University of Utah,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:58:22Z,2021-12-02T01:58:22Z
NCT05035628,NA,9/2/2021,NA,NA,9/2/2021,9/2/2021,9/5/2021,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/5/2021,Actual,15-Aug-21,Actual,8/15/2021,Sep-21,9/30/2021,15-Aug-22,Anticipated,8/15/2022,15-Aug-22,Anticipated,8/15/2022,NA,Interventional,COVID-Rehab,NA,Cardiopulmonary Rehabilitation in Long COVID-19 Patients With Persistent Breathlessness and Fatigue,Cardiopulmonary Rehabilitation in Long COVID-19 Patients With Persistent Breathlessness and Fatigue,Recruiting,NA,Not Applicable,40,Anticipated,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T01:59:27Z,2021-12-02T01:59:27Z
NCT05035563,NA,3/27/2021,NA,NA,9/2/2021,9/2/2021,9/5/2021,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/5/2021,Actual,1-Jun-21,Actual,6/1/2021,Mar-21,3/31/2021,1-Jul-22,Anticipated,7/1/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,NA,NA,Impact of a Communication Strategy in the Prevention of Depressive Symptoms in Patients With Covid-19,"Impact of an Early and Comprehensive Communication Strategy in the Prevention of Depressive Symptoms in Patients With Severe Covid-19, Their Families and Health Personnel",Recruiting,NA,Not Applicable,350,Anticipated,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:59:28Z,2021-12-02T01:59:28Z
NCT05035550,NA,8/12/2021,NA,NA,9/2/2021,9/2/2021,9/5/2021,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/5/2021,Actual,4-Feb-21,Actual,2/4/2021,Sep-21,9/30/2021,5-May-21,Actual,5/5/2021,5-May-21,Actual,5/5/2021,NA,Interventional,NA,NA,Effects of Open-label Placebos on COVID-related Psychological Health,"Effects of Open-label Placebos Administered Through Telehealth on COVID-related Stress, Anxiety, and Depression",Completed,NA,Not Applicable,64,Actual,Michigan State University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,IPD will be available one year after publication,IPD will be available upon request.,NA,Yes,The investigators plan to share the IPD used in the analysis for manuscript submission.,2021-12-02T01:59:28Z,2021-12-02T01:59:28Z
NCT05035524,NA,9/2/2021,NA,NA,9/2/2021,9/2/2021,9/5/2021,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/5/2021,Actual,1-Sep-21,Actual,9/1/2021,Sep-21,9/30/2021,1-Mar-22,Anticipated,3/1/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,NA,NA,A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19,A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19,"Active, not recruiting",NA,Not Applicable,340,Anticipated,Mansoura University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T01:59:33Z,2021-12-02T01:59:33Z
NCT05035186,NA,9/2/2021,NA,NA,9/10/2021,9/2/2021,9/5/2021,Actual,NA,NA,NA,NA,NA,NA,9/10/2021,9/16/2021,Actual,21-Mar-21,Actual,3/21/2021,Sep-21,9/30/2021,21-Nov-21,Anticipated,11/21/2021,20-Sep-21,Anticipated,9/20/2021,NA,Interventional,NA,NA,Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era,Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era: a Randomized Controlled Trial,Recruiting,NA,Not Applicable,270,Anticipated,Alexandria University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T01:59:44Z,2021-12-02T01:59:44Z
NCT04922905,NA,6/9/2021,NA,NA,6/9/2021,6/9/2021,6/11/2021,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/11/2021,Actual,2-Apr-20,Actual,4/2/2020,Jun-21,6/30/2021,2-Apr-21,Actual,4/2/2021,7-May-20,Actual,5/7/2020,NA,Interventional,NS-COV,NA,Nervous System Symptoms Associated With COVID 19,Nervous System Symptoms Associated With COVID 19 : NS-COV,Completed,NA,Not Applicable,99,Actual,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:21:55Z,2021-12-02T03:21:55Z
NCT05033860,NA,8/30/2021,NA,NA,9/1/2021,9/1/2021,9/5/2021,Actual,NA,NA,NA,NA,NA,NA,9/1/2021,9/5/2021,Actual,18-Aug-21,Actual,8/18/2021,Aug-21,8/31/2021,20-Sep-21,Anticipated,9/20/2021,20-Sep-21,Anticipated,9/20/2021,NA,Interventional,NA,NA,The Influence of Education During Waiting Time of Vaccination on the Knowledge Towards COVID-19 Among Chinese Residents,The Influence of Education During Waiting Time of Vaccination on the Knowledge Towards COVID-19 Among Chinese Residents: A Randomized Controlled Trial,Recruiting,NA,Not Applicable,312,Anticipated,Ningbo No. 1 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:00:42Z,2021-12-02T02:00:42Z
NCT05032885,NA,9/1/2021,NA,NA,9/1/2021,9/1/2021,9/2/2021,Actual,NA,NA,NA,NA,NA,NA,9/1/2021,9/2/2021,Actual,4-Apr-21,Actual,4/4/2021,Apr-21,4/30/2021,30-Sep-21,Anticipated,9/30/2021,1-Sep-21,Actual,9/1/2021,NA,Interventional,NA,NA,Early Physiotherapy in Covid Patients,"RANDOMIZED CLINICAL TRIAL OF PHYSIOTHERAPY IN COVID PATIENTS ON THEIR PHYSICAL CONDITIONING, ANXIETY LEVEL AND THEIR QUALITY OF LIFE",Recruiting,NA,Not Applicable,128,Anticipated,Hospital Universitario Getafe,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:01:20Z,2021-12-02T02:01:20Z
NCT05033158,NA,4/2/2021,NA,NA,8/31/2021,8/31/2021,9/2/2021,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/2/2021,Actual,1-Apr-21,Actual,4/1/2021,Apr-21,4/30/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,REAL-V,NA,The Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population.,Investigation to Reveal the Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population: COVID-19 Protection and Vaccine Safety (REAL-V),Recruiting,NA,Not Applicable,3000,Anticipated,"University Hospital, Antwerp",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:01:13Z,2021-12-02T02:01:13Z
NCT05028374,NA,8/23/2021,NA,NA,8/29/2021,8/29/2021,8/31/2021,Actual,NA,NA,NA,NA,NA,NA,8/29/2021,8/31/2021,Actual,17-Aug-21,Actual,8/17/2021,Aug-21,8/31/2021,31-Jan-23,Anticipated,1/31/2023,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies,Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination,Recruiting,NA,Phase 2,171,Anticipated,Barbara Ann Karmanos Cancer Institute,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:04:22Z,2021-12-02T02:04:22Z
NCT05028244,NA,8/30/2021,NA,NA,8/30/2021,8/30/2021,8/31/2021,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,8/31/2021,Actual,15-Jun-21,Actual,6/15/2021,Aug-21,8/31/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Evaluation of Serial Ultrasound Screening in ICU COVID-19 Patients,Evaluation of Serial Ultrasound Screening for Lower Extremity Deep Vein Thrombosis in Patients With COVID-19 Admitted to Intensive Care.,Recruiting,NA,Not Applicable,170,Anticipated,Hospital Universitari Vall d'Hebron Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:04:23Z,2021-12-02T02:04:23Z
NCT05024461,NA,8/16/2021,NA,NA,8/26/2021,8/26/2021,8/27/2021,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/27/2021,Actual,10-Aug-20,Actual,8/10/2020,Aug-21,8/31/2021,12-Nov-21,Anticipated,11/12/2021,12-Nov-20,Actual,11/12/2020,NA,Interventional,COVISAL,NA,Comparison of Detection of SARS-CoV2 (COVID-19) Between Nasopharyngeal Swab Specimens and Those Obtained by Salivary Sputum,"Comparison of the Results, Feasibility and Acceptability of Molecular Detection of SARS-CoV2 Between Nasopharyngeal Swab Specimens Recovered in Virological Transport Medium and Those Obtained by Salivary Sputum","Active, not recruiting",NA,Not Applicable,1159,Actual,Centre Hospitalier de Cayenne,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:07:02Z,2021-12-02T02:07:02Z
NCT05024500,NA,12/18/2020,NA,NA,8/26/2021,8/25/2021,8/27/2021,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,9/1/2021,Actual,4-Jan-21,Actual,1/4/2021,Aug-21,8/31/2021,11-Jul-22,Anticipated,7/11/2022,11-Oct-21,Anticipated,10/11/2021,NA,Interventional,COVIDPTcare,NA,Clinical and Functional Outcomes of Critically Ill Patients With COVID-19,"Clinical, Respiratory, Peripheral, Muscle and Functionality Outcomes of Adult ICU Inpatients and Rehabilitation-center Outpatients With COVID-19",Recruiting,NA,Not Applicable,90,Anticipated,University of Pernambuco,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,end of trial,individual participant data (IPD) access will be granted by the PI after request review for approval via email. It will be shared with researchers and general public of interest on the subject for descriptive analyses related to our sample medical and clinical characteristics. A committee of researchers will be in charge of discussing the request before approving the access.,NA,Yes,"participant characteristics (age, gender)
clinical measurements (blood pressure, heart rate)
medical history
clinical laboratory results
images (X-rays)
adverse events (hemodynamic and respiratory instability, interruptions)
details of randomisation and treatment received",2021-12-02T02:07:04Z,2021-12-02T02:07:04Z
NCT05027672,NA,8/18/2021,NA,NA,8/24/2021,8/24/2021,8/30/2021,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/30/2021,Actual,30-Jul-21,Actual,7/30/2021,Aug-21,8/31/2021,6-Sep-21,Anticipated,9/6/2021,30-Aug-21,Anticipated,8/30/2021,NA,Interventional,NA,NA,Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.,"Randomised Phase II Study to Assess the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schedules (rAd26-rAd5, rAd26-rAd26, rAd26-ChAdOx1 and rAd26-mRNA-1273).","Active, not recruiting",NA,Phase 2,348,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:04:49Z,2021-12-02T02:04:49Z
NCT05024006,NA,8/21/2021,NA,NA,8/21/2021,8/21/2021,8/27/2021,Actual,NA,NA,NA,NA,NA,NA,8/21/2021,8/27/2021,Actual,23-Apr-20,Actual,4/23/2020,Aug-21,8/31/2021,31-Dec-21,Anticipated,12/31/2021,27-Jan-21,Actual,1/27/2021,NA,Interventional,NA,NA,Public Health Emergency: SOLIDARITY TRIAL Philippines,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care Philippines,"Active, not recruiting",NA,Not Applicable,1314,Actual,University of the Philippines,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:07:22Z,2021-12-02T02:07:22Z
NCT05022303,NA,8/9/2021,NA,NA,10/6/2021,8/23/2021,8/26/2021,Actual,NA,NA,NA,NA,NA,NA,10/6/2021,10/11/2021,Actual,Oct-21,Anticipated,10/31/2021,Oct-21,10/31/2021,Dec-22,Anticipated,12/31/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,AT1001 for the Treatment of COVID-19 Related MIS-C,"A Phase 2a (Proof of Concept), Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AT1001 for the Treatment of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C)",Recruiting,NA,Phase 2,20,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:08:35Z,2021-12-02T02:08:35Z
NCT05021588,NA,8/16/2021,NA,NA,8/23/2021,8/23/2021,8/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/25/2021,Actual,12-Apr-20,Actual,4/12/2020,Aug-21,8/31/2021,10-Sep-20,Actual,9/10/2020,2-Aug-20,Actual,8/2/2020,NA,Interventional,SARS-CoV-2,NA,Steroid and Anticoagulant Therapy in covid19,Challenges in Steroid and Anticoagulant Therapy in Severe COVID-19 Pneumonia: A Prospective Study,Completed,NA,Not Applicable,123,Actual,Assiut University,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:08:59Z,2021-12-02T02:08:59Z
NCT05021016,NA,8/19/2021,NA,NA,8/26/2021,8/19/2021,8/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/27/2021,Actual,19-Nov-20,Actual,11/19/2020,Aug-21,8/31/2021,30-Jan-21,Actual,1/30/2021,30-Jan-21,Actual,1/30/2021,NA,Interventional,NA,NA,Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above,"An Open Study of the Safety, Reactogenicity and Immunogenicity of the Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), With the Involvement of Volunteers Aged 60 Years and Above (Phase III-IV)",Completed,NA,Phase 3,150,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:09:19Z,2021-12-02T02:09:19Z
NCT05019287,NA,7/3/2021,NA,NA,8/28/2021,8/22/2021,8/24/2021,Actual,NA,NA,NA,NA,NA,NA,8/28/2021,9/2/2021,Actual,17-Apr-21,Actual,4/17/2021,Aug-21,8/31/2021,9-Jun-21,Actual,6/9/2021,21-May-21,Actual,5/21/2021,NA,Interventional,NA,NA,Menstrual Blood Stem Cells in Severe Covid-19,"Safety and Efficacy Study of Allogeneic Human Menstrual Blood Stem Cells Secretome to Treat Severe Covid-19 Patients, Clinical Trial Phase I&II",Completed,NA,Phase 1/Phase 2,29,Actual,Avicenna Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:10:40Z,2021-12-02T02:10:40Z
NCT05019326,NA,8/21/2021,NA,NA,9/1/2021,8/21/2021,8/24/2021,Actual,NA,NA,NA,NA,NA,NA,9/1/2021,9/9/2021,Actual,30-Aug-21,Actual,8/30/2021,Sep-21,9/30/2021,30-May-22,Anticipated,5/30/2022,30-May-22,Anticipated,5/30/2022,NA,Interventional,NA,NA,Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19,"A Two-stage Adaptive Randomized Controlled Trial of Andrographis Paniculata Extract, Boesenbergia Rotunda Extract, and Standard Treatment in Asymptomatic COVID-19 Patients",Recruiting,NA,Phase 3,3060,Anticipated,Mahidol University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,May shared IPD upon sponsor decision.,2021-12-02T02:10:49Z,2021-12-02T02:10:49Z
NCT05018065,NA,8/23/2021,NA,NA,8/24/2021,8/23/2021,8/24/2021,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/27/2021,Actual,1-May-20,Actual,5/1/2020,Jan-21,1/31/2021,30-Dec-20,Actual,12/30/2020,1-Dec-20,Actual,12/1/2020,NA,Interventional,NA,NA,Sexual Functions and Covid-19,Evaluation of Women's Sexual Functions After Having Covid-19,Completed,NA,Not Applicable,101,Actual,Gaziosmanpasa Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:11:30Z,2021-12-02T02:11:30Z
NCT05018078,NA,8/18/2021,NA,NA,9/1/2021,8/20/2021,8/24/2021,Actual,NA,NA,NA,NA,NA,NA,9/1/2021,9/2/2021,Actual,30-Aug-21,Actual,8/30/2021,Aug-21,8/31/2021,30-Jun-23,Anticipated,6/30/2023,30-Dec-22,Anticipated,12/30/2022,NA,Interventional,NA,NA,Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer,The Fifth Medical Center of Chinese PLA General Hospital,Recruiting,NA,Not Applicable,300,Anticipated,Beijing 302 Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:11:33Z,2021-12-02T02:11:33Z
NCT05017805,NA,8/12/2021,NA,NA,9/12/2021,8/20/2021,8/24/2021,Actual,NA,NA,NA,NA,NA,NA,9/12/2021,9/16/2021,Actual,15-Aug-21,Actual,8/15/2021,Aug-21,8/31/2021,15-Jun-23,Anticipated,6/15/2023,15-Dec-22,Anticipated,12/15/2022,NA,Interventional,NA,NA,COVID-19 Vaccines in Patients With Chronic Liver Disease,Safety and Immunogenicity of COVID-19 Vaccines in Patients With Chronic Liver Disease: A Multi-center Prospective Study,Recruiting,NA,Not Applicable,300,Anticipated,Beijing 302 Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:11:46Z,2021-12-02T02:11:46Z
NCT05017792,NA,8/23/2021,NA,NA,8/29/2021,8/23/2021,8/24/2021,Actual,NA,NA,NA,NA,NA,NA,8/29/2021,9/2/2021,Actual,30-Aug-21,Anticipated,8/30/2021,Aug-21,8/31/2021,31-Dec-22,Anticipated,12/31/2022,30-Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,"Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt","Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt",Recruiting,NA,Phase 3,200,Anticipated,Theodor Bilharz Research Institute,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:11:47Z,2021-12-02T02:11:47Z
NCT05014373,NA,6/14/2021,NA,NA,8/19/2021,8/19/2021,8/20/2021,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/20/2021,Actual,12-Oct-20,Actual,10/12/2020,Aug-21,8/31/2021,31-Aug-21,Anticipated,8/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19,An Investigation of the Efficacy and Safety of Favipiravir in Hospitalized NON- SEVERE COVID-19 Patients - An Open-label Randomized Controlled Multi Center Trial,Recruiting,NA,Phase 3,144,Anticipated,University of the Philippines,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:14:04Z,2021-12-02T02:14:04Z
NCT05012826,NA,8/16/2021,NA,NA,9/27/2021,8/17/2021,8/19/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/28/2021,Actual,20-Sep-21,Anticipated,9/20/2021,Aug-21,8/31/2021,6-Jul-23,Anticipated,7/6/2023,6-Jun-23,Anticipated,6/6/2023,NA,Interventional,NA,NA,Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID,Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID: Study Protocol for a Pragmatic Randomized Controlled Trial,Recruiting,NA,Not Applicable,104,Anticipated,Centro UniversitÃ¡rio Augusto Motta,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:15:22Z,2021-12-02T02:15:22Z
NCT05011513,NA,7/30/2021,NA,NA,11/18/2021,8/16/2021,8/18/2021,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,12/1/2021,Estimate,25-Aug-21,Actual,8/25/2021,Nov-21,11/30/2021,24-Apr-22,Anticipated,4/24/2022,12-Dec-21,Anticipated,12/12/2021,NA,Interventional,NA,NA,Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).,"AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS",Recruiting,NA,Phase 3,1140,Anticipated,Pfizer,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-02T02:16:02Z,2021-12-02T02:16:02Z
NCT05012319,NA,8/17/2021,NA,NA,8/18/2021,8/18/2021,8/19/2021,Actual,NA,NA,NA,NA,NA,NA,8/18/2021,8/19/2021,Actual,5-Aug-21,Actual,8/5/2021,Aug-21,8/31/2021,30-Mar-22,Anticipated,3/30/2022,30-Mar-22,Anticipated,3/30/2022,NA,Interventional,NA,NA,Phase 3 Clinical Study Evaluating Nitric Oxide Nasal Spray (NONS) Efficacy To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19,"A Double-Blinded, Placebo-Controlled Parallel, Phase 3 Clinical Efficacy Study Evaluating Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19",Recruiting,NA,Phase 3,500,Anticipated,Salmaniya Medical Complex,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:15:43Z,2021-12-02T02:15:43Z
NCT05012800,NA,8/12/2021,NA,NA,8/18/2021,8/18/2021,8/19/2021,Actual,NA,NA,NA,NA,NA,NA,8/18/2021,8/19/2021,Actual,28-Jul-21,Actual,7/28/2021,Jul-21,7/31/2021,30-Sep-22,Anticipated,9/30/2022,31-Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults,Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults: A Multicenter Prospective Study,Recruiting,NA,Phase 4,300,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T02:15:19Z,2021-12-02T02:15:19Z
NCT05011344,NA,8/9/2021,NA,NA,8/18/2021,8/16/2021,8/18/2021,Actual,NA,NA,NA,NA,NA,NA,8/18/2021,8/19/2021,Actual,15-Jul-20,Actual,7/15/2020,Aug-21,8/31/2021,15-Dec-22,Anticipated,12/15/2022,15-Jul-22,Anticipated,7/15/2022,NA,Interventional,ICONE,NA,Evolution of Protective Immunization Against COVID-19 Among Hospital Workers in Health Care Facilities,Evolution of Protective Immunization Against SARS-CoV-2 Among Hospital Workers in Health Care Facilities,Recruiting,NA,Not Applicable,1000,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:16:25Z,2021-12-02T02:16:25Z
NCT05009186,NA,8/15/2021,NA,NA,8/15/2021,8/15/2021,8/17/2021,Actual,NA,NA,NA,NA,NA,NA,8/15/2021,8/17/2021,Actual,1-Apr-20,Actual,4/1/2020,Aug-21,8/31/2021,1-Oct-21,Anticipated,10/1/2021,1-Oct-21,Anticipated,10/1/2021,NA,Interventional,NA,NA,Changing of Prostate Specific Antigen Value in Patients With Covid-19,Changing of PSA With Covid-19,Recruiting,NA,Not Applicable,100,Anticipated,Saglik Bilimleri Universitesi,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:17:49Z,2021-12-02T02:17:49Z
NCT05010876,NA,8/16/2021,NA,NA,8/17/2021,8/17/2021,8/18/2021,Actual,NA,NA,NA,NA,NA,NA,8/17/2021,8/18/2021,Actual,4-Feb-21,Actual,2/4/2021,Aug-21,8/31/2021,21-Jun-21,Actual,6/21/2021,13-Jun-21,Actual,6/13/2021,NA,Interventional,AntagoBrad-Cov,NA,Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).,Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).,Completed,NA,Phase 2,44,Actual,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:16:39Z,2021-12-02T02:16:39Z
NCT05009563,NA,8/16/2021,NA,NA,8/16/2021,8/16/2021,8/17/2021,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/17/2021,Actual,4-Jan-21,Actual,1/4/2021,Aug-21,8/31/2021,4-Jan-22,Anticipated,1/4/2022,4-Jan-22,Anticipated,1/4/2022,NA,Interventional,COMPOSIT,NA,COvid iMaging With POSitron Emission Tomography,Evaluation of COVID-19 by Whole-body FDG-PET/CT,Recruiting,NA,Not Applicable,50,Anticipated,Semmelweis University Heart and Vascular Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:17:34Z,2021-12-02T02:17:34Z
NCT05007457,NA,4/12/2021,NA,NA,8/13/2021,8/13/2021,8/16/2021,Actual,NA,NA,NA,NA,NA,NA,8/13/2021,8/16/2021,Actual,12-Jun-21,Actual,6/12/2021,Aug-21,8/31/2021,12-Jun-23,Anticipated,6/12/2023,12-Jun-22,Anticipated,6/12/2022,NA,Interventional,NA,NA,The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial,The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial,Recruiting,NA,Not Applicable,100,Anticipated,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:18:44Z,2021-12-02T02:18:44Z
NCT05008003,NA,8/11/2021,NA,NA,9/9/2021,8/13/2021,8/17/2021,Actual,NA,NA,NA,NA,NA,NA,9/9/2021,9/14/2021,Actual,5-Sep-21,Actual,9/5/2021,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,"Dietary Supplements Vit D, Quercetin and Curcumin Combination for Early Symptoms of COVID-19","Clinical Trial to Investigate the Benefits of Adjuvant Treatment of Combination of Dietary Supplements Curcumin, Quercetin, and Vitamin D for Early Symptoms for COVID-19 Infection",Recruiting,NA,Not Applicable,100,Anticipated,Ayub Teaching Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:18:27Z,2021-12-02T02:18:27Z
NCT05008393,NA,8/16/2021,NA,NA,9/25/2021,8/16/2021,8/17/2021,Actual,NA,NA,NA,NA,NA,NA,9/25/2021,10/1/2021,Actual,25-Sep-21,Actual,9/25/2021,Sep-21,9/30/2021,30-Dec-21,Anticipated,12/30/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,PJS-539,NA,Efficacy of PJS-539 for Adult Patients With COVID-19.,"Efficacy of PJS-539 for Adult Patients With SARS-CoV-2: Multicentre, Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial.",Recruiting,NA,Phase 2,150,Anticipated,Hospital do Coracao,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:18:29Z,2021-12-02T02:18:29Z
NCT05008380,NA,8/16/2021,NA,NA,8/17/2021,8/16/2021,8/17/2021,Actual,NA,NA,NA,NA,NA,NA,8/17/2021,8/20/2021,Actual,16-Aug-21,Actual,8/16/2021,Aug-21,8/31/2021,1-Jun-22,Anticipated,6/1/2022,1-May-22,Anticipated,5/1/2022,NA,Interventional,EpCOT,NA,Efficacy of the Early Prone-positioning in Hospitalized Patients With Mild Covid-19 Pneumonia,"Open-label, Controlled, Randomized Clinical Trial on the Efficacy of Early Prone-positioning in Patients With Mild Pneumonia Due to SARS-CoV-2",Recruiting,NA,Not Applicable,96,Anticipated,University of Milano Bicocca,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:18:10Z,2021-12-02T02:18:10Z
NCT05007678,NA,7/16/2021,NA,NA,8/12/2021,8/12/2021,8/16/2021,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/16/2021,Actual,16-Sep-20,Actual,9/16/2020,Aug-21,8/31/2021,1-Jul-22,Anticipated,7/1/2022,1-Jul-22,Anticipated,7/1/2022,NA,Interventional,DEFEAT-COVID,NA,Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease,Targeting de Novo Pyrimidine Biosynthesis by Leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19),"Active, not recruiting",NA,Phase 3,178,Actual,Ashford and St. Peter's Hospitals NHS Trust,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:18:40Z,2021-12-02T02:18:40Z
NCT05007496,NA,8/11/2021,NA,NA,8/16/2021,8/12/2021,8/16/2021,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/20/2021,Actual,14-Apr-21,Actual,4/14/2021,Aug-21,8/31/2021,31-May-21,Actual,5/31/2021,31-May-21,Actual,5/31/2021,NA,Interventional,NA,NA,"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19","Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19",Completed,NA,Phase 2,145,Actual,"Aivita Biomedical, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:18:52Z,2021-12-02T02:18:52Z
NCT05007600,NA,8/5/2021,NA,NA,8/12/2021,8/12/2021,8/16/2021,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/16/2021,Actual,1-Feb-21,Actual,2/1/2021,Aug-21,8/31/2021,30-Jul-21,Actual,7/30/2021,1-Jul-21,Actual,7/1/2021,NA,Interventional,NA,NA,Online Interactive Courses on Loneliness and Quality of Life of Older Adults,Investigating the Effectiveness of Online Interactive Courses on Loneliness and Quality of Life of Older Adults in the Community During COVID-19 Pandemic: A Pilot Study and a Randomized Controlled Trial,Completed,NA,Not Applicable,89,Actual,National Cheng Kung University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:18:47Z,2021-12-02T02:18:47Z
NCT05005559,NA,8/11/2021,NA,NA,10/4/2021,8/11/2021,8/13/2021,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/5/2021,Actual,7-Aug-21,Actual,8/7/2021,Aug-21,8/31/2021,1-Mar-22,Anticipated,3/1/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,NA,NA,Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)","Active, not recruiting",NA,Phase 3,16876,Anticipated,Cinnagen,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:20:18Z,2021-12-02T02:20:18Z
NCT05007509,NA,8/12/2021,NA,NA,9/22/2021,8/12/2021,8/16/2021,Actual,NA,NA,NA,NA,NA,NA,9/22/2021,9/23/2021,Actual,16-Aug-21,Actual,8/16/2021,Sep-21,9/30/2021,Sep-22,Anticipated,9/30/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19),A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers,"Active, not recruiting",NA,Phase 1/Phase 2,30,Anticipated,"Laboratorios Hipra, S.A.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,To be decided,2021-12-02T02:18:57Z,2021-12-02T02:18:57Z
NCT05007236,NA,8/9/2021,NA,NA,10/5/2021,8/9/2021,8/16/2021,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/6/2021,Actual,20-Sep-21,Actual,9/20/2021,Oct-21,10/31/2021,Feb-22,Anticipated,2/28/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.","A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild SARS-CoV-2 Infection.",Recruiting,NA,Phase 2,204,Anticipated,Rhizen Pharmaceuticals SA,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:19:00Z,2021-12-02T02:19:00Z
NCT04997551,NA,8/3/2021,NA,NA,8/6/2021,8/6/2021,8/9/2021,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/9/2021,Actual,8-Sep-20,Actual,9/8/2020,Aug-21,8/31/2021,1-Jan-22,Anticipated,1/1/2022,1-Sep-21,Anticipated,9/1/2021,NA,Interventional,NA,NA,Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19,Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized Patients With Covid-19 Infection,"Active, not recruiting",NA,Phase 3,752,Anticipated,Asociacion Instituto Biodonostia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:25:42Z,2021-12-02T02:25:42Z
NCT05002517,NA,8/9/2021,NA,NA,8/11/2021,8/11/2021,8/12/2021,Actual,NA,NA,NA,NA,NA,NA,8/11/2021,8/12/2021,Actual,3-Sep-20,Actual,9/3/2020,Aug-21,8/31/2021,31-Oct-21,Anticipated,10/31/2021,31-Jul-21,Actual,7/31/2021,NA,Interventional,NA,NA,"Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab","Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Against Systemic Corticotherapy in Patients Admitted by Covid-19 With Bilateral Pneumonia and Poor Evolution","Active, not recruiting",NA,Phase 3,60,Anticipated,Asociacion Instituto Biodonostia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:22:13Z,2021-12-02T02:22:13Z
NCT05000307,NA,8/10/2021,NA,NA,9/29/2021,8/10/2021,8/11/2021,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,10/7/2021,Actual,28-Jul-20,Actual,7/28/2020,Sep-21,9/30/2021,1-Dec-21,Anticipated,12/1/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,Coser,NA,Co-SÃ©r: Serological Analysis and Viral Neutralization in People With a Documented COVID-19 Infection,Co-SÃ©r: Serological Analysis and Viral Neutralization in People With a Documented COVID-19,Recruiting,NA,Not Applicable,50,Anticipated,"University Hospital, Ghent",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:23:37Z,2021-12-02T02:23:37Z
NCT05000255,NA,7/25/2021,NA,NA,8/9/2021,8/9/2021,8/11/2021,Actual,NA,NA,NA,NA,NA,NA,8/9/2021,8/11/2021,Actual,18-Jan-21,Actual,1/18/2021,Aug-21,8/31/2021,30-Sep-25,Anticipated,9/30/2025,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,"Coping With Covid-19: Loneliness, Self-Efficacy, Social Support, Depression & Anxiety in Patients in Medical Rehab.","Coping With Covid-19: Loneliness, Self-Efficacy, Social Support and Depression and Anxiety in Patients in Medical Rehabilitation. A Field Study in Geriatrics and Physical Medicine",Recruiting,NA,Not Applicable,300,Anticipated,Helios Research Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:23:49Z,2021-12-02T02:23:49Z
NCT04998708,NA,8/8/2021,NA,NA,8/8/2021,8/8/2021,8/10/2021,Actual,NA,NA,NA,NA,NA,NA,8/8/2021,8/10/2021,Actual,1-Dec-20,Actual,12/1/2020,Aug-21,8/31/2021,30-Apr-21,Actual,4/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,NA,NA,Relaxation Exercise in Patients With COVID-19,An Integrated Relaxation Protocol Improves Immune Biomarkers and Reduces COVID-19 Severity and Progression in Patients With COVID-19,Completed,NA,Not Applicable,30,Actual,Beni-Suef University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:24:55Z,2021-12-02T02:24:55Z
NCT05005156,NA,6/7/2021,NA,NA,9/14/2021,8/6/2021,8/13/2021,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/21/2021,Actual,24-Jun-21,Actual,6/24/2021,Sep-21,9/30/2021,30-Sep-22,Anticipated,9/30/2022,30-Sep-22,Anticipated,9/30/2022,NA,Interventional,COVID-19,NA,Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older.,"A Randomized, Double-blind, Placebo-controlled, Phase IIb Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One or Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV, on Stable Treatment, and Virologically Suppressed for at Least 6 Months.",Recruiting,NA,Phase 2,876,Anticipated,FundaciÃ³n HuÃ©sped,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:20:27Z,2021-12-02T02:20:27Z
NCT05004753,NA,7/26/2021,NA,NA,9/1/2021,8/11/2021,8/13/2021,Actual,NA,NA,NA,NA,NA,NA,9/1/2021,9/9/2021,Actual,30-Sep-20,Actual,9/30/2020,Aug-21,8/31/2021,30-Apr-21,Actual,4/30/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects,"A Prospective, Randomized, Multi-center, Open Label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg Capsule in Treatment of Adult Subjects With COVID-19",Completed,NA,Phase 4,120,Actual,Mateon Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:20:41Z,2021-12-02T02:20:41Z
NCT05001542,NA,7/28/2021,NA,NA,10/5/2021,8/5/2021,8/12/2021,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/7/2021,Actual,31-May-21,Actual,5/31/2021,Oct-21,10/31/2021,30-Aug-21,Actual,8/30/2021,30-Aug-21,Actual,8/30/2021,NA,Interventional,VR,NA,Digital Interventions for Detection and Reduction of Moral Distress,"Could Digital Interventions Help Understand And ""Flatten The Curve"" Of Distress Due To Moral Injury Among Health Care Workers During The COVID Pandemic?",Completed,NA,Not Applicable,15,Actual,Unity Health Toronto,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:22:43Z,2021-12-02T02:22:43Z
NCT05002348,NA,7/28/2021,NA,NA,8/17/2021,8/10/2021,8/12/2021,Actual,NA,NA,NA,NA,NA,NA,8/17/2021,8/23/2021,Actual,1-Dec-20,Actual,12/1/2020,Aug-21,8/31/2021,30-Nov-23,Anticipated,11/30/2023,30-Nov-23,Anticipated,11/30/2023,NA,Interventional,NA,NA,Laser Acupuncture Improves Constipation in Patients Hospitalized for Stroke During the COVID-19 Pandemic,Construct and Apply Precision Care: An Informationized Model of Integrated Body Constitution of Chinese Medicine With Constipation Acupoints,Recruiting,NA,Not Applicable,100,Anticipated,Far Eastern Memorial Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:22:45Z,2021-12-02T02:22:45Z
NCT05000008,NA,8/6/2021,NA,NA,8/12/2021,8/6/2021,8/11/2021,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/19/2021,Actual,1-Jan-21,Actual,1/1/2021,Aug-21,8/31/2021,1-Oct-21,Anticipated,10/1/2021,1-Oct-21,Anticipated,10/1/2021,NA,Interventional,NA,NA,Aerobic Versus Anaerobic Exercise on Immune Functions and Disease Severity in Patients With COVID-19,Aerobic Versus Anaerobic Exercise on Immune Functions and Disease Severity in Patients With COVID-19: A Randomized Control Trial,Recruiting,NA,Not Applicable,30,Anticipated,Istanbul Gelisim University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:23:44Z,2021-12-02T02:23:44Z
NCT04998253,NA,5/19/2021,NA,NA,8/9/2021,8/7/2021,8/10/2021,Actual,NA,NA,NA,NA,NA,NA,8/9/2021,8/13/2021,Actual,1-Oct-20,Actual,10/1/2020,Aug-21,8/31/2021,15-May-21,Actual,5/15/2021,30-Nov-20,Actual,11/30/2020,NA,Interventional,COVID-19,NA,Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2,A Randomized Pilot Clinical Trial of the Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction of Sevoflurane in Patient's Whit ARDS Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2),Completed,NA,Early Phase 1,24,Actual,Unidad Temporal COVID-19 en Centro Citibanamex,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:25:22Z,2021-12-02T02:25:22Z
NCT04996238,NA,7/5/2021,NA,NA,8/5/2021,8/5/2021,8/9/2021,Actual,NA,NA,NA,NA,NA,NA,8/5/2021,8/9/2021,Actual,11-Feb-21,Actual,2/11/2021,Aug-21,8/31/2021,31-Jan-22,Anticipated,1/31/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,COVACC2,NA,Local and General Immune Response After Coronavirus Disease (COVID-19) Vaccination in Volunteers,COVACC2: Local and General Immune Response After COVID-19 Vaccination in Volunteers,"Active, not recruiting",NA,Not Applicable,300,Anticipated,"University Hospital, Ghent",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:26:51Z,2021-12-02T02:26:51Z
NCT04993586,NA,7/30/2021,NA,NA,10/4/2021,8/5/2021,8/6/2021,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/6/2021,Actual,29-Jul-21,Actual,7/29/2021,Oct-21,10/31/2021,31-Dec-22,Anticipated,12/31/2022,26-Mar-22,Anticipated,3/26/2022,NA,Interventional,NA,NA,Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose),"A Randomized, Open-label, Uncontrolled, Phase I/II Study to Assess Safety and Immunogenicity of Two or Three Dosing of Intramuscular/Intradermal AG0302-COVID19","Active, not recruiting",NA,Phase 1/Phase 2,400,Anticipated,"AnGes, Inc.",,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:28:33Z,2021-12-02T02:28:33Z
NCT04993547,NA,8/4/2021,NA,NA,8/5/2021,8/5/2021,8/6/2021,Actual,NA,NA,NA,NA,NA,NA,8/5/2021,8/6/2021,Actual,31-Mar-21,Actual,3/31/2021,Mar-21,3/31/2021,10-Jun-21,Actual,6/10/2021,9-Jun-21,Actual,6/9/2021,NA,Interventional,NA,NA,Cluster-RCT Collective Nasopharyngeal COVID-19 Testing Amongst Pupils,Peers' and Parent's Presence During Collective Nasopharyngeal COVID-19 Testing Amongst Pupils: A Cluster-Randomized Controlled Trial,Completed,NA,Not Applicable,952,Actual,"University Hospital, Ghent",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:28:47Z,2021-12-02T02:28:47Z
NCT04992182,NA,8/2/2021,NA,NA,8/4/2021,8/4/2021,8/5/2021,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/5/2021,Actual,8-Jul-21,Actual,7/8/2021,Aug-21,8/31/2021,30-Jun-22,Anticipated,6/30/2022,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,REFUERZO,NA,"Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster","Reactogenicidad, Seguridad e Inmunogenicidad de Dosis de Refuerzo de Vacunas Contra SARS-CoV-2 en Chile (Estudio REFUERZO)","Active, not recruiting",NA,Phase 2,534,Actual,Universidad del Desarrollo,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"Owing to data privacy regulations, the individual-level data in this study cannot be shared (Law N19.628).",2021-12-02T02:29:55Z,2021-12-02T02:29:55Z
NCT04993209,NA,8/3/2021,NA,NA,8/4/2021,8/4/2021,8/6/2021,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/6/2021,Actual,9-Jul-21,Actual,7/9/2021,Aug-21,8/31/2021,Sep-23,Anticipated,9/30/2023,Apr-23,Anticipated,4/30/2023,NA,Interventional,ADAPTCOV,NA,"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","Phase I/II Double-blind, Randomized, Stepwise, Adaptive, Controlled Clinical Trial to Assess the Safety and Immunogenicity of the COVID-19 Vaccine (Recombinant, Inactivated) in Adults, in Brazil - ADAPTCOV.",Recruiting,NA,Phase 1/Phase 2,5394,Anticipated,Butantan Institute,,32,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:28:50Z,2021-12-02T02:28:50Z
NCT04992000,NA,7/29/2021,NA,NA,8/5/2021,7/29/2021,8/5/2021,Actual,NA,NA,NA,NA,NA,NA,8/5/2021,8/12/2021,Actual,1-Jun-20,Actual,6/1/2020,Aug-21,8/31/2021,1-Dec-20,Actual,12/1/2020,1-Sep-20,Actual,9/1/2020,NA,Interventional,NA,NA,Self-Care of Hypertension Among Older Adults During COVID-19,Self-Care of Hypertension of Older Adults During COVID-19 Lockdown Period: A Randomized Controlled Trial,Completed,NA,Not Applicable,120,Actual,"Near East University, Turkey",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:30:18Z,2021-12-02T02:30:18Z
NCT04992390,NA,8/2/2021,NA,NA,9/17/2021,8/4/2021,8/5/2021,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/23/2021,Actual,24-Aug-21,Actual,8/24/2021,Sep-21,9/30/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,GAINS,NA,A Brief GAmeplay Intervention for NHS ICU Staff Affected by COVID-19 Trauma (GAINS Study),A Randomised Optimisation Study of a Brief Digital Imagery-competing Task Intervention to Support NHS ICU Staff Experiencing Intrusive Memories of Traumatic Events From Working in the COVID-19 Pandemic,Recruiting,NA,Not Applicable,150,Anticipated,P1vital Products Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,We aim to share the Study Protocol and Statistical Analysis Plan before the end of recruitment. The Clinical Study Report will be shared when available following publication. Supporting information mentioned above will be shared indefinitely and with no end date on Open Science Framework Platform.,"Anonymised research data will be made available on open science frame work (OSF) indefinitely.

OSF is an open source web application that is freely accessible to public and scientific community.",NA,Yes,"An anonymised database of individual participant data, along with a data dictionary, as well as the Clinical Study Report (which will include summarised anonymised participant data), will be shared on the Open Science Framework.",2021-12-02T02:29:44Z,2021-12-02T02:29:44Z
NCT04990544,NA,8/2/2021,NA,NA,8/2/2021,8/2/2021,8/4/2021,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/4/2021,Actual,31-Jul-21,Actual,7/31/2021,Aug-21,8/31/2021,Oct-22,Anticipated,10/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),"A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above",Recruiting,NA,Phase 2,1056,Anticipated,"Shanghai Zerun Biotechnology Co.,Ltd",,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:31:06Z,2021-12-02T02:31:06Z
NCT04990830,NA,7/29/2021,NA,NA,8/3/2021,8/3/2021,8/5/2021,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/5/2021,Actual,3-Feb-21,Actual,2/3/2021,Aug-21,8/31/2021,21-May-21,Actual,5/21/2021,21-Apr-21,Actual,4/21/2021,NA,Interventional,NA,NA,Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia,Early Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia: A Phase IIb Trial,Completed,NA,Phase 2/Phase 3,80,Actual,Istanbul University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data sharing will be decided on a later date depending on completion of further study Phases,2021-12-02T02:31:00Z,2021-12-02T02:31:00Z
NCT04990531,NA,7/22/2021,NA,NA,9/13/2021,8/2/2021,8/4/2021,Actual,NA,NA,NA,NA,NA,NA,9/13/2021,9/14/2021,Actual,9-Aug-21,Actual,8/9/2021,Jul-21,7/31/2021,1-Dec-21,Anticipated,12/1/2021,1-Nov-21,Anticipated,11/1/2021,NA,Interventional,DECRYPT,NA,Low-field Magnetic Resonance Imaging of Pediatric COVID-19,Low-fielD magnEtiC Resonance Imaging of pulmonarY Parenchyma Changes Associated wiTh Confirmed SARS-CoV-2 Infection in Children and Adolescents,Recruiting,NA,Not Applicable,58,Anticipated,University of Erlangen-NÃ¼rnberg Medical School,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication.,"The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request as follows:

Individual participant data will not be available Study Protocol and Statistical Analysis Plan will be available The data will be available beginning 9 months and ending 36 months following article publication.

The data will be available to researchers who provide a methodologically sound proposal.

The data will be available for individual participant data meta-analysis, only. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at https://www.uk-erlangen.de.

Restrictions may apply due to patient privacy and the General Data Protection Regulation.",NA,Yes,"Individual participant data that underlie the results reported in the primary publication, after deidentification (text, tables, figures, and appendices)",2021-12-02T02:31:10Z,2021-12-02T02:31:10Z
NCT04988217,NA,7/22/2021,NA,NA,9/21/2021,8/1/2021,8/3/2021,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/22/2021,Actual,15-Sep-21,Actual,9/15/2021,Aug-21,8/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,IN2COVID,NA,Inhaled Interferon Î±2b for the Treatment of Coronavirus Disease 19 (COVID-19),"A Phase I/II Randomized, Double-blind, Placebo-controlled Study of Inhaled Interferon Î±2b for the Treatment of Coronavirus Disease 19 (COVID-19)",Recruiting,NA,Phase 1/Phase 2,168,Anticipated,Pontificia Universidad Catolica de Chile,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available 1 year after study completion during 5 years upon reasonable request.,Available upon reasonable request.,NA,Yes,Available upon reasonable request.,2021-12-02T02:32:51Z,2021-12-02T02:32:51Z
NCT04988048,NA,7/29/2021,NA,NA,9/24/2021,7/29/2021,8/3/2021,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/29/2021,Actual,3-Aug-21,Actual,8/3/2021,Sep-21,9/30/2021,15-Feb-22,Anticipated,2/15/2022,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,ECEHeVac,NA,Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina,Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina,Recruiting,NA,Phase 2,1760,Anticipated,"Ministry of Public Health, Argentina",,14,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:32:55Z,2021-12-02T02:32:55Z
NCT04988282,NA,7/22/2021,NA,NA,7/31/2021,7/31/2021,8/3/2021,Actual,NA,NA,NA,NA,NA,NA,7/31/2021,8/3/2021,Actual,24-May-21,Actual,5/24/2021,Jul-21,7/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,STERCOV-ILD,NA,Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease,Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease,Recruiting,NA,Phase 4,642,Anticipated,Turkish Thoracic Society,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:33:08Z,2021-12-02T02:33:08Z
NCT04987554,NA,7/29/2021,NA,NA,7/29/2021,7/29/2021,8/3/2021,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/3/2021,Actual,1-Apr-21,Actual,4/1/2021,Jul-21,7/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2,Modulation of the Immune Response by AM3 Glycoconjugate.,Recruiting,NA,Not Applicable,120,Anticipated,University of Valladolid,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:33:31Z,2021-12-02T02:33:31Z
NCT04982757,NA,7/17/2021,NA,NA,8/26/2021,7/27/2021,7/29/2021,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/27/2021,Actual,18-Aug-21,Actual,8/18/2021,Aug-21,8/31/2021,May-28,Anticipated,5/31/2028,May-26,Anticipated,5/31/2026,NA,Interventional,NA,NA,Accelerated TMS for Depression and OCD,COVID-19 Compatible Accelerated TMS Therapy,Recruiting,NA,Not Applicable,300,Anticipated,Weill Medical College of Cornell University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,"Deidentified data will be available any time following publication of outcomes from this study, with no specified end date.",Deidentified data will be shared with any researcher requesting access.,NA,Yes,Individual data collected during the trial will be available after deidentification upon request to the PI. Data to be shared include deidentified clinical assessment scores and MRI images.,2021-12-02T02:36:40Z,2021-12-02T02:36:40Z
NCT04983537,NA,7/28/2021,NA,NA,7/28/2021,7/28/2021,7/30/2021,Actual,NA,NA,NA,NA,NA,NA,7/28/2021,7/30/2021,Actual,26-Jul-21,Actual,7/26/2021,Jul-21,7/31/2021,26-Sep-21,Anticipated,9/26/2021,26-Sep-21,Anticipated,9/26/2021,NA,Interventional,NA,NA,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Recruiting,NA,Phase 2,120,Anticipated,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:36:15Z,2021-12-02T02:36:15Z
NCT04983394,NA,7/28/2021,NA,NA,10/7/2021,7/29/2021,7/30/2021,Actual,NA,NA,NA,NA,NA,NA,10/7/2021,10/8/2021,Actual,1-Aug-21,Actual,8/1/2021,Oct-21,10/31/2021,1-Nov-21,Anticipated,11/1/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,NA,NA,The Effect of Virtual Reality Exercises on Patients With Post-SARS-CoV-2 Syndrome,"The Effect of Virtual Reality Exercises on Pain, Cardiopulmonary Functional Capacity and Quality of Life in Patients With Post-COVID Syndrome",Recruiting,NA,Not Applicable,63,Anticipated,Sivas Cumhuriyet University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The plan will be shared by the corresponding author at the submission stage if requested.,2021-12-02T02:36:28Z,2021-12-02T02:36:28Z
NCT04982887,NA,5/9/2021,NA,NA,7/29/2021,7/28/2021,7/29/2021,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/5/2021,Actual,8-May-21,Actual,5/8/2021,Jul-21,7/31/2021,15-Dec-21,Anticipated,12/15/2021,8-May-21,Actual,5/8/2021,NA,Interventional,NA,NA,Tele-Rehabilitation in Parkinson's Disease,Comparison of the Effectiveness of Two Different Exercise Programs Adapted to the Tele Rehabilitation Program in Parkinson's Patients During the Covid 19 Pandemic Period,Enrolling by invitation,NA,Not Applicable,12,Anticipated,Hacettepe University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T02:36:51Z,2021-12-02T02:36:51Z
NCT04982068,NA,7/26/2021,NA,NA,7/29/2021,7/27/2021,7/29/2021,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/3/2021,Actual,12-Jul-21,Actual,7/12/2021,Jul-21,7/31/2021,Oct-22,Anticipated,10/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),"A Randomized, Double-blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Immunogenicity of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above",Recruiting,NA,Phase 1,144,Anticipated,"Shanghai Zerun Biotechnology Co.,Ltd",,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:37:21Z,2021-12-02T02:37:21Z
NCT04981743,NA,7/9/2021,NA,NA,7/27/2021,7/27/2021,7/29/2021,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,7/29/2021,Actual,21-Jul-21,Anticipated,7/21/2021,Jul-21,7/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,COVID-19,NA,The Efficacy of Nigella Sativa Versus VitaminD3 as Supplement Therapy in Coronavirus Disease 2019 (COVID-19),Evaluation of The Efficacy of Nigella Sativa Versus VitaminD3 as Supplement Therapy in Management of Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Not Applicable,100,Anticipated,Ain Shams University,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:37:27Z,2021-12-02T02:37:27Z
NCT04981379,NA,7/26/2021,NA,NA,7/26/2021,7/26/2021,7/29/2021,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/29/2021,Actual,16-Nov-20,Actual,11/16/2020,Jun-21,6/30/2021,16-Feb-21,Actual,2/16/2021,31-Jan-21,Actual,1/31/2021,NA,Interventional,NA,NA,Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment,"Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment",Completed,NA,Phase 3,1120,Actual,Health Institutes of Turkey,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:37:50Z,2021-12-02T02:37:50Z
NCT04981314,NA,7/26/2021,NA,NA,8/3/2021,7/26/2021,7/29/2021,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/10/2021,Actual,18-Jun-21,Actual,6/18/2021,Aug-21,8/31/2021,31-Oct-21,Anticipated,10/31/2021,1-Oct-21,Anticipated,10/1/2021,NA,Interventional,ECCO-2,NA,Echinacea Drug for Covid-19,Study on the Effect of an Echinacea Formulation on the Clinical Manifestations and Evolution of Covid-19,Recruiting,NA,Phase 4,230,Anticipated,University of Santiago de Compostela,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,One month after study completion.,Biomedical community.,NA,Yes,Main results will be submitted for publication in a biomedical journal. The remaining IPD will be made availble to researchers upon request.,2021-12-02T02:37:39Z,2021-12-02T02:37:39Z
NCT04982042,NA,7/8/2021,NA,NA,7/28/2021,7/28/2021,7/29/2021,Actual,NA,NA,NA,NA,NA,NA,7/28/2021,8/4/2021,Actual,1-Mar-21,Actual,3/1/2021,Jul-21,7/31/2021,30-Jul-22,Anticipated,7/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,COVID19REHAB,NA,Post COVID-19 Pulmonary Rehabilitation Program,Outpatient and Home Pulmonary Rehabilitation Program for Post COVID-19 Patients,Recruiting,NA,Not Applicable,40,Anticipated,Centro UniversitÃ¡rio de Anapolis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After 02 years,The clinical and demographic data of the patients involved in this study will be made available to other researchers as requested after the end of the study and for an indefinite period.,https://www4.unievangelica.edu.br/ppg/movimento-humano-e-reabilitacao/laboratorios,Yes,Clinical and demographic data of patients involved in this study will be made available to other researchers as requested.,2021-12-02T02:37:35Z,2021-12-02T02:37:35Z
NCT04980508,NA,7/26/2021,NA,NA,7/26/2021,7/26/2021,7/28/2021,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/28/2021,Actual,20-Feb-21,Actual,2/20/2021,Jul-21,7/31/2021,30-May-21,Actual,5/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,NA,NA,Effects of COVID-19 on Cavernous Smooth Muscle,COVID-19 Can Cause Cavernous Smooth Muscle Damage: Investigation of the Effects of COVID-19 on Cavernous Smooth Muscle by Corpus Cavernosum Electromyography,Completed,NA,Not Applicable,29,Actual,Ankara Yildirim BeyazÄ±t University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:38:17Z,2021-12-02T02:38:17Z
NCT04979923,NA,7/27/2021,NA,NA,7/27/2021,7/27/2021,7/28/2021,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,7/28/2021,Actual,1-Jul-21,Actual,7/1/2021,Jul-21,7/31/2021,Aug-21,Anticipated,8/31/2021,31-Jul-21,Anticipated,7/31/2021,NA,Interventional,NA,NA,"Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial","Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial",Recruiting,NA,Phase 1,81,Anticipated,Sheikh Zayed Medical College,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:39:10Z,2021-12-02T02:39:10Z
NCT04979221,NA,7/23/2021,NA,NA,7/27/2021,7/23/2021,7/28/2021,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,8/3/2021,Actual,26-Jul-21,Actual,7/26/2021,Jul-21,7/31/2021,28-Feb-22,Anticipated,2/28/2022,26-Jan-22,Anticipated,1/26/2022,NA,Interventional,NA,NA,Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19,Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19,Recruiting,NA,Phase 3,274,Anticipated,Hospital de Clinicas de Porto Alegre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:39:22Z,2021-12-02T02:39:22Z
NCT04978207,NA,7/19/2021,NA,NA,7/22/2021,7/22/2021,7/27/2021,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/27/2021,Actual,6-Jun-21,Actual,6/6/2021,Jul-21,7/31/2021,31-Mar-23,Anticipated,3/31/2023,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,FR,NA,A Faithful Response to COVID-19 Project,COVID-19 Testing and Linkage to Care With Faith-based and Health Agency Partners: A Faithful Response to COVID-19,Recruiting,NA,Phase 2/Phase 3,960,Anticipated,"University of Missouri, Kansas City",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Mar-23,NA,NA,Yes,De-identified data will be shared per a data agreement plan with NIH and with Duke University as part of the Rapid Acceleration of Diagnostics Underserved Populations initiative. Additionally de-identified data can be requested directly from the primary and secondary contacts. We will make the de-identified data and associated documentation available to potential requesters only under a data sharing agreement (based on the requester's proposed use of the data and under the guidance of our Institutional Review Board) that provides for: (1) a commitment to using the data only for research purposes and to not identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.,2021-12-02T02:40:09Z,2021-12-02T02:40:09Z
NCT04977479,NA,7/24/2021,NA,NA,9/22/2021,7/24/2021,7/27/2021,Actual,NA,NA,NA,NA,NA,NA,9/22/2021,9/23/2021,Actual,8-Sep-21,Actual,9/8/2021,20-Sep-21,9/20/2021,30-Dec-22,Anticipated,12/30/2022,30-Dec-22,Anticipated,12/30/2022,NA,Interventional,NA,NA,The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose,"A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",Recruiting,NA,Phase 2,100,Anticipated,National Institutes of Health Clinical Center (CC),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:40:48Z,2021-12-02T02:40:48Z
NCT04978025,NA,11/5/2020,NA,NA,7/26/2021,7/26/2021,7/27/2021,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/27/2021,Actual,1-Nov-20,Actual,11/1/2020,Jul-21,7/31/2021,1-Nov-21,Anticipated,11/1/2021,1-Nov-21,Anticipated,11/1/2021,NA,Interventional,NA,NA,"Colloidal Silver, Treatment of COVID-19",The Value of Colloidal Silver in the Treatment of COVID-19,Recruiting,NA,Not Applicable,50,Anticipated,HÃ´pital Universitaire Sahloul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:40:23Z,2021-12-02T02:40:23Z
NCT04977921,NA,7/17/2021,NA,NA,7/22/2021,7/22/2021,7/27/2021,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/27/2021,Actual,17-Jan-21,Actual,1/17/2021,Jul-21,7/31/2021,30-May-21,Actual,5/30/2021,15-May-21,Actual,5/15/2021,NA,Interventional,EDU,NA,Lab Skills Nursing Education Into Effective Clinical Practice During COVID-19: Elsevier Clinical Skill Platform,An Authentic Solution to Translate Lab Skills Nursing Education Into Effective Clinical Practice During COVID-19: Elsevier Clinical Skill Platform,Completed,NA,Not Applicable,50,Actual,Beni-Suef University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,data analysis completed July writing paper on August publish paper on September,2021-12-02T02:40:24Z,2021-12-02T02:40:24Z
NCT04978051,NA,6/30/2021,NA,NA,7/23/2021,7/23/2021,7/27/2021,Actual,NA,NA,NA,NA,NA,NA,7/23/2021,7/27/2021,Actual,12-Apr-21,Actual,4/12/2021,Jul-21,7/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,ICATÂ·COVID,NA,Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection,"Randomized, Open, Multicenter Phase II Clinical Trial, Proof of Concept, to Evaluate Efficacy and Safety of Icatibant in Hospitalized Patients With SARS-COV-2 (COVID-19) Without Assisted Ventilation Compared With Standard Care",Recruiting,NA,Phase 2,120,Anticipated,Hospital Universitari de Bellvitge,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:40:40Z,2021-12-02T02:40:40Z
NCT04973462,NA,7/3/2021,NA,NA,7/21/2021,7/21/2021,7/22/2021,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/22/2021,Actual,1-Aug-21,Anticipated,8/1/2021,Jul-21,7/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,COVID-19,NA,Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19,Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Phase 4,80,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:43:22Z,2021-12-02T02:43:22Z
NCT04973488,NA,7/20/2021,NA,NA,7/20/2021,7/20/2021,7/22/2021,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/22/2021,Actual,25-Jul-20,Actual,7/25/2020,Jul-21,7/31/2021,10-Jan-21,Actual,1/10/2021,10-Jan-21,Actual,1/10/2021,NA,Interventional,NA,NA,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Completed,NA,Phase 2/Phase 3,38,Actual,"University of Medicine and Pharmacy ""Victor Babes"" Timisoara",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available at 6 months after registering the study. It will be available for 36 months,"Data will be shared with interested researchers, contact: novacescu_alex@yahoo.com",NA,Yes,"We plan on sharing treatment protocol, demographic data of the study cohort, primary outcomes, secondary outcomes, miscellaneous data, treatment scheme, statystical data",2021-12-02T02:43:29Z,2021-12-02T02:43:29Z
NCT04974203,NA,7/20/2021,NA,NA,7/21/2021,7/21/2021,7/23/2021,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/23/2021,Actual,Jul-21,Anticipated,7/31/2021,Jul-21,7/31/2021,Aug-21,Anticipated,8/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Saliva-based COVID-19 DNA Aptamer Test,Saliva-based COVID-19 DNA Aptamer Test: Formative Usability and Internal Validation Study,Recruiting,NA,Not Applicable,200,Anticipated,Achiko AG,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will be managed by investigators only. Analyzed data or result summary will be shared to related researchers or other parties,2021-12-02T02:43:01Z,2021-12-02T02:43:01Z
NCT04972864,NA,7/15/2021,NA,NA,7/21/2021,7/21/2021,7/22/2021,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/22/2021,Actual,1-Mar-21,Actual,3/1/2021,Jul-21,7/31/2021,18-Jul-21,Actual,7/18/2021,18-Jul-21,Actual,7/18/2021,NA,Interventional,NA,NA,Effects of Respiratory Muscle Training in Patients With Post COVID-19,Effects of Respiratory Muscle Training in Patients With Post COVID-19,Completed,NA,Not Applicable,24,Actual,Gazi University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:44:05Z,2021-12-02T02:44:05Z
NCT04970719,NA,7/20/2021,NA,NA,8/25/2021,7/20/2021,7/21/2021,Actual,NA,NA,NA,NA,NA,NA,8/25/2021,8/27/2021,Actual,10-Jul-21,Actual,7/10/2021,Aug-21,8/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus,The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes Mellitus,Recruiting,NA,Phase 3,382,Anticipated,"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,relative to the time when summary data are published,all data will be available if required,NA,Yes,all IPD that underlie results in a publication,2021-12-02T02:45:35Z,2021-12-02T02:45:35Z
NCT04970563,NA,6/16/2021,NA,NA,7/20/2021,7/20/2021,7/21/2021,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,21-Jun-21,Actual,6/21/2021,Jun-21,6/30/2021,1-Apr-22,Anticipated,4/1/2022,1-Feb-22,Anticipated,2/1/2022,NA,Interventional,NA,NA,"Detection of Asymptomatic SARS-Cov2 Infected Patients by Detection Dogs: ""Proof of Concept"" Study (CoviDetectionDog)-Covid-19","Detection of Asymptomatic SARS-Cov2 Infected Patients by Detection Dogs: ""Proof of Concept"" Study",Recruiting,NA,Not Applicable,160,Anticipated,HÃ´pital EuropÃ©en Marseille,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:45:40Z,2021-12-02T02:45:40Z
NCT04967794,NA,7/9/2021,NA,NA,7/16/2021,7/16/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,7/16/2021,7/20/2021,Actual,1-Jun-21,Actual,6/1/2021,Jul-21,7/31/2021,9-Jul-21,Anticipated,7/9/2021,9-Jul-21,Actual,7/9/2021,NA,Interventional,NA,NA,Effectiveness of Teleorientation in Oral Hygiene During the COVID-19 Pandemic,"Effectiveness of Teleorientation in Oral Hygiene During the COVID-19 Pandemic, a Randomized Clinical Trial",Recruiting,NA,Early Phase 1,30,Anticipated,University of Sao Paulo,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Make the study visible to other researchers through the sharing link,2021-12-02T02:47:47Z,2021-12-02T02:47:47Z
NCT04969991,NA,7/8/2021,NA,NA,8/20/2021,7/19/2021,7/21/2021,Actual,NA,NA,NA,NA,NA,NA,8/20/2021,8/23/2021,Actual,30-Jun-21,Actual,6/30/2021,Aug-21,8/31/2021,Jan-22,Anticipated,1/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,STAIRS,NA,Study of Varespladib in Patients Hospitalized With Severe COVID-19,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2",Recruiting,NA,Phase 2,90,Anticipated,"Ophirex, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:46:16Z,2021-12-02T02:46:16Z
NCT04969263,NA,7/16/2021,NA,NA,10/4/2021,7/16/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/5/2021,Actual,10-Aug-21,Actual,8/10/2021,Oct-21,10/31/2021,Oct-22,Anticipated,10/31/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,CPAT,NA,COVID-19 Protection After Transplant Pilot Study,Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses,"Active, not recruiting",NA,Phase 2,81,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"On average, within 24 months after database lock for the trial.",Open access.,https://www.immport.org/home,Yes,"The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.",2021-12-02T02:46:37Z,2021-12-02T02:46:37Z
NCT04969172,NA,7/18/2021,NA,NA,7/18/2021,7/18/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,7/18/2021,7/20/2021,Actual,11-Jul-21,Actual,7/11/2021,Jul-21,7/31/2021,11-Jul-22,Anticipated,7/11/2022,11-Jul-22,Anticipated,7/11/2022,NA,Interventional,NA,NA,"A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection","A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection","Active, not recruiting",NA,Phase 2,155,Anticipated,Tel-Aviv Sourasky Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:46:48Z,2021-12-02T02:46:48Z
NCT04967430,NA,7/13/2021,NA,NA,9/15/2021,7/13/2021,7/19/2021,Actual,NA,NA,NA,NA,NA,NA,9/15/2021,9/22/2021,Actual,27-Aug-21,Actual,8/27/2021,Jan-21,1/31/2021,14-Dec-21,Anticipated,12/14/2021,14-Oct-21,Anticipated,10/14/2021,NA,Interventional,NA,NA,TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19,"TOGETHER-Toronto: A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19",Recruiting,NA,Phase 3,763,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:47:58Z,2021-12-02T02:47:58Z
NCT04969276,NA,7/16/2021,NA,NA,11/30/2021,7/16/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/1/2021,Estimate,16-Jul-21,Actual,7/16/2021,30-Nov-21,11/30/2021,2-Feb-22,Anticipated,2/2/2022,2-Feb-22,Anticipated,2/2/2022,NA,Interventional,NA,NA,Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine,"A Phase II, Open-label Study to Assess the Safety and Immunogenicity of FluzoneÂ® High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","Active, not recruiting",NA,Phase 2,306,Actual,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-02T02:46:42Z,2021-12-02T02:46:42Z
NCT04967729,NA,7/7/2021,NA,NA,7/20/2021,7/15/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/27/2021,Actual,10-Jun-21,Actual,6/10/2021,Jul-21,7/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,COVID-19 and Lung Ultrasound Utility,The Utility of Self-administered Lung Ultrasound in Patients With COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,Rocket Doctor Inc.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:47:51Z,2021-12-02T02:47:51Z
NCT04967755,NA,7/13/2021,NA,NA,7/18/2021,7/18/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,7/18/2021,7/20/2021,Actual,1-Jun-21,Actual,6/1/2021,Jul-21,7/31/2021,30-Sep-21,Anticipated,9/30/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Jing-Si-Herbal-Tea Accelerates SARS-Cov-2 Load Reduction Among COVID-19 Patients,"Taipei Tzu Chi Hospital,The Buddhist Medical Fundation",Recruiting,NA,Not Applicable,200,Anticipated,"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:47:53Z,2021-12-02T02:47:53Z
NCT04967807,NA,6/29/2021,NA,NA,8/9/2021,7/16/2021,7/20/2021,Actual,NA,NA,NA,NA,NA,NA,8/9/2021,8/16/2021,Actual,5-Aug-21,Actual,8/5/2021,Jun-21,6/30/2021,14-Jun-22,Anticipated,6/14/2022,14-Jun-22,Anticipated,6/14/2022,NA,Interventional,MYOVAX,NA,Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study),Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study),Recruiting,NA,Not Applicable,80,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:47:54Z,2021-12-02T02:47:54Z
NCT04966910,NA,6/25/2021,NA,NA,7/15/2021,7/15/2021,7/19/2021,Actual,NA,NA,NA,NA,NA,NA,7/15/2021,7/19/2021,Actual,6-Apr-21,Actual,4/6/2021,Jul-21,7/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Stay Connected: Testing an Intervention to Combat COVID-19 Related Social Isolation Among Seattle-area Older Adults,Stay Connected: Testing an Intervention to Combat COVID-19 Related Social Isolation Among Seattle-area Older Adults,Recruiting,NA,Not Applicable,120,Anticipated,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:48:27Z,2021-12-02T02:48:27Z
NCT04962308,NA,7/13/2021,NA,NA,9/22/2021,7/13/2021,7/14/2021,Actual,NA,NA,NA,NA,NA,NA,9/22/2021,9/24/2021,Actual,19-Jun-21,Actual,6/19/2021,Jun-21,6/30/2021,19-Dec-21,Anticipated,12/19/2021,19-Aug-21,Actual,8/19/2021,NA,Interventional,NA,NA,Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,"An Open-label,Phase â…£ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.",Recruiting,NA,Phase 4,1400,Anticipated,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:52:04Z,2021-12-02T02:52:04Z
NCT04964154,NA,7/13/2021,NA,NA,7/13/2021,7/13/2021,7/15/2021,Actual,NA,NA,NA,NA,NA,NA,7/13/2021,7/15/2021,Actual,17-Feb-21,Actual,2/17/2021,Jul-21,7/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Mar-22,Anticipated,3/30/2022,NA,Interventional,BRAVE,NA,Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study,Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study,Recruiting,NA,Not Applicable,4000,Anticipated,North Carolina Central University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:50:40Z,2021-12-02T02:50:40Z
NCT04964414,NA,7/15/2021,NA,NA,10/1/2021,7/15/2021,7/16/2021,Actual,NA,NA,NA,NA,NA,NA,10/1/2021,10/4/2021,Actual,30-Sep-21,Actual,9/30/2021,Oct-21,10/31/2021,Dec-24,Anticipated,12/31/2024,Dec-23,Anticipated,12/31/2023,NA,Interventional,NA,NA,Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19,Prospective Randomized Study of the Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,University of Pittsburgh,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Beginning 1 year after publication of summary data. Ending 5 years after publication.,"Proposals should be directed to shafferad@upmc.edu. To gain access, data requestors will need to sign data access agreement.",NA,Yes,"Individual participant data (IPD) may be shared, after de-identification, with researchers who provide a methodologically sound proposal. IPD to be shared will include that necessary to achieve the aims in the approved proposal.",2021-12-02T02:50:42Z,2021-12-02T02:50:42Z
NCT04962906,NA,7/8/2021,NA,NA,8/18/2021,7/13/2021,7/15/2021,Actual,NA,NA,NA,NA,NA,NA,8/18/2021,8/20/2021,Actual,5-Jul-21,Actual,7/5/2021,Jul-21,7/31/2021,15-Aug-21,Actual,8/15/2021,5-Aug-21,Actual,8/5/2021,NA,Interventional,NA,NA,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Completed,NA,Phase 2,192,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:51:35Z,2021-12-02T02:51:35Z
NCT04962893,NA,7/12/2021,NA,NA,10/4/2021,7/14/2021,7/15/2021,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/6/2021,Actual,26-Jun-21,Actual,6/26/2021,Jul-21,7/31/2021,Sep-22,Anticipated,9/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,COVID-19,NA,Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine,"Phase II Study to Assess the Safety, Efficacy, and Immunogenicity of Authentic SARS-CoV-2 or Alpha Variant Spike Containing VLP Vaccines and Their Combination for the Prevention of COVID-19 in Healthy Adult Volunteers (SAVE STUDY)",Recruiting,NA,Phase 2,330,Anticipated,The Scientific and Technological Research Council of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:51:40Z,2021-12-02T02:51:40Z
NCT04964583,NA,6/25/2021,NA,NA,8/3/2021,7/14/2021,7/16/2021,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/4/2021,Actual,20-Jan-21,Actual,1/20/2021,Aug-21,8/31/2021,Aug-21,Anticipated,8/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,Omehecatl,NA,Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19,"Double-blind, Randomized, Prospective, Parallel Study to Demonstrate the Efficacy and Safety of Outpatient Treatment of the Fixed Combination of Hydroxychloroquine With Azithromycin Versus Hydroxychloroquine Treatment and Placebo Treatment in Patients Diagnosed With Mild COVID-19 Infection",Recruiting,NA,Phase 2/Phase 3,105,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months,NA,NA,Yes,Database with all non identifiable data will be available upon request.,2021-12-02T02:50:23Z,2021-12-02T02:50:23Z
NCT04961333,NA,5/7/2021,NA,NA,7/12/2021,7/12/2021,7/14/2021,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/14/2021,Actual,23-Apr-21,Actual,4/23/2021,Jul-21,7/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,COVID-19,NA,Internet-based Multidisciplinary Rehabilitation for Longterm COVID-19 Syndrome,Internet-based Multidisciplinary Rehabilitation for Longterm COVID-19 Syndrome,Recruiting,NA,Not Applicable,200,Anticipated,Danderyd Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:52:41Z,2021-12-02T02:52:41Z
NCT04961359,NA,7/8/2021,NA,NA,7/19/2021,7/8/2021,7/14/2021,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/23/2021,Actual,3-Jul-21,Actual,7/3/2021,Jul-21,7/31/2021,Dec-22,Anticipated,12/31/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2ï¼ˆCOVID-19ï¼‰ Phase I Clinical Trial (3~17 Years Old),"A Randomized, Blinded, Placebo-controlled Phase â…  Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age",Recruiting,NA,Phase 1,75,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:52:35Z,2021-12-02T02:52:35Z
NCT04961502,NA,6/4/2021,NA,NA,7/12/2021,7/12/2021,7/14/2021,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/14/2021,Actual,11-Mar-21,Actual,3/11/2021,Jun-21,6/30/2021,Sep-21,Anticipated,9/30/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,COGEVAX-BIO,NA,Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions,Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions,Recruiting,NA,Not Applicable,80,Anticipated,GÃ©rond'if,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:52:44Z,2021-12-02T02:52:44Z
NCT04958863,NA,6/30/2021,NA,NA,7/9/2021,7/9/2021,7/12/2021,Actual,NA,NA,NA,NA,NA,NA,7/9/2021,7/12/2021,Actual,1-Jan-21,Actual,1/1/2021,Jul-21,7/31/2021,30-Jun-21,Actual,6/30/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,NA,Impact of Facemasks on Running During COVID-19 Pandemic,Running and Facemasks During COVID-19 Pandemic: a Randomized Crossover Trial,Completed,NA,Not Applicable,18,Actual,Fundacion Clinica Valle del Lili,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:54:44Z,2021-12-02T02:54:44Z
NCT04959786,NA,7/1/2021,NA,NA,7/9/2021,7/9/2021,7/13/2021,Actual,NA,NA,NA,NA,NA,NA,7/9/2021,7/13/2021,Actual,1-Apr-21,Actual,4/1/2021,Jul-21,7/31/2021,Dec-22,Anticipated,12/31/2022,Nov-22,Anticipated,11/30/2022,NA,Interventional,NA,NA,MANS-NRIZ Trial for COVID-19 Treatment : Extension Study,"Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: Extension Study",Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Mansoura University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:53:53Z,2021-12-02T02:53:53Z
NCT04957017,NA,7/4/2021,NA,NA,7/7/2021,7/7/2021,7/9/2021,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/9/2021,Actual,15-Aug-20,Actual,8/15/2020,Jul-21,7/31/2021,10-Jun-21,Actual,6/10/2021,25-Jan-21,Actual,1/25/2021,NA,Interventional,NA,NA,Effect of Hand-Washing Training in Covid-19,"Effect of Training on Given to Women With Chronic Disease on Hand-Washing Behaviours, Attitudes and Nutrition During the Covid-19 Pandemic",Completed,NA,Not Applicable,90,Actual,Mehmet Akif Ersoy University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,There is not plan.,2021-12-02T02:55:53Z,2021-12-02T02:55:53Z
NCT04957940,NA,7/6/2021,NA,NA,9/26/2021,7/7/2021,7/12/2021,Actual,NA,NA,NA,NA,NA,NA,9/26/2021,9/28/2021,Actual,5-Jul-21,Actual,7/5/2021,Sep-21,9/30/2021,26-Sep-21,Actual,9/26/2021,20-Sep-21,Actual,9/20/2021,NA,Interventional,NA,NA,Lipid Emulsion Infusion and COVID-19 Patients,Fish-Oil-Based Lipid Emulsion Infusion (FOBLE): Could Early Use Provide a Potential Therapy to Stop Moderate Cases of COVID-19 Diseased Patient's Shift to ICU?,Completed,NA,Phase 3,74,Actual,Assiut University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:55:12Z,2021-12-02T02:55:12Z
NCT04954118,NA,7/4/2021,NA,NA,7/7/2021,7/7/2021,7/8/2021,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/8/2021,Actual,20-Mar-20,Actual,3/20/2020,Jul-21,7/31/2021,30-Sep-20,Actual,9/30/2020,20-Mar-20,Actual,3/20/2020,NA,Interventional,NA,NA,A Different Use of The Aerosol Box in COVID-19 Patients; Internal Jugular Vein Cannulation,Use of Aerosol Box for Ultrasound-guided Internal Jugular Vein Cannulation in COVID-19 Patients; Single Center Experience,Completed,NA,Not Applicable,40,Actual,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:57:49Z,2021-12-02T02:57:49Z
NCT04954469,NA,7/5/2021,NA,NA,7/7/2021,7/7/2021,7/8/2021,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/8/2021,Actual,30-Jun-21,Actual,6/30/2021,Jul-21,7/31/2021,31-Mar-22,Anticipated,3/31/2022,1-Feb-22,Anticipated,2/1/2022,NA,Interventional,B-pVAC,NA,B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency,B-pVAC-SARS-CoV-2: Phase I/II Multicenter Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency,Recruiting,NA,Phase 1/Phase 2,68,Anticipated,University Hospital Tuebingen,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:57:51Z,2021-12-02T02:57:51Z
NCT04954092,NA,7/5/2021,NA,NA,9/8/2021,7/7/2021,7/8/2021,Actual,NA,NA,NA,NA,NA,NA,9/8/2021,9/16/2021,Actual,5-Jul-21,Actual,7/5/2021,Sep-21,9/30/2021,31-Dec-23,Anticipated,12/31/2023,6-Nov-22,Anticipated,11/6/2022,NA,Interventional,OLSTAD,NA,Study of Gam-COVID-Vac in Adolescents,"An Open Label Study With an Open Dose Selection Period to Assess the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac, a Combined Vector Vaccine for the Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Virus"", With the Participation of Adolescent Volunteers",Recruiting,NA,Phase 2/Phase 3,3000,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:57:53Z,2021-12-02T02:57:53Z
NCT04954014,NA,7/6/2021,NA,NA,8/31/2021,7/7/2021,7/8/2021,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/5/2021,Actual,1-Sep-20,Actual,9/1/2020,Aug-21,8/31/2021,31-Aug-21,Actual,8/31/2021,31-Aug-21,Actual,8/31/2021,NA,Interventional,BEVACOR,NA,Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients,Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients,Terminated,NA,Phase 2,21,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,,2,NA,"Lack of financing, lack of COVID19 patients in the ICU.",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,When study is published.,Send request to access.,NA,Yes,NA,2021-12-02T02:58:09Z,2021-12-02T02:58:09Z
NCT04954040,NA,7/6/2021,NA,NA,7/7/2021,7/7/2021,7/8/2021,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/8/2021,Actual,10-Feb-21,Actual,2/10/2021,Apr-21,4/30/2021,Dec-21,Anticipated,12/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,AMBUCOV,NA,Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19,Clinical Trial for the Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19,Recruiting,NA,Phase 2,132,Anticipated,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,When study is published.,Sending request.,NA,Yes,Data will be shared after the study concludes and results are published,2021-12-02T02:58:12Z,2021-12-02T02:58:12Z
NCT04953325,NA,7/5/2021,NA,NA,7/25/2021,7/5/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,7/25/2021,7/27/2021,Actual,9-Jul-21,Actual,7/9/2021,Jul-21,7/31/2021,31-Jan-22,Anticipated,1/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine for Prevention of COVID-19 in Healthy Population Aged 18 Years and Older,Recruiting,NA,Phase 4,270,Anticipated,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:58:29Z,2021-12-02T02:58:29Z
NCT04952766,NA,6/16/2021,NA,NA,7/7/2021,7/6/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/13/2021,Actual,29-Mar-21,Actual,3/29/2021,Jul-21,7/31/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,EREVA,NA,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Recruiting,NA,Phase 4,240,Anticipated,Centre Hospitalier RÃ©gional d'OrlÃ©ans,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:58:52Z,2021-12-02T02:58:52Z
NCT04952805,NA,7/1/2021,NA,NA,7/7/2021,7/5/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/13/2021,Actual,6-Jun-21,Actual,6/6/2021,Jul-21,7/31/2021,31-Aug-22,Anticipated,8/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.,"Randomized, Placebo-controlled, Double-blind, Multicenter, Seamless Adaptive Phase II-III Clinical Trial to Select the Dose and Evaluate Safety and Efficacy of MAD0004J08 Monoclonal Antibody in Adult Patients With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19",Recruiting,NA,Phase 2/Phase 3,800,Anticipated,Toscana Life Sciences Sviluppo s.r.l.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:58:40Z,2021-12-02T02:58:40Z
NCT04952727,NA,7/3/2021,NA,NA,9/23/2021,7/3/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/29/2021,Actual,26-Aug-21,Actual,8/26/2021,Jul-21,7/31/2021,26-May-22,Anticipated,5/26/2022,26-Nov-21,Anticipated,11/26/2021,NA,Interventional,NA,NA,Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults,"Safety and Immunogenicity of Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) inChinese Healthy Adults Aged 60 and Above: a Randomized, Observer-blind,Parallel-controlled Clinical Trial",Recruiting,NA,Phase 4,300,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T02:58:46Z,2021-12-02T02:58:46Z
NCT04894617,NA,5/12/2021,NA,NA,9/29/2021,5/12/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,10/6/2021,Actual,1-Jun-21,Actual,6/1/2021,Sep-21,9/30/2021,Apr-22,Anticipated,4/30/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,ACT,NA,Amantadine for COVID-19,"Amantadine for COVID-19: A Randomized, Placebo Controlled, Double-blinded, Clinical Trial",Recruiting,NA,Phase 3,226,Anticipated,"Copenhagen University Hospital, Hvidovre",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:00:16Z,2021-12-02T04:00:16Z
NCT04952519,NA,6/28/2021,NA,NA,7/2/2021,7/2/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,7/2/2021,7/7/2021,Actual,30-Mar-21,Actual,3/30/2021,Jul-21,7/31/2021,30-Apr-22,Anticipated,4/30/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,TITAN,NA,Efficacy of Amantadine Treatment in COVID-19 Patients,Efficacy of Amantadine Treatment in COVID-19 Patients,Recruiting,NA,Phase 3,500,Anticipated,Noblewell,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T02:59:04Z,2021-12-02T02:59:04Z
NCT04953234,NA,7/4/2021,NA,NA,7/4/2021,7/4/2021,7/7/2021,Actual,NA,NA,NA,NA,NA,NA,7/4/2021,7/7/2021,Actual,23-Feb-21,Actual,2/23/2021,Jul-21,7/31/2021,26-Apr-21,Actual,4/26/2021,26-Apr-21,Actual,4/26/2021,NA,Interventional,NA,NA,"Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge","A Pilot, Open-Label Study of NovoTTF-100L (TTFields, 150Hz) in Hospitalized Patients With COVID-19 and Continued Treatment After Hospitalization",Completed,NA,Not Applicable,10,Actual,NovoCure Ltd.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T02:58:53Z,2021-12-02T02:58:53Z
NCT04951362,NA,6/30/2021,NA,NA,9/11/2021,7/1/2021,7/6/2021,Actual,NA,NA,NA,NA,NA,NA,9/11/2021,9/17/2021,Actual,20-Apr-21,Actual,4/20/2021,Sep-21,9/30/2021,12-Sep-21,Anticipated,9/12/2021,12-Sep-21,Anticipated,9/12/2021,NA,Interventional,NA,NA,Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia,Studying the Expected Effect of Ivermectin Nanosuspension as Nasal Spray Upon Post covid19 Persistant Anosmia,Recruiting,NA,Phase 2/Phase 3,117,Anticipated,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:00:02Z,2021-12-02T03:00:02Z
NCT04951349,NA,6/30/2021,NA,NA,7/1/2021,7/1/2021,7/6/2021,Actual,NA,NA,NA,NA,NA,NA,7/1/2021,7/6/2021,Actual,21-Jan-21,Actual,1/21/2021,Jul-21,7/31/2021,30-May-21,Actual,5/30/2021,30-May-21,Actual,5/30/2021,NA,Interventional,NA,NA,Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.,"Phase 2b Clinical Trial to Evaluate the Tolerability and Efficacy in Reducing the Nasal Viral Load of SARS-CoV-2 of Benzalkonium Chloride 0.0065% (GX-03), in the Form of Nasal Ointment, in Patients Infected With COVID -19, and Evaluation of Its Tolerability in Health Care Providers, as a Preventive of Nasal Colonization, Complementary to Personal Protective Equipment",Completed,NA,Phase 2,85,Actual,Turn Therapeutics,,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,Within 30 days of announcement of study completion.,By official request for qualified use.,NA,Yes,NA,2021-12-02T03:00:04Z,2021-12-02T03:00:04Z
NCT04950803,NA,6/21/2021,NA,NA,7/2/2021,7/2/2021,7/6/2021,Actual,NA,NA,NA,NA,NA,NA,7/2/2021,7/6/2021,Actual,25-Jun-21,Actual,6/25/2021,Jul-21,7/31/2021,31-Dec-25,Anticipated,12/31/2025,31-May-25,Anticipated,5/31/2025,NA,Interventional,NA,NA,A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Recovered COVID-19 Patients,A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Reducing Development of Long-term Co-morbidities in Recovered COVID-19 Patients,Recruiting,NA,Not Applicable,280,Anticipated,Chinese University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:00:27Z,2021-12-02T03:00:27Z
NCT04950725,NA,6/30/2021,NA,NA,7/27/2021,7/1/2021,7/6/2021,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,7/28/2021,Actual,27-Jul-21,Actual,7/27/2021,Jul-21,7/31/2021,12-Jul-22,Anticipated,7/12/2022,12-May-22,Anticipated,5/12/2022,NA,Interventional,NA,NA,Covid-19 Virtual Recovery Study,Covid-19 Virtual Recovery Study,Recruiting,NA,Not Applicable,1500,Anticipated,Mayo Clinic,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:00:39Z,2021-12-02T03:00:39Z
NCT04948203,NA,6/29/2021,NA,NA,7/19/2021,6/29/2021,7/1/2021,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/26/2021,Actual,9-Jul-21,Actual,7/9/2021,Jul-21,7/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis,"SECOVID: A Multi-center, Randomized, Dose-ranging Parallel-group Trial Assessing the Efficacy of Sirolimus in Hospitalized Patients With COVID-19 Pneumonia for the Prevention of Post-COVID Fibrosis",Recruiting,NA,Phase 2/Phase 3,60,Anticipated,University of Chicago,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:02:08Z,2021-12-02T03:02:08Z
NCT04947488,NA,6/30/2021,NA,NA,6/30/2021,6/30/2021,7/1/2021,Actual,NA,NA,NA,NA,NA,NA,6/30/2021,7/6/2021,Actual,18-Jun-21,Actual,6/18/2021,Jun-21,6/30/2021,18-Nov-21,Anticipated,11/18/2021,18-Sep-21,Anticipated,9/18/2021,NA,Interventional,BC,NA,Evaluation of the Effects of Treatment With Bioarginin C in Adult Subjects Belonging to the Post-Covid Day Hospital,"Evaluation of the Effects of Treatment With Bioarginin C on Physical Exhaustion , Systemic Inflammatory State and Endothelial Function in Adult Subjects Belonging to the Post-Covid Day Hospital",Recruiting,NA,Not Applicable,50,Anticipated,University of Milan,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:02:39Z,2021-12-02T03:02:39Z
NCT04945356,NA,6/24/2021,NA,NA,6/29/2021,6/29/2021,6/30/2021,Actual,NA,NA,NA,NA,NA,NA,6/29/2021,6/30/2021,Actual,28-Oct-20,Actual,10/28/2020,Jun-21,6/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Telerehabilitation During Pandemic Containment Measures of COVID19,The Use of Telerehabilitation to Improve Function and Quality of Life for People in the Chronic Phase After Stroke During Pandemic Containment Measures of COVID19 : a Feasibility Pilot Study,Recruiting,NA,Not Applicable,25,Anticipated,UniversitÃ© de Sherbrooke,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:04:12Z,2021-12-02T03:04:12Z
NCT04945811,NA,6/29/2021,NA,NA,6/29/2021,6/29/2021,6/30/2021,Actual,NA,NA,NA,NA,NA,NA,6/29/2021,6/30/2021,Actual,1-Apr-20,Actual,4/1/2020,Jun-21,6/30/2021,30-May-21,Actual,5/30/2021,15-May-21,Actual,5/15/2021,NA,Interventional,NA,NA,Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta,Role of Interleukin-6 and Procalcitonin in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta,Completed,NA,Not Applicable,100,Actual,"Combined Military Hospital, Pakistan",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:04:03Z,2021-12-02T03:04:03Z
NCT04945564,NA,6/28/2021,NA,NA,8/13/2021,6/28/2021,6/30/2021,Actual,NA,NA,NA,NA,NA,NA,8/13/2021,8/16/2021,Actual,30-Jun-21,Actual,6/30/2021,Jun-21,6/30/2021,31-Aug-21,Anticipated,8/31/2021,30-Aug-21,Anticipated,8/30/2021,NA,Interventional,NA,NA,Covid-19 Patients Management During Home Isolation,Covid-19 Patients Management During Home Isolation,"Active, not recruiting",NA,Not Applicable,60,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:04:20Z,2021-12-02T03:04:20Z
NCT04944368,NA,6/19/2021,NA,NA,10/4/2021,6/28/2021,6/29/2021,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/11/2021,Actual,30-May-21,Actual,5/30/2021,Oct-21,10/31/2021,15-Dec-21,Anticipated,12/15/2021,19-Jul-21,Actual,7/19/2021,NA,Interventional,NA,NA,Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)","Active, not recruiting",NA,Phase 2,400,Actual,Cinnagen,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:05:19Z,2021-12-02T03:05:19Z
NCT04944121,NA,6/25/2021,NA,NA,9/23/2021,6/25/2021,6/29/2021,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/29/2021,Actual,25-Jun-21,Actual,6/25/2021,Jun-21,6/30/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Phase 2 Study of RSLV-132 in Subjects With Long COVID,"A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Post-acute COVID-19 (Long COVID)",Recruiting,NA,Phase 2,70,Anticipated,Resolve Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:05:22Z,2021-12-02T03:05:22Z
NCT04942990,NA,6/21/2021,NA,NA,6/29/2021,6/21/2021,6/29/2021,Actual,NA,NA,NA,NA,NA,NA,6/29/2021,7/1/2021,Actual,1-Apr-21,Actual,4/1/2021,Jun-21,6/30/2021,21-Jun-21,Actual,6/21/2021,21-Jun-21,Actual,6/21/2021,NA,Interventional,NA,NA,The Effectiveness of Calistenic Exercise Training in Adolescents,The Effectiveness of Calistenic Exercise Training in Adolescents Receiving Online Education During COVID-19 Pandemic,Completed,NA,Not Applicable,38,Actual,Baskent University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:06:23Z,2021-12-02T03:06:23Z
NCT04942392,NA,6/23/2021,NA,NA,6/24/2021,6/24/2021,6/28/2021,Actual,NA,NA,NA,NA,NA,NA,6/24/2021,6/28/2021,Actual,4-Sep-20,Actual,9/4/2020,Jun-21,6/30/2021,3-Dec-20,Actual,12/3/2020,3-Dec-20,Actual,12/3/2020,NA,Interventional,NA,NA,Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic,Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic: A Feasibility Study,Completed,NA,Not Applicable,33,Actual,UmeÃ¥ University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:06:56Z,2021-12-02T03:06:56Z
NCT04941183,NA,5/4/2021,NA,NA,6/24/2021,6/24/2021,6/28/2021,Actual,NA,NA,NA,NA,NA,NA,6/24/2021,6/28/2021,Actual,14-Apr-21,Actual,4/14/2021,May-21,5/31/2021,Nov-21,Anticipated,11/30/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,"Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients","A Randomized, Placebo-controlled, Double-blind, Single-ascending-dose and Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of IV NTR-441 Solution in HV Adults and COVID-19 Patients",Recruiting,NA,Phase 1,92,Anticipated,Neutrolis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:07:46Z,2021-12-02T03:07:46Z
NCT04941105,NA,6/21/2021,NA,NA,6/24/2021,6/24/2021,6/28/2021,Actual,NA,NA,NA,NA,NA,NA,6/24/2021,6/28/2021,Actual,1-Jun-21,Actual,6/1/2021,Jun-21,6/30/2021,31-Jul-21,Anticipated,7/31/2021,31-Jul-21,Anticipated,7/31/2021,NA,Interventional,IMPACT-SIRIO 5,NA,Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19,"Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19: the Randomized, Double-blind, Phase III IMPACT-SIRIO 5 Study.",Recruiting,NA,Phase 3,60,Anticipated,Collegium Medicum w Bydgoszczy,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:07:49Z,2021-12-02T03:07:49Z
NCT04939519,NA,4/7/2021,NA,NA,8/10/2021,6/23/2021,6/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/10/2021,8/12/2021,Actual,29-Mar-21,Actual,3/29/2021,Aug-21,8/31/2021,22-Sep-22,Anticipated,9/22/2022,22-Sep-22,Anticipated,9/22/2022,NA,Interventional,NA,NA,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Among Utah Community Health Centers,"Active, not recruiting",NA,Not Applicable,110270,Actual,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:08:57Z,2021-12-02T03:08:57Z
NCT04939714,NA,6/17/2021,NA,NA,6/24/2021,6/24/2021,6/25/2021,Actual,NA,NA,NA,NA,NA,NA,6/24/2021,6/25/2021,Actual,7-Jun-21,Actual,6/7/2021,Jun-21,6/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Caregiving During Crisis,Mastering the Challenges of Dementia Family Caregiving in a Time of COVID-19: An Online Course,Recruiting,NA,Not Applicable,100,Anticipated,Emory University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Individual participant data will be available for sharing beginning 3 months and ending 5 years following article publication.,"Individual participant data will be available for sharing with researchers who provide a methodologically sound proposal, in order to achieve aims in the approved proposal. Proposals should be directed to carolyn.clevenger@emory.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website.",NA,Yes,"All of the individual participant data collected during the trial will be made available for sharing, after deidentification.",2021-12-02T03:08:58Z,2021-12-02T03:08:58Z
NCT04939532,NA,4/7/2021,NA,NA,8/10/2021,6/23/2021,6/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/10/2021,8/12/2021,Actual,29-Mar-21,Actual,3/29/2021,Aug-21,8/31/2021,Sep-22,Anticipated,9/30/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Testing Among Utah Community Health Centers,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Among Utah Community Health Centers,"Active, not recruiting",NA,Not Applicable,110270,Actual,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:09:03Z,2021-12-02T03:09:03Z
NCT04940182,NA,6/23/2021,NA,NA,6/30/2021,6/23/2021,6/25/2021,Actual,NA,NA,NA,NA,NA,NA,6/30/2021,7/1/2021,Actual,26-Jun-21,Actual,6/26/2021,Jun-21,6/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19,"A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With Mild COVID-19",Recruiting,NA,Phase 3,274,Anticipated,RSV Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:08:44Z,2021-12-02T03:08:44Z
NCT04939402,NA,4/22/2021,NA,NA,6/24/2021,6/24/2021,6/25/2021,Actual,NA,NA,NA,NA,NA,NA,6/24/2021,6/25/2021,Actual,5-May-21,Actual,5/5/2021,Apr-21,4/30/2021,Jun-22,Anticipated,6/30/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following COVID-19 Vaccination Using an Adenoviral Vector,Recruiting,NA,Not Applicable,200,Anticipated,Universitair Ziekenhuis Brussel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:09:09Z,2021-12-02T03:09:09Z
NCT04939415,NA,6/21/2021,NA,NA,8/23/2021,6/24/2021,6/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/25/2021,Actual,1-Jul-21,Actual,7/1/2021,Aug-21,8/31/2021,31-Dec-22,Anticipated,12/31/2022,1-Jul-22,Anticipated,7/1/2022,NA,Interventional,MACH19,NA,Chinese Herbal Formula for COVID-19,"Multicenter Double Blind, Placebo Controlled RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19",Recruiting,NA,Phase 1,66,Anticipated,"University of California, San Diego",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:09:10Z,2021-12-02T03:09:10Z
NCT04936503,NA,6/2/2021,NA,NA,6/22/2021,6/22/2021,6/23/2021,Actual,NA,NA,NA,NA,NA,NA,6/22/2021,6/23/2021,Actual,18-Jun-20,Actual,6/18/2020,Jun-21,6/30/2021,2-Mar-21,Actual,3/2/2021,2-Mar-21,Actual,3/2/2021,NA,Interventional,ASCCOVID19,NA,Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19,Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19,Completed,NA,Not Applicable,984,Actual,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:10:59Z,2021-12-02T03:10:59Z
NCT04936893,NA,6/7/2021,NA,NA,6/15/2021,6/15/2021,6/23/2021,Actual,NA,NA,NA,NA,NA,NA,6/15/2021,6/23/2021,Actual,19-May-20,Actual,5/19/2020,Jun-21,6/30/2021,31-Jul-21,Anticipated,7/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,NA,Effects of Mindfulness Practice on Healthcare Workers,Effects of Mindfulness Practice on Healthcare Workers During the COVID-19 (Coronavirus Disease) Pandemic,"Active, not recruiting",NA,Not Applicable,80,Actual,Yale-NUS College,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:10:50Z,2021-12-02T03:10:50Z
NCT04935515,NA,6/20/2021,NA,NA,6/22/2021,6/22/2021,6/23/2021,Actual,NA,NA,NA,NA,NA,NA,6/22/2021,6/23/2021,Actual,15-Apr-21,Actual,4/15/2021,Jun-21,6/30/2021,6-Jun-21,Actual,6/6/2021,9-May-21,Actual,5/9/2021,NA,Interventional,NA,NA,C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.,C Reactive Protein Based Early Intervention for Home Quarantined COVID -19 Patients to Avoid Complications and Hospitalization.,Completed,NA,Not Applicable,25,Actual,UR Anoop Research Group,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:11:50Z,2021-12-02T03:11:50Z
NCT04935528,NA,6/18/2021,NA,NA,6/22/2021,6/22/2021,6/23/2021,Actual,NA,NA,NA,NA,NA,NA,6/22/2021,6/23/2021,Actual,2-Jun-21,Actual,6/2/2021,Jun-21,6/30/2021,2-Jun-22,Anticipated,6/2/2022,2-Jun-22,Anticipated,6/2/2022,NA,Interventional,CANSEROVAX,NA,Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center,Study of Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response Between 1 and 3 Months After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center,Recruiting,NA,Not Applicable,430,Anticipated,Centre Georges Francois Leclerc,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:11:45Z,2021-12-02T03:11:45Z
NCT04935437,NA,6/1/2021,NA,NA,6/21/2021,6/21/2021,6/23/2021,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/23/2021,Actual,21-Jan-21,Actual,1/21/2021,Jun-21,6/30/2021,1-Sep-21,Anticipated,9/1/2021,1-Sep-21,Anticipated,9/1/2021,NA,Interventional,NA,NA,Implementing a Rehabilitation Program in Patients Recovering From Covid-19 Infection,Implementing a Rehabilitation Program in Patients Recovering From Covid-19 Infection,Recruiting,NA,Not Applicable,40,Anticipated,Evangelismos Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:11:55Z,2021-12-02T03:11:55Z
NCT04935502,NA,6/14/2021,NA,NA,9/17/2021,6/21/2021,6/23/2021,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/23/2021,Actual,15-Mar-21,Actual,3/15/2021,Sep-21,9/30/2021,30-Aug-21,Actual,8/30/2021,30-Aug-21,Actual,8/30/2021,NA,Interventional,NA,NA,Home Based Exercises With and Without Posture and Ergonomics Training Among Students During COVID-19,Effects of Home Based Exercises With and Without Posture and Ergonomics Training on Pain and Physical Activity Level Among Students With Musculoskeletal Pain Due to COVID-19 Pandemic: A Randomised Controlled Trial,Completed,NA,Not Applicable,216,Actual,Riphah International University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:11:56Z,2021-12-02T03:11:56Z
NCT04933864,NA,6/15/2021,NA,NA,6/21/2021,6/21/2021,6/22/2021,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/22/2021,Actual,24-Apr-20,Actual,4/24/2020,Jun-21,6/30/2021,30-Jul-20,Actual,7/30/2020,20-May-20,Actual,5/20/2020,NA,Interventional,NA,NA,COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy,The Clinical Trial of Methylene Blue Application Combined With Photodynamic Therapy for Treatment of SARS-CoV-2 Infected Patients,Completed,NA,Phase 1,60,Actual,I.M. Sechenov First Moscow State Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The Local Ethics Committee of I.M. Sechenov First Moscow State Medical University did not give permission to provide individual participant data.,2021-12-02T03:13:27Z,2021-12-02T03:13:27Z
NCT04933799,NA,4/23/2021,NA,NA,6/17/2021,6/17/2021,6/22/2021,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/22/2021,Actual,6-Jan-21,Actual,1/6/2021,Jun-21,6/30/2021,6-May-22,Anticipated,5/6/2022,6-Mar-22,Anticipated,3/6/2022,NA,Interventional,NA,NA,IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.,"A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Trial Assessing the Efficacy and Safety of PF-06650833 in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.",Recruiting,NA,Phase 2,68,Anticipated,Bronx-Lebanon Hospital Center Health Care System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:13:18Z,2021-12-02T03:13:18Z
NCT04933929,NA,5/24/2021,NA,NA,6/21/2021,6/21/2021,6/22/2021,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/22/2021,Actual,5-Mar-21,Actual,3/5/2021,May-21,5/31/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,COVINUT,NA,Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (COVID-19) Status (Positive or Negative) During Hospitalization,Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (Covid-19) Status (Positive or Negative) During Hospitalization,Recruiting,NA,Not Applicable,135,Anticipated,GÃ©rond'if,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:13:18Z,2021-12-02T03:13:18Z
NCT04932850,NA,6/15/2021,NA,NA,6/17/2021,6/17/2021,6/21/2021,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/21/2021,Actual,1-Mar-21,Actual,3/1/2021,Jun-21,6/30/2021,Oct-21,Anticipated,10/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,MAD0004J08,NA,Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.,COVID-19: A Phase I Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of Anti-SARS-CoV-2 Monoclonal Antibody MAD0004J08 in Healthy Adults.,"Active, not recruiting",NA,Phase 1,30,Actual,Toscana Life Sciences Sviluppo s.r.l.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:13:58Z,2021-12-02T03:13:58Z
NCT04932824,NA,4/13/2021,NA,NA,6/17/2021,6/17/2021,6/21/2021,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/21/2021,Actual,19-Jan-21,Actual,1/19/2021,Apr-21,4/30/2021,14-Sep-23,Anticipated,9/14/2023,31-May-23,Anticipated,5/31/2023,NA,Interventional,NA,NA,Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.,"A Long-term Follow-up Study to the Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of SCB-2019, a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19",Recruiting,NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:14:04Z,2021-12-02T03:14:04Z
NCT04932369,NA,6/12/2021,NA,NA,8/29/2021,6/12/2021,6/21/2021,Actual,NA,NA,NA,NA,NA,NA,8/29/2021,9/2/2021,Actual,1-Mar-20,Actual,3/1/2020,Aug-21,8/31/2021,1-Mar-21,Actual,3/1/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,NA,NA,"The Effect of Emotion Regulation Training on Anxiety, in College Students in Egypt","The Effect of Emotion Regulation Training on Anxiety, in College Students in Egypt During COVID-19 Lockdown",Completed,NA,Not Applicable,200,Actual,British University In Egypt,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:14:26Z,2021-12-02T03:14:26Z
NCT04930874,NA,6/15/2021,NA,NA,8/31/2021,6/16/2021,6/18/2021,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/1/2021,Actual,22-Jun-21,Actual,6/22/2021,Aug-21,8/31/2021,16-Feb-22,Anticipated,2/16/2022,16-Dec-21,Anticipated,12/16/2021,NA,Interventional,CA-COVID,NA,Cerebral Autoregulation and COVID-19,Cerebral Autoregulation and Severe Coronavirus Disease 19 [CA-COVID]: A Single-center Physiological Study,Recruiting,NA,Not Applicable,37,Anticipated,University of Athens,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:15:35Z,2021-12-02T03:15:35Z
NCT04929691,NA,6/8/2021,NA,NA,6/17/2021,6/15/2021,6/18/2021,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/23/2021,Actual,13-Nov-20,Actual,11/13/2020,Jun-21,6/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,CircumVent,NA,The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Among Patients With COVID-19,The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Using an Implementation Research Framework,Recruiting,NA,Not Applicable,370,Anticipated,New York University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Any study data to be shared will need to conform to Nigeria national data regulations.,2021-12-02T03:16:29Z,2021-12-02T03:16:29Z
NCT04930003,NA,2/22/2021,NA,NA,7/22/2021,6/15/2021,6/18/2021,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/29/2021,Actual,15-Jun-21,Actual,6/15/2021,Jan-21,1/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder","Active, not recruiting",NA,Phase 1/Phase 2,244,Anticipated,Research Institute for Biological Safety Problems,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:16:15Z,2021-12-02T03:16:15Z
NCT04928456,NA,6/11/2021,NA,NA,6/14/2021,6/14/2021,6/16/2021,Actual,NA,NA,NA,NA,NA,NA,6/14/2021,6/16/2021,Actual,11-Jun-21,Actual,6/11/2021,Jun-21,6/30/2021,30-Dec-22,Anticipated,12/30/2022,1-Sep-22,Anticipated,9/1/2022,NA,Interventional,NA,NA,Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps,Augmentation of Immune Response to COVID-19 mRNA Vaccination Through Osteopathic Manipulative Treatment Including Lymphatic Pumps,Recruiting,NA,Not Applicable,200,Anticipated,Western University of Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:17:11Z,2021-12-02T03:17:11Z
NCT04927169,NA,6/14/2021,NA,NA,6/15/2021,6/14/2021,6/15/2021,Actual,NA,NA,NA,NA,NA,NA,6/15/2021,6/18/2021,Actual,1-Mar-21,Actual,3/1/2021,Jun-21,6/30/2021,30-Jun-22,Anticipated,6/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,ILIAD-7-BRA,NA,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort),"Recombinant Human InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic PAtients With COVID-19 Infection - ""ILIAD 7 Trial"" Brazil Cohort",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Publication,2021-12-02T03:18:08Z,2021-12-02T03:18:08Z
NCT04926779,NA,6/11/2021,NA,NA,6/14/2021,6/14/2021,6/15/2021,Actual,NA,NA,NA,NA,NA,NA,6/14/2021,6/15/2021,Actual,24-May-21,Actual,5/24/2021,Jun-21,6/30/2021,21-Sep-21,Anticipated,9/21/2021,20-Sep-21,Anticipated,9/20/2021,NA,Interventional,NA,NA,"Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test","Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test: Comparison of Biozek COVID-19 Antigen Rapid Test Results Performed on Self-collected Samples by the Subjects, to Results of COVID-19 RT-PCR as a Standard of Care",Recruiting,NA,Not Applicable,150,Anticipated,Mach-E B.V.,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:18:34Z,2021-12-02T03:18:34Z
NCT04927845,NA,6/9/2021,NA,NA,6/15/2021,6/9/2021,6/16/2021,Actual,NA,NA,NA,NA,NA,NA,6/15/2021,6/21/2021,Actual,19-May-21,Actual,5/19/2021,Jun-21,6/30/2021,30-Jun-22,Anticipated,6/30/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,StriveWeekly Trial Post-pandemic,Randomized Controlled Trial (RCT) of StriveWeekly for Anxiety and Depression Prevention for College Students During COVID-19 (Coronavirus Disease 2019),Enrolling by invitation,NA,Not Applicable,1000,Anticipated,Harvard University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:17:53Z,2021-12-02T03:17:53Z
NCT04926428,NA,6/13/2021,NA,NA,6/16/2021,6/13/2021,6/15/2021,Actual,NA,NA,NA,NA,NA,NA,6/16/2021,6/21/2021,Actual,25-Dec-20,Actual,12/25/2020,Jun-21,6/30/2021,30-Mar-21,Actual,3/30/2021,30-Mar-21,Actual,3/30/2021,NA,Interventional,NA,NA,In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection,In Situ Thrombolysis With tPA and Inflow Lung Perfusion Analysis in Patient With Severe Covid-19 Infection,Completed,NA,Not Applicable,15,Actual,Grupo Mexicano para el Estudio de la Medicina Intensiva,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,3 months up to 5 years after completion,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2021-12-02T03:18:49Z,2021-12-02T03:18:49Z
NCT04922827,NA,6/10/2021,NA,NA,7/6/2021,6/10/2021,6/11/2021,Actual,NA,NA,NA,NA,NA,NA,7/6/2021,7/7/2021,Actual,18-Jun-21,Actual,6/18/2021,Jul-21,7/31/2021,Jul-23,Anticipated,7/31/2023,Sep-22,Anticipated,9/30/2022,NA,Interventional,INFLIXCOVID,NA,Infliximab in the Treatment of Patients With Severe COVID-19 Disease,"A Randomized, Controlled, Multicenter, Open Label Phase II Clinical Study to Evaluate Infliximab in the Treatment of Patients With Severe COVID-19 Disease",Recruiting,NA,Phase 2,88,Anticipated,Jena University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:21:46Z,2021-12-02T03:21:46Z
NCT04923061,NA,6/5/2021,NA,NA,6/10/2021,6/5/2021,6/11/2021,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/15/2021,Actual,6-Apr-21,Actual,4/6/2021,Jun-21,6/30/2021,Jul-22,Anticipated,7/31/2022,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,The Effect of Acupressure on the Sleep Quality and Fatigue,The Effect of Acupressure on Sleep Quality and Fatigue in Nurses Working in Internal Clinics During the COVID-19 Pandemic Process: A Randomized Controlled Study,Recruiting,NA,Not Applicable,68,Anticipated,Mersin University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:21:51Z,2021-12-02T03:21:51Z
NCT04922957,NA,6/9/2021,NA,NA,8/17/2021,6/9/2021,6/11/2021,Actual,NA,NA,NA,NA,NA,NA,8/17/2021,8/20/2021,Actual,Sep-21,Anticipated,9/30/2021,Aug-21,8/31/2021,Dec-22,Anticipated,12/31/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,"A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)","A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)",Recruiting,NA,Phase 2,152,Anticipated,Enlivex Therapeutics Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Patient data will not contain any information which would make the patient identifiable. Data will be processes and shared using patient study number only.,2021-12-02T03:21:52Z,2021-12-02T03:21:52Z
NCT04922918,NA,6/9/2021,NA,NA,6/9/2021,6/9/2021,6/11/2021,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/11/2021,Actual,1-Oct-20,Actual,10/1/2020,Jun-21,6/30/2021,1-Jul-21,Anticipated,7/1/2021,24-Jun-21,Anticipated,6/24/2021,NA,Interventional,PROBELDERLY,NA,Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home,Administration of Ligilactobacillus Salivarius MP101 in an Elderly Nursing Home During the COVID Pandemics,Recruiting,NA,Not Applicable,25,Anticipated,Universidad Complutense de Madrid,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:22:05Z,2021-12-02T03:22:05Z
NCT04922788,NA,6/8/2021,NA,NA,6/10/2021,6/10/2021,6/11/2021,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/11/2021,Actual,7-Jun-21,Actual,6/7/2021,Jun-21,6/30/2021,7-Aug-22,Anticipated,8/7/2022,7-Jul-22,Anticipated,7/7/2022,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19","a Phase 3, Adaptive, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of the Nanocovax Vaccine Against COVID-19 in Volunteer Subjects 18 Years of Age and Older.",Recruiting,NA,Phase 3,13000,Anticipated,Nanogen Pharmaceutical Biotechnology Joint Stock Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:22:01Z,2021-12-02T03:22:01Z
NCT04920838,NA,5/4/2021,NA,NA,6/8/2021,6/8/2021,6/10/2021,Actual,NA,NA,NA,NA,NA,NA,6/8/2021,6/10/2021,Actual,12-Apr-21,Actual,4/12/2021,Jun-21,6/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,COVERAGE-A,NA,Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection,Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa),Recruiting,NA,Phase 2/Phase 3,600,Anticipated,"ANRS, Emerging Infectious Diseases",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T03:24:39Z,2021-12-02T03:24:39Z
NCT04920773,NA,6/6/2021,NA,NA,6/9/2021,6/9/2021,6/10/2021,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/10/2021,Actual,3-May-21,Actual,5/3/2021,Jun-21,6/30/2021,6-Jun-21,Actual,6/6/2021,21-May-21,Actual,5/21/2021,NA,Interventional,NA,NA,Community-based Post-exposure Prophylaxis for COVID-19,Community-based Post-exposure Prophylaxis for COVID-19: Results and Implications of Ayurveda Practice Guidelines,Completed,NA,Not Applicable,216,Actual,NMP Medical Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:24:46Z,2021-12-02T03:24:46Z
NCT04920916,NA,6/8/2021,NA,NA,6/11/2021,6/8/2021,6/10/2021,Actual,NA,NA,NA,NA,NA,NA,6/11/2021,6/18/2021,Actual,25-May-21,Actual,5/25/2021,Jun-21,6/30/2021,1-Dec-22,Anticipated,12/1/2022,14-Aug-22,Anticipated,8/14/2022,NA,Interventional,SafeDrop,NA,Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients,Safety and Efficacy of the Treatment of Hospitalized Patients With COVID 19 Infection With an Inhibitor of IL-4 and IL-13 Signaling: A Phase IIa Trial,Recruiting,NA,Phase 2,40,Anticipated,University of Virginia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:25:18Z,2021-12-02T03:25:18Z
NCT04918940,NA,6/4/2021,NA,NA,6/7/2021,6/7/2021,6/9/2021,Actual,NA,NA,NA,NA,NA,NA,6/7/2021,6/9/2021,Actual,21-May-21,Actual,5/21/2021,May-21,5/31/2021,21-May-22,Anticipated,5/21/2022,21-Aug-21,Anticipated,8/21/2021,NA,Interventional,VAXIMAB,NA,Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma,Post-vaccination Immunization Against SARS-CoV-2 in Patients Undergoing Maintenance With Anti-CD20 Antibodies for Follicular Lymphoma (FL) or Mantle Cell,Recruiting,NA,Not Applicable,40,Anticipated,Centre Henri Becquerel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:29:42Z,2021-12-02T03:29:42Z
NCT04918914,NA,5/27/2021,NA,NA,6/7/2021,6/7/2021,6/9/2021,Actual,NA,NA,NA,NA,NA,NA,6/7/2021,6/9/2021,Actual,18-Oct-20,Actual,10/18/2020,Jun-21,6/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment,Off Label Use of Dapsone in SARS-CoV-2 Hospitalized Patients,Recruiting,NA,Early Phase 1,100,Anticipated,Hunt Regional Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T03:29:56Z,2021-12-02T03:29:56Z
NCT04918797,NA,5/18/2021,NA,NA,7/1/2021,6/2/2021,6/9/2021,Actual,NA,NA,NA,NA,NA,NA,7/1/2021,7/2/2021,Actual,26-May-21,Actual,5/26/2021,Jul-21,7/31/2021,25-Jan-22,Anticipated,1/25/2022,15-Aug-21,Anticipated,8/15/2021,NA,Interventional,COVAXIN-Peds,NA,COVAXIN in a Pediatric Cohort,"A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXINÂ®) in Healthy Volunteers Ages â‰¤18 to â‰¥ 2 Years.",Recruiting,NA,Phase 2/Phase 3,525,Anticipated,Bharat Biotech International Limited,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:31:56Z,2021-12-02T03:31:56Z
NCT04916886,NA,5/30/2021,NA,NA,6/4/2021,6/4/2021,6/8/2021,Actual,NA,NA,NA,NA,NA,NA,6/4/2021,6/8/2021,Actual,3-Jun-21,Actual,6/3/2021,Jun-21,6/30/2021,Aug-22,Anticipated,8/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.,To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.,Recruiting,NA,Not Applicable,2016,Anticipated,CanSino Biologics Inc.,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:34:37Z,2021-12-02T03:34:37Z
NCT04916821,NA,5/26/2021,NA,NA,6/7/2021,6/7/2021,6/8/2021,Actual,NA,NA,NA,NA,NA,NA,6/7/2021,6/8/2021,Actual,15-May-21,Actual,5/15/2021,Jun-21,6/30/2021,15-Aug-21,Anticipated,8/15/2021,15-Jul-21,Anticipated,7/15/2021,NA,Interventional,NA,NA,Investigation of Clinical Effectiveness of Propolis Extracts as Food Supplements in Patients With SARS-CoV-2(COVID-19),Investigation of Clinical Effectiveness of Propolis Extracts as Food Supplements in Patients With SARS-CoV-2(COVID-19),"Active, not recruiting",NA,Not Applicable,45,Anticipated,Trabzon Kanuni Education and Research Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will not be shared.,2021-12-02T03:34:39Z,2021-12-02T03:34:39Z
NCT04915820,NA,5/28/2021,NA,NA,9/10/2021,6/4/2021,6/7/2021,Actual,NA,NA,NA,NA,NA,NA,9/10/2021,9/14/2021,Actual,29-May-21,Actual,5/29/2021,Sep-21,9/30/2021,9-Sep-21,Actual,9/9/2021,9-Sep-21,Actual,9/9/2021,NA,Interventional,NA,NA,Iron and COVID-19 Vaccine Response,Iron and Vaccine-preventable Viral Disease,Completed,NA,Not Applicable,121,Actual,Jomo Kenyatta University of Agriculture and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:35:56Z,2021-12-02T03:35:56Z
NCT04916574,NA,6/3/2021,NA,NA,6/7/2021,6/4/2021,6/7/2021,Actual,NA,NA,NA,NA,NA,NA,6/7/2021,6/9/2021,Actual,20-Mar-21,Actual,3/20/2021,Jun-21,6/30/2021,3-Jun-21,Actual,6/3/2021,28-Mar-21,Actual,3/28/2021,NA,Interventional,NA,NA,Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum,Clinical Trial of Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum,Completed,NA,Not Applicable,16,Actual,Icosagen Cell Factory,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:35:03Z,2021-12-02T03:35:03Z
NCT04915989,NA,6/3/2021,NA,NA,6/4/2021,6/4/2021,6/7/2021,Actual,NA,NA,NA,NA,NA,NA,6/4/2021,6/7/2021,Actual,16-Feb-21,Actual,2/16/2021,Jun-21,6/30/2021,31-Mar-22,Anticipated,3/31/2022,31-Jul-21,Anticipated,7/31/2021,NA,Interventional,NA,NA,"Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","A Phase 1, Multicenter, Open-Label, Single Arm Study to Investigate the Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","Active, not recruiting",NA,Phase 1,30,Actual,"Genexine, Inc.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:35:37Z,2021-12-02T03:35:37Z
NCT04914767,NA,5/28/2021,NA,NA,6/3/2021,6/3/2021,6/7/2021,Actual,NA,NA,NA,NA,NA,NA,6/3/2021,6/7/2021,Actual,1-Mar-21,Actual,3/1/2021,Jun-21,6/30/2021,30-Nov-21,Anticipated,11/30/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,Nigelle5,NA,Nigella 5 in the Treatment of SARS COV2 (COVID-19),The Effectiveness of Nigella Sativa in the Treatment of SARS COV2 (COVID-19),Recruiting,NA,Phase 1,500,Anticipated,HÃ´pital Universitaire Sahloul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,in the article publication,2021-12-02T03:36:34Z,2021-12-02T03:36:34Z
NCT04914377,NA,6/2/2021,NA,NA,9/2/2021,6/2/2021,6/4/2021,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/10/2021,Actual,8-Jun-21,Actual,6/8/2021,Sep-21,9/30/2021,Nov-21,Anticipated,11/30/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,BOSS,NA,To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TQ Formula in Treating Participants Who Have Tested Positive for Novel Coronavirus 2019 (BOSS-Covid-19)",Recruiting,NA,Phase 2,60,Anticipated,Novatek Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,November - December 2021,NA,NA,Yes,NA,2021-12-02T03:36:43Z,2021-12-02T03:36:43Z
NCT04913740,NA,6/2/2021,NA,NA,6/2/2021,6/2/2021,6/4/2021,Actual,NA,NA,NA,NA,NA,NA,6/2/2021,6/4/2021,Actual,1-Jun-21,Actual,6/1/2021,Jun-21,6/30/2021,1-Jan-22,Anticipated,1/1/2022,1-Sep-21,Anticipated,9/1/2021,NA,Interventional,NA,NA,Nursing Study of Skin Lesions Related to Health Care Protection in Novel Nursing Study of Skin Lesions Related to Health Care Protection in Novel Coronavirus Epidemic,Nursing Study of Skin Lesions Related to Health Care Protection COVID-19 Epidemic,"Active, not recruiting",NA,Not Applicable,170,Anticipated,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:37:25Z,2021-12-02T03:37:25Z
NCT04913779,NA,6/1/2021,NA,NA,9/11/2021,6/2/2021,6/4/2021,Actual,NA,NA,NA,NA,NA,NA,9/11/2021,9/17/2021,Actual,1-Jun-21,Actual,6/1/2021,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,INPB001,NA,Safety and Effectiveness of an Immunobiological Drug in CoViD-19,Study to Evaluate the Safety and Effectiveness of an Immunobiological Drug (Anti SARS-CoV-2) in the Treatment of Coronavirus Disease 2019 (CoViD-19),Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After completion of the study.,By request to the Principal Investigator,NA,Yes,Publication of the results of all data obtained is planned.,2021-12-02T03:37:36Z,2021-12-02T03:37:36Z
NCT04912895,NA,6/2/2021,NA,NA,6/2/2021,6/2/2021,6/3/2021,Actual,NA,NA,NA,NA,NA,NA,6/2/2021,6/3/2021,Actual,14-Apr-21,Actual,4/14/2021,Jun-21,6/30/2021,Dec-22,Anticipated,12/31/2022,Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19,Detection of SARS-CoV-2 RNA and Biomarkers in Coughed Droplets From Patients With COVID-19 and Controls,Recruiting,NA,Not Applicable,90,Anticipated,Emory University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,Data will be available for sharing following the publication of manuscripts related to the primary aims of this study.,"Individual participant data will be available for sharing with researchers who provide a methodologically sound proposal, in order to achieve the aims stated in the approved proposal. Proposals should be directed to Dr. Larry Anderson.",NA,Yes,"Individual participant data collected during the trial will be made available for sharing, after deidentification, as consistent with Health Information Privacy and Portability Act (HIPPA) regulations.",2021-12-02T03:39:17Z,2021-12-02T03:39:17Z
NCT04912011,NA,6/1/2021,NA,NA,6/3/2021,6/2/2021,6/3/2021,Actual,NA,NA,NA,NA,NA,NA,6/3/2021,6/8/2021,Actual,1-Jan-21,Actual,1/1/2021,Jun-21,6/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,SpiroCOVID19,NA,Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.,The Use of a Mineralocorticoid Receptor Antagonist (Spironolactone) in the Treatment of Pulmonary Fibrosis Associated With SARS-CoV-2 Infection,Recruiting,NA,Phase 4,50,Anticipated,Pomeranian Medical University Szczecin,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:41:15Z,2021-12-02T03:41:15Z
NCT04910932,NA,6/1/2021,NA,NA,9/21/2021,6/1/2021,6/2/2021,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/22/2021,Actual,10-Jun-21,Actual,6/10/2021,Sep-21,9/30/2021,14-Sep-21,Actual,9/14/2021,14-Sep-21,Actual,9/14/2021,NA,Interventional,NA,NA,"Effects of Breathing Exercises on Fear of COVID-19, Anxiety, Sleep and Quality of Life During the COVID-19 Pandemic","Effects of Breathing Exercises on Fear of COVID-19, Anxiety, Sleep and Quality of Life During the COVID-19 Pandemic",Completed,NA,Not Applicable,50,Actual,Izmir Bakircay University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:42:08Z,2021-12-02T03:42:08Z
NCT04910516,NA,5/27/2021,NA,NA,6/1/2021,6/1/2021,6/2/2021,Actual,NA,NA,NA,NA,NA,NA,6/1/2021,6/2/2021,Actual,10-Apr-21,Actual,4/10/2021,May-21,5/31/2021,1-Jul-21,Anticipated,7/1/2021,25-May-21,Actual,5/25/2021,NA,Interventional,EFT,NA,Emotional Freedom Technique (EFT) Effect on Nurses,"Examining the Effect of ""Emotional Freedom Technique"" on Covid-19 Reasoned Fear and Anxiety Levels of Nurses Working in the Emergency Department","Active, not recruiting",NA,Not Applicable,88,Anticipated,Marmara University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:42:38Z,2021-12-02T03:42:38Z
NCT04910542,NA,3/30/2021,NA,NA,5/29/2021,5/29/2021,6/2/2021,Actual,NA,NA,NA,NA,NA,NA,5/29/2021,6/2/2021,Actual,9-Mar-21,Actual,3/9/2021,Apr-21,4/30/2021,12-May-22,Anticipated,5/12/2022,12-Nov-21,Anticipated,11/12/2021,NA,Interventional,EpI-Net,NA,Epidemiologic Intelligence Network (EpI-Net) to Promote COVID-19 Testing,Epidemiologic Intelligence Network (EpI-Net) to Promote COVID-19 Testing and Prevention Practices Among Socially Vulnerable Communities in Puerto Rico,Recruiting,NA,Not Applicable,3060,Anticipated,"Ponce Medical School Foundation, Inc.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"At this moment, no individual personal data will be available to others researchers",2021-12-02T03:42:47Z,2021-12-02T03:42:47Z
NCT04910191,NA,2/23/2021,NA,NA,5/30/2021,5/30/2021,6/2/2021,Actual,NA,NA,NA,NA,NA,NA,5/30/2021,6/2/2021,Actual,27-May-20,Actual,5/27/2020,Feb-21,2/28/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Collecting Respiratory Sound Samples From Corona Patients to Extend the Diagnostic Capability of VOQX Electronic Stethoscope to Diagnose COVID-19 Patients,Collecting Respiratory Sound Samples From Corona Patients to Extend the Diagnostic Capability of VOQX Electronic Stethoscope to Diagnose COVID-19 Patients,Recruiting,NA,Not Applicable,200,Anticipated,Sanolla,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:42:57Z,2021-12-02T03:42:57Z
NCT04909996,NA,5/28/2021,NA,NA,5/28/2021,5/28/2021,6/2/2021,Actual,NA,NA,NA,NA,NA,NA,5/28/2021,6/2/2021,Actual,20-May-21,Actual,5/20/2021,May-21,5/31/2021,31-Jul-21,Anticipated,7/31/2021,31-Jul-21,Anticipated,7/31/2021,NA,Interventional,NA,NA,Study on the Performance and Safety of Sentinox in COVID-19 Patients,"Post-market, Confirmatory, Interventional, Randomized and Controlled Clinical Study to Assess the Efficacy and Safety of Sentinox in COVID-19 Patients.",Recruiting,NA,Not Applicable,57,Anticipated,APR Applied Pharma Research s.a.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:43:20Z,2021-12-02T03:43:20Z
NCT04909918,NA,5/30/2021,NA,NA,9/4/2021,5/30/2021,6/2/2021,Actual,NA,NA,NA,NA,NA,NA,9/4/2021,9/8/2021,Actual,28-May-21,Actual,5/28/2021,Sep-21,9/30/2021,20-Aug-21,Actual,8/20/2021,15-Aug-21,Actual,8/15/2021,NA,Interventional,NA,NA,Impact of Steroids on Inflammatory Response in Covid-19,The Impact of Dexamethasone Versus Methylprednisolone Upon Neutrophil/Lymphocyte Ratio (NLR) in COVID-19 Diseased Patients Admitted in ICU,Completed,NA,Phase 3,60,Actual,Assiut University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:43:23Z,2021-12-02T03:43:23Z
NCT04907331,NA,5/25/2021,NA,NA,9/9/2021,5/25/2021,5/28/2021,Actual,NA,NA,NA,NA,NA,NA,9/9/2021,9/10/2021,Actual,10-May-21,Actual,5/10/2021,May-21,5/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,HeVacc,NA,Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2,Comparison of Heterologous Vaccination With an Vaxzevria (ChAdOx1-S) Prime and a Comirnaty (BNT162b2) Boost to Homolog Vaccination,Recruiting,NA,Phase 2,3000,Anticipated,Medical University Innsbruck,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:45:50Z,2021-12-02T03:45:50Z
NCT04904510,NA,5/19/2021,NA,NA,5/25/2021,5/25/2021,5/27/2021,Actual,NA,NA,NA,NA,NA,NA,5/25/2021,5/27/2021,Actual,20-Nov-20,Actual,11/20/2020,May-21,5/31/2021,9-Mar-21,Actual,3/9/2021,9-Mar-21,Actual,3/9/2021,NA,Interventional,NA,NA,Evaluation of the INDICAIDâ„¢ COVID-19 Rapid Antigen Test,Evaluation of the INDICAIDâ„¢ COVID-19 Rapid Antigen Test in Symptomatic Populations and Asymptomatic Community Testing,Completed,NA,Not Applicable,22994,Actual,"University of California, Los Angeles",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:49:53Z,2021-12-02T03:49:53Z
NCT04904783,NA,5/25/2021,NA,NA,7/25/2021,5/25/2021,5/27/2021,Actual,NA,NA,NA,NA,NA,NA,7/25/2021,7/27/2021,Actual,1-Jun-21,Actual,6/1/2021,Jul-21,7/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,LOCORAD,NA,Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study,Low-Dose Radiation Therapy in COVID-19,Recruiting,NA,Not Applicable,20,Anticipated,Mahatma Gandhi Institute of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months from date of publication of the final results.,On request to Principal investigator,NA,Yes,Not yet decided. Will decide later after the study results are available,2021-12-02T03:50:05Z,2021-12-02T03:50:05Z
NCT04904497,NA,4/30/2021,NA,NA,5/26/2021,5/26/2021,5/27/2021,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/27/2021,Actual,1-Apr-21,Actual,4/1/2021,May-21,5/31/2021,31-Dec-21,Anticipated,12/31/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,Early Occupational Therapy in Mechanical Ventilated Patients With Covid-19,Early Occupational Therapy in Mechanical Ventilated Patients With Covid-19: Multicentre Pilot Randomized Clinical Trial,Recruiting,NA,Not Applicable,60,Anticipated,University of Chile,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:50:56Z,2021-12-02T03:50:56Z
NCT04902911,NA,5/21/2021,NA,NA,6/21/2021,5/21/2021,5/26/2021,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/23/2021,Actual,13-Apr-21,Actual,4/13/2021,May-21,5/31/2021,17-Mar-22,Anticipated,3/17/2022,17-Mar-22,Anticipated,3/17/2022,NA,Interventional,NOVIR POC,NA,Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold),Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold),Recruiting,NA,Not Applicable,120,Anticipated,Medical College of Wisconsin,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:52:13Z,2021-12-02T03:52:13Z
NCT04903184,NA,5/21/2021,NA,NA,5/26/2021,5/25/2021,5/26/2021,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/28/2021,Actual,9-Dec-20,Actual,12/9/2020,May-21,5/31/2021,Jan-22,Anticipated,1/31/2022,Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,Exploratory Study to Evaluate the Efficacy of RUTIÂ® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers,"A Exploratory Phase II Clinical Trial, Double-blind, Randomized Placebo-controlled to Evaluate the Efficacy of RUTIÂ® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers",Recruiting,NA,Phase 2,369,Anticipated,RUTI Immunotherapeutics S.L.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:52:36Z,2021-12-02T03:52:36Z
NCT04901676,NA,5/24/2021,NA,NA,9/14/2021,5/24/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/16/2021,Actual,9-Sep-21,Actual,9/9/2021,May-21,5/31/2021,Feb-22,Anticipated,2/28/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia,"A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Moderately Ill Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia",Recruiting,NA,Phase 3,612,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:53:39Z,2021-12-02T03:53:39Z
NCT04902976,NA,5/24/2021,NA,NA,5/26/2021,5/24/2021,5/26/2021,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/28/2021,Actual,4-Apr-21,Actual,4/4/2021,May-21,5/31/2021,30-Aug-21,Anticipated,8/30/2021,31-May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,Evaluation of SARS-COV-2 Viral Load of Covid-19 Patients After Rinsing With Oral Antimicrobial Mouthwashes,Evaluation of Viral Load of SARS-COV-2 Virus in the Oral Cavity After Rinsing With Oral Antimicrobial Mouthwashes in Patients Covid-19.,Recruiting,NA,Not Applicable,105,Anticipated,Hospital Israelita Albert Einstein,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:52:33Z,2021-12-02T03:52:33Z
NCT04902183,NA,5/21/2021,NA,NA,6/12/2021,5/24/2021,5/26/2021,Actual,NA,NA,NA,NA,NA,NA,6/12/2021,6/15/2021,Actual,9-Jun-21,Actual,6/9/2021,Jun-21,6/30/2021,1-Sep-21,Anticipated,9/1/2021,1-Sep-21,Anticipated,9/1/2021,NA,Interventional,NA,NA,Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19,"A Phase II Randomized, Single-blind Dose Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 in 10^9 Dose Versus 10^10 Dose, for the Prevention of Clinical Deterioration in Patients With Moderate or Severe COVID-19",Recruiting,NA,Phase 2,90,Anticipated,Athens Medical Society,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:53:07Z,2021-12-02T03:53:07Z
NCT04901624,NA,3/29/2021,NA,NA,7/1/2021,5/21/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,7/1/2021,7/2/2021,Actual,29-Jun-21,Actual,6/29/2021,Jul-21,7/31/2021,Aug-22,Anticipated,8/31/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities,Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities,Enrolling by invitation,NA,Not Applicable,2160,Anticipated,University of Southern California,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:53:41Z,2021-12-02T03:53:41Z
NCT04900961,NA,5/10/2021,NA,NA,8/30/2021,5/19/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/5/2021,Actual,1-Jun-21,Actual,6/1/2021,Aug-21,8/31/2021,31-Jul-33,Anticipated,7/31/2033,30-Apr-23,Anticipated,4/30/2023,NA,Interventional,CISCO-21,NA,CISCO-21 Prevent and Treat Long COVID-19.,Prevention and Early Treatment of the Long-term Physical Effects of Coronarvirus-19 (COVID-19): a Randomised Clinical Trial of Resistance Exercise.,Recruiting,NA,Not Applicable,220,Anticipated,NHS Greater Glasgow and Clyde,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"The Investigator may share individual participant data (IPD) with bone fide researchers, subject to Sponsor approval.",2021-12-02T03:54:18Z,2021-12-02T03:54:18Z
NCT04900428,NA,5/20/2021,NA,NA,9/24/2021,5/21/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,10/1/2021,Actual,18-Jul-21,Actual,7/18/2021,Sep-21,9/30/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPSâ„¢) in Outpatient Adults With COVID-19 (UK),"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Single Intranasal Dose of STI-2099 (COVI-DROPSâ„¢) in Outpatient Adults With COVID-19",Recruiting,NA,Phase 2,350,Anticipated,"Sorrento Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:54:50Z,2021-12-02T03:54:50Z
NCT04900467,NA,5/21/2021,NA,NA,7/31/2021,5/21/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,7/31/2021,8/3/2021,Actual,28-May-21,Actual,5/28/2021,Jul-21,7/31/2021,Jan-22,Anticipated,1/31/2022,2-Jul-21,Actual,7/2/2021,NA,Interventional,ARNCOMBI,NA,Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine,"Multicenter, Randomized, Open-label Trial Comparing the Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine: Non-inferiority Trial","Active, not recruiting",NA,Not Applicable,418,Actual,Assistance Publique - HÃ´pitaux de Paris,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:54:52Z,2021-12-02T03:54:52Z
NCT04900415,NA,5/17/2021,NA,NA,5/21/2021,5/21/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/25/2021,Actual,22-Jul-20,Actual,7/22/2020,May-21,5/31/2021,30-Jun-21,Anticipated,6/30/2021,12-Mar-21,Actual,3/12/2021,NA,Interventional,NA,NA,Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction,Olfactory and Neurosensory Rehabilitation in Coronavirus 2019 (COVID-19)-Related Olfactory Dysfunction (OD),Recruiting,NA,Phase 2,25,Anticipated,The University of Hong Kong,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:54:57Z,2021-12-02T03:54:57Z
NCT04900337,NA,5/19/2021,NA,NA,5/23/2021,5/23/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,5/23/2021,5/25/2021,Actual,9-Feb-21,Actual,2/9/2021,Apr-21,4/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.","A Phase 1/2 Prospective Randomized Placebo Controlled Study to Assess the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Administered Sublingual and in Inhalation Concomitantly With BAT (Best Available Care) as Compared to Placebo and BAT for the Treatment of Moderate to Severe COVID-19 Patients.",Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Amorphical Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:55:10Z,2021-12-02T03:55:10Z
NCT04900454,NA,5/20/2021,NA,NA,8/3/2021,5/21/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/10/2021,Actual,2-Aug-21,Actual,8/2/2021,Aug-21,8/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Oct-22,Anticipated,10/31/2022,NA,Interventional,NA,NA,Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19,"A Phase 1 Study of DVX201, an Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19",Recruiting,NA,Phase 1,18,Anticipated,"Deverra Therapeutics, Inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:55:12Z,2021-12-02T03:55:12Z
NCT04900155,NA,5/9/2021,NA,NA,5/23/2021,5/23/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,5/23/2021,5/25/2021,Actual,20-Nov-20,Actual,11/20/2020,May-21,5/31/2021,May-22,Anticipated,5/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,CONTRAST-3,NA,Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19,"Evaluation of Long-term Lipid-lowering Therapy on Myocardial Electrical Heterogeneity, Myocardial Deformation, Arterial Stiffness and Quality of Life in Patients With Primary STEMI/NSTEMI With Coronavirus Infection COVID-19",Recruiting,NA,Not Applicable,200,Anticipated,Penza State University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:55:29Z,2021-12-02T03:55:29Z
NCT04900129,NA,5/18/2021,NA,NA,5/23/2021,5/23/2021,5/25/2021,Actual,NA,NA,NA,NA,NA,NA,5/23/2021,5/25/2021,Actual,1-Dec-20,Actual,12/1/2020,May-21,5/31/2021,30-Dec-20,Actual,12/30/2020,30-Dec-20,Actual,12/30/2020,NA,Interventional,NA,NA,"Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study","Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study",Completed,NA,Phase 1,43,Actual,Sher-E-Bangla Medical College,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:55:30Z,2021-12-02T03:55:30Z
NCT04899245,NA,5/19/2021,NA,NA,9/3/2021,5/20/2021,5/24/2021,Actual,NA,NA,NA,NA,NA,NA,9/3/2021,9/9/2021,Actual,4-May-21,Actual,5/4/2021,May-21,5/31/2021,Aug-22,Anticipated,8/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff,ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - SARS-CoV-2 Testing in School With Children and Staff,Enrolling by invitation,NA,Not Applicable,115,Anticipated,"University of Wisconsin, Madison",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:56:04Z,2021-12-02T03:56:04Z
NCT04898205,NA,5/17/2021,NA,NA,5/21/2021,5/20/2021,5/24/2021,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/25/2021,Actual,21-Jan-21,Actual,1/21/2021,May-21,5/31/2021,20-Jan-22,Anticipated,1/20/2022,20-Jan-22,Anticipated,1/20/2022,NA,Interventional,NA,NA,Cardiopulmonary Rehabilitation in COVID-19 Longhaulers,Cardiopulmonary Rehabilitation in COVID-19 Longhaulers,Recruiting,NA,Not Applicable,24,Anticipated,Pulmonary Wellness Foundation,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Upon conclusion of the study, we will share de-identified data upon request.",2021-12-02T03:57:13Z,2021-12-02T03:57:13Z
NCT04898088,NA,5/21/2021,NA,NA,5/21/2021,5/21/2021,5/24/2021,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/24/2021,Actual,1-Jan-20,Actual,1/1/2020,May-21,5/31/2021,30-Sep-20,Actual,9/30/2020,30-Aug-20,Actual,8/30/2020,NA,Interventional,REPAIR,NA,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,Completed,NA,Not Applicable,30,Actual,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T03:57:15Z,2021-12-02T03:57:15Z
NCT04898062,NA,5/20/2021,NA,NA,5/25/2021,5/21/2021,5/24/2021,Actual,NA,NA,NA,NA,NA,NA,5/25/2021,5/28/2021,Actual,5-May-21,Actual,5/5/2021,May-21,5/31/2021,31-Oct-22,Anticipated,10/31/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,CAPMYKCO,NA,"CRP-Apheresis for Attenuation of Pulmonary, MYocardial and/or Kidney Injury in COvid-19","Randomized, Controlled, Proof-Of-Concept Trial of CRP-Apheresis for Attenuation of Pulmonary MYocardial and/or Kidney Injury in COvid-19",Recruiting,NA,Not Applicable,50,Anticipated,"University Hospital, Essen",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:57:33Z,2021-12-02T03:57:33Z
NCT04896710,NA,5/5/2021,NA,NA,5/31/2021,5/19/2021,5/21/2021,Actual,NA,NA,NA,NA,NA,NA,5/31/2021,6/2/2021,Actual,26-May-21,Actual,5/26/2021,May-21,5/31/2021,31-Aug-21,Anticipated,8/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,COVID-19 Rapid Testing for Self-Administration Among an Asymptomatic Sample,Rapid Testing for Self-Administration Among an Asymptomatic Sample,Enrolling by invitation,NA,Not Applicable,569,Anticipated,University of British Columbia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,31-Aug-22,send email to: jonathan.beaumier@ubc.ca,NA,Yes,A de-identified and anonymized dataset can be made available upon request.,2021-12-02T03:58:26Z,2021-12-02T03:58:26Z
NCT04896853,NA,5/18/2021,NA,NA,5/19/2021,5/19/2021,5/21/2021,Actual,NA,NA,NA,NA,NA,NA,5/19/2021,5/21/2021,Actual,18-May-21,Actual,5/18/2021,May-21,5/31/2021,31-Dec-24,Anticipated,12/31/2024,30-Sep-24,Anticipated,9/30/2024,NA,Interventional,NA,NA,Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTransÂ®,Treatment of Respiratory Complications Associated With COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTransÂ®): Open Phase IB Clinical Trial,Recruiting,NA,Phase 1,9,Anticipated,NextCell Pharma Ab,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:58:28Z,2021-12-02T03:58:28Z
NCT04896788,NA,5/18/2021,NA,NA,5/21/2021,5/19/2021,5/21/2021,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/24/2021,Actual,19-May-21,Actual,5/19/2021,May-21,5/31/2021,1-May-24,Anticipated,5/1/2024,1-Nov-23,Anticipated,11/1/2023,NA,Interventional,COVIDIM,NA,Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff,Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff,Recruiting,NA,Not Applicable,300,Anticipated,"University Hospital, Clermont-Ferrand",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T03:58:36Z,2021-12-02T03:58:36Z
NCT04895085,NA,5/14/2021,NA,NA,9/3/2021,5/14/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,9/3/2021,9/5/2021,Actual,27-Apr-21,Actual,4/27/2021,May-21,5/31/2021,Jul-22,Anticipated,7/31/2022,Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,"ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort COVID-19 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance","ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort SARS-CoV-2 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance","Active, not recruiting",NA,Not Applicable,51,Actual,"University of Wisconsin, Madison",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T03:59:44Z,2021-12-02T03:59:44Z
NCT04894435,NA,5/18/2021,NA,NA,8/19/2021,5/19/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/25/2021,Actual,20-May-21,Actual,5/20/2021,Aug-21,8/31/2021,Mar-23,Anticipated,3/31/2023,Mar-23,Anticipated,3/31/2023,NA,Interventional,MOSAIC,NA,Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity,Immunogenicity and Adverse Events Following Immunization With Alternate Schedules of Authorized COVID-19 Vaccines in Canada: MOSAIC Study (Mix and Match of the Second cOvid-19 Vaccine Dose for SAfety and ImmunogeniCity),Recruiting,NA,Phase 2,1200,Anticipated,Canadian Immunization Research Network,,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:00:24Z,2021-12-02T04:00:24Z
NCT04894409,NA,5/16/2021,NA,NA,5/18/2021,5/18/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/20/2021,Actual,24-Apr-20,Actual,4/24/2020,May-21,5/31/2021,29-Sep-20,Actual,9/29/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,COVID-19,NA,Evaluation of Silver Nanoparticles for the Prevention of COVID-19,"Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2",Completed,NA,Not Applicable,231,Actual,"Cluster de Bioeconomia de Baja California, A.C",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:00:40Z,2021-12-02T04:00:40Z
NCT04895267,NA,5/15/2021,NA,NA,8/23/2021,5/15/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/27/2021,Actual,3-Jul-20,Actual,7/3/2020,Aug-21,8/31/2021,17-Sep-21,Anticipated,9/17/2021,3-Sep-21,Anticipated,9/3/2021,NA,Interventional,NA,NA,Low-field Thoracic Magnetic Stimulation Increases Peripheral Oxygen Saturation Levels in COVID-19 Patients,"Low-field Thoracic Magnetic Stimulation Increases Peripheral Oxygen Saturation Levels in Coronavirus Disease (COVID-19) Patients: a Single-blind, Sham-controlled, Crossover Study",Enrolling by invitation,NA,Not Applicable,17,Anticipated,Hospital Univeristario Benemerita Universidad Autonoma de Puebla,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Starting 6 months after publication,open access,NA,Yes,The investigators (Saul M. Dominguez-Nicolas and Elias Manjarrez) plan to make individual participant data (IPD) collected in this study.,2021-12-02T03:59:54Z,2021-12-02T03:59:54Z
NCT04894227,NA,5/10/2021,NA,NA,8/16/2021,5/19/2021,5/20/2021,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/18/2021,Actual,11-May-21,Actual,5/11/2021,May-21,5/31/2021,30-Nov-21,Anticipated,11/30/2021,11-May-21,Actual,5/11/2021,NA,Interventional,NA,NA,Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,"A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVacï¼‰ in Health Adults Aged 26-45 Years","Active, not recruiting",NA,Phase 4,1080,Anticipated,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:00:42Z,2021-12-02T04:00:42Z
NCT04893512,NA,5/14/2021,NA,NA,8/24/2021,5/14/2021,5/19/2021,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/30/2021,Actual,30-Jun-21,Actual,6/30/2021,Aug-21,8/31/2021,5-Oct-22,Anticipated,10/5/2022,5-Oct-21,Anticipated,10/5/2021,NA,Interventional,NA,NA,First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects,First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects,Recruiting,NA,Phase 1,45,Anticipated,Syneos Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:01:14Z,2021-12-02T04:01:14Z
NCT04892979,NA,3/1/2021,NA,NA,5/18/2021,5/18/2021,5/19/2021,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/19/2021,Actual,1-Oct-20,Actual,10/1/2020,Feb-21,2/28/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,3R Rehabilitation Management of COVID-19 Survivors,3R Rehabilitation Management of COVID-19 Survivors Using Centre-based and Online-based Approaches,Recruiting,NA,Not Applicable,400,Anticipated,The Hong Kong Polytechnic University,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:01:34Z,2021-12-02T04:01:34Z
NCT04892459,NA,5/10/2021,NA,NA,6/29/2021,5/16/2021,5/19/2021,Actual,NA,NA,NA,NA,NA,NA,6/29/2021,6/30/2021,Actual,25-May-21,Actual,5/25/2021,Jun-21,6/30/2021,25-Dec-21,Anticipated,12/25/2021,25-Jul-21,Anticipated,7/25/2021,NA,Interventional,NA,NA,Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector),"Safety and Immunogenicity of Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) in Chinese Healthy Adults Aged 18-59 Years: a Randomized, Observer-blind, Parallel-controlled Clinical Trial","Active, not recruiting",NA,Phase 4,300,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:02:41Z,2021-12-02T04:02:41Z
NCT04890626,NA,5/17/2021,NA,NA,5/18/2021,5/17/2021,5/18/2021,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/20/2021,Actual,4-Apr-20,Actual,4/4/2020,May-21,5/31/2021,30-Nov-22,Anticipated,11/30/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19,Randomized Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19,Recruiting,NA,Phase 3,2193,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:04:45Z,2021-12-02T04:04:45Z
NCT04891172,NA,5/17/2021,NA,NA,8/17/2021,5/17/2021,5/18/2021,Actual,NA,NA,NA,NA,NA,NA,8/17/2021,8/24/2021,Actual,1-Aug-21,Actual,8/1/2021,Aug-21,8/31/2021,2-Aug-22,Anticipated,8/2/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,NA,NA,Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients,Phase II/III Clinical Trial Study to Evaluate Efficacy and Safety of Anti COVID 19 Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients,Recruiting,NA,Phase 2/Phase 3,310,Anticipated,Dow University of Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:04:09Z,2021-12-02T04:04:09Z
NCT04891302,NA,5/13/2021,NA,NA,5/17/2021,5/17/2021,5/18/2021,Actual,NA,NA,NA,NA,NA,NA,5/17/2021,5/18/2021,Actual,19-Mar-21,Actual,3/19/2021,May-21,5/31/2021,31-Oct-21,Anticipated,10/31/2021,31-Jul-21,Anticipated,7/31/2021,NA,Interventional,NA,NA,The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19,"A Double Blind, Randomized, Placebo-controlled, Multi-center, Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Mild and Moderate COVID-19",Recruiting,NA,Phase 2,80,Anticipated,Bukwang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:04:22Z,2021-12-02T04:04:22Z
NCT04890665,NA,5/17/2021,NA,NA,9/27/2021,5/17/2021,5/18/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,10/5/2021,Actual,16-Jul-21,Actual,7/16/2021,Sep-21,9/30/2021,20-Jun-22,Anticipated,6/20/2022,20-Jun-22,Anticipated,6/20/2022,NA,Interventional,NA,NA,Online Multi-component Psychological Intervention for Healthcare Workers During COVID-19 Pandemic,"Effectiveness of a Self-applied Multi-component Psychological Online Intervention Based on User Experience, for Anxiety, Depression, Burnout, Fatigue Compassion on Healthcare Workers During the COVID-19 Outbreak: A Randomized Clinical Trial",Recruiting,NA,Not Applicable,42,Anticipated,Universidad Internacional de Valencia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,This data will be available approximately in June 2022 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published.,Through the servers of the journal(s) where we will publish the articles.,NA,Yes,"The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.",2021-12-02T04:05:15Z,2021-12-02T04:05:15Z
NCT04890483,NA,5/17/2021,NA,NA,5/17/2021,5/17/2021,5/18/2021,Actual,NA,NA,NA,NA,NA,NA,5/17/2021,5/18/2021,Actual,17-May-21,Actual,5/17/2021,May-21,5/31/2021,24-Dec-21,Anticipated,12/24/2021,17-May-21,Actual,5/17/2021,NA,Interventional,NA,NA,tDCS in Post-Acute COVID-19 Patients With SARDs,Transcranial Direct Current Stimulation in Post-Acute COVID-19 Patients With Systemic Autoimmune Rheumatic Diseases,Recruiting,NA,Not Applicable,20,Anticipated,University of Sao Paulo,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:05:28Z,2021-12-02T04:05:28Z
NCT04889274,NA,5/6/2021,NA,NA,5/14/2021,5/14/2021,5/17/2021,Actual,NA,NA,NA,NA,NA,NA,5/14/2021,5/17/2021,Actual,10-May-21,Actual,5/10/2021,May-21,5/31/2021,10-May-22,Anticipated,5/10/2022,1-Aug-21,Anticipated,8/1/2021,NA,Interventional,NA,NA,Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19),"A Double-blind, Randomised, Placebo-controlled Parallel Study to Investigate the Effect of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women",Recruiting,NA,Phase 1,98,Anticipated,Queen Mary University of London,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:06:10Z,2021-12-02T04:06:10Z
NCT04888949,NA,5/9/2021,NA,NA,9/9/2021,5/9/2021,5/17/2021,Actual,NA,NA,NA,NA,NA,NA,9/9/2021,9/10/2021,Actual,15-Jun-21,Actual,6/15/2021,Sep-21,9/30/2021,30-Sep-22,Anticipated,9/30/2022,30-Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19),An Phase2 Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Recruiting,NA,Phase 2,20,Anticipated,"Rohto Pharmaceutical Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:06:35Z,2021-12-02T04:06:35Z
NCT04889040,NA,5/10/2021,NA,NA,9/10/2021,5/10/2021,5/17/2021,Actual,NA,NA,NA,NA,NA,NA,9/10/2021,9/14/2021,Actual,28-Apr-21,Actual,4/28/2021,Sep-21,9/30/2021,17-Nov-21,Anticipated,11/17/2021,17-Nov-21,Anticipated,11/17/2021,NA,Interventional,MORNINGSKY,NA,Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19,"A Multicenter, Phase III Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Evaluate the Efficacy, Safety, Antiviral Activity of RO7496998 (AT-527) in Patients With Mild or Moderate COVID-19",Recruiting,NA,Phase 3,1386,Anticipated,"Atea Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2021-12-02T04:06:35Z,2021-12-02T04:06:35Z
NCT04887350,NA,5/5/2021,NA,NA,9/11/2021,5/11/2021,5/14/2021,Actual,NA,NA,NA,NA,NA,NA,9/11/2021,9/17/2021,Actual,9-Aug-21,Actual,8/9/2021,Sep-21,9/30/2021,8-Aug-22,Anticipated,8/8/2022,8-Aug-22,Anticipated,8/8/2022,NA,Interventional,NA,NA,SSIPP vs. PST vs. WLC,Naturalistic Pilot Study Comparing the Feasibility of Applying a Student Senior Isolation Prevention Partnership vs. Problem-solving Therapy vs. Waitlist Control in Patients Suffering From Late-life Depression During the COVID-19 Pandemic: A Randomized Controlled Trial,Recruiting,NA,Phase 1,45,Anticipated,Lawson Health Research Institute,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:07:39Z,2021-12-02T04:07:39Z
NCT04887129,NA,5/13/2021,NA,NA,5/13/2021,5/13/2021,5/14/2021,Actual,NA,NA,NA,NA,NA,NA,5/13/2021,5/14/2021,Actual,3-May-21,Actual,5/3/2021,May-21,5/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities (COV-IDD),COV-IDD: Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities,Recruiting,NA,Not Applicable,950,Anticipated,University of Rochester,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:07:51Z,2021-12-02T04:07:51Z
NCT04885491,NA,2/15/2021,NA,NA,5/18/2021,5/12/2021,5/13/2021,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/20/2021,Actual,7-May-21,Actual,5/7/2021,May-21,5/31/2021,15-Aug-21,Anticipated,8/15/2021,15-Jul-21,Anticipated,7/15/2021,NA,Interventional,NA,NA,"A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH","An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of the Two Regioisomers 1-(Nitrosooxy)Propan-2-ol and 2- (Nitrosooxy)Propan-1-ol (PDNO) Infusion in Covid-19 Patients With Acute Pulmonary Hypertension.",Recruiting,NA,Phase 1/Phase 2,16,Anticipated,Attgeno AB,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:09:25Z,2021-12-02T04:09:25Z
NCT04885907,NA,5/9/2021,NA,NA,6/3/2021,5/9/2021,5/13/2021,Actual,NA,NA,NA,NA,NA,NA,6/3/2021,6/7/2021,Actual,25-May-21,Actual,5/25/2021,Jun-21,6/30/2021,30-Aug-21,Anticipated,8/30/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,NA,NA,Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients,"A Randomised, Blinded, Controlled Trial of a Third Dose of Moderna COVID-19 Vaccine Versus Placebo in Solid Organ Transplant Recipients","Active, not recruiting",NA,Phase 4,120,Actual,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:09:02Z,2021-12-02T04:09:02Z
NCT04885764,NA,5/8/2021,NA,NA,5/8/2021,5/8/2021,5/13/2021,Actual,NA,NA,NA,NA,NA,NA,5/8/2021,5/13/2021,Actual,23-Feb-21,Actual,2/23/2021,May-21,5/31/2021,1-Dec-21,Anticipated,12/1/2021,1-Oct-21,Anticipated,10/1/2021,NA,Interventional,ASU-VAC,NA,Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University,Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University,Recruiting,NA,Phase 2/Phase 3,4000,Anticipated,Ain Shams University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:09:06Z,2021-12-02T04:09:06Z
NCT04885361,NA,5/7/2021,NA,NA,6/8/2021,5/12/2021,5/13/2021,Actual,NA,NA,NA,NA,NA,NA,6/8/2021,6/9/2021,Actual,26-May-21,Actual,5/26/2021,Jun-21,6/30/2021,31-Mar-22,Anticipated,3/31/2022,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,COVEPIT 3,NA,"To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults","A Randomized, Open Label, Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of OSE-13E, a Multiepitope-based Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT-3)",Recruiting,NA,Phase 1,48,Anticipated,OSE Immunotherapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:09:33Z,2021-12-02T04:09:33Z
NCT04885517,NA,5/11/2021,NA,NA,5/12/2021,5/11/2021,5/13/2021,Actual,NA,NA,NA,NA,NA,NA,5/12/2021,5/14/2021,Actual,1-Feb-21,Actual,2/1/2021,May-21,5/31/2021,1-Aug-21,Anticipated,8/1/2021,1-Aug-21,Anticipated,8/1/2021,NA,Interventional,NA,NA,"Breathing Effort in Covid-19 Pneumonia: Effects of Positive Pressure, Inspired Oxygen Fraction and Decubitus","Dynamic Transpulmonary Pressure in Covid-19 Pneumonia: Effects of Positive Pressure, Inspired Oxygen Fraction and Decubitus",Recruiting,NA,Not Applicable,72,Anticipated,San Luigi Gonzaga Hospital,,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:09:29Z,2021-12-02T04:09:29Z
NCT04884776,NA,4/29/2021,NA,NA,8/2/2021,5/7/2021,5/13/2021,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/4/2021,Actual,1-Jun-21,Actual,6/1/2021,Jul-21,7/31/2021,31-May-24,Anticipated,5/31/2024,31-May-24,Anticipated,5/31/2024,NA,Interventional,NA,NA,Modulation of Gut Microbiota to Enhance Health and Immunity,Modulation of Gut Microbiota to Enhance Health and Immunity of Vulnerable Individuals During COVID-19 Pandemic,Recruiting,NA,Not Applicable,484,Anticipated,Chinese University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:10:27Z,2021-12-02T04:10:27Z
NCT04884685,NA,5/7/2021,NA,NA,9/22/2021,5/7/2021,5/13/2021,Actual,NA,NA,NA,NA,NA,NA,9/22/2021,9/24/2021,Actual,3-May-21,Actual,5/3/2021,May-21,5/31/2021,3-Jan-22,Anticipated,1/3/2022,1-Aug-21,Actual,8/1/2021,NA,Interventional,NA,NA,Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents,"A Randomized, Double-Blinded, Placebo-Controlled, Phase â…¡b Clinical Trial, to Evaluate the Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 3 to 17 Years.","Active, not recruiting",NA,Phase 2,500,Anticipated,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:10:29Z,2021-12-02T04:10:29Z
NCT04884529,NA,5/7/2021,NA,NA,9/24/2021,5/7/2021,5/13/2021,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/30/2021,Actual,1-Sep-21,Actual,9/1/2021,Sep-21,9/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Virtual Chair Yoga for Older Adults and Caregivers: Randomized Controlled Trial,Virtual Chair Yoga for Stress in Older Adults (60+) With Mild/Moderate Dementia or Mild Cognitive Impairments and Caregivers (18+) During COVID-19,Recruiting,NA,Not Applicable,60,Anticipated,Lady Davis Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:10:33Z,2021-12-02T04:10:33Z
NCT04883528,NA,5/6/2021,NA,NA,8/10/2021,5/11/2021,5/12/2021,Actual,NA,NA,NA,NA,NA,NA,8/10/2021,8/16/2021,Actual,6-Aug-21,Actual,8/6/2021,May-21,5/31/2021,30-Aug-22,Anticipated,8/30/2022,30-Aug-22,Anticipated,8/30/2022,NA,Interventional,PARACOR-19,NA,Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019,Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Duke University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:11:45Z,2021-12-02T04:11:45Z
NCT04883203,NA,4/20/2021,NA,NA,5/10/2021,5/10/2021,5/12/2021,Actual,NA,NA,NA,NA,NA,NA,5/10/2021,5/12/2021,Actual,22-Apr-20,Actual,4/22/2020,May-21,5/31/2021,31-Oct-20,Actual,10/31/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,COVID-VITD,NA,The Effect of Vitamin D Supplementation on COVID-19 Recovery,The Effect of Vitamin D Supplementation on Recovery Delays for Non Severe COVID-19 Cases,Completed,NA,Phase 3,130,Actual,University of Monastir,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:12:08Z,2021-12-02T04:12:08Z
NCT04883138,NA,5/4/2021,NA,NA,6/4/2021,5/10/2021,5/12/2021,Actual,NA,NA,NA,NA,NA,NA,6/4/2021,6/7/2021,Actual,24-May-21,Actual,5/24/2021,Jun-21,6/30/2021,30-Aug-21,Anticipated,8/30/2021,15-Aug-21,Anticipated,8/15/2021,NA,Interventional,NA,NA,Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients,A Phase 1 Single Ascending Dose Study of a Recombinant Hyperimmune Polyclonal Antibody Against SARS CoV-2 (GIGA-2050) in Patients Hospitalized With COVID-19,Recruiting,NA,Phase 1,18,Anticipated,"GigaGen, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No current plan to share IPD due to evaluation of potential DLTs.,2021-12-02T04:12:10Z,2021-12-02T04:12:10Z
NCT04880694,NA,4/25/2021,NA,NA,6/10/2021,5/9/2021,5/11/2021,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/14/2021,Actual,20-May-21,Actual,5/20/2021,Jun-21,6/30/2021,Nov-21,Anticipated,11/30/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019ï¼ˆCOVID-19ï¼‰Pneumonia,"A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019ï¼ˆCOVID-19ï¼‰Pneumonia",Recruiting,NA,Phase 2,25,Anticipated,Grand Medical Pty Ltd.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:15:28Z,2021-12-02T04:15:28Z
NCT04880174,NA,4/16/2021,NA,NA,5/5/2021,5/5/2021,5/10/2021,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/10/2021,Actual,22-Mar-21,Actual,3/22/2021,Apr-21,4/30/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,Recruiting,NA,Not Applicable,800,Anticipated,Universitair Ziekenhuis Brussel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:15:35Z,2021-12-02T04:15:35Z
NCT04881227,NA,5/10/2021,NA,NA,6/21/2021,5/10/2021,5/11/2021,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/22/2021,Actual,25-May-21,Actual,5/25/2021,Jun-21,6/30/2021,May-23,Anticipated,5/31/2023,May-23,Anticipated,5/31/2023,NA,Interventional,NA,NA,The Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions in ESPERES Cohort (ESPERES-COVID-19-CHATBOT),The ESPERES Prospective Cohort of Healthcare Workers in France: Study on the Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions,Recruiting,NA,Not Applicable,892,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:14:20Z,2021-12-02T04:14:20Z
NCT04881214,NA,7/3/2020,NA,NA,5/10/2021,5/10/2021,5/11/2021,Actual,NA,NA,NA,NA,NA,NA,5/10/2021,5/11/2021,Actual,1-Jul-20,Actual,7/1/2020,May-21,5/31/2021,25-Nov-22,Anticipated,11/25/2022,1-Jul-22,Anticipated,7/1/2022,NA,Interventional,COVISQAR,NA,"COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program","Impact of COVID-19 Pneumonia on Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program (COVISQAR)",Recruiting,NA,Not Applicable,60,Anticipated,"University Hospital, Geneva",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:14:21Z,2021-12-02T04:14:21Z
NCT04878809,NA,4/28/2021,NA,NA,6/17/2021,5/4/2021,5/7/2021,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/18/2021,Actual,22-Apr-21,Actual,4/22/2021,Jun-21,6/30/2021,17-Jun-21,Actual,6/17/2021,17-Jun-21,Actual,6/17/2021,NA,Interventional,NA,NA,"Rapid Screening Circuit of COVID 19 in Schools, Pilot Study","Rapid Screening Circuit of COVID 19 in Schools, Pilot Study",Completed,NA,Not Applicable,153,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:16:42Z,2021-12-02T04:16:42Z
NCT04880161,NA,5/6/2021,NA,NA,5/6/2021,5/6/2021,5/10/2021,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/10/2021,Actual,May-21,Anticipated,5/31/2021,May-21,5/31/2021,Dec-21,Anticipated,12/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID),"A Randomized, Double-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety and Efficacy of Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)",Recruiting,NA,Phase 1,30,Anticipated,Ampio Pharmaceuticals. Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:15:44Z,2021-12-02T04:15:44Z
NCT04880135,NA,5/6/2021,NA,NA,9/17/2021,5/6/2021,5/10/2021,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/20/2021,Actual,1-Mar-21,Actual,3/1/2021,Sep-21,9/30/2021,1-Sep-21,Actual,9/1/2021,30-Aug-21,Actual,8/30/2021,NA,Interventional,NA,NA,Supervised Versus Home Based Exercises Neck and Low Back Pain Among Students Due to Quarantine During COVID-19,Effects of Supervised Versus Home Based Stretching and Strengthening Exercise Program on Neck Pain and Back Pain Among University Students Due to Quarantine During COVID-19: A Randomised Controlled Trial,Completed,NA,Not Applicable,404,Actual,Riphah International University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:15:47Z,2021-12-02T04:15:47Z
NCT04880122,NA,5/5/2021,NA,NA,5/6/2021,5/6/2021,5/10/2021,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/10/2021,Actual,1-Aug-20,Actual,8/1/2020,May-21,5/31/2021,30-Sep-20,Actual,9/30/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,NA,NA,Dried Blood Spots for SARS-CoV-2 Serology (COVID-19).,Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 2 Antibodies in a Population of Nursing Home Residents.,Completed,NA,Not Applicable,440,Actual,University Ghent,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:15:50Z,2021-12-02T04:15:50Z
NCT04878042,NA,5/4/2021,NA,NA,5/6/2021,5/6/2021,5/7/2021,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/7/2021,Actual,9-Apr-21,Actual,4/9/2021,May-21,5/31/2021,Jul-21,Anticipated,7/31/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,COVID-19 Infection Control Using H2O2 Mouth Wash and Nasal Spray,The Negativisation Rate of Positive PCR Swab Tests for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Treatment With Hydrogen Peroxide: a Double-blind Placebo-controlled Randomised Trial.,Recruiting,NA,Not Applicable,200,Anticipated,EPISTATA,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:18:07Z,2021-12-02T04:18:07Z
NCT04878328,NA,4/30/2021,NA,NA,8/11/2021,5/4/2021,5/7/2021,Actual,NA,NA,NA,NA,NA,NA,8/11/2021,8/12/2021,Actual,1-Jul-21,Actual,7/1/2021,Aug-21,8/31/2021,1-Jul-26,Anticipated,7/1/2026,1-Jul-26,Anticipated,7/1/2026,NA,Interventional,NA,NA,Leveraging CHWs to Improve COVID-19 Testing and Mitigation Among CJIs Accessing a Corrections-focused CBO,Leveraging Community Health Workers to Improve COVID-19 Testing and Mitigation Among Criminal Justice-involved Individuals Accessing a Corrections-focused Community-based Organization,Recruiting,NA,Not Applicable,250,Anticipated,Montefiore Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:17:50Z,2021-12-02T04:17:50Z
NCT04877769,NA,5/4/2021,NA,NA,5/4/2021,5/4/2021,5/7/2021,Actual,NA,NA,NA,NA,NA,NA,5/4/2021,5/7/2021,Actual,25-Apr-21,Actual,4/25/2021,Apr-21,4/30/2021,Aug-21,Anticipated,8/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Bronchopulmonary PK of AT-527 (R07496998),"A Phase 1, Open-label, Randomized Study in Healthy Subjects to Assess the Bronchopulmonary Pharmacokinetics, Safety and Tolerability of AT-527, a Potential Treatment for COVID-19",Recruiting,NA,Phase 1,24,Anticipated,"Atea Pharmaceuticals, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:18:21Z,2021-12-02T04:18:21Z
NCT04878055,NA,4/30/2021,NA,NA,9/3/2021,5/6/2021,5/7/2021,Actual,NA,NA,NA,NA,NA,NA,9/3/2021,9/5/2021,Actual,14-Feb-21,Actual,2/14/2021,Sep-21,9/30/2021,Oct-21,Anticipated,10/31/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.,"A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 3,312,Anticipated,DompÃ© Farmaceutici S.p.A,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:18:30Z,2021-12-02T04:18:30Z
NCT04876417,NA,3/15/2021,NA,NA,5/5/2021,5/5/2021,5/6/2021,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/6/2021,Actual,1-Feb-21,Actual,2/1/2021,May-21,5/31/2021,1-Feb-23,Anticipated,2/1/2023,1-Feb-23,Anticipated,2/1/2023,NA,Interventional,NA,NA,tDCS for Post COVID-19 Fatigue,Transcranial Direct Current Stimulation (tDCS) for the Treatment of Fatigue in Post-COVID-19 Patients,Recruiting,NA,Not Applicable,50,Anticipated,University of Iowa,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:20:16Z,2021-12-02T04:20:16Z
NCT04876560,NA,4/27/2021,NA,NA,5/5/2021,5/5/2021,5/6/2021,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/6/2021,Actual,11-Mar-20,Actual,3/11/2020,May-21,5/31/2021,15-Apr-21,Actual,4/15/2021,10-Oct-20,Actual,10/10/2020,NA,Interventional,CDSS,NA,Implementation of a CDSS in Oncology Patients During COVID-19,"The Use of Clinical Decision Support Systems (CDSS) to Provide Nutritional Care to Breast Cancer Patients During the COVID-19 Pandemic: a Randomised Controlled, Pilot Trial",Completed,NA,Not Applicable,44,Actual,"Iaso Maternity Hospital, Athens, Greece",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:21:45Z,2021-12-02T04:21:45Z
NCT04873128,NA,4/30/2021,NA,NA,6/10/2021,5/4/2021,5/5/2021,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/15/2021,Actual,10-Jun-21,Actual,6/10/2021,Jun-21,6/30/2021,1-Jul-23,Anticipated,7/1/2023,1-Jul-22,Anticipated,7/1/2022,NA,Interventional,COVID 19-VAC,NA,Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach,Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach,Recruiting,NA,Not Applicable,110,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available after analysis and unlimited.,NA,NA,Yes,The COVID19-VAC study will provide data in a pseudonymised manner to national and international databases set up to increase the diagnostic yield through advanced analysis tools and matchmaking against other cohorts,2021-12-02T04:25:43Z,2021-12-02T04:25:43Z
NCT04872686,NA,4/26/2021,NA,NA,5/12/2021,5/2/2021,5/4/2021,Actual,NA,NA,NA,NA,NA,NA,5/12/2021,5/13/2021,Actual,10-Apr-21,Actual,4/10/2021,May-21,5/31/2021,May-21,Anticipated,5/31/2021,May-21,Anticipated,5/31/2021,NA,Interventional,COVID-19,NA,Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx,"A Multicenter, Single Blind, Randomized Controlled Trial of Virucidal Effect of Polyvinyl Pyrrol-Iodine on SARS-CoV-2 as Well as Safety of Its Application on Nasopharynx & Oropharynx of COVID-19 Positive Patients",Recruiting,NA,Phase 3,798,Anticipated,Bangladesh Reference Institute of Chemical Measurements (BRICM),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,3 months,"Available on public domain like figure share, research gate, Linkdin and others",NA,Yes,"After completion of the project, a manuscript will be prepared and will be shared to the journal authority for publication. Data will be shared with the journal authority and make public as part of the publication.",2021-12-02T04:26:27Z,2021-12-02T04:26:27Z
NCT04873414,NA,4/26/2021,NA,NA,5/31/2021,5/3/2021,5/5/2021,Actual,NA,NA,NA,NA,NA,NA,5/31/2021,6/2/2021,Actual,1-Dec-20,Actual,12/1/2020,May-21,5/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,PlaSenTer,NA,Convalescent Plasma as Adjunct Therapy for COVID-19,Clinical Trial of Convalescent Plasma Administration as Adjunct Therapy for COVID-19 (Uji Klinik Pemberian Plasma Konvalesen Sebagai Terapi Tambahan COVID-19),Recruiting,NA,Phase 2/Phase 3,364,Anticipated,"National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"January 1 - December 31, 2021",The study protocol and and raw data are only shared to the ClinicalTrials.gov and/or Journal Reviewers.,NA,Yes,"The original datasets used for this study are not publicly available due to the existing regulation, and only can be shared upon the approval of the Sponsor on behalf of the Ministry of Health.",2021-12-02T04:25:49Z,2021-12-02T04:25:49Z
NCT04872712,NA,5/2/2021,NA,NA,9/3/2021,5/2/2021,5/4/2021,Actual,NA,NA,NA,NA,NA,NA,9/3/2021,9/9/2021,Actual,4-May-21,Actual,5/4/2021,Sep-21,9/30/2021,7-Apr-22,Anticipated,4/7/2022,7-Apr-22,Anticipated,4/7/2022,NA,Interventional,NA,NA,Comparing Press and Filiform Needle Acupuncture Effectiveness for Improving Insomnia in COVID-19 Healthcare Workers,Comparison of Press Needle and Filiform Needle Acupuncture Effectiveness for Improving Insomnia and Melatonin Level in COVID-19 Frontline Healthcare Workers,Recruiting,NA,Not Applicable,34,Anticipated,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:26:01Z,2021-12-02T04:26:01Z
NCT04871958,NA,4/29/2021,NA,NA,4/30/2021,4/30/2021,5/4/2021,Actual,NA,NA,NA,NA,NA,NA,4/30/2021,5/4/2021,Actual,19-Mar-21,Actual,3/19/2021,Apr-21,4/30/2021,30-Sep-21,Anticipated,9/30/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,Initiator,NA,"Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward","Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward",Enrolling by invitation,NA,Not Applicable,66,Anticipated,Federico II University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:27:04Z,2021-12-02T04:27:04Z
NCT04871633,NA,1/11/2021,NA,NA,5/2/2021,5/2/2021,5/4/2021,Actual,NA,NA,NA,NA,NA,NA,5/2/2021,5/4/2021,Actual,1-Aug-20,Actual,8/1/2020,May-21,5/31/2021,30-Dec-20,Actual,12/30/2020,15-Nov-20,Actual,11/15/2020,NA,Interventional,NA,NA,Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore,Effectiveness of Remedesvir in SARS-CoV2 Patients Presenting at Mayo Hospital Lahore,Completed,NA,Not Applicable,66,Actual,King Edward Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:27:15Z,2021-12-02T04:27:15Z
NCT04870385,NA,4/7/2021,NA,NA,8/30/2021,4/28/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,8/31/2021,Actual,11-Apr-21,Actual,4/11/2021,Aug-21,8/31/2021,Aug-21,Anticipated,8/31/2021,25-Jun-21,Actual,6/25/2021,NA,Interventional,NA,NA,An Islamic Psychospiritual-Acceptance and Commitment-based Prevention Program for At-risk Young Adults in the COVID-19 Pandemic,An Islamic Psychospiritual-Acceptance and Commitment-based Prevention Program for At-Risk Young Adults in the COVID-19 Pandemic,"Active, not recruiting",NA,Not Applicable,120,Anticipated,International Islamic University Malaysia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:28:27Z,2021-12-02T04:28:27Z
NCT04872075,NA,4/29/2021,NA,NA,7/12/2021,4/29/2021,5/4/2021,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/13/2021,Actual,26-May-21,Actual,5/26/2021,Jul-21,7/31/2021,13-Jun-21,Actual,6/13/2021,13-Jun-21,Actual,6/13/2021,NA,Interventional,SPRING,NA,Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event,Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event,Completed,NA,Not Applicable,6678,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:27:02Z,2021-12-02T04:27:02Z
NCT04871828,NA,5/1/2021,NA,NA,5/5/2021,5/1/2021,5/4/2021,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/10/2021,Actual,28-Feb-21,Actual,2/28/2021,May-21,5/31/2021,Dec-21,Anticipated,12/31/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,PROMISE,NA,The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19),The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19): (Randomized Clinical Trial),Recruiting,NA,Phase 3,66,Anticipated,King Abdullah International Medical Research Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:27:06Z,2021-12-02T04:27:06Z
NCT04871815,NA,4/27/2021,9/27/2021,NA,10/5/2021,4/30/2021,5/4/2021,Actual,10/5/2021,10/7/2021,Actual,NA,NA,NA,10/5/2021,10/7/2021,Actual,27-Apr-21,Actual,4/27/2021,Oct-21,10/31/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.,Preliminary Examination of the Effects of Sodium Pyruvate Nasal Spray (N115) on Symptoms Associated With COVID19 Long Haulers.,"Active, not recruiting",NA,Phase 2/Phase 3,22,Actual,"Cellular Sciences, inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:27:09Z,2021-12-02T04:27:09Z
NCT04871737,NA,4/21/2021,NA,NA,5/26/2021,4/30/2021,5/4/2021,Actual,NA,NA,NA,NA,NA,NA,5/26/2021,5/27/2021,Actual,20-May-21,Actual,5/20/2021,May-21,5/31/2021,Jun-22,Anticipated,6/30/2022,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Study of a Live rNDV Based Vaccine Against COVID-19,"Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers",Recruiting,NA,Phase 1,90,Anticipated,"Laboratorio Avi-Mex, S.A. de C.V.",,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:27:24Z,2021-12-02T04:27:24Z
NCT04871646,NA,4/29/2021,NA,NA,7/27/2021,4/29/2021,5/4/2021,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,8/2/2021,Actual,30-Jun-21,Actual,6/30/2021,Jul-21,7/31/2021,Aug-22,Anticipated,8/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314,"A Double-blind, Multi-center, Multi-regional, Randomized Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19",Recruiting,NA,Phase 3,586,Anticipated,Chong Kun Dang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:27:25Z,2021-12-02T04:27:25Z
NCT04870723,NA,4/23/2021,NA,NA,7/13/2021,4/29/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,7/13/2021,7/20/2021,Actual,1-Mar-21,Actual,3/1/2021,Jul-21,7/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,COVID-19,NA,#SafeHandsSafeHearts: An eHealth Intervention for COVID-19 Prevention and Support,"An International Multi-site, Randomized Controlled Trial of a Brief eHealth Intervention to Increase COVID-19 Knowledge and Protective Behaviors, and Reduce Pandemic Stress Among Diverse LGBT+ People",Recruiting,NA,Not Applicable,900,Anticipated,University of Toronto,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:28:05Z,2021-12-02T04:28:05Z
NCT04870333,NA,3/1/2021,NA,NA,4/28/2021,4/28/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,4/28/2021,5/3/2021,Actual,19-Feb-21,Actual,2/19/2021,Apr-21,4/30/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,PROTECT-V,NA,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion,Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:28:39Z,2021-12-02T04:28:39Z
NCT04870164,NA,4/28/2021,NA,NA,9/23/2021,4/28/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/29/2021,Actual,18-Nov-20,Actual,11/18/2020,Sep-21,9/30/2021,Jan-22,Anticipated,1/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,"Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)","A Phase 1, First-time-in-human, Dose Ascending Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MP0420 (a Novel Drug Candidate With Potential for Treatment of COVID-19) in Healthy Volunteers",Recruiting,NA,Phase 1,72,Anticipated,Molecular Partners AG,,14,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:28:55Z,2021-12-02T04:28:55Z
NCT04869592,NA,4/24/2021,NA,NA,5/5/2021,4/29/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/7/2021,Actual,25-Apr-21,Actual,4/25/2021,May-21,5/31/2021,25-Oct-22,Anticipated,10/25/2022,25-Oct-22,Anticipated,10/25/2022,NA,Interventional,NA,NA,A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19,"Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older",Recruiting,NA,Phase 1/Phase 2,3580,Anticipated,"National Vaccine and Serum Institute, China",,15,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:29:31Z,2021-12-02T04:29:31Z
NCT04868890,NA,4/22/2021,NA,NA,4/26/2021,4/26/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,4/26/2021,5/3/2021,Actual,Apr-21,Anticipated,4/30/2021,Apr-21,4/30/2021,Dec-21,Anticipated,12/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19,"A Randomized, Double-Blinded, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19",Recruiting,NA,Phase 2,200,Anticipated,Ampio Pharmaceuticals. Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:30:14Z,2021-12-02T04:30:14Z
NCT04869072,NA,4/8/2021,NA,NA,4/27/2021,4/27/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,5/3/2021,Actual,29-Apr-20,Actual,4/29/2020,Apr-21,4/30/2021,30-Mar-21,Actual,3/30/2021,30-Nov-20,Actual,11/30/2020,NA,Interventional,CPT-ZHP,NA,Convalescent Plasma Therapy - Zurich Protocol,"A Phase i, Open-label, Single-centre Clinical Study to Evaluate Safety and Efficacy of Passive Immunization of High-risk SARS-CoV-2 Positive Patients With Convalescent Plasma Therapy",Completed,NA,Phase 1,30,Actual,University of Zurich,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:30:16Z,2021-12-02T04:30:16Z
NCT04868903,NA,4/6/2021,NA,NA,4/26/2021,4/26/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,4/26/2021,5/3/2021,Actual,30-Nov-20,Actual,11/30/2020,Apr-21,4/30/2021,30-Dec-22,Anticipated,12/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19,Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19,Recruiting,NA,Not Applicable,2000,Anticipated,University of Chicago,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Uncertain if will share IPD. No plan determined.,2021-12-02T04:30:18Z,2021-12-02T04:30:18Z
NCT04869397,NA,4/29/2021,NA,NA,6/13/2021,4/29/2021,5/3/2021,Actual,NA,NA,NA,NA,NA,NA,6/13/2021,6/15/2021,Actual,14-Jun-21,Actual,6/14/2021,Jun-21,6/30/2021,30-Jul-22,Anticipated,7/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,ProTrans19+,NA,Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells,Treatment of Respiratory Complications Associated With COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTransÂ®): a Randomized Phase II Controlled Clinical Trial,Recruiting,NA,Phase 2,48,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:29:53Z,2021-12-02T04:29:53Z
NCT04867226,NA,4/25/2021,NA,NA,6/19/2021,4/28/2021,4/30/2021,Actual,NA,NA,NA,NA,NA,NA,6/19/2021,6/22/2021,Actual,8-May-21,Actual,5/8/2021,Jun-21,6/30/2021,18-Jun-21,Actual,6/18/2021,18-Jun-21,Actual,6/18/2021,NA,Interventional,NA,NA,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Completed,NA,Phase 2,100,Actual,Hawler Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:31:46Z,2021-12-02T04:31:46Z
NCT04867265,NA,4/26/2021,NA,NA,6/2/2021,4/28/2021,4/30/2021,Actual,NA,NA,NA,NA,NA,NA,6/2/2021,6/3/2021,Actual,3-May-21,Actual,5/3/2021,Jun-21,6/30/2021,2-Jun-21,Actual,6/2/2021,2-Jun-21,Actual,6/2/2021,NA,Interventional,MOVERESP,NA,Mouth-to-mouth Ventilation Efficiency Through Breathable Self-sterilizing Respirator During BLS in COVID-19 Pandemic,Mouth-to-mouth Ventilation Efficiency Through Breathable Self-sterilizing Respirator During BLS in COVID-19 Pandemic: a Crossover Simulation-based Study,Completed,NA,Not Applicable,104,Actual,Brno University Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:32:06Z,2021-12-02T04:32:06Z
NCT04866303,NA,4/27/2021,NA,NA,8/30/2021,4/27/2021,4/29/2021,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,8/31/2021,Actual,26-Apr-21,Actual,4/26/2021,Aug-21,8/31/2021,Oct-21,Anticipated,10/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Protecting Our Community: COVID-19 Testing,Protecting Our Community: A Pragmatic Randomized Trial of Home-Based COVID-19 Testing With Native American and Latino Communities,Recruiting,NA,Not Applicable,400,Anticipated,Montana State University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,"In conjunction with tribal partners on the Flathead Reservation and at Salish Kootenai College in Montana, and with community partners in the Yakima Valley in Washington, we have developed a Data Sharing Plan. We will work closely with the Coordination and Data Collection Center (CDCC); the Social, Ethical, and Behavioral Implications program (SEBI); and the RADx-Up Consortium throughout the study to implement the Plan. All data will be deidentified and assigned an anonymous code by a member of the study team in each community before sharing with the broader study team for analysis. In addition, data collection instruments (including surveys, focus group and key informant interview questions, informed consent forms, community data collection tools, and educational material), deidentified coded data, and analyzed study trial results will be shared with the CDCC, SEBI, and RADx-UP Consortium.",2021-12-02T04:32:56Z,2021-12-02T04:32:56Z
NCT04866069,NA,4/26/2021,NA,NA,5/3/2021,4/26/2021,4/29/2021,Actual,NA,NA,NA,NA,NA,NA,5/3/2021,5/6/2021,Actual,25-Apr-21,Actual,4/25/2021,May-21,5/31/2021,Apr-22,Anticipated,4/30/2022,Oct-21,Anticipated,10/31/2021,NA,Interventional,COVID-19,NA,Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults,"Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.",Recruiting,NA,Phase 1,50,Anticipated,The Scientific and Technological Research Council of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:32:47Z,2021-12-02T04:32:47Z
NCT04865237,NA,4/1/2021,NA,NA,9/7/2021,4/26/2021,4/29/2021,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/8/2021,Actual,6-Mar-21,Actual,3/6/2021,Sep-21,9/30/2021,3-Jun-22,Anticipated,6/3/2022,3-Jun-22,Anticipated,6/3/2022,NA,Interventional,NA,NA,SARS-CoV-2 Human Challenge Characterisation Study,A Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain,"Active, not recruiting",NA,Not Applicable,36,Actual,Imperial College London,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:33:31Z,2021-12-02T04:33:31Z
NCT04865107,NA,4/27/2021,NA,NA,5/4/2021,4/27/2021,4/29/2021,Actual,NA,NA,NA,NA,NA,NA,5/4/2021,5/5/2021,Actual,27-Apr-21,Actual,4/27/2021,May-21,5/31/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,CIRCA-19 RCT,NA,Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial,Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial,Recruiting,NA,Phase 2,54,Anticipated,Ottawa Hospital Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:33:44Z,2021-12-02T04:33:44Z
NCT04864899,NA,3/19/2021,NA,NA,9/29/2021,4/27/2021,4/29/2021,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,9/30/2021,Actual,1-Sep-21,Actual,9/1/2021,Sep-21,9/30/2021,31-Dec-23,Anticipated,12/31/2023,30-Mar-23,Anticipated,3/30/2023,NA,Interventional,R-COVID-CMR,NA,Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR),Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR),Recruiting,NA,Not Applicable,112,Anticipated,The University of Hong Kong,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:34:09Z,2021-12-02T04:34:09Z
NCT04865029,NA,4/21/2021,NA,NA,7/22/2021,4/27/2021,4/29/2021,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/23/2021,Actual,22-Jul-21,Actual,7/22/2021,Jul-21,7/31/2021,May-22,Anticipated,5/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Estradiol and Progesterone in Hospitalized COVID-19 Patients,Acute Estradiol and Progesterone Therapy in Hospitalized Adults to Reduce Coronavirus Disease (COVID-19) Severity: A Randomized Control Trial,Recruiting,NA,Phase 2,120,Anticipated,Tulane University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:34:05Z,2021-12-02T04:34:05Z
NCT04864015,NA,4/27/2021,NA,NA,10/7/2021,4/27/2021,4/28/2021,Actual,NA,NA,NA,NA,NA,NA,10/7/2021,10/8/2021,Actual,17-Mar-21,Actual,3/17/2021,Oct-21,10/31/2021,30-Jun-21,Actual,6/30/2021,15-May-21,Actual,5/15/2021,NA,Interventional,NA,NA,COVID-19 Aerosol in EGD Using a Droplet Reduction Mouthpiece,COVID-19: a Study About Aerosol Formation During Gastroscopy With a Adjusted Mouthpiece for Droplet Reduction,Completed,NA,Not Applicable,80,Actual,Universitaire Ziekenhuizen Leuven,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,We won't share individual participant data,2021-12-02T04:34:28Z,2021-12-02T04:34:28Z
NCT04863638,NA,4/27/2021,NA,NA,5/11/2021,4/27/2021,4/28/2021,Actual,NA,NA,NA,NA,NA,NA,5/11/2021,5/13/2021,Actual,29-Apr-21,Actual,4/29/2021,Apr-21,4/30/2021,31-Mar-24,Anticipated,3/31/2024,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,COVID-19,NA,"A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated","A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged â‰¥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old",Recruiting,NA,Phase 4,4400,Anticipated,China National Biotec Group Company Limited,,18,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:34:54Z,2021-12-02T04:34:54Z
NCT04863131,NA,4/15/2021,NA,NA,4/29/2021,4/23/2021,4/28/2021,Actual,NA,NA,NA,NA,NA,NA,4/29/2021,4/30/2021,Actual,28-Apr-21,Actual,4/28/2021,Apr-21,4/30/2021,31-Jan-23,Anticipated,1/31/2023,31-Jan-23,Anticipated,1/31/2023,NA,Interventional,NA,NA,Safety and Immunogenicity of EXG-5003,Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,Fujita Health University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:35:17Z,2021-12-02T04:35:17Z
NCT04861298,NA,4/25/2021,NA,NA,9/3/2021,4/25/2021,4/27/2021,Actual,NA,NA,NA,NA,NA,NA,9/3/2021,9/8/2021,Actual,11-Jan-21,Actual,1/11/2021,Apr-21,4/30/2021,29-Aug-21,Actual,8/29/2021,29-Aug-21,Actual,8/29/2021,NA,Interventional,NA,NA,Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early COVID-19 Symptoms at Home,Study to Investigate the Benefits of Dietary Supplement Quercetin for COVID-19,Completed,NA,Not Applicable,100,Actual,King Edward Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:36:29Z,2021-12-02T04:36:29Z
NCT04860739,NA,4/22/2021,NA,NA,5/1/2021,4/22/2021,4/27/2021,Actual,NA,NA,NA,NA,NA,NA,5/1/2021,5/4/2021,Actual,24-Apr-21,Actual,4/24/2021,Apr-21,4/30/2021,30-Apr-22,Anticipated,4/30/2022,20-May-21,Anticipated,5/20/2021,NA,Interventional,CombiVacS,NA,Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose,"A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the Immunogenicity Against SARS-Cov2 and Safety of Boosted Vaccination With COMIRNATY in Subjects Having Received Prime Vaccination With VAXZERIA","Active, not recruiting",NA,Phase 2,676,Actual,Spanish Clinical Research Network - SCReN,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within one year after study end,Published in EudraCT,NA,Yes,Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result.,2021-12-02T04:36:55Z,2021-12-02T04:36:55Z
NCT04860895,NA,4/25/2021,NA,NA,5/2/2021,4/25/2021,4/27/2021,Actual,NA,NA,NA,NA,NA,NA,5/2/2021,5/6/2021,Actual,11-Feb-21,Actual,2/11/2021,May-21,5/31/2021,15-May-21,Anticipated,5/15/2021,1-May-21,Anticipated,5/1/2021,NA,Interventional,NA,NA,Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System,The Reliability of the Computer Aided Multi-Spectral Screening System In the Diagnosis of Covid-19,Recruiting,NA,Not Applicable,4400,Anticipated,Fable Biyoteknoloji San ve Tic A.S,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:36:48Z,2021-12-02T04:36:48Z
NCT04860284,NA,4/23/2021,NA,NA,4/23/2021,4/23/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,4/23/2021,4/26/2021,Actual,18-Sep-20,Actual,9/18/2020,Apr-21,4/30/2021,1-Dec-21,Anticipated,12/1/2021,9-Feb-21,Actual,2/9/2021,NA,Interventional,HONEST,NA,Hydroxychloroquine for Treatment of Non-Severe COVID-19,The Efficacy and Safety of Hydroxychloroquine for the Treatment Of Non-Severe COVID-19 in Adults in Uganda: A Randomized Open Label Phase II Clinical Trial,"Active, not recruiting",NA,Phase 2,105,Actual,Makerere University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:37:13Z,2021-12-02T04:37:13Z
NCT04860271,NA,4/23/2021,NA,NA,4/23/2021,4/23/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,4/23/2021,4/26/2021,Actual,9-Mar-21,Actual,3/9/2021,Apr-21,4/30/2021,31-Dec-21,Anticipated,12/31/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Manual Acupuncture Using Acupuncture Needle vs Press Needle for COVID-19 Healthcare Anxiety,Comparison of Manual Acupuncture Effectivity Using Filiform Needles and Press Tack Needle for Healthcare Worker's Anxiety During COVID-19 Outbreak: A Randomized Clinical Trial,Recruiting,NA,Not Applicable,36,Anticipated,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:37:18Z,2021-12-02T04:37:18Z
NCT04860258,NA,4/22/2021,NA,NA,10/1/2021,4/22/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,10/1/2021,10/4/2021,Actual,22-Apr-21,Actual,4/22/2021,Jan-21,1/31/2021,21-Sep-21,Actual,9/21/2021,21-Sep-21,Actual,9/21/2021,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19","COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities",Completed,NA,Phase 3,129,Actual,CureVac AG,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:37:19Z,2021-12-02T04:37:19Z
NCT04860219,NA,4/21/2021,NA,NA,4/23/2021,4/21/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,4/23/2021,4/27/2021,Actual,8-Jul-20,Actual,7/8/2020,Apr-21,4/30/2021,30-Apr-21,Anticipated,4/30/2021,18-Sep-20,Actual,9/18/2020,NA,Interventional,SARS-CoV-2,NA,Lactoferrin Use in (SARS-CoV-2) Management,The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS COV-2 Patients: A Randomized Pilot Study,Recruiting,NA,Not Applicable,54,Anticipated,Zagazig University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The datasets generated and/or analyzed during the current study are available from the corresponding author upon request.,2021-12-02T04:37:40Z,2021-12-02T04:37:40Z
NCT04859023,NA,4/22/2021,NA,NA,5/3/2021,4/22/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,5/3/2021,5/6/2021,Actual,22-Feb-21,Actual,2/22/2021,May-21,5/31/2021,28-Feb-21,Actual,2/28/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,AutoCoV,NA,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection (COVID-19).,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection in General Population Using Self-samples (COVID-19).,Completed,NA,Not Applicable,10000,Actual,Centre Hospitalier Universitaire de Saint Etienne,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:38:14Z,2021-12-02T04:38:14Z
NCT04859244,NA,4/19/2021,NA,NA,8/7/2021,4/21/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,8/7/2021,8/10/2021,Actual,1-Jan-21,Actual,1/1/2021,Apr-21,4/30/2021,1-Aug-21,Actual,8/1/2021,1-May-21,Actual,5/1/2021,NA,Interventional,NA,NA,First-in-Human Study of Orally Administered GS-441524 for COVID-19,"First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer",Completed,NA,Phase 1,1,Actual,Copycat Sciences LLC,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,Within 6 months after publication,Materials available upon request,NA,Yes,All collected IPD,2021-12-02T04:38:06Z,2021-12-02T04:38:06Z
NCT04858633,NA,3/22/2021,NA,NA,6/8/2021,4/22/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,6/8/2021,6/11/2021,Actual,22-Mar-21,Actual,3/22/2021,Jun-21,6/30/2021,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,PEP-CQ,NA,Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Randomized Control Clinical Trial,Recruiting,NA,Phase 3,1000,Anticipated,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All data requests should be submitted to the PI (DPD) for consideration. Data sharing may be considered by the PI after due approval from IEC.,2021-12-02T04:38:37Z,2021-12-02T04:38:37Z
NCT04858789,NA,4/22/2021,NA,NA,6/24/2021,4/22/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,6/24/2021,6/25/2021,Actual,24-Jun-21,Actual,6/24/2021,Jun-21,6/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,The Effectiveness of a CA-CBI on Psychological Distress of University Students During the COVID-19 Pandemic,Effectiveness of a Culturally Adapted Cognitive Behavioral Intervention to Reducing Psychological Distress and Improving Well-Being Among University Students During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,100,Anticipated,KoÃ§ University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:38:10Z,2021-12-02T04:38:10Z
NCT04858412,NA,4/21/2021,NA,NA,4/21/2021,4/21/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,4/21/2021,4/26/2021,Actual,1-Apr-21,Actual,4/1/2021,Apr-21,4/30/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19,Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19,Recruiting,NA,Not Applicable,48,Anticipated,The Cleveland Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:38:36Z,2021-12-02T04:38:36Z
NCT04857060,NA,4/20/2021,NA,NA,7/28/2021,4/20/2021,4/23/2021,Actual,NA,NA,NA,NA,NA,NA,7/28/2021,7/30/2021,Actual,1-Jul-21,Actual,7/1/2021,Jul-21,7/31/2021,Apr-24,Anticipated,4/30/2024,Jan-23,Anticipated,1/31/2023,NA,Interventional,VIDEO-PCE,NA,Palliative Care Educator,Meeting the Challenges of COVID-19 by Expanding the Reach of Palliative Care: Proactive Advance Care Planning With Videos for the Elderly and All Patients With Dementia,Recruiting,NA,Not Applicable,4800,Anticipated,Boston Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:39:54Z,2021-12-02T04:39:54Z
NCT04856111,NA,4/19/2021,NA,NA,4/26/2021,4/19/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,4/26/2021,4/28/2021,Actual,17-Mar-21,Actual,3/17/2021,Apr-21,4/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,PINCER,NA,Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia,A Study of the Efficacy and Safety of Pirfenidone vs. Nintedanib in the Treatment of Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia,Recruiting,NA,Phase 4,48,Anticipated,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:40:12Z,2021-12-02T04:40:12Z
NCT04858542,NA,3/22/2021,NA,NA,4/22/2021,4/22/2021,4/26/2021,Actual,NA,NA,NA,NA,NA,NA,4/22/2021,4/26/2021,Actual,26-Feb-21,Actual,2/26/2021,Apr-21,4/30/2021,Jul-21,Anticipated,7/31/2021,May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,Evaluating the Impact of Vocal Health Education on Mask-wearing Workers During COVID-19,Developing Educational Modules to Improve Communication and Vocal Health Among Mask-wearing Healthcare Workers: Phase 2 of the COVID-19 Critical Community Challenge Grant,Recruiting,NA,Not Applicable,10,Anticipated,University of Cincinnati,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:38:27Z,2021-12-02T04:38:27Z
NCT04854941,NA,4/7/2021,NA,NA,4/21/2021,4/21/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,4/21/2021,4/22/2021,Actual,10-Dec-20,Actual,12/10/2020,Apr-21,4/30/2021,10-Apr-21,Actual,4/10/2021,10-Mar-21,Actual,3/10/2021,NA,Interventional,NA,NA,Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection,"Efficacy of Probiotics (Lactobacillus Rhamnosus, Bifidobacterium Bifidum, Bifidobacterium Longum Subsp. Infantis and Bifidobacterium Longum) in the Treatment of Hospitalised Patients With Novel Coronavirus Infection",Completed,NA,Not Applicable,200,Actual,I.M. Sechenov First Moscow State Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The provision of data is prohibited by Local Ethical Committee and is possible upon receipt of an official request addressed to the principal investigator,2021-12-02T04:41:10Z,2021-12-02T04:41:10Z
NCT04854928,NA,4/21/2021,NA,NA,9/17/2021,4/21/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/20/2021,Actual,3-May-21,Actual,5/3/2021,Apr-21,4/30/2021,May-22,Anticipated,5/31/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.,"A Double-blind, Placebo-controlled, Interventional Parallel Group Study to Evaluate the Antiviral Effect of a Single Nasal Application of LTX-109 3% Gel, in Comparison to Placebo Gel, in Subjects With COVID-19 Infection.",Recruiting,NA,Phase 2,60,Anticipated,Pharma Holdings AS,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:41:21Z,2021-12-02T04:41:21Z
NCT04854772,NA,4/20/2021,NA,NA,6/18/2021,4/20/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,6/18/2021,6/23/2021,Actual,15-May-21,Actual,5/15/2021,Jun-21,6/30/2021,Aug-22,Anticipated,8/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Mind Body Intervention for COVID-19 Long Haul Syndrome,Mind Body Intervention for COVID-19 Long Haul Syndrome,Recruiting,NA,Not Applicable,22,Anticipated,Beth Israel Deaconess Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:41:23Z,2021-12-02T04:41:23Z
NCT04854382,NA,4/13/2021,NA,NA,4/22/2021,4/18/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,4/22/2021,4/26/2021,Actual,14-Apr-21,Actual,4/14/2021,Apr-21,4/30/2021,30-Nov-23,Anticipated,11/30/2023,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,TICCKD,NA,Tailored Information About the Coronavirus in Chronic Kidney Disease Patients,Tailored Information About the Coronavirus and the Coronavirus Pandemic for Patients With Chronic Kidney Disease,Recruiting,NA,Not Applicable,192,Anticipated,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:41:28Z,2021-12-02T04:41:28Z
NCT04854798,NA,4/20/2021,NA,NA,6/1/2021,4/20/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,6/1/2021,6/4/2021,Actual,29-Apr-21,Actual,4/29/2021,Jun-21,6/30/2021,Sep-21,Anticipated,9/30/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,UNITE Study (UMN-SW) for COVID-19,Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UMN-SW) for COVID-19 With Wearable Ultrasound Device,Enrolling by invitation,NA,Not Applicable,58,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:41:14Z,2021-12-02T04:41:14Z
NCT04854759,NA,4/17/2021,NA,NA,8/12/2021,4/20/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/13/2021,Actual,15-Mar-21,Actual,3/15/2021,Aug-21,8/31/2021,31-May-22,Anticipated,5/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,COV-PREVENT,NA,The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms,The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms in Patients Infected With the SARS-CoV-2 Virus,Recruiting,NA,Phase 3,200,Anticipated,Independent Public Clinical Hospital No. 4 in Lublin,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:41:18Z,2021-12-02T04:41:18Z
NCT04853979,NA,4/12/2021,NA,NA,6/8/2021,4/18/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,6/8/2021,6/11/2021,Actual,16-May-21,Actual,5/16/2021,Jun-21,6/30/2021,16-Sep-21,Anticipated,9/16/2021,30-Aug-21,Anticipated,8/30/2021,NA,Interventional,NA,NA,Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure,Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure,Recruiting,NA,Not Applicable,200,Anticipated,Hamad Medical Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:41:44Z,2021-12-02T04:41:44Z
NCT04853927,NA,4/17/2021,NA,NA,4/23/2021,4/17/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,4/23/2021,4/26/2021,Actual,8-Feb-21,Actual,2/8/2021,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,NA,NA,Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit,Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit,Recruiting,NA,Phase 3,600,Anticipated,"Applied Biology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:41:57Z,2021-12-02T04:41:57Z
NCT04853966,NA,4/18/2021,NA,NA,4/18/2021,4/18/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,4/18/2021,4/22/2021,Actual,17-Apr-21,Actual,4/17/2021,Apr-21,4/30/2021,18-Apr-22,Anticipated,4/18/2022,17-Apr-22,Anticipated,4/17/2022,NA,Interventional,NA,NA,The Effects of Physical Activity Counseling on Physical Activity and Quality of Life in Covid-19 Patients,An Investigation of the Effects of Physical Activity Counseling on Physical Activity and Quality of Life in Covid-19 Patients,Recruiting,NA,Not Applicable,30,Anticipated,Gazi University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:41:59Z,2021-12-02T04:41:59Z
NCT04853199,NA,4/18/2021,NA,NA,7/26/2021,4/18/2021,4/21/2021,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/28/2021,Actual,1-Jun-21,Actual,6/1/2021,Jul-21,7/31/2021,30-Aug-21,Anticipated,8/30/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,QUERCOV,NA,Quercetin In The Treatment Of SARS-COV 2,Effectiveness of Quercetin In The Treatment of SARS-COV 2,Recruiting,NA,Early Phase 1,200,Anticipated,HÃ´pital Universitaire Sahloul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Two study groups will be included: 100 patients in the herbal medicine group and 100 patients in the Placebo group.

For each patient included in the study, a PCR test for the detection of SARS-COV2 was performed with the prescription of a prescription containing: antibiotic therapy, paracetamol, cough syrup, mineral and vitamin supplements.

A follow-up will be carried out for each patient included in the study every two days to note the clinical signs present and to verify compliance and adverse events for each.

Data is entered on SPSS 21.0",2021-12-02T04:42:28Z,2021-12-02T04:42:28Z
NCT04853134,NA,4/19/2021,NA,NA,7/20/2021,4/19/2021,4/21/2021,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,1-Nov-20,Actual,11/1/2020,Apr-21,4/30/2021,1-Dec-21,Anticipated,12/1/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,Proxalutamide Treatment for COVID-19 Female Outpatients,Proxalutamide Treatment for COVID-19 Female Outpatients,"Active, not recruiting",NA,Phase 3,200,Anticipated,"Applied Biology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:42:31Z,2021-12-02T04:42:31Z
NCT04853901,NA,3/1/2021,NA,NA,4/17/2021,4/17/2021,4/22/2021,Actual,NA,NA,NA,NA,NA,NA,4/17/2021,4/22/2021,Actual,27-Jul-20,Actual,7/27/2020,Apr-21,4/30/2021,1-Mar-21,Actual,3/1/2021,1-Jan-21,Actual,1/1/2021,NA,Interventional,NA,NA,Remdesivir Efficacy In Management Of COVID-19 Patients,Remdesivir Efficacy In Management Of COVID-19 Patients,Completed,NA,Phase 3,77,Actual,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:42:17Z,2021-12-02T04:42:17Z
NCT04852770,NA,12/22/2020,NA,NA,4/20/2021,4/20/2021,4/21/2021,Actual,NA,NA,NA,NA,NA,NA,4/20/2021,4/21/2021,Actual,23-Apr-21,Anticipated,4/23/2021,Mar-21,3/31/2021,30-Nov-21,Anticipated,11/30/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,"Efficacy of TBCT, MBHP and PPT for PTSD During the Covid-19 Pandemics","A Randomized Clinical Trial to Assess the Efficacy of Online-delivered Treatment With Trial-based Cognitive Therapy, Mindfulness-based Health Promotion and Positive Psychotherapy for Post-traumatic Stress Disorder During the Covid-19 Pandemics",Recruiting,NA,Not Applicable,135,Anticipated,FundaÃ§Ã£o Bahiana de Infectologia,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:43:00Z,2021-12-02T04:43:00Z
NCT04851821,NA,2/6/2021,NA,NA,7/26/2021,4/18/2021,4/20/2021,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/27/2021,Actual,4-Jan-21,Actual,1/4/2021,Jul-21,7/31/2021,30-Jun-21,Actual,6/30/2021,30-May-21,Actual,5/30/2021,NA,Interventional,Quercetix,NA,The Effectiveness of Phytotherapy in SARS-COV2(COVID-19),The Effectiveness of Phytotherapy in the Treatment of SARS-COV2 (COVID-19),Completed,NA,Phase 1,80,Actual,HÃ´pital Universitaire Sahloul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,In the publication of the article,we will publish the Access criteria after the final Statistical analysis,NA,Yes,Statistical analysis Plan can be shared in supplimentary data,2021-12-02T04:43:25Z,2021-12-02T04:43:25Z
NCT04849793,NA,4/8/2021,NA,NA,8/30/2021,4/16/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/1/2021,Actual,13-Apr-21,Actual,4/13/2021,Aug-21,8/31/2021,13-Dec-21,Anticipated,12/13/2021,13-May-21,Actual,5/13/2021,NA,Interventional,Acupres,NA,The Effect of Acupressure on the Anxiety Level,The Effect of Acupressure on the Anxiety Level of Senior Nursing Students in the COVID-19 Pandemic,Enrolling by invitation,NA,Not Applicable,52,Anticipated,Mersin University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:45:07Z,2021-12-02T04:45:07Z
NCT04849637,NA,3/19/2021,NA,NA,4/15/2021,4/15/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,4/15/2021,4/19/2021,Actual,22-Oct-20,Actual,10/22/2020,Apr-21,4/30/2021,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients,Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients,Recruiting,NA,Phase 2,74,Anticipated,University of the Philippines,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:45:10Z,2021-12-02T04:45:10Z
NCT04847583,NA,4/14/2021,NA,NA,7/29/2021,4/14/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,7/30/2021,Actual,29-Jul-21,Actual,7/29/2021,Apr-21,4/30/2021,31-May-22,Anticipated,5/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients","A Phase 2 Open-Label, Randomized Controlled Trial to Evaluate the Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec in Participants With Moderate COVID-19 Disease",Recruiting,NA,Phase 2,66,Anticipated,"Qurient Co., Ltd.",,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:47:00Z,2021-12-02T04:47:00Z
NCT04847661,NA,4/14/2021,NA,NA,4/14/2021,4/14/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,4/14/2021,4/19/2021,Actual,28-Mar-21,Actual,3/28/2021,Apr-21,4/30/2021,30-Aug-21,Anticipated,8/30/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,NA,NA,"Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial","Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial",Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Helwan University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:47:06Z,2021-12-02T04:47:06Z
NCT04847791,NA,4/12/2021,NA,NA,4/13/2021,4/13/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,4/13/2021,4/19/2021,Actual,14-Jan-21,Actual,1/14/2021,Apr-21,4/30/2021,31-Dec-22,Anticipated,12/31/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,LAC,NA,Lactoferrin in Covid-19 Hospitalized Patients,Lactoferrin for Treatment of Acute COVID-19 Infection in Hospitalized Patients: a Double-blind Multicenter Placebo-controlled Randomized Trial,Recruiting,NA,Not Applicable,194,Anticipated,Paolo Manzoni,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:46:47Z,2021-12-02T04:46:47Z
NCT04847349,NA,4/13/2021,NA,NA,4/18/2021,4/14/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,4/18/2021,4/20/2021,Actual,13-Apr-21,Actual,4/13/2021,Apr-21,4/30/2021,1-Oct-22,Anticipated,10/1/2022,13-Oct-21,Anticipated,10/13/2021,NA,Interventional,NA,NA,Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial,Live Microbials to Boost Anti-SARS-CoV-2 Immunity Clinical Trial (Live BASIC Trial),Recruiting,NA,Not Applicable,45,Anticipated,"Rutgers, The State University of New Jersey",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be shared after enrollment and data analysis are completed.,NA,NA,Yes,"Saliva, nasal rinse, blood samples, and stool samples collected will be used for the purposes of this research.

After information that could identify consenting participants has been removed, de-identified information and left over biospecimens collected for this research may be used by or distributed to the study funder (Danisco USA Inc.) or to investigators for other research without obtaining additional informed consent. Personal identifying details, such as name and date of birth, will not be shared without participants' additional permission.",2021-12-02T04:47:20Z,2021-12-02T04:47:20Z
NCT04847544,NA,4/13/2021,NA,NA,4/13/2021,4/13/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,4/13/2021,4/19/2021,Actual,31-Mar-21,Actual,3/31/2021,Apr-21,4/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.","A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment of COVID-19",Recruiting,NA,Phase 2,30,Anticipated,"Aldeyra Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:47:10Z,2021-12-02T04:47:10Z
NCT04847518,NA,4/13/2021,NA,NA,9/21/2021,4/14/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/22/2021,Actual,26-May-21,Actual,5/26/2021,Apr-21,4/30/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Assessment of Efficacy of KAN-JANGÂ® in Mild COVID-19,"Effect of Kan-JangÂ® Supplementation in Patients Diagnosed With COVID-19: A Randomized, Quadruple-blind, Placebo-controlled Trial",Recruiting,NA,Phase 2/Phase 3,140,Anticipated,Swedish Herbal Institute AB,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:47:10Z,2021-12-02T04:47:10Z
NCT04847479,NA,4/14/2021,NA,NA,5/6/2021,4/14/2021,4/19/2021,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/10/2021,Actual,6-May-21,Actual,5/6/2021,May-21,5/31/2021,30-Oct-22,Anticipated,10/30/2022,10-May-22,Anticipated,5/10/2022,NA,Interventional,CloseST,NA,COVID-19 Close Contact Self-Testing Study,Close Contact Self-Testing Among Contacts of Individuals With COVID-19 Infection,Recruiting,NA,Not Applicable,210,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:47:11Z,2021-12-02T04:47:11Z
NCT04845880,NA,4/13/2021,NA,NA,4/13/2021,4/13/2021,4/15/2021,Actual,NA,NA,NA,NA,NA,NA,4/13/2021,4/15/2021,Actual,1-Oct-20,Actual,10/1/2020,Apr-21,4/30/2021,1-Apr-21,Actual,4/1/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,NA,NA,SARS Cov_2 Incidence of Healthy Health Workers,Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 Patients in Our Hospital,Completed,NA,Not Applicable,182,Actual,Baskent University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:48:26Z,2021-12-02T04:48:26Z
NCT04846790,NA,4/14/2021,NA,NA,9/22/2021,4/14/2021,4/15/2021,Actual,NA,NA,NA,NA,NA,NA,9/22/2021,9/23/2021,Actual,16-Jul-21,Actual,7/16/2021,Sep-21,9/30/2021,1-Jun-23,Anticipated,6/1/2023,1-Dec-22,Anticipated,12/1/2022,NA,Interventional,NA,NA,The Effect of a Combined Nature-based and Virtual Mindfulness Intervention on Perceived Stress in Healthcare Workers,The Effect of a Combined Nature-based and Virtual Mindfulness Intervention on Perceived Stress in Healthcare Workers That Care for Patients With COVID-19,Enrolling by invitation,NA,Not Applicable,90,Anticipated,National Institutes of Health Clinical Center (CC),,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:47:47Z,2021-12-02T04:47:47Z
NCT04846010,NA,3/31/2021,NA,NA,5/23/2021,4/12/2021,4/15/2021,Actual,NA,NA,NA,NA,NA,NA,5/23/2021,5/26/2021,Actual,1-Mar-21,Actual,3/1/2021,May-21,5/31/2021,1-Oct-22,Anticipated,10/1/2022,1-May-22,Anticipated,5/1/2022,NA,Interventional,sequelae,NA,"Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2",Treating Sequalae Caused by Post-acute Sequelae of SARS (Severe Acute Respiratory Syndrome)-CoV-2 Infection,Recruiting,NA,Phase 1/Phase 2,2000,Anticipated,"All Natural Medicine Clinic, LLC",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,We will continually publish clinical case study online.,"If you are a conventional medical practitioner, you can open it, and you will experience the different practice in clinic.

If you are a helictical medical practitioner, you can learn how integrative medicine practice in clinic.",https://anmedicine.com/blog/,Yes,"Medical herbs are not directing immunity only, but also recover the damaged structure and function of cells that be destroyed by inflammation. We will publish the process of the treatment as soon as we can.",2021-12-02T04:48:20Z,2021-12-02T04:48:20Z
NCT04845971,NA,11/17/2020,NA,NA,9/7/2021,4/14/2021,4/15/2021,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/8/2021,Actual,5-Nov-20,Actual,11/5/2020,Apr-21,4/30/2021,30-Jun-21,Actual,6/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,COral-MAF1,NA,Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia,Phase II Clinical Trial Evaluating Efficacy and Safety of Oral Immunotherapy With Third Generation Gc Protein Derived Macrophage Activating Factor (GcMAF) in Hospitalized Patients With COVID-19 Pneumonia: the COral-MAF1 Trial,Completed,NA,Phase 2,97,Actual,Ospedale del Mare,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"This is a multicenter trial. However, we reserve the possibility of enrolling further COVID-19 Hospital Units that are interested in participating in the trial, in order to get the correct sample size as needed for the study.Thus, if needed, we'll share IPD with the involved research centers.",2021-12-02T04:48:23Z,2021-12-02T04:48:23Z
NCT04844580,NA,3/25/2021,NA,NA,4/26/2021,4/13/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,4/26/2021,4/27/2021,Actual,10-Mar-21,Actual,3/10/2021,Apr-21,4/30/2021,Dec-22,Anticipated,12/31/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,HOPE,NA,A Clinical Study Evaluating Inhaled Aviptadil on COVID-19,"A Comparative, Multicenter, Placebo-Controlled, Double-Blind Phase II Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Inhaled Aviptadil in Patients 18 Years and Older With COVID-19 Pulmonary Involvement - HOPE",Recruiting,NA,Phase 2,80,Anticipated,Centurion Pharma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:49:30Z,2021-12-02T04:49:30Z
NCT04844554,NA,3/29/2021,NA,NA,7/21/2021,4/13/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/27/2021,Actual,20-Jun-21,Actual,6/20/2021,Jul-21,7/31/2021,12-Oct-22,Anticipated,10/12/2022,12-Apr-22,Anticipated,4/12/2022,NA,Interventional,NA,NA,Protocol of Assistance to Patients With Covid-19 Submitted to Treatment With HD-tDCS,"Protocol of Assistance to Patients With Covid-19 Submitted to Treatment With HD-tDCS: Open Label, Randomized, Controlled Study",Recruiting,NA,Not Applicable,60,Anticipated,Federal University of ParaÃ­ba,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:49:20Z,2021-12-02T04:49:20Z
NCT04844710,NA,4/12/2021,NA,NA,4/12/2021,4/12/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,4/12/2021,4/14/2021,Actual,1-Sep-20,Actual,9/1/2020,Apr-21,4/30/2021,20-Nov-20,Actual,11/20/2020,15-Nov-20,Actual,11/15/2020,NA,Interventional,NA,NA,The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms,The Effects of Combined Treatment of Acupuncture Intervention & Standard of Care on Laboratory and Clinical Outcomes in Hospitalized COVID-19 Patients With Mild-Moderate Symptoms,Completed,NA,Not Applicable,22,Actual,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:49:31Z,2021-12-02T04:49:31Z
NCT04844567,NA,3/18/2021,NA,NA,4/13/2021,4/13/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,4/13/2021,4/14/2021,Actual,26-Nov-20,Actual,11/26/2020,Mar-21,3/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Virtual Reality Intervention to Alleviate Breathlessness (COVID-19),Evaluation of Feasibility and Limited Efficacy of a Virtual Reality Intervention to Alleviate Perceived Breathlessness After Severe COVID-19 Pneumonia,Recruiting,NA,Not Applicable,35,Anticipated,Ecole Polytechnique FÃ©dÃ©rale de Lausanne,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:49:33Z,2021-12-02T04:49:33Z
NCT04844489,NA,4/2/2021,NA,NA,6/15/2021,4/13/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,6/15/2021,6/21/2021,Actual,16-Apr-21,Actual,4/16/2021,Jun-21,6/30/2021,31-Jul-23,Anticipated,7/31/2023,16-Apr-23,Anticipated,4/16/2023,NA,Interventional,COVIVAC-ID,NA,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Recruiting,NA,Not Applicable,485,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:49:36Z,2021-12-02T04:49:36Z
NCT04843930,NA,4/10/2021,NA,NA,6/21/2021,4/10/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/24/2021,Actual,17-Jun-21,Actual,6/17/2021,Jun-21,6/30/2021,Sep-22,Anticipated,9/30/2022,Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,Improving Cognitive Health in COVID-19 Survivors,Improving Cognitive Health in COVID-19 Survivors Through Digital Therapeutics,Recruiting,NA,Phase 2,125,Anticipated,Weill Medical College of Cornell University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:49:55Z,2021-12-02T04:49:55Z
NCT04844346,NA,4/13/2021,NA,NA,4/16/2021,4/13/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,4/16/2021,4/20/2021,Actual,19-Apr-21,Anticipated,4/19/2021,Apr-21,4/30/2021,31-Aug-21,Anticipated,8/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Plant Stanol Esters and COVID-19 Vaccination Response,The Effect of Plant Stanol Ester Consumption on the Vaccination Response to a COVID-19 Vaccine,Recruiting,NA,Not Applicable,100,Anticipated,Maastricht University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:49:46Z,2021-12-02T04:49:46Z
NCT04842708,NA,12/29/2020,NA,NA,4/11/2021,4/11/2021,4/13/2021,Actual,NA,NA,NA,NA,NA,NA,4/11/2021,4/13/2021,Actual,24-Dec-20,Actual,12/24/2020,Dec-20,12/31/2020,24-Oct-21,Anticipated,10/24/2021,24-Oct-21,Anticipated,10/24/2021,NA,Interventional,COVID-19,NA,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Recruiting,NA,Not Applicable,50,Anticipated,Scentech Medical Technologies Ltd,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD is not to be shared with other researchers.,2021-12-02T04:50:55Z,2021-12-02T04:50:55Z
NCT04842292,NA,4/8/2021,NA,NA,6/10/2021,4/12/2021,4/13/2021,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/15/2021,Actual,20-May-21,Actual,5/20/2021,Jun-21,6/30/2021,31-Mar-22,Anticipated,3/31/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Nebulized Heparin for COVID19-associated Acute Respiratory Failure,Utilization of Nebulized Heparin for Patients Receiving Mechanical Ventilation for COVID19-associated Acute Respiratory Failure,Recruiting,NA,Phase 2,40,Anticipated,University of Kentucky,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:51:19Z,2021-12-02T04:51:19Z
NCT04842448,NA,4/9/2021,NA,NA,9/15/2021,4/12/2021,4/13/2021,Actual,NA,NA,NA,NA,NA,NA,9/15/2021,9/22/2021,Actual,15-Sep-21,Actual,9/15/2021,Sep-21,9/30/2021,31-Dec-23,Anticipated,12/31/2023,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,HOT-LoCO,NA,Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome,"Hyperbaric Oxygen for Treatment of Long COVID Syndrome; A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial",Recruiting,NA,Phase 2,80,Anticipated,Karolinska University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,6 months after study completion and for 36 months,A full description of the intended use of the data must be sent to the corresponding author for review and approval. Participant consent for data sharing is conditioned and new ethics approval may be required.,NA,Yes,"The full study protocol, statistical plan and consent form will be publicly available. Data will be available on patient level; data will be pseudonymized, the full dataset and statistical code will be available upon request.",2021-12-02T04:51:24Z,2021-12-02T04:51:24Z
NCT04842435,NA,4/12/2021,NA,NA,5/12/2021,4/12/2021,4/13/2021,Actual,NA,NA,NA,NA,NA,NA,5/12/2021,5/14/2021,Actual,12-Apr-21,Actual,4/12/2021,May-21,5/31/2021,5-Oct-21,Anticipated,10/5/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,Clinical Study in the Treatment of Patients With Moderate Course of COVID-19,"To Study the Efficacy, Safety and Pharmacokinetics of COVID-globulin, in Addition to Standard Therapy for the Treatment of Patients With a Moderate COVID-19 Form",Recruiting,NA,Phase 2/Phase 3,376,Anticipated,Microgen,,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately following publication. No end date,Anyone who wishes to access the data,NA,Yes,"All of the individual participant data collected during the trial, after deidentification",2021-12-02T04:51:11Z,2021-12-02T04:51:11Z
NCT04840992,NA,4/8/2021,NA,NA,7/27/2021,4/8/2021,4/12/2021,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,8/2/2021,Actual,20-Apr-21,Actual,4/20/2021,Apr-21,4/30/2021,15-Jul-22,Anticipated,7/15/2022,15-Apr-22,Anticipated,4/15/2022,NA,Interventional,NA,NA,Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation,"A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and Older",Recruiting,NA,Phase 1/Phase 2,840,Anticipated,CanSino Biologics Inc.,,22,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:52:29Z,2021-12-02T04:52:29Z
NCT04842331,NA,4/12/2021,NA,NA,4/12/2021,4/12/2021,4/13/2021,Actual,NA,NA,NA,NA,NA,NA,4/12/2021,4/13/2021,Actual,Apr-21,Anticipated,4/30/2021,Apr-21,4/30/2021,Jan-22,Anticipated,1/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,PREVENT,NA,PREvent Viral Exposure aNd Transmission Study: a SARS-CoV-2 PEP Study (PREVENT),"A Randomised, Multicentre Post-exposure Prophylaxis (PEP) Clinical Trial Evaluating RESP301, an Inhaled Therapy for Treatment of Lung Infections, for Prevention of Onward Transmission of Viral Infections Including SARS-CoV-2 to Household Members.",Recruiting,NA,Phase 2/Phase 3,600,Anticipated,Thirty Respiratory Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:51:28Z,2021-12-02T04:51:28Z
NCT04841681,NA,4/6/2021,NA,NA,4/8/2021,4/8/2021,4/12/2021,Actual,NA,NA,NA,NA,NA,NA,4/8/2021,4/12/2021,Actual,7-Jun-20,Actual,6/7/2020,Apr-21,4/30/2021,26-Aug-20,Actual,8/26/2020,25-Aug-20,Actual,8/25/2020,NA,Interventional,NA,NA,Video-based Psychotherapy for COVID-19 Patients in Isolation Ward in Jakarta,Effectiveness of Video-based Psychotherapy in Reducing Distress in Patients With COVID-19 Treated in a Hospital Isolation Ward in Jakarta,Completed,NA,Not Applicable,42,Actual,Indonesia University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,1 month after publication.,"The data will be available through request to Petrin Redayani Lukman MD as the contact person, e-mail ptrn1010@yahoo.com.",NA,Yes,We plan to share the data of participants' (identities will be initials only) demographic data and SUDS score before and after watching the video.,2021-12-02T04:51:49Z,2021-12-02T04:51:49Z
NCT04841746,NA,4/9/2021,NA,NA,7/27/2021,4/9/2021,4/12/2021,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,8/3/2021,Actual,2-Jun-21,Actual,6/2/2021,Apr-21,4/30/2021,2-Sep-22,Anticipated,9/2/2022,2-Sep-22,Anticipated,9/2/2022,NA,Interventional,FESrehabCoV,NA,Efficacy of FES Cycling After a Severe Form of COVID-19,Efficacy of Physical Therapy Using Cycling With vs With no Functional Electrical Stimulation in Patient With Severe Form of COVID-19: a Randomized Controlled Trial,Recruiting,NA,Not Applicable,70,Anticipated,Hospices Civils de Lyon,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:51:50Z,2021-12-02T04:51:50Z
NCT04840459,NA,4/5/2021,NA,NA,4/8/2021,4/8/2021,4/12/2021,Actual,NA,NA,NA,NA,NA,NA,4/8/2021,4/12/2021,Actual,20-Nov-20,Actual,11/20/2020,Apr-21,4/30/2021,31-Jan-22,Anticipated,1/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting,Use of Monoclonal Antibodies (Bamlanivimab and Casirivimab + Imdevimab) for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting,Recruiting,NA,Phase 2,1000,Anticipated,DHR Health Institute for Research and Development,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:52:31Z,2021-12-02T04:52:31Z
NCT04839965,NA,4/8/2021,NA,NA,5/10/2021,4/8/2021,4/9/2021,Actual,NA,NA,NA,NA,NA,NA,5/10/2021,5/12/2021,Actual,May-21,Anticipated,5/31/2021,May-21,5/31/2021,Nov-21,Anticipated,11/30/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen,"A Randomized, Double-Blinded, Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of IV Ampion in Adult COVID-19 Patients Requiring Oxygen Supplementation",Recruiting,NA,Phase 2,200,Anticipated,Ampio Pharmaceuticals. Inc.,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:53:11Z,2021-12-02T04:53:11Z
NCT04839315,NA,4/5/2021,NA,NA,4/7/2021,4/7/2021,4/9/2021,Actual,NA,NA,NA,NA,NA,NA,4/7/2021,4/9/2021,Actual,15-Feb-21,Actual,2/15/2021,Apr-21,4/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,COVID-19 Vaccination in Rheumatic Disease Patients,Immunological Consequences of COVID-19 Vaccination in Patients With Rheumatic Diseases,Recruiting,NA,Early Phase 1,100,Anticipated,Mayo Clinic,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:53:35Z,2021-12-02T04:53:35Z
NCT04838821,NA,3/23/2021,NA,NA,5/20/2021,4/7/2021,4/9/2021,Actual,NA,NA,NA,NA,NA,NA,5/20/2021,5/21/2021,Actual,29-Mar-21,Actual,3/29/2021,May-21,5/31/2021,29-Sep-21,Anticipated,9/29/2021,29-Jul-21,Anticipated,7/29/2021,NA,Interventional,SECR-02,NA,Efficacy and Safety of Three Different Doses of an Anti SARS-CoV-2 Hyperimmune Equine Serum in COVID-19 Patients,"Randomized, Placebo-controlled, Double-blind, Multicenter Clinical Study to Compare the Efficacy and Safety of the Administration of Three Different Doses of an Anti-SARS-CoV-2 Hyperimmune Equine Serum Formulation in Hospitalized COVID-19 Patients (SECR-02)",Recruiting,NA,Phase 2/Phase 3,156,Anticipated,Caja Costarricense de Seguro Social,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:53:47Z,2021-12-02T04:53:47Z
NCT04838080,NA,4/6/2021,NA,NA,4/10/2021,4/7/2021,4/8/2021,Actual,NA,NA,NA,NA,NA,NA,4/10/2021,4/13/2021,Actual,19-Mar-21,Actual,3/19/2021,Apr-21,4/30/2021,20-Oct-21,Anticipated,10/20/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,Safety and Immunogenicity of the Inactivated KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine Compared to Placebo,"Phase 1 Study for the Determination of Safety and Immunogenicity of Different Strengths of KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Recruiting,NA,Phase 1,38,Anticipated,Kocak Farma,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:54:35Z,2021-12-02T04:54:35Z
NCT04836780,NA,3/18/2021,NA,NA,9/14/2021,4/6/2021,4/8/2021,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/20/2021,Actual,10-Jun-21,Actual,6/10/2021,Sep-21,9/30/2021,30-Mar-22,Anticipated,3/30/2022,30-Mar-22,Anticipated,3/30/2022,NA,Interventional,EARLYDEXCoV2,NA,DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia,DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia and High Risk of Developing Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 3,126,Anticipated,Hospital Universitario Infanta Leonor,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:55:37Z,2021-12-02T04:55:37Z
NCT04836260,NA,4/6/2021,NA,NA,4/6/2021,4/6/2021,4/8/2021,Actual,NA,NA,NA,NA,NA,NA,4/6/2021,4/8/2021,Actual,8-Apr-21,Anticipated,4/8/2021,Apr-21,4/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19,Preemptive Use of Convalescent Plasma for High-risk Patients With SARS-CoV-2 Infection: Phase III-IV Non-controlled Non-randomised Swiss Multicentric Trial,Recruiting,NA,Phase 3,100,Anticipated,"University Hospital, Geneva",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T04:55:46Z,2021-12-02T04:55:46Z
NCT04834908,NA,3/23/2021,NA,NA,6/30/2021,4/6/2021,4/8/2021,Actual,NA,NA,NA,NA,NA,NA,6/30/2021,7/1/2021,Actual,Jun-21,Anticipated,6/30/2021,Apr-21,4/30/2021,Sep-22,Anticipated,9/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,PROTECT,NA,Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection,A Prospective Randomized Multi-center Open Label Phase 1/2 Study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2](BSVEQAb) Plus Standard of Care in Comparison to Standard of Care Alone in COVID-19 RT-PCR Positive Patients,Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Bharat Serums and Vaccines Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:56:47Z,2021-12-02T04:56:47Z
NCT04836052,NA,3/14/2021,NA,NA,4/6/2021,4/6/2021,4/8/2021,Actual,NA,NA,NA,NA,NA,NA,4/6/2021,4/8/2021,Actual,24-Dec-20,Actual,12/24/2020,Mar-21,3/31/2021,24-Dec-21,Anticipated,12/24/2021,24-Aug-21,Anticipated,8/24/2021,NA,Interventional,Omega3,NA,Omega-3 Oil Use in COVID-19 Patients in Qatar,Omega-3 Oil Use in COVID-19 Patients in Qatar: a Randomized Controlled Trial,Recruiting,NA,Phase 3,372,Anticipated,Hamad Medical Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:55:47Z,2021-12-02T04:55:47Z
NCT04836351,NA,3/29/2021,NA,NA,4/6/2021,4/6/2021,4/8/2021,Actual,NA,NA,NA,NA,NA,NA,4/6/2021,4/8/2021,Actual,1-Mar-21,Actual,3/1/2021,Apr-21,4/30/2021,30-Dec-23,Anticipated,12/30/2023,30-Dec-23,Anticipated,12/30/2023,NA,Interventional,NA,NA,Rehabilitation for Patients With Persistent Symptoms Post COVID-19,"Feasibility, Usefulness and Evaluation of a Concentrated Rehabilitation for Patients With Persistent Symptoms Post COVID-19",Recruiting,NA,Not Applicable,20,Anticipated,Western Norway University of Applied Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"In accordance with the approvals granted for this study by The Regional Committee on Medical Research Ethics and The Norwegian Data Inspectorate, the data files are stored securely and in accordance with the Norwegian Law of Privacy Protection. A subset of the data file with anonymized data can be made available to interested researchers upon reasonable request to Bente Frisk providing Norwegian privacy legislation and General Data Protection Regulation (GDPR) are respected, and that permission is granted from The Norwegian Data Inspectorate and the data protection officer Western Norway University og Applied Sciences",2021-12-02T04:55:53Z,2021-12-02T04:55:53Z
NCT04834856,NA,4/6/2021,NA,NA,9/7/2021,4/6/2021,4/8/2021,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/8/2021,Actual,1-Apr-21,Actual,4/1/2021,Sep-21,9/30/2021,20-Aug-21,Actual,8/20/2021,20-Aug-21,Actual,8/20/2021,NA,Interventional,NA,NA,"Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients","A Phase 2a Open Label, Non-comparative, Single Dose Escalation Study to Evaluate the Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep in Patients With Symptomatic COVID-19 Disease",Completed,NA,Phase 2,12,Actual,Molecular Partners AG,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:56:38Z,2021-12-02T04:56:38Z
NCT04834739,NA,1/10/2021,NA,NA,8/23/2021,4/6/2021,4/8/2021,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/24/2021,Actual,4-Jan-21,Actual,1/4/2021,Jan-21,1/31/2021,30-Apr-21,Actual,4/30/2021,28-Mar-21,Actual,3/28/2021,NA,Interventional,NA,NA,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Completed,NA,Not Applicable,60,Actual,Gaziosmanpasa Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:57:11Z,2021-12-02T04:57:11Z
NCT04834726,NA,4/6/2021,NA,NA,8/30/2021,4/6/2021,4/8/2021,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/1/2021,Actual,29-Apr-21,Actual,4/29/2021,Aug-21,8/31/2021,6-Jul-21,Actual,7/6/2021,4-Jun-21,Actual,6/4/2021,NA,Interventional,NA,NA,COVID-19 Vaccine Text Outreach,Pragmatic Trial of COVID Vaccine Text Outreach Interventions,Completed,NA,Not Applicable,19554,Actual,University of Pennsylvania,,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:57:04Z,2021-12-02T04:57:04Z
NCT04834115,NA,3/28/2021,NA,NA,4/4/2021,4/4/2021,4/6/2021,Actual,NA,NA,NA,NA,NA,NA,4/4/2021,4/6/2021,Actual,17-Nov-20,Actual,11/17/2020,Apr-21,4/30/2021,30-May-21,Anticipated,5/30/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Efficacy of Ivermectin in Outpatients With Non-severe COVID-19,Efficacy of Ivermectin in Outpatients With Non-severe COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 3,400,Anticipated,Universidad Nacional de AsunciÃ³n,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The investigators will publish the results to compare data with other studies with ivermectin and SARS-CoV-2 infection.,2021-12-02T04:57:31Z,2021-12-02T04:57:31Z
NCT04833101,NA,4/3/2021,NA,NA,8/4/2021,4/3/2021,4/6/2021,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/11/2021,Actual,7-Apr-21,Actual,4/7/2021,Jun-21,6/30/2021,15-Dec-21,Anticipated,12/15/2021,15-Jun-21,Actual,6/15/2021,NA,Interventional,NA,NA,Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine,Safety and Immunogenicity of a Heterologous Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine Against COVID-19 in Chinese Healthy Population,"Active, not recruiting",NA,Phase 4,120,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T04:58:24Z,2021-12-02T04:58:24Z
NCT04832919,NA,4/2/2021,NA,NA,8/16/2021,4/2/2021,4/6/2021,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/17/2021,Actual,23-Jul-21,Actual,7/23/2021,Jul-21,7/31/2021,May-22,Anticipated,5/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,A Nurse-Community Health Worker-Family Partnership Model: Addressing Uptake of COVID-19 Testing and Control Measures,A Nurse-Community Health Worker-Family Partnership Model to Increase COVID19 Testing in Urban Underserved and Vulnerable Communities,Recruiting,NA,Not Applicable,810,Anticipated,New York University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T04:58:34Z,2021-12-02T04:58:34Z
NCT04830943,NA,12/24/2020,NA,NA,4/1/2021,4/1/2021,4/5/2021,Actual,NA,NA,NA,NA,NA,NA,4/1/2021,4/5/2021,Actual,1-Aug-20,Actual,8/1/2020,Apr-21,4/30/2021,30-Mar-21,Actual,3/30/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,NA,NA,Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia,The Effectiveness of Cerebrolycin for Treatment of Post-covid Olfactory and Gustatory Dysfunctions: A Pilot Study,Completed,NA,Phase 4,100,Actual,Assiut University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:00:05Z,2021-12-02T05:00:05Z
NCT04830800,NA,3/12/2021,NA,NA,4/1/2021,4/1/2021,4/5/2021,Actual,NA,NA,NA,NA,NA,NA,4/1/2021,4/5/2021,Actual,10-Mar-21,Actual,3/10/2021,Apr-21,4/30/2021,30-Sep-22,Anticipated,9/30/2022,30-May-22,Anticipated,5/30/2022,NA,Interventional,NA,NA,A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC,"A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of COVIVAC Vaccine Produced by IVAC in Adults Aged 18-75 Years in Vietnam",Recruiting,NA,Phase 1/Phase 2,420,Anticipated,"Institute of Vaccines and Medical Biologicals, Vietnam",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There should be an agreement and approval by IRB before sharing IDP,2021-12-02T05:00:04Z,2021-12-02T05:00:04Z
NCT04830020,NA,3/31/2021,NA,NA,3/31/2021,3/31/2021,4/2/2021,Actual,NA,NA,NA,NA,NA,NA,3/31/2021,4/2/2021,Actual,26-Feb-21,Actual,2/26/2021,Feb-21,2/28/2021,31-Aug-21,Anticipated,8/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,HA-COVID,NA,Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes,Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes,Recruiting,NA,Phase 2,200,Anticipated,Campus Bio-Medico University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:00:52Z,2021-12-02T05:00:52Z
NCT04828135,NA,3/11/2021,NA,NA,9/17/2021,3/30/2021,4/1/2021,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/20/2021,Actual,26-May-21,Actual,5/26/2021,Sep-21,9/30/2021,30-Dec-22,Anticipated,12/30/2022,30-Dec-22,Anticipated,12/30/2022,NA,Interventional,NA,NA,Dual MRI for Cardiopulmonary COVID-19 Long Haulers,Characterizing the Long-Term Cardiopulmonary Effects of COVID-19 With Hyperpolarized Xenon and Cardiac MRI,Recruiting,NA,Phase 2,30,Anticipated,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:02:34Z,2021-12-02T05:02:34Z
NCT04826822,NA,3/28/2021,NA,NA,3/31/2021,3/31/2021,4/1/2021,Actual,NA,NA,NA,NA,NA,NA,3/31/2021,4/1/2021,Actual,24-Feb-21,Actual,2/24/2021,Mar-21,3/31/2021,2-Sep-21,Anticipated,9/2/2021,8-Jul-21,Anticipated,7/8/2021,NA,Interventional,SPIDEX-II,NA,Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19,Spironolactone and Dexamethasone in Patients Hospitalized With Moderate-to-severe COVID-19 (SPIDEX-II): a Randomized Clinical Trial,Recruiting,NA,Phase 3,440,Anticipated,Chita State Regional Clinical Hospital Number 1,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Sharing IPD would require material transfer agreement according to the local rules and regulations. The study protocol, statistical analysis plan, and the translated version of the informed consent form can be shared upon request.",2021-12-02T05:04:00Z,2021-12-02T05:04:00Z
NCT04826367,NA,3/29/2021,NA,NA,3/31/2021,3/29/2021,4/1/2021,Actual,NA,NA,NA,NA,NA,NA,3/31/2021,4/2/2021,Actual,20-Jan-21,Actual,1/20/2021,Mar-21,3/31/2021,Feb-22,Anticipated,2/28/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Relaxation Training by Tele-Rehabilitation in Patients With Breast Cancer,Relaxation Training By Tele-Rehabilitation Program In Patients With Breast Cancer Receiving Chemotherapy During COVID-19.,Recruiting,NA,Not Applicable,64,Anticipated,Hacettepe University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is not a recent plan to make IPD available,2021-12-02T05:04:24Z,2021-12-02T05:04:24Z
NCT04824638,NA,3/7/2021,NA,NA,8/2/2021,3/30/2021,4/1/2021,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/9/2021,Actual,8-Mar-21,Actual,3/8/2021,Aug-21,8/31/2021,30-Oct-23,Anticipated,10/30/2023,29-Jun-21,Actual,6/29/2021,NA,Interventional,CoviCompareP,NA,BNT162b2 Vaccination With Two Doses in COVID-19 Negative Adult Volunteers and With a Single Dose in COVID-19 Positive Adult Volunteers,A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of Vaccine,"Active, not recruiting",NA,Phase 2,267,Actual,"ANRS, Emerging Infectious Diseases",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:05:42Z,2021-12-02T05:05:42Z
NCT04824443,NA,3/29/2021,NA,NA,6/23/2021,3/29/2021,4/1/2021,Actual,NA,NA,NA,NA,NA,NA,6/23/2021,6/24/2021,Actual,29-Mar-21,Actual,3/29/2021,Jun-21,6/30/2021,29-Mar-23,Anticipated,3/29/2023,29-Mar-23,Anticipated,3/29/2023,NA,Interventional,NA,NA,Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19,Exercise Therapy in Cancer Patients Hospitalized for COVID-19: A Digitized Clinical Trial,Recruiting,NA,Phase 1,20,Anticipated,Memorial Sloan Kettering Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-12-02T05:06:16Z,2021-12-02T05:06:16Z
NCT04824365,NA,3/26/2021,NA,NA,4/27/2021,3/29/2021,4/1/2021,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/29/2021,Actual,12-Apr-21,Actual,4/12/2021,Apr-21,4/30/2021,Jun-22,Anticipated,6/30/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Sodium Pyruvate Nasal Spray Treatment of COVID-19 and Influenza Infections,"Two Week Sub-chronic Double-blinded Placebo Controlled Trial Designed to Determine if Sodium Pyruvate Nasal Spray Will Reduce the Symptoms, Duration and Replication of COVID-19 and Influenza Infections",Recruiting,NA,Phase 2/Phase 3,60,Anticipated,"Cellular Sciences, inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:06:16Z,2021-12-02T05:06:16Z
NCT04824391,NA,3/25/2021,NA,NA,3/30/2021,3/30/2021,4/1/2021,Actual,NA,NA,NA,NA,NA,NA,3/30/2021,4/1/2021,Actual,10-Feb-21,Actual,2/10/2021,Mar-21,3/31/2021,30-Apr-22,Anticipated,4/30/2022,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19","Phase 2 Study for the Determination of Efficacy, Immunogenicity and Safety of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, in a Placebo Controlled, Randomized, Double Blind Study Design.",Recruiting,NA,Phase 2,250,Anticipated,Health Institutes of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:06:25Z,2021-12-02T05:06:25Z
NCT04822285,NA,3/26/2021,NA,NA,3/26/2021,3/26/2021,3/30/2021,Actual,NA,NA,NA,NA,NA,NA,3/26/2021,3/30/2021,Actual,22-Jan-20,Actual,1/22/2020,Mar-21,3/31/2021,21-Mar-21,Actual,3/21/2021,22-Apr-20,Actual,4/22/2020,NA,Interventional,Triaging,NA,Effect Psychological Triaging Intervention on Students' Psychological Distress and Resilience Capacity,Psychological Triaging Intervention: Rescue From Psychological Distress and Improving Senior Nursing Students' Resilience Capacity During COVID-19 Crisis,Completed,NA,Not Applicable,64,Actual,Alexandria University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:08:04Z,2021-12-02T05:08:04Z
NCT04821037,NA,3/26/2021,NA,NA,5/27/2021,3/26/2021,3/29/2021,Actual,NA,NA,NA,NA,NA,NA,5/27/2021,6/2/2021,Actual,1-Jun-21,Anticipated,6/1/2021,May-21,5/31/2021,1-Aug-21,Anticipated,8/1/2021,1-Jul-21,Anticipated,7/1/2021,NA,Interventional,NHP,NA,Nurse Health Pilot: Feasibility and Acceptability of a Virtual ACT-intervention in Nurses During COVID-19,Feasibility and Acceptability of a Virtual ACT-intervention in Nurses Working During the COVID-19 Pandemic (Pilot Study),Recruiting,NA,Not Applicable,10,Anticipated,University of Basel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:09:07Z,2021-12-02T05:09:07Z
NCT04821973,NA,3/25/2021,NA,NA,3/29/2021,3/29/2021,3/30/2021,Actual,NA,NA,NA,NA,NA,NA,3/29/2021,3/30/2021,Actual,22-Sep-20,Actual,9/22/2020,Mar-21,3/31/2021,15-Nov-21,Anticipated,11/15/2021,15-May-21,Anticipated,5/15/2021,NA,Interventional,NA,NA,Respiratory Tele Monitoring COVID 19 (TMR COVID-19),Interest of Respiratory Tele Monitoring in COVID-19 Pneumonia,Recruiting,NA,Not Applicable,80,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:08:09Z,2021-12-02T05:08:09Z
NCT04820803,NA,3/23/2021,NA,NA,7/1/2021,3/26/2021,3/29/2021,Actual,NA,NA,NA,NA,NA,NA,7/1/2021,7/7/2021,Actual,3-Feb-21,Actual,2/3/2021,Mar-21,3/31/2021,30-Jun-21,Actual,6/30/2021,29-Apr-21,Actual,4/29/2021,NA,Interventional,NA,NA,Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19,PILOT CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETIL PYRIDINIUM CHLORIDE TO REDUCE THE VIRAL LOAD OF SARS-CoV-2,Completed,NA,Not Applicable,80,Actual,Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:09:19Z,2021-12-02T05:09:19Z
NCT04818970,NA,3/24/2021,NA,NA,5/21/2021,3/25/2021,3/26/2021,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/25/2021,Actual,21-May-21,Actual,5/21/2021,May-21,5/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients,Adaptive Photo-Protection Trial: To Demonstrate the Safety and Efficacy of NB-UVB Light Therapy to Improve Outcomes in Hospitalized High-risk Patients With COVID-19,Recruiting,NA,Not Applicable,30,Anticipated,"Cytokind, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:10:49Z,2021-12-02T05:10:49Z
NCT04818216,NA,3/24/2021,NA,NA,8/3/2021,3/24/2021,3/26/2021,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/5/2021,Actual,11-Jun-21,Actual,6/11/2021,Aug-21,8/31/2021,Jun-23,Anticipated,6/30/2023,Jun-22,Anticipated,6/30/2022,NA,Interventional,NIRVANA,NA,Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection,NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection,Recruiting,NA,Phase 2,100,Anticipated,The University of Texas Health Science Center at San Antonio,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:11:35Z,2021-12-02T05:11:35Z
NCT04818281,NA,3/24/2021,NA,NA,7/12/2021,3/24/2021,3/26/2021,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/13/2021,Actual,27-Mar-21,Actual,3/27/2021,Jul-21,7/31/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,COVID-19,NA,Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults,"Phase I Study Evaluating the Basic Pharmacological and Toxicological Effects of the Protective VLP Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously, in Two Different Dosages.",Recruiting,NA,Phase 1,36,Anticipated,The Scientific and Technological Research Council of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:11:39Z,2021-12-02T05:11:39Z
NCT04817371,NA,3/15/2021,NA,NA,3/25/2021,3/25/2021,3/26/2021,Actual,NA,NA,NA,NA,NA,NA,3/25/2021,3/30/2021,Actual,1-Mar-21,Actual,3/1/2021,Mar-21,3/31/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,VOCSARSCOVDep,NA,Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for COVID-19 Infection.,Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for SARS-CoV-2 Infection.,Recruiting,NA,Not Applicable,192,Anticipated,Hopital Foch,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:12:08Z,2021-12-02T05:12:08Z
NCT04817332,NA,1/25/2021,NA,NA,8/12/2021,3/25/2021,3/26/2021,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/17/2021,Actual,5-Jun-20,Actual,6/5/2020,Aug-21,8/31/2021,28-Feb-21,Actual,2/28/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,STOP-COVID19,NA,STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19,A Randomised Double-blind Placebo-controlled Trial of Brensocatib (INS1007) in Patients With Severe COVID-19,Completed,NA,Phase 3,406,Actual,University of Dundee,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:12:12Z,2021-12-02T05:12:12Z
NCT04816942,NA,2/12/2021,NA,NA,3/24/2021,3/24/2021,3/25/2021,Actual,NA,NA,NA,NA,NA,NA,3/24/2021,3/25/2021,Actual,23-Apr-20,Actual,4/23/2020,Mar-21,3/31/2021,12-Oct-20,Actual,10/12/2020,21-Jul-20,Actual,7/21/2020,NA,Interventional,NA,NA,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Completed,NA,Phase 3,102,Actual,"Ministry of Health and Population, Egypt",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:12:43Z,2021-12-02T05:12:43Z
NCT04816656,NA,3/24/2021,NA,NA,3/25/2021,3/24/2021,3/25/2021,Actual,NA,NA,NA,NA,NA,NA,3/25/2021,3/26/2021,Actual,3-Aug-20,Actual,8/3/2020,Mar-21,3/31/2021,22-Mar-21,Actual,3/22/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,COVID-ONCO,NA,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,Completed,NA,Not Applicable,43,Actual,Jessa Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:13:00Z,2021-12-02T05:13:00Z
NCT04816682,NA,3/19/2021,NA,NA,9/23/2021,3/24/2021,3/25/2021,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/24/2021,Actual,17-Mar-21,Actual,3/17/2021,Sep-21,9/30/2021,30-Dec-21,Anticipated,12/30/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,SILCOVINT-21,NA,Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes,Does Silymarin Mitigate Clinical Course of COVID-19 in Patients Admitted to an Internal Medicine Ward With Elevated Liver Enzymes?,Recruiting,NA,Phase 4,30,Anticipated,F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Dataset / protocol / ICF will be open for audit anytime Dataset will be shared after completion of upload,Journal editors Investigators - by the hypothesis testable on the dataset Auditing authority,http://www.fnspfdr.sk,Yes,Complete dataset will be shared on request under GDPR rules,2021-12-02T05:12:51Z,2021-12-02T05:12:51Z
NCT04816084,NA,3/19/2021,NA,NA,3/24/2021,3/24/2021,3/25/2021,Actual,NA,NA,NA,NA,NA,NA,3/24/2021,3/25/2021,Actual,5-Nov-20,Actual,11/5/2020,Mar-21,3/31/2021,15-Mar-21,Actual,3/15/2021,1-Dec-20,Actual,12/1/2020,NA,Interventional,SERUR,NA,SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes,SERUR : Etude sÃ©rologique COVID-19 (Anti-SARS CoV 2) du Personnel de l'UniversitÃ© de Reims Champagne-Ardenne,Completed,NA,Not Applicable,389,Actual,UniversitÃ© de Reims Champagne-Ardenne,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:13:35Z,2021-12-02T05:13:35Z
NCT04815096,NA,3/23/2021,NA,NA,8/2/2021,3/23/2021,3/24/2021,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,15-Apr-21,Actual,4/15/2021,Mar-21,3/31/2021,1-Mar-23,Anticipated,3/1/2023,1-Mar-23,Anticipated,3/1/2023,NA,Interventional,NA,NA,Imaging Immune Activation in COVID-19,Imaging Immune Activation in COVID-19,Recruiting,NA,Early Phase 1,20,Anticipated,"CellSight Technologies, Inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:14:12Z,2021-12-02T05:14:12Z
NCT04815057,NA,3/11/2021,NA,NA,4/11/2021,3/23/2021,3/24/2021,Actual,NA,NA,NA,NA,NA,NA,4/11/2021,4/14/2021,Actual,2-Nov-20,Actual,11/2/2020,Apr-21,4/30/2021,8-Mar-21,Actual,3/8/2021,23-Nov-20,Actual,11/23/2020,NA,Interventional,NA,NA,The Effects of Wellness Training Given to Fifth Grade Students During the Covid-19 Epidemic Period,The Effects of Wellness Education Given to 5th Grade Students During the Covid-19 Pandemic Process on Their Quality of Life and Physical Activity,Completed,NA,Not Applicable,176,Actual,Saglik Bilimleri Universitesi,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:14:40Z,2021-12-02T05:14:40Z
NCT04813796,NA,3/22/2021,NA,NA,9/17/2021,3/22/2021,3/24/2021,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/21/2021,Actual,11-Mar-21,Actual,3/11/2021,Sep-21,9/30/2021,13-Apr-22,Anticipated,4/13/2022,13-Apr-22,Anticipated,4/13/2022,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19","A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years","Active, not recruiting",NA,Phase 1,106,Actual,"ModernaTX, Inc.",,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:15:18Z,2021-12-02T05:15:18Z
NCT04813471,NA,3/22/2021,NA,NA,3/22/2021,3/22/2021,3/24/2021,Actual,NA,NA,NA,NA,NA,NA,3/22/2021,3/24/2021,Actual,20-Jan-21,Actual,1/20/2021,Mar-21,3/31/2021,30-Apr-21,Anticipated,4/30/2021,20-Mar-21,Anticipated,3/20/2021,NA,Interventional,NA,NA,Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH,Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at the Lebanese American University Medical Center- Rizk Hospital,Recruiting,NA,Phase 3,70,Anticipated,Lebanese American University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:15:55Z,2021-12-02T05:15:55Z
NCT04813770,NA,3/23/2021,NA,NA,5/5/2021,3/23/2021,3/24/2021,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/10/2021,Actual,6-Apr-21,Actual,4/6/2021,May-21,5/31/2021,26-Apr-21,Actual,4/26/2021,26-Apr-21,Actual,4/26/2021,NA,Interventional,NA,NA,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,Completed,NA,Not Applicable,1113,Actual,University of Glasgow,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,On publication of the study results for a period of ten years.,Data will be made publicly available.,NA,Yes,Anonymised individual level study data will be shared via the University of Glasgow's repository Enlighten: Research Data.,2021-12-02T05:15:30Z,2021-12-02T05:15:30Z
NCT04813718,NA,3/15/2021,NA,NA,6/2/2021,3/23/2021,3/24/2021,Actual,NA,NA,NA,NA,NA,NA,6/2/2021,6/7/2021,Actual,2-Jun-21,Actual,6/2/2021,Jun-21,6/30/2021,31-Dec-22,Anticipated,12/31/2022,1-May-22,Anticipated,5/1/2022,NA,Interventional,NA,NA,Post COVID-19 Syndrome and the Gut-lung Axis,Post COVID-19 Syndrome: A Pilot Study to Explore the Gut-lung Axis,Recruiting,NA,Not Applicable,20,Anticipated,Medical University of Graz,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will be shared upon reasonable request,2021-12-02T05:15:39Z,2021-12-02T05:15:39Z
NCT04813562,NA,3/19/2021,NA,NA,5/22/2021,3/23/2021,3/24/2021,Actual,NA,NA,NA,NA,NA,NA,5/22/2021,5/25/2021,Actual,23-Mar-21,Actual,3/23/2021,May-21,5/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,NA,NA,Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells),"A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above",Recruiting,NA,Phase 2,480,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:15:48Z,2021-12-02T05:15:48Z
NCT04811664,NA,3/19/2021,NA,NA,8/6/2021,3/19/2021,3/23/2021,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/9/2021,Actual,24-Mar-21,Actual,3/24/2021,Aug-21,8/31/2021,22-Dec-21,Anticipated,12/22/2021,22-Dec-21,Anticipated,12/22/2021,NA,Interventional,CoVPN 3006,NA,A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine,"A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine",Recruiting,NA,Phase 3,37500,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:17:14Z,2021-12-02T05:17:14Z
NCT04813575,NA,2/8/2021,NA,NA,8/31/2021,3/23/2021,3/24/2021,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/1/2021,Actual,1-Aug-21,Actual,8/1/2021,Aug-21,8/31/2021,1-Jun-22,Anticipated,6/1/2022,1-Apr-22,Anticipated,4/1/2022,NA,Interventional,NA,NA,COVID-19 Pathophysiology of Long Term Implications,COVID 19 A Prospective Case Control Pathophysiological Study of Long Term Implications,Enrolling by invitation,NA,Not Applicable,60,Anticipated,King Faisal Specialist Hospital & Research Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:15:55Z,2021-12-02T05:15:55Z
NCT04811859,NA,2/25/2021,NA,NA,3/22/2021,3/22/2021,3/23/2021,Actual,NA,NA,NA,NA,NA,NA,3/22/2021,3/23/2021,Actual,10-Jan-21,Actual,1/10/2021,Mar-21,3/31/2021,10-Mar-22,Anticipated,3/10/2022,10-Jan-22,Anticipated,1/10/2022,NA,Interventional,NA,NA,The Effect of Inspiratory Muscle Training in Post COVID-19 Patients,"The Effect of Inspiratory Muscle Training on Respiratory Muscle Strength, Respiratory Functions and Functional Capacity in Post COVID-19 Patients",Recruiting,NA,Not Applicable,40,Anticipated,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:17:11Z,2021-12-02T05:17:11Z
NCT04811339,NA,3/20/2021,NA,NA,3/23/2021,3/21/2021,3/23/2021,Actual,NA,NA,NA,NA,NA,NA,3/23/2021,3/26/2021,Actual,2-Sep-20,Actual,9/2/2020,Mar-21,3/31/2021,31-Aug-23,Anticipated,8/31/2023,31-Aug-23,Anticipated,8/31/2023,NA,Interventional,SABER-C,NA,Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol),"Pilot and Randomized, Controlled Studies to Assess Stool Frequency of COVID + Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol): SABER-C and Lite-SABER-C (Specific Administration of Bismuth for Early Recovery of COVID-19)",Recruiting,NA,Phase 4,35,Anticipated,University of Louisville,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:17:19Z,2021-12-02T05:17:19Z
NCT04810949,NA,3/18/2021,NA,NA,3/22/2021,3/22/2021,3/23/2021,Actual,NA,NA,NA,NA,NA,NA,3/22/2021,3/23/2021,Actual,5-Aug-20,Actual,8/5/2020,Mar-21,3/31/2021,1-Mar-21,Actual,3/1/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,NA,NA,Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml,Effect of Vitamin D Supplementation on the Development of Respiratory Infections (COVID-19) in Health Personnel at Hospital ClÃ­nica NOVA With Serum Values> 20ng / ml,Terminated,NA,Not Applicable,41,Actual,Hospital Clinica Nova,,2,NA,patients enrolled got vaccinated vs COVID-19 and Influenza,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:17:44Z,2021-12-02T05:17:44Z
NCT04810689,NA,3/17/2021,NA,NA,3/19/2021,3/19/2021,3/23/2021,Actual,NA,NA,NA,NA,NA,NA,3/19/2021,3/23/2021,Actual,1-Mar-21,Actual,3/1/2021,Mar-21,3/31/2021,1-Sep-22,Anticipated,9/1/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,NA,NA,"Pilot Trial of XFBD, a TCM, in Persons With COVID-19","A Randomized, Double-Blind, Placebo-Control Pilot Trial of Xuanfei Baidu Granules (XFBD), a Traditional Chinese Medicine (TCM), in Persons With COVID-19",Recruiting,NA,Phase 2,60,Anticipated,University of Southern California,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:18:00Z,2021-12-02T05:18:00Z
NCT04810637,NA,3/17/2021,NA,NA,3/22/2021,3/19/2021,3/23/2021,Actual,NA,NA,NA,NA,NA,NA,3/22/2021,3/24/2021,Actual,1-Nov-20,Actual,11/1/2020,Mar-21,3/31/2021,Sep-21,Anticipated,9/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19,"A Phase 2, Randomized, Double Blinded, Placebo Controlled, Parallel Group, Single Administration Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19",Recruiting,NA,Phase 2,210,Anticipated,PT Kalbe Genexine Biologics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:18:03Z,2021-12-02T05:18:03Z
NCT04809974,NA,3/19/2021,NA,NA,7/22/2021,3/19/2021,3/22/2021,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/29/2021,Actual,22-Jul-21,Actual,7/22/2021,Jul-21,7/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID),"Randomized, Placebo-controlled Parallel Group Clinical Trial of Nicotinamide Riboside to Evaluate NAD+ Levels in Individuals With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (""Long-COVID"")",Recruiting,NA,Phase 4,100,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:18:44Z,2021-12-02T05:18:44Z
NCT04810728,NA,3/16/2021,NA,NA,4/17/2021,3/20/2021,3/23/2021,Actual,NA,NA,NA,NA,NA,NA,4/17/2021,4/20/2021,Actual,20-Jun-20,Actual,6/20/2020,Apr-21,4/30/2021,30-Jan-21,Actual,1/30/2021,4-Dec-20,Actual,12/4/2020,NA,Interventional,NA,NA,Efficacy of Psidii Guava's Extract For COVID-19,Efficacy of Psidii Guava's Extract For Mild And Symptomless Coronavirus Disease-19 (COVID-19),Completed,NA,Phase 3,90,Actual,Faculty of Medicine Baiturrahmah University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:18:18Z,2021-12-02T05:18:18Z
NCT04810065,NA,3/19/2021,NA,NA,9/27/2021,3/19/2021,3/22/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/28/2021,Actual,29-Mar-21,Actual,3/29/2021,Sep-21,9/30/2021,1-Sep-21,Actual,9/1/2021,29-Jul-21,Actual,7/29/2021,NA,Interventional,ss,NA,SingStrong: Strong Lungs Through Song - Long COVID-19 Study,SingStrong: Strong Lungs Through Song,Completed,NA,Not Applicable,30,Actual,University of Limerick,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:18:46Z,2021-12-02T05:18:46Z
NCT04809389,NA,3/19/2021,NA,NA,9/24/2021,3/19/2021,3/22/2021,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/27/2021,Actual,29-Mar-21,Actual,3/29/2021,Apr-21,4/30/2021,Sep-22,Anticipated,9/30/2022,Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19,"A Phase 1, Randomized, Double-blinded, Placebo-controlled, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults","Active, not recruiting",NA,Phase 1,115,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The results of this study will be publicly disseminated by ways of publication(s) in peer-reviewed scientific journal(s), presentation(s) in scientific conference(s), posting on public clinical trial registry(ies) and/or otherwise instead of individual participant data (IPD) sharing.",2021-12-02T05:19:04Z,2021-12-02T05:19:04Z
NCT04809272,NA,3/15/2021,NA,NA,9/27/2021,3/18/2021,3/22/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/28/2021,Actual,8-Mar-21,Actual,3/8/2021,Sep-21,9/30/2021,1-Dec-21,Anticipated,12/1/2021,1-Nov-21,Anticipated,11/1/2021,NA,Interventional,ePLH,NA,ePLH Pilot Study: Online Support Parent Groups - ParentChat,COVID-19 e-Parenting for Lifelong Health (ePLH) Pilot Study: Promoting Positive Parenting and Preventing Violence Through Online Parent Support Groups - ParentChat,Recruiting,NA,Not Applicable,900,Anticipated,University of Oxford,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Indefinitely,"Accessibility of the data will require approval from the study team. The study investigators, led by the PI, will jointly make decisions on whether to supply research data to potential new users. Research data will be deposited in and available in the UK Data Archive solely for non-profit use.",NA,Yes,Anonymised data will be shared on Open Science Framework after the completion of the study and results are published,2021-12-02T05:19:08Z,2021-12-02T05:19:08Z
NCT04808882,NA,3/8/2021,NA,NA,7/12/2021,3/19/2021,3/22/2021,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/14/2021,Actual,14-Apr-21,Actual,4/14/2021,Dec-20,12/31/2020,1-Feb-22,Anticipated,2/1/2022,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,ANTICOVID,NA,ANTIcoagulation in Severe COVID-19 Patients,"ANTIcoagulation in Severe COVID-19 Patients: a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial",Recruiting,NA,Phase 2,353,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION",2021-12-02T05:19:22Z,2021-12-02T05:19:22Z
NCT04808921,NA,3/18/2021,NA,NA,4/5/2021,3/18/2021,3/22/2021,Actual,NA,NA,NA,NA,NA,NA,4/5/2021,4/8/2021,Actual,9-Jan-21,Actual,1/9/2021,Apr-21,4/30/2021,28-Jan-21,Actual,1/28/2021,18-Jan-21,Actual,1/18/2021,NA,Interventional,NA,NA,Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test,Rapid Diagnostic Test for Detection of SARS-CoV-2 Antigen,Completed,NA,Not Applicable,151,Actual,"Sky Medical Supplies & Equipments, LLC",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:19:20Z,2021-12-02T05:19:20Z
NCT04805931,NA,3/11/2021,NA,NA,6/25/2021,3/17/2021,3/18/2021,Actual,NA,NA,NA,NA,NA,NA,6/25/2021,6/28/2021,Actual,15-Mar-21,Actual,3/15/2021,Jun-21,6/30/2021,1-Nov-21,Anticipated,11/1/2021,1-May-21,Actual,5/1/2021,NA,Interventional,VEText,NA,VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,COVID-19 Vaccine Rollout: VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,Recruiting,NA,Not Applicable,4311,Anticipated,VA Puget Sound Health Care System,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:21:39Z,2021-12-02T05:21:39Z
NCT04806113,NA,3/12/2021,NA,NA,6/13/2021,3/17/2021,3/19/2021,Actual,NA,NA,NA,NA,NA,NA,6/13/2021,6/15/2021,Actual,11-Mar-21,Actual,3/11/2021,Jun-21,6/30/2021,15-Jun-22,Anticipated,6/15/2022,13-Jun-21,Actual,6/13/2021,NA,Interventional,COVIAAD,NA,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,"Active, not recruiting",NA,Phase 3,220,Actual,McGill University Health Centre/Research Institute of the McGill University Health Centre,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:21:40Z,2021-12-02T05:21:40Z
NCT04805892,NA,3/17/2021,NA,NA,6/11/2021,3/17/2021,3/18/2021,Actual,NA,NA,NA,NA,NA,NA,6/11/2021,6/16/2021,Actual,17-Mar-21,Actual,3/17/2021,Jun-21,6/30/2021,17-Aug-21,Anticipated,8/17/2021,27-Jul-21,Anticipated,7/27/2021,NA,Interventional,NA,NA,"Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.","Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test as Compared to Standard Testing Technique. Test Performed by a Professional Versus Self-collection and Standard of Care",Recruiting,NA,Not Applicable,250,Anticipated,Mach-E B.V.,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:21:50Z,2021-12-02T05:21:50Z
NCT04805203,NA,12/15/2020,NA,NA,3/17/2021,3/17/2021,3/18/2021,Actual,NA,NA,NA,NA,NA,NA,3/17/2021,3/18/2021,Actual,16-Dec-20,Actual,12/16/2020,Mar-21,3/31/2021,Dec-22,Anticipated,12/31/2022,Dec-22,Anticipated,12/31/2022,NA,Interventional,Covimmunomm,NA,Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma,Analysis of the Immune Parameters Involved in the Onset and Fate of SARS-CoV-2 Infection in Patients With Multiple Myeloma (COVIMMUNOMM) COVID-19 and Multiple Myeloma,Recruiting,NA,Not Applicable,400,Anticipated,Intergroupe Francophone du Myelome,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:22:13Z,2021-12-02T05:22:13Z
NCT04805684,NA,3/15/2021,NA,NA,3/17/2021,3/17/2021,3/18/2021,Actual,NA,NA,NA,NA,NA,NA,3/17/2021,3/18/2021,Actual,1-Jan-21,Actual,1/1/2021,Mar-21,3/31/2021,5-Mar-21,Actual,3/5/2021,5-Mar-21,Actual,3/5/2021,NA,Interventional,NA,NA,Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia,Comparison of Two Different Lung Ultrasound Imaging Protocols in COVID -19 Pneumonia,Completed,NA,Not Applicable,59,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:21:55Z,2021-12-02T05:21:55Z
NCT04803227,NA,2/12/2021,NA,NA,3/16/2021,3/16/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,3/16/2021,3/17/2021,Actual,11-Mar-21,Actual,3/11/2021,Mar-21,3/31/2021,Jun-21,Anticipated,6/30/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19,Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19,Recruiting,NA,Phase 1,50,Anticipated,Histogen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:23:59Z,2021-12-02T05:23:59Z
NCT04805086,NA,3/3/2021,NA,NA,3/17/2021,3/17/2021,3/18/2021,Actual,NA,NA,NA,NA,NA,NA,3/17/2021,3/18/2021,Actual,8-Mar-21,Anticipated,3/8/2021,Mar-21,3/31/2021,5-Mar-23,Anticipated,3/5/2023,1-Jun-22,Anticipated,6/1/2022,NA,Interventional,MONACO,NA,The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19,Phase I/II MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19,Recruiting,NA,Phase 1/Phase 2,5,Anticipated,Guy's and St Thomas' NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:22:22Z,2021-12-02T05:22:22Z
NCT04805125,NA,3/15/2021,NA,NA,6/14/2021,3/15/2021,3/18/2021,Actual,NA,NA,NA,NA,NA,NA,6/14/2021,6/15/2021,Actual,19-Apr-21,Actual,4/19/2021,Jun-21,6/30/2021,Jul-22,Anticipated,7/31/2022,Jul-22,Anticipated,7/31/2022,NA,Interventional,COVERALL,NA,Immunocompromised Swiss Cohorts Based Trial Platform,Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform,"Active, not recruiting",NA,Phase 3,431,Actual,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:22:25Z,2021-12-02T05:22:25Z
NCT04803370,NA,3/9/2021,NA,NA,3/16/2021,3/16/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,3/16/2021,3/17/2021,Actual,8-Jul-20,Actual,7/8/2020,Mar-21,3/31/2021,1-Sep-21,Anticipated,9/1/2021,1-Sep-21,Anticipated,9/1/2021,NA,Interventional,NA,NA,Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma,Study of the Efficacy of Reinforcing of the Standard Therapy in COVID-19 Patients With Repeated Transfusion of Immune Plasma From COVID-19 Convalescents vs Exclusive Standard Therapy in Hospitalized COVID-19 Patients,Recruiting,NA,Not Applicable,100,Anticipated,Hospital Son Llatzer,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:24:00Z,2021-12-02T05:24:00Z
NCT04802187,NA,3/12/2021,NA,NA,9/10/2021,3/12/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,9/10/2021,9/17/2021,Actual,1-Dec-20,Actual,12/1/2020,Sep-21,9/30/2021,31-Aug-22,Anticipated,8/31/2022,31-Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,Implementation of COVID-19 Testing Strategies in Community Health Centers,Implementation of COVID-19 Testing Strategies in Community Health Centers,Recruiting,NA,Not Applicable,76300,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:24:38Z,2021-12-02T05:24:38Z
NCT04802382,NA,3/10/2021,NA,NA,6/28/2021,3/16/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,6/28/2021,6/29/2021,Actual,11-Jun-21,Actual,6/11/2021,Jun-21,6/30/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,CimetrA,NA,Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19,"A Phase III, Double-blind , Controlled Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19",Recruiting,NA,Phase 3,252,Anticipated,MGC Pharmaceuticals d.o.o,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:24:42Z,2021-12-02T05:24:42Z
NCT04801836,NA,3/12/2021,NA,NA,7/30/2021,3/12/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,7/30/2021,8/2/2021,Actual,19-Nov-20,Actual,11/19/2020,May-21,5/31/2021,5-Aug-22,Anticipated,8/5/2022,4-Mar-22,Anticipated,3/4/2022,NA,Interventional,NA,NA,Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection,"A Randomized, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection","Active, not recruiting",NA,Phase 2,162,Actual,NEURALIS s.a.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:24:52Z,2021-12-02T05:24:52Z
NCT04801888,NA,3/15/2021,NA,NA,7/23/2021,3/15/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,7/23/2021,7/26/2021,Actual,23-Mar-21,Actual,3/23/2021,Mar-21,3/31/2021,28-May-21,Actual,5/28/2021,28-May-21,Actual,5/28/2021,NA,Interventional,NA,NA,Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine,A Study to Evaluate the Safety and Immunogenicity of Concomitant Administration of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) With Quadrivalent Influenza Vaccine in Adults Aged From 18 to 59 Years,Completed,NA,Phase 4,480,Actual,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:24:57Z,2021-12-02T05:24:57Z
NCT04801940,NA,3/12/2021,NA,NA,7/19/2021,3/16/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/23/2021,Actual,19-May-21,Actual,5/19/2021,Jul-21,7/31/2021,31-Jan-24,Anticipated,1/31/2024,31-Jan-24,Anticipated,1/31/2024,NA,Interventional,HEAL-COVID,NA,HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID),HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID): a National Platform Trial,Recruiting,NA,Phase 3,2631,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,Proposals for data sharing can be submitted for consideration via contact details on the HEAL-COVID website.,http://www.heal-covid.net,Yes,"At the end of the trial, after the primary results have been published, all requests for access to trial data will be reviewed by the Trial Management Group and where possible access will be granted.",2021-12-02T05:24:58Z,2021-12-02T05:24:58Z
NCT04802018,NA,3/16/2021,NA,NA,8/31/2021,3/16/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/1/2021,Actual,9-Mar-21,Actual,3/9/2021,Aug-21,8/31/2021,Dec-21,Anticipated,12/31/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,SOY+,NA,Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients,Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients With Domiciliary Follow-up,"Active, not recruiting",NA,Not Applicable,500,Anticipated,Increase-Tech,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:24:58Z,2021-12-02T05:24:58Z
NCT04801524,NA,3/15/2021,NA,NA,3/22/2021,3/15/2021,3/17/2021,Actual,NA,NA,NA,NA,NA,NA,3/22/2021,3/24/2021,Actual,7-Feb-21,Actual,2/7/2021,Mar-21,3/31/2021,1-Jan-22,Anticipated,1/1/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Text-based Reminders to Promote COVID-19 Vaccinations,Text-based Reminders to Promote COVID-19 Vaccinations,Enrolling by invitation,NA,Not Applicable,250000,Anticipated,"University of California, Los Angeles",,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:25:23Z,2021-12-02T05:25:23Z
NCT04800939,NA,3/11/2021,NA,NA,8/30/2021,3/14/2021,3/16/2021,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/1/2021,Actual,25-Mar-21,Actual,3/25/2021,Aug-21,8/31/2021,22-Jul-22,Anticipated,7/22/2022,15-May-21,Actual,5/15/2021,NA,Interventional,NA,NA,The Effect of Acupressure on the Sleep Quality and Daytime Sleepiness,The Effect of Acupressure on the Sleep Quality and Daytime Sleepiness of Surgical Nurses During the COVID-19 Pandemic Process,Enrolling by invitation,NA,Not Applicable,60,Anticipated,Mersin University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:25:39Z,2021-12-02T05:25:39Z
NCT04800965,NA,2/6/2021,NA,NA,3/22/2021,3/14/2021,3/16/2021,Actual,NA,NA,NA,NA,NA,NA,3/22/2021,3/24/2021,Actual,31-Jan-21,Actual,1/31/2021,Mar-21,3/31/2021,1-Jan-22,Anticipated,1/1/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Text-based Interventions to Promote COVID-19 Vaccinations,Text-based Interventions to Promote COVID-19 Vaccinations,Enrolling by invitation,NA,Not Applicable,400000,Anticipated,"University of California, Los Angeles",,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:25:42Z,2021-12-02T05:25:42Z
NCT04800120,NA,11/13/2020,NA,NA,3/15/2021,3/15/2021,3/16/2021,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/16/2021,Actual,15-Feb-21,Actual,2/15/2021,Mar-21,3/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,HBOT,NA,Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress,The Use of Hyperbaric Oxygen Therapy (HBOT) for the Treatment of COVID-19 Patients With Mild-to-moderate Respiratory Distress,Recruiting,NA,Not Applicable,10,Anticipated,"Steward St. Elizabeth's Medical Center of Boston, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:26:14Z,2021-12-02T05:26:14Z
NCT04800224,NA,3/12/2021,NA,NA,4/12/2021,3/15/2021,3/16/2021,Actual,NA,NA,NA,NA,NA,NA,4/12/2021,4/14/2021,Actual,12-Apr-21,Actual,4/12/2021,Apr-21,4/30/2021,30-Jul-21,Anticipated,7/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,BeeCovid2,NA,Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2),"The Use of the Standardized Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients: A Randomized, Double-blind, Placebo-controlled Trial",Recruiting,NA,Phase 2/Phase 3,200,Anticipated,D'Or Institute for Research and Education,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The data presented in this study are available on request from the corresponding author.,2021-12-02T05:26:19Z,2021-12-02T05:26:19Z
NCT04799743,NA,3/10/2021,NA,NA,7/10/2021,3/15/2021,3/16/2021,Actual,NA,NA,NA,NA,NA,NA,7/10/2021,7/16/2021,Actual,1-Apr-21,Actual,4/1/2021,Jul-21,7/31/2021,May-22,Anticipated,5/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,HKCOVID19Res,NA,The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients,A Pilot Randomized Controlled Clinical Study of Resveratrol for Discharged COVID 19 Patients in Order to Evaluate Its Therapeutic Effects Against Fibrosis,Recruiting,NA,Not Applicable,30,Anticipated,Hong Kong Baptist University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:26:40Z,2021-12-02T05:26:40Z
NCT04799561,NA,3/1/2021,NA,NA,9/24/2021,3/11/2021,3/16/2021,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/30/2021,Actual,12-Mar-21,Actual,3/12/2021,Sep-21,9/30/2021,15-Dec-22,Anticipated,12/15/2022,15-Sep-22,Anticipated,9/15/2022,NA,Interventional,NA,NA,Teleprehabilitation for Surgical Cancer Patients,Virtual Prehabilitation of Surgical Cancer Patients in Times of the Covid-19 Pandemic,Recruiting,NA,Not Applicable,100,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:26:58Z,2021-12-02T05:26:58Z
NCT04798677,NA,3/12/2021,NA,NA,7/20/2021,3/12/2021,3/15/2021,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,29-Oct-20,Actual,10/29/2020,Mar-21,3/31/2021,Jul-21,Anticipated,7/31/2021,Jul-21,Anticipated,7/31/2021,NA,Interventional,NA,NA,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,"Efficacy and Tolerability of a Nutritional Supplementation With ABBC-1, a Symbiotic Combination of Beta-glucans and Selenium and Zinc Enriched Probiotics, in Volunteers Receiving the Influenza or the Covid-19 Vaccines",Recruiting,NA,Not Applicable,90,Anticipated,AB Biotek,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will be available upon request (blood analysis results and clinical assessment outcomes),2021-12-02T05:27:23Z,2021-12-02T05:27:23Z
NCT04798001,NA,3/9/2021,NA,NA,7/1/2021,3/12/2021,3/15/2021,Actual,NA,NA,NA,NA,NA,NA,7/1/2021,7/7/2021,Actual,12-Apr-21,Actual,4/12/2021,Jul-21,7/31/2021,31-Oct-22,Anticipated,10/31/2022,31-Oct-22,Anticipated,10/31/2022,NA,Interventional,NA,NA,Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults,"Phase 1, Open-Label, Dose-Escalation Study to Evaluate Tolerability, Safety, and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine Expressing Spike Protein of SARS-CoV-2 in Healthy Adults Ages 18 - 69 Years",Recruiting,NA,Phase 1,130,Anticipated,"Meissa Vaccines, Inc.",,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:27:50Z,2021-12-02T05:27:50Z
NCT04798599,NA,3/8/2021,NA,NA,3/12/2021,3/12/2021,3/15/2021,Actual,NA,NA,NA,NA,NA,NA,3/12/2021,3/15/2021,Actual,1-Dec-20,Actual,12/1/2020,Mar-21,3/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Information and Communication Technologies (ICTS) in Dentistry for SUS,Using Information and Communication Technologies (ICTs) to Solve the Repressed Demand for Primary Dental Care in the SUS Due to the COVID-19 Pandemic,Recruiting,NA,Not Applicable,368,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:27:31Z,2021-12-02T05:27:31Z
NCT04798053,NA,3/10/2021,NA,NA,8/6/2021,3/12/2021,3/15/2021,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/9/2021,Actual,8-Apr-21,Actual,4/8/2021,Aug-21,8/31/2021,Oct-22,Anticipated,10/31/2022,Oct-22,Anticipated,10/31/2022,NA,Interventional,EMOPTION,NA,Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients,Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients,Recruiting,NA,Not Applicable,318,Anticipated,"University Hospital, Bordeaux",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:27:52Z,2021-12-02T05:27:52Z
NCT04797871,NA,3/8/2021,NA,NA,3/12/2021,3/12/2021,3/15/2021,Actual,NA,NA,NA,NA,NA,NA,3/12/2021,3/15/2021,Actual,8-Mar-21,Actual,3/8/2021,Mar-21,3/31/2021,15-Mar-22,Anticipated,3/15/2022,15-Mar-22,Anticipated,3/15/2022,NA,Interventional,EXER-COVID,NA,Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19,"Resistance Training Intervention on the Clinical Status in Patients With Post Discharge Symptoms After Covid-19: The ""EXER-COVID Study""",Enrolling by invitation,NA,Not Applicable,100,Anticipated,Universidad PÃºblica de Navarra,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:27:52Z,2021-12-02T05:27:52Z
NCT04797858,NA,3/5/2021,NA,NA,5/6/2021,3/12/2021,3/15/2021,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/10/2021,Actual,5-May-21,Actual,5/5/2021,May-21,5/31/2021,31-Oct-22,Anticipated,10/31/2022,30-Mar-22,Anticipated,3/30/2022,NA,Interventional,C-STRAND,NA,COVID-19 Self-Testing Through Rapid Network Distribution,Secondary Distribution of COVID-19 Self-tests vs. Referrals to Increase Test Uptake in Underserved Populations,Recruiting,NA,Not Applicable,1048,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:27:54Z,2021-12-02T05:27:54Z
NCT04797936,NA,3/8/2021,NA,NA,3/12/2021,3/12/2021,3/15/2021,Actual,NA,NA,NA,NA,NA,NA,3/12/2021,3/15/2021,Actual,1-May-20,Actual,5/1/2020,Mar-21,3/31/2021,8-Jan-21,Actual,1/8/2021,19-Dec-20,Actual,12/19/2020,NA,Interventional,NA,NA,BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19,"A Randomized, Open-label, Multicentre, Comparative Study of Therapeutic Efficacy, Safety, and Tolerability of BNO 1030 Extract, in the Treatment of Mild Forms of COVID-19",Completed,NA,Phase 4,133,Actual,Ivano-Frankivsk National Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:27:57Z,2021-12-02T05:27:57Z
NCT04796402,NA,3/10/2021,NA,NA,8/24/2021,3/11/2021,3/12/2021,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/26/2021,Actual,17-Mar-21,Actual,3/17/2021,Aug-21,8/31/2021,31-Dec-21,Anticipated,12/31/2021,7-Jun-21,Actual,6/7/2021,NA,Interventional,B-EPIC,NA,A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19,A Pragmatic Eight Week Phase IV Study of Bamlanivimab/LY-CoV555 for Emergency Passive Immunity Against COVID-19,"Active, not recruiting",NA,Phase 4,576,Anticipated,Fraser Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:28:53Z,2021-12-02T05:28:53Z
NCT04794946,NA,3/8/2021,NA,NA,6/18/2021,3/11/2021,3/12/2021,Actual,NA,NA,NA,NA,NA,NA,6/18/2021,6/23/2021,Actual,19-Mar-21,Actual,3/19/2021,Mar-21,3/31/2021,19-Mar-22,Anticipated,3/19/2022,19-Mar-22,Anticipated,3/19/2022,NA,Interventional,NA,NA,"Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis","Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis - A Pilot Study",Recruiting,NA,Not Applicable,2200,Anticipated,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:30:11Z,2021-12-02T05:30:11Z
NCT04796064,NA,3/10/2021,NA,NA,3/11/2021,3/11/2021,3/12/2021,Actual,NA,NA,NA,NA,NA,NA,3/11/2021,3/12/2021,Actual,30-Mar-20,Actual,3/30/2020,Mar-21,3/31/2021,15-Dec-20,Actual,12/15/2020,5-Nov-20,Actual,11/5/2020,NA,Interventional,NA,NA,Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 (SARS-CoV-2) Sarcopenia,Comparative Effectiveness Study of Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 Sarcopenia,Completed,NA,Not Applicable,76,Actual,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:29:10Z,2021-12-02T05:29:10Z
NCT04794036,NA,3/1/2021,NA,NA,9/30/2021,3/10/2021,3/11/2021,Actual,NA,NA,NA,NA,NA,NA,9/30/2021,10/1/2021,Actual,5-Apr-21,Actual,4/5/2021,Apr-21,4/30/2021,31-Mar-22,Anticipated,3/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patient,Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patients: a Feasibility Study,Recruiting,NA,Not Applicable,32,Anticipated,Universidad San Jorge,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:30:59Z,2021-12-02T05:30:59Z
NCT04794803,NA,3/8/2021,NA,NA,3/12/2021,3/11/2021,3/12/2021,Actual,NA,NA,NA,NA,NA,NA,3/12/2021,3/16/2021,Actual,5-May-20,Actual,5/5/2020,Mar-21,3/31/2021,2-Feb-21,Actual,2/2/2021,30-Nov-20,Actual,11/30/2020,NA,Interventional,NA,NA,Reparixin in COVID-19 Pneumonia - Efficacy and Safety,Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With COVID-19 Pneumonia,Terminated,NA,Phase 2/Phase 3,55,Actual,DompÃ© Farmaceutici S.p.A,,2,NA,The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:30:28Z,2021-12-02T05:30:28Z
NCT04794374,NA,3/9/2021,NA,NA,3/11/2021,3/10/2021,3/12/2021,Actual,NA,NA,NA,NA,NA,NA,3/11/2021,3/15/2021,Actual,16-Nov-20,Actual,11/16/2020,Mar-21,3/31/2021,16-Jan-22,Anticipated,1/16/2022,16-Jan-22,Anticipated,1/16/2022,NA,Interventional,NA,NA,Effects of Telerehabilitation After Discharge in COVID-19 Survivors,"Effects of Telerehabilitation After Discharge on Quality of Life, Psychosocial Status, Physical Activity, Daily Activities of Living, and Sleep Quality in Patients Treated as Inpatients With the Diagnosis of COVID-19",Recruiting,NA,Not Applicable,30,Anticipated,Hacettepe University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:30:48Z,2021-12-02T05:30:48Z
NCT04794400,NA,3/10/2021,NA,NA,6/5/2021,3/10/2021,3/12/2021,Actual,NA,NA,NA,NA,NA,NA,6/5/2021,6/9/2021,Actual,4-Feb-21,Actual,2/4/2021,Jun-21,6/30/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,NA,The Application of a Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,The Application of a Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,Completed,NA,Not Applicable,18,Actual,Region Skane,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:30:48Z,2021-12-02T05:30:48Z
NCT04793984,NA,3/9/2021,NA,NA,3/10/2021,3/10/2021,3/11/2021,Actual,NA,NA,NA,NA,NA,NA,3/10/2021,3/11/2021,Actual,8-Mar-21,Actual,3/8/2021,Mar-21,3/31/2021,30-Oct-21,Anticipated,10/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients,Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients,Recruiting,NA,Not Applicable,228,Anticipated,Marinomed Biotech AG,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:31:01Z,2021-12-02T05:31:01Z
NCT04794088,NA,2/26/2021,NA,NA,3/23/2021,3/10/2021,3/11/2021,Actual,NA,NA,NA,NA,NA,NA,3/23/2021,3/24/2021,Actual,14-Mar-21,Actual,3/14/2021,Mar-21,3/31/2021,Feb-22,Anticipated,2/28/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,INVENT COVID,NA,Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients,"A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Intravenous Imatinib Mesylate (ImpentriÂ®) in Subjects With Acute Respiratory Distress Syndrome Induced by COVID-19",Recruiting,NA,Phase 2,90,Anticipated,VU University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:30:58Z,2021-12-02T05:30:58Z
NCT04793243,NA,3/3/2021,NA,NA,3/9/2021,3/9/2021,3/11/2021,Actual,NA,NA,NA,NA,NA,NA,3/9/2021,3/11/2021,Actual,17-Aug-20,Actual,8/17/2020,Mar-21,3/31/2021,24-Oct-20,Actual,10/24/2020,10-Oct-20,Actual,10/10/2020,NA,Interventional,NA,NA,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico: Clinical Correlation and Effect of Its Supplementation,Completed,NA,Not Applicable,42,Actual,University of Guadalajara,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:31:48Z,2021-12-02T05:31:48Z
NCT04792021,NA,3/7/2021,NA,NA,3/9/2021,3/9/2021,3/10/2021,Actual,NA,NA,NA,NA,NA,NA,3/9/2021,3/10/2021,Actual,9-Mar-21,Actual,3/9/2021,Mar-21,3/31/2021,Nov-21,Anticipated,11/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients,Effect of N-acetylcysteine on Oxidative Stress And Occurrence of Complications in Patients With COVID 19 Infections,Recruiting,NA,Phase 3,60,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:32:52Z,2021-12-02T05:32:52Z
NCT04791423,NA,2/22/2021,NA,NA,7/26/2021,3/9/2021,3/10/2021,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/30/2021,Actual,15-Mar-21,Actual,3/15/2021,Mar-21,3/31/2021,30-Apr-22,Anticipated,4/30/2022,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,COVITAR,NA,Study of GRAd-COV2 for the Prevention of COVID-19 in Adults,"A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 2/Phase 3,10300,Anticipated,ReiThera Srl,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:33:19Z,2021-12-02T05:33:19Z
NCT04791241,NA,2/22/2021,NA,NA,9/21/2021,3/8/2021,3/10/2021,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/22/2021,Actual,3-Mar-21,Actual,3/3/2021,Sep-21,9/30/2021,4-Jan-22,Anticipated,1/4/2022,3-Jan-22,Anticipated,1/3/2022,NA,Interventional,CHECKIRA-COVID,NA,A Check-list Including Lung Ultrasound for ED Patients With ARF,Evaluation of a Check-list Including Lung Ultrasound for the Management of Patients With Acute Respiratory Failure at the Emergency Department During the COVID-19 Era,Recruiting,NA,Not Applicable,105,Anticipated,Centre Hospitalier Metropole Savoie,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:33:35Z,2021-12-02T05:33:35Z
NCT04790786,NA,2/26/2021,NA,NA,7/13/2021,3/8/2021,3/10/2021,Actual,NA,NA,NA,NA,NA,NA,7/13/2021,7/20/2021,Actual,10-Mar-21,Actual,3/10/2021,Jul-21,7/31/2021,Dec-22,Anticipated,12/31/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,OPTIMISE-C19,NA,"UPMC OPTIMISE-C19 Trial, a COVID-19 Study",The UPMC OPtimizing Treatment and Impact of Monocolonal antIbodieS Through Evaluation for COVID-19 Trial,Recruiting,NA,Phase 3,5000,Anticipated,University of Pittsburgh,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Relevant data may be available 1 year following publication,Data access is subject to a methodologically sound proposal and the necessary data sharing agreements.,NA,Yes,"De-identified participant-level data underlying the results reported in journal articles, subject to appropriate security controls, may be available for sharing with other researchers.",2021-12-02T05:34:00Z,2021-12-02T05:34:00Z
NCT04789525,NA,3/5/2021,NA,NA,3/9/2021,3/8/2021,3/9/2021,Actual,NA,NA,NA,NA,NA,NA,3/9/2021,3/11/2021,Actual,10-Mar-20,Actual,3/10/2020,Mar-21,3/31/2021,25-Dec-20,Actual,12/25/2020,1-Oct-20,Actual,10/1/2020,NA,Interventional,NA,NA,Physical Training and Diet for Childhood Obesity,"Clinical (BMI & MRI) and Biochemical (Adiponectin, Leptin, TNF-Î± & IL-6) Effects of High-intensity Aerobic Training With High Protein Diet in Childhood Obesity Following COVID-19 Infection",Completed,NA,Not Applicable,76,Actual,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:34:59Z,2021-12-02T05:34:59Z
NCT04789499,NA,3/8/2021,NA,NA,7/6/2021,3/8/2021,3/9/2021,Actual,NA,NA,NA,NA,NA,NA,7/6/2021,7/7/2021,Actual,15-Mar-21,Actual,3/15/2021,Jul-21,7/31/2021,Dec-21,Anticipated,12/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,SCENT2,NA,Smell in Covid-19 and Efficacy of Nasal Theophylline,Smell in Covid-19 and Efficacy of Nasal Theophylline,Recruiting,NA,Phase 2,50,Anticipated,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:35:09Z,2021-12-02T05:35:09Z
NCT04789603,NA,3/4/2021,NA,NA,5/10/2021,3/8/2021,3/9/2021,Actual,NA,NA,NA,NA,NA,NA,5/10/2021,5/11/2021,Actual,10-May-21,Anticipated,5/10/2021,Mar-21,3/31/2021,1-Jun-21,Anticipated,6/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,Effects of Using Mask During the 6-minute Walking Test in Times of COVID-19,"Effects of Using the Surgical Mask and FFp2 in the Distance Walked, Heart Rate, Oxygenometry, and Tone of the Accessory Inspiratory Muscles During the 6-minute Walking Test",Recruiting,NA,Not Applicable,50,Anticipated,Universitat Internacional de Catalunya,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:35:21Z,2021-12-02T05:35:21Z
NCT04787211,NA,3/4/2021,NA,NA,8/26/2021,3/4/2021,3/8/2021,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/30/2021,Actual,20-Jun-21,Actual,6/20/2021,Aug-21,8/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","A Phase 2 Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients",Recruiting,NA,Phase 2,24,Anticipated,Brii Biosciences Limited,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:36:50Z,2021-12-02T05:36:50Z
NCT04789356,NA,3/5/2021,NA,NA,7/22/2021,3/8/2021,3/9/2021,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/26/2021,Actual,18-Mar-21,Actual,3/18/2021,Jul-21,7/31/2021,Mar-22,Anticipated,3/31/2022,5-Jul-21,Actual,7/5/2021,NA,Interventional,COVACMANAUS,NA,Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity,"Phase IV Study to Evaluate the Effectiveness of the Inactivated Adsorbed Vaccine Against COVID-19 CoronaVac, Among Public Safety and Education Workers With Risk Factors for Severity, in Manaus (Amazonas)","Active, not recruiting",NA,Phase 4,6233,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:35:26Z,2021-12-02T05:35:26Z
NCT04788355,NA,9/5/2020,NA,NA,3/6/2021,3/6/2021,3/9/2021,Actual,NA,NA,NA,NA,NA,NA,3/6/2021,3/9/2021,Actual,1-Jul-20,Actual,7/1/2020,Mar-21,3/31/2021,23-Dec-20,Actual,12/23/2020,15-Nov-20,Actual,11/15/2020,NA,Interventional,NA,NA,Prevention of Complications (SARS-CoV-2): Clinical Study,Hydroxychloroquine and Apixaban: Analysis of Physiological Parameters for the Prevention of Complications in Patients With Infection With the New Coronavirus (Covid-19). A Randomized Clinical Trial,Completed,NA,Phase 3,176,Actual,Universidade do Vale do Sapucai,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:35:52Z,2021-12-02T05:35:52Z
NCT04788407,NA,3/7/2021,NA,NA,7/1/2021,3/8/2021,3/9/2021,Actual,NA,NA,NA,NA,NA,NA,7/1/2021,7/2/2021,Actual,1-Dec-20,Actual,12/1/2020,Jul-21,7/31/2021,30-Apr-22,Anticipated,4/30/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,PENTZ,NA,Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts,Pilot Study of Safety and Efficacy of Nitazoxanide in Post-exposure Prophylaxis in Household Contacts of Patients With Confirmed SARS-CoV-2 Infection,Recruiting,NA,Phase 4,456,Anticipated,FundaciÃ³n HuÃ©sped,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.huesped.org.ar/que-hacemos/ciencia/investigaciones-biomedicas/,Yes,to publish study results,2021-12-02T05:35:59Z,2021-12-02T05:35:59Z
NCT04786483,NA,2/24/2021,NA,NA,3/5/2021,3/5/2021,3/8/2021,Actual,NA,NA,NA,NA,NA,NA,3/5/2021,3/8/2021,Actual,1-Nov-20,Actual,11/1/2020,Mar-21,3/31/2021,10-May-21,Anticipated,5/10/2021,30-Jan-21,Actual,1/30/2021,NA,Interventional,NA,NA,The Effect of Laughter Therapy on Students in the COVID-19 Pandemic,"The Effect of Laughter Therapy on Students' Anxiety, Life Satisfaction and Psychological Well-being in the Covid-19 Pandemic","Active, not recruiting",NA,Not Applicable,80,Anticipated,Zonguldak Bulent Ecevit University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:37:45Z,2021-12-02T05:37:45Z
NCT04786080,NA,2/24/2021,NA,NA,8/9/2021,3/3/2021,3/8/2021,Actual,NA,NA,NA,NA,NA,NA,8/9/2021,8/16/2021,Actual,19-May-21,Actual,5/19/2021,Jan-21,1/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,SPARKLE,NA,Supporting Parents & Kids Through Lockdown Experiences (SPARKLE).,Supporting Parents & Kids Through Lockdown Experiences (SPARKLE): A Parallel Randomised Controlled Trial of a Digital Parenting Support Application Implemented in the General Population During the COVID-19 Pandemic.,"Active, not recruiting",NA,Not Applicable,616,Anticipated,King's College London,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be made publicly accessible on publication of research findings or no later than 12 months after the completion of the grant, whichever is sooner.",The data will be deposited with the UK Data Service or another suitable repository and will therefore be made publicly and freely accessible.,https://www.kcl.ac.uk/research/supporting-parents-and-kids-through-lockdown-experiences-sparkle-trial,Yes,"On completion of the study a clean, pseudonymised data set will be made available for open access via the UK Data Service or another suitable repository. Questionnaire and app data will be shared along with a procedures document, curation document and description of variables. Links to the data record will be provided in all papers published using the data.",2021-12-02T05:37:52Z,2021-12-02T05:37:52Z
NCT04785898,NA,3/1/2021,NA,NA,8/20/2021,3/5/2021,3/8/2021,Actual,NA,NA,NA,NA,NA,NA,8/20/2021,8/23/2021,Actual,9-Nov-20,Actual,11/9/2020,Aug-21,8/31/2021,30-Dec-21,Anticipated,12/30/2021,22-Dec-20,Actual,12/22/2020,NA,Interventional,COVID-IDNow,NA,Diagnostic Performance of the ID Nowâ„¢ COVID-19 Screening Test Versus Simplexaâ„¢ COVID-19 Direct Assay,Diagnostic Performance of the ID Nowâ„¢ COVID-19 Screening Test Versus Simplexaâ„¢ COVID-19 Direct Assay in Off-site Biology in Emergency Rooms for COVID-19 Screenin,"Active, not recruiting",NA,Not Applicable,1000,Anticipated,Groupe Hospitalier Paris Saint Joseph,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:38:02Z,2021-12-02T05:38:02Z
NCT04784754,NA,2/22/2021,NA,NA,6/9/2021,3/4/2021,3/5/2021,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/11/2021,Actual,1-Apr-21,Actual,4/1/2021,Jun-21,6/30/2021,31-Dec-21,Anticipated,12/31/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection,Recruiting,NA,Phase 2,50,Anticipated,State University of New York at Buffalo,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:38:49Z,2021-12-02T05:38:49Z
NCT04784897,NA,3/3/2021,NA,NA,8/11/2021,3/3/2021,3/5/2021,Actual,NA,NA,NA,NA,NA,NA,8/11/2021,8/13/2021,Actual,22-Feb-21,Actual,2/22/2021,Aug-21,8/31/2021,30-Jul-21,Actual,7/30/2021,1-Jul-21,Actual,7/1/2021,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19",Completed,NA,Phase 2,120,Actual,"Innovation Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:38:55Z,2021-12-02T05:38:55Z
NCT04784481,NA,2/20/2021,NA,NA,4/22/2021,3/3/2021,3/5/2021,Actual,NA,NA,NA,NA,NA,NA,4/22/2021,4/26/2021,Actual,20-Sep-20,Actual,9/20/2020,Apr-21,4/30/2021,18-Jan-21,Actual,1/18/2021,20-Dec-20,Actual,12/20/2020,NA,Interventional,IVER-Leve,NA,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,Ivermectin Reproposing for COVID-19 Treatment in Outpatients With Mild Stage,Completed,NA,Phase 1/Phase 2,254,Actual,"Ministry of Public Health, Argentina",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,N/D,2021-12-02T05:39:14Z,2021-12-02T05:39:14Z
NCT04784767,NA,3/3/2021,NA,NA,9/13/2021,3/3/2021,3/5/2021,Actual,NA,NA,NA,NA,NA,NA,9/13/2021,9/14/2021,Actual,5-Apr-21,Actual,4/5/2021,Sep-21,9/30/2021,30-Oct-23,Anticipated,10/30/2023,30-Oct-22,Anticipated,10/30/2022,NA,Interventional,NA,NA,SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults,"A PHASE 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Ranging Doses of SARS-COV-2-Spike-Ferritin-Nanoparticle (SPFN_1B-06-PL) Vaccine With Army Liposomal Formulation QS21 (ALFQ) for Prevention of COVID-19 in Healthy Adults.","Active, not recruiting",NA,Phase 1,29,Actual,U.S. Army Medical Research and Development Command,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:39:06Z,2021-12-02T05:39:06Z
NCT04783311,NA,3/3/2021,NA,NA,4/23/2021,3/3/2021,3/5/2021,Actual,NA,NA,NA,NA,NA,NA,4/23/2021,4/26/2021,Actual,23-Feb-21,Actual,2/23/2021,Feb-21,2/28/2021,Jan-23,Anticipated,1/31/2023,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,"Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults","A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,280,Anticipated,"EuBiologics Co.,Ltd",,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:40:20Z,2021-12-02T05:40:20Z
NCT04783025,NA,2/25/2021,NA,NA,5/11/2021,3/3/2021,3/4/2021,Actual,NA,NA,NA,NA,NA,NA,5/11/2021,5/12/2021,Actual,1-Jun-21,Anticipated,6/1/2021,May-21,5/31/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,BGCTS,NA,A Blended Gaming COVID-19 Training System (BGCTS) With WHO Guidelines for Staff in Residential Care Homes,A Blended Gaming COVID-19 Training System (BGCTS) With WHO Guidelines for Staff in Residential Care Homes: A Cluster Randomized Controlled Trial,Recruiting,NA,Not Applicable,188,Anticipated,The Hong Kong Polytechnic University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:40:27Z,2021-12-02T05:40:27Z
NCT04782700,NA,2/25/2021,NA,NA,6/17/2021,3/3/2021,3/4/2021,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/18/2021,Actual,1-Apr-21,Actual,4/1/2021,Jun-21,6/30/2021,8-Jun-21,Actual,6/8/2021,8-Jun-21,Actual,6/8/2021,NA,Interventional,NA,NA,P-Co-Li (Pulmonary Covid-19 Study),P-CO-Li (Pulmonary Covid-19 Longterm Intervention Study),Completed,NA,Not Applicable,6,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:40:37Z,2021-12-02T05:40:37Z
NCT04782336,NA,2/17/2021,NA,NA,3/3/2021,3/3/2021,3/4/2021,Actual,NA,NA,NA,NA,NA,NA,3/3/2021,3/4/2021,Actual,12-Dec-20,Actual,12/12/2020,Mar-21,3/31/2021,31-May-22,Anticipated,5/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,INFORM,NA,"Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test","Sample Collection to Facilitate the Performance Evaluation of the LumiraDx Point of Care Device for the Detection of Influenza A/B, Respiratory Syncytial Virus (RSV) & COVID-19 (SARS-COV-2 Virus)",Recruiting,NA,Not Applicable,3500,Anticipated,LumiraDx UK Limited,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:41:01Z,2021-12-02T05:41:01Z
NCT04780659,NA,2/19/2021,NA,NA,9/8/2021,3/2/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,9/8/2021,9/9/2021,Actual,23-Feb-21,Actual,2/23/2021,Sep-21,9/30/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,COVAXID,NA,COVID-19 Vaccination of Immunodeficient Persons (COVAXID),"Immunological Responses After Vaccination for COVID-19 With the Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter Study","Active, not recruiting",NA,Phase 4,540,Anticipated,Karolinska University Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Within one year after study end.,Published in EudraCT and national COVID-19 data portal (SciLifeLab Data Centre),https://eudract.ema.europa.eu/index.html,Yes,"Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result. Will share research results and data through national COVID-19 data portal, operated by SciLifeLab Data Centre, Sweden.",2021-12-02T05:42:16Z,2021-12-02T05:42:16Z
NCT04780698,NA,2/12/2021,NA,NA,6/17/2021,3/2/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/23/2021,Actual,12-Feb-21,Actual,2/12/2021,Jun-21,6/30/2021,Feb-22,Anticipated,2/28/2022,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,DCI COVID-19 Surveillance Project,DCI COVID-19 Surveillance Project,Recruiting,NA,Not Applicable,160,Anticipated,Temple University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:42:22Z,2021-12-02T05:42:22Z
NCT04780672,NA,2/25/2021,NA,NA,10/8/2021,3/2/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,10/8/2021,10/11/2021,Actual,9-Mar-21,Actual,3/9/2021,Feb-21,2/28/2021,30-Sep-22,Anticipated,9/30/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Clinical Study in the Treatment of Patients With COVID-19,Clinical Study to Analyze the Safety and Efficacy of MolixanÂ® as Part of Standard Therapy in the Treatment of Patients With the Severe Course of New Coronavirus Infection (COVID-19),Recruiting,NA,Phase 3,330,Anticipated,Pharma VAM,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,Immediately following publication. No end date,Anyone who wishes to access the data.,NA,Yes,"All of the individual participant data collected during the trial, after deidentification",2021-12-02T05:42:25Z,2021-12-02T05:42:25Z
NCT04780581,NA,2/15/2021,NA,NA,7/5/2021,3/2/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,7/5/2021,7/7/2021,Actual,1-Feb-21,Actual,2/1/2021,Jul-21,7/31/2021,31-Dec-21,Anticipated,12/31/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients,MP3-pulses-COVID-19. Methylprednisolone Pulses Versus Dexamethasone According RECOVERY Protocol in Patients With Pneumonia Due to SARS-COV-2 Coronavirus Infection,Recruiting,NA,Phase 4,290,Anticipated,FundaciÃ³n Instituto de Estudios de Ciencias de la Salud de Castilla y LeÃ³n,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:42:28Z,2021-12-02T05:42:28Z
NCT04780685,NA,3/1/2021,NA,NA,8/1/2021,3/2/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,8/1/2021,8/3/2021,Actual,20-Mar-21,Actual,3/20/2021,Mar-21,3/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19,"A Phase II, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Moderate to Severe ARDS Due to COVID-19",Recruiting,NA,Phase 2,40,Anticipated,"Stemedica Cell Technologies, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:42:23Z,2021-12-02T05:42:23Z
NCT04780425,NA,2/28/2021,NA,NA,3/10/2021,2/28/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,3/10/2021,3/11/2021,Actual,26-Jan-21,Actual,1/26/2021,Mar-21,3/31/2021,31-May-21,Anticipated,5/31/2021,22-May-21,Anticipated,5/22/2021,NA,Interventional,SMSCOVID,NA,"Structured Diabetes Self-Management Education and Care Outcomes in Adults liVIng With Type 2 Diabetes in Accra, Ghana","A Randomised Parallel-group Multi-centre Study to Evaluate the Effect of Structured Diabetes Self-management Education Versus Standard of Care on Glycaemic Control, Self-efficacy and Quality of Life in Adults in Two Low Resource Settings in Accra Subsequent to COVID-19","Active, not recruiting",NA,Not Applicable,206,Actual,"Korle-Bu Teaching Hospital, Accra, Ghana",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:42:41Z,2021-12-02T05:42:41Z
NCT04780035,NA,2/25/2021,NA,NA,3/2/2021,3/2/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,3/2/2021,3/3/2021,Actual,18-Nov-20,Actual,11/18/2020,Feb-21,2/28/2021,Sep-21,Anticipated,9/30/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,"Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19","Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)","Active, not recruiting",NA,Phase 3,3000,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:42:48Z,2021-12-02T05:42:48Z
NCT04780152,NA,3/2/2021,NA,NA,6/2/2021,3/2/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,6/2/2021,6/4/2021,Actual,Oct-21,Anticipated,10/31/2021,Jun-21,6/30/2021,Sep-22,Anticipated,9/30/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic,Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics,Recruiting,NA,Phase 2/Phase 3,172,Anticipated,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Personal data information will remain with strictly confidential character in the research center. However, personal data will be examined by all individuals related to the research project and/or those selected for its analysis, including representatives of Mexican health authorities and other regulatory agencies with inspection purposes.

If the data obtained through this study is published, the report will be written in a way no person could identify their personal data or identity, unless such information is officially required by any mexican or foreign authority.",2021-12-02T05:42:58Z,2021-12-02T05:42:58Z
NCT04779827,NA,2/21/2021,NA,NA,5/6/2021,3/1/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/7/2021,Actual,4-May-21,Actual,5/4/2021,May-21,5/31/2021,30-Dec-22,Anticipated,12/30/2022,30-Oct-22,Anticipated,10/30/2022,NA,Interventional,NA,NA,Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks,Improving Health Equity for COVID-19 Vaccination and Related Health Behaviors for At-risk Populations Using Online Social Networks,Recruiting,NA,Not Applicable,1920,Anticipated,University of Pennsylvania,,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available when the primary intervention paper is published.,"Data will be shared as a part of the published paper, in forms of supplementary materials. The public can access the data through the publisher's website.",NA,Yes,We will share the data collected from our online experiments. All sets of data are anonymous.,2021-12-02T05:43:01Z,2021-12-02T05:43:01Z
NCT04780061,NA,3/1/2021,NA,NA,7/15/2021,3/1/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,7/15/2021,7/21/2021,Actual,12-Jul-21,Actual,7/12/2021,Jul-21,7/31/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Dietary Supplements for COVID-19,"Dietary Supplements to Reduce Symptom Severity and Duration in People With SARS-CoV-2: A Randomized, Double Blind, Placebo Controlled Clinical Trial",Recruiting,NA,Phase 3,200,Anticipated,The Canadian College of Naturopathic Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:43:09Z,2021-12-02T05:43:09Z
NCT04779047,NA,2/25/2021,NA,NA,3/15/2021,3/1/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,1-Oct-20,Actual,10/1/2020,Mar-21,3/31/2021,5-Apr-21,Anticipated,4/5/2021,10-Mar-21,Anticipated,3/10/2021,NA,Interventional,NA,NA,Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.,Comparative Therapeutic Efficacy and Safety of Remdesivir Plus Lopinavir/ Ritonavir and Tocilizumab Versus Hydroxychloroquine Plus Ivermectin and Tocilizumab in COVID-19 Patients.,Recruiting,NA,Phase 4,150,Anticipated,October 6 University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:43:58Z,2021-12-02T05:43:58Z
NCT04779879,NA,3/1/2021,NA,NA,10/6/2021,3/1/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,10/6/2021,10/8/2021,Actual,18-Feb-21,Actual,2/18/2021,Oct-21,10/31/2021,Jun-22,Anticipated,6/30/2022,29-Oct-21,Anticipated,10/29/2021,NA,Interventional,COMET-PEAK,NA,"Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19","A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants With Mild to Moderate Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,352,Actual,"Vir Biotechnology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:43:11Z,2021-12-02T05:43:11Z
NCT04779450,NA,3/1/2021,NA,NA,5/10/2021,3/1/2021,3/3/2021,Actual,NA,NA,NA,NA,NA,NA,5/10/2021,5/13/2021,Actual,1-Aug-21,Anticipated,8/1/2021,May-21,5/31/2021,Dec-21,Anticipated,12/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,"Effect of Telemonitoring on Functionality, Quality of Life and Risk of Lymphedema in Breast Cancer Survivors","The Effect of Telemonitoring on Upper Limb Function, Quality of Life and Risk of Lymphedema During and After Pandemic COVID-19 in Women Submitted to Treatment for Breast Cancer: A Randomized Controlled Trial",Recruiting,NA,Not Applicable,30,Anticipated,University of the State of Santa Catarina,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:43:29Z,2021-12-02T05:43:29Z
NCT04778059,NA,2/26/2021,NA,NA,8/2/2021,2/26/2021,3/2/2021,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/4/2021,Actual,27-Jul-21,Actual,7/27/2021,Aug-21,8/31/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19,"Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients With Respiratory Distress Due to COVID-19 Infection",Recruiting,NA,Phase 2,184,Anticipated,"US Biotest, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:44:26Z,2021-12-02T05:44:26Z
NCT04776941,NA,2/9/2021,NA,NA,2/25/2021,2/25/2021,3/2/2021,Actual,NA,NA,NA,NA,NA,NA,2/25/2021,3/2/2021,Actual,7-Aug-20,Actual,8/7/2020,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Expressive Writing for the Management of Stress in Cancer Survivors,COVID-19: A Virtual Feasibility Study to Manage Stress,Recruiting,NA,Not Applicable,120,Anticipated,M.D. Anderson Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:45:04Z,2021-12-02T05:45:04Z
NCT04775069,NA,2/24/2021,NA,NA,5/21/2021,2/26/2021,3/1/2021,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/25/2021,Actual,21-May-21,Actual,5/21/2021,May-21,5/31/2021,31-Mar-22,Anticipated,3/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Antibody Response to COVID-19 Vaccines in Liver Disease Patients,"A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 Vaccines",Recruiting,NA,Phase 4,900,Anticipated,Humanity & Health Medical Group Limited,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:46:45Z,2021-12-02T05:46:45Z
NCT04773665,NA,2/24/2021,NA,NA,10/1/2021,2/25/2021,2/26/2021,Actual,NA,NA,NA,NA,NA,NA,10/1/2021,10/8/2021,Actual,15-Mar-21,Actual,3/15/2021,Oct-21,10/31/2021,Nov-22,Anticipated,11/30/2022,Nov-22,Anticipated,11/30/2022,NA,Interventional,NA,NA,"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a","A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults",Recruiting,NA,Phase 1,141,Anticipated,VBI Vaccines Inc.,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:47:49Z,2021-12-02T05:47:49Z
NCT04772859,NA,2/13/2021,NA,NA,9/23/2021,2/24/2021,2/26/2021,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/27/2021,Actual,1-Feb-21,Actual,2/1/2021,Sep-21,9/30/2021,16-Jul-21,Actual,7/16/2021,16-Jul-21,Actual,7/16/2021,NA,Interventional,NA,NA,Evaluation of an Online Lifestyle Intervention in Mexican School Children During COVID-19 Pandemic,Evaluation of a 4-month Online Lifestyle Intervention on the BMI Z-score of Mexican School Children During COVID-19 Pandemic: Randomized Controlled Pilot Trial,Completed,NA,Not Applicable,54,Actual,Universidad de Sonora,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:48:29Z,2021-12-02T05:48:29Z
NCT04771585,NA,1/26/2021,NA,NA,8/25/2021,2/24/2021,2/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/25/2021,8/26/2021,Actual,29-Mar-21,Actual,3/29/2021,Aug-21,8/31/2021,20-Aug-21,Actual,8/20/2021,20-Aug-21,Actual,8/20/2021,NA,Interventional,QUELLE,NA,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of COVID-19,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of SARS-Co-V-2,Completed,NA,Not Applicable,30,Actual,Fraunhofer-Institute of Toxicology and Experimental Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:49:18Z,2021-12-02T05:49:18Z
NCT04771559,NA,2/17/2021,NA,NA,8/1/2021,2/24/2021,2/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/1/2021,8/3/2021,Actual,1-Mar-21,Actual,3/1/2021,Aug-21,8/31/2021,1-Jul-21,Actual,7/1/2021,1-Jun-21,Actual,6/1/2021,NA,Interventional,NA,NA,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Completed,NA,Not Applicable,1500,Actual,Bezmialem Vakif University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:49:19Z,2021-12-02T05:49:19Z
NCT04771611,NA,2/24/2021,NA,NA,7/23/2021,2/24/2021,2/25/2021,Actual,NA,NA,NA,NA,NA,NA,7/23/2021,7/27/2021,Actual,14-Jul-21,Actual,7/14/2021,Jul-21,7/31/2021,Jun-23,Anticipated,6/30/2023,Dec-22,Anticipated,12/31/2022,NA,Interventional,COVFIS-HOME,NA,COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications,COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients,Enrolling by invitation,NA,Phase 2,150,Anticipated,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:49:23Z,2021-12-02T05:49:23Z
NCT04771351,NA,2/23/2021,NA,NA,4/9/2021,2/23/2021,2/25/2021,Actual,NA,NA,NA,NA,NA,NA,4/9/2021,4/12/2021,Actual,Apr-21,Anticipated,4/30/2021,Apr-21,4/30/2021,Oct-21,Anticipated,10/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Hospitalized Adults With COVID-19,"A Randomized, Blinded-controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMGâ„¢) in Hospitalized Adult Patients With COVID-19",Recruiting,NA,Phase 2,280,Anticipated,"Sorrento Therapeutics, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:49:30Z,2021-12-02T05:49:30Z
NCT04771000,NA,2/24/2021,NA,NA,8/4/2021,2/24/2021,2/25/2021,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/5/2021,Actual,8-Feb-21,Actual,2/8/2021,Aug-21,8/31/2021,31-Oct-22,Anticipated,10/31/2022,31-Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19,"A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19",Recruiting,NA,Phase 2,150,Anticipated,Noorik Biopharmaceuticals AG,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Not yet discussed or decided,2021-12-02T05:49:49Z,2021-12-02T05:49:49Z
NCT04771013,NA,2/24/2021,NA,NA,5/14/2021,2/24/2021,2/25/2021,Actual,NA,NA,NA,NA,NA,NA,5/14/2021,5/18/2021,Actual,10-Feb-21,Actual,2/10/2021,May-21,5/31/2021,14-May-21,Actual,5/14/2021,14-May-21,Actual,5/14/2021,NA,Interventional,NA,NA,Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras,"A Single-arm, Open-Label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras",Completed,NA,Phase 2,22,Actual,Universidad CatÃ³lica de Honduras,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 5 years following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose.

For individual participant data meta-analysis.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-12-02T05:49:45Z,2021-12-02T05:49:45Z
NCT04770740,NA,2/24/2021,NA,NA,2/28/2021,2/24/2021,2/25/2021,Actual,NA,NA,NA,NA,NA,NA,2/28/2021,3/3/2021,Actual,22-Feb-21,Actual,2/22/2021,Feb-21,2/28/2021,1-Oct-21,Anticipated,10/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,KOVIT,NA,Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19,"A Phase 2, Double Blind, Randomized, Placebo-controlled Clinical Trial to Investigate the Safety and Effects of Oral Vitamin K2 Supplementation in COVID-19",Recruiting,NA,Phase 2,40,Anticipated,Canisius-Wilhelmina Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Not sure yet.,2021-12-02T05:49:55Z,2021-12-02T05:49:55Z
NCT04769297,NA,2/22/2021,NA,NA,2/23/2021,2/23/2021,2/24/2021,Actual,NA,NA,NA,NA,NA,NA,2/23/2021,2/24/2021,Actual,15-Apr-20,Actual,4/15/2020,Feb-21,2/28/2021,Apr-21,Anticipated,4/30/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,"Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic","Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic","Active, not recruiting",NA,Phase 4,30,Actual,Limbic Medical,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:50:51Z,2021-12-02T05:50:51Z
NCT04769999,NA,7/13/2020,NA,NA,2/22/2021,2/22/2021,2/25/2021,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/25/2021,Actual,4-Jun-20,Actual,6/4/2020,Dec-20,12/31/2020,30-Oct-20,Actual,10/30/2020,16-Oct-20,Actual,10/16/2020,NA,Interventional,CALM-ED,NA,Computer Assisted Lessening of Intrusive Memories in the Emergency Department,"Reducing Intrusive Memories of Work-Related Traumatic Events, Including Events During the COVID-19 Pandemic, in NHS Staff Using a Brief Cognitive Task Intervention",Completed,NA,Not Applicable,14,Actual,University of Oxford,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:50:43Z,2021-12-02T05:50:43Z
NCT04767477,NA,12/21/2020,NA,NA,10/4/2021,2/22/2021,2/23/2021,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/5/2021,Actual,28-Mar-21,Actual,3/28/2021,Oct-21,10/31/2021,10-Sep-21,Actual,9/10/2021,31-Aug-21,Actual,8/31/2021,NA,Interventional,NA,NA,Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors,Telerehabilitation and Face-to-face Rehabilitation on Tolerance to Exercise and Quality of Life of COVID-19 Survivors: a Study Protocol,Completed,NA,Not Applicable,26,Actual,Universidade Federal de Pernambuco,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:52:29Z,2021-12-02T05:52:29Z
NCT04767958,NA,2/19/2021,NA,NA,3/22/2021,2/22/2021,2/23/2021,Actual,NA,NA,NA,NA,NA,NA,3/22/2021,3/25/2021,Actual,19-Mar-21,Actual,3/19/2021,Mar-21,3/31/2021,31-Jul-22,Anticipated,7/31/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,RAPID COVID,NA,The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing,"The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing to Optimize Patient Care, Resource Allocation and Safety for Frontline Staff",Recruiting,NA,Not Applicable,2500,Anticipated,Ottawa Heart Institute Research Corporation,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:52:13Z,2021-12-02T05:52:13Z
NCT04766931,NA,2/4/2021,NA,NA,9/28/2021,2/19/2021,2/23/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,10/6/2021,Actual,26-Mar-21,Actual,3/26/2021,Sep-21,9/30/2021,Mar-22,Anticipated,3/31/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection,"A Two-part, Phase I/II, Multi-center, Double-Blind, Randomized, Vehicle-controlled Study of the Safety and Efficacy of FB2001 in Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19) Infection",Recruiting,NA,Phase 1,72,Anticipated,Frontier Biotechnologies Inc.,,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:52:49Z,2021-12-02T05:52:49Z
NCT04767087,NA,2/20/2021,NA,NA,7/1/2021,2/20/2021,2/23/2021,Actual,NA,NA,NA,NA,NA,NA,7/1/2021,7/2/2021,Actual,5-Mar-21,Actual,3/5/2021,Jul-21,7/31/2021,15-Apr-22,Anticipated,4/15/2022,15-Feb-22,Anticipated,2/15/2022,NA,Interventional,HNS-COVID-PK,NA,Honey and Nigella Sativa in COVID-19 Prophylaxis,Honey and Nigella Sativa in the Prophylaxis of COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 2/Phase 3,1000,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:52:50Z,2021-12-02T05:52:50Z
NCT04765475,NA,1/29/2021,NA,NA,3/23/2021,2/19/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,3/23/2021,3/24/2021,Actual,8-Mar-21,Actual,3/8/2021,Mar-21,3/31/2021,Sep-22,Anticipated,9/30/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Protecting Native Families From COVID-19,Protecting Native Families From COVID-19 (PROTECT),Recruiting,NA,Not Applicable,600,Anticipated,Johns Hopkins Bloomberg School of Public Health,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Investigators only plan to share de-identified participant data with approved researchers.,2021-12-02T05:53:51Z,2021-12-02T05:53:51Z
NCT04764981,NA,2/14/2021,NA,NA,2/18/2021,2/18/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,2/18/2021,2/21/2021,Actual,May-21,Anticipated,5/31/2021,Feb-21,2/28/2021,1-May-24,Anticipated,5/1/2024,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19),Clinical Outcomes of Olfactory Training for Treatment of Olfactory Dysfunction After COVID-19,Enrolling by invitation,NA,Not Applicable,350,Anticipated,Universidade do Estado do ParÃ¡,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T05:54:13Z,2021-12-02T05:54:13Z
NCT04765839,NA,2/2/2021,NA,NA,7/28/2021,2/19/2021,2/23/2021,Actual,NA,NA,NA,NA,NA,NA,7/28/2021,7/30/2021,Actual,12-Feb-21,Actual,2/12/2021,Jul-21,7/31/2021,3-Apr-21,Actual,4/3/2021,3-Apr-21,Actual,4/3/2021,NA,Interventional,CERC,NA,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With Minority Populations,Completed,NA,Not Applicable,74,Actual,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:53:35Z,2021-12-02T05:53:35Z
NCT04765436,NA,2/16/2021,NA,NA,6/28/2021,2/19/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,6/28/2021,6/30/2021,Actual,14-Jan-21,Actual,1/14/2021,Jun-21,6/30/2021,12-Feb-22,Anticipated,2/12/2022,12-Feb-22,Anticipated,2/12/2022,NA,Interventional,NA,NA,"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","A Phase I, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","Active, not recruiting",NA,Phase 1,60,Anticipated,Providence Therapeutics Holdings Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:54:00Z,2021-12-02T05:54:00Z
NCT04762628,NA,2/11/2021,NA,NA,8/6/2021,2/18/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/9/2021,Actual,27-Oct-20,Actual,10/27/2020,Aug-21,8/31/2021,6-Aug-21,Actual,8/6/2021,5-Jul-21,Actual,7/5/2021,NA,Interventional,SaiseiCovUKR,NA,"Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients","Randomized Trial to Assess the Efficacy and Safety of Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Addition to the Standard of Care (SOC) Compared SOC in the Treatment of Hospitalized With COVID-19 Patients Who Not Requiring the Mechanical Ventilation",Completed,NA,Not Applicable,600,Actual,Saisei Pharma,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be indefinitely available for requesting,Reasonable request to investigators,NA,Yes,The data will be shared via ISARIC COVID-19 Clinical Database.,2021-12-02T05:56:08Z,2021-12-02T05:56:08Z
NCT04762173,NA,2/15/2021,NA,NA,7/9/2021,2/18/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,7/9/2021,7/12/2021,Actual,6-Nov-20,Actual,11/6/2020,Jul-21,7/31/2021,31-May-21,Actual,5/31/2021,31-May-21,Actual,5/31/2021,NA,Interventional,NA,NA,Self-Help for Stress Related to COVID-19,Self-Help for Stress Related to COVID-19,Completed,NA,Not Applicable,585,Actual,Penn State University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:56:26Z,2021-12-02T05:56:26Z
NCT04763681,NA,2/13/2021,NA,NA,6/2/2021,2/17/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,6/2/2021,6/8/2021,Actual,1-Jan-21,Actual,1/1/2021,Jun-21,6/30/2021,31-Aug-21,Anticipated,8/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,HOPES,NA,Couple HOPES (Helping Overcome PTSD and Enhance Satisfaction),"Expanding a Randomized Controlled Trial of a Couple Internet-Delivered PTSD Intervention to Reach Military Members, Veterans, and First Responders With COVID-19-Related Trauma Exposure",Recruiting,NA,Not Applicable,140,Anticipated,York University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:55:12Z,2021-12-02T05:55:12Z
NCT04761822,NA,2/17/2021,NA,NA,8/31/2021,2/17/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/1/2021,Actual,7-Apr-21,Actual,4/7/2021,Aug-21,8/31/2021,Nov-21,Anticipated,11/30/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,SARS,NA,COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations,Systemic Allergic Reactions to SARS-CoV-2 Vaccination,Recruiting,NA,Phase 2,3400,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"After completion of the trial, within 24 months status post database lock.","Registration is available for the Immunology Database and Analysis Portal (ImmPort) at: https://www.immport.org/registration. Submit a rationale for the purpose of requesting study data access.

ImmPort is a long-term archive of clinical and mechanistic data, a National Institute of Allergy and Infectious Diseases Division of Allergy, Immunology and Transplantation (NIAID DAIT)-funded data repository. This archive is in support of the NIH mission to share data with the public. Data shared through ImmPort is provided by NIH-funded programs, other research organizations and individual scientists, ensuring these discoveries will be the foundation of future research.",https://www.immport.org/home,Yes,Participant level data access and additional relevant materials will be made available upon completion of the trial.,2021-12-02T05:56:34Z,2021-12-02T05:56:34Z
NCT04760743,NA,2/17/2021,NA,NA,2/17/2021,2/17/2021,2/18/2021,Actual,NA,NA,NA,NA,NA,NA,2/17/2021,2/18/2021,Actual,17-Dec-20,Actual,12/17/2020,Feb-21,2/28/2021,Apr-22,Anticipated,4/30/2022,Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19),"A Phase I, Placebo-controlled, Randomized, Observer-blinded, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults Aged at 19 to 55 Years","Active, not recruiting",NA,Phase 1,50,Actual,"SK Chemicals Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:57:36Z,2021-12-02T05:57:36Z
NCT04761874,NA,2/15/2021,NA,NA,4/19/2021,2/17/2021,2/21/2021,Actual,NA,NA,NA,NA,NA,NA,4/19/2021,4/22/2021,Actual,1-Dec-19,Actual,12/1/2019,Apr-21,4/30/2021,29-Sep-20,Actual,9/29/2020,29-Jun-20,Actual,6/29/2020,NA,Interventional,TELECAST-CSC,NA,Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic,TELEstroke to CAre for STroke Patients at a Comprehensive Stroke Center During the COVID-19 Pandemic,Completed,NA,Not Applicable,296,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T05:56:39Z,2021-12-02T05:56:39Z
NCT04760821,NA,2/17/2021,NA,NA,2/18/2021,2/17/2021,2/18/2021,Actual,NA,NA,NA,NA,NA,NA,2/18/2021,2/21/2021,Actual,10-Dec-20,Actual,12/10/2020,Feb-21,2/28/2021,30-Apr-21,Anticipated,4/30/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,PREMIER,NA,Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19,Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for Moderate to Severe Acute Respiratory Syndrome Caused by SARS-CoV-2,Recruiting,NA,Phase 2,80,Anticipated,"Ministry of Health, Brazil",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:57:32Z,2021-12-02T05:57:32Z
NCT04760418,NA,2/10/2021,NA,NA,7/9/2021,2/15/2021,2/18/2021,Actual,NA,NA,NA,NA,NA,NA,7/9/2021,7/15/2021,Actual,26-May-21,Actual,5/26/2021,Jul-21,7/31/2021,1-Aug-22,Anticipated,8/1/2022,1-Aug-22,Anticipated,8/1/2022,NA,Interventional,NA,NA,Trauma and Trauma-Focused Therapy in the University of Kentucky SMART Clinic,"Evaluating the Impact of Trauma, Trauma-Focused Therapy Services, and COVID-19 Among Patients in the University of Kentucky SMART Clinic",Recruiting,NA,Not Applicable,6,Anticipated,University of Kentucky,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be shared upon request from investigators beginning immediately after publication,Researchers who provide a methodologically sound proposal.,NA,Yes,All IPD that underlie results in a publication and are de-identified will be shared with investigators upon request.,2021-12-02T05:58:06Z,2021-12-02T05:58:06Z
NCT04756141,NA,2/12/2021,NA,NA,3/24/2021,2/13/2021,2/16/2021,Actual,NA,NA,NA,NA,NA,NA,3/24/2021,3/25/2021,Actual,3-Mar-21,Actual,3/3/2021,Mar-21,3/31/2021,28-Jan-22,Anticipated,1/28/2022,28-Jan-22,Anticipated,1/28/2022,NA,Interventional,NA,NA,CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)),Continuous Glucose Monitor (CGM) Use in COVID-19 Patients,Recruiting,NA,Not Applicable,20,Anticipated,Mayo Clinic,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:01:43Z,2021-12-02T06:01:43Z
NCT04760132,NA,2/8/2021,NA,NA,2/23/2021,2/17/2021,2/18/2021,Actual,NA,NA,NA,NA,NA,NA,2/23/2021,2/26/2021,Actual,8-Feb-21,Actual,2/8/2021,Feb-21,2/28/2021,31-Dec-24,Anticipated,12/31/2024,31-Dec-24,Anticipated,12/31/2024,NA,Interventional,ENFORCE,NA,National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE),National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines,Recruiting,NA,Phase 4,10000,Anticipated,"Rigshospitalet, Denmark",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T05:58:28Z,2021-12-02T05:58:28Z
NCT04758286,NA,2/11/2021,NA,NA,2/16/2021,2/16/2021,2/17/2021,Actual,NA,NA,NA,NA,NA,NA,2/16/2021,2/17/2021,Actual,1-Jul-20,Actual,7/1/2020,Feb-21,2/28/2021,11-Feb-21,Actual,2/11/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,NA,NA,Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19,Protocol for Anesthesia for Emergency Surgery,Completed,NA,Not Applicable,209,Actual,Benha University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,after publishing,email,NA,Yes,The study protocol may be shared,2021-12-02T05:59:59Z,2021-12-02T05:59:59Z
NCT04756466,NA,1/21/2021,NA,NA,3/3/2021,2/15/2021,2/16/2021,Actual,NA,NA,NA,NA,NA,NA,3/3/2021,3/5/2021,Actual,1-Jan-21,Actual,1/1/2021,Mar-21,3/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly,"Multicenter, Randomized, Double-blind Parallel Group Pilot Study to Evaluate the Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly","Active, not recruiting",NA,Not Applicable,201,Actual,Biosearch S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:01:16Z,2021-12-02T06:01:16Z
NCT04756128,NA,1/28/2021,NA,NA,9/15/2021,2/13/2021,2/16/2021,Actual,NA,NA,NA,NA,NA,NA,9/15/2021,9/21/2021,Actual,25-Jan-21,Actual,1/25/2021,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,COLTREXONE,NA,Impact of Colchicine and Low-dose Naltrexone on COVID-19,Impact of Colchicine and Low-dose Naltrexone on COVID-19 Disease Progression and Clinical Course in Hospitalized Patients,Enrolling by invitation,NA,Phase 2,164,Anticipated,HealthPartners Institute,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,There is no plan to share IPD with investigators not currently involved in the study.,2021-12-02T06:01:38Z,2021-12-02T06:01:38Z
NCT04758273,NA,2/9/2021,NA,NA,2/16/2021,2/16/2021,2/17/2021,Actual,NA,NA,NA,NA,NA,NA,2/16/2021,2/17/2021,Actual,7-Oct-20,Actual,10/7/2020,Feb-21,2/28/2021,28-Feb-22,Anticipated,2/28/2022,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial","Active, not recruiting",NA,Phase 1,180,Actual,"Beijing Minhai Biotechnology Co., Ltd",,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:00:01Z,2021-12-02T06:00:01Z
NCT04758299,NA,2/12/2021,NA,NA,5/21/2021,2/16/2021,2/17/2021,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/25/2021,Actual,13-Mar-21,Actual,3/13/2021,May-21,5/31/2021,30-Apr-21,Actual,4/30/2021,15-Apr-21,Actual,4/15/2021,NA,Interventional,NA,NA,Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits,At Home Self-testing Kits for SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) : A Randomized Trial Assessing How Consumers Interpret and Act on Test Results,Completed,NA,Not Applicable,360,Actual,Carnegie Mellon University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:00:04Z,2021-12-02T06:00:04Z
NCT04757818,NA,2/16/2021,NA,NA,7/13/2021,2/16/2021,2/17/2021,Actual,NA,NA,NA,NA,NA,NA,7/13/2021,7/19/2021,Actual,17-Feb-21,Actual,2/17/2021,Jul-21,7/31/2021,3-Jun-21,Actual,6/3/2021,25-May-21,Actual,5/25/2021,NA,Interventional,CPC COVID,NA,"Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 (COVID-19) in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.","Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%",Completed,NA,Not Applicable,118,Actual,Dentaid SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:00:06Z,2021-12-02T06:00:06Z
NCT04757857,NA,2/8/2021,NA,NA,8/24/2021,2/16/2021,2/17/2021,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/25/2021,Actual,29-Sep-20,Actual,9/29/2020,Aug-21,8/31/2021,30-Oct-21,Anticipated,10/30/2021,28-Sep-21,Anticipated,9/28/2021,NA,Interventional,CARE,NA,COVID-19 Antithrombotic Rivaroxaban Evaluation,"Randomized, Pragmatic, Open Controlled Multicentre Study, Evaluating the Use of Rivaroxaban in Mild or Moderate COVID-19 Patients",Recruiting,NA,Phase 4,1000,Anticipated,Hospital AlemÃ£o Oswaldo Cruz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:00:08Z,2021-12-02T06:00:08Z
NCT04757298,NA,2/15/2021,NA,NA,2/16/2021,2/15/2021,2/17/2021,Actual,NA,NA,NA,NA,NA,NA,2/16/2021,2/18/2021,Actual,12-Feb-21,Actual,2/12/2021,Jan-21,1/31/2021,31-Dec-22,Anticipated,12/31/2022,30-Jan-22,Anticipated,1/30/2022,NA,Interventional,NA,NA,COVID-19 Treatment Cascade Optimization Study,Optimization of a New Adaptive Intervention to Increase COVID-19 Testing Among People at High Risk in an Urban Community,Recruiting,NA,Not Applicable,670,Anticipated,University of Illinois at Urbana-Champaign,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Upon request after the study is complete,Must sign a data sharing agreement,NA,Yes,De-identified data can be shared upon request for research purposes and under a data sharing agreement.,2021-12-02T06:00:58Z,2021-12-02T06:00:58Z
NCT04756856,NA,2/15/2021,NA,NA,4/21/2021,2/15/2021,2/16/2021,Actual,NA,NA,NA,NA,NA,NA,4/21/2021,4/23/2021,Actual,21-Apr-21,Actual,4/21/2021,Apr-21,4/30/2021,1-Dec-21,Anticipated,12/1/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,RE-COVID,NA,Muscle-targeted Nutritional Therapy for the Recovery From COVID-19,Impact of a Muscle-targeted Nutritional Therapy in the Recovery of Post-discharge COVID19 Patients Suffering From Sarcopenia,Recruiting,NA,Not Applicable,50,Anticipated,IRCCS Policlinico S. Matteo,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:01:07Z,2021-12-02T06:01:07Z
NCT04756830,NA,2/15/2021,NA,NA,7/6/2021,2/15/2021,2/16/2021,Actual,NA,NA,NA,NA,NA,NA,7/6/2021,7/9/2021,Actual,19-Feb-21,Actual,2/19/2021,Jul-21,7/31/2021,Jun-23,Anticipated,6/30/2023,Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19,An Open-label Uncontrolled Study to Assess the Safety and Immunogenicity of the Inactivated Adsorbed Vaccine Against COVID-19 (Coronavac) in Individuals Over 18 Years of Age During 24 Months of Follow-up,"Active, not recruiting",NA,Phase 4,1200,Actual,D'Or Institute for Research and Education,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:01:18Z,2021-12-02T06:01:18Z
NCT04756323,NA,2/9/2021,NA,NA,2/16/2021,2/14/2021,2/16/2021,Actual,NA,NA,NA,NA,NA,NA,2/16/2021,2/17/2021,Actual,27-Oct-20,Actual,10/27/2020,Feb-21,2/28/2021,28-Feb-22,Anticipated,2/28/2022,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial","Active, not recruiting",NA,Phase 2,1000,Actual,"Beijing Minhai Biotechnology Co., Ltd",,12,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:01:24Z,2021-12-02T06:01:24Z
NCT04530409,NA,8/24/2020,NA,NA,7/16/2021,8/27/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,7/16/2021,7/19/2021,Actual,10-Feb-21,Actual,2/10/2021,Jul-21,7/31/2021,15-Aug-21,Anticipated,8/15/2021,1-Aug-21,Anticipated,8/1/2021,NA,Interventional,NA,NA,Timing of Corticosteroids in COVID-19,Timing of Corticosteroids in COVID-19,Recruiting,NA,Phase 4,450,Anticipated,ClinAmygate,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:12:55Z,2021-12-02T09:12:55Z
NCT04755972,NA,2/6/2021,NA,NA,2/13/2021,2/13/2021,2/16/2021,Actual,NA,NA,NA,NA,NA,NA,2/13/2021,2/16/2021,Actual,29-Jan-21,Actual,1/29/2021,Feb-21,2/28/2021,29-Aug-21,Anticipated,8/29/2021,29-Jul-21,Anticipated,7/29/2021,NA,Interventional,NA,NA,Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2,Mucolytic Agents and Ventilator-associated Pneumonia in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2,Recruiting,NA,Not Applicable,40,Anticipated,"Clinical Hospital Center, Split",,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:02:08Z,2021-12-02T06:02:08Z
NCT04754113,NA,2/6/2021,NA,NA,8/15/2021,2/12/2021,2/15/2021,Actual,NA,NA,NA,NA,NA,NA,8/15/2021,8/20/2021,Actual,8-Feb-21,Actual,2/8/2021,Aug-21,8/31/2021,27-Sep-21,Anticipated,9/27/2021,20-Sep-21,Anticipated,9/20/2021,NA,Interventional,NA,NA,Effect of Prone Position onV/Q Matching in Non-intubated Patients With COVID-19,Effect of Prone Position on Lung Ventilation and Perfusion Matching in Non-intubated Patients With COVID-19 Pneumonia,Recruiting,NA,Not Applicable,15,Anticipated,"Southeast University, China",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:03:12Z,2021-12-02T06:03:12Z
NCT04753645,NA,2/11/2021,NA,NA,5/9/2021,2/11/2021,2/15/2021,Actual,NA,NA,NA,NA,NA,NA,5/9/2021,5/12/2021,Actual,19-Sep-20,Actual,9/19/2020,May-21,5/31/2021,May-21,Anticipated,5/31/2021,May-21,Anticipated,5/31/2021,NA,Interventional,(BIGD-HBCC),NA,BRAC Institute of Governance and Development-Hygiene Behavioural Change and Coalition,The Effect of Public Handwashing Stations on Health Behaviour and Outcomes During COVID-19,"Active, not recruiting",NA,Not Applicable,3840,Actual,BRAC University,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:03:30Z,2021-12-02T06:03:30Z
NCT04753476,NA,2/11/2021,NA,NA,5/19/2021,2/12/2021,2/15/2021,Actual,NA,NA,NA,NA,NA,NA,5/19/2021,5/24/2021,Actual,8-Jun-20,Actual,6/8/2020,May-21,5/31/2021,1-Mar-22,Anticipated,3/1/2022,1-Feb-22,Anticipated,2/1/2022,NA,Interventional,NA,NA,Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia,The Effect of Secretome of Hypoxia-Mesenchymal Stem Cells in Improving Survival of Severe Covid-19 Patients,Recruiting,NA,Phase 2,48,Anticipated,Stem Cell and Cancer Research Indonesia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:03:35Z,2021-12-02T06:03:35Z
NCT04753619,NA,2/10/2021,NA,NA,6/19/2021,2/11/2021,2/15/2021,Actual,NA,NA,NA,NA,NA,NA,6/19/2021,6/22/2021,Actual,3-Jan-21,Actual,1/3/2021,Jun-21,6/30/2021,3-Dec-21,Anticipated,12/3/2021,3-Dec-21,Anticipated,12/3/2021,NA,Interventional,NA,NA,Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management,Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management (Randomized Controlled Clinical Trial),Recruiting,NA,Phase 2,150,Anticipated,University of Baghdad,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months after publication,Will be given by the principle investgator,NA,Yes,"All collected IPD, all IPD that underlie results in a publication",2021-12-02T06:03:47Z,2021-12-02T06:03:47Z
NCT04751617,NA,2/5/2021,NA,NA,2/11/2021,2/11/2021,2/12/2021,Actual,NA,NA,NA,NA,NA,NA,2/11/2021,2/12/2021,Actual,1-Jan-21,Actual,1/1/2021,Feb-21,2/28/2021,31-Mar-21,Anticipated,3/31/2021,31-Jan-21,Actual,1/31/2021,NA,Interventional,NA,NA,Pulmonary Rehabilitation of Patients With a History of COVID-19,"Impact of Pulmonary Rehabilitation on Quality of Life, Body Composition and Respiratory Function of Patients With a History of COVID-19",Enrolling by invitation,NA,Not Applicable,60,Actual,University of Rzeszow,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:05:28Z,2021-12-02T06:05:28Z
NCT04751474,NA,2/8/2021,NA,NA,4/18/2021,2/8/2021,2/12/2021,Actual,NA,NA,NA,NA,NA,NA,4/18/2021,4/20/2021,Actual,1-Feb-21,Actual,2/1/2021,Apr-21,4/30/2021,31-Mar-21,Actual,3/31/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,NA,NA,"The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction","The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction of Intensive Care Nurses During the COVID-19 Pandemic : A Randomized Controlled Study",Completed,NA,Not Applicable,93,Actual,Saglik Bilimleri Universitesi,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:05:32Z,2021-12-02T06:05:32Z
NCT04751630,NA,2/9/2021,NA,NA,9/28/2021,2/11/2021,2/12/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,10/6/2021,Actual,1-Jun-21,Actual,6/1/2021,Sep-21,9/30/2021,1-Feb-22,Anticipated,2/1/2022,1-Oct-21,Anticipated,10/1/2021,NA,Interventional,NA,NA,Effects of COVID-19 Hospitalization on Physical Performance,Effects of a Structured Online Therapeutic Exercise Program on Physical Performance in COVID-19 Patients at Discharge Time.,Recruiting,NA,Not Applicable,60,Anticipated,Universitat Internacional de Catalunya,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:05:39Z,2021-12-02T06:05:39Z
NCT04751604,NA,2/3/2021,NA,NA,8/13/2021,2/9/2021,2/12/2021,Actual,NA,NA,NA,NA,NA,NA,8/13/2021,8/19/2021,Actual,1-Feb-21,Actual,2/1/2021,Aug-21,8/31/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,COVit-2,NA,Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19,Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19,Recruiting,NA,Not Applicable,840,Anticipated,University Hospital Schleswig-Holstein,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:05:58Z,2021-12-02T06:05:58Z
NCT04751682,NA,2/8/2021,NA,NA,6/17/2021,2/11/2021,2/12/2021,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/22/2021,Actual,1-Mar-21,Actual,3/1/2021,Jun-21,6/30/2021,30-Nov-21,Anticipated,11/30/2021,25-Jun-21,Anticipated,6/25/2021,NA,Interventional,NA,NA,Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19,"A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine (BBV154) in Healthy Volunteers","Active, not recruiting",NA,Phase 1,175,Anticipated,Bharat Biotech International Limited,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:05:41Z,2021-12-02T06:05:41Z
NCT04751643,NA,2/5/2021,NA,NA,4/20/2021,2/10/2021,2/12/2021,Actual,NA,NA,NA,NA,NA,NA,4/20/2021,4/21/2021,Actual,19-Apr-21,Actual,4/19/2021,Apr-21,4/30/2021,Dec-22,Anticipated,12/31/2022,Dec-22,Anticipated,12/31/2022,NA,Interventional,CovidEP,NA,Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections,Assessment of Therapeutic Plasma Exchange to Improve Respiratory Function by Alleviating Cytokine Storm During Severe Covid-19 Infections Randomised Open-label Controlled Trial,Recruiting,NA,Not Applicable,132,Anticipated,Hospices Civils de Lyon,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:05:44Z,2021-12-02T06:05:44Z
NCT04750720,NA,2/9/2021,NA,NA,3/14/2021,2/9/2021,2/11/2021,Actual,NA,NA,NA,NA,NA,NA,3/14/2021,3/16/2021,Actual,27-Aug-20,Actual,8/27/2020,Mar-21,3/31/2021,Dec-23,Anticipated,12/31/2023,Dec-23,Anticipated,12/31/2023,NA,Interventional,ABCOVID,NA,Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection,Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection According to the Clinical Severity of the Infection.,Recruiting,NA,Not Applicable,300,Anticipated,Centre Hospitalier RÃ©gional d'OrlÃ©ans,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:06:31Z,2021-12-02T06:06:31Z
NCT04750265,NA,2/9/2021,NA,NA,3/17/2021,2/10/2021,2/11/2021,Actual,NA,NA,NA,NA,NA,NA,3/17/2021,3/18/2021,Actual,21-Jan-21,Actual,1/21/2021,Mar-21,3/31/2021,Dec-21,Anticipated,12/31/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19,"Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19: an Interventional Randomized, Controlled Feasibility Study (ROBEM II Study)",Recruiting,NA,Not Applicable,20,Anticipated,"Charite University, Berlin, Germany",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After publishing results.,Data will be shared to other researchers on reasonable request.,NA,Yes,Depersonalized data can be requested from the PI after publication of the study for scientific purpose.,2021-12-02T06:06:50Z,2021-12-02T06:06:50Z
NCT04750278,NA,2/2/2021,NA,NA,8/20/2021,2/10/2021,2/11/2021,Actual,NA,NA,NA,NA,NA,NA,8/20/2021,8/23/2021,Actual,6-Apr-21,Actual,4/6/2021,Aug-21,8/31/2021,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,"A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)","A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)",Recruiting,NA,Phase 2/Phase 3,403,Anticipated,"Foresee Pharmaceuticals Co., Ltd.",,3,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:06:50Z,2021-12-02T06:06:50Z
NCT04750317,NA,2/10/2021,NA,NA,2/11/2021,2/10/2021,2/11/2021,Actual,NA,NA,NA,NA,NA,NA,2/11/2021,2/15/2021,Actual,11-May-20,Actual,5/11/2020,Feb-21,2/28/2021,1-Sep-20,Actual,9/1/2020,1-Aug-20,Actual,8/1/2020,NA,Interventional,TOFA-COV-2,NA,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Completed,NA,Phase 2,414,Actual,I.M. Sechenov First Moscow State Medical University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:06:43Z,2021-12-02T06:06:43Z
NCT04749121,NA,2/4/2021,NA,NA,2/9/2021,2/9/2021,2/11/2021,Actual,NA,NA,NA,NA,NA,NA,2/9/2021,2/11/2021,Actual,1-Apr-20,Actual,4/1/2020,Feb-21,2/28/2021,5-Feb-21,Actual,2/5/2021,5-Feb-21,Actual,2/5/2021,NA,Interventional,NA,NA,Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators,"Impact of Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators (VJR-NMU) Respirator Performances, Structural Integrity and Sterility During COVID -19 Pandemic:",Completed,NA,Not Applicable,20,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Plan to share in protocol.io,2021-12-02T06:07:47Z,2021-12-02T06:07:47Z
NCT04748757,NA,2/2/2021,NA,NA,4/23/2021,2/9/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,4/23/2021,4/27/2021,Actual,20-Apr-21,Actual,4/20/2021,Apr-21,4/30/2021,Dec-22,Anticipated,12/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,AX-COVID,NA,Annexin A5 in Patients With Severe COVID-19 Disease,"Annexin A5 in Patients With Severe COVID-19 Disease: A Single Centre, Randomized, Double-blind, Placebo-controlled Pilot Trial",Recruiting,NA,Phase 2,60,Anticipated,Lawson Health Research Institute,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,To be evaluated on individual basis,NA,NA,Yes,Information and data sharing will be considered on individual basis at conclusion of the study.,2021-12-02T06:08:07Z,2021-12-02T06:08:07Z
NCT04748783,NA,2/9/2021,NA,NA,4/7/2021,2/9/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,4/7/2021,4/12/2021,Actual,26-Mar-21,Actual,3/26/2021,Apr-21,4/30/2021,7-Apr-21,Actual,4/7/2021,7-Apr-21,Actual,4/7/2021,NA,Interventional,COL,NA,Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19,Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus,Terminated,NA,Phase 2,2,Actual,"University of North Carolina, Chapel Hill",,5,NA,Funding withdrawn,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Following publication up to 1 year,"Investigator who proposes to use the data has approval from an IRB, IEC, or REB as applicable, and an executed data use/sharing agreement with UNC.",NA,Yes,"Deidentified individual data that supports the results will be shared beginning following publication up to 1 year provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-12-02T06:07:59Z,2021-12-02T06:07:59Z
NCT04748536,NA,2/1/2021,NA,NA,4/22/2021,2/8/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,4/22/2021,4/26/2021,Actual,29-Jan-21,Actual,1/29/2021,Feb-21,2/28/2021,5-Apr-21,Actual,4/5/2021,5-Apr-21,Actual,4/5/2021,NA,Interventional,NA,NA,Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers,"A Randomised, Double-blind, Placebo-controlled, Parallel Group Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of IRL201104 to Support a Future COVID-19 Patient Study",Completed,NA,Phase 1,18,Actual,Revolo Biotherapeutics,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:08:32Z,2021-12-02T06:08:32Z
NCT04748120,NA,2/5/2021,NA,NA,8/3/2021,2/8/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/9/2021,Actual,28-Dec-20,Actual,12/28/2020,Aug-21,8/31/2021,6-Apr-21,Actual,4/6/2021,6-Apr-21,Actual,4/6/2021,NA,Interventional,NA,NA,Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients,Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients,Terminated,NA,Not Applicable,2,Actual,The Cleveland Clinic,,2,NA,Insufficient eligible patients,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:08:35Z,2021-12-02T06:08:35Z
NCT04747756,NA,2/3/2021,NA,NA,9/27/2021,2/9/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/29/2021,Actual,1-Mar-21,Actual,3/1/2021,Feb-21,2/28/2021,Dec-22,Anticipated,12/31/2022,Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Creating a Virtual Village for People Aging With HIV During COVID-19,A Solution to Halt Further Isolation of People Aging With HIV During the COVID-19 Pandemic,Enrolling by invitation,NA,Not Applicable,80,Anticipated,"University of California, Riverside",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:08:41Z,2021-12-02T06:08:41Z
NCT04747574,NA,1/26/2021,NA,NA,3/2/2021,2/9/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,3/2/2021,3/4/2021,Actual,25-Sep-20,Actual,9/25/2020,Mar-21,3/31/2021,25-Mar-21,Anticipated,3/25/2021,25-Feb-21,Anticipated,2/25/2021,NA,Interventional,NA,NA,Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection,A Phase I Feasibility Study to Evaluate the Safety of CD24-Exosomes in Patients With Moderate/Severe COVID-19 Infection,Recruiting,NA,Phase 1,35,Anticipated,Tel-Aviv Sourasky Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:09:07Z,2021-12-02T06:09:07Z
NCT04747821,NA,2/5/2021,NA,NA,4/6/2021,2/8/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,4/6/2021,4/8/2021,Actual,7-Feb-21,Actual,2/7/2021,Apr-21,4/30/2021,Feb-22,Anticipated,2/28/2022,May-21,Anticipated,5/31/2021,NA,Interventional,Projeto S,NA,An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine,A Stepped-wedge Cluster Randomized Trial to Assess the Effectiveness of the Use of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac,"Active, not recruiting",NA,Phase 4,27711,Actual,Butantan Institute,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:08:56Z,2021-12-02T06:08:56Z
NCT04747158,NA,1/27/2021,NA,NA,2/25/2021,2/8/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,2/25/2021,3/2/2021,Actual,10-Aug-20,Actual,8/10/2020,Feb-21,2/28/2021,10-Jan-21,Actual,1/10/2021,10-Dec-20,Actual,12/10/2020,NA,Interventional,TPCC,NA,COVID-19 Convalescent Plasma Therapy,COVID-19 Convalescent Plasma Therapy,Completed,NA,Phase 2/Phase 3,350,Actual,Universidad Nacional de AsunciÃ³n,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The investigators will publish the results to compare data with other studies with COVID-19 convalescent plasma patients,2021-12-02T06:09:39Z,2021-12-02T06:09:39Z
NCT04747249,NA,2/8/2021,NA,NA,7/13/2021,2/9/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,7/13/2021,7/15/2021,Actual,18-Jun-21,Actual,6/18/2021,Feb-21,2/28/2021,Jun-22,Anticipated,6/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,COVIPACT 2,NA,Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19,Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19,Recruiting,NA,Not Applicable,115,Anticipated,Centre Francois Baclesse,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:09:22Z,2021-12-02T06:09:22Z
NCT04747132,NA,2/6/2021,NA,NA,2/8/2021,2/8/2021,2/10/2021,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/10/2021,Actual,20-Jul-20,Actual,7/20/2020,Feb-21,2/28/2021,16-Nov-20,Actual,11/16/2020,20-Oct-20,Actual,10/20/2020,NA,Interventional,NA,NA,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Completed,NA,Not Applicable,110,Actual,"Universidad Iberoamericana A.C., Mexico",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:09:41Z,2021-12-02T06:09:41Z
NCT04746430,NA,2/8/2021,NA,NA,5/7/2021,2/8/2021,2/9/2021,Actual,NA,NA,NA,NA,NA,NA,5/7/2021,5/11/2021,Actual,16-Feb-21,Actual,2/16/2021,May-21,5/31/2021,23-Apr-21,Actual,4/23/2021,23-Apr-21,Actual,4/23/2021,NA,Interventional,COPPER,NA,COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study,COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study: an Open-label Randomized Controlled Trial,Terminated,NA,Phase 4,17,Actual,General Practitioners Research Institute,,2,NA,Too few patients,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:10:02Z,2021-12-02T06:10:02Z
NCT04746365,NA,2/6/2021,NA,NA,2/8/2021,2/8/2021,2/9/2021,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/9/2021,Actual,6-Dec-20,Actual,12/6/2020,Feb-21,2/28/2021,6-Feb-21,Actual,2/6/2021,31-Jan-21,Actual,1/31/2021,NA,Interventional,IRICT,NA,Ivermectin Role in Covid-19 Clinical Trial,"Ivermectin Role in Severe Covid-19 Treatment; a Double-blinded, Randomized Clinical Trial",Completed,NA,Phase 4,300,Actual,Elaraby Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:10:08Z,2021-12-02T06:10:08Z
NCT04746339,NA,2/8/2021,NA,NA,3/15/2021,2/8/2021,2/9/2021,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,4-Mar-21,Actual,3/4/2021,Feb-21,2/28/2021,Dec-21,Anticipated,12/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,APOLLO,NA,Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19,Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 - the Apollo Trial,Recruiting,NA,Phase 4,1000,Anticipated,Brazilian Clinical Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.,2021-12-02T06:10:11Z,2021-12-02T06:10:11Z
NCT04746183,NA,10/13/2020,NA,NA,8/24/2021,2/8/2021,2/9/2021,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/25/2021,Actual,3-Jul-20,Actual,7/3/2020,Aug-21,8/31/2021,30-Apr-22,Anticipated,4/30/2022,18-Nov-21,Anticipated,11/18/2021,NA,Interventional,NA,NA,AGILE (Early Phase Platform Trial for COVID-19),AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment,Recruiting,NA,Phase 1/Phase 2,600,Anticipated,University of Liverpool,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Master protocol published 19 June 2020,Master protocol available from https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04473-1,NA,Yes,Master protocol publication. Data sets will be registered on CSDR,2021-12-02T06:10:20Z,2021-12-02T06:10:20Z
NCT04745442,NA,2/8/2021,NA,NA,2/8/2021,2/8/2021,2/9/2021,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/9/2021,Actual,27-Apr-20,Actual,4/27/2020,Feb-21,2/28/2021,15-Jan-21,Actual,1/15/2021,20-Dec-20,Actual,12/20/2020,NA,Interventional,NA,NA,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Completed,NA,Phase 2,48,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The information will be provided after the results are published in a journal.,Upon request to uicec@imibic.org,NA,Yes,NA,2021-12-02T06:11:04Z,2021-12-02T06:11:04Z
NCT04743349,NA,2/5/2021,NA,NA,2/5/2021,2/5/2021,2/8/2021,Actual,NA,NA,NA,NA,NA,NA,2/5/2021,2/8/2021,Actual,26-Jan-21,Actual,1/26/2021,Feb-21,2/28/2021,31-Oct-21,Anticipated,10/31/2021,31-Oct-21,Anticipated,10/31/2021,NA,Interventional,Steam-COVID,NA,Steam Inhalations in COVID-19 Patients,Steam Inhalations in Asymptomatic and Paucisymptomatic COVID-19 Patients,Recruiting,NA,Not Applicable,200,Anticipated,Meyer Children's Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:12:42Z,2021-12-02T06:12:42Z
NCT04743232,NA,2/3/2021,NA,NA,8/16/2021,2/4/2021,2/8/2021,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/17/2021,Actual,1-Mar-21,Actual,3/1/2021,Aug-21,8/31/2021,31-Jan-22,Anticipated,1/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,CORDEAL,NA,COVID-19 Resuscitation Plans and Decisions on Escalation and Limitation of Treatment,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or COVID-19 Pandemic Resuscitation Plans and Decisions on Escalation and Limitation of Treatment,Recruiting,NA,Not Applicable,1000,Anticipated,Erasmus Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:12:55Z,2021-12-02T06:12:55Z
NCT04743401,NA,1/12/2021,NA,NA,7/29/2021,2/5/2021,2/8/2021,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/2/2021,Actual,5-Jul-21,Actual,7/5/2021,Jul-21,7/31/2021,31-Mar-23,Anticipated,3/31/2023,30-Sep-22,Anticipated,9/30/2022,NA,Interventional,NA,NA,Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients,Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,VA Office of Research and Development,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:12:48Z,2021-12-02T06:12:48Z
NCT04743011,NA,2/3/2021,NA,NA,9/27/2021,2/5/2021,2/8/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/29/2021,Actual,1-Jun-21,Actual,6/1/2021,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,EnHanCed,NA,Enriched Heparin Anti COVID-19 Trial,Nebulized Enriched Heparin to Treat no Critical Patients With Sars-Cov-2 - Triple Blind Clinical Trial,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,UPECLIN HC FM Botucatu Unesp,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The summary data will be published or made available 6 months after publication.,"Epidemiological data, clinical data, and patient evolution will be shared during the study only for researchers who request access to the data. Access requests will be analyzed by the main researcher, and they will only be released for scientific purposes.",NA,Yes,There is a plan to make IPD and related data dictionaries available,2021-12-02T06:12:59Z,2021-12-02T06:12:59Z
NCT04742725,NA,2/3/2021,NA,NA,9/28/2021,2/5/2021,2/8/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,10/5/2021,Actual,25-May-21,Actual,5/25/2021,Sep-21,9/30/2021,30-Sep-21,Anticipated,9/30/2021,30-Jul-21,Actual,7/30/2021,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Prothioneâ„¢ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19),"A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Prothioneâ„¢ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,231,Actual,"Prothione, LLC",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:13:27Z,2021-12-02T06:13:27Z
NCT04739462,NA,2/1/2021,NA,NA,9/28/2021,2/3/2021,2/4/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/30/2021,Actual,28-Sep-21,Actual,9/28/2021,Sep-21,9/30/2021,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,SMS Maama Project COVID-19,mHealth for Improvement of Access to Maternal Health Services in the Era of COVID-19 Pandemic (SMS Maama Project),"Active, not recruiting",NA,Not Applicable,248,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:15:41Z,2021-12-02T06:15:41Z
NCT04739410,NA,2/2/2021,NA,NA,2/3/2021,2/3/2021,2/4/2021,Actual,NA,NA,NA,NA,NA,NA,2/3/2021,2/4/2021,Actual,1-May-20,Actual,5/1/2020,Feb-21,2/28/2021,30-Jun-20,Actual,6/30/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,NA,NA,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Completed,NA,Phase 4,50,Actual,FMH College of Medicine and Dentistry,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,as soon as i will have time to respond,NA,NA,Yes,"whatever is needed, will share if needed at any time",2021-12-02T06:15:55Z,2021-12-02T06:15:55Z
NCT04738045,NA,1/31/2021,NA,NA,3/15/2021,2/2/2021,2/4/2021,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,1-Nov-20,Actual,11/1/2020,Mar-21,3/31/2021,1-Apr-21,Anticipated,4/1/2021,28-Mar-21,Anticipated,3/28/2021,NA,Interventional,NA,NA,Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients,Comparative Therapeutic Efficacy and Safety of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients,Recruiting,NA,Phase 4,90,Anticipated,October 6 University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:17:04Z,2021-12-02T06:17:04Z
NCT04734717,NA,2/1/2021,NA,NA,2/1/2021,2/1/2021,2/2/2021,Actual,NA,NA,NA,NA,NA,NA,2/1/2021,2/2/2021,Actual,12-Jan-21,Actual,1/12/2021,Feb-21,2/28/2021,12-Apr-21,Anticipated,4/12/2021,12-Apr-21,Anticipated,4/12/2021,NA,Interventional,NA,NA,Coordination and Locomotor Problems in Patients With Covid-19 Virus,Coordination and Locomotor Problems in Patients With Covid-19 Virus,Enrolling by invitation,NA,Not Applicable,2,Actual,Somogy Megyei Kaposi MÃ³r Teaching Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:19:55Z,2021-12-02T06:19:55Z
NCT04734873,NA,1/29/2021,NA,NA,8/20/2021,1/29/2021,2/2/2021,Actual,NA,NA,NA,NA,NA,NA,8/20/2021,8/23/2021,Actual,25-Feb-21,Actual,2/25/2021,Aug-21,8/31/2021,16-Aug-21,Actual,8/16/2021,16-Aug-21,Actual,8/16/2021,NA,Interventional,NA,NA,CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients,"Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients",Terminated,NA,Phase 3,46,Actual,"Corvus Pharmaceuticals, Inc.",,3,NA,Sponsor decision. Not related to safety issues.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:19:43Z,2021-12-02T06:19:43Z
NCT04734912,NA,1/13/2021,NA,NA,1/30/2021,1/30/2021,2/2/2021,Actual,NA,NA,NA,NA,NA,NA,1/30/2021,2/2/2021,Actual,13-Jan-21,Actual,1/13/2021,Jan-21,1/31/2021,31-Dec-21,Anticipated,12/31/2021,15-Jun-21,Anticipated,6/15/2021,NA,Interventional,NA,NA,Evaluation of Transnasal Endoscopy During COVID-19 Pandemic,Evaluation of Transnasal Endoscopy During COVID-19 Pandemic,Recruiting,NA,Not Applicable,500,Anticipated,Johannes Gutenberg University Mainz,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,A publication of the results is planned.,2021-12-02T06:19:28Z,2021-12-02T06:19:28Z
NCT04734860,NA,1/29/2021,NA,NA,4/8/2021,1/29/2021,2/2/2021,Actual,NA,NA,NA,NA,NA,NA,4/8/2021,4/13/2021,Actual,Apr-21,Anticipated,4/30/2021,Apr-21,4/30/2021,Nov-21,Anticipated,11/30/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Adults With Mild COVID-19 Symptoms,"A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMGâ„¢) in Adults With Mild COVID-19 Symptoms",Recruiting,NA,Phase 2,500,Anticipated,"Sorrento Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:19:44Z,2021-12-02T06:19:44Z
NCT04734561,NA,12/31/2020,NA,NA,9/29/2021,1/30/2021,2/2/2021,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,9/30/2021,Actual,8-Feb-21,Actual,2/8/2021,Sep-21,9/30/2021,29-Sep-21,Actual,9/29/2021,31-Jul-21,Actual,7/31/2021,NA,Interventional,NA,NA,Effects of Respiratory Muscle Training in People Who Have Had COVID-19 Disease,"Effects of Respiratory Muscle Training on Quality of Life, Physical and Pulmonary Function and Psychological Status in Patients Who Have Had COVID-19 Disease",Completed,NA,Not Applicable,88,Actual,Universidad Complutense de Madrid,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:19:53Z,2021-12-02T06:19:53Z
NCT04734171,NA,1/29/2021,NA,NA,2/1/2021,2/1/2021,2/2/2021,Actual,NA,NA,NA,NA,NA,NA,2/1/2021,2/2/2021,Actual,2-Apr-20,Actual,4/2/2020,Feb-21,2/28/2021,16-Apr-20,Actual,4/16/2020,16-Apr-20,Actual,4/16/2020,NA,Interventional,NA,NA,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak","COVID-19 and Its Implications on Social Activity, Loneliness and Stigma",Completed,NA,Not Applicable,1200,Actual,Columbia University,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:20:22Z,2021-12-02T06:20:22Z
NCT04733833,NA,1/27/2021,NA,NA,1/31/2021,1/31/2021,2/2/2021,Actual,NA,NA,NA,NA,NA,NA,1/31/2021,2/2/2021,Actual,26-Jan-21,Actual,1/26/2021,Jan-21,1/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19,"A Randomized, Controlled Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19",Recruiting,NA,Phase 2,30,Anticipated,Vascular Biogenics Ltd. operating as VBL Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:20:38Z,2021-12-02T06:20:38Z
NCT04733625,NA,1/31/2021,NA,NA,1/31/2021,1/31/2021,2/2/2021,Actual,NA,NA,NA,NA,NA,NA,1/31/2021,2/2/2021,Actual,15-Sep-20,Actual,9/15/2020,Jan-21,1/31/2021,17-Dec-20,Actual,12/17/2020,17-Dec-20,Actual,12/17/2020,NA,Interventional,NA,NA,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,Completed,NA,Not Applicable,56,Actual,Kasr El Aini Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:20:55Z,2021-12-02T06:20:55Z
NCT04732819,NA,1/27/2021,7/22/2021,NA,9/1/2021,1/29/2021,2/1/2021,Actual,9/1/2021,9/5/2021,Actual,NA,NA,NA,9/1/2021,9/5/2021,Actual,21-Dec-20,Actual,12/21/2020,Sep-21,9/30/2021,16-Apr-21,Actual,4/16/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,"The overall number of baseline participants includes the number of residents and staff in each arm. The unit analyzed was nursing home facility. Baseline characteristics were obtained for residents and nursing home facilities, but not for staff.",Improving COVID-19 Vaccine Uptake in Nursing Homes,IMPACT-C: Improving Vaccine Uptake in Skilled Nursing Facilities,Completed,NA,Not Applicable,23768,Actual,Brown University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The IPD and supporting documentation will be available through the CDCC within 6 months of the completion of the trial.,"Staff and patient data will be aggregated at the level of the facility. This data will be shared with the RADx-UP CDCC, who plans to make a central database that will ultimately be publicly available.",NA,Yes,"Data will be aggregated at the level of the facility. We will provide aggregated data to the RADx-UP Coordination and Data Collection Center (CDCC); however, given the nature of this data it will not be identifiable or linkable. The CDCC will facilitate cross-site pooling of data, whenever possible, and create a publicly available dataset with this information.",2021-12-02T06:21:40Z,2021-12-02T06:21:40Z
NCT04730856,NA,1/14/2021,NA,NA,6/1/2021,1/28/2021,1/29/2021,Actual,NA,NA,NA,NA,NA,NA,6/1/2021,6/4/2021,Actual,1-Feb-21,Actual,2/1/2021,Apr-21,4/30/2021,31-Jul-21,Anticipated,7/31/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID),Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID),Recruiting,NA,Phase 3,600,Anticipated,Hospital Universitario Infanta Leonor,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:23:08Z,2021-12-02T06:23:08Z
NCT04732468,NA,1/27/2021,NA,NA,7/19/2021,1/28/2021,2/1/2021,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/20/2021,Actual,24-Feb-21,Actual,2/24/2021,Jan-21,1/31/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Subcutaneously and Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral COVID-19 in Normal Healthy Volunteers","Active, not recruiting",NA,Phase 1,26,Actual,"ImmunityBio, Inc.",,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:21:55Z,2021-12-02T06:21:55Z
NCT04731116,NA,1/28/2021,NA,NA,1/28/2021,1/28/2021,1/29/2021,Actual,NA,NA,NA,NA,NA,NA,1/28/2021,1/29/2021,Actual,10-Jan-21,Actual,1/10/2021,Jan-21,1/31/2021,30-Apr-22,Anticipated,4/30/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection,Cannabidiol Treatment for Severe and Critical COVID-19 Pulmonary Infection,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,Rabin Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:22:57Z,2021-12-02T06:22:57Z
NCT04730401,NA,1/26/2021,NA,NA,3/4/2021,1/28/2021,1/29/2021,Actual,NA,NA,NA,NA,NA,NA,3/4/2021,3/8/2021,Actual,27-Jan-21,Actual,1/27/2021,Jan-21,1/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,CP_COVID-19,NA,Convalescent Plasma in the Treatment of Covid-19,"Randomized, Double-Blind, Placebo-Controlled Study of Convalescent Plasma in the Treatment of Covid-19",Recruiting,NA,Phase 2,390,Anticipated,Helsinki University Central Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:23:31Z,2021-12-02T06:23:31Z
NCT04730284,NA,8/25/2020,NA,NA,1/28/2021,1/28/2021,1/29/2021,Actual,NA,NA,NA,NA,NA,NA,1/28/2021,1/29/2021,Actual,25-Aug-20,Actual,8/25/2020,Jan-21,1/31/2021,31-Mar-22,Anticipated,3/31/2022,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,Evaluation of a Synbiotic Formula in Patient With COVID-19,Evaluation of a Synbiotic Formula in Patient With COVID-19,Recruiting,NA,Not Applicable,20,Anticipated,Chinese University of Hong Kong,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:23:44Z,2021-12-02T06:23:44Z
NCT04730661,NA,1/19/2021,NA,NA,2/4/2021,1/28/2021,1/29/2021,Actual,NA,NA,NA,NA,NA,NA,2/4/2021,2/9/2021,Actual,21-Dec-20,Actual,12/21/2020,Jan-21,1/31/2021,28-Dec-21,Anticipated,12/28/2021,21-Dec-21,Anticipated,12/21/2021,NA,Interventional,SITCOV,NA,Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19,Efficacy of the Sit to Stand Test (STST) in the Decision to Hospitalize a Patient Consulting the Emergency Department for COVID 19 (Coronavirus Infectious Disease),Recruiting,NA,Not Applicable,146,Anticipated,"University Hospital, Rouen",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:23:40Z,2021-12-02T06:23:40Z
NCT04730427,NA,1/20/2021,NA,NA,1/27/2021,1/27/2021,1/29/2021,Actual,NA,NA,NA,NA,NA,NA,1/27/2021,1/29/2021,Actual,Jan-21,Anticipated,1/31/2021,Jan-21,1/31/2021,Apr-22,Anticipated,4/30/2022,May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19,A Phase 1b Study to Investigate the Safety and Preliminary Efficacy of GX-I7 in Patients With COVID-19,Recruiting,NA,Phase 1,40,Anticipated,"Genexine, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:23:26Z,2021-12-02T06:23:26Z
NCT04730323,NA,1/26/2021,NA,NA,1/28/2021,1/28/2021,1/29/2021,Actual,NA,NA,NA,NA,NA,NA,1/28/2021,1/29/2021,Actual,12-May-20,Actual,5/12/2020,Jan-21,1/31/2021,12-Jun-20,Actual,6/12/2020,12-Jun-20,Actual,6/12/2020,NA,Interventional,NA,NA,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,NA,Phase 4,93,Actual,FMH College of Medicine and Dentistry,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Whenever will be asked to, within few days",Only officials can access the data,NA,Yes,IPD can be shared with researchers in future too,2021-12-02T06:23:26Z,2021-12-02T06:23:26Z
NCT04730206,NA,1/28/2021,NA,NA,8/11/2021,1/28/2021,1/29/2021,Actual,NA,NA,NA,NA,NA,NA,8/11/2021,8/12/2021,Actual,15-Jun-21,Actual,6/15/2021,Aug-21,8/31/2021,May-23,Anticipated,5/31/2023,May-22,Anticipated,5/31/2022,NA,Interventional,DAWN,NA,The DAWN Camostat Trial for Ambulatory COVID-19 Patients,The DAWN Camostat Trial: the Efficacy of Camostat for COVID-19 Infections Presenting to Ambulatory Care: a Randomized Controlled Trial,Recruiting,NA,Phase 3,1316,Anticipated,KU Leuven,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:23:48Z,2021-12-02T06:23:48Z
NCT04729491,NA,1/25/2021,NA,NA,1/25/2021,1/25/2021,1/28/2021,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/28/2021,Actual,30-Jun-20,Actual,6/30/2020,Jun-20,6/30/2020,7-Oct-20,Actual,10/7/2020,15-Sep-20,Actual,9/15/2020,NA,Interventional,NA,NA,EAT-DUTA AndroCoV Trial,Early Antiandrogen Treatment (EAT) With Dutasteride for COVID-19 (EAT-DUTA AndroCoV Trial),Completed,NA,Phase 2/Phase 3,138,Actual,Corpometria Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:24:18Z,2021-12-02T06:24:18Z
NCT04728802,NA,1/27/2021,6/15/2021,NA,6/22/2021,1/27/2021,1/28/2021,Actual,6/15/2021,6/23/2021,Actual,NA,NA,NA,6/22/2021,6/24/2021,Actual,1-Feb-21,Actual,2/1/2021,Jun-21,6/30/2021,15-Apr-21,Actual,4/15/2021,15-Apr-21,Actual,4/15/2021,NA,Interventional,NA,NA,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Completed,NA,Phase 3,645,Actual,"Applied Biology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Available upon request after peer review and publication.,Available upon request at data@appliedbiology.com,NA,Yes,"Yes, study data sets will be made available upon request after peer review and publication.",2021-12-02T06:24:34Z,2021-12-02T06:24:34Z
NCT04728594,NA,1/26/2021,7/16/2021,NA,7/22/2021,1/26/2021,1/28/2021,Actual,7/22/2021,7/26/2021,Actual,NA,NA,NA,7/22/2021,7/26/2021,Actual,15-Jan-21,Actual,1/15/2021,Jul-21,7/31/2021,20-Jan-21,Actual,1/20/2021,17-Jan-21,Actual,1/17/2021,NA,Interventional,NA,"The baseline outcome measure was not applicable, since registration for vaccination was the outcome, and all participants were selected for not being registered.",Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Evaluation of an Email Intervention Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,NA,Not Applicable,9566,Actual,Geisinger Clinic,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.,The data on the Open Science Framework will be open to anyone requesting that information.,http://osf.io,Yes,Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.,2021-12-02T06:24:45Z,2021-12-02T06:24:45Z
NCT04729140,NA,12/30/2020,NA,NA,3/27/2021,1/25/2021,1/28/2021,Actual,NA,NA,NA,NA,NA,NA,3/27/2021,4/1/2021,Actual,28-Dec-20,Actual,12/28/2020,Mar-21,3/31/2021,28-Mar-22,Anticipated,3/28/2022,28-Dec-21,Anticipated,12/28/2021,NA,Interventional,NA,NA,An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization,A Randomized Double-blinded Placebo-controlled Outpatient Clinical Trial in High Risk Population Confirmed COVID-19 Patients Using Ivermectin and Doxycycline to Prevent COVID-19 Illness-related Hospitalization (COVIVER-OUT PLUS),Recruiting,NA,Phase 4,150,Anticipated,"Max Health, Subsero Health",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,December 28 2020 to March 28 2022,NA,NA,Yes,We will release data once the clinical trial has completed course. An independent data safety committee will analyze interim data for effectiveness and safety.,2021-12-02T06:25:13Z,2021-12-02T06:25:13Z
NCT04727424,NA,1/25/2021,NA,NA,7/5/2021,1/26/2021,1/27/2021,Actual,NA,NA,NA,NA,NA,NA,7/5/2021,7/8/2021,Actual,19-Jan-21,Actual,1/19/2021,Jul-21,7/31/2021,1-Mar-22,Anticipated,3/1/2022,1-Feb-22,Anticipated,2/1/2022,NA,Interventional,NA,NA,Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms,"A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Fluvoxamine, Ivermectin, Doxasozin and Interferon Lambda 1A in Mild COVID-19 and High Risk of Complications",Recruiting,NA,Phase 3,3645,Anticipated,Cardresearch,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,As of protocol termination,Upon request,NA,Yes,Patient tables and main data.,2021-12-02T06:25:57Z,2021-12-02T06:25:57Z
NCT04726111,NA,1/21/2021,NA,NA,1/26/2021,1/26/2021,1/27/2021,Actual,NA,NA,NA,NA,NA,NA,1/26/2021,1/27/2021,Actual,30-Dec-20,Actual,12/30/2020,Jan-21,1/31/2021,30-Aug-21,Anticipated,8/30/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,MaterCov,NA,COVID-19 and Pregnancy: Placental and Immunological Impacts,COVID-19 and Pregnancy: Placental and Immunological Impacts,Recruiting,NA,Not Applicable,200,Anticipated,Hopital Foch,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:27:09Z,2021-12-02T06:27:09Z
NCT04726371,NA,1/15/2021,NA,NA,1/26/2021,1/26/2021,1/27/2021,Actual,NA,NA,NA,NA,NA,NA,1/26/2021,1/27/2021,Actual,8-Jan-21,Actual,1/8/2021,Jan-21,1/31/2021,Oct-22,Anticipated,10/31/2022,Oct-22,Anticipated,10/31/2022,NA,Interventional,NA,NA,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Recruiting,NA,Not Applicable,5350,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:26:54Z,2021-12-02T06:26:54Z
NCT04726163,NA,1/19/2021,NA,NA,1/29/2021,1/26/2021,1/27/2021,Actual,NA,NA,NA,NA,NA,NA,1/29/2021,2/1/2021,Actual,29-Jan-21,Actual,1/29/2021,Jan-21,1/31/2021,14-Jun-21,Anticipated,6/14/2021,14-Jun-21,Anticipated,6/14/2021,NA,Interventional,COVIDEX,NA,Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection,Tele-expertise for Glycemic Control Monitoring in Patients With Diabetes Hospitalized for Covid-19 Infection,Recruiting,NA,Not Applicable,60,Anticipated,"University Hospital, Strasbourg, France",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:26:58Z,2021-12-02T06:26:58Z
NCT04724720,NA,1/13/2021,NA,NA,6/10/2021,1/25/2021,1/26/2021,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/15/2021,Actual,19-Jan-21,Actual,1/19/2021,Jun-21,6/30/2021,Dec-21,Anticipated,12/31/2021,3-May-21,Actual,5/3/2021,NA,Interventional,NA,NA,Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19,"A Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Famotidine vs Placebo for the Treatment of Non-Hospitalized Symptomatic Adults With COVID-19","Active, not recruiting",NA,Phase 2,56,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:27:59Z,2021-12-02T06:27:59Z
NCT04724629,NA,10/5/2020,NA,NA,1/23/2021,1/23/2021,1/26/2021,Actual,NA,NA,NA,NA,NA,NA,1/23/2021,1/26/2021,Actual,5-Jan-21,Actual,1/5/2021,Jan-21,1/31/2021,30-Jul-21,Anticipated,7/30/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,STRUCK,NA,Survival TRial Using CytoKines in COVID-19 (STRUCK Trial),"Prospective-randomized Adaptive Study, With Active Control to Evaluate the Efficacy and Safety of Interleukin (IL)-17 Inhibitor Treatment Versus Low Doses of IL-2 Versus Indirect IL-6 Inhibitor in Hospitalized Patients With Severe Forms of COVID-19",Recruiting,NA,Phase 3,60,Anticipated,University of Sao Paulo,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:28:12Z,2021-12-02T06:28:12Z
NCT04724616,NA,1/10/2021,NA,NA,1/24/2021,1/24/2021,1/26/2021,Actual,NA,NA,NA,NA,NA,NA,1/24/2021,1/26/2021,Actual,6-Jan-21,Actual,1/6/2021,Jan-21,1/31/2021,Jun-21,Anticipated,6/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,CARTOON,NA,CARTOON: CoronAviRus (COVID-19) educaTional prOgram fOr childreN,CARTOON: CoronAviRus educaTional prOgram fOr childreN to Promote Knowledge and Hygiene Measures and Dispel Fear During the COVID- 19 Pandemic,Recruiting,NA,Not Applicable,60,Anticipated,Medical University of Vienna,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T06:28:20Z,2021-12-02T06:28:20Z
NCT04724681,NA,10/21/2020,NA,NA,1/24/2021,1/24/2021,1/26/2021,Actual,NA,NA,NA,NA,NA,NA,1/24/2021,1/26/2021,Actual,1-Feb-21,Anticipated,2/1/2021,Jan-21,1/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,WARD COVID-19,NA,Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection,Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection,Recruiting,NA,Not Applicable,800,Anticipated,University Hospital Bispebjerg and Frederiksberg,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:28:13Z,2021-12-02T06:28:13Z
NCT04724538,NA,12/29/2020,5/2/2021,NA,7/4/2021,1/23/2021,1/26/2021,Actual,7/4/2021,7/7/2021,Actual,NA,NA,NA,7/4/2021,7/7/2021,Actual,15-Oct-20,Actual,10/15/2020,Jul-21,7/31/2021,15-Mar-21,Actual,3/15/2021,10-Feb-21,Actual,2/10/2021,NA,Interventional,NA,NA,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Inhalation Low Dose Radionuclide Therapy in Comprehensive Treatment of COVID-19 Viral Pneumonia,Completed,NA,Phase 1/Phase 2,25,Actual,National Medical Research Radiological Centre of the Ministry of Health of Russia,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:28:21Z,2021-12-02T06:28:21Z
NCT04723394,NA,1/14/2021,NA,NA,9/17/2021,1/22/2021,1/25/2021,Actual,NA,NA,NA,NA,NA,NA,9/17/2021,9/20/2021,Actual,28-Jan-21,Actual,1/28/2021,Sep-21,9/30/2021,21-Oct-22,Anticipated,10/21/2022,21-Aug-21,Actual,8/21/2021,NA,Interventional,TACKLE,NA,Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults,"A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults","Active, not recruiting",NA,Phase 3,910,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-12-02T06:29:18Z,2021-12-02T06:29:18Z
NCT04723576,NA,1/14/2021,NA,NA,1/22/2021,1/22/2021,1/25/2021,Actual,NA,NA,NA,NA,NA,NA,1/22/2021,1/25/2021,Actual,3-Dec-20,Actual,12/3/2020,Jan-21,1/31/2021,30-Nov-23,Anticipated,11/30/2023,Feb-22,Anticipated,2/28/2022,NA,Interventional,COVER-HCW,NA,Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19),Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Not Applicable,2132,Anticipated,RAND,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:28:54Z,2021-12-02T06:28:54Z
NCT04723550,NA,1/21/2021,NA,NA,1/23/2021,1/21/2021,1/25/2021,Actual,NA,NA,NA,NA,NA,NA,1/23/2021,1/26/2021,Actual,5-Jan-21,Actual,1/5/2021,Jan-21,1/31/2021,5-Jan-22,Anticipated,1/5/2022,5-Nov-21,Anticipated,11/5/2021,NA,Interventional,NA,NA,COVID-19 Lockdown Related Telemedicine for Type 2 Diabetes,Impact of Telemedicine on Young and Middle-aged Obese Patients With Type 2 Diabetes Mellitus During COVID-19 Pandemic,Recruiting,NA,Not Applicable,120,Anticipated,Xuzhou No.1 Peoples Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:29:01Z,2021-12-02T06:29:01Z
NCT04723563,NA,1/22/2021,NA,NA,9/3/2021,1/22/2021,1/25/2021,Actual,NA,NA,NA,NA,NA,NA,9/3/2021,9/5/2021,Actual,22-Feb-21,Actual,2/22/2021,Sep-21,9/30/2021,23-Aug-21,Actual,8/23/2021,23-Aug-21,Actual,8/23/2021,NA,Interventional,INHALE-HEP,NA,Nebulized Heparin for the Treatment of COVID-19,INHALEd Unfractionated HEParin for the Treatment of Hospitalized Patients With COVID-19 Pneumonia,Completed,NA,Phase 4,50,Actual,Frederick Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:29:03Z,2021-12-02T06:29:03Z
NCT04723524,NA,1/22/2021,NA,NA,10/5/2021,1/22/2021,1/25/2021,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/6/2021,Actual,22-Sep-20,Actual,9/22/2020,Oct-21,10/31/2021,23-Aug-21,Actual,8/23/2021,23-Aug-21,Actual,8/23/2021,NA,Interventional,RCT,NA,Jinhua Qinggan Granules in the Treatment of COVID-19,"Multi-center, Randomized, Double Blind and Placebo Controlled Clinical Trial on the Effectiveness and Safety of Jinhua Qinggan Granules (JHQG) for the Treatment of COVID 19 Patients",Completed,NA,Phase 2,402,Actual,University of Karachi,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:29:04Z,2021-12-02T06:29:04Z
NCT04723459,NA,1/20/2021,NA,NA,3/15/2021,1/22/2021,1/25/2021,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,23-Jan-21,Actual,1/23/2021,Mar-21,3/31/2021,28-Mar-21,Anticipated,3/28/2021,19-Feb-21,Actual,2/19/2021,NA,Interventional,NA,NA,Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff,Nano-Ivermectin Impregnated Masks Versus Ordinary Surgical Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff,Recruiting,NA,Not Applicable,150,Anticipated,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T06:29:10Z,2021-12-02T06:29:10Z
NCT04723290,NA,1/21/2021,NA,NA,3/24/2021,1/21/2021,1/25/2021,Actual,NA,NA,NA,NA,NA,NA,3/24/2021,3/25/2021,Actual,20-Jun-20,Actual,6/20/2020,Mar-21,3/31/2021,31-Dec-20,Actual,12/31/2020,31-Oct-20,Actual,10/31/2020,NA,Interventional,NA,NA,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,SARS-CoV-2 Seroconversion Study Among GHdC Staff Members,Completed,NA,Not Applicable,2817,Actual,Grand HÃ´pital de Charleroi,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"At this moment, there is no plan to share the results",2021-12-02T06:29:12Z,2021-12-02T06:29:12Z
NCT04719208,NA,10/21/2020,NA,NA,1/20/2021,1/20/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,1/20/2021,1/22/2021,Actual,6-Oct-20,Actual,10/6/2020,Jan-21,1/31/2021,Jun-21,Anticipated,6/30/2021,May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse,Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse,Recruiting,NA,Not Applicable,60,Anticipated,Augusta University,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:33:05Z,2021-12-02T06:33:05Z
NCT04720794,NA,10/13/2020,NA,NA,1/22/2021,1/20/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,1/22/2021,1/26/2021,Actual,25-Sep-20,Actual,9/25/2020,Jan-21,1/31/2021,20-Oct-20,Actual,10/20/2020,20-Oct-20,Actual,10/20/2020,NA,Interventional,NA,NA,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay,Completed,NA,Not Applicable,101,Actual,Lucira Health Inc,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:31:21Z,2021-12-02T06:31:21Z
NCT04720235,NA,1/15/2021,NA,NA,4/9/2021,1/20/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,4/9/2021,4/12/2021,Actual,9-Dec-20,Actual,12/9/2020,Jan-21,1/31/2021,30-Mar-21,Actual,3/30/2021,9-Mar-21,Actual,3/9/2021,NA,Interventional,NA,NA,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay Among Asymptomatic Subjects,Completed,NA,Not Applicable,304,Actual,Lucira Health Inc,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:31:56Z,2021-12-02T06:31:56Z
NCT04719234,NA,1/20/2021,NA,NA,1/21/2021,1/21/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,1/21/2021,1/22/2021,Actual,15-Jun-20,Actual,6/15/2020,Jan-21,1/31/2021,1-Dec-20,Actual,12/1/2020,1-Dec-20,Actual,12/1/2020,NA,Interventional,NA,NA,Lung Ultrasonography in COVID-19 Pneumonia,Comparison of Lung Ultrasonography Findings With Chest Computerized Tomography Results in Corona virÃ¼s (COVID-19) Pneumonia,Completed,NA,Not Applicable,60,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:32:44Z,2021-12-02T06:32:44Z
NCT04721236,NA,1/20/2021,NA,NA,1/21/2021,1/21/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,1/21/2021,1/22/2021,Actual,19-Nov-20,Actual,11/19/2020,Jan-21,1/31/2021,19-May-22,Anticipated,5/19/2022,19-Nov-21,Anticipated,11/19/2021,NA,Interventional,COV-II-PLA,NA,Early Use of Hyperimmune Plasma in COVID-19,COVID-19 Wave II Study for Assessing the Early Use of Hyperimmune Plasma for the Treatment of COVID-19 Patients Needing Non-invasive or Invasive Mechanical Ventilation,Recruiting,NA,Not Applicable,300,Anticipated,IRCCS Policlinico S. Matteo,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,may be available upon motivated requesto to PI,2021-12-02T06:31:05Z,2021-12-02T06:31:05Z
NCT04720404,NA,1/12/2021,NA,NA,1/21/2021,1/21/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,1/21/2021,1/22/2021,Actual,23-Jun-20,Actual,6/23/2020,Jan-21,1/31/2021,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Mindful Prevention of Psychopathology in Healthcare Workers During the COVID-19 Crisis (COVID-19 MindPreP),Mindful Prevention of Psychopathology in Healthcare Workers During the COVID-19 Crisis (COVID-19 MindPreP),Recruiting,NA,Not Applicable,220,Anticipated,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:31:46Z,2021-12-02T06:31:46Z
NCT04720378,NA,1/21/2021,NA,NA,9/23/2021,1/21/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/24/2021,Actual,30-May-21,Actual,5/30/2021,Sep-21,9/30/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Safety and Tolerability Study of IV ST266 in COVID-19 Subjects,"A Phase 1, Multi-Center, Open-Label, Safety and Tolerability Study of Intravenous Administration of ST266 in Subjects With Confirmed COVID-19 Infection",Recruiting,NA,Phase 1,12,Anticipated,"Noveome Biotherapeutics, formerly Stemnion",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:31:47Z,2021-12-02T06:31:47Z
NCT04718220,NA,1/16/2021,NA,NA,4/7/2021,1/19/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,4/7/2021,4/8/2021,Actual,1-Mar-21,Actual,3/1/2021,Apr-21,4/30/2021,Nov-22,Anticipated,11/30/2022,Nov-22,Anticipated,11/30/2022,NA,Interventional,STOPCOVID19,NA,"Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19","Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19",Recruiting,NA,Not Applicable,420,Anticipated,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:34:13Z,2021-12-02T06:34:13Z
NCT04718480,NA,1/18/2021,NA,NA,9/24/2021,1/20/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/27/2021,Actual,27-Nov-20,Actual,11/27/2020,Sep-21,9/30/2021,Dec-22,Anticipated,12/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients,"A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients",Recruiting,NA,Phase 2,100,Anticipated,SigmaDrugs Research Ltd.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Study results will be published at the end of the study.,2021-12-02T06:33:42Z,2021-12-02T06:33:42Z
NCT04718506,NA,1/16/2021,NA,NA,1/20/2021,1/20/2021,1/22/2021,Actual,NA,NA,NA,NA,NA,NA,1/20/2021,1/22/2021,Actual,12-Jan-21,Actual,1/12/2021,Jan-21,1/31/2021,12-Dec-21,Anticipated,12/12/2021,12-Jun-21,Anticipated,6/12/2021,NA,Interventional,RECOVE,NA,Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention,"Rehabilitation for Post-COVID-19 Syndrome Through a Multicomponent, Educational and Supervised Exercise Intervention [RECOVE]",Recruiting,NA,Not Applicable,56,Anticipated,Universidad de Murcia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:33:37Z,2021-12-02T06:33:37Z
NCT04716556,NA,1/14/2021,NA,NA,8/25/2021,1/19/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,8/25/2021,8/26/2021,Actual,16-Jul-20,Actual,7/16/2020,Aug-21,8/31/2021,31-May-21,Actual,5/31/2021,14-Jan-21,Actual,1/14/2021,NA,Interventional,NA,NA,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa Due to SARS-CoV2 (TSUNAMI Study): a Multicenter Open Label Randomized Control Trial,Completed,NA,Not Applicable,474,Actual,Istituto Superiore di SanitÃ ,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:35:08Z,2021-12-02T06:35:08Z
NCT04716998,NA,1/17/2021,NA,NA,6/30/2021,1/19/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,6/30/2021,7/2/2021,Actual,14-Jan-21,Actual,1/14/2021,Jan-21,1/31/2021,Jan-22,Anticipated,1/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19,A Controlled Study to Evaluate the Safety and Efficacy of Allogeneic MesenCure for the Treatment of Pulmonary Manifestations in Patients With COVID19,Recruiting,NA,Phase 1/Phase 2,35,Anticipated,BonusBio Group Ltd,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:34:55Z,2021-12-02T06:34:55Z
NCT04716647,NA,1/18/2021,NA,NA,1/19/2021,1/19/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,1/19/2021,1/20/2021,Actual,9-Oct-20,Actual,10/9/2020,Jan-21,1/31/2021,18-Dec-20,Actual,12/18/2020,12-Dec-20,Actual,12/12/2020,NA,Interventional,NA,NA,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,A Community-Based Participatory Research to Assess the Feasibility of Ayurveda Intervention in Patients With Mild-to-Moderate COVID-19,Completed,NA,Not Applicable,28,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:35:09Z,2021-12-02T06:35:09Z
NCT04716569,NA,1/19/2021,NA,NA,3/15/2021,1/19/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,20-Jan-21,Actual,1/20/2021,Mar-21,3/31/2021,20-Mar-21,Anticipated,3/20/2021,20-Feb-21,Actual,2/20/2021,NA,Interventional,NA,NA,Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19,"Faculty of Medicine ,South Valley University",Recruiting,NA,Phase 2/Phase 3,150,Anticipated,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:35:10Z,2021-12-02T06:35:10Z
NCT04716179,NA,1/17/2021,NA,NA,7/21/2021,1/19/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/22/2021,Actual,18-Jan-21,Actual,1/18/2021,Jul-21,7/31/2021,31-Aug-21,Anticipated,8/31/2021,18-May-21,Actual,5/18/2021,NA,Interventional,NA,NA,Prospective Two-arm Study of Fertility in Men With COVID-19,Prospective Two-arm Study of Fertility in Men With COVID-19,Recruiting,NA,Not Applicable,88,Anticipated,I.M. Sechenov First Moscow State Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:35:51Z,2021-12-02T06:35:51Z
NCT04716426,NA,1/18/2021,3/31/2021,NA,4/6/2021,1/18/2021,1/20/2021,Actual,4/6/2021,4/8/2021,Actual,NA,NA,NA,4/6/2021,4/8/2021,Actual,28-Jan-21,Actual,1/28/2021,Apr-21,4/30/2021,25-Mar-21,Actual,3/25/2021,25-Mar-21,Actual,3/25/2021,NA,Interventional,NA,NA,APTâ„¢ T3X on the COVID-19 Contamination Rate,Use of APTâ„¢ T3X to Decrease the COVID-19 Contamination Rate in Humans,Completed,NA,Not Applicable,100,Actual,University of Nove de Julho,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:35:47Z,2021-12-02T06:35:47Z
NCT04715932,NA,1/15/2021,NA,NA,7/8/2021,1/19/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,7/8/2021,7/12/2021,Actual,18-Feb-21,Actual,2/18/2021,Jul-21,7/31/2021,7-Jun-21,Actual,6/7/2021,25-May-21,Actual,5/25/2021,NA,Interventional,Hesperidin,NA,Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN),"A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)",Completed,NA,Phase 2,216,Actual,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:35:59Z,2021-12-02T06:35:59Z
NCT04715763,NA,1/14/2021,NA,NA,9/3/2021,1/14/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,9/3/2021,9/5/2021,Actual,1-Sep-21,Actual,9/1/2021,Sep-21,9/30/2021,31-Dec-22,Anticipated,12/31/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,INTEL,NA,INvestigating TELmisartin Study,"Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Treatment of COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 2,40,Anticipated,University of Hawaii,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:36:04Z,2021-12-02T06:36:04Z
NCT04715607,NA,1/12/2021,NA,NA,9/28/2021,1/15/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/30/2021,Actual,22-Jan-21,Actual,1/22/2021,Sep-21,9/30/2021,31-May-21,Actual,5/31/2021,30-May-21,Actual,5/30/2021,NA,Interventional,NA,NA,"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens","Comparison of Detection Rate of SARS-CoV-2 in Saliva, Oropharyngeal and Nasopharyngeal Specimens in a Public COVID-19 Test Setting",Completed,NA,Not Applicable,27947,Actual,"Rigshospitalet, Denmark",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:36:05Z,2021-12-02T06:36:05Z
NCT04715360,NA,1/15/2021,NA,NA,1/17/2021,1/17/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,1/17/2021,1/20/2021,Actual,29-Dec-20,Actual,12/29/2020,Jan-21,1/31/2021,27-Dec-21,Anticipated,12/27/2021,29-Nov-21,Anticipated,11/29/2021,NA,Interventional,NA,NA,Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy,Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Hayandra Peduli Foundation,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:36:39Z,2021-12-02T06:36:39Z
NCT04715295,NA,10/2/2020,NA,NA,1/19/2021,1/19/2021,1/20/2021,Actual,NA,NA,NA,NA,NA,NA,1/19/2021,1/20/2021,Actual,5-Oct-20,Actual,10/5/2020,Jan-21,1/31/2021,5-Sep-21,Anticipated,9/5/2021,30-May-21,Anticipated,5/30/2021,NA,Interventional,DOXYCOV,NA,Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19,"Open-label, Randomized Trial of the Safety and Efficacy of Doxycycline and Rivaroxaban Therapy Versus National Standard Therapy in Ambulatory Patients With Mild Symptomatic COVID-19",Recruiting,NA,Phase 4,200,Anticipated,Yaounde Central Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,one year after completion,Data will be shared upon request and approval by the National COVID19 Scientific Board,NA,Yes,Data will be shared upon request and approval by the National COVID19 Scientific Board,2021-12-02T06:36:42Z,2021-12-02T06:36:42Z
NCT04713878,NA,1/9/2021,NA,NA,1/16/2021,1/15/2021,1/19/2021,Actual,NA,NA,NA,NA,NA,NA,1/16/2021,1/20/2021,Actual,8-May-20,Actual,5/8/2020,Jan-21,1/31/2021,15-Jul-20,Actual,7/15/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,NA,NA,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,A 8-Week Trial of Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,Completed,NA,Not Applicable,21,Actual,Kanuni Sultan Suleyman Training and Research Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:37:44Z,2021-12-02T06:37:44Z
NCT04713488,NA,1/13/2021,NA,NA,2/1/2021,1/15/2021,1/19/2021,Actual,NA,NA,NA,NA,NA,NA,2/1/2021,2/2/2021,Actual,15-Jan-21,Actual,1/15/2021,Jan-21,1/31/2021,31-Jul-21,Anticipated,7/31/2021,20-Jul-21,Anticipated,7/20/2021,NA,Interventional,NA,NA,"An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" Vaccine","An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" t Vaccine for Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Viruso","Active, not recruiting",NA,Phase 1/Phase 2,110,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:38:00Z,2021-12-02T06:38:00Z
NCT04713553,NA,1/15/2021,NA,NA,8/4/2021,1/15/2021,1/19/2021,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/5/2021,Actual,15-Feb-21,Actual,2/15/2021,Aug-21,8/31/2021,22-Jul-21,Actual,7/22/2021,22-Jul-21,Actual,7/22/2021,NA,Interventional,NA,NA,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE",Completed,NA,Phase 3,1530,Actual,BioNTech SE,,7,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-02T06:38:06Z,2021-12-02T06:38:06Z
NCT04712357,NA,1/7/2021,NA,NA,1/14/2021,1/14/2021,1/15/2021,Actual,NA,NA,NA,NA,NA,NA,1/14/2021,1/15/2021,Actual,9-Nov-20,Actual,11/9/2020,Jan-21,1/31/2021,Jan-23,Anticipated,1/31/2023,Jan-22,Anticipated,1/31/2022,NA,Interventional,ARTAN-C19,NA,Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19,"Clinical, Control, Double-blind, Randomized Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19",Recruiting,NA,Not Applicable,219,Anticipated,Universidade Federal do Ceara,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:38:59Z,2021-12-02T06:38:59Z
NCT04713176,NA,1/14/2021,NA,NA,2/26/2021,1/14/2021,1/19/2021,Actual,NA,NA,NA,NA,NA,NA,2/26/2021,3/3/2021,Actual,2-Feb-21,Actual,2/2/2021,Jan-21,1/31/2021,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients,"A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DW1248 With Remdesivir in Severe COVID-19 Patients",Recruiting,NA,Phase 3,1022,Anticipated,Daewoong Pharmaceutical Co. LTD.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:38:14Z,2021-12-02T06:38:14Z
NCT04713111,NA,1/8/2021,NA,NA,3/10/2021,1/14/2021,1/19/2021,Actual,NA,NA,NA,NA,NA,NA,3/10/2021,3/12/2021,Actual,4-May-20,Actual,5/4/2020,Jan-21,1/31/2021,30-Nov-20,Actual,11/30/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,NA,NA,Stress and Recovery in Frontline COVID-19 Workers,Stress and Recovery in Frontline Healthcare COVID-19 Workers: A Feasibility Study Using Wearable and Smartphone Devices,Completed,NA,Not Applicable,383,Actual,4YouandMe,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Internal collaborative researchers will have access to all coded data during the full duration of the study. Consented participants' coded data will be available in the Synapse at Sage Bionetworks for selected researchers to access indefinitely, one year after study completion.","As coded study data will then exist among consenting participants in the Synapse at Sage Bionetworks in de-identified form, the electronic data files will be kept indefinitely. The Principal Investigator will be responsible for receipt and/or transmission of data as required.",NA,Yes,"Under the 4YouandMe open source model, we will make all data, findings, digital health applications and algorithms available in the public domain. Accordingly, de-identified data produced from this project will be shared broadly with qualified researchers (among participants who opt in) through Sage Bionetworks Synapse and will serve as an immense resource, reflecting a highly granular and high- dimensional map of physiological stress responses and knowledge surrounding inadvertent consequences of objective stress measurement. Only data from consenting participants will be shared through Sage Bionetworks Synapse. Additionally, Source code for the developed app will be made available as open source software on GitHub so it can be evolved for future work by others.",2021-12-02T06:38:20Z,2021-12-02T06:38:20Z
NCT04712110,NA,1/14/2021,NA,NA,4/2/2021,1/14/2021,1/15/2021,Actual,NA,NA,NA,NA,NA,NA,4/2/2021,4/5/2021,Actual,24-Feb-21,Actual,2/24/2021,Apr-21,4/30/2021,4-Apr-22,Anticipated,4/4/2022,4-Apr-22,Anticipated,4/4/2022,NA,Interventional,NA,NA,A Study of TAK-019 in Healthy Japanese Adults (COVID-19),"A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TAK-019 by Intramuscular Injection in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)","Active, not recruiting",NA,Phase 1/Phase 2,200,Actual,Takeda,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2021-12-02T06:38:57Z,2021-12-02T06:38:57Z
NCT04709172,NA,1/12/2021,NA,NA,10/5/2021,1/13/2021,1/14/2021,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/6/2021,Actual,5-Jan-21,Actual,1/5/2021,Jan-21,1/31/2021,15-Aug-21,Actual,8/15/2021,15-Aug-21,Actual,8/15/2021,NA,Interventional,NA,NA,Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia,"Prospective, Non-controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia",Completed,NA,Phase 4,20,Actual,Meiji Pharma Spain S.A.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:41:24Z,2021-12-02T06:41:24Z
NCT04712344,NA,12/30/2020,NA,NA,1/19/2021,1/14/2021,1/15/2021,Actual,NA,NA,NA,NA,NA,NA,1/19/2021,1/20/2021,Actual,18-Jan-21,Actual,1/18/2021,Jan-21,1/31/2021,Sep-21,Anticipated,9/30/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,IPCO,NA,Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO),Randomized Controlled Phase 2b Clinical Study in Parallel Groups for the Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma Plus Standard Treatment vs. Standard Treatment Alone of Subjects With Severe COVID-19,Recruiting,NA,Phase 2,58,Anticipated,University of Erlangen-NÃ¼rnberg Medical School,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:39:08Z,2021-12-02T06:39:08Z
NCT04712045,NA,1/11/2021,NA,NA,1/13/2021,1/13/2021,1/15/2021,Actual,NA,NA,NA,NA,NA,NA,1/13/2021,1/15/2021,Actual,1-Aug-20,Actual,8/1/2020,Jan-21,1/31/2021,12-Dec-20,Actual,12/12/2020,12-Dec-20,Actual,12/12/2020,NA,Interventional,RUPERT,NA,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,Rational Use of Personal Protective Equipment: a Randomised Trial and Quality Improvement Intervention During COVID-19 Pandemic,Completed,NA,Not Applicable,67,Actual,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:39:11Z,2021-12-02T06:39:11Z
NCT04710394,NA,1/13/2021,NA,NA,4/2/2021,1/13/2021,1/14/2021,Actual,NA,NA,NA,NA,NA,NA,4/2/2021,4/5/2021,Actual,11-Jan-21,Actual,1/11/2021,Apr-21,4/30/2021,11-Mar-22,Anticipated,3/11/2022,11-Mar-22,Anticipated,3/11/2022,NA,Interventional,VOLT,NA,Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell,Efficacy of Bimodal Visual-Olfactory Training in Participants With COVID-19 Resultant Hyposmia or Anosmia Using Participant-Preferred Scents,"Active, not recruiting",NA,Not Applicable,240,Actual,Washington University School of Medicine,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"The data will be made available within 12 months of the completion date of the research project, for 2 subsequent years.","Data access will be arranged through a data-sharing agreement, which will indicate the criteria for data access, documentation of IRB approval from requestor's institution, incorporation of appropriate privacy and confidentiality standards to ensure data security at the recipient site, and prohibit manipulation of data for the purposes of identifying subjects or redistribution to third parties. Data access will be managed by the Research Compliance and Recruitment Coordinator, and data maintenance will be managed by the Study Biostatistician.",http://otolaryngologyoutcomesresearch.wustl.edu/,Yes,"Data and research resources generated from this clinical trial will be made available by request, while safeguarding the privacy of participants in accordance with NIH policy and HIPAA guidelines.

The data to be shared will include information about the project, protocol, data dictionary, and the final individual de-identified research subject data. These data will include the responses to the baseline and post-intervention Olfactory Dysfunction Outcomes Rating (ODOR), Clinical Global Impression Severity (CGI-S) Scale , University of Pennsylvania Smell Identification Test (UPSIT), post-intervention Clinical Global Impression Improvement (CGI-I) Scale, and treatment assignment.",2021-12-02T06:40:31Z,2021-12-02T06:40:31Z
NCT04710381,NA,1/13/2021,NA,NA,7/20/2021,1/13/2021,1/14/2021,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,1-Feb-21,Actual,2/1/2021,Jul-21,7/31/2021,2-Jun-21,Actual,6/2/2021,2-Jun-21,Actual,6/2/2021,NA,Interventional,NA,NA,IMUNORÂ® Preparation in the Prevention of COVID-19,"Pilot, Monocentric, Phase-IV Clinical Trial Assessing the Clinical Effect of Peroral Immunomodulation Treatment Using the IMUNORÂ® Preparation in the Prevention of COVID-19 Disease",Completed,NA,Phase 4,56,Actual,University Hospital Ostrava,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no plan to make individual participant data available to other researchers.,2021-12-02T06:40:29Z,2021-12-02T06:40:29Z
NCT04710303,NA,1/13/2021,NA,NA,3/9/2021,1/13/2021,1/14/2021,Actual,NA,NA,NA,NA,NA,NA,3/9/2021,3/11/2021,Actual,2-Mar-21,Actual,3/2/2021,Jan-21,1/31/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Prophylactic COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults (ProVIVA-SA-1)",Recruiting,NA,Phase 1,35,Anticipated,"ImmunityBio, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:40:43Z,2021-12-02T06:40:43Z
NCT04710316,NA,1/8/2021,NA,NA,9/22/2021,1/13/2021,1/14/2021,Actual,NA,NA,NA,NA,NA,NA,9/22/2021,9/27/2021,Actual,15-Feb-21,Actual,2/15/2021,Dec-20,12/31/2020,30-Sep-22,Anticipated,9/30/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,BAMACOV,NA,"Study of COVID-19 Outbreak in Hospital Departments of Bamako, Mali","Ã‰tude de l'Ã©pidÃ©mie de SARS-CoV-2 Dans Les Services Hospitaliers de Bamako, Mali",Recruiting,NA,Not Applicable,450,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:40:44Z,2021-12-02T06:40:44Z
NCT04708340,NA,1/4/2021,NA,NA,5/18/2021,1/12/2021,1/13/2021,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/19/2021,Actual,25-Mar-21,Actual,3/25/2021,May-21,5/31/2021,Feb-23,Anticipated,2/28/2023,Oct-22,Anticipated,10/31/2022,NA,Interventional,RJX,NA,Tolerability and Efficacy of RJX in Patients With COVID-19,"A Two-part, Two-cohort, Double-blind, Randomized, Placebo-controlled, Multicenter Phase 1/2 Study to Evaluate the Safety, Tolerability and Efficacy of REJUVEINIX (RJX) in Patients With COVID-19",Recruiting,NA,Phase 1/Phase 2,237,Anticipated,"Reven Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:41:59Z,2021-12-02T06:41:59Z
NCT04707833,NA,12/29/2020,NA,NA,1/12/2021,1/12/2021,1/13/2021,Actual,NA,NA,NA,NA,NA,NA,1/12/2021,1/13/2021,Actual,26-Nov-20,Actual,11/26/2020,Jan-21,1/31/2021,1-Dec-23,Anticipated,12/1/2023,1-Dec-23,Anticipated,12/1/2023,NA,Interventional,SeroCOV,NA,Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Protocol for the Collection of Clinical Samples for Evaluation and Implementation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Recruiting,NA,Not Applicable,385,Anticipated,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:42:24Z,2021-12-02T06:42:24Z
NCT04707703,NA,1/8/2021,NA,NA,5/12/2021,1/11/2021,1/13/2021,Actual,NA,NA,NA,NA,NA,NA,5/12/2021,5/13/2021,Actual,16-Mar-21,Actual,3/16/2021,May-21,5/31/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,Isavu-CAPA,NA,Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis,Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients,Recruiting,NA,Phase 3,162,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:42:40Z,2021-12-02T06:42:40Z
NCT04707820,NA,12/29/2020,NA,NA,1/12/2021,1/12/2021,1/13/2021,Actual,NA,NA,NA,NA,NA,NA,1/12/2021,1/13/2021,Actual,16-Apr-20,Actual,4/16/2020,Dec-20,12/31/2020,10-Jun-21,Anticipated,6/10/2021,10-Jun-21,Anticipated,6/10/2021,NA,Interventional,ImmuCoV,NA,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Recruiting,NA,Not Applicable,80,Anticipated,"University Hospital, Rouen",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:42:34Z,2021-12-02T06:42:34Z
NCT04707742,NA,1/7/2021,NA,NA,10/6/2021,1/12/2021,1/13/2021,Actual,NA,NA,NA,NA,NA,NA,10/6/2021,10/11/2021,Actual,15-Jun-20,Actual,6/15/2020,Sep-21,9/30/2021,30-Sep-21,Actual,9/30/2021,18-Sep-21,Actual,9/18/2021,NA,Interventional,BUCOSARS,NA,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,Clinical Evaluation of Antiseptic Mouth Rinses to Reduce Salivary Viral Load of SARS-CoV-2 in COVID-19 Patients,Completed,NA,Not Applicable,160,Actual,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:42:36Z,2021-12-02T06:42:36Z
NCT04707534,NA,1/11/2021,NA,NA,6/29/2021,1/12/2021,1/13/2021,Actual,NA,NA,NA,NA,NA,NA,6/29/2021,6/30/2021,Actual,21-Jan-21,Actual,1/21/2021,Jun-21,6/30/2021,21-Sep-21,Anticipated,9/21/2021,21-Aug-21,Anticipated,8/21/2021,NA,Interventional,NA,NA,Dexamethasone for COVID-19,Effects of Higher Dose and Lower Dose of Dexamethasone for Hospitalized Patients With COVID-19,Recruiting,NA,Phase 4,300,Anticipated,University of Oklahoma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:42:37Z,2021-12-02T06:42:37Z
NCT04706403,NA,1/5/2021,NA,NA,7/26/2021,1/11/2021,1/12/2021,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,8/2/2021,Actual,12-Jan-21,Actual,1/12/2021,Jul-21,7/31/2021,1-Feb-21,Actual,2/1/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,NA,NA,Views on COVID-19 and Vaccination,"If We Build It, Will They Come? A Pilot Study to Develop and Test Messages to Maximize Uptake of Coronavirus Vaccine When Available",Completed,NA,Not Applicable,1706,Actual,"University of Massachusetts, Worcester",,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:43:34Z,2021-12-02T06:43:34Z
NCT04705831,NA,1/7/2021,NA,NA,1/8/2021,1/8/2021,1/12/2021,Actual,NA,NA,NA,NA,NA,NA,1/8/2021,1/12/2021,Actual,30-Dec-20,Actual,12/30/2020,Jan-21,1/31/2021,Jan-22,Anticipated,1/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection,"A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection",Recruiting,NA,Phase 4,40,Anticipated,IMMUNOe Research Centers,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:43:58Z,2021-12-02T06:43:58Z
NCT04705753,NA,1/6/2021,NA,NA,1/11/2021,1/11/2021,1/12/2021,Actual,NA,NA,NA,NA,NA,NA,1/11/2021,1/12/2021,Actual,1-Apr-20,Actual,4/1/2020,Jan-21,1/31/2021,15-Oct-20,Actual,10/15/2020,15-Oct-20,Actual,10/15/2020,NA,Interventional,COVID-19-IAMA,NA,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients","Evaluation of the Clinical Outcomes and the Quality of Life of Patients Exhibiting Symptoms Characteristic of Viral Respiratory Infection (VRI), Including Infection by SARS-CoV-2 (COVID-19), and Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in These Patients and the People Cohabiting With Them Via an Open-label, Single-arm Trial",Completed,NA,Phase 2/Phase 3,20,Actual,University of Crete,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T06:44:26Z,2021-12-02T06:44:26Z
NCT04706039,NA,1/8/2021,NA,NA,7/12/2021,1/11/2021,1/12/2021,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/14/2021,Actual,1-Mar-21,Actual,3/1/2021,Jul-21,7/31/2021,Sep-21,Anticipated,9/30/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,COVIDAIR,NA,Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air,Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air,Recruiting,NA,Not Applicable,5000,Anticipated,Hospices Civils de Lyon,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:44:27Z,2021-12-02T06:44:27Z
NCT04703907,NA,1/8/2021,NA,NA,1/8/2021,1/8/2021,1/11/2021,Actual,NA,NA,NA,NA,NA,NA,1/8/2021,1/11/2021,Actual,3-Dec-20,Actual,12/3/2020,Jan-21,1/31/2021,Aug-21,Anticipated,8/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,AA_COVID,NA,Auricular Stimulation for Relief of Stress and Anxiety,"Auricular Stimulation (AS) vs. ""Waiting List"" for Relief of Stress and Anxiety in Health Care Workers During COVID-19 Pandemic - a Prospective Controlled Investigation",Recruiting,NA,Not Applicable,60,Anticipated,University Medicine Greifswald,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:45:52Z,2021-12-02T06:45:52Z
NCT04704063,NA,1/7/2021,NA,NA,9/28/2021,1/7/2021,1/11/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,10/6/2021,Actual,1-Jan-21,Actual,1/1/2021,Sep-21,9/30/2021,1-Jun-23,Anticipated,6/1/2023,30-Jan-23,Anticipated,1/30/2023,NA,Interventional,T3-NAFL,NA,Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL),"A Randomized, Double-Blind, Placebo-Controlled Study, to Assess the Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)",Recruiting,NA,Phase 2,170,Anticipated,Universiti Sains Malaysia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:45:58Z,2021-12-02T06:45:58Z
NCT04703608,NA,1/6/2021,NA,NA,6/3/2021,1/8/2021,1/11/2021,Actual,NA,NA,NA,NA,NA,NA,6/3/2021,6/4/2021,Actual,22-Jan-21,Actual,1/22/2021,Jun-21,6/30/2021,Jul-22,Anticipated,7/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,PaTS-COVID,NA,Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia,Prevention and Treatment for COVID -19 Associated Severe Pneumonia in The Gambia: a Single-Blinded Randomised Clinical Trial (PaTS-COVID),Recruiting,NA,Phase 3,1200,Anticipated,London School of Hygiene and Tropical Medicine,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:46:11Z,2021-12-02T06:46:11Z
NCT04703036,NA,1/6/2021,NA,NA,2/2/2021,1/8/2021,1/11/2021,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/4/2021,Actual,11-Jan-21,Actual,1/11/2021,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,"Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19",Randomized Trial of Supplementing Glycine and N-acetylcysteine vs. Placebo in COVID-19,Recruiting,NA,Early Phase 1,64,Anticipated,Baylor College of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:46:42Z,2021-12-02T06:46:42Z
NCT04703140,NA,11/30/2020,NA,NA,2/12/2021,1/8/2021,1/11/2021,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/15/2021,Actual,11-Feb-21,Actual,2/11/2021,Feb-21,2/28/2021,11-Sep-22,Anticipated,9/11/2022,11-Aug-22,Anticipated,8/11/2022,NA,Interventional,COVIDISC,NA,COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19,Evaluation of the Performance of COVIDISC Rapid Test for Diagnosis of SARS-CoV-2,Recruiting,NA,Not Applicable,350,Anticipated,CMC Ambroise ParÃ©,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:46:33Z,2021-12-02T06:46:33Z
NCT04703114,NA,11/30/2020,NA,NA,9/27/2021,1/7/2021,1/11/2021,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,9/28/2021,Actual,5-Feb-21,Actual,2/5/2021,Sep-21,9/30/2021,15-Sep-21,Actual,9/15/2021,15-Sep-21,Actual,9/15/2021,NA,Interventional,AMBUCOV,NA,Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV),Study of the Immunological and Virological Response of Patients Infected With SARS-CoV-2 and Presenting an Asymptomatic or Pauci-symptomatic Form,Completed,NA,Not Applicable,57,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:46:50Z,2021-12-02T06:46:50Z
NCT04701710,NA,1/7/2021,NA,NA,2/22/2021,1/7/2021,1/8/2021,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/23/2021,Actual,15-Oct-20,Actual,10/15/2020,Feb-21,2/28/2021,31-Dec-20,Actual,12/31/2020,18-Dec-20,Actual,12/18/2020,NA,Interventional,Ivercar-Tuc,NA,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,A Randomized Trial - Intensive Treatment Based in Ivermectin and Iota-carrageenan as Prophylaxis for Covid-19 In Healthcare Agents,Completed,NA,Phase 1/Phase 2,300,Actual,"Ministry of Public Health, Argentina",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,N/C,2021-12-02T06:48:02Z,2021-12-02T06:48:02Z
NCT04701528,NA,10/27/2020,NA,NA,1/7/2021,1/7/2021,1/8/2021,Actual,NA,NA,NA,NA,NA,NA,1/7/2021,1/8/2021,Actual,15-Nov-20,Actual,11/15/2020,Jan-21,1/31/2021,25-Oct-22,Anticipated,10/25/2022,25-Mar-22,Anticipated,3/25/2022,NA,Interventional,VOCOVID,NA,Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients,An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients - the VOCOVID Study,Recruiting,NA,Phase 2,20,Anticipated,Leiden University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:48:12Z,2021-12-02T06:48:12Z
NCT04701606,NA,1/6/2021,NA,NA,9/28/2021,1/6/2021,1/8/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/30/2021,Actual,29-Mar-21,Actual,3/29/2021,Sep-21,9/30/2021,15-Apr-22,Anticipated,4/15/2022,15-Apr-22,Anticipated,4/15/2022,NA,Interventional,PROVIDENCE,NA,The Safety and Efficacy of Pyronaridine-artesunate (PyramaxÂ® or ArtecomÂ®)in COVID-19 Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2/3 Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine-artesunate (ArtecomÂ®) in COVID-19 Patients",Recruiting,NA,Phase 2/Phase 3,402,Anticipated,Shin Poong Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:47:55Z,2021-12-02T06:47:55Z
NCT04701489,NA,1/5/2021,NA,NA,6/1/2021,1/6/2021,1/8/2021,Actual,NA,NA,NA,NA,NA,NA,6/1/2021,6/4/2021,Actual,14-Jan-21,Actual,1/14/2021,Jun-21,6/30/2021,7-Apr-21,Actual,4/7/2021,15-Mar-21,Actual,3/15/2021,NA,Interventional,NA,NA,UNITE Study (UMN-GE) for COVID-19,Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UMN-GE) for COVID-19,Completed,NA,Not Applicable,30,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:48:13Z,2021-12-02T06:48:13Z
NCT04700163,NA,1/5/2021,NA,NA,7/7/2021,1/5/2021,1/7/2021,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/8/2021,Actual,11-Jan-21,Actual,1/11/2021,Jul-21,7/31/2021,30-Jun-22,Anticipated,6/30/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,RU,NA,RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers,"A Phase 1, Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of a Combination of Two Anti-SARS-CoV-2 mAbs (C144-LS and C135-LS) in Healthy Volunteers","Active, not recruiting",NA,Phase 1,23,Actual,Rockefeller University,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:49:07Z,2021-12-02T06:49:07Z
NCT04700137,NA,1/5/2021,NA,NA,4/28/2021,1/5/2021,1/7/2021,Actual,NA,NA,NA,NA,NA,NA,4/28/2021,5/3/2021,Actual,18-Jan-21,Actual,1/18/2021,Apr-21,4/30/2021,17-Jan-22,Anticipated,1/17/2022,17-Jan-22,Anticipated,1/17/2022,NA,Interventional,MHAPPS,NA,"Mental Health Among Patients, Providers, and Staff During the COVID-19 Era","Investigating the Mental Health Impact of COVID-19 and Comparing the Effectiveness of Two Caring Contact Interventions on Patients, Providers, and Staff of St. Luke's Health System",Enrolling by invitation,NA,Not Applicable,660,Anticipated,"St. Luke's Health System, Boise, Idaho",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,5 years following the completion of the primary endpoint,"Data from this trial may be requested by other researchers 5 years after the completion of the primary endpoint by contacting the PI. The PI will ensure all mechanisms used to share data will include proper plans and safeguards for the protection of privacy, confidentiality, and security for data dissemination and reuse (e.g., all data will be thoroughly de-identified and will not be traceable to a specific study participant).",NA,Yes,Data from this trial may be requested from other researchers 5 years after the completion of the primary endpoint by contacting the PIs.,2021-12-02T06:49:20Z,2021-12-02T06:49:20Z
NCT04699851,NA,11/25/2020,NA,NA,1/6/2021,1/6/2021,1/7/2021,Actual,NA,NA,NA,NA,NA,NA,1/6/2021,1/8/2021,Actual,18-Nov-20,Actual,11/18/2020,Jan-21,1/31/2021,18-May-21,Anticipated,5/18/2021,18-Apr-21,Anticipated,4/18/2021,NA,Interventional,VIGIE-COVID,NA,Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens,Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens,Recruiting,NA,Not Applicable,1200,Anticipated,Laval University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,PULSAR santÃ© durable platform,2021-12-02T06:49:32Z,2021-12-02T06:49:32Z
NCT04699227,NA,1/6/2021,NA,NA,9/28/2021,1/6/2021,1/7/2021,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,9/29/2021,Actual,23-Apr-20,Actual,4/23/2020,Sep-21,9/30/2021,30-Apr-23,Anticipated,4/30/2023,30-Apr-23,Anticipated,4/30/2023,NA,Interventional,NA,NA,Can RIC Prevent Deterioration to Critical Care in Covid19,"CAN REMOTE ISCHAEMIC CONDITIONING REDUCE INFLAMMATORY MARKERS IN COVID-19 PATIENTS - A MULTI-SITE, RANDOMISED PILOT STUDY",Recruiting,NA,Not Applicable,20,Anticipated,University College London Hospitals,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"No identifiable, personal data will be collected as part of this study.",2021-12-02T06:50:12Z,2021-12-02T06:50:12Z
NCT04699916,NA,1/6/2021,NA,NA,9/23/2021,1/6/2021,1/7/2021,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/24/2021,Actual,4-Jan-21,Actual,1/4/2021,Sep-21,9/30/2021,23-Sep-21,Actual,9/23/2021,23-May-21,Actual,5/23/2021,NA,Interventional,NA,NA,EEG-based Sedation Protocol for Patients on Mechanical Ventilation Due to SARS-CoV-2 Pneumonia,EEG-based Protocol to Guide Deep Sedation Decreases the Days of Mechanical Ventilation in Patients With SARS-CoV-2 Pneumonia: Randomized Clinical Trial,Completed,NA,Not Applicable,50,Actual,University of Chile,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:49:27Z,2021-12-02T06:49:27Z
NCT04698993,NA,1/5/2021,6/16/2021,NA,7/19/2021,1/6/2021,1/7/2021,Actual,6/23/2021,6/25/2021,Actual,NA,NA,NA,7/19/2021,7/20/2021,Actual,12-Feb-21,Actual,2/12/2021,Jul-21,7/31/2021,22-Mar-21,Actual,3/22/2021,22-Mar-21,Actual,3/22/2021,NA,Interventional,NA,NA,DrÃ¤ger COVID-19 Antigen Test Clinical Performance Study,DrÃ¤ger Antigen Test SARS-CoV-2 Clinical Performance Study,Terminated,NA,Not Applicable,388,Actual,DrÃ¤gerwerk AG & Co. KGaA,,2,NA,poor recruitment,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:50:47Z,2021-12-02T06:50:47Z
NCT04698798,NA,1/4/2021,NA,NA,7/7/2021,1/4/2021,1/7/2021,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/8/2021,Actual,2-Jan-21,Actual,1/2/2021,Jul-21,7/31/2021,3-Apr-21,Actual,4/3/2021,3-Apr-21,Actual,4/3/2021,NA,Interventional,SMW,NA,Skeletal Muscle Wasting in SARS-CoV-2,Skeletal Muscle Wasting in SARS-CoV-2 Infected ICU (Intensive Care Unit) Patients,Completed,NA,Not Applicable,22,Actual,Hasselt University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T06:50:43Z,2021-12-02T06:50:43Z
NCT04695743,NA,12/11/2020,NA,NA,1/4/2021,1/4/2021,1/5/2021,Actual,NA,NA,NA,NA,NA,NA,1/4/2021,1/5/2021,Actual,1-Sep-20,Actual,9/1/2020,Jan-21,1/31/2021,1-Sep-22,Anticipated,9/1/2022,1-Jun-22,Anticipated,6/1/2022,NA,Interventional,NA,NA,Group CST Using Zoom: A Proof of Concept Study,Virtual CST - A Collaborative Proof of Concept Study With FaceCog HK in Response to the Covid-19 Pandemic,Recruiting,NA,Not Applicable,50,Anticipated,"University College, London",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:53:16Z,2021-12-02T06:53:16Z
NCT04695197,NA,12/14/2020,NA,NA,2/23/2021,1/4/2021,1/5/2021,Actual,NA,NA,NA,NA,NA,NA,2/23/2021,2/24/2021,Actual,8-Jan-21,Actual,1/8/2021,Feb-21,2/28/2021,31-Jul-23,Anticipated,7/31/2023,1-Nov-22,Anticipated,11/1/2022,NA,Interventional,MALCOV,NA,Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso,Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso,Recruiting,NA,Phase 3,142,Anticipated,Liverpool School of Tropical Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,As soon as the full study findings have been published or based on any data requests that may occur during the study or analysis is still ongoing.,"Data access will be provided to researchers after a proposal has been approved by an independent review committee identified for this purpose. An agreement on how to collaborate will be reached based on any overlap between the proposal and any ongoing efforts. Proposals can be directed to email addresses provided in the publications and websites. To gain access, data requesters will need to sign a data-sharing agreement. The only limits to data sharing will be to safeguard research participants' confidentiality. External users will be bound by data-sharing agreements in line with the Data Sharing Policy from the respective Sponsors and the Gates Foundation to ensure that the privacy of individuals is protected. The agreement will prohibit any attempt to (a) identify study participants from the data or otherwise breach confidentiality, (b) make unapproved contact with study participants.",NA,Yes,"We will encourage data sharing to ensure that the scientific potential of this study is maximized. The full anonymized research database will be made publicly available as soon as the full study findings have been published or based on any data requests that may occur during the study or analysis is still ongoing. For the databases, we will use a controlled access approach.",2021-12-02T06:53:26Z,2021-12-02T06:53:26Z
NCT04695301,NA,12/29/2020,NA,NA,1/26/2021,1/4/2021,1/5/2021,Actual,NA,NA,NA,NA,NA,NA,1/26/2021,1/29/2021,Actual,1-Jul-20,Actual,7/1/2020,Jul-20,7/31/2020,Aug-21,Anticipated,8/31/2021,1-Jul-21,Anticipated,7/1/2021,NA,Interventional,NA,NA,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Recruiting,NA,Not Applicable,50,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,when to published,NA,NA,Yes,all IPD that underlie results in a publication,2021-12-02T06:53:45Z,2021-12-02T06:53:45Z
NCT04694612,NA,12/15/2020,NA,NA,1/3/2021,1/3/2021,1/5/2021,Actual,NA,NA,NA,NA,NA,NA,1/3/2021,1/5/2021,Actual,1-Jan-21,Anticipated,1/1/2021,Jan-21,1/31/2021,31-May-21,Anticipated,5/31/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal,"Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal: a Multi-center, Randomized, Open-labelled, Phase III Clinical Trial",Recruiting,NA,Phase 3,676,Anticipated,Nepal Health Research Council,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:53:48Z,2021-12-02T06:53:48Z
NCT04694638,NA,7/14/2020,NA,NA,8/12/2021,1/3/2021,1/5/2021,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/13/2021,Actual,21-May-20,Actual,5/21/2020,Aug-21,8/31/2021,Jul-22,Anticipated,7/31/2022,Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,"Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection","The Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in Acute Hypoxemic and/or Hypercapnic Respiratory Failure Secondary to COVID-19 Infection: A Feasibility, Safety Phase One, Open Label Study",Recruiting,NA,Not Applicable,24,Anticipated,Mayo Clinic,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:54:05Z,2021-12-02T06:54:05Z
NCT04693026,NA,12/30/2020,NA,NA,12/31/2020,12/31/2020,1/5/2021,Actual,NA,NA,NA,NA,NA,NA,12/31/2020,1/5/2021,Actual,10-Sep-20,Actual,9/10/2020,Dec-20,12/31/2020,5-Mar-21,Anticipated,3/5/2021,15-Feb-21,Anticipated,2/15/2021,NA,Interventional,NA,NA,Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients,Efficacy of Ramdicivir and Baricitinib Combination Therapy for the Treatment of COVID 19 ARDS,Recruiting,NA,Phase 3,150,Anticipated,M Abdur Rahim Medical College and Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:55:33Z,2021-12-02T06:55:33Z
NCT04691947,NA,11/14/2020,NA,NA,12/31/2020,12/30/2020,12/31/2020,Actual,NA,NA,NA,NA,NA,NA,12/31/2020,1/5/2021,Actual,5-Nov-20,Actual,11/5/2020,Dec-20,12/31/2020,15-Mar-22,Anticipated,3/15/2022,1-Mar-21,Anticipated,3/1/2021,NA,Interventional,ERUCOV-VAC,NA,Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC,"Phase 1 Study for the Determination of Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Recruiting,NA,Phase 1,44,Anticipated,Health Institutes of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:56:33Z,2021-12-02T06:56:33Z
NCT04690920,NA,12/19/2020,NA,NA,12/30/2020,12/30/2020,12/31/2020,Actual,NA,NA,NA,NA,NA,NA,12/30/2020,12/31/2020,Actual,23-Jul-20,Actual,7/23/2020,Dec-20,12/31/2020,10-Dec-20,Actual,12/10/2020,10-Dec-20,Actual,12/10/2020,NA,Interventional,NA,NA,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach,Completed,NA,Not Applicable,200,Actual,University of Lahore,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,"statistical analysis, results",2021-12-02T06:56:58Z,2021-12-02T06:56:58Z
NCT04690413,NA,8/31/2020,NA,NA,3/2/2021,12/29/2020,12/30/2020,Actual,NA,NA,NA,NA,NA,NA,3/2/2021,3/3/2021,Actual,1-Sep-20,Actual,9/1/2020,Mar-21,3/31/2021,31-Dec-20,Actual,12/31/2020,31-Dec-20,Actual,12/31/2020,NA,Interventional,NA,NA,NOWDx Test for the Detection of Antibodies to COVID-19,NOWDx Test for the Detection of Antibodies to COVID-19,Completed,NA,Not Applicable,129,Actual,"NOWDiagnostics, Inc.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:57:46Z,2021-12-02T06:57:46Z
NCT04691908,NA,12/21/2020,NA,NA,7/23/2021,12/29/2020,12/31/2020,Actual,NA,NA,NA,NA,NA,NA,7/23/2021,7/26/2021,Actual,25-Dec-20,Actual,12/25/2020,Dec-20,12/31/2020,11-Jul-21,Actual,7/11/2021,26-Apr-21,Actual,4/26/2021,NA,Interventional,NA,NA,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine","Multicenter, Randomized, Blind, Placebo-controlled Clinical Study of III Phase on Assessment of Preventive Efficiency, Safety and Immunogenicity QazCovid-inÂ®-Vaccine Against COVID-19 in Healthy Adult Volunteers",Completed,NA,Phase 3,3000,Actual,Research Institute for Biological Safety Problems,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:56:25Z,2021-12-02T06:56:25Z
NCT04689399,NA,12/26/2020,NA,NA,3/25/2021,12/28/2020,12/30/2020,Actual,NA,NA,NA,NA,NA,NA,3/25/2021,3/30/2021,Actual,26-Dec-20,Actual,12/26/2020,Mar-21,3/31/2021,25-Mar-21,Actual,3/25/2021,25-Mar-21,Actual,3/25/2021,NA,Interventional,NA,NA,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Completed,NA,Not Applicable,4697,Actual,"Rigshospitalet, Denmark",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T06:58:40Z,2021-12-02T06:58:40Z
NCT04687488,NA,12/3/2020,NA,NA,12/22/2020,12/22/2020,12/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/22/2020,12/29/2020,Actual,23-Jul-20,Actual,7/23/2020,Dec-20,12/31/2020,9-Nov-20,Actual,11/9/2020,9-Nov-20,Actual,11/9/2020,NA,Interventional,NA,NA,Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations,COVID-19: The Study of Aerosol Generation and Droplet Dispersion and Deposition During Naso-gastric Intubation for Gastrointestinal Motility Investigations,Completed,NA,Not Applicable,15,Actual,Universitaire Ziekenhuizen Leuven,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:00:52Z,2021-12-02T07:00:52Z
NCT04686760,NA,12/24/2020,NA,NA,5/20/2021,12/25/2020,12/29/2020,Actual,NA,NA,NA,NA,NA,NA,5/20/2021,5/24/2021,Actual,15-Nov-20,Actual,11/15/2020,May-21,5/31/2021,15-Nov-21,Anticipated,11/15/2021,15-Nov-21,Anticipated,11/15/2021,NA,Interventional,NA,NA,Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients,Efficacy of Inhaled Nitroglycerin in Moderate to Severe Cases of COVID-19 Patients,Recruiting,NA,Not Applicable,30,Anticipated,University of Lahore,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:01:33Z,2021-12-02T07:01:33Z
NCT04686539,NA,12/18/2020,NA,NA,9/26/2021,12/24/2020,12/28/2020,Actual,NA,NA,NA,NA,NA,NA,9/26/2021,9/28/2021,Actual,20-Jan-21,Actual,1/20/2021,Sep-21,9/30/2021,Jan-22,Anticipated,1/31/2022,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Synthetic CBD as a Therapy for COVID-19,Synthetic CBD Oil Droplets as a Therapy for Mild to Moderate SARS-CoV-2 Infection. Assesment of Efficacy and Safety.,Recruiting,NA,Phase 1,50,Anticipated,Sheba Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:01:37Z,2021-12-02T07:01:37Z
NCT04684446,NA,12/23/2020,NA,NA,9/20/2021,12/23/2020,12/24/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/21/2021,Actual,15-Sep-21,Actual,9/15/2021,Sep-21,9/30/2021,8-Apr-22,Anticipated,4/8/2022,8-Apr-22,Anticipated,4/8/2022,NA,Interventional,NA,NA,Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19,A Phase I/II Single-Blinded Randomized Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID 19,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,R-Pharm,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-12-02T07:04:09Z,2021-12-02T07:04:09Z
NCT04685447,NA,12/22/2020,NA,NA,4/11/2021,12/23/2020,12/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/11/2021,4/13/2021,Actual,16-Mar-20,Actual,3/16/2020,Apr-21,4/30/2021,1-Dec-21,Anticipated,12/1/2021,20-Apr-20,Actual,4/20/2020,NA,Interventional,NA,NA,Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients,Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients Affected by COVID-19: Effects of 2 Different Dialysis Strategies,Recruiting,NA,Not Applicable,30,Anticipated,Universita degli Studi di Genova,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:02:51Z,2021-12-02T07:02:51Z
NCT04685512,NA,11/16/2020,NA,NA,6/29/2021,12/24/2020,12/28/2020,Actual,NA,NA,NA,NA,NA,NA,6/29/2021,7/1/2021,Actual,18-Nov-20,Actual,11/18/2020,Jun-21,6/30/2021,1-May-21,Actual,5/1/2021,1-Apr-21,Actual,4/1/2021,NA,Interventional,AR0-CORONA,NA,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Effect of Tenofovir/Emtricitabine Short Course on Viral Clearance in Patients Recently Infected With SARS-COV2 (Covid-19) Not Requiring Hospitalization: a Phase IIB/III Multicenter Open-label Randomized Controlled Trial,Completed,NA,Phase 2/Phase 3,60,Actual,"University Hospital, Caen",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,We encourage contact the corresponding author for academic IPD sharing,2021-12-02T07:02:44Z,2021-12-02T07:02:44Z
NCT04685603,NA,12/22/2020,NA,NA,12/24/2020,12/24/2020,12/28/2020,Actual,NA,NA,NA,NA,NA,NA,12/24/2020,12/29/2020,Actual,7-Dec-20,Actual,12/7/2020,Dec-20,12/31/2020,31-Jan-22,Anticipated,1/31/2022,31-Jan-21,Anticipated,1/31/2021,NA,Interventional,NA,NA,Dendritic Cell Vaccine to Prevent COVID-19,"Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Recruiting,NA,Phase 1,27,Anticipated,Indonesia-MoH,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:02:50Z,2021-12-02T07:02:50Z
NCT04685213,NA,12/23/2020,NA,NA,4/22/2021,12/23/2020,12/28/2020,Actual,NA,NA,NA,NA,NA,NA,4/22/2021,4/26/2021,Actual,18-Aug-20,Actual,8/18/2020,Apr-21,4/30/2021,18-Aug-21,Anticipated,8/18/2021,18-Aug-21,Anticipated,8/18/2021,NA,Interventional,COVID-19,NA,Electrical Stimulation for Critically Ill Covid-19 Patients,Electrical Stimulation Therapy for Preventing Hospital-acquired Weakness in Critically Ill COVID-19 Patients - A Proof of Concept Randomized Controlled Trial,Recruiting,NA,Phase 1,20,Anticipated,Baylor College of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:03:19Z,2021-12-02T07:03:19Z
NCT04681859,NA,12/22/2020,NA,NA,7/24/2021,12/22/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,7/24/2021,7/27/2021,Actual,17-Apr-21,Actual,4/17/2021,Jul-21,7/31/2021,9-Aug-21,Anticipated,8/9/2021,9-Jul-21,Actual,7/9/2021,NA,Interventional,OxyJet-CPAP,NA,Evaluation of a Low-cost CPAP Device on Hospitalized COVID-19 Patients,Safety and Efficacy Evaluation of a Low-cost CPAP Device for Hypoxemic COVID-19 Patients: A Pilot Study,"Active, not recruiting",NA,Not Applicable,45,Actual,Bangladesh University of Engineering and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:06:17Z,2021-12-02T07:06:17Z
NCT04682574,NA,12/22/2020,NA,NA,12/24/2020,12/22/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,12/24/2020,12/28/2020,Actual,2-Nov-20,Actual,11/2/2020,Dec-20,12/31/2020,10-Jan-21,Anticipated,1/10/2021,30-Dec-20,Anticipated,12/30/2020,NA,Interventional,NA,NA,Role of Mega Dose of Vitamin C in Critical COVID-19 Patients,Efficacy of Mega Dose Vitamin C in Critically Ill COVID-19 Patients,Recruiting,NA,Not Applicable,15,Anticipated,University of Lahore,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:06:05Z,2021-12-02T07:06:05Z
NCT04682041,NA,12/18/2020,NA,NA,1/27/2021,12/22/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,1/27/2021,1/28/2021,Actual,22-Dec-20,Actual,12/22/2020,Jan-21,1/31/2021,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,PICNIC,NA,Evaluating the Impact of EnteraGam In People With COVID-19,"Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention Containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People With COVID-19",Recruiting,NA,Not Applicable,420,Anticipated,"Entera Health, Inc",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:06:40Z,2021-12-02T07:06:40Z
NCT04680858,NA,12/17/2020,NA,NA,12/28/2020,12/17/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,12/28/2020,12/31/2020,Actual,1-Jul-20,Actual,7/1/2020,Dec-20,12/31/2020,15-Feb-21,Anticipated,2/15/2021,31-Jan-21,Anticipated,1/31/2021,NA,Interventional,EndoCom,NA,Impact of Digital Communication Assist Tools in Endoscopic Team Communication During COVID-19,Impact of Digital Enhanced Telecommunication for Team Communication in Endoscopic Procedures During COVID-19 Pandemic,Enrolling by invitation,NA,Not Applicable,500,Anticipated,University of Ulm,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:07:40Z,2021-12-02T07:07:40Z
NCT04679909,NA,12/21/2020,NA,NA,7/14/2021,12/21/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,7/14/2021,7/15/2021,Actual,25-Feb-21,Actual,2/25/2021,Jul-21,7/31/2021,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,NA,NA,Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study),"A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses","Active, not recruiting",NA,Phase 1,92,Actual,"Altimmune, Inc.",,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:08:19Z,2021-12-02T07:08:19Z
NCT04679493,NA,12/18/2020,NA,NA,9/21/2021,12/21/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/22/2021,Actual,17-Dec-20,Actual,12/17/2020,Sep-21,9/30/2021,9-Apr-21,Actual,4/9/2021,9-Apr-21,Actual,4/9/2021,NA,Interventional,NA,NA,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers","Double Blind, Randomized, Placebo-controlled Study of Safety, Tolerability, and Pharmacokinetics of Ascending Doses of XC7 After Single and Multiple Oral Administration in Healthy Volunteers",Completed,NA,Phase 1,16,Actual,NP Therapeutics,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:08:53Z,2021-12-02T07:08:53Z
NCT04681053,NA,12/16/2020,NA,NA,2/22/2021,12/21/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/24/2021,Actual,25-Feb-21,Anticipated,2/25/2021,Dec-20,12/31/2020,31-Dec-21,Anticipated,12/31/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,CCOVID-19,NA,Inhaled Ivermectin and COVID-19,Efficacy and Safety of Inhaled Ivermectin in the Treatment of SARS-COV-2 (COVID-19),Recruiting,NA,Phase 3,80,Anticipated,Mansoura University,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:07:23Z,2021-12-02T07:07:23Z
NCT04681430,NA,12/17/2020,NA,NA,5/3/2021,12/22/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,5/3/2021,5/4/2021,Actual,8-Jan-21,Actual,1/8/2021,May-21,5/31/2021,Nov-21,Anticipated,11/30/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,RES-Q-HR,NA,Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Recruiting,NA,Phase 2,1094,Anticipated,"Heinrich-Heine University, Duesseldorf",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:07:24Z,2021-12-02T07:07:24Z
NCT04681001,NA,12/21/2020,NA,NA,1/7/2021,12/22/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,1/7/2021,1/11/2021,Actual,20-Dec-20,Actual,12/20/2020,Dec-20,12/31/2020,30-Jun-21,Anticipated,6/30/2021,30-May-21,Anticipated,5/30/2021,NA,Interventional,NA,NA,"Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers",Clinical Trial to Evaluate the Efficacy of an Iota-Carrageenan Nasal Spray to Reduce Symptoms Caused by SARS-CoV-2 and Other Respiratory Viruses in Healthcare Workers Managing COVID-19 Patients,Recruiting,NA,Not Applicable,300,Anticipated,Marinomed Biotech AG,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:07:26Z,2021-12-02T07:07:26Z
NCT04680949,NA,12/18/2020,NA,NA,4/2/2021,12/22/2020,12/23/2020,Actual,NA,NA,NA,NA,NA,NA,4/2/2021,4/5/2021,Actual,23-Dec-20,Actual,12/23/2020,Apr-21,4/30/2021,20-Dec-21,Anticipated,12/20/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,SAVE-MORE,NA,suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19,"suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial","Active, not recruiting",NA,Phase 3,606,Actual,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:07:31Z,2021-12-02T07:07:31Z
NCT04679350,NA,12/21/2020,NA,NA,8/24/2021,12/21/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/26/2021,Actual,18-Mar-21,Actual,3/18/2021,Dec-20,12/31/2020,30-Dec-21,Anticipated,12/30/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia,"A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous(IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients",Recruiting,NA,Phase 2,48,Anticipated,"ImmuneMed, Inc.",,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:09:15Z,2021-12-02T07:09:15Z
NCT04679415,NA,12/21/2020,NA,NA,8/24/2021,12/21/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/26/2021,Actual,17-Dec-20,Actual,12/17/2020,Dec-20,12/31/2020,19-Aug-21,Actual,8/19/2021,19-Aug-21,Actual,8/19/2021,NA,Interventional,NA,NA,Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia,"A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous (IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients",Completed,NA,Phase 2,63,Actual,"ImmuneMed, Inc.",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:09:17Z,2021-12-02T07:09:17Z
NCT04676867,NA,12/17/2020,NA,NA,6/1/2021,12/18/2020,12/21/2020,Actual,NA,NA,NA,NA,NA,NA,6/1/2021,6/2/2021,Actual,11-Jan-21,Actual,1/11/2021,Jun-21,6/30/2021,17-May-21,Actual,5/17/2021,17-May-21,Actual,5/17/2021,NA,Interventional,NA,NA,Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19,"A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19",Completed,NA,Phase 2,227,Actual,DalCor Pharmaceuticals,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:11:51Z,2021-12-02T07:11:51Z
NCT04678700,NA,12/12/2020,NA,NA,2/1/2021,12/19/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,2/1/2021,2/3/2021,Actual,1-Mar-21,Anticipated,3/1/2021,Dec-20,12/31/2020,1-Aug-21,Anticipated,8/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Recruiting,NA,Not Applicable,40,Anticipated,European University of Madrid,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:09:55Z,2021-12-02T07:09:55Z
NCT04678739,NA,12/19/2020,NA,NA,3/31/2021,12/21/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,3/31/2021,4/2/2021,Actual,15-Aug-20,Actual,8/15/2020,Mar-21,3/31/2021,10-Feb-21,Actual,2/10/2021,30-Jan-21,Actual,1/30/2021,NA,Interventional,NA,NA,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Completed,NA,Phase 3,205,Actual,M Abdur Rahim Medical College and Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:09:56Z,2021-12-02T07:09:56Z
NCT04678830,NA,12/14/2020,NA,NA,7/30/2021,12/18/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,7/30/2021,8/2/2021,Actual,1-Mar-21,Actual,3/1/2021,Jul-21,7/31/2021,8-Jul-21,Actual,7/8/2021,5-Jun-21,Actual,6/5/2021,NA,Interventional,NA,NA,COVID-19 Long-Haulers Study,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]",Completed,NA,Phase 2,56,Actual,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:09:52Z,2021-12-02T07:09:52Z
NCT04678778,NA,12/11/2020,NA,NA,4/27/2021,12/21/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/29/2021,Actual,19-Mar-19,Actual,3/19/2019,Apr-21,4/30/2021,19-Feb-21,Actual,2/19/2021,19-Feb-21,Actual,2/19/2021,NA,Interventional,NRVR,NA,Virtual Reality Study - COVID-19 Protocol,Targeted Physical and Cognitive Activity in a VR Environment - COVID-19 Protocol,Completed,NA,Not Applicable,14,Actual,University of Southern California,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:09:53Z,2021-12-02T07:09:53Z
NCT04678687,NA,12/2/2020,NA,NA,2/2/2021,12/19/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/3/2021,Actual,1-Jan-21,Actual,1/1/2021,Feb-21,2/28/2021,1-Jan-22,Anticipated,1/1/2022,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,COVID-19 and Tissue Damage in Vital Organs,Evaluation of Postmortem Biopsy Specimens of COVID-19 Cases,"Active, not recruiting",NA,Not Applicable,10,Anticipated,Dokuz Eylul University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:10:36Z,2021-12-02T07:10:36Z
NCT04677270,NA,12/18/2020,NA,NA,12/18/2020,12/18/2020,12/21/2020,Actual,NA,NA,NA,NA,NA,NA,12/18/2020,12/21/2020,Actual,31-Aug-20,Actual,8/31/2020,Dec-20,12/31/2020,30-Nov-20,Actual,11/30/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,COVIDPROBLEM,NA,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Completed,NA,Not Applicable,397,Actual,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:11:52Z,2021-12-02T07:11:52Z
NCT04677660,NA,12/18/2020,NA,NA,5/17/2021,12/18/2020,12/21/2020,Actual,NA,NA,NA,NA,NA,NA,5/17/2021,5/19/2021,Actual,21-Jan-21,Actual,1/21/2021,May-21,5/31/2021,3-Mar-22,Anticipated,3/3/2022,3-Mar-22,Anticipated,3/3/2022,NA,Interventional,NA,NA,A Study of TAK-919 in Healthy Japanese Adults (COVID-19),"A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TAK-919 by Intramuscular Injection in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)","Active, not recruiting",NA,Phase 1/Phase 2,200,Anticipated,Takeda,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2021-12-02T07:11:11Z,2021-12-02T07:11:11Z
NCT04676971,NA,12/16/2020,NA,NA,11/29/2021,12/17/2020,12/21/2020,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,12/1/2021,Estimate,11-Dec-20,Actual,12/11/2020,Dec-20,12/31/2020,28-Oct-21,Actual,10/28/2021,29-Aug-21,Actual,8/29/2021,NA,Interventional,NA,NA,Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia,"Efficacy and Safety of Intravenously Administered hzVSF-v13 in Patients With COVID-19 Pneumonia: a Phase II, Proof of Concept, Multicentre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study",Completed,NA,Phase 2,115,Actual,"ImmuneMed, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:11:49Z,2021-12-02T07:11:49Z
NCT04674189,NA,12/14/2020,NA,NA,7/20/2021,12/14/2020,12/19/2020,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,23-Dec-20,Actual,12/23/2020,Jan-21,1/31/2021,12-Jul-22,Anticipated,7/12/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19,"COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)","Active, not recruiting",NA,Phase 3,2360,Actual,CureVac AG,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:14:04Z,2021-12-02T07:14:04Z
NCT04674644,NA,12/16/2020,1/2/2021,NA,1/30/2021,12/17/2020,12/19/2020,Actual,1/27/2021,1/29/2021,Actual,NA,NA,NA,1/30/2021,2/2/2021,Actual,16-Oct-20,Actual,10/16/2020,Jan-21,1/31/2021,23-Oct-20,Actual,10/23/2020,23-Oct-20,Actual,10/23/2020,NA,Interventional,NA,NA,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department,Completed,NA,Not Applicable,850,Actual,Suleyman Demirel University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:13:39Z,2021-12-02T07:13:39Z
NCT04674566,NA,12/17/2020,NA,NA,8/2/2021,12/17/2020,12/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/4/2021,Actual,21-Apr-21,Actual,4/21/2021,May-21,5/31/2021,30-Oct-21,Anticipated,10/30/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,NA,NA,Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19,"Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, First-in-human, Phase Ib/II Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of COR-101 in Hospitalized Patients",Recruiting,NA,Phase 1/Phase 2,45,Anticipated,Corat Therapeutics Gmbh,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:13:43Z,2021-12-02T07:13:43Z
NCT04673149,NA,12/11/2020,NA,NA,12/23/2020,12/15/2020,12/17/2020,Actual,NA,NA,NA,NA,NA,NA,12/23/2020,12/24/2020,Actual,23-Dec-20,Actual,12/23/2020,Dec-20,12/31/2020,31-Dec-22,Anticipated,12/31/2022,31-Jul-22,Anticipated,7/31/2022,NA,Interventional,NA,NA,GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19),"Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,345,Anticipated,"GeneOne Life Science, Inc.",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:15:10Z,2021-12-02T07:15:10Z
NCT04673318,NA,10/23/2020,NA,NA,4/27/2021,12/16/2020,12/17/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/28/2021,Actual,26-Feb-21,Actual,2/26/2021,Oct-20,10/31/2020,Dec-24,Anticipated,12/31/2024,Dec-24,Anticipated,12/31/2024,NA,Interventional,NA,NA,Physical Rehabilitation of COVID-19 Survivors by Heat Therapy,Physical Rehabilitation of COVID-19 Survivors by Heat Therapy,Recruiting,NA,Not Applicable,87,Anticipated,"University of Massachusetts, Amherst",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:14:49Z,2021-12-02T07:14:49Z
NCT04673214,NA,12/16/2020,3/8/2021,NA,8/12/2021,12/16/2020,12/17/2020,Actual,8/12/2021,8/16/2021,Actual,NA,NA,NA,8/12/2021,8/16/2021,Actual,16-Dec-20,Actual,12/16/2020,Aug-21,8/31/2021,25-Feb-21,Actual,2/25/2021,25-Feb-21,Actual,2/25/2021,NA,Interventional,NA,"Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.",Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20,Completed,NA,Phase 3,114,Actual,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,SHARED VIA EMAIL IF OTHER RESEARCHERS REQUIRE IT,2021-12-02T07:15:11Z,2021-12-02T07:15:11Z
NCT04672291,NA,10/5/2020,NA,NA,8/17/2021,12/15/2020,12/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/17/2021,8/18/2021,Actual,21-Jul-21,Actual,7/21/2021,Feb-21,2/28/2021,31-Jan-23,Anticipated,1/31/2023,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Nasal Poly-ICLC (HiltonolÂ®) in Healthy COVID-19 Vaccinated Adults,"A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Center, Safety and Immunogenicity Study of Nasal Poly-ICLC (HiltonolÂ®) in Healthy COVID-19 Vaccinated Adults",Recruiting,NA,Phase 1,43,Anticipated,"Oncovir, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:15:55Z,2021-12-02T07:15:55Z
NCT04669015,NA,12/14/2020,NA,NA,7/26/2021,12/14/2020,12/16/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/27/2021,Actual,10-Jun-21,Actual,6/10/2021,Jul-21,7/31/2021,Aug-21,Anticipated,8/31/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NOVATION-1,NA,Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19,"NOVATION-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients With Moderate to Severe COVID-19",Recruiting,NA,Phase 3,914,Anticipated,Genova Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:18:34Z,2021-12-02T07:18:34Z
NCT04668625,NA,12/9/2020,NA,NA,2/5/2021,12/14/2020,12/16/2020,Actual,NA,NA,NA,NA,NA,NA,2/5/2021,2/8/2021,Actual,30-Nov-20,Actual,11/30/2020,Jan-21,1/31/2021,8-Jan-21,Actual,1/8/2021,20-Dec-20,Actual,12/20/2020,NA,Interventional,NA,NA,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures: Randomized Study,Completed,NA,Not Applicable,1000,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:18:49Z,2021-12-02T07:18:49Z
NCT04668339,NA,11/25/2020,NA,NA,3/26/2021,12/10/2020,12/16/2020,Actual,NA,NA,NA,NA,NA,NA,3/26/2021,3/29/2021,Actual,7-Jan-21,Actual,1/7/2021,Mar-21,3/31/2021,30-Apr-22,Anticipated,4/30/2022,30-Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,"A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants","Active, not recruiting",NA,Phase 2,600,Anticipated,"Arcturus Therapeutics, Inc.",,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-12-02T07:19:03Z,2021-12-02T07:19:03Z
NCT04668469,NA,11/25/2020,NA,NA,12/11/2020,12/11/2020,12/16/2020,Actual,NA,NA,NA,NA,NA,NA,12/11/2020,12/16/2020,Actual,8-Jun-20,Actual,6/8/2020,Dec-20,12/31/2020,30-Oct-20,Actual,10/30/2020,15-Sep-20,Actual,9/15/2020,NA,Interventional,NA,NA,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Completed,NA,Not Applicable,600,Actual,Benha University,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:19:04Z,2021-12-02T07:19:04Z
NCT04668950,NA,12/11/2020,NA,NA,11/29/2021,12/11/2020,12/16/2020,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,12/1/2021,Estimate,22-Dec-20,Actual,12/22/2020,Nov-21,11/30/2021,28-Sep-21,Actual,9/28/2021,4-Jun-21,Actual,6/4/2021,NA,Interventional,NA,NA,Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2),"Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial",Completed,NA,Phase 3,683,Actual,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:18:47Z,2021-12-02T07:18:47Z
NCT04668235,NA,12/4/2020,NA,NA,9/14/2021,12/14/2020,12/16/2020,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/20/2021,Actual,23-Apr-21,Actual,4/23/2021,May-21,5/31/2021,Dec-21,Anticipated,12/31/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected),"Evaluation of Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected): Phase III, Randomized, Double-blind, PLACEBO Controlled Trial",Recruiting,NA,Phase 3,342,Anticipated,HRH Pharmaceuticals Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:19:16Z,2021-12-02T07:19:16Z
NCT04665193,NA,12/8/2020,NA,NA,4/29/2021,12/10/2020,12/11/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2021,5/4/2021,Actual,23-Nov-20,Actual,11/23/2020,Apr-21,4/30/2021,28-Apr-21,Actual,4/28/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,NA,NA,An Approach to Screening for COVID-19 at Vancouver Airport,An Approach to Screening for SARS-CoV-2 at YVR: UBC-PHC-WestJet-YVR COVID-19 Screening Study,Completed,NA,Not Applicable,592,Actual,University of British Columbia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:21:57Z,2021-12-02T07:21:57Z
NCT04666012,NA,12/10/2020,NA,NA,7/26/2021,12/11/2020,12/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/28/2021,Actual,29-Dec-20,Actual,12/29/2020,Jul-21,7/31/2021,Apr-22,Anticipated,4/30/2022,9-Jul-21,Actual,7/9/2021,NA,Interventional,NA,NA,Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Phase 1/2a Study (Dose Escalation, Single Center, Open, Phase 1 and Multicenter, Open, Phase 2a) to Assess the Safety and Immunogenicity of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,150,Actual,"Cellid Co., Ltd.",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:21:10Z,2021-12-02T07:21:10Z
NCT04666116,NA,4/25/2020,NA,NA,12/11/2020,12/11/2020,12/14/2020,Actual,NA,NA,NA,NA,NA,NA,12/11/2020,12/16/2020,Actual,1-Apr-20,Actual,4/1/2020,Dec-20,12/31/2020,Feb-21,Anticipated,2/28/2021,Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Changes in Viral Load in COVID-19 After Probiotics,Changes in Viral Load in Patients With COVID-19 Disease After Dietary Supplementation With Probiotics: A Randomized Clinical Trial,Recruiting,NA,Not Applicable,96,Anticipated,Hospital de Sagunto,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:21:17Z,2021-12-02T07:21:17Z
NCT04667286,NA,12/11/2020,NA,NA,4/15/2021,12/11/2020,12/14/2020,Actual,NA,NA,NA,NA,NA,NA,4/15/2021,4/19/2021,Actual,16-Jan-21,Actual,1/16/2021,Apr-21,4/30/2021,1-Jul-21,Anticipated,7/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,Awake Pronation for Covid-19 Treatment,"Pronation in Spontaneously Breathing Patients With Acute Respiratory Failure Deu to Covid-19: Multicenter, Randomised Study",Recruiting,NA,Not Applicable,100,Anticipated,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:19:48Z,2021-12-02T07:19:48Z
NCT04666441,NA,12/10/2020,NA,NA,9/30/2021,12/10/2020,12/14/2020,Actual,NA,NA,NA,NA,NA,NA,9/30/2021,10/8/2021,Actual,15-Dec-20,Actual,12/15/2020,Sep-21,9/30/2021,21-Sep-21,Actual,9/21/2021,4-Mar-21,Actual,3/4/2021,NA,Interventional,NA,NA,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection,Completed,NA,Phase 2,1164,Actual,Regeneron Pharmaceuticals,,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-12-02T07:20:53Z,2021-12-02T07:20:53Z
NCT04666558,NA,11/30/2020,NA,NA,12/7/2020,12/7/2020,12/14/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2020,12/14/2020,Actual,30-Nov-20,Actual,11/30/2020,Dec-20,12/31/2020,17-Dec-21,Anticipated,12/17/2021,17-Dec-21,Anticipated,12/17/2021,NA,Interventional,PiONEeR,NA,Heal-Me Personalized Online Nutrition and Exercise Routines,Heal-Me PiONEeR (Personalized Online Nutrition and Exercise Routines) - Reconnecting Vulnerable Outpatients With Multidisciplinary Care - a Randomized Controlled Trial Assessing 3 Levels of Online Programming in the Time of COVID,Recruiting,NA,Not Applicable,216,Anticipated,University of Alberta,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:20:54Z,2021-12-02T07:20:54Z
NCT04666493,NA,12/11/2020,NA,NA,12/11/2020,12/11/2020,12/14/2020,Actual,NA,NA,NA,NA,NA,NA,12/11/2020,12/14/2020,Actual,4-Dec-20,Actual,12/4/2020,Dec-20,12/31/2020,30-Nov-21,Anticipated,11/30/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Adapting Anxiety Intervention for Youth With Autism for Rapid Response to COVID-19,Adapting Anxiety Intervention for Youth With Autism for Rapid Response to COVID-19: A Research Project to Provide and Evaluate Virtual Mental Health Care,Recruiting,NA,Not Applicable,100,Anticipated,"Anagnostou, Evdokia, M.D.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:20:59Z,2021-12-02T07:20:59Z
NCT04666233,NA,12/11/2020,NA,NA,3/27/2021,12/11/2020,12/14/2020,Actual,NA,NA,NA,NA,NA,NA,3/27/2021,4/1/2021,Actual,16-Mar-21,Actual,3/16/2021,Mar-21,3/31/2021,23-Mar-21,Actual,3/23/2021,23-Mar-21,Actual,3/23/2021,NA,Interventional,NA,NA,Personal Protective Equipment for the Prevention of SARS-Cov-2 During Neonatal Resuscitation,Does Personal Protective Equipment for the Prevention of SARS-Cov-2 Infection Impact the Timing of Ventilation in Neonates Needing Resuscitation at Birth? A Crossover Randomized Controlled Trial,Completed,NA,Not Applicable,48,Actual,University Hospital Padova,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:21:00Z,2021-12-02T07:21:00Z
NCT04664010,NA,12/7/2020,NA,NA,12/9/2020,12/9/2020,12/11/2020,Actual,NA,NA,NA,NA,NA,NA,12/9/2020,12/11/2020,Actual,6-Feb-20,Actual,2/6/2020,Dec-20,12/31/2020,31-Jan-21,Anticipated,1/31/2021,14-Jan-21,Anticipated,1/14/2021,NA,Interventional,NA,NA,Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19),Efficacy and Safety of High-dose Vitamin C Combined With Traditional Chinese Medicine in the Treatment of Moderate and Severe Coronavirus Pneumonia (COVID-19),"Active, not recruiting",NA,Not Applicable,60,Actual,Xi'an International Medical Center Hospital,,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:22:42Z,2021-12-02T07:22:42Z
NCT04663594,NA,11/27/2020,NA,NA,10/1/2021,12/4/2020,12/11/2020,Actual,NA,NA,NA,NA,NA,NA,10/1/2021,10/8/2021,Actual,4-Dec-20,Actual,12/4/2020,Nov-20,11/30/2020,10-Feb-21,Actual,2/10/2021,10-Feb-21,Actual,2/10/2021,NA,Interventional,O-ACEPOP,NA,Online Culture for Mental Health in People Aged 16-24,An Online Cultural Experience to Support Mental Health in People Aged 16-24 During COVID-19: the O-ACEPOP (Online Active Community Engagement Proof of Principle) Study,Completed,NA,Not Applicable,413,Actual,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will be made available on OSF once peer reviewed,NA,NA,Yes,The data will be made available on OSF once peer reviewed,2021-12-02T07:23:03Z,2021-12-02T07:23:03Z
NCT04662021,NA,12/4/2020,NA,NA,1/8/2021,12/4/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,1/8/2021,1/11/2021,Actual,10-Dec-20,Actual,12/10/2020,Jan-21,1/31/2021,25-Feb-21,Anticipated,2/25/2021,10-Feb-21,Anticipated,2/10/2021,NA,Interventional,NA,NA,Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety,"The Effect of Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety, Depression and Stress-related to Covid 19 Pandemics Among University Students: a Comparative Study",Enrolling by invitation,NA,Not Applicable,40,Actual,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:24:29Z,2021-12-02T07:24:29Z
NCT04661839,NA,12/9/2020,NA,NA,8/16/2021,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,8/16/2021,8/17/2021,Actual,24-Dec-20,Actual,12/24/2020,Aug-21,8/31/2021,27-Jul-21,Actual,7/27/2021,27-Jul-21,Actual,7/27/2021,NA,Interventional,NA,NA,A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults,"A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) Administered as a Single Dose Regimen to Healthy Adults",Completed,NA,Phase 1,28,Actual,Emergent BioSolutions,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Study Protocol, Statistical Analysis Plan, and Informed Consent Form (redacted) to be shared.",2021-12-02T07:24:43Z,2021-12-02T07:24:43Z
NCT04663555,NA,12/9/2020,NA,NA,2/2/2021,12/10/2020,12/11/2020,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/4/2021,Actual,2-Feb-21,Actual,2/2/2021,Feb-21,2/28/2021,31-Mar-23,Anticipated,3/31/2023,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,REMED,NA,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,"Effect of Dexamethasone in Patients With ARDS and COVID-19 - Prospective, Multi-centre, Open-label, Parallel-group, Randomized Controlled Trial (REMED Trial)",Recruiting,NA,Phase 4,300,Anticipated,Brno University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,De-identified participant-level dataset will be made available 6 months after the publication of the results of the study at www.mendeley.com,Planned IPD metaanalysis or other relevant request,NA,Yes,Collected data will be shared with other ongoing clinical trials on the same topic for individual patient Ìs data (IPD) metaanalysis or shared upon relevant requests. Also de-identified participant-level dataset will be made available 6 months after the publication of the results of the study at www.mendeley.com,2021-12-02T07:23:19Z,2021-12-02T07:23:19Z
NCT04663737,NA,12/1/2020,NA,NA,8/30/2021,12/10/2020,12/11/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,8/31/2021,Actual,3-Dec-20,Actual,12/3/2020,Aug-21,8/31/2021,30-Sep-21,Anticipated,9/30/2021,16-Aug-21,Actual,8/16/2021,NA,Interventional,NA,NA,"Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19","A Phase II, Randomized and Controlled Investigator Initiated Trial Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Outpatient Adult Subjects With Moderate Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,20,Actual,"Senhwa Biosciences, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:23:26Z,2021-12-02T07:23:26Z
NCT04662684,NA,12/8/2020,NA,NA,8/2/2021,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,16-Oct-20,Actual,10/16/2020,Aug-21,8/31/2021,30-Aug-21,Anticipated,8/30/2021,10-Aug-21,Anticipated,8/10/2021,NA,Interventional,MICHELLE,NA,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,"Active, not recruiting",NA,Phase 3,320,Actual,Science Valley Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,Red Cap open file,2021-12-02T07:23:54Z,2021-12-02T07:23:54Z
NCT04662671,NA,12/9/2020,NA,NA,2/10/2021,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,2/10/2021,2/11/2021,Actual,18-Nov-20,Actual,11/18/2020,Feb-21,2/28/2021,30-Jan-21,Actual,1/30/2021,9-Dec-20,Actual,12/9/2020,NA,Interventional,NA,NA,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19","Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Completed,NA,Phase 1/Phase 2,31,Actual,KNOWBio Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:23:54Z,2021-12-02T07:23:54Z
NCT04661930,NA,12/9/2020,NA,NA,12/9/2020,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/9/2020,12/10/2020,Actual,13-Dec-20,Anticipated,12/13/2020,Dec-20,12/31/2020,1-Dec-21,Anticipated,12/1/2021,1-Apr-21,Anticipated,4/1/2021,NA,Interventional,FENOC,NA,Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Controlled Trial of Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Recruiting,NA,Phase 3,50,Anticipated,Hebrew University of Jerusalem,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:24:19Z,2021-12-02T07:24:19Z
NCT04661540,NA,12/4/2020,NA,NA,7/26/2021,12/8/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,8/2/2021,Actual,2-Mar-21,Actual,3/2/2021,Mar-21,3/31/2021,Oct-21,Anticipated,10/31/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,A Study of Auxora in Patients With Critical COVID-19 Pneumonia,A Single-Blind Dose-Ranging Pharmacodynamic Study of Auxora for the Treatment of Patients With Critical COVID-19 Pneumonia,Recruiting,NA,Phase 2,36,Anticipated,"CalciMedica, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:24:57Z,2021-12-02T07:24:57Z
NCT04661527,NA,9/10/2020,NA,NA,12/14/2020,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,12/14/2020,12/16/2020,Actual,22-Apr-20,Actual,4/22/2020,Apr-20,4/30/2020,30-Dec-20,Anticipated,12/30/2020,30-Dec-20,Anticipated,12/30/2020,NA,Interventional,STRIKESARS,NA,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Recruiting,NA,Phase 2,60,Anticipated,"Clinica Universidad de Navarra, Universidad de Navarra",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:24:39Z,2021-12-02T07:24:39Z
NCT04661410,NA,12/7/2020,NA,NA,1/20/2021,12/9/2020,12/10/2020,Actual,NA,NA,NA,NA,NA,NA,1/20/2021,1/22/2021,Actual,1-Dec-20,Actual,12/1/2020,Oct-20,10/31/2020,30-Mar-22,Anticipated,3/30/2022,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,60,Anticipated,Drexel University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:25:13Z,2021-12-02T07:25:13Z
NCT04659941,NA,12/8/2020,NA,NA,12/8/2020,12/8/2020,12/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/8/2020,12/9/2020,Actual,1-Oct-20,Actual,10/1/2020,Dec-20,12/31/2020,1-Oct-22,Anticipated,10/1/2022,1-Oct-21,Anticipated,10/1/2021,NA,Interventional,ProBCG,NA,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,NA,Phase 2,1000,Anticipated,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:26:18Z,2021-12-02T07:26:18Z
NCT04659486,NA,12/1/2020,NA,NA,12/8/2020,12/8/2020,12/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/8/2020,12/9/2020,Actual,24-Sep-20,Actual,9/24/2020,Dec-20,12/31/2020,30-Apr-21,Anticipated,4/30/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Adolescents With COVID-19/MIS-C at HCFMUSP,Prospective Studies in School-aged Children and Adolescents With COVID-19 Treated at HCFMUSP,Enrolling by invitation,NA,Not Applicable,100,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:26:44Z,2021-12-02T07:26:44Z
NCT04659707,NA,12/7/2020,NA,NA,2/22/2021,12/7/2020,12/9/2020,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/24/2021,Actual,22-Feb-21,Actual,2/22/2021,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Hyperpolarized 129Xe MRI of Survivors of COVID-19,Evaluating Lung Structure and Function in Survivors of COVID-19 Using Hyperpolarized 129Xe MRI,Recruiting,NA,Phase 1,20,Anticipated,University of Kansas Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Deidentified imaging data will be shared with researchers upon reasonable request.,2021-12-02T07:26:28Z,2021-12-02T07:26:28Z
NCT04659239,NA,12/5/2020,NA,NA,2/9/2021,12/8/2020,12/9/2020,Actual,NA,NA,NA,NA,NA,NA,2/9/2021,2/10/2021,Actual,28-Jan-21,Actual,1/28/2021,Feb-21,2/28/2021,Jul-22,Anticipated,7/31/2022,Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","A Randomized, Double-Blinded, Placebo Controlled Phase III Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above",Enrolling by invitation,NA,Phase 3,34020,Anticipated,Chinese Academy of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:27:00Z,2021-12-02T07:27:00Z
NCT04659122,NA,12/4/2020,NA,NA,8/26/2021,12/7/2020,12/9/2020,Actual,NA,NA,NA,NA,NA,NA,8/26/2021,8/31/2021,Actual,17-Aug-21,Actual,8/17/2021,Aug-21,8/31/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection,"Phase 1b Open-label, Single Arm, Cohort Dose Escalation Study Evaluating the Safety, Tolerability, and Feasibility of Intervention With AT-100 (rhSP-D) in Intubated Patients Receiving Invasive Mechanical Ventilation With Severe COVID-19 Infection",Recruiting,NA,Phase 1,9,Anticipated,"Airway Therapeutics, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:27:14Z,2021-12-02T07:27:14Z
NCT04659109,NA,11/30/2020,NA,NA,9/10/2021,12/7/2020,12/9/2020,Actual,NA,NA,NA,NA,NA,NA,9/10/2021,9/13/2021,Actual,16-Dec-20,Actual,12/16/2020,Sep-21,9/30/2021,6-Aug-21,Actual,8/6/2021,6-Aug-21,Actual,8/6/2021,NA,Interventional,GARDEN,NA,Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19,"A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Exploratory Efficacy and Safety Study of Glenzocimab in SARS-Cov-2-related Acute Respiratory Distress Syndrome",Completed,NA,Phase 2,60,Actual,Acticor Biotech,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:27:03Z,2021-12-02T07:27:03Z
NCT04658979,NA,12/2/2020,NA,NA,12/9/2020,12/2/2020,12/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/9/2020,12/10/2020,Actual,Dec-20,Anticipated,12/31/2020,Dec-20,12/31/2020,Jan-22,Anticipated,1/31/2022,Mar-21,Anticipated,3/31/2021,NA,Interventional,Tele-RehaB,NA,Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study,Evaluation of the Feasibility and Safety of a Pulmonary Tele-rehabilitation Program in the Times of COVID-19,Recruiting,NA,Not Applicable,30,Anticipated,"Institut universitaire de cardiologie et de pneumologie de QuÃ©bec, University Laval",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:27:07Z,2021-12-02T07:27:07Z
NCT04658433,NA,12/5/2020,NA,NA,12/7/2020,12/7/2020,12/8/2020,Actual,NA,NA,NA,NA,NA,NA,12/7/2020,12/8/2020,Actual,5-Dec-20,Actual,12/5/2020,Dec-20,12/31/2020,30-Mar-21,Anticipated,3/30/2021,15-Feb-21,Anticipated,2/15/2021,NA,Interventional,NA,NA,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the COVID-19 Uninfected Jordanian People,Recruiting,NA,Not Applicable,100,Anticipated,Applied Science Private University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:27:42Z,2021-12-02T07:27:42Z
NCT04657471,NA,12/6/2020,NA,NA,3/12/2021,12/6/2020,12/8/2020,Actual,NA,NA,NA,NA,NA,NA,3/12/2021,3/15/2021,Actual,8-Dec-20,Actual,12/8/2020,Dec-20,12/31/2020,8-Mar-21,Actual,3/8/2021,8-Mar-21,Actual,3/8/2021,NA,Interventional,NA,NA,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Hospitalization or Outpatient ManagEment of Patients With Suspected or Confirmed SRAS-CoV-2 Infection: the Revised HOME-CoV Score Study.,Completed,NA,Not Applicable,1300,Actual,"University Hospital, Angers",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:28:13Z,2021-12-02T07:28:13Z
NCT04657497,NA,11/9/2020,NA,NA,6/11/2021,12/6/2020,12/8/2020,Actual,NA,NA,NA,NA,NA,NA,6/11/2021,6/14/2021,Actual,9-Nov-20,Actual,11/9/2020,May-21,5/31/2021,9-Apr-21,Actual,4/9/2021,26-Mar-21,Actual,3/26/2021,NA,Interventional,NA,NA,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),"A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 3,155,Actual,Ono Pharmaceutical Co. Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,https://www.ono.co.jp/eng/rd/policy.html,Yes,NA,2021-12-02T07:28:23Z,2021-12-02T07:28:23Z
NCT04657484,NA,12/5/2020,NA,NA,6/22/2021,12/5/2020,12/8/2020,Actual,NA,NA,NA,NA,NA,NA,6/22/2021,6/25/2021,Actual,8-Dec-20,Actual,12/8/2020,Jun-21,6/30/2021,7-Dec-21,Anticipated,12/7/2021,7-Dec-21,Anticipated,12/7/2021,NA,Interventional,COLDSTER,NA,Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease,Comparison of the Efficacy and Safety of Two Corticosteroid Regimens in the Treatment of Diffuse Lung Disease After Coronavirus Disease 2019 (COVID-19) Pneumonia,Recruiting,NA,Not Applicable,100,Anticipated,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:28:27Z,2021-12-02T07:28:27Z
NCT04656626,NA,12/4/2020,NA,NA,12/8/2020,12/4/2020,12/7/2020,Actual,NA,NA,NA,NA,NA,NA,12/8/2020,12/10/2020,Actual,7-Jul-20,Actual,7/7/2020,Dec-20,12/31/2020,5-Sep-20,Actual,9/5/2020,21-Jul-20,Actual,7/21/2020,NA,Interventional,NA,NA,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,"Brief Mindfulness Based Intervention for Front-Line Medical Staff in the COVID19 Pandemic to Improve Psychological Wellbeing, a Randomized Controlled Multicenter Trial",Completed,NA,Not Applicable,146,Actual,Imam Abdulrahman Bin Faisal University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:28:58Z,2021-12-02T07:28:58Z
NCT04656691,NA,12/4/2020,NA,NA,4/27/2021,12/4/2020,12/7/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/29/2021,Actual,4-Jan-21,Actual,1/4/2021,Apr-21,4/30/2021,18-Apr-21,Actual,4/18/2021,18-Apr-21,Actual,4/18/2021,NA,Interventional,UNITED,NA,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,Completed,NA,Phase 4,4000,Actual,UnitedHealth Group,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plan to share participant level data with other projects or researchers.,2021-12-02T07:29:08Z,2021-12-02T07:29:08Z
NCT04655716,NA,12/4/2020,NA,NA,8/6/2021,12/4/2020,12/7/2020,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/12/2021,Actual,19-Jul-21,Actual,7/19/2021,Dec-20,12/31/2020,31-Dec-22,Anticipated,12/31/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Urine Alkalinisation to Prevent AKI in COVID-19,Urine Alkalinisation to Prevent Acute Kidney Injury in COVID-19,Recruiting,NA,Phase 3,80,Anticipated,Guy's and St Thomas' NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:29:56Z,2021-12-02T07:29:56Z
NCT04655625,NA,11/26/2020,NA,NA,4/5/2021,12/4/2020,12/7/2020,Actual,NA,NA,NA,NA,NA,NA,4/5/2021,4/8/2021,Actual,23-Nov-20,Actual,11/23/2020,Apr-21,4/30/2021,31-Mar-22,Anticipated,3/31/2022,2-Apr-21,Actual,4/2/2021,NA,Interventional,NA,NA,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults","Active, not recruiting",NA,Phase 2/Phase 3,500,Actual,"AnGes, Inc.",,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:29:48Z,2021-12-02T07:29:48Z
NCT04654481,NA,12/3/2020,NA,NA,12/3/2020,12/3/2020,12/4/2020,Actual,NA,NA,NA,NA,NA,NA,12/3/2020,12/4/2020,Actual,Dec-20,Anticipated,12/31/2020,Dec-20,12/31/2020,Nov-21,Anticipated,11/30/2021,Feb-21,Anticipated,2/28/2021,NA,Interventional,NA,NA,Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic,Feasibility of Using a Home-Based High Frequency Chest Wall Oscillation Device (AffloVest) in At-Risk Respiratory Patients to Decrease Acute Respiratory Care Burden During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,30,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:30:42Z,2021-12-02T07:30:42Z
NCT04653831,NA,10/27/2020,NA,NA,12/3/2020,12/3/2020,12/4/2020,Actual,NA,NA,NA,NA,NA,NA,12/3/2020,12/4/2020,Actual,8-Nov-20,Actual,11/8/2020,Dec-20,12/31/2020,Dec-21,Anticipated,12/31/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Treatment With Pirfenidone for COVID-19 Related Severe ARDS,Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial,Recruiting,NA,Not Applicable,100,Anticipated,Soroka University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:31:29Z,2021-12-02T07:31:29Z
NCT04652674,NA,12/2/2020,NA,NA,5/5/2021,12/2/2020,12/3/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/7/2021,Actual,28-Sep-20,Actual,9/28/2020,May-21,5/31/2021,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,70,Anticipated,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:32:24Z,2021-12-02T07:32:24Z
NCT04652648,NA,12/2/2020,NA,NA,12/2/2020,12/2/2020,12/3/2020,Actual,NA,NA,NA,NA,NA,NA,12/2/2020,12/3/2020,Actual,27-May-20,Actual,5/27/2020,Dec-20,12/31/2020,15-Nov-20,Actual,11/15/2020,31-Oct-20,Actual,10/31/2020,NA,Interventional,NA,NA,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,NA,Phase 4,54,Actual,Bryn Mawr Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:32:25Z,2021-12-02T07:32:25Z
NCT04652765,NA,12/2/2020,NA,NA,9/15/2021,12/2/2020,12/3/2020,Actual,NA,NA,NA,NA,NA,NA,9/15/2021,9/22/2021,Actual,3-Feb-21,Actual,2/3/2021,Jul-21,7/31/2021,15-Sep-21,Actual,9/15/2021,15-Sep-21,Actual,9/15/2021,NA,Interventional,COMBO,NA,Camostat With Bicalutamide for COVID-19,COMBO Trial: Camostat With Bicalutamide for COVID-19,Terminated,NA,Phase 1,6,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2,NA,PI Decision to close/stop the study due to no new accrual.,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:32:33Z,2021-12-02T07:32:33Z
NCT04651790,NA,11/20/2020,NA,NA,2/25/2021,12/1/2020,12/3/2020,Actual,NA,NA,NA,NA,NA,NA,2/25/2021,3/2/2021,Actual,27-Nov-20,Actual,11/27/2020,Feb-21,2/28/2021,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,CoronaVac3CL,NA,"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults.",Recruiting,NA,Phase 3,2300,Anticipated,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:33:28Z,2021-12-02T07:33:28Z
NCT04652102,NA,12/1/2020,NA,NA,7/21/2021,12/1/2020,12/3/2020,Actual,NA,NA,NA,NA,NA,NA,7/21/2021,7/22/2021,Actual,14-Dec-20,Actual,12/14/2020,Oct-20,10/31/2020,15-May-22,Anticipated,5/15/2022,16-Apr-21,Actual,4/16/2021,NA,Interventional,NA,NA,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19,"COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","Active, not recruiting",NA,Phase 2/Phase 3,39693,Actual,CureVac AG,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:33:04Z,2021-12-02T07:33:04Z
NCT04652115,NA,12/1/2020,NA,NA,7/23/2021,12/2/2020,12/3/2020,Actual,NA,NA,NA,NA,NA,NA,7/23/2021,7/29/2021,Actual,1-Jan-21,Actual,1/1/2021,Jul-21,7/31/2021,1-Nov-23,Anticipated,11/1/2023,1-Nov-22,Anticipated,11/1/2022,NA,Interventional,NA,NA,Defibrotide for the Treatment of Severe COVID-19,A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19,Recruiting,NA,Phase 2,42,Anticipated,Brigham and Women's Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:33:05Z,2021-12-02T07:33:05Z
NCT04649515,NA,11/26/2020,NA,NA,12/11/2020,11/30/2020,12/2/2020,Actual,NA,NA,NA,NA,NA,NA,12/11/2020,12/14/2020,Actual,4-Dec-20,Anticipated,12/4/2020,Dec-20,12/31/2020,30-Dec-21,Anticipated,12/30/2021,31-Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,"Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans","Phase 3 Multi-Site, Randomised, Placebo Controlled, Double Blind, Single Dose Study of TY027 for Early Treatment of COVID-19",Recruiting,NA,Phase 3,1305,Anticipated,Tychan Pte Ltd.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:35:01Z,2021-12-02T07:35:01Z
NCT04649775,NA,10/14/2020,NA,NA,9/23/2021,12/1/2020,12/2/2020,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/24/2021,Actual,9-Apr-21,Actual,4/9/2021,Apr-21,4/30/2021,31-Jul-22,Anticipated,7/31/2022,31-Jul-22,Anticipated,7/31/2022,NA,Interventional,AirFLO2,NA,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,Recruiting,NA,Not Applicable,50,Anticipated,Duke University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:34:56Z,2021-12-02T07:34:56Z
NCT04649424,NA,11/27/2020,NA,NA,7/14/2021,11/30/2020,12/2/2020,Actual,NA,NA,NA,NA,NA,NA,7/14/2021,7/15/2021,Actual,22-Dec-20,Actual,12/22/2020,Jul-21,7/31/2021,13-Apr-21,Actual,4/13/2021,13-Apr-21,Actual,4/13/2021,NA,Interventional,NA,NA,COVID-19 Nasal Swab Trial,Comparative Evaluation of Nasopharyngeal Swabs for Sampling and Detection of SARS-CoV2,Completed,NA,Not Applicable,169,Actual,Orthopaedic Innovation Centre,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:35:00Z,2021-12-02T07:35:00Z
NCT04649151,NA,11/30/2020,NA,NA,8/19/2021,11/30/2020,12/2/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/20/2021,Actual,9-Dec-20,Actual,12/9/2020,Aug-21,8/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,TeenCove,NA,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age","Active, not recruiting",NA,Phase 2/Phase 3,3732,Actual,"ModernaTX, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:35:21Z,2021-12-02T07:35:21Z
NCT04649021,NA,11/17/2020,NA,NA,2/12/2021,11/30/2020,12/2/2020,Actual,NA,NA,NA,NA,NA,NA,2/12/2021,2/15/2021,Actual,4-Dec-20,Actual,12/4/2020,Feb-21,2/28/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study","Active, not recruiting",NA,Phase 2,950,Actual,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:35:43Z,2021-12-02T07:35:43Z
NCT04649086,NA,9/29/2020,NA,NA,5/18/2021,11/30/2020,12/2/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/19/2021,Actual,5-Jun-20,Actual,6/5/2020,May-21,5/31/2021,Oct-22,Anticipated,10/31/2022,Oct-22,Anticipated,10/31/2022,NA,Interventional,CovExc,NA,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection: Research Protocol for Randomized Controlled Trial (CovExc),Recruiting,NA,Not Applicable,120,Anticipated,"University Hospital, Clermont-Ferrand",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:35:27Z,2021-12-02T07:35:27Z
NCT04646655,NA,11/22/2020,NA,NA,11/25/2020,11/25/2020,11/30/2020,Actual,NA,NA,NA,NA,NA,NA,11/25/2020,11/30/2020,Actual,27-Jul-20,Actual,7/27/2020,Nov-20,11/30/2020,31-Jul-21,Anticipated,7/31/2021,31-May-21,Anticipated,5/31/2021,NA,Interventional,EMOS-COVID,NA,Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19,Enoxaparin at Prophylactic or Therapeutic Doses With Monitoring of Outcomes in Subjects Infected With COVID-19: a Pilot Study on 300 Cases Enrolled at ASST-FBF-Sacco,Recruiting,NA,Phase 3,300,Anticipated,ASST Fatebenefratelli Sacco,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:37:30Z,2021-12-02T07:37:30Z
NCT04647747,NA,11/27/2020,NA,NA,2/3/2021,11/27/2020,12/1/2020,Actual,NA,NA,NA,NA,NA,NA,2/3/2021,2/4/2021,Actual,30-Nov-20,Actual,11/30/2020,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,30-Mar-21,Anticipated,3/30/2021,NA,Interventional,SHYCOV,NA,Silent Hypoxia and Awake Proning in COVID-19 Patients,Silent Hypoxia and Awake Proning in COVID-19 Patients: Home Monitoring and Self-Reporting,Recruiting,NA,Not Applicable,40,Anticipated,Ostfold Hospital Trust,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:36:39Z,2021-12-02T07:36:39Z
NCT04646603,NA,11/24/2020,NA,NA,8/12/2021,11/25/2020,11/30/2020,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/19/2021,Actual,28-Jan-21,Actual,1/28/2021,Aug-21,8/31/2021,1-Mar-22,Anticipated,3/1/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients,"A Combined Phase I Double-blind Randomized Placebo-controlled Study in Healthy Subjects/Phase II, Randomized, Double-blind, Placebo-Controlled, Multi-center Study in Hospitalized Patients Infected With Severe and Critical SARS-CoV-2 to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of MRG-001 (Plerixafor Plus Low-dose Tacrolimus)","Active, not recruiting",NA,Phase 1/Phase 2,18,Actual,MedRegen LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Participants will be given a unique unidentifiable study ID number and all data will be recorded according to unidentifiable number to protect patients personal health information.,2021-12-02T07:37:28Z,2021-12-02T07:37:28Z
NCT04648800,NA,10/18/2020,NA,NA,11/30/2020,11/30/2020,12/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/30/2020,12/2/2020,Actual,7-Jul-20,Actual,7/7/2020,Nov-20,11/30/2020,Apr-21,Anticipated,4/30/2021,Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,"A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland",Recruiting,NA,Phase 3,1000,Anticipated,University of Rzeszow,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:35:33Z,2021-12-02T07:35:33Z
NCT04647695,NA,11/27/2020,NA,NA,12/9/2020,11/27/2020,12/1/2020,Actual,NA,NA,NA,NA,NA,NA,12/9/2020,12/10/2020,Actual,20-Nov-20,Actual,11/20/2020,Nov-20,11/30/2020,30-Sep-21,Anticipated,9/30/2021,31-Jul-21,Anticipated,7/31/2021,NA,Interventional,NA,NA,IFN-beta 1b and Remdesivir for COVID19,An Open-label Randomized Controlled Trial on Interferon Î²-1b and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 Infection,Recruiting,NA,Phase 2,100,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Upon study publication for 12 months,Approval by the IRB panel,NA,Yes,Anonymous IPD will be shared upon request to the HKU IRB and approved by the panel,2021-12-02T07:36:52Z,2021-12-02T07:36:52Z
NCT04647604,NA,6/12/2020,NA,NA,11/27/2020,11/27/2020,12/1/2020,Actual,NA,NA,NA,NA,NA,NA,11/27/2020,12/1/2020,Actual,23-Jun-20,Actual,6/23/2020,Nov-20,11/30/2020,30-Apr-21,Anticipated,4/30/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,"Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - A Single-blind, Randomized, Placebo-controlled Feasibility Study",Recruiting,NA,Phase 2,40,Anticipated,Karolinska University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months following article publication and finishing 36 months following article publication.,Study protocol will be published. Investigators interested in data should contact the principal investigator.,NA,Yes,"Individual participant data that underlie the results reported will be shared, after deidentification, with researchers who provide a methodologically sound proposal.",2021-12-02T07:36:56Z,2021-12-02T07:36:56Z
NCT04647305,NA,11/24/2020,NA,NA,4/26/2021,11/25/2020,11/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/26/2021,4/27/2021,Actual,16-Jan-21,Actual,1/16/2021,Apr-21,4/30/2021,4-Mar-21,Actual,3/4/2021,4-Mar-21,Actual,3/4/2021,NA,Interventional,COVPROSHIELD,NA,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission: A Randomized Controlled Trial,Completed,NA,Not Applicable,233,Actual,"University of Los Andes, Columbia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months after publication,A formal request sent to the principal investigator.,NA,Yes,"After publication of main results, data will be available for other researchers such as: Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report and Analytic Code.",2021-12-02T07:36:59Z,2021-12-02T07:36:59Z
NCT04646590,NA,11/25/2020,NA,NA,5/6/2021,11/25/2020,11/30/2020,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/7/2021,Actual,16-Dec-20,Actual,12/16/2020,Feb-21,2/28/2021,Apr-22,Anticipated,4/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,NA,NA,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,"A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO Cell) for Prevention of COVID-19",Recruiting,NA,Phase 3,29000,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:37:40Z,2021-12-02T07:37:40Z
NCT04646616,NA,11/25/2020,NA,NA,6/28/2021,11/25/2020,11/30/2020,Actual,NA,NA,NA,NA,NA,NA,6/28/2021,6/30/2021,Actual,15-Jan-21,Actual,1/15/2021,Jun-21,6/30/2021,31-Oct-21,Anticipated,10/31/2021,31-Oct-21,Anticipated,10/31/2021,NA,Interventional,CRISOL Contigo,NA,CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.,CRISOL: Building Community Resilience and Integrating Efforts to Understand and Address Syndemic Health Conditions Afflicting Young LatinoImmigrants,Recruiting,NA,Not Applicable,800,Anticipated,Drexel University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:37:42Z,2021-12-02T07:37:42Z
NCT04646109,NA,11/15/2020,12/3/2020,NA,1/25/2021,11/25/2020,11/27/2020,Actual,1/25/2021,1/27/2021,Actual,NA,NA,NA,1/25/2021,1/27/2021,Actual,11-May-20,Actual,5/11/2020,Jan-21,1/31/2021,2-Sep-20,Actual,9/2/2020,2-Sep-20,Actual,9/2/2020,NA,Interventional,NA,"36 patients were included in the study group. But, 6 patients in the study group were excluded from the study and analysis because ivermectin treatments were terminated due to the detection of a mutation that impairs ivermectin metabolism. As a result, overall number of baseline participants in the study group was 30.",Ivermectin for Severe COVID-19 Management,The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management,Completed,NA,Phase 3,66,Actual,Afyonkarahisar Health Sciences University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:38:08Z,2021-12-02T07:38:08Z
NCT04645407,NA,2/15/2020,NA,NA,11/25/2020,11/25/2020,11/27/2020,Actual,NA,NA,NA,NA,NA,NA,11/25/2020,11/27/2020,Actual,1-Feb-20,Actual,2/1/2020,Nov-20,11/30/2020,15-Apr-20,Actual,4/15/2020,15-Apr-20,Actual,4/15/2020,NA,Interventional,NA,NA,Effects of Fuzheng Huayu Tablets on COVID-19,Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in Patients With COVID-19: A Case-Control Study,Completed,NA,Phase 4,66,Actual,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:38:33Z,2021-12-02T07:38:33Z
NCT04643964,NA,11/12/2020,NA,NA,7/15/2021,11/20/2020,11/25/2020,Actual,NA,NA,NA,NA,NA,NA,7/15/2021,7/22/2021,Actual,17-Nov-20,Actual,11/17/2020,Jul-21,7/31/2021,5-Jun-21,Actual,6/5/2021,5-Jun-21,Actual,6/5/2021,NA,Interventional,NA,NA,Brief Video Interventions for Depression,Building Mental Health Resilience in the COVID-19 Pandemic.,Completed,NA,Not Applicable,531,Actual,Ohio State University,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,IPD will be available upon reasonable request within one year of primary outcome manuscript being published.,Proposals should be directed to Daniel R. Strunk at strunk.20@osu.edu,NA,Yes,"Results will be posted to clinicaltrials.gov within one year after completion of the final participant's participation in the clinical trial. Following initial publication, deidentified individual participant data (IPD) that underlie results in the primary outcome data reported will be available on reasonable request for 5 years after study completion.",2021-12-02T07:39:51Z,2021-12-02T07:39:51Z
NCT04644185,NA,11/22/2020,NA,NA,4/7/2021,11/24/2020,11/25/2020,Actual,NA,NA,NA,NA,NA,NA,4/7/2021,4/12/2021,Actual,27-Mar-21,Actual,3/27/2021,Apr-21,4/30/2021,27-Dec-21,Anticipated,12/27/2021,27-Jun-21,Anticipated,6/27/2021,NA,Interventional,NA,NA,The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19,"A Multicenter, Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Hospitalized Patients With Severe COVID-19",Recruiting,NA,Phase 2/Phase 3,795,Anticipated,Sinocelltech Ltd.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:39:46Z,2021-12-02T07:39:46Z
NCT04644198,NA,11/18/2020,NA,NA,5/10/2021,11/24/2020,11/25/2020,Actual,NA,NA,NA,NA,NA,NA,5/10/2021,5/12/2021,Actual,1-Jun-21,Anticipated,6/1/2021,Nov-20,11/30/2020,1-Dec-21,Anticipated,12/1/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica,Pilot Study of Convalescent COVID-19 Plasma Transfusion in Severe COVID-19 Patients at a Type A Teaching Hospital in Jamaica,Recruiting,NA,Phase 2,30,Anticipated,The University of The West Indies,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:39:53Z,2021-12-02T07:39:53Z
NCT04644120,NA,11/23/2020,NA,NA,8/30/2021,11/23/2020,11/25/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,9/2/2021,Actual,10-Dec-20,Actual,12/10/2020,Aug-21,8/31/2021,24-Aug-21,Actual,8/24/2021,24-Aug-21,Actual,8/24/2021,NA,Interventional,NA,NA,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19),"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ABBV-47D11 and ABBV-2B04 as Monotherapy or Combination Therapy in Adults With COVID-19",Completed,NA,Phase 1,25,Actual,AbbVie,,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:39:50Z,2021-12-02T07:39:50Z
NCT04643691,NA,11/24/2020,NA,NA,11/24/2020,11/24/2020,11/25/2020,Actual,NA,NA,NA,NA,NA,NA,11/24/2020,11/25/2020,Actual,11-Sep-20,Actual,9/11/2020,Nov-20,11/30/2020,30-Oct-22,Anticipated,10/30/2022,30-Sep-22,Anticipated,9/30/2022,NA,Interventional,COVIDANCE,NA,Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS,Benefit of Treatment With Losartan and Spironolactone on the Regulation of the Renin-angiotensin System in the Prognosis of Patients Infected With COVID-19 and Suffering From Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 2,90,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:40:15Z,2021-12-02T07:40:15Z
NCT04643561,NA,11/24/2020,NA,NA,11/24/2020,11/24/2020,11/25/2020,Actual,NA,NA,NA,NA,NA,NA,11/24/2020,11/27/2020,Actual,1-Nov-20,Actual,11/1/2020,Nov-20,11/30/2020,31-Dec-20,Anticipated,12/31/2020,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Using Travelan to Boost Immune Response in Vitro to COVID-19,A Feasibility Trial Using Trevalan in Healthy Volunteers for Increasing an in Vitro Immune Response to COVID-19 Proteins,"Active, not recruiting",NA,Phase 1/Phase 2,5,Anticipated,Hadassah Medical Organization,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:40:23Z,2021-12-02T07:40:23Z
NCT04643678,NA,11/24/2020,NA,NA,2/7/2021,11/24/2020,11/25/2020,Actual,NA,NA,NA,NA,NA,NA,2/7/2021,2/10/2021,Actual,30-Oct-20,Actual,10/30/2020,Feb-21,2/28/2021,30-Oct-21,Anticipated,10/30/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Anakinra in the Management of COVID-19 Infection,Efficacy of Anakinra in the Management of Patients With COVID-19 Infection in Qatar: A Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,80,Anticipated,Hamad Medical Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:40:12Z,2021-12-02T07:40:12Z
NCT04641481,NA,11/9/2020,NA,NA,3/18/2021,11/20/2020,11/23/2020,Actual,NA,NA,NA,NA,NA,NA,3/18/2021,3/19/2021,Actual,16-Nov-20,Actual,11/16/2020,Mar-21,3/31/2021,Dec-22,Anticipated,12/31/2022,8-Jan-21,Actual,1/8/2021,NA,Interventional,NA,NA,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,"An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy, Safety, Immunogenicity, Lot-to-Lot Consistency of BBV152, a Whole-Virion Inactivated SARS-CoV-2 Vaccine in Adultsâ‰¥18 Yrs of Age","Active, not recruiting",NA,Phase 3,25800,Actual,Bharat Biotech International Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:42:10Z,2021-12-02T07:42:10Z
NCT04642326,NA,11/16/2020,NA,NA,11/20/2020,11/20/2020,11/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/20/2020,11/24/2020,Actual,26-Jun-20,Actual,6/26/2020,Nov-20,11/30/2020,4-May-21,Anticipated,5/4/2021,1-Jul-20,Actual,7/1/2020,NA,Interventional,NA,NA,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Prospective, Parallel, Multicenter Randomized Controlled Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis","Active, not recruiting",NA,Not Applicable,50,Anticipated,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"During or when the study ends, the data will be shared for scientific publication.",2021-12-02T07:41:34Z,2021-12-02T07:41:34Z
NCT04642040,NA,11/21/2020,NA,NA,11/21/2020,11/21/2020,11/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/21/2020,11/24/2020,Actual,30-Jun-20,Actual,6/30/2020,Nov-20,11/30/2020,Jan-21,Anticipated,1/31/2021,Jan-21,Anticipated,1/31/2021,NA,Interventional,NA,NA,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Recruiting,NA,Not Applicable,100,Anticipated,Sisli Hamidiye Etfal Training and Research Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:41:40Z,2021-12-02T07:41:40Z
NCT04641195,NA,11/19/2020,NA,NA,4/23/2021,11/20/2020,11/23/2020,Actual,NA,NA,NA,NA,NA,NA,4/23/2021,4/27/2021,Actual,22-Apr-21,Actual,4/22/2021,Apr-21,4/30/2021,31-Mar-22,Anticipated,3/31/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India,A Randomized Trial to Determine the Effect of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India,Recruiting,NA,Phase 3,700,Anticipated,Harvard School of Public Health (HSPH),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:42:12Z,2021-12-02T07:42:12Z
NCT04640038,NA,11/19/2020,NA,NA,1/25/2021,11/19/2020,11/23/2020,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/27/2021,Actual,18-Dec-20,Actual,12/18/2020,Jan-21,1/31/2021,Dec-22,Anticipated,12/31/2022,Dec-22,Anticipated,12/31/2022,NA,Interventional,NA,NA,Contrast Enhanced Ultrasound in COVID-19,Contrast Enhanced Ultrasound (CEUS) Detection of Microvascular Perfusion Impairment in COVID-19 Pediatric Patients,Recruiting,NA,Phase 3,30,Anticipated,Children's Hospital of Philadelphia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:43:06Z,2021-12-02T07:43:06Z
NCT04639349,NA,11/19/2020,NA,NA,11/19/2020,11/19/2020,11/20/2020,Actual,NA,NA,NA,NA,NA,NA,11/19/2020,11/20/2020,Actual,19-Nov-20,Actual,11/19/2020,Nov-20,11/30/2020,1-Mar-21,Anticipated,3/1/2021,1-Mar-21,Anticipated,3/1/2021,NA,Interventional,NA,NA,Effect of Home Exercise Activity on Cortisol and Depression in COPD During the Pandemic COVID,Effect of Home Exercise Activity on Cortisol and Depression in COPD Patients During the Pandemic COVID-19,Recruiting,NA,Not Applicable,40,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:43:37Z,2021-12-02T07:43:37Z
NCT04640402,NA,11/19/2020,NA,NA,3/28/2021,11/20/2020,11/23/2020,Actual,NA,NA,NA,NA,NA,NA,3/28/2021,3/30/2021,Actual,17-Nov-20,Actual,11/17/2020,Nov-20,11/30/2020,18-Nov-21,Anticipated,11/18/2021,18-Feb-21,Actual,2/18/2021,NA,Interventional,NA,NA,A Phase â…¡ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),"A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase â…¡ Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above",Recruiting,NA,Phase 2,960,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,16,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:43:17Z,2021-12-02T07:43:17Z
NCT04638673,NA,11/18/2020,NA,NA,7/12/2021,11/19/2020,11/20/2020,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/16/2021,Actual,19-Nov-20,Actual,11/19/2020,Jul-21,7/31/2021,Dec-21,Anticipated,12/31/2021,30-Jun-21,Actual,6/30/2021,NA,Interventional,NA,NA,NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis,Testing a Wearable Telemedicine-controllable taVNS Device for NeuroCovid Recovery and Rehab,"Active, not recruiting",NA,Phase 2,30,Anticipated,Medical University of South Carolina,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:44:26Z,2021-12-02T07:44:26Z
NCT04640233,NA,11/17/2020,NA,NA,5/31/2021,11/20/2020,11/23/2020,Actual,NA,NA,NA,NA,NA,NA,5/31/2021,6/2/2021,Actual,30-Nov-20,Actual,11/30/2020,May-21,5/31/2021,Sep-21,Anticipated,9/30/2021,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Ð¡ov-2) Infection,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Ð¡ov-2 Infection in Indian Healthy Subjects","Active, not recruiting",NA,Phase 2/Phase 3,1600,Actual,Dr. Reddy's Laboratories Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:43:03Z,2021-12-02T07:43:03Z
NCT04640181,NA,11/19/2020,NA,NA,6/28/2021,11/19/2020,11/23/2020,Actual,NA,NA,NA,NA,NA,NA,6/28/2021,6/30/2021,Actual,1-Dec-20,Actual,12/1/2020,Jun-21,6/30/2021,28-Jun-21,Actual,6/28/2021,28-Jun-21,Actual,6/28/2021,NA,Interventional,XACT,NA,Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT),"A Phase 2-3, Multi-Center, Randomized Trial to Study the Potential Benefit of Factor Xa Inhibitor (Rivaroxaban) Versus Standard of Care Low Molecular Weight Heparin (Lovenox) in Hospitalized Patients With COVID-19 (XACT)",Completed,NA,Phase 2,150,Actual,St. David's HealthCare,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:43:04Z,2021-12-02T07:43:04Z
NCT04639375,NA,11/16/2020,NA,NA,8/23/2021,11/19/2020,11/20/2020,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/27/2021,Actual,15-Nov-20,Actual,11/15/2020,Aug-21,8/31/2021,12-Jun-22,Anticipated,6/12/2022,12-Jun-21,Actual,6/12/2021,NA,Interventional,NA,NA,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),A Proof-of-concept Study of Poliovirus Vaccine (IPV) Activity to Induce an Immune Response That Cross-reacts With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2),"Active, not recruiting",NA,Phase 4,300,Actual,E-MO Biology Inc,,1,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:43:52Z,2021-12-02T07:43:52Z
NCT04637477,NA,11/6/2020,NA,NA,9/14/2021,11/18/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/16/2021,Actual,1-Aug-20,Actual,8/1/2020,Sep-21,9/30/2021,25-Aug-21,Actual,8/25/2021,31-Dec-20,Actual,12/31/2020,NA,Interventional,NA,NA,Virtual Enhanced Lifestyle for Metabolic Syndrome (ELM) Proof-of-Concept Study,Rush Coronavirus Disease Virtual Lifestyle Program to Boost Host Resistance in Patients With Elevated Cardiometabolic Risk: A Proof-of-Concept Study,Completed,NA,Not Applicable,10,Actual,Rush University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:45:19Z,2021-12-02T07:45:19Z
NCT04636671,NA,11/18/2020,NA,NA,4/29/2021,11/18/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2021,5/5/2021,Actual,14-Apr-21,Actual,4/14/2021,Apr-21,4/30/2021,1-Oct-21,Anticipated,10/1/2021,1-Aug-21,Anticipated,8/1/2021,NA,Interventional,MEDEAS,NA,Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT),Randomized Controlled Trial of Methylprednisolone Versus Dexamethasone in COVID-19 Pneumonia (MEDEAS Trial),Recruiting,NA,Phase 3,680,Anticipated,University of Trieste,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,36 months following article publication,NA,NA,Yes,"Individual participant data that underlie the results of this study after deidentification, as well as study protocol, statistical analysis plan, informed consent form, clinical study report and analytic code will be made available to Researchers who provide a written proposal for their purposes. Proposals must be submitted to the study PI or co-PI up to 36 months following article publication. Requestors must sign a data access agreement.",2021-12-02T07:45:55Z,2021-12-02T07:45:55Z
NCT04637906,NA,11/18/2020,NA,NA,3/15/2021,11/19/2020,11/20/2020,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/16/2021,Actual,18-Nov-20,Actual,11/18/2020,Mar-21,3/31/2021,18-Sep-21,Anticipated,9/18/2021,18-Apr-21,Anticipated,4/18/2021,NA,Interventional,NA,NA,Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With COVID-19 (SARS-CoV-2),"Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Randomized, Parallel Group, Double-blind Placebo-controlled Clinical Trial",Recruiting,NA,Not Applicable,290,Anticipated,"University of Campania ""Luigi Vanvitelli""",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:45:00Z,2021-12-02T07:45:00Z
NCT04637867,NA,11/16/2020,NA,NA,6/3/2021,11/19/2020,11/20/2020,Actual,NA,NA,NA,NA,NA,NA,6/3/2021,6/4/2021,Actual,23-Nov-20,Actual,11/23/2020,Jun-21,6/30/2021,12-May-21,Actual,5/12/2021,12-May-21,Actual,5/12/2021,NA,Interventional,NA,NA,COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO),Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study,Completed,NA,Not Applicable,189,Actual,Hospices Civils de Lyon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:45:04Z,2021-12-02T07:45:04Z
NCT04637828,NA,11/17/2020,NA,NA,7/27/2021,11/19/2020,11/20/2020,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,7/28/2021,Actual,18-Nov-20,Actual,11/18/2020,Nov-20,11/30/2020,30-Dec-21,Anticipated,12/30/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,CureCovid-2019,NA,A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection,"Cure COVID: A Prospective, Controlled, Randomized Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection",Recruiting,NA,Phase 2,178,Anticipated,Genoscience Pharma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:45:05Z,2021-12-02T07:45:05Z
NCT04636697,NA,11/12/2020,NA,NA,9/7/2021,11/18/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/9/2021,Actual,19-Nov-20,Actual,11/19/2020,Jun-21,6/30/2021,30-Apr-22,Anticipated,4/30/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,"Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older","Active, not recruiting",NA,Phase 2/Phase 3,30918,Anticipated,Medicago,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:46:08Z,2021-12-02T07:46:08Z
NCT04635605,NA,9/28/2020,NA,NA,1/29/2021,11/18/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,1/29/2021,2/2/2021,Actual,5-Nov-20,Actual,11/5/2020,Jan-21,1/31/2021,31-Dec-22,Anticipated,12/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Methylene Blue Treatment of COVID-19,"Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV2- Affected Patients: a Phase 2, Randomized, Placebo- Controlled, Single Blind Clinical Trial",Recruiting,NA,Phase 2,64,Anticipated,Fondazione Epatocentro Ticino,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:46:52Z,2021-12-02T07:46:52Z
NCT04636320,NA,11/18/2020,NA,NA,11/18/2020,11/18/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2020,11/19/2020,Actual,13-Jun-20,Actual,6/13/2020,Nov-20,11/30/2020,13-Apr-21,Anticipated,4/13/2021,13-Jan-21,Anticipated,1/13/2021,NA,Interventional,COVID-CMR,NA,Prevalence of Myocardial Scars on CMR After COVID-19 Infection,Prevalence of Silent Myocardial Scars on Cardiac Magnetic Resonance Following COVID-19 Infection,Recruiting,NA,Not Applicable,240,Anticipated,"University Hospital, Bordeaux",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:46:32Z,2021-12-02T07:46:32Z
NCT04636333,NA,11/17/2020,NA,NA,5/22/2021,11/17/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,5/22/2021,5/25/2021,Actual,30-Oct-20,Actual,10/30/2020,May-21,5/31/2021,7-Jan-22,Anticipated,1/7/2022,7-Dec-21,Anticipated,12/7/2021,NA,Interventional,NA,NA,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Safety and Immunogenicity of a Recombinant COVID-19 Vaccine (CHO Cell) in Healthy Population Aged 18 Years and Older: A Phase I Study,Recruiting,NA,Phase 1,216,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:46:33Z,2021-12-02T07:46:33Z
NCT04636086,NA,11/17/2020,NA,NA,4/27/2021,11/18/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/28/2021,Actual,12-Nov-20,Actual,11/12/2020,Apr-21,4/30/2021,28-Feb-22,Anticipated,2/28/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection,"Vitamin D Supplementation and Covid-19: a Randomised, Double- Blind, Controlled Study",Recruiting,NA,Phase 4,100,Anticipated,University of Liege,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:46:20Z,2021-12-02T07:46:20Z
NCT04635618,NA,11/5/2020,NA,NA,11/18/2020,11/18/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2020,11/19/2020,Actual,5-Nov-20,Actual,11/5/2020,Nov-20,11/30/2020,20-Jul-21,Anticipated,7/20/2021,13-Jul-21,Anticipated,7/13/2021,NA,Interventional,NA,NA,Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19,"A Pragmatic Superiority Randomized Controlled Trial Comparing Brief Cognitive Behavioral Telepsychotherapy, Brief Interpersonal Telepsychotherapy and Telepsychoeducation for the Reduction of Emotional Distress During COVID-19 Outbreak in Professionals and Students From Essential Services With a High Level of Emotional Distress in Brazil in the Context of COVID-19",Enrolling by invitation,NA,Not Applicable,999,Anticipated,Hospital de Clinicas de Porto Alegre,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Avaliable six months after study completion (antecipated - January 2022),Researchers and civil society,NA,Yes,"Plan to share study protocol, SAP, ICF, CRS, analytic code and individual-based variables.",2021-12-02T07:46:41Z,2021-12-02T07:46:41Z
NCT04635241,NA,11/14/2020,NA,NA,7/29/2021,11/17/2020,11/19/2020,Actual,NA,NA,NA,NA,NA,NA,7/29/2021,8/4/2021,Actual,1-Jun-20,Actual,6/1/2020,Jul-21,7/31/2021,1-Dec-21,Anticipated,12/1/2021,1-Nov-21,Anticipated,11/1/2021,NA,Interventional,INHALE-HEP,NA,Inhaled Heparin for Hospitalised COVID-19 Patients,INHALEd Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 Meta-trial,Recruiting,NA,Phase 2/Phase 3,712,Anticipated,Australian National University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,This meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled trials and early phase studies.,2021-12-02T07:47:12Z,2021-12-02T07:47:12Z
NCT04634903,NA,11/11/2020,5/18/2021,NA,5/21/2021,11/17/2020,11/18/2020,Actual,5/21/2021,5/25/2021,Actual,NA,NA,NA,5/21/2021,5/25/2021,Actual,19-Nov-20,Actual,11/19/2020,May-21,5/31/2021,15-Mar-21,Actual,3/15/2021,15-Mar-21,Actual,3/15/2021,NA,Interventional,NA,NA,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19",Comparing Two Online Single-Session Interventions for Adolescent Depression: Outcomes of a Randomized Trial,Completed,NA,Not Applicable,2452,Actual,Stony Brook University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Protocol and statistical plan have been posted to Open Science Framework prior to the start of this trial as part of study pre-registration (https://osf.io/kumdv/). Code will be made available upon publication of trial results.,NA,https://osf.io/8mk6x,Yes,NA,2021-12-02T07:47:37Z,2021-12-02T07:47:37Z
NCT04634799,NA,11/17/2020,NA,NA,1/20/2021,11/17/2020,11/18/2020,Actual,NA,NA,NA,NA,NA,NA,1/20/2021,1/22/2021,Actual,8-Jan-21,Actual,1/8/2021,Jan-21,1/31/2021,30-Jun-22,Anticipated,6/30/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19 (STOP Severe COVID-19),Recruiting,NA,Phase 1/Phase 2,80,Anticipated,Northwestern University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:47:40Z,2021-12-02T07:47:40Z
NCT04634422,NA,11/14/2020,NA,NA,12/17/2020,11/17/2020,11/18/2020,Actual,NA,NA,NA,NA,NA,NA,12/17/2020,12/21/2020,Actual,16-Nov-20,Actual,11/16/2020,Dec-20,12/31/2020,30-Jun-22,Anticipated,6/30/2022,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,COVID-PLEX,NA,Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure,Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure - the COVID PLEX+CCP Trial,Recruiting,NA,Not Applicable,220,Anticipated,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,June 30st 2024 - June 30st 2029,Study Website,http://www.covid-plex.com,Yes,Deidentified data will be released after primary publication,2021-12-02T07:47:53Z,2021-12-02T07:47:53Z
NCT04634318,NA,11/17/2020,NA,NA,8/27/2021,11/17/2020,11/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/27/2021,9/1/2021,Actual,10-Dec-20,Actual,12/10/2020,Aug-21,8/31/2021,Jan-22,Anticipated,1/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,REHABCOVID,NA,Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID),Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae. Assessment and Therapeutic Indication of Tele-rehabilitation Versus Conventional Rehabilitation,Recruiting,NA,Not Applicable,118,Anticipated,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:48:02Z,2021-12-02T07:48:02Z
NCT04632602,NA,11/16/2020,NA,NA,8/12/2021,11/16/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/12/2021,8/13/2021,Actual,14-Apr-20,Actual,4/14/2020,Aug-21,8/31/2021,31-Dec-20,Actual,12/31/2020,29-Nov-20,Actual,11/29/2020,NA,Interventional,ProneSpontCov,NA,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure: a Randomized Cross Over Electrical Impedance Tomography Study,Completed,NA,Not Applicable,20,Actual,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:49:06Z,2021-12-02T07:49:06Z
NCT04632719,NA,11/14/2020,NA,NA,11/16/2020,11/16/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2020,11/17/2020,Actual,8-Nov-20,Actual,11/8/2020,Nov-20,11/30/2020,29-Dec-23,Anticipated,12/29/2023,29-Dec-20,Anticipated,12/29/2020,NA,Interventional,MP-COVID,NA,The MentalPlusÂ® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,MentalPlusÂ® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19,Recruiting,NA,Not Applicable,200,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months,Access will be made available by MentalPlusÂ® APP and email.,NA,Yes,"The study will be shared with researchers from international centers. Therefore, the information will be made available between centers so that everyone can follow the same research protocol.",2021-12-02T07:49:11Z,2021-12-02T07:49:11Z
NCT04632082,NA,11/5/2020,NA,NA,11/18/2020,11/15/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2020,11/20/2020,Actual,5-Nov-20,Actual,11/5/2020,Nov-20,11/30/2020,20-Jul-21,Anticipated,7/20/2021,13-Jul-21,Anticipated,7/13/2021,NA,Interventional,NA,NA,Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19,A Pragmatic Superiority Randomized Controlled Trial Comparing Telepsychoeducation Plus Personalized Videos vs. Telepsychoeducation Without Personalized Videos for the Prevention of Future Emotional Distress in Professionals From Essential Services With Low to Moderate Levels of Emotional Distress in Brazil in the Context of COVID-19,Enrolling by invitation,NA,Not Applicable,2200,Anticipated,Hospital de Clinicas de Porto Alegre,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Avaliable six months after study completion (antecipated - January 2022),Researchers and civil society,NA,Yes,"Plan to share study protocol, SAP, ICF, CRS, analytic code and individual-based variables.",2021-12-02T07:49:41Z,2021-12-02T07:49:41Z
NCT04632368,NA,11/11/2020,NA,NA,8/19/2021,11/16/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/23/2021,Actual,20-Nov-20,Actual,11/20/2020,May-21,5/31/2021,16-Aug-21,Actual,8/16/2021,10-Aug-21,Actual,8/10/2021,NA,Interventional,NA,NA,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Completed,NA,Not Applicable,80,Actual,Duke University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:49:19Z,2021-12-02T07:49:19Z
NCT04631380,NA,8/4/2020,NA,NA,11/13/2020,11/13/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,11/13/2020,11/17/2020,Actual,1-Aug-20,Actual,8/1/2020,Aug-20,8/31/2020,Jan-21,Anticipated,1/31/2021,Jan-21,Anticipated,1/31/2021,NA,Interventional,NA,NA,Prayer in Commbate to Corona Virus - Covid -19,"A Double Blind, Controlled, Randomized, Prospective Study That Will Evaluate the Impact of Remote Intercession Prayer on the Clinical Evolution of Patients Diagnosed With COVID -19 in HCOR.",Recruiting,NA,Not Applicable,200,Anticipated,Hospital do Coracao,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,They will not,2021-12-02T07:50:06Z,2021-12-02T07:50:06Z
NCT04629989,NA,11/13/2020,NA,NA,3/8/2021,11/13/2020,11/16/2020,Actual,NA,NA,NA,NA,NA,NA,3/8/2021,3/9/2021,Actual,13-Nov-20,Actual,11/13/2020,Mar-21,3/31/2021,5-Mar-21,Actual,3/5/2021,5-Mar-21,Actual,3/5/2021,NA,Interventional,NA,NA,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,The Effects of Two Systems Above Low-flow Nasal Cannula on Arterial Oxygen Tension in Patients With COVID-19 : Surgical Face Mask Versus Double-trunk Mask,Completed,NA,Not Applicable,27,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:51:28Z,2021-12-02T07:51:28Z
NCT04632043,NA,11/15/2020,NA,NA,2/28/2021,11/15/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,2/28/2021,3/3/2021,Actual,18-Nov-20,Actual,11/18/2020,Feb-21,2/28/2021,1-Jun-21,Anticipated,6/1/2021,1-May-21,Anticipated,5/1/2021,NA,Interventional,EUDOCO,NA,Early Versus Delayed Intubation of Patients With COVID-19,Effect of Early versUs Delayed intubatiOn on Clinical Outcomes of Patients With COVID-19 (EUDOCO): a Feasibility Randomized Controlled Trial,Recruiting,NA,Not Applicable,80,Anticipated,Evangelismos Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 3 months from publication,To anyone who is interested in writing a meta-analysis or review.,NA,Yes,NA,2021-12-02T07:49:53Z,2021-12-02T07:49:53Z
NCT04631536,NA,10/28/2020,NA,NA,3/24/2021,11/14/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,3/24/2021,3/29/2021,Actual,10-Jan-21,Actual,1/10/2021,Mar-21,3/31/2021,1-Jun-21,Anticipated,6/1/2021,31-May-21,Anticipated,5/31/2021,NA,Interventional,MEDIC-LAUMC,NA,Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC,Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at the Lebanese American University Medical Center- Rizk Hospital,Recruiting,NA,Phase 3,80,Anticipated,Lebanese American University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:50:16Z,2021-12-02T07:50:16Z
NCT04631666,NA,11/5/2020,NA,NA,8/22/2021,11/14/2020,11/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/22/2021,8/24/2021,Actual,8-Dec-20,Actual,12/8/2020,Aug-21,8/31/2021,11-Aug-21,Actual,8/11/2021,11-Aug-21,Actual,8/11/2021,NA,Interventional,NA,NA,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion,A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,Completed,NA,Phase 1/Phase 2,57,Actual,University of Cologne,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:50:20Z,2021-12-02T07:50:20Z
NCT04630054,NA,11/13/2020,NA,NA,8/5/2021,11/13/2020,11/16/2020,Actual,NA,NA,NA,NA,NA,NA,8/5/2021,8/12/2021,Actual,15-Nov-20,Actual,11/15/2020,Aug-21,8/31/2021,29-Jun-21,Actual,6/29/2021,29-Jun-21,Actual,6/29/2021,NA,Interventional,NA,NA,Face Masks to Reduce COVID-19 in Bangladesh,Can Face Masks Reduce Transmission of SARS-CoV-2 in Bangladesh? A Cluster Randomized Controlled Trial,Completed,NA,Not Applicable,350000,Actual,Yale University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,We do not plan to share individual participant data with other researchers,2021-12-02T07:51:22Z,2021-12-02T07:51:22Z
NCT04629105,NA,9/29/2020,NA,NA,9/24/2021,11/12/2020,11/16/2020,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/30/2021,Actual,24-Jul-20,Actual,7/24/2020,Sep-21,9/30/2021,Jul-25,Anticipated,7/31/2025,Aug-23,Anticipated,8/31/2023,NA,Interventional,RECOVER,NA,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER),"A Phase 1 Double-blinded, Randomized, Placebo-controlled Study for COVID-19 and Influenza Virus-Elicited Acute Respiratory Distress Syndrome (ARDS) Using Lomecel-B",Recruiting,NA,Phase 1,70,Anticipated,Longeveron Inc.,,4,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:52:09Z,2021-12-02T07:52:09Z
NCT04629157,NA,11/4/2020,NA,NA,8/2/2021,11/13/2020,11/16/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,5-Nov-20,Actual,11/5/2020,Nov-20,11/30/2020,1-Feb-21,Actual,2/1/2021,1-Feb-21,Actual,2/1/2021,NA,Interventional,LAVA,NA,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Completed,NA,Not Applicable,185,Actual,Alder Hey Children's NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will not be shared outside of the research team,2021-12-02T07:52:27Z,2021-12-02T07:52:27Z
NCT04628143,NA,11/10/2020,NA,NA,8/9/2021,11/10/2020,11/13/2020,Actual,NA,NA,NA,NA,NA,NA,8/9/2021,8/13/2021,Actual,21-Dec-20,Actual,12/21/2020,Apr-21,4/30/2021,5-Apr-21,Actual,4/5/2021,5-Apr-21,Actual,4/5/2021,NA,Interventional,NA,NA,A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"Open-label, Multi-center, Randomized Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19",Completed,NA,Phase 2,13,Actual,Chong Kun Dang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:53:15Z,2021-12-02T07:53:15Z
NCT04627584,NA,11/12/2020,NA,NA,2/24/2021,11/12/2020,11/13/2020,Actual,NA,NA,NA,NA,NA,NA,2/24/2021,2/26/2021,Actual,29-Dec-20,Actual,12/29/2020,Feb-21,2/28/2021,Sep-21,Anticipated,9/30/2021,May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of MW33 Injection to Evaluate the Efficacy and Safety in Patients With Mild or Moderate COVID-19",Recruiting,NA,Phase 2,150,Anticipated,"Mabwell (Shanghai) Bioscience Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:53:29Z,2021-12-02T07:53:29Z
NCT04627519,NA,11/10/2020,NA,NA,6/7/2021,11/12/2020,11/13/2020,Actual,NA,NA,NA,NA,NA,NA,6/7/2021,6/10/2021,Actual,9-Dec-20,Actual,12/9/2020,Jun-21,6/30/2021,Sep-21,Anticipated,9/30/2021,19-May-21,Actual,5/19/2021,NA,Interventional,RHEA-COVID19,NA,Effectiveness and Safety of Rhea Health ToneÂ® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia,"A Multicenter, Randomized, Open-label, Controlled Trial to Assess Effectiveness and Safety of Rhea Health ToneÂ® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia","Active, not recruiting",NA,Not Applicable,85,Actual,Universitas Padjadjaran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:53:29Z,2021-12-02T07:53:29Z
NCT04627467,NA,10/30/2020,NA,NA,10/5/2021,11/11/2020,11/13/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/7/2021,Actual,28-Mar-20,Actual,3/28/2020,Sep-20,9/30/2020,30-Sep-21,Actual,9/30/2021,9-Jul-20,Actual,7/9/2020,NA,Interventional,TS-COVID,NA,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19),Completed,NA,Phase 2,3217,Actual,Fundacion Clinica Valle del Lili,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"We do not plan to share IPD, since we are not allowed to share information concerning medical history of our patients or health workers.",2021-12-02T07:53:31Z,2021-12-02T07:53:31Z
NCT04627675,NA,11/6/2020,NA,NA,6/2/2021,11/12/2020,11/13/2020,Actual,NA,NA,NA,NA,NA,NA,6/2/2021,6/3/2021,Actual,30-Dec-20,Actual,12/30/2020,Jun-21,6/30/2021,May-22,Anticipated,5/31/2022,Jul-21,Anticipated,7/31/2021,NA,Interventional,CORVax12,NA,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),"CORVax12 - a Phase I Trial of SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine (CORVax) +/- pIL-12 (Tavokinogene Telseplasmid) in Healthy Volunteers, With Immunodynamic Biomarker Monitoring of Coordinated Cellular/Humoral Response","Active, not recruiting",NA,Phase 1,36,Anticipated,Providence Health & Services,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:53:49Z,2021-12-02T07:53:49Z
NCT04625985,NA,10/23/2020,NA,NA,4/5/2021,11/10/2020,11/12/2020,Actual,NA,NA,NA,NA,NA,NA,4/5/2021,4/8/2021,Actual,14-Jul-20,Actual,7/14/2020,Apr-21,4/30/2021,18-Mar-21,Actual,3/18/2021,8-Mar-21,Actual,3/8/2021,NA,Interventional,DMMETCOV19-2,NA,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.","Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb",Completed,NA,Phase 2,20,Actual,Laboratorios Silanes S.A. de C.V.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:54:58Z,2021-12-02T07:54:58Z
NCT04625114,NA,11/5/2020,NA,NA,8/18/2021,11/10/2020,11/12/2020,Actual,NA,NA,NA,NA,NA,NA,8/18/2021,8/25/2021,Actual,4-Nov-20,Actual,11/4/2020,Aug-21,8/31/2021,1-Jan-23,Anticipated,1/1/2023,1-Oct-22,Anticipated,10/1/2022,NA,Interventional,NA,NA,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,Recruiting,NA,Phase 2,150,Anticipated,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:55:47Z,2021-12-02T07:55:47Z
NCT04623671,NA,10/7/2020,NA,NA,6/28/2021,11/9/2020,11/10/2020,Actual,NA,NA,NA,NA,NA,NA,6/28/2021,6/30/2021,Actual,15-Nov-20,Actual,11/15/2020,Apr-21,4/30/2021,30-Dec-21,Anticipated,12/30/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,INSPIRE,NA,Intravenous Infusion of CAP-1002 in Patients With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)",Recruiting,NA,Phase 2,60,Anticipated,Capricor Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:56:41Z,2021-12-02T07:56:41Z
NCT04622865,NA,11/9/2020,NA,NA,9/16/2021,11/9/2020,11/10/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2021,9/17/2021,Actual,1-Jun-20,Actual,6/1/2020,Sep-21,9/30/2021,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19,"Randomized, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib Combined With Isoquercetin, and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19",Recruiting,NA,Phase 2,200,Anticipated,AB Science,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:57:25Z,2021-12-02T07:57:25Z
NCT04623255,NA,6/11/2020,NA,NA,11/9/2020,11/9/2020,11/10/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2020,11/10/2020,Actual,16-Oct-20,Actual,10/16/2020,Nov-20,11/30/2020,1-Nov-21,Anticipated,11/1/2021,15-Oct-21,Anticipated,10/15/2021,NA,Interventional,COVIPLEX,NA,Randomised Study of Plasma Exchange in Severe COVID-19,A Randomised Controlled Trial of Plasma Exchange With Standard of Care Compared to Standard of Care Alone in the Treatment of Severe COVID-19 Infection (COVIPLEX),Recruiting,NA,Phase 2,20,Anticipated,"University College, London",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:57:03Z,2021-12-02T07:57:03Z
NCT04623021,NA,11/5/2020,NA,NA,1/31/2021,11/9/2020,11/10/2020,Actual,NA,NA,NA,NA,NA,NA,1/31/2021,2/2/2021,Actual,25-Sep-20,Actual,9/25/2020,Jan-21,1/31/2021,12-Dec-20,Actual,12/12/2020,12-Dec-20,Actual,12/12/2020,NA,Interventional,NA,NA,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia",Completed,NA,Phase 2,104,Actual,Chong Kun Dang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:57:20Z,2021-12-02T07:57:20Z
NCT04622826,NA,11/4/2020,NA,NA,11/7/2020,11/7/2020,11/10/2020,Actual,NA,NA,NA,NA,NA,NA,11/7/2020,11/10/2020,Actual,15-May-20,Actual,5/15/2020,Nov-20,11/30/2020,31-Dec-20,Anticipated,12/31/2020,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients,"Studio in Aperto Sulla Somministrazione di Plasma di Paziente Convalescente da COVID- 19 a Paziente Con Polmonite COVID-19 Ospedalizzato, Non in Terapia Intensiva",Recruiting,NA,Phase 2,50,Anticipated,Azienda USL Toscana Nord Ovest,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:57:28Z,2021-12-02T07:57:28Z
NCT04622891,NA,11/6/2020,NA,NA,11/7/2020,11/7/2020,11/10/2020,Actual,NA,NA,NA,NA,NA,NA,11/7/2020,11/10/2020,Actual,1-Apr-20,Actual,4/1/2020,Nov-20,11/30/2020,30-Jul-20,Actual,7/30/2020,30-Jul-20,Actual,7/30/2020,NA,Interventional,NA,NA,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,"Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial",Completed,NA,Not Applicable,300,Actual,South Valley University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:57:36Z,2021-12-02T07:57:36Z
NCT04621461,NA,11/6/2020,NA,NA,2/8/2021,11/6/2020,11/9/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/11/2021,Actual,20-Dec-20,Actual,12/20/2020,Feb-21,2/28/2021,8-Feb-21,Actual,2/8/2021,8-Feb-21,Actual,2/8/2021,NA,Interventional,NA,NA,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,"A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting",Completed,NA,Phase 4,3,Actual,"St. Francis Hospital, New York",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:58:34Z,2021-12-02T07:58:34Z
NCT04621903,NA,11/6/2020,NA,NA,11/18/2020,11/6/2020,11/9/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2020,11/19/2020,Actual,8-Oct-20,Actual,10/8/2020,Nov-20,11/30/2020,3-Nov-20,Actual,11/3/2020,27-Oct-20,Actual,10/27/2020,NA,Interventional,NA,NA,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19: Community Based Participatory Research,Completed,NA,Not Applicable,26,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:58:21Z,2021-12-02T07:58:21Z
NCT04621058,NA,11/6/2020,NA,NA,12/22/2020,11/6/2020,11/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/22/2020,12/23/2020,Actual,9-Nov-20,Actual,11/9/2020,Dec-20,12/31/2020,30-Nov-21,Anticipated,11/30/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.,Efficacy of Treatment With Vitamin D in Patients Diagnosed With COVID-19 Who Presenting Vitamin D Deficiency and Pneumonia.,Recruiting,NA,Phase 3,108,Anticipated,Bioaraba Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T07:58:54Z,2021-12-02T07:58:54Z
NCT04621149,NA,11/5/2020,NA,NA,12/27/2020,11/6/2020,11/9/2020,Actual,NA,NA,NA,NA,NA,NA,12/27/2020,12/29/2020,Actual,15-Nov-20,Actual,11/15/2020,Dec-20,12/31/2020,31-Mar-21,Anticipated,3/31/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,PROFACT-01,NA,An Outpatient Study Investigating Non-prescription Treatments for COVID-19,"A Phase 2 Screening Study of Candidate Non-prescription Treatments for COVID-19: A Patient-driven, Randomized, Factorial Study Evaluating Patient-reported Outcomes (PROFACT-01)",Recruiting,NA,Phase 2,120,Anticipated,"Profact, Inc.",,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:58:49Z,2021-12-02T07:58:49Z
NCT04621123,NA,11/4/2020,NA,NA,9/4/2021,11/6/2020,11/9/2020,Actual,NA,NA,NA,NA,NA,NA,9/4/2021,9/8/2021,Actual,10-Nov-20,Actual,11/10/2020,Sep-21,9/30/2021,28-Jul-21,Actual,7/28/2021,31-May-21,Actual,5/31/2021,NA,Interventional,NA,NA,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Convalescent Methylene Blue Treated (MBT) Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients: a Randomized Double Blind Study (COnV-ert),Completed,NA,Phase 2,384,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T07:59:02Z,2021-12-02T07:59:02Z
NCT04619628,NA,11/5/2020,NA,NA,7/26/2021,11/5/2020,11/6/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/28/2021,Actual,11-Dec-20,Actual,12/11/2020,Jul-21,7/31/2021,May-22,Anticipated,5/31/2022,26-Jun-21,Actual,6/26/2021,NA,Interventional,NA,NA,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19","Active, not recruiting",NA,Phase 1,48,Anticipated,"Codagenix, Inc",,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:00:00Z,2021-12-02T08:00:00Z
NCT04620798,NA,11/4/2020,NA,NA,8/23/2021,11/5/2020,11/9/2020,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/24/2021,Actual,14-Sep-20,Actual,9/14/2020,Aug-21,8/31/2021,11-Nov-20,Actual,11/11/2020,11-Nov-20,Actual,11/11/2020,NA,Interventional,NA,NA,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Completed,NA,Not Applicable,1076,Actual,Indiana University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"These study protocol documents will be made available upon completion of the study and the analyses. A de-identified, limited data set and analytic code will be available from the Principal Investigator upon request.","Protocol will be available on clinicaltrials.gov while the other documents, data, and analytic code from the Principal Investigator upon request.",NA,Yes,"The study team will make the following documents available to the public upon completion of the study: (1) Study Protocol, (2) Statistical Analysis Plan (SAP), (3) Informed Consent Form (ICF), and (4) Clinical Study Report (CSR). The individual participant data as well as the analytic code will not be made available to the public due to privacy concerns and in order to protect participants' private health information but will be available from the Principal Investigator upon request.",2021-12-02T07:59:06Z,2021-12-02T07:59:06Z
NCT04619719,NA,11/5/2020,NA,NA,8/30/2021,11/5/2020,11/6/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2021,8/31/2021,Actual,15-Mar-21,Actual,3/15/2021,Aug-21,8/31/2021,15-Jun-23,Anticipated,6/15/2023,15-Dec-22,Anticipated,12/15/2022,NA,Interventional,NA,NA,Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia,"Multi-Center, Randomized Control Trial to Study the Effectiveness of Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia",Recruiting,NA,Not Applicable,360,Anticipated,Legacy Health System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to David.Lee@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.",2021-12-02T08:00:03Z,2021-12-02T08:00:03Z
NCT04619706,NA,11/5/2020,NA,NA,5/14/2021,11/5/2020,11/6/2020,Actual,NA,NA,NA,NA,NA,NA,5/14/2021,5/17/2021,Actual,14-Dec-20,Actual,12/14/2020,May-21,5/31/2021,5-Dec-21,Anticipated,12/5/2021,14-Aug-21,Anticipated,8/14/2021,NA,Interventional,NA,NA,Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIA Study of FSD201 (Ultramicronized PEA) + Standard of Care (SOC) Vs SOC in the Treatment of Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,350,Anticipated,"FSD Pharma, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T07:59:57Z,2021-12-02T07:59:57Z
NCT04619290,NA,11/4/2020,NA,NA,11/9/2020,11/4/2020,11/6/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2020,11/12/2020,Actual,12-Oct-20,Actual,10/12/2020,Nov-20,11/30/2020,30-Dec-20,Anticipated,12/30/2020,30-Nov-20,Anticipated,11/30/2020,NA,Interventional,NA,NA,Outpatient Treatment With CoVid-19 With Prexablu,Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic,Recruiting,NA,Phase 1,46,Anticipated,Hospital Reg. Lic. Adolfo Lopez Mateos,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:00:15Z,2021-12-02T08:00:15Z
NCT04618042,NA,10/23/2020,NA,NA,6/21/2021,11/4/2020,11/5/2020,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/22/2021,Actual,13-Nov-20,Actual,11/13/2020,Jun-21,6/30/2021,13-Jun-21,Actual,6/13/2021,14-May-21,Actual,5/14/2021,NA,Interventional,FX-COVID,NA,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Completed,NA,Phase 2,50,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:03:03Z,2021-12-02T08:03:03Z
NCT04617483,NA,11/4/2020,NA,NA,7/26/2021,11/4/2020,11/5/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/27/2021,Actual,31-Oct-20,Actual,10/31/2020,Nov-20,11/30/2020,31-May-21,Actual,5/31/2021,28-Nov-20,Actual,11/28/2020,NA,Interventional,NA,NA,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults","A Randomized, Double-Blinded Clinical Trial, to Evaluate the Non-inferiority of the Commercial Scale Inactivated SARS-CoV-2 Vaccine Against That of the Pilot Scale Among Adults Aged 26-45 Years, and the Open-labelled, Bridging Non-inferiority of the Vaccine Induced Immunogenicity in Elderly Against That in Adults",Completed,NA,Phase 3,1040,Actual,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:04:10Z,2021-12-02T08:04:10Z
NCT04616989,NA,10/20/2020,NA,NA,6/1/2021,11/3/2020,11/5/2020,Actual,NA,NA,NA,NA,NA,NA,6/1/2021,6/2/2021,Actual,1-Nov-20,Actual,11/1/2020,Jun-21,6/30/2021,30-Jan-21,Actual,1/30/2021,30-Jan-21,Actual,1/30/2021,NA,Interventional,NA,NA,Mental Health in Communities Affected by COVID-19 in Uganda,Integration of Mental Health Care in Communities Affected by the COVID-19 Pandemic in Central Uganda,Completed,NA,Not Applicable,814,Actual,Makerere University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:05:24Z,2021-12-02T08:05:24Z
NCT04617262,NA,11/2/2020,NA,NA,7/12/2021,11/4/2020,11/5/2020,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/14/2021,Actual,27-Jan-21,Actual,1/27/2021,Jul-21,7/31/2021,Dec-21,Anticipated,12/31/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,PM+,NA,Pilot Feasibility Study of Remote Problem Management Plus for Adults Affected by COVID-19,Pilot Feasibility Study of Remote Problem Management Plus to Improve Well-being and Functioning of Adults Affected by COVID-,Recruiting,NA,Not Applicable,100,Anticipated,The New School,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Materials will be shared after publication of primary results.,Contact investigators.,NA,Yes,De-identified individual patient data will be available through NIMH Data Archive after publication of primary results.,2021-12-02T08:05:06Z,2021-12-02T08:05:06Z
NCT04615975,NA,10/31/2020,NA,NA,11/3/2020,11/3/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,11/3/2020,11/4/2020,Actual,1-Nov-20,Actual,11/1/2020,Nov-20,11/30/2020,30-Aug-21,Anticipated,8/30/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,NA,NA,Ketogenic Diet as Protective Factor During COVID-19,Pilot Study: Ketogenic Diet as Protective Factor During SARS-CoV-2 Infection,Recruiting,NA,Not Applicable,28,Anticipated,University of Padova,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:06:17Z,2021-12-02T08:06:17Z
NCT04615741,NA,10/29/2020,NA,NA,4/28/2021,10/29/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,4/28/2021,4/29/2021,Actual,9-Nov-20,Actual,11/9/2020,Apr-21,4/30/2021,20-Apr-21,Actual,4/20/2021,22-Jan-21,Actual,1/22/2021,NA,Interventional,NA,NA,Finding Wellness in the Pandemic,Improving Health and Wellness During COVID-19,Completed,NA,Not Applicable,187,Actual,University of Lethbridge,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"After April 2021, for up to 10 years",Researchers must make a reasonable request to the PI,NA,Yes,De-identified data relevant to the researcher's research question may be shared upon a reasonable request,2021-12-02T08:06:24Z,2021-12-02T08:06:24Z
NCT04615416,NA,10/26/2020,NA,NA,10/4/2021,11/2/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/11/2021,Actual,1-May-20,Actual,5/1/2020,Oct-21,10/31/2021,Jan-23,Anticipated,1/31/2023,Mar-22,Anticipated,3/31/2022,NA,Interventional,ERT-P,NA,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,Open Trial of Emotion Regulation Training Via Telehealth for Distressed Adults During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,100,Anticipated,"Teachers College, Columbia University",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:06:51Z,2021-12-02T08:06:51Z
NCT04614844,NA,11/2/2020,NA,NA,2/24/2021,11/2/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,2/24/2021,2/25/2021,Actual,6-Jan-21,Actual,1/6/2021,Feb-21,2/28/2021,15-Nov-22,Anticipated,11/15/2022,15-Sep-22,Anticipated,9/15/2022,NA,Interventional,NA,NA,COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS),COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS) Randomized Control Trial,Recruiting,NA,Not Applicable,84,Anticipated,Yale University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T08:07:09Z,2021-12-02T08:07:09Z
NCT04614883,NA,11/2/2020,NA,NA,6/11/2021,11/3/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,6/11/2021,6/16/2021,Actual,21-Oct-20,Actual,10/21/2020,Jun-21,6/30/2021,26-Feb-21,Actual,2/26/2021,26-Feb-21,Actual,2/26/2021,NA,Interventional,VOC-COVID-Diag,NA,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in Patients Referred to the Emergency Reception Service for Suspected COVID-19 Infection: Diagnostic Value and for Rapid Screening,Completed,NA,Not Applicable,130,Actual,Hopital Foch,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:07:07Z,2021-12-02T08:07:07Z
NCT04615052,NA,10/29/2020,NA,NA,5/5/2021,11/2/2020,11/4/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/7/2021,Actual,26-Sep-20,Actual,9/26/2020,May-21,5/31/2021,21-Dec-21,Anticipated,12/21/2021,31-Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Home-based Exercise in COVID-19 Survivors,Home-based Exercise Training in COVID-19 Survivors: a Randomized Controlled Trial,Recruiting,NA,Not Applicable,60,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:07:13Z,2021-12-02T08:07:13Z
NCT04614025,NA,11/2/2020,NA,NA,8/8/2021,11/2/2020,11/3/2020,Actual,NA,NA,NA,NA,NA,NA,8/8/2021,8/10/2021,Actual,19-Oct-20,Actual,10/19/2020,Aug-21,8/31/2021,Sep-22,Anticipated,9/30/2022,4-Aug-21,Actual,8/4/2021,NA,Interventional,NA,NA,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,"A Randomized, Controlled, Multicenter, Parallel-Group Phase IIa Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Severe COVID-19","Active, not recruiting",NA,Phase 2,23,Actual,Pluristem Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:07:54Z,2021-12-02T08:07:54Z
NCT04614012,NA,11/2/2020,NA,NA,11/2/2020,11/2/2020,11/3/2020,Actual,NA,NA,NA,NA,NA,NA,11/2/2020,11/3/2020,Actual,2-Jul-20,Actual,7/2/2020,Nov-20,11/30/2020,2-Jul-22,Anticipated,7/2/2022,2-Jul-22,Anticipated,7/2/2022,NA,Interventional,IMMUNO-COVID19,NA,Hyperimmune Plasma for Patients With COVID-19,The Use of Hyperimmune Plasma for the Treatment of COVID-19 Infection,Recruiting,NA,Not Applicable,100,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:07:55Z,2021-12-02T08:07:55Z
NCT04613297,NA,11/2/2020,NA,NA,11/2/2020,11/2/2020,11/3/2020,Actual,NA,NA,NA,NA,NA,NA,11/2/2020,11/3/2020,Actual,19-Oct-20,Actual,10/19/2020,Nov-20,11/30/2020,Oct-21,Anticipated,10/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,HLA-G-COVID,NA,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,Recruiting,NA,Not Applicable,120,Anticipated,Hopital Foch,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:08:41Z,2021-12-02T08:08:41Z
NCT04613739,NA,10/29/2020,NA,NA,2/26/2021,11/2/2020,11/3/2020,Actual,NA,NA,NA,NA,NA,NA,2/26/2021,3/2/2021,Actual,8-Dec-20,Actual,12/8/2020,Feb-21,2/28/2021,31-Jan-23,Anticipated,1/31/2023,1-Sep-21,Anticipated,9/1/2021,NA,Interventional,AFFORD COVID,NA,Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19,Comparing Patient-Centered Outcomes for Adults and Children With Asthma in High-Deductible Health Plans With and Without Preventive Drug Lists: COVID Enhancement,Recruiting,NA,Not Applicable,430,Anticipated,Harvard Pilgrim Health Care,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:08:12Z,2021-12-02T08:08:12Z
NCT04613271,NA,10/25/2020,NA,NA,10/3/2021,11/1/2020,11/3/2020,Actual,NA,NA,NA,NA,NA,NA,10/3/2021,10/5/2021,Actual,15-Oct-20,Actual,10/15/2020,Oct-21,10/31/2021,30-Dec-21,Anticipated,12/30/2021,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,FVR,NA,Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia,"Phase III, Random-Open, Clinical Trials on the Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia",Recruiting,NA,Phase 3,210,Anticipated,Ina-Respond,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:08:27Z,2021-12-02T08:08:27Z
NCT04613050,NA,10/30/2020,NA,NA,1/26/2021,11/2/2020,11/3/2020,Actual,NA,NA,NA,NA,NA,NA,1/26/2021,1/27/2021,Actual,2-Jul-20,Actual,7/2/2020,Jan-21,1/31/2021,20-Feb-22,Anticipated,2/20/2022,24-Dec-21,Anticipated,12/24/2021,NA,Interventional,NA,NA,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Recruiting,NA,Not Applicable,80,Anticipated,Cairo University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:08:32Z,2021-12-02T08:08:32Z
NCT04613310,NA,10/26/2020,NA,NA,11/10/2020,11/1/2020,11/3/2020,Actual,NA,NA,NA,NA,NA,NA,11/10/2020,11/12/2020,Actual,25-Sep-20,Actual,9/25/2020,Nov-20,11/30/2020,31-Dec-20,Anticipated,12/31/2020,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,RaDiCo,NA,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19),PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2: a Comparative Clinical Trial,Recruiting,NA,Not Applicable,1250,Anticipated,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:08:32Z,2021-12-02T08:08:32Z
NCT04611399,NA,10/8/2020,NA,NA,3/17/2021,10/30/2020,11/2/2020,Actual,NA,NA,NA,NA,NA,NA,3/17/2021,3/19/2021,Actual,5-Mar-21,Actual,3/5/2021,Feb-21,2/28/2021,5-Mar-22,Anticipated,3/5/2022,5-Mar-22,Anticipated,3/5/2022,NA,Interventional,NA,NA,MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support,MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support,Recruiting,NA,Not Applicable,90,Anticipated,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:09:50Z,2021-12-02T08:09:50Z
NCT04612972,NA,8/18/2020,NA,NA,4/27/2021,10/29/2020,11/3/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/30/2021,Actual,9-Sep-20,Actual,9/9/2020,Apr-21,4/30/2021,19-Dec-21,Anticipated,12/19/2021,19-Feb-21,Actual,2/19/2021,NA,Interventional,Covid-Peru,NA,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru","Ensayo ClÃ­nico de Fase III, Aleatorio, Doble Ciego y Controlado Con Placebo Paralelo, Para Evaluar la Seguridad y la Eficacia Protectora de la Vacuna Inactivada Contra el SARS-CoV-2 en la PoblaciÃ³n Sana de 18 aÃ±os o mÃ¡s, en PerÃº","Active, not recruiting",NA,Phase 3,12000,Actual,Universidad Peruana Cayetano Heredia,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:08:40Z,2021-12-02T08:08:40Z
NCT04611802,NA,10/30/2020,NA,NA,11/18/2021,10/30/2020,11/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,12/1/2021,Estimate,27-Dec-20,Actual,12/27/2020,Nov-21,11/30/2021,30-Jun-23,Anticipated,6/30/2023,30-Jun-23,Anticipated,6/30/2023,NA,Interventional,NA,NA,"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2","A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)","Active, not recruiting",NA,Phase 3,33000,Anticipated,Novavax,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:09:49Z,2021-12-02T08:09:49Z
NCT04605887,NA,10/27/2020,NA,NA,1/18/2021,10/27/2020,10/28/2020,Actual,NA,NA,NA,NA,NA,NA,1/18/2021,1/22/2021,Actual,18-Jan-21,Actual,1/18/2021,Jan-21,1/31/2021,Apr-24,Anticipated,4/30/2024,Nov-23,Anticipated,11/30/2023,NA,Interventional,NA,NA,Angiotensin 1-7 as a Therapy in the Treatment of COVID-19,Angiotensin 1-7 as a Therapy for Pneumonia Caused by Coronavirus 2(SARS-CoV-2),Recruiting,NA,Phase 2,120,Anticipated,Rambam Health Care Campus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:14:45Z,2021-12-02T08:14:45Z
NCT04611256,NA,10/29/2020,NA,NA,11/9/2020,10/29/2020,11/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2020,11/12/2020,Actual,1-Aug-20,Actual,8/1/2020,Nov-20,11/30/2020,30-Dec-20,Anticipated,12/30/2020,30-Nov-20,Anticipated,11/30/2020,NA,Interventional,NA,NA,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,Adjuvant Therapy With Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 in Critical Condition,Recruiting,NA,Phase 1,20,Anticipated,Hospital Reg. Lic. Adolfo Lopez Mateos,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:10:05Z,2021-12-02T08:10:05Z
NCT04610567,NA,10/24/2020,NA,NA,1/13/2021,10/29/2020,10/30/2020,Actual,NA,NA,NA,NA,NA,NA,1/13/2021,1/14/2021,Actual,27-Oct-20,Actual,10/27/2020,Jan-21,1/31/2021,15-Jul-21,Anticipated,7/15/2021,15-Mar-21,Anticipated,3/15/2021,NA,Interventional,Nano-COVID19,NA,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Two Phases Clinical Trial to Evaluate Safety and Efficacy of Methotrexate Associated to LDL Like Nanoparticles (LDE-MTX) in the Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease.,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,University of Sao Paulo General Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:10:36Z,2021-12-02T08:10:36Z
NCT04610541,NA,10/11/2020,NA,NA,11/23/2020,10/29/2020,10/30/2020,Actual,NA,NA,NA,NA,NA,NA,11/23/2020,11/27/2020,Actual,12-Oct-20,Actual,10/12/2020,Oct-20,10/31/2020,30-Nov-21,Anticipated,11/30/2021,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,NA,NA,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients,"Active, not recruiting",NA,Phase 3,2000,Anticipated,University of Pecs,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:10:37Z,2021-12-02T08:10:37Z
NCT04609969,NA,10/28/2020,NA,NA,12/4/2020,10/28/2020,10/30/2020,Actual,NA,NA,NA,NA,NA,NA,12/4/2020,12/7/2020,Actual,13-Oct-20,Actual,10/13/2020,Dec-20,12/31/2020,17-Oct-20,Actual,10/17/2020,17-Oct-20,Actual,10/17/2020,NA,Interventional,COVID-VIRO,NA,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test on Nasopharyngeal Specimens i,Completed,NA,Not Applicable,200,Actual,Centre Hospitalier RÃ©gional d'OrlÃ©ans,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:11:07Z,2021-12-02T08:11:07Z
NCT04609722,NA,10/26/2020,NA,NA,1/12/2021,10/26/2020,10/30/2020,Actual,NA,NA,NA,NA,NA,NA,1/12/2021,1/13/2021,Actual,1-Jul-20,Actual,7/1/2020,Nov-20,11/30/2020,15-Feb-21,Anticipated,2/15/2021,1-Feb-21,Anticipated,2/1/2021,NA,Interventional,NA,NA,Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic,Effect of Solution-Focused Support Program on Anxiety Levels of Parents With Children Aged 3-6 Years During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,60,Anticipated,Adiyaman University Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:11:20Z,2021-12-02T08:11:20Z
NCT04610502,NA,9/15/2020,NA,NA,3/18/2021,10/29/2020,10/30/2020,Actual,NA,NA,NA,NA,NA,NA,3/18/2021,3/19/2021,Actual,6-Sep-20,Actual,9/6/2020,Mar-21,3/31/2021,6-Dec-20,Actual,12/6/2020,6-Oct-20,Actual,10/6/2020,NA,Interventional,SECR-01,NA,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,"Randomized, Controlled, Double-blind, Multicenter Clinical Study to Compare the Efficacy and Safety of the Administration of Two Hyperimmune Equine Anti-Sars-CoV-2 (""S"" and ""M"") Serum Formulations in Hospitalized Patients With COVID-19",Completed,NA,Phase 2,26,Actual,Caja Costarricense de Seguro Social,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:11:02Z,2021-12-02T08:11:02Z
NCT04610489,NA,10/27/2020,6/28/2021,NA,8/15/2021,10/29/2020,10/30/2020,Actual,8/15/2021,8/17/2021,Actual,NA,NA,NA,8/15/2021,8/17/2021,Actual,13-Nov-20,Actual,11/13/2020,Aug-21,8/31/2021,10-Mar-21,Actual,3/10/2021,10-Mar-21,Actual,3/10/2021,NA,Interventional,NA,NA,Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19),Diagnostic Performance of an Antigen Test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Terminated,NA,Not Applicable,117,Actual,Carilion Clinic,,1,NA,Difficulty with recruiting for the study and with staffing the study.,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:11:03Z,2021-12-02T08:11:03Z
NCT04609865,NA,10/23/2020,NA,NA,1/19/2021,10/29/2020,10/30/2020,Actual,NA,NA,NA,NA,NA,NA,1/19/2021,1/20/2021,Actual,4-Nov-20,Actual,11/4/2020,Jan-21,1/31/2021,4-Feb-24,Anticipated,2/4/2024,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,LidoCovid,NA,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Recruiting,NA,Phase 3,100,Anticipated,"University Hospital, Strasbourg, France",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:11:14Z,2021-12-02T08:11:14Z
NCT04609371,NA,10/19/2020,NA,NA,9/20/2021,10/25/2020,10/30/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/21/2021,Actual,21-Oct-20,Actual,10/21/2020,Sep-21,9/30/2021,1-May-21,Actual,5/1/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,NA,NA,PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics,Assisting Family Physicians With Gaps in Mental Health Care Generated by the COVID-19 Pandemic: A Randomized Controlled Trial,Completed,NA,Not Applicable,90,Actual,"St. Mary's Research Center, Canada",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:11:54Z,2021-12-02T08:11:54Z
NCT04609462,NA,9/24/2020,NA,NA,3/26/2021,10/28/2020,10/30/2020,Actual,NA,NA,NA,NA,NA,NA,3/26/2021,4/1/2021,Actual,11-Aug-20,Actual,8/11/2020,Mar-21,3/31/2021,10-Feb-21,Actual,2/10/2021,13-Jan-21,Actual,1/13/2021,NA,Interventional,HiFlo-COVID,NA,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,A Trial of High-Flow Nasal Cannula vs. Conventional Oxygen Therapy in Patients With SARS-CoV-2-Related Acute Respiratory Failure: the HiFlo-COVID Trial.,Completed,NA,Not Applicable,199,Actual,Fundacion Clinica Valle del Lili,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:11:39Z,2021-12-02T08:11:39Z
NCT04608201,NA,10/23/2020,NA,NA,12/11/2020,10/28/2020,10/29/2020,Actual,NA,NA,NA,NA,NA,NA,12/11/2020,12/14/2020,Actual,9-Dec-20,Actual,12/9/2020,Dec-20,12/31/2020,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NICOVID,NA,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Recruiting,NA,Phase 3,220,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:12:44Z,2021-12-02T08:12:44Z
NCT04608097,NA,10/28/2020,NA,NA,4/29/2021,10/28/2020,10/29/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2021,4/30/2021,Actual,28-Oct-20,Actual,10/28/2020,Apr-21,4/30/2021,12-Mar-21,Actual,3/12/2021,12-Mar-21,Actual,3/12/2021,NA,Interventional,NA,NA,Understanding Reactions to Emotional Material in the Media During COVID-19,Understanding Reactions to Emotional Material in the Media During COVID-19 and the Connections to Cognitive Activities,Completed,NA,Not Applicable,74,Actual,Uppsala University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:12:51Z,2021-12-02T08:12:51Z
NCT04608305,NA,10/26/2020,NA,NA,4/25/2021,10/27/2020,10/29/2020,Actual,NA,NA,NA,NA,NA,NA,4/25/2021,4/27/2021,Actual,28-Oct-20,Actual,10/28/2020,Apr-21,4/30/2021,1-Jun-22,Anticipated,6/1/2022,1-May-21,Anticipated,5/1/2021,NA,Interventional,NA,NA,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine","A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults",Recruiting,NA,Phase 1/Phase 2,1040,Anticipated,Israel Institute for Biological Research (IIBR),,18,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:12:31Z,2021-12-02T08:12:31Z
NCT04607915,NA,7/30/2020,NA,NA,8/3/2021,10/28/2020,10/29/2020,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/10/2021,Actual,4-May-21,Actual,5/4/2021,Aug-21,8/31/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Technology-enabled Collaborative Care for Diabetes Management During COVID-19,Technology-enabled Collaborative Care for Diabetes (TECC-Diabetes) Management During COVID: A Feasibility Study,Recruiting,NA,Not Applicable,30,Anticipated,Centre for Addiction and Mental Health,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:13:07Z,2021-12-02T08:13:07Z
NCT04608266,NA,10/28/2020,NA,NA,4/2/2021,10/28/2020,10/29/2020,Actual,NA,NA,NA,NA,NA,NA,4/2/2021,4/5/2021,Actual,3-Dec-20,Actual,12/3/2020,Oct-20,10/31/2020,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,CAMOVID,NA,CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients,A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID),Recruiting,NA,Phase 3,596,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T08:12:58Z,2021-12-02T08:12:58Z
NCT04606563,NA,10/27/2020,NA,NA,10/27/2020,10/27/2020,10/28/2020,Actual,NA,NA,NA,NA,NA,NA,10/27/2020,10/28/2020,Actual,9-Oct-20,Actual,10/9/2020,Oct-20,10/31/2020,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,ARBs CORONA II,NA,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,NA,Phase 3,1372,Anticipated,University of British Columbia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:14:04Z,2021-12-02T08:14:04Z
NCT04606784,NA,10/27/2020,NA,NA,3/23/2021,10/27/2020,10/28/2020,Actual,NA,NA,NA,NA,NA,NA,3/23/2021,3/24/2021,Actual,28-Oct-20,Actual,10/28/2020,Mar-21,3/31/2021,18-Jun-21,Anticipated,6/18/2021,18-Mar-21,Actual,3/18/2021,NA,Interventional,NA,NA,Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress,A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Nebulized Ampion In Adults With Respiratory Distress Secondary to COVID-19 Infection,"Active, not recruiting",NA,Phase 1,40,Anticipated,Ampio Pharmaceuticals. Inc.,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:14:04Z,2021-12-02T08:14:04Z
NCT04606069,NA,10/26/2020,NA,NA,9/27/2021,10/27/2020,10/28/2020,Actual,NA,NA,NA,NA,NA,NA,9/27/2021,10/4/2021,Actual,6-May-21,Actual,5/6/2021,Sep-21,9/30/2021,31-Jan-22,Anticipated,1/31/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Treat COVID-19 Patients With Regadenoson,Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,"University of Maryland, Baltimore",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:14:37Z,2021-12-02T08:14:37Z
NCT04605588,NA,10/26/2020,NA,NA,7/2/2021,10/26/2020,10/28/2020,Actual,NA,NA,NA,NA,NA,NA,7/2/2021,7/8/2021,Actual,2-Dec-20,Actual,12/2/2020,Jul-21,7/31/2021,4-Feb-21,Actual,2/4/2021,17-Jan-21,Actual,1/17/2021,NA,Interventional,TriACT,NA,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,"A Triple Combination Antiviral Coronavirus Therapy (TriACT) RCT Comparing Nitazoxanide, Ribavirin and Hydroxychloroquine vs. Placebo",Terminated,NA,Phase 2,7,Actual,"Rutgers, The State University of New Jersey",,2,NA,Lack of participants willing to enroll,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:14:58Z,2021-12-02T08:14:58Z
NCT04604977,NA,10/20/2020,NA,NA,10/25/2020,10/25/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,10/25/2020,10/27/2020,Actual,15-Sep-20,Actual,9/15/2020,Oct-20,10/31/2020,Dec-21,Anticipated,12/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,Be-Home-Kids,NA,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Chronic Migraine and High Frequency Migraine Without Aura After the Covid-19 Emergency,Recruiting,NA,Not Applicable,25,Anticipated,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T08:15:18Z,2021-12-02T08:15:18Z
NCT04604743,NA,10/25/2020,NA,NA,5/21/2021,10/26/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/25/2021,Actual,20-Apr-21,Actual,4/20/2021,May-21,5/31/2021,30-Jun-23,Anticipated,6/30/2023,30-Jun-23,Anticipated,6/30/2023,NA,Interventional,NA,NA,Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama,Exploratory Sequential Mixed Methods Cluster Randomized Controlled Implementation Science Trial to Develop a Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for African American Older Adolescents in Rural Alabama,Recruiting,NA,Not Applicable,4,Anticipated,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data sharing with occur in compliance with Merck's data sharing policy.,2021-12-02T08:15:38Z,2021-12-02T08:15:38Z
NCT04604704,NA,10/26/2020,NA,NA,10/4/2021,10/26/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/11/2021,Actual,28-Jan-21,Actual,1/28/2021,Oct-21,10/31/2021,Mar-22,Anticipated,3/31/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD+) for Treatment of Patients With Post-COVID-19 Syndrome (Long-COVID19),Recruiting,NA,Phase 2,60,Anticipated,AgelessRx,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:15:42Z,2021-12-02T08:15:42Z
NCT04604184,NA,10/26/2020,NA,NA,8/2/2021,10/26/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,3-Nov-20,Actual,11/3/2020,Aug-21,8/31/2021,31-May-21,Actual,5/31/2021,24-Mar-21,Actual,3/24/2021,NA,Interventional,NA,NA,ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19,BI 764198 Efficacy and Safety in Prevention/Progression of ARDS and ARDS-related Complications Secondary to COVID-19 (ACTION ON COVID-19),Terminated,NA,Phase 2,133,Actual,Boehringer Ingelheim,,2,NA,Company decision,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.","For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.",https://www.mystudywindow.com/msw/datasharing,Yes,"After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed ""Document Sharing Agreement"".

Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

The data shared are the raw clinical study data sets.",2021-12-02T08:15:50Z,2021-12-02T08:15:50Z
NCT04604327,NA,10/23/2020,NA,NA,10/26/2020,10/26/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,10/26/2020,10/27/2020,Actual,26-Oct-20,Anticipated,10/26/2020,Oct-20,10/31/2020,31-Jul-21,Anticipated,7/31/2021,31-May-21,Anticipated,5/31/2021,NA,Interventional,BEMICOP,NA,Comparison of Two Different Doses of Bemiparin in COVID-19,"Ensayo clÃ­nico Aleatorizado, Abierto, Para Evaluar el Efecto de Dosis profilÃ¡cticas o terapÃ©uticas de Bemiparina en Pacientes Con COVID-19",Recruiting,NA,Phase 3,164,Anticipated,"Clinica Universidad de Navarra, Universidad de Navarra",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:15:55Z,2021-12-02T08:15:55Z
NCT04604145,NA,10/23/2020,NA,NA,8/24/2021,10/23/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/30/2021,Actual,3-Feb-21,Actual,2/3/2021,Aug-21,8/31/2021,18-Aug-21,Actual,8/18/2021,18-Aug-21,Actual,8/18/2021,NA,Interventional,NA,NA,Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR,Evaluation of Self-Collected Saliva Samples Without Viral Transport Media for SARS-CoV-2 Testing Via RT-PCR,Completed,NA,Not Applicable,60,Actual,David Grant U.S. Air Force Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:16:01Z,2021-12-02T08:16:01Z
NCT04604223,NA,10/26/2020,NA,NA,3/15/2021,10/26/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,18-Jan-21,Actual,1/18/2021,Oct-20,10/31/2020,29-Jun-21,Anticipated,6/29/2021,29-Jun-21,Anticipated,6/29/2021,NA,Interventional,PIOQ8,NA,Effect of Pioglitazone on T2DM Patients With COVID-19,Effect of Pioglitazone on Inflammatory Response and Clinical Outcome in T2DM Patients With COVID-19,Recruiting,NA,Phase 4,1506,Anticipated,Dasman Diabetes Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:16:02Z,2021-12-02T08:16:02Z
NCT04603963,NA,10/25/2020,NA,NA,10/26/2020,10/26/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,10/26/2020,10/28/2020,Actual,1-Jun-20,Actual,6/1/2020,Oct-20,10/31/2020,23-Oct-20,Actual,10/23/2020,10-Oct-20,Actual,10/10/2020,NA,Interventional,NA,NA,Inspiratory Muscle Training in Patients With COVID-19,Efects of Inspiratory Muscle Training in Patients With COVID-19 After Acute Phase. Prospective Study,Terminated,NA,Not Applicable,55,Actual,Hospital Israelita Albert Einstein,,2,NA,There was a change in the institutional flow reducing the cases of covid 19,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:16:10Z,2021-12-02T08:16:10Z
NCT04603781,NA,10/3/2020,NA,NA,2/23/2021,10/23/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,2/23/2021,2/26/2021,Actual,4-Dec-20,Actual,12/4/2020,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,CBDOIL,NA,CBD Oil for Reducing Emotional Impact of COVID-19,Use of CBD Oil for Reducing the Negative Emotional Impact of COVID-19: A Randomized Placebo-Controlled Clinical Trial,Recruiting,NA,Phase 2/Phase 3,160,Anticipated,University of Texas at Austin,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:16:20Z,2021-12-02T08:16:20Z
NCT04603794,NA,10/21/2020,NA,NA,10/23/2020,10/23/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,10/23/2020,10/27/2020,Actual,1-Oct-20,Actual,10/1/2020,Oct-20,10/31/2020,Nov-20,Anticipated,11/30/2020,Nov-20,Anticipated,11/30/2020,NA,Interventional,NA,NA,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,"Comparison of Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in COVID-19 Patients",Recruiting,NA,Phase 4,60,Anticipated,Ohio State University,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,As per The Ohio State University Office for Responsible Research Practices (Human Studies IRB),2021-12-02T08:16:25Z,2021-12-02T08:16:25Z
NCT04603924,NA,10/20/2020,NA,NA,9/8/2021,10/23/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,9/8/2021,9/9/2021,Actual,7-Oct-20,Actual,10/7/2020,Sep-21,9/30/2021,Jun-22,Anticipated,6/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients,A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients,Recruiting,NA,Phase 2/Phase 3,436,Anticipated,NeuroBo Pharmaceuticals Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:16:24Z,2021-12-02T08:16:24Z
NCT04603729,NA,10/21/2020,NA,NA,10/24/2020,10/24/2020,10/27/2020,Actual,NA,NA,NA,NA,NA,NA,10/24/2020,10/27/2020,Actual,30-May-20,Actual,5/30/2020,Oct-20,10/31/2020,1-Jul-20,Actual,7/1/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,covid19,NA,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,NA,Phase 3,100,Actual,Fatima Memorial Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"patient name and medical record will be confidential, onle the principal investigator will have access to data. Results of study will be shared with other researchers",2021-12-02T08:16:15Z,2021-12-02T08:16:15Z
NCT04602949,NA,10/21/2020,NA,NA,4/11/2021,10/23/2020,10/26/2020,Actual,NA,NA,NA,NA,NA,NA,4/11/2021,4/14/2021,Actual,12-Nov-20,Actual,11/12/2020,Oct-20,10/31/2020,28-Jul-21,Anticipated,7/28/2021,28-Jul-21,Anticipated,7/28/2021,NA,Interventional,COVID-19,NA,Detection of COVID-19 Using Breath Analysis - Validation Study,Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Validation Study,Recruiting,NA,Not Applicable,4000,Anticipated,Scentech Medical Technologies Ltd,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No IPD is to be shared with other researchers.,2021-12-02T08:17:20Z,2021-12-02T08:17:20Z
NCT04602871,NA,10/21/2020,NA,NA,4/11/2021,10/23/2020,10/26/2020,Actual,NA,NA,NA,NA,NA,NA,4/11/2021,4/13/2021,Actual,3-Jul-20,Actual,7/3/2020,Oct-20,10/31/2020,30-Jan-21,Actual,1/30/2021,30-Jan-21,Actual,1/30/2021,NA,Interventional,COVID-19,NA,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Feasibility Study,Completed,NA,Not Applicable,108,Actual,Scentech Medical Technologies Ltd,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No IPDs are to be shared with other researchers.,2021-12-02T08:17:04Z,2021-12-02T08:17:04Z
NCT04602832,NA,10/23/2020,NA,NA,11/2/2020,10/23/2020,10/26/2020,Actual,NA,NA,NA,NA,NA,NA,11/2/2020,11/4/2020,Actual,14-Oct-20,Actual,10/14/2020,Oct-20,10/31/2020,Dec-20,Anticipated,12/31/2020,Dec-20,Anticipated,12/31/2020,NA,Interventional,EN-COVID-19,NA,Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,A Randomized Controlled Trial of an Online Well-Being Intervention (The ENHANCE Program) for Improving Individuals Health and Well-Being During the COVID-19 Pandemic,Enrolling by invitation,NA,Not Applicable,350,Anticipated,University of British Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,We are currently consulting with others on the grant team regarding our long-term data plan and will update with our final data sharing plan in January 2021,2021-12-02T08:17:10Z,2021-12-02T08:17:10Z
NCT04602442,NA,10/21/2020,NA,NA,10/23/2020,10/23/2020,10/26/2020,Actual,NA,NA,NA,NA,NA,NA,10/23/2020,10/26/2020,Actual,1-Oct-20,Actual,10/1/2020,Oct-20,10/31/2020,30-Dec-21,Anticipated,12/30/2021,1-Aug-21,Anticipated,8/1/2021,NA,Interventional,COVID-19EXO2,NA,Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia,The Extended Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Two-Sided Pneumonia,Enrolling by invitation,NA,Phase 2,90,Anticipated,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:17:27Z,2021-12-02T08:17:27Z
NCT04602312,NA,10/19/2020,NA,NA,5/4/2021,10/22/2020,10/26/2020,Actual,NA,NA,NA,NA,NA,NA,5/4/2021,5/6/2021,Actual,28-Oct-20,Actual,10/28/2020,Oct-20,10/31/2020,Jun-21,Anticipated,6/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),"Online RCT Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Coronavirus-related Catastrophizing in Adults",Recruiting,NA,Not Applicable,624,Anticipated,The University of Queensland,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately following publication up and for a further 10 years .,"Investigators whose proposed use of the data has been approved by an independent review committee. Initial contact should be directed to the contact person for scientific enquiries (Mr Jonathan Davies, jonathan.davies@uq.edu.au).

Note: Requestors will need to sign a data access agreement.",https://sites.google.com/view/uqcovidmeditation,Yes,"All of the individual trial-related participant data collected during the trial, after de-identification.",2021-12-02T08:17:31Z,2021-12-02T08:17:31Z
NCT04602286,NA,10/19/2020,NA,NA,5/4/2021,10/22/2020,10/26/2020,Actual,NA,NA,NA,NA,NA,NA,5/4/2021,5/6/2021,Actual,28-Oct-20,Actual,10/28/2020,Oct-20,10/31/2020,Jun-21,Anticipated,6/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample),"An Online Randomized Controlled Trial Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Pain Experience in Adults With Recurrent and Chronic Pain",Recruiting,NA,Not Applicable,292,Anticipated,The University of Queensland,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately following publication up and for a further 10 years .,"Investigators whose proposed use of the data has been approved by an independent review committee. Initial contact should be directed to the contact person for scientific enquiries (Mr Jonathan Davies, jonathan.davies@uq.edu.au).

Note: Requestors will need to sign a data access agreement.",https://sites.google.com/view/uqcovidmeditation,Yes,"All of the individual trial-related participant data collected during the trial, after de-identification.",2021-12-02T08:17:32Z,2021-12-02T08:17:32Z
NCT04600999,NA,10/8/2020,NA,NA,10/22/2020,10/22/2020,10/23/2020,Actual,NA,NA,NA,NA,NA,NA,10/22/2020,10/23/2020,Actual,7-Oct-20,Actual,10/7/2020,Oct-20,10/31/2020,Jun-21,Anticipated,6/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study -,Recruiting,NA,Phase 3,150,Anticipated,University of Pecs,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:18:14Z,2021-12-02T08:18:14Z
NCT04601077,NA,10/21/2020,NA,NA,8/20/2021,10/22/2020,10/23/2020,Actual,NA,NA,NA,NA,NA,NA,8/20/2021,8/23/2021,Actual,1-Nov-20,Actual,11/1/2020,Aug-21,8/31/2021,31-Dec-21,Anticipated,12/31/2021,1-Nov-21,Anticipated,11/1/2021,NA,Interventional,NA,NA,The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin,Pilot Study: The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Nitric Oxide Innovations LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:18:22Z,2021-12-02T08:18:22Z
NCT04598581,NA,10/20/2020,NA,NA,4/14/2021,10/20/2020,10/22/2020,Actual,NA,NA,NA,NA,NA,NA,4/14/2021,4/19/2021,Actual,2-Nov-20,Actual,11/2/2020,Apr-21,4/30/2021,9-Apr-21,Actual,4/9/2021,9-Apr-21,Actual,4/9/2021,NA,Interventional,COVID-RT-01,NA,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2),Completed,NA,Not Applicable,22,Actual,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:20:20Z,2021-12-02T08:20:20Z
NCT04599959,NA,10/22/2020,7/21/2021,NA,7/21/2021,10/22/2020,10/23/2020,Actual,7/21/2021,7/26/2021,Actual,NA,NA,NA,7/21/2021,7/26/2021,Actual,26-Oct-20,Actual,10/26/2020,Jul-21,7/31/2021,20-Jan-21,Actual,1/20/2021,20-Jan-21,Actual,1/20/2021,NA,Interventional,NA,All eligible participants in this study who had been diagnosed with COVID-19 confirmed by polymerase chain reaction (PCR) test within the past 5 days before study entry.,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,"COVID-19 Tests: a Systematic Comparison of Viral RNA Test Sample Taking for RT-qPCR, in This Case With a Nasopharyngeal Swab or Saliva Collected With SalivetteÂ® Cortisol, to Diagnose SARS-CoV-2 Virus Infection",Completed,NA,Not Applicable,151,Actual,Boehringer Ingelheim,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:

studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).

For more details refer to: http://trials.boehringer-ingelheim.com/",2021-12-02T08:19:02Z,2021-12-02T08:19:02Z
NCT04600440,NA,10/20/2020,NA,NA,10/22/2020,10/22/2020,10/23/2020,Actual,NA,NA,NA,NA,NA,NA,10/22/2020,10/23/2020,Actual,25-Apr-20,Actual,4/25/2020,Oct-20,10/31/2020,28-Feb-22,Anticipated,2/28/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,COP20,NA,Convalescent Plasma in the Treatment of Covid-19,Convalescent Plasma in the Treatment of Covid-19,Recruiting,NA,Not Applicable,100,Anticipated,Skane University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:18:56Z,2021-12-02T08:18:56Z
NCT04600141,NA,10/22/2020,NA,NA,2/18/2021,10/22/2020,10/23/2020,Actual,NA,NA,NA,NA,NA,NA,2/18/2021,2/21/2021,Actual,10-Nov-20,Actual,11/10/2020,Feb-21,2/28/2021,31-Dec-21,Anticipated,12/31/2021,20-Oct-21,Anticipated,10/20/2021,NA,Interventional,HEPMAB,NA,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection: a Randomized Clinical Trial,Recruiting,NA,Phase 3,308,Anticipated,University of Sao Paulo,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:18:58Z,2021-12-02T08:18:58Z
NCT04598594,NA,10/15/2020,NA,NA,6/21/2021,10/21/2020,10/22/2020,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/22/2021,Actual,6-Nov-20,Actual,11/6/2020,Jun-21,6/30/2021,20-Jun-21,Actual,6/20/2021,29-Apr-21,Actual,4/29/2021,NA,Interventional,NICOVID-REA,NA,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Completed,NA,Phase 3,220,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:20:26Z,2021-12-02T08:20:26Z
NCT04597047,NA,10/19/2020,NA,NA,10/20/2020,10/20/2020,10/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/20/2020,10/22/2020,Actual,20-Aug-20,Actual,8/20/2020,Oct-20,10/31/2020,31-Dec-22,Anticipated,12/31/2022,31-Oct-22,Anticipated,10/31/2022,NA,Interventional,CAPTURE-2,NA,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,"A Multicenter Covid-19 Study Conducted to Evaluate the Agreement Between Fingerstick Whole Blood, Venous Whole Blood, Plasma & Serum as Determined on the LumiraDx POC SARS-CoV-2 Ab Test & to Evaluate the Ease of Use at Point of Care Sites",Recruiting,NA,Not Applicable,200,Anticipated,LumiraDx UK Limited,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:21:45Z,2021-12-02T08:21:45Z
NCT04597034,NA,10/3/2020,NA,NA,10/20/2020,10/20/2020,10/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/20/2020,10/22/2020,Actual,2-Oct-20,Actual,10/2/2020,Sep-20,9/30/2020,30-Mar-22,Anticipated,3/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,oXAKI-COV,NA,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,"A Randomized, Controlled Trial to Evaluate Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) in Comparison With a Semi Selective Semipermeable Membrane (Standard AN-69) in COVID-19 Associated Acute Kidney Injury: oXAKI-COV Study.",Recruiting,NA,Not Applicable,35,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:21:38Z,2021-12-02T08:21:38Z
NCT04596085,NA,10/19/2020,7/29/2021,NA,8/11/2021,10/20/2020,10/22/2020,Actual,8/11/2021,8/12/2021,Actual,NA,NA,NA,8/11/2021,8/12/2021,Actual,16-Sep-20,Actual,9/16/2020,Aug-21,8/31/2021,12-Dec-20,Actual,12/12/2020,12-Dec-20,Actual,12/12/2020,NA,Interventional,NA,NA,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)","A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of ""VIRACIDE"" in the Management of Corona Virus Disease 2019 (COVID-19)",Completed,NA,Not Applicable,118,Actual,"The Herb, Inc",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:22:23Z,2021-12-02T08:22:23Z
NCT04596839,NA,10/20/2020,NA,NA,8/9/2021,10/20/2020,10/22/2020,Actual,NA,NA,NA,NA,NA,NA,8/9/2021,8/10/2021,Actual,4-Sep-20,Actual,9/4/2020,Aug-21,8/31/2021,30-Apr-21,Actual,4/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,NA,NA,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),"Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial",Completed,NA,Phase 2,60,Actual,Beximco Pharmaceuticals Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:21:50Z,2021-12-02T08:21:50Z
NCT04595136,NA,10/15/2020,NA,NA,5/21/2021,10/19/2020,10/20/2020,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/26/2021,Actual,2-Nov-20,Actual,11/2/2020,May-21,5/31/2021,30-Aug-21,Anticipated,8/30/2021,30-Jul-21,Anticipated,7/30/2021,NA,Interventional,COVID-19,NA,Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient,A Two-arm Randomized Double-blind Study With COVID19-0001-USR Administered Via Nebulization to Patients With Mild and/or Moderate Severe Acute Respiratory Syndrome (SARS-COV-2) Infection to Decrease Viral Load,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,United Medical Specialties,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:23:07Z,2021-12-02T08:23:07Z
NCT04595097,NA,10/19/2020,NA,NA,6/11/2021,10/19/2020,10/20/2020,Actual,NA,NA,NA,NA,NA,NA,6/11/2021,6/14/2021,Actual,1-Mar-21,Actual,3/1/2021,Jun-21,6/30/2021,31-May-22,Anticipated,5/31/2022,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,ADDIMTCOVID,NA,Inspiratory Muscle Training in COVID-19 Patients,Adjunctive Inspiratory Muscle Training for Patients With COVID-19,Recruiting,NA,Not Applicable,138,Anticipated,Escola Superior de Ciencias da Saude,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:23:25Z,2021-12-02T08:23:25Z
NCT04595084,NA,10/19/2020,NA,NA,8/4/2021,10/19/2020,10/20/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/6/2021,Actual,15-Mar-21,Actual,3/15/2021,Aug-21,8/31/2021,1-Nov-22,Anticipated,11/1/2022,1-Nov-21,Anticipated,11/1/2021,NA,Interventional,NA,NA,Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use,Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use,Recruiting,NA,Not Applicable,240,Anticipated,Cambridge Health Alliance,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:23:16Z,2021-12-02T08:23:16Z
NCT04594668,NA,10/7/2020,NA,NA,10/19/2020,10/19/2020,10/20/2020,Actual,NA,NA,NA,NA,NA,NA,10/19/2020,10/20/2020,Actual,24-Apr-20,Actual,4/24/2020,Apr-20,4/30/2020,31-Dec-21,Anticipated,12/31/2021,24-Apr-21,Anticipated,4/24/2021,NA,Interventional,COVIPOC,NA,Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency,"Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency - A Randomized, Open-Label, Phase II Trial",Recruiting,NA,Phase 2,46,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available following publication with no planned end date.,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics approval (if applicable). Proposal should be addressed to us@biomed.au.dk,NA,Yes,"Data sharing plan: Individual de-identified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared included de-identified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan).",2021-12-02T08:23:32Z,2021-12-02T08:23:32Z
NCT04594343,NA,10/18/2020,NA,NA,9/30/2021,10/19/2020,10/20/2020,Actual,NA,NA,NA,NA,NA,NA,9/30/2021,10/8/2021,Actual,20-Nov-20,Actual,11/20/2020,Sep-21,9/30/2021,25-Sep-21,Actual,9/25/2021,10-Sep-21,Actual,9/10/2021,NA,Interventional,NA,NA,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,"A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19",Completed,NA,Phase 2,140,Actual,ETICA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T08:23:58Z,2021-12-02T08:23:58Z
NCT04593433,NA,10/13/2020,NA,NA,8/23/2021,10/13/2020,10/20/2020,Actual,NA,NA,NA,NA,NA,NA,8/23/2021,8/27/2021,Actual,4-Mar-21,Actual,3/4/2021,Aug-21,8/31/2021,4-Jul-21,Actual,7/4/2021,4-Jul-21,Actual,7/4/2021,NA,Interventional,VGV,NA,A 3-month Cycle of Virtual Guided Tours to Promote Health in Older Community Members in a Context of COVID-19 Induced Social Isolation: a Pilot Study,"A 3-month Cycle of Virtual Weekly Montreal Museum of Fine Arts Tours to Promote Social Inclusion, Well-being, Quality of Life and Health in Older Community Members : a Pilot Study",Completed,NA,Not Applicable,44,Actual,Jewish General Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:24:33Z,2021-12-02T08:24:33Z
NCT04594330,NA,10/5/2020,NA,NA,10/19/2020,10/19/2020,10/20/2020,Actual,NA,NA,NA,NA,NA,NA,10/19/2020,10/20/2020,Actual,1-Jun-20,Actual,6/1/2020,Oct-20,10/31/2020,31-Dec-20,Anticipated,12/31/2020,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Pilot Trial for the Benefit of Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,NA,Phase 2,60,Anticipated,Gadjah Mada University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:23:53Z,2021-12-02T08:23:53Z
NCT04593641,NA,10/5/2020,NA,NA,10/18/2020,10/18/2020,10/20/2020,Actual,NA,NA,NA,NA,NA,NA,10/18/2020,10/20/2020,Actual,4-Sep-20,Actual,9/4/2020,Oct-20,10/31/2020,23-Dec-20,Anticipated,12/23/2020,22-Oct-20,Anticipated,10/22/2020,NA,Interventional,NA,NA,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient With Mild Symptoms of SARS-CoV-2 Infection","Active, not recruiting",NA,Phase 1,18,Actual,Celltrion,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:24:08Z,2021-12-02T08:24:08Z
NCT04592549,NA,10/12/2020,NA,NA,9/18/2021,10/16/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/18/2021,9/24/2021,Actual,4-Dec-20,Actual,12/4/2020,Sep-21,9/30/2021,30-Mar-23,Anticipated,3/30/2023,30-Mar-23,Anticipated,3/30/2023,NA,Interventional,NA,NA,Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820 in Adults",Recruiting,NA,Phase 1,40,Anticipated,Ology Bioservices,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:25:08Z,2021-12-02T08:25:08Z
NCT04593069,NA,10/12/2020,NA,NA,10/20/2020,10/12/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,10/20/2020,10/22/2020,Actual,7-Oct-20,Actual,10/7/2020,Oct-20,10/31/2020,28-Feb-21,Anticipated,2/28/2021,28-Feb-21,Anticipated,2/28/2021,NA,Interventional,COGCOV,NA,The COGCOV Study in ICU Patients,"Long-term Cognitive Impairment in ICU Patients, Admitted for COVID-19 Pneumonia: a Single Centre, Prospective Cohort Study",Recruiting,NA,Not Applicable,60,Anticipated,Ziekenhuis Oost-Limburg,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:24:50Z,2021-12-02T08:24:50Z
NCT04592354,NA,10/15/2020,NA,NA,10/16/2020,10/16/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,10/16/2020,10/19/2020,Actual,15-Oct-20,Actual,10/15/2020,Oct-20,10/31/2020,15-Jun-21,Anticipated,6/15/2021,15-Apr-21,Anticipated,4/15/2021,NA,Interventional,AEO,NA,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Recruiting,NA,Not Applicable,40,Anticipated,Terra Biological LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available after the conclusion of the study,Unknown at this point.,NA,Yes,The plan is to publish the data so that it is available to other researchers.,2021-12-02T08:25:27Z,2021-12-02T08:25:27Z
NCT04591717,NA,10/13/2020,NA,NA,7/19/2021,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/20/2021,Actual,19-Oct-20,Actual,10/19/2020,Oct-20,10/31/2020,19-Nov-21,Anticipated,11/19/2021,19-Nov-21,Anticipated,11/19/2021,NA,Interventional,NA,NA,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers","Active, not recruiting",NA,Phase 1,34,Actual,"ImmunityBio, Inc.",,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:25:48Z,2021-12-02T08:25:48Z
NCT04591600,NA,10/15/2020,NA,NA,10/16/2020,10/16/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,10/16/2020,10/19/2020,Actual,1-Jul-20,Actual,7/1/2020,Oct-20,10/31/2020,14-Oct-20,Actual,10/14/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,NA,NA,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,"Controlled Randomized Clinical Trial on Using Ivermectin With Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq",Completed,NA,Phase 1/Phase 2,140,Actual,Alkarkh Health Directorate-Baghdad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:26:12Z,2021-12-02T08:26:12Z
NCT04591158,NA,9/15/2020,NA,NA,7/12/2021,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,7/12/2021,7/14/2021,Actual,15-Sep-20,Actual,9/15/2020,Jul-21,7/31/2021,9-Jun-21,Actual,6/9/2021,9-Jun-21,Actual,6/9/2021,NA,Interventional,NA,NA,COVID-19 and Lung Ultrasound Utility,The Utility of Self-administered Lung Ultrasound in Patients With COVID-19,Completed,NA,Not Applicable,6,Actual,Bridge to Health Medical and Dental USA,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"Notes pertaining to performance characterization of the device, as well as imaging data for additional quantitative evaluation of the image quality will be collected. This date is recorded for future device development. No IPD will be made available to other researchers.",2021-12-02T08:26:16Z,2021-12-02T08:26:16Z
NCT04590053,NA,10/15/2020,NA,NA,10/21/2020,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,10/21/2020,10/22/2020,Actual,20-Oct-20,Actual,10/20/2020,Oct-20,10/31/2020,Mar-21,Anticipated,3/31/2021,Feb-21,Anticipated,2/28/2021,NA,Interventional,NA,NA,"Allocetra-OTS in COVID-19, Phase II","A Multi-Center Open-Label Study, Evaluating Safety and Preliminary Efficacy of Allocetra-OTS for the Treatment and Prevention of Organ-Failure Deterioration in Severe and Critical Patients With COVID-19 and Respiratory Dysfunction",Recruiting,NA,Phase 2,24,Anticipated,Hadassah Medical Organization,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:27:08Z,2021-12-02T08:27:08Z
NCT04591613,NA,10/10/2020,NA,NA,1/25/2021,10/16/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/28/2021,Actual,31-Dec-20,Actual,12/31/2020,Jan-21,1/31/2021,Aug-22,Anticipated,8/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,COCO-LATE,NA,Late Clinical Events Associated With COVID-19 Infection,Late Clinical Events Associated With COVID-19 Infection: Multicenter Cohort,Recruiting,NA,Not Applicable,1000,Anticipated,Tourcoing Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:25:57Z,2021-12-02T08:25:57Z
NCT04591210,NA,10/6/2020,NA,NA,6/9/2021,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,6/9/2021,6/14/2021,Actual,27-Jan-21,Actual,1/27/2021,Jun-21,6/30/2021,Dec-22,Anticipated,12/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,The COVID-RASi Trial (COVID-19),"Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial",Recruiting,NA,Phase 3,1155,Anticipated,Ottawa Heart Institute Research Corporation,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:26:17Z,2021-12-02T08:26:17Z
NCT04591184,NA,9/23/2020,NA,NA,9/7/2021,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/14/2021,Actual,7-Apr-21,Actual,4/7/2021,Sep-21,9/30/2021,Aug-22,Anticipated,8/31/2022,Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults,"Phase I/II Trial to Evaluate Safety, Tolerability, and Immunogenicity of a Prophylactic Plasmid DNA Vaccine Against SARS CoV-2 [Covigenix VAX-001] in Healthy Adults 18 Years and Older","Active, not recruiting",NA,Phase 1/Phase 2,36,Anticipated,Entos Pharmaceuticals Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:26:23Z,2021-12-02T08:26:23Z
NCT04590469,NA,10/13/2020,NA,NA,5/25/2021,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,5/25/2021,5/28/2021,Actual,1-Mar-21,Actual,3/1/2021,May-21,5/31/2021,1-Jan-22,Anticipated,1/1/2022,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,COVIDWHELD,NA,Improving Wellbeing and Health for Care Home Residents During COVID-19,Evidence-Based Supported Digital Intervention for Improving Wellbeing and Health of People Living in Care Homes and Care Home Staff (WHELD) During COVID-19: An RCT to Evaluate COVID-19 Adapted E-WHELD: Benefits and Cost-Effectiveness,Recruiting,NA,Not Applicable,2880,Anticipated,University of Exeter,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:26:42Z,2021-12-02T08:26:42Z
NCT04590430,NA,10/8/2020,NA,NA,3/4/2021,10/14/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,3/4/2021,3/5/2021,Actual,20-Oct-20,Actual,10/20/2020,Mar-21,3/31/2021,Jul-21,Anticipated,7/31/2021,Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults","A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose First-in-Human Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered HFB30132A, a Monoclonal Antibody Directed Against SARS-CoV-2, in Healthy Adult Subjects","Active, not recruiting",NA,Phase 1,24,Actual,HiFiBiO Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:26:58Z,2021-12-02T08:26:58Z
NCT04589936,NA,10/6/2020,NA,NA,10/15/2020,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,10/15/2020,10/19/2020,Actual,3-Sep-20,Actual,9/3/2020,Oct-20,10/31/2020,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,PRONE-COVID,NA,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care (PRONE-COVID Study),Recruiting,NA,Not Applicable,56,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:27:05Z,2021-12-02T08:27:05Z
NCT04589949,NA,10/12/2020,NA,NA,10/15/2020,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,10/15/2020,10/19/2020,Actual,12-Oct-20,Actual,10/12/2020,Oct-20,10/31/2020,1-Nov-23,Anticipated,11/1/2023,1-Nov-22,Anticipated,11/1/2022,NA,Interventional,CoV-Early,NA,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Recruiting,NA,Phase 3,690,Anticipated,Erasmus Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:27:06Z,2021-12-02T08:27:06Z
NCT04588415,NA,10/8/2020,NA,NA,2/26/2021,10/13/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,2/26/2021,3/1/2021,Actual,3-Jan-21,Actual,1/3/2021,Feb-21,2/28/2021,1-Jan-22,Anticipated,1/1/2022,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,Supporting Family Members With Severe Grief Reaction During the COVID-19 Pandemic,Supporting Family Members With Severe Grief Reaction During the COVID-19 Pandemic,Enrolling by invitation,NA,Not Applicable,200,Anticipated,Ottawa Hospital Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All data will be de-identified prior to entering analysis with anyone outside of the research team,2021-12-02T08:28:04Z,2021-12-02T08:28:04Z
NCT04589104,NA,10/12/2020,NA,NA,10/14/2020,10/14/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2020,10/19/2020,Actual,26-May-20,Actual,5/26/2020,Oct-20,10/31/2020,17-Aug-20,Actual,8/17/2020,17-Aug-20,Actual,8/17/2020,NA,Interventional,NA,NA,Expressive Writing for COVID-19 Resilience,Expressive Writing for COVID-19 Resilience,Completed,NA,Not Applicable,63,Actual,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:27:54Z,2021-12-02T08:27:54Z
NCT04588792,NA,10/14/2020,NA,NA,4/19/2021,10/14/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,4/19/2021,4/21/2021,Actual,16-Apr-21,Actual,4/16/2021,Apr-21,4/30/2021,1-Mar-22,Anticipated,3/1/2022,1-Jan-22,Anticipated,1/1/2022,NA,Interventional,FaST-1,NA,Furosemide as Supportive Therapy for COVID-19 Respiratory Failure,Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19 - A Phase 2/3 Study,Recruiting,NA,Phase 2/Phase 3,640,Anticipated,Queen's University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:28:07Z,2021-12-02T08:28:07Z
NCT04587921,NA,8/18/2020,NA,NA,10/13/2020,10/13/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/13/2020,10/14/2020,Actual,22-Jun-20,Actual,6/22/2020,Oct-20,10/31/2020,22-Jun-21,Anticipated,6/22/2021,22-Jan-21,Anticipated,1/22/2021,NA,Interventional,MoxiCov,NA,Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19,Feasibility and Impact of Remote Oximetry and Cardiac Frequency Monitoring in Patients Hospitalized and Isolated With Covid-19,Recruiting,NA,Not Applicable,90,Anticipated,University of Sao Paulo General Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:28:26Z,2021-12-02T08:28:26Z
NCT04587414,NA,9/8/2020,NA,NA,10/13/2020,10/13/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/13/2020,10/14/2020,Actual,6-Mar-19,Actual,3/6/2019,Oct-20,10/31/2020,31-Oct-20,Anticipated,10/31/2020,31-Oct-20,Anticipated,10/31/2020,NA,Interventional,MySteps-CoV,NA,eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19,Personalized eHealth Intervention in Patients With Type 2 Diabetes to Promote Daily Physical Activity Utilizing 24h Self-monitoring - Implementation Frustrated by COVID-19 Epidemic,"Active, not recruiting",NA,Not Applicable,122,Actual,UKK Institute,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:28:46Z,2021-12-02T08:28:46Z
NCT04587219,NA,10/13/2020,NA,NA,1/20/2021,10/13/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,1/20/2021,1/22/2021,Actual,22-Oct-20,Actual,10/22/2020,Oct-20,10/31/2020,30-Apr-21,Anticipated,4/30/2021,30-Mar-21,Anticipated,3/30/2021,NA,Interventional,NA,NA,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","An Open Study of the Safety, Tolerability and Immunogenicity of the ""Gam-COVID-Vac""Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years","Active, not recruiting",NA,Phase 2,110,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:29:13Z,2021-12-02T08:29:13Z
NCT04586153,NA,10/12/2020,NA,NA,7/28/2021,10/13/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/28/2021,8/3/2021,Actual,15-Feb-21,Actual,2/15/2021,Nov-20,11/30/2020,30-Jul-22,Anticipated,7/30/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Study to Assess the Effect of Meplazumab on COVID-19,"A Multicenter, Seamless, Randomized, Third-Party-Blind, Clinical Trial to Evaluate the Safety and Efficacy of Meplazumab in Addition to Standard of Care for the Treatment of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 2/Phase 3,456,Anticipated,Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:29:49Z,2021-12-02T08:29:49Z
NCT04584593,NA,10/12/2020,NA,NA,11/2/2020,10/12/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,11/2/2020,11/3/2020,Actual,2-Oct-20,Actual,10/2/2020,Nov-20,11/30/2020,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,COVSPERM,NA,Pilot Study to Detect SARS-CoV-2 Virus in Sperm,Pilot Study to Detect SARS-CoV-2 Virus in Sperm : a COVID-19 Study.,Recruiting,NA,Not Applicable,50,Anticipated,"University Hospital, Toulouse",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:31:09Z,2021-12-02T08:31:09Z
NCT04584710,NA,10/8/2020,NA,NA,2/5/2021,10/9/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,2/5/2021,2/9/2021,Actual,13-Oct-20,Actual,10/13/2020,Feb-21,2/28/2021,Feb-21,Anticipated,2/28/2021,Feb-21,Anticipated,2/28/2021,NA,Interventional,NA,NA,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,"A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age â‰¥65 Years","Active, not recruiting",NA,Phase 2,60,Anticipated,Restorbio Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:31:11Z,2021-12-02T08:31:11Z
NCT04584541,NA,6/10/2020,NA,NA,4/30/2021,10/12/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,4/30/2021,5/3/2021,Actual,11-Jun-20,Actual,6/11/2020,Apr-21,4/30/2021,Dec-23,Anticipated,12/31/2023,Jul-23,Anticipated,7/31/2023,NA,Interventional,COVIRIC,NA,SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism,Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthritis and Spondyloarthritis Under Immunosuppressive Treatments,Recruiting,NA,Not Applicable,150,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:31:12Z,2021-12-02T08:31:12Z
NCT04579393,NA,10/6/2020,NA,NA,7/9/2021,10/6/2020,10/8/2020,Actual,NA,NA,NA,NA,NA,NA,7/9/2021,7/12/2021,Actual,8-Oct-20,Actual,10/8/2020,May-21,5/31/2021,30-Apr-21,Actual,4/30/2021,30-Mar-21,Actual,3/30/2021,NA,Interventional,NA,NA,Fostamatinib for Hospitalized Adults With COVID-19,A Phase II Study Evaluating Fostamatinib for Hospitalized Adults With COVID-19,Completed,NA,Phase 2,62,Actual,National Institutes of Health Clinical Center (CC),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:35:15Z,2021-12-02T08:35:15Z
NCT04583592,NA,10/7/2020,NA,NA,4/1/2021,10/8/2020,10/12/2020,Actual,NA,NA,NA,NA,NA,NA,4/1/2021,4/2/2021,Actual,9-Nov-20,Actual,11/9/2020,Apr-21,4/30/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,NA,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients",Completed,NA,Phase 2,295,Actual,Sagent Pharmaceuticals Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:31:53Z,2021-12-02T08:31:53Z
NCT04584580,NA,10/6/2020,NA,NA,10/10/2020,10/10/2020,10/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/10/2020,10/14/2020,Actual,1-Aug-20,Actual,8/1/2020,Oct-20,10/31/2020,31-Dec-20,Anticipated,12/31/2020,31-Oct-20,Anticipated,10/31/2020,NA,Interventional,NA,NA,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 4,50,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:31:04Z,2021-12-02T08:31:04Z
NCT04583410,NA,9/28/2020,NA,NA,2/15/2021,10/9/2020,10/12/2020,Actual,NA,NA,NA,NA,NA,NA,2/15/2021,2/17/2021,Actual,22-Oct-20,Actual,10/22/2020,Feb-21,2/28/2021,Jun-22,Anticipated,6/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NICOVID-PREV,NA,Efficacy of Nicotine in Preventing COVID-19 Infection,Efficacy of Nicotine in Preventing COVID-19 Infection,Recruiting,NA,Phase 3,1633,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:31:57Z,2021-12-02T08:31:57Z
NCT04583449,NA,10/2/2020,NA,NA,10/9/2020,10/9/2020,10/12/2020,Actual,NA,NA,NA,NA,NA,NA,10/9/2020,10/12/2020,Actual,19-Aug-20,Actual,8/19/2020,Oct-20,10/31/2020,1-Dec-20,Anticipated,12/1/2020,1-Dec-20,Anticipated,12/1/2020,NA,Interventional,NA,NA,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,250,Anticipated,University of East London,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be made available on completion of article publication. Data will be made permanently available.,NA,NA,Yes,We will share the anonymised data as a Supplementary file when submitting a research write-up as an article to a suitable academic journal.,2021-12-02T08:31:58Z,2021-12-02T08:31:58Z
NCT04582214,NA,10/6/2020,NA,NA,10/8/2020,10/8/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/8/2020,10/9/2020,Actual,28-Sep-20,Actual,9/28/2020,Oct-20,10/31/2020,1-Jan-21,Anticipated,1/1/2021,1-Jan-21,Anticipated,1/1/2021,NA,Interventional,NA,NA,Oscillation and Lung Expansion Therapy in Patients With COVID-19,A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized With COVID-19,Recruiting,NA,Not Applicable,30,Anticipated,Hill-Rom,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:32:56Z,2021-12-02T08:32:56Z
NCT04583189,NA,10/1/2020,NA,NA,12/1/2020,10/9/2020,10/12/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2020,12/2/2020,Actual,1-Oct-20,Actual,10/1/2020,Dec-20,12/31/2020,25-Nov-20,Actual,11/25/2020,25-Nov-20,Actual,11/25/2020,NA,Interventional,NA,NA,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Evaluation Des Performances du Test Rapide antigÃ©nique Covid-19 Ag BSS Chez l'Enfant Symptomatique Dans un Service d'Urgences pÃ©diatriques,Completed,NA,Not Applicable,500,Actual,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:32:12Z,2021-12-02T08:32:12Z
NCT04582318,NA,10/7/2020,NA,NA,11/19/2020,10/8/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,11/19/2020,11/23/2020,Actual,8-Nov-20,Actual,11/8/2020,Nov-20,11/30/2020,Sep-21,Anticipated,9/30/2021,Jun-21,Anticipated,6/30/2021,NA,Interventional,NA,NA,"A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19","A Randomized, Double Blind, Placebo Controlled, Combined Phase 1/2 Single Dose and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of NGM621 in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Subjects With Confirmed SARS-CoV-2 Infection",Recruiting,NA,Phase 1/Phase 2,48,Anticipated,"NGM Biopharmaceuticals, Inc",,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"This is a proof-of-concept study assessing the safety, tolerability, PK, and efficacy of systemic use of NGM621 versus placebo in both healthy subjects and subjects confirmed with SARS-CoV-2 infection. We will continue to evaluate whether IPD will be shared with other researchers.",2021-12-02T08:32:45Z,2021-12-02T08:32:45Z
NCT04581915,NA,9/16/2020,NA,NA,4/7/2021,10/7/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,4/7/2021,4/12/2021,Actual,8-Sep-20,Actual,9/8/2020,Oct-20,10/31/2020,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,PHRUCov01,NA,PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19,"A Pragmatic, Individually Randomised, Double-blind, Placebo-controlled Trial of Triazavirin (TZV) for the Treatment of Mild-moderate SARS-CoV-2 Infection A Phase II and III Clinical Trial",Recruiting,NA,Phase 2/Phase 3,420,Anticipated,Wits Health Consortium (Pty) Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:33:07Z,2021-12-02T08:33:07Z
NCT04581811,NA,10/7/2020,NA,NA,5/21/2021,10/7/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,5/21/2021,5/25/2021,Actual,10-Nov-20,Actual,11/10/2020,May-21,5/31/2021,20-Mar-21,Actual,3/20/2021,20-Mar-21,Actual,3/20/2021,NA,Interventional,NA,NA,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS): A Pilot Study,Completed,NA,Not Applicable,52,Actual,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:33:12Z,2021-12-02T08:33:12Z
NCT04582344,NA,10/1/2020,NA,NA,7/26/2021,10/8/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/27/2021,Actual,14-Sep-20,Actual,9/14/2020,Feb-21,2/28/2021,15-Apr-22,Anticipated,4/15/2022,15-Feb-22,Anticipated,2/15/2022,NA,Interventional,NA,NA,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated","Active, not recruiting",NA,Phase 3,13000,Anticipated,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:32:54Z,2021-12-02T08:32:54Z
NCT04581954,NA,10/5/2020,NA,NA,9/1/2021,10/8/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,9/1/2021,9/2/2021,Actual,2-Oct-20,Actual,10/2/2020,Sep-21,9/30/2021,1-Dec-21,Anticipated,12/1/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,MATIS,NA,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia,Recruiting,NA,Phase 1/Phase 2,456,Anticipated,Imperial College London,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,To be determined,2021-12-02T08:33:07Z,2021-12-02T08:33:07Z
NCT04581746,NA,9/22/2020,NA,NA,1/25/2021,10/7/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/26/2021,Actual,25-Nov-20,Actual,11/25/2020,Jan-21,1/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,coVIHd-19,NA,Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Evaluation of the Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Recruiting,NA,Not Applicable,1800,Anticipated,Tourcoing Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:33:31Z,2021-12-02T08:33:31Z
NCT04581031,NA,5/4/2020,NA,NA,4/29/2021,10/6/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,4/29/2021,4/30/2021,Actual,11-Jul-20,Actual,7/11/2020,Oct-20,10/31/2020,1-Dec-21,Anticipated,12/1/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,COSMIC-19,NA,COntinuous Signs Monitoring In Covid-19 Patients,COntinuous Signs Monitoring In Covid-19 Patients,Recruiting,NA,Not Applicable,60,Anticipated,The Christie NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:33:55Z,2021-12-02T08:33:55Z
NCT04581291,NA,10/4/2020,NA,NA,10/7/2020,10/7/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/7/2020,10/9/2020,Actual,1-Jan-20,Actual,1/1/2020,Oct-20,10/31/2020,1-Oct-20,Actual,10/1/2020,1-Jun-20,Actual,6/1/2020,NA,Interventional,NA,NA,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,NA,Not Applicable,30,Actual,Istanbul Gelisim University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:33:44Z,2021-12-02T08:33:44Z
NCT04581018,NA,8/11/2020,NA,NA,10/12/2020,10/6/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/12/2020,10/14/2020,Actual,13-Aug-20,Actual,8/13/2020,Oct-20,10/31/2020,30-Apr-22,Anticipated,4/30/2022,30-Oct-21,Anticipated,10/30/2021,NA,Interventional,NA,NA,An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection,An Evaluation of a Synbiotic Formula for Symptom Improvement in Hospitalised Patients With COVID-19 Infection,Recruiting,NA,Not Applicable,50,Anticipated,Chinese University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:34:12Z,2021-12-02T08:34:12Z
NCT04579549,NA,10/6/2020,NA,NA,8/31/2021,10/6/2020,10/8/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/8/2021,Actual,29-Sep-20,Actual,9/29/2020,Jul-21,7/31/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,NA,NA,Repeat Testing for SARS-CoV-2,Repeat Saliva Testing for SARS-CoV-2 Using RT-LAMP Assay,Completed,NA,Not Applicable,464,Actual,"University of Wisconsin, Madison",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin -Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2021-12-02T08:35:09Z,2021-12-02T08:35:09Z
NCT04581161,NA,8/19/2020,NA,NA,10/6/2020,10/6/2020,10/9/2020,Actual,NA,NA,NA,NA,NA,NA,10/6/2020,10/9/2020,Actual,28-Aug-20,Actual,8/28/2020,Oct-20,10/31/2020,Oct-20,Anticipated,10/31/2020,Oct-20,Anticipated,10/31/2020,NA,Interventional,NA,NA,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,A Novel Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,Recruiting,NA,Not Applicable,10,Anticipated,Hill-Rom,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:34:04Z,2021-12-02T08:34:04Z
NCT04579640,NA,10/6/2020,NA,NA,5/24/2021,10/6/2020,10/8/2020,Actual,NA,NA,NA,NA,NA,NA,5/24/2021,5/26/2021,Actual,27-Oct-20,Actual,10/27/2020,Nov-20,11/30/2020,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,CORONAVIT,NA,Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections,Phase 3 Randomised Controlled Trial of Vitamin D Supplementation to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections in the UK Population,"Active, not recruiting",NA,Phase 3,6200,Actual,Queen Mary University of London,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,De-identified IPD will be shared with other researchers subject to terms of Data Transfer Agreement and IRB approval,2021-12-02T08:35:13Z,2021-12-02T08:35:13Z
NCT04575038,NA,10/1/2020,NA,NA,7/26/2021,10/1/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/27/2021,Actual,19-Nov-20,Actual,11/19/2020,Jul-21,7/31/2021,28-Apr-21,Actual,4/28/2021,28-Apr-21,Actual,4/28/2021,NA,Interventional,CRISIS2,NA,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,"The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2",Completed,NA,Phase 2,115,Actual,"Clear Creek Bio, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:38:57Z,2021-12-02T08:38:57Z
NCT04577534,NA,9/3/2020,NA,NA,6/17/2021,10/5/2020,10/8/2020,Actual,NA,NA,NA,NA,NA,NA,6/17/2021,6/21/2021,Actual,14-Aug-20,Actual,8/14/2020,Jun-21,6/30/2021,16-Jun-21,Actual,6/16/2021,16-Jun-21,Actual,6/16/2021,NA,Interventional,COVIDSTORM,NA,COVID-19: Salvage TOcilizumab as a Rescue Measure,COVID-19: Salvage TOcilizumab as a Rescue Measure. Use of Tocilizumab in the Inflammatory Phase of COVID-19 / New Coronavirus Disease,Completed,NA,Phase 3,88,Actual,Turku University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,plan to investigate if it is possible by law,2021-12-02T08:36:46Z,2021-12-02T08:36:46Z
NCT04577235,NA,9/29/2020,NA,NA,10/5/2020,10/5/2020,10/6/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2020,10/6/2020,Actual,5-Jun-20,Actual,6/5/2020,Oct-20,10/31/2020,5-Sep-20,Actual,9/5/2020,5-Aug-20,Actual,8/5/2020,NA,Interventional,NA,NA,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Evaluation of the Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores of Patients With Severe COVID 19 Pneumonia in Intensive Care.,Completed,NA,Not Applicable,29,Actual,Gaziosmanpasa Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:37:23Z,2021-12-02T08:37:23Z
NCT04575584,NA,9/30/2020,NA,NA,9/2/2021,10/2/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/9/2021,Actual,19-Oct-20,Actual,10/19/2020,Aug-21,8/31/2021,11-Aug-21,Actual,8/11/2021,11-Aug-21,Actual,8/11/2021,NA,Interventional,NA,NA,Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001),"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19",Terminated,NA,Phase 2/Phase 3,304,Actual,Merck Sharp & Dohme Corp.,,6,NA,Business reasons,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-02T08:38:18Z,2021-12-02T08:38:18Z
NCT04578158,NA,10/6/2020,NA,NA,4/21/2021,10/6/2020,10/8/2020,Actual,NA,NA,NA,NA,NA,NA,4/21/2021,4/22/2021,Actual,29-Sep-20,Actual,9/29/2020,Apr-21,4/30/2021,15-Apr-21,Actual,4/15/2021,28-Mar-21,Actual,3/28/2021,NA,Interventional,NA,NA,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,"A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.",Completed,NA,Phase 3,152,Actual,Liaquat University of Medical & Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:36:26Z,2021-12-02T08:36:26Z
NCT04578210,NA,10/1/2020,NA,NA,10/14/2020,10/6/2020,10/8/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2020,10/19/2020,Actual,4-Sep-20,Actual,9/4/2020,Oct-20,10/31/2020,Mar-21,Anticipated,3/31/2021,Jan-21,Anticipated,1/31/2021,NA,Interventional,RELEASE,NA,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,A Phase I/II Dose-escalation Multi Center Study to Evaluate the Safety of Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in coronaviruS pnEumonia and/or Lymphopenia,Recruiting,NA,Phase 1/Phase 2,58,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T08:36:26Z,2021-12-02T08:36:26Z
NCT04576728,NA,9/24/2020,NA,NA,6/15/2021,10/5/2020,10/6/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2021,6/16/2021,Actual,6-Oct-20,Actual,10/6/2020,Jun-21,6/30/2021,Jul-21,Anticipated,7/31/2021,Jul-21,Anticipated,7/31/2021,NA,Interventional,ESsCOVID,NA,Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19,"A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase II Trial Investigating the Efficacy and Safety of Trimodulin (BT588) as add-on Therapy to Standard of Care in Adult Subjects With Severe COVID-19","Active, not recruiting",NA,Phase 2,164,Anticipated,Biotest,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:37:40Z,2021-12-02T08:37:40Z
NCT04576312,NA,9/28/2020,NA,NA,8/20/2021,10/5/2020,10/6/2020,Actual,NA,NA,NA,NA,NA,NA,8/20/2021,8/26/2021,Actual,29-Jun-20,Actual,6/29/2020,Aug-21,8/31/2021,4-Dec-20,Actual,12/4/2020,4-Dec-20,Actual,12/4/2020,NA,Interventional,NA,NA,Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers,"Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19",Completed,NA,Phase 1,64,Actual,UNION therapeutics,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:38:00Z,2021-12-02T08:38:00Z
NCT04575064,NA,9/30/2020,NA,NA,10/2/2020,10/2/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,10/2/2020,10/5/2020,Actual,29-Jun-20,Actual,6/29/2020,Oct-20,10/31/2020,Nov-22,Anticipated,11/30/2022,Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,"Active, not recruiting",NA,Phase 2/Phase 3,400,Anticipated,"Klinikum Bremen-Mitte, gGmbH",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:39:28Z,2021-12-02T08:39:28Z
NCT04573764,NA,10/1/2020,NA,NA,4/8/2021,10/1/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,4/8/2021,4/13/2021,Actual,1-Feb-21,Actual,2/1/2021,Apr-21,4/30/2021,1-Jan-22,Anticipated,1/1/2022,1-Oct-21,Anticipated,10/1/2021,NA,Interventional,KetoCOVID,NA,Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19,Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19,Recruiting,NA,Not Applicable,12,Anticipated,Steno Diabetes Center Copenhagen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:40:18Z,2021-12-02T08:40:18Z
NCT04574219,NA,9/24/2020,NA,NA,1/6/2021,9/29/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,1/6/2021,1/7/2021,Actual,3-Nov-20,Actual,11/3/2020,Jan-21,1/31/2021,Dec-22,Anticipated,12/31/2022,Oct-22,Anticipated,10/31/2022,NA,Interventional,VPPIA,NA,Virtual Parental Presence on Induction,Feasibility and Acceptability of Virtual Parental Presence on Induction of Anesthesia - Modernizing Solutions for Pediatric Anesthesia in Response to COVID-19,Recruiting,NA,Not Applicable,184,Anticipated,"Children's Hospital Medical Center, Cincinnati",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:39:38Z,2021-12-02T08:39:38Z
NCT04573361,NA,9/29/2020,NA,NA,9/30/2020,9/30/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,9/30/2020,10/5/2020,Actual,2-May-20,Actual,5/2/2020,Sep-20,9/30/2020,27-May-20,Actual,5/27/2020,27-May-20,Actual,5/27/2020,NA,Interventional,NA,NA,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Access to Chiropractic Care During the State of Emergency Generated by the COVID-19 Pandemic in Spain: a Pragmatic Controlled Trial,Completed,NA,Not Applicable,723,Actual,Real Centro Universitario Maria Cristina,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"All collected IPD will be shared, though a next phase of the study is being debated, which is why we are still undecided.",2021-12-02T08:40:21Z,2021-12-02T08:40:21Z
NCT04573153,NA,9/30/2020,NA,NA,10/4/2020,9/30/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,10/4/2020,10/6/2020,Actual,21-Sep-20,Actual,9/21/2020,Sep-20,9/30/2020,31-Mar-21,Anticipated,3/31/2021,31-Jan-21,Anticipated,1/31/2021,NA,Interventional,NA,NA,Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients,"A Multi Centre, Randomised, Controlled, Open-Label Phase 2/3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients",Recruiting,NA,Phase 2/Phase 3,400,Anticipated,ScandiBio Therapeutics AB,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:40:28Z,2021-12-02T08:40:28Z
NCT04573270,NA,9/23/2020,NA,NA,9/30/2020,9/30/2020,10/5/2020,Actual,NA,NA,NA,NA,NA,NA,9/30/2020,10/5/2020,Actual,24-Apr-20,Actual,4/24/2020,Sep-20,9/30/2020,1-Sep-20,Actual,9/1/2020,20-Aug-20,Actual,8/20/2020,NA,Interventional,NA,NA,Mesenchymal Stem Cells for the Treatment of COVID-19,A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients,Completed,NA,Phase 1,40,Actual,Thomas Advanced Medical LLC,,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Data will be blinded and password protected. Research publications will be produced for medical journals. Participating Investigators will have password protected access only.,2021-12-02T08:40:33Z,2021-12-02T08:40:33Z
NCT04572399,NA,9/28/2020,NA,NA,12/28/2020,9/29/2020,10/1/2020,Actual,NA,NA,NA,NA,NA,NA,12/28/2020,12/30/2020,Actual,30-Oct-20,Actual,10/30/2020,Dec-20,12/31/2020,28-Dec-20,Actual,12/28/2020,28-Dec-20,Actual,12/28/2020,NA,Interventional,NA,NA,UVA Light Device to Treat COVID-19,Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Pilot Study,Completed,NA,Not Applicable,5,Actual,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:41:08Z,2021-12-02T08:41:08Z
NCT04572412,NA,9/29/2020,NA,NA,8/31/2021,9/30/2020,10/1/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/1/2021,Actual,25-Nov-20,Actual,11/25/2020,Sep-20,9/30/2020,30-Jun-22,Anticipated,6/30/2022,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia (a Phase I Feasibility Trial),Recruiting,NA,Not Applicable,13,Anticipated,Lancashire Teaching Hospitals NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All data will be kept anonymized and confidential. Data will be held securely for 15 years pending further study.,2021-12-02T08:41:04Z,2021-12-02T08:41:04Z
NCT04572360,NA,9/27/2020,NA,NA,6/21/2021,9/30/2020,10/1/2020,Actual,NA,NA,NA,NA,NA,NA,6/21/2021,6/24/2021,Actual,1-Oct-20,Actual,10/1/2020,Jun-21,6/30/2021,30-Jun-23,Anticipated,6/30/2023,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,Covid19Reh,NA,Cardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19) Patients,Would Cardiorespiratory Exercise and Chinese Herbal Medicine Facilitate Rehabilitation Among Post-discharge Patients With COVID-19? Clinical Efficacy and Mechanisms,Recruiting,NA,Not Applicable,172,Anticipated,Hong Kong Baptist University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,1 year after the completion of study.,All researchers can get the information by sending requests to the study contact person.,NA,Yes,All individual participant data collected during the trial will be deidentified and available for anyone who wish to access the data immediately following publication.,2021-12-02T08:41:08Z,2021-12-02T08:41:08Z
NCT04570488,NA,9/25/2020,NA,NA,4/19/2021,9/29/2020,9/30/2020,Actual,NA,NA,NA,NA,NA,NA,4/19/2021,4/20/2021,Actual,15-May-20,Actual,5/15/2020,Apr-21,4/30/2021,30-Dec-21,Anticipated,12/30/2021,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,NA,Not Applicable,1200,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T08:42:45Z,2021-12-02T08:42:45Z
NCT04570384,NA,9/17/2020,NA,NA,9/8/2021,9/29/2020,9/30/2020,Actual,NA,NA,NA,NA,NA,NA,9/8/2021,9/9/2021,Actual,15-Oct-20,Actual,10/15/2020,Sep-21,9/30/2021,30-Oct-21,Anticipated,10/30/2021,30-Aug-21,Actual,8/30/2021,NA,Interventional,NA,NA,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,"Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness",Recruiting,NA,Phase 2,66,Anticipated,"Asklepion Pharmaceuticals, LLC",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:42:41Z,2021-12-02T08:42:41Z
NCT04570397,NA,9/29/2020,NA,NA,1/12/2021,9/29/2020,9/30/2020,Actual,NA,NA,NA,NA,NA,NA,1/12/2021,1/14/2021,Actual,18-Dec-20,Actual,12/18/2020,Jan-21,1/31/2021,Nov-21,Anticipated,11/30/2021,May-21,Anticipated,5/31/2021,NA,Interventional,NA,NA,Ravulizumab and COVID-19,C5 Complement Inhbition Using Ravulizumab for the Treatment of COVID-19 Induced Thrombotic Microangiopathy,Recruiting,NA,Phase 3,32,Anticipated,Brigham and Women's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:42:48Z,2021-12-02T08:42:48Z
NCT04570254,NA,9/26/2020,NA,NA,5/19/2021,9/28/2020,9/30/2020,Actual,NA,NA,NA,NA,NA,NA,5/19/2021,5/21/2021,Actual,19-Aug-20,Actual,8/19/2020,May-21,5/31/2021,1-Dec-20,Actual,12/1/2020,1-Dec-20,Actual,12/1/2020,NA,Interventional,ANTIOX-COVID,NA,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia,Completed,NA,Not Applicable,110,Actual,Unidad Temporal COVID-19 en Centro Citibanamex,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:42:52Z,2021-12-02T08:42:52Z
NCT04568811,NA,9/28/2020,NA,NA,2/8/2021,9/28/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/10/2021,Actual,26-Sep-20,Actual,9/26/2020,Sep-20,9/30/2020,27-Sep-21,Anticipated,9/27/2021,25-Oct-20,Actual,10/25/2020,NA,Interventional,NA,NA,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years","Active, not recruiting",NA,Phase 1,89,Actual,Jiangsu Province Centers for Disease Control and Prevention,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:43:46Z,2021-12-02T08:43:46Z
NCT04569877,NA,9/25/2020,NA,NA,5/18/2021,9/29/2020,9/30/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/19/2021,Actual,24-Sep-20,Actual,9/24/2020,May-21,5/31/2021,25-Dec-22,Anticipated,12/25/2022,25-Dec-22,Anticipated,12/25/2022,NA,Interventional,GI-COVID,NA,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID),Recruiting,NA,Phase 2,238,Anticipated,University of Giessen,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,3 Months after publication,Central server,NA,Yes,Study protocol will be provided after publication,2021-12-02T08:43:06Z,2021-12-02T08:43:06Z
NCT04569825,NA,9/29/2020,NA,NA,9/29/2020,9/29/2020,9/30/2020,Actual,NA,NA,NA,NA,NA,NA,9/29/2020,9/30/2020,Actual,1-Aug-20,Actual,8/1/2020,Aug-20,8/31/2020,15-Oct-20,Anticipated,10/15/2020,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Recruiting,NA,Early Phase 1,250,Anticipated,University Of Anbar,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:43:07Z,2021-12-02T08:43:07Z
NCT04570202,NA,9/28/2020,NA,NA,7/15/2021,9/29/2020,9/30/2020,Actual,NA,NA,NA,NA,NA,NA,7/15/2021,7/16/2021,Actual,20-Nov-20,Actual,11/20/2020,Jul-21,7/31/2021,19-Feb-23,Anticipated,2/19/2023,19-Feb-22,Anticipated,2/19/2022,NA,Interventional,HARD-COVID19,NA,Health cAre woRkers exposeD to COVID-19,"Symptoms of Depression, Stress and Burnout, and Long-term Psychological Impact in Health Care Professionals Exposed to the Novel Coronavirus Disease 2019 Outbreak (HARD-COVID-19 - Health cAre woRkers exposeD to covID-19)",Recruiting,NA,Not Applicable,900,Anticipated,"University Hospital, Tours",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:42:58Z,2021-12-02T08:42:58Z
NCT04569188,NA,9/4/2020,NA,NA,9/30/2020,9/28/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,9/30/2020,10/5/2020,Actual,15-May-20,Actual,5/15/2020,Sep-20,9/30/2020,3-Sep-20,Actual,9/3/2020,15-Aug-20,Actual,8/15/2020,NA,Interventional,RESCUE,NA,Convalescent Plasma in COVID-19 Elderly Patients,Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19,Completed,NA,Phase 2,21,Actual,Azienda Socio Sanitaria Territoriale di Mantova,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:43:33Z,2021-12-02T08:43:33Z
NCT04569227,NA,9/28/2020,NA,NA,6/8/2021,9/28/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,6/8/2021,6/10/2021,Actual,30-Apr-21,Actual,4/30/2021,Apr-21,4/30/2021,Nov-21,Anticipated,11/30/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,Prevention of COVID-19 Infection to Severe Pneumonia or ARDS,"Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS",Recruiting,NA,Phase 2,60,Anticipated,Enzychem Lifesciences Corporation,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:43:49Z,2021-12-02T08:43:49Z
NCT04568889,NA,9/24/2020,NA,NA,8/11/2021,9/25/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,8/11/2021,8/13/2021,Actual,28-Sep-20,Actual,9/28/2020,Aug-21,8/31/2021,31-Aug-22,Anticipated,8/31/2022,31-Aug-22,Anticipated,8/31/2022,NA,Interventional,NA,NA,Minnesota COVID-19 Testing Project,Minnesota COVID-19 Testing Project,"Active, not recruiting",NA,Not Applicable,1000,Anticipated,Harvard University,,16,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:43:53Z,2021-12-02T08:43:53Z
NCT04568863,NA,9/28/2020,NA,NA,3/17/2021,9/28/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,3/17/2021,3/18/2021,Actual,20-Jun-20,Actual,6/20/2020,Sep-20,9/30/2020,30-Nov-20,Actual,11/30/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,MELCOVID,NA,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,"A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)",Completed,NA,Phase 2,18,Actual,Pharmamel S.L.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:43:55Z,2021-12-02T08:43:55Z
NCT04568876,NA,9/24/2020,NA,NA,8/24/2021,9/25/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/25/2021,Actual,23-Oct-20,Actual,10/23/2020,Aug-21,8/31/2021,28-Feb-21,Actual,2/28/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,NA,NA,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,"Efficacy of Palmitoylethanolamide, in add-on to Standard Therapy, on Inflammatory Markers of Patients With Interstitial Pneumonia Due to COVID-19. A Pilot Controlled, Randomized, Open Lable Clinical Study",Completed,NA,Phase 4,40,Actual,Epitech Group SpA,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:43:59Z,2021-12-02T08:43:59Z
NCT04568525,NA,9/23/2020,NA,NA,9/28/2020,9/28/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2020,9/29/2020,Actual,1-Jul-20,Actual,7/1/2020,Sep-20,9/30/2020,1-Aug-20,Actual,8/1/2020,25-Jul-20,Actual,7/25/2020,NA,Interventional,NA,NA,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Microwave Radiation for Early Diagnostics of Pneumonia in Patients With COVID-19,Completed,NA,Not Applicable,195,Actual,Kyrgyz State Medical Academy,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:44:00Z,2021-12-02T08:44:00Z
NCT04568707,NA,8/31/2020,NA,NA,2/24/2021,9/28/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,2/24/2021,2/25/2021,Actual,23-Oct-20,Actual,10/23/2020,Feb-21,2/28/2021,15-Oct-22,Anticipated,10/15/2022,15-Oct-22,Anticipated,10/15/2022,NA,Interventional,NA,NA,Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES),Evaluation of Biological Response to SARS-COV2 in Patients With Pre-existing Neurological Disease or With New Neurological Manifestations of COVID-19,Recruiting,NA,Not Applicable,200,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:44:01Z,2021-12-02T08:44:01Z
NCT04567810,NA,9/18/2020,NA,NA,9/16/2021,9/25/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2021,9/20/2021,Actual,18-Sep-20,Actual,9/18/2020,Sep-21,9/30/2021,14-Dec-20,Actual,12/14/2020,14-Dec-20,Actual,12/14/2020,NA,Interventional,NA,NA,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)","A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)",Completed,NA,Phase 1,48,Actual,Stanford University,,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:44:22Z,2021-12-02T08:44:22Z
NCT04567953,NA,9/25/2020,NA,NA,9/25/2020,9/25/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,9/25/2020,9/29/2020,Actual,28-Jul-20,Actual,7/28/2020,Sep-20,9/30/2020,27-Jun-21,Anticipated,6/27/2021,30-Jan-21,Anticipated,1/30/2021,NA,Interventional,NA,NA,COVID-19 Tests With Saliva Specimens,COVID-19 Tests With Saliva Specimens,"Active, not recruiting",NA,Not Applicable,2000,Anticipated,Paradigm Laboratories LLC,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:44:28Z,2021-12-02T08:44:28Z
NCT04568356,NA,9/27/2020,NA,NA,10/16/2020,9/27/2020,9/29/2020,Actual,NA,NA,NA,NA,NA,NA,10/16/2020,10/19/2020,Actual,24-Apr-20,Actual,4/24/2020,Oct-20,10/31/2020,24-Sep-20,Actual,9/24/2020,12-Jun-20,Actual,6/12/2020,NA,Interventional,NA,NA,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,"A Clinical Performance Evaluation of the SARS-COV-2 Direct Antigen Rapid Test ""DART""",Completed,NA,Not Applicable,200,Actual,"E25Bio, Inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,One month after the USA-FDA approval date and for the duration of one year after the date of approval,"via email to: Irene Bosch, PhD at ibosch@e25bio.com",http://www.e25bio.com,Yes,"The sponsor E25Bio, Inc. is in agreement to share the outcome of this Clinical Trial. Because the device product has not been previously approved or cleared by FDA, we will be publicly posting not earlier than the date of FDA approval or clearance.",2021-12-02T08:44:37Z,2021-12-02T08:44:37Z
NCT04566770,NA,9/22/2020,NA,NA,11/25/2020,9/24/2020,9/28/2020,Actual,NA,NA,NA,NA,NA,NA,11/25/2020,11/27/2020,Actual,24-Sep-20,Actual,9/24/2020,Sep-20,9/30/2020,20-Oct-22,Anticipated,10/20/2022,21-Aug-21,Anticipated,8/21/2021,NA,Interventional,NA,NA,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),"A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV",Recruiting,NA,Phase 2,481,Anticipated,CanSino Biologics Inc.,,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:45:12Z,2021-12-02T08:45:12Z
NCT04567173,NA,9/24/2020,NA,NA,9/26/2020,9/24/2020,9/28/2020,Actual,NA,NA,NA,NA,NA,NA,9/26/2020,9/29/2020,Actual,21-Sep-20,Actual,9/21/2020,Sep-20,9/30/2020,30-Jun-21,Anticipated,6/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,Co-CLARITY,NA,Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19,"A Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission: Co-CLARITY Trial",Recruiting,NA,Phase 2/Phase 3,136,Anticipated,University of the Philippines,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:45:00Z,2021-12-02T08:45:00Z
NCT04565509,NA,9/24/2020,NA,NA,7/19/2021,9/24/2020,9/25/2020,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/26/2021,Actual,20-Nov-20,Actual,11/20/2020,Jul-21,7/31/2021,31-Mar-23,Anticipated,3/31/2023,30-Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Recruiting,NA,Not Applicable,3000,Anticipated,Washington University School of Medicine,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:46:11Z,2021-12-02T08:46:11Z
NCT04565379,NA,9/23/2020,NA,NA,3/15/2021,9/23/2020,9/25/2020,Actual,NA,NA,NA,NA,NA,NA,3/15/2021,3/17/2021,Actual,25-Sep-20,Actual,9/25/2020,Mar-21,3/31/2021,30-Apr-21,Anticipated,4/30/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Clinical Trial to Investigate the Efficacy and Safety of NuSepinÂ® in COVID-19 Pneumonia Patients,"A Randomized, Double Blind, Placebo-controlled, Phase 2 Clinical Trial to Investigate the Efficacy and Safety of 2 Doses of NuSepinÂ® Intravenous Infusion in COVID-19 Pneumonia Patients",Recruiting,NA,Phase 2,60,Anticipated,Shaperon,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:46:18Z,2021-12-02T08:46:18Z
NCT04563702,NA,9/21/2020,NA,NA,4/5/2021,9/23/2020,9/24/2020,Actual,NA,NA,NA,NA,NA,NA,4/5/2021,4/8/2021,Actual,21-Sep-20,Actual,9/21/2020,Apr-21,4/30/2021,Oct-21,Anticipated,10/31/2021,10-May-21,Anticipated,5/10/2021,NA,Interventional,NA,NA,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1,35,Actual,Vaxart,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,A plan on how to share individual subject's outcomes will be defined within the next few months.,2021-12-02T08:47:23Z,2021-12-02T08:47:23Z
NCT04564716,NA,9/24/2020,NA,NA,12/1/2020,9/24/2020,9/25/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2020,12/2/2020,Actual,28-Sep-20,Actual,9/28/2020,Sep-20,9/30/2020,10-Apr-21,Anticipated,4/10/2021,28-Mar-21,Anticipated,3/28/2021,NA,Interventional,NA,NA,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Ð¡linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-Ð¡oV-2 Infection Prophylactic Treatment in Republic of Belarus","Active, not recruiting",NA,Phase 3,100,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:46:50Z,2021-12-02T08:46:50Z
NCT04565197,NA,9/24/2020,NA,NA,12/4/2020,9/24/2020,9/25/2020,Actual,NA,NA,NA,NA,NA,NA,12/4/2020,12/8/2020,Actual,1-May-20,Actual,5/1/2020,Dec-20,12/31/2020,30-Dec-20,Anticipated,12/30/2020,30-Dec-20,Anticipated,12/30/2020,NA,Interventional,NA,NA,Convalescent Plasma Therapy for COVID-19 Patients,Convalescent Plasma for Passive Immunization in COVID-19 ICU Patients: An Interventional Study,"Active, not recruiting",NA,Early Phase 1,20,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:46:31Z,2021-12-02T08:46:31Z
NCT04563689,NA,9/22/2020,NA,NA,11/19/2020,9/23/2020,9/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/19/2020,11/20/2020,Actual,18-Jun-20,Actual,6/18/2020,Sep-20,9/30/2020,23-Oct-20,Actual,10/23/2020,22-Oct-20,Actual,10/22/2020,NA,Interventional,NA,NA,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado mÃ©dico en Casa en Cali - 2020.,Completed,NA,Not Applicable,23,Actual,Dentaid SL,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:47:25Z,2021-12-02T08:47:25Z
NCT04563208,NA,9/21/2020,NA,NA,9/9/2021,9/21/2020,9/24/2020,Actual,NA,NA,NA,NA,NA,NA,9/9/2021,9/16/2021,Actual,9-Dec-20,Actual,12/9/2020,Sep-21,9/30/2021,28-Feb-22,Anticipated,2/28/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,DuACT,NA,Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19,"A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)",Recruiting,NA,Phase 2,80,Anticipated,"University of Witwatersrand, South Africa",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:47:58Z,2021-12-02T08:47:58Z
NCT04563676,NA,9/23/2020,NA,NA,7/20/2021,9/23/2020,9/24/2020,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,22-Sep-20,Actual,9/22/2020,Jul-21,7/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,SEQ-COV-PHYSIO,NA,Physiopathology and Sequelae of COVID-19 Infection,Physiopathology and Sequelae of COVID-19 Infection,Recruiting,NA,Not Applicable,400,Anticipated,"Centre Hospitalier Universitaire, Amiens",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:47:19Z,2021-12-02T08:47:19Z
NCT04563650,NA,9/18/2020,NA,NA,7/20/2021,9/23/2020,9/24/2020,Actual,NA,NA,NA,NA,NA,NA,7/20/2021,7/21/2021,Actual,18-Sep-20,Actual,9/18/2020,Jul-21,7/31/2021,Nov-21,Anticipated,11/30/2021,1-May-21,Actual,5/1/2021,NA,Interventional,SERO-CoV-OLD,NA,COVID-19 Serology and Immunosenescence,Kinetics of COVID-19-neutralising Antibodies in Patients Residing in EHPAD / USLD: Influence of Immunosenescence,Recruiting,NA,Not Applicable,330,Anticipated,"Centre Hospitalier Universitaire, Amiens",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:47:21Z,2021-12-02T08:47:21Z
NCT04563065,NA,9/19/2020,NA,NA,7/7/2021,9/23/2020,9/24/2020,Actual,NA,NA,NA,NA,NA,NA,7/7/2021,7/13/2021,Actual,1-Aug-20,Actual,8/1/2020,Jul-21,7/31/2021,31-Dec-23,Anticipated,12/31/2023,30-Nov-20,Actual,11/30/2020,NA,Interventional,ACPREGCOV,NA,Active Pregnancy Against COVID-19,"Active Pregnancy, Prevention Against the Effects of COVID-19",Recruiting,NA,Not Applicable,280,Anticipated,Universidad Politecnica de Madrid,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:48:03Z,2021-12-02T08:48:03Z
NCT04561154,NA,9/9/2020,NA,NA,9/22/2020,9/22/2020,9/23/2020,Actual,NA,NA,NA,NA,NA,NA,9/22/2020,9/23/2020,Actual,11-Jun-20,Actual,6/11/2020,Sep-20,9/30/2020,11-Jun-22,Anticipated,6/11/2022,11-Jun-21,Anticipated,6/11/2021,NA,Interventional,REPERCOV,NA,Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV,Identifying Functional and Psycho-social Complaints After Hospitalization for Severe SARS-CoV-2 Infection (COVID19)- REPERCOV,Recruiting,NA,Not Applicable,134,Anticipated,Centre Hospitalier le Mans,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:49:20Z,2021-12-02T08:49:20Z
NCT04561219,NA,9/22/2020,NA,NA,7/15/2021,9/22/2020,9/23/2020,Actual,NA,NA,NA,NA,NA,NA,7/15/2021,7/22/2021,Actual,19-Apr-20,Actual,4/19/2020,Jul-21,7/31/2021,2-Oct-20,Actual,10/2/2020,2-Oct-20,Actual,10/2/2020,NA,Interventional,NA,NA,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,"Nitazoxanide for Moderate to Severe COVID-19 Pneumonia: a Multicenter, Randomized, Placebo-controlled, Double-Blind Clinical Trial",Completed,NA,Phase 2,500,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-12-02T08:49:11Z,2021-12-02T08:49:11Z
NCT04560881,NA,9/16/2020,NA,NA,11/25/2020,9/21/2020,9/23/2020,Actual,NA,NA,NA,NA,NA,NA,11/25/2020,11/27/2020,Actual,16-Sep-20,Actual,9/16/2020,Nov-20,11/30/2020,1-Dec-21,Anticipated,12/1/2021,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,NA,NA,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years","Active, not recruiting",NA,Phase 3,3000,Actual,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:49:34Z,2021-12-02T08:49:34Z
NCT04561063,NA,9/21/2020,NA,NA,9/28/2021,9/21/2020,9/23/2020,Actual,NA,NA,NA,NA,NA,NA,9/28/2021,10/6/2021,Actual,8-Dec-20,Actual,12/8/2020,Sep-21,9/30/2021,28-Feb-22,Anticipated,2/28/2022,28-Feb-22,Anticipated,2/28/2022,NA,Interventional,COVER,NA,COVID-19 Prophylaxis South Africa (COVER HCW),"A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2",Recruiting,NA,Phase 2,1950,Anticipated,"University of Witwatersrand, South Africa",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:49:35Z,2021-12-02T08:49:35Z
NCT04560257,NA,7/13/2020,NA,NA,12/4/2020,9/22/2020,9/23/2020,Actual,NA,NA,NA,NA,NA,NA,12/4/2020,12/8/2020,Actual,1-May-20,Actual,5/1/2020,Dec-20,12/31/2020,30-Dec-20,Anticipated,12/30/2020,30-Dec-20,Anticipated,12/30/2020,NA,Interventional,HFNC19LGH,NA,High Flow Nasal Cannula HFNC In Covid-19 Patients,Prone Positioning and High Flow Nasal Canula (HFNC) Therapy: A Game Changer in COVID-19 Outcome,Recruiting,NA,Not Applicable,30,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:50:03Z,2021-12-02T08:50:03Z
NCT04560231,NA,7/11/2020,NA,NA,9/24/2020,9/22/2020,9/23/2020,Actual,NA,NA,NA,NA,NA,NA,9/24/2020,9/25/2020,Actual,1-Jun-20,Actual,6/1/2020,Sep-20,9/30/2020,30-Nov-20,Anticipated,11/30/2020,30-Nov-20,Anticipated,11/30/2020,NA,Interventional,RC19LGH,NA,Remdesivir in COVID-19 Lahore General Hospital,Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study,Recruiting,NA,Early Phase 1,30,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:50:09Z,2021-12-02T08:50:09Z
NCT04560205,NA,7/11/2020,NA,NA,12/4/2020,9/22/2020,9/23/2020,Actual,NA,NA,NA,NA,NA,NA,12/4/2020,12/8/2020,Actual,1-May-20,Actual,5/1/2020,Dec-20,12/31/2020,30-Dec-20,Anticipated,12/30/2020,30-Dec-20,Anticipated,12/30/2020,NA,Interventional,TC19LGH,NA,Tocilizumab in COVID-19 Lahore General Hospital,Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19,Recruiting,NA,Phase 1,50,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:50:16Z,2021-12-02T08:50:16Z
NCT04559113,NA,9/15/2020,NA,NA,12/4/2020,9/21/2020,9/22/2020,Actual,NA,NA,NA,NA,NA,NA,12/4/2020,12/8/2020,Actual,1-May-20,Actual,5/1/2020,Dec-20,12/31/2020,30-Dec-20,Anticipated,12/30/2020,30-Dec-20,Anticipated,12/30/2020,NA,Interventional,Methyl19LGH,NA,Methylprednisolone in COVID-19 Patients (Methyl19LGH),Perks of Methylprednisolone for Hospitalized COVID-19 Patients: A Clinical Trial,Recruiting,NA,Not Applicable,200,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:50:46Z,2021-12-02T08:50:46Z
NCT04559074,NA,8/26/2020,NA,NA,11/11/2020,9/21/2020,9/22/2020,Actual,NA,NA,NA,NA,NA,NA,11/11/2020,11/13/2020,Actual,23-Oct-20,Actual,10/23/2020,Aug-20,8/31/2020,31-Jul-21,Anticipated,7/31/2021,30-Apr-21,Anticipated,4/30/2021,NA,Interventional,NA,NA,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Recruiting,NA,Phase 4,1000,Anticipated,Queen Mary University of London,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Fully anonymised data will be shared with fellow researchers via conference presentation and via publication of the results in scientific journals. Pseudonymised data will be shared between the research teams named in the application.,2021-12-02T08:50:54Z,2021-12-02T08:50:54Z
NCT04558476,NA,9/14/2020,NA,NA,5/25/2021,9/21/2020,9/22/2020,Actual,NA,NA,NA,NA,NA,NA,5/25/2021,5/28/2021,Actual,1-Sep-20,Actual,9/1/2020,May-21,5/31/2021,1-Sep-22,Anticipated,9/1/2022,1-Sep-22,Anticipated,9/1/2022,NA,Interventional,CONFIDENT,NA,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation: the CONFIDENT Trial,Recruiting,NA,Phase 2,500,Anticipated,University of Liege,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:51:25Z,2021-12-02T08:51:25Z
NCT04558463,NA,9/3/2020,NA,NA,9/21/2020,9/21/2020,9/22/2020,Actual,NA,NA,NA,NA,NA,NA,9/21/2020,9/22/2020,Actual,16-Apr-20,Actual,4/16/2020,Sep-20,9/30/2020,30-Oct-20,Anticipated,10/30/2020,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19: An Open Label Trial,Recruiting,NA,Phase 3,100,Anticipated,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:51:25Z,2021-12-02T08:51:25Z
NCT04558411,NA,9/20/2020,NA,NA,9/23/2021,9/20/2020,9/22/2020,Actual,NA,NA,NA,NA,NA,NA,9/23/2021,9/29/2021,Actual,12-Sep-20,Actual,9/12/2020,Sep-21,9/30/2021,15-Dec-20,Actual,12/15/2020,15-Dec-20,Actual,12/15/2020,NA,Interventional,NA,NA,"Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students","Pilot Study of a Brief, Scaleable Intervention for COVID-19 Mental Health Sequelae in College Students",Completed,NA,Not Applicable,153,Actual,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,We will share data after the publication of primary manuscripts.,NA,NA,Yes,We will share data after the publication of primary manuscripts.,2021-12-02T08:51:26Z,2021-12-02T08:51:26Z
NCT04558372,NA,9/20/2020,NA,NA,12/28/2020,9/21/2020,9/22/2020,Actual,NA,NA,NA,NA,NA,NA,12/28/2020,12/29/2020,Actual,1-Apr-20,Actual,4/1/2020,Dec-20,12/31/2020,12-Dec-20,Actual,12/12/2020,12-Dec-20,Actual,12/12/2020,NA,Interventional,NA,NA,Genosvid Diagnostic Test for Early Detection of COVID-19,Genosvid Diagnostic Test for Early Detection of COVID-19: UGM Electronic-Nose Innovation for Indonesia,Completed,NA,Not Applicable,1999,Actual,Gadjah Mada University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:51:38Z,2021-12-02T08:51:38Z
NCT04557241,NA,9/16/2020,NA,NA,2/8/2021,9/17/2020,9/21/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/9/2021,Actual,14-Jan-20,Actual,1/14/2020,Feb-21,2/28/2021,31-Jan-21,Actual,1/31/2021,14-Jan-21,Actual,1/14/2021,NA,Interventional,NA,NA,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Completed,NA,Not Applicable,1017,Actual,Indiana University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Fully de-identified data will be made available along with the publication of the primary results paper from this study.,NA,NA,Yes,Fully de-identified data (full dataset) will be made available along with the publication of the primary results paper from this study.,2021-12-02T08:52:05Z,2021-12-02T08:52:05Z
NCT04558021,NA,9/18/2020,NA,NA,10/9/2020,9/19/2020,9/22/2020,Actual,NA,NA,NA,NA,NA,NA,10/9/2020,10/12/2020,Actual,8-Oct-20,Actual,10/8/2020,Oct-20,10/31/2020,14-Feb-21,Anticipated,2/14/2021,30-Jan-21,Anticipated,1/30/2021,NA,Interventional,NICLONEX,NA,A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,"A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19)",Recruiting,NA,Phase 3,200,Anticipated,Imuneks Farma ilac San. Tic. A.S.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:51:46Z,2021-12-02T08:51:46Z
NCT04557605,NA,9/9/2020,NA,NA,10/16/2020,9/15/2020,9/21/2020,Actual,NA,NA,NA,NA,NA,NA,10/16/2020,10/20/2020,Actual,14-Sep-20,Actual,9/14/2020,Oct-20,10/31/2020,15-Oct-20,Actual,10/15/2020,15-Oct-20,Actual,10/15/2020,NA,Interventional,NA,NA,Effects of a Face Mask on Oxygenation During Exercise,The Effects of Wearing a Face Mask During COVID-19 on Blood and Muscle Oxygenation While Performing Exercise,Completed,NA,Not Applicable,14,Actual,University of Saskatchewan,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:52:22Z,2021-12-02T08:52:22Z
NCT04557046,NA,9/17/2020,NA,NA,1/28/2021,9/17/2020,9/21/2020,Actual,NA,NA,NA,NA,NA,NA,1/28/2021,1/29/2021,Actual,26-Jun-20,Actual,6/26/2020,Jan-21,1/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,ASPIRE,NA,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,A Multicenter COVID-19 Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 Ag Test at Point of Care Testing Sites,Recruiting,NA,Not Applicable,400,Anticipated,LumiraDx UK Limited,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:52:37Z,2021-12-02T08:52:37Z
NCT04555213,NA,9/16/2020,NA,NA,8/24/2021,9/16/2020,9/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/26/2021,Actual,30-Sep-20,Actual,9/30/2020,Aug-21,8/31/2021,10-Aug-21,Actual,8/10/2021,10-Aug-21,Actual,8/10/2021,NA,Interventional,NOXCOVID,NA,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID),Completed,NA,Phase 1,41,Actual,Noxopharm Limited,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:53:48Z,2021-12-02T08:53:48Z
NCT04555005,NA,6/11/2020,NA,NA,9/17/2020,9/17/2020,9/18/2020,Actual,NA,NA,NA,NA,NA,NA,9/17/2020,9/18/2020,Actual,10-Mar-20,Actual,3/10/2020,Mar-20,3/31/2020,26-Apr-20,Actual,4/26/2020,26-Apr-20,Actual,4/26/2020,NA,Interventional,NA,NA,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,"Implementation of a Mindfulness-based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain",Completed,NA,Not Applicable,1000,Actual,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:54:07Z,2021-12-02T08:54:07Z
NCT04555148,NA,9/16/2020,NA,NA,8/17/2021,9/16/2020,9/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/17/2021,8/24/2021,Actual,19-Sep-20,Actual,9/19/2020,Aug-21,8/31/2021,23-Apr-21,Actual,4/23/2021,22-Jan-21,Actual,1/22/2021,NA,Interventional,NA,NA,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),"A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19",Completed,NA,Phase 2,63,Actual,Green Cross Corporation,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:54:00Z,2021-12-02T08:54:00Z
NCT04555096,NA,9/16/2020,NA,NA,7/9/2021,9/16/2020,9/18/2020,Actual,NA,NA,NA,NA,NA,NA,7/9/2021,7/14/2021,Actual,9-Sep-20,Actual,9/9/2020,Jul-21,7/31/2021,28-May-21,Actual,5/28/2021,28-May-21,Actual,5/28/2021,NA,Interventional,NA,NA,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,"A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)",Terminated,NA,Phase 2,17,Actual,"Galera Therapeutics, Inc.",,2,NA,Participants are no longer receiving intervention,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:54:01Z,2021-12-02T08:54:01Z
NCT04554992,NA,8/26/2020,NA,NA,10/29/2020,9/16/2020,9/18/2020,Actual,NA,NA,NA,NA,NA,NA,10/29/2020,11/2/2020,Actual,20-Mar-20,Actual,3/20/2020,Oct-20,10/31/2020,Jun-22,Anticipated,6/30/2022,Jun-22,Anticipated,6/30/2022,NA,Interventional,NA,NA,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),Convalescent Plasma for the Treatment of Coronavirus Disease 2019,"Active, not recruiting",NA,Phase 1,350,Actual,The Methodist Hospital Research Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:54:17Z,2021-12-02T08:54:17Z
NCT04554264,NA,9/2/2020,NA,NA,9/17/2020,9/17/2020,9/18/2020,Actual,NA,NA,NA,NA,NA,NA,9/17/2020,9/18/2020,Actual,1-Sep-20,Actual,9/1/2020,Sep-20,9/30/2020,Sep-22,Anticipated,9/30/2022,Sep-21,Anticipated,9/30/2021,NA,Interventional,DEPARTS,NA,Complicated Grief in ICU in the Aftermath of COVID-19,Complicated Grief in ICU in the Aftermath of COVID-19,Recruiting,NA,Not Applicable,160,Anticipated,"Centre Hospitalier Universitaire, Amiens",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:54:36Z,2021-12-02T08:54:36Z
NCT04553705,NA,9/15/2020,NA,NA,9/16/2020,9/16/2020,9/17/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2020,9/18/2020,Actual,20-Sep-20,Anticipated,9/20/2020,Sep-20,9/30/2020,4-Dec-20,Anticipated,12/4/2020,4-Nov-20,Anticipated,11/4/2020,NA,Interventional,NA,NA,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Impact of Different Treatment Modalities on Immunity Against COVID-19,Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Beni-Suef University,,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:55:06Z,2021-12-02T08:55:06Z
NCT04552379,NA,8/21/2020,NA,NA,9/2/2021,9/16/2020,9/17/2020,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/10/2021,Actual,1-Dec-20,Actual,12/1/2020,Dec-20,12/31/2020,30-Jun-21,Actual,6/30/2021,31-May-21,Actual,5/31/2021,NA,Interventional,ConCorD-19,NA,The Containing Coronavirus Disease 19 (COVID-19) Trial,A Cluster Randomised Trial of Interferon Versus Standard of Care in the Reduction of Transmission of SARS-Cov-2. The Containing Coronavirus Disease 19 Trial (ConCorD-19),Completed,NA,Phase 3,1173,Actual,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,We are evaluating the best time to share the information.,We are evaluating the best way to share the information.,NA,Yes,We are evaluating the best way to share the information.,2021-12-02T08:56:07Z,2021-12-02T08:56:07Z
NCT04552951,NA,5/21/2020,NA,NA,9/16/2020,9/16/2020,9/17/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2020,9/17/2020,Actual,4-Apr-20,Actual,4/4/2020,Sep-20,9/30/2020,30-Dec-20,Anticipated,12/30/2020,14-Sep-20,Anticipated,9/14/2020,NA,Interventional,COVID-VIT-D,NA,Effect of Vitamin D on Morbidity and Mortality of the COVID-19,Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infecciÃ³n Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias,Recruiting,NA,Phase 4,80,Anticipated,FundaciÃ³n para la InvestigaciÃ³n Biosanitaria del Principado de Asturias,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:55:53Z,2021-12-02T08:55:53Z
NCT04552483,NA,9/9/2020,NA,NA,11/1/2020,9/15/2020,9/17/2020,Actual,NA,NA,NA,NA,NA,NA,11/1/2020,11/3/2020,Actual,8-Jun-20,Actual,6/8/2020,Nov-20,11/30/2020,5-Sep-20,Actual,9/5/2020,20-Aug-20,Actual,8/20/2020,NA,Interventional,NA,NA,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19,Completed,NA,Phase 2,392,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-12-02T08:56:02Z,2021-12-02T08:56:02Z
NCT04552366,NA,9/15/2020,NA,NA,12/3/2020,9/16/2020,9/17/2020,Actual,NA,NA,NA,NA,NA,NA,12/3/2020,12/7/2020,Actual,29-Sep-20,Actual,9/29/2020,Sep-20,9/30/2020,30-Jun-21,Anticipated,6/30/2021,31-Dec-20,Anticipated,12/31/2020,NA,Interventional,NA,NA,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older,"Active, not recruiting",NA,Phase 1,149,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:56:20Z,2021-12-02T08:56:20Z
NCT04551768,NA,9/15/2020,NA,NA,8/25/2021,9/15/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,8/25/2021,8/26/2021,Actual,10-Feb-21,Actual,2/10/2021,Aug-21,8/31/2021,17-Aug-21,Actual,8/17/2021,17-Aug-21,Actual,8/17/2021,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,"An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19",Completed,NA,Phase 1,51,Actual,"Bausch Health Americas, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T08:56:44Z,2021-12-02T08:56:44Z
NCT04551781,NA,9/13/2020,NA,NA,9/14/2020,9/14/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,9/14/2020,9/16/2020,Actual,1-Apr-20,Actual,4/1/2020,Sep-20,9/30/2020,30-Jul-20,Actual,7/30/2020,30-Jul-20,Actual,7/30/2020,NA,Interventional,NA,NA,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Short Term Low Dose Corticosteroids for Management of Post Covid-19 Pulmonary Fibrosis,Completed,NA,Not Applicable,450,Actual,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T08:56:45Z,2021-12-02T08:56:45Z
NCT04551339,NA,9/9/2020,NA,NA,8/7/2021,9/15/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,8/7/2021,8/10/2021,Actual,28-Sep-20,Actual,9/28/2020,Aug-21,8/31/2021,28-May-21,Actual,5/28/2021,28-May-21,Actual,5/28/2021,NA,Interventional,ZnCOVID-19,NA,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic: A Randomized Study,Completed,NA,Not Applicable,2700,Actual,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:56:57Z,2021-12-02T08:56:57Z
NCT04551547,NA,9/15/2020,NA,NA,7/26/2021,9/15/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,7/26/2021,7/27/2021,Actual,31-Oct-20,Actual,10/31/2020,Jun-21,6/30/2021,Feb-22,Anticipated,2/28/2022,30-Apr-21,Actual,4/30/2021,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years",Enrolling by invitation,NA,Phase 1/Phase 2,552,Anticipated,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:57:08Z,2021-12-02T08:57:08Z
NCT04536376,NA,8/26/2020,NA,NA,9/20/2021,9/1/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/21/2021,Actual,15-Jan-21,Actual,1/15/2021,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,2-Sep-21,Actual,9/2/2021,NA,Interventional,NA,NA,First Responder Resiliency Program During COVID-19,First Responder Resiliency Program for Health Care Professionals During a Pandemic,"Active, not recruiting",NA,Not Applicable,10,Actual,Mayo Clinic,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:08:19Z,2021-12-02T09:08:19Z
NCT04550325,NA,9/10/2020,NA,NA,1/4/2021,9/13/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,1/4/2021,1/5/2021,Actual,5-Aug-20,Actual,8/5/2020,Jan-21,1/31/2021,26-Nov-20,Actual,11/26/2020,26-Nov-20,Actual,11/26/2020,NA,Interventional,NA,NA,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19","A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia",Completed,NA,Phase 1/Phase 2,12,Actual,"Kamada, Ltd.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:57:36Z,2021-12-02T08:57:36Z
NCT04550351,NA,8/16/2020,NA,NA,1/26/2021,9/14/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,1/26/2021,1/27/2021,Actual,19-Aug-20,Actual,8/19/2020,Aug-20,8/31/2020,31-Dec-21,Anticipated,12/31/2021,18-Dec-20,Actual,12/18/2020,NA,Interventional,NA,NA,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:57:31Z,2021-12-02T08:57:31Z
NCT04549376,NA,9/11/2020,NA,NA,9/12/2020,9/12/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,9/12/2020,9/16/2020,Actual,1-Jul-20,Actual,7/1/2020,Sep-20,9/30/2020,30-Oct-20,Anticipated,10/30/2020,20-Oct-20,Anticipated,10/20/2020,NA,Interventional,VEP-COV,NA,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial,Recruiting,NA,Phase 2,200,Anticipated,"Pi Research Consultancy Center, Bangladesh",,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,6 months,"Available on public domain like figshare, researchgate and others",NA,Yes,"After completion of the project, a manuscript will be prepared and will be shared to the journal authority for publication. Data will be shared with the journal authority and make public as part of the publication.",2021-12-02T08:58:27Z,2021-12-02T08:58:27Z
NCT04549922,NA,9/9/2020,NA,NA,4/15/2021,9/11/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,4/15/2021,4/19/2021,Actual,22-Oct-20,Actual,10/22/2020,Apr-21,4/30/2021,Feb-22,Anticipated,2/28/2022,Feb-22,Anticipated,2/28/2022,NA,Interventional,ASKCOV,NA,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19: A Phase II Randomized Controlled Trial,"Active, not recruiting",NA,Phase 2,111,Actual,Hospital do Coracao,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Protocol will be available in December, together with analysis plan",Protocol and analysis plan will be uploaded to Clinicaltrials.gov,NA,Yes,Data will be available under reasonable request after approval by the steering committee.,2021-12-02T08:57:56Z,2021-12-02T08:57:56Z
NCT04548934,NA,9/2/2020,NA,NA,2/1/2021,9/14/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,2/1/2021,2/2/2021,Actual,13-Sep-20,Actual,9/13/2020,Sep-20,9/30/2020,31-Jan-21,Actual,1/31/2021,31-Oct-20,Actual,10/31/2020,NA,Interventional,NA,NA,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Completed,NA,Not Applicable,34,Actual,Institute of Mountain Emergency Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:58:51Z,2021-12-02T08:58:51Z
NCT04548531,NA,9/9/2020,NA,NA,8/31/2021,9/11/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2021,9/1/2021,Actual,10-Sep-20,Actual,9/10/2020,Aug-21,8/31/2021,30-Apr-21,Actual,4/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,NA,NA,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Completed,NA,Not Applicable,800,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Three months after the end of the funded grant period, the study materials and de-identified data will be available, by request, from the PI. Once data are placed on an open access service such as ICPSR they will be available indefinitely.","The PI will share a de-identified data set with outside investigators at no cost, according to approved Partners and Massachusetts General Hospital policies for data sharing. Investigators from other sites will be able to request the data and will be required to complete a data use agreement that ensures that all local Institutional Review Board requirements are met before using the data, that they will not attempt to identify any data in the dataset, and that they will not share the data set with anyone outside their project team.

On ICPSR, individuals must register and agree to ICPSR's Responsible Use statement prior to accessing datasets.",NA,Yes,"Yes To promote research replicability, transparency and future use of the data, de-identified data sets of the patient survey data will be created and will be available, by request, to outside researchers.

After the main manuscripts have been published, de-identified data sets will also be deposited in an open access service such as, ICPSR (https://www.icpsr.umich.edu/icpsrweb/). Before a dataset is made available for access, ICPSR completes a detailed review of all datasets to assess disclosure risk. If necessary, ICPSR modifies data to reduce disclosure risk or limits access to datasets for which modifying the data would substantially limit their utility or the risk of disclosure remains high. No information that contains identifiers or that could be used to link an individual to the data will be included in the de-identified data set.",2021-12-02T08:59:00Z,2021-12-02T08:59:00Z
NCT04548544,NA,9/11/2020,NA,NA,9/11/2020,9/11/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,9/11/2020,9/14/2020,Actual,18-Oct-19,Actual,10/18/2019,Sep-20,9/30/2020,20-May-20,Actual,5/20/2020,20-May-20,Actual,5/20/2020,NA,Interventional,NA,NA,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During the COVID-19 Pandemic,Completed,NA,Not Applicable,21,Actual,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:59:02Z,2021-12-02T08:59:02Z
NCT04549337,NA,9/9/2020,NA,NA,11/25/2020,9/14/2020,9/16/2020,Actual,NA,NA,NA,NA,NA,NA,11/25/2020,11/30/2020,Actual,25-Sep-20,Actual,9/25/2020,Nov-20,11/30/2020,1-May-21,Anticipated,5/1/2021,1-May-21,Anticipated,5/1/2021,NA,Interventional,NA,NA,Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19,Investigator-blinded Randomized Controlled Trial Examining the Safety and Feasibility of Different Exercise Training Programs in Patients Who Have Survived COVID-19,Recruiting,NA,Not Applicable,10,Anticipated,"Rigshospitalet, Denmark",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Individual participant data that underlie the results reported in publications from this study (after deidentification), and the analytic code can be shared beginning 6 months after publication of pre-specified primary, and secondary outcomes and ending 5 years following this to researchers, who provide a methodologically sound proposal. Proposals should be directed to the corresponding or last author of this manuscript. To gain access, data requestors will need to sign a data access agreement.",2021-12-02T08:58:23Z,2021-12-02T08:58:23Z
NCT04547660,NA,9/9/2020,NA,NA,2/8/2021,9/11/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/9/2021,Actual,16-Jul-20,Actual,7/16/2020,Feb-21,2/28/2021,7-Jan-21,Actual,1/7/2021,7-Jan-21,Actual,1/7/2021,NA,Interventional,PLACOVID,NA,Convalescent Plasma for Severe COVID-19 Patients,"Convalescent Plasma for Severe COVID-19 Patients: a Randomized, Open-label, Phase 3 Trial",Completed,NA,Phase 3,160,Actual,Hospital de Clinicas de Porto Alegre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T08:59:33Z,2021-12-02T08:59:33Z
NCT04547283,NA,9/9/2020,NA,NA,7/3/2021,9/11/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,7/3/2021,7/7/2021,Actual,14-Jun-20,Actual,6/14/2020,Jul-21,7/31/2021,30-Sep-20,Actual,9/30/2020,20-Sep-20,Actual,9/20/2020,NA,Interventional,NA,NA,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19: A Pilot Randomized Controlled Trial,Completed,NA,Not Applicable,40,Actual,Atrium Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be accessible to researchers who provide a methodologically sound proposal After approval by the AtriumHealth Institutional Review Board and the study investigators.,NA,Yes,Individual patient data underlying reported results will be made available with data dictionaries after de-identification.,2021-12-02T08:59:50Z,2021-12-02T08:59:50Z
NCT04547634,NA,8/17/2020,NA,NA,9/7/2020,9/7/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2020,9/14/2020,Actual,1-Jul-20,Actual,7/1/2020,Sep-20,9/30/2020,Dec-20,Anticipated,12/31/2020,Nov-20,Anticipated,11/30/2020,NA,Interventional,NA,NA,Telerehabilitation in Oncology Patients,Effect of a Telerehabilitation-exercise Intervention in Oncology Patients in the Covid-19 Pandemic,Enrolling by invitation,NA,Not Applicable,30,Actual,University of Malaga,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T08:59:40Z,2021-12-02T08:59:40Z
NCT04547257,NA,4/29/2020,NA,NA,8/11/2021,9/11/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,8/11/2021,8/17/2021,Actual,4-May-21,Actual,5/4/2021,Apr-21,4/30/2021,15-Oct-21,Anticipated,10/15/2021,15-Aug-21,Anticipated,8/15/2021,NA,Interventional,CP022,NA,Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19,Safety and Effectiveness Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the Treatment of Patients With COVID-19,Recruiting,NA,Not Applicable,42,Anticipated,ExThera Medical Europe BV,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,in 9 months,NA,http://extheramedical.com,Yes,"The Sponsor will be responsible for determining whether to register the clinical investigation on www.clinicaltrials.gov or any other clinical trials, in accordance with the International Committee of Medical Journal Editors guidelines, or any other applicable guidelines.",2021-12-02T08:59:58Z,2021-12-02T08:59:58Z
NCT04547127,NA,9/10/2020,NA,NA,3/2/2021,9/10/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,3/2/2021,3/3/2021,Actual,29-Apr-20,Actual,4/29/2020,Mar-21,3/31/2021,4-Feb-21,Actual,2/4/2021,4-Feb-21,Actual,2/4/2021,NA,Interventional,NA,NA,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)",Completed,NA,Phase 2,200,Actual,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:00:11Z,2021-12-02T09:00:11Z
NCT04546581,NA,9/8/2020,NA,NA,8/9/2021,9/8/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,8/9/2021,8/11/2021,Actual,8-Oct-20,Actual,10/8/2020,Aug-21,8/31/2021,21-May-21,Actual,5/21/2021,21-May-21,Actual,5/21/2021,NA,Interventional,NA,NA,Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC),"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19",Completed,NA,Phase 3,593,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,A public data set will be made available at the end of the trial,2021-12-02T09:00:26Z,2021-12-02T09:00:26Z
NCT04546841,NA,8/26/2020,NA,NA,9/7/2021,9/11/2020,9/14/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/8/2021,Actual,27-Nov-20,Actual,11/27/2020,Aug-21,8/31/2021,20-Dec-21,Anticipated,12/20/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,pVAC,NA,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,P-pVAC-SARS-CoV-2: Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,"Active, not recruiting",NA,Phase 1,36,Anticipated,University Hospital Tuebingen,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:00:14Z,2021-12-02T09:00:14Z
NCT04545541,NA,9/5/2020,NA,NA,1/14/2021,9/10/2020,9/11/2020,Actual,NA,NA,NA,NA,NA,NA,1/14/2021,1/19/2021,Actual,1-Nov-20,Actual,11/1/2020,Nov-20,11/30/2020,Jun-22,Anticipated,6/30/2022,Apr-22,Anticipated,4/30/2022,NA,Interventional,CHARTER-MT,NA,Nebulised Heparin in Patients With Severe COVID-19,Can Nebulised HepArin Reduce morTality and Time to Extubation in Patients With COVID-19 Requiring Mechanical Ventilation Meta-Trial (CHARTER-MT): Protocol for an Investigator-initiated International Meta-trial of Randomised Studies,Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Australian National University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Real-time,NA,NA,Yes,"The CHARTER-MT Collaborative Research Group's executive committee, with representatives from each individual country/trial, is responsible for the meta-trial's study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication. Investigators from individual trials have ownership of their trial data. A memorandum of understanding and data sharing agreement between investigators will facilitate and govern the pooling and meta-analysing of de-identified individual patient data from individual trials, as well as outline authorship.",2021-12-02T09:01:19Z,2021-12-02T09:01:19Z
NCT04545749,NA,9/2/2020,NA,NA,6/4/2021,9/10/2020,9/11/2020,Actual,NA,NA,NA,NA,NA,NA,6/4/2021,6/7/2021,Actual,25-Sep-20,Actual,9/25/2020,Jun-21,6/30/2021,24-May-21,Actual,5/24/2021,18-Jan-21,Actual,1/18/2021,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,NA,Phase 1,60,Actual,"United Biomedical Inc., Asia",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:01:16Z,2021-12-02T09:01:16Z
NCT04545060,NA,9/4/2020,NA,NA,9/24/2021,9/9/2020,9/10/2020,Actual,NA,NA,NA,NA,NA,NA,9/24/2021,9/27/2021,Actual,27-Aug-20,Actual,8/27/2020,Sep-21,9/30/2021,2-Sep-21,Actual,9/2/2021,8-Apr-21,Actual,4/8/2021,NA,Interventional,COMET-ICE,NA,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,"A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients",Completed,NA,Phase 2/Phase 3,1057,Actual,"Vir Biotechnology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:01:40Z,2021-12-02T09:01:40Z
NCT04543760,NA,9/8/2020,NA,NA,5/18/2021,9/9/2020,9/10/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/19/2021,Actual,1-Oct-20,Actual,10/1/2020,May-21,5/31/2021,14-Mar-21,Actual,3/14/2021,15-Jan-21,Actual,1/15/2021,NA,Interventional,DeCOPO,NA,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to Sars-covid-2: a Randomized Crossover Trial.,Completed,NA,Not Applicable,18,Actual,"Hospital St. Joseph, Marseille, France",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:02:31Z,2021-12-02T09:02:31Z
NCT04542694,NA,9/4/2020,10/11/2020,NA,11/3/2020,9/4/2020,9/9/2020,Actual,11/3/2020,11/5/2020,Actual,NA,NA,NA,11/3/2020,11/5/2020,Actual,21-May-20,Actual,5/21/2020,Nov-20,11/30/2020,20-Aug-20,Actual,8/20/2020,10-Aug-20,Actual,8/10/2020,NA,Interventional,NA,NA,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19",Completed,NA,Phase 3,200,Actual,"Promomed, LLC",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:03:26Z,2021-12-02T09:03:26Z
NCT04542941,NA,8/31/2020,NA,NA,1/13/2021,9/7/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,1/13/2021,1/15/2021,Actual,16-Jun-20,Actual,6/16/2020,Jan-21,1/31/2021,31-Dec-20,Actual,12/31/2020,31-Dec-20,Actual,12/31/2020,NA,Interventional,COVIDIT,NA,Assessment of Safety and Efficacy of CCP,Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial,Completed,NA,Not Applicable,136,Actual,Makerere University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Arrangments to enable sharing of de-identified data will be instituted by the research team.,2021-12-02T09:03:16Z,2021-12-02T09:03:16Z
NCT04542967,NA,9/4/2020,NA,NA,5/6/2021,9/8/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,5/6/2021,5/10/2021,Actual,23-Jun-20,Actual,6/23/2020,Sep-20,9/30/2020,30-Sep-20,Actual,9/30/2020,2-Sep-20,Actual,9/2/2020,NA,Interventional,PC-COVID-HCM,NA,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease,Completed,NA,Phase 2,150,Actual,Hospital Central Militar,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,From 6 months after publication,PRIOR APPLICATION,NA,Yes,Plan to make IPD still not decided and would need approval by regulatory authorities,2021-12-02T09:03:20Z,2021-12-02T09:03:20Z
NCT04542993,NA,9/8/2020,NA,NA,3/1/2021,9/8/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,3/1/2021,3/3/2021,Actual,8-Sep-20,Actual,9/8/2020,Mar-21,3/31/2021,Jun-22,Anticipated,6/30/2022,5-Feb-21,Actual,2/5/2021,NA,Interventional,Reszinate,NA,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,"Can SARS-CoV-2 Viral Shedding in COVID-19 Disease be Reduced by Resveratrol-assisted Zinc Ingestion, a Direct Inhibitor of SARS-CoV-2-RNA Polymerase? A Single Blinded Phase II Protocol (Reszinate Trial)","Active, not recruiting",NA,Phase 2,60,Anticipated,Swedish Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Currently no plan to make IPD available,2021-12-02T09:03:28Z,2021-12-02T09:03:28Z
NCT04542876,NA,9/8/2020,NA,NA,9/8/2020,9/8/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,9/8/2020,9/9/2020,Actual,1-May-20,Actual,5/1/2020,Sep-20,9/30/2020,18-Aug-20,Actual,8/18/2020,31-Jul-20,Actual,7/31/2020,NA,Interventional,NA,NA,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study,Completed,NA,Not Applicable,46,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:03:30Z,2021-12-02T09:03:30Z
NCT04542343,NA,9/3/2020,NA,NA,1/22/2021,9/4/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,1/22/2021,1/26/2021,Actual,1-Nov-20,Actual,11/1/2020,Sep-20,9/30/2020,30-Sep-21,Anticipated,9/30/2021,30-Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,COVID-19 Risk Reduction Among African American Parishioners,"Multilevel, Multidisciplinary, Faith-Based Participatory Interventions to Reduce COVID-19 Related-Risks Among Underserved African Americans",Recruiting,NA,Not Applicable,265,Anticipated,Charles Drew University of Medicine and Science,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:03:44Z,2021-12-02T09:03:44Z
NCT04542330,NA,9/7/2020,NA,NA,11/22/2020,9/7/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,11/22/2020,11/24/2020,Actual,15-Sep-20,Actual,9/15/2020,Nov-20,11/30/2020,Mar-22,Anticipated,3/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Senior Citizens During the COVID-19 Pandemic. A Randomized Clinical Trial.,Recruiting,NA,Phase 3,1900,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed,Per justified request on email (cbenn@health.sdu.dk),NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2021-12-02T09:03:47Z,2021-12-02T09:03:47Z
NCT04542213,NA,9/3/2020,NA,NA,3/19/2021,9/4/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,3/19/2021,3/23/2021,Actual,1-Aug-20,Actual,8/1/2020,Mar-21,3/31/2021,28-Feb-21,Actual,2/28/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,Covid19DPP4i,NA,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19,Completed,NA,Phase 3,70,Actual,Hospital Regional de Alta Especialidad del Bajio,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be available once the main results of the study are published, and in accordance with the journal",Direct contact with the principal investigator,NA,Yes,"Sharing of the data can be done, depending on the requested purposes",2021-12-02T09:03:50Z,2021-12-02T09:03:50Z
NCT04542447,NA,9/6/2020,NA,NA,9/8/2020,9/6/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,9/8/2020,9/10/2020,Actual,1-Sep-20,Actual,9/1/2020,Sep-20,9/30/2020,30-Sep-20,Anticipated,9/30/2020,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,An Open Label Proof of Concept Study to Assess Aspects of Safety and Efficacy of Nuvastaticâ„¢ (C5OSEW5050ESA) as an Immunomodulator Adjuvant Therapy to the Standard Care of Treatment in Covid 19 Patients.,Recruiting,NA,Phase 1,10,Anticipated,Natureceuticals Sdn Bhd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Institutional sharing,2021-12-02T09:03:40Z,2021-12-02T09:03:40Z
NCT04542421,NA,9/4/2020,NA,NA,8/19/2021,9/6/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2021,8/23/2021,Actual,1-Jul-20,Actual,7/1/2020,Aug-21,8/31/2021,1-Dec-21,Anticipated,12/1/2021,1-Jul-21,Actual,7/1/2021,NA,Interventional,NA,NA,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Recruiting,NA,Not Applicable,90,Anticipated,"University of Colorado, Denver",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:03:41Z,2021-12-02T09:03:41Z
NCT04542395,NA,9/3/2020,NA,NA,7/27/2021,9/4/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,7/27/2021,8/2/2021,Actual,1-Jun-21,Actual,6/1/2021,Sep-20,9/30/2020,30-Nov-22,Anticipated,11/30/2022,30-Nov-22,Anticipated,11/30/2022,NA,Interventional,NA,NA,COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents,Multilevel Participatory Intervention to Reduce Barriers and Promote Social and Behavioral Facilitators of COVID-19 Testing Among African Americans and Latinx Public Housing Residents,Recruiting,NA,Not Applicable,310,Anticipated,Charles Drew University of Medicine and Science,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:03:42Z,2021-12-02T09:03:42Z
NCT04542031,NA,9/7/2020,NA,NA,9/14/2021,9/7/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/21/2021,Actual,14-Dec-20,Actual,12/14/2020,Apr-21,4/30/2021,Oct-21,Anticipated,10/31/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,CRISP,NA,COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL,COVID-19 Prevalence in a Single Large UK Rheumatology Centre and the Impact on Quality of Life From Stringent Social Distancing,Recruiting,NA,Not Applicable,7911,Anticipated,The Royal Wolverhampton Hospitals NHS Trust,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:04:03Z,2021-12-02T09:04:03Z
NCT04541979,NA,6/5/2020,NA,NA,2/24/2021,9/7/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,2/24/2021,2/25/2021,Actual,4-Jun-20,Actual,6/4/2020,Feb-21,2/28/2021,1-Jun-21,Anticipated,6/1/2021,1-May-21,Anticipated,5/1/2021,NA,Interventional,NA,NA,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,"Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 - a Phase 2, Single-blinded, Randomized Study",Recruiting,NA,Phase 2,100,Anticipated,Region Skane,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,nn,2021-12-02T09:04:03Z,2021-12-02T09:04:03Z
NCT04540120,NA,8/13/2020,NA,NA,9/21/2021,9/3/2020,9/7/2020,Actual,NA,NA,NA,NA,NA,NA,9/21/2021,9/23/2021,Actual,25-Sep-20,Actual,9/25/2020,Sep-21,9/30/2021,Nov-21,Anticipated,11/30/2021,Oct-21,Anticipated,10/31/2021,NA,Interventional,NA,NA,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome",Recruiting,NA,Phase 2,80,Anticipated,Olatec Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:05:27Z,2021-12-02T09:05:27Z
NCT04540419,NA,8/17/2020,NA,NA,7/19/2021,9/4/2020,9/7/2020,Actual,NA,NA,NA,NA,NA,NA,7/19/2021,7/20/2021,Actual,11-Sep-20,Actual,9/11/2020,Jul-21,7/31/2021,31-Jul-21,Anticipated,7/31/2021,19-Jun-21,Actual,6/19/2021,NA,Interventional,NA,NA,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers","Active, not recruiting",NA,Phase 3,500,Actual,NPO Petrovax,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:05:05Z,2021-12-02T09:05:05Z
NCT04541680,NA,8/17/2020,NA,NA,3/1/2021,9/7/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,3/1/2021,3/2/2021,Actual,29-Oct-20,Actual,10/29/2020,Feb-21,2/28/2021,Dec-21,Anticipated,12/31/2021,Mar-21,Anticipated,3/31/2021,NA,Interventional,NINTECOR,NA,Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis,"""Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis""",Recruiting,NA,Phase 3,250,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:04:19Z,2021-12-02T09:04:19Z
NCT04541485,NA,9/7/2020,NA,NA,9/16/2021,9/7/2020,9/9/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2021,9/23/2021,Actual,4-Dec-20,Actual,12/4/2020,Sep-21,9/30/2021,23-Mar-21,Actual,3/23/2021,3-Mar-21,Actual,3/3/2021,NA,Interventional,NA,NA,"To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)","Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients",Terminated,NA,Phase 1,2,Actual,Daewoong Pharmaceutical Co. LTD.,,5,NA,Enrolment was suspended since 09Dec2020 due to a lack of COVID-19 patients.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:04:33Z,2021-12-02T09:04:33Z
NCT04540406,NA,9/3/2020,NA,NA,9/2/2021,9/4/2020,9/7/2020,Actual,NA,NA,NA,NA,NA,NA,9/2/2021,9/5/2021,Actual,1-Oct-21,Anticipated,10/1/2021,Apr-21,4/30/2021,1-Jan-22,Anticipated,1/1/2022,1-Dec-21,Anticipated,12/1/2021,NA,Interventional,COVGUT20,NA,NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients,Modulation of Gut Microbiota With NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients,Recruiting,NA,Phase 2,100,Anticipated,Notitia Biotechnologies Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:05:15Z,2021-12-02T09:05:15Z
NCT04540185,NA,9/4/2020,NA,NA,9/5/2020,9/4/2020,9/7/2020,Actual,NA,NA,NA,NA,NA,NA,9/5/2020,9/9/2020,Actual,1-Nov-20,Anticipated,11/1/2020,Sep-20,9/30/2020,31-Dec-22,Anticipated,12/31/2022,1-Nov-22,Anticipated,11/1/2022,NA,Interventional,OPV-NA831,NA,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,"A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19",Enrolling by invitation,NA,Phase 3,3600,Anticipated,"NeuroActiva, Inc.",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,90 days after completion of the study,To be verified and determined at a later date,NA,Yes,We plan to share the Study Protocol and other information if needed,2021-12-02T09:05:42Z,2021-12-02T09:05:42Z
NCT04539262,NA,8/26/2020,NA,NA,4/8/2021,9/3/2020,9/4/2020,Actual,NA,NA,NA,NA,NA,NA,4/8/2021,4/9/2021,Actual,14-Sep-20,Actual,9/14/2020,Apr-21,4/30/2021,22-Mar-21,Actual,3/22/2021,26-Feb-21,Actual,2/26/2021,NA,Interventional,NA,NA,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation","A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Completed,NA,Phase 1/Phase 2,156,Actual,Gilead Sciences,,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:06:08Z,2021-12-02T09:06:08Z
NCT04539626,NA,9/3/2020,NA,NA,3/9/2021,9/3/2020,9/7/2020,Actual,NA,NA,NA,NA,NA,NA,3/9/2021,3/11/2021,Actual,1-Oct-20,Actual,10/1/2020,Mar-21,3/31/2021,Dec-22,Anticipated,12/31/2022,Jul-21,Anticipated,7/31/2021,NA,Interventional,NA,NA,Estrogen Therapy in Non-severe COVID-19 Patients,Estrogen Therapy in Non-severe COVID-19 Patients: Proposed Treatment Scheme in a Tertiary Hospital,Recruiting,NA,Not Applicable,60,Anticipated,"CMN ""20 de Noviembre""",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:05:53Z,2021-12-02T09:05:53Z
NCT04539821,NA,9/3/2020,NA,NA,8/13/2021,9/3/2020,9/7/2020,Actual,NA,NA,NA,NA,NA,NA,8/13/2021,8/16/2021,Actual,1-Oct-20,Actual,10/1/2020,Aug-21,8/31/2021,12-Aug-21,Actual,8/12/2021,31-May-21,Actual,5/31/2021,NA,Interventional,VCPM,NA,Virtual Pain Care Management (COVID-19),Virtual Pain Care for High Risk Veterans on Opioids During COVID19 (and Beyond),Completed,NA,Not Applicable,51,Actual,VA Office of Research and Development,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:05:55Z,2021-12-02T09:05:55Z
NCT04537949,NA,9/2/2020,NA,NA,6/23/2021,9/2/2020,9/3/2020,Actual,NA,NA,NA,NA,NA,NA,6/23/2021,6/25/2021,Actual,9-Sep-20,Actual,9/9/2020,Jun-21,6/30/2021,Feb-22,Anticipated,2/28/2022,12-Mar-21,Actual,3/12/2021,NA,Interventional,NA,NA,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults","Active, not recruiting",NA,Phase 1/Phase 2,96,Actual,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:07:07Z,2021-12-02T09:07:07Z
NCT04537351,NA,8/25/2020,NA,NA,5/18/2021,9/1/2020,9/3/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/20/2021,Actual,24-Aug-20,Actual,8/24/2020,May-21,5/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,MEND,NA,The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause,"A Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care With Respiratory Failure",Recruiting,NA,Phase 1/Phase 2,24,Anticipated,Cynata Therapeutics Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Data requests will be considered after the completion of the study. There is no specified end date.,"All reasonable requests for raw and analysed data that are not included in primary publications from this study may be available upon request and discretion from the Sponsor from the beginning to the trial. Data may be made available to active collaborators in the COVID-19 Stem Cell Treatment (CSCT) Group, subject to permission from the Sponsor and ethics approval if required. All other reasonable requests for raw and analysed data will be considered by the Sponsor. Data may be obtained upon permission from the Sponsor.",NA,Yes,"IPD relating to efficacy of MSCs in COVID-19 may be shared, subject to permission from Sponsor and ethics approval if required. All de-identified data collected during this study may be shared confidentially to contribute to meta-analysis of mesenchymal stem cell treatments for COVID-19. Request for IPD from this trial for other purposes will be considered by the Sponsor.",2021-12-02T09:07:50Z,2021-12-02T09:07:50Z
NCT04537962,NA,7/14/2020,NA,NA,5/5/2021,9/2/2020,9/3/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/10/2021,Actual,11-Jun-20,Actual,6/11/2020,Jun-20,6/30/2020,30-Aug-21,Anticipated,8/30/2021,30-Dec-20,Actual,12/30/2020,NA,Interventional,NA,NA,Salivary SARS-CoV-2 Load of Covid-19 Patients After Oral Antimicrobial Solutions and Dentifrices,AvaliaÃ§Ã£o da Carga do vÃ­rus SARS-CoV-2 na Cavidade Oral e na Saliva apÃ³s desinfecÃ§Ã£o Com soluÃ§Ãµes Antimicrobianas Orais e dentifrÃ­cios.,Enrolling by invitation,NA,Not Applicable,202,Anticipated,Hospital Israelita Albert Einstein,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:07:03Z,2021-12-02T09:07:03Z
NCT04537663,NA,8/28/2020,NA,NA,5/18/2021,9/2/2020,9/3/2020,Actual,NA,NA,NA,NA,NA,NA,5/18/2021,5/21/2021,Actual,25-Aug-20,Actual,8/25/2020,May-21,5/31/2021,25-Jul-21,Anticipated,7/25/2021,25-Jun-21,Anticipated,6/25/2021,NA,Interventional,BCG-PRIME,NA,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Bacillus Calmette-GuÃ©rin Vaccination To Prevent Serious Respiratory Tract Infection And Covid-19 In Vulnerable Elderly - An Adaptive Randomized Controlled Trial,Recruiting,NA,Phase 4,5200,Anticipated,UMC Utrecht,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:07:29Z,2021-12-02T09:07:29Z
NCT04537858,NA,8/29/2020,NA,NA,9/1/2020,9/1/2020,9/3/2020,Actual,NA,NA,NA,NA,NA,NA,9/1/2020,9/3/2020,Actual,18-Jun-20,Actual,6/18/2020,Sep-20,9/30/2020,1-Dec-20,Anticipated,12/1/2020,20-Aug-20,Actual,8/20/2020,NA,Interventional,NA,NA,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,Analysis of the Influence of Rehabilitation With Virtual Reality on the Heart Rate Variability of Individuals Under Treatment of COVID-19 in a Hospital Unit.,"Active, not recruiting",NA,Not Applicable,50,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:07:30Z,2021-12-02T09:07:30Z
NCT04537806,NA,9/1/2020,NA,NA,8/6/2021,9/1/2020,9/3/2020,Actual,NA,NA,NA,NA,NA,NA,8/6/2021,8/13/2021,Actual,18-Dec-20,Actual,12/18/2020,Aug-21,8/31/2021,1-Jul-21,Actual,7/1/2021,1-Jul-21,Actual,7/1/2021,NA,Interventional,NA,NA,A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19,A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19,Terminated,NA,Phase 3,29,Actual,Sage Therapeutics,,2,NA,Internal company decision,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.,2021-12-02T09:07:31Z,2021-12-02T09:07:31Z
NCT04537299,NA,9/1/2020,NA,NA,10/5/2021,9/1/2020,9/3/2020,Actual,NA,NA,NA,NA,NA,NA,10/5/2021,10/6/2021,Actual,Oct-21,Anticipated,10/31/2021,Oct-21,10/31/2021,Dec-23,Anticipated,12/31/2023,Dec-23,Anticipated,12/31/2023,NA,Interventional,COVID-FIS,NA,COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes,COVID-FIS: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes,Enrolling by invitation,NA,Phase 2,150,Anticipated,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:07:55Z,2021-12-02T09:07:55Z
NCT04536935,NA,8/22/2020,NA,NA,6/28/2021,8/27/2020,9/3/2020,Actual,NA,NA,NA,NA,NA,NA,6/28/2021,6/29/2021,Actual,30-Nov-20,Actual,11/30/2020,Jun-21,6/30/2021,20-Jun-21,Actual,6/20/2021,20-Jun-21,Actual,6/20/2021,NA,Interventional,NA,NA,Mobile Mental Health Apps for Suicide Prevention,"Acceptability, Usability and Effectiveness of Mental Health Apps for Suicide Prevention in Essential Workers and the Unemployed During SARS-CoV-2",Completed,NA,Not Applicable,3000,Actual,University of Washington,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:08:04Z,2021-12-02T09:08:04Z
NCT04536350,NA,8/21/2020,NA,NA,5/20/2021,9/1/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,5/20/2021,5/21/2021,Actual,18-May-21,Actual,5/18/2021,May-21,5/31/2021,Apr-22,Anticipated,4/30/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS,"Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial",Recruiting,NA,Phase 2,82,Anticipated,"Cantonal Hosptal, Baselland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:08:22Z,2021-12-02T09:08:22Z
NCT04536441,NA,8/26/2020,NA,NA,9/1/2020,9/1/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,9/1/2020,9/2/2020,Actual,1-Apr-20,Actual,4/1/2020,Sep-20,9/30/2020,30-Jun-20,Actual,6/30/2020,30-May-20,Actual,5/30/2020,NA,Interventional,NA,NA,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Effects of an Ultra-brief Online Mindfulness-based Intervention on Mental Health During the Coronavirus Disease (COVID-19) Outbreak in Malaysia: A Randomised Controlled Trial,Completed,NA,Not Applicable,161,Actual,Universiti Tunku Abdul Rahman,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"The data will be become available once the study is being published, for 5 years.",The data will be made available upon request to the corresponding author.,NA,Yes,NA,2021-12-02T09:08:22Z,2021-12-02T09:08:22Z
NCT04535869,NA,8/28/2020,NA,NA,2/22/2021,8/31/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,2/22/2021,2/24/2021,Actual,28-Dec-20,Actual,12/28/2020,Aug-20,8/31/2020,3-Sep-21,Anticipated,9/3/2021,1-Apr-21,Anticipated,4/1/2021,NA,Interventional,CCOVID-19,NA,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Recruiting,NA,Phase 3,50,Anticipated,Mansoura University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:08:50Z,2021-12-02T09:08:50Z
NCT04535856,NA,8/28/2020,NA,NA,1/25/2021,8/31/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,1/25/2021,1/27/2021,Actual,14-Nov-20,Actual,11/14/2020,Jan-21,1/31/2021,14-Jan-21,Actual,1/14/2021,14-Jan-21,Actual,1/14/2021,NA,Interventional,DW-MSC,NA,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled",Completed,NA,Phase 1,9,Actual,Ina-Respond,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:08:53Z,2021-12-02T09:08:53Z
NCT04535674,NA,8/31/2020,NA,NA,8/3/2021,9/1/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/4/2021,Actual,9-Oct-20,Actual,10/9/2020,Jul-21,7/31/2021,Dec-21,Anticipated,12/31/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,ASUNCTIS,NA,Asunercept in Patients With Severe COVID-19,"A Multicenter, Randomised, Controlled, Open Label Trial on the Efficacy and Safety of Asunercept for Patients With Severe COVID-19 Disease",Recruiting,NA,Phase 2,400,Anticipated,Apogenix AG,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:08:56Z,2021-12-02T09:08:56Z
NCT04536298,NA,8/27/2020,NA,NA,6/10/2021,9/1/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,6/10/2021,6/14/2021,Actual,28-Dec-20,Actual,12/28/2020,Jun-21,6/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,VIVID,NA,Vitamin D and COVID-19 Trial,"A Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons With Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household Members",Recruiting,NA,Phase 3,2700,Anticipated,Brigham and Women's Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Details will be provided at a later date.,2021-12-02T09:08:34Z,2021-12-02T09:08:34Z
NCT04536051,NA,9/1/2020,NA,NA,11/23/2020,9/1/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/23/2020,11/27/2020,Actual,2-Jun-20,Actual,6/2/2020,Sep-20,9/30/2020,Sep-21,Anticipated,9/30/2021,Sep-21,Anticipated,9/30/2021,NA,Interventional,NA,NA,A Study of a Candidate COVID-19 Vaccine (COV003),"A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine",Recruiting,NA,Phase 3,10300,Anticipated,University of Oxford,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:08:39Z,2021-12-02T09:08:39Z
NCT04535778,NA,8/12/2020,NA,NA,9/14/2021,9/1/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/21/2021,Actual,16-Nov-20,Actual,11/16/2020,Feb-21,2/28/2021,1-Jan-22,Anticipated,1/1/2022,1-Jul-21,Actual,7/1/2021,NA,Interventional,COMPASS,NA,COMPASS Study: an Online Cognitive-behavioural Therapy (CBT) Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic,Pilot RCT for COMPASS: an Online CBT Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic.,"Active, not recruiting",NA,Not Applicable,194,Actual,King's College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,The data will only be available on request.,NA,Yes,The data that support the findings of this study will be available on request from the corresponding author. The data will not be available publicly due to privacy or ethical restrictions.,2021-12-02T09:09:08Z,2021-12-02T09:09:08Z
NCT04535700,NA,8/27/2020,NA,NA,11/16/2020,9/1/2020,9/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/16/2020,11/17/2020,Actual,18-Sep-20,Actual,9/18/2020,Nov-20,11/30/2020,10-Apr-21,Anticipated,4/10/2021,10-Mar-21,Anticipated,3/10/2021,NA,Interventional,NA,NA,Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19,"Non-blinded, Randomized and Controlled Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19",Recruiting,NA,Phase 4,76,Anticipated,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:09:09Z,2021-12-02T09:09:09Z
NCT04535063,NA,8/29/2020,NA,NA,8/31/2020,8/29/2020,9/1/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2020,9/2/2020,Actual,18-Apr-20,Actual,4/18/2020,Aug-20,8/31/2020,25-Feb-21,Anticipated,2/25/2021,30-Dec-20,Anticipated,12/30/2020,NA,Interventional,NA,NA,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Recruiting,NA,Phase 3,200,Anticipated,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,we will to share results to compare data with other studies with convalescent plasma infusion in COVID 19 patients after finishing our study,2021-12-02T09:09:31Z,2021-12-02T09:09:31Z
NCT04535167,NA,8/21/2020,NA,NA,6/23/2021,8/31/2020,9/1/2020,Actual,NA,NA,NA,NA,NA,NA,6/23/2021,6/24/2021,Actual,9-Sep-20,Actual,9/9/2020,Jun-21,6/30/2021,7-Jun-21,Actual,6/7/2021,7-Jun-21,Actual,6/7/2021,NA,Interventional,NA,NA,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.","A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND MULTIPLE ASCENDING (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19",Completed,NA,Phase 1,26,Actual,Pfizer,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-02T09:09:23Z,2021-12-02T09:09:23Z
NCT04534790,NA,8/5/2020,NA,NA,2/8/2021,8/30/2020,9/1/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/9/2021,Actual,24-Jul-20,Actual,7/24/2020,Feb-21,2/28/2021,8-Jan-21,Actual,1/8/2021,12-Dec-20,Actual,12/12/2020,NA,Interventional,NA,NA,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,"Randomized Trial, Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia",Completed,NA,Not Applicable,30,Actual,Instituto Mexicano del Seguro Social,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:09:48Z,2021-12-02T09:09:48Z
NCT04534673,NA,4/20/2020,NA,NA,8/30/2020,8/30/2020,9/1/2020,Actual,NA,NA,NA,NA,NA,NA,8/30/2020,9/1/2020,Actual,5-Aug-20,Actual,8/5/2020,Aug-20,8/31/2020,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Pegylated Interferon Lambda for Treatment of COVID-19 Infection,Pegylated Interferon Lambda for Treatment of COVID-19 Infection- A Randomized Open Label Pilot Trial,Recruiting,NA,Phase 2,40,Anticipated,Soroka University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:09:49Z,2021-12-02T09:09:49Z
NCT04534725,NA,8/30/2020,NA,NA,8/11/2021,8/30/2020,9/1/2020,Actual,NA,NA,NA,NA,NA,NA,8/11/2021,8/12/2021,Actual,17-Dec-20,Actual,12/17/2020,Aug-21,8/31/2021,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,C-SMART,NA,COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;,COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART Study.,Recruiting,NA,Phase 3,2282,Anticipated,"Peter MacCallum Cancer Centre, Australia",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:09:51Z,2021-12-02T09:09:51Z
NCT04533399,NA,8/28/2020,NA,NA,10/30/2020,8/28/2020,8/31/2020,Actual,NA,NA,NA,NA,NA,NA,10/30/2020,11/2/2020,Actual,17-Aug-20,Actual,8/17/2020,Oct-20,10/31/2020,Nov-21,Anticipated,11/30/2021,Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,"A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Recruiting,NA,Phase 2,4400,Anticipated,Novavax,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:10:43Z,2021-12-02T09:10:43Z
NCT04533347,NA,8/28/2020,NA,NA,10/4/2021,8/28/2020,8/31/2020,Actual,NA,NA,NA,NA,NA,NA,10/4/2021,10/7/2021,Actual,19-Feb-21,Actual,2/19/2021,Sep-21,9/30/2021,28-Feb-22,Anticipated,2/28/2022,31-Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Tafenoquine in Patients With Mild to Moderate COVID-19,A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease,"Active, not recruiting",NA,Phase 2,275,Anticipated,60 Degrees Pharmaceuticals LLC,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:10:54Z,2021-12-02T09:10:54Z
NCT04532931,NA,8/26/2020,NA,NA,9/16/2021,8/28/2020,8/31/2020,Actual,NA,NA,NA,NA,NA,NA,9/16/2021,9/20/2021,Actual,3-Sep-20,Actual,9/3/2020,Sep-21,9/30/2021,23-Aug-21,Actual,8/23/2021,5-Aug-21,Actual,8/5/2021,NA,Interventional,NA,NA,COVID-19 Treatment in South Africa,"Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19",Completed,NA,Phase 2,192,Actual,Shin Poong Pharmaceutical Co. Ltd.,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:10:57Z,2021-12-02T09:10:57Z
NCT04532372,NA,8/25/2020,NA,NA,5/5/2021,8/27/2020,8/31/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/6/2021,Actual,23-Oct-20,Actual,10/23/2020,May-21,5/31/2021,18-Sep-22,Anticipated,9/18/2022,18-Sep-22,Anticipated,9/18/2022,NA,Interventional,NA,NA,Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,City of Hope Medical Center,,3,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:11:35Z,2021-12-02T09:11:35Z
NCT04532294,NA,8/27/2020,NA,NA,5/17/2021,8/27/2020,8/31/2020,Actual,NA,NA,NA,NA,NA,NA,5/17/2021,5/18/2021,Actual,8-Sep-20,Actual,9/8/2020,May-21,5/31/2021,13-Feb-21,Actual,2/13/2021,15-Jan-21,Actual,1/15/2021,NA,Interventional,NA,NA,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants","A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects",Completed,NA,Phase 1,18,Actual,BeiGene,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T09:11:38Z,2021-12-02T09:11:38Z
NCT04531774,NA,8/26/2020,NA,NA,10/14/2020,8/27/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2020,10/19/2020,Actual,28-Aug-20,Actual,8/28/2020,Oct-20,10/31/2020,1-Jun-21,Anticipated,6/1/2021,1-Jun-21,Anticipated,6/1/2021,NA,Interventional,NA,NA,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,Recruiting,NA,Not Applicable,160,Anticipated,University of Zurich,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,One year after conclusion of the study.,NA,NA,Yes,"We follow open science practices and will use open access journals and repositories to publish results, anonymized original data, and meta-data describing the data and procedures (e.g., study protocol, statistical codes, instructions concerning the use of the data) to ensure full transparency and reproducibility.",2021-12-02T09:11:59Z,2021-12-02T09:11:59Z
NCT04531618,NA,8/19/2020,NA,NA,8/28/2020,8/26/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,8/28/2020,8/31/2020,Actual,13-Aug-20,Actual,8/13/2020,Aug-20,8/31/2020,Dec-21,Anticipated,12/31/2021,Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Mother-infant Bonding During COVID-19,Promoting Mother-Infant Emotional Connection During the COVID-19 Pandemic: an Randomized Controlled Trial (RCT) of Virtual Family Nurture Intervention,Recruiting,NA,Not Applicable,280,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:12:12Z,2021-12-02T09:12:12Z
NCT04530435,NA,8/25/2020,NA,NA,7/22/2021,8/27/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/23/2021,Actual,6-Oct-20,Actual,10/6/2020,Jul-21,7/31/2021,1-Sep-21,Anticipated,9/1/2021,29-Mar-21,Actual,3/29/2021,NA,Interventional,PEP-CoV,NA,PEP Flute-selfcare in COVID-19,PEP Flute-selfcare to Prevent Respiratory Deterioration and Hospitalization Among COVID-19 Patients: a Randomized Trial,"Active, not recruiting",NA,Not Applicable,400,Anticipated,Bispebjerg Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:12:53Z,2021-12-02T09:12:53Z
NCT04530422,NA,8/26/2020,NA,NA,8/27/2020,8/27/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,8/27/2020,8/28/2020,Actual,15-Apr-20,Actual,4/15/2020,Aug-20,8/31/2020,23-Jul-20,Actual,7/23/2020,8-Jul-20,Actual,7/8/2020,NA,Interventional,NA,NA,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,NA,Phase 3,250,Actual,Almaza Military Fever Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:12:56Z,2021-12-02T09:12:56Z
NCT04530370,NA,8/26/2020,NA,NA,8/27/2020,8/27/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,8/27/2020,8/28/2020,Actual,29-May-20,Actual,5/29/2020,Aug-20,8/31/2020,1-Sep-20,Anticipated,9/1/2020,Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Recruiting,NA,Early Phase 1,30,Anticipated,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T09:13:04Z,2021-12-02T09:13:04Z
NCT04530617,NA,8/26/2020,NA,NA,6/15/2021,8/26/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2021,6/21/2021,Actual,5-Oct-20,Actual,10/5/2020,Aug-20,8/31/2020,10-Jun-21,Actual,6/10/2021,10-Jun-21,Actual,6/10/2021,NA,Interventional,NA,NA,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,"Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients",Terminated,NA,Phase 2,246,Actual,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,4,NA,Results from the interim analysis,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All IPD results in the publication,2021-12-02T09:13:00Z,2021-12-02T09:13:00Z
NCT04530656,NA,8/27/2020,NA,NA,2/8/2021,8/27/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,2/8/2021,2/11/2021,Actual,28-Aug-20,Actual,8/28/2020,Aug-20,8/31/2020,28-Aug-21,Anticipated,8/28/2021,28-Oct-20,Actual,10/28/2020,NA,Interventional,NA,NA,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),"Safety, Tolerability and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population Aged 18 Years and Older: A Phase I, Single-center, Randomized, Placebo-controlled, Double-blind Study","Active, not recruiting",NA,Phase 1,168,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:13:01Z,2021-12-02T09:13:01Z
NCT04530136,NA,8/26/2020,NA,NA,12/8/2020,8/26/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,12/8/2020,12/10/2020,Actual,30-Nov-20,Actual,11/30/2020,Aug-20,8/31/2020,30-Nov-21,Anticipated,11/30/2021,15-Aug-21,Anticipated,8/15/2021,NA,Interventional,NA,NA,Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,"Recombinant Human C1 Esterase Inhibitor (RuconestÂ®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)",Recruiting,NA,Phase 2,120,Anticipated,Pharming Technologies B.V.,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:13:14Z,2021-12-02T09:13:14Z
NCT04530448,NA,8/20/2020,NA,NA,8/4/2021,8/26/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/5/2021,Actual,5-Oct-20,Actual,10/5/2020,Aug-21,8/31/2021,Mar-22,Anticipated,3/31/2022,15-Jul-21,Actual,7/15/2021,NA,Interventional,NA,NA,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,"Active, not recruiting",NA,Phase 4,3,Actual,West Virginia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:12:47Z,2021-12-02T09:12:47Z
NCT04530396,NA,8/25/2020,NA,NA,1/20/2021,8/27/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,1/20/2021,1/22/2021,Actual,7-Sep-20,Actual,9/7/2020,Aug-20,8/31/2020,1-May-21,Anticipated,5/1/2021,1-May-21,Anticipated,5/1/2021,NA,Interventional,RESIST,NA,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-Ð¡oV-2 Infection Prophylactic Treatment","Active, not recruiting",NA,Phase 3,33758,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:12:51Z,2021-12-02T09:12:51Z
NCT04530578,NA,8/17/2020,NA,NA,8/27/2020,8/26/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,8/27/2020,8/31/2020,Actual,1-Jun-20,Actual,6/1/2020,Aug-20,8/31/2020,1-Jun-21,Anticipated,6/1/2021,30-Oct-20,Anticipated,10/30/2020,NA,Interventional,NEBUHEPA,NA,Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2),Recruiting,NA,Phase 4,200,Anticipated,"Clinica San Camilo, Argentina",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:12:52Z,2021-12-02T09:12:52Z
NCT04530357,NA,8/26/2020,NA,NA,5/1/2021,8/27/2020,8/28/2020,Actual,NA,NA,NA,NA,NA,NA,5/1/2021,5/4/2021,Actual,19-Sep-20,Actual,9/19/2020,Feb-21,2/28/2021,25-Apr-21,Actual,4/25/2021,25-Nov-20,Actual,11/25/2020,NA,Interventional,NA,NA,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-INÂ®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder",Completed,NA,Phase 1/Phase 2,244,Actual,Research Institute for Biological Safety Problems,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:13:10Z,2021-12-02T09:13:10Z
NCT04529525,NA,8/21/2020,NA,NA,7/4/2021,8/26/2020,8/27/2020,Actual,NA,NA,NA,NA,NA,NA,7/4/2021,7/7/2021,Actual,19-Aug-20,Actual,8/19/2020,Sep-20,9/30/2020,22-Feb-21,Actual,2/22/2021,22-Feb-21,Actual,2/22/2021,NA,Interventional,IVERCORCOVID19,NA,Ivermectin to Prevent Hospitalizations in COVID-19,"Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled",Completed,NA,Phase 2/Phase 3,501,Actual,Instituto de CardiologÃ­a de Corrientes,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:13:43Z,2021-12-02T09:13:43Z
NCT04529499,NA,8/19/2020,NA,NA,2/1/2021,8/26/2020,8/27/2020,Actual,NA,NA,NA,NA,NA,NA,2/1/2021,2/3/2021,Actual,20-Aug-20,Actual,8/20/2020,Sep-20,9/30/2020,31-Mar-21,Anticipated,3/31/2021,31-Mar-21,Anticipated,3/31/2021,NA,Interventional,NA,NA,Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,"A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients","Active, not recruiting",NA,Phase 3,780,Anticipated,Dr. Reddy's Laboratories Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:13:46Z,2021-12-02T09:13:46Z
NCT04528641,NA,8/19/2020,NA,NA,7/9/2021,8/25/2020,8/27/2020,Actual,NA,NA,NA,NA,NA,NA,7/9/2021,7/12/2021,Actual,10-Aug-20,Actual,8/10/2020,Aug-20,8/31/2020,19-May-21,Actual,5/19/2021,19-May-21,Actual,5/19/2021,NA,Interventional,NA,NA,GRAd-COV2 Vaccine Against COVID-19,"A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects",Completed,NA,Phase 1,90,Actual,ReiThera Srl,,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:14:13Z,2021-12-02T09:14:13Z
NCT04528368,NA,8/19/2020,NA,NA,8/4/2021,8/25/2020,8/27/2020,Actual,NA,NA,NA,NA,NA,NA,8/4/2021,8/6/2021,Actual,11-Dec-20,Actual,12/11/2020,Jan-21,1/31/2021,30-Jan-22,Anticipated,1/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Efficacy and Safety of Using Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Recruiting,NA,Phase 2,60,Anticipated,D'Or Institute for Research and Education,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:14:35Z,2021-12-02T09:14:35Z
NCT04528888,NA,8/21/2020,NA,NA,5/3/2021,8/25/2020,8/27/2020,Actual,NA,NA,NA,NA,NA,NA,5/3/2021,5/6/2021,Actual,25-Nov-20,Actual,11/25/2020,May-21,5/31/2021,30-Jul-21,Anticipated,7/30/2021,30-Jun-21,Anticipated,6/30/2021,NA,Interventional,STAUNCH-19,NA,Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection,"Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design",Recruiting,NA,Phase 3,210,Anticipated,University of Modena and Reggio Emilia,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,There is no plan to share individual participant data,2021-12-02T09:14:20Z,2021-12-02T09:14:20Z
NCT04528329,NA,8/24/2020,NA,NA,7/16/2021,8/26/2020,8/27/2020,Actual,NA,NA,NA,NA,NA,NA,7/16/2021,7/19/2021,Actual,30-Mar-21,Actual,3/30/2021,Jul-21,7/31/2021,15-Oct-21,Anticipated,10/15/2021,1-Sep-21,Anticipated,9/1/2021,NA,Interventional,NA,NA,Anosmia and / or Ageusia and Early Corticosteroid Use,"Anosmia and / or Ageusia in COVID-19: Timeline, Treatment With Early Corticosteroid and Recovery",Recruiting,NA,Phase 4,300,Anticipated,ClinAmygate,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:14:44Z,2021-12-02T09:14:44Z
NCT04527575,NA,8/11/2020,NA,NA,2/20/2021,8/25/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,2/20/2021,2/23/2021,Actual,27-Jul-20,Actual,7/27/2020,Feb-21,2/28/2021,May-21,Anticipated,5/31/2021,May-21,Anticipated,5/31/2021,NA,Interventional,EpiVacCorona,NA,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)","Active, not recruiting",NA,Phase 1/Phase 2,100,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:15:11Z,2021-12-02T09:15:11Z
NCT04527354,NA,8/24/2020,NA,NA,4/2/2021,8/24/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,4/2/2021,4/5/2021,Actual,1-Sep-20,Actual,9/1/2020,Mar-21,3/31/2021,10-Feb-21,Actual,2/10/2021,10-Feb-21,Actual,2/10/2021,NA,Interventional,NA,NA,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,"Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia",Completed,NA,Phase 2,60,Actual,PHARMENTERPRISES LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:15:14Z,2021-12-02T09:15:14Z
NCT04527432,NA,8/24/2020,NA,NA,5/5/2021,8/24/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,5/5/2021,5/6/2021,Actual,16-Dec-20,Actual,12/16/2020,May-21,5/31/2021,31-Mar-22,Anticipated,3/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,CHIP,NA,COVID-19 Health Professional Impact Study,"A Pilot Assessment of the COVID-19 Antibody Status and Associated Factors, in Individuals Employed by a Large Acute NHS Trust During the Coronavirus Pandemic","Active, not recruiting",NA,Not Applicable,1504,Actual,The Royal Wolverhampton Hospitals NHS Trust,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Results will be published in journal,2021-12-02T09:15:15Z,2021-12-02T09:15:15Z
NCT04527562,NA,8/25/2020,NA,NA,1/7/2021,8/25/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,1/7/2021,1/11/2021,Actual,14-Jul-20,Actual,7/14/2020,Jan-21,1/31/2021,10-Dec-20,Actual,12/10/2020,15-Nov-20,Actual,11/15/2020,NA,Interventional,COLCOVIDBD,NA,Colchicine in Moderate Symptomatic COVID-19 Patients,"Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy",Completed,NA,Not Applicable,299,Actual,Dhaka Medical College,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:15:01Z,2021-12-02T09:15:01Z
NCT04527471,NA,8/6/2020,NA,NA,4/19/2021,8/24/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,4/19/2021,4/20/2021,Actual,4-Sep-20,Actual,9/4/2020,Aug-20,8/31/2020,15-May-21,Anticipated,5/15/2021,15-Feb-21,Actual,2/15/2021,NA,Interventional,NA,NA,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19","Active, not recruiting",NA,Phase 2,45,Actual,Verona Pharma plc,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Verona Pharma will not be sharing individual deidentified participant data or other relevant study documents.,2021-12-02T09:15:03Z,2021-12-02T09:15:03Z
NCT05139433,NA,11/4/2021,NA,NA,11/17/2021,11/17/2021,12/1/2021,Estimate,NA,NA,NA,NA,NA,NA,11/17/2021,12/1/2021,Estimate,15-Oct-21,Actual,10/15/2021,Nov-21,11/30/2021,31-Mar-23,Anticipated,3/31/2023,31-Mar-23,Anticipated,3/31/2023,NA,Interventional,NA,NA,Brief Internet-delivered Intervention for Children and Adolescents With Anxiety and Depression Symptoms,Brief Internet-delivered Cognitive-behavioral Intervention for Children and Adolescents With Anxiety and Depression Symptoms During the COVID-19 Pandemic: a Randomized Clinical Trial,Recruiting,NA,Not Applicable,280,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:26:25Z,2021-12-02T09:26:25Z
NCT05139979,NA,9/23/2021,NA,NA,11/29/2021,11/29/2021,12/1/2021,Estimate,NA,NA,NA,NA,NA,NA,11/29/2021,12/1/2021,Estimate,15-Sep-21,Actual,9/15/2021,Nov-21,11/30/2021,31-Dec-23,Anticipated,12/31/2023,31-Dec-23,Anticipated,12/31/2023,NA,Interventional,NA,NA,Yogic Breathing and Guided Meditation for Long Covid Symptoms,Yogic Breathing and Guided Meditation for Long Covid Symptoms,Enrolling by invitation,NA,Not Applicable,68,Anticipated,Beth Israel Deaconess Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:25:58Z,2021-12-02T09:25:58Z
NCT05121701,NA,11/15/2021,NA,NA,11/30/2021,11/15/2021,11/16/2021,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/1/2021,Estimate,30-Nov-21,Actual,11/30/2021,Nov-21,11/30/2021,1-Mar-22,Anticipated,3/1/2022,15-Feb-22,Anticipated,2/15/2022,NA,Interventional,NA,NA,Covid-19 Pandemic and Use of Video Laryngoscopy,Airway Management During the Covid-19 Pandemic: A Comparison of Direct Laryngoscopy Versus Video Laryngoscopy,Recruiting,NA,Not Applicable,150,Anticipated,Van BÃ¶lge EÄŸitim ve AraÅŸtÄ±rma Hastanesi,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:27:59Z,2021-12-02T09:27:59Z
NCT05108584,NA,10/18/2021,NA,NA,11/18/2021,11/1/2021,11/5/2021,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,12/1/2021,Estimate,19-Nov-21,Actual,11/19/2021,Nov-21,11/30/2021,10-Feb-22,Anticipated,2/10/2022,4-Jan-22,Anticipated,1/4/2022,NA,Interventional,NA,NA,Intubation in Coronavirus Disease 19 With Level 3 PPE,The Intubation Procedure in COVID-19 Pandemic,Recruiting,NA,Not Applicable,39,Anticipated,Indonesia University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T09:28:09Z,2021-12-02T09:28:09Z
NCT05107479,NA,10/11/2021,NA,NA,11/18/2021,11/2/2021,11/4/2021,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,12/1/2021,Estimate,9-Nov-21,Actual,11/9/2021,Nov-21,11/30/2021,Jan-22,Anticipated,1/31/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Effectiveness of Interactive Voice Response for COVID-19 Vaccination Training in the Democratic Republic of the Congo,Effectiveness of Interactive Voice Response (IVR) for COVID-19 Vaccination Training of Frontline Health Workers: Experimental Evidence From the Democratic Republic of the Congo,"Active, not recruiting",NA,Not Applicable,8959,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-02T09:28:11Z,2021-12-02T09:28:11Z
NCT05080179,NA,10/12/2021,NA,NA,11/18/2021,10/13/2021,10/15/2021,Actual,NA,NA,NA,NA,NA,NA,11/18/2021,12/1/2021,Estimate,11-Dec-20,Actual,12/11/2020,Nov-21,11/30/2021,28-Jan-21,Actual,1/28/2021,28-Jan-21,Actual,1/28/2021,NA,Interventional,NA,NA,Impact of Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial,The Interactive Effect of Social Norm and Self (vs. Others) Benefit Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial,Completed,NA,Not Applicable,39937,Actual,University of Pennsylvania,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:28:59Z,2021-12-02T09:28:59Z
NCT05047601,NA,9/1/2021,NA,NA,11/29/2021,9/15/2021,9/17/2021,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,12/1/2021,Estimate,9-Sep-21,Actual,9/9/2021,Nov-21,11/30/2021,2-Mar-22,Anticipated,3/2/2022,2-Mar-22,Anticipated,3/2/2022,NA,Interventional,NA,NA,A Post-Exposure Prophylaxis Study of PF-07321332/Ritonavir in Adult Household Contacts of an Individual With Symptomatic COVID-19,"A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19",Recruiting,NA,Phase 3,2634,Anticipated,Pfizer,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-02T09:29:41Z,2021-12-02T09:29:41Z
NCT04844658,NA,4/12/2021,NA,NA,11/30/2021,4/12/2021,4/14/2021,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/1/2021,Estimate,17-Feb-21,Actual,2/17/2021,Nov-21,11/30/2021,29-Oct-21,Actual,10/29/2021,29-Oct-21,Actual,10/29/2021,NA,Interventional,NA,NA,"Covid-19, Hospitalized, PatIents, Nasafytol",A Comparative Randomized Clinical Trial on Covid-19 Positive Hospitalized Patients Treated With NASAFYTOL,Completed,NA,Not Applicable,51,Actual,Tilman S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:32:07Z,2021-12-02T09:32:07Z
NCT04583969,NA,10/9/2020,NA,NA,11/29/2021,10/9/2020,10/12/2020,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,12/1/2021,Estimate,19-Oct-20,Actual,10/19/2020,21-Jul-21,7/21/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults,Recruiting,NA,Phase 2,400,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-02T09:33:54Z,2021-12-02T09:33:54Z
NCT04516746,NA,8/17/2020,NA,NA,11/19/2021,8/17/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,12/1/2021,Estimate,28-Aug-20,Actual,8/28/2020,Nov-21,11/30/2021,14-Feb-23,Anticipated,2/14/2023,5-Mar-21,Actual,3/5/2021,NA,Interventional,NA,NA,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19","Active, not recruiting",NA,Phase 3,32459,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-02T09:34:20Z,2021-12-02T09:34:20Z
NCT04432272,NA,6/12/2020,11/12/2021,NA,11/29/2021,6/12/2020,6/16/2020,Actual,11/12/2021,11/22/2021,Actual,NA,NA,NA,11/29/2021,12/1/2021,Estimate,16-Jul-20,Actual,7/16/2020,Nov-21,11/30/2021,28-Nov-20,Actual,11/28/2020,13-Nov-20,Actual,11/13/2020,NA,Interventional,ABACCuS,NA,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Terminated,NA,Phase 2,54,Actual,William Beaumont Hospitals,,2,NA,"The EUA for CCP was updated by FDA, stipulating that only high titer units be used. This study required untitered units. The study became infeasible",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:34:55Z,2021-12-02T09:34:55Z
NCT04426695,NA,6/8/2020,NA,NA,11/29/2021,6/10/2020,6/11/2020,Actual,NA,NA,NA,NA,NA,NA,11/29/2021,12/1/2021,Estimate,11-Jun-20,Actual,6/11/2020,Nov-21,11/30/2021,22-Oct-21,Actual,10/22/2021,7-May-21,Actual,5/7/2021,NA,Interventional,NA,NA,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19","A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19",Completed,NA,Phase 1/Phase 2,2252,Actual,Regeneron Pharmaceuticals,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-12-02T09:34:58Z,2021-12-02T09:34:58Z
NCT04360096,NA,4/21/2020,NA,NA,11/30/2021,4/22/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/1/2021,Estimate,15-Feb-21,Actual,2/15/2021,Nov-21,11/30/2021,31-Dec-21,Anticipated,12/31/2021,15-Dec-21,Anticipated,12/15/2021,NA,Interventional,AVICOVID-2,NA,Inhaled ZYESAMIâ„¢ (Aviptadil Acetate) for the Treatment of Severe COVID-19,Inhaled ZYESAMIâ„¢ for the Treatment of Severe COVID-19,Recruiting,NA,Phase 2/Phase 3,144,Anticipated,"NeuroRx, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-02T09:35:15Z,2021-12-02T09:35:15Z
NCT04412486,NA,5/28/2020,NA,NA,11/30/2021,5/29/2020,6/2/2020,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/1/2021,Estimate,1-Jun-20,Actual,6/1/2020,Nov-21,11/30/2021,31-May-22,Anticipated,5/31/2022,31-May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma (CCP) Transfusion,An Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients With Moderate to Severe COVID-19,Recruiting,NA,Early Phase 1,100,Anticipated,University of Mississippi Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-02T09:35:03Z,2021-12-02T09:35:03Z
NCT04389294,NA,5/8/2020,NA,NA,2/10/2021,5/13/2020,5/15/2020,Actual,NA,NA,NA,NA,NA,NA,2/10/2021,2/11/2021,Actual,5-May-20,Actual,5/5/2020,Feb-21,2/28/2021,4-Sep-20,Actual,9/4/2020,16-Jun-20,Actual,6/16/2020,NA,Interventional,NA,NA,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020,Completed,NA,Not Applicable,143,Actual,"Hospital for Special Surgery, New York",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-03T00:50:25Z,2021-12-03T00:50:25Z
NCT04361344,NA,4/16/2020,NA,NA,2/2/2021,4/23/2020,4/24/2020,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/4/2021,Actual,19-May-20,Actual,5/19/2020,Feb-21,2/28/2021,25-Oct-20,Actual,10/25/2020,25-Oct-20,Actual,10/25/2020,NA,Interventional,MARNEVO-Covid,NA,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection - MARNEVO-Covid,Terminated,NA,Not Applicable,2,Actual,Centre Hospitalier de PAU,,NA,NA,objective of the study demonstrated by other research teams,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-03T01:12:26Z,2021-12-03T01:12:26Z
NCT05142514,NA,11/17/2021,NA,NA,12/1/2021,12/1/2021,12/2/2021,Estimate,NA,NA,NA,NA,NA,NA,12/1/2021,12/2/2021,Estimate,11-Nov-21,Actual,11/11/2021,Dec-21,12/31/2021,27-Jun-22,Anticipated,6/27/2022,27-Dec-21,Anticipated,12/27/2021,NA,Interventional,NA,NA,"Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)","A Phase IIb Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Candidate Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) in Adult Healthy Volunteers",Recruiting,NA,Phase 2,256,Anticipated,"Hipra Scientific, S.L.U",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T11:51:57Z,2021-12-03T11:51:57Z
NCT05142488,NA,11/30/2021,NA,NA,12/1/2021,12/1/2021,12/2/2021,Estimate,NA,NA,NA,NA,NA,NA,12/1/2021,12/2/2021,Estimate,9-Nov-21,Actual,11/9/2021,Dec-21,12/31/2021,30-Mar-23,Anticipated,3/30/2023,30-Mar-22,Anticipated,3/30/2022,NA,Interventional,NA,NA,Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine,"Study of Immunogenicity Equivalence After a Homologous Third Dose of Covid-19 (Recombinante) Vaccine, 6 Months After the Second Dose, Comparing Intervals of 8 and 12 Weeks Between the First Two Doses.",Recruiting,NA,Phase 4,662,Anticipated,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-03T11:51:58Z,2021-12-03T11:51:58Z
NCT05142319,NA,11/30/2021,NA,NA,11/30/2021,11/30/2021,12/2/2021,Estimate,NA,NA,NA,NA,NA,NA,11/30/2021,12/2/2021,Estimate,12-Oct-21,Actual,10/12/2021,Nov-21,11/30/2021,Apr-23,Anticipated,4/30/2023,Apr-23,Anticipated,4/30/2023,NA,Interventional,PRIBIVAC,NA,Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC],Heterologous Prime-boost-boost Vaccine Combinations for Long-term Humoral and Cellular Immunity Against COVID-19,Recruiting,NA,Phase 3,600,Anticipated,Tan Tock Seng Hospital,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,All study findings and documents will be regarded as confidential. The investigators and other study personnel must not disclose such information without prior written approval from the PI. Participant confidentiality will be strictly maintained to the extent possible under the law and local hospital policy. Identifiable information will be removed from any published data.,2021-12-03T11:52:09Z,2021-12-03T11:52:09Z
NCT05141058,NA,11/10/2021,NA,NA,11/30/2021,11/30/2021,12/2/2021,Estimate,NA,NA,NA,NA,NA,NA,11/30/2021,12/2/2021,Estimate,19-Oct-21,Actual,10/19/2021,Nov-21,11/30/2021,15-Dec-27,Anticipated,12/15/2027,1-Nov-25,Anticipated,11/1/2025,NA,Interventional,TONI,NA,T CELL THERAPY OPPOSING NOVEL COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS,T CELL THERAPY OPPOSING NOVEL COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS,Recruiting,NA,Phase 1,24,Anticipated,Children's National Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T11:53:15Z,2021-12-03T11:53:15Z
NCT05142553,NA,11/17/2021,NA,NA,12/1/2021,12/1/2021,12/2/2021,Estimate,NA,NA,NA,NA,NA,NA,12/1/2021,12/2/2021,Estimate,16-Nov-21,Actual,11/16/2021,Dec-21,12/31/2021,30-Nov-22,Anticipated,11/30/2022,7-Jan-22,Anticipated,1/7/2022,NA,Interventional,NA,NA,"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against the Virus That Cause COVID-19, Know as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) in Healthy Adults Volunteers Fully Vaccinated","A Phase IIb, Double-blind, Randomised, Active-controlled, Multi-centre, Non-inferiority Trial Followed by a Phase III, Single-arm, Open-label Trial, to Assess Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against the Virus That Cause COVID-19, Know as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)SARS-CoV-2, in Adults Fully Vaccinated Against COVID-19",Recruiting,NA,Phase 2,1075,Anticipated,"Hipra Scientific, S.L.U",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T11:51:56Z,2021-12-03T11:51:56Z
NCT05060978,NA,9/27/2021,NA,NA,11/21/2021,9/27/2021,9/29/2021,Actual,NA,NA,NA,NA,NA,NA,11/21/2021,12/2/2021,Estimate,10-Nov-21,Actual,11/10/2021,Nov-21,11/30/2021,Nov-22,Anticipated,11/30/2022,Jan-22,Anticipated,1/31/2022,NA,Interventional,NA,NA,Evaluation of the Effect of Two Online Interventions -Watch Your Weight During the Holidays Program and the Relative 5:2 Fasting- for the Prevention of Body Weight Gain at 8 Weeks in Mexican Adults in the Covid-19 Pandemic,Evaluation of the Effect of Two Online Interventions -Watch Your Weight During the Holidays Program and the Relative 5:2 Fasting- for the Prevention of Body Weight Gain at 8 Weeks in Mexican Adults in the Covid-19 Pandemic: A Pilot Three Arm Parallel-Group Randomized Controlled Trial,"Active, not recruiting",NA,Not Applicable,32,Actual,Universidad de Sonora,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-03T11:56:02Z,2021-12-03T11:56:02Z
NCT05040763,NA,9/8/2021,NA,NA,11/19/2021,9/8/2021,9/10/2021,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,12/2/2021,Estimate,10-Nov-21,Actual,11/10/2021,Nov-21,11/30/2021,31-May-22,Anticipated,5/31/2022,31-Mar-22,Anticipated,3/31/2022,NA,Interventional,NA,NA,Abbott ID NOW COVID-19,A Multi-Center Evaluation of Buccal Swabs With the Abbott ID NOW COVID-19 for Point-of-Care Detection SARS-CoV-2 in Pediatric Emergency Departments,Recruiting,NA,Not Applicable,2882,Anticipated,University of Calgary,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-03T11:56:25Z,2021-12-03T11:56:25Z
NCT05017493,NA,4/4/2021,9/21/2021,NA,11/30/2021,8/16/2021,8/24/2021,Actual,11/30/2021,12/2/2021,Estimate,NA,NA,NA,11/30/2021,12/2/2021,Estimate,1-Jul-20,Actual,7/1/2020,Nov-21,11/30/2021,8-Feb-21,Actual,2/8/2021,7-Dec-20,Actual,12/7/2020,NA,Interventional,NA,Both paitients who received and NOT received Xagrotin,"Treatment of Covid-19 With a Herbal Compound, Xagrotin","Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin",Completed,NA,Phase 1/Phase 2,661,Actual,Biomad AS,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T11:56:50Z,2021-12-03T11:56:50Z
NCT04960202,NA,7/10/2021,NA,NA,11/19/2021,7/10/2021,7/13/2021,Actual,NA,NA,NA,NA,NA,NA,11/19/2021,12/2/2021,Estimate,16-Jul-21,Actual,7/16/2021,Nov-21,11/30/2021,21-Apr-22,Anticipated,4/21/2022,9-Dec-21,Anticipated,12/9/2021,NA,Interventional,NA,NA,EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19,"AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS",Recruiting,NA,Phase 3,3000,Anticipated,Pfizer,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-12-03T11:57:34Z,2021-12-03T11:57:34Z
NCT04317040,NA,3/19/2020,9/28/2021,NA,10/13/2021,3/19/2020,3/20/2020,Actual,10/13/2021,10/15/2021,Actual,NA,NA,NA,10/13/2021,10/15/2021,Actual,24-Apr-20,Actual,4/24/2020,Oct-21,10/31/2021,20-Oct-20,Actual,10/20/2020,20-Oct-20,Actual,10/20/2020,NA,Interventional,SAC-COVID,All randomized participants.,CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007),"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Completed,NA,Phase 3,234,Actual,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-12-04T17:06:18Z,2021-12-04T17:06:18Z
NCT04590365,NA,5/28/2020,NA,NA,12/1/2021,10/15/2020,10/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/2/2021,Estimate,17-Dec-20,Actual,12/17/2020,Apr-21,4/30/2021,1-Dec-22,Anticipated,12/1/2022,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,ICE-COVID,NA,Carrageenan Nasal Spray for COVID-19 Prophylaxis,Efficacy of Carrageenan Nasal and Throat Spray for COVID-19 Prophylaxis - A Double Blind Randomised Placebo-controlled Trial,Recruiting,NA,Not Applicable,480,Anticipated,Swansea University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T12:01:13Z,2021-12-03T12:01:13Z
NCT04479358,NA,7/13/2020,NA,NA,12/1/2021,7/18/2020,7/21/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/2/2021,Estimate,10-Sep-20,Actual,9/10/2020,Dec-21,12/31/2021,1-Mar-23,Anticipated,3/1/2023,1-Mar-22,Anticipated,3/1/2022,NA,Interventional,COVIDOSE-2,NA,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,"COVIDOSE-2: A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive Ventilation",Recruiting,NA,Phase 2,332,Anticipated,University of Chicago,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,From 1 month following publication of data. Available indefinitely thereafter.,Proposals will need to be sent to study principal investigators. Requestors will need to sign a data access request form. Link to be determined.,NA,Yes,"Individual participant data that underlie the results of this article, after de-identification. Sharing period will be 1 month after data are published and available indefinitely thereafter. Researchers who provide methodologically sound proposals for the purposes of achieving stated aims in their proposal will be eligible for data-sharing.",2021-12-03T12:02:29Z,2021-12-03T12:02:29Z
NCT04374149,NA,4/20/2020,11/19/2021,NA,11/30/2021,5/2/2020,5/5/2020,Actual,11/30/2021,12/2/2021,Estimate,NA,NA,NA,11/30/2021,12/2/2021,Estimate,30-Apr-20,Actual,4/30/2020,Nov-21,11/30/2021,1-Dec-20,Actual,12/1/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,NA,NA,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)",Completed,NA,Phase 2,20,Actual,Prisma Health-Upstate,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Available April 2021 through December 2021,Data can be requested from the Principal Investigator via email and should include a description of the request and the associated project or use of the data.,NA,Yes,All individual participant date (IPD) that underlie results in a publication.,2021-12-03T12:03:23Z,2021-12-03T12:03:23Z
NCT04364763,NA,4/20/2020,NA,NA,11/30/2021,4/24/2020,4/28/2020,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/2/2021,Estimate,5-Aug-20,Actual,8/5/2020,Nov-21,11/30/2021,30-Jun-22,Anticipated,6/30/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),"A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)",Recruiting,NA,Phase 2,252,Anticipated,"Renibus Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T12:03:27Z,2021-12-03T12:03:27Z
NCT04363463,NA,4/22/2020,NA,NA,12/1/2021,4/24/2020,4/27/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2021,12/2/2021,Estimate,28-Aug-20,Actual,8/28/2020,Dec-21,12/31/2021,28-Aug-22,Anticipated,8/28/2022,28-Aug-22,Anticipated,8/28/2022,NA,Interventional,PROVID-19,NA,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Recruiting,NA,Not Applicable,268,Anticipated,Centre Hospitalier RÃ©gional d'OrlÃ©ans,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-03T12:03:28Z,2021-12-03T12:03:28Z
NCT04912921,NA,10/15/2020,NA,NA,11/30/2021,6/2/2021,6/3/2021,Actual,NA,NA,NA,NA,NA,NA,11/30/2021,12/2/2021,Estimate,20-Oct-20,Actual,10/20/2020,Nov-21,11/30/2021,May-22,Anticipated,5/31/2022,May-22,Anticipated,5/31/2022,NA,Interventional,NA,NA,Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19,Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19,Recruiting,NA,Not Applicable,60,Anticipated,Arizona State University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T11:58:10Z,2021-12-03T11:58:10Z
NCT04678843,NA,12/17/2020,NA,NA,11/26/2021,12/18/2020,12/22/2020,Actual,NA,NA,NA,NA,NA,NA,11/26/2021,12/2/2021,Estimate,9-Feb-21,Actual,2/9/2021,Nov-21,11/30/2021,Jan-22,Anticipated,1/31/2022,31-Jul-21,Actual,7/31/2021,NA,Interventional,vFBT,NA,Adapting and Adopting Highly Specialized Pediatric Eating Disorder Treatment to Virtual Care: Implementation Research for the COVID-19 Context and Beyond,Adapting and Adopting Highly Specialized Pediatric Eating Disorder Treatment to Virtual Care: Implementation Research for the COVID-19 Context and Beyond,"Active, not recruiting",NA,Early Phase 1,36,Anticipated,McMaster University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-03T12:00:17Z,2021-12-03T12:00:17Z
NCT04348500,NA,4/13/2020,11/23/2021,NA,11/30/2021,4/13/2020,4/16/2020,Actual,11/30/2021,12/2/2021,Estimate,NA,NA,NA,11/30/2021,12/2/2021,Estimate,28-Apr-20,Actual,4/28/2020,Nov-21,11/30/2021,30-Sep-20,Actual,9/30/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,NA,Enrolled patients who received the initial dose of the IP were analyzed.,Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19),A Phase II Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® (Anti-IL-6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection,Completed,NA,Phase 2,17,Actual,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-03T12:03:33Z,2021-12-03T12:03:33Z
NCT04347941,NA,4/8/2020,11/20/2021,NA,11/30/2021,4/14/2020,4/15/2020,Actual,11/30/2021,12/2/2021,Estimate,NA,NA,NA,11/30/2021,12/2/2021,Estimate,11-Jul-20,Actual,7/11/2020,Nov-21,11/30/2021,26-Jan-21,Actual,1/26/2021,26-Jan-21,Actual,1/26/2021,NA,Interventional,APPROVE-CARE,Patients with suspected or confirmed COVID-19 pneumonia requiring high flow nasal cannula oxygen were randomized to either awake prone positioning or standard of care. The primary outcome was the requirement for invasive mechanical or death post 28 days randomization.,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Terminated,NA,Not Applicable,24,Actual,University College Hospital Galway,,2,NA,"Enrollment for trial was terminated on January 26, 2021 after a third interim analysis demonstrated that a pre-defined statistical criteria for efficacy were met as part of meta-trial study of awake prone positioning.",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,up to 15 years post study,NA,NA,Yes,"Electronic Case report form following informed consent, all patient identification removed, and individual patient response to intervention will be shared.",2021-12-03T12:03:35Z,2021-12-03T12:03:35Z
NCT04331899,NA,3/27/2020,4/8/2021,NA,11/24/2021,4/1/2020,4/2/2020,Actual,4/19/2021,4/22/2021,Actual,NA,NA,NA,11/24/2021,11/30/2021,Estimate,25-Apr-20,Actual,4/25/2020,Nov-21,11/30/2021,6-May-21,Actual,5/6/2021,14-Aug-20,Actual,8/14/2020,NA,Interventional,COVID-Lambda,NA,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19",Completed,NA,Phase 2,120,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,The datasets generated and analyzed during the current study are permanently available in the Stanford Digital Repository,Full access,https://purl.stanford.edu/hc972ys6733,Yes,Sharing of generated and analyzed datasets.,2021-12-04T17:06:27Z,2021-12-04T17:06:27Z
NCT04347954,NA,4/13/2020,10/15/2021,NA,10/19/2021,4/13/2020,4/15/2020,Actual,10/19/2021,10/21/2021,Actual,NA,NA,NA,10/19/2021,10/21/2021,Actual,15-Aug-20,Actual,8/15/2020,Oct-21,10/31/2021,13-Dec-20,Actual,12/13/2020,13-Dec-20,Actual,12/13/2020,NA,Interventional,NA,Participants who received the allocated intervention and completed the study; participants with negative PCR nasal swab results at baseline or incomplete data were excluded.,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers,Completed,NA,Phase 1/Phase 2,47,Actual,Stanford University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:32Z,2021-12-04T17:06:32Z
NCT04349098,NA,4/14/2020,10/5/2021,NA,10/27/2021,4/14/2020,4/16/2020,Actual,10/27/2021,11/1/2021,Actual,NA,NA,NA,10/27/2021,11/1/2021,Actual,17-Apr-20,Actual,4/17/2020,Oct-21,10/31/2021,5-Oct-20,Actual,10/5/2020,5-Oct-20,Actual,10/5/2020,NA,Interventional,Coronavirus,PV 1-6 population included participants randomized into the study under protocol versions 1-6.,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Completed,NA,Phase 2,190,Actual,Karyopharm Therapeutics Inc,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-04T17:06:33Z,2021-12-04T17:06:33Z
NCT04353037,NA,4/9/2020,7/22/2021,NA,10/15/2021,4/15/2020,4/20/2020,Actual,10/15/2021,10/19/2021,Actual,NA,NA,NA,10/15/2021,10/19/2021,Actual,7-Apr-20,Actual,4/7/2020,Oct-21,10/31/2021,11-Jul-20,Actual,7/11/2020,11-Jul-20,Actual,7/11/2020,NA,Interventional,NA,All eligible randomized patients,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19,Terminated,NA,Phase 2,39,Actual,UnitedHealth Group,,2,NA,As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,1 year,NA,NA,Yes,Data will be collected and managed by Optumcare and UnitedHealth Group Research & Development. Redacted/aggregate data will be shared with the University Of Penn using approved data sharing protocols.,2021-12-04T17:06:35Z,2021-12-04T17:06:35Z
NCT04355767,NA,4/17/2020,10/13/2021,NA,10/15/2021,4/17/2020,4/21/2020,Actual,10/15/2021,10/19/2021,Actual,NA,NA,NA,10/15/2021,10/19/2021,Actual,11-Aug-20,Actual,8/11/2020,Oct-21,10/31/2021,29-Mar-21,Actual,3/29/2021,29-Mar-21,Actual,3/29/2021,NA,Interventional,C3PO,NA,Convalescent Plasma in Outpatients With COVID-19,Clinical-trial of COVID-19 Convalescent Plasma in Outpatients,Completed,NA,Phase 3,511,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will be available indefinitely.,"Data requests will be managed by National Heart, Lung, and Blood Institute (NHLBI).",https://biodatacatalyst.nhlbi.nih.gov/,Yes,The complete de-identified patient data set will be shared.,2021-12-04T17:06:38Z,2021-12-04T17:06:38Z
NCT04358068,NA,4/20/2020,2/24/2021,NA,11/12/2021,4/20/2020,4/22/2020,Actual,3/24/2021,4/1/2021,Actual,NA,NA,NA,11/12/2021,11/16/2021,Estimate,13-May-20,Actual,5/13/2020,Oct-21,10/31/2021,8-Jul-20,Actual,7/8/2020,8-Jul-20,Actual,7/8/2020,NA,Interventional,NA,Participants who initiated study treatment,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,"A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",Terminated,NA,Phase 2,20,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,Slow enrollment and lack of community enthusiasm,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom?

Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.

For what types of analyses?

To achieve aims in the proposal approved by the AIDS Clinical Trials Group.

By what mechanism will data be made available?

Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2021-12-04T17:06:41Z,2021-12-04T17:06:41Z
NCT04382053,NA,5/8/2020,11/15/2021,NA,11/25/2021,5/8/2020,5/11/2020,Actual,11/25/2021,11/30/2021,Estimate,NA,NA,NA,11/25/2021,11/30/2021,Estimate,27-May-20,Actual,5/27/2020,Nov-21,11/30/2021,24-Dec-20,Actual,12/24/2020,10-Dec-20,Actual,12/10/2020,NA,Interventional,NA,NA,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,143,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-12-04T17:06:49Z,2021-12-04T17:06:49Z
NCT04388826,NA,5/13/2020,10/20/2021,NA,11/22/2021,5/13/2020,5/14/2020,Actual,11/22/2021,11/24/2021,Estimate,NA,NA,NA,11/22/2021,11/24/2021,Estimate,18-Jun-20,Actual,6/18/2020,Nov-21,11/30/2021,13-Aug-21,Actual,8/13/2021,18-Dec-20,Actual,12/18/2020,NA,Interventional,NA,NA,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)",Completed,NA,Phase 2,39,Actual,Veru Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:50Z,2021-12-04T17:06:50Z
NCT04475588,NA,7/16/2020,8/2/2020,NA,6/10/2021,7/16/2020,7/17/2020,Actual,5/17/2021,5/20/2021,Actual,NA,NA,NA,6/10/2021,6/14/2021,Actual,1-May-20,Actual,5/1/2020,Jun-21,6/30/2021,7-Jul-20,Actual,7/7/2020,7-Jul-20,Actual,7/7/2020,NA,Interventional,NA,NA,Efficacy and Safety of Itolizumab in COVID-19 Complications,"A Multi-Centre, Open Label, Two Arm Randomized, Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications",Completed,NA,Phase 2,32,Actual,Biocon Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:27:41Z,2021-12-04T22:27:41Z
NCT04401293,NA,5/20/2020,10/29/2021,NA,11/17/2021,5/21/2020,5/26/2020,Actual,11/17/2021,11/22/2021,Estimate,NA,NA,NA,11/17/2021,11/22/2021,Estimate,26-Apr-20,Actual,4/26/2020,Nov-21,11/30/2021,14-May-21,Actual,5/14/2021,14-May-21,Actual,5/14/2021,NA,Interventional,NA,NA,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial),Completed,NA,Phase 3,257,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:56Z,2021-12-04T17:06:56Z
NCT04411628,NA,5/29/2020,11/1/2021,NA,11/10/2021,5/29/2020,6/2/2020,Actual,11/1/2021,11/9/2021,Actual,NA,NA,NA,11/10/2021,11/12/2021,Estimate,28-May-20,Actual,5/28/2020,Nov-21,11/30/2021,26-Aug-20,Actual,8/26/2020,26-Aug-20,Actual,8/26/2020,NA,Interventional,NA,All randomized participants who received at least one dose of study drug.,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19",Completed,NA,Phase 1,26,Actual,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:58Z,2021-12-04T17:06:58Z
NCT04418947,NA,5/29/2020,10/25/2021,NA,10/26/2021,6/2/2020,6/5/2020,Actual,10/26/2021,10/28/2021,Actual,NA,NA,NA,10/26/2021,10/28/2021,Actual,15-Jun-20,Actual,6/15/2020,Oct-21,10/31/2021,17-Jul-20,Actual,7/17/2020,17-Jul-20,Actual,7/17/2020,NA,Interventional,NA,NA,Project Resurgence Communication Trial,Comparison of the Effectiveness of Communication Strategies on the Return to In-Person Visits to a Medical Center After the Emergence of COVID-19: A Randomized Trial,Completed,NA,Not Applicable,11120,Actual,University of Pennsylvania,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:06:59Z,2021-12-04T17:06:59Z
NCT04497948,NA,6/16/2020,10/29/2021,NA,11/16/2021,7/31/2020,8/4/2020,Actual,10/29/2021,11/5/2021,Actual,NA,NA,NA,11/16/2021,11/17/2021,Estimate,21-Sep-20,Actual,9/21/2020,Nov-21,11/30/2021,18-Nov-20,Actual,11/18/2020,18-Nov-20,Actual,11/18/2020,NA,Interventional,NA,NA,Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,"An Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19",Terminated,NA,Phase 1,9,Actual,Acerta Pharma BV,,1,NA,"Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19 did not meet their primary efficacy endpoints.

Based on this higher management made the decision to prematurely terminate the D822FC00005 PK study.",FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-12-04T17:07:20Z,2021-12-04T17:07:20Z
NCT04501952,NA,8/5/2020,11/4/2021,NA,11/4/2021,8/5/2020,8/6/2020,Actual,11/4/2021,11/16/2021,Estimate,NA,NA,NA,11/4/2021,11/16/2021,Estimate,18-Sep-20,Actual,9/18/2020,Nov-21,11/30/2021,6-May-21,Actual,5/6/2021,6-May-21,Actual,5/6/2021,NA,Interventional,NA,Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,"A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of COVID-19 in an Outpatient Setting",Terminated,NA,Phase 3,584,Actual,Gilead Sciences,,2,NA,The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-12-04T17:07:23Z,2021-12-04T17:07:23Z
NCT04504032,NA,8/5/2020,9/29/2021,NA,10/20/2021,8/5/2020,8/7/2020,Actual,10/20/2021,10/22/2021,Actual,NA,NA,NA,10/20/2021,10/22/2021,Actual,2-Sep-20,Actual,9/2/2020,Oct-21,10/31/2021,29-Mar-21,Actual,3/29/2021,10-Mar-21,Actual,3/10/2021,NA,Interventional,NA,NA,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),"A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (XareltoÂ®) for High Risk People With Mild COVID-19",Terminated,NA,Phase 2,497,Actual,Bill & Melinda Gates Medical Research Institute,,2,NA,"Based on Data Monitoring Committee''s recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-12-04T17:07:25Z,2021-12-04T17:07:25Z
NCT04507867,NA,8/6/2020,9/22/2021,NA,10/13/2021,8/9/2020,8/11/2020,Actual,10/13/2021,10/15/2021,Actual,NA,NA,NA,10/13/2021,10/15/2021,Actual,7-Sep-20,Actual,9/7/2020,Oct-21,10/31/2021,10-Apr-21,Actual,4/10/2021,10-Apr-21,Actual,4/10/2021,NA,Interventional,NA,"all participants enrolled in the study, a total of 80 patients were compared.",Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Completed,NA,Not Applicable,80,Actual,Anahuac University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:07:28Z,2021-12-04T17:07:28Z
NCT04701658,NA,1/7/2021,11/11/2021,NA,11/11/2021,1/7/2021,1/8/2021,Actual,11/11/2021,11/16/2021,Estimate,NA,NA,NA,11/11/2021,11/16/2021,Estimate,1-Feb-21,Actual,2/1/2021,Nov-21,11/30/2021,22-Jun-21,Actual,6/22/2021,22-Jun-21,Actual,6/22/2021,NA,Interventional,BLAZE-5,All participants who received single dose of Bamlanivimab.,A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),"A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls",Completed,NA,Phase 2,109,Actual,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2021-12-04T17:07:54Z,2021-12-04T17:07:54Z
NCT04706416,NA,12/31/2020,10/27/2021,NA,11/2/2021,1/11/2021,1/12/2021,Actual,11/2/2021,11/4/2021,Actual,NA,NA,NA,11/2/2021,11/4/2021,Actual,14-Nov-20,Actual,11/14/2020,Nov-21,11/30/2021,15-Jan-21,Actual,1/15/2021,15-Jan-21,Actual,1/15/2021,NA,Interventional,NA,NA,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),Completed,NA,Phase 1,150,Actual,Quantinosis.ai LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"We will publish based on summary data, but make individual participant data available upon request. There are no plans to publish individual participant data.",2021-12-04T17:07:56Z,2021-12-04T17:07:56Z
NCT04502056,NA,8/2/2020,5/28/2021,NA,7/24/2021,8/4/2020,8/6/2020,Actual,7/24/2021,7/27/2021,Actual,NA,NA,NA,7/24/2021,7/27/2021,Actual,7-Aug-20,Actual,8/7/2020,Jul-21,7/31/2021,6-Sep-20,Actual,9/6/2020,6-Sep-20,Actual,9/6/2020,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Completed,NA,Not Applicable,20460,Actual,"National Bureau of Economic Research, Inc.",,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:27:27Z,2021-12-04T22:27:27Z
NCT04491994,NA,7/28/2020,7/31/2020,NA,8/18/2020,7/28/2020,7/30/2020,Actual,8/18/2020,8/21/2020,Actual,NA,NA,NA,8/18/2020,8/21/2020,Actual,10-Apr-20,Actual,4/10/2020,Aug-20,8/31/2020,31-May-20,Actual,5/31/2020,31-May-20,Actual,5/31/2020,NA,Interventional,COVID-19,sample size calculation was done and 540 patients enrolled,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Completed,NA,Phase 3,540,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,any time when asked,by email,NA,Yes,data can be shared on demand in SPSS sheet,2021-12-04T22:27:34Z,2021-12-04T22:27:34Z
NCT04491240,NA,7/27/2020,10/21/2020,NA,10/28/2020,7/27/2020,7/29/2020,Actual,10/28/2020,11/4/2020,Actual,NA,NA,NA,10/28/2020,11/4/2020,Actual,20-Jul-20,Actual,7/20/2020,Oct-20,10/31/2020,20-Oct-20,Actual,10/20/2020,1-Oct-20,Actual,10/1/2020,NA,Interventional,COVID-19EXO,NA,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia,Completed,NA,Phase 1/Phase 2,30,Actual,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:27:35Z,2021-12-04T22:27:35Z
NCT04420273,NA,6/3/2020,10/25/2021,NA,11/19/2021,6/5/2020,6/9/2020,Actual,11/19/2021,11/23/2021,Estimate,NA,NA,NA,11/19/2021,11/23/2021,Estimate,2-Jul-20,Actual,7/2/2020,Nov-21,11/30/2021,1-Mar-21,Actual,3/1/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,TMD,NA,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter,Completed,NA,Not Applicable,1000,Actual,Northwestern University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:07:01Z,2021-12-04T17:07:01Z
NCT04435184,NA,6/16/2020,11/3/2021,NA,11/3/2021,6/16/2020,6/17/2020,Actual,11/3/2021,11/9/2021,Actual,NA,NA,NA,11/3/2021,11/9/2021,Actual,9-Jul-20,Actual,7/9/2020,Nov-21,11/30/2021,4-Jan-21,Actual,1/4/2021,28-Nov-20,Actual,11/28/2020,NA,Interventional,CRITICAL,Baseline characteristics data was collected for the 42 participants who completed the study.,Crizanlizumab for Treating COVID-19 Vasculopathy,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,NA,Phase 2,54,Actual,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T17:07:07Z,2021-12-04T17:07:07Z
NCT04484207,NA,7/21/2020,10/12/2021,NA,10/26/2021,7/21/2020,7/23/2020,Actual,10/26/2021,10/28/2021,Actual,NA,NA,NA,10/26/2021,10/28/2021,Actual,6-Jul-20,Actual,7/6/2020,Oct-21,10/31/2021,26-Oct-20,Actual,10/26/2020,20-Oct-20,Actual,10/20/2020,NA,Interventional,NA,NA,Addressing COVID-19 Mental Health Problems Among US Veterans,Addressing COVID-19 Mental Health Problems Among US Veterans,Completed,NA,Not Applicable,172,Actual,"Research Foundation for Mental Hygiene, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,two months,Co-Is,NA,Yes,"Data will be shared as needed with investigators, IRB etc. A plan will be determined in the short future",2021-12-04T17:07:13Z,2021-12-04T17:07:13Z
NCT04492475,NA,7/28/2020,10/28/2021,NA,11/18/2021,7/28/2020,7/30/2020,Actual,11/18/2021,11/22/2021,Estimate,NA,NA,NA,11/18/2021,11/22/2021,Estimate,5-Aug-20,Actual,8/5/2020,Nov-20,11/30/2020,21-Dec-20,Actual,12/21/2020,21-Dec-20,Actual,12/21/2020,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)",Completed,NA,Phase 3,969,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T17:07:17Z,2021-12-04T17:07:17Z
NCT04523831,NA,8/19/2020,9/30/2020,NA,10/7/2020,8/20/2020,8/24/2020,Actual,10/7/2020,10/9/2020,Actual,NA,NA,NA,10/7/2020,10/9/2020,Actual,1-Jun-20,Actual,6/1/2020,Oct-20,10/31/2020,10-Sep-20,Actual,9/10/2020,22-Aug-20,Actual,8/22/2020,NA,Interventional,NA,We followed intention to treat analysis; SPSS (Statistical Package for Social Sciences) version 20 was used to analyze data. To compare mean of the two group chi square test was done.,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care,Completed,NA,Phase 3,400,Actual,Dhaka Medical College,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,September 2020 to December 2020,Person who are investigating covid-19 in various aspects,NA,Yes,"Patients age, sex, Date of covid positive report, Symtoms,Date of covid negative report, post covid symptoms, time to recover.",2021-12-04T22:27:19Z,2021-12-04T22:27:19Z
NCT04463004,NA,7/7/2020,8/4/2021,NA,8/4/2021,7/7/2020,7/9/2020,Actual,8/4/2021,8/11/2021,Actual,NA,NA,NA,8/4/2021,8/11/2021,Actual,2-Sep-20,Actual,9/2/2020,Aug-21,8/31/2021,30-Nov-20,Actual,11/30/2020,30-Nov-20,Actual,11/30/2020,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,2,Actual,Virginia Commonwealth University,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:27:48Z,2021-12-04T22:27:48Z
NCT04452435,NA,6/29/2020,3/24/2021,NA,6/21/2021,6/29/2020,6/30/2020,Actual,4/28/2021,4/30/2021,Actual,NA,NA,NA,6/21/2021,6/23/2021,Actual,21-Jul-20,Actual,7/21/2020,Jun-21,6/30/2021,13-Oct-20,Actual,10/13/2020,13-Oct-20,Actual,10/13/2020,NA,Interventional,NA,NA,Safety and Efficacy of C21 in Subjects With COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation",Completed,NA,Phase 2,206,Actual,Vicore Pharma AB,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:27:54Z,2021-12-04T22:27:54Z
NCT04411667,NA,5/29/2020,6/10/2021,NA,6/23/2021,6/1/2020,6/2/2020,Actual,6/23/2021,6/25/2021,Actual,NA,NA,NA,6/23/2021,6/25/2021,Actual,28-Apr-20,Actual,4/28/2020,Jun-21,6/30/2021,23-Jun-20,Actual,6/23/2020,23-Jun-20,Actual,6/23/2020,NA,Interventional,NA,NA,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,Completed,NA,Phase 4,34,Actual,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:13Z,2021-12-04T22:28:13Z
NCT04435808,NA,6/4/2020,8/10/2020,NA,11/12/2020,6/16/2020,6/17/2020,Actual,11/12/2020,11/16/2020,Actual,NA,NA,NA,11/12/2020,11/16/2020,Actual,14-Apr-20,Actual,4/14/2020,Nov-20,11/30/2020,15-Jul-20,Actual,7/15/2020,15-Jul-20,Actual,7/15/2020,NA,Interventional,NA,DSMB stopped the study,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Off Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2,Terminated,NA,Phase 1/Phase 2,1,Actual,University of New Mexico,,2,NA,Stopped for futility by DSMB,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:03Z,2021-12-04T22:28:03Z
NCT04409886,NA,5/27/2020,5/25/2021,NA,6/25/2021,5/28/2020,6/1/2020,Actual,6/25/2021,6/29/2021,Actual,NA,NA,NA,6/25/2021,6/29/2021,Actual,1-Jun-20,Actual,6/1/2020,Jun-21,6/30/2021,31-Jan-21,Actual,1/31/2021,31-Jan-21,Actual,1/31/2021,NA,Interventional,HBOT,NA,Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients,The Application of Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients - Randomized Controlled Trial,Terminated,NA,Phase 4,1,Actual,Maimonides Medical Center,,1,NA,"This study is part of a larger national study. Only 1 patient was enrolled at Maimonides; Medical Center. The study was ended by the sponsor because the PI left; funding ended; , and no time, or personnel to do the study",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will not be shared,2021-12-04T22:28:13Z,2021-12-04T22:28:13Z
NCT04407507,NA,5/27/2020,5/10/2021,NA,5/19/2021,5/27/2020,5/29/2020,Actual,5/19/2021,5/21/2021,Actual,NA,NA,NA,5/19/2021,5/21/2021,Actual,1-Jul-20,Actual,7/1/2020,May-21,5/31/2021,29-Jan-21,Actual,1/29/2021,29-Jan-21,Actual,1/29/2021,NA,Interventional,SILVERBULLET,NA,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms",Completed,NA,Phase 2,66,Actual,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:14Z,2021-12-04T22:28:14Z
NCT04402970,NA,5/20/2020,3/12/2021,NA,4/12/2021,5/22/2020,5/27/2020,Actual,4/12/2021,4/14/2021,Actual,NA,NA,NA,4/12/2021,4/14/2021,Actual,19-Jun-20,Actual,6/19/2020,Apr-21,4/30/2021,31-Dec-20,Actual,12/31/2020,31-Dec-20,Actual,12/31/2020,NA,Interventional,DORNASESARS2,NA,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,Completed,NA,Phase 3,30,Actual,University of Missouri-Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:16Z,2021-12-04T22:28:16Z
NCT04399980,NA,5/21/2020,5/6/2021,NA,5/11/2021,5/21/2020,5/22/2020,Actual,5/11/2021,5/13/2021,Actual,NA,NA,NA,5/11/2021,5/13/2021,Actual,20-May-20,Actual,5/20/2020,May-21,5/31/2021,23-Apr-21,Actual,4/23/2021,23-Apr-21,Actual,4/23/2021,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,40,Actual,The Cleveland Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:20Z,2021-12-04T22:28:20Z
NCT04410159,NA,5/27/2020,7/8/2020,NA,7/17/2020,5/28/2020,6/1/2020,Actual,7/17/2020,7/21/2020,Actual,NA,NA,NA,7/17/2020,7/21/2020,Actual,22-Jun-20,Actual,6/22/2020,Jul-20,7/31/2020,6-Jul-20,Actual,7/6/2020,29-Jun-20,Actual,6/29/2020,NA,Interventional,GARGLES,NA,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients",Completed,NA,Phase 2,20,Actual,Universiti Sains Islam Malaysia,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,September to December 2020,email to drnurul@usim.edu.my,NA,Yes,The participant data from the final research dataset used in the published manuscript will be shared upon reasonable request. The protocol and data analysis will be shared in clinicaltrial,2021-12-04T22:28:08Z,2021-12-04T22:28:08Z
NCT04422561,NA,6/6/2020,8/23/2020,NA,8/23/2020,6/6/2020,6/9/2020,Actual,8/23/2020,8/27/2020,Actual,NA,NA,NA,8/23/2020,8/27/2020,Actual,31-May-20,Actual,5/31/2020,Aug-20,8/31/2020,27-Jul-20,Actual,7/27/2020,14-Jul-20,Actual,7/14/2020,NA,Interventional,NA,NA,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Completed,NA,Phase 2/Phase 3,340,Actual,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:10Z,2021-12-04T22:28:10Z
NCT04421404,NA,6/3/2020,5/18/2021,NA,8/23/2021,6/5/2020,6/9/2020,Actual,8/23/2021,8/25/2021,Actual,NA,NA,NA,8/23/2021,8/25/2021,Actual,9-Jun-20,Actual,6/9/2020,Aug-21,8/31/2021,30-Apr-21,Actual,4/30/2021,30-Apr-21,Actual,4/30/2021,NA,Interventional,CAPRI,NA,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients,Completed,NA,Phase 2,34,Actual,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:11Z,2021-12-04T22:28:11Z
NCT04392219,NA,4/29/2020,6/15/2021,NA,7/15/2021,5/15/2020,5/18/2020,Actual,7/15/2021,7/19/2021,Actual,NA,NA,NA,7/15/2021,7/19/2021,Actual,10-Apr-20,Actual,4/10/2020,Jul-21,7/31/2021,11-Aug-20,Actual,8/11/2020,11-Aug-20,Actual,8/11/2020,NA,Interventional,NA,Safety population,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers",Completed,NA,Phase 1,130,Actual,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:25Z,2021-12-04T22:28:25Z
NCT04392141,NA,5/15/2020,11/25/2020,NA,4/16/2021,5/15/2020,5/18/2020,Actual,4/16/2021,4/20/2021,Actual,NA,NA,NA,4/16/2021,4/20/2021,Actual,1-Apr-20,Actual,4/1/2020,Apr-21,4/30/2021,1-Nov-20,Actual,11/1/2020,1-Nov-20,Actual,11/1/2020,NA,Interventional,NA,NA,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19,Completed,NA,Phase 1/Phase 2,120,Actual,Kermanshah University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:25Z,2021-12-04T22:28:25Z
NCT04401202,NA,5/21/2020,5/23/2021,NA,5/25/2021,5/22/2020,5/26/2020,Actual,5/25/2021,5/26/2021,Actual,NA,NA,NA,5/25/2021,5/26/2021,Actual,21-May-20,Actual,5/21/2020,May-21,5/31/2021,31-Dec-20,Actual,12/31/2020,31-Dec-20,Actual,12/31/2020,NA,Interventional,NA,NA,Nigella Sativa in COVID-19,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study",Completed,NA,Phase 2,183,Actual,King Abdulaziz University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-04T22:28:17Z,2021-12-04T22:28:17Z
NCT04372186,NA,4/29/2020,8/4/2021,NA,9/23/2021,4/29/2020,5/1/2020,Actual,9/23/2021,9/27/2021,Actual,NA,NA,NA,9/23/2021,9/27/2021,Actual,14-May-20,Actual,5/14/2020,Sep-21,9/30/2021,1-Dec-21,Anticipated,12/1/2021,18-Aug-20,Actual,8/18/2020,NA,Interventional,EMPACTA,"mITT population = all randomized participants who received study treatment, grouped according to the treatment assigned at randomization. Participants not receiving study treatment were excluded from analyses.",A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia","Active, not recruiting",NA,Phase 3,377,Actual,"Genentech, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-12-04T22:28:33Z,2021-12-04T22:28:33Z
NCT04371419,NA,4/28/2020,5/28/2021,NA,7/24/2021,4/28/2020,5/1/2020,Actual,7/24/2021,7/27/2021,Actual,NA,NA,NA,7/24/2021,7/27/2021,Actual,13-May-20,Actual,5/13/2020,Jul-21,7/31/2021,26-May-20,Actual,5/26/2020,24-May-20,Actual,5/24/2020,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Completed,NA,Not Applicable,14267,Actual,"National Bureau of Economic Research, Inc.",,17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Generally, social scientists post code and de-identified data when the findings are published","To be determined, if published alongside the paper data and code may be gated.",NA,Yes,"Generally, economists will post code and de-identified data when the findings are published",2021-12-04T22:28:34Z,2021-12-04T22:28:34Z
NCT04370834,NA,4/30/2020,5/28/2021,NA,7/16/2021,4/30/2020,5/1/2020,Actual,5/28/2021,6/4/2021,Actual,NA,NA,NA,7/16/2021,7/20/2021,Actual,28-May-20,Actual,5/28/2020,Jul-21,7/31/2021,14-Jan-21,Actual,1/14/2021,14-Jan-21,Actual,1/14/2021,NA,Interventional,NA,NA,Tocilizumab for Patients With Cancer and COVID-19 Disease,Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19),Terminated,NA,Phase 2,1,Actual,National Cancer Institute (NCI),,1,NA,Other - Randomized data no longer support continuation,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://grants.nih.gov/policy/sharing.htm,Yes,"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.",2021-12-04T22:28:35Z,2021-12-04T22:28:35Z
NCT04390022,NA,5/7/2020,12/9/2020,NA,12/10/2020,5/14/2020,5/15/2020,Actual,12/10/2020,12/17/2020,Actual,NA,NA,NA,12/10/2020,12/17/2020,Actual,31-Jul-20,Actual,7/31/2020,Dec-20,12/31/2020,9-Oct-20,Actual,10/9/2020,17-Sep-20,Actual,9/17/2020,NA,Interventional,SAINT,NA,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,Completed,NA,Phase 2,24,Actual,"Clinica Universidad de Navarra, Universidad de Navarra",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:26Z,2021-12-04T22:28:26Z
NCT04401579,NA,5/22/2020,2/25/2021,NA,4/22/2021,5/22/2020,5/26/2020,Actual,4/22/2021,4/26/2021,Actual,NA,NA,NA,4/22/2021,4/26/2021,Actual,8-May-20,Actual,5/8/2020,Apr-20,4/30/2020,31-Jul-20,Actual,7/31/2020,31-Jul-20,Actual,7/31/2020,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)",Completed,NA,Phase 3,1033,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:18Z,2021-12-04T22:28:18Z
NCT04365699,NA,4/25/2020,9/1/2021,NA,9/10/2021,4/25/2020,4/28/2020,Actual,9/10/2021,9/16/2021,Actual,NA,NA,NA,9/10/2021,9/16/2021,Actual,8-Apr-20,Actual,4/8/2020,Sep-21,9/30/2021,31-Jan-21,Actual,1/31/2021,31-Jan-21,Actual,1/31/2021,NA,Interventional,NA,NA,Cardiovascular Effects of COVID-19,A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection,Completed,NA,Phase 2,81,Actual,NYU Langone Health,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Beginning 9 months and ending 36 months following article publication,Requests may be directed to Stuart.Katz@nyulangone.org.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to Stuart.Katz@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-12-04T22:28:38Z,2021-12-04T22:28:38Z
NCT04365153,NA,4/24/2020,4/5/2021,NA,4/13/2021,4/24/2020,4/28/2020,Actual,4/13/2021,4/15/2021,Actual,NA,NA,NA,4/13/2021,4/15/2021,Actual,24-Apr-20,Actual,4/24/2020,Apr-21,4/30/2021,1-Apr-21,Actual,4/1/2021,2-Feb-21,Actual,2/2/2021,NA,Interventional,NA,NA,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation,Completed,NA,Phase 2,45,Actual,The Cleveland Clinic,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:38Z,2021-12-04T22:28:38Z
NCT04382066,NA,5/7/2020,8/2/2021,NA,9/22/2021,5/8/2020,5/11/2020,Actual,9/22/2021,9/24/2021,Actual,NA,NA,NA,9/22/2021,9/24/2021,Actual,12-May-20,Actual,5/12/2020,Sep-21,9/30/2021,26-Nov-20,Actual,11/26/2020,26-Nov-20,Actual,11/26/2020,NA,Interventional,APLICOV-PC,NA,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization",Completed,NA,Phase 1,46,Actual,PharmaMar,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Data of the final publication of the study will be shared upon request.,2021-12-04T22:28:30Z,2021-12-04T22:28:30Z
NCT04363736,NA,4/21/2020,7/30/2021,NA,8/26/2021,4/24/2020,4/27/2020,Actual,8/26/2021,8/30/2021,Actual,NA,NA,NA,8/26/2021,8/30/2021,Actual,5-May-20,Actual,5/5/2020,Aug-21,8/31/2021,12-Aug-20,Actual,8/12/2020,12-Aug-20,Actual,8/12/2020,NA,Interventional,MARIPOSA,NA,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia",Completed,NA,Phase 2,97,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-12-04T22:28:37Z,2021-12-04T22:28:37Z
NCT04380688,NA,5/7/2020,8/19/2021,NA,9/8/2021,5/7/2020,5/8/2020,Actual,9/8/2021,9/13/2021,Actual,NA,NA,NA,9/8/2021,9/13/2021,Actual,13-Jun-20,Actual,6/13/2020,Sep-21,9/30/2021,16-Nov-20,Actual,11/16/2020,16-Nov-20,Actual,11/16/2020,NA,Interventional,CALAVI US,NA,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,62,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",2021-12-04T22:28:31Z,2021-12-04T22:28:31Z
NCT04362813,NA,4/24/2020,7/30/2021,,8/12/2021,4/24/2020,4/27/2020,Actual,8/12/2021,8/16/2021,Actual,,,,8/12/2021,8/16/2021,Actual,30-Apr-20,Actual,4/30/2020,Aug-21,8/31/2021,22-Dec-20,Actual,12/22/2020,16-Sep-20,Actual,9/16/2020,NA,Interventional,CAN-COVID,"While patient flow and baseline measure tables show 454 participants enrolled, only 451 randomized. 3 were ""mis-randomized"" i.e. assigned a randomization number in error and not treated.",Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)",Completed,NA,Phase 3,454,Actual,Novartis,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-12-04T22:28:40Z,2021-12-04T22:28:40Z
NCT04346199,NA,4/9/2020,9/8/2021,NA,9/15/2021,4/14/2020,4/15/2020,Actual,9/8/2021,9/13/2021,Actual,NA,NA,NA,9/15/2021,9/17/2021,Actual,12-Jun-20,Actual,6/12/2020,Sep-21,9/30/2021,17-Nov-20,Actual,11/17/2020,17-Nov-20,Actual,11/17/2020,NA,Interventional,CALAVI,NA,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,177,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2021-12-04T22:28:49Z,2021-12-04T22:28:49Z
NCT04356937,NA,4/19/2020,6/23/2021,NA,7/23/2021,4/19/2020,4/22/2020,Actual,7/23/2021,7/27/2021,Actual,NA,NA,NA,7/23/2021,7/27/2021,Actual,20-Apr-20,Actual,4/20/2020,Jul-21,7/31/2021,27-Aug-20,Actual,8/27/2020,13-Jul-20,Actual,7/13/2020,NA,Interventional,NA,All randomized patients,Efficacy of Tocilizumab on Patients With COVID-19,Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19,Completed,NA,Phase 3,243,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Request for IPD can be submitted to PI for review,2021-12-04T22:28:43Z,2021-12-04T22:28:43Z
NCT04362137,NA,4/22/2020,4/15/2021,NA,10/7/2021,4/22/2020,4/24/2020,Actual,5/28/2021,6/2/2021,Actual,NA,NA,NA,10/7/2021,10/11/2021,Actual,2-May-20,Actual,5/2/2020,Oct-21,10/31/2021,17-Oct-20,Actual,10/17/2020,17-Oct-20,Actual,10/17/2020,NA,Interventional,RUXCOVID,NA,Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,NA,Phase 3,432,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-12-04T22:28:40Z,2021-12-04T22:28:40Z
NCT04354870,NA,4/16/2020,9/29/2021,NA,10/4/2021,4/16/2020,4/21/2020,Actual,10/4/2021,10/6/2021,Actual,NA,NA,NA,10/4/2021,10/6/2021,Actual,3-Apr-20,Actual,4/3/2020,Oct-21,10/31/2021,1-Oct-20,Actual,10/1/2020,15-Sep-20,Actual,9/15/2020,NA,Interventional,NA,NA,COVID-19 PrEP HCW HCQ Study,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2,Completed,NA,Phase 2,130,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Study internal to NYU at this time,2021-12-04T22:28:44Z,2021-12-04T22:28:44Z
NCT04345653,NA,4/8/2020,4/1/2021,NA,5/10/2021,4/13/2020,4/14/2020,Actual,5/5/2021,5/10/2021,Actual,NA,NA,NA,5/10/2021,5/12/2021,Actual,14-Apr-20,Actual,4/14/2020,May-21,5/31/2021,10-May-21,Actual,5/10/2021,5-Jun-20,Actual,6/5/2020,NA,Interventional,NA,High risk healthcare providers,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers",Completed,NA,Phase 2,48,Actual,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:49Z,2021-12-04T22:28:49Z
NCT04343261,NA,4/8/2020,9/1/2020,NA,9/22/2020,4/8/2020,4/13/2020,Actual,9/15/2020,9/17/2020,Actual,NA,NA,NA,9/22/2020,9/24/2020,Actual,10-Apr-20,Actual,4/10/2020,Sep-20,9/30/2020,13-Aug-20,Actual,8/13/2020,23-Jul-20,Actual,7/23/2020,NA,Interventional,NA,NA,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:50Z,2021-12-04T22:28:50Z
NCT04358081,NA,4/8/2020,3/8/2021,NA,10/7/2021,4/20/2020,4/22/2020,Actual,3/8/2021,3/17/2021,Actual,NA,NA,NA,10/7/2021,10/11/2021,Actual,1-May-20,Actual,5/1/2020,Oct-21,10/31/2021,27-Jul-20,Actual,7/27/2020,27-Jul-20,Actual,7/27/2020,NA,Interventional,NA,Full Analysis Set (FAS) was comprised of all participants to whom study treatment had been assigned by randomization excluding one mis-randomized participant.,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",Completed,NA,Phase 3,20,Actual,Novartis,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-12-04T22:28:42Z,2021-12-04T22:28:42Z
NCT04343092,NA,4/5/2020,6/11/2020,NA,11/2/2020,4/8/2020,4/13/2020,Actual,11/2/2020,11/4/2020,Actual,NA,NA,NA,11/2/2020,11/4/2020,Actual,18-Apr-20,Actual,4/18/2020,Nov-20,11/30/2020,1-Jun-20,Actual,6/1/2020,31-May-20,Actual,5/31/2020,NA,Interventional,NA,NA,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Completed,NA,Phase 1,16,Actual,University of Baghdad,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:51Z,2021-12-04T22:28:51Z
NCT04342663,NA,4/8/2020,7/1/2021,NA,7/7/2021,4/8/2020,4/13/2020,Actual,7/7/2021,7/9/2021,Actual,NA,NA,NA,7/7/2021,7/9/2021,Actual,10-Apr-20,Actual,4/10/2020,Jul-21,7/31/2021,12-Dec-20,Actual,12/12/2020,20-Aug-20,Actual,8/20/2020,NA,Interventional,STOP COVID,NA,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,NA,Phase 2,152,Actual,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:51Z,2021-12-04T22:28:51Z
NCT04342897,NA,4/10/2020,8/4/2021,NA,8/4/2021,4/10/2020,4/13/2020,Actual,8/4/2021,8/12/2021,Actual,NA,NA,NA,8/4/2021,8/12/2021,Actual,20-Apr-20,Actual,4/20/2020,Aug-21,8/31/2021,12-Oct-20,Actual,10/12/2020,12-Oct-20,Actual,10/12/2020,NA,Interventional,NA,All randomized participants who received at least 1 dose of study drug.,A Study of LY3127804 in Participants With COVID-19,"A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19",Terminated,NA,Phase 2,95,Actual,Eli Lilly and Company,,2,NA,Trial terminated for futility.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2021-12-04T22:28:51Z,2021-12-04T22:28:51Z
NCT04340557,NA,4/6/2020,5/20/2021,NA,5/24/2021,4/8/2020,4/9/2020,Actual,5/24/2021,5/26/2021,Actual,NA,NA,NA,5/24/2021,5/26/2021,Actual,27-Mar-20,Actual,3/27/2020,May-21,5/31/2021,13-Jun-20,Actual,6/13/2020,13-Jun-20,Actual,6/13/2020,NA,Interventional,NA,NA,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Completed,NA,Phase 4,31,Actual,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:52Z,2021-12-04T22:28:52Z
NCT04333225,NA,4/1/2020,8/2/2021,NA,8/18/2021,4/2/2020,4/3/2020,Actual,8/18/2021,8/20/2021,Actual,NA,NA,NA,8/18/2021,8/20/2021,Actual,3-Apr-20,Actual,4/3/2020,May-20,5/31/2020,30-Jun-20,Actual,6/30/2020,30-Jun-20,Actual,6/30/2020,NA,Interventional,NA,NA,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,Completed,NA,Phase 2,221,Actual,Baylor Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:58Z,2021-12-04T22:28:58Z
NCT04332991,NA,3/31/2020,2/9/2021,NA,3/12/2021,3/31/2020,4/3/2020,Actual,3/12/2021,3/17/2021,Actual,NA,NA,NA,3/12/2021,3/17/2021,Actual,2-Apr-20,Actual,4/2/2020,Mar-21,3/31/2021,23-Jul-20,Actual,7/23/2020,19-Jun-20,Actual,6/19/2020,NA,Interventional,ORCHID,NA,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,NA,Phase 3,479,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:58Z,2021-12-04T22:28:58Z
NCT04338009,NA,4/1/2020,1/28/2021,NA,4/7/2021,4/7/2020,4/8/2020,Actual,4/7/2021,4/9/2021,Actual,NA,NA,NA,4/7/2021,4/9/2021,Actual,31-Mar-20,Actual,3/31/2020,Apr-21,4/30/2021,20-Aug-20,Actual,8/20/2020,20-Aug-20,Actual,8/20/2020,NA,Interventional,REPLACECOVID,NA,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Completed,NA,Not Applicable,152,Actual,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Not making it available,2021-12-04T22:28:54Z,2021-12-04T22:28:54Z
NCT04338074,NA,4/6/2020,4/21/2021,NA,5/11/2021,4/6/2020,4/8/2020,Actual,5/11/2021,5/13/2021,Actual,NA,NA,NA,5/11/2021,5/13/2021,Actual,1-Jun-20,Actual,6/1/2020,May-21,5/31/2021,21-Apr-21,Actual,4/21/2021,21-Apr-21,Actual,4/21/2021,NA,Interventional,TCOutpatient,NA,TXA and Corona Virus 2019 (COVID19) in Outpatients,Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients,Terminated,NA,Phase 2,5,Actual,University of Alabama at Birmingham,,2,NA,Lack of recruitment,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:54Z,2021-12-04T22:28:54Z
NCT04329923,NA,3/30/2020,11/13/2020,NA,12/8/2020,3/30/2020,4/1/2020,Actual,12/8/2020,12/10/2020,Actual,NA,NA,NA,12/8/2020,12/10/2020,Actual,9-Apr-20,Actual,4/9/2020,Dec-20,12/31/2020,13-Nov-20,Actual,11/13/2020,11-Nov-20,Actual,11/11/2020,NA,Interventional,PATCH,All randomized patients,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,NA,Phase 2,173,Actual,University of Pennsylvania,,6,NA,Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met pre-specificied futility analysis at planned second interim analysis,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,One year after study completion,Open access,NA,Yes,We will publish our results in a peer-reviewed journal and make available de-identified data for additional analysis,2021-12-04T22:29:04Z,2021-12-04T22:29:04Z
NCT04328467,NA,3/27/2020,6/25/2021,NA,6/30/2021,3/30/2020,3/31/2020,Actual,6/25/2021,6/30/2021,Actual,NA,NA,NA,6/30/2021,7/2/2021,Actual,6-Apr-20,Actual,4/6/2020,Jun-21,6/30/2021,13-Jul-20,Actual,7/13/2020,13-Jul-20,Actual,7/13/2020,NA,Interventional,NA,NA,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1483,Actual,University of Minnesota,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-12-04T22:29:05Z,2021-12-04T22:29:05Z
NCT04327388,NA,3/26/2020,4/28/2021,NA,5/11/2021,3/26/2020,3/31/2020,Actual,5/11/2021,5/13/2021,Actual,NA,NA,NA,5/11/2021,5/13/2021,Actual,28-Mar-20,Actual,3/28/2020,May-21,5/31/2021,2-Sep-20,Actual,9/2/2020,31-Jul-20,Actual,7/31/2020,NA,Interventional,NA,Analysis was performed on randomized population.,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Completed,NA,Phase 3,420,Actual,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-12-04T22:29:05Z,2021-12-04T22:29:05Z
NCT04332081,NA,3/30/2020,6/14/2021,NA,6/16/2021,4/1/2020,4/2/2020,Actual,6/16/2021,6/22/2021,Actual,NA,NA,NA,6/16/2021,6/22/2021,Actual,6-Apr-20,Actual,4/6/2020,Jun-21,6/30/2021,29-May-20,Actual,5/29/2020,29-May-20,Actual,5/29/2020,NA,Interventional,NA,NA,Hyperbaric Oxygen for COVID-19 Patients,Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19,Terminated,NA,Not Applicable,80,Actual,NYU Langone Health,,2,NA,The IRB has determined that the design of this trial should be changed to a randomized controlled trial. A new record will be created for the redesigned study.,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,Immediately following publication. No end date.,"Requests should be directed to David.Lee@nyulangone.org and Scott.Gorenstein@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be made available immediately following publication, upon reasonable request by an investigator who proposes to use the data.",2021-12-04T22:29:01Z,2021-12-04T22:29:01Z
NCT04322682,NA,3/23/2020,8/10/2021,NA,9/3/2021,3/25/2020,3/26/2020,Actual,9/3/2021,9/8/2021,Actual,NA,NA,NA,9/3/2021,9/8/2021,Actual,23-Mar-20,Actual,3/23/2020,Sep-21,9/30/2021,21-Jan-21,Actual,1/21/2021,21-Jan-21,Actual,1/21/2021,NA,Interventional,COVID-19,Characteristics of the patients at randomisation in the intent-to-treat population.,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Terminated,NA,Phase 3,4506,Actual,Montreal Heart Institute,,2,NA,"Due to several considerations (logistical, human and budgetary), the study was stopped early.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:29:07Z,2021-12-04T22:29:07Z
NCT04322396,NA,3/23/2020,6/15/2021,NA,6/28/2021,3/24/2020,3/26/2020,Actual,6/24/2021,6/28/2021,Actual,NA,NA,NA,6/28/2021,6/29/2021,Actual,6-Apr-20,Actual,4/6/2020,Jun-21,6/30/2021,2-Feb-21,Actual,2/2/2021,2-Feb-21,Actual,2/2/2021,NA,Interventional,ProPAC-COVID,NA,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,"Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19",Terminated,NA,Phase 2,117,Actual,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",,2,NA,Recommended by the DSMB,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:29:08Z,2021-12-04T22:29:08Z
NCT04335136,NA,4/1/2020,6/7/2021,NA,7/29/2021,4/3/2020,4/6/2020,Actual,7/29/2021,8/2/2021,Actual,NA,NA,NA,7/29/2021,8/2/2021,Actual,30-Apr-20,Actual,4/30/2020,Jul-21,7/31/2021,26-Dec-20,Actual,12/26/2020,26-Dec-20,Actual,12/26/2020,NA,Interventional,APN01-COVID-19,All randomized patients who received at least 1 dose of investigational medicinal product (IMP).,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,NA,Phase 2,185,Actual,Apeiron Biologics,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:28:56Z,2021-12-04T22:28:56Z
NCT04335552,NA,4/3/2020,5/3/2021,NA,5/13/2021,4/3/2020,4/6/2020,Actual,5/3/2021,5/12/2021,Actual,NA,NA,NA,5/13/2021,5/17/2021,Actual,17-Apr-20,Actual,4/17/2020,May-21,5/31/2021,26-Jun-20,Actual,6/26/2020,17-Jun-20,Actual,6/17/2020,NA,Interventional,NA,NA,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,NA,Phase 2,11,Actual,Duke University,,4,NA,"Poor recruitment, strong evidence from larger trials of no therapeutic benefit",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:56Z,2021-12-04T22:28:56Z
NCT04334876,NA,4/2/2020,7/19/2021,NA,9/10/2021,4/2/2020,4/6/2020,Actual,9/10/2021,9/16/2021,Actual,NA,NA,NA,9/10/2021,9/16/2021,Actual,1-Apr-20,Actual,4/1/2020,Sep-21,9/30/2021,1-Jan-21,Actual,1/1/2021,1-Nov-20,Actual,11/1/2020,NA,Interventional,COVID-Antibody,NA,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers and Candidacy for Convalescent Plasma Therapy/Prophylaxis,Completed,NA,Not Applicable,571,Actual,Indiana University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-12-04T22:28:57Z,2021-12-04T22:28:57Z
NCT04320615,NA,3/23/2020,6/23/2021,NA,6/28/2021,3/23/2020,3/25/2020,Actual,6/28/2021,6/30/2021,Actual,NA,NA,NA,6/28/2021,6/30/2021,Actual,3-Apr-20,Actual,4/3/2020,Jun-21,6/30/2021,28-Jul-20,Actual,7/28/2020,24-Jun-20,Actual,6/24/2020,NA,Interventional,COVACTA,NA,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,452,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.

Further details on Roche's criteria for eligible studies are available here: https://vivli.org.

For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2021-12-04T22:29:09Z,2021-12-04T22:29:09Z
NCT04332107,NA,3/30/2020,8/9/2021,NA,10/5/2021,4/1/2020,4/2/2020,Actual,8/31/2021,9/9/2021,Actual,NA,NA,NA,10/5/2021,10/7/2021,Actual,22-May-20,Actual,5/22/2020,Oct-21,10/31/2021,30-Mar-21,Actual,3/30/2021,16-Mar-21,Actual,3/16/2021,NA,Interventional,ACTION,A single participant in the Azithromycin group did not have baseline symptom information.,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19,Terminated,NA,Phase 3,263,Actual,"University of California, San Francisco",,2,NA,Futility,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-12-04T22:29:02Z,2021-12-04T22:29:02Z
NCT04292899,NA,2/28/2020,12/15/2020,NA,12/15/2020,2/28/2020,3/3/2020,Actual,12/15/2020,12/31/2020,Actual,NA,NA,NA,12/15/2020,12/31/2020,Actual,6-Mar-20,Actual,3/6/2020,Dec-20,12/31/2020,30-Jun-20,Actual,6/30/2020,9-Apr-20,Actual,4/9/2020,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment.

Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into part B of the study and received at least 1 dose of study treatment.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Completed,NA,Phase 3,4891,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-12-04T22:29:24Z,2021-12-04T22:29:24Z
NCT04308668,NA,3/11/2020,4/26/2021,NA,5/11/2021,3/11/2020,3/16/2020,Actual,5/11/2021,5/13/2021,Actual,NA,NA,NA,5/11/2021,5/13/2021,Actual,17-Mar-20,Actual,3/17/2020,May-21,5/31/2021,20-May-20,Actual,5/20/2020,20-May-20,Actual,5/20/2020,NA,Interventional,COVID-19 PEP,NA,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1312,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,Yes,De-identified dataset will be available within 1 month of publication.,2021-12-04T22:29:18Z,2021-12-04T22:29:18Z
NCT04315298,NA,3/15/2020,7/23/2021,NA,9/16/2021,3/17/2020,3/19/2020,Actual,9/16/2021,9/23/2021,Actual,NA,NA,NA,9/16/2021,9/23/2021,Actual,18-Mar-20,Actual,3/18/2020,Sep-21,9/30/2021,2-Sep-20,Actual,9/2/2020,24-Jul-20,Actual,7/24/2020,NA,Interventional,NA,NA,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Completed,NA,Phase 2/Phase 3,1912,Actual,Regeneron Pharmaceuticals,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All IPD that underlie publicly available results will be considered for sharing,2021-12-04T22:29:12Z,2021-12-04T22:29:12Z
NCT04292730,NA,2/28/2020,12/15/2020,NA,1/21/2021,2/28/2020,3/3/2020,Actual,1/21/2021,1/26/2021,Actual,NA,NA,NA,1/21/2021,1/26/2021,Actual,15-Mar-20,Actual,3/15/2020,Jan-21,1/31/2021,26-Jun-20,Actual,6/26/2020,29-Apr-20,Actual,4/29/2020,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group).

Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Completed,NA,Phase 3,1113,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-12-04T22:29:25Z,2021-12-04T22:29:25Z
NCT04280705,NA,2/20/2020,9/16/2020,NA,12/5/2020,2/20/2020,2/21/2020,Actual,9/22/2020,9/25/2020,Actual,NA,NA,NA,12/5/2020,12/9/2020,Actual,21-Feb-20,Actual,2/21/2020,Apr-20,4/30/2020,21-May-20,Actual,5/21/2020,21-May-20,Actual,5/21/2020,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,1062,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-12-04T22:29:29Z,2021-12-04T22:29:29Z
NCT04526990,NA,8/22/2020,NA,NA,1/21/2021,8/22/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,1/21/2021,1/22/2021,Actual,15-Sep-20,Actual,9/15/2020,Dec-20,12/31/2020,30-Jan-22,Anticipated,1/30/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,"A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase â…¢ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,40000,Anticipated,CanSino Biologics Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:18Z,2021-10-12T06:56:18Z
NCT04525820,NA,8/17/2020,NA,NA,9/20/2021,8/24/2020,8/25/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/21/2021,Actual,15-Dec-20,Actual,12/15/2020,Sep-21,9/30/2021,30-Nov-21,Anticipated,11/30/2021,30-Aug-21,Actual,8/30/2021,NA,Interventional,VitCov,NA,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study","High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study","Active, not recruiting",NA,Not Applicable,80,Actual,"Cantonal Hosptal, Baselland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:27Z,2021-10-12T06:56:27Z
NCT04527081,NA,8/24/2020,NA,NA,10/1/2021,8/24/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,10/1/2021,10/4/2021,Actual,31-Aug-20,Actual,8/31/2020,Oct-21,10/31/2021,24-Sep-21,Actual,9/24/2021,9-Nov-20,Actual,11/9/2020,NA,Interventional,NA,NA,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:20Z,2021-10-12T06:56:20Z
NCT04525378,NA,7/31/2020,NA,NA,8/24/2020,8/22/2020,8/25/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2020,8/26/2020,Actual,1-Jul-20,Actual,7/1/2020,Aug-20,8/31/2020,31-Oct-20,Anticipated,10/31/2020,30-Sep-20,Anticipated,9/30/2020,NA,Interventional,NA,NA,MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,Mesenchymal Stromal Cell-based Therapy for COVID-19-associated Acute Respiratory Distress Syndrome: a Pilot Clinical Study,Recruiting,NA,Phase 1,20,Anticipated,D'Or Institute for Research and Education,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:33Z,2021-10-12T06:56:33Z
NCT04526145,NA,8/10/2020,NA,NA,9/14/2021,8/20/2020,8/25/2020,Actual,NA,NA,NA,NA,NA,NA,9/14/2021,9/16/2021,Actual,1-May-21,Actual,5/1/2021,Sep-21,9/30/2021,30-Jan-23,Anticipated,1/30/2023,1-Dec-22,Anticipated,12/1/2022,NA,Interventional,OUR-Project,NA,OUR Stress/ Emotion Management for Black/African American Women With Hypertension,Operating Under Resilience (OUR) Project: Stress and Emotion Management for Black/African American Women With Hypertension In a Covid--19 Social Distancing Society,Recruiting,NA,Not Applicable,30,Anticipated,Ohio State University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:27Z,2021-10-12T06:56:27Z
NCT04522466,NA,8/19/2020,NA,NA,9/4/2020,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,9/4/2020,9/7/2020,Actual,3-Apr-20,Actual,4/3/2020,Sep-20,9/30/2020,28-May-20,Actual,5/28/2020,28-May-20,Actual,5/28/2020,NA,Interventional,PREAVIS,NA,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Terminated,NA,Phase 3,7,Actual,Centre Hospitalier Universitaire de Saint Etienne,,1,NA,Stop of the study by competent authority (ANSM),FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:53Z,2021-10-12T06:56:53Z
NCT04527133,NA,8/24/2020,NA,NA,8/25/2020,8/25/2020,8/26/2020,Actual,NA,NA,NA,NA,NA,NA,8/25/2020,8/26/2020,Actual,11-Jun-20,Actual,6/11/2020,Aug-20,8/31/2020,31-Aug-20,Anticipated,8/31/2020,11-Aug-20,Actual,8/11/2020,NA,Interventional,NA,NA,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,"Active, not recruiting",NA,Not Applicable,30,Actual,Aviron LLC,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,not planned,2021-10-12T06:56:20Z,2021-10-12T06:56:20Z
NCT04525742,NA,6/28/2020,NA,NA,10/31/2020,8/23/2020,8/25/2020,Actual,NA,NA,NA,NA,NA,NA,10/31/2020,11/3/2020,Actual,5-Jul-20,Actual,7/5/2020,Oct-20,10/31/2020,15-Sep-20,Actual,9/15/2020,30-Aug-20,Actual,8/30/2020,NA,Interventional,NA,NA,COVID-19 Pandemic and Parents of Disabled Children,COVID-19 Pandemic From the Perspective of Parents of Disabled Children,Completed,NA,Not Applicable,309,Actual,Gaziosmanpasa Research and Education Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Research is planned to bu conducted between June 15 th and July 15 th 2020. After 15 th of July in 1 week coming statistical analysis will be finished and than in 3 weeks article will be written,In necessary cases colleced data from the research will be shared with the local ethical committe,NA,Yes,Study protocol was established by Berrin Huner and Ebru Yilmaz YalcÄ±nkaya Statistical analysis (Power analysis) was established by Ozden Ozyemisci Taskiran Informed consent was written by Berrin Huner,2021-10-12T06:56:29Z,2021-10-12T06:56:29Z
NCT04525417,NA,8/21/2020,NA,NA,2/2/2021,8/22/2020,8/25/2020,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/3/2021,Actual,25-Apr-20,Actual,4/25/2020,Aug-20,8/31/2020,25-Oct-20,Actual,10/25/2020,25-Sep-20,Actual,9/25/2020,NA,Interventional,NA,NA,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Use of Rapid Covid-19 Antibody Test Marketed by AAZ Laboratories in Healthcare Workers Presumably Being Infected by SARS-CoV-2,Completed,NA,Not Applicable,75,Actual,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:30Z,2021-10-12T06:56:30Z
NCT04526054,NA,8/3/2020,NA,NA,10/1/2020,8/21/2020,8/25/2020,Actual,NA,NA,NA,NA,NA,NA,10/1/2020,10/5/2020,Actual,3-Sep-20,Actual,9/3/2020,Oct-20,10/31/2020,3-Sep-21,Anticipated,9/3/2021,3-Sep-21,Anticipated,9/3/2021,NA,Interventional,NA,NA,Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Longitudinal and Comparative Study of Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Recruiting,NA,Not Applicable,30,Anticipated,Hopital Foch,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:25Z,2021-10-12T06:56:25Z
NCT04522492,NA,8/7/2020,NA,NA,8/24/2021,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,8/24/2021,8/25/2021,Actual,11-Aug-20,Actual,8/11/2020,Aug-21,8/31/2021,Dec-21,Anticipated,12/31/2021,1-Mar-21,Actual,3/1/2021,NA,Interventional,NA,NA,Impact of COVID-19 on Mental Health of Patients With Skin Picking,Impact of COVID-19 Pandemia on the Mental Health of Patients With Skin Picking Disorder and Their Treatment With Remote Cognitive Behavioral Therapy: Controlled Clinical Trial,"Active, not recruiting",NA,Not Applicable,18,Actual,Hospital de Clinicas de Porto Alegre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:52Z,2021-10-12T06:56:52Z
NCT04521309,NA,5/7/2020,NA,NA,3/21/2021,8/19/2020,8/20/2020,Actual,NA,NA,NA,NA,NA,NA,3/21/2021,3/24/2021,Actual,19-Jun-20,Actual,6/19/2020,Mar-21,3/31/2021,8-Feb-21,Actual,2/8/2021,26-Jan-21,Actual,1/26/2021,NA,Interventional,NA,NA,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients,Completed,NA,Phase 1/Phase 2,50,Actual,Dow University of Health Sciences,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:03Z,2021-10-12T06:57:03Z
NCT04522986,NA,8/20/2020,NA,NA,3/16/2021,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,3/16/2021,3/18/2021,Actual,21-Aug-20,Actual,8/21/2020,Mar-21,3/31/2021,2-Feb-21,Actual,2/2/2021,2-Feb-21,Actual,2/2/2021,NA,Interventional,COVID-19,NA,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Completed,NA,Phase 1,6,Actual,"Rohto Pharmaceutical Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:52Z,2021-10-12T06:56:52Z
NCT04524663,NA,4/10/2020,NA,NA,6/8/2021,8/20/2020,8/24/2020,Actual,NA,NA,NA,NA,NA,NA,6/8/2021,6/11/2021,Actual,19-Dec-20,Actual,12/19/2020,Jun-21,6/30/2021,15-May-21,Actual,5/15/2021,15-May-21,Actual,5/15/2021,NA,Interventional,COPS-2003,NA,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19",Completed,NA,Phase 2,48,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:36Z,2021-10-12T06:56:36Z
NCT04522830,NA,8/18/2020,NA,NA,4/9/2021,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,4/9/2021,4/13/2021,Actual,30-Jul-20,Actual,7/30/2020,Apr-21,4/30/2021,28-Feb-21,Actual,2/28/2021,28-Feb-21,Actual,2/28/2021,NA,Interventional,BTL-TML-COVID,NA,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,"A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection",Completed,NA,Phase 2,28,Actual,"Beech Tree Labs, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:50Z,2021-10-12T06:56:50Z
NCT04522128,NA,5/12/2020,NA,NA,9/29/2021,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,9/30/2021,Actual,22-May-20,Actual,5/22/2020,Sep-21,9/30/2021,1-Sep-21,Actual,9/1/2021,1-Sep-21,Actual,9/1/2021,NA,Interventional,NA,NA,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Completed,NA,Not Applicable,274,Actual,University of Manchester,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,WHOQOL COMBI data cannot be shared with researchers outside of the research team.,2021-10-12T06:56:56Z,2021-10-12T06:56:56Z
NCT04523090,NA,8/20/2020,NA,NA,6/3/2021,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,6/3/2021,6/7/2021,Actual,27-Aug-20,Actual,8/27/2020,Jun-21,6/30/2021,Feb-22,Anticipated,2/28/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,C3-RCT,NA,Catalysing the Containment of COVID-19,"The C3 Nitazoxanide for Mild to Moderate COVID-19 in HIV-infected and HIV-uninfected Adults With Enhanced Risk: a Double-blind, Randomised, Placebo-controlled Trial in a Resource-poor Setting",Recruiting,NA,Phase 2/Phase 3,440,Anticipated,University of Cape Town,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:48Z,2021-10-12T06:56:48Z
NCT04521322,NA,8/19/2020,NA,NA,8/19/2020,8/19/2020,8/20/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2020,8/21/2020,Actual,24-Jul-20,Actual,7/24/2020,Aug-20,8/31/2020,30-Nov-20,Anticipated,11/30/2020,30-Oct-20,Anticipated,10/30/2020,NA,Interventional,CARR-COV-02,NA,Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,"Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02)",Recruiting,NA,Phase 4,400,Anticipated,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:57:02Z,2021-10-12T06:57:02Z
NCT04523181,NA,8/19/2020,NA,NA,9/29/2021,8/20/2020,8/21/2020,Actual,NA,NA,NA,NA,NA,NA,9/29/2021,10/1/2021,Actual,8-Oct-20,Actual,10/8/2020,Aug-21,8/31/2021,31-Dec-21,Anticipated,12/31/2021,30-Nov-21,Anticipated,11/30/2021,NA,Interventional,NA,NA,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,"A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19",Recruiting,NA,Phase 2,174,Anticipated,Golden Biotechnology Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:46Z,2021-10-12T06:56:46Z
NCT04518969,NA,4/25/2020,NA,NA,8/18/2020,8/18/2020,8/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/18/2020,8/19/2020,Actual,3-May-20,Actual,5/3/2020,Aug-20,8/31/2020,1-Dec-20,Anticipated,12/1/2020,1-Dec-20,Anticipated,12/1/2020,NA,Interventional,NA,NA,Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,"Comparing the Cytokine Clearances of Pro-, and Anti-inflammatory Mediators, Chemokines and Complement in the COVID-19 Patients Treated With CytoSorb as Compared to the Same Patient Population Who do Not Receive Blood Purification Treatment",Recruiting,NA,Not Applicable,24,Anticipated,Brugmann University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:20Z,2021-10-12T06:57:20Z
NCT04519320,NA,8/18/2020,NA,NA,8/2/2021,8/18/2020,8/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/2/2021,8/3/2021,Actual,18-May-20,Actual,5/18/2020,Aug-21,8/31/2021,18-Aug-25,Anticipated,8/18/2025,18-Aug-21,Anticipated,8/18/2021,NA,Interventional,COV-RECUP,NA,Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,Medium and Long Term Follow-up of SARS-COV-2 Infected Patients Treated at BesanÃ§on and Dijon Hospitals: Research and Characterization of Pulmonary Sequelae,"Active, not recruiting",NA,Not Applicable,140,Anticipated,Centre Hospitalier Universitaire de Besancon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:18Z,2021-10-12T06:57:18Z
NCT04518514,NA,7/28/2020,NA,NA,8/14/2020,8/14/2020,8/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/14/2020,8/19/2020,Actual,20-Apr-20,Actual,4/20/2020,Aug-20,8/31/2020,30-Nov-20,Anticipated,11/30/2020,31-Oct-20,Anticipated,10/31/2020,NA,Interventional,NA,NA,Telemedical Risk Assessment and Preoperative Evaluation (TAPE),Telemedical Risk Assessment and Preoperative Evaluation for Anesthesia During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,100,Anticipated,RWTH Aachen University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:57:23Z,2021-10-12T06:57:23Z
NCT04519411,NA,8/18/2020,NA,NA,1/28/2021,8/18/2020,8/19/2020,Actual,NA,NA,NA,NA,NA,NA,1/28/2021,2/1/2021,Actual,21-May-20,Actual,5/21/2020,Jan-21,1/31/2021,31-Jan-22,Anticipated,1/31/2022,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Recruiting,NA,Not Applicable,10,Anticipated,Mayo Clinic,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:16Z,2021-10-12T06:57:16Z
NCT04514627,NA,7/8/2020,NA,NA,8/17/2020,8/13/2020,8/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/17/2020,8/19/2020,Actual,13-Jul-20,Actual,7/13/2020,Aug-20,8/31/2020,31-Jul-21,Anticipated,7/31/2021,31-Jul-21,Anticipated,7/31/2021,NA,Interventional,PENFS COVID-19,NA,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,Olive View-UCLA Education & Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:51Z,2021-10-12T06:57:51Z
NCT04516954,NA,8/17/2020,NA,NA,8/18/2020,8/17/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/18/2020,8/20/2020,Actual,1-Aug-20,Actual,8/1/2020,Aug-20,8/31/2020,30-Dec-20,Anticipated,12/30/2020,30-Nov-20,Anticipated,11/30/2020,NA,Interventional,CPCP,NA,Convalescent Plasma for COVID-19 Patients,Assessment of the Safety of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above Illness,Enrolling by invitation,NA,Early Phase 1,10,Anticipated,Vinmec Research Institute of Stem Cell and Gene Technology,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:34Z,2021-10-12T06:57:34Z
NCT04517123,NA,8/14/2020,NA,NA,10/7/2021,8/14/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,10/7/2021,10/8/2021,Actual,1-Sep-20,Actual,9/1/2020,Oct-21,10/31/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,PRONE,NA,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study","Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Recruiting,NA,Not Applicable,100,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:33Z,2021-10-12T06:57:33Z
NCT04516759,NA,8/14/2020,NA,NA,9/9/2021,8/16/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,9/9/2021,9/16/2021,Actual,12-Aug-20,Actual,8/12/2020,Sep-21,9/30/2021,12-May-21,Actual,5/12/2021,25-Apr-21,Actual,4/25/2021,NA,Interventional,ARCADIA,NA,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,"A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19",Completed,NA,Phase 2,156,Actual,St George Street Capital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Requests for access to the data will be accepted beginning 6 months after article publication and will continue to be accepted for up to 5 years after publication.,Researchers must submit a methodologically sound research proposal to St George Street using the contact details provided on our website. See link below.,http://www.sgscapital.org,Yes,Qualified researchers can request access to deidentified individual participant data (IDP) that underlie the published clinical trial results.,2021-10-12T06:57:35Z,2021-10-12T06:57:35Z
NCT04514705,NA,8/11/2020,NA,NA,8/13/2020,8/13/2020,8/17/2020,Actual,NA,NA,NA,NA,NA,NA,8/13/2020,8/17/2020,Actual,11-Aug-20,Actual,8/11/2020,Aug-20,8/31/2020,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,NA,NA,Characteristics in Post Covid-19 Patients,Clinical Respiratory Investigation in Post Covid-19 Patients,Recruiting,NA,Not Applicable,20,Anticipated,Universidade Metodista de Piracicaba,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:57:50Z,2021-10-12T06:57:50Z
NCT04516837,NA,8/16/2020,NA,NA,8/31/2020,8/16/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/31/2020,9/1/2020,Actual,31-Aug-20,Actual,8/31/2020,Aug-20,8/31/2020,Aug-22,Anticipated,8/31/2022,Aug-21,Anticipated,8/31/2021,NA,Interventional,NA,NA,Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19),The Combination of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) Versus Eltrombopag Monotherapy as Subsequent Treatment for Immune Thrombocytopenia During the COVID-19 Pandemic,Recruiting,NA,Phase 2,120,Anticipated,Peking University People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:34Z,2021-10-12T06:57:34Z
NCT04513158,NA,8/6/2020,NA,NA,10/14/2020,8/12/2020,8/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2020,10/19/2020,Actual,14-Aug-20,Actual,8/14/2020,Oct-20,10/31/2020,31-Dec-21,Anticipated,12/31/2021,1-Aug-21,Anticipated,8/1/2021,NA,Interventional,NA,NA,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,NA,Phase 2,100,Anticipated,Norton Healthcare,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:11Z,2021-10-12T06:58:11Z
NCT04508868,NA,8/10/2020,NA,NA,12/29/2020,8/10/2020,8/11/2020,Actual,NA,NA,NA,NA,NA,NA,12/29/2020,12/31/2020,Actual,31-Aug-20,Actual,8/31/2020,Dec-20,12/31/2020,23-Dec-20,Actual,12/23/2020,23-Dec-20,Actual,12/23/2020,NA,Interventional,CoviDep,NA,Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19,Behavioral Activation and Mental Imagery Delivered Via Telephone for the Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19: A Randomized Clinical Trial,Terminated,NA,Not Applicable,41,Actual,Uppsala University,,2,NA,Study terminated due to changes in government restrictions. Collected data to be presented as a pilot study.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Study protocol to be shared before data collection is completed
Statistical Analysis Plan to be shared before data analysis begin",Data will be shared upon reasonable requests assessed by the investigators.,NA,Yes,De-identified outcome measure IPD will be shared upon reasonable requests from academic researchers.,2021-10-12T06:58:38Z,2021-10-12T06:58:38Z
NCT04509973,NA,8/11/2020,NA,NA,9/20/2021,8/11/2020,8/12/2020,Actual,NA,NA,NA,NA,NA,NA,9/20/2021,9/21/2021,Actual,27-Aug-20,Actual,8/27/2020,Sep-21,9/30/2021,17-Nov-21,Anticipated,11/17/2021,17-Jun-21,Actual,6/17/2021,NA,Interventional,COVIDSTEROID2,NA,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,Higher vs. Lower Doses of Dexamethasone in Patients With COVID-19 and Severe Hypoxia,"Active, not recruiting",NA,Phase 3,1000,Actual,Scandinavian Critical Care Trials Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-2/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2021-10-12T06:58:27Z,2021-10-12T06:58:27Z
NCT04511819,NA,8/8/2020,NA,NA,8/3/2021,8/11/2020,8/13/2020,Actual,NA,NA,NA,NA,NA,NA,8/3/2021,8/9/2021,Actual,28-Aug-20,Actual,8/28/2020,Aug-21,8/31/2021,31-Mar-21,Actual,3/31/2021,31-Mar-21,Actual,3/31/2021,NA,Interventional,LOSVID,NA,Losmapimod Safety and Efficacy in COVID-19,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)",Terminated,NA,Phase 3,52,Actual,Fulcrum Therapeutics,,2,NA,Study terminated due to the rapidly evolving environment for the treatment of Covid-19 and ongoing challenges to identify and enroll qualified patients to participate.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:14Z,2021-10-12T06:58:14Z
NCT04512079,NA,8/11/2020,NA,NA,2/10/2021,8/11/2020,8/13/2020,Actual,NA,NA,NA,NA,NA,NA,2/10/2021,2/11/2021,Actual,8-Sep-20,Actual,9/8/2020,Feb-21,2/28/2021,Mar-22,Anticipated,3/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,FREEDOM COVID,NA,FREEDOM COVID-19 Anticoagulation Strategy,FREEDOM COVID Anticoagulation Strategy Randomized Trial,Recruiting,NA,Phase 4,3600,Anticipated,Icahn School of Medicine at Mount Sinai,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose. The type of analysis that will be conducted is for individual participant data meta-analysis. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.",NA,Yes,"Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).",2021-10-12T06:58:11Z,2021-10-12T06:58:11Z
NCT04513470,NA,8/10/2020,NA,NA,10/14/2020,8/13/2020,8/14/2020,Actual,NA,NA,NA,NA,NA,NA,10/14/2020,10/19/2020,Actual,1-Aug-20,Actual,8/1/2020,Oct-20,10/31/2020,Feb-21,Anticipated,2/28/2021,Jan-21,Anticipated,1/31/2021,NA,Interventional,NA,NA,Allocetra-OTS in COVID-19,"A Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory Dysfunction","Active, not recruiting",NA,Phase 1,5,Actual,Hadassah Medical Organization,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:58Z,2021-10-12T06:57:58Z
NCT04511949,NA,8/12/2020,NA,NA,2/2/2021,8/12/2020,8/13/2020,Actual,NA,NA,NA,NA,NA,NA,2/2/2021,2/3/2021,Actual,12-Jul-20,Actual,7/12/2020,Feb-21,2/28/2021,30-Nov-20,Actual,11/30/2020,30-Sep-20,Actual,9/30/2020,NA,Interventional,FAMICOV,NA,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,NA,Not Applicable,500,Actual,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:58:15Z,2021-10-12T06:58:15Z
NCT04511923,NA,8/10/2020,NA,NA,2/5/2021,8/11/2020,8/13/2020,Actual,NA,NA,NA,NA,NA,NA,2/5/2021,2/10/2021,Actual,23-Dec-20,Actual,12/23/2020,Feb-21,2/28/2021,Jan-22,Anticipated,1/31/2022,Dec-21,Anticipated,12/31/2021,NA,Interventional,CHARTER-Irl,NA,Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury,Can Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Respiratory Support in Ireland,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,University College Hospital Galway,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Investigator will consider release of the above data once the study report has been completed.,"To be confirmed, prior to enrollment of the first patient.",NA,Yes,Investigator will consider requests to share anonymised data for the purposes of meta-analysis following discussion with the sponsor.,2021-10-12T06:58:15Z,2021-10-12T06:58:15Z
NCT04510662,NA,8/11/2020,NA,NA,8/11/2020,8/11/2020,8/12/2020,Actual,NA,NA,NA,NA,NA,NA,8/11/2020,8/12/2020,Actual,Aug-20,Anticipated,8/31/2020,Aug-20,8/31/2020,Apr-21,Anticipated,4/30/2021,Mar-21,Anticipated,3/31/2021,NA,Interventional,STAR-COVID,NA,Telmisartan in Respiratory Failure Due to COVID-19,Effectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19,Recruiting,NA,Phase 2,60,Anticipated,Hospital Regional de Alta Especialidad de Zumpango,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no plan to share individual participant data with other researchers to avoid misuse of patient information.,2021-10-12T06:58:24Z,2021-10-12T06:58:24Z
NCT04513184,NA,8/12/2020,NA,NA,11/9/2020,8/12/2020,8/14/2020,Actual,NA,NA,NA,NA,NA,NA,11/9/2020,11/12/2020,Actual,14-Jul-20,Actual,7/14/2020,Nov-20,11/30/2020,31-Jul-21,Anticipated,7/31/2021,30-Mar-21,Anticipated,3/30/2021,NA,Interventional,NA,NA,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Recruiting,NA,Phase 2,60,Anticipated,Universidad Nacional Autonoma de Mexico,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Upon study completion, by request",NA,NA,Yes,Information exchange for research purposes,2021-10-12T06:58:04Z,2021-10-12T06:58:04Z
NCT04510207,NA,8/3/2020,NA,NA,4/2/2021,8/10/2020,8/12/2020,Actual,NA,NA,NA,NA,NA,NA,4/2/2021,4/5/2021,Actual,16-Jul-20,Actual,7/16/2020,Apr-21,4/30/2021,16-Sep-21,Anticipated,9/16/2021,16-Jun-21,Anticipated,6/16/2021,NA,Interventional,COVID-19,NA,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,NA,Phase 3,45000,Anticipated,China National Biotec Group Company Limited,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:26Z,2021-10-12T06:58:26Z
NCT04519437,NA,7/24/2020,NA,NA,12/1/2020,8/18/2020,8/19/2020,Actual,NA,NA,NA,NA,NA,NA,12/1/2020,12/2/2020,Actual,26-Jul-20,Actual,7/26/2020,Oct-20,10/31/2020,25-Oct-21,Anticipated,10/25/2021,25-Oct-21,Anticipated,10/25/2021,NA,Interventional,NA,NA,"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers","Active, not recruiting",NA,Phase 1,974,Actual,Regeneron Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-12T06:57:13Z,2021-10-12T06:57:13Z
NCT04519385,NA,8/17/2020,NA,NA,8/21/2020,8/17/2020,8/19/2020,Actual,NA,NA,NA,NA,NA,NA,8/21/2020,8/25/2020,Actual,1-Mar-20,Actual,3/1/2020,Aug-20,8/31/2020,5-Aug-20,Actual,8/5/2020,1-Jul-20,Actual,7/1/2020,NA,Interventional,NA,NA,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,NA,Not Applicable,69,Actual,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:57:18Z,2021-10-12T06:57:18Z
NCT04517006,NA,8/14/2020,NA,NA,5/25/2021,8/17/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,5/25/2021,5/26/2021,Actual,31-Jan-21,Actual,1/31/2021,May-21,5/31/2021,4-Apr-21,Actual,4/4/2021,4-Apr-21,Actual,4/4/2021,NA,Interventional,NA,NA,Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic,Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic: A Randomized Clinical Trial,Completed,NA,Not Applicable,1328,Actual,University of Toronto,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"After the publication of the paper and perpetually. The investigators plan to publish the study as a registered report, so study information will also be available as part of the report protocol.",NA,https://osf.io/63yg9/,Yes,"Using an OSF repository, other researchers and readers of the published study will have access to the IPD.",2021-10-12T06:57:34Z,2021-10-12T06:57:34Z
NCT04516941,NA,8/5/2020,NA,NA,7/22/2021,8/17/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,7/22/2021,7/26/2021,Actual,21-Jan-21,Actual,1/21/2021,Jul-21,7/31/2021,30-Jun-23,Anticipated,6/30/2023,31-Dec-22,Anticipated,12/31/2022,NA,Interventional,CONVINCE,NA,CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19,Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting,Recruiting,NA,Phase 3,420,Anticipated,"University Hospital Inselspital, Berne",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:34Z,2021-10-12T06:57:34Z
NCT04517396,NA,8/17/2020,NA,NA,9/26/2021,8/17/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,9/26/2021,10/4/2021,Actual,18-Aug-20,Actual,8/18/2020,Sep-21,9/30/2021,31-Dec-21,Anticipated,12/31/2021,31-Dec-21,Anticipated,12/31/2021,NA,Interventional,FERMIN,NA,FEnofibRate as a Metabolic INtervention for COVID-19,FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019,Enrolling by invitation,NA,Phase 2,700,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Not making it available,2021-10-12T06:57:31Z,2021-10-12T06:57:31Z
NCT04516915,NA,8/10/2020,NA,NA,8/19/2020,8/17/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,8/19/2020,8/21/2020,Actual,15-Jun-20,Actual,6/15/2020,Aug-20,8/31/2020,Jul-21,Anticipated,7/31/2021,May-21,Anticipated,5/31/2021,NA,Interventional,IONIC,NA,IMU-838 and Oseltamivir in the Treatment of COVID-19,"Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19",Recruiting,NA,Phase 2,120,Anticipated,University Hospitals Coventry and Warwickshire NHS Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:35Z,2021-10-12T06:57:35Z
NCT04516811,NA,8/12/2020,NA,NA,9/24/2020,8/17/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,9/24/2020,9/25/2020,Actual,21-Sep-20,Actual,9/21/2020,Sep-20,9/30/2020,31-Jul-22,Anticipated,7/31/2022,30-Dec-21,Anticipated,12/30/2021,NA,Interventional,NA,NA,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,"A Prospective, Randomized, Placebo-controlled, Double-blinded, Phase III Clinical Trial of the Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19",Recruiting,NA,Phase 3,600,Anticipated,South African National Blood Service,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Undecided,undecided,NA,Yes,"Where available and applicable, the results of this study will be reported to the appropriate scientific and management divisions of participating institutions. In addition, interim results may be communicated to lay press if doing so is deemed appropriate and relevant by the Study Management Committee. Interim and final results will be presented at various scientific congresses, meeting and in appropriate peer-reviewed scientific journals. Under no circumstances will personal identifier be revealed to any party not legally entitled to such information.",2021-10-12T06:57:35Z,2021-10-12T06:57:35Z
NCT04517422,NA,8/16/2020,NA,NA,5/2/2021,8/16/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,5/2/2021,5/6/2021,Actual,19-Aug-20,Actual,8/19/2020,May-21,5/31/2021,2-Feb-21,Actual,2/2/2021,2-Feb-21,Actual,2/2/2021,NA,Interventional,NA,NA,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota: A Randomized Clinical Trial,Completed,NA,Not Applicable,300,Actual,"AB Biotics, SA",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"From the moment of manuscript publication, without time limit.",Formal request with a defined analysis plan. Please contact espadaler@ab-biotics.com or medical@ab-biotics.com,NA,Yes,"Deidentified individual patient data (IPD), together with data dictionary defining each field in the set, will be made public upon any formal requests with a defined analysis plan.",2021-10-12T06:57:31Z,2021-10-12T06:57:31Z
NCT04514900,NA,7/20/2020,NA,NA,4/27/2021,8/12/2020,8/17/2020,Actual,NA,NA,NA,NA,NA,NA,4/27/2021,4/30/2021,Actual,23-Sep-20,Actual,9/23/2020,Apr-21,4/30/2021,8-Mar-21,Actual,3/8/2021,8-Mar-21,Actual,3/8/2021,NA,Interventional,iREACH,NA,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,Exploring the Optimal Treatment Components for a Contactless Online Group-based Behavioral Weight Loss Program for the COVID 19 Pandemic,Completed,NA,Not Applicable,73,Actual,University of South Carolina,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:49Z,2021-10-12T06:57:49Z
NCT04517162,NA,8/14/2020,NA,NA,2/13/2021,8/14/2020,8/18/2020,Actual,NA,NA,NA,NA,NA,NA,2/13/2021,2/17/2021,Actual,19-Aug-20,Actual,8/19/2020,Feb-21,2/28/2021,19-Jun-21,Anticipated,6/19/2021,19-Feb-21,Anticipated,2/19/2021,NA,Interventional,NA,NA,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will be provided based on requirement,2021-10-12T06:57:35Z,2021-10-12T06:57:35Z
NCT04512027,NA,8/11/2020,NA,NA,10/16/2020,8/12/2020,8/13/2020,Actual,NA,NA,NA,NA,NA,NA,10/16/2020,10/19/2020,Actual,15-Sep-20,Actual,9/15/2020,Oct-20,10/31/2020,16-Oct-20,Actual,10/16/2020,19-Sep-20,Actual,9/19/2020,NA,Interventional,Prolectin-M,NA,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,"Effect of Prolectin-M; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers: A Proof of Concept, Open Label Randomized Controlled Trial",Completed,NA,Not Applicable,10,Actual,Composite Interceptive Med Science,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:11Z,2021-10-12T06:58:11Z
NCT04510493,NA,8/11/2020,NA,NA,9/7/2021,8/11/2020,8/12/2020,Actual,NA,NA,NA,NA,NA,NA,9/7/2021,9/8/2021,Actual,23-Oct-20,Actual,10/23/2020,Sep-21,9/30/2021,17-Aug-21,Actual,8/17/2021,17-Aug-21,Actual,8/17/2021,NA,Interventional,CanCovDia,NA,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial,Completed,NA,Phase 3,116,Actual,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:58:24Z,2021-10-12T06:58:24Z
NCT04511650,NA,8/7/2020,NA,NA,6/15/2021,8/11/2020,8/13/2020,Actual,NA,NA,NA,NA,NA,NA,6/15/2021,6/18/2021,Actual,21-Oct-20,Actual,10/21/2020,Jun-21,6/30/2021,26-Feb-21,Actual,2/26/2021,26-Feb-21,Actual,2/26/2021,NA,Interventional,RESCUE,NA,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (RESCUE Study)",Terminated,NA,Phase 2,31,Actual,Aerpio Therapeutics,,2,NA,"After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges associated with recruiting and monitoring patients in the current pandemic environment.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:15Z,2021-10-12T06:58:15Z
NCT04508439,NA,8/5/2020,NA,NA,8/8/2020,8/8/2020,8/11/2020,Actual,NA,NA,NA,NA,NA,NA,8/8/2020,8/11/2020,Actual,20-Jun-20,Actual,6/20/2020,Aug-20,8/31/2020,30-Dec-20,Anticipated,12/30/2020,30-Aug-20,Anticipated,8/30/2020,NA,Interventional,NA,NA,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Recruiting,NA,Not Applicable,130,Anticipated,Hospital Regional de Alta especialidad de Ixtapaluca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:39Z,2021-10-12T06:58:39Z
